In	O
spite	O
of	O
medical	O
help	O
:	O
the	O
puzzle	O
of	O
an	O
eighteenth	O
-	O
century	O
Prime	O
Minister	O
'	O
s	O
illness	O
.	O

Abstract	O

Medical	O
History	O
,	O
1990	O
,	O
34	O
:	O
178	O
-	O
184	O
.	O

IN	O
SPITE	O
OF	O
MEDICAL	O
HELP	O
:	O
THE	O
PUZZLE	O
OF	O
AN	O

EIGHTEENTH	O
-	O
CENTURY	O
PRIME	O
MINISTER	O
'	O
S	O

ILLNESS	O

by	O

MARJORIE	O
BLOY	O
*	O

Charles	O
Watson	O
Wentworth	O
,	O
second	O
Marquis	O
of	O
Rockingham	O
,	O
died	O
suddenly	O
and	O
unexpectedly	O
on	O
1	O
July	O
1782	O
,	O
when	O
he	O
was	O
only	O
52	O
years	O
old	O
.	O

He	O
had	O
suffered	O
-	O
or	O
enjoyed	O
-	O
ill	O
health	O
all	O
his	O
life	O
but	O
in	O
1782	O
appeared	O
to	O
be	O
no	O
worse	O
than	O
he	O
had	O
ever	O
been	O
.	O

His	O
death	O
in	O
London	O
terminated	O
his	O
second	O
period	O
of	O
office	O
as	O
Prime	O
Minister	O
,	O
to	O
which	O
he	O
had	O
been	O
appointed	O
only	O
14	O
weeks	O
earlier	O
.	O

In	O
May	O
he	O
had	O
reported	O
to	O
the	O
Duke	O
of	O
Portland	O
that	O
he	O
had	O
"	O
for	O
some	O
weeks	O
past	O
undergone	O
much	O
Pain	O
and	O
much	O
inconvenience	O
from	O
something	O
similar	O
to	O
my	O
old	O
Complaint	O
in	O
my	O
Side	O
and	O
Stomach	O
"	O
but	O
that	O
he	O
felt	O
much	O
better	O
than	O
he	O
had	O
.	O
'	O
By	O
17	O
June	O
he	O
was	O
recovering	O
from	O
both	O
influenza	O
and	O
his	O
"	O
old	O
complaint	O
"	O
.	O
2	O
On	O
1	O
July	O
he	O
died	O
and	O
on	O
the	O
20th	O
he	O
was	O
interred	O
in	O
York	O
Minster	O
.	O

The	O
first	O
recorded	O
bout	O
of	O
illness	O
suffered	O
by	O
the	O
marquis	O
,	O
then	O
Lord	O
Higham	O
,	O
was	O
in	O
July	O
1741	O
when	O
the	O
11	O
-	O
year	O
-	O
old	O
was	O
"	O
a	O
little	O
indisposed	O
,	O
something	O
Feaverish	O
I	O
guess	O
it	O
proceeds	O
from	O
Worms	O
and	O
will	O
Soon	O
be	O
removed	O
"	O
.	O
3	O
He	O
also	O
had	O
a	O
rash	O
and	O
it	O
was	O
thought	O
that	O
the	O
cause	O
of	O
the	O
problem	O
was	O
that	O
the	O
boy	S-Species
had	O
overheated	O
himself	O
.	O
4	O
He	O
was	O
still	O
ill	O
at	O
the	O
beginning	O
of	O
August	O
:	O
he	O
had	O
been	O
"	O
much	O
out	O
of	O
order	O
"	O
for	O
a	O
long	O
time	O
but	O
had	O
been	O
recommended	O
to	O
take	O
warm	O
baths	O
by	O
Dr	O
Wilmot	O
and	O
Mr	O
Ranby	O
when	O
they	O
were	O
consulted	O
in	O
London	O
.	O
5	O
Charles	O
'	O
s	O
aunt	O
,	O
Lady	O
Isabella	O
Finch	O
,	O
was	O
sure	O
that	O
the	O
baths	O
"	O
and	O
other	O
Things	O
They	O
'	O
ll	O
prescribe	O
will	O
in	O
a	O
short	O
Time	O
entirely	O
Cure	O
his	O
Complaints	O
w	O
[	O
hic	O
]	O
h	O
neither	O
of	O
Them	O
thought	O
proceed	O
from	O
any	O
dangerous	O
Causes	O
"	O
.	O
6	O
In	O
spite	O
of	O
Lady	O
Isabella	O
'	O
s	O
hopes	O
,	O
Charles	O
did	O
not	O
greatly	O
improve	O
,	O
even	O
though	O
his	O
mother	O
believed	O
that	O
he	O
continued	O
mending	O
every	O
day	O
.	O

The	O
main	O
reason	O
that	O
Higham	O
and	O
his	O
mother	O
had	O
gone	O
to	O
London	O
to	O
consult	O
Dr	O
Wilmot	O
and	O
Mr	O

*	O
Marjorie	O
Bloy	O
,	O
Ph	O
.	O
D	O
.	O
,	O
18	O
Farm	O
View	O
Road	O
,	O
Kimberworth	O
,	O
Rotherham	O
,	O
S	O
.	O

Yorks	O
.	O

S61	O
2BA	O
.	O

The	O
Rockingham	O
Papers	O
are	O
in	O
the	O
holdings	O
of	O
the	O
Wentworth	O
Woodhouse	O
Muniments	O
at	O
Sheffield	O
City	O
Archives	O
Department	O
,	O
Sheffield	O
City	O
Library	O
.	O

I	O
am	O
grateful	O
to	O
Dr	O
R	O
.	O

S	O
.	O

Morton	O
for	O
his	O
advice	O
and	O
help	O
with	O
the	O
diagnostic	O
sections	O
of	O
this	O
essay	O
.	O

'	O
WWM	O
,	O
RI	O
-	O
2094	O
.	O

Rockingham	O
to	O
Portland	O
,	O
25	O
May	O
1782	O
.	O

2WWM	O
,	O
RI	O
-	O
2094	O
.	O

Rockingham	O
to	O
Charlemont	O
,	O
17	O
June	O
1782	O
.	O

3	O
WWM	O
,	O
M8	O
-	O
25	O
.	O

Malton	O
to	O
Nottingham	O
,	O
after	O
16	O
June	O
1741	O
.	O

4	O
WWM	O
,	O
M8	O
-	O
26	O
.	O

Lady	O
Finch	O
to	O
Lady	O
Malton	O
,	O
30	O
July	O
1741	O
.	O

5	O
WWM	O
,	O
M8	O
-	O
28	O
.	O

Winchelsea	O
to	O
Malton	O
,	O
7	O
August	O
1741	O
.	O

6	O
WWM	O
,	O
M8	O
-	O
29	O
.	O

Lady	O
Finch	O
to	O
Malton	O
,	O
7	O
August	O
1741	O
.	O

178	O

An	O
eighteenth	O
-	O
century	O
Prime	O
Minister	O
'	O
s	O
illness	O

Ranby	O
was	O
his	O
mother	O
'	O
s	O
concern	O
about	O
a	O
"	O
swelling	O
in	O
a	O
certain	O
part	O
which	O
was	O
larger	O
than	O
when	O
we	O
left	O
Wentworth	O
"	O
.	O

The	O
doctors	O
hoped	O
that	O
it	O
would	O
burst	O
outwards	O
"	O
which	O
they	O
assure	O
me	O
will	O
be	O
the	O
safest	O
way	O
and	O
give	O
the	O
poor	O
Monkey	O
but	O
very	O
little	O
pain	O
'	O
7	O

On	O
20	O
August	O
Lord	O
Winchelsea	O
,	O
Higham	O
'	O
s	O
uncle	O
,	O
surprised	O
to	O
see	O
the	O
boy	S-Species
so	O
well	O
and	O
brisk	O
,	O
hoped	O
that	O
Charles	O
was	O
"	O
now	O
safe	O
from	O
this	O
complaint	O
"	O
-	O
the	O
same	O
one	O
from	O
which	O
he	O
had	O
suffered	O
in	O
1738	O
-	O
39	O
-	O
but	O
thought	O
that	O
he	O
would	O
never	O
be	O
safe	O
"	O
if	O
he	O
continues	O
the	O
practice	O
of	O
overheating	O
himself	O
and	O
then	O
drinking	O
Cold	O
Water	O
"	O
.	O

He	O
said	O
that	O
Charles	O
was	O
of	O
a	O
"	O
pretty	O
healthy	O
strong	O
Constitution	O
"	O
;	O
8	O
Lady	O
Malton	O
was	O
not	O
so	O
sure	O
.	O

The	O
same	O
day	O
she	O
wrote	O
a	O
progress	O
report	O
to	O
her	O
husband	O
saying	O
that	O
Charles	O
'	O
s	O
swelling	O
continued	O
to	O
grow	O
,	O
as	O
did	O
the	O
pain	O
"	O
in	O
that	O
part	O
(	O
but	O
not	O
the	O
lease	O
[	O
sic	O
]	O
trouble	O
in	O
making	O
Water	O
or	O
going	O
to	O
Stool	O
)	O
&	O
less	O
Fever	O
than	O
c	O
[	O
oulJd	O
be	O
imagined	O
where	O
Matter	O
is	O
as	O
they	O
now	O
imagine	O
certainly	O
gathering	O
and	O
must	O
end	O
in	O
an	O
operation	O
"	O
.	O

In	O
spite	O
of	O
it	O
all	O
,	O
Charles	O
was	O
in	O
fine	O
spirits	O
.	O
9	O
Lady	O
Malton	O
dosed	O
the	O
boy	S-Species
with	O
cinchona	S-Species
bark	O
,	O
which	O
removed	O
the	O
pains	O
in	O
his	O
legs	O
and	O
reduced	O
his	O
fever	O
,	O
and	O
she	O
was	O
convinced	O
that	O
they	O
would	O
soon	O
have	O
"	O
a	O
clear	O
Stage	O
to	O
act	O
in	O
a	O
proper	O
manner	O
a	O
[	O
bou	O
]	O
t	O
his	O
other	O
Complaints	O
w	O
[	O
hic	O
]	O
h	O
the	O
Learned	O
assure	O
me	O
are	O
to	O
be	O
conquered	O
also	O
"	O
.	O

10	O
Charles	O
was	O
soon	O
allowed	O
to	O
eat	O
meat	O
and	O
Mr	O
Ranby	O
still	O
assured	O
her	O
that	O
the	O
swelling	O
would	O
break	O
outwards	O
.	O

1	O
"	O
Three	O
days	O
later	O
he	O
decided	O
to	O
lance	O
it	O
,	O
even	O
though	O
Dr	O
Bourne	O
disagreed	O
.	O

The	O
boy	S-Species
'	O
s	O
mother	O
was	O
puzzled	O
because	O
the	O
swelling	O
"	O
sometimes	O
pushes	O
forward	O
very	O
fast	O
then	O
retires	O
a	O
little	O
"	O
but	O
the	O
doctor	O
and	O
Ranby	O
seemed	O
happy	O
with	O
his	O
condition	O
.	O
'	O
2	O
At	O
this	O
point	O
the	O
letters	O
cease	O
,	O
presumably	O
because	O
Malton	O
arrived	O
in	O
London	O
with	O
his	O
daughters	O
,	O
to	O
have	O
them	O
inoculated	O
against	O
smallpox	S-Species
,	O
but	O
a	O
later	O
letter	O
states	O
that	O
surgery	O
to	O
open	O
the	O
swelling	O
was	O
not	O
undertaken	O
.	O

13	O

By	O
the	O
end	O
of	O
October	O
the	O
correspondence	O
had	O
recommenced	O
.	O

Charles	O
was	O
ill	O
again	O
.	O

He	O
was	O
just	O
the	O
same	O
as	O
when	O
he	O
left	O
Kensington	O
,	O
so	O
John	O
Bourne	O
had	O
bled	O
him	O
and	O
the	O
child	S-Species
had	O
started	O
on	O
Sir	O
Edward	O
Hulse	O
'	O
s	O
prescription	O
,	O
unfortunately	O
not	O
defined	O
in	O
the	O
letter	O
,	O
but	O
which	O
was	O
apparently	O
as	O
bad	O
as	O
the	O
last	O
one	O
,	O
if	O
not	O
worse	O
.	O

Lady	O
Malton	O
thought	O
that	O
"	O
with	O
such	O
a	O
State	O
of	O
Blood	O
the	O
Continuation	O
of	O
Health	O
cannot	O
be	O
expected	O
"	O
but	O
was	O
hopeful	O
that	O
the	O
"	O
Cinnabar	O
may	O
prove	O
a	O
more	O
Efficacious	O
remedie	O
than	O
any	O
than	O
has	O
been	O
tryed	O
yet	O
"	O
"	O
.	O
"	O
4	O
That	O
night	O
she	O
applied	O
"	O
a	O
Blister	O
.	O
.	O
.	O
without	O
the	O
least	O
Symptom	O
or	O
tendency	O
to	O
anything	O
like	O
Strangury	O
"	O
.	O

He	O
bore	O
the	O
treatment	O
well	O
,	O
as	O
he	O
had	O
done	O
three	O
years	O
previously	O
,	O
and	O
it	O
seemed	O
so	O
successful	O
that	O
Lady	O
Malton	O
was	O
"	O
determined	O
to	O
keep	O
it	O
running	O
full	O
as	O
long	O
as	O
I	O
did	O
last	O
time	O
by	O
the	O
help	O
of	O
John	O
Borne	O
[	O
sic	O
]	O
with	O
much	O
ease	O
to	O
the	O
Dear	O
Child	S-Species
"	O
.	O
'	O
5	O
She	O

7	O
WWM	O
,	O
M7	O
-	O
51	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
18	O
August	O
1741	O
.	O

8	O
WWM	O
,	O
M2	O
-	O
84	O
.	O

Winchelsea	O
to	O
Malton	O
,	O
20	O
August	O
1741	O
.	O

9	O
WWM	O
,	O
M7	O
-	O
52	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
20	O
August	O
1741	O
.	O

'	O
0	O
WWM	O
,	O
M7	O
-	O
53	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
25	O
August	O
1741	O
.	O

WWM	O
,	O
M7	O
-	O
54	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
29	O
August	O
1741	O
.	O

WWM	O
,	O
M7	O
-	O
55	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
1	O
September	O
1741	O
.	O

3	O
WWM	O
,	O
R170	O
-	O
20	O
.	O

Nicol6	O
Scanagati	O
of	O
Padua	O
,	O
20	O
July	O
1750	O
.	O

I	O
am	O
grateful	O
to	O
Fr	O
John	O
McMahon	O
and	O
Dr	O
Stephen	O
Bemrose	O
for	O
their	O
translations	O
of	O
this	O
letter	O
.	O

4	O
WWM	O
,	O
M7	O
-	O
14	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
31	O
October	O
1741	O
.	O

5	O
WWM	O
,	O
M7	O
-	O
19	O
.	O

Lady	O
Malton	O
to	O
Lady	O
Finch	O
,	O
2	O
November	O
1741	O
.	O

179	O

Marjorie	O
Bloy	O

continued	O
with	O
the	O
blister	O
and	O
applied	O
"	O
ointment	O
with	O
flyes	O
"	O
,	O
apparently	O
some	O
sort	O
of	O
irritant	O
potion	O
,	O
with	O
no	O
sign	O
of	O
strangury	O
.	O

Charles	O
found	O
her	O
treatment	O
"	O
not	O
near	O
the	O
pain	O
he	O
expected	O
"	O
and	O
she	O
was	O
"	O
full	O
of	O
hopes	O
that	O
he	O
will	O
rec	O
[	O
eiv	O
]	O
e	O
great	O
benefit	O
from	O
it	O
"	O
.	O
1	O

Apart	O
from	O
his	O
other	O
troubles	O
,	O
one	O
of	O
Charles	O
'	O
s	O
knees	O
had	O
swollen	O
but	O
this	O
had	O
much	O
abated	O
since	O
the	O
application	O
of	O
the	O
blisters	O
which	O
Lady	O
Malton	O
believed	O
"	O
must	O
be	O
acting	O
upon	O
the	O
whole	O
Mass	O
of	O
Blood	O
"	O
since	O
it	O
had	O
"	O
reached	O
the	O
remote	O
part	O
"	O
.	O

She	O
thought	O
that	O
Sir	O
Edward	O
Hulse	O
'	O
s	O
powders	O
were	O
too	O
slow	O
in	O
taking	O
effect	O
although	O
the	O
boy	S-Species
took	O
them	O
very	O
quietly	O
.	O
'	O
7	O
Sir	O
Edward	O
did	O
not	O
"	O
apprehend	O
any	O
great	O
danger	O
from	O
the	O
Siziness	O
[	O
thickness	O
]	O
of	O
Charles	O
'	O
blood	O
"	O
;	O
Lady	O
Malton	O
thought	O
that	O
the	O
condition	O
was	O
the	O
cause	O
of	O
all	O
the	O
child	S-Species
'	O
s	O
problems	O
,	O
which	O
would	O
not	O
end	O
until	O
it	O
was	O
set	O
to	O
rights	O
.	O

At	O
any	O
rate	O
,	O
he	O
was	O
fit	O
enough	O
to	O
go	O
hunting	O
.	O
'	O
8	O
Charles	O
continued	O
in	O
the	O
same	O
state	O
of	O
health	O
.	O

He	O
slept	O
well	O
at	O
night	O
,	O
ate	O
more	O
than	O
his	O
mother	O
thought	O
was	O
good	O
for	O
him	O
,	O
and	O
was	O
able	O
to	O
exercise	O
strenuously	O
without	O
tiring	O
.	O

He	O
put	O
on	O
no	O
weight	O
though	O
,	O
and	O
"	O
as	O
for	O
them	O
swellings	O
at	O
his	O
throat	O
,	O
they	O
are	O
almost	O
gone	O
one	O
day	O
and	O
rise	O
the	O
next	O
"	O
.	O

His	O
mother	O
did	O
not	O
expect	O
a	O
speedy	O
recovery	O
and	O
"	O
if	O
the	O
D	O
[	O
octo	O
]	O
rs	O
think	O
him	O
in	O
a	O
good	O
state	O
of	O
health	O
now	O
,	O
I	O
s	O
[	O
houl	O
]	O
d	O
be	O
glad	O
to	O
see	O
him	O
in	O
a	O
better	O
"	O
.	O
'	O
9	O
He	O
began	O
to	O
improve	O
and	O
by	O
the	O
end	O
of	O
November	O
even	O
she	O
thought	O
he	O
was	O
on	O
the	O
mend	O
and	O
gaining	O
weight	O
.	O
20	O
Unfortunately	O
,	O
Lady	O
Malton	O
again	O
had	O
cause	O
for	O
concern	O
over	O
his	O
health	O
in	O
January	O
1742	O
when	O
he	O
began	O
to	O
suffer	O
from	O
an	O
intermittent	O
hoarseness	O
.	O
2	O
'	O
Otherwise	O
he	O
was	O
as	O
well	O
as	O
one	O
could	O
expect	O
,	O
with	O
no	O
other	O
complaints	O
.	O
22	O
It	O
was	O
not	O
to	O
last	O
.	O

In	O
May	O
1742	O
Charles	O
and	O
his	O
mother	O
were	O
again	O
in	O
Bristol	O
,	O
taking	O
the	O
waters	O
because	O
he	O
had	O
been	O
indisposed	O
.	O

Lady	O
Malton	O
thought	O
the	O
waters	O
were	O
doing	O
them	O
good	O
because	O
they	O
were	O
both	O
being	O
violently	O
sick	O
.	O
23	O
However	O
,	O
Charles	O
had	O
had	O
no	O
dinner	O
on	O
25	O
or	O
26	O
May	O
and	O
was	O
hot	O
,	O
lazy	O
,	O
and	O
inclined	O
to	O
stir	O
,	O
"	O
from	O
which	O
I	O
conclude	O
he	O
is	O
not	O
well	O
,	O
.	O

.	O
.	O
and	O
therefore	O
Intend	O
to	O
give	O
him	O
a	O
gentle	O
Vomit	O
.	O
.	O
.	O
and	O
to	O
let	O
him	O
take	O
his	O
old	O
Remedie	O
the	O
Salt	O
Draughts	O
for	O
a	O
few	O
Daies	O
which	O
I	O
dare	O
say	O
will	O
set	O
him	O
quite	O
to	O
rights	O
"	O
.	O
24	O
By	O
29	O
May	O
Dr	O
Boume	O
had	O
bled	O
the	O
boy	S-Species
"	O
which	O
succeeded	O
very	O
well	O
but	O
.	O
.	O
.	O
found	O
it	O
[	O
his	O
blood	O
]	O
as	O
bad	O
as	O
ever	O
"	O
.	O

The	O
waters	O
were	O
not	O
working	O
"	O
but	O
there	O
is	O
a	O
great	O
deal	O
for	O
them	O
to	O
do	O
which	O
grant	O
God	O
they	O
may	O
effect	O
"	O
.	O

The	O
weather	O
had	O
turned	O
warm	O
so	O
Lady	O
Malton	O
had	O
"	O
shorn	O
him	O
.	O
.	O
.	O
which	O
has	O
display	O
'	O
d	O
a	O
most	O
scabby	O
head	O
and	O
indeed	O
several	O
other	O
untoward	O
Blotches	O
he	O
has	O
out	O
upon	O
other	O
parts	O
of	O
his	O
Body	O
"	O
,	O
which	O
made	O
her	O
uneasy	O
.	O
25	O
The	O
blotches	O
on	O
his	O
head	O
were	O
not	O
numerous	O
"	O
yet	O
they	O
made	O
up	O
in	O
quality	O
for	O
so	O
virulent	O
a	O
Corrosive	O
Humour	O
is	O
not	O
easily	O
conceived	O
without	O
seeing	O
it	O
"	O
.	O

The	O
pustules	O
on	O
his	O
body	O
were	O
of	O
the	O
same	O
sort	O

16	O
WWM	O
,	O
M7	O
-	O
17	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
4	O
November	O
1741	O
.	O

7	O
WWM	O
,	O
M7	O
-	O
18	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
4	O
November	O
1741	O
.	O

18	O
WWM	O
,	O
M7	O
-	O
16	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
7	O
November	O
1741	O
.	O

'	O
9WWM	O
,	O
M7	O
-	O
15	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
9	O
November	O
1741	O
.	O

20	O
WWM	O
,	O
M7	O
-	O
22	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
25	O
November	O
1741	O
.	O

21	O
WWM	O
,	O
M7	O
-	O
1	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
25	O
January	O
1742	O
.	O

22	O
WWM	O
,	O
M7	O
-	O
4	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
8	O
February	O
1742	O
and	O
WWM	O
,	O
M7	O
-	O
9	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
22	O
February	O
1742	O
.	O

23	O
WWM	O
,	O
M7	O
-	O
29	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
12	O
May	O
1742	O
.	O

24	O
WWM	O
,	O
M7	O
-	O
35	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
26	O
May	O
1742	O
.	O

25	O
WWM	O
,	O
M7	O
-	O
36	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
29	O
May	O
1742	O
.	O

180	O

An	O
eighteenth	O
-	O
century	O
Prime	O
Minister	O
'	O
s	O
illness	O

and	O
his	O
mother	O
intended	O
to	O
put	O
plasters	O
on	O
them	O
to	O
prevent	O
them	O
from	O
spreading	O
.	O

Charles	O
was	O
also	O
feverish	O
;	O
his	O
glands	O
were	O
swollen	O
and	O
his	O
pulse	O
was	O
erratic	O
"	O
but	O
out	O
of	O
compassion	O
to	O
you	O
I	O
must	O
tell	O
you	O
that	O
he	O
is	O
with	O
me	O
as	O
Brisk	O
and	O
lively	O
as	O
you	O
ever	O
Saw	O
him	O
"	O
.	O

Lady	O
Malton	O
had	O
called	O
in	O
two	O
eminent	O
Bristol	O
men	S-Species
,	O
Dr	O
Logan	O
and	O
Mr	O
Pye	O
,	O
to	O
treat	O
the	O
boy	S-Species
;	O
Mr	O
Pye	O
prescribed	O
"	O
the	O
Precipitate	O
Per	O
se	O
"	O
as	O
the	O
cure	O
for	O
the	O
"	O
hectic	O
"	O
.	O

Pye	O
made	O
it	O
himself	O
and	O
said	O
that	O
it	O
was	O
the	O
only	O
remedy	O
that	O
would	O
work	O
.	O

Clearly	O
Charles	O
was	O
impatient	O
to	O
be	O
cured	O
because	O
he	O
told	O
his	O
mother	O
to	O
give	O
him	O
the	O
medicine	O
"	O
to	O
cure	O
me	O
which	O
I	O
am	O
sure	O
it	O
will	O
do	O
or	O
shoot	O
me	O
through	O
the	O
head	O
at	O
once	O
"	O
.	O

She	O
thought	O
that	O
this	O
attitude	O
was	O
"	O
odd	O
from	O
one	O
of	O
his	O
Age	O
and	O
[	O
it	O
]	O
does	O
not	O
a	O
little	O
disturb	O
"	O
.	O
26	O
The	O
blotches	O
began	O
to	O
burst	O
and	O
indent	O
but	O
the	O
doctor	O
thought	O
that	O
all	O
would	O
be	O
well	O
in	O
the	O
end	O
.	O
27	O
Meanwhile	O
,	O
Charles	O
was	O
still	O
losing	O
weight	O
even	O
though	O
"	O
he	O
had	O
none	O
to	O
spare	O
before	O
"	O
and	O
he	O
was	O
inclined	O
to	O
be	O
lazy	O
which	O
was	O
not	O
his	O
natural	O
turn	O
.	O

His	O
father	O
recommended	O
some	O
unknown	O
cure	O
which	O
he	O
called	O
Gascoin	O
'	O
s	O
Powder	O
-	O
a	O
dose	O
of	O
five	O
grains	O
made	O
up	O
with	O
syrup	O
into	O
a	O
pill	O
-	O
every	O
night	O
.	O

To	O
make	O
matters	O
worse	O
,	O
the	O
doctors	O
disagreed	O
about	O
the	O
treatment	O
.	O

"	O
Dr	O
Pye	O
is	O
Vehemently	O
for	O
the	O
P	O
.	O

Per	O
se	O
,	O
Dr	O
Logan	O
saies	O
that	O
it	O
is	O
a	O
Medicine	O
that	O
may	O
prove	O
too	O
rough	O
in	O
its	O
operation	O
for	O
his	O
Constitution	O
&	O
therefore	O
begs	O
a	O
tryal	O
of	O
Beazor	O
mineral	O
[	O
gall	O
stones	O
from	O
a	O
goat	S-Species
]	O
and	O
Viper	O
Broth	O
"	O
.	O

The	O
Bristol	O
water	O
had	O
not	O
yet	O
acted	O
"	O
because	O
his	O
case	O
is	O
of	O
too	O
obstinate	O
a	O
Nature	O
"	O
and	O
Lady	O
Malton	O
herself	O
was	O
satisfied	O
that	O
since	O
nothing	O
else	O
had	O
worked	O
to	O
cure	O
the	O
boy	S-Species
,	O
the	O
time	O
had	O
come	O
to	O
try	O
mercurials	O
,	O
even	O
though	O
she	O
knew	O
that	O
they	O
were	O
"	O
powerful	O
and	O
perhaps	O
in	O
some	O
cases	O
hazardous	O
medicines	O
"	O
.	O
28	O
She	O
wanted	O
to	O
see	O
some	O
remedy	O
succeed	O
but	O
was	O
"	O
afraid	O
of	O
violent	O
ones	O
and	O
at	O
the	O
same	O
time	O
vastly	O
distrustfull	O
[	O
sic	O
]	O
of	O
mild	O
ones	O
"	O
.	O

It	O
would	O
appear	O
that	O
the	O
"	O
precipitate	O
Per	O
se	O
"	O
,	O
probably	O
mercury	O
-	O
based	O
,	O
could	O
be	O
a	O
kill	O
-	O
or	O
-	O
cure	O
remedy	O
.	O

Her	O
"	O
terrors	O
"	O
did	O
not	O
arise	O
from	O
any	O
immediate	O
danger	O
to	O
her	O
son	O
,	O
and	O
her	O
"	O
perfect	O
Knowledge	O
"	O
of	O
his	O
disorder	O
convinced	O
her	O
that	O
whatever	O
remedies	O
he	O
took	O
,	O
the	O
cure	O
was	O
in	O
the	O
hands	O
of	O
God	O
.	O
29	O

To	O
add	O
to	O
Charles	O
'	O
disorders	O
,	O
on	O
12	O
June	O
he	O
developed	O
a	O
"	O
very	O
inflamed	O
bad	O
Eye	O
.	O
.	O
.	O
the	O
same	O
Eye	O
that	O
.	O
.	O
.	O

he	O
did	O
not	O
see	O
so	O
well	O
of	O
[	O
as	O
]	O
the	O
other	O
.	O
.	O
.	O

He	O
sais	O
[	O
sic	O
]	O
that	O
from	O
that	O
eye	O
Alone	O
he	O
can	O
Scarcely	O
distinguish	O
anything	O
"	O
.	O

The	O
doctors	O
suggested	O
bathing	O
the	O
eye	O
:	O
Lady	O
Malton	O
knew	O
that	O
the	O
"	O
frightful	O
symptoms	O
"	O
which	O
were	O
"	O
shocking	O
to	O
behold	O
"	O
were	O
a	O
result	O
of	O
"	O
the	O
Same	O
as	O
produces	O
all	O
the	O
rest	O
of	O
his	O
complaints	O
in	O
whichever	O
Shape	O
they	O
appear	O
"	O
.	O

30	O
The	O
eye	O
was	O
very	O
bloodshot	O
and	O
inflamed	O
;	O
the	O
eyelid	O
was	O
swollen	O
so	O
he	O
could	O
hardly	O
open	O
it	O
.	O

The	O
other	O
eye	O
was	O
dull	O
and	O
"	O
he	O
had	O
very	O
little	O
sight	O
of	O
it	O
"	O
.	O
31	O
By	O
14	O
June	O
the	O
eye	O
problem	O
had	O
eased	O
somewhat	O
but	O
Lady	O
Malton	O
could	O
find	O
no	O
cause	O
to	O
attribute	O
the	O
improvement	O
to	O
any	O
of	O
the	O
"	O
cures	O
"	O
.	O

Charles	O
was	O
still	O
being	O
subjected	O
to	O
Bristol	O
water	O
,	O
Beazor	O
mineral	O
,	O
Viper	O
broth	O
,	O
cinnabar	O
and	O
the	O
precipitate	O
per	O
se	O
.	O
32	O
She	O
decided	O
to	O
take	O
the	O
boy	S-Species
home	O
to	O
Wentworth	O
because	O
he	O
was	O

26	O
WWM	O
,	O
M7	O
-	O
38	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
1	O
June	O
1742	O
.	O

27	O
WWM	O
,	O
M7	O
-	O
39	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
2	O
June	O
1742	O
.	O

28	O
WWM	O
,	O
M7	O
-	O
41	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
5	O
June	O
1742	O
.	O

29	O
WWM	O
,	O
M7	O
-	O
43	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
7	O
June	O
1742	O
.	O

30	O
WWM	O
,	O
M7	O
-	O
45	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
12	O
June	O
1742	O
.	O

31	O
WWM	O
,	O
M7	O
-	O
56	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
undated	O
:	O
12	O
June	O
?	O

1742	O
.	O

32	O
WWM	O
,	O
M7	O
-	O
46	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
14	O
June	O
?	O

1742	O
.	O

181	O

Marjorie	O
Bloy	O

more	O
likely	O
to	O
recover	O
there	O
than	O
anywhere	O
else	O
.	O
33	O
He	O
still	O
ate	O
and	O
slept	O
well	O
and	O
was	O
"	O
pretty	O
cheerful	O
but	O
his	O
looks	O
are	O
bitter	O
bad	O
still	O
.	O

The	O
flesh	O
he	O
lost	O
in	O
the	O
Accidental	O
Feavour	O
he	O
has	O
not	O
Recover	O
'	O
d	O
and	O
his	O
complexion	O
is	O
of	O
the	O
most	O
sickly	O
sort	O
his	O
hands	O
of	O
the	O
same	O
Hue	O
his	O
legs	O
are	O
tollerable	O
[	O
sic	O
]	O
well	O
"	O
.	O
34	O

They	O
returned	O
to	O
Wentworth	O
in	O
short	O
stages	O
and	O
by	O
6	O
September	O
Higham	O
was	O
"	O
perfectly	O
recovered	O
.	O

.	O
.	O
after	O
the	O
long	O
and	O
successful	O
Care	O
that	O
Lady	O
Malton	O
has	O
taken	O
"	O
of	O
him	O
.	O
35	O
In	O
May	O
1743	O
he	O
was	O
inoculated	O
against	O
smallpox	S-Species
and	O
made	O
a	O
perfect	O
recovery	O
after	O
which	O
he	O
caught	O
cold	O
"	O
by	O
stripping	O
when	O
He	O
was	O
hot	O
"	O
.	O
36	O
Lord	O
Higham	O
does	O
not	O
seem	O
to	O
have	O
been	O
seriously	O
ill	O
after	O
that	O
until	O
,	O
at	O
the	O
age	O
of	O
19	O
,	O
he	O
undertook	O
his	O
Grand	O
Tour	O
in	O
1749	O
.	O

In	O
July	O
1750	O
,	O
by	O
then	O
Lord	O
Malton	O
,	O
he	O
had	O
cause	O
to	O
consult	O
Nicolo	O
Scanagati	O
in	O
Padua	O
for	O
the	O
treatment	O
of	O
gonorrhoea	O
.	O

Scanagati	O
produced	O
a	O
lengthy	O
medical	O
report	O
of	O
Malton	O
'	O
s	O
treatment	O
,	O
presumably	O
for	O
his	O
English	O
doctor	O
'	O
s	O
enlightenment	O
.	O
37	O
The	O
initial	O
treatment	O
was	O
an	O
"	O
electuary	O
,	O
consisting	O
of	O
three	O
ounces	O
of	O
emollient	O
,	O
three	O
drams	O
of	O
powdered	O
jalap	S-Species
,	O
a	O
half	O
[	O
dram	O
]	O
of	O
purified	O
nitre	O
,	O
bound	O
together	O
with	O
lemon	S-Species
juice	O
taken	O
twice	O
a	O
day	O
"	O
.	O

The	O
result	O
was	O
satisfactory	O
:	O
"	O
The	O
dark	O
greenish	O
poison	O
was	O
oozing	O
slowly	O
from	O
his	O
penis	O
,	O
which	O
was	O
all	O
contracted	O
and	O
the	O
sharp	O
and	O
constant	O
pain	O
extended	O
from	O
the	O
perineum	O
up	O
to	O
the	O
urinary	O
bladder	O
,	O
producing	O
small	O
swellings	O
now	O
in	O
this	O
place	O
,	O
now	O
in	O
that	O
.	O
"	O
There	O
was	O
a	O
fierce	O
burning	O
sensation	O
in	O
the	O
glands	O
,	O
which	O
prevented	O
him	O
from	O
sleeping	O
.	O

Because	O
of	O
this	O
,	O
it	O
seemed	O
reasonable	O
to	O
bathe	O
that	O
part	O
in	O
tepid	O
water	O
and	O
milk	O
,	O
and	O
to	O
apply	O
poultices	O
to	O
the	O
areas	O
affected	O
by	O
swelling	O
and	O
contractions	O
,	O
together	O
with	O
cold	O
drinks	O
and	O
a	O
few	O
grains	O
of	O
laudanum	O
at	O
night	O
.	O

Malton	O
was	O
blooded	O
regularly	O
besides	O
being	O
given	O
purgatives	O
;	O
the	O
treatment	O
then	O
moved	O
on	O
to	O
the	O
administration	O
of	O
mercury	O
,	O
both	O
internal	O
and	O
on	O
the	O
gums	O
,	O
since	O
it	O
was	O
widely	O
believed	O
at	O
the	O
time	O
that	O
gonorrhoea	O
and	O
syphilis	O
were	O
steps	O
of	O
the	O
same	O
disease	O
,	O
"	O
the	O
Venereal	O
"	O
.	O

Scanagati	O
at	O
this	O
point	O
ruled	O
out	O
the	O
suggestion	O
of	O
syphilitic	O
chancre	O
because	O
Malton	O
'	O
s	O
urine	O
was	O
fine	O
and	O
light	O
with	O
a	O
pungent	O
odour	O
.	O

Scanagati	O
did	O
ask	O
if	O
Malton	O
had	O
previously	O
ever	O
had	O
a	O
similar	O
peculiarity	O
of	O
his	O
urine	O
.	O

Malton	O
replied	O
that	O
when	O
he	O
was	O
very	O
young	O
and	O
still	O
inexperienced	O
sexually	O
,	O
for	O
some	O
time	O
following	O
a	O
fever	O
he	O
had	O
had	O
the	O
same	O
unusual	O
urine	O
,	O
and	O
indeed	O
that	O
on	O
one	O
occasion	O
this	O
symptom	O
coincided	O
with	O
certain	O
tumours	O
on	O
the	O
testicles	O
.	O

It	O
was	O
only	O
by	O
chance	O
that	O
he	O
had	O
not	O
had	O
recourse	O
to	O
surgery	O
,	O
the	O
reason	O
being	O
that	O
he	O
was	O
also	O
afflicted	O
with	O
a	O
throat	O
infection	O
-	O
to	O
which	O
he	O
was	O
prone	O
-	O
and	O
therefore	O
had	O
his	O
vein	O
opened	O
four	O
times	O
.	O

Thereupon	O
the	O
inflammation	O
subsided	O
,	O
and	O
equally	O
the	O
tumours	O
and	O
sediment	O
disappeared	O
.	O

He	O
told	O
me	O
that	O
as	O
a	O
youth	O
he	O
had	O
sometimes	O
experienced	O
some	O
difficulty	O
and	O
a	O
burning	O
sensation	O
when	O
urinating	O
,	O
which	O
subsided	O
when	O
his	O
blood	O
was	O
let	O
and	O
with	O
the	O
application	O
of	O
poultices	O
.	O

I	O
observed	O
that	O
from	O
time	O
to	O
time	O
his	O
face	O
and	O
body	O
were	O
covered	O
with	O
purplish	O
spots	O
,	O
which	O
,	O
having	O
produced	O
a	O
little	O
fluid	O
,	O
would	O
disappearas	O
indeed	O
happened	O
in	O
the	O
course	O
of	O
the	O
cure	O
,	O
at	O
the	O
end	O
of	O
which	O
his	O
face	O
was	O
entirely	O

33	O
WWM	O
,	O
M7	O
-	O
47	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
15	O
June	O
1742	O
.	O

34	O
WWM	O
,	O
M7	O
-	O
48	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
16	O
June	O
1742	O
.	O

35	O
WWM	O
,	O
M2	O
-	O
104	O
/	O
5	O
.	O

Lady	O
Finch	O
to	O
Lady	O
Malton	O
,	O
6	O
September	O
1742	O
.	O

36	O
WWM	O
,	O
M2	O
-	O
135	O
.	O

Lady	O
Finch	O
to	O
Malton	O
,	O
18	O
June	O
1742	O
.	O

37	O
WWM	O
,	O
R170	O
-	O
20	O
.	O

Nicol6	O
Scanagati	O
'	O
s	O
report	O
.	O

182	O

An	O
eighteenth	O
-	O
century	O
Prime	O
Minister	O
'	O
s	O
illness	O

free	O
from	O
these	O
spots	O
.	O

From	O
this	O
observation	O
,	O
it	O
seemed	O
to	O
me	O
simple	O
to	O
deduce	O
both	O
the	O
original	O
cause	O
and	O
the	O
more	O
immediate	O
cause	O
of	O
the	O
said	O
sediment	O
:	O
namely	O
a	O
natural	O
complexion	O
of	O
humours	O
which	O
are	O
exacerbated	O
by	O
muriatic	O
[	O
i	O
.	O
e	O
.	O
,	O
acidic	O
]	O
sourness	O
,	O
together	O
with	O
the	O
marked	O
inflammation	O
of	O
the	O
blood	O
and	O
the	O
motion	O
of	O
the	O
contracted	O
poison	O
.	O

Scanagati	O
then	O
recommended	O
the	O
continuation	O
of	O
the	O
electuary	O
made	O
of	O
emollient	O
,	O
guaiacum	O
resin	O
,	O
balsam	O
,	O
rhubarb	S-Species
,	O
and	O
nitre	O
.	O

What	O
does	O
all	O
this	O
add	O
up	O
to	O
in	O
terms	O
of	O
diagnosis	O
?	O

The	O
early	O
illness	O
is	O
a	O
mystery	O
.	O

Did	O
he	O
have	O
an	O
inguinal	O
hernia	O
;	O
or	O
perhaps	O
mumps	O
or	O
epididymitis	O
?	O

His	O
was	O
a	O
childless	O
marriage	O
.	O

He	O
seems	O
to	O
have	O
been	O
too	O
fit	O
for	O
the	O
illness	O
to	O
have	O
been	O
rheumatic	O
fever	O
.	O

Cystitis	O
was	O
not	O
uncommon	O
and	O
this	O
could	O
certainly	O
lead	O
to	O
"	O
strangury	O
"	O
.	O

Perhaps	O
Rockingham	O
suffered	O
from	O
a	O
congenital	O
defect	O
of	O
his	O
urinogenitary	O
system	O
which	O
would	O
result	O
in	O
recurrent	O
attacks	O
of	O
cystitis	O
and	O
might	O
cause	O
long	O
-	O
term	O
damage	O
to	O
the	O
urinary	O
tract	O
and	O
eventual	O
destruction	O
of	O
the	O
kidneys	O
,	O
precipitating	O
sudden	O
and	O
unexpected	O
death	O
.	O

Another	O
possibility	O
might	O
be	O
diabetes	O
.	O

Rockingham	O
had	O
a	O
urinary	O
infection	O
and	O
certainly	O
suffered	O
from	O
recurrent	O
skin	O
infections	O
,	O
although	O
it	O
appears	O
from	O
Scanagati	O
'	O
s	O
report	O
that	O
these	O
cleared	O
up	O
when	O
mercury	O
was	O
administered	O
.	O

Certainly	O
the	O
marquis	O
complained	O
often	O
about	O
pains	O
in	O
his	O
side	O
and	O
stomach	O
and	O
made	O
no	O
secret	O
of	O
his	O
"	O
old	O
complaint	O
"	O
.	O

He	O
was	O
noticeably	O
less	O
physically	O
active	O
as	O
he	O
moved	O
into	O
his	O
thirties	O
and	O
only	O
occasionally	O
exerted	O
himself	O
by	O
riding	O
any	O
distance	O
,	O
even	O
though	O
he	O
had	O
enjoyed	O
hunting	O
when	O
he	O
was	O
younger	O
.	O

He	O
found	O
the	O
pains	O
caused	O
by	O
his	O
"	O
old	O
complaint	O
"	O
made	O
him	O
feel	O
so	O
ill	O
that	O
he	O
was	O
unable	O
to	O
concentrate	O
on	O
"	O
any	O
Manner	O
of	O
Business	O
"	O
and	O
on	O
occasion	O
it	O
seemed	O
likely	O
to	O
prevent	O
him	O
from	O
attending	O
Parliament	O
.	O
38	O
He	O
may	O
well	O
have	O
suffered	O
from	O
a	O
problem	O
with	O
gallstones	O
from	O
an	O
early	O
age	O
.	O
39	O
He	O
appears	O
to	O
have	O
suffered	O
from	O
a	O
nervous	O
disorder	O
which	O
manifested	O
itself	O
in	O
severe	O
palpitations	O
,	O
trembling	O
,	O
and	O
other	O
types	O
of	O
physical	O
discomforts	O
such	O
as	O
boils	O
and	O
headaches	O
with	O
which	O
he	O
was	O
frequently	O
afflicted	O
.	O
40	O
He	O
probably	O
had	O
constipation	O
too	O
,	O
since	O
he	O
was	O
always	O
dosing	O
himself	O
with	O
purgatives	O
.	O

In	O
fact	O
in	O
April	O
1772	O
the	O
Duke	O
of	O
Richmond	O
decided	O
that	O
Rockingham	O
'	O
s	O
real	O
problem	O
was	O
a	O
"	O
surfeit	O
of	O
physick	O
"	O
41	O
although	O
Edmund	O
Burke	O
noted	O
in	O
June	O
1772	O
that	O
the	O
marquis	O
had	O
had	O
a	O
long	O
and	O
severe	O
illness	O
.	O
42	O
Whatever	O
his	O
many	O
and	O
varied	O
ailments	O
,	O
Rockingham	O
survived	O
until	O
he	O
was	O
52	O
in	O
spite	O
of	O
the	O
attentions	O
of	O
both	O
doctors	O
and	O
quacks	O
and	O
that	O
,	O
for	O
the	O
mid	O
-	O
eighteenth	O
century	O
,	O
was	O
a	O
good	O
age	O
.	O

The	O
mystery	O
still	O
remains	O
,	O
however	O
.	O

Contemporary	O
opinion	O
had	O
it	O
that	O
he	O
died	O
of	O
pneumonia	O
but	O
it	O
must	O
have	O
struck	O

38	O
WWM	O
,	O
R153	O
-	O
1	O
.	O

Rockingham	O
to	O
Burke	O
,	O
31	O
October	O
1767	O
;	O
WWM	O
,	O
RI	O
-	O
1238	O
.	O

Rockingham	O
to	O
Dowdeswell	O
,	O
20	O
October	O
1769	O
;	O
WWM	O
,	O
RI	O
-	O
1928	O
.	O

Rockingham	O
to	O
Savile	O
,	O
September	O
1780	O
.	O

39	O
Ross	O
J	O
.	O

S	O
.	O

Hoffman	O
,	O
The	O
Marquis	O
.	O

A	O
study	O
of	O
Lord	O
Rockingham	O
,	O
1730	O
-	O
1782	O
,	O
New	O
York	O
,	O
Fordham	O
University	O
Press	O
,	O
1973	O
,	O
p	O
.	O

35	O
.	O

This	O
is	O
the	O
only	O
recent	O
biography	O
of	O
the	O
second	O
Marquis	O
of	O
Rockingham	O
,	O
and	O
does	O
not	O
deal	O
with	O
his	O
illnesses	O
.	O

Although	O
he	O
does	O
not	O
give	O
the	O
source	O
of	O
his	O
information	O
,	O
Hoffman	O
asserts	O
that	O
Rockingham	O
was	O
in	O
Bath	O
between	O
March	O
and	O
August	O
1761	O
suffering	O
from	O
gallstones	O
.	O

The	O
marquis	O
would	O
then	O
have	O
been	O
31	O
years	O
old	O
.	O

40	O
Historical	O
Manuscripts	O
Commission	O
,	O
Lindley	O
Wood	O
,	O
p	O
.	O

184	O
.	O

41	O
WWM	O
,	O
RI	O
-	O
1403	O
.	O

Richmond	O
to	O
Rockingham	O
,	O
26	O
April	O
1772	O
.	O

42	O
Burke	O
to	O
James	O
de	O
Lancey	O
,	O
30	O
June	O
1772	O
.	O

The	O
correspondence	O
of	O
Edmund	O
Burke	O
,	O
vol	O
.	O

2	O
,	O
ed	O
.	O

T	O
.	O

W	O
.	O

Copeland	O
and	O
others	O
,	O
Cambridge	O
University	O
Press	O
,	O
1958	O
-	O
1978	O
,	O
p	O
.	O

311	O
.	O

183	O

Marjorie	O
Bloy	O

suddenly	O
:	O
it	O
was	O
only	O
two	O
weeks	O
from	O
him	O
"	O
recovering	O
"	O
to	O
dying	O
.	O

Another	O
almost	O
contemporary	O
account	O
of	O
the	O
marquis	O
'	O
s	O
death	O
came	O
from	O
the	O
Earl	O
of	O
Albemarle	O
.	O

He	O
noted	O
that	O
Rockingham	O
had	O
"	O
for	O
some	O
time	O
past	O
been	O
afflicted	O
with	O
water	O
on	O
the	O
chest	O
:	O
and	O
to	O
this	O
well	O
-	O
known	O
malady	O
was	O
superadded	O
the	O
then	O
novel	O
disease	O
of	O
influenza	O
"	O
.	O
43	O
This	O
conceivably	O
could	O
be	O
an	O
uninformed	O
account	O
,	O
handed	O
down	O
orally	O
by	O
surviving	O
members	O
of	O
the	O
marquis	O
'	O
s	O
family	O
,	O
of	O
emphysema	O
.	O

More	O
fascinating	O
than	O
the	O
diagnosis	O
of	O
the	O
cause	O
of	O
death	O
,	O
however	O
,	O
is	O
-	O
what	O
was	O
wrong	O
with	O
him	O
during	O
his	O
lifetime	O
?	O

Or	O
is	O
it	O
yet	O
another	O
example	O
of	O
the	O
"	O
English	O
disease	O
"	O
:	O
hypochondria	O
?	O

43Albemarle	O
,	O
George	O
Thomas	O
,	O
Earl	O
of	O
,	O
Memoirs	O
of	O
the	O
Marquis	O
of	O
Rockingham	O
and	O
his	O
contemporaries	O
,	O
London	O
,	O
Richard	O
Bentley	O
,	O
2	O
vols	O
.	O
,	O
1852	O
,	O
vol	O
.	O

2	O
,	O
p	O
.	O

483	O
.	O

This	O
is	O
the	O
only	O
contemporary	O
work	O
concerning	O
Rockingham	O
,	O
but	O
does	O
not	O
mention	O
his	O
early	O
life	O
and	O
illnesses	O
.	O

184	O

Tissue	O
-	O
dependent	O
isoforms	O
of	O
mammalian	O
Fox	O
-	O
1	O
homologs	O
are	O
associated	O
with	O
tissue	O
-	O
specific	O
splicing	O
activities	O

Abstract	O

An	O
intronic	O
hexanucleotide	O
UGCAUG	O
has	O
been	O
shown	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
of	O
pre	O
-	O
mRNAs	O
in	O
a	O
wide	O
range	O
of	O
tissues	O
.	O

Vertebrate	O
Fox	O
-	O
1	O
has	O
been	O
shown	O
to	O
bind	O
to	O
this	O
element	O
,	O
in	O
a	O
highly	O
sequence	O
-	O
specific	O
manner	O
,	O
through	O
its	O
RNA	O
recognition	O
motif	O
(	O
RRM	O
)	O
.	O

In	O
mammals	O
,	O
there	O
are	O
at	O
least	O
two	O
Fox	O
-	O
1	O
-	O
related	O
genes	O
,	O
ataxin	O
-	O
2	O
binding	O
protein	O
1	O
(	O
A2BP1	O
)	O
/	O
Fox	O
-	O
1	O
and	O
Fxh	O
/	O
Rbm9	O
,	O
which	O
encode	O
an	O
identical	O
RRM	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
both	O
mouse	S-Species
Fxh	O
and	O
A2BP1	O
transcripts	O
undergo	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
,	O
generating	O
protein	O
isoforms	O
specific	O
to	O
brain	O
and	O
muscle	O
.	O

These	O
tissue	O
-	O
specific	O
isoforms	O
are	O
characterized	O
for	O
their	O
abilities	O
to	O
regulate	O
neural	O
cell	O
-	O
specific	O
alternative	O
splicing	O
of	O
a	O
cassette	O
exon	O
,	O
N30	O
,	O
in	O
the	O
non	O
-	O
muscle	O
myosin	O
heavy	O
chain	O
II	O
-	O
B	O
pre	O
-	O
mRNA	O
,	O
previously	O
shown	O
to	O
be	O
regulated	O
through	O
an	O
intronic	O
distal	O
downstream	O
enhancer	O
(	O
IDDE	O
)	O
.	O

All	O
Fxh	O
and	O
A2BP1	O
isoforms	O
with	O
the	O
RRM	O
are	O
capable	O
of	O
binding	O
to	O
the	O
IDDE	O
in	O
vitro	O
through	O
the	O
UGCAUG	O
elements	O
.	O

Each	O
isoform	O
,	O
however	O
,	O
shows	O
quantitative	O
differences	O
in	O
splicing	O
activity	O
and	O
nuclear	O
distribution	O
in	O
transfected	O
cells	O
.	O

All	O
Fxh	O
isoforms	O
and	O
a	O
brain	O
isoform	O
of	O
A2BP1	O
show	O
a	O
predominant	O
nuclear	O
localization	O
.	O

Brain	O
isoforms	O
of	O
both	O
Fxh	O
and	O
A2BP1	O
promote	O
N30	O
splicing	O
much	O
more	O
efficiently	O
than	O
do	O
the	O
muscle	O
-	O
specific	O
isoforms	O
.	O

Skeletal	O
muscles	O
express	O
additional	O
isoforms	O
that	O
lack	O
a	O
part	O
of	O
the	O
RRM	O
.	O

These	O
isoforms	O
are	O
incapable	O
of	O
activating	O
neural	O
cell	O
-	O
specific	O
splicing	O
and	O
,	O
moreover	O
,	O
can	O
inhibit	O
UGCAUG	O
-	O
dependent	O
N30	O
splicing	O
.	O

These	O
findings	O
suggest	O
that	O
tissue	O
-	O
specific	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
play	O
an	O
important	O
role	O
in	O
determining	O
tissue	O
specificity	O
of	O
UGCAUG	O
-	O
mediated	O
alternative	O
splicing	O
.	O

INTRODUCTION	O

Alternative	O
splicing	O
of	O
pre	O
-	O
mRNA	O
is	O
one	O
of	O
the	O
fundamental	O
mechanisms	O
for	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
higher	O
eukaryotes	O
(	O
1	O
,	O
2	O
)	O
.	O

Developmentally	O
regulated	O
,	O
cell	O
type	O
-	O
or	O
tissue	O
-	O
specific	O
,	O
and	O
signal	O
-	O
induced	O
alternative	O
splicing	O
of	O
pre	O
-	O
mRNAs	O
takes	O
place	O
in	O
multicellular	O
organisms	O
throughout	O
their	O
lifetimes	O
.	O

Misregulation	O
or	O
abnormalities	O
in	O
pre	O
-	O
mRNA	O
splicing	O
,	O
in	O
some	O
instances	O
,	O
leads	O
to	O
cellular	O
dysfunctions	O
found	O
in	O
human	S-Species
and	O
animal	O
diseases	O
(	O
3	O
-	O
5	O
)	O
.	O

Using	O
various	O
model	O
systems	O
of	O
regulated	O
alternative	O
splicing	O
,	O
a	O
number	O
of	O
pre	O
-	O
mRNA	O
features	O
that	O
influence	O
alternative	O
splice	O
site	O
selection	O
have	O
been	O
defined	O
(	O
1	O
,	O
2	O
)	O
.	O

These	O
include	O
enhancer	O
and	O
repressor	O
RNA	O
sequences	O
located	O
in	O
exons	O
and	O
introns	O
.	O

Identification	O
of	O
RNA	O
-	O
binding	O
proteins	O
targeting	O
these	O
cis	O
-	O
regulatory	O
elements	O
is	O
currently	O
in	O
progress	O
.	O

In	O
vertebrates	O
,	O
participation	O
of	O
the	O
SR	O
family	O
proteins	O
and	O
hnRNP	O
proteins	O
,	O
such	O
as	O
PTB	O
and	O
hnRNPA1	O
,	O
in	O
alternative	O
splicing	O
regulation	O
via	O
binding	O
to	O
the	O
cis	O
-	O
regulatory	O
elements	O
have	O
been	O
shown	O
in	O
many	O
tissue	O
-	O
specific	O
splicing	O
models	O
(	O
6	O
,	O
7	O
)	O
.	O

Although	O
these	O
RNA	O
-	O
binding	O
proteins	O
are	O
ubiquitously	O
expressed	O
,	O
their	O
different	O
abundance	O
in	O
different	O
cells	O
,	O
differences	O
in	O
their	O
post	O
-	O
translational	O
modifications	O
in	O
different	O
cellular	O
contexts	O
and	O
their	O
different	O
abilities	O
to	O
assemble	O
multiprotein	O
complexes	O
in	O
different	O
pre	O
-	O
mRNA	O
contexts	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
determination	O
of	O
cell	O
type	O
-	O
specific	O
patterns	O
of	O
alternative	O
splicing	O
.	O

For	O
the	O
last	O
few	O
years	O
,	O
tissue	O
-	O
specific	O
and	O
tissue	O
-	O
enriched	O
RNA	O
-	O
binding	O
proteins	O
have	O
begun	O
to	O
be	O
identified	O
as	O
splicing	O
regulators	O
.	O

These	O
include	O
brain	O
-	O
specific	O
(	O
or	O
enriched	O
)	O
Nova	O
-	O
1	O
,	O
nPTB	O
(	O
brPTB	O
)	O
and	O
some	O
of	O
the	O
CELF	O
family	O
proteins	O
(	O
8	O
-	O
12	O
)	O
.	O

Discovery	O
of	O
these	O
proteins	O
has	O
had	O
a	O
great	O
impact	O
on	O
studies	O
aimed	O
at	O
understanding	O
the	O
molecular	O
mechanisms	O
of	O
alternative	O
splicing	O
regulation	O
.	O

One	O
of	O
the	O
intronic	O
cis	O
-	O
elements	O
,	O
which	O
are	O
involved	O
in	O
tissue	O
-	O
specific	O
or	O
differentiation	O
stage	O
-	O
dependent	O
regulation	O
of	O
alternative	O
splicing	O
,	O
is	O
the	O
hexanucleotide	O
UGCAUG	O
.	O

The	O
importance	O
of	O
this	O
element	O
was	O
originally	O
recognized	O
in	O
fibronectin	O
pre	O
-	O
mRNA	O
by	O
Huh	O
and	O
Hynes	O
(	O
13	O
)	O
.	O

Since	O
then	O
,	O
alternative	O
splicing	O
specific	O
to	O
a	O
variety	O
of	O
tissues	O
or	O
cell	O
types	O
,	O
including	O
neural	O
cells	O
,	O
muscles	O
,	O
epithelial	O
cells	O
and	O
erythrocytes	O
,	O
has	O
been	O
shown	O
to	O
be	O
modulated	O
via	O
this	O
element	O
(	O
14	O
-	O
21	O
)	O
.	O

Recently	O
,	O
Jin	O
et	O
al	O
.	O

(	O
21	O
)	O
discovered	O
that	O
a	O
zebrafish	S-Species
homolog	O
of	O
Caenorhabditis	B-Species
elegans	E-Species
Fox	O
-	O
1	O
(	O
22	O
)	O
could	O
bind	O
specifically	O
to	O
the	O
pentanucleotide	O
GCAUG	O
by	O
in	O
vitro	O
selection	O
from	O
randomized	O
RNA	O
sequences	O
.	O

This	O
pentanucleotide	O
is	O
almost	O
identical	O
to	O
the	O
hexanucleotide	O
UGCAUG	O
except	O
for	O
the	O
first	O
U	O
.	O

Moreover	O
,	O
the	O
zebrafish	S-Species
Fox	O
-	O
1	O
homolog	O
,	O
as	O
well	O
as	O
the	O
mouse	S-Species
Fox	O
-	O
1	O
homolog	O
,	O
are	O
capable	O
of	O
repressing	O
the	O
inclusion	O
of	O
an	O
alternative	O
cassette	O
exon	O
of	O
the	O
ATP	O
synthase	O
F1	O
gamma	O
pre	O
-	O
mRNA	O
via	O
binding	O
to	O
GCAUG	O
,	O
which	O
mimics	O
muscle	O
-	O
specific	O
exclusion	O
of	O
this	O
exon	O
.	O

This	O
mouse	S-Species
homolog	O
is	O
identical	O
to	O
the	O
ataxin	O
-	O
2	O
binding	O
protein	O
1	O
(	O
A2BP1	O
)	O
,	O
which	O
has	O
been	O
previously	O
cloned	O
in	O
humans	S-Species
and	O
mice	S-Species
as	O
the	O
cDNA	O
encoding	O
a	O
protein	O
,	O
which	O
interacts	O
with	O
ataxin	O
-	O
2	O
,	O
the	O
product	O
of	O
the	O
causative	O
gene	O
for	O
spinocerebellar	O
ataxia	O
type	O
2	O
(	O
23	O
,	O
24	O
)	O
.	O

In	O
addition	O
to	O
A2BP1	O
/	O
Fox	O
-	O
1	O
,	O
another	O
mouse	S-Species
homolog	O
of	O
C	B-Species
.	I-Species
elegans	E-Species
Fox	O
-	O
1	O
,	O
Fxh	O
,	O
has	O
been	O
independently	O
cloned	O
as	O
a	O
cDNA	O
,	O
which	O
is	O
induced	O
by	O
androgen	O
in	O
motor	O
neurons	O
(	O
25	O
)	O
.	O

Of	O
note	O
is	O
that	O
A2BP1	O
/	O
Fox	O
-	O
1	O
and	O
Fxh	O
share	O
an	O
identical	O
RNA	O
recognition	O
motif	O
(	O
RRM	O
)	O
at	O
the	O
amino	O
acid	O
level	O
.	O

Therefore	O
,	O
two	O
genes	O
in	O
the	O
mouse	S-Species
genome	O
encode	O
homologs	O
of	O
nematode	O
Fox	O
-	O
1	O
.	O

According	O
to	O
the	O
names	O
given	O
by	O
the	O
first	O
cDNA	O
cloning	O
,	O
we	O
used	O
the	O
nomenclature	O
of	O
A2BP1	O
and	O
Fxh	O
in	O
this	O
report	O
.	O

A2BP1	O
and	O
Fxh	O
have	O
been	O
named	O
A2BP1	O
and	O
Rbm9	O
,	O
respectively	O
,	O
in	O
the	O
human	S-Species
and	O
mouse	S-Species
genomes	O
.	O

We	O
have	O
been	O
studying	O
regulatory	O
mechanisms	O
of	O
neural	O
cell	O
-	O
specific	O
alternative	O
splicing	O
using	O
the	O
non	O
-	O
muscle	O
myosin	O
heavy	O
chain	O
II	O
-	O
B	O
(	O
NMHC	O
-	O
B	O
)	O
gene	O
as	O
a	O
model	O
system	O
(	O
14	O
,	O
26	O
)	O
.	O

NMHC	O
-	O
B	O
mRNA	O
is	O
expressed	O
ubiquitously	O
.	O

However	O
,	O
an	O
alternative	O
exon	O
,	O
N30	O
,	O
which	O
encodes	O
a	O
30	O
nt	O
coding	O
sequence	O
,	O
is	O
included	O
in	O
the	O
mRNAs	O
from	O
some	O
neural	O
cells	O
,	O
but	O
is	O
skipped	O
in	O
those	O
from	O
all	O
other	O
cells	O
in	O
mammals	O
and	O
birds	O
(	O
27	O
,	O
28	O
)	O
.	O

In	O
cultured	O
cells	O
,	O
a	O
switch	O
in	O
N30	O
splicing	O
from	O
exclusion	O
to	O
inclusion	O
can	O
be	O
seen	O
in	O
neural	O
retinoblastoma	O
Y79	O
cells	O
during	O
the	O
post	O
-	O
mitotic	O
and	O
differentiated	O
stages	O
triggered	O
by	O
butyrate	O
treatment	O
.	O

We	O
have	O
previously	O
defined	O
an	O
intronic	O
distal	O
downstream	O
enhancer	O
(	O
IDDE	O
)	O
,	O
which	O
confers	O
neural	O
cell	O
specificity	O
on	O
N30	O
inclusion	O
,	O
using	O
this	O
cell	O
line	O
(	O
14	O
)	O
.	O

The	O
IDDE	O
includes	O
two	O
copies	O
of	O
UGCAUG	O
.	O

Mutation	O
of	O
these	O
hexanucleotides	O
results	O
in	O
N30	O
skipping	O
in	O
post	O
-	O
mitotic	O
differentiated	O
Y79	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
A2BP1	O
and	O
Fxh	O
in	O
the	O
regulation	O
of	O
N30	O
splicing	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
isolated	O
cDNA	O
clones	O
for	O
A2BP1	O
and	O
Fxh	O
from	O
brain	O
and	O
muscles	O
.	O

cDNA	O
cloning	O
revealed	O
the	O
existence	O
of	O
tissue	O
-	O
specific	O
(	O
enriched	O
)	O
isoforms	O
of	O
both	O
A2BP1	O
and	O
Fxh	O
.	O

Of	O
importance	O
,	O
different	O
isoforms	O
of	O
A2BP1	O
and	O
Fxh	O
show	O
different	O
activities	O
with	O
respect	O
to	O
N30	O
splicing	O
as	O
well	O
as	O
different	O
subcellular	O
localizations	O
.	O

MATERIALS	O
AND	O
METHODS	O

Database	O
disposition	O

The	O
sequences	O
reported	O
in	O
this	O
paper	O
have	O
been	O
deposited	O
in	O
the	O
GenBank	O
database	O
with	O
accession	O
numbers	O
AY659951	O
(	O
F011	O
)	O
,	O
AY659952	O
(	O
F411	O
)	O
,	O
AY659953	O
(	O
F402	O
)	O
,	O
AY659954	O
(	O
A016	O
)	O
,	O
AY659955	O
(	O
A030	O
)	O
,	O
AY659956	O
(	O
A713	O
)	O
,	O
AY659957	O
(	O
A715	O
)	O
and	O
AY659958	O
(	O
A704	O
)	O
.	O

RNA	O
preparation	O
and	O
RT	O
-	O
PCR	O

Total	O
RNAs	O
were	O
isolated	O
from	O
mouse	S-Species
tissues	O
and	O
cultured	O
cells	O
using	O
an	O
RNA	O
isolation	O
kit	O
(	O
Stratagene	O
)	O
or	O
an	O
RNeasy	O
mini	O
kit	O
(	O
Qiagen	O
)	O
.	O

To	O
obtain	O
the	O
full	O
-	O
length	O
coding	O
regions	O
of	O
cDNAs	O
for	O
Fxh	O
and	O
A2BP1	O
,	O
RT	O
-	O
PCRs	O
were	O
performed	O
using	O
Superscript	O
II	O
RNase	O
H	O
-	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
and	O
Pfu	O
Turbo	O
DNA	O
polymerase	O
(	O
Stratagene	O
)	O
.	O

The	O
PCR	O
primers	O
used	O
to	O
obtain	O
all	O
Fxh	O
cDNAs	O
were	O
5	O
'	O
-	O
ctcaggcctccactagttATGGAGAAAAAGAAAATGGTAACTC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
ctcaggcctcctctagaaGTAGGGGGCAAATCGGCTGTA	O
-	O
3	O
'	O
.	O

The	O
upstream	O
primers	O
for	O
the	O
brain	O
(	O
A016	O
and	O
A030	O
)	O
and	O
muscle	O
(	O
A713	O
,	O
A715	O
and	O
A704	O
)	O
A2BP1	O
cDNAs	O
were	O
5	O
'	O
-	O
ctcaggcctccactagtgATGAATTGTGAAAGAGAGCAGCT	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
ctcaggcctccactagtcATGTTGGCGTCGCAAGGAGTCC	O
-	O
3	O
'	O
,	O
respectively	O
,	O
and	O
the	O
downstream	O
primer	O
for	O
all	O
A2BP1	O
cDNAs	O
was	O
5	O
'	O
-	O
ctcaggcctcctctagagATATGGAGCAAAACGGTTGTATCC	O
-	O
3	O
'	O
.	O

Lower	O
case	O
letters	O
represent	O
adapter	O
sequences	O
including	O
restriction	O
enzyme	O
sites	O
.	O

5	O
'	O
Rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
RACE	O
)	O
was	O
performed	O
using	O
Marathon	O
-	O
Ready	O
cDNA	O
(	O
BD	O
Biosciences	O
Clontech	O
)	O
.	O

For	O
the	O
analysis	O
of	O
minigene	O
and	O
NMHC	O
-	O
B	O
mRNAs	O
,	O
RT	O
-	O
PCRs	O
were	O
performed	O
as	O
described	O
previously	O
(	O
14	O
,	O
26	O
)	O
.	O

Sequences	O
of	O
primers	O
P1	O
-	O
P9	O
shown	O
in	O
Figures	O
1	O
,	O
4	O
and	O
6	O
are	O
as	O
follows	O
:	O
P1	O
,	O
5	O
'	O
-	O
AATTCACCCAGCAACCAGAAT	O
-	O
3	O
'	O
;	O
P2	O
,	O
5	O
'	O
-	O
TAGAGGGATGTAAGTGTTGATGCC	O
-	O
3	O
'	O
;	O
P3	O
,	O
5	O
'	O
-	O
CAGAGGGCGGACAGTGTATGGT	O
-	O
3	O
'	O
;	O
P4	O
,	O
5	O
'	O
-	O
GGCGGCAGGGGCGAGGGCAT	O
-	O
3	O
'	O
;	O
P5	O
,	O
5	O
'	O
-	O
CCGTGGTCGCACCGTGTACAAC	O
-	O
3	O
'	O
;	O
P6	O
,	O
5	O
'	O
-	O
CAGCGGCAGTGGCAGGGGTG	O
-	O
3	O
'	O
;	O
P7	O
,	O
5	O
'	O
-	O
AGGAAGAAAGGACCATAATATTCC	O
-	O
3	O
'	O
;	O
P8	O
,	O
5	O
'	O
-	O
CCTCCACCCAGCTCCAGTTGT	O
-	O
3	O
'	O
;	O
and	O
P9	O
,	O
5	O
'	O
-	O
CCTGTAGTTATTAAATCCTTCAAG	O
-	O
3	O
'	O
.	O

Preparation	O
of	O
expression	O
constructs	O
and	O
minigenes	O

The	O
cDNAs	O
of	O
Fxh	O
and	O
A2BP1	O
were	O
introduced	O
into	O
a	O
plasmid	O
pCS3	O
+	O
MT	O
,	O
which	O
contains	O
a	O
myc	O
-	O
epitope	O
,	O
and	O
its	O
modified	O
version	O
pCS3	O
+	O
MT	O
+	O
NLS	O
,	O
which	O
in	O
addition	O
contains	O
the	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
of	O
the	O
SV40	S-Species
large	O
T	O
antigen	O
(	O
26	O
)	O
.	O

Minigenes	O
G	O
,	O
J	O
without	O
the	O
IDDE	O
,	O
and	O
H	O
with	O
the	O
wild	O
-	O
type	O
IDDE	O
are	O
the	O
same	O
as	O
minigenes	O
W	O
,	O
D4	O
and	O
Cm0	O
,	O
respectively	O
in	O
ref	O
.	O

(	O
14	O
)	O
.	O

The	O
201	O
nt	O
IDDEs	O
with	O
mutations	O
were	O
generated	O
by	O
recombinant	O
PCR	O
using	O
the	O
appropriate	O
primers	O
,	O
which	O
included	O
mutated	O
sequences	O
.	O

The	O
hexanucleotide	O
TGCATG	O
sequences	O
at	O
the	O
5	O
'	O
and	O
3	O
'	O
sides	O
were	O
changed	O
to	O
GTTACT	O
and	O
ACCTAC	O
,	O
respectively	O
.	O

Electrophoresis	O
mobility	O
shift	O
assay	O

Template	O
DNAs	O
for	O
in	O
vitro	O
RNA	O
transcription	O
were	O
prepared	O
by	O
PCR	O
using	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
IDDEs	O
in	O
the	O
minigenes	O
as	O
templates	O
and	O
an	O
upstream	O
primer	O
that	O
included	O
the	O
T7	O
promoter	O
sequence	O
at	O
the	O
5	O
'	O
end	O
.	O

The	O
probe	O
and	O
competitor	O
RNAs	O
were	O
transcribed	O
by	O
T7	O
RNA	O
polymerase	O
in	O
the	O
presence	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
UTP	O
and	O
a	O
trace	O
amount	O
of	O
[	O
35S	O
]	O
UTP	O
alpha	O
S	O
,	O
respectively	O
,	O
using	O
a	O
MAXIscript	O
kit	O
(	O
Ambion	O
)	O
.	O

Mole	O
concentrations	O
of	O
synthesized	O
RNAs	O
were	O
estimated	O
by	O
radioactivities	O
.	O

Fxh	O
and	O
A2BP1	O
proteins	O
with	O
a	O
myc	O
tag	O
were	O
synthesized	O
in	O
vitro	O
by	O
using	O
a	O
TNT	O
quick	O
-	O
coupled	O
transcription	O
/	O
translation	O
system	O
(	O
Promega	O
)	O
from	O
pCS3	O
+	O
MT	O
constructs	O
,	O
which	O
include	O
the	O
SP6	O
promoter	O
.	O

Binding	O
reactions	O
were	O
carried	O
out	O
in	O
a	O
10	O
mu	O
l	O
mixture	O
that	O
contains	O
10	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
9	O
)	O
,	O
2	O
mM	O
MgCl2	O
,	O
50	O
mM	O
KCl	O
,	O
5	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
5	O
mu	O
g	O
tRNA	O
,	O
1	O
mu	O
l	O
reticulocyte	O
lysate	O
reaction	O
mixture	O
and	O
15	O
fmol	O
of	O
probe	O
,	O
on	O
ice	O
for	O
20	O
-	O
30	O
min	O
.	O

An	O
aliquot	O
of	O
5	O
mu	O
g	O
of	O
heparin	O
was	O
added	O
to	O
the	O
reaction	O
10	O
min	O
before	O
gel	O
electrophoresis	O
.	O

The	O
reaction	O
mixtures	O
were	O
analyzed	O
by	O
electrophoresis	O
in	O
a	O
6	O
%	O
polyacrylamide	O
gel	O
using	O
a	O
0	O
.	O
5	O
x	O
TBE	O
buffer	O
(	O
Invitrogen	O
)	O
.	O

Cell	O
culture	O
and	O
transfection	O

The	O
human	S-Species
retinoblastoma	O
cell	O
line	O
Y79	O
was	O
cultured	O
and	O
transfected	O
with	O
DNAs	O
as	O
described	O
previously	O
(	O
14	O
,	O
26	O
)	O
.	O

Total	O
amounts	O
of	O
transfected	O
DNAs	O
were	O
adjusted	O
to	O
be	O
constant	O
by	O
addition	O
of	O
the	O
empty	O
vector	O
.	O

Either	O
Lipofectin	O
(	O
Invitrogen	O
)	O
or	O
Effectene	O
transfection	O
reagent	O
(	O
Qiagen	O
)	O
was	O
used	O
for	O
the	O
transfection	O
.	O

For	O
stable	O
transfection	O
,	O
the	O
pCS3	O
+	O
MT	O
expression	O
constructs	O
were	O
co	O
-	O
transfected	O
with	O
a	O
plasmid	O
carrying	O
a	O
neomycin	O
resistant	O
gene	O
and	O
selected	O
by	O
0	O
.	O
2	O
mM	O
geneticin	O
(	O
Invitrogen	O
)	O
.	O

For	O
differentiation	O
of	O
Y79	O
cells	O
,	O
cells	O
were	O
plated	O
on	O
the	O
poly	O
-	O
d	O
-	O
lysine	O
-	O
coated	O
plates	O
and	O
then	O
treated	O
with	O
2	O
.	O
0	O
-	O
2	O
.	O
5	O
mM	O
sodium	O
butyrate	O
for	O
4	O
-	O
5	O
days	O
.	O

HeLa	O
cells	O
were	O
cultured	O
as	O
described	O
and	O
transfected	O
with	O
DNA	O
using	O
Effectene	O
reagent	O
(	O
14	O
,	O
26	O
)	O
.	O

Immunoblot	O
analysis	O

Samples	O
that	O
required	O
both	O
protein	O
and	O
mRNA	O
analysis	O
were	O
split	O
upon	O
harvesting	O
.	O

Total	O
cell	O
proteins	O
were	O
subjected	O
to	O
SDS	O
-	O
PAGE	O
and	O
blotted	O
as	O
described	O
previously	O
(	O
26	O
)	O
.	O

The	O
primary	O
antibodies	O
used	O
are	O
monoclonal	O
antibodies	O
to	O
a	O
myc	O
-	O
epitope	O
(	O
Invitrogen	O
)	O
and	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
(	O
Clontech	O
)	O
.	O

Binding	O
of	O
antibodies	O
was	O
detected	O
with	O
the	O
SuperSignal	O
System	O
(	O
Pierce	O
)	O
or	O
ECL	O
(	O
Amersham	O
)	O
.	O

Immunofluorescent	O
microscopy	O

HeLa	O
or	O
Y79	O
cells	O
grown	O
in	O
a	O
four	O
-	O
chamber	O
glass	O
slide	O
were	O
transfected	O
as	O
described	O
above	O
.	O

Cells	O
were	O
fixed	O
with	O
10	O
%	O
formaldehyde	O
24	O
-	O
48	O
h	O
after	O
transfection	O
,	O
and	O
permealized	O
with	O
0	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
then	O
blocked	O
with	O
5	O
%	O
goat	S-Species
serum	O
.	O

Primary	O
antibodies	O
used	O
were	O
mouse	S-Species
anti	O
-	O
myc	O
(	O
Invitrogen	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
NMHC	O
-	O
B	O
(	O
29	O
)	O
.	O

Secondary	O
antibodies	O
were	O
Alexa	O
Fluor	O
594	O
goat	S-Species
anti	O
-	O
mouse	S-Species
IgG	O
and	O
Alexa	O
Fluor	O
488	O
goat	S-Species
anti	O
-	O
rabbit	S-Species
IgG	O
(	O
Molecular	O
Probes	O
)	O
.	O

DAPI	O
was	O
used	O
for	O
DNA	O
staining	O
.	O

Specimens	O
were	O
mounted	O
in	O
ProLong	O
antifed	O
kit	O
(	O
Molecular	O
Probe	O
)	O
.	O

The	O
images	O
were	O
collected	O
using	O
Leica	O
SP	O
confocal	O
microscopy	O
(	O
Leica	O
)	O
.	O

RESULTS	O

Tissue	O
-	O
dependent	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
and	O
their	O
subcellular	O
distribution	O

The	O
A2BP1	O
mRNAs	O
are	O
detected	O
almost	O
exclusively	O
in	O
brain	O
and	O
striated	O
muscles	O
(	O
heart	O
and	O
skeletal	O
muscles	O
)	O
in	O
adult	O
mice	S-Species
,	O
whereas	O
the	O
Fxh	O
mRNAs	O
are	O
expressed	O
in	O
a	O
wide	O
variety	O
of	O
tissues	O
with	O
the	O
highest	O
expression	O
in	O
brain	O
and	O
heart	O
[	O
(	O
21	O
,	O
25	O
)	O
and	O
S	O
.	O
Kawamoto	O
,	O
unpublished	O
data	O
]	O
.	O

These	O
expression	O
profiles	O
prompted	O
us	O
to	O
characterize	O
the	O
mRNAs	O
of	O
A2BP1	O
and	O
Fxh	O
in	O
brain	O
and	O
muscles	O
.	O

We	O
have	O
cloned	O
cDNAs	O
for	O
two	O
gene	O
transcripts	O
from	O
brain	O
,	O
heart	O
and	O
skeletal	O
muscles	O
by	O
RT	O
-	O
PCR	O
and	O
5	O
'	O
RACE	O
.	O

The	O
isolated	O
cDNAs	O
are	O
schematically	O
presented	O
with	O
genomic	O
structures	O
in	O
Figure	O
1	O
(	O
for	O
amino	O
acid	O
sequences	O
see	O
also	O
Figure	O
8	O
)	O
.	O

Both	O
gene	O
transcripts	O
are	O
found	O
to	O
undergo	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
.	O

In	O
both	O
cases	O
,	O
brain	O
and	O
striated	O
muscles	O
express	O
unique	O
splice	O
variants	O
generated	O
by	O
mutually	O
exclusive	O
splicing	O
of	O
exons	O
B40	O
and	O
M43	O
,	O
respectively	O
,	O
which	O
provide	O
different	O
coding	O
sequences	O
in	O
the	O
middle	O
of	O
the	O
carboxyl	O
half	O
of	O
the	O
molecules	O
.	O

Southern	O
blot	O
analysis	O
of	O
the	O
RT	O
-	O
PCR	O
products	O
of	O
the	O
Fxh	O
mRNAs	O
from	O
the	O
different	O
tissues	O
probed	O
by	O
oligonucleotides	O
corresponding	O
to	O
B40	O
and	O
M43	O
shows	O
that	O
M43	O
is	O
exclusively	O
used	O
in	O
heart	O
and	O
skeletal	O
muscles	O
,	O
while	O
B40	O
is	O
predominantly	O
used	O
in	O
brain	O
(	O
Figure	O
2A	O
)	O
.	O

Digestion	O
of	O
the	O
RT	O
-	O
PCR	O
products	O
of	O
the	O
A2BP1	O
mRNAs	O
with	O
restriction	O
enzymes	O
unique	O
to	O
B40	O
and	O
M43	O
demonstrates	O
that	O
B40	O
and	O
M43	O
are	O
used	O
almost	O
exclusively	O
in	O
brain	O
and	O
muscles	O
,	O
respectively	O
(	O
Figure	O
2B	O
)	O
.	O

A2BP1	O
contains	O
an	O
additional	O
cassette	O
type	O
alternative	O
exon	O
A53	O
,	O
consisting	O
of	O
53	O
nt	O
.	O

Inclusion	O
and	O
exclusion	O
of	O
exon	O
A53	O
results	O
in	O
two	O
different	O
amino	O
acid	O
sequences	O
at	O
the	O
C	O
-	O
terminal	O
region	O
owing	O
to	O
a	O
frame	O
shift	O
.	O

In	O
the	O
case	O
of	O
the	O
A2BP1	O
gene	O
,	O
moreover	O
,	O
it	O
appears	O
that	O
brain	O
and	O
striated	O
muscle	O
utilize	O
alternative	O
promoters	O
,	O
resulting	O
in	O
different	O
amino	O
acid	O
sequences	O
at	O
the	O
N	O
-	O
terminus	O
.	O

The	O
5	O
'	O
RACE	O
of	O
skeletal	O
muscle	O
mRNAs	O
yielded	O
essentially	O
a	O
single	O
species	O
of	O
sequence	O
with	O
29	O
unique	O
N	O
-	O
terminal	O
amino	O
acids	O
.	O

The	O
5	O
'	O
RACE	O
using	O
brain	O
mRNAs	O
;	O
however	O
,	O
yielded	O
multiple	O
products	O
with	O
multiple	O
deduced	O
amino	O
acid	O
sequences	O
,	O
all	O
of	O
which	O
differ	O
from	O
the	O
muscle	O
amino	O
acid	O
sequence	O
at	O
the	O
very	O
N	O
-	O
terminus	O
.	O

Here	O
,	O
we	O
focus	O
our	O
analysis	O
on	O
a	O
clone	O
containing	O
nine	O
unique	O
amino	O
acids	O
at	O
the	O
N	O
-	O
terminus	O
,	O
which	O
was	O
obtained	O
most	O
frequently	O
.	O

Exon	O
-	O
intron	O
organization	O
of	O
Fxh	O
and	O
A2BP1	O
shows	O
remarkable	O
similarities	O
and	O
a	O
RRM	O
is	O
encoded	O
in	O
four	O
exons	O
(	O
Figure	O
1B	O
)	O
.	O

Of	O
note	O
is	O
that	O
the	O
significant	O
amounts	O
of	O
Fxh	O
and	O
A2BP1	O
mRNAs	O
from	O
skeletal	O
muscles	O
are	O
missing	O
a	O
part	O
of	O
the	O
RRM	O
by	O
exon	O
skipping	O
.	O

Typically	O
,	O
as	O
shown	O
in	O
Figure	O
2C	O
,	O
they	O
lack	O
the	O
93	O
nt	O
exon	O
that	O
encodes	O
RNP1	O
,	O
one	O
of	O
the	O
two	O
most	O
critical	O
motifs	O
of	O
the	O
RRM	O
(	O
30	O
)	O
.	O

Some	O
of	O
them	O
lack	O
almost	O
the	O
entire	O
RRM	O
(	O
e	O
.	O
g	O
.	O
F402	O
in	O
Figure	O
1A	O
)	O
.	O

To	O
examine	O
the	O
subcellular	O
distribution	O
of	O
each	O
isoform	O
of	O
Fxh	O
and	O
A2BP1	O
,	O
myc	O
-	O
tagged	O
proteins	O
were	O
transiently	O
expressed	O
in	O
cultured	O
cells	O
and	O
immunostained	O
with	O
an	O
anti	O
-	O
myc	O
antibody	O
.	O

Initially	O
,	O
HeLa	O
cells	O
were	O
used	O
to	O
investigate	O
subcellular	O
localization	O
,	O
since	O
these	O
cells	O
are	O
more	O
suited	O
for	O
these	O
studies	O
.	O

Representative	O
confocal	O
images	O
are	O
shown	O
in	O
Figure	O
3A	O
.	O

DAPI	O
and	O
anti	O
-	O
NMHC	O
-	O
B	O
antibodies	O
serve	O
as	O
markers	O
for	O
nuclei	O
and	O
cytoplasm	O
,	O
respectively	O
.	O

As	O
noted	O
,	O
the	O
ratio	O
of	O
protein	O
distributed	O
between	O
nuclei	O
and	O
cytoplasm	O
differs	O
among	O
the	O
proteins	O
.	O

All	O
isoforms	O
of	O
Fxh	O
have	O
a	O
predominant	O
nuclear	O
localization	O
.	O

The	O
brain	O
isoform	O
of	O
A2BP1	O
without	O
the	O
A53	O
exon	O
(	O
A016	O
)	O
localizes	O
to	O
both	O
nuclei	O
and	O
cytoplasm	O
,	O
whereas	O
the	O
other	O
brain	O
isoform	O
with	O
the	O
A53	O
exon	O
(	O
A030	O
)	O
localizes	O
predominantly	O
to	O
cytoplasm	O
with	O
only	O
a	O
minimum	O
being	O
in	O
the	O
nuclei	O
.	O

The	O
relative	O
amounts	O
of	O
both	O
muscle	O
isoforms	O
of	O
A2BP1	O
(	O
A713	O
and	O
A715	O
)	O
are	O
somewhat	O
between	O
the	O
amounts	O
of	O
the	O
two	O
brain	O
isoforms	O
.	O

These	O
data	O
are	O
summarized	O
in	O
Figure	O
1A	O
.	O

The	O
subcellular	O
distribution	O
of	O
representative	O
isoforms	O
(	O
F011	O
,	O
A016	O
and	O
A030	O
)	O
was	O
also	O
examined	O
in	O
retinoblastoma	O
Y79	O
cells	O
,	O
which	O
were	O
used	O
as	O
host	O
cells	O
for	O
the	O
transfection	O
experiments	O
in	O
order	O
to	O
characterize	O
splicing	O
activities	O
of	O
Fxh	O
and	O
A2BP	O
proteins	O
(	O
see	O
below	O
)	O
.	O

Although	O
Y79	O
cells	O
have	O
a	O
spherical	O
shape	O
and	O
have	O
only	O
thin	O
cytoplasm	O
,	O
exogenously	O
expressed	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
show	O
a	O
similar	O
subcellular	O
distribution	O
as	O
in	O
HeLa	O
cells	O
(	O
Figure	O
3B	O
)	O
.	O

F011	O
localizes	O
predominantly	O
to	O
nuclei	O
,	O
A016	O
to	O
both	O
nuclei	O
and	O
cytoplasm	O
and	O
A030	O
predominantly	O
to	O
cytoplasm	O
.	O

Specific	O
interaction	O
of	O
Fxh	O
and	O
A2BP1	O
with	O
IDDE	O
via	O
a	O
hexanucleotide	O
UGCAUG	O

Fxh	O
and	O
A2BP1	O
share	O
an	O
identical	O
RRM	O
and	O
A2BP1	O
has	O
been	O
reported	O
to	O
bind	O
specifically	O
to	O
the	O
pentanucleotide	O
GCAUG	O
through	O
this	O
RRM	O
(	O
21	O
)	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
IDDE	O
of	O
the	O
NMHC	O
-	O
B	O
transcript	O
,	O
which	O
is	O
indispensable	O
for	O
the	O
regulation	O
of	O
neural	O
cell	O
-	O
specific	O
cassette	O
type	O
exon	O
N30	O
splicing	O
,	O
has	O
two	O
copies	O
of	O
GCAUG	O
(	O
14	O
)	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
Fxh	O
and	O
/	O
or	O
A2BP1	O
bound	O
to	O
the	O
IDDE	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
were	O
carried	O
out	O
using	O
labeled	O
IDDE	O
and	O
in	O
vitro	O
transcribed	O
and	O
translated	O
Fxh	O
and	O
A2BP1	O
,	O
which	O
include	O
a	O
myc	O
-	O
epitope	O
.	O

Since	O
all	O
Fxh	O
and	O
A2BP1	O
isoforms	O
,	O
except	O
F402	O
and	O
A704	O
,	O
contain	O
the	O
identical	O
RRM	O
,	O
representative	O
isoforms	O
were	O
analyzed	O
.	O

The	O
expression	O
of	O
F011	O
in	O
reticulocyte	O
lysate	O
causes	O
the	O
formation	O
of	O
a	O
RNA	O
-	O
protein	O
complex	O
whose	O
migration	O
shift	O
distinguishes	O
it	O
from	O
those	O
of	O
the	O
control	O
reticulocyte	O
lysate	O
(	O
C	O
in	O
Figure	O
4B	O
,	O
lanes	O
3	O
and	O
10	O
)	O
.	O

The	O
unlabeled	O
wild	O
-	O
type	O
IDDE	O
competes	O
with	O
the	O
probe	O
efficiently	O
for	O
the	O
formation	O
of	O
the	O
specific	O
complex	O
C	O
(	O
Figure	O
4B	O
,	O
lane	O
4	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
mutant	O
mc	O
(	O
Figure	O
4A	O
)	O
,	O
which	O
has	O
a	O
mutation	O
in	O
both	O
copies	O
of	O
UGCAUG	O
,	O
does	O
not	O
(	O
Figure	O
4B	O
,	O
lane	O
7	O
)	O
.	O

The	O
mutant	O
ma	O
,	O
which	O
has	O
a	O
mutation	O
in	O
the	O
hexanucleotide	O
at	O
the	O
5	O
'	O
side	O
,	O
shows	O
less	O
efficient	O
competition	O
,	O
compared	O
with	O
mb	O
,	O
which	O
has	O
a	O
mutation	O
in	O
the	O
3	O
'	O
side	O
of	O
the	O
hexanucleotide	O
(	O
Figure	O
4B	O
,	O
lanes	O
5	O
and	O
6	O
)	O
,	O
indicating	O
that	O
the	O
nucleotides	O
at	O
the	O
5	O
'	O
side	O
are	O
more	O
important	O
than	O
those	O
at	O
the	O
3	O
'	O
side	O
.	O

The	O
presence	O
of	O
an	O
anti	O
-	O
myc	O
antibody	O
,	O
but	O
not	O
a	O
non	O
-	O
specific	O
antibody	O
,	O
inhibits	O
the	O
formation	O
of	O
the	O
specific	O
complex	O
(	O
Figure	O
4B	O
,	O
lane	O
8	O
)	O
.	O

Synthesis	O
of	O
the	O
full	O
-	O
length	O
F011	O
protein	O
using	O
a	O
reticulocyte	O
lysate	O
and	O
specificity	O
of	O
the	O
myc	O
antibody	O
for	O
the	O
expressed	O
protein	O
are	O
verified	O
by	O
immunoblot	O
analysis	O
(	O
Figure	O
4B	O
,	O
lanes	O
11	O
and	O
12	O
)	O
.	O

A016	O
and	O
A030	O
show	O
essentially	O
identical	O
results	O
to	O
those	O
with	O
F011	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
indicate	O
that	O
Fxh	O
and	O
A2BP1	O
can	O
bind	O
to	O
the	O
IDDE	O
and	O
that	O
the	O
hexanucleotide	O
UGCAUG	O
is	O
required	O
for	O
their	O
binding	O
.	O

Fxh	O
and	O
A2BP1	O
enhance	O
N30	O
inclusion	O
in	O
a	O
UGCAUG	O
-	O
dependent	O
manner	O

To	O
study	O
whether	O
Fxh	O
and	O
A2BP1	O
regulate	O
neural	O
cell	O
-	O
specific	O
splicing	O
via	O
binding	O
to	O
UGCAUG	O
,	O
the	O
Fxh	O
and	O
A2BP1	O
expression	O
constructs	O
were	O
co	O
-	O
transfected	O
into	O
retinoblastoma	O
Y79	O
cells	O
with	O
a	O
number	O
of	O
the	O
reporter	O
minigene	O
constructs	O
,	O
which	O
include	O
the	O
wild	O
-	O
type	O
or	O
a	O
mutant	O
version	O
of	O
UGCAUG	O
in	O
the	O
IDDE	O
(	O
Figure	O
4A	O
)	O
.	O

Minigenes	O
H	O
and	O
J	O
consist	O
of	O
the	O
exons	O
E5	O
,	O
N30	O
and	O
E6	O
and	O
their	O
flanking	O
introns	O
with	O
some	O
deletions	O
in	O
the	O
introns	O
.	O

The	O
IDDE	O
with	O
or	O
without	O
mutations	O
in	O
the	O
hexanucleotide	O
is	O
included	O
or	O
excluded	O
between	O
N30	O
and	O
E6	O
.	O

As	O
described	O
above	O
,	O
each	O
isoform	O
of	O
Fxh	O
and	O
A2BP1	O
enters	O
the	O
nucleus	O
to	O
a	O
different	O
extent	O
.	O

To	O
see	O
the	O
effects	O
of	O
different	O
proteins	O
on	O
N30	O
splicing	O
itself	O
,	O
independent	O
of	O
their	O
differential	O
properties	O
in	O
nuclear	O
localization	O
,	O
an	O
exogenous	O
NLS	O
was	O
added	O
to	O
the	O
expressed	O
proteins	O
.	O

Since	O
Fxh	O
and	O
A2BP1	O
proteins	O
contain	O
the	O
identical	O
RRM	O
,	O
and	O
F011	O
,	O
A016	O
and	O
A030	O
all	O
show	O
the	O
same	O
UGCAUG	O
-	O
dependent	O
binding	O
to	O
the	O
IDDE	O
in	O
vitro	O
,	O
F011	O
and	O
A030	O
were	O
used	O
for	O
these	O
experiments	O
.	O

Host	O
cells	O
Y79	O
at	O
the	O
proliferating	O
stage	O
exclude	O
the	O
N30	O
exon	O
in	O
~	O
90	O
%	O
of	O
the	O
endogenous	O
NMHC	O
-	O
B	O
mRNAs	O
(	O
e	O
.	O
g	O
.	O
see	O
Figure	O
6A	O
,	O
lane	O
1	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
4C	O
,	O
the	O
mRNAs	O
derived	O
from	O
minigene	O
J	O
exclude	O
N30	O
without	O
exogenous	O
expression	O
of	O
Fxh	O
or	O
A2BP1	O
in	O
Y79	O
cells	O
,	O
similar	O
to	O
the	O
endogenous	O
NMHC	O
-	O
B	O
mRNAs	O
(	O
Figure	O
4C	O
,	O
upper	O
panel	O
,	O
lanes	O
1	O
-	O
5	O
)	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
exogenous	O
expression	O
of	O
F011	O
and	O
A030	O
,	O
the	O
N30	O
inclusion	O
is	O
increased	O
(	O
Figure	O
4C	O
,	O
upper	O
panel	O
,	O
lanes	O
7	O
and	O
12	O
)	O
.	O

The	O
N30	O
inclusion	O
is	O
absolutely	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
IDDE	O
(	O
Figure	O
4C	O
,	O
upper	O
panel	O
,	O
lanes	O
6	O
and	O
11	O
)	O
.	O

Moreover	O
,	O
mutation	O
of	O
either	O
one	O
of	O
the	O
two	O
copies	O
of	O
UGCAUG	O
(	O
ma	O
,	O
mb	O
)	O
abolishes	O
the	O
inclusion	O
of	O
N30	O
(	O
Figure	O
4C	O
,	O
upper	O
panel	O
,	O
lanes	O
8	O
-	O
10	O
,	O
13	O
-	O
15	O
)	O
.	O

In	O
the	O
context	O
of	O
minigene	O
H	O
,	O
which	O
contains	O
shorter	O
introns	O
,	O
the	O
larger	O
extent	O
of	O
N30	O
inclusion	O
is	O
induced	O
by	O
either	O
F011	O
or	O
A030	O
overexpression	O
(	O
Figure	O
4C	O
,	O
middle	O
panel	O
,	O
lanes	O
7	O
and	O
12	O
)	O
.	O

The	O
N30	O
inclusion	O
of	O
the	O
minigene	O
H	O
mRNAs	O
also	O
depends	O
on	O
the	O
presence	O
of	O
the	O
IDDE	O
(	O
Figure	O
4C	O
,	O
middle	O
panel	O
,	O
lanes	O
6	O
and	O
11	O
)	O
.	O

Mutation	O
of	O
both	O
copies	O
of	O
UGCAUG	O
(	O
mc	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
N30	O
inclusion	O
(	O
Figure	O
4C	O
,	O
middle	O
panel	O
,	O
lanes	O
10	O
and	O
15	O
)	O
.	O

The	O
mutant	O
ma	O
shows	O
stronger	O
inhibition	O
of	O
N30	O
inclusion	O
compared	O
with	O
mb	O
(	O
Figure	O
4C	O
,	O
middle	O
panel	O
,	O
lanes	O
8	O
and	O
9	O
)	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
competition	O
experiments	O
of	O
the	O
EMSA	O
shown	O
in	O
Figure	O
4B	O
,	O
indicating	O
that	O
the	O
5	O
'	O
hexanucleotide	O
is	O
more	O
important	O
than	O
the	O
3	O
'	O
hexanucleotide	O
for	O
binding	O
of	O
Fxh	O
or	O
A2BP1	O
to	O
the	O
IDDE	O
as	O
well	O
as	O
an	O
activation	O
of	O
N30	O
splicing	O
.	O

Comparable	O
amounts	O
of	O
F011	O
and	O
A030	O
are	O
expressed	O
in	O
each	O
transfection	O
as	O
verified	O
by	O
immunoblots	O
using	O
an	O
anti	O
-	O
myc	O
antibody	O
(	O
Figure	O
4C	O
,	O
lower	O
panel	O
,	O
lanes	O
6	O
-	O
17	O
)	O
.	O

Since	O
minigenes	O
J	O
and	O
H	O
lack	O
a	O
portion	O
of	O
the	O
intron	O
between	O
exons	O
N30	O
and	O
E6	O
and	O
,	O
therefore	O
,	O
the	O
IDDE	O
is	O
located	O
~	O
100	O
nt	O
downstream	O
of	O
N30	O
,	O
instead	O
of	O
1	O
.	O
5	O
kb	O
as	O
in	O
the	O
native	O
gene	O
,	O
we	O
also	O
analyzed	O
the	O
effects	O
of	O
Fxh	O
and	O
A2BP1	O
on	O
the	O
N30	O
splicing	O
of	O
the	O
wild	O
-	O
type	O
minigene	O
G	O
,	O
which	O
includes	O
full	O
-	O
length	O
introns	O
among	O
E5	O
,	O
N30	O
and	O
E6	O
(	O
Figure	O
4A	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
4C	O
(	O
right	O
panel	O
)	O
,	O
both	O
F011	O
and	O
A030	O
are	O
capable	O
of	O
promoting	O
N30	O
inclusion	O
,	O
with	O
F011	O
showing	O
a	O
higher	O
activity	O
(	O
Figure	O
4C	O
,	O
lanes	O
16	O
and	O
17	O
)	O
.	O

Although	O
A030	O
can	O
promote	O
N30	O
inclusion	O
as	O
efficiently	O
as	O
F011	O
in	O
the	O
contexts	O
of	O
the	O
minigene	O
J	O
and	O
H	O
transcripts	O
,	O
it	O
can	O
do	O
so	O
less	O
efficiently	O
than	O
F011	O
in	O
the	O
context	O
of	O
the	O
minigene	O
G	O
transcript	O
.	O

Interpretation	O
of	O
this	O
observation	O
will	O
be	O
discussed	O
below	O
.	O

Taken	O
together	O
,	O
Fxh	O
and	O
A2BP1	O
can	O
activate	O
N30	O
inclusion	O
in	O
an	O
IDDE	O
-	O
dependent	O
manner	O
.	O

The	O
hexanucleotide	O
motif	O
UGCAUG	O
is	O
indispensable	O
for	O
this	O
activation	O
.	O

Differential	O
activities	O
of	O
alternatively	O
spliced	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
in	O
promoting	O
N30	O
inclusion	O

Both	O
Fxh	O
and	O
A2BP1	O
mRNAs	O
are	O
expressed	O
in	O
brain	O
and	O
A2BP1	O
is	O
also	O
expressed	O
in	O
striated	O
muscles	O
and	O
Fxh	O
is	O
expressed	O
in	O
an	O
even	O
wider	O
variety	O
of	O
tissues	O
.	O

As	O
demonstrated	O
above	O
,	O
however	O
,	O
both	O
Fxh	O
and	O
A2BP1	O
transcripts	O
undergo	O
tissue	O
-	O
dependent	O
alternative	O
splicing	O
,	O
producing	O
muscle	O
-	O
specific	O
and	O
brain	O
-	O
enriched	O
isoforms	O
.	O

Therefore	O
,	O
the	O
relative	O
activity	O
of	O
individual	O
isoform	O
of	O
Fxh	O
and	O
A2BP1	O
in	O
promoting	O
N30	O
inclusion	O
was	O
compared	O
using	O
minigene	O
G	O
.	O

First	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
relative	O
specific	O
activity	O
of	O
each	O
isoform	O
in	O
the	O
splicing	O
reaction	O
separately	O
from	O
its	O
ability	O
to	O
localize	O
to	O
nuclei	O
,	O
an	O
exogenous	O
NLS	O
was	O
included	O
in	O
the	O
expressed	O
protein	O
to	O
equalize	O
the	O
nuclear	O
concentration	O
of	O
the	O
expressed	O
protein	O
in	O
these	O
experiments	O
.	O

Essentially	O
,	O
all	O
of	O
the	O
expressed	O
proteins	O
with	O
the	O
exogenous	O
NLS	O
are	O
localized	O
to	O
the	O
nucleus	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
the	O
relative	O
nuclear	O
concentrations	O
of	O
the	O
expressed	O
proteins	O
can	O
be	O
estimated	O
easily	O
by	O
immunoblots	O
.	O

As	O
shown	O
in	O
immunoblots	O
in	O
Figure	O
5A	O
,	O
similar	O
quantities	O
of	O
proteins	O
are	O
expressed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Expression	O
of	O
the	O
brain	O
isoform	O
F011	O
causes	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
N30	O
inclusion	O
and	O
the	O
extent	O
of	O
N30	O
inclusion	O
reaches	O
a	O
plateau	O
with	O
~	O
85	O
%	O
of	O
the	O
mRNAs	O
including	O
N30	O
.	O

In	O
contrast	O
,	O
inclusion	O
of	O
N30	O
promoted	O
by	O
F411	O
,	O
the	O
predominant	O
isoform	O
from	O
skeletal	O
muscles	O
,	O
reaches	O
a	O
plateau	O
with	O
only	O
40	O
%	O
of	O
the	O
mRNAs	O
.	O

With	O
respect	O
to	O
A2BP1	O
,	O
the	O
brain	O
isoform	O
A030	O
shows	O
higher	O
activity	O
in	O
N30	O
inclusion	O
than	O
the	O
muscle	O
isoform	O
A715	O
,	O
which	O
shows	O
almost	O
no	O
activation	O
,	O
as	O
shown	O
in	O
Figure	O
5A	O
.	O

Including	O
additional	O
isoforms	O
,	O
the	O
activities	O
of	O
individual	O
isoforms	O
with	O
an	O
exogenous	O
NLS	O
in	O
promoting	O
N30	O
inclusion	O
are	O
shown	O
in	O
Figure	O
5B	O
(	O
lanes	O
8	O
-	O
13	O
)	O
and	O
are	O
also	O
summarized	O
in	O
Figure	O
1A	O
(	O
nls	O
)	O
.	O

Special	O
care	O
was	O
taken	O
to	O
ensure	O
that	O
a	O
similar	O
quantity	O
of	O
each	O
protein	O
was	O
expressed	O
and	O
,	O
if	O
not	O
,	O
different	O
amounts	O
were	O
tested	O
to	O
obtain	O
comparable	O
expression	O
.	O

In	O
the	O
presence	O
of	O
the	O
exogenous	O
NLS	O
(	O
nls	O
)	O
,	O
F011	O
and	O
A016	O
show	O
the	O
highest	O
activities	O
among	O
all	O
isoforms	O
tested	O
.	O

A30	O
shows	O
a	O
considerably	O
lower	O
activity	O
than	O
A016	O
.	O

Each	O
of	O
the	O
muscle	O
isoforms	O
(	O
F411	O
,	O
A713	O
and	O
A715	O
)	O
has	O
a	O
lower	O
activity	O
than	O
that	O
of	O
their	O
brain	O
counterparts	O
(	O
F011	O
,	O
A016	O
and	O
A030	O
,	O
respectively	O
)	O
.	O

As	O
expected	O
,	O
isoforms	O
lacking	O
a	O
part	O
or	O
all	O
of	O
the	O
RRM	O
(	O
F402	O
and	O
A704	O
)	O
have	O
no	O
activity	O
for	O
N30	O
inclusion	O
.	O

Next	O
,	O
the	O
splicing	O
activities	O
of	O
the	O
wild	O
-	O
type	O
proteins	O
without	O
an	O
exogenous	O
NLS	O
were	O
examined	O
.	O

Representative	O
data	O
are	O
shown	O
in	O
Figure	O
5B	O
(	O
lanes	O
2	O
-	O
7	O
)	O
and	O
the	O
relative	O
activities	O
are	O
summarized	O
in	O
Figure	O
1A	O
(	O
wt	O
)	O
.	O

The	O
protein	O
amounts	O
detected	O
by	O
immunoblots	O
in	O
these	O
experiments	O
represent	O
the	O
total	O
amounts	O
of	O
the	O
proteins	O
distributed	O
to	O
both	O
the	O
nuclei	O
and	O
the	O
cytoplasm	O
.	O

The	O
splicing	O
activities	O
of	O
the	O
wild	O
-	O
type	O
proteins	O
are	O
consistent	O
with	O
the	O
activities	O
that	O
combine	O
the	O
splicing	O
activities	O
of	O
the	O
proteins	O
with	O
the	O
exogenous	O
NLS	O
and	O
the	O
activities	O
of	O
the	O
native	O
proteins	O
to	O
localize	O
to	O
nuclei	O
.	O

In	O
the	O
absence	O
of	O
the	O
exogenous	O
NLS	O
(	O
wt	O
)	O
,	O
the	O
brain	O
isoforms	O
F011	O
,	O
and	O
A016	O
to	O
a	O
lesser	O
extent	O
,	O
are	O
still	O
capable	O
of	O
activating	O
N30	O
inclusion	O
efficiently	O
.	O

The	O
muscle	O
isoforms	O
for	O
both	O
Fxh	O
and	O
A2BP1	O
(	O
F411	O
,	O
A713	O
and	O
A715	O
)	O
,	O
as	O
well	O
as	O
the	O
brain	O
isoform	O
A030	O
,	O
show	O
only	O
minimal	O
activities	O
.	O

Therefore	O
,	O
F011	O
and	O
A016	O
appear	O
to	O
have	O
the	O
most	O
physiological	O
relevance	O
to	O
N30	O
splicing	O
activation	O
.	O

Overexpression	O
of	O
Fxh	O
and	O
A2BP1	O
activates	O
N30	O
inclusion	O
of	O
endogenous	O
NMHC	O
-	O
B	O
mRNAs	O

The	O
human	S-Species
NMHC	O
-	O
B	O
gene	O
consists	O
of	O
41	O
constitutive	O
exons	O
and	O
3	O
alternative	O
exons	O
.	O

Its	O
pre	O
-	O
mRNA	O
is	O
~	O
156	O
kb	O
in	O
length	O
and	O
it	O
is	O
much	O
more	O
complex	O
than	O
the	O
pre	O
-	O
mRNA	O
from	O
the	O
minigenes	O
.	O

In	O
addition	O
,	O
the	O
minigene	O
pre	O
-	O
mRNAs	O
are	O
driven	O
by	O
a	O
heterologous	O
promoter	O
.	O

Therefore	O
,	O
we	O
next	O
examined	O
if	O
Fxh	O
and	O
A2BP1	O
were	O
capable	O
of	O
promoting	O
N30	O
inclusion	O
of	O
the	O
endogenous	O
transcript	O
.	O

Y79	O
cells	O
were	O
stably	O
transfected	O
with	O
the	O
expression	O
construct	O
for	O
F011	O
or	O
A016	O
.	O

Both	O
F011	O
and	O
A016	O
are	O
enriched	O
in	O
the	O
brain	O
and	O
show	O
higher	O
activation	O
of	O
N30	O
inclusion	O
in	O
the	O
minigene	O
transcripts	O
.	O

mRNAs	O
encoding	O
endogenous	O
NMHC	O
-	O
B	O
were	O
analyzed	O
by	O
using	O
RT	O
-	O
PCR	O
.	O

As	O
shown	O
in	O
Figure	O
6	O
,	O
the	O
inclusion	O
of	O
exon	O
N30	O
with	O
and	O
without	O
another	O
alternative	O
exon	O
,	O
R18	O
,	O
in	O
the	O
endogenous	O
mRNAs	O
is	O
markedly	O
increased	O
in	O
the	O
clones	O
which	O
were	O
stably	O
transfected	O
with	O
the	O
construct	O
for	O
F011	O
or	O
A016	O
containing	O
an	O
exogenous	O
NLS	O
(	O
Figure	O
6	O
,	O
lanes	O
4	O
and	O
5	O
)	O
.	O

Although	O
to	O
a	O
lesser	O
extent	O
,	O
transfection	O
of	O
the	O
wild	O
-	O
type	O
constructs	O
without	O
an	O
exogenous	O
NLS	O
also	O
results	O
in	O
a	O
significant	O
increase	O
in	O
N30	O
inclusion	O
(	O
Figure	O
6	O
,	O
lanes	O
2	O
and	O
3	O
)	O
.	O

Thus	O
,	O
exogenously	O
expressed	O
Fxh	O
and	O
A2BP1	O
are	O
capable	O
of	O
activating	O
N30	O
inclusion	O
not	O
only	O
in	O
the	O
transcripts	O
from	O
the	O
minigenes	O
,	O
but	O
also	O
in	O
those	O
from	O
the	O
native	O
NMHC	O
-	O
B	O
gene	O
in	O
Y79	O
cells	O
.	O

Fxh	O
may	O
cooperate	O
with	O
other	O
factor	O
(	O
s	O
)	O
to	O
promote	O
N30	O
inclusion	O

To	O
address	O
the	O
role	O
of	O
endogenous	O
Fxh	O
and	O
its	O
potential	O
interaction	O
with	O
other	O
proteins	O
in	O
promoting	O
N30	O
inclusion	O
,	O
we	O
made	O
use	O
of	O
an	O
isoform	O
of	O
Fxh	O
,	O
F402	O
,	O
which	O
lacks	O
the	O
RRM	O
.	O

The	O
mutant	O
proteins	O
lacking	O
an	O
RRM	O
for	O
other	O
RNA	O
-	O
binding	O
proteins	O
have	O
previously	O
been	O
reported	O
to	O
function	O
in	O
a	O
dominant	O
-	O
negative	O
fashion	O
and	O
inhibit	O
the	O
activities	O
of	O
the	O
wild	O
-	O
type	O
proteins	O
(	O
26	O
,	O
31	O
)	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
F402	O
on	O
the	O
N30	O
inclusion	O
of	O
minigene	O
H	O
mRNAs	O
were	O
examined	O
in	O
the	O
context	O
of	O
the	O
Y79	O
cells	O
treated	O
with	O
butyrate	O
.	O

Upon	O
butyrate	O
treatment	O
,	O
as	O
reported	O
previously	O
,	O
Y79	O
cells	O
enter	O
in	O
a	O
post	O
-	O
mitotic	O
and	O
differentiated	O
stage	O
,	O
and	O
importantly	O
,	O
the	O
endogenous	O
as	O
well	O
as	O
the	O
minigene	O
mRNAs	O
in	O
those	O
cells	O
include	O
N30	O
to	O
a	O
large	O
extent	O
,	O
unlike	O
those	O
in	O
the	O
untreated	O
cells	O
that	O
predominantly	O
exclude	O
N30	O
(	O
14	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
7	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
expression	O
of	O
F402	O
,	O
large	O
quantities	O
of	O
the	O
mRNAs	O
derived	O
from	O
minigene	O
H	O
-	O
wt	O
,	O
which	O
contains	O
the	O
wild	O
-	O
type	O
IDDE	O
,	O
include	O
N30	O
(	O
Figure	O
7	O
,	O
upper	O
panel	O
,	O
lane	O
4	O
)	O
.	O

In	O
contrast	O
,	O
only	O
small	O
quantities	O
of	O
N30	O
inclusion	O
are	O
detected	O
in	O
the	O
mRNAs	O
from	O
minigene	O
H	O
-	O
mc	O
,	O
which	O
has	O
mutations	O
in	O
both	O
copies	O
of	O
UGCAUG	O
in	O
the	O
IDDE	O
(	O
Figure	O
7	O
,	O
upper	O
panel	O
,	O
lane	O
8	O
)	O
.	O

Therefore	O
,	O
the	O
butyrate	O
-	O
treated	O
Y79	O
cells	O
contain	O
factor	O
(	O
s	O
)	O
,	O
which	O
are	O
capable	O
of	O
activating	O
the	O
UGCAUG	O
-	O
dependent	O
N30	O
inclusion	O
.	O

Co	O
-	O
transfection	O
of	O
the	O
wild	O
-	O
type	O
minigene	O
H	O
-	O
wt	O
with	O
the	O
F402	O
expression	O
construct	O
causes	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
N30	O
inclusion	O
(	O
Figure	O
7	O
,	O
lanes	O
1	O
-	O
3	O
)	O
,	O
indicating	O
that	O
F402	O
has	O
an	O
antagonistic	O
effect	O
on	O
the	O
endogenous	O
factors	O
with	O
respect	O
to	O
N30	O
inclusion	O
.	O

Notably	O
,	O
the	O
UGCAUG	O
-	O
independent	O
N30	O
inclusion	O
seen	O
in	O
the	O
mutant	O
minigene	O
H	O
-	O
mc	O
is	O
not	O
affected	O
by	O
the	O
co	O
-	O
expression	O
of	O
F402	O
(	O
Figure	O
7	O
,	O
lanes	O
5	O
-	O
7	O
)	O
,	O
indicating	O
that	O
the	O
inhibitory	O
activity	O
of	O
F402	O
depends	O
on	O
the	O
UGCAUG	O
element	O
.	O

The	O
parallel	O
experiment	O
with	O
the	O
F011	O
expression	O
construct	O
does	O
not	O
show	O
a	O
significant	O
effect	O
on	O
N30	O
splicing	O
in	O
either	O
the	O
wild	O
-	O
type	O
or	O
mutant	O
minigene	O
(	O
Figure	O
7	O
,	O
lanes	O
9	O
-	O
16	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
N30	O
inclusion	O
of	O
the	O
wild	O
-	O
type	O
minigene	O
mRNAs	O
has	O
already	O
reached	O
a	O
maximal	O
level	O
and	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
butyrate	O
-	O
treated	O
Y79	O
cells	O
contain	O
sufficient	O
amounts	O
of	O
protein	O
(	O
s	O
)	O
functionally	O
equivalent	O
to	O
F011	O
,	O
which	O
can	O
promote	O
N30	O
inclusion	O
in	O
a	O
UGCAUG	O
-	O
dependent	O
manner	O
.	O

Since	O
F402	O
does	O
not	O
bind	O
to	O
the	O
UGCAUG	O
element	O
,	O
and	O
has	O
a	O
UGCAUG	O
-	O
dependent	O
antagonistic	O
effect	O
on	O
N30	O
splicing	O
,	O
it	O
most	O
probably	O
disrupts	O
protein	O
-	O
protein	O
interactions	O
of	O
the	O
endogenous	O
proteins	O
that	O
are	O
required	O
for	O
the	O
UGCAUG	O
-	O
dependent	O
activation	O
of	O
N30	O
splicing	O
.	O

Endogenous	O
Fxh	O
(	O
and	O
/	O
or	O
A2BP1	O
)	O
would	O
be	O
a	O
good	O
candidate	O
whose	O
function	O
could	O
be	O
antagonized	O
by	O
exogenously	O
expressed	O
F402	O
.	O

Thus	O
,	O
this	O
observation	O
suggests	O
that	O
the	O
endogenous	O
Fxh	O
has	O
an	O
effect	O
on	O
the	O
activation	O
of	O
N30	O
splicing	O
and	O
that	O
other	O
proteins	O
cooperate	O
with	O
Fxh	O
for	O
N30	O
activation	O
.	O

Since	O
muscle	O
cells	O
express	O
the	O
RRM	O
-	O
defective	O
isoforms	O
to	O
a	O
significant	O
extent	O
(	O
Figure	O
2C	O
)	O
and	O
the	O
wild	O
-	O
type	O
F402	O
localize	O
to	O
nuclei	O
efficiently	O
,	O
this	O
also	O
raises	O
the	O
possibility	O
that	O
the	O
RRM	O
-	O
defective	O
isoforms	O
may	O
have	O
an	O
inhibitory	O
function	O
on	O
the	O
N30	O
splicing	O
in	O
muscle	O
cells	O
.	O

DISCUSSION	O

Two	O
major	O
findings	O
are	O
described	O
in	O
this	O
report	O
.	O

First	O
,	O
Fxh	O
and	O
A2BP1	O
facilitate	O
neural	O
cell	O
-	O
specific	O
inclusion	O
of	O
the	O
cassette	O
-	O
type	O
exon	O
via	O
binding	O
to	O
the	O
specific	O
intronic	O
sequence	O
UGCAUG	O
.	O

In	O
addition	O
to	O
a	O
minigene	O
model	O
system	O
,	O
Fxh	O
and	O
A2BP1	O
are	O
capable	O
of	O
facilitating	O
N30	O
inclusion	O
of	O
the	O
endogenous	O
pre	O
-	O
mRNA	O
.	O

This	O
result	O
provides	O
an	O
important	O
demonstration	O
of	O
physiological	O
relevance	O
and	O
supports	O
the	O
notion	O
that	O
the	O
NMHC	O
-	O
B	O
pre	O
-	O
mRNA	O
is	O
likely	O
to	O
be	O
the	O
true	O
target	O
for	O
Fxh	O
or	O
A2BP1	O
-	O
mediated	O
regulation	O
.	O

However	O
,	O
whether	O
the	O
endogenous	O
Fxh	O
or	O
A2BP1	O
regulates	O
endogenous	O
NMHC	O
-	O
B	O
pre	O
-	O
mRNA	O
splicing	O
needs	O
to	O
be	O
determined	O
in	O
a	O
future	O
study	O
.	O

In	O
vertebrates	O
,	O
small	O
interfering	O
RNAs	O
and	O
gene	O
targeting	O
strategies	O
have	O
recently	O
been	O
used	O
successfully	O
to	O
address	O
the	O
roles	O
of	O
endogenous	O
splicing	O
regulators	O
in	O
alternative	O
splicing	O
of	O
endogenous	O
target	O
pre	O
-	O
mRNAs	O
(	O
8	O
,	O
32	O
-	O
36	O
)	O
.	O

A	O
second	O
and	O
more	O
novel	O
finding	O
is	O
the	O
identification	O
of	O
tissue	O
-	O
specific	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
with	O
different	O
splicing	O
activities	O
as	O
well	O
as	O
different	O
subcellular	O
localizations	O
.	O

This	O
finding	O
raises	O
the	O
possibility	O
that	O
the	O
products	O
of	O
the	O
Fxh	O
and	O
A2BP1	O
genes	O
can	O
contribute	O
to	O
a	O
mechanism	O
as	O
to	O
how	O
tissue	O
specificity	O
of	O
alternative	O
splicing	O
is	O
achieved	O
.	O

Many	O
splicing	O
factors	O
are	O
detected	O
not	O
only	O
in	O
the	O
nuclei	O
,	O
but	O
also	O
in	O
the	O
cytoplasm	O
(	O
37	O
)	O
.	O

They	O
are	O
shuttling	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
and	O
,	O
in	O
some	O
instances	O
,	O
extracellular	O
stimuli	O
trigger	O
changes	O
in	O
subcellular	O
distribution	O
of	O
these	O
proteins	O
.	O

Such	O
translocations	O
have	O
been	O
reported	O
for	O
hnRNPA1	O
and	O
PTB	O
(	O
38	O
,	O
39	O
)	O
.	O

Moreover	O
,	O
a	O
number	O
of	O
RNA	O
-	O
binding	O
proteins	O
have	O
been	O
demonstrated	O
to	O
play	O
a	O
role	O
in	O
multiple	O
steps	O
during	O
gene	O
expression	O
in	O
different	O
subcellular	O
compartments	O
,	O
such	O
as	O
pre	O
-	O
mRNA	O
processing	O
in	O
nuclei	O
,	O
mRNA	O
export	O
from	O
nuclei	O
to	O
cytoplasm	O
and	O
mRNA	O
localization	O
,	O
stability	O
and	O
translation	O
in	O
cytoplasm	O
(	O
37	O
,	O
40	O
)	O
.	O

Therefore	O
,	O
not	O
surprisingly	O
,	O
Fxh	O
and	O
A2BP1	O
isoforms	O
were	O
found	O
to	O
be	O
distributed	O
in	O
both	O
the	O
nuclei	O
and	O
the	O
cytoplasm	O
in	O
HeLa	O
and	O
Y79	O
cells	O
.	O

However	O
,	O
the	O
relative	O
ratios	O
of	O
proteins	O
distributed	O
between	O
the	O
two	O
subcellular	O
compartments	O
at	O
steady	O
-	O
state	O
differ	O
among	O
the	O
isoforms	O
.	O

In	O
agreement	O
with	O
Jin	O
et	O
al	O
.	O

(	O
21	O
)	O
,	O
substantial	O
amounts	O
of	O
the	O
brain	O
isoform	O
A016	O
are	O
detected	O
in	O
nuclei	O
.	O

Other	O
A2BP1	O
isoforms	O
,	O
the	O
brain	O
isoform	O
A030	O
and	O
the	O
muscle	O
isoforms	O
A713	O
and	O
A715	O
,	O
are	O
only	O
poorly	O
detected	O
in	O
nuclei	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
reports	O
where	O
endogenous	O
A2BP1	O
in	O
cerebellar	O
Purkinje	O
cells	O
,	O
hippocampus	O
neurons	O
and	O
cardiac	O
myocytes	O
were	O
shown	O
to	O
be	O
localized	O
essentially	O
to	O
the	O
cytoplasm	O
(	O
23	O
,	O
24	O
)	O
.	O

Thus	O
,	O
inclusion	O
and	O
exclusion	O
of	O
A53	O
and	O
differences	O
in	O
the	O
very	O
N	O
-	O
terminal	O
sequences	O
results	O
in	O
A2BP1	O
isoforms	O
with	O
a	O
distinct	O
subcellular	O
localization	O
.	O

It	O
is	O
likely	O
that	O
A2BP1	O
proteins	O
have	O
multiple	O
roles	O
,	O
involving	O
both	O
nuclear	O
and	O
cytoplasmic	O
events	O
.	O

In	O
contrast	O
,	O
all	O
three	O
Fxh	O
isoforms	O
predominantly	O
localized	O
to	O
the	O
nuclei	O
.	O

Therefore	O
,	O
in	O
terms	O
of	O
their	O
localization	O
,	O
Fxh	O
proteins	O
are	O
better	O
candidates	O
for	O
regulators	O
of	O
the	O
pre	O
-	O
mRNA	O
splicing	O
that	O
takes	O
place	O
in	O
nuclei	O
.	O

Of	O
note	O
,	O
however	O
,	O
our	O
preliminary	O
results	O
of	O
5	O
'	O
RACE	O
,	O
as	O
well	O
as	O
the	O
EST	O
database	O
,	O
detect	O
multiple	O
5	O
'	O
end	O
sequences	O
for	O
both	O
Fxh	O
and	O
A2BP1	O
mRNAs	O
,	O
which	O
are	O
presumably	O
generated	O
by	O
alternative	O
promoters	O
and	O
alternative	O
splicing	O
.	O

The	O
diversity	O
of	O
the	O
5	O
'	O
end	O
cDNA	O
sequences	O
leads	O
to	O
the	O
generation	O
of	O
a	O
number	O
of	O
unique	O
N	O
-	O
terminal	O
amino	O
acid	O
sequences	O
.	O

Therefore	O
,	O
this	O
study	O
does	O
not	O
exclude	O
the	O
possible	O
existence	O
of	O
other	O
isoforms	O
with	O
different	O
subcellular	O
localizations	O
for	O
both	O
Fxh	O
and	O
A2BP1	O
.	O

Our	O
study	O
also	O
does	O
not	O
exclude	O
the	O
possibility	O
that	O
some	O
of	O
the	O
isoforms	O
translocate	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
following	O
stimuli	O
.	O

The	O
main	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
relative	O
activities	O
of	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
in	O
neural	O
cell	O
-	O
specific	O
and	O
UGCAUG	O
element	O
-	O
dependent	O
alternative	O
splicing	O
.	O

To	O
obtain	O
an	O
indication	O
of	O
the	O
relative	O
specific	O
activity	O
of	O
each	O
isoform	O
in	O
transfected	O
cells	O
,	O
the	O
same	O
amounts	O
of	O
the	O
expressed	O
proteins	O
should	O
be	O
available	O
for	O
the	O
splicing	O
reaction	O
in	O
the	O
nuclei	O
.	O

For	O
this	O
reason	O
,	O
an	O
exogenous	O
NLS	O
was	O
included	O
in	O
the	O
expressed	O
proteins	O
.	O

Essentially	O
,	O
all	O
of	O
the	O
expressed	O
proteins	O
with	O
the	O
exogenous	O
NLS	O
localized	O
to	O
nuclei	O
.	O

Thus	O
,	O
the	O
amounts	O
of	O
the	O
expressed	O
proteins	O
determined	O
by	O
immunoblots	O
represent	O
the	O
nuclear	O
concentrations	O
.	O

The	O
analysis	O
using	O
the	O
proteins	O
expressed	O
with	O
the	O
exogenous	O
NLS	O
allowed	O
us	O
to	O
compare	O
directly	O
the	O
splicing	O
activities	O
of	O
these	O
proteins	O
.	O

Furthermore	O
,	O
this	O
analysis	O
also	O
allowed	O
us	O
to	O
define	O
the	O
critical	O
regions	O
of	O
the	O
proteins	O
for	O
splicing	O
activation	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
,	O
the	O
splicing	O
activities	O
of	O
the	O
various	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
are	O
intrinsically	O
different	O
,	O
regardless	O
of	O
the	O
subcellular	O
localization	O
properties	O
of	O
the	O
wild	O
-	O
type	O
proteins	O
.	O

Among	O
the	O
isoforms	O
tested	O
in	O
this	O
study	O
,	O
F011	O
and	O
A016	O
,	O
which	O
include	O
B40	O
,	O
are	O
found	O
to	O
have	O
higher	O
activities	O
in	O
promoting	O
N30	O
inclusion	O
.	O

When	O
the	O
primary	O
amino	O
acid	O
sequences	O
,	O
outside	O
of	O
the	O
RRM	O
,	O
of	O
these	O
two	O
proteins	O
are	O
compared	O
,	O
the	O
C	O
-	O
terminal	O
regions	O
(	O
amino	O
acids	O
190	O
-	O
377	O
of	O
F011	O
)	O
show	O
a	O
higher	O
homology	O
with	O
71	O
%	O
identity	O
,	O
whereas	O
the	O
N	O
-	O
terminal	O
regions	O
(	O
amino	O
acids	O
1	O
-	O
112	O
of	O
F011	O
)	O
show	O
only	O
53	O
%	O
identity	O
.	O

The	O
C	O
-	O
terminal	O
region	O
includes	O
four	O
subregions	O
of	O
nearly	O
identical	O
stretches	O
of	O
amino	O
acids	O
(	O
Figure	O
8	O
,	O
I	O
-	O
IV	O
)	O
.	O

One	O
subregion	O
(	O
II	O
)	O
includes	O
13	O
amino	O
acids	O
encoded	O
by	O
exon	O
B40	O
.	O

Substitution	O
of	O
this	O
subregion	O
with	O
exon	O
M43	O
in	O
Fxh	O
causes	O
substantial	O
changes	O
in	O
amino	O
acid	O
sequences	O
resulting	O
in	O
only	O
a	O
21	O
%	O
identity	O
in	O
this	O
region	O
between	O
F011	O
and	O
F411	O
.	O

Another	O
subregion	O
(	O
IV	O
)	O
is	O
located	O
at	O
the	O
C	O
-	O
terminal	O
end	O
and	O
A030	O
lacks	O
this	O
homologous	O
region	O
by	O
the	O
inclusion	O
of	O
exon	O
A53	O
,	O
which	O
results	O
in	O
a	O
frame	O
shift	O
.	O

Since	O
F411	O
and	O
A030	O
show	O
poor	O
splicing	O
activation	O
compared	O
with	O
F011	O
and	O
A016	O
,	O
respectively	O
,	O
these	O
two	O
subregions	O
of	O
F011	O
and	O
A016	O
appear	O
to	O
serve	O
as	O
activation	O
domains	O
,	O
presumably	O
by	O
interacting	O
with	O
other	O
proteins	O
.	O

This	O
notion	O
is	O
supported	O
by	O
the	O
finding	O
that	O
the	O
RRM	O
-	O
lacking	O
isoform	O
F402	O
,	O
which	O
includes	O
the	O
same	O
subregions	O
II	O
and	O
IV	O
as	O
F011	O
,	O
functions	O
apparently	O
as	O
a	O
dominant	O
-	O
negative	O
mutant	O
to	O
the	O
wild	O
-	O
type	O
Fxh	O
,	O
consistent	O
with	O
the	O
interpretation	O
that	O
the	O
mutant	O
and	O
wild	O
-	O
type	O
are	O
competing	O
to	O
interact	O
with	O
other	O
protein	O
(	O
s	O
)	O
.	O

To	O
date	O
,	O
Fyn	O
tyrosine	O
kinase	O
and	O
estrogen	O
receptor	O
-	O
alpha	O
have	O
been	O
reported	O
to	O
interact	O
with	O
Fxh	O
,	O
and	O
ataxin	O
-	O
2	O
with	O
A2BP1	O
(	O
23	O
,	O
41	O
,	O
42	O
)	O
.	O

Whether	O
these	O
proteins	O
participate	O
in	O
the	O
regulation	O
of	O
pre	O
-	O
mRNA	O
splicing	O
is	O
currently	O
unknown	O
.	O

Of	O
interest	O
,	O
A030	O
with	O
the	O
exogenous	O
NLS	O
activates	O
N30	O
splicing	O
as	O
efficiently	O
as	O
F011	O
in	O
the	O
pre	O
-	O
mRNAs	O
derived	O
from	O
minigenes	O
J	O
and	O
H	O
,	O
which	O
contain	O
the	O
shorter	O
intron	O
,	O
whereas	O
this	O
isoform	O
poorly	O
activates	O
N30	O
splicing	O
in	O
the	O
pre	O
-	O
mRNA	O
from	O
minigene	O
G	O
,	O
which	O
contains	O
the	O
full	O
-	O
length	O
intron	O
.	O

This	O
observation	O
implies	O
that	O
the	O
interactions	O
of	O
A030	O
with	O
different	O
factors	O
are	O
required	O
in	O
the	O
different	O
pre	O
-	O
mRNA	O
contexts	O
.	O

Therefore	O
,	O
the	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
described	O
here	O
may	O
have	O
different	O
effects	O
on	O
other	O
UGCAUG	O
-	O
regulated	O
alternative	O
splicing	O
.	O

The	O
involvement	O
of	O
the	O
hexanucleotide	O
UGCAUG	O
in	O
regulated	O
alternative	O
splicing	O
has	O
been	O
experimentally	O
demonstrated	O
in	O
a	O
number	O
of	O
neural	O
cell	O
-	O
specific	O
,	O
as	O
well	O
as	O
other	O
tissue	O
-	O
specific	O
,	O
model	O
systems	O
(	O
13	O
-	O
21	O
)	O
.	O

This	O
hexanucleotide	O
element	O
plays	O
a	O
role	O
,	O
in	O
most	O
cases	O
,	O
as	O
an	O
enhancer	O
in	O
regulating	O
alternative	O
splicing	O
of	O
cassette	O
-	O
type	O
exons	O
as	O
well	O
as	O
mutually	O
exclusive	O
exons	O
.	O

Furthermore	O
,	O
computational	O
analysis	O
has	O
revealed	O
that	O
UGCAUG	O
is	O
over	O
-	O
represented	O
in	O
the	O
introns	O
in	O
which	O
splicing	O
is	O
regulated	O
,	O
compared	O
with	O
the	O
constitutively	O
spliced	O
introns	O
(	O
43	O
)	O
.	O

This	O
analysis	O
also	O
pointed	O
to	O
the	O
UGCAUG	O
element	O
as	O
playing	O
a	O
role	O
in	O
the	O
regulation	O
of	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
in	O
a	O
wide	O
range	O
of	O
tissues	O
,	O
but	O
not	O
in	O
specific	O
tissues	O
.	O

To	O
date	O
,	O
KH	O
-	O
type	O
splicing	O
regulatory	O
protein	O
(	O
KSRP	O
)	O
(	O
44	O
)	O
,	O
A2BP1	O
(	O
21	O
)	O
and	O
Fxh	O
(	O
this	O
study	O
)	O
are	O
known	O
to	O
be	O
capable	O
of	O
binding	O
to	O
UGCAUG	O
.	O

KSRP	O
is	O
expressed	O
ubiquitously	O
and	O
tissue	O
-	O
specific	O
variants	O
of	O
this	O
gene	O
have	O
not	O
been	O
described	O
so	O
far	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
described	O
the	O
existence	O
of	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
,	O
which	O
,	O
while	O
not	O
identical	O
in	O
some	O
areas	O
of	O
the	O
molecule	O
,	O
may	O
contain	O
the	O
same	O
RRM	O
.	O

The	O
physiological	O
relevance	O
of	O
these	O
isoforms	O
is	O
that	O
they	O
have	O
different	O
splicing	O
activities	O
and	O
different	O
subcellular	O
localizations	O
.	O

The	O
brain	O
isoforms	O
promote	O
N30	O
inclusion	O
more	O
efficiently	O
than	O
the	O
muscle	O
isoforms	O
of	O
both	O
Fxh	O
and	O
A2BP1	O
.	O

The	O
isoforms	O
lacking	O
the	O
RRM	O
are	O
normally	O
expressed	O
to	O
a	O
significant	O
extent	O
in	O
skeletal	O
muscles	O
.	O

This	O
isoform	O
is	O
incapable	O
of	O
activating	O
N30	O
splicing	O
and	O
,	O
moreover	O
,	O
can	O
inhibit	O
N30	O
inclusion	O
.	O

The	O
properties	O
of	O
these	O
isoforms	O
are	O
consistent	O
with	O
Fxh	O
and	O
A2BP1	O
acting	O
as	O
regulators	O
for	O
N30	O
splicing	O
,	O
since	O
N30	O
is	O
included	O
in	O
neuronal	O
cells	O
,	O
but	O
excluded	O
in	O
muscles	O
.	O

Therefore	O
,	O
despite	O
the	O
tissue	O
-	O
independent	O
occurrence	O
of	O
UGCAUG	O
as	O
a	O
regulatory	O
element	O
,	O
given	O
the	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
the	O
UGCAUG	O
-	O
binding	O
proteins	O
(	O
Fxh	O
and	O
A2BP1	O
)	O
with	O
different	O
activities	O
,	O
the	O
hexanucleotide	O
UGCAUG	O
could	O
confer	O
tissue	O
specificity	O
on	O
regulated	O
splicing	O
.	O

One	O
of	O
the	O
major	O
problems	O
in	O
understanding	O
the	O
mechanisms	O
responsible	O
for	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
is	O
the	O
manner	O
in	O
which	O
tissue	O
specificity	O
is	O
determined	O
.	O

In	O
vertebrates	O
,	O
to	O
date	O
,	O
only	O
a	O
few	O
tissue	O
-	O
specific	O
proteins	O
have	O
been	O
identified	O
as	O
splicing	O
regulators	O
(	O
8	O
-	O
12	O
)	O
.	O

Here	O
,	O
we	O
have	O
shown	O
that	O
the	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
the	O
sequence	O
-	O
specific	O
RNA	O
-	O
binding	O
proteins	O
,	O
which	O
themselves	O
are	O
generated	O
by	O
alternative	O
splicing	O
,	O
have	O
different	O
activities	O
in	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
of	O
target	O
pre	O
-	O
mRNA	O
.	O

Therefore	O
,	O
these	O
isoforms	O
play	O
a	O
role	O
in	O
the	O
determination	O
of	O
tissue	O
specificity	O
of	O
target	O
pre	O
-	O
mRNA	O
splicing	O
.	O

The	O
discovery	O
of	O
these	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
the	O
UGCAUG	O
-	O
binding	O
proteins	O
with	O
different	O
splicing	O
activities	O
adds	O
an	O
important	O
new	O
dimension	O
to	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
regulating	O
tissue	O
-	O
dependent	O
alternative	O
splicing	O
mediated	O
via	O
UGCAUG	O
.	O

Mutations	O
of	O
PIK3CA	O
in	O
gastric	O
adenocarcinoma	O

Abstract	O

Background	O

Activation	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
through	O
mutational	O
inactivation	O
of	O
PTEN	O
tumour	O
suppressor	O
gene	O
is	O
common	O
in	O
diverse	O
cancer	O
types	O
,	O
but	O
rarely	O
reported	O
in	O
gastric	O
cancer	O
.	O

Recently	O
,	O
mutations	O
in	O
PIK3CA	O
,	O
which	O
encodes	O
the	O
p110	O
alpha	O
catalytic	O
subunit	O
of	O
PI3K	O
,	O
have	O
been	O
identified	O
in	O
various	O
human	S-Species
cancers	O
,	O
including	O
3	O
of	O
12	O
gastric	O
cancers	O
.	O

Eighty	O
percent	O
of	O
these	O
reported	O
mutations	O
clustered	O
within	O
2	O
regions	O
involving	O
the	O
helical	O
and	O
kinase	O
domains	O
.	O

In	O
vitro	O
study	O
on	O
one	O
of	O
the	O
"	O
hot	O
-	O
spot	O
"	O
mutants	O
has	O
demonstrated	O
it	O
as	O
an	O
activating	O
mutation	O
.	O

Methods	O

Based	O
on	O
these	O
data	O
,	O
we	O
initiated	O
PIK3CA	O
mutation	O
screening	O
in	O
94	O
human	S-Species
gastric	O
cancers	O
by	O
direct	O
sequencing	O
of	O
the	O
gene	O
regions	O
in	O
which	O
80	O
%	O
of	O
all	O
the	O
known	O
PIK3CA	O
mutations	O
were	O
found	O
.	O

We	O
also	O
examined	O
PIK3CA	O
expression	O
level	O
by	O
extracting	O
data	O
from	O
the	O
previous	O
large	O
-	O
scale	O
gene	O
expression	O
profiling	O
study	O
.	O

Using	O
Significance	O
Analysis	O
of	O
Microarrays	O
(	O
SAM	O
)	O
,	O
we	O
further	O
searched	O
for	O
genes	O
that	O
show	O
correlating	O
expression	O
with	O
PIK3CA	O
.	O

Results	O

We	O
have	O
identified	O
PIK3CA	O
mutations	O
in	O
4	O
cases	O
(	O
4	O
.	O
3	O
%	O
)	O
,	O
all	O
involving	O
the	O
previously	O
reported	O
hotspots	O
.	O

Among	O
these	O
4	O
cases	O
,	O
3	O
tumours	O
demonstrated	O
microsatellite	O
instability	O
and	O
2	O
tumours	O
harboured	O
concurrent	O
KRAS	O
mutation	O
.	O

Data	O
extracted	O
from	O
microarray	O
studies	O
showed	O
an	O
increased	O
expression	O
of	O
PIK3CA	O
in	O
gastric	O
cancers	O
when	O
compared	O
with	O
the	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

SAM	O
further	O
identified	O
2910	O
genes	O
whose	O
expression	O
levels	O
were	O
positively	O
associated	O
with	O
that	O
of	O
PIK3CA	O
.	O

Conclusion	O

Our	O
data	O
suggested	O
that	O
activation	O
of	O
the	O
PI3K	O
signalling	O
pathway	O
in	O
gastric	O
cancer	O
may	O
be	O
achieved	O
through	O
up	O
-	O
regulation	O
or	O
mutation	O
of	O
PIK3CA	O
,	O
in	O
which	O
the	O
latter	O
may	O
be	O
a	O
consequence	O
of	O
mismatch	O
repair	O
deficiency	O
.	O

Background	O

The	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
-	O
AKT	O
signalling	O
pathway	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
diverse	O
cellular	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
survival	O
and	O
motility	O
.	O

Abnormal	O
activation	O
of	O
this	O
pathway	O
is	O
frequently	O
observed	O
in	O
various	O
cancer	O
types	O
,	O
leading	O
to	O
aberrant	O
cell	O
cycle	O
progression	O
,	O
altered	O
adhesion	O
and	O
motility	O
,	O
inhibition	O
of	O
apoptosis	O
and	O
induction	O
of	O
angiogenesis	O
[	O
1	O
]	O
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
genetic	O
alterations	O
involving	O
various	O
members	O
along	O
this	O
signalling	O
pathway	O
could	O
lead	O
to	O
its	O
activation	O
in	O
cancer	O
.	O

These	O
include	O
mutation	O
,	O
allelic	O
loss	O
or	O
promoter	O
methylation	O
of	O
the	O
negative	O
regulator	O
PTEN	O
[	O
2	O
]	O
;	O
or	O
alternatively	O
,	O
chromosomal	O
amplification	O
or	O
over	O
-	O
expression	O
of	O
the	O
positive	O
regulators	O
PIK3CA	O
[	O
3	O
-	O
5	O
]	O
and	O
the	O
various	O
AKT	O
kinases	O
[	O
6	O
,	O
7	O
]	O
.	O

Furthermore	O
,	O
changes	O
in	O
other	O
related	O
pathways	O
that	O
are	O
commonly	O
altered	O
in	O
cancer	O
,	O
such	O
as	O
those	O
involved	O
in	O
growth	O
factor	O
stimulation	O
via	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
or	O
through	O
direct	O
interaction	O
with	O
the	O
activated	O
form	O
of	O
small	O
GTPase	O
RAS	O
,	O
can	O
also	O
lead	O
to	O
PI3K	O
-	O
AKT	O
pathway	O
activation	O
[	O
8	O
]	O
.	O

Activation	O
of	O
this	O
pathway	O
results	O
in	O
the	O
phosphorylation	O
of	O
AKT	O
at	O
Thr	O
-	O
308	O
/	O
309	O
and	O
Ser	O
-	O
473	O
/	O
474	O
.	O

These	O
phosphorylated	O
forms	O
of	O
AKT	O
proteins	O
have	O
been	O
detected	O
by	O
Western	O
blot	O
or	O
immunohistochemistry	O
in	O
various	O
cancer	O
types	O
,	O
suggesting	O
the	O
frequent	O
activation	O
of	O
PI3K	O
-	O
AKT	O
pathway	O
in	O
the	O
carcinogenic	O
process	O
[	O
7	O
,	O
9	O
]	O
.	O

Although	O
genetic	O
changes	O
along	O
the	O
PI3K	O
-	O
AKT	O
pathway	O
have	O
been	O
repeatedly	O
documented	O
in	O
brain	O
,	O
ovarian	O
,	O
endometrial	O
,	O
breast	O
,	O
prostate	O
and	O
thyroid	O
cancers	O
[	O
1	O
,	O
2	O
]	O
,	O
reports	O
on	O
its	O
mechanism	O
of	O
activation	O
in	O
gastric	O
cancer	O
are	O
limited	O
.	O

Gastric	O
cancer	O
is	O
the	O
second	O
most	O
common	O
cancer	O
worldwide	O
but	O
its	O
molecular	O
basis	O
of	O
tumourigenesis	O
is	O
still	O
poorly	O
understood	O
.	O

Previous	O
immunohistochemical	O
study	O
has	O
demonstrated	O
the	O
presence	O
of	O
the	O
phosphorylated	O
form	O
of	O
AKT	O
in	O
78	O
%	O
of	O
gastric	O
cancer	O
[	O
10	O
]	O
,	O
suggesting	O
that	O
activation	O
of	O
this	O
pathway	O
may	O
also	O
be	O
common	O
in	O
gastric	O
cancer	O
.	O

Though	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
involving	O
the	O
PTEN	O
locus	O
has	O
been	O
demonstrated	O
in	O
47	O
%	O
of	O
gastric	O
cancer	O
in	O
a	O
recent	O
study	O
,	O
mutation	O
or	O
promoter	O
methylation	O
was	O
absent	O
even	O
in	O
cases	O
with	O
LOH	O
[	O
11	O
]	O
.	O

Thus	O
data	O
from	O
this	O
study	O
could	O
not	O
support	O
the	O
two	O
-	O
hit	O
inactivation	O
of	O
PTEN	O
in	O
gastric	O
cancer	O
,	O
while	O
the	O
biological	O
significance	O
of	O
PTEN	O
haploinsufficiency	O
remains	O
controversial	O
.	O

Alternatively	O
,	O
amplification	O
of	O
AKT1	O
has	O
been	O
reported	O
in	O
a	O
single	O
case	O
of	O
gastric	O
cancer	O
[	O
12	O
]	O
,	O
and	O
amplification	O
of	O
PIK3CA	O
associated	O
with	O
elevated	O
mRNA	O
levels	O
has	O
been	O
found	O
in	O
36	O
%	O
of	O
gastric	O
cancer	O
[	O
11	O
]	O
.	O

More	O
recently	O
,	O
Samuels	O
et	O
al	O
.	O
screened	O
a	O
diverse	O
spectrum	O
of	O
human	S-Species
cancers	O
for	O
mutation	O
in	O
16	O
PI3K	O
or	O
PI3K	O
-	O
like	O
genes	O
and	O
found	O
a	O
high	O
frequency	O
of	O
somatic	O
mutation	O
in	O
PIK3CA	O
,	O
which	O
encodes	O
the	O
p110	O
alpha	O
catalytic	O
subunit	O
.	O

Major	O
screening	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
identified	O
PIK3CA	O
mutations	O
in	O
74	O
out	O
of	O
234	O
(	O
32	O
%	O
)	O
cases	O
,	O
while	O
mutations	O
were	O
also	O
noted	O
in	O
3	O
out	O
of	O
12	O
(	O
25	O
%	O
)	O
gastric	O
cancers	O
.	O

Reported	O
mutations	O
were	O
mostly	O
of	O
missense	O
type	O
,	O
and	O
clustered	O
within	O
2	O
regions	O
in	O
the	O
helical	O
and	O
kinase	O
domains	O
.	O

Expression	O
of	O
a	O
"	O
hot	O
-	O
spot	O
"	O
mutant	O
,	O
H1047R	O
,	O
conferred	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
lipid	O
kinase	O
activity	O
of	O
PIK3CA	O
,	O
suggesting	O
it	O
as	O
an	O
activating	O
mutation	O
[	O
13	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
a	O
series	O
of	O
94	O
human	S-Species
gastric	O
adenocarcinomas	O
for	O
PIK3CA	O
mutation	O
.	O

We	O
have	O
also	O
examined	O
PIK3CA	O
expression	O
level	O
by	O
extracting	O
data	O
from	O
a	O
large	O
-	O
scale	O
gene	O
expression	O
profiling	O
study	O
previously	O
performed	O
for	O
these	O
cases	O
[	O
14	O
,	O
15	O
]	O
.	O

Using	O
SAM	O
,	O
genes	O
with	O
significant	O
correlating	O
expression	O
with	O
PIK3CA	O
have	O
also	O
been	O
identified	O
.	O

Methods	O

Patient	S-Species
samples	O
preparation	O

DNA	O
samples	O
used	O
for	O
sequencing	O
were	O
prepared	O
from	O
frozen	O
tumour	O
and	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
from	O
94	O
gastric	O
cancer	O
patients	S-Species
who	O
underwent	O
gastrectomy	O
in	O
the	O
Department	O
of	O
Surgery	O
,	O
Queen	O
Mary	O
Hospital	O
,	O
The	O
University	O
of	O
Hong	O
Kong	O
,	O
as	O
previously	O
described	O
[	O
16	O
]	O
.	O

Majority	O
of	O
the	O
frozen	O
samples	O
(	O
n	O
=	O
81	O
)	O
showed	O
tumour	O
component	O
of	O
over	O
70	O
%	O
,	O
whereas	O
in	O
13	O
cases	O
a	O
lower	O
proportion	O
between	O
50	O
to	O
70	O
%	O
was	O
accepted	O
due	O
to	O
the	O
tumours	O
'	O
inherent	O
diffuse	O
infiltrative	O
nature	O
with	O
entrapment	O
of	O
non	O
-	O
neoplastic	O
components	O
.	O

Analysis	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
BRAF	O
and	O
KRAS	O
mutation	O
have	O
been	O
performed	O
and	O
reported	O
previously	O
[	O
16	O
]	O
.	O

RNA	O
preparation	O
and	O
gene	O
expression	O
profiling	O
using	O
a	O
cDNA	O
microarray	O
containing	O
44	O
,	O
500	O
cDNA	O
clones	O
,	O
representing	O
around	O
30	O
,	O
300	O
unique	O
genes	O
,	O
has	O
been	O
performed	O
and	O
reported	O
in	O
90	O
of	O
these	O
tumours	O
in	O
comparison	O
to	O
22	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
[	O
14	O
,	O
15	O
]	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
University	O
of	O
Hong	O
Kong	O
.	O

Mutational	O
screening	O

Mutation	O
screening	O
of	O
PIK3CA	O
was	O
performed	O
for	O
exons	O
9	O
and	O
20	O
,	O
covering	O
the	O
mutational	O
hotspots	O
;	O
and	O
for	O
exon	O
18	O
,	O
from	O
which	O
a	O
mutation	O
was	O
found	O
in	O
a	O
gastric	O
cancer	O
.	O

Mutations	O
in	O
these	O
3	O
exons	O
constituted	O
80	O
%	O
of	O
all	O
PIK3CA	O
mutations	O
detected	O
in	O
the	O
previous	O
study	O
[	O
13	O
]	O
.	O

PIK3CA	O
intron	O
-	O
specific	O
external	O
amplification	O
primers	O
and	O
internal	O
sequencing	O
primers	O
were	O
designed	O
according	O
to	O
the	O
previous	O
study	O
[	O
13	O
]	O
with	O
some	O
modifications	O
[	O
see	O
Additional	O
file	O
1	O
]	O
.	O

In	O
particular	O
,	O
primers	O
for	O
exon	O
9	O
have	O
been	O
modified	O
to	O
avoid	O
amplification	O
of	O
homologous	O
sequences	O
located	O
in	O
other	O
chromosomes	O
.	O

PCR	O
products	O
were	O
generated	O
using	O
the	O
external	O
primers	O
and	O
directly	O
sequenced	O
using	O
the	O
internal	O
primers	O
with	O
the	O
DYEnamic	O
(TM)	O
ET	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
(	O
Amersham	O
Biosciences	O
,	O
Freiburg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Electrophoresis	O
was	O
performed	O
in	O
the	O
ABI	O
Prism	O
(R)	O
3700	O
DNA	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
each	O
exon	O
,	O
PCR	O
products	O
were	O
generated	O
from	O
2	O
independent	O
PCR	O
reactions	O
for	O
sequencing	O
of	O
the	O
forward	O
and	O
reverse	O
strands	O
.	O

For	O
exon	O
9	O
,	O
2	O
independent	O
PCR	O
followed	O
by	O
sequencing	O
of	O
the	O
forward	O
strand	O
were	O
performed	O
.	O

Analysis	O
of	O
the	O
chromatograms	O
was	O
performed	O
using	O
the	O
mutation	O
analysis	O
software	O
Mutation	O
Explorer	O
(TM)	O
(	O
SoftGenetics	O
,	O
State	O
College	O
,	O
PA	O
,	O
USA	O
)	O
.	O

Extraction	O
of	O
expression	O
data	O
and	O
statistical	O
analysis	O

Gene	O
expression	O
data	O
were	O
extracted	O
from	O
the	O
microarray	O
database	O
containing	O
126	O
samples	O
(	O
90	O
gastric	O
cancers	O
,	O
14	O
lymph	O
node	O
metastasis	O
and	O
22	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
)	O
based	O
on	O
a	O
3	O
-	O
fold	O
signal	O
above	O
background	O
ratio	O
for	O
either	O
channel	O
and	O
with	O
80	O
%	O
good	O
data	O
[	O
14	O
]	O
.	O

Gene	O
expression	O
data	O
from	O
20	O
,	O
336	O
cDNA	O
clones	O
satisfied	O
this	O
selection	O
criteria	O
and	O
were	O
extracted	O
,	O
which	O
included	O
a	O
cDNA	O
clone	O
corresponding	O
to	O
PIK3CA	O
(	O
IMAGE	O
clone	O
number	O
345430	O
,	O
GenBank	O
accession	O
no	O
.	O
W72473	O
)	O
.	O

Expression	O
data	O
for	O
PIK3CA	O
was	O
extracted	O
and	O
the	O
differences	O
in	O
expression	O
levels	O
between	O
tumour	O
and	O
non	O
-	O
tumour	O
tissues	O
were	O
examined	O
using	O
the	O
Student	O
'	O
s	O
t	O
-	O
Test	O
.	O

SAM	O
was	O
performed	O
to	O
identify	O
genes	O
with	O
significant	O
correlating	O
expression	O
with	O
PIK3CA	O
[	O
17	O
]	O
.	O

The	O
missing	O
values	O
in	O
the	O
dataset	O
were	O
estimated	O
by	O
a	O
K	O
-	O
nearest	O
neighbours	O
impute	O
algorithm	O
using	O
10	O
nearest	O
neighbour	O
[	O
18	O
]	O
followed	O
by	O
5000	O
permutations	O
in	O
the	O
SAM	O
analysis	O
.	O

Results	O

Among	O
the	O
94	O
gastric	O
adenocarcinoma	O
analysed	O
,	O
we	O
have	O
detected	O
PIK3CA	O
mutation	O
in	O
4	O
cases	O
.	O

Two	O
cases	O
harboured	O
the	O
mutation	O
A3140G	O
(	O
H1047R	O
)	O
in	O
exon	O
20	O
,	O
and	O
the	O
other	O
2	O
cases	O
with	O
mutations	O
G1624A	O
(	O
E542K	O
)	O
and	O
G1633A	O
(	O
E545K	O
)	O
in	O
exon	O
9	O
.	O

Representative	O
sequence	O
chromatograms	O
are	O
shown	O
in	O
figure	O
1	O
.	O

All	O
four	O
mutations	O
were	O
absent	O
in	O
the	O
corresponding	O
non	O
-	O
neoplastic	O
mucosae	O
and	O
thus	O
were	O
confirmed	O
as	O
somatic	O
mutations	O
.	O

Though	O
the	O
overall	O
mutation	O
frequency	O
(	O
4	O
.	O
3	O
%	O
)	O
was	O
lower	O
than	O
that	O
of	O
the	O
previous	O
study	O
,	O
the	O
nature	O
of	O
the	O
4	O
mutations	O
found	O
were	O
consistent	O
with	O
those	O
identified	O
at	O
the	O
reported	O
hotspots	O
.	O

In	O
particular	O
,	O
the	O
H1047R	O
mutation	O
has	O
been	O
reported	O
in	O
2	O
gastric	O
cancers	O
and	O
15	O
colorectal	O
cancers	O
[	O
13	O
]	O
.	O

While	O
the	O
E542K	O
and	O
the	O
E545K	O
mutations	O
were	O
not	O
found	O
in	O
gastric	O
cancer	O
in	O
the	O
previous	O
series	O
,	O
a	O
large	O
number	O
of	O
colorectal	O
tumours	O
did	O
harbour	O
these	O
2	O
mutations	O
.	O

PIK3CA	O
mutation	O
spectrum	O
and	O
their	O
corresponding	O
clinico	O
-	O
pathological	O
features	O
were	O
listed	O
in	O
Table	O
1	O
.	O

We	O
noted	O
a	O
higher	O
tendency	O
of	O
high	O
-	O
level	O
MSI	O
in	O
gastric	O
cancers	O
with	O
PIK3CA	O
mutations	O
(	O
3	O
in	O
4	O
,	O
75	O
%	O
)	O
than	O
in	O
those	O
without	O
(	O
18	O
in	O
90	O
,	O
20	O
%	O
)	O
.	O

Moreover	O
,	O
though	O
the	O
overall	O
incidence	O
of	O
KRAS	O
mutation	O
in	O
the	O
studied	O
population	O
was	O
low	O
(	O
8	O
in	O
94	O
)	O
,	O
2	O
of	O
the	O
4	O
gastric	O
cancers	O
with	O
PIK3CA	O
mutation	O
also	O
harboured	O
a	O
KRAS	O
mutation	O
.	O

Since	O
over	O
-	O
expression	O
of	O
PIK3CA	O
has	O
been	O
reported	O
in	O
gastric	O
cancer	O
[	O
11	O
]	O
,	O
we	O
have	O
also	O
extracted	O
PIK3CA	O
expression	O
data	O
from	O
our	O
previous	O
cDNA	O
microarray	O
study	O
of	O
these	O
cases	O
[	O
14	O
,	O
15	O
]	O
.	O

We	O
have	O
confirmed	O
that	O
expression	O
level	O
of	O
PIK3CA	O
was	O
significantly	O
higher	O
in	O
gastric	O
cancers	O
(	O
n	O
=	O
87	O
,	O
mean	O
=	O
0	O
.	O
099	O
,	O
SD	O
=	O
0	O
.	O
428	O
)	O
when	O
compared	O
with	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
(	O
n	O
=	O
22	O
,	O
mean	O
=	O
-	O
0	O
.	O
418	O
,	O
SD	O
=	O
0	O
.	O
426	O
;	O
Student	O
'	O
s	O
t	O
-	O
Test	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Using	O
PIK3CA	O
expression	O
level	O
as	O
a	O
continuous	O
variable	O
for	O
SAM	O
analysis	O
[	O
17	O
]	O
,	O
we	O
found	O
2910	O
cDNA	O
clones	O
(	O
corresponding	O
to	O
about	O
2546	O
unique	O
genes	O
)	O
whose	O
expression	O
associated	O
positively	O
with	O
PIK3CA	O
expression	O
(	O
median	O
number	O
of	O
false	O
significant	O
=	O
0	O
.	O
372	O
,	O
Delta	O
=	O
1	O
.	O
107	O
)	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

Interestingly	O
,	O
no	O
gene	O
was	O
found	O
to	O
be	O
negatively	O
associated	O
with	O
PIK3CA	O
expression	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
have	O
reported	O
the	O
presence	O
of	O
PIK3CA	O
gene	O
mutation	O
in	O
4	O
.	O
3	O
%	O
of	O
gastric	O
cancer	O
.	O

A	O
high	O
tendency	O
(	O
3	O
in	O
4	O
)	O
of	O
mismatch	O
repair	O
deficiency	O
was	O
noted	O
in	O
cases	O
harbouring	O
PIK3CA	O
mutation	O
.	O

Though	O
the	O
small	O
number	O
of	O
PIK3CA	O
mutations	O
in	O
our	O
study	O
may	O
not	O
justify	O
statistical	O
claim	O
of	O
significance	O
;	O
suggestion	O
of	O
such	O
,	O
despite	O
of	O
its	O
not	O
being	O
mentioned	O
by	O
the	O
authors	O
,	O
can	O
be	O
found	O
from	O
a	O
previous	O
study	O
in	O
CRC	O
by	O
Samuels	O
et	O
al	O
.	O
.	O

From	O
their	O
study	O
of	O
33	O
MSI	O
and	O
201	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
CRC	O
cases	O
,	O
PIK3CA	O
mutation	O
was	O
present	O
in	O
48	O
%	O
of	O
the	O
MSI	O
tumours	O
,	O
but	O
only	O
in	O
29	O
%	O
of	O
the	O
MSS	O
tumours	O
.	O

A	O
significant	O
association	O
would	O
have	O
been	O
revealed	O
if	O
statistical	O
analysis	O
had	O
been	O
applied	O
(	O
Fisher	O
'	O
s	O
exact	O
test	O
,	O
p	O
=	O
0	O
.	O
014	O
)	O
[	O
13	O
]	O
.	O

Gastrointestinal	O
tract	O
cancers	O
with	O
MSI	O
are	O
known	O
to	O
have	O
a	O
different	O
molecular	O
pathway	O
of	O
tumour	O
evolution	O
compared	O
with	O
their	O
MSS	O
counterparts	O
[	O
19	O
,	O
20	O
]	O
.	O

This	O
can	O
be	O
attributed	O
to	O
their	O
propensity	O
for	O
frameshift	O
mutations	O
in	O
repeat	O
sequences	O
,	O
resulting	O
in	O
selective	O
disruption	O
of	O
genes	O
with	O
such	O
sequences	O
within	O
their	O
coding	O
regions	O
.	O

With	O
2	O
poly	O
-	O
adenine	O
tracts	O
within	O
its	O
coding	O
region	O
,	O
PTEN	O
can	O
be	O
inactivated	O
through	O
frameshift	O
mutations	O
in	O
MSI	O
CRC	O
,	O
resulting	O
in	O
the	O
selective	O
targeting	O
of	O
the	O
PI3K	O
-	O
AKT	O
signalling	O
pathway	O
[	O
21	O
,	O
22	O
]	O
.	O

It	O
is	O
also	O
known	O
that	O
mismatch	O
repair	O
deficiency	O
would	O
lead	O
to	O
an	O
elevated	O
rate	O
of	O
missense	O
mutation	O
due	O
to	O
impaired	O
single	O
nucleotide	O
mismatch	O
repair	O
[	O
23	O
]	O
.	O

Thus	O
,	O
the	O
observed	O
higher	O
incidence	O
of	O
PIK3CA	O
missense	O
mutation	O
in	O
MSI	O
colorectal	O
and	O
gastric	O
cancers	O
suggests	O
yet	O
another	O
mechanism	O
for	O
the	O
activation	O
of	O
the	O
PI3K	O
-	O
AKT	O
signalling	O
pathway	O
through	O
mismatch	O
repair	O
deficiency	O
.	O

Our	O
data	O
also	O
showed	O
a	O
higher	O
tendency	O
of	O
KRAS	O
mutation	O
in	O
cases	O
with	O
PIK3CA	O
mutations	O
(	O
2	O
in	O
4	O
)	O
than	O
in	O
those	O
without	O
(	O
6	O
in	O
90	O
)	O
.	O

Yet	O
again	O
due	O
to	O
the	O
low	O
incidence	O
of	O
both	O
mutations	O
in	O
our	O
samples	O
,	O
statistical	O
significance	O
may	O
not	O
be	O
claimed	O
.	O

In	O
the	O
study	O
by	O
Samuels	O
et	O
al	O
.	O
,	O
some	O
of	O
the	O
colorectal	O
tumours	O
with	O
PIK3CA	O
mutation	O
also	O
harboured	O
KRAS	O
or	O
BRAF	O
mutation	O
[	O
13	O
]	O
.	O

The	O
PI3K	O
-	O
AKT	O
pathway	O
is	O
known	O
to	O
have	O
a	O
close	O
association	O
with	O
the	O
RAS	O
-	O
MEKK	O
signalling	O
pathway	O
[	O
8	O
]	O
.	O

Constitutively	O
active	O
RAS	O
can	O
interact	O
with	O
the	O
catalytic	O
subunit	O
of	O
PI3K	O
and	O
lead	O
to	O
its	O
activation	O
.	O

Ras	O
-	O
dependent	O
PI3K	O
activation	O
contributes	O
to	O
the	O
transforming	O
phenotype	O
by	O
mediating	O
anchorage	O
-	O
independent	O
growth	O
,	O
cytoskeletal	O
reorganisation	O
and	O
apoptosis	O
evasion	O
.	O

It	O
has	O
been	O
observed	O
that	O
genes	O
involved	O
in	O
the	O
same	O
signalling	O
pathway	O
may	O
manifest	O
mutations	O
in	O
cancer	O
cells	O
in	O
a	O
mutually	O
exclusive	O
manner	O
,	O
presumably	O
due	O
to	O
the	O
lack	O
of	O
selective	O
growth	O
advantage	O
in	O
having	O
a	O
second	O
hit	O
in	O
the	O
already	O
altered	O
pathway	O
.	O

A	O
prominent	O
example	O
is	O
the	O
mutually	O
exclusive	O
occurrence	O
of	O
the	O
BRAF	O
hotspot	O
mutation	O
(	O
V600E	O
)	O
and	O
KRAS	O
mutations	O
in	O
colorectal	O
cancer	O
[	O
24	O
,	O
25	O
]	O
.	O

However	O
,	O
there	O
exist	O
other	O
examples	O
of	O
alterations	O
in	O
multiple	O
components	O
of	O
the	O
same	O
signalling	O
pathway	O
that	O
may	O
lead	O
to	O
a	O
multi	O
-	O
level	O
modulation	O
of	O
its	O
activity	O
.	O

For	O
example	O
,	O
non	O
-	O
V600E	O
BRAF	O
mutations	O
tend	O
to	O
occur	O
together	O
with	O
KRAS	O
mutations	O
[	O
26	O
]	O
,	O
and	O
inactivation	O
of	O
the	O
secreted	O
frizzled	O
-	O
related	O
proteins	O
(	O
antagonists	O
of	O
WNT	O
)	O
by	O
promoter	O
methylation	O
frequently	O
coincides	O
with	O
mutations	O
in	O
the	O
Adenomatous	O
Polyposis	O
Coli	O
gene	O
to	O
achieve	O
multi	O
-	O
level	O
activation	O
of	O
the	O
WNT	O
signalling	O
pathway	O
in	O
colorectal	O
cancers	O
[	O
27	O
]	O
.	O

Whether	O
PIK3CA	O
functions	O
independently	O
from	O
RAS	O
,	O
or	O
acts	O
synergistically	O
with	O
RAS	O
to	O
produce	O
additive	O
effects	O
on	O
the	O
activation	O
of	O
the	O
same	O
pathway	O
awaits	O
further	O
clarification	O
.	O

By	O
extracting	O
data	O
from	O
microarray	O
,	O
we	O
have	O
confirmed	O
the	O
up	O
-	O
regulation	O
of	O
PIK3CA	O
expression	O
in	O
gastric	O
cancer	O
tissues	O
compared	O
with	O
the	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
and	O
identified	O
a	O
large	O
number	O
of	O
genes	O
that	O
showed	O
a	O
significant	O
positive	O
correlation	O
in	O
expression	O
level	O
with	O
PIK3CA	O
.	O

These	O
genes	O
participate	O
in	O
diverse	O
cellular	O
processes	O
with	O
177	O
as	O
putative	O
cell	O
cycle	O
-	O
regulated	O
genes	O
[	O
28	O
]	O
and	O
126	O
mapped	O
to	O
genes	O
with	O
known	O
functions	O
in	O
cell	O
cycle	O
regulation	O
,	O
cell	O
proliferation	O
or	O
DNA	O
replication	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

While	O
some	O
of	O
these	O
genes	O
maybe	O
induced	O
by	O
PIK3CA	O
,	O
others	O
maybe	O
co	O
-	O
ordinately	O
regulated	O
by	O
common	O
upstream	O
signals	O
.	O

Expression	O
data	O
set	O
at	O
one	O
point	O
was	O
limited	O
in	O
differentiating	O
the	O
above	O
cause	O
and	O
consequence	O
,	O
yet	O
it	O
certainly	O
revealed	O
the	O
complexity	O
of	O
the	O
carcinogenic	O
process	O
and	O
the	O
intricate	O
relationship	O
of	O
PIK3CA	O
signalling	O
with	O
other	O
cellular	O
processes	O
.	O

Contrary	O
to	O
our	O
expectation	O
,	O
the	O
incidence	O
of	O
PIK3CA	O
mutation	O
found	O
in	O
the	O
current	O
study	O
(	O
4	O
%	O
)	O
is	O
much	O
lower	O
compared	O
with	O
that	O
observed	O
by	O
Samuel	O
et	O
al	O
.	O

(	O
25	O
%	O
)	O
[	O
13	O
]	O
.	O

The	O
reason	O
for	O
discrepancy	O
may	O
simply	O
be	O
a	O
result	O
of	O
sample	O
bias	O
as	O
the	O
previous	O
study	O
involved	O
only	O
a	O
small	O
number	O
of	O
gastric	O
cancers	O
(	O
n	O
=	O
12	O
)	O
.	O

However	O
,	O
ethnic	O
differences	O
can	O
also	O
be	O
another	O
possibility	O
.	O

The	O
diverse	O
pathological	O
spectrum	O
and	O
aetiological	O
factors	O
of	O
gastric	O
cancers	O
in	O
different	O
geographical	O
locations	O
may	O
be	O
paralleled	O
by	O
differences	O
in	O
molecular	O
pathway	O
of	O
tumour	O
development	O
.	O

Since	O
our	O
current	O
study	O
is	O
only	O
based	O
on	O
a	O
Chinese	O
population	O
with	O
an	O
intermediate	O
gastric	O
cancer	O
incidence	O
,	O
further	O
studies	O
involving	O
patients	S-Species
from	O
different	O
ethnic	O
groups	O
will	O
be	O
able	O
to	O
address	O
this	O
possibility	O
.	O

Conclusion	O

Large	O
-	O
scale	O
screening	O
of	O
gastric	O
adenocarcinomas	O
for	O
PIK3CA	O
mutations	O
revealed	O
a	O
mutation	O
incidence	O
of	O
4	O
.	O
3	O
%	O
.	O

Increased	O
PIK3CA	O
expression	O
level	O
was	O
observed	O
in	O
gastric	O
tumours	O
compared	O
with	O
non	O
-	O
neoplastic	O
mucosae	O
.	O

This	O
increase	O
in	O
PIK3CA	O
level	O
was	O
associated	O
with	O
the	O
elevated	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
,	O
which	O
may	O
constitute	O
the	O
upstream	O
regulators	O
or	O
downstream	O
targets	O
of	O
PIK3CA	O
along	O
the	O
PI3K	O
signalling	O
pathway	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

VSWL	O
carried	O
out	O
the	O
molecular	O
analysis	O
,	O
performed	O
data	O
analysis	O
and	O
drafted	O
the	O
manuscript	O
.	O

CWW	O
,	O
TLC	O
,	O
WZ	O
assisted	O
in	O
the	O
molecular	O
analysis	O
.	O

KMC	O
provided	O
the	O
clinical	O
data	O
.	O

ASWC	O
assisted	O
in	O
data	O
analysis	O
and	O
edited	O
the	O
manuscript	O
.	O

SS	O
and	O
XC	O
participated	O
in	O
the	O
microarray	O
study	O
and	O
data	O
analysis	O
.	O

STY	O
and	O
SYL	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
,	O
coordination	O
and	O
data	O
analysis	O
,	O
and	O
edited	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Supplementary	O
Material	O

Identification	O
of	O
kinectin	O
as	O
a	O
novel	O
Beh	O
c	O
et	O
'	O
s	O
disease	O
autoantigen	O

Abstract	O

There	O
has	O
been	O
some	O
evidence	O
that	O
Beh	O
c	O
et	O
'	O
s	O
disease	O
(	O
BD	O
)	O
has	O
a	O
significant	O
autoimmune	O
component	O
but	O
the	O
molecular	O
identity	O
of	O
putative	O
autoantigens	O
has	O
not	O
been	O
well	O
characterized	O
.	O

In	O
the	O
initial	O
analysis	O
of	O
the	O
autoantibody	O
profile	O
in	O
39	O
Chinese	O
BD	O
patients	S-Species
,	O
autoantibodies	O
to	O
cellular	O
proteins	O
were	O
uncovered	O
in	O
23	O
%	O
as	O
determined	O
by	O
immunoblotting	O
.	O

We	O
have	O
now	O
identified	O
one	O
of	O
the	O
major	O
autoantibody	O
specificities	O
using	O
expression	O
cloning	O
.	O

Serum	O
from	O
a	O
BD	O
patient	S-Species
was	O
used	O
as	O
a	O
probe	O
to	O
immunoscreen	O
a	O
lambda	O
ZAP	O
expression	O
cDNA	O
library	O
.	O

Candidate	O
autoantigen	O
cDNAs	O
were	O
characterized	O
by	O
direct	O
nucleotide	O
sequencing	O
and	O
their	O
expressed	O
products	O
were	O
examined	O
for	O
reactivity	O
to	O
the	O
entire	O
panel	O
of	O
BD	O
sera	O
using	O
immunoprecipitation	O
.	O

Reactivity	O
was	O
also	O
examined	O
with	O
normal	O
control	O
sera	O
and	O
disease	O
control	O
sera	O
from	O
patients	S-Species
with	O
lupus	O
and	O
Sj	O
o	O
gren	O
'	O
s	O
syndrome	O
.	O

Six	O
independent	O
candidate	O
clones	O
were	O
isolated	O
from	O
the	O
cDNA	O
library	O
screen	O
and	O
were	O
identified	O
as	O
overlapping	O
partial	O
human	S-Species
kinectin	O
cDNAs	O
.	O

The	O
finding	O
that	O
kinectin	O
was	O
an	O
autoantigen	O
was	O
verified	O
in	O
9	O
out	O
of	O
39	O
(	O
23	O
%	O
)	O
BD	O
patient	S-Species
sera	O
by	O
immunoprecipitation	O
of	O
the	O
in	O
vitro	O
translation	O
products	O
.	O

Sera	O
from	O
controls	O
showed	O
no	O
reactivity	O
.	O

The	O
significance	O
of	O
kinectin	O
as	O
a	O
participant	O
in	O
autoimmune	O
pathogenesis	O
in	O
BD	O
and	O
the	O
potential	O
use	O
of	O
autoantibody	O
to	O
kinectin	O
in	O
serodiagnostics	O
are	O
discussed	O
.	O

Introduction	O

Beh	O
c	O
et	O
'	O
s	O
disease	O
(	O
BD	O
)	O
is	O
a	O
systemic	O
vasculitic	O
disease	O
typified	O
by	O
a	O
triad	O
of	O
symptoms	O
including	O
recurrent	O
oral	O
ulcers	O
,	O
genital	O
ulcers	O
and	O
uveitis	O
.	O

In	O
addition	O
,	O
skin	O
,	O
joint	O
,	O
large	O
vessels	O
,	O
nervous	O
system	O
and	O
gastrointestinal	O
systems	O
may	O
be	O
involved	O
.	O

BD	O
is	O
a	O
global	O
disease	O
but	O
has	O
the	O
highest	O
prevalence	O
in	O
the	O
region	O
along	O
the	O
ancient	O
'	O
Silk	O
Road	O
'	O
in	O
China	O
.	O

The	O
etiopathogenesis	O
of	O
the	O
disease	O
remains	O
unclear	O
but	O
microbial	O
agent	O
triggers	O
,	O
environmental	O
factors	O
,	O
genetic	O
predisposition	O
,	O
neutrophil	O
hyperfunction	O
,	O
endothelial	O
cell	O
dysfunction	O
and	O
immunological	O
abnormalities	O
involving	O
both	O
T	O
and	O
B	O
cells	O
have	O
been	O
implicated	O
.	O

Increasing	O
amounts	O
of	O
research	O
evidence	O
supports	O
the	O
possibility	O
that	O
it	O
is	O
an	O
immune	O
-	O
mediated	O
vasculitis	O
,	O
and	O
that	O
abnormal	O
T	O
-	O
cell	O
and	O
B	O
-	O
cell	O
reactions	O
and	O
autoantigen	O
-	O
driven	O
autoimmunity	O
play	O
pivotal	O
roles	O
[	O
1	O
]	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
is	O
the	O
prototypic	O
systemic	O
autoimmune	O
rheumatic	O
disease	O
with	O
autoantibodies	O
against	O
cellular	O
(	O
particularly	O
nuclear	O
)	O
antigens	O
,	O
some	O
of	O
which	O
are	O
critically	O
implicated	O
in	O
the	O
autoimmune	O
pathology	O
while	O
others	O
provide	O
valuable	O
serodiagnostic	O
markers	O
for	O
the	O
disease	O
.	O

Unlike	O
the	O
picture	O
in	O
SLE	O
and	O
other	O
related	O
rheumatic	O
diseases	O
,	O
in	O
BD	O
,	O
antinuclear	O
antibodies	O
and	O
antibodies	O
to	O
neutrophil	O
cytoplasmic	O
antigens	O
etc	O
.	O
are	O
not	O
present	O
.	O

To	O
date	O
,	O
since	O
neither	O
a	O
specific	O
autoantibody	O
nor	O
pathognomonic	O
pathological	O
index	O
is	O
available	O
to	O
help	O
establish	O
the	O
diagnosis	O
of	O
BD	O
,	O
it	O
is	O
largely	O
or	O
solely	O
based	O
on	O
clinical	O
manifestations	O
[	O
2	O
]	O
,	O
and	O
a	O
dilemma	O
in	O
diagnosis	O
is	O
not	O
a	O
rare	O
occurrence	O
in	O
clinical	O
practice	O
.	O

Nevertheless	O
,	O
since	O
the	O
1960s	O
,	O
there	O
have	O
been	O
reports	O
of	O
autoantibodies	O
against	O
certain	O
unknown	O
components	O
of	O
human	S-Species
oral	O
mucosa	O
in	O
sera	O
of	O
patients	S-Species
with	O
BD	O
.	O

Since	O
then	O
,	O
sporadic	O
reports	O
on	O
findings	O
of	O
autoantibodies	O
in	O
this	O
disease	O
have	O
been	O
described	O
,	O
such	O
as	O
antibodies	O
to	O
retinal	O
antigen	O
(	O
s	O
)	O
,	O
heat	O
shock	O
protein	O
(	O
HSP	O
)	O
of	O
some	O
strains	O
of	O
Streptococcus	B-Species
sanguis	E-Species
cross	O
-	O
reactive	O
with	O
human	S-Species
HSP	O
polypeptide	O
[	O
3	O
]	O
,	O
antibodies	O
to	O
endothelial	O
cell	O
antigens	O
(	O
AECA	O
)	O
and	O
antibodies	O
to	O
alpha	O
-	O
tropomyosin	O
[	O
4	O
,	O
5	O
]	O
,	O
attesting	O
to	O
the	O
complicated	O
humoral	O
immune	O
disorders	O
in	O
this	O
disease	O
.	O

This	O
investigation	O
was	O
aimed	O
at	O
defining	O
target	O
cellular	O
autoantigens	O
using	O
time	O
-	O
tested	O
and	O
well	O
-	O
established	O
molecular	O
techniques	O
.	O

Immunoscreening	O
of	O
expression	O
libraries	O
using	O
BD	O
sera	O
was	O
used	O
since	O
this	O
approach	O
has	O
been	O
successfully	O
employed	O
in	O
the	O
characterization	O
of	O
many	O
clinically	O
relevant	O
antigens	O
in	O
systemic	O
rheumatic	O
diseases	O
such	O
as	O
SS	O
-	O
A	O
/	O
Ro	O
[	O
6	O
-	O
9	O
]	O
and	O
SS	O
-	O
B	O
/	O
La	O
[	O
10	O
]	O
antigens	O
in	O
Sj	O
o	O
gren	O
'	O
s	O
syndrome	O
(	O
SjS	O
)	O
and	O
centromere	O
antigen	O
CENP	O
-	O
B	O
[	O
11	O
]	O
in	O
scleroderma	O
.	O

In	O
addition	O
,	O
we	O
have	O
been	O
successful	O
in	O
using	O
this	O
strategy	O
to	O
identify	O
interesting	O
autoantigens	O
that	O
have	O
other	O
biological	O
significance	O
.	O

Examples	O
of	O
these	O
include	O
NOR90	O
/	O
hUBF	O
[	O
12	O
]	O
,	O
p80	O
-	O
coilin	O
[	O
13	O
]	O
,	O
Golgi	O
autoantigens	O
[	O
14	O
-	O
16	O
]	O
and	O
,	O
more	O
recently	O
,	O
GW182	O
[	O
17	O
]	O
.	O

Materials	O
and	O
methods	O

Patients	S-Species
and	O
sera	O

The	O
currently	O
used	O
empirical	O
criteria	O
for	O
the	O
diagnosis	O
of	O
BD	O
in	O
this	O
study	O
were	O
the	O
criteria	O
proposed	O
by	O
the	O
International	O
Study	O
Group	O
for	O
BD	O
(	O
abbreviated	O
as	O
'	O
International	O
Criteria	O
'	O
)	O
[	O
2	O
]	O
.	O

The	O
study	O
subjects	O
of	O
39	O
Chinese	O
BD	O
patients	S-Species
comprised	O
17	O
males	O
and	O
22	O
females	O
,	O
mean	O
age	O
37	O
+/-	O
11	O
.	O
3	O
years	O
old	O
,	O
who	O
were	O
divided	O
into	O
two	O
subgroups	O
:	O
25	O
typical	O
BD	O
patients	S-Species
(	O
Group	O
I	O
,	O
satisfying	O
the	O
International	O
Criteria	O
)	O
and	O
14	O
clinically	O
diagnosed	O
BD	O
patients	S-Species
who	O
had	O
recurrent	O
oral	O
ulcers	O
and	O
one	O
of	O
the	O
symptoms	O
of	O
genital	O
ulcers	O
,	O
eye	O
symptoms	O
or	O
skin	O
lesions	O
as	O
defined	O
by	O
the	O
International	O
Criteria	O
,	O
as	O
well	O
as	O
additional	O
symptom	O
(	O
s	O
)	O
closely	O
related	O
to	O
BD	O
as	O
listed	O
in	O
the	O
International	O
Criteria	O
,	O
that	O
is	O
,	O
gastrointestinal	O
ulcerations	O
,	O
deep	O
vein	O
thrombosis	O
or	O
arthralgia	O
/	O
arthritis	O
without	O
evidence	O
that	O
the	O
latter	O
symptoms	O
might	O
be	O
related	O
to	O
any	O
other	O
disease	O
(	O
Group	O
II	O
,	O
defined	O
as	O
'	O
probable	O
BD	O
'	O
in	O
this	O
study	O
)	O
.	O

Disease	O
controls	O
included	O
10	O
patients	S-Species
with	O
SLE	O
and	O
10	O
with	O
SjS	O
,	O
all	O
satisfying	O
corresponding	O
international	O
classification	O
criteria	O
.	O

All	O
BD	O
patients	S-Species
and	O
disease	O
controls	O
involved	O
in	O
the	O
study	O
were	O
patients	S-Species
treated	O
at	O
the	O
Rheumatology	O
Department	O
of	O
Ren	O
Ji	O
Hospital	O
,	O
Shanghai	O
,	O
China	O
,	O
where	O
their	O
clinical	O
data	O
and	O
serum	O
samples	O
were	O
collected	O
.	O

Twenty	O
normal	O
control	O
sera	O
were	O
randomly	O
selected	O
from	O
healthy	O
blood	O
donors	O
working	O
in	O
the	O
same	O
hospital	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
institution	O
review	O
board	O
of	O
Ren	O
Ji	O
Hospital	O
which	O
is	O
affiliated	O
with	O
Shanghai	O
Second	O
Medical	O
University	O
,	O
and	O
each	O
patient	S-Species
involved	O
gave	O
informed	O
consent	O
.	O

All	O
serum	O
samples	O
were	O
preserved	O
at	O
-	O
20	O
degrees	O
C	O
or	O
-	O
70	O
degrees	O
C	O
until	O
use	O
.	O

Cell	O
lines	O
and	O
cell	O
extracts	O

HeLa	O
(	O
ATCC	O
CCL	O
2	O
.	O
2	O
)	O
and	O
T24	O
(	O
human	S-Species
transitional	O
cell	O
bladder	O
carcinoma	O
)	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

A	O
bovine	S-Species
aortic	O
endothelial	O
cell	O
line	O
was	O
kindly	O
provided	O
by	O
Dr	O
Eugene	O
G	O
Levin	O
from	O
the	O
Scripps	O
Research	O
Institute	O
(	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cells	O
were	O
cultured	O
in	O
DMEM	O
containing	O
10	O
%	O
calf	S-Species
serum	O
,	O
harvested	O
and	O
extracted	O
in	O
Buffer	O
A	O
(	O
150	O
mM	O
NaCl	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH7	O
.	O
2	O
,	O
0	O
.	O
5	O
%	O
Nonidet	O
P	O
-	O
40	O
)	O
with	O
protease	O
inhibitor	O
(	O
Complete	O
(TM)	O
;	O
Boehringer	O
Mannheim	O
,	O
Indianapolis	O
,	O
IN	O
,	O
USA	O
)	O
.	O

For	O
the	O
preparation	O
of	O
whole	O
cell	O
extract	O
,	O
10	O
volumes	O
of	O
Laemmli	O
gel	O
sample	O
buffer	O
[	O
18	O
]	O
were	O
added	O
to	O
the	O
cell	O
pellet	O
,	O
boiled	O
for	O
3	O
min	O
and	O
stored	O
at	O
-	O
20	O
degrees	O
C	O
until	O
use	O
.	O

Western	O
blot	O

Whole	O
cell	O
lysates	O
from	O
bovine	S-Species
aortic	O
endothelial	O
cell	O
,	O
HeLa	O
and	O
T24	O
cells	O
were	O
resolved	O
individually	O
by	O
discontinuous	O
7	O
.	O
5	O
%	O
gel	O
SDS	O
-	O
PAGE	O
according	O
to	O
Laemmli	O
'	O
s	O
method	O
[	O
18	O
]	O
.	O

Immunoblotting	O
was	O
performed	O
as	O
described	O
by	O
Towbin	O
et	O
al	O
.	O

[	O
19	O
]	O
with	O
modifications	O
.	O

Nitrocellulose	O
strips	O
were	O
blocked	O
with	O
3	O
%	O
nonfat	O
milk	O
in	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
-	O
20	O
(	O
PBS	O
-	O
T	O
)	O
and	O
then	O
incubated	O
with	O
BD	O
patient	S-Species
sera	O
and	O
normal	O
control	O
sera	O
(	O
1	O
:	O
100	O
dilution	O
)	O
at	O
room	O
temperature	O
for	O
1	O
h	O
.	O

Filters	O
were	O
washed	O
extensively	O
with	O
PBS	O
-	O
T	O
to	O
remove	O
any	O
unbound	O
antibodies	O
.	O

Bound	O
antibodies	O
were	O
detected	O
with	O
polyvalent	O
,	O
peroxidase	O
-	O
conjugated	O
goat	S-Species
anti	O
-	O
human	S-Species
Ig	O
and	O
visualized	O
by	O
incubating	O
the	O
nitrocellulose	O
strips	O
in	O
chemiluminescent	O
reagents	O
(	O
NEN	O
Life	O
Science	O
Products	O
Inc	O
.	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
and	O
exposing	O
to	O
Kodak	O
XAR	O
-	O
5	O
films	O
.	O

Screening	O
of	O
phage	O
cDNA	O
expression	O
library	O
with	O
antibody	O
probes	O

Serum	O
from	O
a	O
BD	O
patient	S-Species
showing	O
the	O
highest	O
antibody	O
titer	O
in	O
immunoblotting	O
was	O
selected	O
as	O
a	O
probe	O
and	O
used	O
at	O
a	O
dilution	O
of	O
1	O
:	O
300	O
for	O
initial	O
immunoscreening	O
of	O
approximately	O
106	O
recombinants	O
from	O
a	O
T24	O
cDNA	O
expression	O
library	O
.	O

The	O
latter	O
was	O
constructed	O
in	O
lambda	O
ZAPExpress	O
vector	O
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
and	O
screened	O
as	O
previously	O
described	O
[	O
20	O
-	O
22	O
]	O
.	O

All	O
screenings	O
were	O
performed	O
on	O
duplicate	O
isopropyl	O
beta	O
-	O
D	O
-	O
thiogalactoside	O
(	O
IPTG	O
)	O
pre	O
-	O
impregnated	O
nitrocellulose	O
filters	O
,	O
and	O
immunoreactive	O
clones	O
were	O
detected	O
by	O
chemiluminescence	O
.	O

Positive	O
phages	O
were	O
subsequently	O
plaque	O
purified	O
to	O
100	O
%	O
by	O
two	O
repeated	O
rounds	O
of	O
screening	O
at	O
low	O
plaque	O
densities	O
.	O

Before	O
screening	O
the	O
cDNA	O
library	O
,	O
the	O
BD	O
serum	O
was	O
extensively	O
adsorbed	O
against	O
bacteria	O
and	O
wild	O
-	O
type	O
lambda	O
ZAP	O
phage	O
mixture	O
to	O
reduce	O
background	O
binding	O
.	O

Analysis	O
of	O
candidate	O
cDNAs	O

Purified	O
candidate	O
plaques	O
were	O
subcloned	O
in	O
vivo	O
into	O
pBK	O
-	O
CMV	O
plasmids	O
using	O
ExAssist	O
(TM)	O
helper	O
phage	O
as	O
recommended	O
in	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Stratagene	O
)	O
.	O

The	O
recombinant	O
pBK	O
-	O
CMV	O
plasmids	O
were	O
then	O
purified	O
using	O
QIAprep	O
Spin	O
Minprep	O
Kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Restriction	O
enzyme	O
digestion	O
of	O
plasmids	O
with	O
EcoRI	O
and	O
XhoI	O
and	O
electrophoresis	O
in	O
a	O
standard	O
1	O
.	O
0	O
%	O
agarose	O
gel	O
was	O
used	O
to	O
analyze	O
the	O
length	O
of	O
cDNA	O
insert	O
of	O
each	O
candidate	O
plasmid	O
.	O

The	O
complete	O
nucleotide	O
sequence	O
was	O
determined	O
using	O
Bigdye	O
terminator	O
sequencing	O
and	O
a	O
semi	O
-	O
automated	O
sequencer	O
model	O
377	O
(	O
ABI	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Both	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
were	O
analyzed	O
for	O
similarity	O
with	O
known	O
sequences	O
using	O
BLAST	O
search	O
[	O
23	O
]	O
and	O
ExPASy	O
Proteomics	O
tools	O
.	O

Secondary	O
structure	O
analysis	O
for	O
coiled	O
-	O
coil	O
motifs	O
was	O
conducted	O
with	O
the	O
software	O
program	O
COILS	O
[	O
24	O
]	O
.	O

Immunoprecipitation	O
of	O
in	O
vitro	O
translation	O
products	O

Candidate	O
cDNA	O
clones	O
were	O
used	O
as	O
templates	O
for	O
in	O
vitro	O
transcription	O
and	O
translation	O
and	O
the	O
products	O
were	O
used	O
as	O
substrates	O
for	O
immunoprecipitation	O
to	O
confirm	O
the	O
specificity	O
of	O
reaction	O
with	O
BD	O
sera	O
.	O

In	O
brief	O
,	O
1	O
mu	O
g	O
of	O
the	O
pBK	O
-	O
CMV	O
plasmid	O
identified	O
in	O
the	O
screening	O
outlined	O
above	O
was	O
added	O
as	O
template	O
in	O
a	O
50	O
-	O
mu	O
l	O
reaction	O
for	O
the	O
coupled	O
in	O
vitro	O
transcription	O
and	O
translation	O
reaction	O
with	O
a	O
rabbit	S-Species
reticulocyte	O
lysate	O
system	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
in	O
the	O
presence	O
of	O
35S	O
-	O
methionine	O
(	O
Trans	O
-	O
35S	O
label	O
;	O
ICN	O
Biochemicals	O
,	O
Costa	O
Mesa	O
,	O
CA	O
,	O
USA	O
)	O
and	O
RNasin	O
(R)	O
Ribonuclease	O
Inhibitor	O
(	O
Stratagene	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
Promega	O
)	O
.	O

Translation	O
was	O
carried	O
out	O
at	O
30	O
degrees	O
C	O
for	O
1	O
.	O
5	O
h	O
.	O

Products	O
were	O
analyzed	O
in	O
a	O
12	O
.	O
5	O
%	O
gel	O
SDS	O
-	O
PAGE	O
and	O
stored	O
at	O
-	O
80	O
degrees	O
C	O
for	O
further	O
immunoprecipitation	O
analysis	O
.	O

The	O
in	O
vitro	O
translation	O
proteins	O
were	O
examined	O
for	O
reactivity	O
by	O
sera	O
using	O
immunoprecipitation	O
described	O
[	O
8	O
,	O
25	O
]	O
.	O

Results	O
and	O
discussion	O

Autoantibody	O
detection	O
in	O
sera	O
from	O
BD	O
patients	S-Species

Initial	O
examination	O
of	O
a	O
group	O
of	O
39	O
BD	O
patients	S-Species
using	O
indirect	O
immunofluorescence	O
(	O
IIF	O
)	O
on	O
a	O
HEp	O
-	O
2	O
cell	O
substrate	O
did	O
not	O
yield	O
any	O
characteristic	O
nuclear	O
or	O
cytoplasmic	O
staining	O
patterns	O
.	O

BD	O
is	O
thought	O
by	O
some	O
to	O
be	O
a	O
vasculitic	O
disease	O
involving	O
pathophysiology	O
of	O
endothelial	O
cells	O
,	O
and	O
antibody	O
to	O
endothelial	O
cell	O
antigen	O
(	O
AECA	O
)	O
has	O
been	O
reported	O
.	O

Reports	O
on	O
the	O
prevalence	O
of	O
AECA	O
have	O
varied	O
largely	O
and	O
alpha	O
-	O
enolase	O
was	O
reported	O
as	O
one	O
of	O
the	O
putative	O
target	O
antigens	O
[	O
26	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
use	O
of	O
bovine	S-Species
aortic	O
endothelial	O
cells	O
as	O
substrate	O
for	O
IIF	O
did	O
not	O
provide	O
any	O
additional	O
data	O
.	O

However	O
,	O
Western	O
blot	O
analysis	O
of	O
the	O
BD	O
sera	O
began	O
to	O
show	O
some	O
interesting	O
autoreactivity	O
using	O
cell	O
lysates	O
from	O
both	O
HeLa	O
and	O
bovine	S-Species
aortic	O
endothelial	O
cells	O
.	O

HeLa	O
cells	O
were	O
initially	O
used	O
for	O
this	O
analysis	O
because	O
they	O
are	O
commonly	O
used	O
in	O
the	O
laboratory	O
as	O
Western	O
blot	O
substrate	O
.	O

Fig	O
.	O

1	O
illustrates	O
the	O
common	O
reactivity	O
to	O
49	O
kDa	O
and	O
120	O
kDa	O
proteins	O
in	O
the	O
endothelial	O
cell	O
lysates	O
.	O

These	O
antigens	O
were	O
also	O
detected	O
in	O
HeLa	O
and	O
T24	O
cells	O
;	O
the	O
latter	O
cell	O
line	O
was	O
analyzed	O
because	O
our	O
laboratory	O
at	O
The	O
Scripps	O
Research	O
Institute	O
has	O
produced	O
an	O
excellent	O
expression	O
cDNA	O
library	O
from	O
the	O
T24	O
line	O
and	O
the	O
positive	O
result	O
with	O
the	O
T24	O
cell	O
extracts	O
allowed	O
us	O
to	O
screen	O
the	O
T24	O
library	O
.	O

Ig	O
isotype	O
analysis	O
showed	O
that	O
all	O
reactivity	O
was	O
largely	O
IgG	O
antibodies	O
.	O

Since	O
the	O
49	O
kDa	O
and	O
120	O
kDa	O
bands	O
were	O
observed	O
in	O
cell	O
extracts	O
from	O
bovine	S-Species
as	O
well	O
as	O
human	S-Species
cell	O
lines	O
,	O
these	O
autoantigens	O
might	O
be	O
evolutionarily	O
conserved	O
.	O

In	O
total	O
,	O
nine	O
out	O
of	O
39	O
BD	O
sera	O
(	O
23	O
%	O
)	O
had	O
autoantibody	O
to	O
the	O
49	O
kDa	O
antigen	O
and	O
eight	O
(	O
20	O
%	O
)	O
to	O
the	O
120	O
kDa	O
antigen	O
.	O

Four	O
BD	O
sera	O
(	O
10	O
%	O
)	O
reacted	O
with	O
both	O
proteins	O
.	O

Additionally	O
,	O
sera	O
that	O
showed	O
common	O
reactivity	O
to	O
the	O
120	O
kDa	O
protein	O
also	O
demonstrated	O
a	O
common	O
band	O
that	O
migrated	O
at	O
~	O
150	O
kDa	O
,	O
although	O
it	O
appeared	O
weaker	O
than	O
the	O
120	O
kDa	O
band	O
.	O

These	O
antigens	O
appeared	O
to	O
have	O
different	O
molecular	O
weights	O
than	O
those	O
of	O
the	O
known	O
autoantigens	O
in	O
systemic	O
rheumatic	O
diseases	O
.	O

In	O
addition	O
,	O
other	O
reactive	O
bands	O
were	O
detected	O
but	O
they	O
were	O
not	O
as	O
commonly	O
shared	O
as	O
the	O
49	O
kDa	O
and	O
120	O
kDa	O
bands	O
.	O

The	O
49	O
kDa	O
protein	O
was	O
shown	O
to	O
be	O
distinct	O
from	O
48	O
kDa	O
SS	O
-	O
B	O
/	O
La	O
or	O
50	O
kDa	O
Jo	O
-	O
1	O
proteins	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
120	O
kDa	O
antigen	O
was	O
also	O
shown	O
to	O
migrate	O
differently	O
from	O
alanyl	O
tRNA	O
synthetase	O
in	O
another	O
Western	O
blot	O
analysis	O
(	O
data	O
not	O
shown	O
)	O
and	O
did	O
not	O
share	O
any	O
apparent	O
crossreactive	O
epitopes	O
with	O
the	O
49	O
kDa	O
antigen	O
.	O

Western	O
blot	O
analyses	O
of	O
20	O
normal	O
control	O
sera	O
did	O
not	O
show	O
the	O
reactivities	O
observed	O
with	O
BD	O
sera	O
.	O

In	O
order	O
to	O
further	O
characterize	O
these	O
autoreactivities	O
,	O
a	O
serum	O
sample	O
from	O
the	O
Group	O
I	O
definitive	O
BD	O
patients	S-Species
with	O
the	O
strongest	O
reactivity	O
to	O
49	O
kDa	O
and	O
120	O
kDa	O
antigens	O
(	O
Fig	O
.	O
1	O
,	O
lane	O
2	O
)	O
was	O
selected	O
as	O
antibody	O
probe	O
for	O
expression	O
library	O
screening	O
.	O

Kinectin	O
identified	O
as	O
a	O
novel	O
BD	O
autoantigen	O

After	O
screening	O
500	O
,	O
000	O
clones	O
from	O
the	O
T24	O
cell	O
lambda	O
ZAPExpress	O
expression	O
library	O
,	O
seven	O
immunoreactive	O
clones	O
were	O
isolated	O
and	O
plaque	O
purified	O
in	O
two	O
to	O
three	O
rounds	O
to	O
achieve	O
100	O
%	O
homogeneity	O
.	O

The	O
cDNA	O
inserts	O
were	O
subcloned	O
in	O
vivo	O
into	O
pBK	O
-	O
CMV	O
plasmids	O
,	O
analyzed	O
by	O
restriction	O
digestion	O
using	O
EcoRI	O
and	O
XhoI	O
enzymes	O
,	O
and	O
submitted	O
to	O
direct	O
nucleotide	O
sequencing	O
across	O
the	O
polylinker	O
arms	O
.	O

The	O
cDNA	O
inserts	O
represented	O
six	O
independent	O
clones	O
designated	O
BD41	O
(	O
identical	O
to	O
BD44	O
)	O
,	O
BD481	O
,	O
BD42	O
,	O
BD47	O
,	O
BD482	O
and	O
BD49	O
.	O

Their	O
identities	O
were	O
established	O
as	O
overlapping	O
partial	O
cDNAs	O
of	O
human	S-Species
kinectin	O
,	O
ranging	O
from	O
1	O
.	O
9	O
kb	O
to	O
3	O
kb	O
(	O
Fig	O
.	O
2a	O
)	O
.	O

The	O
full	O
-	O
length	O
human	S-Species
kinectin	O
(	O
GenBank	O
accession	O
number	O
NM	O
_	O
182926	O
[	O
27	O
]	O
)	O
has	O
4	O
,	O
816	O
bases	O
containing	O
an	O
open	O
reading	O
frame	O
coding	O
1	O
,	O
357	O
amino	O
acid	O
residues	O
with	O
molecular	O
mass	O
156	O
kDa	O
.	O

All	O
six	O
cDNAs	O
lacked	O
the	O
5	O
'	O
portion	O
of	O
the	O
kinectin	O
sequence	O
to	O
different	O
degrees	O
but	O
spanned	O
a	O
sequence	O
of	O
kinectin	O
that	O
extended	O
to	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
.	O

Secondary	O
structure	O
analysis	O
of	O
kinectin	O
protein	O
using	O
the	O
program	O
COILS	O
identified	O
a	O
long	O
region	O
of	O
alpha	O
-	O
helical	O
coiled	O
-	O
coil	O
domain	O
that	O
extended	O
from	O
amino	O
acid	O
residue	O
327	O
to	O
the	O
C	O
-	O
terminus	O
(	O
Fig	O
.	O
2a	O
,	O
hatched	O
boxes	O
)	O
.	O

In	O
vitro	O
coupled	O
transcription	O
and	O
translation	O
of	O
BD44	O
and	O
BD42	O
clones	O
directed	O
the	O
synthesis	O
of	O
[	O
35S	O
]	O
-	O
methionine	O
-	O
labeled	O
polypeptides	O
that	O
migrated	O
at	O
95	O
and	O
60	O
kDa	O
,	O
respectively	O
,	O
in	O
addition	O
to	O
smaller	O
polypeptides	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

These	O
products	O
had	O
predicted	O
molecular	O
weights	O
of	O
103	O
kDa	O
and	O
75	O
kDa	O
.	O

Kinectin	O
was	O
initially	O
identified	O
in	O
chick	S-Species
embryo	O
brain	O
microsome	O
as	O
an	O
integral	O
membrane	O
protein	O
anchored	O
in	O
endoplasmic	O
reticulum	O
and	O
involved	O
in	O
kinesin	O
-	O
driven	O
vesicle	O
motility	O
along	O
microtubules	O
[	O
28	O
,	O
29	O
]	O
.	O

Kinectin	O
consists	O
of	O
a	O
120	O
-	O
kDa	O
and	O
a	O
160	O
-	O
kDa	O
polypeptide	O
interacting	O
through	O
the	O
alpha	O
-	O
helical	O
coiled	O
-	O
coil	O
domain	O
to	O
form	O
a	O
heterodimer	O
[	O
30	O
]	O
.	O

The	O
full	O
-	O
length	O
kinectin	O
is	O
the	O
160	O
kDa	O
polypeptide	O
containing	O
an	O
N	O
-	O
terminal	O
transmembrane	O
helix	O
followed	O
by	O
a	O
bipartite	O
nuclear	O
localization	O
sequence	O
and	O
two	O
C	O
-	O
terminal	O
leucine	O
zipper	O
motifs	O
.	O

We	O
presume	O
that	O
the	O
120	O
kDa	O
polypeptide	O
detected	O
in	O
Western	O
blot	O
(	O
Fig	O
.	O
1	O
)	O
is	O
the	O
truncated	O
version	O
of	O
the	O
160	O
-	O
kDa	O
polypeptide	O
,	O
lacking	O
the	O
N	O
-	O
terminal	O
first	O
232	O
amino	O
acids	O
[	O
30	O
]	O
.	O

The	O
N	O
-	O
terminus	O
of	O
the	O
160	O
-	O
kDa	O
polypeptide	O
consists	O
of	O
a	O
transmembrane	O
domain	O
that	O
anchors	O
kinectin	O
to	O
endoplasmic	O
reticulum	O
[	O
30	O
,	O
31	O
]	O
.	O

This	O
120	O
kDa	O
polypeptide	O
is	O
probably	O
the	O
predominant	O
form	O
detected	O
in	O
the	O
Western	O
blot	O
analysis	O
(	O
Fig	O
.	O
1	O
)	O
because	O
of	O
its	O
preferential	O
solubility	O
due	O
to	O
the	O
omission	O
of	O
the	O
N	O
-	O
terminal	O
transmembrane	O
domain	O
.	O

Other	O
functions	O
for	O
kinectin	O
have	O
been	O
reported	O
.	O

Yeast	S-Species
two	O
-	O
hybrid	O
screen	O
studies	O
from	O
several	O
laboratories	O
have	O
revealed	O
the	O
interaction	O
of	O
the	O
Rho	O
family	O
of	O
GTPase	O
with	O
kinectin	O
,	O
and	O
have	O
shown	O
the	O
functional	O
links	O
among	O
RhoG	O
,	O
kinectin	O
and	O
kinesin	O
,	O
with	O
kinectin	O
as	O
a	O
key	O
effector	O
of	O
RhoG	O
microtubule	O
-	O
dependent	O
cellular	O
activity	O
[	O
32	O
]	O
.	O

Kinectin	O
was	O
also	O
identified	O
as	O
an	O
important	O
constituent	O
of	O
integrin	O
-	O
based	O
adhesion	O
complexes	O
,	O
which	O
link	O
integrins	O
to	O
the	O
cytoskeleton	O
and	O
recruit	O
signaling	O
molecules	O
[	O
33	O
]	O
.	O

A	O
new	O
study	O
reported	O
that	O
a	O
kinectin	O
isoform	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
kinesin	O
-	O
binding	O
domain	O
is	O
very	O
probably	O
the	O
most	O
conservative	O
form	O
of	O
kinectin	O
;	O
it	O
does	O
not	O
bind	O
kinesin	O
but	O
act	O
as	O
a	O
membrane	O
anchor	O
for	O
the	O
translation	O
elongation	O
factor	O
-	O
1	O
delta	O
in	O
the	O
endoplasmic	O
reticulum	O
[	O
34	O
]	O
.	O

Prevalence	O
and	O
specificity	O
of	O
anti	O
-	O
kinectin	O
autoantibodies	O

The	O
in	O
vitro	O
[	O
35S	O
]	O
-	O
methionine	O
-	O
labeled	O
translation	O
product	O
of	O
BD44	O
,	O
representing	O
the	O
largest	O
recombinant	O
kinectin	O
fragment	O
available	O
,	O
was	O
used	O
as	O
the	O
antigen	O
substrate	O
in	O
an	O
immunoprecipitation	O
assay	O
.	O

Out	O
of	O
39	O
BD	O
patient	S-Species
sera	O
,	O
nine	O
(	O
23	O
%	O
)	O
recognized	O
the	O
BD44	O
translation	O
product	O
(	O
Fig	O
.	O
3	O
)	O
,	O
whereas	O
sera	O
from	O
20	O
normal	O
controls	O
,	O
10	O
SLE	O
and	O
10	O
SjS	O
patients	S-Species
did	O
not	O
show	O
reactivity	O
.	O

Among	O
the	O
nine	O
anti	O
-	O
kinectin	O
positive	O
patients	S-Species
,	O
six	O
(	O
6	O
/	O
25	O
,	O
24	O
%	O
)	O
were	O
from	O
Group	O
I	O
(	O
definitive	O
BD	O
)	O
including	O
the	O
BD	O
patient	S-Species
whose	O
serum	O
was	O
used	O
in	O
the	O
immunoscreening	O
of	O
expression	O
cDNA	O
library	O
,	O
and	O
three	O
(	O
3	O
/	O
14	O
,	O
21	O
.	O
4	O
%	O
)	O
patients	S-Species
were	O
from	O
the	O
Group	O
II	O
(	O
probable	O
BD	O
)	O
in	O
this	O
study	O
.	O

According	O
to	O
the	O
Fisher	O
Exact	O
Probability	O
calculation	O
(	O
P	O
=	O
1	O
.	O
00	O
)	O
,	O
there	O
is	O
no	O
statistically	O
significant	O
difference	O
for	O
antibody	O
to	O
kinectin	O
between	O
the	O
two	O
groups	O
.	O

The	O
combined	O
data	O
substantiated	O
the	O
finding	O
that	O
kinectin	O
is	O
an	O
autoantigen	O
that	O
can	O
be	O
recognized	O
by	O
sera	O
from	O
23	O
%	O
of	O
Chinese	O
BD	O
patients	S-Species
in	O
this	O
study	O
with	O
at	O
least	O
one	O
immunoreactive	O
region	O
or	O
autoepitope	O
residing	O
within	O
the	O
BD44	O
encoded	O
polypeptide	O
.	O

Currently	O
,	O
there	O
are	O
more	O
than	O
six	O
diagnostic	O
/	O
classification	O
criteria	O
for	O
BD	O
,	O
among	O
which	O
the	O
International	O
Criteria	O
have	O
been	O
applied	O
most	O
extensively	O
due	O
to	O
its	O
relatively	O
high	O
sensitivity	O
(	O
91	O
%	O
)	O
and	O
specificity	O
(	O
96	O
%	O
)	O
[	O
2	O
]	O
.	O

As	O
discussed	O
above	O
,	O
differential	O
diagnosis	O
of	O
BD	O
might	O
be	O
confusing	O
in	O
clinical	O
practice	O
since	O
no	O
specific	O
laboratory	O
test	O
is	O
available	O
,	O
and	O
some	O
patients	S-Species
may	O
have	O
symptoms	O
and	O
signs	O
strongly	O
suggestive	O
of	O
BD	O
but	O
do	O
not	O
fully	O
satisfy	O
the	O
International	O
Criteria	O
,	O
as	O
in	O
the	O
Group	O
II	O
(	O
probable	O
BD	O
)	O
patients	S-Species
in	O
our	O
study	O
group	O
.	O

A	O
number	O
of	O
investigators	O
have	O
pointed	O
out	O
that	O
a	O
comprehensive	O
analysis	O
of	O
the	O
clinical	O
data	O
for	O
a	O
given	O
patient	S-Species
is	O
very	O
important	O
for	O
correct	O
clinical	O
diagnosis	O
of	O
BD	O
,	O
and	O
that	O
classification	O
/	O
diagnosis	O
criteria	O
,	O
including	O
the	O
International	O
Criteria	O
,	O
should	O
be	O
followed	O
but	O
should	O
not	O
be	O
exclusive	O
.	O

The	O
observation	O
that	O
three	O
out	O
of	O
14	O
patients	S-Species
in	O
the	O
probable	O
BD	O
group	O
also	O
had	O
antibody	O
to	O
kinectin	O
and	O
the	O
similar	O
percentage	O
of	O
positive	O
reactors	O
between	O
this	O
group	O
and	O
Group	O
I	O
(	O
21	O
.	O
4	O
%	O
versus	O
24	O
%	O
)	O
supports	O
this	O
notion	O
.	O

The	O
further	O
use	O
of	O
non	O
-	O
clinical	O
parameters	O
such	O
as	O
immunological	O
biomarkers	O
as	O
adjuncts	O
to	O
identify	O
BD	O
patients	S-Species
could	O
be	O
of	O
help	O
in	O
the	O
classification	O
of	O
this	O
disease	O
entity	O

While	O
our	O
work	O
was	O
ongoing	O
,	O
anti	O
-	O
kinectin	O
antibodies	O
were	O
reported	O
in	O
sera	O
from	O
patients	S-Species
with	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
[	O
35	O
,	O
36	O
]	O
and	O
aplastic	O
anemia	O
[	O
37	O
,	O
38	O
]	O
.	O

The	O
first	O
HCC	O
report	O
[	O
35	O
]	O
identified	O
kinectin	O
as	O
a	O
tumor	O
-	O
associated	O
antigen	O
from	O
the	O
screening	O
of	O
an	O
autologous	O
cDNA	O
library	O
constructed	O
from	O
the	O
cancer	O
of	O
a	O
30	O
-	O
year	O
-	O
old	O
patient	S-Species
from	O
Guangxi	O
,	O
China	O
.	O

This	O
report	O
stated	O
that	O
four	O
out	O
of	O
five	O
HCC	O
patients	S-Species
tested	O
were	O
positive	O
for	O
anti	O
-	O
kinectin	O
antibody	O
[	O
35	O
]	O
.	O

In	O
2004	O
,	O
another	O
laboratory	O
also	O
reported	O
the	O
cloning	O
of	O
kinectin	O
as	O
a	O
tumor	O
-	O
associated	O
antigen	O
from	O
a	O
(	O
presumably	O
)	O
different	O
30	O
-	O
year	O
-	O
old	O
Chinese	O
HCC	O
patient	S-Species
[	O
36	O
]	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
kinectin	O
antibodies	O
were	O
not	O
detected	O
in	O
other	O
studies	O
of	O
HCC	O
patients	S-Species
associated	O
with	O
our	O
laboratory	O
[	O
39	O
,	O
40	O
]	O
.	O

The	O
reports	O
of	O
anti	O
-	O
kinectin	O
antibodies	O
in	O
aplastic	O
anemia	O
are	O
also	O
very	O
interesting	O
[	O
37	O
,	O
38	O
]	O
.	O

The	O
initial	O
report	O
by	O
Hirano	O
et	O
al	O
.	O
identified	O
kinectin	O
by	O
screening	O
an	O
aplastic	O
anemia	O
patient	S-Species
for	O
candidate	O
antigens	O
using	O
a	O
Clontech	O
human	S-Species
fetal	O
liver	O
cDNA	O
expression	O
library	O
and	O
it	O
was	O
concluded	O
that	O
seven	O
out	O
of	O
18	O
aplastic	O
anemia	O
patients	S-Species
were	O
positive	O
for	O
anti	O
-	O
kinectin	O
while	O
none	O
of	O
the	O
normal	O
or	O
disease	O
controls	O
had	O
this	O
antibody	O
[	O
37	O
]	O
.	O

In	O
their	O
recent	O
report	O
,	O
Hirano	O
et	O
al	O
.	O
reported	O
that	O
anti	O
-	O
kinectin	O
antibodies	O
were	O
found	O
in	O
39	O
%	O
of	O
aplastic	O
anemia	O
patients	S-Species
from	O
the	O
United	O
States	O
but	O
only	O
in	O
three	O
out	O
of	O
30	O
(	O
10	O
%	O
)	O
cases	O
in	O
Japan	O
[	O
38	O
]	O
.	O

In	O
our	O
study	O
reported	O
here	O
,	O
kinectin	O
antibodies	O
were	O
only	O
detected	O
in	O
BD	O
patients	S-Species
and	O
not	O
in	O
normal	O
controls	O
and	O
SLE	O
and	O
SjS	O
disease	O
controls	O
.	O

None	O
of	O
the	O
BD	O
patients	S-Species
with	O
anti	O
-	O
kinectin	O
had	O
signs	O
of	O
HCC	O
or	O
aplastic	O
anemia	O
at	O
the	O
time	O
of	O
diagnosis	O
and	O
at	O
up	O
to	O
4	O
years	O
of	O
follow	O
-	O
up	O
.	O

Mapping	O
of	O
epitope	O
(	O
s	O
)	O
recognized	O
by	O
anti	O
-	O
kinectin	O
antibodies	O
may	O
shed	O
light	O
on	O
the	O
question	O
of	O
whether	O
different	O
autoepitopes	O
reside	O
within	O
the	O
kinectin	O
molecule	O
recognized	O
by	O
sera	O
from	O
different	O
diseases	O
.	O

Kinectin	O
-	O
a	O
new	O
member	O
of	O
coiled	O
-	O
coil	O
cytoplasmic	O
autoantigens	O

We	O
have	O
recently	O
reviewed	O
the	O
literature	O
on	O
the	O
growing	O
number	O
of	O
cytoplasmic	O
autoantigens	O
rich	O
in	O
alpha	O
-	O
helical	O
coiled	O
-	O
coil	O
domains	O
as	O
typified	O
from	O
our	O
study	O
of	O
Golgi	O
autoantigens	O
[	O
41	O
]	O
.	O

Golgi	O
autoantigens	O
are	O
generally	O
high	O
molecular	O
weight	O
proteins	O
between	O
100	O
and	O
350	O
kDa	O
and	O
rich	O
in	O
coiled	O
-	O
coil	O
domains	O
in	O
the	O
central	O
region	O
with	O
non	O
-	O
coiled	O
-	O
coil	O
or	O
globular	O
domains	O
at	O
both	O
N	O
and	O
C	O
termini	O
.	O

Golgi	O
autoantigens	O
are	O
displayed	O
on	O
the	O
cytoplasmic	O
face	O
of	O
the	O
Golgi	O
complex	O
and	O
are	O
not	O
localized	O
to	O
apoptotic	O
blebs	O
during	O
apoptosis	O
[	O
42	O
]	O
.	O

Giantin	O
,	O
the	O
highest	O
molecular	O
weight	O
Golgi	O
autoantigen	O
reported	O
,	O
is	O
the	O
predominant	O
target	O
of	O
human	S-Species
anti	O
-	O
Golgi	O
complex	O
antibodies	O
and	O
multiple	O
non	O
-	O
cross	O
-	O
reactive	O
epitopes	O
have	O
been	O
mapped	O
spanning	O
the	O
350	O
kDa	O
protein	O
[	O
43	O
]	O
.	O

Other	O
high	O
molecular	O
weight	O
autoantigens	O
with	O
similar	O
features	O
have	O
been	O
reported	O
in	O
cytoplasmic	O
and	O
mitotic	O
organelles	O
suggesting	O
that	O
these	O
selected	O
proteins	O
become	O
autoimmunogenic	O
based	O
on	O
their	O
subcellular	O
association	O
and	O
molecular	O
features	O
[	O
41	O
]	O
.	O

For	O
example	O
,	O
in	O
the	O
endosomal	O
compartment	O
,	O
the	O
two	O
known	O
autoantigens	O
are	O
early	O
endosomal	O
protein	O
EEA1	O
(	O
180	O
kDa	O
)	O
[	O
44	O
]	O
and	O
CLIP	O
-	O
170	O
(	O
170	O
kDa	O
)	O
[	O
45	O
]	O
.	O

There	O
is	O
also	O
a	O
series	O
of	O
centrosomal	O
autoantigens	O
identified	O
as	O
coiled	O
-	O
coil	O
-	O
rich	O
proteins	O
including	O
pericentrin	O
,	O
a	O
220	O
kDa	O
protein	O
[	O
46	O
]	O
,	O
ninein	O
,	O
a	O
protein	O
with	O
alternatively	O
spliced	O
products	O
of	O
245	O
and	O
249	O
kDa	O
[	O
47	O
]	O
,	O
Cep250	O
(	O
250	O
kDa	O
)	O
and	O
Cep110	O
(	O
110	O
kDa	O
)	O
[	O
48	O
]	O
.	O

Centromere	O
autoantigens	O
have	O
been	O
described	O
but	O
the	O
two	O
interesting	O
ones	O
related	O
to	O
this	O
discussion	O
are	O
CENP	O
-	O
E	O
[	O
49	O
]	O
and	O
CENP	O
-	O
F	O
[	O
50	O
]	O
;	O
both	O
are	O
high	O
molecular	O
weight	O
proteins	O
(	O
312	O
to	O
400	O
kDa	O
)	O
and	O
have	O
the	O
same	O
type	O
of	O
overall	O
structure	O
as	O
discussed	O
above	O
.	O

NuMA	O
is	O
another	O
large	O
coiled	O
-	O
coil	O
protein	O
located	O
at	O
the	O
mitotic	O
spindle	O
pole	O
and	O
is	O
the	O
most	O
common	O
target	O
autoantigen	O
in	O
sera	O
with	O
mitotic	O
spindle	O
apparatus	O
staining	O
[	O
51	O
]	O
.	O

Non	O
-	O
muscle	O
myosin	O
(	O
~	O
200	O
kDa	O
)	O
is	O
a	O
cytoskeletal	O
autoantigen	O
[	O
52	O
]	O
that	O
falls	O
in	O
the	O
same	O
group	O
of	O
high	O
molecular	O
weight	O
and	O
coiled	O
-	O
coil	O
-	O
rich	O
autoantigens	O
.	O

These	O
endosomal	O
,	O
centrosomal	O
,	O
mitotic	O
apparatus	O
and	O
intracellular	O
autoantigens	O
are	O
,	O
like	O
the	O
golgins	O
,	O
proteins	O
with	O
high	O
molecular	O
weights	O
and	O
an	O
overall	O
high	O
content	O
of	O
coiled	O
-	O
coil	O
domains	O
.	O

The	O
combination	O
of	O
these	O
two	O
physical	O
features	O
in	O
autoantigens	O
may	O
contribute	O
to	O
the	O
induction	O
and	O
production	O
of	O
autoimmune	O
antibodies	O
in	O
certain	O
disease	O
states	O
.	O

Kinectin	O
is	O
an	O
integral	O
membrane	O
protein	O
largely	O
confined	O
to	O
the	O
endoplasmic	O
reticulum	O
[	O
28	O
,	O
31	O
]	O
and	O
it	O
fits	O
into	O
this	O
new	O
category	O
of	O
autoantigens	O
that	O
are	O
large	O
coiled	O
-	O
coil	O
rich	O
proteins	O
(	O
>=	O
100	O
kDa	O
)	O
in	O
the	O
cytoplasm	O
.	O

Conclusion	O

Here	O
we	O
report	O
the	O
detection	O
of	O
kinectin	O
autoantibody	O
in	O
23	O
%	O
of	O
Chinese	O
patients	S-Species
with	O
BD	O
.	O

The	O
identity	O
of	O
kinectin	O
as	O
a	O
BD	O
-	O
related	O
autoantigen	O
has	O
not	O
been	O
reported	O
to	O
date	O
.	O

Autoantibody	O
reaction	O
against	O
kinectin	O
in	O
BD	O
observed	O
in	O
this	O
study	O
further	O
confirms	O
the	O
autoimmune	O
involvement	O
in	O
BD	O
and	O
may	O
provide	O
new	O
inroads	O
into	O
elucidating	O
the	O
immunopathogenesis	O
of	O
the	O
disease	O
.	O

In	O
an	O
effort	O
to	O
clarify	O
the	O
association	O
of	O
BD	O
with	O
antibody	O
to	O
kinectin	O
,	O
it	O
is	O
essential	O
to	O
measure	O
antibody	O
to	O
kinectin	O
in	O
larger	O
patient	S-Species
populations	O
including	O
both	O
BD	O
,	O
probable	O
BD	O
and	O
important	O
autoimmune	O
rheumatic	O
diseases	O
such	O
as	O
SLE	O
,	O
SjS	O
,	O
rheumatoid	O
arthritis	O
etc	O
.	O
,	O
as	O
well	O
as	O
those	O
diseases	O
not	O
easily	O
differentiated	O
from	O
BD	O
,	O
such	O
as	O
recurrent	O
aphthous	O
oral	O
ulcer	O
,	O
Reiter	O
'	O
s	O
syndrome	O
,	O
inflammatory	O
bowel	O
diseases	O
etc	O
.	O

On	O
the	O
other	O
hand	O
,	O
further	O
analysis	O
of	O
the	O
association	O
of	O
anti	O
-	O
kinectin	O
antibody	O
with	O
different	O
manifestations	O
or	O
disease	O
'	O
subtypes	O
'	O
of	O
BD	O
is	O
another	O
important	O
project	O
.	O

Anti	O
-	O
kinectin	O
is	O
clearly	O
only	O
one	O
of	O
the	O
antigen	O
-	O
antibody	O
systems	O
identified	O
because	O
there	O
were	O
many	O
other	O
antibodies	O
observed	O
in	O
the	O
Western	O
blot	O
analysis	O
of	O
BD	O
sera	O
.	O

Using	O
other	O
sera	O
for	O
immunoscreening	O
would	O
probably	O
lead	O
to	O
the	O
identification	O
of	O
other	O
potentially	O
important	O
antigen	O
-	O
antibody	O
systems	O
.	O

Abbreviations	O

AECA	O
=	O
antibody	O
to	O
endothelial	O
cell	O
antigen	O
;	O
BD	O
=	O
Beh	O
c	O
et	O
'	O
s	O
disease	O
;	O
DMEM	O
=	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
;	O
HCC	O
=	O
hepatocellular	O
carcinoma	O
;	O
HSP	O
=	O
heat	O
shock	O
protein	O
;	O
IIF	O
=	O
indirect	O
immunofluorescence	O
;	O
PBS	O
=	O
phosphate	O
buffered	O
saline	O
;	O
SjS	O
=	O
Sj	O
o	O
gren	O
'	O
s	O
syndrome	O
;	O
SLE	O
=	O
systemic	O
lupus	O
erythematosus	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

YL	O
performed	O
the	O
study	O
and	O
drafted	O
the	O
manuscript	O
.	O

PY	O
provided	O
technical	O
help	O
throughout	O
the	O
study	O
.	O

SLC	O
and	O
EMT	O
conceived	O
the	O
study	O
,	O
participated	O
in	O
the	O
design	O
and	O
helped	O
in	O
the	O
analysis	O
of	O
the	O
data	O
.	O

EKLC	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
interpreted	O
data	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

EndoNet	O
:	O
an	O
information	O
resource	O
about	O
endocrine	O
networks	O

Abstract	O

EndoNet	O
is	O
a	O
new	O
database	O
that	O
provides	O
information	O
about	O
the	O
components	O
of	O
endocrine	O
networks	O
and	O
their	O
relations	O
.	O

It	O
focuses	O
on	O
the	O
endocrine	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
and	O
enables	O
the	O
analysis	O
of	O
intercellular	O
regulatory	O
pathways	O
in	O
humans	S-Species
.	O

In	O
the	O
EndoNet	O
data	O
model	O
,	O
two	O
classes	O
of	O
components	O
span	O
a	O
bipartite	O
directed	O
graph	O
.	O

One	O
class	O
represents	O
the	O
hormones	O
(	O
in	O
the	O
broadest	O
sense	O
)	O
secreted	O
by	O
defined	O
donor	O
cells	O
.	O

The	O
other	O
class	O
consists	O
of	O
the	O
acceptor	O
or	O
target	O
cells	O
expressing	O
the	O
corresponding	O
hormone	O
receptors	O
.	O

The	O
identity	O
and	O
anatomical	O
environment	O
of	O
cell	O
types	O
,	O
tissues	O
and	O
organs	O
is	O
defined	O
through	O
references	O
to	O
the	O
CYTOMER	O
(R)	O
ontology	O
.	O

With	O
the	O
EndoNet	O
user	O
interface	O
,	O
it	O
is	O
possible	O
to	O
query	O
the	O
database	O
for	O
hormones	O
,	O
receptors	O
or	O
tissues	O
and	O
to	O
combine	O
several	O
items	O
from	O
different	O
search	O
rounds	O
in	O
one	O
complex	O
result	O
set	O
,	O
from	O
which	O
a	O
network	O
can	O
be	O
reconstructed	O
and	O
visualized	O
.	O

For	O
each	O
entity	O
,	O
a	O
detailed	O
characteristics	O
page	O
is	O
available	O
.	O

Some	O
well	O
-	O
established	O
endocrine	O
pathways	O
are	O
offered	O
as	O
showcases	O
in	O
the	O
form	O
of	O
predefined	O
result	O
sets	O
.	O

These	O
sets	O
can	O
be	O
used	O
as	O
a	O
starting	O
point	O
for	O
a	O
more	O
complex	O
query	O
or	O
for	O
obtaining	O
a	O
quick	O
overview	O
.	O

The	O
EndoNet	O
database	O
is	O
accessible	O
at	O
.	O

INTRODUCTION	O

Theoretical	O
analyses	O
in	O
the	O
post	O
-	O
sequencing	O
era	O
,	O
in	O
particular	O
in	O
the	O
context	O
of	O
systems	O
biology	O
approaches	O
,	O
increasingly	O
investigate	O
the	O
properties	O
of	O
all	O
kinds	O
of	O
pathways	O
and	O
networks	O
such	O
as	O
metabolic	O
and	O
signaling	O
pathways	O
.	O

It	O
is	O
commonly	O
accepted	O
that	O
we	O
need	O
formal	O
descriptions	O
of	O
these	O
networks	O
to	O
make	O
systematic	O
use	O
of	O
the	O
overwhelming	O
body	O
of	O
facts	O
gathered	O
over	O
decades	O
of	O
laboratory	O
work	O
both	O
in	O
narrow	O
or	O
global	O
scale	O
.	O

Corresponding	O
databases	O
have	O
been	O
created	O
and	O
are	O
available	O
now	O
for	O
metabolic	O
networks	O
(	O
KEGG	O
)	O
(	O
1	O
,	O
2	O
)	O
,	O
protein	O
interaction	O
networks	O
(	O
BIND	O
and	O
DIP	O
)	O
(	O
3	O
,	O
4	O
)	O
and	O
signaling	O
pathways	O
(	O
CSNDB	O
,	O
Patika	O
and	O
TRANSPATH	O
(R)	O
)	O
(	O
5	O
-	O
8	O
)	O
,	O
just	O
to	O
name	O
a	O
few	O
.	O

So	O
far	O
,	O
however	O
,	O
their	O
main	O
focus	O
is	O
on	O
intracellular	O
processes	O
.	O

Intercellular	O
signaling	O
is	O
addressed	O
only	O
insofar	O
as	O
usually	O
the	O
pathways	O
modeled	O
start	O
with	O
extracellular	O
ligands	O
,	O
and	O
as	O
there	O
exist	O
catalogs	O
and	O
databases	O
about	O
secreted	O
proteins	O
,	O
or	O
the	O
'	O
secretome	O
'	O
,	O
of	O
certain	O
systems	O
(	O
9	O
-	O
12	O
)	O
.	O

This	O
shortcoming	O
is	O
part	O
of	O
the	O
more	O
comprehensive	O
problem	O
,	O
the	O
genotype	O
-	O
phenotype	O
gap	O
:	O
from	O
a	O
certain	O
genotype	O
,	O
we	O
are	O
able	O
to	O
infer	O
a	O
'	O
molecular	O
phenotype	O
'	O
,	O
but	O
for	O
correlating	O
it	O
with	O
a	O
more	O
complex	O
phenotype	O
such	O
as	O
a	O
biological	O
process	O
,	O
or	O
even	O
a	O
certain	O
disease	O
and	O
its	O
clinical	O
appearance	O
,	O
we	O
still	O
depend	O
largely	O
on	O
the	O
mere	O
description	O
of	O
an	O
observed	O
correlation	O
.	O

There	O
is	O
no	O
way	O
to	O
infer	O
such	O
a	O
phenotype	O
through	O
all	O
the	O
different	O
layers	O
of	O
increasing	O
complexity	O
between	O
genomic	O
DNA	O
sequences	O
and	O
the	O
physiological	O
function	O
of	O
whole	O
organs	O
and	O
their	O
interplay	O
within	O
an	O
organism	O
.	O

There	O
may	O
be	O
principal	O
barriers	O
preventing	O
such	O
an	O
inference	O
across	O
different	O
complexity	O
levels	O
,	O
but	O
even	O
to	O
explore	O
these	O
limits	O
,	O
we	O
have	O
to	O
make	O
attempts	O
to	O
bridge	O
the	O
genotype	O
-	O
phenotype	O
gap	O
.	O

We	O
have	O
to	O
do	O
the	O
next	O
step	O
towards	O
modeling	O
intercellular	O
networks	O
that	O
are	O
inextricably	O
linked	O
to	O
the	O
physiology	O
of	O
multicellular	O
organisms	O
(	O
13	O
)	O
.	O

Being	O
one	O
of	O
the	O
most	O
complex	O
constructs	O
in	O
the	O
body	O
,	O
the	O
endocrine	O
system	O
comprises	O
numerous	O
cells	O
and	O
tissues	O
that	O
secrete	O
hormones	O
which	O
pass	O
through	O
the	O
body	O
,	O
activate	O
specific	O
receptors	O
of	O
target	O
cells	O
and	O
initiate	O
there	O
multiple	O
intracellular	O
signaling	O
pathways	O
.	O

Here	O
,	O
we	O
present	O
a	O
new	O
database	O
,	O
EndoNet	O
,	O
which	O
provides	O
information	O
about	O
the	O
components	O
of	O
endocrine	O
networks	O
and	O
their	O
relations	O
,	O
and	O
enables	O
the	O
analysis	O
of	O
intercellular	O
regulatory	O
pathways	O
in	O
humans	S-Species
.	O

The	O
EndoNet	O
database	O
is	O
accessible	O
at	O
.	O

RESULTS	O

The	O
biological	O
schema	O
of	O
endocrine	O
actions	O

Development	O
and	O
function	O
of	O
different	O
organs	O
as	O
well	O
as	O
the	O
response	O
of	O
a	O
whole	O
multicellular	O
organism	O
to	O
its	O
environment	O
is	O
coordinated	O
through	O
a	O
complex	O
communication	O
system	O
between	O
specialized	O
cells	O
that	O
are	O
part	O
of	O
its	O
organs	O
.	O

This	O
communication	O
is	O
mostly	O
mediated	O
by	O
hormones	O
.	O

In	O
a	O
broader	O
sense	O
,	O
this	O
functional	O
class	O
of	O
biomolecules	O
also	O
comprises	O
growth	O
factors	O
,	O
cytokines	O
,	O
chemokines	O
and	O
other	O
signal	O
transmitters	O
.	O

This	O
generic	O
view	O
is	O
supported	O
,	O
for	O
instance	O
,	O
by	O
the	O
definition	O
given	O
for	O
'	O
hormone	O
activity	O
'	O
by	O
Gene	O
Ontology	O
(	O
GO	O
)	O
(	O
14	O
)	O
:	O
'	O
Any	O
substance	O
formed	O
in	O
very	O
small	O
amounts	O
in	O
one	O
specialized	O
organ	O
or	O
group	O
of	O
cells	O
and	O
carried	O
(	O
sometimes	O
in	O
the	O
bloodstream	O
)	O
to	O
another	O
organ	O
or	O
group	O
of	O
cells	O
,	O
in	O
the	O
same	O
organism	O
,	O
upon	O
which	O
it	O
has	O
a	O
specific	O
regulatory	O
action	O
'	O
.	O

This	O
definition	O
is	O
also	O
broad	O
enough	O
to	O
include	O
modes	O
of	O
hormonal	O
actions	O
as	O
diverse	O
as	O
endocrine	O
,	O
paracrine	O
and	O
autocrine	O
effects	O
.	O

Accordingly	O
,	O
with	O
the	O
term	O
'	O
hormone	O
'	O
one	O
might	O
refer	O
to	O
any	O
extracellular	O
substance	O
that	O
induces	O
specific	O
responses	O
in	O
target	O
cell	O
and	O
helps	O
to	O
coordinate	O
growth	O
,	O
differentiation	O
,	O
gene	O
expression	O
and	O
metabolic	O
activities	O
of	O
various	O
cells	O
,	O
tissues	O
and	O
organs	O
in	O
multicellular	O
organisms	O
(	O
15	O
)	O
.	O

Hormones	O
can	O
be	O
classified	O
based	O
on	O
their	O
chemical	O
nature	O
,	O
solubility	O
,	O
the	O
distance	O
over	O
which	O
the	O
signal	O
acts	O
and	O
so	O
on	O
(	O
15	O
,	O
16	O
)	O
.	O

From	O
the	O
viewpoint	O
of	O
genome	O
-	O
phenotype	O
relations	O
,	O
it	O
is	O
reasonable	O
to	O
distinguish	O
between	O
polypeptide	O
,	O
thus	O
,	O
genome	O
-	O
encoded	O
hormones	O
,	O
on	O
one	O
hand	O
,	O
and	O
those	O
low	O
-	O
molecular	O
weight	O
hormones	O
such	O
as	O
steroids	O
,	O
with	O
only	O
the	O
machinery	O
of	O
their	O
synthesis	O
being	O
genome	O
-	O
encoded	O
,	O
on	O
the	O
other	O
hand	O
.	O

Another	O
classification	O
of	O
hormones	O
,	O
which	O
seems	O
to	O
be	O
overlapping	O
with	O
the	O
previous	O
one	O
refers	O
to	O
the	O
intracellular	O
location	O
of	O
their	O
receptors	O
and	O
,	O
thus	O
,	O
how	O
the	O
subsequent	O
signal	O
is	O
further	O
transduced	O
:	O
membrane	O
-	O
bound	O
receptors	O
usually	O
trigger	O
more	O
or	O
less	O
complex	O
signaling	O
cascades	O
towards	O
the	O
nucleus	O
,	O
whereas	O
nuclear	O
receptors	O
,	O
mainly	O
bound	O
by	O
low	O
-	O
molecular	O
weight	O
hormones	O
,	O
have	O
a	O
very	O
short	O
signaling	O
pathway	O
downstream	O
since	O
they	O
act	O
as	O
transcription	O
factors	O
themselves	O
(	O
15	O
,	O
16	O
)	O
.	O

In	O
intercellular	O
communication	O
,	O
we	O
can	O
basically	O
differentiate	O
between	O
two	O
kinds	O
of	O
cells	O
:	O
donor	O
cells	O
which	O
synthesize	O
and	O
secrete	O
a	O
hormone	O
,	O
and	O
acceptor	O
cells	O
which	O
express	O
a	O
hormone	O
receptor	O
(	O
Figure	O
1a	O
)	O
.	O

Donor	O
cells	O
become	O
active	O
under	O
the	O
influence	O
of	O
an	O
external	O
,	O
mostly	O
environmental	O
,	O
stimulus	O
.	O

In	O
the	O
acceptor	O
cell	O
,	O
binding	O
of	O
the	O
hormone	O
to	O
a	O
receptor	O
triggers	O
an	O
intracellular	O
signal	O
transduction	O
cascade	O
with	O
different	O
kinds	O
of	O
end	O
nodes	O
and	O
effects	O
:	O
transcription	O
factors	O
affecting	O
the	O
gene	O
expression	O
program	O
of	O
the	O
acceptor	O
cell	O
,	O
metabolic	O
enzymes	O
controlling	O
the	O
cell	O
'	O
s	O
metabolism	O
,	O
structural	O
components	O
which	O
define	O
the	O
acceptor	O
'	O
s	O
morphological	O
features	O
,	O
or	O
components	O
of	O
the	O
secretory	O
apparatus	O
regulating	O
the	O
release	O
of	O
other	O
extracellular	O
molecules	O
.	O

If	O
synthesis	O
and	O
secretion	O
of	O
another	O
hormone	O
is	O
among	O
the	O
effects	O
exerted	O
by	O
receptor	O
activation	O
,	O
the	O
acceptor	O
is	O
turned	O
into	O
a	O
donor	O
cell	O
,	O
thus	O
becoming	O
an	O
internal	O
node	O
of	O
the	O
organism	O
'	O
s	O
endocrine	O
network	O
.	O

Acceptor	O
cells	O
which	O
do	O
not	O
become	O
producers	O
of	O
another	O
hormone	O
are	O
called	O
'	O
terminal	O
target	O
cells	O
'	O
of	O
the	O
endocrine	O
network	O
,	O
but	O
finally	O
constitute	O
the	O
overall	O
physiological	O
effect	O
of	O
the	O
respective	O
hormonal	O
pathway	O
,	O
or	O
simply	O
the	O
phenotype	O
(	O
Figure	O
1a	O
)	O
.	O

The	O
EndoNet	O
data	O
model	O

In	O
the	O
EndoNet	O
data	O
model	O
,	O
two	O
classes	O
of	O
entities	O
--	O
hormones	O
(	O
in	O
the	O
broadest	O
sense	O
)	O
and	O
their	O
acceptor	O
or	O
target	O
cells	O
expressing	O
the	O
corresponding	O
receptors	O
--	O
span	O
a	O
bipartite	O
directed	O
graph	O
.	O

Since	O
one	O
and	O
the	O
same	O
hormone	O
may	O
be	O
secreted	O
by	O
multiple	O
cell	O
types	O
(	O
donor	O
cells	O
)	O
,	O
each	O
such	O
secretion	O
event	O
is	O
represented	O
by	O
a	O
hormone	O
node	O
on	O
its	O
own	O
.	O

Similarly	O
,	O
each	O
cell	O
type	O
known	O
to	O
express	O
a	O
hormone	O
receptor	O
(	O
acceptor	O
cell	O
)	O
leads	O
to	O
an	O
individual	O
node	O
.	O

The	O
graph	O
'	O
s	O
edges	O
represent	O
hormone	O
transport	O
and	O
binding	O
to	O
a	O
receptor	O
(	O
intercellular	O
edges	O
)	O
,	O
on	O
one	O
hand	O
,	O
and	O
triggering	O
or	O
inhibition	O
of	O
hormone	O
secretion	O
by	O
a	O
receptor	O
activated	O
by	O
hormone	O
binding	O
(	O
intracellular	O
edges	O
)	O
,	O
on	O
the	O
other	O
hand	O
.	O

Optionally	O
,	O
an	O
edge	O
representing	O
the	O
transport	O
of	O
a	O
hormone	O
can	O
be	O
subdivided	O
by	O
introducing	O
the	O
transport	O
medium	O
(	O
usually	O
blood	O
)	O
as	O
an	O
additional	O
,	O
intermediary	O
node	O
.	O

Thus	O
,	O
in	O
the	O
conceptual	O
schema	O
of	O
the	O
EndoNet	O
database	O
(	O
Figure	O
1b	O
)	O
,	O
the	O
links	O
between	O
cells	O
/	O
organs	O
and	O
hormone	O
define	O
donor	O
cells	O
(	O
'	O
D	O
'	O
)	O
,	O
those	O
between	O
cells	O
/	O
organs	O
and	O
receptors	O
acceptor	O
cells	O
(	O
'	O
A	O
'	O
)	O
.	O

If	O
an	O
acceptor	O
cell	O
synthesizes	O
another	O
hormone	O
in	O
response	O
to	O
an	O
incoming	O
signal	O
,	O
it	O
becomes	O
an	O
internal	O
node	O
in	O
the	O
emerging	O
hormonal	O
network	O
.	O

In	O
EndoNet	O
,	O
the	O
pathway	O
between	O
a	O
hormone	O
receptor	O
expressed	O
in	O
an	O
acceptor	O
cell	O
and	O
a	O
hormone	O
synthesized	O
in	O
the	O
same	O
cell	O
(	O
intracellular	O
edge	O
)	O
is	O
handled	O
as	O
a	O
black	O
box	O
.	O

In	O
case	O
of	O
genome	O
-	O
encoded	O
peptide	O
hormones	O
,	O
cross	O
-	O
references	O
to	O
entries	O
in	O
the	O
TRANSPATH	O
(R)	O
database	O
,	O
which	O
describe	O
the	O
signaling	O
cascade	O
starting	O
from	O
the	O
hormone	O
'	O
s	O
receptor	O
and	O
ending	O
at	O
the	O
hormone	O
'	O
s	O
gene	O
,	O
are	O
provided	O
,	O
if	O
available	O
.	O

Datasets	O
on	O
non	O
-	O
peptide	O
hormones	O
will	O
in	O
future	O
be	O
enriched	O
by	O
a	O
specific	O
metabolic	O
add	O
-	O
on	O
which	O
will	O
include	O
references	O
to	O
the	O
databases	O
KEGG	O
(	O
1	O
)	O
and	O
BRENDA	O
(	O
17	O
)	O
,	O
allowing	O
for	O
further	O
characterization	O
of	O
the	O
steps	O
performed	O
during	O
the	O
hormone	O
'	O
s	O
synthesis	O
and	O
the	O
regulation	O
of	O
both	O
activity	O
and	O
expression	O
of	O
the	O
enzymes	O
involved	O
.	O

By	O
now	O
,	O
the	O
EndoNet	O
structure	O
already	O
allows	O
for	O
including	O
descriptions	O
of	O
the	O
physiological	O
effects	O
induced	O
by	O
hormone	O
binding	O
(	O
see	O
below	O
,	O
Future	O
Developments	O
)	O
.	O

The	O
contents	O
of	O
EndoNet	O

In	O
the	O
present	O
version	O
of	O
EndoNet	O
,	O
and	O
as	O
a	O
first	O
approach	O
,	O
we	O
consider	O
the	O
endocrine	O
(	O
hormonal	O
)	O
network	O
of	O
the	O
human	S-Species
body	O
.	O

For	O
each	O
molecule	O
(	O
hormone	O
or	O
receptor	O
)	O
,	O
a	O
primary	O
name	O
and	O
synonyms	O
are	O
given	O
.	O

In	O
case	O
of	O
peptide	O
hormones	O
,	O
the	O
sequence	O
of	O
the	O
processed	O
polypeptide	O
,	O
rather	O
than	O
that	O
of	O
the	O
protein	O
precursor	O
,	O
is	O
specified	O
.	O

For	O
a	O
multimeric	O
protein	O
hormone	O
,	O
the	O
subunit	O
composition	O
as	O
well	O
as	O
the	O
sequences	O
of	O
all	O
subunits	O
are	O
stored	O
;	O
the	O
same	O
holds	O
true	O
for	O
hormone	O
receptors	O
.	O

Additionally	O
,	O
all	O
peptide	O
hormone	O
and	O
receptor	O
datasets	O
have	O
links	O
to	O
HumanPSD	O
(TM)	O
(	O
18	O
)	O
and	O
to	O
the	O
Swiss	O
-	O
Prot	O
database	O
,	O
The	O
structures	O
of	O
non	O
-	O
peptide	O
hormones	O
can	O
be	O
accessed	O
through	O
the	O
corresponding	O
hyperlinks	O
to	O
the	O
KEGG	O
COMPOUND	O
section	O
.	O

Finally	O
,	O
all	O
molecules	O
may	O
have	O
links	O
to	O
the	O
TRANSPATH	O
(R)	O
database	O
.	O

As	O
described	O
,	O
EndoNet	O
utilizes	O
data	O
about	O
the	O
tissues	O
from	O
which	O
hormones	O
are	O
secreted	O
and	O
in	O
which	O
receptors	O
are	O
expressed	O
to	O
define	O
donor	O
and	O
acceptor	O
cells	O
,	O
respectively	O
.	O

The	O
identity	O
and	O
anatomical	O
environment	O
of	O
cell	O
types	O
,	O
tissues	O
and	O
organs	O
is	O
defined	O
through	O
references	O
to	O
the	O
CYTOMER	O
(R)	O
ontology	O
(	O
19	O
,	O
20	O
)	O
;	O
in	O
the	O
numerous	O
cases	O
where	O
the	O
receptors	O
are	O
ubiquitously	O
expressed	O
,	O
just	O
the	O
root	O
term	O
'	O
human	S-Species
body	O
'	O
is	O
linked	O
.	O

Data	O
on	O
whether	O
a	O
hormone	O
'	O
s	O
synthesis	O
is	O
triggered	O
or	O
inhibited	O
by	O
another	O
hormone	O
through	O
its	O
respective	O
receptor	O
in	O
a	O
particular	O
cell	O
was	O
obtained	O
by	O
manual	O
selection	O
from	O
textbooks	O
[	O
e	O
.	O
g	O
.	O
(	O
16	O
)	O
,	O
]	O
,	O
monographies	O
(	O
21	O
)	O
,	O
original	O
literature	O
,	O
the	O
EST	O
library	O
information	O
and	O
the	O
linked	O
databases	O
(	O
TRANSPATH	O
(R)	O
,	O
HumanPSD	O
(TM)	O
and	O
Swiss	O
-	O
Prot	O
)	O
.	O

The	O
contents	O
of	O
EndoNet	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Web	O
interface	O
,	O
queries	O
and	O
visualization	O

EndoNet	O
can	O
be	O
accessed	O
through	O
the	O
WWW	O
via	O
a	O
JSP	O
-	O
based	O
web	O
interface	O
.	O

Hormones	O
,	O
receptors	O
and	O
tissues	O
can	O
be	O
queried	O
for	O
their	O
names	O
,	O
and	O
detailed	O
information	O
on	O
all	O
identified	O
components	O
is	O
available	O
through	O
individual	O
characteristics	O
pages	O
.	O

Each	O
hormone	O
'	O
s	O
individual	O
entry	O
page	O
displays	O
its	O
source	O
and	O
target	O
tissues	O
(	O
donor	O
and	O
acceptor	O
cells	O
)	O
as	O
well	O
as	O
its	O
receptors	O
,	O
along	O
with	O
some	O
molecular	O
data	O
.	O

Similarly	O
,	O
each	O
receptor	O
entry	O
exhibits	O
the	O
tissues	O
in	O
which	O
the	O
receptor	O
is	O
expressed	O
,	O
and	O
the	O
hormones	O
it	O
interacts	O
with	O
.	O

Finally	O
,	O
each	O
tissue	O
entry	O
lists	O
the	O
hormone	O
receptors	O
that	O
are	O
found	O
in	O
,	O
as	O
well	O
as	O
the	O
hormones	O
that	O
are	O
synthesized	O
and	O
secreted	O
by	O
the	O
tissue	O
.	O

It	O
is	O
also	O
indicated	O
whether	O
the	O
corresponding	O
tissue	O
exerts	O
gender	O
-	O
specific	O
properties	O
;	O
additional	O
information	O
based	O
on	O
the	O
CYTOMER	O
(R)	O
ontology	O
is	O
available	O
through	O
the	O
corresponding	O
link	O
on	O
the	O
tissue	O
detail	O
page	O
.	O

Instead	O
of	O
searching	O
for	O
a	O
name	O
of	O
a	O
hormone	O
,	O
one	O
can	O
also	O
browse	O
the	O
hierarchical	O
hormone	O
classification	O
featured	O
by	O
EndoNet	O
(	O
available	O
at	O
the	O
'	O
Search	O
'	O
page	O
)	O
.	O

Each	O
query	O
result	O
can	O
be	O
used	O
as	O
starting	O
point	O
for	O
an	O
extended	O
query	O
.	O

Different	O
items	O
of	O
interest	O
can	O
be	O
selected	O
and	O
added	O
to	O
a	O
common	O
result	O
set	O
.	O

Since	O
several	O
search	O
results	O
can	O
be	O
combined	O
,	O
it	O
is	O
possible	O
to	O
create	O
sets	O
with	O
multiple	O
search	O
parameters	O
.	O

At	O
any	O
step	O
of	O
this	O
incremental	O
retrieval	O
process	O
,	O
the	O
sets	O
of	O
hormones	O
,	O
receptors	O
and	O
tissues	O
obtained	O
so	O
far	O
can	O
be	O
used	O
as	O
starting	O
points	O
for	O
reconstructing	O
a	O
network	O
by	O
a	O
depth	O
-	O
first	O
graph	O
traversal	O
algorithm	O
.	O

The	O
maximum	O
number	O
of	O
steps	O
can	O
be	O
selected	O
separately	O
for	O
the	O
upstream	O
and	O
downstream	O
part	O
of	O
the	O
reconstruction	O
process	O
.	O

Subsequently	O
,	O
the	O
graph	O
will	O
be	O
displayed	O
using	O
a	O
Graphviz	O
-	O
based	O
visualization	O
method	O
[	O
(	O
22	O
)	O
,	O
]	O
.	O

In	O
the	O
resulting	O
image	O
,	O
hormones	O
and	O
receptors	O
are	O
represented	O
as	O
nodes	O
grouped	O
together	O
into	O
subgraphs	O
representing	O
the	O
tissues	O
(	O
cells	O
/	O
organs	O
)	O
they	O
are	O
secreted	O
from	O
or	O
expressed	O
in	O
,	O
respectively	O
(	O
Figure	O
2	O
)	O
.	O

Autocrine	O
loops	O
(	O
donor	O
and	O
acceptor	O
cell	O
being	O
identical	O
)	O
are	O
treated	O
specially	O
for	O
visualization	O
.	O

On	O
demand	O
,	O
the	O
hormones	O
'	O
transport	O
media	O
can	O
be	O
included	O
in	O
the	O
visualization	O
of	O
intercellular	O
edges	O
,	O
enabling	O
the	O
user	O
to	O
choose	O
between	O
different	O
complexities	O
of	O
output	O
.	O

Intracellular	O
edges	O
,	O
which	O
connect	O
a	O
receptor	O
to	O
a	O
hormone	O
,	O
represent	O
the	O
influence	O
of	O
a	O
receptor	O
'	O
s	O
activation	O
on	O
the	O
secretion	O
of	O
a	O
hormone	O
from	O
the	O
same	O
cell	O
and	O
are	O
displayed	O
differently	O
,	O
depending	O
on	O
whether	O
this	O
influence	O
is	O
triggering	O
or	O
inhibitory	O
in	O
nature	O
.	O

The	O
graph	O
is	O
displayed	O
as	O
a	O
clickable	O
image	O
map	O
,	O
linking	O
each	O
entity	O
to	O
its	O
detailed	O
characteristics	O
page	O
,	O
thus	O
making	O
the	O
database	O
entries	O
accessible	O
from	O
the	O
graphical	O
overview	O
of	O
a	O
network	O
,	O
too	O
.	O

The	O
graph	O
is	O
available	O
in	O
two	O
different	O
formats	O
:	O
PNG	O
and	O
SVG	O
.	O

While	O
virtually	O
every	O
browser	O
supports	O
PNG	O
(	O
a	O
'	O
pixel	O
'	O
or	O
'	O
bitmap	O
'	O
format	O
)	O
,	O
only	O
a	O
few	O
of	O
them	O
provide	O
a	O
zoom	O
functionality	O
for	O
bitmap	O
pictures	O
.	O

Scalable	O
vector	O
graphics	O
,	O
(	O
SVG	O
)	O
provides	O
more	O
functionality	O
(	O
including	O
perfect	O
image	O
quality	O
throughout	O
all	O
zoom	O
factors	O
)	O
,	O
but	O
until	O
now	O
most	O
browsers	O
do	O
not	O
support	O
SVG	O
natively	O
and	O
require	O
an	O
SVG	O
plugin	O
(	O
)	O
for	O
displaying	O
this	O
vector	O
-	O
based	O
format	O
.	O

Some	O
well	O
-	O
established	O
endocrine	O
pathways	O
are	O
offered	O
as	O
showcases	O
in	O
the	O
form	O
of	O
predefined	O
result	O
sets	O
.	O

For	O
instance	O
,	O
sets	O
representing	O
the	O
hypothalamic	O
-	O
hypophyseal	O
axis	O
with	O
a	O
focus	O
on	O
either	O
thyroid	O
hormones	O
,	O
adrenal	O
hormones	O
,	O
growth	O
hormones	O
or	O
prolactin	O
are	O
provided	O
.	O

These	O
predefined	O
sets	O
can	O
be	O
used	O
for	O
obtaining	O
a	O
quick	O
overview	O
or	O
as	O
starting	O
points	O
for	O
more	O
complex	O
queries	O
.	O

FUTURE	O
DEVELOPMENTS	O

Among	O
the	O
important	O
improvements	O
of	O
EndoNet	O
which	O
we	O
are	O
currently	O
working	O
on	O
is	O
the	O
possibility	O
to	O
represent	O
intercellular	O
communication	O
at	O
different	O
levels	O
of	O
the	O
hierarchical	O
organization	O
of	O
organs	O
,	O
tissues	O
and	O
cells	O
in	O
the	O
organism	O
,	O
as	O
well	O
as	O
to	O
distinguish	O
between	O
such	O
communications	O
in	O
male	O
and	O
female	O
organisms	O
.	O

These	O
options	O
will	O
be	O
introduced	O
by	O
a	O
tighter	O
integration	O
with	O
the	O
CYTOMER	O
-	O
based	O
ontology	O
(	O
19	O
,	O
20	O
)	O
.	O

The	O
next	O
step	O
will	O
be	O
to	O
expand	O
the	O
contents	O
of	O
EndoNet	O
towards	O
the	O
details	O
of	O
the	O
processes	O
occurring	O
in	O
the	O
transport	O
medium	O
,	O
usually	O
the	O
blood	O
.	O

Since	O
not	O
all	O
hormones	O
are	O
transported	O
as	O
free	O
molecules	O
and	O
some	O
hydrophobic	O
hormones	O
(	O
e	O
.	O
g	O
.	O
steroids	O
and	O
thyroids	O
)	O
need	O
to	O
be	O
bound	O
to	O
specific	O
carrier	O
proteins	O
,	O
proper	O
description	O
of	O
such	O
transporters	O
and	O
their	O
interaction	O
with	O
the	O
corresponding	O
hormones	O
will	O
be	O
required	O
.	O

It	O
is	O
planned	O
to	O
involve	O
quantitative	O
data	O
about	O
the	O
regular	O
or	O
pathological	O
levels	O
of	O
the	O
hormones	O
,	O
the	O
overall	O
kinetics	O
of	O
each	O
hormone	O
in	O
the	O
blood	O
(	O
monotonous	O
decay	O
,	O
oscillating	O
concentrations	O
,	O
increase	O
in	O
response	O
to	O
certain	O
stimuli	O
,	O
etc	O
.	O
)	O
,	O
its	O
turnover	O
and	O
metabolic	O
products	O
,	O
etc	O
.	O

That	O
will	O
allow	O
utilization	O
of	O
EndoNet	O
contents	O
for	O
diagnostic	O
purposes	O
.	O

In	O
future	O
,	O
the	O
EndoNet	O
data	O
model	O
will	O
be	O
extended	O
in	O
order	O
to	O
incorporate	O
external	O
stimuli	O
(	O
e	O
.	O
g	O
.	O
light	O
)	O
and	O
physiological	O
states	O
(	O
stress	O
,	O
age	O
,	O
etc	O
.	O
)	O
in	O
a	O
formalized	O
manner	O
,	O
allowing	O
to	O
determine	O
whether	O
or	O
not	O
and	O
in	O
which	O
quantity	O
a	O
hormone	O
will	O
be	O
secreted	O
under	O
the	O
given	O
circumstances	O
.	O

EndoNet	O
will	O
then	O
link	O
the	O
physiological	O
effects	O
of	O
hormones	O
with	O
the	O
intracellular	O
molecular	O
processes	O
leading	O
to	O
its	O
synthesis	O
and	O
secretion	O
in	O
the	O
donor	O
cells	O
,	O
and	O
to	O
the	O
effects	O
on	O
its	O
acceptor	O
cells	O
.	O

At	O
many	O
places	O
of	O
these	O
intracellular	O
and	O
intercellular	O
networks	O
,	O
genetically	O
determined	O
aberrations	O
may	O
cause	O
specific	O
,	O
sometimes	O
pathological	O
phenotypes	O
.	O

Thus	O
,	O
EndoNet	O
will	O
enable	O
to	O
bridge	O
the	O
gap	O
between	O
known	O
genotypes	O
and	O
their	O
molecular	O
and	O
clinical	O
phenotypes	O
in	O
this	O
area	O
of	O
medical	O
research	O
and	O
its	O
applications	O
.	O

DISCUSSION	O

At	O
its	O
present	O
state	O
,	O
EndoNet	O
provides	O
a	O
high	O
coverage	O
of	O
molecules	O
that	O
are	O
conventionally	O
considered	O
as	O
hormones	O
as	O
well	O
as	O
other	O
molecules	O
that	O
are	O
involved	O
in	O
intercellular	O
communication	O
,	O
such	O
as	O
growth	O
factors	O
,	O
lymphokines	O
and	O
chemokines	O
and	O
their	O
known	O
receptors	O
.	O

The	O
aim	O
of	O
the	O
database	O
is	O
to	O
provide	O
a	O
useful	O
resource	O
for	O
studying	O
the	O
principal	O
features	O
of	O
hormonal	O
networks	O
in	O
a	O
comprehensive	O
way	O
,	O
as	O
it	O
was	O
done	O
more	O
exemplarily	O
in	O
the	O
past	O
for	O
these	O
kinds	O
of	O
networks	O
(	O
23	O
)	O
,	O
but	O
was	O
done	O
globally	O
for	O
many	O
other	O
intracellular	O
network	O
types	O
,	O
such	O
as	O
metabolic	O
,	O
protein	O
interaction	O
and	O
transcription	O
networks	O
[	O
reviewed	O
in	O
(	O
24	O
,	O
25	O
)	O
]	O
.	O

EndoNet	O
database	O
certainly	O
is	O
not	O
yet	O
complete	O
but	O
will	O
grow	O
rapidly	O
.	O

Gender	O
differences	O
in	O
factors	O
influencing	O
insulin	O
resistance	O
in	O
elderly	O
hyperlipemic	O
non	O
-	O
diabetic	O
subjects	O

Abstract	O

Background	O

The	O
increase	O
in	O
the	O
prevalence	O
of	O
insulin	O
resistance	O
-	O
related	O
metabolic	O
syndrome	O
,	O
a	O
disorder	O
that	O
greatly	O
increases	O
the	O
risk	O
of	O
diabetes	O
,	O
heart	O
attack	O
and	O
stroke	O
,	O
is	O
alarming	O
.	O

One	O
of	O
the	O
most	O
frequent	O
and	O
early	O
symptoms	O
of	O
metabolic	O
syndrome	O
is	O
hypertriglyceridemia	O
.	O

We	O
examined	O
the	O
gender	O
differences	O
between	O
various	O
metabolic	O
factors	O
related	O
to	O
insulin	O
resistance	O
in	O
elderly	O
non	O
-	O
diabetic	O
men	S-Species
and	O
postmenopausal	O
women	S-Species
of	O
comparable	O
age	O
suffering	O
from	O
hypertriglyceridemia	O
,	O
and	O
compared	O
them	O
with	O
healthy	O
subjects	O
of	O
equal	O
age	O
.	O

Results	O

The	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
were	O
significantly	O
higher	O
in	O
both	O
hyperlipemic	O
men	S-Species
and	O
women	S-Species
than	O
in	O
controls	O
;	O
95	O
%	O
confidence	O
limits	O
of	O
hyperlipemic	O
subjects	O
did	O
not	O
overlap	O
with	O
controls	O
.	O

In	O
both	O
normolipemic	O
and	O
hyperlipemic	O
men	S-Species
and	O
women	S-Species
serum	O
leptin	O
correlated	O
significantly	O
with	O
insulin	O
resistance	O
,	O
while	O
HDL	O
-	O
cholesterol	O
correlated	O
inversely	O
with	O
HOMA	O
-	O
IR	O
only	O
in	O
women	S-Species
(	O
both	O
normo	O
-	O
and	O
hyperlipemic	O
)	O
,	O
and	O
serum	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
only	O
in	O
hyperlipemic	O
women	S-Species
.	O

According	O
to	O
results	O
of	O
multiple	O
regression	O
analysis	O
with	O
HOMA	O
-	O
IR	O
as	O
a	O
dependent	O
variable	O
,	O
leptin	O
played	O
a	O
significant	O
role	O
in	O
determining	O
insulin	O
resistance	O
in	O
both	O
genders	O
,	O
but	O
-	O
aside	O
from	O
leptin	O
-	O
triglycerides	O
,	O
TNF	O
alpha	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
were	O
significant	O
determinants	O
in	O
women	S-Species
,	O
while	O
body	O
mass	O
index	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
were	O
significant	O
determinants	O
in	O
men	S-Species
.	O

The	O
coefficient	O
of	O
determination	O
(	O
R2	O
)	O
of	O
HOMA	O
IR	O
by	O
above	O
mentioned	O
metabolic	O
variables	O
was	O
in	O
women	S-Species
above	O
60	O
%	O
,	O
in	O
men	S-Species
only	O
about	O
40	O
%	O
.	O

Conclusion	O

The	O
significant	O
role	O
of	O
serum	O
leptin	O
in	O
determination	O
of	O
insulin	O
resistance	O
in	O
both	O
elderly	O
men	S-Species
and	O
postmenopausal	O
women	S-Species
of	O
equal	O
age	O
was	O
confirmed	O
.	O

However	O
,	O
the	O
study	O
also	O
revealed	O
significant	O
gender	O
differences	O
:	O
in	O
women	S-Species
a	O
strong	O
influence	O
of	O
triglycerides	O
,	O
TNF	O
alpha	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
,	O
in	O
men	S-Species
only	O
a	O
mild	O
role	O
of	O
BMI	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
.	O

Background	O

In	O
association	O
with	O
pandemic	O
obesity	O
the	O
prevalence	O
of	O
the	O
insulin	O
resistance	O
-	O
related	O
metabolic	O
syndrome	O
is	O
constantly	O
growing	O
[	O
1	O
]	O
.	O

As	O
a	O
consequence	O
of	O
this	O
fact	O
,	O
type	O
2	O
diabetes	O
mellitus	O
and	O
cardiovascular	O
mortality	O
occurs	O
in	O
much	O
younger	O
age	O
groups	O
[	O
2	O
]	O
.	O

A	O
typical	O
hyperlipemia	O
,	O
consisting	O
of	O
an	O
increase	O
of	O
serum	O
triglycerides	O
and	O
a	O
decrease	O
of	O
serum	O
HDL	O
-	O
cholesterol	O
,	O
is	O
a	O
characteristic	O
and	O
an	O
early	O
symptom	O
of	O
this	O
syndrome	O
[	O
3	O
]	O
.	O

With	O
increasing	O
age	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
adiposity	O
,	O
insulin	O
sensitivity	O
declines	O
and	O
the	O
number	O
of	O
cardiovascular	O
risk	O
factors	O
increases	O
in	O
both	O
genders	O
[	O
4	O
-	O
6	O
]	O
.	O

It	O
was	O
repeatedly	O
demonstrated	O
that	O
plasma	O
concentration	O
of	O
leptin	O
-	O
a	O
hormone	O
produced	O
mainly	O
by	O
adipose	O
tissue	O
-	O
is	O
substantially	O
higher	O
in	O
all	O
age	O
groups	O
of	O
women	S-Species
than	O
in	O
men	S-Species
[	O
7	O
-	O
10	O
]	O
.	O

This	O
may	O
be	O
caused	O
by	O
different	O
size	O
and	O
/	O
or	O
distribution	O
of	O
fat	O
tissue	O
compartments	O
influenced	O
by	O
hormones	O
:	O
estrogens	O
stimulate	O
,	O
whereas	O
testosterone	O
inhibits	O
leptin	O
secretion	O
.	O

In	O
women	S-Species
subcutaneous	O
fat	O
mass	O
prevails	O
-	O
and	O
during	O
augmentation	O
of	O
overweight	O
it	O
increases	O
-	O
while	O
in	O
men	S-Species
intra	O
-	O
abdominal	O
fat	O
mass	O
prevails	O
[	O
11	O
-	O
13	O
]	O
.	O

Subcutaneous	O
fat	O
in	O
particular	O
serves	O
as	O
a	O
substantial	O
source	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
,	O
which	O
represents	O
one	O
of	O
the	O
factors	O
that	O
interfere	O
with	O
insulin	O
signal	O
transduction	O
into	O
the	O
cells	O
[	O
14	O
-	O
16	O
]	O
.	O

Leptin	O
,	O
TNF	O
alpha	O
and	O
some	O
other	O
factors	O
are	O
abundantly	O
expressed	O
in	O
adipose	O
tissue	O
and	O
contribute	O
to	O
the	O
insulin	O
resistance	O
that	O
accompanies	O
overweight	O
and	O
obesity	O
.	O

Leptin	O
correlates	O
positively	O
with	O
hyperinsulinemia	O
,	O
BMI	O
,	O
fat	O
mass	O
and	O
hypertriglyceridemia	O
,	O
respectively	O
,	O
and	O
correlates	O
inversely	O
with	O
HDL	O
-	O
cholesterol	O
and	O
lean	O
body	O
mass	O
[	O
17	O
-	O
25	O
]	O
.	O

The	O
incidence	O
and	O
mortality	O
of	O
ischemic	O
heart	O
disease	O
and	O
of	O
other	O
consequences	O
of	O
atherosclerosis	O
increases	O
with	O
age	O
in	O
both	O
genders	O
,	O
especially	O
after	O
the	O
age	O
of	O
sixty	O
.	O

In	O
premenopausal	O
women	S-Species
,	O
however	O
,	O
the	O
incidence	O
of	O
these	O
disorders	O
is	O
considerably	O
less	O
frequent	O
than	O
in	O
men	S-Species
of	O
appropriate	O
age	O
.	O

After	O
the	O
menopause	O
the	O
prevalence	O
of	O
metabolic	O
syndrome	O
and	O
cardiovascular	O
mortality	O
in	O
women	S-Species
gradually	O
increases	O
,	O
attaining	O
values	O
comparable	O
to	O
men	S-Species
at	O
about	O
the	O
age	O
of	O
70	O
[	O
2	O
,	O
26	O
]	O
.	O

Paradoxically	O
,	O
it	O
takes	O
place	O
at	O
the	O
time	O
when	O
serum	O
leptin	O
concentration	O
in	O
women	S-Species
has	O
relatively	O
decreased	O
[	O
27	O
,	O
28	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
interrelations	O
between	O
several	O
metabolic	O
variables	O
and	O
factors	O
related	O
to	O
insulin	O
resistance	O
in	O
groups	O
of	O
both	O
normal	O
and	O
hyperlipemic	O
postmenopausal	O
women	S-Species
and	O
men	S-Species
of	O
appropriate	O
age	O
,	O
and	O
to	O
attempt	O
to	O
elucidate	O
the	O
gender	O
differences	O
and	O
some	O
pathophysiologic	O
mechanisms	O
of	O
these	O
differences	O
.	O

We	O
compared	O
homeostatic	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
,	O
serum	O
lipid	O
and	O
insulin	O
parameters	O
,	O
uric	O
acid	O
,	O
leptin	O
and	O
TNF	O
alpha	O
between	O
groups	O
of	O
subjects	O
without	O
apparent	O
symptoms	O
of	O
metabolic	O
syndrome	O
,	O
and	O
groups	O
showing	O
mild	O
hypertriglyceridemia	O
with	O
decreased	O
HDL	O
-	O
cholesterol	O
.	O

In	O
addition	O
,	O
serum	O
concentration	O
of	O
the	O
heart	O
fraction	O
of	O
fatty	O
acid	O
binding	O
protein	O
(	O
hFATP	O
)	O
was	O
explored	O
as	O
a	O
factor	O
that	O
might	O
reflect	O
the	O
regulative	O
role	O
of	O
PPAR	O
gamma	O
in	O
lipid	O
homeostasis	O
[	O
29	O
,	O
30	O
]	O
,	O
and	O
serum	O
IgG	O
anticardiolipin	O
(	O
ACL	O
-	O
IgG	O
)	O
was	O
investigated	O
as	O
an	O
indirect	O
indicator	O
of	O
oxidized	O
lipid	O
fractions	O
related	O
to	O
atherosclerotic	O
complications	O
[	O
31	O
,	O
32	O
]	O
.	O

Methods	O

Subjects	O

The	O
study	O
was	O
carried	O
out	O
on	O
70	O
out	O
-	O
patients	S-Species
of	O
the	O
Metabolic	O
Center	O
at	O
the	O
hospital	O
in	O
Sternberk	O
,	O
Czech	O
Republic	O
.	O

From	O
these	O
,	O
40	O
patients	S-Species
(	O
20	O
men	S-Species
and	O
20	O
women	S-Species
)	O
were	O
selected	O
with	O
mild	O
hyperlipidemia	O
,	O
i	O
.	O
e	O
.	O
with	O
plasma	O
triglyceride	O
concentration	O
exceeding	O
2	O
.	O
0	O
mmol	O
/	O
l	O
,	O
total	O
cholesterol	O
exceeding	O
6	O
.	O
0	O
mmol	O
/	O
l	O
,	O
LDL	O
cholesterol	O
exceeding	O
4	O
.	O
0	O
mmol	O
/	O
l	O
,	O
and	O
with	O
HDL	O
cholesterol	O
concentration	O
in	O
men	S-Species
under	O
1	O
.	O
0	O
mmol	O
/	O
l	O
,	O
and	O
in	O
women	S-Species
under	O
1	O
.	O
2	O
mmol	O
/	O
l	O
.	O

These	O
groups	O
were	O
denominated	O
as	O
"	O
hyperlipemic	O
"	O
.	O

Two	O
other	O
groups	O
(	O
10	O
men	S-Species
and	O
20	O
women	S-Species
)	O
with	O
approximately	O
normal	O
serum	O
values	O
of	O
these	O
variables	O
were	O
taken	O
as	O
"	O
controls	O
"	O
.	O

The	O
average	O
age	O
in	O
men	S-Species
was	O
59	O
.	O
1	O
+/-	O
10	O
.	O
6	O
y	O
,	O
and	O
in	O
women	S-Species
59	O
.	O
4	O
+/-	O
10	O
.	O
1	O
y	O
,	O
respectively	O
.	O

The	O
differences	O
between	O
lipid	O
parameters	O
of	O
hyperlipemic	O
and	O
control	O
groups	O
were	O
highly	O
statistically	O
significant	O
,	O
while	O
the	O
age	O
differences	O
were	O
insignificant	O
(	O
see	O
Table	O
1	O
)	O
.	O

None	O
of	O
the	O
patients	S-Species
had	O
clinically	O
apparent	O
diabetes	O
mellitus	O
,	O
but	O
some	O
of	O
the	O
hyperlipemic	O
patients	S-Species
exerted	O
impaired	O
glucose	O
tolerance	O
or	O
impaired	O
fasting	O
glucose	O
(	O
values	O
between	O
6	O
.	O
1	O
and	O
7	O
.	O
0	O
mmol	O
/	O
l	O
,	O
or	O
between	O
6	O
.	O
1	O
and	O
7	O
.	O
8	O
mmol	O
/	O
l	O
,	O
respectively	O
)	O
.	O

None	O
of	O
the	O
patients	S-Species
was	O
treated	O
with	O
insulin	O
,	O
peroral	O
antidiabetics	O
or	O
antihyperlipemic	O
drugs	O
;	O
some	O
of	O
them	O
were	O
treated	O
with	O
antihypertensive	O
therapy	O
.	O

No	O
signs	O
of	O
major	O
clinical	O
or	O
laboratory	O
symptoms	O
of	O
other	O
diseases	O
were	O
present	O
in	O
any	O
group	O
of	O
the	O
explored	O
patients	S-Species
.	O

Blood	O
samples	O
were	O
obtained	O
in	O
the	O
morning	O
via	O
a	O
venipuncture	O
after	O
overnight	O
fasting	O
.	O

After	O
clotting	O
the	O
serum	O
was	O
separated	O
and	O
stored	O
at	O
-	O
20	O
degrees	O
until	O
used	O
.	O

An	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
probands	O
.	O

Body	O
mass	O
indexes	O
(	O
BMI	O
)	O
,	O
defined	O
as	O
weight	O
in	O
kilograms	O
divided	O
by	O
the	O
square	O
of	O
height	O
in	O
meters	O
,	O
were	O
calculated	O
.	O

Biochemical	O
methods	O

Serum	O
leptin	O
concentrations	O
were	O
measured	O
by	O
a	O
sandwich	O
ELISA	O
test	O
kit	O
(	O
Human	S-Species
Leptin	O
ELISA	O
,	O
BioVendor	O
Laboratory	O
Medicine	O
,	O
Inc	O
,	O
Czech	O
Republic	O
)	O
.	O

Its	O
sensitivity	O
limit	O
was	O
0	O
.	O
2	O
ng	O
/	O
ml	O
,	O
intraassay	O
CV	O
6	O
.	O
1	O
%	O
at	O
the	O
level	O
of	O
7	O
.	O
5	O
ng	O
/	O
m	O
,	O
inter	O
-	O
assay	O
CV	O
8	O
.	O
5	O
%	O
at	O
the	O
level	O
of	O
4	O
.	O
8	O
ng	O
/	O
ml	O
.	O

Tetramethylbenzidine	O
was	O
used	O
as	O
a	O
substrate	O
;	O
quality	O
controls	O
were	O
human	S-Species
based	O
.	O

Several	O
other	O
hormones	O
and	O
peptides	O
were	O
estimated	O
by	O
routine	O
immunochemical	O
tests	O
:	O
insulin	O
,	O
C	O
-	O
peptide	O
,	O
TNF	O
alpha	O
(	O
IMMULITE	O
,	O
Diagnostic	O
Products	O
Corporation	O
,	O
Los	O
Angeles	O
,	O
CA	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
)	O
,	O
proinsulin	O
intact	O
(	O
DAKO	O
,	O
Denmark	O
)	O
,	O
IgG	O
anticardiolipin	O
(	O
ACL	O
-	O
IgG	O
,	O
IMMCO	O
Diagnostics	O
,	O
Buffalo	O
,	O
NY	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
)	O
and	O
heart	O
fatty	O
acid	O
binding	O
protein	O
(	O
hFABP	O
,	O
Hbt	O
HUMAN	O
H	O
-	O
FABP	O
,	O
HyCult	O
Biotechnology	O
,	O
Uden	O
,	O
the	O
Netherlands	O
)	O
.	O

Serum	O
concentration	O
of	O
glucose	O
,	O
total	O
cholesterol	O
,	O
triglycerides	O
,	O
HDL	O
-	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
,	O
Apoprotein	O
B	O
and	O
uric	O
acid	O
were	O
measured	O
on	O
a	O
ILAB	O
-	O
600	O
biochemical	O
analyzer	O
(	O
Instrumentation	O
Laboratory	O
,	O
Lexington	O
,	O
Ma	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
)	O
using	O
BioVendor	O
sets	O
.	O

All	O
samples	O
were	O
processed	O
and	O
examined	O
according	O
to	O
principles	O
of	O
good	O
laboratory	O
practice	O
and	O
under	O
constant	O
intralaboratory	O
and	O
external	O
quality	O
control	O
.	O

The	O
homeostatic	O
indexes	O
of	O
insulin	O
resistance	O
(	O
HOMA	O
IR	O
and	O
QUICKI	O
)	O
were	O
calculated	O
according	O
to	O
the	O
homeostasis	O
model	O
of	O
assessment	O
[	O
33	O
-	O
35	O
]	O
as	O
follows	O
:	O

HOMA	O
IR	O
=	O
fasting	O
insulin	O
(	O
mu	O
U	O
/	O
ml	O
)	O
*	O
fasting	O
glucose	O
(	O
mmol	O
/	O
l	O
)	O
/	O
22	O
.	O
5	O
;	O

QUICKI	O
=	O
1	O
/	O
[	O
log	O
fasting	O
insulin	O
(	O
mu	O
U	O
/	O
ml	O
)	O
+	O
log	O
fasting	O
glucose	O
(	O
mg	O
/	O
100	O
ml	O
)	O
]	O
.	O

Statistics	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Version	O
6	O
SAS	O
/	O
STAT	O
software	O
(	O
SAS	O
Institute	O
,	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
)	O
.	O

The	O
Shapiro	O
-	O
Wilks	O
tests	O
were	O
used	O
in	O
testing	O
the	O
normality	O
of	O
distribution	O
.	O

Some	O
of	O
the	O
data	O
obtained	O
were	O
not	O
normally	O
distributed	O
.	O

The	O
statistical	O
significance	O
of	O
differences	O
between	O
the	O
means	O
in	O
the	O
hyperlipemic	O
and	O
control	O
groups	O
were	O
evaluated	O
using	O
the	O
unpaired	O
Student	O
'	O
s	O
T	O
-	O
test	O
in	O
the	O
case	O
of	O
normal	O
distribution	O
of	O
data	O
sets	O
,	O
and	O
using	O
the	O
Kolmogorov	O
-	O
Smirnov	O
test	O
when	O
at	O
least	O
in	O
one	O
of	O
the	O
data	O
sets	O
the	O
normal	O
distribution	O
was	O
excluded	O
.	O

Spearman	O
'	O
s	O
rank	O
-	O
order	O
correlation	O
was	O
used	O
for	O
correlation	O
analysis	O
.	O

Multiple	O
regression	O
analysis	O
was	O
performed	O
using	O
HOMA	O
IR	O
indexes	O
of	O
insulin	O
resistance	O
as	O
dependent	O
variables	O
,	O
and	O
other	O
metabolic	O
and	O
hormonal	O
factors	O
(	O
lipid	O
parameters	O
,	O
BMI	O
,	O
leptin	O
,	O
TNF	O
alpha	O
,	O
hFABP	O
,	O
ACL	O
-	O
IgG	O
)	O
as	O
independent	O
variables	O
.	O

The	O
so	O
-	O
called	O
step	O
-	O
down	O
regression	O
model	O
was	O
used	O
to	O
select	O
dominant	O
independent	O
variables	O
.	O

Various	O
four	O
-	O
member	O
groups	O
of	O
independent	O
(	O
explanatory	O
)	O
variables	O
were	O
used	O
for	O
the	O
analysis	O
and	O
the	O
non	O
-	O
zero	O
intercept	O
was	O
taken	O
into	O
account	O
.	O

The	O
independent	O
variables	O
were	O
then	O
dropped	O
,	O
one	O
at	O
a	O
time	O
;	O
at	O
each	O
stage	O
one	O
variable	O
making	O
the	O
least	O
contribution	O
to	O
the	O
dependent	O
variable	O
(	O
i	O
.	O
e	O
.	O
that	O
showed	O
the	O
least	O
p	O
-	O
value	O
in	O
the	O
test	O
of	O
the	O
regression	O
coefficient	O
being	O
zero	O
)	O
was	O
excluded	O
.	O

The	O
coefficient	O
of	O
determination	O
R2	O
,	O
which	O
can	O
be	O
viewed	O
as	O
a	O
percentage	O
explaining	O
the	O
total	O
variance	O
,	O
was	O
simultaneously	O
monitored	O
.	O

A	O
great	O
drop	O
in	O
R2	O
after	O
excluding	O
some	O
independent	O
variable	O
enabled	O
selection	O
of	O
those	O
independent	O
variables	O
that	O
could	O
be	O
thought	O
to	O
be	O
the	O
most	O
important	O
determinants	O
of	O
the	O
dependent	O
variable	O
.	O

Results	O

Table	O
1	O
demonstrates	O
mean	O
parameters	O
in	O
individual	O
groups	O
of	O
subjects	O
matched	O
according	O
to	O
sex	O
,	O
lipid	O
parameters	O
and	O
age	O
.	O

While	O
the	O
age	O
of	O
all	O
four	O
groups	O
did	O
not	O
differ	O
substantially	O
,	O
the	O
concentrations	O
of	O
total	O
serum	O
cholesterol	O
,	O
triglycerides	O
,	O
HDL	O
-	O
cholesterol	O
and	O
LDL	O
-	O
cholesterol	O
differ	O
very	O
significantly	O
in	O
both	O
male	O
and	O
female	O
hyperlipemic	O
groups	O
as	O
compared	O
with	O
controls	O
.	O

In	O
addition	O
,	O
the	O
concentration	O
of	O
triglycerides	O
in	O
control	O
women	S-Species
was	O
significantly	O
higher	O
than	O
in	O
control	O
men	S-Species
,	O
the	O
concentration	O
of	O
triglycerides	O
in	O
hyperlipemic	O
women	S-Species
was	O
lower	O
than	O
in	O
hyperlipemic	O
men	S-Species
,	O
and	O
the	O
concentration	O
of	O
HDL	O
-	O
cholesterol	O
in	O
hyperlipemic	O
women	S-Species
was	O
very	O
significantly	O
higher	O
when	O
compared	O
with	O
hyperlipemic	O
men	S-Species
.	O

Table	O
2	O
shows	O
the	O
values	O
of	O
other	O
metabolic	O
and	O
insulin	O
parameters	O
,	O
factors	O
related	O
to	O
insulin	O
resistance	O
and	O
indexes	O
of	O
insulin	O
resistance	O
,	O
respectively	O
.	O

Body	O
mass	O
indexes	O
and	O
uric	O
acid	O
concentration	O
were	O
significantly	O
higher	O
in	O
hyperlipemic	O
men	S-Species
as	O
compared	O
to	O
controls	O
,	O
but	O
not	O
in	O
hyperlipemic	O
women	S-Species
.	O

Uric	O
acid	O
concentration	O
was	O
substantially	O
lower	O
in	O
hyperlipemic	O
women	S-Species
than	O
in	O
hyperlipemic	O
men	S-Species
.	O

Plasma	O
concentrations	O
of	O
glycemia	O
,	O
insulin	O
and	O
intact	O
proinsulin	O
were	O
significantly	O
higher	O
in	O
both	O
hyperlipemic	O
men	S-Species
and	O
women	S-Species
as	O
compared	O
with	O
controls	O
of	O
identical	O
gender	O
,	O
while	O
the	O
concentration	O
of	O
leptin	O
increased	O
only	O
in	O
hyperlipemic	O
men	S-Species
.	O

However	O
,	O
serum	O
leptin	O
concentrations	O
of	O
both	O
control	O
and	O
hyperlipemic	O
women	S-Species
were	O
significantly	O
higher	O
than	O
in	O
corresponding	O
groups	O
of	O
men	S-Species
.	O

Serum	O
concentrations	O
of	O
TNF	O
alpha	O
,	O
hFABP	O
and	O
ACL	O
-	O
IgG	O
in	O
hyperlipemic	O
groups	O
of	O
both	O
men	S-Species
and	O
women	S-Species
were	O
not	O
significantly	O
different	O
from	O
control	O
groups	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
differed	O
very	O
significantly	O
in	O
hyperlipemic	O
groups	O
of	O
both	O
men	S-Species
and	O
women	S-Species
as	O
compared	O
with	O
corresponding	O
control	O
groups	O
,	O
more	O
distinctly	O
in	O
women	S-Species
.	O

From	O
Fig	O
.	O

1	O
,	O
presenting	O
95	O
%	O
confidence	O
limits	O
of	O
insulin	O
resistance	O
indexes	O
HOMA	O
IR	O
and	O
QUICKI	O
,	O
we	O
concluded	O
that	O
in	O
groups	O
of	O
hyperlipemic	O
patients	S-Species
of	O
both	O
genders	O
the	O
insulin	O
resistance	O
was	O
substantially	O
higher	O
than	O
in	O
control	O
groups	O
;	O
the	O
groups	O
did	O
not	O
overlap	O
each	O
other	O
.	O

In	O
Table	O
3	O
the	O
results	O
of	O
Spearman	O
'	O
s	O
correlations	O
between	O
insulin	O
resistance	O
index	O
HOMA	O
IR	O
and	O
various	O
metabolic	O
parameters	O
are	O
presented	O
.	O

In	O
the	O
control	O
group	O
of	O
men	S-Species
,	O
positive	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
leptin	O
concentration	O
,	O
and	O
inverse	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
ACL	O
IgG	O
,	O
respectively	O
,	O
were	O
found	O
.	O

In	O
the	O
control	O
group	O
of	O
women	S-Species
,	O
the	O
significance	O
of	O
Spearman	O
'	O
s	O
correlation	O
between	O
HOMA	O
IR	O
and	O
leptin	O
was	O
more	O
expressive	O
;	O
inverse	O
correlation	O
between	O
HOMA	O
IR	O
and	O
HDL	O
-	O
cholesterol	O
was	O
also	O
present	O
.	O

In	O
the	O
hyperlipemic	O
group	O
of	O
men	S-Species
,	O
the	O
significance	O
of	O
the	O
correlation	O
between	O
HOMA	O
IR	O
was	O
more	O
expressive	O
in	O
relation	O
to	O
the	O
control	O
group	O
,	O
and	O
no	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
ACL	O
IgG	O
was	O
found	O
.	O

In	O
the	O
hyperlipemic	O
group	O
of	O
women	S-Species
,	O
however	O
,	O
the	O
significance	O
of	O
Spearman	O
'	O
s	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
leptin	O
concentration	O
weakened	O
,	O
the	O
inverse	O
correlation	O
between	O
HOMA	O
IR	O
and	O
HDL	O
-	O
cholesterol	O
remained	O
approximately	O
unchanged	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
concentration	O
of	O
TNF	O
alpha	O
appeared	O
.	O

Table	O
4	O
shows	O
results	O
of	O
multiple	O
regression	O
analysis	O
,	O
when	O
data	O
from	O
both	O
control	O
and	O
hyperlipemic	O
groups	O
of	O
each	O
gender	O
were	O
judged	O
together	O
.	O

HOMA	O
IR	O
was	O
considered	O
as	O
a	O
dependent	O
variable	O
and	O
differently	O
changed	O
constellations	O
of	O
metabolic	O
and	O
other	O
factors	O
were	O
taken	O
as	O
independent	O
variables	O
.	O

In	O
men	S-Species
,	O
BMI	O
and	O
leptin	O
seemed	O
to	O
play	O
a	O
main	O
role	O
in	O
influencing	O
the	O
insulin	O
resistance	O
index	O
HOMA	O
IR	O
,	O
while	O
TGL	O
,	O
ACL	O
IgG	O
and	O
LDL	O
-	O
cholesterol	O
didn	O
'	O
t	O
play	O
any	O
significant	O
role	O
(	O
see	O
left	O
columns	O
of	O
Table	O
4	O
)	O
.	O

The	O
decreasing	O
of	O
HDL	O
-	O
cholesterol	O
concentration	O
may	O
also	O
have	O
some	O
influence	O
(	O
see	O
a	O
significant	O
drop	O
of	O
R2	O
after	O
exclusion	O
of	O
this	O
factor	O
in	O
Table	O
4A	O
,	O
4B	O
)	O
.	O

But	O
in	O
the	O
presence	O
of	O
leptin	O
in	O
the	O
group	O
of	O
independent	O
factors	O
,	O
the	O
drop	O
of	O
R2	O
after	O
exclusion	O
of	O
HDL	O
-	O
cholesterol	O
from	O
these	O
factors	O
was	O
minimal	O
(	O
see	O
Table	O
4C	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
after	O
the	O
exclusion	O
of	O
TNF	O
alpha	O
from	O
the	O
group	O
of	O
independent	O
variables	O
(	O
see	O
Table	O
4B	O
,	O
4D	O
)	O
the	O
value	O
of	O
R2	O
has	O
unexpectedly	O
risen	O
,	O
which	O
could	O
reflect	O
the	O
interference	O
of	O
TNF	O
alpha	O
with	O
factors	O
increasing	O
the	O
insulin	O
resistance	O
.	O

In	O
women	S-Species
(	O
see	O
right	O
columns	O
of	O
Table	O
4	O
)	O
,	O
the	O
maximal	O
values	O
of	O
R2	O
were	O
achieved	O
with	O
combination	O
of	O
independent	O
variables	O
containing	O
TGL	O
,	O
leptin	O
and	O
HDL	O
-	O
cholesterol	O
(	O
about	O
60	O
%	O
influence	O
on	O
HOMA	O
IR	O
!	O
-	O
see	O
Table	O
4A	O
,	O
4B	O
,	O
4C	O
)	O
.	O

TNF	O
alpha	O
seemed	O
to	O
play	O
quite	O
a	O
different	O
role	O
than	O
in	O
men	S-Species
:	O
after	O
exclusion	O
of	O
this	O
factor	O
from	O
the	O
group	O
of	O
independent	O
factors	O
R2significantly	O
decreased	O
(	O
see	O
Table	O
4B	O
,	O
4D	O
)	O
.	O

In	O
contrast	O
to	O
men	S-Species
,	O
the	O
role	O
of	O
BMI	O
seemed	O
to	O
be	O
minimal	O
.	O

As	O
in	O
men	S-Species
,	O
the	O
role	O
of	O
ACL	O
IgG	O
and	O
LDL	O
-	O
cholesterol	O
in	O
influencing	O
HOMA	O
IR	O
was	O
negligible	O
,	O
but	O
in	O
contrast	O
to	O
men	S-Species
,	O
hFABP	O
might	O
play	O
a	O
certain	O
role	O
in	O
this	O
process	O
(	O
see	O
Table	O
4D	O
)	O
.	O

Generally	O
,	O
the	O
insulin	O
resistance	O
(	O
represented	O
by	O
HOMA	O
IR	O
)	O
was	O
in	O
men	S-Species
much	O
less	O
influenced	O
by	O
metabolic	O
variables	O
than	O
in	O
women	S-Species
;	O
while	O
in	O
women	S-Species
in	O
some	O
combinations	O
of	O
dependent	O
variables	O
R2	O
reached	O
64	O
%	O
,	O
in	O
men	S-Species
the	O
maximal	O
value	O
of	O
R2	O
was	O
only	O
39	O
%	O
.	O

Discussion	O

In	O
our	O
previous	O
paper	O
[	O
36	O
]	O
,	O
the	O
mean	O
value	O
of	O
HOMA	O
IR	O
in	O
healthy	O
subjects	O
of	O
both	O
genders	O
and	O
of	O
age	O
comparable	O
with	O
our	O
controls	O
was	O
1	O
.	O
57	O
+/-	O
0	O
.	O
87	O
,	O
and	O
the	O
mean	O
value	O
of	O
index	O
QUICKI	O
0	O
.	O
366	O
+/-	O
0	O
.	O
029	O
,	O
respectively	O
.	O

These	O
values	O
,	O
as	O
well	O
as	O
the	O
95	O
%	O
confidence	O
limits	O
,	O
correspond	O
to	O
values	O
found	O
in	O
controls	O
in	O
this	O
study	O
.	O

In	O
accordance	O
with	O
many	O
previous	O
papers	O
,	O
serum	O
concentrations	O
of	O
leptin	O
in	O
women	S-Species
(	O
both	O
control	O
and	O
hyperlipemic	O
)	O
were	O
substantially	O
higher	O
than	O
in	O
men	S-Species
.	O

In	O
the	O
control	O
group	O
of	O
women	S-Species
the	O
correlation	O
between	O
leptin	O
and	O
HOMA	O
IR	O
was	O
highly	O
significant	O
.	O

However	O
,	O
in	O
hyperlipemic	O
women	S-Species
the	O
significance	O
of	O
this	O
correlation	O
lessened	O
,	O
because	O
HOMA	O
IR	O
increased	O
considerably	O
(	O
and	O
significantly	O
)	O
but	O
serum	O
concentration	O
of	O
leptin	O
only	O
slightly	O
(	O
insignificantly	O
)	O
.	O

In	O
men	S-Species
the	O
significance	O
of	O
correlations	O
between	O
serum	O
leptin	O
and	O
HOMA	O
IR	O
was	O
high	O
and	O
approximately	O
the	O
same	O
in	O
both	O
the	O
control	O
and	O
hyperlipemic	O
groups	O
,	O
because	O
the	O
values	O
of	O
HOMA	O
IR	O
as	O
well	O
as	O
serum	O
leptin	O
have	O
nearly	O
doubled	O
in	O
hyperlipemic	O
in	O
relation	O
to	O
control	O
groups	O
.	O

In	O
non	O
-	O
hyperlipemic	O
postmenopausal	O
women	S-Species
the	O
high	O
concentration	O
of	O
serum	O
leptin	O
was	O
not	O
associated	O
with	O
higher	O
insulin	O
resistance	O
:	O
HOMA	O
IR	O
did	O
not	O
differ	O
substantially	O
from	O
men	S-Species
.	O

A	O
significant	O
increase	O
of	O
insulin	O
resistance	O
in	O
hyperlipemic	O
women	S-Species
was	O
associated	O
by	O
only	O
slight	O
and	O
insignificant	O
increase	O
of	O
leptin	O
concentration	O
.	O

According	O
to	O
Spearman	O
'	O
s	O
correlations	O
,	O
an	O
increase	O
of	O
serum	O
TNF	O
alpha	O
and	O
/	O
or	O
a	O
decrease	O
of	O
HDL	O
-	O
cholesterol	O
might	O
also	O
play	O
a	O
distinct	O
role	O
in	O
this	O
respect	O
.	O

(	O
see	O
Table	O
3	O
)	O
.	O

In	O
contrast	O
to	O
women	S-Species
,	O
in	O
hyperlipemic	O
men	S-Species
the	O
increase	O
of	O
insulin	O
resistance	O
index	O
was	O
approximately	O
proportional	O
with	O
the	O
increase	O
of	O
leptin	O
concentration	O
.	O

Multiple	O
regression	O
analysis	O
affirmed	O
the	O
importance	O
of	O
leptin	O
serum	O
in	O
increasing	O
of	O
insulin	O
resistance	O
in	O
both	O
genders	O
.	O

In	O
men	S-Species
,	O
only	O
BMI	O
and	O
HDL	O
-	O
cholesterol	O
from	O
other	O
factors	O
studied	O
seemed	O
to	O
play	O
a	O
certain	O
role	O
,	O
but	O
the	O
maximal	O
values	O
of	O
influencing	O
HOMA	O
IR	O
reached	O
only	O
39	O
%	O
,	O
with	O
leptin	O
and	O
BMI	O
being	O
the	O
more	O
important	O
factors	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
women	S-Species
the	O
maximal	O
determination	O
of	O
HOMA	O
IR	O
as	O
high	O
as	O
60	O
%	O
was	O
registered	O
in	O
combination	O
of	O
serum	O
leptin	O
,	O
TGL	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
as	O
independent	O
factors	O
;	O
the	O
role	O
of	O
BMI	O
was	O
insignificant	O
.	O

It	O
is	O
not	O
known	O
how	O
leptin	O
is	O
regulated	O
.	O

A	O
strong	O
correlation	O
between	O
plasma	O
leptin	O
and	O
fasting	O
insulin	O
undoubtedly	O
exists	O
,	O
but	O
hyperleptinemia	O
in	O
both	O
obese	O
and	O
lean	O
humans	S-Species
is	O
not	O
likely	O
the	O
result	O
of	O
hyperinsulinemia	O
[	O
37	O
]	O
.	O

A	O
relationship	O
between	O
leptin	O
and	O
insulin	O
dependent	O
on	O
sex	O
or	O
BMI	O
was	O
reported	O
,	O
but	O
relationship	O
between	O
triglyceride	O
concentrations	O
and	O
leptin	O
was	O
independent	O
of	O
sex	O
,	O
BMI	O
,	O
and	O
insulin	O
[	O
18	O
,	O
24	O
]	O
.	O

Hyperleptinemia	O
,	O
as	O
an	O
early	O
sign	O
of	O
obesity	O
,	O
was	O
closely	O
linked	O
to	O
subcutaneous	O
fat	O
mass	O
[	O
39	O
,	O
40	O
]	O
.	O

Percentage	O
of	O
body	O
fat	O
has	O
been	O
shown	O
to	O
be	O
the	O
strongest	O
predictor	O
of	O
leptin	O
levels	O
even	O
in	O
lean	O
women	S-Species
[	O
41	O
]	O
.	O

Leptin	O
was	O
highly	O
correlated	O
with	O
percentage	O
of	O
body	O
fat	O
and	O
with	O
fat	O
mass	O
in	O
adults	O
irrespective	O
of	O
gender	O
and	O
age	O
;	O
however	O
,	O
the	O
mean	O
determinant	O
of	O
leptin	O
plasma	O
concentration	O
in	O
men	S-Species
and	O
postmenopausal	O
women	S-Species
was	O
BMI	O
,	O
while	O
in	O
premenopausal	O
women	S-Species
it	O
was	O
only	O
the	O
fat	O
mass	O
[	O
42	O
]	O
.	O

These	O
findings	O
contrast	O
with	O
our	O
results	O
showing	O
minimal	O
influence	O
of	O
BMI	O
on	O
HOMA	O
IR	O
in	O
postmenopausal	O
women	S-Species
.	O

All	O
factors	O
mentioned	O
are	O
connected	O
with	O
fat	O
tissue	O
:	O
leptin	O
and	O
TNF	O
alpha	O
are	O
directly	O
produced	O
chiefly	O
by	O
adipocytes	O
,	O
BMI	O
growth	O
is	O
obviously	O
accompanied	O
by	O
fat	O
mass	O
increase	O
,	O
and	O
the	O
typical	O
hypertriglyceridemia	O
associated	O
with	O
a	O
decrease	O
of	O
HDL	O
-	O
cholesterol	O
goes	O
along	O
with	O
obesity	O
and	O
fat	O
mass	O
growth	O
.	O

The	O
gender	O
differences	O
in	O
circulating	O
leptin	O
were	O
best	O
explained	O
by	O
percentage	O
of	O
body	O
fat	O
and	O
-	O
inversely	O
-	O
by	O
lean	O
body	O
mass	O
[	O
25	O
]	O
.	O

In	O
both	O
genders	O
the	O
intra	O
-	O
abdominal	O
fat	O
correlated	O
with	O
insulin	O
resistance	O
,	O
while	O
the	O
subcutaneous	O
fat	O
correlated	O
with	O
circulating	O
leptin	O
[	O
11	O
,	O
12	O
]	O
.	O

In	O
men	S-Species
obesity	O
led	O
to	O
a	O
prevalent	O
increase	O
of	O
intra	O
-	O
abdominal	O
fat	O
,	O
while	O
in	O
women	S-Species
of	O
subcutaneous	O
fat	O
[	O
13	O
]	O
.	O

Influences	O
of	O
different	O
compartments	O
of	O
adipose	O
tissues	O
could	O
elucidate	O
the	O
variability	O
of	O
correlations	O
between	O
insulin	O
resistance	O
and	O
high	O
leptin	O
concentrations	O
in	O
lean	O
and	O
obese	O
subjects	O
of	O
both	O
genders	O
[	O
43	O
]	O
.	O

In	O
our	O
non	O
-	O
hyperlipemic	O
postmenopausal	O
women	S-Species
the	O
content	O
of	O
subcutaneous	O
fat	O
mass	O
might	O
be	O
higher	O
than	O
in	O
non	O
-	O
hyperlipemic	O
men	S-Species
of	O
appropriate	O
age	O
,	O
which	O
indicated	O
a	O
higher	O
serum	O
concentration	O
of	O
leptin	O
.	O

However	O
,	O
the	O
insulin	O
resistance	O
-	O
related	O
to	O
intra	O
-	O
abdominal	O
fat	O
mass	O
-	O
did	O
not	O
differ	O
from	O
men	S-Species
.	O

The	O
significant	O
increase	O
of	O
insulin	O
resistance	O
and	O
leptin	O
concentration	O
in	O
hyperlipemic	O
men	S-Species
might	O
reflect	O
the	O
growing	O
content	O
of	O
both	O
subcutaneous	O
and	O
intra	O
-	O
abdominal	O
fat	O
mass	O
(	O
see	O
the	O
significant	O
increase	O
of	O
BMI	O
)	O
.	O

In	O
hyperlipemic	O
women	S-Species
the	O
significant	O
increase	O
of	O
insulin	O
resistance	O
accompanying	O
only	O
minimal	O
insignificant	O
increase	O
of	O
leptin	O
could	O
be	O
caused	O
by	O
prevalent	O
growing	O
of	O
intra	O
-	O
abdominal	O
fat	O
mass	O
.	O

In	O
elderly	O
postmenopausal	O
women	S-Species
,	O
an	O
association	O
between	O
leptin	O
and	O
plasma	O
lipoprotein	O
concentration	O
was	O
found	O
which	O
depended	O
on	O
adiposity	O
[	O
17	O
]	O
,	O
and	O
inverse	O
correlations	O
between	O
serum	O
leptin	O
and	O
HDL	O
-	O
cholesterol	O
were	O
described	O
[	O
44	O
]	O
.	O

In	O
our	O
study	O
,	O
insulin	O
resistance	O
in	O
women	S-Species
seemed	O
to	O
be	O
more	O
notably	O
than	O
in	O
men	S-Species
influenced	O
by	O
lipid	O
disorders	O
,	O
i	O
.	O
e	O
.	O
positively	O
by	O
serum	O
triglycerides	O
and	O
inversely	O
by	O
HDL	O
-	O
cholesterol	O
.	O

These	O
findings	O
might	O
be	O
important	O
in	O
considering	O
the	O
concept	O
of	O
treatment	O
of	O
insulin	O
resistance	O
-	O
related	O
disorders	O
in	O
postmenopausal	O
women	S-Species
.	O

The	O
significant	O
role	O
of	O
TNF	O
alpha	O
in	O
insulin	O
resistance	O
,	O
caused	O
by	O
inhibiting	O
the	O
transduction	O
of	O
insulin	O
signaling	O
and	O
by	O
down	O
-	O
regulation	O
of	O
glucose	O
transporter	O
GLUT	O
-	O
4	O
and	O
insulin	O
receptor	O
substrate	O
-	O
1	O
,	O
has	O
been	O
repeatedly	O
confirmed	O
[	O
45	O
-	O
48	O
]	O
.	O

Our	O
results	O
supported	O
these	O
findings	O
unambiguously	O
only	O
in	O
women	S-Species
,	O
while	O
in	O
men	S-Species
TNF	O
alpha	O
seemed	O
paradoxically	O
to	O
interfere	O
with	O
other	O
factors	O
-	O
mainly	O
BMI	O
and	O
leptin	O
-	O
in	O
influencing	O
insulin	O
resistance	O
,	O
thus	O
playing	O
a	O
quite	O
different	O
role	O
.	O

Previously	O
it	O
was	O
found	O
[	O
46	O
]	O
that	O
correlation	O
between	O
serum	O
TNF	O
alpha	O
on	O
the	O
one	O
side	O
,	O
and	O
insulin	O
,	O
HOMA	O
IR	O
,	O
serum	O
triglycerids	O
,	O
respectively	O
,	O
on	O
the	O
other	O
side	O
,	O
was	O
substantially	O
more	O
significant	O
in	O
women	S-Species
than	O
in	O
men	S-Species
.	O

Serum	O
concentration	O
of	O
TNF	O
alpha	O
in	O
patients	S-Species
with	O
type	O
2	O
diabetes	O
of	O
both	O
genders	O
correlated	O
only	O
with	O
the	O
quantity	O
of	O
intra	O
-	O
abdominal	O
fat	O
compartment	O
[	O
50	O
]	O
.	O

Visceral	O
obesity	O
correlated	O
with	O
plasmatic	O
aldosterone	O
and	O
with	O
insulin	O
resistance	O
only	O
in	O
premenopausal	O
women	S-Species
,	O
but	O
not	O
in	O
men	S-Species
[	O
51	O
]	O
.	O

From	O
all	O
these	O
data	O
we	O
might	O
support	O
our	O
above	O
mentioned	O
conclusion	O
-	O
that	O
rising	O
of	O
insulin	O
resistance	O
in	O
hyperlipemic	O
women	S-Species
was	O
associated	O
with	O
an	O
increase	O
of	O
intra	O
-	O
abdominal	O
fat	O
,	O
because	O
this	O
fat	O
mass	O
in	O
particular	O
is	O
a	O
source	O
of	O
TNF	O
alpha	O
,	O
which	O
interfered	O
with	O
insulin	O
sensitivity	O
only	O
in	O
women	S-Species
.	O

We	O
came	O
to	O
this	O
conclusion	O
irrespective	O
of	O
the	O
finding	O
that	O
the	O
increase	O
of	O
serum	O
TNF	O
alpha	O
in	O
hyperlipemic	O
women	S-Species
was	O
statistically	O
insignificant	O
;	O
results	O
of	O
Spearman	O
'	O
s	O
correlation	O
(	O
Table	O
3	O
)	O
and	O
multiple	O
regression	O
analysis	O
confirm	O
a	O
distinct	O
role	O
of	O
this	O
factor	O
.	O

In	O
hyperlipemic	O
men	S-Species
not	O
only	O
the	O
serum	O
concentration	O
of	O
TNF	O
alpha	O
has	O
decreased	O
instead	O
of	O
increasing	O
,	O
but	O
according	O
to	O
multiple	O
regression	O
analysis	O
it	O
played	O
a	O
quite	O
different	O
role	O
in	O
influencing	O
insulin	O
sensitivity	O
,	O
interfering	O
with	O
factors	O
that	O
determined	O
insulin	O
resistance	O
(	O
leptin	O
and	O
BMI	O
)	O
.	O

In	O
the	O
control	O
group	O
of	O
men	S-Species
IgG	O
anticardiolipin	O
was	O
inversely	O
correlated	O
to	O
HOMA	O
IR	O
.	O

The	O
significance	O
of	O
this	O
finding	O
is	O
not	O
clear	O
.	O

These	O
antibodies	O
indicate	O
vascular	O
and	O
thrombotic	O
complications	O
and	O
oxidative	O
modification	O
of	O
lipoproteins	O
[	O
52	O
,	O
53	O
]	O
and	O
may	O
represent	O
an	O
increased	O
risk	O
of	O
atherogenic	O
and	O
inflammatory	O
complications	O
.	O

In	O
this	O
case	O
,	O
however	O
,	O
their	O
growing	O
might	O
be	O
connected	O
with	O
an	O
increase	O
in	O
insulin	O
sensitivity	O
.	O

Anyway	O
,	O
ACL	O
IgG	O
evidently	O
did	O
not	O
participate	O
significantly	O
in	O
influencing	O
the	O
increase	O
of	O
insulin	O
resistance	O
associated	O
with	O
hyperlipidemia	O
,	O
although	O
other	O
anti	O
-	O
cardiolipin	O
correlations	O
could	O
be	O
masked	O
by	O
the	O
relatively	O
large	O
inter	O
-	O
individual	O
variations	O
in	O
this	O
parameter	O
.	O

Neither	O
serum	O
concentration	O
of	O
hFABP	O
,	O
a	O
factor	O
ensuring	O
transmembrane	O
transport	O
and	O
oxidative	O
metabolisation	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
[	O
54	O
,	O
55	O
]	O
,	O
was	O
significantly	O
changed	O
in	O
hyperlipemic	O
and	O
insulin	O
resistant	O
subjects	O
of	O
both	O
genders	O
.	O

This	O
factor	O
was	O
very	O
weakly	O
associated	O
only	O
with	O
HOMA	O
IR	O
in	O
women	S-Species
(	O
see	O
Table	O
4D	O
)	O
,	O
indicating	O
that	O
enhanced	O
metabolisation	O
of	O
fatty	O
acids	O
in	O
cells	O
might	O
to	O
some	O
degree	O
contribute	O
to	O
insulin	O
resistance	O
.	O

Conclusions	O

In	O
postmenopausal	O
women	S-Species
as	O
well	O
as	O
in	O
men	S-Species
of	O
approximately	O
equal	O
age	O
serum	O
leptin	O
plays	O
a	O
significant	O
role	O
as	O
an	O
important	O
determinant	O
of	O
insulin	O
resistance	O
.	O

In	O
addition	O
to	O
this	O
factor	O
,	O
in	O
women	S-Species
the	O
grade	O
of	O
insulin	O
resistance	O
is	O
very	O
considerably	O
influenced	O
by	O
serum	O
triglycerides	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
by	O
decreased	O
concentration	O
of	O
HDL	O
-	O
cholesterol	O
,	O
while	O
in	O
men	S-Species
only	O
a	O
mild	O
influence	O
of	O
BMI	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
is	O
observed	O
.	O

These	O
findings	O
are	O
explained	O
as	O
a	O
consequence	O
of	O
gender	O
-	O
related	O
differences	O
in	O
adipose	O
tissue	O
composition	O
and	O
/	O
or	O
distribution	O
in	O
both	O
normal	O
-	O
weight	O
and	O
over	O
-	O
weight	O
subjects	O
and	O
should	O
be	O
taken	O
into	O
account	O
in	O
treatment	O
of	O
patients	S-Species
with	O
metabolic	O
risk	O
factors	O
of	O
cardiovascular	O
diseases	O
.	O

List	O
of	O
abbreviations	O

HDL	O
-	O
Cholesterol	O
=	O
high	O
-	O
density	O
cholesterol	O

LDL	O
-	O
cholesterol	O
=	O
low	O
-	O
density	O
cholesterol	O

HOMA	O
IR	O
=	O
Homeostasis	O
Assessment	O
of	O
Insulin	O
Resistance	O

=	O
fasting	O
insulin	O
(	O
mu	O
U	O
/	O
ml	O
)	O
*	O
fasting	O
glucose	O
(	O
mmol	O
/	O
l	O
)	O
/	O
22	O
,	O
5	O

QUICKI	O
=	O
1	O
/	O
[	O
log	O
fasting	O
insulin	O
(	O
mu	O
U	O
/	O
ml	O
)	O
+	O
log	O
fasting	O
glucose	O
(	O
mg	O
/	O
100	O
ml	O
)	O
]	O

TNF	O
alpha	O
=	O
tumor	O
necrosis	O
factor	O
alpha	O

BMI	O
=	O
body	O
mass	O
index	O

R2	O
=	O
coefficient	O
of	O
determination	O

hFABP	O
=	O
heart	O
fatty	O
acid	O
binding	O
protein	O

ACL	O
-	O
IgG	O
=	O
IgG	O
fraction	O
of	O
anticardiolipin	O

TGL	O
=	O
triglycerides	O

GLUT	O
-	O
4	O
=	O
glucose	O
transporter	O
-	O
4	O

PPAR	O
gamma	O
=	O
Peroxisome	O
Proliferator	O
-	O
Associated	O
Receptor	O
gamma	O

CV	O
=	O
coefficient	O
of	O
variation	O

Authors	O
'	O
contributions	O

Dr	O
.	O
Radka	O
Lichnovsk	O
a	O
collected	O
the	O
clinical	O
material	O
,	O
performed	O
analysis	O
of	O
biochemical	O
values	O
and	O
edited	O
the	O
manuscript	O
.	O

Dr	O
.	O
Simona	O
Gwozdziewiczov	O
a	O
performed	O
analysis	O
of	O
clinical	O
and	O
biochemical	O
data	O
and	O
edited	O
the	O
manuscript	O
.	O

Prof	O
.	O

Jir	O
i	O
Hreb	O
i	O
cek	O
initiated	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
wrote	O
and	O
edited	O
the	O
manuscript	O
.	O

Alexithymia	O
and	O
anxiety	O
in	O
female	O
chronic	O
pain	O
patients	S-Species

Abstract	O

Objectives	O

Alexithymia	O
is	O
highly	O
prevalent	O
among	O
chronic	O
pain	O
patients	S-Species
.	O

Pain	O
is	O
a	O
remarkable	O
cause	O
for	O
high	O
levels	O
of	O
chronic	O
anxiety	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
alexithymia	O
and	O
to	O
determine	O
anxiety	O
levels	O
among	O
DSM	O
-	O
IV	O
somatoform	O
pain	O
disorder	O
(	O
chronic	O
pain	O
)	O
female	O
patients	S-Species
and	O
to	O
examine	O
the	O
relationship	O
between	O
alexithymia	O
and	O
the	O
self	O
-	O
reporting	O
of	O
pain	O
.	O

Methods	O

Thirty	O
adult	O
females	O
(	O
mean	O
age	O
:	O
34	O
,	O
63	O
+/-	O
10	O
,	O
62	O
years	O
)	O
,	O
who	O
applied	O
to	O
the	O
outpatient	O
psychiatry	O
clinic	O
at	O
a	O
public	O
hospital	O
with	O
the	O
diagnosis	O
of	O
chronic	O
pain	O
disorder	O
(	O
DSM	O
-	O
IV	O
)	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

Thirty	O
seven	O
healthy	O
females	O
(	O
mean	O
age	O
:	O
34	O
,	O
46	O
+/-	O
7	O
,	O
43	O
years	O
)	O
,	O
who	O
matched	O
for	O
sociodemographic	O
features	O
with	O
the	O
patient	S-Species
group	O
,	O
consisted	O
the	O
control	O
group	O
.	O

A	O
sociodemographic	O
data	O
form	O
,	O
26	O
-	O
item	O
Toronto	O
Alexithymia	O
Scale	O
(	O
TAS	O
-	O
26	O
)	O
,	O
Spielberger	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
were	O
administered	O
to	O
each	O
subject	O
and	O
information	O
was	O
obtained	O
on	O
several	O
aspects	O
of	O
the	O
patients	S-Species
'	O
pain	O
,	O
including	O
intensity	O
(	O
measured	O
by	O
VAS	O
)	O
,	O
and	O
duration	O
.	O

Results	O

Chronic	O
pain	O
patients	S-Species
were	O
found	O
significantly	O
more	O
alexithymic	O
than	O
controls	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
TAS	O
-	O
26	O
scores	O
and	O
the	O
duration	O
of	O
pain	O
.	O

The	O
alexithymic	O
and	O
nonalexithymic	O
group	O
did	O
not	O
differ	O
in	O
their	O
perception	O
of	O
pain	O
.	O

Neither	O
positive	O
correlation	O
nor	O
significant	O
difference	O
was	O
found	O
between	O
alexithymia	O
and	O
trait	O
anxiety	O
in	O
pain	O
patients	S-Species
.	O

Discussion	O

Alexithymia	O
may	O
be	O
important	O
in	O
addressing	O
the	O
diversity	O
of	O
subjective	O
factors	O
involved	O
in	O
pain	O
.	O

The	O
conceptualization	O
of	O
alexithymia	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
is	O
underlined	O
by	O
our	O
data	O
.	O

Background	O

The	O
original	O
definition	O
of	O
alexithymia	O
is	O
the	O
inability	O
to	O
identify	O
and	O
use	O
verbal	O
language	O
to	O
describe	O
feelings	O
[	O
1	O
,	O
2	O
]	O
.	O

Alexithymia	O
has	O
been	O
associated	O
with	O
a	O
variety	O
of	O
psychiatric	O
disorders	O
as	O
well	O
as	O
physical	O
illness	O
[	O
3	O
-	O
10	O
]	O
.	O

As	O
a	O
measure	O
,	O
Toronto	O
Alexithymia	O
Scale	O
was	O
significantly	O
correlated	O
with	O
the	O
measures	O
of	O
the	O
tendency	O
to	O
experience	O
and	O
report	O
physical	O
signs	O
and	O
symptoms	O
[	O
11	O
]	O
.	O

Several	O
studies	O
have	O
found	O
a	O
high	O
prevalence	O
of	O
alexithymia	O
in	O
pain	O
patients	S-Species
.	O

Chronic	O
pain	O
patients	S-Species
frequently	O
exhibit	O
many	O
of	O
the	O
core	O
features	O
of	O
alexithymia	O
,	O
such	O
as	O
problems	O
in	O
identifying	O
and	O
describing	O
subjective	O
feelings	O
,	O
impoverished	O
imaginative	O
abilities	O
,	O
and	O
excessive	O
preoccupation	O
with	O
physical	O
symptoms	O
and	O
external	O
events	O
.	O

Although	O
several	O
studies	O
have	O
found	O
a	O
high	O
prevalence	O
of	O
alexithymia	O
in	O
pain	O
patients	S-Species
,	O
the	O
way	O
alexithymia	O
may	O
possibly	O
influence	O
pain	O
experience	O
is	O
still	O
unclear	O
[	O
12	O
,	O
13	O
]	O
.	O

DSM	O
-	O
IV	O
-	O
TR	O
defines	O
pain	O
disorder	O
as	O
the	O
presence	O
of	O
pain	O
that	O
is	O
"	O
the	O
predominant	O
focus	O
of	O
clinical	O
attention	O
"	O
[	O
14	O
]	O
.	O

In	O
chronic	O
pain	O
disorder	O
,	O
patients	S-Species
complain	O
of	O
chronic	O
pain	O
,	O
for	O
which	O
no	O
physical	O
etiology	O
could	O
be	O
found	O
or	O
the	O
underlying	O
disorder	O
is	O
insufficient	O
in	O
explaining	O
the	O
symptoms	O
.	O

The	O
pain	O
causes	O
clinically	O
significant	O
distress	O
or	O
impairment	O
in	O
social	O
,	O
occupational	O
,	O
or	O
other	O
important	O
areas	O
of	O
functioning	O
.	O

Psychological	O
factors	O
are	O
judged	O
to	O
have	O
an	O
important	O
role	O
in	O
the	O
onset	O
,	O
severity	O
,	O
exacerbation	O
,	O
or	O
maintenance	O
of	O
the	O
pain	O
[	O
15	O
]	O
.	O

The	O
alexithymic	O
person	S-Species
'	O
s	O
difficulty	O
in	O
identifying	O
and	O
describing	O
feelings	O
may	O
increase	O
symptom	O
reporting	O
by	O
several	O
mechanisms	O
.	O

Consequently	O
,	O
due	O
to	O
the	O
difficulty	O
to	O
experience	O
and	O
express	O
emotions	O
,	O
alexithymia	O
has	O
been	O
linked	O
with	O
somatosensory	O
amplification	O
,	O
which	O
is	O
the	O
tendency	O
to	O
focus	O
on	O
benign	O
somatic	O
sensations	O
.	O

Alexithymic	O
subjects	O
are	O
considered	O
to	O
focus	O
on	O
somatic	O
manifestations	O
of	O
emotional	O
arousal	O
,	O
resulting	O
in	O
misinterpretation	O
of	O
somatic	O
sensations	O
as	O
signs	O
of	O
physical	O
illness	O
[	O
12	O
,	O
13	O
,	O
16	O
]	O
.	O

Accordingly	O
,	O
previous	O
studies	O
have	O
found	O
evidence	O
of	O
an	O
association	O
between	O
alexithymia	O
and	O
the	O
development	O
of	O
functional	O
somatic	O
symptoms	O
,	O
as	O
seen	O
in	O
patients	S-Species
with	O
somatoform	O
disorders	O
.	O

On	O
the	O
other	O
hand	O
,	O
alexithymia	O
may	O
also	O
occur	O
as	O
a	O
secondary	O
state	O
reaction	O
in	O
response	O
to	O
severe	O
and	O
chronic	O
medical	O
illness	O
[	O
17	O
-	O
21	O
]	O
.	O

Based	O
on	O
previous	O
findings	O
,	O
these	O
factors	O
are	O
worth	O
receiving	O
more	O
attention	O
in	O
terms	O
of	O
clinical	O
research	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
alexithymia	O
among	O
DSM	O
-	O
IV	O
somatoform	O
pain	O
disorder	O
(	O
chronic	O
pain	O
)	O
female	O
patients	S-Species
and	O
to	O
examine	O
the	O
relationship	O
between	O
alexithymia	O
and	O
the	O
self	O
-	O
reporting	O
of	O
pain	O
in	O
this	O
group	O
of	O
patients	S-Species
.	O

Besides	O
,	O
the	O
study	O
searched	O
for	O
the	O
anxiety	O
levels	O
of	O
chronic	O
pain	O
patients	S-Species
with	O
or	O
without	O
alexithymia	O
.	O

Materials	O
and	O
methods	O

Sample	O

The	O
sample	O
consisted	O
of	O
30	O
females	O
who	O
applied	O
to	O
the	O
outpatient	O
psychiatry	O
clinic	O
at	O
a	O
public	O
hospital	O
and	O
who	O
met	O
DSM	O
-	O
IV	O
diagnostic	O
criteria	O
for	O
chronic	O
pain	O
disorder	O
.	O

Patients	S-Species
with	O
concomitant	O
psychiatric	O
disorders	O
,	O
such	O
as	O
major	O
depression	O
,	O
anxiety	O
disorders	O
and	O
somatoform	O
disorders	O
other	O
than	O
pain	O
disorder	O
were	O
excluded	O
.	O

Patients	S-Species
either	O
directly	O
applied	O
to	O
the	O
psychiatry	O
clinic	O
themselves	O
or	O
were	O
referred	O
for	O
psychiatric	O
assessment	O
from	O
another	O
outpatient	O
clinic	O
,	O
mainly	O
physical	O
medicine	O
and	O
rehabilitation	O
.	O

After	O
complete	O
description	O
of	O
the	O
study	O
,	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
subject	O
.	O

The	O
control	O
group	O
was	O
37	O
healthy	O
females	O
,	O
who	O
matched	O
for	O
age	O
,	O
and	O
education	O
with	O
the	O
subjects	O
.	O

All	O
subjects	O
participated	O
voluntarily	O
in	O
the	O
study	O
and	O
gave	O
consent	O
after	O
the	O
procedure	O
had	O
been	O
fully	O
explained	O
to	O
them	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	S-Species
and	O
the	O
healthy	O
controls	O
was	O
34	O
,	O
63	O
+/-	O
10	O
,	O
62	O
(	O
range	O
:	O
16	O
-	O
62	O
)	O
and	O
34	O
,	O
46	O
+/-	O
7	O
,	O
43	O
(	O
range	O
:	O
22	O
-	O
57	O
)	O
years	O
and	O
the	O
educational	O
level	O
was	O
6	O
,	O
13	O
+/-	O
3	O
,	O
03	O
(	O
range	O
:	O
5	O
-	O
11	O
)	O
and	O
6	O
,	O
59	O
+/-	O
2	O
,	O
9	O
(	O
range	O
:	O
5	O
-	O
14	O
)	O
years	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
age	O
(	O
t	O
=	O
0	O
,	O
79	O
,	O
df	O
=	O
65	O
,	O
P	O
>	O
0	O
,	O
05	O
)	O
,	O
educational	O
level	O
(	O
t	O
=	O
1	O
,	O
02	O
,	O
df	O
=	O
65	O
,	O
P	O
>	O
0	O
,	O
05	O
)	O
,	O
and	O
marital	O
status	O
(	O
x2	O
=	O
0	O
,	O
51	O
,	O
df	O
=	O
1	O
,	O
P	O
>	O
0	O
,	O
05	O
)	O
.	O

Measures	O

A	O
detailed	O
sociodemographic	O
data	O
form	O
was	O
used	O
for	O
all	O
subjects	O
.	O

All	O
participants	S-Species
were	O
applied	O
Structured	O
Clinical	O
Interview	O
for	O
DSM	O
-	O
IV	O
(	O
SCID	O
-	O
I	O
)	O
[	O
22	O
]	O
,	O
Turkish	O
version	O
[	O
23	O
]	O
.	O

Regarding	O
the	O
pain	O
assessment	O
,	O
information	O
was	O
first	O
obtained	O
on	O
several	O
aspects	O
of	O
the	O
patients	S-Species
'	O
pain	O
,	O
such	O
as	O
intensity	O
,	O
and	O
duration	O
.	O

Pain	O
intensity	O
was	O
measured	O
by	O
Visual	O
Analogue	O
Scale	O
(	O
VAS	O
)	O
,	O
using	O
a	O
horizontal	O
10	O
-	O
cm	O
line	O
with	O
the	O
statement	O
'	O
no	O
pain	O
at	O
all	O
'	O
at	O
the	O
extreme	O
left	O
-	O
hand	O
end	O
and	O
'	O
the	O
worst	O
possible	O
pain	O
'	O
or	O
'	O
unbearable	O
'	O
at	O
the	O
right	O
-	O
hand	O
extreme	O
.	O

VAS	O
is	O
scored	O
by	O
measuring	O
the	O
distance	O
from	O
the	O
end	O
of	O
the	O
scale	O
indicating	O
absence	O
of	O
pain	O
(	O
or	O
no	O
distress	O
or	O
no	O
pain	O
relief	O
)	O
to	O
the	O
place	O
marked	O
by	O
the	O
patient	S-Species
[	O
24	O
]	O
.	O

The	O
psychometric	O
scales	O
used	O
in	O
the	O
study	O
were	O
the	O
26	O
-	O
item	O
Toronto	O
Alexithymia	O
Scale	O
(	O
TAS	O
-	O
26	O
]	O
and	O
the	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
,	O
which	O
were	O
both	O
validated	O
in	O
Turkish	O
population	O
studies	O
[	O
25	O
-	O
28	O
]	O
.	O

TAS	O
is	O
a	O
psychometrically	O
well	O
validated	O
and	O
reliable	O
instrument	O
in	O
the	O
assessment	O
of	O
alexithymia	O
.	O
TAS	O
has	O
been	O
validated	O
in	O
Turkish	O
studies	O
as	O
a	O
true	O
or	O
false	O
scale	O
.	O

Twenty	O
-	O
six	O
items	O
are	O
scored	O
either	O
as	O
1	O
or	O
0	O
and	O
the	O
higher	O
scores	O
indicate	O
higher	O
degrees	O
of	O
alexithymia	O
.	O

TAS	O
has	O
an	O
interval	O
consistency	O
of	O
0	O
.	O
65	O
[	O
Kuder	O
-	O
Richardson	O
)	O
and	O
test	O
-	O
retest	O
reliability	O
is	O
r	O
=	O
0	O
.	O
71	O
,	O
p	O
<	O
0	O
.	O
01	O
in	O
Turkish	O
reliability	O
and	O
validity	O
study	O
.	O

The	O
sample	O
was	O
divided	O
into	O
nonalexithymic	O
and	O
alexityhmic	O
groups	O
,	O
with	O
the	O
recommended	O
cut	O
-	O
off	O
score	O
of	O
11	O
[	O
27	O
]	O
.	O

Spielberger	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
is	O
one	O
of	O
the	O
two	O
sections	O
of	O
the	O
Spielberger	O
Anxiety	O
Inventory	O
(	O
the	O
other	O
,	O
measuring	O
state	O
anxiety	O
)	O
.	O

'	O
Trait	O
anxiety	O
'	O
has	O
been	O
defined	O
as	O
anxiety	O
proneness	O
,	O
that	O
is	O
,	O
the	O
tendency	O
to	O
respond	O
to	O
situations	O
perceived	O
as	O
threatening	O
with	O
elevations	O
in	O
the	O
intensity	O
of	O
state	O
anxiety	O
[	O
26	O
]	O
.	O

Statistical	O
analysis	O

In	O
order	O
to	O
determine	O
the	O
relative	O
importance	O
of	O
a	O
number	O
of	O
factors	O
in	O
pain	O
disorders	O
,	O
we	O
used	O
both	O
correlation	O
analyses	O
.	O

The	O
alexithymic	O
and	O
nonalexithymic	O
groups	O
were	O
compared	O
using	O
the	O
independent	O
sample	O
t	O
-	O
tests	O
on	O
scores	O
of	O
psychological	O
tests	O
.	O

The	O
statistical	O
procedure	O
,	O
which	O
was	O
carried	O
out	O
by	O
a	O
SPSS	O
package	O
program	O
for	O
Windows	O
using	O
Chi	O
-	O
square	O
,	O
Fisher	O
'	O
s	O
exact	O
test	O
,	O
two	O
tailed	O
t	O
test	O
and	O
Pearson	O
correlation	O
coefficients	O
,	O
was	O
also	O
used	O
to	O
determine	O
group	O
differences	O
(	O
alexithymics	O
versus	O
nonalexithymics	O
)	O
in	O
sociodemographic	O
variables	O
and	O
various	O
aspects	O
of	O
pain	O
.	O

Results	O

In	O
the	O
chronic	O
pain	O
group	O
,	O
56	O
.	O
7	O
%	O
of	O
patients	S-Species
(	O
n	O
=	O
17	O
)	O
had	O
a	O
score	O
greater	O
than	O
11	O
on	O
the	O
TAS	O
-	O
26	O
,	O
and	O
were	O
considered	O
alexithymic	O
.	O

The	O
mean	O
TAS	O
-	O
26	O
score	O
of	O
the	O
alexithymic	O
group	O
(	O
n	O
=	O
17	O
)	O
was	O
17	O
.	O
88	O
+/-	O
3	O
.	O
43	O
and	O
the	O
nonalexithymic	O
group	O
(	O
n	O
=	O
13	O
)	O
was	O
8	O
.	O
39	O
+/-	O
2	O
.	O
02	O
.	O

Age	O
(	O
t	O
=	O
1	O
,	O
38	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0	O
,	O
18	O
)	O
,	O
education	O
(	O
t	O
=	O
-	O
0	O
,	O
21	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0	O
,	O
16	O
)	O
and	O
marital	O
status	O
(	O
x2	O
=	O
0	O
,	O
27	O
,	O
df	O
=	O
1	O
,	O
p	O
>	O
0	O
,	O
87	O
)	O
were	O
not	O
associated	O
with	O
alexithymia	O
(	O
Table	O
1	O
)	O
.	O

In	O
the	O
control	O
group	O
,	O
24	O
,	O
3	O
%	O
of	O
patients	S-Species
(	O
n	O
=	O
9	O
)	O
were	O
alexithymic	O
according	O
to	O
TAS	O
-	O
26	O
.	O

The	O
mean	O
TAS	O
-	O
26	O
score	O
of	O
the	O
alexithymic	O
group	O
(	O
n	O
=	O
9	O
)	O
was	O
13	O
,	O
82	O
+/-	O
1	O
,	O
93	O
and	O
the	O
nonalexithymic	O
group	O
(	O
n	O
=	O
28	O
)	O
was	O
10	O
,	O
33	O
+/-	O
0	O
,	O
86	O
.	O

Alexithymia	O
was	O
not	O
associated	O
with	O
age	O
(	O
t	O
=	O
-	O
1	O
,	O
08	O
,	O
df	O
=	O
35	O
,	O
p	O
>	O
0	O
,	O
29	O
)	O
,	O
educational	O
level	O
(	O
t	O
=	O
1	O
,	O
1	O
,	O
df	O
=	O
35	O
,	O
p	O
>	O
0	O
,	O
28	O
)	O
,	O
or	O
marital	O
status	O
(	O
x2	O
=	O
0	O
,	O
74	O
,	O
df	O
=	O
1	O
,	O
p	O
>	O
0	O
,	O
79	O
)	O
or	O
anxiety	O
levels	O
in	O
the	O
control	O
subjects	O
(	O
Table	O
1	O
)	O
.	O

The	O
duration	O
and	O
severity	O
of	O
pain	O
,	O
TAS	O
-	O
26	O
scores	O
,	O
and	O
STAI	O
scores	O
of	O
the	O
female	O
pain	O
patients	S-Species
are	O
shown	O
in	O
Table	O
2	O
.	O

Comparison	O
of	O
the	O
alexithymics	O
with	O
nonalexithymics	O
on	O
either	O
the	O
severity	O
of	O
pain	O
or	O
pain	O
duration	O
showed	O
no	O
statistical	O
significance	O
(	O
t	O
=	O
0	O
,	O
64	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0	O
,	O
52	O
,	O
t	O
=	O
2	O
,	O
05	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0	O
,	O
05	O
,	O
respectively	O
)	O
.	O

TAS	O
-	O
26	O
score	O
and	O
duration	O
of	O
pain	O
were	O
found	O
positively	O
correlated	O
(	O
r	O
=	O
0	O
,	O
50	O
,	O
n	O
=	O
30	O
,	O
p	O
>	O
0	O
,	O
005	O
)	O
.	O

STAI	O
(	O
trait	O
)	O
scores	O
of	O
the	O
alexithymics	O
in	O
the	O
pain	O
group	O
did	O
not	O
significantly	O
differ	O
from	O
the	O
nonlalexithymics	O
(	O
t	O
=	O
0	O
,	O
06	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0	O
,	O
95	O
)	O
and	O
besides	O
,	O
TAS	O
-	O
26	O
and	O
STAI	O
scores	O
were	O
not	O
correlated	O
(	O
r	O
=	O
0	O
,	O
06	O
,	O
p	O
>	O
0	O
,	O
72	O
)	O
.	O

In	O
summary	O
,	O
there	O
are	O
three	O
points	O
to	O
be	O
emphasized	O
.	O

First	O
,	O
chronic	O
pain	O
patients	S-Species
were	O
found	O
significantly	O
more	O
alexithymic	O
than	O
controls	O
(	O
56	O
,	O
7	O
%	O
to	O
24	O
,	O
3	O
%	O
)	O
.	O

Second	O
,	O
a	O
positive	O
correlation	O
was	O
observed	O
between	O
TAS	O
-	O
26	O
scores	O
and	O
duration	O
of	O
pain	O
.	O

Third	O
,	O
neither	O
positive	O
correlation	O
nor	O
significant	O
difference	O
was	O
found	O
between	O
alexithymia	O
and	O
trait	O
anxiety	O
in	O
pain	O
patients	S-Species
.	O

Discussion	O

The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
patients	S-Species
with	O
chronic	O
pain	O
disorder	O
are	O
more	O
alexithymic	O
than	O
individuals	O
with	O
no	O
pain	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
results	O
obtained	O
with	O
earlier	O
measures	O
of	O
alexithymia	O
[	O
11	O
-	O
13	O
]	O
.	O

Although	O
they	O
may	O
share	O
common	O
clinical	O
features	O
,	O
alexithymia	O
and	O
somatoform	O
pain	O
are	O
independent	O
constructs	O
.	O

Alexithymia	O
may	O
be	O
a	O
consequence	O
to	O
the	O
effects	O
of	O
severe	O
physical	O
symptoms	O
,	O
such	O
as	O
a	O
reduced	O
quality	O
of	O
life	O
and	O
limitations	O
in	O
daily	O
activities	O
.	O

Besides	O
,	O
alexithymia	O
may	O
be	O
conceptualized	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
[	O
2	O
,	O
3	O
,	O
15	O
-	O
17	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
question	O
investigated	O
was	O
whether	O
alexithymia	O
has	O
any	O
correlation	O
with	O
the	O
duration	O
or	O
severity	O
of	O
the	O
pain	O
itself	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
alexithymic	O
and	O
nonalexitymic	O
patients	S-Species
on	O
self	O
reports	O
of	O
current	O
pain	O
severity	O
.	O

This	O
is	O
in	O
accordance	O
with	O
Cox	O
'	O
s	O
study	O
[	O
1994	O
]	O
in	O
which	O
it	O
was	O
further	O
pointed	O
out	O
that	O
alexithymic	O
patients	S-Species
were	O
found	O
to	O
use	O
significantly	O
more	O
verbal	O
descriptors	O
of	O
pain	O
compared	O
to	O
nonalexithymic	O
patients	S-Species
[	O
13	O
]	O
.	O

In	O
our	O
study	O
,	O
pain	O
intensity	O
was	O
only	O
evaluated	O
by	O
using	O
VAS	O
.	O

One	O
problem	O
in	O
trying	O
to	O
measure	O
the	O
intensity	O
of	O
pain	O
is	O
the	O
lack	O
of	O
an	O
objective	O
way	O
.	O

Pain	O
is	O
a	O
subjective	O
experience	O
and	O
each	O
patient	S-Species
may	O
communicate	O
in	O
a	O
different	O
way	O
,	O
verbally	O
or	O
nonverbally	O
[	O
29	O
]	O
.	O

Patients	S-Species
in	O
this	O
sample	O
were	O
sufferers	O
of	O
chronic	O
pain	O
,	O
who	O
had	O
already	O
chosen	O
an	O
approved	O
way	O
of	O
expressing	O
their	O
distress	O
.	O

Since	O
this	O
is	O
true	O
regardless	O
of	O
alexithymia	O
,	O
alexithymic	O
groups	O
and	O
nonalexithymic	O
groups	O
in	O
this	O
sample	O
showed	O
no	O
difference	O
on	O
pain	O
severity	O
.	O

The	O
positive	O
correlation	O
between	O
alexithymia	O
and	O
the	O
duration	O
of	O
pain	O
in	O
this	O
sample	O
supports	O
the	O
assumption	O
of	O
a	O
two	O
-	O
way	O
hypothesis	O
.	O

It	O
is	O
often	O
assumed	O
that	O
pain	O
can	O
be	O
caused	O
by	O
alexithymic	O
personality	O
traits	O
and	O
also	O
that	O
severe	O
and	O
chronic	O
pain	O
may	O
cause	O
emotional	O
change	O
.	O

One	O
of	O
the	O
limitations	O
of	O
this	O
study	O
is	O
that	O
because	O
of	O
the	O
cross	O
-	O
sectional	O
design	O
,	O
we	O
are	O
unable	O
to	O
draw	O
conclusions	O
about	O
the	O
direction	O
of	O
causality	O
between	O
alexithymia	O
and	O
pain	O
.	O

The	O
duration	O
of	O
the	O
patients	S-Species
'	O
pain	O
could	O
approximately	O
be	O
determined	O
,	O
yet	O
the	O
preexisting	O
level	O
of	O
alexithymia	O
was	O
not	O
known	O
.	O

In	O
the	O
usual	O
absence	O
of	O
internal	O
stimuli	O
,	O
alexithymic	O
person	S-Species
may	O
be	O
expected	O
to	O
maintain	O
an	O
external	O
focus	O
of	O
attention	O
,	O
such	O
as	O
pain	O
.	O

Symptom	O
chronicity	O
may	O
force	O
the	O
alexithymic	O
person	S-Species
to	O
attent	O
to	O
and	O
amplify	O
this	O
somatic	O
sensation	O
.	O

Difficulties	O
in	O
the	O
ability	O
to	O
identify	O
and	O
differentiate	O
emotions	O
and	O
somatic	O
experiences	O
are	O
core	O
features	O
of	O
the	O
alexithymic	O
construct	O
.	O

Therefore	O
,	O
alexithymic	O
patients	S-Species
might	O
be	O
expected	O
to	O
differ	O
from	O
nonalexithymic	O
ones	O
in	O
their	O
anxiety	O
levels	O
.	O

Yet	O
,	O
in	O
our	O
pain	O
group	O
alexithymic	O
patients	S-Species
showed	O
no	O
significant	O
difference	O
from	O
the	O
nonalexithymics	O
on	O
trait	O
anxiety	O
.	O

Besides	O
,	O
alexithymia	O
and	O
anxiety	O
were	O
not	O
correlated	O
at	O
all	O
.	O

The	O
reasons	O
may	O
be	O
lying	O
in	O
the	O
specific	O
characteristics	O
of	O
this	O
patient	S-Species
group	O
itself	O
.	O

The	O
study	O
included	O
patients	S-Species
suffering	O
from	O
chronic	O
symptoms	O
;	O
with	O
an	O
average	O
of	O
7	O
,	O
44	O
+/-	O
6	O
,	O
82	O
years	O
of	O
pain	O
in	O
the	O
alexithymic	O
and	O
3	O
,	O
31	O
+/-	O
2	O
,	O
79	O
years	O
in	O
the	O
nonalexithymic	O
groups	O
.	O

Persistency	O
of	O
any	O
physical	O
symptom	O
may	O
bring	O
along	O
alexithymia	O
as	O
a	O
coping	O
strategy	O
.	O

In	O
their	O
paper	O
,	O
Crook	O
and	O
Tunks	O
(	O
1988	O
)	O
examined	O
the	O
types	O
of	O
coping	O
strategies	O
used	O
by	O
persistent	O
pain	O
sufferers	O
and	O
addressed	O
to	O
the	O
importance	O
to	O
alter	O
their	O
attitudes	O
and	O
behavior	O
that	O
tend	O
toward	O
catastrophizing	O
,	O
avoidance	O
and	O
withdrawal	O
,	O
rather	O
than	O
simply	O
concentrate	O
on	O
trying	O
to	O
teach	O
them	O
techniques	O
for	O
'	O
coping	O
with	O
stress	O
'	O
to	O
help	O
persistent	O
pain	O
sufferers	O
[	O
30	O
]	O
.	O

Sufferers	O
of	O
chronic	O
symptoms	O
in	O
this	O
sample	O
were	O
members	O
of	O
a	O
subgroup	O
who	O
have	O
been	O
seeking	O
medical	O
care	O
for	O
a	O
long	O
time	O
and	O
besides	O
given	O
the	O
chance	O
of	O
being	O
referred	O
to	O
a	O
psychiatrist	O
.	O

Therefore	O
,	O
alexithymic	O
or	O
not	O
,	O
their	O
anxiety	O
might	O
have	O
induced	O
unique	O
coping	O
strategies	O
and	O
illness	O
behavior	O
.	O

Alexithymia	O
may	O
be	O
important	O
in	O
addressing	O
the	O
diversity	O
of	O
subjective	O
factors	O
involved	O
in	O
pain	O
[	O
31	O
]	O
.	O

It	O
is	O
not	O
known	O
whether	O
it	O
should	O
be	O
addressed	O
in	O
the	O
treatment	O
of	O
pain	O
patients	S-Species
,	O
but	O
a	O
high	O
level	O
of	O
alexithymia	O
may	O
effect	O
the	O
nature	O
of	O
assessment	O
.	O

In	O
summary	O
,	O
the	O
conceptualization	O
of	O
alexithymia	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
is	O
underlined	O
by	O
our	O
data	O
.	O

However	O
,	O
regarding	O
the	O
cross	O
-	O
sectional	O
design	O
of	O
this	O
study	O
,	O
only	O
limited	O
conclusions	O
can	O
be	O
drawn	O
about	O
the	O
nature	O
of	O
the	O
causal	O
relationship	O
between	O
alexithymia	O
and	O
chronic	O
pain	O
.	O

Therefore	O
,	O
future	O
longitudinal	O
studies	O
assessing	O
the	O
cause	O
of	O
alexithymic	O
characteristics	O
are	O
required	O
to	O
fully	O
elucidate	O
the	O
concepts	O
of	O
primary	O
and	O
secondary	O
alexithymia	O
.	O

Molecular	O
polymorphism	O
,	O
differentiation	O
and	O
introgression	O
in	O
the	O
period	O
gene	O
between	O
Lutzomyia	B-Species
intermedia	E-Species
and	O
Lutzomyia	B-Species
whitmani	E-Species

Abstract	O

Background	O

Lutzomyia	B-Species
intermedia	E-Species
and	O
Lutzomyia	B-Species
whitmani	E-Species
(	O
Diptera	O
:	O
Psychodidae	O
)	O
are	O
important	O
and	O
very	O
closely	O
related	O
vector	O
species	O
of	O
cutaneous	O
leishmaniasis	O
in	O
Brazil	O
,	O
which	O
are	O
distinguishable	O
by	O
a	O
few	O
morphological	O
differences	O
.	O

There	O
is	O
evidence	O
of	O
mitochondrial	O
introgression	O
between	O
the	O
two	O
species	O
but	O
it	O
is	O
not	O
clear	O
whether	O
gene	O
flow	O
also	O
occurs	O
in	O
nuclear	O
genes	O
.	O

Results	O

We	O
analyzed	O
the	O
molecular	O
variation	O
within	O
the	O
clock	O
gene	O
period	O
(	O
per	O
)	O
of	O
these	O
two	O
species	O
in	O
five	O
different	O
localities	O
in	O
Eastern	O
Brazil	O
.	O

AMOVA	O
and	O
Fst	O
estimates	O
showed	O
no	O
evidence	O
for	O
geographical	O
differentiation	O
within	O
species	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
values	O
were	O
highly	O
significant	O
for	O
both	O
analyses	O
between	O
species	O
.	O

The	O
two	O
species	O
show	O
no	O
fixed	O
differences	O
and	O
a	O
higher	O
number	O
of	O
shared	O
polymorphisms	O
compared	O
to	O
exclusive	O
mutations	O
.	O

In	O
addition	O
,	O
some	O
haplotypes	O
that	O
are	O
"	O
typical	O
"	O
of	O
one	O
species	O
were	O
found	O
in	O
some	O
individuals	O
of	O
the	O
other	O
species	O
suggesting	O
either	O
the	O
persistence	O
of	O
old	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
.	O

Two	O
tests	O
of	O
gene	O
flow	O
,	O
one	O
based	O
on	O
linkage	O
disequilibrium	O
and	O
a	O
MCMC	O
analysis	O
based	O
on	O
coalescence	O
,	O
suggest	O
that	O
the	O
two	O
species	O
might	O
be	O
exchanging	O
alleles	O
at	O
the	O
per	O
locus	O
.	O

Conclusion	O

Introgression	O
might	O
be	O
occurring	O
between	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
in	O
period	O
,	O
a	O
gene	O
controlling	O
behavioral	O
rhythms	O
in	O
Drosophila	O
.	O

This	O
result	O
raises	O
the	O
question	O
of	O
whether	O
similar	O
phenomena	O
are	O
occurring	O
at	O
other	O
loci	O
controlling	O
important	O
aspects	O
of	O
behavior	O
and	O
vectorial	O
capacity	O
.	O

Background	O

The	O
Phlebotominae	O
sand	O
flies	O
Lutzomyia	B-Species
intermedia	E-Species
Lutz	O
&	O
Neiva	O
1912	O
and	O
Lutzomyia	B-Species
whitmani	E-Species
Antunes	O
&	O
Coutinho	O
1912	O
are	O
vectors	O
of	O
cutaneous	O
leishmaniasis	O
in	O
Brazil	O
.	O

These	O
are	O
closely	O
related	O
species	O
that	O
can	O
be	O
only	O
distinguished	O
by	O
a	O
few	O
morphological	O
differences	O
[	O
1	O
]	O
and	O
both	O
show	O
high	O
anthropophily	O
and	O
reported	O
natural	O
infections	O
with	O
Leishmania	O
in	O
different	O
regions	O
of	O
Brazil	O
[	O
2	O
]	O
.	O

Despite	O
their	O
importance	O
as	O
vectors	O
,	O
only	O
a	O
handful	O
of	O
studies	O
have	O
been	O
carried	O
out	O
in	O
these	O
two	O
species	O
using	O
molecular	O
techniques	O
[	O
3	O
-	O
6	O
]	O
.	O

One	O
of	O
the	O
most	O
important	O
findings	O
from	O
an	O
epidemiological	O
perspective	O
is	O
the	O
evidence	O
obtained	O
for	O
introgression	O
between	O
the	O
two	O
species	O
using	O
mitochondrial	O
DNA	O
[	O
4	O
]	O
.	O

This	O
was	O
particularly	O
interesting	O
because	O
apparently	O
,	O
only	O
lineages	O
of	O
L	B-Species
.	I-Species
whitmani	E-Species
sympatric	O
with	O
L	B-Species
.	I-Species
intermedia	E-Species
have	O
been	O
involved	O
in	O
cutaneous	O
leishmaniasis	O
transmission	O
in	O
the	O
peridomestic	O
environment	O
[	O
4	O
]	O
,	O
which	O
suggests	O
that	O
genes	O
controlling	O
aspects	O
of	O
vectorial	O
capacity	O
could	O
be	O
passing	O
from	O
one	O
species	O
to	O
the	O
other	O
.	O

In	O
fact	O
,	O
mitochondrial	O
introgression	O
has	O
been	O
reported	O
in	O
other	O
sand	O
fly	O
species	O
[	O
7	O
,	O
8	O
]	O
suggesting	O
that	O
might	O
be	O
a	O
common	O
phenomenon	O
in	O
these	O
insect	O
vectors	O
.	O

However	O
,	O
because	O
mitochondrial	O
genes	O
can	O
introgress	O
relatively	O
easily	O
between	O
closely	O
related	O
species	O
[	O
9	O
]	O
,	O
it	O
becomes	O
important	O
to	O
examine	O
whether	O
introgression	O
can	O
occur	O
with	O
nuclear	O
genes	O
.	O

The	O
Drosophila	O
period	O
(	O
per	O
)	O
gene	O
homologue	O
was	O
isolated	O
in	O
sand	O
flies	O
by	O
Peixoto	O
et	O
al	O
.	O

[	O
10	O
]	O
.	O

This	O
circadian	O
clock	O
gene	O
was	O
originally	O
identified	O
using	O
mutagenesis	O
by	O
Konopka	O
and	O
Benzer	O
[	O
11	O
]	O
,	O
but	O
is	O
also	O
known	O
to	O
control	O
the	O
differences	O
in	O
the	O
"	O
lovesong	O
"	O
rhythms	O
between	O
D	B-Species
.	I-Species
melanogaster	E-Species
and	O
D	B-Species
.	I-Species
simulans	E-Species
[	O
12	O
]	O
,	O
that	O
are	O
important	O
to	O
the	O
sexual	O
isolation	O
between	O
these	O
two	O
species	O
[	O
13	O
-	O
15	O
]	O
.	O

In	O
addition	O
,	O
per	O
was	O
implicated	O
in	O
the	O
control	O
of	O
species	O
-	O
specific	O
circadian	O
mating	O
rhythms	O
in	O
Drosophila	O
and	O
Bractocera	O
,	O
which	O
might	O
also	O
constitute	O
a	O
reproductive	O
isolation	O
mechanism	O
[	O
16	O
-	O
18	O
]	O
.	O

Thus	O
per	O
may	O
possibly	O
represent	O
an	O
example	O
of	O
a	O
Drosophila	O
speciation	O
gene	O
[	O
19	O
]	O
,	O
and	O
in	O
fact	O
it	O
has	O
been	O
used	O
as	O
a	O
molecular	O
marker	O
in	O
a	O
number	O
of	O
speciation	O
and	O
evolutionary	O
studies	O
,	O
not	O
only	O
in	O
Drosophila	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
but	O
also	O
in	O
other	O
insects	O
(	O
e	O
.	O
g	O
.	O
[	O
21	O
]	O
)	O
including	O
sand	O
flies	O
[	O
22	O
-	O
24	O
]	O
.	O

Because	O
per	O
controls	O
the	O
circadian	O
clock	O
in	O
different	O
insects	O
[	O
25	O
]	O
,	O
it	O
is	O
almost	O
certainly	O
involved	O
in	O
the	O
rhythms	O
of	O
activity	O
and	O
biting	O
of	O
sand	O
flies	O
[	O
26	O
]	O
,	O
which	O
are	O
very	O
important	O
to	O
leishmaniasis	O
transmission	O
.	O

In	O
addition	O
,	O
per	O
might	O
be	O
involved	O
in	O
reproductive	O
isolation	O
in	O
sand	O
flies	O
,	O
via	O
mating	O
rhythms	O
,	O
or	O
via	O
their	O
"	O
lovesongs	O
"	O
[	O
2	O
,	O
27	O
]	O
.	O
per	O
is	O
thus	O
a	O
particularly	O
interesting	O
marker	O
,	O
among	O
the	O
few	O
available	O
,	O
for	O
an	O
introgression	O
analysis	O
in	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
.	O

Evidence	O
for	O
introgression	O
in	O
per	O
might	O
suggest	O
that	O
gene	O
flow	O
between	O
these	O
two	O
vector	O
species	O
is	O
occurring	O
at	O
other	O
genes	O
controlling	O
important	O
aspects	O
of	O
behavior	O
and	O
vectorial	O
capacity	O
.	O

It	O
might	O
also	O
suggest	O
that	O
per	O
does	O
not	O
have	O
a	O
strong	O
role	O
in	O
their	O
reproductive	O
isolation	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
analyzed	O
the	O
molecular	O
variation	O
within	O
the	O
per	O
gene	O
of	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
in	O
five	O
different	O
localities	O
in	O
Eastern	O
Brazil	O
.	O

Results	O

Polymorphism	O
and	O
divergence	O
between	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species

A	O
total	O
of	O
68	O
sequences	O
from	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
53	O
from	O
L	B-Species
.	I-Species
whitmani	E-Species
homologue	O
to	O
a	O
fragment	O
of	O
the	O
period	O
gene	O
were	O
analyzed	O
from	O
populations	O
of	O
five	O
localities	O
in	O
Eastern	O
Brazil	O
(	O
Fig	O
1	O
)	O
.	O

The	O
alignment	O
of	O
72	O
variable	O
sites	O
is	O
shown	O
in	O
Fig	O
2	O
.	O

Although	O
most	O
of	O
the	O
changes	O
are	O
either	O
synonymous	O
or	O
occur	O
within	O
the	O
58	O
bp	O
intron	O
,	O
non	O
-	O
synonymous	O
substitutions	O
are	O
observed	O
causing	O
9	O
amino	O
acid	O
differences	O
among	O
the	O
sequences	O
(	O
Fig	O
2	O
)	O
.	O

Table	O
1	O
shows	O
the	O
number	O
of	O
sequences	O
of	O
each	O
population	O
of	O
the	O
two	O
species	O
,	O
the	O
number	O
of	O
polymorphic	O
sites	O
(	O
S	O
)	O
and	O
the	O
estimates	O
of	O
molecular	O
polymorphism	O
theta	O
(	O
based	O
on	O
the	O
total	O
number	O
of	O
mutations	O
)	O
and	O
pi	O
.	O

Table	O
1	O
also	O
shows	O
the	O
Tajima	O
'	O
s	O
[	O
28	O
]	O
and	O
Fu	O
&	O
Li	O
'	O
s	O
[	O
29	O
]	O
statistics	O
.	O

Within	O
each	O
species	O
,	O
all	O
populations	O
present	O
similar	O
levels	O
of	O
polymorphism	O
with	O
the	O
exception	O
of	O
L	B-Species
.	I-Species
whitmani	E-Species
from	O
Ilh	O
e	O
us	O
,	O
which	O
seems	O
to	O
be	O
less	O
polymorphic	O
than	O
the	O
others	O
.	O

This	O
population	O
was	O
also	O
the	O
only	O
one	O
presenting	O
a	O
significant	O
value	O
in	O
the	O
Fu	O
&	O
Li	O
test	O
but	O
only	O
at	O
the	O
5	O
%	O
level	O
.	O

Finally	O
,	O
the	O
last	O
column	O
of	O
Table	O
1	O
presents	O
the	O
recombination	O
estimator	O
gamma	O
[	O
30	O
]	O
indicating	O
that	O
both	O
species	O
show	O
evidence	O
of	O
intragenic	O
recombination	O
in	O
the	O
per	O
gene	O
.	O

To	O
investigate	O
the	O
level	O
of	O
intra	O
and	O
interspecific	O
differences	O
,	O
initially	O
an	O
AMOVA	O
was	O
carried	O
out	O
as	O
shown	O
in	O
Table	O
2	O
.	O

The	O
results	O
show	O
a	O
non	O
-	O
significant	O
within	O
species	O
and	O
a	O
significant	O
between	O
species	O
molecular	O
variation	O
at	O
the	O
per	O
locus	O
.	O

Table	O
3	O
shows	O
a	O
more	O
detailed	O
analysis	O
of	O
the	O
intraspecific	O
differentiation	O
among	O
populations	O
of	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
.	O

None	O
of	O
the	O
pairwise	O
and	O
overall	O
fixation	O
indexes	O
(	O
Fst	O
)	O
are	O
significant	O
in	O
the	O
case	O
of	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
only	O
one	O
(	O
Posse	O
x	O
Ilh	O
e	O
us	O
)	O
has	O
a	O
borderline	O
significant	O
value	O
in	O
L	B-Species
.	I-Species
whitmani	E-Species
.	O

The	O
results	O
therefore	O
show	O
that	O
no	O
significant	O
geographical	O
heterogeneity	O
was	O
detected	O
among	O
the	O
populations	O
of	O
the	O
two	O
species	O
.	O

The	O
estimated	O
number	O
of	O
migrants	O
per	O
generation	O
,	O
based	O
on	O
the	O
overall	O
Fst	O
values	O
,	O
is	O
20	O
.	O
683	O
for	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
23	O
.	O
125	O
for	O
L	B-Species
.	I-Species
whitmani	E-Species
.	O

Table	O
4	O
shows	O
measures	O
for	O
DNA	O
divergence	O
between	O
species	O
(	O
Dxy	O
and	O
Da	O
)	O
,	O
as	O
well	O
as	O
the	O
Fst	O
and	O
Nm	O
values	O
considering	O
each	O
species	O
as	O
a	O
unique	O
population	O
.	O

Dxy	O
is	O
the	O
average	O
number	O
of	O
nucleotide	O
substitutions	O
per	O
site	O
between	O
alleles	O
from	O
two	O
different	O
populations	O
and	O
Da	O
is	O
the	O
number	O
of	O
net	O
nucleotide	O
substitutions	O
between	O
two	O
populations	O
.	O

Table	O
4	O
also	O
shows	O
the	O
number	O
of	O
polymorphisms	O
exclusive	O
for	O
each	O
species	O
(	O
Sint	O
and	O
Swhit	O
)	O
,	O
the	O
number	O
of	O
shared	O
polymorphisms	O
(	O
Ss	O
)	O
and	O
the	O
number	O
of	O
fixed	O
differences	O
(	O
Sf	O
)	O
between	O
species	O
.	O

As	O
one	O
can	O
note	O
,	O
there	O
is	O
a	O
high	O
number	O
of	O
shared	O
polymorphisms	O
between	O
species	O
,	O
and	O
no	O
fixed	O
differences	O
between	O
them	O
suggesting	O
either	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
.	O

In	O
fact	O
,	O
there	O
is	O
one	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
(	O
IPO13	O
,	O
WPO10	O
and	O
WPO19	O
)	O
and	O
three	O
L	B-Species
.	I-Species
whitmani	E-Species
sequences	O
(	O
WAC02	O
,	O
WPO13	O
and	O
WPO14	O
)	O
which	O
show	O
only	O
one	O
nucleotide	O
difference	O
to	O
"	O
typical	O
"	O
L	B-Species
.	I-Species
intermedia	E-Species
haplotypes	O
(	O
see	O
also	O
below	O
)	O
.	O

Genealogy	O
of	O
period	O
sequences	O

A	O
phylogenetic	O
analysis	O
of	O
the	O
period	O
gene	O
sequences	O
from	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
was	O
carried	O
out	O
with	O
the	O
Minimum	O
Evolution	O
method	O
using	O
the	O
Kimura	O
2	O
-	O
parameter	O
distance	O
(	O
Fig	O
3	O
)	O
.	O

A	O
sequence	O
from	O
L	B-Species
.	I-Species
umbratilis	E-Species
,	O
a	O
related	O
species	O
from	O
the	O
same	O
subgenus	O
Nyssomyia	O
,	O
was	O
used	O
as	O
outgroup	O
[	O
24	O
]	O
.	O

The	O
tree	O
shows	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
as	O
non	O
-	O
monophyletic	O
.	O

However	O
,	O
despite	O
the	O
low	O
bootstrap	O
values	O
,	O
which	O
are	O
below	O
50	O
%	O
in	O
most	O
cases	O
,	O
there	O
is	O
a	O
large	O
group	O
that	O
contains	O
most	O
L	B-Species
.	I-Species
intermedia	E-Species
sequences	O
and	O
a	O
second	O
large	O
group	O
with	O
most	O
L	B-Species
.	I-Species
whitmani	E-Species
sequences	O
.	O

A	O
few	O
other	O
sequences	O
are	O
clustered	O
outside	O
these	O
two	O
main	O
groups	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
there	O
are	O
three	O
L	B-Species
.	I-Species
whitmani	E-Species
alleles	O
(	O
WAC2	O
,	O
WPO13	O
and	O
WPO14	O
)	O
inside	O
L	B-Species
.	I-Species
intermedia	E-Species
main	O
group	O
,	O
as	O
well	O
as	O
one	O
L	B-Species
.	I-Species
intermedia	E-Species
allele	O
(	O
ICP16	O
)	O
inside	O
the	O
L	B-Species
.	I-Species
whitmani	E-Species
main	O
group	O
.	O

In	O
addition	O
,	O
a	O
second	O
L	B-Species
.	I-Species
intermedia	E-Species
allele	O
(	O
IPO13	O
)	O
is	O
a	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
as	O
mentioned	O
above	O
.	O

Again	O
,	O
the	O
results	O
suggest	O
either	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
between	O
the	O
two	O
species	O
.	O

Very	O
similar	O
results	O
were	O
obtained	O
using	O
the	O
maximum	O
likelihood	O
algorithm	O
as	O
implemented	O
in	O
PAUP	O
4	O
.	O
0b10	O
software	O
[	O
31	O
]	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
mentioned	O
before	O
,	O
there	O
is	O
evidence	O
of	O
intragenic	O
recombination	O
in	O
the	O
per	O
gene	O
fragment	O
of	O
both	O
species	O
(	O
see	O
Table	O
1	O
)	O
and	O
for	O
that	O
reason	O
the	O
bifurcating	O
tree	O
shown	O
in	O
Fig	O
3	O
has	O
to	O
be	O
viewed	O
with	O
caution	O
,	O
as	O
different	O
regions	O
of	O
the	O
gene	O
might	O
have	O
different	O
phylogenetic	O
histories	O
[	O
32	O
]	O
.	O

Therefore	O
,	O
we	O
constructed	O
Minimum	O
Evolution	O
trees	O
with	O
the	O
two	O
most	O
polymorphic	O
non	O
-	O
recombining	O
blocks	O
of	O
the	O
per	O
gene	O
fragment	O
identified	O
using	O
the	O
Hudson	O
and	O
Kaplan	O
[	O
33	O
]	O
method	O
available	O
in	O
the	O
DNAsp	O
4	O
.	O
1	O
program	O
[	O
34	O
]	O
.	O

We	O
did	O
not	O
observed	O
major	O
changes	O
in	O
the	O
genealogy	O
of	O
the	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
per	O
sequences	O
,	O
especially	O
regarding	O
the	O
five	O
haplotypes	O
(	O
ICP16	O
,	O
IPO13	O
,	O
WAC2	O
,	O
WPO13	O
and	O
WPO14	O
)	O
that	O
clearly	O
cluster	O
with	O
sequences	O
of	O
the	O
other	O
species	O
(	O
data	O
not	O
shown	O
)	O
.	O

Finally	O
,	O
a	O
haplotype	O
network	O
was	O
estimated	O
from	O
per	O
sequences	O
using	O
statistical	O
parsimony	O
,	O
as	O
described	O
by	O
Templeton	O
et	O
al	O
.	O

[	O
35	O
]	O
and	O
implemented	O
in	O
the	O
TCS1	O
.	O
21	O
software	O
[	O
36	O
]	O
(	O
Fig	O
4	O
)	O
.	O

A	O
small	O
number	O
of	O
ambiguities	O
were	O
resolved	O
as	O
suggested	O
by	O
Crandall	O
and	O
Templeton	O
[	O
37	O
]	O
.	O

The	O
haplotype	O
network	O
shows	O
connections	O
between	O
sequences	O
from	O
each	O
species	O
,	O
separating	O
most	O
of	O
the	O
sequences	O
of	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
in	O
two	O
groups	O
.	O

No	O
intraspecific	O
geographical	O
structuring	O
was	O
found	O
.	O

Once	O
again	O
,	O
some	O
of	O
the	O
L	B-Species
.	I-Species
whitmani	E-Species
sequences	O
(	O
WAC2	O
,	O
WAC10	O
,	O
WPO13	O
and	O
WPO14	O
)	O
appear	O
more	O
closely	O
related	O
to	O
L	B-Species
.	I-Species
intermedia	E-Species
haplotypes	O
.	O

In	O
addition	O
,	O
one	O
L	B-Species
.	I-Species
intermedia	E-Species
allele	O
(	O
ICP16	O
)	O
is	O
connected	O
by	O
a	O
small	O
number	O
of	O
mutations	O
to	O
some	O
of	O
the	O
main	O
L	B-Species
.	I-Species
whitmani	E-Species
haplotypes	O
and	O
IPO13	O
is	O
a	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
.	O

These	O
results	O
confirm	O
the	O
same	O
putative	O
introgressed	O
sequences	O
indicated	O
by	O
the	O
phylogenetic	O
reconstructions	O
.	O

LD	O
test	O
of	O
introgression	O

We	O
tested	O
the	O
hypothesis	O
of	O
gene	O
flow	O
between	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
using	O
a	O
method	O
based	O
on	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
developed	O
by	O
Machado	O
et	O
al	O
.	O

[	O
38	O
]	O
.	O

In	O
this	O
test	O
,	O
x	O
is	O
the	O
difference	O
between	O
the	O
average	O
LD	O
found	O
among	O
all	O
pairs	O
of	O
shared	O
polymorphisms	O
(	O
DSS	O
)	O
between	O
the	O
two	O
species	O
and	O
the	O
average	O
LD	O
among	O
all	O
pairs	O
of	O
sites	O
for	O
which	O
one	O
member	O
is	O
a	O
shared	O
polymorphism	O
and	O
the	O
other	O
is	O
an	O
exclusive	O
polymorphism	O
(	O
DSX	O
)	O
.	O

In	O
case	O
of	O
gene	O
flow	O
x	O
should	O
tend	O
to	O
be	O
positive	O
[	O
see	O
[	O
38	O
]	O
for	O
more	O
details	O
]	O
.	O

Because	O
of	O
limitations	O
on	O
the	O
total	O
number	O
of	O
sequences	O
that	O
could	O
be	O
handled	O
by	O
the	O
WH	O
program	O
we	O
could	O
not	O
perform	O
the	O
simulations	O
with	O
all	O
sequences	O
.	O

Therefore	O
,	O
we	O
carried	O
out	O
the	O
LD	O
test	O
of	O
introgression	O
between	O
each	O
pair	O
of	O
sympatric	O
populations	O
of	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
from	O
the	O
localities	O
of	O
Posse	O
,	O
Afonso	O
Claudio	O
and	O
Corte	O
de	O
Pedra	O
.	O

The	O
input	O
files	O
were	O
prepared	O
using	O
the	O
values	O
of	O
recombination	O
and	O
linkage	O
disequilibrium	O
calculated	O
by	O
the	O
SITES	O
program	O
[	O
30	O
]	O
for	O
each	O
population	O
(	O
data	O
not	O
shown	O
)	O
.	O

Although	O
no	O
significant	O
values	O
were	O
found	O
for	O
the	O
smaller	O
samples	O
of	O
Afonso	O
Claudio	O
and	O
Corte	O
de	O
Pedra	O
,	O
the	O
results	O
(	O
Table	O
5	O
)	O
present	O
evidence	O
for	O
introgression	O
in	O
the	O
period	O
gene	O
in	O
both	O
directions	O
(	O
from	O
L	B-Species
.	I-Species
intermedia	E-Species
to	O
L	B-Species
.	I-Species
whitmani	E-Species
and	O
vice	O
-	O
versa	O
)	O
in	O
the	O
locality	O
of	O
Posse	O
.	O

Isolation	O
with	O
Migration	O
model	O

To	O
further	O
examine	O
the	O
gene	O
flow	O
between	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
we	O
used	O
the	O
IM	O
software	O
[	O
39	O
]	O
.	O

The	O
Isolation	O
with	O
Migration	O
model	O
has	O
six	O
demographic	O
parameters	O
that	O
include	O
two	O
migration	O
rates	O
,	O
one	O
for	O
each	O
population	O
.	O

The	O
IM	O
software	O
estimates	O
the	O
posterior	O
probability	O
for	O
each	O
of	O
the	O
model	O
parameters	O
,	O
fitting	O
the	O
Isolation	O
with	O
Migration	O
model	O
to	O
the	O
data	O
.	O

One	O
of	O
the	O
assumptions	O
of	O
this	O
model	O
is	O
that	O
the	O
loci	O
studied	O
do	O
not	O
have	O
internal	O
recombination	O
.	O

Therefore	O
,	O
we	O
identified	O
four	O
different	O
non	O
-	O
recombining	O
blocks	O
of	O
our	O
fragment	O
of	O
per	O
,	O
which	O
were	O
then	O
treated	O
as	O
different	O
loci	O
in	O
the	O
analysis	O
.	O

The	O
four	O
-	O
gametes	O
test	O
[	O
33	O
]	O
implemented	O
in	O
DnaSP4	O
.	O
1	O
was	O
used	O
for	O
the	O
identification	O
of	O
possible	O
recombination	O
events	O
.	O

Since	O
the	O
program	O
estimates	O
parameters	O
for	O
a	O
pair	O
of	O
closely	O
related	O
populations	O
or	O
species	O
,	O
all	O
sequences	O
of	O
each	O
species	O
were	O
used	O
in	O
the	O
analysis	O
as	O
a	O
single	O
population	O
.	O

We	O
performed	O
MCMC	O
runs	O
using	O
the	O
IM	O
software	O
with	O
different	O
seed	O
numbers	O
,	O
in	O
order	O
to	O
guarantee	O
convergence	O
of	O
the	O
sample	O
.	O

Maximum	O
likelihood	O
estimates	O
of	O
migration	O
parameters	O
revealed	O
a	O
non	O
-	O
zero	O
value	O
for	O
both	O
species	O
,	O
m1	O
=	O
1	O
.	O
398	O
and	O
m2	O
=	O
1	O
.	O
014	O
(	O
m1	O
-	O
from	O
L	B-Species
.	I-Species
whitmani	E-Species
towards	O
L	B-Species
.	I-Species
intermedia	E-Species
;	O
m2	O
-	O
from	O
L	B-Species
.	I-Species
whitmani	E-Species
towards	O
L	B-Species
.	I-Species
intermedia	E-Species
)	O
.	O

Fig	O
5	O
shows	O
the	O
posterior	O
distributions	O
for	O
migration	O
rates	O
and	O
reveals	O
a	O
null	O
probability	O
for	O
the	O
absence	O
of	O
migration	O
from	O
L	B-Species
.	I-Species
whitmani	E-Species
towards	O
L	B-Species
.	I-Species
intermedia	E-Species
.	O

In	O
addition	O
,	O
the	O
absence	O
of	O
migration	O
in	O
the	O
opposite	O
direction	O
is	O
not	O
included	O
in	O
the	O
95	O
%	O
confidence	O
interval	O
(	O
values	O
range	O
from	O
0	O
.	O
222	O
to	O
8	O
.	O
898	O
)	O
,	O
thus	O
supporting	O
the	O
presence	O
of	O
migration	O
in	O
both	O
directions	O
.	O

The	O
conversion	O
of	O
the	O
migration	O
rate	O
estimate	O
to	O
population	O
migration	O
rate	O
per	O
generation	O
(	O
m1	O
and	O
m2	O
)	O
is	O
not	O
accurate	O
when	O
the	O
population	O
size	O
is	O
based	O
on	O
a	O
single	O
locus	O
.	O

However	O
,	O
the	O
average	O
of	O
the	O
migrant	O
number	O
per	O
generation	O
for	O
both	O
species	O
was	O
very	O
close	O
to	O
the	O
Nm	O
estimate	O
based	O
on	O
Fst	O
values	O
(	O
Nm	O
~	O
0	O
.	O
49	O
in	O
Table	O
4	O
,	O
m1	O
~	O
0	O
.	O
52	O
and	O
m2	O
~	O
0	O
.	O
34	O
)	O
.	O

Discussion	O

There	O
is	O
some	O
evidence	O
that	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
might	O
represent	O
sibling	O
-	O
species	O
complexes	O
in	O
Brazil	O
.	O

Lutzomyia	B-Species
neivai	E-Species
Pinto	O
1926	O
,	O
a	O
sibling	O
of	O
L	B-Species
.	I-Species
intermedia	E-Species
is	O
found	O
in	O
parts	O
of	O
Southern	O
and	O
Western	O
Brazil	O
and	O
some	O
other	O
countries	O
of	O
South	O
America	O
[	O
40	O
]	O
.	O

The	O
present	O
study	O
did	O
not	O
include	O
populations	O
of	O
this	O
species	O
.	O

In	O
the	O
case	O
of	O
L	B-Species
.	I-Species
whitmani	E-Species
,	O
mitochondrial	O
data	O
[	O
3	O
,	O
6	O
]	O
indicates	O
three	O
main	O
lineages	O
in	O
Brazil	O
:	O
an	O
Amazonian	O
group	O
,	O
a	O
North	O
-	O
South	O
group	O
and	O
a	O
Northeast	O
group	O
.	O

We	O
did	O
not	O
find	O
strong	O
evidence	O
of	O
a	O
geographical	O
differentiation	O
in	O
the	O
period	O
gene	O
among	O
populations	O
of	O
L	B-Species
.	I-Species
whitmani	E-Species
although	O
one	O
of	O
the	O
pairwise	O
Fst	O
comparisons	O
(	O
Posse	O
x	O
Ilh	O
e	O
us	O
)	O
was	O
significant	O
at	O
the	O
5	O
%	O
level	O
.	O

When	O
we	O
compare	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
,	O
we	O
find	O
a	O
highly	O
significant	O
Fst	O
value	O
(	O
0	O
.	O
3373	O
)	O
,	O
which	O
is	O
however	O
smaller	O
than	O
that	O
observed	O
for	O
the	O
period	O
gene	O
between	O
sympatric	O
siblings	O
of	O
Lutzomyia	B-Species
longipalpis	E-Species
(	O
Fst	O
=	O
0	O
.	O
3952	O
)	O
[	O
23	O
]	O
,	O
a	O
complex	O
of	O
cryptic	O
species	O
that	O
are	O
vectors	O
of	O
American	O
visceral	O
leishmaniasis	O
.	O

Therefore	O
,	O
despite	O
the	O
presence	O
of	O
diagnostic	O
morphological	O
characters	O
to	O
identify	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
[	O
1	O
]	O
the	O
level	O
of	O
molecular	O
divergence	O
in	O
period	O
is	O
not	O
as	O
high	O
as	O
the	O
cryptic	O
L	B-Species
.	I-Species
longipalpis	E-Species
siblings	O
.	O

Even	O
though	O
it	O
is	O
hard	O
to	O
distinguish	O
introgression	O
from	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
,	O
a	O
test	O
of	O
gene	O
flow	O
based	O
on	O
the	O
signature	O
introgression	O
leaves	O
on	O
the	O
patterns	O
of	O
linkage	O
disequilibrium	O
[	O
38	O
]	O
as	O
well	O
as	O
simulations	O
that	O
fit	O
the	O
"	O
Isolation	O
with	O
Migration	O
"	O
model	O
to	O
the	O
data	O
suggest	O
that	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
might	O
be	O
exchanging	O
alleles	O
at	O
the	O
per	O
locus	O
.	O

This	O
is	O
further	O
supported	O
by	O
the	O
presence	O
of	O
shared	O
haplotypes	O
between	O
the	O
two	O
species	O
in	O
Posse	O
and	O
very	O
similar	O
sequences	O
in	O
all	O
sympatric	O
populations	O
.	O

There	O
is	O
mounting	O
evidence	O
that	O
introgression	O
plays	O
a	O
major	O
role	O
in	O
the	O
evolution	O
of	O
closely	O
related	O
insect	O
vector	O
species	O
.	O

Introgression	O
among	O
vectors	O
may	O
have	O
important	O
epidemiological	O
consequences	O
.	O

Gene	O
flow	O
in	O
loci	O
that	O
affect	O
vectorial	O
capacity	O
,	O
such	O
as	O
those	O
controlling	O
host	O
preference	O
and	O
susceptibility	O
to	O
parasite	O
infection	O
,	O
can	O
change	O
the	O
transmission	O
patterns	O
and	O
consequently	O
make	O
the	O
disease	O
control	O
a	O
harder	O
task	O
.	O

Introgression	O
of	O
genes	O
that	O
control	O
adaptation	O
to	O
particular	O
types	O
of	O
environment	O
can	O
also	O
have	O
a	O
major	O
impact	O
on	O
the	O
spread	O
of	O
vector	O
-	O
borne	O
diseases	O
as	O
was	O
proposed	O
for	O
the	O
major	O
African	O
malaria	O
vector	O
Anopheles	B-Species
gambiae	E-Species
[	O
41	O
]	O
.	O

The	O
same	O
can	O
be	O
said	O
about	O
genes	O
controlling	O
insecticide	O
resistance	O
.	O

For	O
example	O
,	O
Weill	O
et	O
al	O
.	O

[	O
42	O
]	O
found	O
a	O
kdr	O
mutation	O
responsible	O
for	O
pyrethroid	O
resistance	O
in	O
the	O
Mopti	O
form	O
of	O
Anopheles	B-Species
gambiae	E-Species
,	O
a	O
normally	O
susceptible	O
taxon	O
of	O
this	O
species	O
complex	O
.	O

Sequence	O
analysis	O
reveals	O
that	O
this	O
resistant	O
allele	O
probably	O
originates	O
through	O
introgression	O
from	O
the	O
Savanna	O
form	O
.	O

Although	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
are	O
closely	O
related	O
and	O
only	O
distinguished	O
by	O
a	O
few	O
morphological	O
differences	O
,	O
they	O
do	O
show	O
differentiation	O
in	O
some	O
other	O
important	O
traits	O
.	O

For	O
example	O
,	O
in	O
Posse	O
,	O
one	O
of	O
the	O
localities	O
we	O
studied	O
,	O
the	O
two	O
species	O
show	O
differences	O
in	O
abundance	O
during	O
the	O
year	O
.	O

L	B-Species
.	I-Species
intermedia	E-Species
is	O
more	O
abundant	O
in	O
the	O
summer	O
while	O
L	B-Species
.	I-Species
whitmani	E-Species
is	O
more	O
frequent	O
in	O
the	O
winter	O
months	O
[	O
2	O
]	O
.	O

They	O
also	O
show	O
differences	O
in	O
microhabitat	O
preferences	O
,	O
L	B-Species
.	I-Species
intermedia	E-Species
being	O
more	O
common	O
in	O
the	O
peridomestic	O
area	O
while	O
L	B-Species
.	I-Species
whitmani	E-Species
is	O
found	O
mainly	O
in	O
the	O
surrounding	O
forest	O
[	O
2	O
]	O
.	O

In	O
addition	O
,	O
the	O
two	O
species	O
show	O
marked	O
differences	O
in	O
their	O
tendencies	O
to	O
bite	O
humans	S-Species
in	O
the	O
early	O
morning	O
,	O
with	O
L	B-Species
.	I-Species
whitmani	E-Species
showing	O
higher	O
feeding	O
rates	O
than	O
L	B-Species
.	I-Species
intermedia	E-Species
[	O
26	O
]	O
.	O

Therefore	O
,	O
despite	O
the	O
evidence	O
of	O
introgression	O
in	O
the	O
period	O
gene	O
in	O
this	O
locality	O
,	O
there	O
are	O
important	O
ecological	O
and	O
behavioral	O
differences	O
between	O
the	O
two	O
species	O
in	O
Posse	O
suggesting	O
that	O
gene	O
flow	O
is	O
probably	O
rather	O
limited	O
in	O
loci	O
controlling	O
these	O
traits	O
.	O

Hence	O
,	O
it	O
is	O
yet	O
not	O
clear	O
whether	O
introgression	O
has	O
played	O
an	O
important	O
role	O
in	O
the	O
evolution	O
of	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
.	O

Further	O
work	O
with	O
other	O
genes	O
might	O
help	O
clarify	O
the	O
issue	O
.	O

Conclusion	O

Evidence	O
for	O
introgression	O
between	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
obtained	O
using	O
mitochondrial	O
DNA	O
[	O
4	O
]	O
seems	O
to	O
be	O
corroborated	O
by	O
our	O
data	O
on	O
the	O
period	O
gene	O
,	O
a	O
nuclear	O
marker	O
.	O

Nevertheless	O
,	O
considering	O
that	O
period	O
is	O
potentially	O
involved	O
in	O
reproductive	O
isolation	O
and	O
might	O
be	O
,	O
therefore	O
,	O
less	O
prone	O
to	O
introgression	O
than	O
the	O
"	O
average	O
"	O
gene	O
[	O
43	O
]	O
,	O
it	O
is	O
possible	O
that	O
much	O
higher	O
levels	O
of	O
gene	O
flow	O
between	O
the	O
two	O
species	O
occur	O
at	O
other	O
genes	O
.	O

It	O
might	O
,	O
on	O
the	O
other	O
hand	O
,	O
suggest	O
that	O
this	O
behavioral	O
gene	O
,	O
or	O
at	O
least	O
the	O
fragment	O
we	O
analyzed	O
,	O
did	O
not	O
play	O
a	O
role	O
in	O
speciation	O
between	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
.	O

In	O
fact	O
the	O
same	O
has	O
been	O
suggested	O
for	O
some	O
Drosophila	O
species	O
[	O
44	O
]	O
despite	O
per	O
'	O
s	O
role	O
controlling	O
lovesong	O
and	O
mating	O
rhythm	O
differences	O
between	O
D	B-Species
.	I-Species
melanogaster	E-Species
and	O
D	B-Species
.	I-Species
simulans	E-Species
[	O
13	O
-	O
16	O
]	O
.	O

Although	O
the	O
evidence	O
for	O
introgression	O
in	O
the	O
per	O
gene	O
between	O
L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
is	O
not	O
overwhelming	O
,	O
it	O
does	O
indicate	O
the	O
need	O
to	O
extend	O
this	O
analysis	O
to	O
other	O
loci	O
in	O
the	O
future	O
.	O

We	O
are	O
currently	O
isolating	O
new	O
molecular	O
markers	O
in	O
the	O
two	O
species	O
to	O
carry	O
out	O
a	O
multi	O
-	O
locus	O
approach	O
[	O
39	O
]	O
that	O
might	O
help	O
determining	O
how	O
much	O
variation	O
in	O
gene	O
flow	O
and	O
differentiation	O
there	O
is	O
across	O
the	O
genome	O
of	O
these	O
two	O
very	O
important	O
leishmaniasis	O
vectors	O
.	O

Methods	O

Sand	O
fly	O
samples	O

Sand	O
fly	O
samples	O
used	O
in	O
this	O
work	O
were	O
all	O
the	O
F1	O
generation	O
from	O
wild	O
collected	O
females	O
from	O
the	O
Brazilian	O
localities	O
of	O
Posse	O
(	O
Petr	O
o	O
polis	O
,	O
Rio	O
de	O
Janeiro	O
State	O
,	O
22	O
degrees	O
30	O
'	O
S	O
43	O
degrees	O
10	O
'	O
W	O
)	O
,	O
Jacarepagu	O
a	O
(	O
Rio	O
de	O
Janeiro	O
,	O
Rio	O
de	O
Janeiro	O
State	O
,	O
22	O
degrees	O
55	O
'	O
S	O
43	O
degrees	O
21	O
'	O
W	O
)	O
,	O
Afonso	O
Claudio	O
(	O
Esp	O
i	O
rito	O
Santo	O
State	O
,	O
20	O
degrees	O
04	O
'	O
S	O
41	O
degrees	O
07	O
'	O
W	O
)	O
,	O
Corte	O
de	O
Pedra	O
(	O
Presidente	O
Tancredo	O
Neves	O
,	O
Bahia	O
State	O
,	O
13	O
degrees	O
27	O
'	O
S	O
39	O
degrees	O
25	O
'	O
W	O
)	O
and	O
Ilh	O
e	O
us	O
(	O
Bahia	O
State	O
,	O
14	O
degrees	O
50	O
'	O
S	O
39	O
degrees	O
06	O
'	O
W	O
)	O
.	O

L	B-Species
.	I-Species
intermedia	E-Species
and	O
L	B-Species
.	I-Species
whitmani	E-Species
were	O
identified	O
according	O
to	O
Young	O
and	O
Duncan	O
[	O
1	O
]	O
.	O

The	O
progeny	O
of	O
each	O
wild	O
caught	O
female	O
was	O
raised	O
separately	O
according	O
to	O
Souza	O
et	O
al	O
.	O

[	O
45	O
]	O
and	O
only	O
one	O
F1	O
male	O
of	O
each	O
female	O
was	O
used	O
for	O
the	O
molecular	O
analysis	O
,	O
which	O
included	O
68	O
individuals	O
of	O
L	B-Species
.	I-Species
intermedia	E-Species
(	O
12	O
from	O
Afonso	O
Claudio	O
,	O
18	O
from	O
Posse	O
,	O
20	O
from	O
Corte	O
de	O
Pedra	O
and	O
18	O
from	O
Jacarepagu	O
a	O
)	O
and	O
51	O
individuals	O
of	O
L	B-Species
.	I-Species
whitmani	E-Species
(	O
12	O
from	O
Afonso	O
Claudio	O
,	O
17	O
from	O
Posse	O
,	O
3	O
from	O
Corte	O
de	O
Pedra	O
and	O
19	O
from	O
Ilh	O
e	O
us	O
)	O
.	O

Note	O
that	O
,	O
although	O
the	O
distribution	O
of	O
the	O
two	O
species	O
shows	O
considerable	O
overlap	O
in	O
Eastern	O
Brazil	O
,	O
in	O
many	O
localities	O
only	O
one	O
species	O
is	O
found	O
or	O
is	O
far	O
more	O
abundant	O
than	O
the	O
other	O
.	O

There	O
are	O
also	O
seasonal	O
and	O
microhabitat	O
differences	O
in	O
abundance	O
between	O
them	O
in	O
areas	O
of	O
sympatry	O
[	O
2	O
]	O
.	O

DNA	O
methods	O

Genomic	O
DNA	O
was	O
prepared	O
according	O
to	O
Jowett	O
[	O
46	O
]	O
with	O
slight	O
modifications	O
and	O
the	O
PCR	O
was	O
carried	O
out	O
for	O
30	O
cycles	O
at	O
95	O
degrees	O
C	O
for	O
30	O
sec	O
,	O
60	O
degrees	O
C	O
for	O
30	O
sec	O
and	O
72	O
degrees	O
C	O
for	O
30	O
sec	O
,	O
using	O
Abgene	O
,	O
Amersham	O
Biosciences	O
or	O
Biotools	O
reagents	O
according	O
to	O
manufacturers	O
directions	O
.	O

The	O
per	O
primer	O
sequences	O
are	O
:	O
5llper2	O
:	O
5	O
'	O
-	O
AGCATCCTTTTGTAGCAAAC	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
3llper2	O
:	O
5	O
'	O
-	O
TCAGATGAACTCTTGCTGTC	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O

These	O
primers	O
amplify	O
a	O
486	O
bp	O
fragment	O
of	O
the	O
sand	O
fly	O
per	O
gene	O
homologue	O
that	O
includes	O
part	O
of	O
the	O
PAS	O
/	O
CLD	O
domain	O
,	O
an	O
intron	O
(	O
58	O
bp	O
)	O
and	O
the	O
beginning	O
of	O
the	O
perS	O
domain	O
[	O
24	O
]	O
.	O

The	O
amplified	O
fragments	O
were	O
cloned	O
using	O
the	O
pMOSBlue	O
blunt	O
ended	O
cloning	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
plasmid	O
DNA	O
preparation	O
was	O
carried	O
out	O
using	O
the	O
"	O
Flexiprep	O
"	O
Kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Cloned	O
PCR	O
fragments	O
were	O
sequenced	O
at	O
Funda	O
c	O
a	O
o	O
Oswaldo	O
Cruz	O
and	O
at	O
University	O
of	O
Leicester	O
using	O
ABI	O
377	O
sequencers	O
.	O

With	O
the	O
exception	O
of	O
two	O
L	B-Species
.	I-Species
whitmani	E-Species
individuals	O
from	O
Corte	O
de	O
Pedra	O
(	O
see	O
below	O
)	O
,	O
only	O
one	O
sequence	O
of	O
each	O
sand	O
fly	O
(	O
representing	O
one	O
of	O
the	O
two	O
possible	O
alleles	O
)	O
was	O
used	O
in	O
the	O
analysis	O
but	O
an	O
average	O
of	O
three	O
sequences	O
per	O
individual	O
were	O
obtained	O
in	O
order	O
to	O
check	O
possible	O
PCR	O
induced	O
mutations	O
.	O

In	O
addition	O
,	O
PCR	O
fragments	O
were	O
also	O
sequenced	O
directly	O
in	O
some	O
cases	O
for	O
the	O
same	O
reason	O
.	O

In	O
the	O
case	O
of	O
the	O
two	O
L	B-Species
.	I-Species
whitmani	E-Species
mentioned	O
above	O
6	O
and	O
9	O
clones	O
were	O
sequenced	O
respectively	O
from	O
specimens	O
WCP01	O
and	O
WCP03	O
to	O
determine	O
both	O
alleles	O
simply	O
to	O
increase	O
the	O
size	O
of	O
this	O
small	O
sample	O
.	O

Negative	O
controls	O
were	O
performed	O
for	O
all	O
amplification	O
reactions	O
.	O

In	O
addition	O
,	O
PCR	O
,	O
cloning	O
and	O
sequencing	O
were	O
repeated	O
for	O
two	O
individuals	O
to	O
confirm	O
putative	O
introgressed	O
sequences	O
and	O
to	O
exclude	O
the	O
possibility	O
that	O
they	O
were	O
the	O
result	O
of	O
PCR	O
contamination	O
.	O

Finally	O
,	O
for	O
at	O
least	O
two	O
individuals	O
with	O
putative	O
introgressed	O
sequences	O
,	O
we	O
could	O
define	O
the	O
other	O
allele	O
from	O
additional	O
clones	O
(	O
not	O
included	O
in	O
the	O
analysis	O
)	O
,	O
which	O
showed	O
to	O
be	O
typical	O
of	O
the	O
species	O
,	O
indicating	O
no	O
identification	O
problems	O
.	O

The	O
sequences	O
were	O
submitted	O
to	O
GenBank	O
(	O
accession	O
numbers	O
AY927062	O
to	O
AY927182	O
)	O
.	O

Sequence	O
analyses	O

The	O
preliminary	O
sequence	O
editing	O
was	O
carried	O
out	O
using	O
the	O
Wisconsin	O
Package	O
Version	O
9	O
.	O
1	O
,	O
Genetics	O
Computer	O
Group	O
(	O
GCG	O
)	O
,	O
Madison	O
,	O
and	O
ClustalX	O
[	O
47	O
]	O
was	O
used	O
to	O
perform	O
the	O
multiple	O
alignment	O
.	O

Analyses	O
of	O
population	O
polymorphisms	O
and	O
differentiation	O
between	O
populations	O
were	O
carried	O
out	O
using	O
DNAsp4	O
.	O
1	O
[	O
34	O
]	O
and	O
ProSeq	O
[	O
48	O
]	O
softwares	O
,	O
while	O
Arlequin	O
v	O
.	O

2	O
.	O
0	O
[	O
49	O
]	O
was	O
used	O
for	O
an	O
analysis	O
of	O
molecular	O
variance	O
(	O
AMOVA	O
)	O
between	O
populations	O
.	O

The	O
Minimum	O
Evolution	O
phylogenetic	O
tree	O
was	O
constructed	O
using	O
MEGA	O
3	O
.	O
1	O
software	O
[	O
50	O
]	O
.	O

The	O
haplotype	O
network	O
was	O
estimated	O
using	O
TCS1	O
.	O
21	O
[	O
36	O
]	O
.	O

Recombination	O
and	O
linkage	O
disequilibrium	O
analyses	O
were	O
performed	O
using	O
the	O
DNAsp4	O
.	O
1	O
and	O
SITES	O
program	O
[	O
30	O
]	O
.	O

Linkage	O
disequilibrium	O
simulations	O
were	O
carried	O
out	O
by	O
the	O
WH	O
program	O
[	O
51	O
,	O
52	O
]	O
and	O
Markov	O
Chain	O
Monte	O
Carlo	O
(	O
MCMC	O
)	O
simulations	O
of	O
the	O
isolation	O
with	O
migration	O
model	O
were	O
performed	O
using	O
the	O
algorithm	O
implemented	O
in	O
the	O
IM	O
program	O
[	O
39	O
]	O
.	O

Authors	O
'	O
contributions	O

CJM	O
generate	O
and	O
analyzed	O
all	O
the	O
data	O
and	O
drafted	O
the	O
manuscript	O
.	O

NAS	O
and	O
CAC	O
collected	O
and	O
maintained	O
sand	O
fly	O
samples	O
.	O

CPK	O
helped	O
to	O
write	O
the	O
manuscript	O
and	O
supervised	O
CJM	O
during	O
her	O
stay	O
in	O
Leicester	O
.	O

AAP	O
is	O
the	O
principal	O
investigator	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
helped	O
to	O
write	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Presence	O
of	O
antibodies	O
against	O
cyclic	O
citrullinated	O
peptides	O
in	O
patients	S-Species
with	O
'	O
rhupus	O
'	O
:	O
a	O
cross	O
-	O
sectional	O
study	O

Abstract	O

'	O
Rhupus	O
'	O
is	O
a	O
rare	O
condition	O
sharing	O
features	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

If	O
rhupus	O
is	O
a	O
distinctive	O
entity	O
,	O
an	O
overlap	O
between	O
RA	O
and	O
SLE	O
or	O
a	O
subset	O
of	O
SLE	O
is	O
currently	O
debated	O
.	O

This	O
study	O
was	O
performed	O
to	O
explore	O
the	O
prevalence	O
of	O
antibodies	O
against	O
cyclic	O
citrullinated	O
peptides	O
(	O
anti	O
-	O
CCP	O
antibodies	O
)	O
in	O
rhupus	O
.	O

Patients	S-Species
meeting	O
American	O
College	O
of	O
Rheumatology	O
criteria	O
for	O
RA	O
,	O
SLE	O
,	O
or	O
both	O
were	O
included	O
.	O

Clinical	O
and	O
radiographic	O
features	O
were	O
recorded	O
and	O
sera	O
were	O
searched	O
for	O
anti	O
-	O
CCP	O
antibodies	O
,	O
rheumatoid	O
factor	O
,	O
antinuclear	O
antibodies	O
,	O
anti	O
-	O
extractable	O
nuclear	O
antigens	O
,	O
and	O
antibodies	O
against	O
double	O
-	O
stranded	O
DNA	O
(	O
anti	O
-	O
dsDNA	O
antibodies	O
)	O
.	O

Seven	O
patients	S-Species
for	O
each	O
group	O
were	O
included	O
.	O

Clinical	O
and	O
serological	O
features	O
for	O
RA	O
or	O
SLE	O
were	O
similar	O
between	O
rhupus	O
and	O
RA	O
patients	S-Species
,	O
and	O
between	O
rhupus	O
and	O
SLE	O
patients	S-Species
,	O
respectively	O
.	O

Values	O
for	O
anti	O
-	O
CCP	O
antibodies	O
obtained	O
were	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
higher	O
in	O
RA	O
(	O
6	O
/	O
7	O
)	O
and	O
rhupus	O
(	O
4	O
/	O
7	O
)	O
than	O
in	O
SLE	O
patients	S-Species
(	O
0	O
/	O
7	O
)	O
and	O
healthy	O
subjects	O
(	O
0	O
/	O
7	O
)	O
.	O

Our	O
data	O
support	O
the	O
possibility	O
that	O
rhupus	O
is	O
an	O
overlap	O
between	O
RA	O
and	O
SLE	O
,	O
because	O
highly	O
specific	O
autoantibodies	O
for	O
RA	O
(	O
anti	O
-	O
CCP	O
)	O
and	O
for	O
SLE	O
(	O
anti	O
-	O
dsDNA	O
and	O
anti	O
-	O
Sm	O
)	O
are	O
detected	O
in	O
coexistence	O
.	O

Introduction	O

The	O
clinical	O
coexistence	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
was	O
first	O
described	O
in	O
1969	O
by	O
Kantor	O
and	O
was	O
termed	O
'	O
rhupus	O
syndrome	O
'	O
by	O
Schur	O
(	O
both	O
cited	O
in	O
[	O
1	O
]	O
)	O
.	O

Since	O
then	O
,	O
fewer	O
than	O
100	O
cases	O
of	O
rhupus	O
have	O
been	O
published	O
[	O
1	O
-	O
3	O
]	O
.	O

In	O
an	O
epidemiological	O
study	O
including	O
about	O
7	O
,	O
000	O
new	O
patients	S-Species
,	O
the	O
prevalence	O
of	O
RA	O
was	O
15	O
%	O
and	O
for	O
SLE	O
it	O
was	O
8	O
.	O
9	O
%	O
.	O

The	O
expected	O
coincidence	O
of	O
RA	O
and	O
SLE	O
by	O
chance	O
would	O
therefore	O
be	O
1	O
.	O
2	O
%	O
.	O

However	O
,	O
the	O
observed	O
prevalence	O
of	O
rhupus	O
was	O
0	O
.	O
09	O
%	O
,	O
less	O
than	O
one	O
-	O
tenth	O
of	O
that	O
expected	O
[	O
1	O
]	O
.	O

Previous	O
reports	O
have	O
shown	O
that	O
the	O
patients	S-Species
with	O
rhupus	O
display	O
an	O
array	O
of	O
autoantibodies	O
including	O
anti	O
-	O
double	O
-	O
stranded	O
DNA	O
(	O
anti	O
-	O
dsDNA	O
)	O
,	O
anti	O
-	O
Sm	O
(	O
both	O
highly	O
specific	O
for	O
SLE	O
)	O
,	O
anti	O
-	O
SSA	O
,	O
anti	O
-	O
SSB	O
,	O
anti	O
-	O
ribonucleoprotein	O
,	O
antinuclear	O
antibodies	O
(	O
ANA	O
)	O
,	O
anti	O
-	O
cardiolipins	O
,	O
and	O
rheumatoid	O
factor	O
(	O
RF	O
)	O
[	O
1	O
,	O
2	O
]	O
.	O

However	O
,	O
no	O
study	O
has	O
yet	O
been	O
performed	O
to	O
investigate	O
the	O
presence	O
of	O
antibodies	O
against	O
cyclic	O
citrullinated	O
peptides	O
(	O
anti	O
-	O
CCP	O
antibodies	O
)	O
,	O
which	O
have	O
a	O
specificity	O
for	O
RA	O
of	O
96	O
to	O
98	O
%	O
(	O
for	O
second	O
-	O
generation	O
assays	O
(	O
anti	O
-	O
CCP2	O
)	O
)	O
[	O
4	O
,	O
5	O
]	O
.	O

Recent	O
data	O
have	O
confirmed	O
that	O
these	O
antibodies	O
are	O
rarely	O
if	O
ever	O
present	O
in	O
other	O
autoimmune	O
diseases	O
such	O
as	O
SLE	O
,	O
Sj	O
o	O
gren	O
'	O
s	O
syndrome	O
(	O
SS	O
)	O
,	O
scleroderma	O
and	O
myositis	O
[	O
6	O
]	O
.	O

Nowadays	O
,	O
it	O
is	O
a	O
matter	O
of	O
debate	O
whether	O
rhupus	O
is	O
a	O
clinically	O
and	O
immunologically	O
distinctive	O
entity	O
[	O
2	O
]	O
,	O
a	O
true	O
overlap	O
between	O
SLE	O
and	O
RA	O
[	O
7	O
]	O
,	O
or	O
a	O
subgroup	O
of	O
patients	S-Species
with	O
lupus	O
[	O
8	O
]	O
.	O

This	O
descriptive	O
,	O
cross	O
-	O
sectional	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
frequency	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
a	O
cohort	O
of	O
patients	S-Species
with	O
rhupus	O
.	O

Materials	O
and	O
methods	O

We	O
included	O
all	O
patients	S-Species
fulfilling	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
classification	O
criteria	O
for	O
both	O
RA	O
[	O
9	O
]	O
and	O
SLE	O
[	O
10	O
]	O
who	O
belonged	O
to	O
our	O
cohorts	O
of	O
patients	S-Species
with	O
RA	O
and	O
with	O
SLE	O
.	O

Comparisons	O
were	O
made	O
with	O
age	O
-	O
and	O
gender	O
-	O
matched	O
patients	S-Species
with	O
RA	O
and	O
with	O
SLE	O
,	O
and	O
healthy	O
subjects	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
ethics	O
committee	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
.	O

Serum	O
samples	O
were	O
obtained	O
and	O
stored	O
at	O
-	O
75	O
degrees	O
C	O
until	O
use	O
.	O

Sera	O
were	O
analyzed	O
for	O
anti	O
-	O
CCP2	O
antibodies	O
by	O
ELISA	O
(	O
Inova	O
Diagnostics	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
with	O
a	O
cutoff	O
value	O
of	O
60	O
U	O
/	O
ml	O
.	O

Fine	O
antinuclear	O
reactivities	O
(	O
ELISA	O
;	O
Inova	O
Diagnostics	O
)	O
,	O
RF	O
(	O
nephelometry	O
)	O
,	O
ANA	O
(	O
indirect	O
immunofluorescence	O
on	O
HEp	O
-	O
2	O
slides	O
)	O
,	O
and	O
anti	O
-	O
dsDNA	O
(	O
indirect	O
immunofluorescence	O
on	O
Crithidia	O
luciliae	O
substrate	O
)	O
antibodies	O
were	O
also	O
determined	O
.	O

Except	O
for	O
healthy	O
individuals	O
,	O
standard	O
radiographs	O
of	O
hands	O
were	O
available	O
.	O

For	O
statistical	O
analysis	O
,	O
ANOVA	O
and	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
were	O
performed	O
as	O
appropriate	O
with	O
GraphPad	O
Prism	O
4	O
.	O
0	O
software	O
(	O
GraphPad	O
Inc	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Results	O

Seven	O
female	O
patients	S-Species
with	O
a	O
median	O
age	O
of	O
44	O
years	O
(	O
range	O
25	O
to	O
64	O
)	O
met	O
our	O
inclusion	O
criteria	O
.	O

The	O
major	O
clinical	O
and	O
laboratory	O
findings	O
are	O
presented	O
in	O
Table	O
1	O
.	O

Healthy	O
individuals	O
and	O
all	O
patients	S-Species
belonged	O
to	O
cohorts	O
from	O
the	O
same	O
ethnic	O
group	O
(	O
Hispanic	O
mestizo	O
)	O
.	O

No	O
differences	O
in	O
demographic	O
data	O
were	O
found	O
between	O
groups	O
.	O

Mean	O
ACR	O
criteria	O
for	O
SLE	O
were	O
5	O
.	O
57	O
(	O
range	O
4	O
to	O
8	O
)	O
in	O
the	O
SLE	O
group	O
,	O
and	O
5	O
.	O
57	O
(	O
4	O
to	O
8	O
)	O
in	O
the	O
rhupus	O
group	O
.	O

In	O
the	O
same	O
way	O
,	O
mean	O
ACR	O
criteria	O
for	O
RA	O
were	O
6	O
(	O
4	O
to	O
7	O
)	O
in	O
the	O
RA	O
group	O
,	O
and	O
5	O
.	O
14	O
(	O
4	O
to	O
6	O
)	O
for	O
the	O
patients	S-Species
with	O
rhupus	O
.	O

In	O
all	O
patients	S-Species
with	O
rhupus	O
,	O
RA	O
was	O
presented	O
as	O
the	O
initial	O
disease	O
,	O
as	O
has	O
been	O
described	O
previously	O
[	O
2	O
]	O
.	O

In	O
accordance	O
with	O
another	O
report	O
,	O
in	O
two	O
patients	S-Species
the	O
disease	O
started	O
during	O
their	O
childhood	O
as	O
juvenile	O
chronic	O
arthritis	O
[	O
1	O
]	O
.	O

Anti	O
-	O
CCP	O
antibodies	O
were	O
found	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
patients	S-Species
with	O
rhupus	O
,	O
and	O
in	O
six	O
of	O
seven	O
(	O
86	O
%	O
)	O
patients	S-Species
with	O
RA	O
,	O
whereas	O
neither	O
patients	S-Species
with	O
SLE	O
nor	O
healthy	O
individuals	O
showed	O
reactivity	O
.	O

When	O
the	O
concentrations	O
in	O
each	O
group	O
were	O
compared	O
,	O
a	O
statistical	O
significant	O
difference	O
between	O
groups	O
was	O
found	O
(	O
ANOVA	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
concentration	O
of	O
anti	O
-	O
CCP	O
antibodies	O
was	O
584	O
U	O
/	O
ml	O
(	O
range	O
0	O
to	O
1	O
,	O
237	O
)	O
in	O
patients	S-Species
with	O
rhupus	O
(	O
Figure	O
1	O
)	O
,	O
875	O
U	O
/	O
ml	O
(	O
0	O
to	O
1	O
,	O
178	O
)	O
in	O
the	O
RA	O
group	O
(	O
not	O
significant	O
compared	O
with	O
rhupus	O
)	O
,	O
1	O
U	O
/	O
ml	O
(	O
0	O
to	O
10	O
)	O
for	O
SLE	O
individuals	O
(	O
p	O
<	O
0	O
.	O
05	O
compared	O
with	O
rhupus	O
)	O
,	O
and	O
0	O
U	O
/	O
ml	O
(	O
0	O
to	O
2	O
)	O
for	O
healthy	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
compared	O
with	O
rhupus	O
)	O
.	O

Two	O
of	O
three	O
patients	S-Species
with	O
rhupus	O
who	O
were	O
negative	O
for	O
anti	O
-	O
CCP	O
antibodies	O
were	O
also	O
negative	O
for	O
anti	O
-	O
dsDNA	O
antibodies	O
,	O
RF	O
and	O
anti	O
-	O
extractable	O
nuclear	O
antigen	O
antibodies	O
,	O
although	O
both	O
patients	S-Species
met	O
RA	O
and	O
SLE	O
classification	O
criteria	O
,	O
including	O
ANA	O
and	O
erosive	O
arthritis	O
.	O

Differences	O
in	O
ANA	O
,	O
anti	O
-	O
dsDNA	O
and	O
anti	O
-	O
extractable	O
nuclear	O
antigen	O
autoantibodies	O
between	O
patients	S-Species
with	O
rhupus	O
and	O
those	O
with	O
SLE	O
were	O
not	O
found	O
.	O

We	O
also	O
found	O
no	O
difference	O
in	O
the	O
prevalence	O
of	O
RF	O
between	O
patients	S-Species
with	O
rhupus	O
and	O
those	O
with	O
RA	O
.	O

Surprisingly	O
,	O
one	O
healthy	O
subject	O
was	O
positive	O
for	O
RF	O
,	O
ANA	O
and	O
anti	O
-	O
SSA	O
antibodies	O
,	O
although	O
she	O
was	O
asymptomatic	O
and	O
no	O
features	O
of	O
any	O
disease	O
were	O
found	O
.	O

Discussion	O

The	O
close	O
association	O
between	O
different	O
type	O
II	O
human	S-Species
leukocyte	O
antigen	O
(	O
HLA	O
)	O
molecules	O
and	O
the	O
risk	O
of	O
RA	O
is	O
well	O
established	O
.	O

These	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
molecules	O
share	O
the	O
same	O
amino	O
acid	O
sequence	O
(	O
QKRAA	O
or	O
QRRAA	O
)	O
in	O
positions	O
69	O
to	O
74	O
of	O
the	O
beta	O
-	O
chain	O
,	O
namely	O
the	O
'	O
shared	O
epitope	O
'	O
.	O

Recent	O
works	O
have	O
demonstrated	O
that	O
this	O
'	O
shared	O
epitope	O
'	O
preferentially	O
binds	O
peptides	O
containing	O
the	O
non	O
-	O
standard	O
amino	O
acid	O
citrulline	O
(	O
deiminated	O
arginine	O
)	O
[	O
11	O
]	O
.	O

In	O
addition	O
,	O
an	O
abnormally	O
increased	O
function	O
of	O
the	O
enzyme	O
peptidylarginine	O
deiminase	O
4	O
(	O
PAD4	O
;	O
responsible	O
for	O
the	O
deimination	O
of	O
arginine	O
)	O
and	O
an	O
elevated	O
anti	O
-	O
CCP	O
autoantibody	O
production	O
in	O
patients	S-Species
with	O
RA	O
have	O
been	O
demonstrated	O
[	O
12	O
]	O
.	O

These	O
facts	O
have	O
built	O
the	O
first	O
bridge	O
between	O
cellular	O
and	O
humoral	O
autoimmunity	O
in	O
a	O
major	O
rheumatic	O
disease	O
,	O
supporting	O
a	O
pathogenetic	O
role	O
for	O
an	O
abnormal	O
metabolism	O
of	O
citrulline	O
in	O
the	O
development	O
of	O
RA	O
[	O
13	O
,	O
14	O
]	O
.	O

Patients	S-Species
with	O
SLE	O
are	O
often	O
part	O
of	O
the	O
control	O
group	O
when	O
determining	O
the	O
specificity	O
of	O
anti	O
-	O
CCP	O
antibodies	O
for	O
RA	O
[	O
15	O
]	O
,	O
although	O
some	O
studies	O
have	O
been	O
performed	O
specifically	O
on	O
patients	S-Species
with	O
SLE	O
.	O

These	O
studies	O
contribute	O
some	O
clues	O
to	O
the	O
role	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
rhupus	O
.	O

Mediwake	O
and	O
colleagues	O
[	O
16	O
]	O
,	O
in	O
a	O
study	O
exploring	O
the	O
predictive	O
value	O
of	O
anti	O
-	O
CCP	O
antibodies	O
to	O
distinguish	O
erosive	O
arthritis	O
in	O
SLE	O
,	O
found	O
ten	O
patients	S-Species
(	O
out	O
of	O
231	O
)	O
with	O
erosive	O
arthritis	O
,	O
two	O
of	O
whom	O
had	O
anti	O
-	O
CCP	O
antibodies	O
.	O

In	O
concord	O
with	O
this	O
,	O
Hoffman	O
and	O
colleagues	O
[	O
15	O
]	O
demonstrate	O
that	O
three	O
patients	S-Species
with	O
erosive	O
arthritis	O
,	O
included	O
in	O
a	O
cohort	O
of	O
235	O
patients	S-Species
with	O
SLE	O
,	O
were	O
positive	O
for	O
anti	O
-	O
CCP	O
antibodies	O
.	O

These	O
authors	O
suggest	O
that	O
the	O
presence	O
of	O
anti	O
-	O
CCP	O
antibodies	O
can	O
predispose	O
for	O
a	O
chronic	O
RA	O
-	O
like	O
arthritis	O
in	O
patients	S-Species
with	O
SLE	O
.	O

Additionally	O
Weissman	O
and	O
colleagues	O
[	O
17	O
]	O
demonstrated	O
that	O
patients	S-Species
with	O
SLE	O
can	O
display	O
radiographic	O
abnormalities	O
similar	O
to	O
those	O
of	O
RA	O
,	O
although	O
the	O
presence	O
of	O
marginal	O
erosions	O
is	O
a	O
rare	O
finding	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
the	O
patients	S-Species
with	O
rhupus	O
show	O
a	O
very	O
similar	O
arthritis	O
pattern	O
(	O
including	O
erosive	O
disease	O
)	O
and	O
similar	O
autoantibody	O
production	O
(	O
RF	O
and	O
anti	O
-	O
CCP	O
antibodies	O
)	O
to	O
those	O
in	O
patients	S-Species
with	O
RA	O
.	O

In	O
addition	O
,	O
patients	S-Species
with	O
rhupus	O
display	O
a	O
clinical	O
and	O
serological	O
profile	O
indistinguishable	O
from	O
patients	S-Species
with	O
SLE	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
other	O
coexistent	O
autoimmune	O
diseases	O
was	O
similar	O
in	O
all	O
groups	O
of	O
patients	S-Species
(	O
two	O
patients	S-Species
with	O
rhupus	O
,	O
three	O
patients	S-Species
with	O
RA	O
,	O
and	O
three	O
patients	S-Species
with	O
SLE	O
also	O
had	O
SS	O
)	O
.	O

We	O
found	O
high	O
titers	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
patients	S-Species
with	O
rhupus	O
,	O
a	O
frequency	O
similar	O
to	O
that	O
reported	O
for	O
RA	O
[	O
4	O
]	O
.	O

This	O
finding	O
,	O
together	O
with	O
the	O
clinical	O
similarity	O
,	O
supports	O
the	O
contention	O
that	O
rhupus	O
belongs	O
to	O
the	O
RA	O
spectrum	O
.	O

The	O
high	O
prevalence	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
RA	O
found	O
in	O
our	O
study	O
could	O
be	O
explained	O
by	O
a	O
selection	O
bias	O
because	O
only	O
patients	S-Species
with	O
RA	O
with	O
an	O
aggressive	O
disease	O
(	O
namely	O
erosive	O
arthritis	O
and	O
RF	O
+	O
)	O
were	O
included	O
.	O

In	O
contrast	O
,	O
the	O
mean	O
ACR	O
criterion	O
for	O
SLE	O
was	O
similar	O
between	O
patients	S-Species
with	O
rhupus	O
and	O
those	O
with	O
SLE	O
,	O
including	O
the	O
'	O
robust	O
'	O
features	O
of	O
SLE	O
such	O
as	O
renal	O
and	O
neurological	O
involvement	O
,	O
and	O
anti	O
-	O
dsDNA	O
and	O
anti	O
-	O
Sm	O
antibodies	O
.	O

These	O
clinical	O
and	O
serological	O
features	O
shared	O
between	O
patients	S-Species
with	O
rhupus	O
and	O
those	O
with	O
SLE	O
also	O
place	O
rhupus	O
in	O
the	O
SLE	O
spectrum	O
.	O

Titration	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
the	O
rhupus	O
group	O
clearly	O
shows	O
a	O
bimodal	O
distribution	O
,	O
suggesting	O
the	O
existence	O
of	O
two	O
different	O
subpopulations	O
.	O

Because	O
of	O
the	O
small	O
number	O
of	O
patients	S-Species
,	O
we	O
are	O
unable	O
to	O
define	O
the	O
differential	O
features	O
underlying	O
each	O
subset	O
.	O

However	O
,	O
two	O
of	O
three	O
patients	S-Species
negative	O
for	O
anti	O
-	O
CCP	O
antibodies	O
were	O
also	O
negative	O
for	O
both	O
RF	O
and	O
anti	O
-	O
dsDNA	O
antibodies	O
.	O

Conclusion	O

On	O
the	O
basis	O
of	O
the	O
presence	O
of	O
shared	O
clinical	O
features	O
of	O
RA	O
(	O
mainly	O
erosive	O
arthritis	O
)	O
and	O
SLE	O
(	O
including	O
renal	O
and	O
neurological	O
involvement	O
)	O
along	O
with	O
the	O
presence	O
of	O
anti	O
-	O
dsDNA	O
and	O
anti	O
-	O
CCP	O
autoantibodies	O
in	O
our	O
patients	S-Species
with	O
rhupus	O
,	O
our	O
findings	O
strongly	O
support	O
the	O
contention	O
that	O
rhupus	O
is	O
a	O
true	O
overlap	O
between	O
RA	O
and	O
SLE	O
,	O
not	O
merely	O
a	O
part	O
of	O
the	O
clinical	O
spectrum	O
of	O
the	O
articular	O
involvement	O
seen	O
in	O
SLE	O
.	O

Moreover	O
,	O
on	O
the	O
basis	O
of	O
the	O
mean	O
ACR	O
criteria	O
for	O
both	O
diseases	O
,	O
we	O
have	O
confirmed	O
that	O
patients	S-Species
with	O
rhupus	O
have	O
more	O
RA	O
-	O
associated	O
and	O
less	O
SLE	O
-	O
associated	O
damage	O
,	O
an	O
issue	O
that	O
has	O
been	O
suggested	O
previously	O
[	O
2	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
exploring	O
the	O
prevalence	O
of	O
anti	O
-	O
CCP	O
antibodies	O
specifically	O
in	O
patients	S-Species
with	O
rhupus	O
.	O

More	O
studies	O
are	O
needed	O
to	O
expand	O
the	O
pathogenetic	O
knowledge	O
of	O
this	O
overlap	O
syndrome	O
.	O

Abbreviations	O

ANA	O
=	O
antinuclear	O
antibodies	O
;	O
anti	O
-	O
CCP	O
antibodies	O
=	O
antibodies	O
against	O
cyclic	O
citrullinated	O
peptides	O
;	O
anti	O
-	O
dsDNA	O
antibodies	O
=	O
antibodies	O
against	O
double	O
-	O
stranded	O
DNA	O
;	O
ELISA	O
=	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
;	O
RF	O
=	O
rheumatoid	O
factor	O
;	O
SLE	O
=	O
systemic	O
lupus	O
erythematosus	O
;	O
SS	O
=	O
Sj	O
o	O
gren	O
'	O
s	O
syndrome	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

LA	O
-	O
G	O
participated	O
in	O
the	O
conception	O
and	O
design	O
of	O
the	O
experiments	O
,	O
in	O
the	O
acquisition	O
,	O
analysis	O
and	O
interpretation	O
of	O
data	O
,	O
and	O
was	O
involved	O
in	O
drafting	O
the	O
manuscript	O
.	O

RS	O
performed	O
the	O
immunoassays	O
.	O

RM	O
-	O
V	O
participated	O
in	O
the	O
analysis	O
and	O
interpretation	O
of	O
data	O
and	O
performed	O
the	O
statistical	O
analysis	O
.	O

LG	O
-	O
G	O
participated	O
in	O
the	O
analysis	O
and	O
interpretation	O
of	O
data	O
.	O

AV	O
participated	O
in	O
the	O
recruitment	O
of	O
patients	S-Species
and	O
the	O
acquisition	O
of	O
data	O
.	O

RB	O
participated	O
in	O
the	O
interpretation	O
of	O
data	O
,	O
revising	O
the	O
manuscript	O
for	O
intellectual	O
content	O
and	O
giving	O
the	O
final	O
approval	O
of	O
the	O
version	O
to	O
be	O
published	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Identification	O
of	O
a	O
human	S-Species
peripheral	O
blood	O
monocyte	O
subset	O
that	O
differentiates	O
into	O
osteoclasts	O

Abstract	O

Increased	O
bone	O
resorption	O
mediated	O
by	O
osteoclasts	O
causes	O
various	O
diseases	O
such	O
as	O
osteoporosis	O
and	O
bone	O
erosion	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

Osteoclasts	O
are	O
derived	O
from	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
but	O
the	O
precise	O
origin	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
the	O
purified	O
CD16	O
-	O
human	S-Species
peripheral	O
blood	O
monocyte	O
subset	O
,	O
but	O
not	O
the	O
CD16	O
+	O
monocyte	O
subset	O
,	O
differentiates	O
into	O
osteoclast	O
by	O
stimulation	O
with	O
receptor	O
activator	O
of	O
NF	O
-	O
kappa	O
B	O
ligand	O
(	O
RANKL	O
)	O
in	O
combination	O
with	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
.	O

Integrin	O
-	O
beta	O
3	O
mRNA	O
and	O
the	O
integrin	O
-	O
alpha	O
v	O
beta	O
3	O
heterodimer	O
were	O
only	O
expressed	O
on	O
CD16	O
-	O
monocytes	O
,	O
when	O
they	O
were	O
stimulated	O
with	O
RANKL	O
+	O
M	O
-	O
CSF	O
.	O

Downregulation	O
of	O
beta	O
3	O
-	O
subunit	O
expression	O
by	O
small	O
interfering	O
RNA	O
targeting	O
beta	O
3	O
abrogated	O
osteoclastogenesis	O
from	O
the	O
CD16	O
-	O
monocyte	O
subset	O
.	O

In	O
contrast	O
,	O
the	O
CD16	O
+	O
monocyte	O
subset	O
expressed	O
larger	O
amounts	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
IL	O
-	O
6	O
than	O
the	O
CD16	O
-	O
subset	O
,	O
which	O
was	O
further	O
enhanced	O
by	O
RANKL	O
stimulation	O
.	O

Examination	O
of	O
RA	O
synovial	O
tissue	O
showed	O
accumulation	O
of	O
both	O
CD16	O
+	O
and	O
CD16	O
-	O
macrophages	O
.	O

Our	O
results	O
suggest	O
that	O
peripheral	O
blood	O
monocytes	O
consist	O
of	O
two	O
functionally	O
heterogeneous	O
subsets	O
with	O
distinct	O
responses	O
to	O
RANKL	O
.	O

Osteoclasts	O
seem	O
to	O
originate	O
from	O
CD16	O
-	O
monocytes	O
,	O
and	O
integrin	O
beta	O
3	O
is	O
necessary	O
for	O
osteoclastogenesis	O
.	O

Blockade	O
of	O
accumulation	O
and	O
activation	O
of	O
CD16	O
-	O
monocytes	O
could	O
therefore	O
be	O
a	O
beneficial	O
approach	O
as	O
an	O
anti	O
-	O
bone	O
resorptive	O
therapy	O
,	O
especially	O
for	O
RA	O
.	O

Introduction	O

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
an	O
autoimmune	O
disease	O
characterized	O
by	O
chronic	O
inflammation	O
and	O
proliferation	O
of	O
the	O
synovium	O
in	O
multiple	O
joints	O
.	O

A	O
large	O
number	O
of	O
inflammatory	O
cells	O
,	O
including	O
T	O
cells	O
,	O
B	O
cells	O
,	O
macrophages	O
and	O
dendritic	O
cells	O
,	O
accumulate	O
in	O
the	O
affected	O
synovium	O
,	O
and	O
these	O
inflammatory	O
cells	O
,	O
together	O
with	O
fibroblast	O
-	O
like	O
synoviocytes	O
,	O
express	O
various	O
cytokines	O
,	O
such	O
as	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
,	O
IL	O
-	O
6	O
and	O
receptor	O
activator	O
of	O
NF	O
-	O
kappa	O
B	O
ligand	O
(	O
RANKL	O
)	O
,	O
which	O
are	O
known	O
to	O
induce	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	O
.	O

The	O
inflammatory	O
synovial	O
tissue	O
,	O
known	O
as	O
pannus	O
,	O
invades	O
the	O
articular	O
bone	O
and	O
causes	O
focal	O
bone	O
erosion	O
,	O
which	O
is	O
the	O
hallmark	O
of	O
RA	O
.	O

Histopathologically	O
,	O
osteoclasts	O
are	O
present	O
at	O
the	O
interface	O
of	O
the	O
pannus	O
and	O
bone	O
.	O

Interestingly	O
,	O
the	O
deletion	O
of	O
RANKL	O
or	O
c	O
-	O
Fos	O
gene	O
,	O
which	O
is	O
important	O
for	O
osteoclastogenesis	O
,	O
results	O
in	O
minimal	O
bone	O
destruction	O
in	O
mouse	S-Species
models	O
of	O
arthritis	O
[	O
1	O
,	O
2	O
]	O
.	O

Furthermore	O
,	O
other	O
studies	O
indicated	O
that	O
inhibition	O
of	O
osteoclastogenesis	O
by	O
osteoprotegerin	O
,	O
a	O
decoy	O
receptor	O
for	O
RANKL	O
,	O
limits	O
bone	O
destruction	O
in	O
experimental	O
models	O
of	O
arthritis	O
.	O

These	O
studies	O
suggest	O
that	O
osteoclasts	O
are	O
involved	O
in	O
focal	O
bone	O
erosion	O
in	O
RA	O
[	O
3	O
]	O
.	O

Osteoclasts	O
are	O
derived	O
from	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O

It	O
is	O
reported	O
that	O
osteoclast	O
precursors	O
reside	O
in	O
human	S-Species
peripheral	O
blood	O
monocytes	O
[	O
4	O
,	O
5	O
]	O
.	O

A	O
marked	O
increase	O
of	O
the	O
circulating	O
osteoclast	O
precursors	O
was	O
demonstrated	O
in	O
patients	S-Species
with	O
erosive	O
psoriatic	O
arthritis	O
as	O
well	O
as	O
in	O
arthritic	O
TNF	O
alpha	O
transgenic	O
mice	S-Species
[	O
6	O
,	O
7	O
]	O
.	O

It	O
was	O
also	O
shown	O
that	O
peripheral	O
monocytes	O
differentiate	O
into	O
osteoclasts	O
when	O
seeded	O
on	O
RANKL	O
/	O
osteoclast	O
differentiation	O
factor	O
-	O
producing	O
RA	O
synovial	O
fibroblasts	O
[	O
8	O
]	O
.	O

In	O
addition	O
,	O
RA	O
synovial	O
macrophages	O
thought	O
to	O
originate	O
from	O
peripheral	O
blood	O
monocytes	O
were	O
shown	O
to	O
differentiate	O
into	O
osteoclasts	O
[	O
9	O
,	O
10	O
]	O
.	O

Monocytes	O
are	O
therefore	O
involved	O
not	O
only	O
in	O
synovial	O
inflammation	O
,	O
but	O
also	O
in	O
bone	O
remodeling	O
as	O
potential	O
precursors	O
for	O
synovial	O
macrophages	O
and	O
osteoclasts	O
.	O

Human	S-Species
peripheral	O
blood	O
monocytes	O
consist	O
of	O
two	O
major	O
subsets	O
,	O
CD16	O
+	O
and	O
CD16	O
-	O
,	O
comprising	O
5	O
-	O
10	O
%	O
and	O
90	O
-	O
95	O
%	O
of	O
the	O
monocytes	O
,	O
respectively	O
.	O

These	O
two	O
subsets	O
exhibit	O
different	O
chemotaxis	O
activities	O
and	O
potential	O
of	O
cytokine	O
production	O
[	O
11	O
,	O
12	O
]	O
.	O

Moreover	O
,	O
activation	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
induces	O
distinct	O
subsets	O
,	O
CD1b	O
+	O
dendritic	O
cells	O
and	O
DC	O
-	O
SIGN	O
+	O
(	O
dendritic	O
cell	O
-	O
specific	O
C	O
-	O
type	O
lectin	O
ICAM	O
-	O
3	O
-	O
grabbing	O
nonintegrin	O
)	O
macrophages	O
from	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O
,	O
respectively	O
[	O
13	O
]	O
.	O

It	O
has	O
not	O
been	O
revealed	O
,	O
however	O
,	O
which	O
monocyte	O
subset	O
develops	O
into	O
osteoclasts	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
human	S-Species
peripheral	O
blood	O
monocyte	O
subset	O
that	O
differentiates	O
into	O
osteoclasts	O
,	O
and	O
revealed	O
that	O
each	O
subset	O
exhibits	O
a	O
different	O
response	O
for	O
osteoclastogenic	O
stimuli	O
.	O

Materials	O
and	O
methods	O

Purification	O
of	O
peripheral	O
blood	O
monocytes	O

Peripheral	O
blood	O
monocytes	O
from	O
healthy	O
donors	O
were	O
collected	O
using	O
Ficoll	O
-	O
Conray	O
(	O
Imuuno	O
-	O
Biological	O
Laboratories	O
,	O
Gunma	O
,	O
Japan	O
)	O
gradient	O
centrifugation	O
.	O

Negative	O
selection	O
of	O
monocytes	O
was	O
performed	O
using	O
MACS	O
microbeads	O
(	O
Miltenyi	O
Biotec	O
,	O
Auburn	O
,	O
CA	O
,	O
USA	O
)	O
according	O
to	O
the	O
protocol	O
supplied	O
by	O
the	O
manufacturer	O
.	O

The	O
purified	O
monocytes	O
were	O
separated	O
into	O
two	O
subsets	O
,	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O
,	O
using	O
CD16	O
MicroBeads	O
(	O
Miltenyi	O
Biotec	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
using	O
FITC	O
-	O
conjugated	O
mouse	S-Species
anti	O
-	O
CD14	O
mAb	O
(	O
MY4	O
;	O
Bechman	O
Coulter	O
,	O
Fullerton	O
,	O
CA	O
,	O
USA	O
)	O
and	O
phycoerythin	O
-	O
conjugated	O
mouse	S-Species
anti	O
-	O
CD16	O
mAb	O
(	O
3G8	O
;	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
showed	O
that	O
the	O
purities	O
of	O
the	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O
were	O
more	O
than	O
90	O
%	O
and	O
92	O
%	O
,	O
respectively	O
.	O

For	O
the	O
other	O
experiment	O
,	O
monocytes	O
were	O
purified	O
using	O
CD14	O
MicroBeads	O
(	O
Miltenyi	O
Biotec	O
)	O
,	O
and	O
then	O
stained	O
either	O
with	O
FITC	O
-	O
conjugated	O
mouse	S-Species
anti	O
-	O
CD33	O
mAb	O
(	O
MY9	O
;	O
Bechman	O
Coulter	O
)	O
or	O
phycoerythin	O
-	O
conjugated	O
mouse	S-Species
anti	O
-	O
CD16	O
mAb	O
(	O
3G8	O
)	O
.	O

Cell	O
sorting	O
of	O
the	O
stained	O
cells	O
was	O
performed	O
using	O
a	O
FACS	O
Vantage	O
cytometer	O
(	O
BD	O
Biosciences	O
)	O
or	O
a	O
MoFlo	O
cell	O
sorter	O
(	O
Dako	O
,	O
Glostrup	O
,	O
Denmark	O
)	O
.	O

Osteoclast	O
differentiation	O

Purified	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O
(	O
5	O
x	O
104	O
cells	O
/	O
well	O
)	O
were	O
incubated	O
in	O
96	O
-	O
well	O
plates	O
in	O
alpha	O
MEM	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
fetal	O
bovine	S-Species
serum	O
(	O
FBS	O
)	O
(	O
Sigma	O
)	O
or	O
with	O
Ultra	O
-	O
Low	O
IgG	O
FBS	O
(	O
IgG	O
<	O
5	O
mu	O
g	O
/	O
ml	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
where	O
indicated	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
(	O
Peprotech	O
,	O
Rocky	O
Hill	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

For	O
the	O
other	O
experiments	O
,	O
varied	O
numbers	O
of	O
CD16	O
+	O
monocytes	O
(	O
1	O
x	O
103	O
,	O
2	O
.	O
5	O
x	O
103	O
,	O
5	O
x	O
103	O
)	O
were	O
mixed	O
with	O
CD16	O
-	O
monocytes	O
(	O
5	O
x	O
104	O
cells	O
/	O
well	O
)	O
,	O
and	O
were	O
cultured	O
in	O
96	O
-	O
well	O
plates	O
in	O
alpha	O
MEM	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
FBS	O
.	O

The	O
medium	O
was	O
replaced	O
with	O
fresh	O
medium	O
3	O
days	O
later	O
,	O
and	O
after	O
incubation	O
for	O
7	O
days	O
the	O
cells	O
were	O
stained	O
for	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
expression	O
using	O
a	O
commercial	O
kit	O
(	O
Hokudo	O
,	O
Sapporo	O
,	O
Japan	O
)	O
.	O

The	O
number	O
of	O
TRAP	O
-	O
positive	O
multinucleated	O
cells	O
(	O
MNC	O
)	O
in	O
three	O
randomly	O
selected	O
fields	O
examined	O
at	O
100	O
x	O
magnification	O
or	O
the	O
total	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
per	O
well	O
was	O
counted	O
under	O
light	O
microscopy	O
.	O

Resorption	O
assay	O

Monocytes	O
were	O
seeded	O
onto	O
plates	O
coated	O
with	O
calcium	O
phosphate	O
thin	O
films	O
(	O
Biocoat	O
Osteologic	O
;	O
BD	O
Biosciences	O
)	O
and	O
were	O
incubated	O
with	O
RANKL	O
(	O
40	O
ng	O
/	O
ml	O
)	O
+	O
M	O
-	O
CSF	O
(	O
25	O
ng	O
/	O
ml	O
)	O
for	O
7	O
days	O
.	O

The	O
cells	O
were	O
then	O
lysed	O
in	O
bleach	O
solution	O
(	O
6	O
%	O
NaOCl	O
,	O
5	O
.	O
2	O
%	O
NaCl	O
)	O
.	O

The	O
resorption	O
lacunae	O
were	O
examined	O
under	O
light	O
microscopy	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O

Purified	O
monocytes	O
were	O
cultured	O
in	O
96	O
-	O
well	O
plates	O
where	O
indicated	O
either	O
with	O
RANKL	O
or	O
M	O
-	O
CSF	O
for	O
24	O
hours	O
.	O

Concentrations	O
of	O
TNF	O
alpha	O
and	O
IL	O
-	O
6	O
in	O
the	O
culture	O
supernatant	O
were	O
measured	O
with	O
an	O
ELISA	O
kit	O
(	O
BioSourse	O
International	O
,	O
Camarillo	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
experiments	O
of	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-	O
9	O
and	O
TRAP	O
-	O
5b	O
,	O
culture	O
supernatants	O
were	O
collected	O
on	O
day	O
7	O
and	O
the	O
concentrations	O
of	O
these	O
enzymes	O
were	O
measured	O
using	O
an	O
MMP	O
-	O
9	O
ELISA	O
kit	O
(	O
Amersham	O
Biosciences	O
,	O
Piscataway	O
,	O
NJ	O
,	O
USA	O
)	O
or	O
a	O
TRAP	O
-	O
5b	O
ELISA	O
kit	O
(	O
Suomen	O
,	O
Turku	O
,	O
Finland	O
)	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O

Monocytes	O
(	O
1	O
x	O
106	O
cells	O
/	O
well	O
)	O
were	O
cultured	O
in	O
six	O
-	O
well	O
plates	O
with	O
M	O
-	O
CSF	O
alone	O
or	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
for	O
3	O
days	O
.	O

Total	O
RNA	O
was	O
extracted	O
using	O
RNeasy	O
Micro	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
RNA	O
was	O
then	O
treated	O
with	O
DNase	O
I	O
(	O
Qiagen	O
)	O
.	O

The	O
oligo	O
(	O
dT	O
)	O
-	O
primed	O
cDNA	O
was	O
synthesized	O
using	O
Superscript	O
II	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

The	O
amount	O
of	O
cDNA	O
for	O
amplification	O
was	O
adjusted	O
by	O
the	O
amount	O
of	O
RNA	O
measured	O
by	O
an	O
optical	O
density	O
meter	O
and	O
also	O
by	O
beta	O
-	O
actin	O
or	O
GAPDH	O
PCR	O
products	O
.	O

One	O
microliter	O
of	O
cDNA	O
was	O
amplified	O
in	O
a	O
50	O
mu	O
l	O
final	O
volume	O
containing	O
25	O
pmol	O
appropriate	O
primer	O
pair	O
,	O
10	O
pmol	O
each	O
of	O
the	O
four	O
deoxynucleotide	O
triphosphates	O
,	O
and	O
5	O
units	O
FastStart	O
Taq	O
DNA	O
Polymerase	O
(	O
Roche	O
,	O
Manheim	O
,	O
Germany	O
)	O
in	O
a	O
thermal	O
cycler	O
(	O
PTC	O
-	O
200	O
;	O
MJ	O
GeneWorks	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
.	O

The	O
PCR	O
conditions	O
were	O
25	O
-	O
40	O
cycles	O
of	O
denaturation	O
(	O
95	O
degrees	O
C	O
for	O
30	O
s	O
)	O
,	O
annealing	O
(	O
60	O
-	O
62	O
degrees	O
C	O
for	O
1	O
min	O
)	O
and	O
extension	O
(	O
72	O
degrees	O
C	O
for	O
1	O
min	O
)	O
.	O

The	O
sequences	O
of	O
the	O
primers	O
are	O
presented	O
in	O
Table	O
1	O
.	O

The	O
PCR	O
products	O
were	O
separated	O
by	O
electrophoresis	O
through	O
2	O
%	O
agarose	O
gel	O
.	O

Western	O
immunoblot	O
analysis	O

Purified	O
monocytes	O
were	O
cultured	O
for	O
3	O
days	O
in	O
the	O
presence	O
of	O
40	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
with	O
or	O
without	O
25	O
ng	O
/	O
ml	O
RANKL	O
.	O

Cells	O
were	O
lysed	O
in	O
RIPA	O
Lysis	O
buffer	O
(	O
upstate	O
,	O
Lake	O
Placid	O
,	O
NY	O
,	O
USA	O
)	O
containing	O
protease	O
inhibitors	O
(	O
Roche	O
)	O
for	O
15	O
min	O
at	O
4	O
degrees	O
C	O
.	O

A	O
total	O
of	O
20	O
mu	O
g	O
protein	O
was	O
boiled	O
in	O
the	O
presence	O
of	O
6	O
x	O
sodium	O
dodecyl	O
sulfate	O
sample	O
buffer	O
,	O
and	O
was	O
separated	O
on	O
7	O
.	O
5	O
%	O
or	O
10	O
%	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
(	O
ATTO	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Proteins	O
were	O
then	O
electrotransferred	O
to	O
a	O
polyvinylidene	O
fluoride	O
microporous	O
membrane	O
(	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
in	O
a	O
semidry	O
system	O
.	O

Membranes	O
were	O
incubated	O
in	O
10	O
%	O
skim	O
milk	O
prepared	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
containing	O
0	O
.	O
1	O
%	O
Tween	O
20	O
,	O
and	O
were	O
subjected	O
to	O
immunoblotting	O
.	O

Antibodies	O
used	O
were	O
goat	S-Species
anti	O
-	O
RANK	O
antibody	O
(	O
Techne	O
Corporation	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
,	O
goat	S-Species
anti	O
-	O
c	O
-	O
fms	O
antibody	O
(	O
R	O
&	O
D	O
systems	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
,	O
and	O
mouse	S-Species
anti	O
-	O
beta	O
-	O
actin	O
mAb	O
(	O
AC	O
-	O
15	O
;	O
Sigma	O
)	O
.	O

Peroxidase	O
-	O
conjugated	O
rabbit	S-Species
anti	O
-	O
goat	S-Species
IgG	O
antibody	O
(	O
Dako	O
)	O
or	O
peroxidase	O
-	O
conjugated	O
rabbit	S-Species
anti	O
-	O
mouse	S-Species
IgG	O
antibody	O
(	O
Dako	O
)	O
was	O
used	O
as	O
the	O
second	O
antibody	O
.	O

The	O
signals	O
were	O
visualized	O
by	O
chemiluminescence	O
reagent	O
(	O
ECL	O
;	O
Amersham	O
Biocsiences	O
,	O
Little	O
Chalfont	O
,	O
UK	O
)	O
.	O

Cell	O
surface	O
expression	O
of	O
c	O
-	O
fms	O

The	O
following	O
mAbs	O
were	O
used	O
for	O
analysis	O
of	O
c	O
-	O
fms	O
expression	O
:	O
Alexa	O
647	O
-	O
conjugated	O
anti	O
-	O
CD14	O
mAb	O
(	O
UCHM1	O
;	O
Serotec	O
,	O
Oxford	O
,	O
UK	O
)	O
,	O
FITC	O
-	O
conjugated	O
anti	O
-	O
CD16	O
mAb	O
(	O
3G8	O
;	O
Bechman	O
Coulter	O
)	O
and	O
phycoerythin	O
-	O
conjugated	O
anti	O
-	O
c	O
-	O
fms	O
mAb	O
(	O
61708	O
;	O
R	O
&	O
D	O
systems	O
)	O
.	O

Alexa	O
647	O
-	O
conjugated	O
mouse	S-Species
IgG2a	O
(	O
Serotec	O
)	O
,	O
FITC	O
-	O
conjugated	O
mouse	S-Species
IgG1	O
(	O
BD	O
Biosciences	O
)	O
and	O
phycoerythin	O
-	O
conjugated	O
mouse	S-Species
IgG1	O
(	O
Bechman	O
Coulter	O
)	O
were	O
used	O
as	O
isotype	O
controls	O
.	O

Peripheral	O
blood	O
monocytes	O
(	O
1	O
x	O
105	O
cells	O
)	O
were	O
incubated	O
with	O
1	O
mu	O
g	O
human	S-Species
IgG	O
for	O
15	O
minutes	O
,	O
and	O
were	O
then	O
stained	O
with	O
three	O
fluorochrome	O
-	O
labeled	O
mAbs	O
for	O
45	O
minutes	O
on	O
ice	O
.	O

The	O
stained	O
cells	O
were	O
analyzed	O
with	O
a	O
FACS	O
Calibur	O
(	O
BD	O
Biosciences	O
)	O
.	O

Immunofluorescent	O
staining	O

Monocytes	O
(	O
8	O
x	O
104	O
cells	O
/	O
well	O
)	O
were	O
allowed	O
to	O
adhere	O
on	O
96	O
-	O
well	O
plates	O
overnight	O
or	O
were	O
cultured	O
with	O
M	O
-	O
CSF	O
and	O
RANKL	O
for	O
2	O
-	O
4	O
days	O
.	O

The	O
cells	O
were	O
fixed	O
in	O
acetone	O
and	O
then	O
stained	O
with	O
anti	O
-	O
alpha	O
v	O
beta	O
3	O
mAb	O
(	O
LM609	O
;	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
or	O
mouse	S-Species
IgG1	O
(	O
11711	O
;	O
R	O
&	O
D	O
Systems	O
)	O
as	O
an	O
isotype	O
-	O
matched	O
control	O
.	O

Alexa	O
fluor546	O
-	O
conjugated	O
goat	S-Species
anti	O
-	O
mouse	S-Species
IgG1	O
antibody	O
(	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
was	O
used	O
as	O
the	O
second	O
antibody	O
.	O

TOTO	O
-	O
3	O
(	O
Molecular	O
Probes	O
)	O
was	O
used	O
for	O
nuclear	O
staining	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
p38	O
MAPK	O
and	O
ERK1	O
/	O
2	O
phosphorylation	O

Purified	O
monocytes	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
25	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
for	O
3	O
days	O
,	O
and	O
were	O
either	O
left	O
unstimulated	O
or	O
were	O
stimulated	O
with	O
40	O
ng	O
/	O
ml	O
RANKL	O
at	O
37	O
degrees	O
C	O
.	O

Stimulations	O
were	O
stopped	O
by	O
adding	O
an	O
equal	O
volume	O
of	O
PhosFlow	O
Fix	O
Buffer	O
I	O
solution	O
(	O
BD	O
Biosciences	O
)	O
to	O
the	O
cell	O
culture	O
.	O

After	O
incubation	O
for	O
10	O
minutes	O
at	O
37	O
degrees	O
C	O
,	O
the	O
cells	O
were	O
permeabilized	O
by	O
washing	O
twice	O
at	O
room	O
temperature	O
in	O
PhosFlow	O
Perm	O
/	O
Wash	O
Buffer	O
I	O
(	O
BD	O
Biosciences	O
)	O
.	O

A	O
total	O
of	O
1	O
x	O
105	O
cells	O
was	O
then	O
Fc	O
blocked	O
with	O
1	O
mu	O
g	O
human	S-Species
IgG	O
for	O
15	O
minutes	O
,	O
and	O
was	O
stained	O
with	O
Alexa	O
Fluor	O
647	O
-	O
conjugated	O
mAb	O
either	O
to	O
phospho	O
-	O
p38	O
MAPK	O
(	O
T180	O
/	O
Y182	O
)	O
or	O
to	O
phospho	O
-	O
ERK1	O
/	O
2	O
(	O
T202	O
/	O
Y204	O
)	O
(	O
BD	O
Biosciences	O
)	O
for	O
30	O
minutes	O
at	O
room	O
temperature	O
.	O

Alexa	O
Fluor	O
647	O
-	O
conjugated	O
mouse	S-Species
IgG1	O
(	O
BD	O
Biosciences	O
)	O
was	O
used	O
as	O
an	O
isotype	O
control	O
.	O

The	O
cells	O
were	O
washed	O
in	O
PhosFlow	O
Perm	O
/	O
Wash	O
Buffer	O
I	O
,	O
and	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
,	O
as	O
already	O
described	O
.	O

RNA	O
interference	O

RNA	O
oligonucleotides	O
(	O
iGENE	O
,	O
Tsukuba	O
,	O
Japan	O
)	O
were	O
designed	O
based	O
on	O
the	O
algorithm	O
that	O
incorporates	O
single	O
nucleotide	O
polymorphism	O
and	O
homology	O
screening	O
to	O
ensure	O
a	O
target	O
-	O
specific	O
RNA	O
interference	O
effect	O
.	O

The	O
following	O
sense	O
and	O
antisense	O
oligonucleotides	O
were	O
used	O
:	O
integrin	O
beta	O
3	O
,	O
5	O
'	O
-	O
GCU	O
UCA	O
AUG	O
AGG	O
AAG	O
UGA	O
AGA	O
AGC	O
A	O
-	O
AG	O
and	O
3	O
'	O
-	O
UA	O
-	O
CGA	O
AGU	O
UAC	O
UCC	O
UUC	O
ACU	O
UCU	O
UCG	O
U	O
;	O
randomized	O
control	O
,	O
5	O
'	O
-	O
CGA	O
UUC	O
GCU	O
AGA	O
CCG	O
GCU	O
UCA	O
UUG	O
C	O
-	O
AG	O
and	O
3	O
'	O
-	O
UA	O
-	O
GCU	O
AAG	O
CGA	O
UCU	O
GGC	O
CGA	O
AGU	O
AAC	O
G	O
;	O
and	O
lamin	O
,	O
5	O
'	O
-	O
GAG	O
GAA	O
CUG	O
GAC	O
UUC	O
CAG	O
AAG	O
AAC	O
A	O
-	O
AG	O
and	O
3	O
'	O
-	O
UA	O
-	O
CUC	O
CUU	O
GAC	O
CUG	O
AAG	O
GUC	O
UUC	O
UUG	O
U	O
.	O

CD16	O
-	O
monocytes	O
(	O
8	O
x	O
104	O
cells	O
/	O
well	O
)	O
were	O
incubated	O
in	O
96	O
-	O
well	O
plates	O
in	O
optimem	O
(	O
Invitrogen	O
)	O
.	O

After	O
1	O
hour	O
,	O
siRNAs	O
were	O
transfected	O
into	O
the	O
cells	O
using	O
oligofectamine	O
(	O
Qiagen	O
)	O
based	O
on	O
the	O
method	O
recommended	O
by	O
the	O
manufacturer	O
.	O

After	O
2	O
hours	O
,	O
the	O
cells	O
were	O
washed	O
once	O
with	O
PBS	O
,	O
followed	O
by	O
the	O
addition	O
of	O
alpha	O
MEM	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
M	O
-	O
CSF	O
and	O
RANKL	O
.	O

After	O
a	O
2	O
-	O
day	O
incubation	O
,	O
the	O
beta	O
3	O
mRNA	O
expression	O
was	O
analyzed	O
by	O
RT	O
-	O
PCR	O
with	O
different	O
PCR	O
cycles	O
,	O
as	O
described	O
earlier	O
.	O

Immunofluorescent	O
staining	O
for	O
the	O
alpha	O
v	O
beta	O
3	O
heterodimer	O
was	O
also	O
performed	O
as	O
described	O
above	O
,	O
and	O
numbers	O
of	O
alpha	O
v	O
beta	O
3	O
-	O
positive	O
cells	O
were	O
counted	O
in	O
randomly	O
selected	O
three	O
fields	O
at	O
100	O
x	O
magnification	O
.	O

Seven	O
days	O
after	O
the	O
transfection	O
of	O
siRNAs	O
,	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
in	O
five	O
fields	O
examined	O
at	O
100	O
x	O
magnification	O
was	O
counted	O
under	O
light	O
microscopy	O
.	O

Inhibition	O
of	O
osteoclastogenesis	O
with	O
cyclic	O
RGDfV	O
peptide	O

CD16	O
-	O
monocytes	O
were	O
incubated	O
in	O
96	O
-	O
well	O
plates	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
for	O
2	O
days	O
.	O

A	O
medium	O
containing	O
either	O
cyclic	O
RGDfV	O
peptide	O
(	O
Arg	O
-	O
Gly	O
-	O
Asp	O
-	O
D	O
-	O
Phe	O
-	O
Val	O
)	O
(	O
Calbiochem	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
or	O
dimethyl	O
sulfoxide	O
was	O
then	O
added	O
.	O

After	O
incubation	O
for	O
a	O
further	O
5	O
days	O
,	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
in	O
five	O
fields	O
examined	O
at	O
100	O
x	O
magnification	O
was	O
counted	O
under	O
light	O
microscopy	O
.	O

Immunohistochemistry	O

Synovial	O
tissue	O
samples	O
were	O
obtained	O
during	O
total	O
knee	O
joint	O
replacement	O
surgery	O
from	O
four	O
RA	O
patients	S-Species
.	O

Signed	O
consent	O
forms	O
were	O
obtained	O
before	O
the	O
operation	O
.	O

The	O
experimental	O
protocol	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
.	O

RA	O
was	O
diagnosed	O
according	O
to	O
the	O
American	O
College	O
of	O
Rheumatology	O
criteria	O
[	O
14	O
]	O
.	O

Double	O
immunofluorescent	O
staining	O
for	O
CD68	O
and	O
CD16	O
antigens	O
was	O
conducted	O
on	O
optimal	O
cutting	O
temperature	O
-	O
embedded	O
sections	O
of	O
frozen	O
synovial	O
samples	O
.	O

Eight	O
-	O
micrometer	O
-	O
thick	O
cryostat	O
sections	O
of	O
RA	O
synovium	O
were	O
fixed	O
in	O
acetone	O
for	O
3	O
minutes	O
and	O
were	O
then	O
rehydrated	O
in	O
PBS	O
for	O
5	O
minutes	O
.	O

The	O
samples	O
were	O
incubated	O
in	O
5	O
mu	O
g	O
/	O
ml	O
proteinase	O
K	O
(	O
Roche	O
)	O
,	O
50	O
mM	O
ethylenediamine	O
tetraacetic	O
acid	O
,	O
100	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
8	O
.	O
0	O
,	O
for	O
15	O
minutes	O
at	O
room	O
temperature	O
followed	O
by	O
a	O
wash	O
in	O
PBS	O
.	O

The	O
samples	O
were	O
then	O
blocked	O
with	O
10	O
%	O
goat	S-Species
serum	O
in	O
PBS	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
,	O
and	O
were	O
incubated	O
with	O
anti	O
-	O
CD16	O
mAb	O
(	O
3G8	O
;	O
Immunotech	O
,	O
Marseille	O
,	O
France	O
)	O
or	O
mouse	S-Species
IgG1	O
(	O
11711	O
)	O
as	O
an	O
isotype	O
-	O
matched	O
control	O
in	O
1	O
%	O
bovine	S-Species
serum	O
albumin	O
/	O
PBS	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
.	O

The	O
samples	O
were	O
then	O
washed	O
three	O
times	O
in	O
PBS	O
,	O
for	O
5	O
minutes	O
each	O
,	O
and	O
incubated	O
with	O
Alexa	O
fluor546	O
-	O
conjugated	O
goat	S-Species
anti	O
-	O
mouse	S-Species
IgG1	O
antibody	O
(	O
Molecular	O
Probes	O
)	O
in	O
1	O
%	O
bovine	S-Species
serum	O
albumin	O
/	O
PBS	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
.	O

The	O
samples	O
were	O
then	O
sequentially	O
stained	O
for	O
CD68	O
antigen	O
in	O
a	O
manner	O
similar	O
to	O
that	O
used	O
for	O
CD16	O
staining	O
.	O

The	O
samples	O
were	O
stained	O
with	O
anti	O
-	O
CD68	O
mAb	O
(	O
PGM1	O
;	O
Immunotech	O
)	O
or	O
mouse	S-Species
IgG3	O
(	O
6A3	O
;	O
MBL	O
,	O
Nagoya	O
,	O
Japan	O
)	O
followed	O
by	O
labeling	O
with	O
Alexa	O
fluor488	O
-	O
conjugated	O
goat	S-Species
anti	O
-	O
mouse	S-Species
IgG3	O
antibody	O
(	O
Molecular	O
Probes	O
)	O
.	O

The	O
samples	O
were	O
examined	O
by	O
confocal	O
laser	O
scanning	O
microscope	O
(	O
Olympus	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
the	O
mean	O
+/-	O
standard	O
error	O
of	O
the	O
mean	O
.	O

A	O
nonpaired	O
Student	O
'	O
s	O
t	O
test	O
was	O
used	O
for	O
comparison	O
,	O
using	O
the	O
StatView	O
program	O
(	O
Abacus	O
Concepts	O
,	O
Berkeley	O
,	O
CA	O
,	O
USA	O
)	O
.	O

P	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

Results	O

Induction	O
of	O
osteoclasts	O
from	O
CD16	O
-	O
peripheral	O
blood	O
monocytes	O

To	O
identify	O
the	O
monocyte	O
subset	O
that	O
differentiates	O
into	O
osteoclasts	O
,	O
we	O
examined	O
osteoclast	O
formation	O
from	O
CD16	O
+	O
and	O
CD16	O
-	O
human	S-Species
peripheral	O
blood	O
monocytes	O
.	O

The	O
monocyte	O
subsets	O
were	O
purified	O
using	O
magnetic	O
beads	O
.	O

Incubation	O
with	O
M	O
-	O
CSF	O
alone	O
did	O
not	O
induce	O
osteoclast	O
formation	O
from	O
either	O
subset	O
(	O
Figure	O
1a	O
)	O
.	O

Culture	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
induced	O
a	O
significant	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
from	O
the	O
CD16	O
-	O
subset	O
,	O
whereas	O
only	O
few	O
CD16	O
+	O
monocytes	O
differentiated	O
into	O
TRAP	O
-	O
positive	O
MNC	O
(	O
Figure	O
1a	O
,	O
b	O
)	O
.	O

We	O
then	O
assessed	O
the	O
bone	O
resorptive	O
ability	O
by	O
culturing	O
cells	O
on	O
calcium	O
phosphate	O
-	O
coated	O
plates	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
.	O

Resorption	O
lacunae	O
were	O
detected	O
only	O
in	O
the	O
CD16	O
-	O
subset	O
(	O
Figure	O
1c	O
)	O
,	O
indicating	O
the	O
TRAP	O
-	O
positive	O
CD16	O
-	O
-	O
derived	O
MNC	O
possessed	O
the	O
osteoclast	O
phenotype	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
purified	O
monocytes	O
by	O
FACS	O
sorting	O
(	O
purities	O
:	O
CD16	O
+	O
,	O
96	O
%	O
;	O
CD16	O
-	O
,	O
97	O
%	O
)	O
.	O

The	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
induced	O
were	O
36	O
+/-	O
3	O
cells	O
/	O
well	O
and	O
348	O
+/-	O
13	O
cells	O
/	O
well	O
from	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O
,	O
respectively	O
.	O

To	O
exclude	O
the	O
possibility	O
that	O
the	O
anti	O
-	O
CD16	O
antibody	O
used	O
for	O
isolation	O
of	O
CD16	O
+	O
monocytes	O
inhibits	O
osteoclast	O
formation	O
,	O
we	O
separated	O
the	O
two	O
subsets	O
,	O
CD33low	O
monocytes	O
and	O
CD33high	O
monocytes	O
,	O
using	O
anti	O
-	O
CD33	O
mAb	O
and	O
a	O
fluorescent	O
cell	O
sorter	O
,	O
since	O
it	O
was	O
reported	O
that	O
CD33low	O
monocytes	O
correspond	O
to	O
CD16	O
+	O
,	O
and	O
that	O
CD33high	O
correspond	O
to	O
CD16	O
-	O
monocytes	O
[	O
15	O
]	O
.	O

On	O
average	O
,	O
the	O
CD33low	O
population	O
contained	O
CD16	O
-	O
(	O
10	O
.	O
2	O
%	O
)	O
/	O
CD16	O
+	O
(	O
89	O
.	O
8	O
%	O
)	O
monocytes	O
,	O
and	O
the	O
CD33high	O
population	O
contained	O
CD16	O
-	O
(	O
86	O
.	O
3	O
%	O
)	O
/	O
CD16	O
+	O
(	O
13	O
.	O
7	O
%	O
)	O
monocytes	O
.	O

Culture	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
induced	O
TRAP	O
-	O
positive	O
MNC	O
from	O
CD33high	O
monocytes	O
,	O
whereas	O
no	O
or	O
few	O
CD33low	O
monocytes	O
differentiated	O
into	O
TRAP	O
-	O
positive	O
MNC	O
(	O
CD33low	O
vs	O
CD33high	O
,	O
2	O
+/-	O
1	O
vs	O
192	O
+/-	O
71	O
cells	O
/	O
well	O
;	O
n	O
=	O
3	O
)	O
.	O

TRAP	O
-	O
5b	O
and	O
MMP	O
-	O
9	O
in	O
the	O
culture	O
supernatants	O
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
produced	O
by	O
osteoclasts	O
,	O
were	O
measured	O
by	O
ELISA	O
.	O

The	O
concentrations	O
of	O
both	O
enzymes	O
were	O
significantly	O
higher	O
in	O
the	O
culture	O
supernatant	O
of	O
CD16	O
-	O
monocytes	O
than	O
in	O
that	O
of	O
CD16	O
+	O
monocytes	O
(	O
Figure	O
1d	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
CD16	O
-	O
peripheral	O
blood	O
monocyte	O
subset	O
,	O
but	O
not	O
the	O
CD16	O
+	O
subset	O
,	O
differentiate	O
into	O
osteoclasts	O
by	O
incubation	O
with	O
RANKL	O
+	O
M	O
-	O
CSF	O
.	O

CD16	O
+	O
monocytes	O
do	O
not	O
affect	O
the	O
osteoclastogenesis	O
from	O
CD16	O
-	O
monocytes	O

To	O
examine	O
whether	O
CD16	O
+	O
monocytes	O
affect	O
osteoclastogenesis	O
from	O
CD16	O
-	O
monocytes	O
,	O
varied	O
numbers	O
of	O
CD16	O
+	O
monocytes	O
were	O
mixed	O
with	O
CD16	O
-	O
monocytes	O
(	O
5	O
x	O
104	O
cells	O
/	O
well	O
)	O
,	O
and	O
were	O
cultured	O
for	O
7	O
days	O
in	O
the	O
presence	O
of	O
M	O
-	O
CSF	O
+	O
RANKL	O
.	O

The	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
was	O
not	O
altered	O
by	O
the	O
presence	O
of	O
CD16	O
+	O
monocytes	O
(	O
Figure	O
2	O
)	O
.	O

The	O
results	O
indicated	O
that	O
CD16	O
+	O
monocytes	O
did	O
not	O
hamper	O
or	O
enhance	O
the	O
osteoclastogenesis	O
from	O
CD16	O
-	O
monocytes	O
.	O

Differences	O
in	O
cytokine	O
production	O
by	O
RANKL	O
-	O
stimulated	O
or	O
M	O
-	O
CSF	O
-	O
stimulated	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O

To	O
compare	O
the	O
biological	O
response	O
of	O
CD16	O
+	O
and	O
CD16	O
-	O
subsets	O
with	O
either	O
RANKL	O
or	O
M	O
-	O
CSF	O
stimulation	O
,	O
we	O
measured	O
the	O
amount	O
of	O
TNF	O
alpha	O
and	O
IL	O
-	O
6	O
production	O
after	O
exposure	O
of	O
cells	O
to	O
various	O
concentrations	O
of	O
RANKL	O
or	O
M	O
-	O
CSF	O
with	O
an	O
ELISA	O
.	O

Without	O
RANKL	O
the	O
CD16	O
+	O
subset	O
produced	O
a	O
significant	O
amount	O
of	O
TNF	O
alpha	O
and	O
IL	O
-	O
6	O
,	O
whereas	O
the	O
CD16	O
-	O
subset	O
produced	O
undetectable	O
levels	O
(	O
Figure	O
3a	O
)	O
.	O

RANKL	O
stimulation	O
increased	O
TNF	O
alpha	O
production	O
from	O
both	O
subsets	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
although	O
the	O
CD16	O
+	O
subset	O
produced	O
more	O
TNF	O
alpha	O
than	O
did	O
the	O
CD16	O
-	O
subset	O
.	O

RANKL	O
stimulation	O
also	O
enhanced	O
IL	O
-	O
6	O
production	O
from	O
the	O
CD16	O
+	O
subset	O
,	O
but	O
not	O
from	O
the	O
CD16	O
-	O
subset	O
.	O

M	O
-	O
CSF	O
stimulation	O
increased	O
TNF	O
alpha	O
and	O
IL	O
-	O
6	O
production	O
from	O
both	O
subsets	O
,	O
although	O
the	O
CD16	O
+	O
subset	O
produced	O
more	O
than	O
the	O
CD16	O
-	O
subset	O
(	O
Figure	O
3b	O
)	O
.	O

These	O
results	O
suggest	O
that	O
CD16	O
+	O
monocytes	O
also	O
respond	O
both	O
to	O
RANKL	O
and	O
M	O
-	O
CSF	O
stimulation	O
,	O
although	O
such	O
stimulation	O
does	O
not	O
result	O
in	O
differentiation	O
into	O
osteoclasts	O
.	O

CD16	O
+	O
monocytes	O
were	O
also	O
noted	O
to	O
express	O
higher	O
amounts	O
of	O
inflammatory	O
cytokines	O
compared	O
with	O
CD16	O
-	O
monocytes	O
with	O
or	O
without	O
RANKL	O
or	O
M	O
-	O
CSF	O
stimulation	O
.	O

Comparison	O
of	O
expression	O
levels	O
of	O
molecules	O
involved	O
in	O
osteoclastogenesis	O
between	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O

Diverse	O
molecules	O
are	O
involved	O
in	O
RANKL	O
/	O
RANK	O
and	O
its	O
costimulatory	O
signal	O
transduction	O
pathways	O
[	O
16	O
]	O
.	O

The	O
different	O
response	O
to	O
RANKL	O
+	O
M	O
-	O
CSF	O
stimulation	O
between	O
the	O
CD16	O
+	O
monocyte	O
subset	O
and	O
the	O
CD16	O
-	O
monocytes	O
subset	O
might	O
be	O
explained	O
by	O
the	O
expression	O
profiles	O
of	O
these	O
molecules	O
.	O

We	O
therefore	O
examined	O
the	O
mRNA	O
levels	O
of	O
the	O
following	O
molecules	O
:	O
receptor	O
activator	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
RANK	O
)	O
,	O
the	O
receptor	O
for	O
RANKL	O
;	O
c	O
-	O
fms	O
,	O
the	O
receptor	O
for	O
M	O
-	O
CSF	O
;	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
6	O
(	O
TRAF	O
-	O
6	O
)	O
,	O
the	O
adaptor	O
protein	O
for	O
RANK	O
;	O
c	O
-	O
Fos	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
c1	O
(	O
NFATc1	O
)	O
,	O
transcription	O
factors	O
that	O
are	O
essential	O
for	O
osteoclastogenesis	O
;	O
DNAX	O
-	O
activation	O
protein	O
12	O
(	O
DAP12	O
)	O
and	O
Fc	O
receptor	O
gamma	O
chain	O
(	O
FcR	O
gamma	O
)	O
,	O
adaptor	O
proteins	O
known	O
to	O
deliver	O
costimulatory	O
signals	O
in	O
RANKL	O
-	O
induced	O
osteoclastogenesis	O
;	O
signal	O
regulatory	O
protein	O
beta	O
1	O
(	O
SIRP	O
-	O
beta	O
1	O
)	O
,	O
triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
2	O
(	O
TREM	O
-	O
2	O
)	O
and	O
osteoclast	O
-	O
associated	O
receptor	O
(	O
OSCAR	O
)	O
,	O
transmembrane	O
receptors	O
that	O
associate	O
with	O
either	O
DAP12	O
or	O
FcR	O
gamma	O
;	O
and	O
alpha	O
v	O
and	O
beta	O
3	O
,	O
integrins	O
known	O
to	O
be	O
expressed	O
as	O
the	O
alpha	O
v	O
beta	O
3	O
heterodimer	O
on	O
osteoclasts	O
.	O

The	O
mRNA	O
levels	O
of	O
RANK	O
,	O
c	O
-	O
fms	O
,	O
TRAF	O
-	O
6	O
,	O
DAP12	O
and	O
SIRP	O
-	O
beta	O
1	O
under	O
the	O
baseline	O
condition	O
(	O
no	O
stimulation	O
)	O
varied	O
between	O
the	O
donors	O
;	O
however	O
,	O
we	O
did	O
not	O
find	O
consistent	O
differences	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
molecules	O
between	O
the	O
CD16	O
+	O
monocyte	O
subset	O
and	O
the	O
CD16	O
-	O
monocyte	O
subset	O
among	O
three	O
to	O
six	O
donors	O
(	O
Figure	O
4a	O
)	O
.	O

The	O
mRNA	O
levels	O
of	O
other	O
molecules	O
,	O
apart	O
from	O
integrin	O
beta	O
3	O
,	O
were	O
similar	O
between	O
the	O
two	O
subsets	O
under	O
the	O
no	O
-	O
stimulation	O
condition	O
.	O

Although	O
the	O
mRNA	O
levels	O
of	O
RANK	O
,	O
c	O
-	O
fms	O
,	O
DAP12	O
,	O
FcR	O
gamma	O
,	O
TREM	O
-	O
2	O
and	O
OSCAR	O
increased	O
in	O
response	O
to	O
M	O
-	O
CSF	O
alone	O
or	O
M	O
-	O
CSF	O
+	O
RANKL	O
in	O
both	O
subsets	O
,	O
the	O
expression	O
levels	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
subsets	O
.	O

Expressions	O
of	O
TRAF	O
-	O
6	O
,	O
c	O
-	O
Fos	O
and	O
SIRP	O
-	O
beta	O
1	O
mRNA	O
did	O
not	O
change	O
following	O
stimulation	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
.	O

Of	O
note	O
,	O
the	O
expression	O
of	O
NFATc1	O
mRNA	O
was	O
enhanced	O
by	O
M	O
-	O
CSF	O
+	O
RANKL	O
treatment	O
only	O
in	O
the	O
CD16	O
-	O
subset	O
.	O

Furthermore	O
,	O
expression	O
of	O
integrin	O
alpha	O
v	O
in	O
both	O
subsets	O
was	O
enhanced	O
by	O
M	O
-	O
CSF	O
with	O
or	O
without	O
RANKL	O
;	O
however	O
,	O
the	O
expression	O
level	O
was	O
greater	O
in	O
the	O
CD16	O
-	O
subset	O
.	O

It	O
was	O
noted	O
that	O
integrin	O
-	O
beta	O
3	O
mRNA	O
was	O
detected	O
only	O
in	O
the	O
CD16	O
-	O
subset	O
and	O
was	O
increased	O
by	O
M	O
-	O
CSF	O
+	O
RANKL	O
stimulation	O
,	O
but	O
not	O
by	O
M	O
-	O
CSF	O
alone	O
.	O

The	O
protein	O
expression	O
of	O
RANK	O
under	O
the	O
baseline	O
condition	O
was	O
weakly	O
detected	O
in	O
both	O
subsets	O
,	O
and	O
the	O
levels	O
were	O
varied	O
between	O
donors	O
by	O
western	O
immunoblotting	O
.	O

The	O
protein	O
expression	O
of	O
c	O
-	O
fms	O
was	O
weakly	O
detected	O
in	O
unstimulated	O
CD16	O
+	O
monocytes	O
,	O
but	O
not	O
in	O
CD16	O
-	O
monocytes	O
(	O
Figure	O
4b	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
of	O
c	O
-	O
fms	O
in	O
fresh	O
monocytes	O
,	O
however	O
,	O
showed	O
that	O
both	O
subsets	O
express	O
the	O
molecule	O
on	O
the	O
cell	O
surface	O
(	O
Figure	O
4c	O
)	O
.	O

Expressions	O
of	O
both	O
RANK	O
and	O
c	O
-	O
fms	O
were	O
upregulated	O
by	O
M	O
-	O
CSF	O
alone	O
and	O
by	O
M	O
-	O
CSF	O
+	O
RANKL	O
,	O
and	O
we	O
did	O
not	O
find	O
consistent	O
differences	O
in	O
the	O
protein	O
levels	O
of	O
these	O
molecules	O
between	O
the	O
two	O
monocyte	O
subsets	O
.	O

The	O
profiles	O
of	O
expression	O
levels	O
of	O
molecules	O
involved	O
in	O
RANKL	O
/	O
RANK	O
and	O
its	O
costimulatory	O
pathways	O
are	O
similar	O
between	O
the	O
two	O
subsets	O
,	O
except	O
for	O
NFATc1	O
,	O
integrin	O
alpha	O
v	O
and	O
integrin	O
beta	O
3	O
.	O

We	O
therefore	O
assumed	O
that	O
the	O
distinct	O
induction	O
of	O
NFATc1	O
,	O
integrin	O
alpha	O
v	O
and	O
integrin	O
beta	O
3	O
in	O
response	O
to	O
RANKL	O
stimulation	O
among	O
the	O
two	O
monocyte	O
subsets	O
might	O
explain	O
the	O
differences	O
in	O
their	O
abilities	O
to	O
differentiate	O
into	O
osteoclasts	O
.	O

RANKL	O
stimulation	O
induces	O
alpha	O
v	O
beta	O
3	O
expression	O
on	O
CD16	O
-	O
monocytes	O

The	O
integrin	O
-	O
beta	O
3	O
subunit	O
binds	O
to	O
integrin	O
alpha	O
v	O
only	O
and	O
is	O
expressed	O
as	O
the	O
heterodimeric	O
protein	O
alpha	O
v	O
beta	O
3	O
on	O
monocytes	O
and	O
osteoclasts	O
[	O
17	O
]	O
.	O

We	O
examined	O
the	O
expression	O
of	O
alpha	O
v	O
beta	O
3	O
on	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O
by	O
immunofluorescent	O
staining	O
.	O

Neither	O
unstimulated	O
nor	O
M	O
-	O
CSF	O
-	O
stimulated	O
monocyte	O
subsets	O
expressed	O
alpha	O
v	O
beta	O
3	O
(	O
Figure	O
4d	O
and	O
data	O
not	O
shown	O
)	O
.	O

After	O
48	O
and	O
72	O
hours	O
of	O
treatment	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
,	O
alpha	O
v	O
beta	O
3	O
-	O
positive	O
mononuclear	O
cells	O
were	O
observed	O
in	O
CD16	O
-	O
monocyte	O
cultures	O
but	O
not	O
in	O
CD16	O
+	O
monocyte	O
cultures	O
.	O

At	O
96	O
hours	O
,	O
both	O
alpha	O
v	O
beta	O
3	O
-	O
positive	O
mononuclear	O
cells	O
and	O
multinucleated	O
cells	O
were	O
present	O
in	O
the	O
CD16	O
-	O
monocyte	O
culture	O
.	O

The	O
results	O
indicated	O
that	O
alpha	O
v	O
beta	O
3	O
was	O
selectively	O
expressed	O
on	O
CD16	O
-	O
monocytes	O
in	O
the	O
presence	O
of	O
M	O
-	O
CSF	O
+	O
RANKL	O
,	O
and	O
the	O
expression	O
was	O
revealed	O
before	O
the	O
cells	O
differentiate	O
into	O
typical	O
multinucleated	O
osteoclasts	O
.	O

RANKL	O
activates	O
ERK	O
and	O
p38	O
kinases	O
only	O
in	O
CD16	O
-	O
monocytes	O

Since	O
ERK	O
and	O
p38	O
MAPK	O
are	O
essential	O
in	O
RANKL	O
-	O
induced	O
osteoclastogenesis	O
[	O
18	O
-	O
20	O
]	O
,	O
we	O
next	O
examined	O
whether	O
these	O
kinases	O
were	O
activated	O
differently	O
in	O
CD16	O
+	O
monocytes	O
and	O
in	O
CD16	O
-	O
monocytes	O
.	O

Purified	O
monocytes	O
were	O
precultured	O
with	O
25	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
for	O
3	O
days	O
to	O
enhance	O
RANK	O
expression	O
,	O
and	O
were	O
then	O
treated	O
with	O
RANKL	O
.	O

The	O
RANKL	O
treatment	O
induced	O
phosphorylation	O
of	O
both	O
ERK	O
and	O
p38	O
MAPK	O
in	O
CD16	O
-	O
monocytes	O
at	O
5	O
minutes	O
postexposure	O
,	O
although	O
the	O
p38	O
MAPK	O
phosphorylation	O
was	O
weak	O
.	O

Both	O
phosphorylations	O
declined	O
to	O
a	O
basal	O
level	O
within	O
20	O
minutes	O
(	O
Figure	O
5	O
)	O
.	O

In	O
contrast	O
,	O
ERK	O
and	O
p38	O
MAPK	O
were	O
not	O
detectably	O
phosphorylated	O
in	O
CD16	O
+	O
monocytes	O
with	O
RANKL	O
.	O

siRNA	O
targeting	O
integrin	O
beta	O
3	O
inhibits	O
osteoclastogenesis	O
from	O
CD16	O
-	O
monocytes	O

The	O
integrin	O
-	O
beta	O
3	O
cytoplasmic	O
domain	O
is	O
essential	O
for	O
activation	O
of	O
intracellular	O
signals	O
from	O
alpha	O
v	O
beta	O
3	O
heterodimers	O
[	O
17	O
]	O
.	O

We	O
therefore	O
examined	O
the	O
involvement	O
of	O
alpha	O
v	O
beta	O
3	O
in	O
RANKL	O
+	O
M	O
-	O
CSF	O
-	O
induced	O
osteoclastogenesis	O
in	O
human	S-Species
CD16	O
-	O
monocytes	O
using	O
siRNA	O
targeting	O
the	O
integrin	O
-	O
beta	O
3	O
subunit	O
.	O

The	O
integrin	O
-	O
beta	O
3	O
siRNA	O
or	O
control	O
randomized	O
siRNA	O
were	O
transfected	O
into	O
CD16	O
-	O
monocytes	O
.	O

At	O
48	O
hours	O
post	O
-	O
transfection	O
,	O
we	O
determined	O
the	O
integrin	O
-	O
beta	O
3	O
mRNA	O
level	O
and	O
alpha	O
v	O
beta	O
3	O
heterodimer	O
protein	O
expression	O
.	O

The	O
integrin	O
-	O
beta	O
3	O
mRNA	O
level	O
was	O
reduced	O
in	O
the	O
integrin	O
-	O
beta	O
3	O
siRNA	O
-	O
transfected	O
monocytes	O
compared	O
with	O
control	O
siRNA	O
-	O
transfected	O
monocytes	O
(	O
Figure	O
6a	O
)	O
.	O

The	O
alpha	O
v	O
beta	O
3	O
heterodimer	O
expression	O
was	O
evaluated	O
by	O
immunofluorescent	O
staining	O
.	O

The	O
number	O
of	O
alpha	O
v	O
beta	O
3	O
-	O
positive	O
cells	O
was	O
significantly	O
decreased	O
in	O
integrin	O
-	O
beta	O
3	O
siRNA	O
-	O
transfected	O
monocytes	O
compared	O
with	O
that	O
in	O
control	O
siRNA	O
(	O
Figure	O
6b	O
)	O
.	O

After	O
7	O
days	O
of	O
incubation	O
,	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
was	O
counted	O
.	O

Transfection	O
with	O
integrin	O
-	O
beta	O
3	O
siRNA	O
significantly	O
reduced	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
compared	O
with	O
control	O
siRNA	O
transfection	O
(	O
Figure	O
6c	O
)	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
siRNA	O
directed	O
toward	O
a	O
different	O
site	O
of	O
integrin	O
-	O
beta	O
3	O
mRNA	O
also	O
inhibited	O
osteoclast	O
formation	O
from	O
CD16	O
-	O
monocytes	O
(	O
data	O
not	O
shown	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
siRNA	O
that	O
targeted	O
lamin	O
,	O
which	O
was	O
used	O
as	O
a	O
negative	O
control	O
,	O
did	O
not	O
inhibit	O
the	O
induction	O
of	O
osteoclasts	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
indicate	O
the	O
importance	O
of	O
integrin	O
beta	O
3	O
in	O
RANKL	O
-	O
induced	O
osteoclast	O
formation	O
from	O
CD16	O
-	O
peripheral	O
blood	O
monocytes	O
.	O

Cyclic	O
RGDfV	O
peptide	O
inhibits	O
the	O
osteoclastogenesis	O
from	O
CD16	O
-	O
monocytes	O

Integrin	O
alpha	O
v	O
beta	O
3	O
recognizes	O
a	O
common	O
tripeptide	O
sequence	O
,	O
RGD	O
(	O
Arg	O
-	O
Gly	O
-	O
Asp	O
)	O
,	O
which	O
is	O
present	O
in	O
bone	O
matrix	O
proteins	O
such	O
as	O
vitronectin	O
and	O
fibronectin	O
[	O
21	O
]	O
.	O

Cyclic	O
RGDfV	O
peptide	O
(	O
Arg	O
-	O
Gly	O
-	O
Asp	O
-	O
D	O
-	O
Phe	O
-	O
Val	O
)	O
inhibits	O
binding	O
of	O
the	O
RGD	O
-	O
containing	O
molecules	O
to	O
alpha	O
v	O
beta	O
3	O
[	O
22	O
]	O
.	O

To	O
investigate	O
the	O
role	O
of	O
ligand	O
binding	O
to	O
the	O
alpha	O
v	O
beta	O
3	O
heterodimer	O
in	O
the	O
osteoclastogenesis	O
,	O
we	O
examined	O
whether	O
cyclic	O
RGDfV	O
peptide	O
inhibits	O
the	O
formation	O
of	O
osteoclasts	O
.	O

Cyclic	O
RGDfV	O
peptide	O
significantly	O
reduced	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
6d	O
)	O
.	O

The	O
results	O
imply	O
possible	O
involvement	O
of	O
ligand	O
bindings	O
to	O
alpha	O
v	O
beta	O
3	O
in	O
the	O
osteoclastogenesis	O
.	O

Knockdown	O
of	O
integrin	O
beta	O
3	O
did	O
not	O
affect	O
the	O
expression	O
of	O
NFATc1	O
mRNA	O

In	O
the	O
next	O
step	O
,	O
we	O
determined	O
whether	O
integrin	O
-	O
beta	O
3	O
-	O
siRNA	O
-	O
induced	O
inhibition	O
of	O
the	O
osteoclastogenesis	O
reflects	O
downregulation	O
of	O
NFATc1	O
,	O
which	O
is	O
a	O
key	O
transcription	O
factor	O
in	O
osteoclastogenesis	O
[	O
23	O
]	O
.	O

For	O
this	O
purpose	O
,	O
we	O
compared	O
NFATc1	O
mRNA	O
levels	O
between	O
integrin	O
beta	O
3	O
and	O
control	O
siRNA	O
-	O
transfected	O
monocytes	O
.	O

Interestingly	O
,	O
integrin	O
-	O
beta	O
3	O
knockdown	O
did	O
not	O
alter	O
the	O
NFATc1	O
mRNA	O
level	O
(	O
Figure	O
7	O
)	O
,	O
suggesting	O
that	O
signal	O
transduction	O
mediated	O
by	O
integrin	O
beta	O
3	O
does	O
not	O
affect	O
the	O
expression	O
of	O
NFATc1	O
.	O

Detection	O
of	O
CD16	O
+	O
and	O
CD16	O
-	O
macrophages	O
in	O
synovium	O
of	O
RA	O
patients	S-Species

RA	O
synovial	O
macrophages	O
are	O
derived	O
from	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
their	O
recruitment	O
into	O
the	O
synovium	O
is	O
facilitated	O
by	O
various	O
adhesion	O
molecules	O
and	O
chemokines	O
[	O
24	O
]	O
.	O

To	O
analyze	O
CD16	O
expression	O
on	O
synovial	O
macrophages	O
,	O
RA	O
synovial	O
tissues	O
were	O
double	O
-	O
stained	O
for	O
CD16	O
and	O
a	O
macrophage	O
marker	O
,	O
CD68	O
.	O

CD16	O
-	O
/	O
CD68	O
+	O
macrophages	O
were	O
widespread	O
in	O
the	O
synovium	O
.	O

Although	O
less	O
frequent	O
,	O
CD16	O
+	O
/	O
CD68	O
+	O
macrophages	O
were	O
also	O
observed	O
both	O
in	O
the	O
synovial	O
intima	O
and	O
subintima	O
(	O
Figure	O
8	O
)	O
.	O

The	O
presence	O
of	O
two	O
subsets	O
of	O
macrophages	O
,	O
CD16	O
+	O
and	O
CD16	O
-	O
,	O
in	O
RA	O
synovium	O
indicates	O
that	O
both	O
CD16	O
+	O
and	O
CD16	O
-	O
peripheral	O
blood	O
monocytes	O
are	O
recruited	O
into	O
the	O
synovium	O
.	O

Discussion	O

Human	S-Species
peripheral	O
blood	O
monocytes	O
are	O
a	O
heterogeneous	O
population	O
,	O
and	O
they	O
are	O
divided	O
into	O
two	O
subsets	O
based	O
on	O
the	O
expression	O
of	O
CD16	O
.	O

The	O
CD16	O
+	O
and	O
CD16	O
-	O
monocyte	O
subsets	O
show	O
functional	O
differences	O
in	O
migration	O
,	O
cytokine	O
production	O
and	O
differentiation	O
into	O
macrophages	O
or	O
dendritic	O
cells	O
[	O
11	O
-	O
13	O
,	O
15	O
]	O
.	O

We	O
focused	O
on	O
the	O
heterogeneity	O
of	O
the	O
monocytes	O
,	O
and	O
the	O
primary	O
question	O
addressed	O
in	O
this	O
study	O
was	O
which	O
monocyte	O
subset	O
could	O
be	O
the	O
source	O
of	O
osteoclasts	O
.	O

The	O
results	O
demonstrated	O
that	O
CD16	O
-	O
peripheral	O
blood	O
monocytes	O
,	O
but	O
not	O
CD16	O
+	O
monocytes	O
,	O
differentiated	O
in	O
vitro	O
into	O
osteoclasts	O
by	O
treatment	O
with	O
RANKL	O
+	O
M	O
-	O
CSF	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
the	O
different	O
response	O
to	O
RANKL	O
and	O
the	O
differentiation	O
into	O
osteoclasts	O
between	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O
,	O
we	O
examined	O
the	O
expression	O
of	O
molecules	O
known	O
to	O
be	O
involved	O
in	O
osteoclastogenesis	O
.	O

The	O
expression	O
profiles	O
of	O
integrin	O
alpha	O
v	O
,	O
integrin	O
beta	O
3	O
and	O
NFATc1	O
were	O
different	O
between	O
the	O
two	O
subsets	O
.	O

Integrin	O
alpha	O
v	O
beta	O
3	O
heterodimer	O
was	O
expressed	O
only	O
on	O
RANKL	O
and	O
M	O
-	O
CSF	O
-	O
stimulated	O
CD16	O
-	O
monocytes	O
.	O

It	O
is	O
known	O
that	O
alpha	O
v	O
beta	O
3	O
expressed	O
on	O
osteoclasts	O
is	O
important	O
in	O
bone	O
resorption	O
as	O
well	O
as	O
in	O
attachment	O
of	O
osteoclasts	O
to	O
the	O
bone	O
matrix	O
[	O
25	O
]	O
.	O

It	O
was	O
recently	O
reported	O
that	O
bone	O
marrow	O
macrophages	O
of	O
integrin	O
-	O
beta	O
3	O
-	O
deficient	O
mice	S-Species
could	O
not	O
differentiate	O
into	O
mature	O
osteoclasts	O
in	O
vitro	O
,	O
suggesting	O
that	O
alpha	O
v	O
beta	O
3	O
is	O
involved	O
not	O
only	O
in	O
activation	O
,	O
but	O
also	O
in	O
differentiation	O
,	O
of	O
osteoclasts	O
in	O
mice	S-Species
[	O
26	O
,	O
27	O
]	O
.	O

The	O
authors	O
also	O
showed	O
that	O
alpha	O
v	O
beta	O
3	O
and	O
c	O
-	O
fms	O
share	O
a	O
common	O
intracellular	O
signaling	O
pathway	O
,	O
including	O
the	O
activation	O
of	O
ERK	O
and	O
the	O
induction	O
of	O
c	O
-	O
Fos	O
[	O
27	O
]	O
,	O
both	O
of	O
which	O
are	O
essential	O
for	O
osteoclastogenesis	O
[	O
28	O
,	O
29	O
]	O
.	O

In	O
addition	O
,	O
it	O
was	O
reported	O
that	O
echistatin	O
,	O
an	O
alpha	O
v	O
beta	O
3	O
antagonist	O
,	O
inhibited	O
osteoclast	O
formation	O
of	O
mouse	S-Species
bone	O
marrow	O
cells	O
[	O
30	O
]	O
.	O

In	O
accordance	O
with	O
these	O
reports	O
,	O
our	O
data	O
showed	O
that	O
knockdown	O
of	O
integrin	O
-	O
beta	O
3	O
expression	O
resulted	O
in	O
downregulation	O
of	O
the	O
alpha	O
v	O
beta	O
3	O
heterodimer	O
,	O
and	O
abrogated	O
osteoclastogenesis	O
from	O
human	S-Species
peripheral	O
blood	O
CD16	O
-	O
monocytes	O
.	O

We	O
also	O
showed	O
that	O
blocking	O
of	O
adhesive	O
ligands	O
to	O
bind	O
to	O
alpha	O
v	O
beta	O
3	O
by	O
RGDfV	O
peptide	O
inhibited	O
osteoclast	O
formation	O
from	O
CD16	O
-	O
monocytes	O
.	O

Taken	O
together	O
,	O
the	O
process	O
of	O
ligand	O
binding	O
to	O
alpha	O
v	O
beta	O
3	O
may	O
be	O
involved	O
in	O
the	O
osteoclastogenesis	O
.	O

Blockade	O
of	O
alpha	O
v	O
beta	O
3	O
could	O
therefore	O
be	O
a	O
therapeutically	O
beneficial	O
approach	O
to	O
modulate	O
osteoclastogenesis	O
.	O

Indeed	O
,	O
integrin	O
alpha	O
v	O
beta	O
3	O
antagonists	O
effectively	O
treated	O
osteoporosis	O
in	O
mice	S-Species
,	O
rats	S-Species
and	O
humans	S-Species
,	O
and	O
protected	O
bone	O
destruction	O
in	O
rat	O
adjuvant	O
-	O
induced	O
arthritis	O
in	O
vivo	O
[	O
31	O
-	O
34	O
]	O
.	O

Of	O
note	O
,	O
it	O
is	O
reported	O
that	O
patients	S-Species
with	O
Iraqi	O
-	O
Jewish	O
-	O
type	O
Glanzmann	O
thrombasthenia	O
who	O
are	O
deficient	O
in	O
integrin	O
beta	O
3	O
do	O
not	O
develop	O
osteopetrosis	O
because	O
of	O
the	O
upregulation	O
of	O
alpha	O
2	O
beta	O
1	O
expression	O
on	O
osteoclasts	O
,	O
although	O
the	O
bone	O
-	O
resorptive	O
ability	O
of	O
the	O
osteoclasts	O
was	O
decreased	O
in	O
vitro	O
[	O
35	O
]	O
.	O

The	O
function	O
of	O
alpha	O
v	O
beta	O
3	O
in	O
vivo	O
in	O
osteoclast	O
formation	O
and	O
resorptive	O
function	O
could	O
therefore	O
be	O
partially	O
compensated	O
by	O
other	O
integrins	O
.	O

Although	O
all	O
the	O
multinucleated	O
osteoclasts	O
expressed	O
alpha	O
v	O
beta	O
3	O
(	O
Figure	O
4d	O
)	O
[	O
36	O
]	O
,	O
a	O
small	O
number	O
of	O
M	O
-	O
CSF	O
+	O
RANKL	O
-	O
stimulated	O
mononuclear	O
CD16	O
-	O
monocytes	O
expressed	O
alpha	O
v	O
beta	O
3	O
(	O
Figure	O
4d	O
)	O
.	O

Multinucleated	O
osteoclasts	O
are	O
formed	O
by	O
fusion	O
of	O
osteoclast	O
precursor	O
cells	O
[	O
37	O
]	O
.	O

It	O
was	O
reported	O
that	O
alpha	O
v	O
beta	O
3	O
is	O
involved	O
in	O
the	O
migration	O
of	O
osteoclast	O
precursors	O
[	O
30	O
]	O
.	O

The	O
alpha	O
v	O
beta	O
3	O
-	O
positive	O
cells	O
could	O
therefore	O
be	O
forced	O
to	O
migrate	O
by	O
the	O
ligands	O
and	O
may	O
fuse	O
with	O
closed	O
alpha	O
v	O
beta	O
3	O
-	O
negative	O
cells	O
.	O

Alternatively	O
,	O
only	O
alpha	O
v	O
beta	O
3	O
-	O
positive	O
cells	O
may	O
be	O
fused	O
with	O
each	O
other	O
.	O

It	O
is	O
possible	O
to	O
consider	O
that	O
signaling	O
from	O
CD16	O
by	O
anti	O
-	O
CD16	O
mAb	O
-	O
coated	O
magnetic	O
beads	O
,	O
which	O
were	O
used	O
for	O
the	O
cell	O
separation	O
,	O
or	O
by	O
IgG	O
contained	O
in	O
FBS	O
might	O
inhibit	O
osteoclastogenesis	O
from	O
CD16	O
+	O
monocytes	O
.	O

We	O
therefore	O
separated	O
the	O
two	O
subsets	O
using	O
anti	O
-	O
CD33	O
mAb	O
and	O
a	O
fluorescent	O
cell	O
sorter	O
,	O
and	O
stimulated	O
the	O
cells	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
.	O

The	O
results	O
showed	O
that	O
CD33low	O
monocytes	O
,	O
which	O
correspond	O
to	O
CD16	O
+	O
monocytes	O
,	O
still	O
could	O
not	O
differentiate	O
into	O
osteoclasts	O
.	O

CD16	O
is	O
a	O
heterodimer	O
consisting	O
of	O
Fc	O
gamma	O
IIIa	O
and	O
Fc	O
gamma	O
,	O
and	O
has	O
low	O
affinity	O
for	O
the	O
Fc	O
region	O
of	O
IgG	O
.	O

Aggregation	O
of	O
CD16	O
by	O
immune	O
complexes	O
leads	O
to	O
transmission	O
of	O
activating	O
signals	O
via	O
the	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
in	O
the	O
gamma	O
chain	O
[	O
38	O
]	O
.	O

We	O
also	O
assessed	O
osteoclastogenesis	O
from	O
the	O
two	O
monocyte	O
subsets	O
using	O
IgG	O
-	O
depleted	O
bovine	S-Species
serum	O
.	O

Even	O
in	O
the	O
IgG	O
-	O
free	O
medium	O
,	O
CD16	O
-	O
monocytes	O
but	O
not	O
CD16	O
+	O
monocytes	O
differentiated	O
into	O
osteoclasts	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
could	O
therefore	O
exclude	O
the	O
possibility	O
that	O
signal	O
transduction	O
through	O
CD16	O
inhibits	O
osteoclastogenesis	O
from	O
CD16	O
+	O
monocytes	O
.	O

NFATc1	O
is	O
a	O
key	O
transcription	O
factor	O
in	O
osteoclastogenesis	O
[	O
16	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
stimulation	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
increased	O
the	O
NFATc1	O
mRNA	O
expression	O
in	O
the	O
CD16	O
-	O
subset	O
only	O
,	O
similar	O
to	O
integrin	O
alpha	O
v	O
and	O
integrin	O
beta	O
3	O
.	O

The	O
differences	O
in	O
NFATc1	O
induction	O
might	O
therefore	O
also	O
explain	O
the	O
difference	O
in	O
osteoclastogenesis	O
between	O
the	O
two	O
monocyte	O
subsets	O
.	O

It	O
is	O
of	O
interest	O
that	O
knockdown	O
of	O
integrin	O
beta	O
3	O
did	O
not	O
lower	O
the	O
mRNA	O
level	O
of	O
NFATc1	O
.	O

This	O
result	O
supports	O
the	O
notion	O
that	O
NFATc1	O
is	O
located	O
upstream	O
of	O
integrin	O
-	O
beta	O
3	O
expression	O
[	O
39	O
]	O
.	O

It	O
is	O
also	O
possible	O
that	O
parallel	O
activation	O
of	O
two	O
signaling	O
pathways	O
mediated	O
by	O
integrin	O
beta	O
3	O
and	O
NFATc1	O
contributes	O
to	O
osteoclastogenesis	O
independently	O
or	O
cooperatively	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
mechanisms	O
of	O
integrin	O
beta	O
3	O
involvement	O
in	O
RANKL	O
/	O
RANK	O
-	O
mediated	O
osteoclast	O
differentiation	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
MAPK	O
families	O
,	O
ERK	O
and	O
p38	O
MAPK	O
,	O
were	O
activated	O
by	O
RANKL	O
-	O
induced	O
intracellular	O
signalings	O
in	O
osteoclasts	O
and	O
osteoclast	O
precursors	O
[	O
18	O
,	O
19	O
]	O
.	O

In	O
addition	O
,	O
these	O
kinases	O
are	O
involved	O
in	O
the	O
differentiation	O
of	O
osteoclasts	O
[	O
20	O
]	O
.	O

We	O
showed	O
that	O
RANKL	O
stimulation	O
induced	O
phosphorylation	O
of	O
ERK	O
and	O
p38	O
MAPK	O
only	O
in	O
CD16	O
-	O
monocytes	O
.	O

It	O
is	O
suggested	O
that	O
differential	O
activation	O
of	O
these	O
kinases	O
may	O
partially	O
explain	O
the	O
distinct	O
properties	O
of	O
the	O
two	O
monocyte	O
subsets	O
upon	O
RANKL	O
stimulation	O
.	O

Our	O
results	O
showed	O
that	O
CD16	O
+	O
monocytes	O
produce	O
higher	O
levels	O
of	O
inflammatory	O
cytokines	O
including	O
TNF	O
alpha	O
and	O
IL	O
-	O
6	O
compared	O
with	O
CD16	O
-	O
monocytes	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
previous	O
report	O
showing	O
that	O
CD16	O
+	O
monocytes	O
produced	O
larger	O
amounts	O
of	O
TNF	O
alpha	O
upon	O
lipopolysaccharide	O
or	O
lipopeptide	O
stimulation	O
than	O
did	O
CD16	O
-	O
monocytes	O
[	O
40	O
]	O
.	O

Interestingly	O
,	O
we	O
showed	O
that	O
stimulation	O
either	O
with	O
RANKL	O
or	O
M	O
-	O
CSF	O
upregulated	O
the	O
TNF	O
alpha	O
and	O
IL	O
-	O
6	O
production	O
by	O
CD16	O
+	O
monocytes	O
.	O

A	O
marked	O
increase	O
of	O
CD16	O
+	O
monocytes	O
in	O
peripheral	O
blood	O
is	O
reported	O
in	O
inflammatory	O
diseases	O
,	O
such	O
as	O
infection	O
,	O
malignancy	O
,	O
Kawasaki	O
disease	O
and	O
RA	O
[	O
41	O
-	O
44	O
]	O
.	O

Taken	O
together	O
,	O
CD16	O
+	O
monocytes	O
may	O
be	O
an	O
important	O
source	O
of	O
inflammatory	O
cytokines	O
.	O

In	O
mice	S-Species
,	O
peripheral	O
blood	O
Ly	O
-	O
6Chigh	O
monocytes	O
,	O
which	O
are	O
thought	O
to	O
correspond	O
to	O
human	S-Species
CD16	O
-	O
monocytes	O
,	O
increase	O
in	O
inflammatory	O
conditions	O
,	O
and	O
these	O
cells	O
are	O
recruited	O
into	O
sites	O
of	O
inflammation	O
[	O
45	O
]	O
.	O

In	O
contrast	O
,	O
Ly	O
-	O
6Clow	O
monocytes	O
,	O
which	O
are	O
thought	O
to	O
correspond	O
to	O
human	S-Species
CD16	O
+	O
,	O
migrate	O
into	O
noninflamed	O
tissues	O
[	O
12	O
]	O
.	O

These	O
data	O
on	O
mouse	S-Species
monocytes	O
seem	O
to	O
be	O
in	O
contrast	O
to	O
the	O
data	O
on	O
human	S-Species
monocytes	O
,	O
which	O
show	O
expansion	O
of	O
CD16	O
+	O
monocytes	O
in	O
inflammatory	O
conditions	O
where	O
they	O
produce	O
larger	O
amounts	O
of	O
inflammatory	O
cytokines	O
.	O

At	O
present	O
,	O
it	O
is	O
not	O
clear	O
whether	O
mouse	S-Species
monocyte	O
subsets	O
,	O
Ly	O
-	O
6Clow	O
/	O
Ly	O
-	O
6Chigh	O
,	O
represent	O
human	S-Species
monocyte	O
subsets	O
,	O
CD16	O
+	O
/	O
CD16	O
-	O
monocytes	O
,	O
and	O
whether	O
the	O
biologic	O
functions	O
of	O
mouse	S-Species
monocytes	O
are	O
analogous	O
to	O
those	O
of	O
human	S-Species
monocytes	O
.	O

In	O
mice	S-Species
,	O
blood	O
monocytes	O
newly	O
released	O
from	O
the	O
bone	O
marrow	O
are	O
exclusively	O
Ly	O
-	O
6Chigh	O
and	O
the	O
level	O
of	O
Ly	O
-	O
6C	O
is	O
downregulated	O
while	O
in	O
circulation	O
[	O
45	O
]	O
.	O

It	O
is	O
thus	O
suggested	O
that	O
in	O
mice	S-Species
the	O
two	O
monocyte	O
subsets	O
differing	O
in	O
Ly	O
-	O
6C	O
expression	O
represent	O
different	O
stages	O
in	O
the	O
maturation	O
pathway	O
.	O

In	O
the	O
human	S-Species
,	O
transition	O
from	O
CD16	O
-	O
monocytes	O
to	O
CD16	O
+	O
monocytes	O
is	O
observed	O
upon	O
culture	O
with	O
IL	O
-	O
10	O
,	O
M	O
-	O
CSF	O
and	O
transforming	O
growth	O
factor	O
beta	O
in	O
vitro	O
[	O
42	O
,	O
46	O
]	O
.	O

Similar	O
to	O
mouse	S-Species
monocytes	O
,	O
therefore	O
,	O
human	S-Species
peripheral	O
blood	O
CD16	O
-	O
monocytes	O
may	O
also	O
maturate	O
into	O
CD16	O
+	O
monocytes	O
.	O

It	O
is	O
reported	O
that	O
a	O
significant	O
number	O
of	O
RA	O
synovial	O
cells	O
in	O
the	O
intima	O
express	O
CD16	O
,	O
suggesting	O
that	O
CD16	O
+	O
cells	O
are	O
synovial	O
macrophages	O
[	O
47	O
]	O
.	O

We	O
confirmed	O
that	O
both	O
CD16	O
+	O
and	O
CD16	O
-	O
macrophages	O
accumulate	O
in	O
the	O
RA	O
synovium	O
by	O
double	O
-	O
color	O
immunohistochemical	O
staining	O
for	O
CD68	O
and	O
CD16	O
.	O

A	O
number	O
of	O
chemokines	O
are	O
abundantly	O
expressed	O
in	O
the	O
RA	O
synovium	O
[	O
24	O
,	O
48	O
]	O
.	O

Among	O
these	O
cytokines	O
,	O
MCP	O
-	O
1	O
,	O
MIP	O
-	O
1	O
alpha	O
,	O
SDF	O
-	O
1	O
,	O
RANTES	O
and	O
fractalkine	O
can	O
induce	O
migration	O
of	O
CD16	O
-	O
monocytes	O
in	O
vitro	O
(	O
[	O
11	O
,	O
12	O
]	O
and	O
unpublished	O
data	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
migration	O
of	O
CD16	O
+	O
monocytes	O
is	O
induced	O
only	O
by	O
fractalkine	O
.	O

These	O
chemokines	O
therefore	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
recruitment	O
of	O
CD16	O
+	O
and	O
CD16	O
-	O
monocytes	O
from	O
the	O
circulating	O
pool	O
into	O
the	O
RA	O
synovium	O
.	O

The	O
osteoclast	O
inducers	O
are	O
also	O
produced	O
in	O
the	O
RA	O
synovium	O
.	O

RANKL	O
is	O
expressed	O
by	O
synovial	O
fibroblasts	O
and	O
activated	O
T	O
cells	O
[	O
49	O
-	O
51	O
]	O
,	O
while	O
M	O
-	O
CSF	O
is	O
expressed	O
on	O
RA	O
synovial	O
macrophages	O
and	O
fibroblasts	O
[	O
52	O
,	O
53	O
]	O
.	O

TNF	O
alpha	O
and	O
IL	O
-	O
6	O
,	O
which	O
are	O
mainly	O
expressed	O
on	O
RA	O
synovial	O
macrophages	O
and	O
fibroblasts	O
,	O
respectively	O
,	O
could	O
also	O
enhance	O
osteoclast	O
differentiation	O
[	O
54	O
]	O
.	O

Collectively	O
,	O
it	O
is	O
probable	O
that	O
the	O
recruited	O
CD16	O
-	O
monocytes	O
/	O
macrophages	O
differentiate	O
into	O
osteoclasts	O
in	O
the	O
RA	O
synovium	O
,	O
and	O
contribute	O
to	O
bone	O
destruction	O
.	O

On	O
the	O
other	O
hand	O
,	O
CD16	O
+	O
monocytes	O
/	O
macrophages	O
might	O
also	O
be	O
involved	O
in	O
RA	O
pathogenesis	O
by	O
producing	O
inflammatory	O
cytokines	O
including	O
TNF	O
alpha	O
and	O
IL	O
-	O
6	O
.	O

Since	O
TNF	O
alpha	O
and	O
IL	O
-	O
6	O
enhance	O
osteoclast	O
formation	O
[	O
54	O
,	O
55	O
]	O
,	O
CD16	O
+	O
monocytes	O
/	O
macrophages	O
may	O
also	O
contribute	O
to	O
osteoclastogenesis	O
in	O
RA	O
synovium	O
.	O

Conclusion	O

We	O
have	O
shown	O
that	O
human	S-Species
peripheral	O
blood	O
monocytes	O
consist	O
of	O
two	O
functionally	O
heterogeneous	O
subsets	O
with	O
distinct	O
response	O
to	O
osteoclastogenic	O
stimuli	O
.	O

Osteoclasts	O
seem	O
to	O
originate	O
from	O
CD16	O
-	O
monocytes	O
,	O
and	O
integrin	O
beta	O
3	O
is	O
necessary	O
for	O
the	O
osteoclastogenesis	O
.	O

The	O
blockade	O
of	O
accumulation	O
and	O
activation	O
of	O
CD16	O
-	O
monocytes	O
could	O
therefore	O
be	O
a	O
beneficial	O
approach	O
as	O
an	O
anti	O
-	O
bone	O
resorptive	O
therapy	O
,	O
especially	O
for	O
RA	O
.	O

Abbreviations	O

DAP	O
=	O
DNAX	O
-	O
activation	O
protein	O
;	O
ELISA	O
=	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
FBS	O
=	O
fetal	O
bovine	S-Species
serum	O
;	O
FcR	O
gamma	O
=	O
Fc	O
receptor	O
gamma	O
chain	O
;	O
IL	O
=	O
interleukin	O
;	O
FITC	O
=	O
fluorescein	O
isothiocianate	O
;	O
mAb	O
,	O
monoclonal	O
antibody	O
;	O
M	O
-	O
CSF	O
=	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
;	O
MEM	O
=	O
modified	O
Eagle	O
'	O
s	O
medium	O
;	O
MMP	O
=	O
matrix	O
metalloproteinase	O
;	O
MNC	O
=	O
multinucleated	O
cells	O
;	O
NF	O
=	O
nuclear	O
factor	O
;	O
OSCAR	O
=	O
osteoclast	O
-	O
associated	O
receptor	O
;	O
PBS	O
=	O
phosphate	O
-	O
buffered	O
saline	O
;	O
PCR	O
=	O
polymerase	O
chain	O
reaction	O
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
;	O
RANK	O
=	O
receptor	O
activator	O
of	O
NF	O
-	O
kappa	O
B	O
;	O
RANKL	O
=	O
receptor	O
activator	O
of	O
NF	O
-	O
kappa	O
B	O
ligand	O
;	O
RT	O
=	O
reverse	O
transcriptase	O
;	O
siRNA	O
=	O
small	O
interfering	O
RNA	O
;	O
SIRP	O
-	O
beta	O
1	O
=	O
signal	O
regulatory	O
protein	O
-	O
beta	O
1	O
;	O
TNF	O
alpha	O
=	O
tumor	O
necrosis	O
factor	O
alpha	O
;	O
TRAF	O
=	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
;	O
TRAP	O
=	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
;	O
TREM	O
=	O
triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

YK	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
carried	O
out	O
the	O
experiments	O
and	O
statistical	O
analysis	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

KH	O
and	O
KT	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
its	O
coordination	O
.	O

TN	O
and	O
NM	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Embryonic	O
sympathoblasts	O
transiently	O
express	O
TrkB	O
in	O
vivo	O
and	O
proliferate	O
in	O
response	O
to	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
in	O
vitro	O

Abstract	O

Background	O

Nerve	O
growth	O
factor	O
and	O
neurotrophin	O
-	O
3	O
are	O
involved	O
in	O
the	O
development	O
of	O
sympathetic	O
neurons	O
;	O
however	O
,	O
whether	O
brain	O
derived	O
neurotrophic	O
factor	O
also	O
plays	O
a	O
role	O
is	O
not	O
known	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
BDNF	O
and	O
its	O
receptor	O
,	O
TrkB	O
,	O
are	O
expressed	O
during	O
the	O
development	O
of	O
paravertebral	O
sympathetic	O
ganglia	O
in	O
vivo	O
and	O
to	O
determine	O
the	O
effect	O
of	O
BDNF	O
in	O
vitro	O
.	O

Results	O

As	O
neural	O
crest	O
cells	O
coalesce	O
to	O
form	O
sympathetic	O
ganglia	O
,	O
TrkB	O
-	O
positive	O
cells	O
are	O
seen	O
in	O
both	O
chicken	S-Species
and	O
mouse	S-Species
embryos	O
.	O

In	O
chicken	S-Species
embryos	O
,	O
TrkB	O
-	O
expressing	O
cells	O
first	O
appear	O
at	O
Hamburger	O
-	O
Hamilton	O
Stage	O
(	O
St	O
)	O
27	O
and	O
they	O
co	O
-	O
express	O
HNK	O
-	O
1	O
,	O
confirming	O
that	O
they	O
are	O
migrating	O
neural	O
crest	O
cells	O
.	O

The	O
TrkB	O
-	O
positive	O
cells	O
lack	O
neural	O
markers	O
at	O
this	O
stage	O
;	O
however	O
,	O
they	O
migrate	O
with	O
other	O
neurally	O
differentiating	O
cells	O
that	O
are	O
TrkA	O
and	O
TrkC	O
-	O
positive	O
.	O

By	O
St	O
.	O

29	O
/	O
30	O
,	O
TrkB	O
-	O
positive	O
cells	O
begin	O
to	O
express	O
the	O
neural	O
specific	O
markers	O
Hu	O
C	O
/	O
D	O
and	O
Islet	O
-	O
1	O
;	O
eventually	O
,	O
all	O
TrkB	O
positive	O
cells	O
commence	O
neural	O
differentiation	O
.	O

By	O
St	O
.	O

34	O
,	O
TrkB	O
and	O
TrkC	O
staining	O
are	O
lost	O
.	O

BDNF	O
transcript	O
expression	O
parallels	O
that	O
of	O
TrkB	O
.	O

In	O
the	O
mouse	S-Species
,	O
TrkB	O
-	O
positive	O
cells	O
surround	O
newly	O
formed	O
sympathetic	O
ganglia	O
and	O
a	O
small	O
number	O
of	O
TrkB	O
positive	O
cells	O
that	O
co	O
-	O
express	O
tyrosine	O
hydroxylase	O
are	O
seen	O
within	O
ganglia	O
between	O
E13	O
.	O
5	O
-	O
15	O
.	O

In	O
cell	O
culture	O
,	O
many	O
cells	O
from	O
St	O
.	O

29	O
-	O
30	O
chicken	S-Species
lumbar	O
sympathetic	O
ganglia	O
express	O
neural	O
markers	O
and	O
are	O
dividing	O
,	O
indicating	O
that	O
they	O
are	O
sympathoblasts	O
.	O

Sympathoblasts	O
and	O
neurons	O
require	O
both	O
nerve	O
growth	O
factor	O
and	O
neurotrophin	O
-	O
3	O
for	O
survival	O
.	O

BDNF	O
increases	O
the	O
number	O
of	O
cells	O
expressing	O
neural	O
markers	O
in	O
culture	O
by	O
increasing	O
number	O
of	O
cells	O
that	O
incorporate	O
bromodeoxyuridine	O
.	O

In	O
contrast	O
,	O
most	O
TrkB	O
-	O
positive	O
sympathetic	O
cells	O
in	O
vivo	O
are	O
not	O
actively	O
proliferating	O
between	O
E6	O
-	O
E8	O
.	O

Conclusion	O

Developing	O
paravertebral	O
sympathetic	O
ganglia	O
in	O
avian	O
and	O
murine	O
embryos	O
contain	O
a	O
subpopulation	O
of	O
sympathoblasts	O
that	O
transiently	O
express	O
TrkB	O
and	O
ultimately	O
commence	O
neuronal	O
differentiation	O
.	O

These	O
TrkB	O
expressing	O
sympathoblasts	O
are	O
not	O
actively	O
dividing	O
in	O
vivo	O
;	O
yet	O
,	O
when	O
placed	O
in	O
vitro	O
,	O
will	O
divide	O
in	O
response	O
to	O
BDNF	O
.	O

This	O
suggests	O
that	O
the	O
availability	O
of	O
BDNF	O
in	O
vivo	O
fails	O
to	O
reach	O
a	O
threshold	O
necessary	O
to	O
induce	O
proliferation	O
.	O

We	O
suggest	O
that	O
excess	O
TrkB	O
stimulation	O
of	O
sympathoblasts	O
in	O
vivo	O
may	O
lead	O
to	O
the	O
genesis	O
of	O
neuroblastoma	O
.	O

Background	O

Neural	O
crest	O
cells	O
destined	O
to	O
become	O
paravertebral	O
sympathetic	O
neurons	O
proliferate	O
and	O
differentiate	O
during	O
migration	O
and	O
gangliogenesis	O
.	O

In	O
chicken	S-Species
embryos	O
,	O
migrating	O
neural	O
crest	O
cells	O
express	O
catecholamines	O
at	O
Hamburger	O
/	O
Hamilton	O
Stage	O
(	O
St	O
.	O
)	O
19	O
,	O
and	O
these	O
cells	O
form	O
the	O
primary	O
sympathetic	O
chain	O
dorsolateral	O
to	O
the	O
aorta	O
at	O
St	O
.	O

22	O
(	O
E3	O
.	O
5	O
)	O
[	O
1	O
]	O
.	O

Between	O
St	O
.	O

23	O
(	O
E4	O
)	O
and	O
St	O
.	O

28	O
(	O
E6	O
)	O
,	O
these	O
cells	O
disperse	O
and	O
undergo	O
a	O
secondary	O
migration	O
to	O
form	O
the	O
paravertebral	O
sympathetic	O
chain	O
that	O
resides	O
ventral	O
to	O
the	O
spinal	O
cord	O
and	O
dorsal	O
root	O
ganglion	O
[	O
1	O
]	O
.	O

After	O
ganglia	O
coalesce	O
,	O
sympathoblasts	O
express	O
markers	O
of	O
neuronal	O
differentiation	O
,	O
such	O
as	O
Q211	O
and	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
,	O
at	O
a	O
time	O
when	O
they	O
also	O
incorporate	O
[	O
3H	O
]	O
-	O
thymidine	O
[	O
2	O
]	O
.	O

Time	O
lapse	O
photography	O
has	O
shown	O
that	O
cultured	O
E15	O
.	O
5	O
-	O
E16	O
.	O
5	O
sympathetic	O
neurons	O
from	O
rat	S-Species
embryos	O
extend	O
axons	O
while	O
they	O
divide	O
[	O
3	O
-	O
5	O
]	O
.	O

Although	O
proliferation	O
appears	O
to	O
be	O
an	O
important	O
process	O
to	O
expand	O
the	O
sympathetic	O
neuron	O
population	O
during	O
differentiation	O
,	O
the	O
mechanisms	O
that	O
guide	O
sympathoblast	O
proliferation	O
have	O
not	O
been	O
identified	O
.	O

The	O
development	O
of	O
sympathetic	O
neurons	O
is	O
guided	O
by	O
neurotrophins	O
.	O

Neurotrophin	O
-	O
3	O
(	O
NT	O
-	O
3	O
)	O
binds	O
to	O
its	O
receptor	O
,	O
TrkC	O
,	O
to	O
promote	O
the	O
survival	O
of	O
cultured	O
sympathoblasts	O
from	O
early	O
lumbar	O
paravertebral	O
ganglia	O
[	O
6	O
]	O
.	O

Nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
signals	O
through	O
its	O
receptor	O
,	O
TrkA	O
,	O
to	O
promote	O
the	O
survival	O
of	O
sympathetic	O
neurons	O
upon	O
target	O
innervation	O
[	O
7	O
]	O
.	O

There	O
are	O
severe	O
sympathetic	O
defects	O
in	O
the	O
superior	O
cervical	O
ganglion	O
of	O
individual	O
NT	O
-	O
3	O
and	O
NGF	O
knockout	O
mice	S-Species
[	O
8	O
-	O
10	O
]	O
.	O

Furthermore	O
,	O
there	O
is	O
no	O
additional	O
cell	O
death	O
in	O
the	O
superior	O
cervical	O
ganglion	O
of	O
NT	O
-	O
3	O
and	O
NGF	O
double	O
knockout	O
mouse	S-Species
embryos	O
,	O
suggesting	O
that	O
all	O
of	O
the	O
neurons	O
are	O
dependent	O
on	O
both	O
neurotrophins	O
for	O
survival	O
[	O
11	O
]	O
.	O

There	O
is	O
also	O
an	O
increase	O
in	O
sympathetic	O
neuron	O
cell	O
death	O
in	O
TrkA	O
knockout	O
mice	S-Species
[	O
12	O
]	O
.	O

However	O
,	O
in	O
TrkB	O
and	O
BDNF	O
knockout	O
mice	S-Species
,	O
there	O
is	O
no	O
apparent	O
phenotype	O
in	O
the	O
superior	O
cervical	O
ganglion	O
,	O
and	O
there	O
is	O
little	O
evidence	O
that	O
TrkB	O
or	O
BDNF	O
is	O
expressed	O
in	O
sympathetic	O
ganglia	O
.	O

Thus	O
,	O
it	O
is	O
generally	O
thought	O
that	O
TrkB	O
and	O
BDNF	O
have	O
little	O
or	O
no	O
roles	O
in	O
guiding	O
the	O
development	O
of	O
sympathetic	O
neurons	O
.	O

In	O
addition	O
to	O
their	O
developmental	O
functions	O
,	O
neurotrophin	O
receptors	O
regulate	O
cell	O
behavior	O
in	O
neuroblastoma	O
,	O
a	O
tumor	O
found	O
in	O
sympathetic	O
ganglia	O
and	O
adrenal	O
medulla	O
.	O

Tumors	O
that	O
express	O
TrkA	O
often	O
spontaneously	O
regress	O
,	O
while	O
those	O
that	O
express	O
TrkB	O
and	O
its	O
ligand	O
,	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
,	O
grow	O
aggressively	O
,	O
are	O
invasive	O
,	O
and	O
fail	O
to	O
respond	O
to	O
chemotherapeutic	O
agents	O
[	O
13	O
]	O
.	O

The	O
presence	O
of	O
TrkA	O
in	O
neuroblastoma	O
tumors	O
is	O
consistent	O
with	O
its	O
expression	O
in	O
developing	O
sympathetic	O
neurons	O
,	O
and	O
suggests	O
that	O
regressive	O
neuroblastoma	O
tumors	O
arise	O
from	O
early	O
sympathetic	O
neurons	O
that	O
express	O
TrkA	O
.	O

The	O
function	O
of	O
TrkB	O
in	O
early	O
sympathetic	O
development	O
is	O
unknown	O
,	O
which	O
makes	O
understanding	O
the	O
etiology	O
of	O
aggressive	O
neuroblastoma	O
tumors	O
difficult	O
.	O

Based	O
on	O
its	O
function	O
in	O
neuroblastoma	O
tumors	O
,	O
we	O
hypothesize	O
that	O
BDNF	O
and	O
TrkB	O
expression	O
in	O
differentiating	O
sympathoblasts	O
is	O
responsible	O
for	O
expanding	O
the	O
neuronal	O
population	O
through	O
proliferation	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
BDNF	O
and	O
TrkB	O
are	O
involved	O
in	O
sympathetic	O
development	O
.	O

We	O
report	O
that	O
during	O
early	O
embryonic	O
development	O
,	O
TrkB	O
is	O
expressed	O
in	O
a	O
subset	O
of	O
differentiating	O
sympathoblasts	O
in	O
both	O
avian	O
and	O
murine	O
embryos	O
.	O

We	O
also	O
find	O
that	O
BDNF	O
promotes	O
the	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
in	O
cell	O
culture	O
.	O

However	O
,	O
the	O
majority	O
of	O
TrkB	O
positive	O
cells	O
in	O
vivo	O
fail	O
to	O
take	O
up	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
over	O
a	O
24	O
hr	O
period	O
,	O
suggesting	O
that	O
endogenous	O
BDNF	O
concentrations	O
do	O
not	O
reach	O
a	O
threshold	O
necessary	O
to	O
stimulate	O
proliferation	O
of	O
sympathoblasts	O
.	O

Shortly	O
after	O
all	O
of	O
the	O
TrkB	O
positive	O
cells	O
commence	O
neuronal	O
differentiation	O
,	O
TrkB	O
immunoreactivity	O
is	O
lost	O
.	O

These	O
results	O
suggest	O
that	O
prolonged	O
expression	O
and	O
/	O
or	O
activation	O
of	O
TrkB	O
signaling	O
at	O
these	O
early	O
stages	O
may	O
be	O
an	O
early	O
event	O
triggering	O
the	O
formation	O
of	O
neuroblastoma	O
.	O

Results	O

TrkB	O
is	O
expressed	O
during	O
migration	O
of	O
neural	O
crest	O
cells	O
to	O
sympathetic	O
ganglia	O

We	O
first	O
determined	O
whether	O
TrkB	O
is	O
expressed	O
in	O
neural	O
crest	O
-	O
derived	O
cells	O
in	O
the	O
region	O
ventral	O
to	O
the	O
spinal	O
cord	O
and	O
dorsal	O
root	O
ganglia	O
where	O
sympathetic	O
ganglia	O
coalesce	O
between	O
Hamburger	O
/	O
Hamilton	O
Stages	O
(	O
St	O
.	O
)	O
25	O
-	O
28	O
/	O
29	O
.	O

To	O
identify	O
cells	O
that	O
have	O
commenced	O
neuronal	O
differentiation	O
,	O
transverse	O
sections	O
of	O
the	O
lumbar	O
spinal	O
column	O
region	O
were	O
stained	O
with	O
antibodies	O
against	O
Hu	O
C	O
/	O
D	O
[	O
14	O
]	O
,	O
a	O
neuronal	O
-	O
specific	O
RNA	O
-	O
binding	O
protein	O
,	O
or	O
Islet	O
-	O
1	O
,	O
a	O
transcription	O
factor	O
found	O
in	O
sympathetic	O
neurons	O
[	O
15	O
]	O
.	O

We	O
found	O
that	O
Hu	O
C	O
/	O
D	O
and	O
Islet	O
-	O
1	O
are	O
expressed	O
in	O
the	O
same	O
cells	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
throughout	O
sympathetic	O
development	O
.	O

In	O
experiments	O
done	O
between	O
St	O
.	O

25	O
and	O
28	O
,	O
Islet	O
-	O
1	O
staining	O
appeared	O
weaker	O
than	O
Hu	O
C	O
/	O
D	O
staining	O
,	O
and	O
thus	O
we	O
used	O
Hu	O
C	O
/	O
D	O
to	O
identify	O
differentiating	O
neurons	O
at	O
these	O
stages	O
.	O

At	O
later	O
stages	O
,	O
Islet	O
-	O
1	O
was	O
used	O
to	O
facilitate	O
the	O
identification	O
of	O
neurons	O
because	O
of	O
the	O
nuclear	O
location	O
of	O
its	O
immunoreactivity	O
.	O

Cells	O
expressing	O
Hu	O
C	O
/	O
D	O
are	O
first	O
detected	O
at	O
St	O
.	O

25	O
ventral	O
to	O
the	O
spinal	O
cord	O
and	O
dorsal	O
root	O
ganglion	O
and	O
lateral	O
to	O
the	O
dorsal	O
aorta	O
(	O
Figure	O
1A	O
,	O
1B	O
)	O
.	O

By	O
St	O
.	O

26	O
,	O
the	O
number	O
of	O
cells	O
that	O
express	O
Hu	O
C	O
/	O
D	O
in	O
this	O
region	O
increases	O
dramatically	O
(	O
Figure	O
1C	O
)	O
.	O

TrkB	O
-	O
expressing	O
cells	O
first	O
appear	O
at	O
St	O
.	O

27	O
in	O
the	O
same	O
region	O
and	O
are	O
adjacent	O
to	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
(	O
Figure	O
1D	O
,	O
2A	O
,	O
2H	O
)	O
.	O

TrkB	O
-	O
positive	O
cells	O
co	O
-	O
localize	O
with	O
a	O
neural	O
crest	O
marker	O
,	O
HNK	O
-	O
1	O
(	O
Figures	O
2B	O
,	O
2C	O
,	O
2D	O
)	O
.	O

The	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
in	O
this	O
region	O
are	O
likely	O
to	O
be	O
sympathetic	O
neurons	O
,	O
since	O
they	O
appear	O
in	O
the	O
region	O
where	O
sympathetic	O
ganglia	O
form	O
and	O
express	O
tyrosine	O
hydroxylase	O
,	O
a	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
synthesis	O
of	O
catecholamines	O
(	O
Figures	O
2E	O
,	O
2F	O
,	O
2G	O
)	O
.	O

At	O
St	O
.	O

28	O
/	O
29	O
,	O
the	O
cells	O
begin	O
to	O
coalesce	O
ventral	O
to	O
the	O
dorsal	O
root	O
ganglion	O
and	O
the	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
and	O
TrkB	O
-	O
positive	O
cells	O
remain	O
as	O
two	O
separate	O
cell	O
populations	O
(	O
Figure	O
1E	O
)	O
;	O
however	O
,	O
shortly	O
afterwards	O
,	O
all	O
of	O
the	O
TrkB	O
-	O
positive	O
cells	O
begin	O
to	O
express	O
Islet	O
-	O
1	O
(	O
Figure	O
3B	O
)	O
and	O
Hu	O
C	O
/	O
D	O
(	O
data	O
not	O
shown	O
)	O
.	O

Developmental	O
regulation	O
of	O
TrkA	O
,	O
TrkB	O
,	O
TrkC	O
,	O
and	O
BDNF	O
expression	O

In	O
contrast	O
to	O
TrkB	O
,	O
the	O
other	O
neurotrophin	O
receptors	O
,	O
TrkA	O
and	O
TrkC	O
,	O
are	O
co	O
-	O
expressed	O
in	O
both	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
and	O
Hu	O
C	O
/	O
D	O
-	O
negative	O
cells	O
at	O
St	O
.	O

27	O
(	O
Figures	O
2I	O
,	O
2J	O
)	O
.	O

We	O
find	O
that	O
approximately	O
30	O
%	O
of	O
the	O
Islet	O
-	O
1	O
-	O
positive	O
cells	O
express	O
TrkA	O
(	O
Figure	O
3A	O
)	O
,	O
while	O
50	O
%	O
express	O
TrkB	O
(	O
Figure	O
3B	O
)	O
and	O
100	O
%	O
express	O
TrkC	O
(	O
Figure	O
3C	O
)	O
at	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
.	O

Thus	O
,	O
all	O
developing	O
neurons	O
express	O
TrkC	O
in	O
combination	O
with	O
either	O
TrkA	O
or	O
TrkB	O
.	O

By	O
St	O
.	O

31	O
(	O
E7	O
)	O
,	O
the	O
number	O
of	O
TrkA	O
-	O
positive	O
,	O
Islet	O
-	O
1	O
-	O
positive	O
cells	O
increases	O
to	O
100	O
%	O
(	O
Figure	O
3D	O
)	O
and	O
immunoreactivities	O
for	O
both	O
TrkB	O
and	O
TrkC	O
appear	O
dispersed	O
(	O
Figure	O
3E	O
,	O
3F	O
)	O
.	O

By	O
St	O
.	O

34	O
(	O
E8	O
)	O
,	O
TrkA	O
expression	O
is	O
well	O
-	O
sustained	O
(	O
Figure	O
3G	O
)	O
and	O
TrkB	O
and	O
TrkC	O
immunoreactivities	O
are	O
lost	O
(	O
Figure	O
3H	O
,	O
3I	O
)	O
.	O

We	O
also	O
examined	O
the	O
early	O
development	O
of	O
murine	O
sympathetic	O
ganglia	O
(	O
Figure	O
4	O
)	O
.	O

At	O
E13	O
,	O
the	O
newly	O
formed	O
lumbar	O
sympathetic	O
ganglia	O
can	O
be	O
observed	O
ventral	O
to	O
the	O
spinal	O
cord	O
and	O
notochord	O
by	O
their	O
staining	O
for	O
Hu	O
C	O
/	O
D	O
and	O
TH	O
(	O
Figure	O
4A	O
)	O
.	O

TrkB	O
-	O
positive	O
cells	O
can	O
be	O
seen	O
surrounding	O
developing	O
ganglia	O
,	O
as	O
well	O
as	O
in	O
occasional	O
cells	O
within	O
the	O
ganglia	O
(	O
Figure	O
4C	O
,	O
D	O
)	O
.	O

These	O
TrkB	O
-	O
positive	O
cells	O
within	O
the	O
ganglia	O
co	O
-	O
express	O
TH	O
and	O
are	O
seen	O
at	O
a	O
frequency	O
of	O
1	O
-	O
2	O
cells	O
per	O
section	O
starting	O
at	O
E13	O
(	O
Figure	O
4A	O
-	O
D	O
)	O
and	O
are	O
still	O
present	O
at	O
E15	O
.	O
5	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
neuroblastoma	O
cells	O
,	O
BDNF	O
is	O
co	O
-	O
expressed	O
with	O
TrkB	O
,	O
suggesting	O
that	O
autocrine	O
stimulation	O
is	O
a	O
means	O
by	O
which	O
proliferation	O
is	O
sustained	O
in	O
the	O
transformed	O
cells	O
.	O

To	O
test	O
whether	O
BDNF	O
,	O
the	O
ligand	O
for	O
TrkB	O
,	O
was	O
present	O
in	O
embryonic	O
chick	S-Species
sympathetic	O
ganglia	O
,	O
we	O
used	O
quantitative	O
real	O
-	O
time	O
PCR	O
with	O
TaqMan	O
probes	O
to	O
determine	O
the	O
relative	O
abundance	O
of	O
BDNF	O
transcripts	O
in	O
total	O
RNA	O
extracted	O
from	O
lumbar	O
sympathetic	O
ganglia	O
at	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
,	O
St	O
.	O

31	O
(	O
E7	O
)	O
,	O
St	O
.	O

34	O
(	O
E8	O
)	O
,	O
and	O
E9	O
.	O

BDNF	O
expression	O
within	O
the	O
ganglia	O
parallels	O
that	O
of	O
TrkB	O
:	O
BDNF	O
mRNA	O
expression	O
levels	O
are	O
highest	O
at	O
St	O
29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
,	O
and	O
these	O
levels	O
decrease	O
2	O
-	O
fold	O
at	O
St	O
.	O

31	O
(	O
E7	O
)	O
and	O
St	O
.	O

34	O
(	O
E8	O
;	O
Figure	O
5	O
)	O
.	O

By	O
E9	O
,	O
BDNF	O
levels	O
are	O
7	O
times	O
lower	O
than	O
at	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
;	O
Figure	O
5	O
)	O
.	O

NT3	O
and	O
NGF	O
promote	O
survival	O
of	O
differentiating	O
sympathetic	O
neurons	O
in	O
culture	O

To	O
determine	O
the	O
effect	O
of	O
neurotrophins	O
,	O
we	O
cultured	O
cells	O
dispersed	O
from	O
lumbar	O
sympathetic	O
ganglia	O
at	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
because	O
,	O
at	O
this	O
stage	O
,	O
ganglion	O
formation	O
is	O
complete	O
,	O
the	O
number	O
of	O
TrkA	O
-	O
,	O
TrkB	O
-	O
,	O
and	O
TrkC	O
-	O
positive	O
cells	O
have	O
peaked	O
,	O
and	O
all	O
Trk	O
-	O
expressing	O
cells	O
have	O
initiated	O
neural	O
differentiation	O
.	O

First	O
,	O
we	O
identified	O
markers	O
expressed	O
by	O
acutely	O
isolated	O
cells	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
80	O
-	O
91	O
%	O
of	O
the	O
cells	O
are	O
p75	O
neurotrophin	O
receptor	O
(	O
NTR	O
)	O
-	O
positive	O
,	O
indicating	O
that	O
most	O
of	O
the	O
cells	O
are	O
neural	O
crest	O
-	O
derived	O
and	O
little	O
mesenchymal	O
contamination	O
is	O
introduced	O
by	O
the	O
isolation	O
procedure	O
.	O

In	O
addition	O
,	O
28	O
-	O
33	O
%	O
of	O
the	O
cultured	O
cells	O
express	O
the	O
neural	O
marker	O
Hu	O
C	O
/	O
D	O
.	O

Approximately	O
half	O
of	O
these	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
express	O
TrkB	O
.	O

Conversely	O
,	O
all	O
of	O
the	O
TrkB	O
positive	O
cells	O
express	O
Hu	O
C	O
/	O
D	O
.	O

These	O
TrkB	O
-	O
positive	O
cells	O
comprise	O
approximately	O
14	O
-	O
17	O
%	O
of	O
the	O
total	O
cell	O
population	O
.	O

We	O
then	O
determined	O
how	O
many	O
of	O
the	O
acutely	O
isolated	O
cells	O
were	O
proliferating	O
by	O
incubating	O
them	O
for	O
12	O
hrs	O
in	O
BrdU	O
-	O
containing	O
medium	O
.	O

For	O
these	O
experiments	O
,	O
we	O
identified	O
differentiating	O
neurons	O
with	O
the	O
transcription	O
factor	O
Islet	O
-	O
1	O
because	O
this	O
marker	O
labels	O
nuclei	O
,	O
thus	O
it	O
co	O
localizes	O
with	O
any	O
BrdU	O
that	O
has	O
been	O
incorporated	O
into	O
the	O
DNA	O
,	O
allowing	O
us	O
to	O
determine	O
whether	O
the	O
cell	O
had	O
undergone	O
S	O
-	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

After	O
12	O
hrs	O
in	O
BrdU	O
,	O
59	O
%	O
of	O
Islet	O
-	O
1	O
-	O
positive	O
nuclei	O
stain	O
for	O
BrdU	O
immunoreactivity	O
.	O

Thus	O
,	O
cultures	O
of	O
St	O
.	O

29	O
/	O
30	O
sympathetic	O
ganglia	O
contain	O
many	O
cells	O
that	O
proliferate	O
while	O
exhibiting	O
markers	O
of	O
neuronal	O
differentiation	O
,	O
confirming	O
previous	O
observations	O
[	O
2	O
]	O
.	O

We	O
call	O
these	O
dividing	O
neuronal	O
precursors	O
sympathoblasts	O
.	O

The	O
remaining	O
non	O
-	O
BrdU	O
incorporating	O
,	O
Islet	O
-	O
1	O
positive	O
cells	O
are	O
likely	O
to	O
be	O
post	O
mitotic	O
neurons	O
.	O

Finally	O
,	O
we	O
determined	O
the	O
trophic	O
requirements	O
of	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
sympathetic	O
neurons	O
and	O
sympathoblasts	O
.	O

We	O
monitored	O
cultures	O
over	O
a	O
three	O
day	O
period	O
after	O
plating	O
and	O
counted	O
the	O
number	O
of	O
phase	O
bright	O
cells	O
with	O
neurites	O
,	O
a	O
morphological	O
feature	O
of	O
both	O
neurons	O
and	O
sympathoblasts	O
.	O

In	O
the	O
absence	O
of	O
trophic	O
factors	O
,	O
more	O
than	O
2	O
/	O
3	O
of	O
the	O
cells	O
die	O
by	O
24	O
hours	O
in	O
culture	O
and	O
BDNF	O
,	O
NT	O
-	O
3	O
,	O
or	O
NGF	O
alone	O
is	O
not	O
sufficient	O
to	O
promote	O
survival	O
(	O
Figure	O
6	O
)	O
.	O

However	O
,	O
NGF	O
together	O
with	O
NT	O
-	O
3	O
supports	O
the	O
survival	O
of	O
a	O
significantly	O
larger	O
number	O
of	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

For	O
the	O
subsequent	O
experiments	O
,	O
all	O
neurons	O
were	O
cultured	O
with	O
25	O
ng	O
/	O
ml	O
NT	O
-	O
3	O
and	O
1	O
mu	O
g	O
/	O
ml	O
7S	O
NGF	O
to	O
optimize	O
survival	O
.	O

BDNF	O
promotes	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
sympathetic	O
neurons	O
in	O
culture	O

To	O
determine	O
the	O
effects	O
of	O
BDNF	O
,	O
cultures	O
of	O
cells	O
from	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
sympathetic	O
ganglia	O
were	O
supplemented	O
with	O
200	O
ng	O
/	O
ml	O
BDNF	O
and	O
the	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
were	O
counted	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
hours	O
using	O
phase	O
microscopy	O
(	O
Figure	O
7A	O
)	O
.	O

A	O
1	O
.	O
6	O
-	O
fold	O
increase	O
in	O
the	O
number	O
of	O
neurons	O
due	O
to	O
BDNF	O
is	O
observed	O
by	O
24	O
hours	O
and	O
this	O
number	O
does	O
not	O
increase	O
further	O
at	O
48	O
or	O
72	O
hours	O
.	O

This	O
effect	O
of	O
BDNF	O
is	O
concentration	O
-	O
dependent	O
with	O
an	O
EC50	O
of	O
75	O
ng	O
/	O
ml	O
(	O
Figure	O
7B	O
)	O
.	O

To	O
test	O
whether	O
the	O
increase	O
in	O
the	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
caused	O
by	O
BDNF	O
is	O
due	O
to	O
the	O
differentiation	O
of	O
pluripotent	O
neural	O
crest	O
cells	O
,	O
we	O
quantified	O
the	O
effects	O
of	O
BDNF	O
on	O
the	O
number	O
of	O
neurally	O
differentiating	O
cells	O
(	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
)	O
versus	O
the	O
number	O
of	O
non	O
-	O
neuronal	O
cells	O
(	O
Hu	O
C	O
/	O
D	O
-	O
negative	O
)	O
after	O
identifying	O
all	O
neural	O
crest	O
-	O
derived	O
cells	O
by	O
staining	O
for	O
p75NTR	O
in	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
cultures	O
.	O

If	O
BDNF	O
increases	O
the	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
by	O
inducing	O
a	O
non	O
-	O
neuronal	O
cell	O
to	O
express	O
Hu	O
C	O
/	O
D	O
,	O
then	O
we	O
expected	O
that	O
the	O
total	O
cell	O
number	O
would	O
remain	O
the	O
same	O
and	O
that	O
there	O
would	O
be	O
a	O
decrease	O
in	O
the	O
number	O
of	O
non	O
-	O
neuronal	O
cells	O
as	O
well	O
as	O
a	O
corresponding	O
increase	O
in	O
the	O
number	O
of	O
neurons	O
.	O

After	O
24	O
hours	O
,	O
BDNF	O
significantly	O
increases	O
the	O
number	O
of	O
p75NTR	O
-	O
positive	O
cells	O
as	O
well	O
as	O
the	O
number	O
of	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
(	O
Figure	O
8A	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
change	O
in	O
the	O
number	O
of	O
non	O
-	O
neuronal	O
cells	O
.	O

Thus	O
,	O
it	O
is	O
unlikely	O
that	O
BDNF	O
increases	O
the	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
by	O
inducing	O
differentiation	O
of	O
non	O
-	O
neuronal	O
cells	O
.	O

To	O
determine	O
whether	O
the	O
increase	O
in	O
the	O
total	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
is	O
caused	O
by	O
BDNF	O
-	O
induced	O
proliferation	O
,	O
control	O
and	O
BDNF	O
-	O
treated	O
sympathetic	O
cultures	O
were	O
exposed	O
to	O
BrdU	O
for	O
12	O
hours	O
after	O
plating	O
,	O
and	O
the	O
number	O
of	O
cells	O
that	O
incorporated	O
BrdU	O
into	O
their	O
DNA	O
was	O
determined	O
after	O
24	O
hours	O
in	O
culture	O
.	O

Even	O
in	O
the	O
control	O
condition	O
,	O
a	O
number	O
of	O
cells	O
in	O
the	O
culture	O
are	O
dividing	O
,	O
giving	O
a	O
high	O
baseline	O
of	O
BrdU	O
incorporation	O
(	O
Figure	O
8B	O
)	O
.	O

When	O
BDNF	O
is	O
added	O
,	O
the	O
total	O
number	O
of	O
BrdU	O
positive	O
cells	O
increases	O
approximately	O
1	O
.	O
6	O
-	O
fold	O
(	O
Figure	O
8B	O
)	O
.	O

This	O
BDNF	O
-	O
induced	O
increase	O
in	O
the	O
total	O
number	O
of	O
BrdU	O
positive	O
cells	O
occurs	O
in	O
sympathoblasts	O
because	O
the	O
number	O
of	O
Islet	O
-	O
1	O
-	O
positive	O
nuclei	O
from	O
control	O
cultures	O
that	O
label	O
with	O
BrdU	O
is	O
268	O
+/-	O
59	O
and	O
BDNF	O
treatment	O
raises	O
this	O
number	O
to	O
424	O
+/-	O
80	O
,	O
which	O
corresponds	O
to	O
an	O
increase	O
of	O
1	O
.	O
6	O
-	O
fold	O
.	O

This	O
accounts	O
for	O
the	O
1	O
.	O
6	O
-	O
fold	O
increase	O
in	O
total	O
neuron	O
number	O
and	O
total	O
BrdU	O
-	O
positive	O
cells	O
described	O
above	O
.	O

We	O
then	O
confirmed	O
that	O
BDNF	O
acts	O
on	O
TrkB	O
-	O
positive	O
cells	O
:	O
BDNF	O
increases	O
the	O
number	O
of	O
TrkB	O
-	O
expressing	O
cells	O
that	O
incorporate	O
BrdU	O
2	O
.	O
6	O
-	O
4	O
-	O
fold	O
over	O
control	O
(	O
Table	O
2	O
)	O
and	O
it	O
also	O
increases	O
the	O
overall	O
number	O
of	O
TrkB	O
-	O
positive	O
cells	O
2	O
-	O
2	O
.	O
5	O
-	O
fold	O
over	O
control	O
(	O
Table	O
2	O
)	O
.	O

BDNF	O
does	O
not	O
increase	O
the	O
number	O
of	O
BrdU	O
-	O
positive	O
,	O
TrkB	O
-	O
negative	O
cells	O
or	O
the	O
overall	O
number	O
of	O
TrkB	O
-	O
negative	O
cells	O
(	O
Table	O
2	O
)	O
.	O

In	O
further	O
support	O
that	O
BDNF	O
acts	O
directly	O
on	O
TrkB	O
-	O
expressing	O
cells	O
,	O
an	O
antibody	O
directed	O
against	O
the	O
extracellular	O
domain	O
of	O
TrkB	O
completely	O
prevents	O
the	O
effect	O
of	O
BDNF	O
in	O
promoting	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
,	O
but	O
not	O
TrkB	O
-	O
negative	O
cells	O
(	O
compare	O
Figure	O
9A	O
to	O
9B	O
)	O
.	O

Thus	O
,	O
the	O
effect	O
of	O
BDNF	O
is	O
restricted	O
to	O
the	O
population	O
that	O
expresses	O
TrkB	O
,	O
which	O
are	O
developing	O
sympathoblasts	O
.	O

To	O
determine	O
whether	O
TrkB	O
-	O
positive	O
cells	O
are	O
actively	O
proliferating	O
in	O
vivo	O
,	O
embryos	O
were	O
injected	O
with	O
BrdU	O
at	O
St	O
.	O

27	O
and	O
harvested	O
at	O
St	O
.	O

29	O
,	O
approximately	O
24	O
hrs	O
later	O
.	O

The	O
majority	O
(	O
85	O
-	O
90	O
%	O
)	O
of	O
TrkB	O
-	O
positive	O
cells	O
do	O
not	O
incorporate	O
BrdU	O
into	O
their	O
nuclei	O
under	O
basal	O
conditions	O
in	O
vivo	O
(	O
Figure	O
10	O
)	O
,	O
although	O
a	O
few	O
TrkB	O
positive	O
cells	O
with	O
labeled	O
nuclei	O
could	O
be	O
observed	O
(	O
arrows	O
)	O
.	O

This	O
contrasts	O
with	O
our	O
observation	O
that	O
71	O
-	O
76	O
%	O
of	O
TrkB	O
-	O
positive	O
cells	O
incorporate	O
BrdU	O
in	O
culture	O
after	O
treatment	O
with	O
BDNF	O
(	O
Table	O
2	O
)	O
,	O
suggesting	O
that	O
endogenous	O
BDNF	O
does	O
not	O
achieve	O
a	O
threshold	O
sufficient	O
to	O
support	O
a	O
high	O
level	O
of	O
sympathoblast	O
proliferation	O
in	O
vivo	O
.	O

Discussion	O

We	O
report	O
that	O
the	O
neurotrophin	O
receptor	O
TrkB	O
is	O
expressed	O
in	O
a	O
subset	O
of	O
embryonic	O
sympathoblasts	O
during	O
the	O
early	O
development	O
of	O
lumbar	O
paravertebral	O
sympathetic	O
ganglia	O
in	O
chicken	S-Species
and	O
mouse	S-Species
embryos	O
.	O

In	O
the	O
chicken	S-Species
,	O
TrkB	O
expression	O
is	O
transient	O
,	O
and	O
completely	O
lost	O
by	O
St	O
34	O
(	O
E8	O
)	O
.	O

Since	O
BDNF	O
induces	O
the	O
proliferation	O
of	O
sympathoblasts	O
in	O
cell	O
culture	O
,	O
yet	O
in	O
vivo	O
there	O
is	O
little	O
proliferation	O
observed	O
in	O
TrkB	O
-	O
positive	O
cells	O
in	O
nascent	O
ganglia	O
,	O
we	O
propose	O
that	O
if	O
TrkB	O
activation	O
becomes	O
unregulated	O
by	O
excess	O
BDNF	O
or	O
constitutive	O
phosphorylation	O
of	O
TrkB	O
[	O
16	O
]	O
,	O
this	O
transient	O
population	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
may	O
trigger	O
the	O
genesis	O
of	O
neuroblastoma	O
,	O
a	O
childhood	O
tumor	O
found	O
in	O
the	O
paravertebral	O
chain	O
and	O
adrenal	O
medulla	O
.	O

The	O
two	O
populations	O
of	O
sympathoblasts	O
that	O
we	O
observe	O
support	O
previous	O
findings	O
of	O
heterogeneity	O
among	O
developing	O
sympathetic	O
neurons	O
and	O
neural	O
crest	O
cells	O
.	O

Early	O
sympathetic	O
ganglia	O
contain	O
at	O
least	O
two	O
subpopulations	O
:	O
early	O
differentiating	O
neurons	O
that	O
lack	O
TrkB	O
expression	O
and	O
express	O
TrkA	O
and	O
TrkC	O
,	O
and	O
late	O
differentiating	O
sympathoblasts	O
that	O
express	O
TrkB	O
.	O

Explant	O
cultures	O
of	O
sympathetic	O
ganglia	O
from	O
E16	O
chick	S-Species
embryos	O
give	O
rise	O
to	O
two	O
neuronal	O
populations	O
:	O
one	O
that	O
remains	O
close	O
to	O
the	O
explant	O
,	O
and	O
one	O
that	O
migrates	O
away	O
from	O
the	O
explant	O
[	O
1	O
]	O
.	O

In	O
addition	O
,	O
early	O
neuronal	O
subpopulations	O
have	O
been	O
observed	O
in	O
cultures	O
of	O
neural	O
crest	O
cells	O
from	O
St	O
.	O

13	O
/	O
14	O
quail	O
embryos	O
as	O
evidenced	O
by	O
the	O
expression	O
of	O
neuronal	O
cell	O
type	O
-	O
specific	O
gangliosides	O
[	O
17	O
]	O
.	O

Perhaps	O
these	O
different	O
subpopulations	O
will	O
ultimately	O
give	O
rise	O
to	O
the	O
two	O
neurochemically	O
distinct	O
populations	O
found	O
in	O
lumbar	O
sympathetic	O
ganglia	O
:	O
the	O
noradrenergic	O
,	O
NPY	O
-	O
containing	O
neurons	O
that	O
innervate	O
internal	O
organs	O
and	O
enteric	O
ganglia	O
and	O
the	O
cholinergic	O
,	O
VIP	O
-	O
containing	O
neurons	O
that	O
innervate	O
vasculature	O
in	O
the	O
hind	O
limbs	O
.	O

The	O
effects	O
of	O
BDNF	O
and	O
TrkB	O
deletion	O
and	O
over	O
expression	O
have	O
been	O
studied	O
on	O
superior	O
cervical	O
ganglion	O
and	O
preganglionic	O
neurons	O
in	O
thoracic	O
segments	O
of	O
the	O
spinal	O
column	O
,	O
but	O
not	O
on	O
paravertebral	O
sympathetic	O
neurons	O
.	O

In	O
the	O
superior	O
cervical	O
ganglion	O
,	O
an	O
increase	O
in	O
the	O
number	O
of	O
neurons	O
of	O
BDNF	O
null	O
mice	S-Species
is	O
likely	O
due	O
to	O
apoptosis	O
induced	O
by	O
BDNF	O
via	O
p75NTR	O
[	O
18	O
]	O
.	O

In	O
contrast	O
,	O
the	O
responses	O
of	O
paravertebral	O
sympathetic	O
neurons	O
to	O
BDNF	O
are	O
complex	O
and	O
subtype	O
dependent	O
.	O

Over	O
expression	O
of	O
BDNF	O
leads	O
to	O
an	O
increase	O
in	O
the	O
number	O
of	O
noradrenergic	O
fibers	O
innervating	O
the	O
erector	O
pilli	O
muscles	O
of	O
hair	O
follicles	O
,	O
while	O
noradrenergic	O
fibers	O
innervating	O
blood	O
vessels	O
were	O
unaffected	O
[	O
19	O
]	O
.	O

If	O
our	O
results	O
indicating	O
that	O
BDNF	O
promotes	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
in	O
the	O
chicken	S-Species
embryo	O
can	O
be	O
extrapolated	O
to	O
the	O
subset	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
in	O
murine	O
ganglia	O
,	O
then	O
these	O
TrkB	O
-	O
positive	O
cells	O
may	O
be	O
neurons	O
destined	O
to	O
innervate	O
the	O
erector	O
pilli	O
.	O

In	O
other	O
studies	O
,	O
TrkB	O
null	O
mice	S-Species
showed	O
no	O
changes	O
in	O
morphology	O
or	O
cell	O
number	O
in	O
superior	O
cervical	O
ganglia	O
[	O
12	O
]	O
or	O
in	O
the	O
intermediolateral	O
column	O
[	O
20	O
]	O
;	O
but	O
this	O
may	O
not	O
be	O
predictive	O
of	O
a	O
phenotype	O
in	O
the	O
lumbar	O
paravertebral	O
chain	O
.	O

It	O
is	O
thus	O
possible	O
that	O
BDNF	O
/	O
TrkB	O
signaling	O
could	O
play	O
a	O
specific	O
role	O
in	O
other	O
regions	O
of	O
the	O
paravertebral	O
sympathetic	O
chain	O
,	O
such	O
as	O
the	O
lumbar	O
region	O
.	O

However	O
,	O
if	O
TrkB	O
-	O
positive	O
cells	O
are	O
not	O
normally	O
actively	O
proliferating	O
in	O
vivo	O
,	O
then	O
it	O
would	O
not	O
be	O
surprising	O
that	O
the	O
development	O
of	O
the	O
paravertebral	O
sympathetic	O
chain	O
is	O
not	O
disrupted	O
in	O
TrkB	O
or	O
BDNF	O
null	O
mice	S-Species
.	O

It	O
may	O
be	O
more	O
informative	O
to	O
examine	O
mice	S-Species
that	O
over	O
express	O
BDNF	O
on	O
a	O
promoter	O
that	O
targets	O
expression	O
to	O
embryonic	O
lumbar	O
ganglia	O
.	O

Unfortunately	O
,	O
such	O
mice	S-Species
do	O
not	O
exist	O
.	O

Our	O
findings	O
that	O
the	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
sympathoblasts	O
are	O
dependent	O
on	O
both	O
NT	O
-	O
3	O
and	O
NGF	O
for	O
survival	O
in	O
culture	O
are	O
consistent	O
with	O
previous	O
work	O
on	O
mouse	S-Species
sympathoblasts	O
from	O
the	O
superior	O
cervical	O
ganglion	O
[	O
11	O
]	O
.	O

In	O
these	O
studies	O
,	O
NT	O
-	O
3	O
and	O
NGF	O
deletion	O
separately	O
led	O
to	O
a	O
decrease	O
in	O
the	O
number	O
of	O
sympathetic	O
neurons	O
at	O
E17	O
.	O
5	O
compared	O
to	O
control	O
.	O

Deletion	O
of	O
both	O
NT	O
-	O
3	O
and	O
NGF	O
together	O
did	O
not	O
enhance	O
cell	O
death	O
.	O

In	O
contrast	O
,	O
cultured	O
rat	S-Species
superior	O
cervical	O
ganglion	O
sympathetic	O
neurons	O
respond	O
to	O
NT	O
-	O
3	O
at	O
E14	O
.	O
5	O
and	O
then	O
to	O
NGF	O
at	O
E19	O
.	O
5	O
,	O
although	O
time	O
points	O
in	O
between	O
were	O
not	O
analyzed	O
[	O
6	O
]	O
.	O

In	O
addition	O
to	O
promoting	O
survival	O
,	O
NT	O
-	O
3	O
,	O
NGF	O
,	O
and	O
BDNF	O
also	O
induce	O
proliferation	O
of	O
various	O
neuronal	O
precursors	O
at	O
different	O
stages	O
of	O
development	O
.	O

NT	O
-	O
3	O
can	O
promote	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
-	O
thymidine	O
into	O
cultured	O
quail	O
neural	O
crest	O
cells	O
from	O
the	O
trunk	O
region	O
[	O
21	O
,	O
22	O
]	O
,	O
Later	O
in	O
rat	S-Species
sympathetic	O
development	O
,	O
NT	O
-	O
3	O
supports	O
survival	O
of	O
neurons	O
,	O
but	O
does	O
not	O
promote	O
proliferation	O
[	O
6	O
]	O
,	O
which	O
is	O
consistent	O
with	O
our	O
results	O
.	O

NGF	O
promotes	O
an	O
increase	O
in	O
BrdU	O
incorporation	O
from	O
25	O
%	O
to	O
35	O
%	O
in	O
the	O
DRG	O
cervical	O
segment	O
2	O
in	O
the	O
chick	S-Species
embryo	O
[	O
23	O
]	O
.	O

In	O
chicken	S-Species
embryos	O
that	O
are	O
treated	O
with	O
NGF	O
in	O
ovo	O
at	O
St	O
.	O

18	O
and	O
21	O
,	O
there	O
is	O
an	O
increase	O
in	O
BrdU	O
uptake	O
after	O
formation	O
of	O
the	O
primary	O
sympathetic	O
chain	O
at	O
St	O
.	O

23	O
[	O
24	O
]	O
.	O

Since	O
NGF	O
does	O
not	O
appear	O
to	O
affect	O
proliferation	O
of	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
chick	S-Species
sympathoblasts	O
,	O
NGF	O
may	O
only	O
promote	O
proliferation	O
in	O
primary	O
,	O
but	O
not	O
secondary	O
chain	O
sympathoblasts	O
.	O

Motor	O
neuron	O
progenitors	O
in	O
the	O
ventral	O
neural	O
tube	O
from	O
the	O
chick	S-Species
embryo	O
express	O
TrkB	O
and	O
when	O
ventral	O
neural	O
tube	O
explants	O
are	O
treated	O
with	O
BDNF	O
,	O
there	O
is	O
an	O
increase	O
in	O
the	O
number	O
of	O
motor	O
neurons	O
produced	O
and	O
BrdU	O
incorporation	O
[	O
25	O
]	O
.	O

BDNF	O
also	O
promotes	O
the	O
proliferation	O
of	O
cultured	O
neuroblastoma	O
cells	O
[	O
13	O
]	O
.	O

Taken	O
together	O
,	O
these	O
results	O
are	O
consistent	O
with	O
our	O
findings	O
that	O
NT	O
-	O
3	O
and	O
NGF	O
do	O
not	O
promote	O
proliferation	O
of	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
sympathoblasts	O
,	O
and	O
support	O
the	O
assertion	O
that	O
BDNF	O
promotes	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
in	O
culture	O
.	O

Our	O
observations	O
suggest	O
a	O
transient	O
function	O
of	O
TrkB	O
during	O
early	O
sympathetic	O
development	O
in	O
supporting	O
proliferation	O
of	O
this	O
early	O
subpopulation	O
of	O
sympathoblasts	O
.	O

However	O
,	O
the	O
in	O
vivo	O
labeling	O
suggests	O
that	O
only	O
a	O
minority	O
(	O
10	O
-	O
20	O
%	O
)	O
of	O
this	O
population	O
is	O
dividing	O
during	O
the	O
window	O
that	O
TrkB	O
is	O
expressed	O
.	O

In	O
light	O
of	O
the	O
very	O
strong	O
proliferative	O
effect	O
produced	O
in	O
cell	O
culture	O
,	O
these	O
TrkB	O
expressing	O
cells	O
could	O
respond	O
more	O
strongly	O
if	O
endogenous	O
BDNF	O
rises	O
to	O
higher	O
levels	O
,	O
or	O
if	O
the	O
mechanism	O
that	O
down	O
regulates	O
TrkB	O
expression	O
becomes	O
nonfunctional	O
.	O

Such	O
events	O
could	O
trigger	O
an	O
early	O
proliferative	O
event	O
that	O
leads	O
to	O
a	O
cascade	O
of	O
changes	O
that	O
initiates	O
transformation	O
of	O
cells	O
to	O
neuroblastoma	O
.	O

Thus	O
,	O
these	O
early	O
TrkB	O
expressing	O
cells	O
help	O
solve	O
the	O
puzzle	O
as	O
to	O
why	O
TrkB	O
is	O
expressed	O
in	O
aggressive	O
and	O
invasive	O
forms	O
of	O
neuroblastoma	O
,	O
particularly	O
because	O
BDNF	O
induces	O
cultured	O
neuroblastoma	O
cells	O
to	O
become	O
more	O
proliferative	O
,	O
invasive	O
,	O
angiogenic	O
,	O
and	O
resistant	O
to	O
chemotherapeutic	O
reagents	O
than	O
untreated	O
cultures	O
[	O
13	O
]	O
.	O

Future	O
studies	O
will	O
determine	O
whether	O
constitutive	O
expression	O
of	O
BDNF	O
and	O
TrkB	O
in	O
the	O
chick	S-Species
embryo	O
sustains	O
proliferation	O
of	O
differentiating	O
sympathoblasts	O
.	O

Conclusion	O

We	O
have	O
identified	O
a	O
time	O
point	O
during	O
development	O
when	O
differentiating	O
lumbar	O
sympathetic	O
neurons	O
transiently	O
express	O
TrkB	O
and	O
proliferate	O
in	O
response	O
to	O
high	O
concentrations	O
of	O
BDNF	O
in	O
culture	O
.	O

These	O
studies	O
suggest	O
that	O
elevated	O
BDNF	O
expression	O
above	O
basal	O
levels	O
and	O
signaling	O
through	O
TrkB	O
may	O
be	O
a	O
mechanism	O
that	O
contributes	O
to	O
the	O
onset	O
of	O
neuroblastoma	O
.	O

A	O
further	O
understanding	O
of	O
the	O
two	O
populations	O
of	O
sympathetic	O
neurons	O
and	O
the	O
fate	O
of	O
the	O
TrkB	O
-	O
positive	O
cells	O
will	O
provide	O
additional	O
insight	O
into	O
the	O
development	O
of	O
paravertebral	O
sympathetic	O
ganglia	O
and	O
the	O
genesis	O
of	O
neuroblastoma	O
.	O

Methods	O

Preparation	O
of	O
tissue	O
for	O
immunohistochemistry	O

The	O
lumbar	O
spinal	O
column	O
and	O
surrounding	O
tissues	O
were	O
dissected	O
from	O
chicken	S-Species
embryos	O
at	O
the	O
indicated	O
stages	O
and	O
placed	O
in	O
Zamboni	O
'	O
s	O
fixative	O
(	O
4	O
%	O
(	O
w	O
/	O
v	O
)	O
paraformaldehyde	O
,	O
15	O
%	O
(	O
v	O
/	O
v	O
)	O
picric	O
acid	O
in	O
0	O
.	O
1	O
M	O
sodium	O
phosphate	O
buffer	O
,	O
pH	O
7	O
.	O
4	O
)	O
for	O
two	O
hours	O
at	O
room	O
temperature	O
.	O

Mouse	S-Species
embryos	O
at	O
13	O
-	O
15	O
days	O
post	O
-	O
coitus	O
were	O
collected	O
according	O
to	O
an	O
IACUC	O
-	O
approved	O
protocol	O
to	O
Dr	O
.	O
L	O
.	O

Sherman	O
at	O
the	O
Oregon	O
Health	O
and	O
Science	O
University	O
.	O

The	O
mouse	S-Species
embryos	O
were	O
immersion	O
-	O
fixed	O
in	O
Zamboni	O
'	O
s	O
fixative	O
overnight	O
at	O
4	O
degrees	O
C	O
then	O
washed	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
;	O
130	O
mM	O
NaCl	O
,	O
20	O
mM	O
sodium	O
phosphate	O
buffer	O
,	O
pH	O
7	O
.	O
4	O
)	O
.	O

Fixed	O
tissues	O
were	O
equilibrated	O
in	O
30	O
%	O
sucrose	O
in	O
1	O
x	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
.	O

Fixed	O
mouse	S-Species
embryos	O
were	O
shipped	O
to	O
Vermont	O
in	O
sucrose	O
.	O

Transverse	O
30	O
mu	O
M	O
sections	O
of	O
the	O
spinal	O
columns	O
were	O
cut	O
at	O
on	O
a	O
Microm	O
HM	O
cryostat	O
(	O
knife	O
temperature	O
:	O
16	O
degrees	O
C	O
;	O
object	O
temperature	O
:	O
23	O
degrees	O
C	O
)	O
and	O
collected	O
on	O
Superfrost	O
Plus	O
slides	O
(	O
Fisher	O
)	O
.	O

Sections	O
were	O
dried	O
at	O
room	O
temperature	O
,	O
washed	O
in	O
1	O
x	O
PBS	O
and	O
incubated	O
overnight	O
in	O
blocking	O
buffer	O
(	O
1	O
x	O
PBS	O
consisting	O
of	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
heat	O
-	O
inactivated	O
horse	S-Species
serum	O
(	O
Invitrogen	O
/	O
Gibco	O
)	O
,	O
0	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
(	O
Sigma	O
)	O
,	O
and	O
0	O
.	O
1	O
%	O
sodium	O
azide	O
(	O
Fisher	O
)	O
)	O
.	O

Immunohistochemistry	O

Sections	O
were	O
incubated	O
with	O
primary	O
antibodies	O
overnight	O
at	O
4	O
degrees	O
C	O
,	O
followed	O
by	O
incubation	O
with	O
secondary	O
antibodies	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

Primary	O
antibodies	O
used	O
were	O
:	O
rabbit	S-Species
anti	O
-	O
p75	O
(	O
1	O
:	O
1500	O
,	O
generous	O
gift	O
from	O
Louis	O
Reichardt	O
,	O
UCSF	O
[	O
26	O
]	O
)	O
,	O
mouse	S-Species
IgG2b	O
anti	O
-	O
Hu	O
C	O
/	O
D	O
,	O
(	O
1	O
:	O
250	O
,	O
Molecular	O
Probes	O
)	O
;	O
mouse	S-Species
IgG1	O
anti	O
-	O
Islet	O
-	O
1	O
,	O
(	O
1	O
:	O
10	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
)	O
;	O
rabbit	S-Species
anti	O
-	O
chicken	S-Species
TrkA	O
(	O
1	O
:	O
500	O
)	O
;	O
rabbit	S-Species
anti	O
-	O
chicken	S-Species
TrkB	O
(	O
1	O
:	O
500	O
)	O
;	O
rabbit	S-Species
anti	O
-	O
chicken	S-Species
TrkC	O
(	O
1	O
:	O
500	O
)	O
(	O
all	O
Trk	O
antibodies	O
were	O
generous	O
gifts	O
of	O
Dr	O
.	O
Louis	O
Reichardt	O
,	O
UCSF	O
[	O
26	O
-	O
28	O
]	O
)	O
;	O
mouse	S-Species
anti	O
-	O
HNK	O
-	O
1	O
(	O
1	O
:	O
50	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
)	O
;	O
mouse	S-Species
IgG2a	O
anti	O
-	O
tyrosine	O
hydroxylase	O
(	O
1	O
:	O
10	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
)	O
,	O
sheep	S-Species
anti	O
-	O
BrdU	O
(	O
1	O
:	O
100	O
,	O
Biodesign	O
International	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
tyrosine	O
hydroxylase	O
(	O
1	O
:	O
100	O
,	O
Chemicon	O
)	O
,	O
and	O
goat	S-Species
anti	O
-	O
TrkB	O
(	O
1	O
:	O
1000	O
,	O
R	O
&	O
D	O
Systems	O
)	O
.	O

Immunofluorescence	O
was	O
imaged	O
using	O
a	O
Nikon	O
C1	O
confocal	O
mounted	O
on	O
a	O
Nikon	O
Eclipse	O
E800	O
microscope	O
with	O
a	O
10	O
x	O
Plan	O
Apo	O
(	O
NA	O
0	O
.	O
785	O
)	O
air	O
objective	O
or	O
a	O
60	O
x	O
Plan	O
Apo	O
(	O
NA	O
1	O
.	O
4	O
)	O
oil	O
objective	O
lens	O
,	O
E7	O
-	O
C1	O
software	O
,	O
and	O
UV	O
,	O
Argon	O
,	O
and	O
He	O
/	O
Ne	O
lasers	O
exciting	O
at	O
408	O
,	O
488	O
,	O
and	O
543	O
nm	O
and	O
emitting	O
at	O
404	O
500	O
-	O
530	O
,	O
and	O
555	O
-	O
615	O
nm	O
,	O
respectively	O
.	O

A	O
Nikon	O
Eclipse	O
E800	O
microscope	O
in	O
the	O
nearby	O
COBRE	O
Molecular	O
/	O
Cellular	O
Core	O
Facility	O
was	O
used	O
for	O
counting	O
immunofluorescent	O
cells	O
at	O
200	O
x	O
using	O
epifluorescence	O
optics	O
.	O

RNA	O
Extraction	O
/	O
cDNA	O
synthesis	O

Sympathetic	O
ganglia	O
were	O
removed	O
from	O
chick	S-Species
embryos	O
and	O
RNA	O
was	O
isolated	O
using	O
TriReagent	O
(	O
Molecular	O
Research	O
Center	O
)	O
,	O
an	O
acidified	O
guanidinium	O
with	O
phenol	O
extraction	O
method	O
[	O
29	O
]	O
.	O

RNA	O
was	O
transcribed	O
to	O
cDNA	O
using	O
oligo	O
-	O
dT	O
with	O
Superscript	O
II	O
Reverse	O
Transcriptase	O
(	O
Invitrogen	O
)	O
at	O
42	O
degrees	O
C	O
for	O
1	O
hour	O
.	O

Real	O
-	O
time	O
PCR	O

Relative	O
RNA	O
levels	O
were	O
determined	O
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
with	O
an	O
ABI	O
7500	O
Fast	O
Real	O
Time	O
PCR	O
System	O
.	O

TaqMan	O
probes	O
were	O
used	O
to	O
quantify	O
the	O
progression	O
of	O
the	O
PCR	O
reaction	O
and	O
reactions	O
were	O
normalized	O
using	O
the	O
constitutively	O
expressed	O
gene	O
chick	S-Species
ribosomal	O
binding	O
protein	O
s17	O
(	O
CHRPS	O
)	O
.	O

The	O
sequences	O
were	O
used	O
for	O
primer	O
/	O
probes	O
sets	O
:	O
for	O
BDNF	O
:	O
forward	O
:	O
5	O
'	O
-	O
AGCCCAGTGAGGAAAACAAG	O
-	O
3	O
'	O
,	O
reverse	O
:	O
5	O
'	O
-	O
ACTCCTCGAGCAGAAAGAGC	O
-	O
3	O
'	O
,	O
probe	O
:	O
5	O
'	O
-	O
[	O
6	O
-	O
FAM	O
]	O
-	O
TACACATCCCGAGTCATGCTGAGCA	O
-	O
[	O
BHQ	O
]	O
-	O
3	O
'	O
;	O
for	O
CHRPS	O
(	O
chick	S-Species
ribosomal	O
binding	O
protein	O
S	O
-	O
17	O
)	O
:	O
5	O
'	O
AACGACTTCCACACCAACAA3	O
'	O
,	O
reverse	O
:	O
5	O
'	O
CTTCATCAGGTGGGTGACAT3	O
'	O
,	O
probe	O
:	O
5	O
'	O
-	O
[	O
6	O
-	O
FAM	O
]	O
-	O
CGCCATCATCCCCAGCAAGA	O
[	O
BHQ	O
]	O
-	O
3	O
'	O
.	O

Primers	O
and	O
probes	O
were	O
synthesized	O
by	O
Operon	O
Technologies	O
,	O
Inc	O
(	O
Alameda	O
,	O
CA	O
)	O
.	O

The	O
primers	O
for	O
BDNF	O
were	O
validated	O
against	O
primers	O
for	O
CHRPS	O
according	O
to	O
an	O
Applied	O
BioSystems	O
protocol	O
by	O
serially	O
diluting	O
the	O
target	O
cDNA	O
1	O
:	O
10	O
,	O
determining	O
the	O
cycle	O
threshold	O
(	O
Ct	O
)	O
for	O
each	O
reaction	O
,	O
and	O
plotting	O
the	O
Ct	O
versus	O
log	O
concentration	O
.	O

Slopes	O
of	O
the	O
resulting	O
lines	O
were	O
calculated	O
and	O
primers	O
were	O
accepted	O
if	O
their	O
Ct	O
slopes	O
were	O
between	O
-	O
3	O
.	O
2	O
and	O
-	O
3	O
.	O
4	O
(	O
a	O
perfect	O
efficiency	O
of	O
1	O
.	O
0	O
yields	O
a	O
slope	O
of	O
-	O
3	O
.	O
3	O
)	O
.	O

To	O
analyze	O
the	O
data	O
,	O
the	O
delta	O
Ct	O
method	O
of	O
relative	O
quantification	O
was	O
used	O
,	O
where	O
the	O
Ct	O
of	O
Chrps	O
was	O
subtracted	O
from	O
the	O
Ct	O
of	O
the	O
gene	O
of	O
interest	O
(	O
Delta	O
Ct	O
)	O
and	O
the	O
arbitrary	O
units	O
of	O
mRNA	O
were	O
expressed	O
as	O
10000	O
/	O
2	O
^	O
(	O
Delta	O
Ct	O
)	O
.	O

Cell	O
culture	O

Sympathetic	O
neurons	O
were	O
cultured	O
as	O
previously	O
described	O
[	O
30	O
]	O
with	O
a	O
few	O
modifications	O
.	O

Sympathetic	O
ganglia	O
were	O
removed	O
from	O
the	O
lumbar	O
region	O
of	O
the	O
paravertebral	O
chain	O
of	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
chick	S-Species
embryos	O
and	O
placed	O
in	O
Modified	O
Puck	O
'	O
s	O
solution	O
with	O
glucose	O
(	O
MPG	O
)	O
.	O

The	O
cells	O
were	O
dissociated	O
by	O
incubation	O
of	O
sympathetic	O
ganglia	O
with	O
0	O
.	O
1	O
%	O
trypsin	O
in	O
MPG	O
at	O
37	O
degrees	O
C	O
for	O
10	O
minutes	O
followed	O
by	O
triturating	O
with	O
a	O
fire	O
polished	O
9	O
"	O
Pasteur	O
pipette	O
.	O

Cells	O
were	O
then	O
resuspended	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
(	O
DMEM	O
)	O
consisting	O
of	O
10	O
%	O
horse	S-Species
serum	O
,	O
2	O
%	O
fetal	O
calf	O
serum	O
,	O
and	O
10	O
mg	O
/	O
ml	O
penicillin	O
/	O
streptomycin	O
.	O

For	O
neurotrophin	O
studies	O
,	O
the	O
culture	O
medium	O
was	O
supplemented	O
with	O
25	O
ng	O
/	O
ml	O
NT	O
-	O
3	O
(	O
R	O
&	O
D	O
Systems	O
)	O
and	O
1	O
mu	O
g	O
/	O
ml	O
7S	O
NGF	O
(	O
Alomone	O
Labs	O
)	O
upon	O
plating	O
,	O
and	O
50	O
ng	O
/	O
ml	O
,	O
100	O
ng	O
/	O
ml	O
,	O
or	O
200	O
ng	O
/	O
ml	O
BDNF	O
(	O
R	O
&	O
D	O
Systems	O
)	O
once	O
the	O
cells	O
adhered	O
to	O
the	O
wells	O
.	O

Cells	O
were	O
plated	O
on	O
poly	O
-	O
D	O
-	O
lysine	O
/	O
laminin	O
coated	O
wells	O
or	O
cover	O
slips	O
(	O
Fisher	O
)	O
as	O
previously	O
described	O
[	O
30	O
]	O
.	O

Quantification	O
of	O
neurons	O
and	O
sympathoblasts	O
using	O
phase	O
microscopy	O

Embryonic	O
sympathoblasts	O
and	O
neurons	O
are	O
small	O
,	O
phase	O
bright	O
cells	O
with	O
neurites	O
.	O

The	O
total	O
number	O
of	O
cells	O
with	O
neurites	O
the	O
length	O
of	O
two	O
cell	O
bodies	O
were	O
counted	O
in	O
10	O
non	O
-	O
overlapping	O
fields	O
of	O
view	O
evenly	O
spaced	O
in	O
a	O
grid	O
-	O
like	O
pattern	O
across	O
the	O
bottom	O
of	O
a	O
well	O
from	O
a	O
24	O
well	O
plate	O
at	O
200	O
x	O
using	O
a	O
Nikon	O
Eclipse	O
TE200	O
microscope	O
.	O

BrdU	O
labeling	O

For	O
in	O
vitro	O
studies	O
,	O
approximately	O
2	O
hours	O
after	O
plating	O
cells	O
from	O
St	O
.	O

29	O
/	O
30	O
(	O
E6	O
.	O
5	O
)	O
sympathetic	O
ganglia	O
,	O
cells	O
were	O
labeled	O
with	O
10	O
mu	O
M	O
bromodeoxyuridine	O
(	O
BrdU	O
,	O
Sigma	O
)	O
for	O
12	O
hours	O
at	O
37	O
degrees	O
C	O
.	O

Following	O
this	O
labeling	O
period	O
,	O
cells	O
were	O
incubated	O
in	O
complete	O
medium	O
without	O
BrdU	O
for	O
an	O
additional	O
10	O
hrs	O
.	O

Cells	O
were	O
then	O
fixed	O
in	O
Zamboni	O
'	O
s	O
fixative	O
for	O
30	O
min	O
at	O
room	O
temperature	O
and	O
rinsed	O
with	O
1	O
x	O
PBS	O
.	O

For	O
in	O
vivo	O
studies	O
,	O
25	O
mu	O
g	O
BrdU	O
was	O
injected	O
into	O
the	O
amnion	O
of	O
chick	S-Species
embryos	O
at	O
St	O
.	O

27	O
.	O

The	O
cells	O
and	O
sections	O
were	O
denatured	O
with	O
2	O
N	O
HCl	O
at	O
37	O
degrees	O
C	O
for	O
1	O
hr	O
,	O
and	O
were	O
then	O
neutralized	O
with	O
0	O
.	O
1	O
M	O
borate	O
buffer	O
,	O
pH	O
8	O
.	O
5	O
,	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

Immunochemistry	O
was	O
performed	O
as	O
described	O
above	O
.	O

Abbreviations	O

BDNF	O
,	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
;	O
BrdU	O
,	O
Bromodeoxyuridine	O
;	O
DA	O
,	O
dorsal	O
aorta	O
;	O
DMEM	O
,	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
Medium	O
;	O
DRG	O
,	O
dorsal	O
root	O
ganglion	O
;	O
E	O
,	O
embryonic	O
day	O
;	O
HS	O
,	O
horse	S-Species
serum	O
;	O
MPG	O
,	O
Modified	O
Puck	O
'	O
s	O
solution	O
with	O
glucose	O
;	O
NGF	O
,	O
nerve	O
growth	O
factor	O
;	O
NC	O
,	O
notochord	O
;	O
NT	O
,	O
neural	O
tube	O
;	O
NT	O
-	O
3	O
,	O
neurotrophin	O
-	O
3	O
;	O
NTR	O
,	O
neurotrophin	O
receptor	O
;	O
PBS	O
,	O
phosphate	O
-	O
buffered	O
saline	O
;	O
SC	O
,	O
spinal	O
cord	O
;	O
SCG	O
,	O
superior	O
cervical	O
ganglion	O
;	O
SEM	O
,	O
standard	O
error	O
of	O
the	O
mean	O
;	O
SG	O
,	O
sympathetic	O
ganglion	O
;	O
St	O
.	O
,	O
stage	O
;	O
w	O
/	O
v	O
,	O
weight	O
/	O
volume	O
;	O
v	O
/	O
v	O
,	O
volume	O
/	O
volume	O
.	O

Authors	O
'	O
contributions	O

JAS	O
designed	O
the	O
experiments	O
,	O
performed	O
the	O
experiments	O
,	O
analyzed	O
the	O
data	O
,	O
and	O
wrote	O
the	O
manuscript	O
.	O

GLSS	O
contributed	O
intellectually	O
to	O
the	O
conception	O
and	O
design	O
of	O
this	O
study	O
,	O
and	O
assisted	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
.	O

RN	O
supervised	O
the	O
study	O
,	O
participated	O
in	O
the	O
design	O
of	O
experiments	O
,	O
edited	O
the	O
manuscript	O
,	O
and	O
obtained	O
funding	O
for	O
the	O
project	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Video	O
analysis	O
of	O
the	O
escape	O
flight	O
of	O
Pileated	B-Species
Woodpecker	E-Species
Dryocopus	B-Species
pileatus	E-Species
:	O
does	O
the	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
Campephilus	B-Species
principalis	E-Species
persist	O
in	O
continental	O
North	O
America	O
?	O

Abstract	O

Background	O

The	O
apparent	O
rediscovery	O
of	O
the	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
Campephilus	B-Species
principalis	E-Species
in	O
Arkansas	O
,	O
USA	O
,	O
previously	O
feared	O
extinct	O
,	O
was	O
supported	O
by	O
video	O
evidence	O
of	O
a	O
single	O
bird	O
in	O
flight	O
(	O
Fitzpatrick	O
et	O
al	O
,	O
Science	O
2005	O
,	O
308	O
:	O
1460	O
-	O
1462	O
)	O
.	O

Plumage	O
patterns	O
and	O
wingbeat	O
frequency	O
of	O
the	O
putative	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
were	O
said	O
to	O
be	O
incompatible	O
with	O
the	O
only	O
possible	O
confusion	O
species	O
native	O
to	O
the	O
area	O
,	O
the	O
Pileated	B-Species
Woodpecker	E-Species
Dryocopus	B-Species
pileatus	E-Species
.	O

Results	O

New	O
video	O
analysis	O
of	O
Pileated	B-Species
Woodpeckers	E-Species
in	O
escape	O
flights	O
comparable	O
to	O
that	O
of	O
the	O
putative	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
filmed	O
in	O
Arkansas	O
shows	O
that	O
Pileated	B-Species
Woodpeckers	E-Species
can	O
display	O
a	O
wingbeat	O
frequency	O
equivalent	O
to	O
that	O
of	O
the	O
Arkansas	O
bird	O
during	O
escape	O
flight	O
.	O

The	O
critical	O
frames	O
from	O
the	O
Arkansas	O
video	O
that	O
were	O
used	O
to	O
identify	O
the	O
bird	O
as	O
an	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
are	O
shown	O
to	O
be	O
equally	O
,	O
or	O
more	O
,	O
compatible	O
with	O
the	O
Pileated	B-Species
Woodpecker	E-Species
.	O

Conclusion	O

The	O
identification	O
of	O
the	O
bird	O
filmed	O
in	O
Arkansas	O
in	O
April	O
2004	O
as	O
an	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
is	O
best	O
regarded	O
as	O
unsafe	O
.	O

The	O
similarities	O
between	O
the	O
Arkansas	O
bird	O
and	O
known	O
Pileated	B-Species
Woodpeckers	E-Species
suggest	O
that	O
it	O
was	O
most	O
likely	O
a	O
Pileated	B-Species
Woodpecker	E-Species
.	O

Background	O

The	O
reported	O
rediscovery	O
of	O
the	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
in	O
2004	O
-	O
5	O
in	O
the	O
Big	O
Woods	O
of	O
Arkansas	O
gave	O
new	O
impetus	O
to	O
efforts	O
to	O
conserve	O
the	O
mature	O
bottomland	O
woodlands	O
of	O
the	O
south	O
-	O
eastern	O
USA	O
.	O

Several	O
sightings	O
have	O
been	O
reported	O
without	O
photographic	O
evidence	O
being	O
obtained	O
[	O
1	O
]	O
.	O

Unless	O
sightings	O
are	O
,	O
however	O
,	O
independently	O
verifiable	O
on	O
the	O
basis	O
of	O
photographic	O
or	O
other	O
recorded	O
evidence	O
,	O
the	O
possibility	O
that	O
mistakes	O
have	O
been	O
made	O
cannot	O
be	O
eliminated	O
.	O

Crucial	O
to	O
the	O
scientific	O
case	O
for	O
the	O
persistence	O
of	O
the	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
was	O
a	O
4	O
s	O
video	O
of	O
a	O
large	O
woodpecker	O
in	O
flight	O
recorded	O
by	O
M	O
.	O
D	O
.	O

Luneau	O
on	O
25	O
April	O
2004	O
(	O
henceforth	O
referred	O
to	O
as	O
the	O
'	O
Luneau	O
video	O
'	O
)	O
and	O
published	O
in	O
2005	O
[	O
1	O
]	O
,	O
which	O
was	O
claimed	O
to	O
be	O
inconsistent	O
with	O
the	O
plumage	O
patterns	O
of	O
the	O
superficially	O
similar	O
Pileated	B-Species
Woodpecker	E-Species
(	O
a	O
common	O
resident	O
bird	O
of	O
the	O
area	O
)	O
.	O

Both	O
species	O
are	O
large	O
,	O
black	O
-	O
and	O
-	O
white	O
woodpeckers	O
[	O
2	O
]	O
.	O

The	O
upperwing	O
of	O
the	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
is	O
black	O
,	O
with	O
white	O
secondary	O
feathers	O
and	O
white	O
on	O
some	O
inner	O
primary	O
feathers	O
.	O

Pileated	B-Species
Woodpeckers	E-Species
have	O
a	O
largely	O
black	O
upperwing	O
,	O
with	O
white	O
restricted	O
to	O
the	O
'	O
wrist	O
'	O
due	O
to	O
white	O
bases	O
to	O
the	O
primary	O
feathers	O
.	O

The	O
underwing	O
of	O
Pileated	B-Species
Woodpecker	E-Species
has	O
all	O
-	O
white	O
underwing	O
coverts	O
,	O
giving	O
an	O
appearance	O
of	O
a	O
white	O
underwing	O
with	O
a	O
broad	O
black	O
outline	O
(	O
the	O
black	O
flight	O
feathers	O
)	O
.	O

These	O
plumage	O
differences	O
result	O
in	O
the	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
having	O
a	O
white	O
trailing	O
edge	O
to	O
the	O
wings	O
(	O
upper	O
and	O
lower	O
sides	O
)	O
,	O
whereas	O
the	O
Pileated	B-Species
Woodpecker	E-Species
has	O
a	O
black	O
trailing	O
edge	O
to	O
the	O
wings	O
.	O

Both	O
species	O
have	O
black	O
wing	O
-	O
tips	O
.	O

These	O
and	O
other	O
plumage	O
characteristics	O
are	O
shown	O
in	O
[	O
1	O
,	O
2	O
]	O
.	O

The	O
wingbeat	O
frequency	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
was	O
measured	O
at	O
8	O
.	O
6	O
beats	O
s	O
-	O
1	O
,	O
similar	O
to	O
that	O
inferred	O
from	O
archival	O
sound	O
recording	O
of	O
a	O
single	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
,	O
but	O
claimed	O
to	O
be	O
outside	O
the	O
range	O
of	O
Pileated	B-Species
Woodpeckers	E-Species
(	O
which	O
generally	O
have	O
slower	O
wingbeats	O
)	O
[	O
1	O
,	O
3	O
]	O
.	O

Sibley	O
et	O
al	O
[	O
4	O
]	O
questioned	O
the	O
video	O
evidence	O
,	O
in	O
particular	O
providing	O
alternative	O
explanations	O
for	O
the	O
plumage	O
patterns	O
of	O
the	O
Luneau	O
bird	O
in	O
flight	O
and	O
at	O
rest	O
.	O

They	O
pointed	O
out	O
individual	O
frames	O
of	O
the	O
Luneau	O
video	O
that	O
appear	O
to	O
show	O
three	O
features	O
that	O
are	O
each	O
inconsistent	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
:	O
(	O
1	O
)	O
apparently	O
black	O
secondary	O
feathers	O
on	O
the	O
upper	O
surface	O
of	O
the	O
left	O
wing	O
,	O
(	O
2	O
)	O
particularly	O
bright	O
white	O
primary	O
bases	O
,	O
and	O
(	O
3	O
)	O
a	O
black	O
band	O
curving	O
smoothly	O
round	O
the	O
wing	O
tip	O
(	O
see	O
Figure	O
3	O
in	O
[	O
4	O
]	O
)	O
.	O

They	O
hypothesized	O
that	O
flexing	O
of	O
a	O
Pileated	B-Species
Woodpecker	E-Species
'	O
s	O
wings	O
during	O
flight	O
could	O
produce	O
the	O
appearance	O
of	O
white	O
trailing	O
edges	O
on	O
both	O
wings	O
in	O
low	O
-	O
quality	O
videos	O
[	O
4	O
]	O
.	O

They	O
offered	O
,	O
however	O
,	O
no	O
direct	O
evidence	O
to	O
show	O
that	O
this	O
could	O
cause	O
a	O
video	O
of	O
a	O
Pileated	B-Species
Woodpecker	E-Species
to	O
look	O
like	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
.	O

Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
in	O
turn	O
rebutted	O
some	O
aspects	O
of	O
the	O
hypothesis	O
of	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
,	O
publishing	O
video	O
stills	O
of	O
Pileated	B-Species
Woodpeckers	E-Species
,	O
and	O
a	O
model	O
of	O
a	O
Pileated	B-Species
Woodpecker	E-Species
,	O
that	O
appeared	O
to	O
show	O
a	O
black	O
trailing	O
edge	O
to	O
the	O
wings	O
inconsistent	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
and	O
the	O
Luneau	O
video	O
.	O

Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
neither	O
rebutted	O
nor	O
discussed	O
the	O
three	O
key	O
inconsistencies	O
described	O
above	O
.	O

Without	O
further	O
evidence	O
,	O
this	O
became	O
largely	O
a	O
theoretical	O
debate	O
over	O
interpretation	O
of	O
field	O
characters	O
that	O
were	O
barely	O
visible	O
in	O
the	O
very	O
small	O
images	O
originally	O
obtained	O
.	O

On	O
one	O
hand	O
,	O
as	O
pointed	O
out	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
,	O
some	O
of	O
the	O
frames	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
do	O
appear	O
to	O
be	O
inconsistent	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
flight	O
pattern	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
asserted	O
to	O
be	O
atypical	O
for	O
Pileated	B-Species
Woodpecker	E-Species
(	O
but	O
matching	O
anecdotal	O
descriptions	O
of	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
)	O
.	O

Furthermore	O
,	O
the	O
general	O
impression	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
was	O
that	O
there	O
is	O
far	O
too	O
much	O
white	O
in	O
the	O
wings	O
for	O
it	O
to	O
be	O
a	O
Pileated	B-Species
Woodpecker	E-Species
,	O
and	O
that	O
if	O
it	O
was	O
a	O
Pileated	O
,	O
then	O
it	O
must	O
be	O
an	O
aberrant	O
one	O
with	O
abnormally	O
extensive	O
white	O
plumage	O
.	O

Such	O
birds	O
occasionally	O
occur	O
,	O
and	O
have	O
been	O
observed	O
in	O
the	O
Arkansas	O
study	O
area	O
[	O
6	O
]	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
the	O
flight	O
and	O
plumage	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
really	O
was	O
inconsistent	O
with	O
either	O
a	O
normal	O
or	O
partial	O
albino	O
Pileated	B-Species
Woodpecker	E-Species
.	O

Independent	O
analyses	O
of	O
the	O
plumage	O
patterns	O
and	O
wingbeat	O
frequencies	O
observable	O
in	O
Pileated	B-Species
Woodpeckers	E-Species
are	O
presented	O
,	O
and	O
it	O
is	O
concluded	O
that	O
the	O
identification	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
as	O
definite	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
is	O
probably	O
unsafe	O
.	O

Results	O

On	O
January	O
28	O
and	O
February	O
5	O
,	O
2006	O
,	O
David	O
Nolin	O
(	O
DN	O
)	O
video	O
-	O
recorded	O
Pileated	B-Species
Woodpeckers	E-Species
Dryocopus	B-Species
pileatus	E-Species
at	O
a	O
bird	O
-	O
feeder	O
in	O
Dayton	O
,	O
Ohio	O
,	O
USA	O
.	O

A	O
Hi	O
-	O
8	O
Sony	O
Handycam	O
was	O
used	O
,	O
hand	O
-	O
held	O
,	O
at	O
approximately	O
5	O
m	O
from	O
the	O
feeder	O
.	O

Birds	O
on	O
the	O
tree	O
trunk	O
were	O
alarmed	O
by	O
movement	O
,	O
and	O
their	O
escape	O
flights	O
recorded	O
.	O

Four	O
escape	O
flights	O
were	O
captured	O
that	O
approximate	O
to	O
that	O
recorded	O
for	O
the	O
putative	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
Campephilus	B-Species
principalis	E-Species
by	O
Luneau	O
in	O
April	O
2004	O
and	O
published	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
1	O
]	O
.	O

The	O
videos	O
are	O
not	O
directly	O
equivalent	O
because	O
the	O
Pileated	B-Species
Woodpeckers	E-Species
made	O
only	O
short	O
escape	O
flights	O
to	O
nearby	O
trees	O
,	O
whereas	O
the	O
putative	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
in	O
the	O
Luneau	O
video	O
showed	O
little	O
sign	O
of	O
coming	O
to	O
rest	O
before	O
being	O
lost	O
from	O
view	O
.	O

Nevertheless	O
,	O
interesting	O
comparisons	O
can	O
be	O
made	O
.	O

Wingbeat	O
frequency	O
of	O
Pileated	B-Species
Woodpecker	E-Species

The	O
woodpecker	O
in	O
the	O
Luneau	O
video	O
maintains	O
a	O
steady	O
rapid	O
wingbeat	O
rate	O
of	O
8	O
.	O
6	O
beats	O
s	O
-	O
1	O
for	O
at	O
least	O
8	O
wingbeats	O
[	O
1	O
]	O
,	O
a	O
figure	O
that	O
was	O
confirmed	O
by	O
independent	O
analysis	O
during	O
preparation	O
of	O
this	O
paper	O
.	O

The	O
Pileated	B-Species
woodpeckers	E-Species
in	O
DN	O
'	O
s	O
video	O
do	O
not	O
do	O
this	O
-	O
after	O
initial	O
rapid	O
flapping	O
immediately	O
after	O
take	O
-	O
off	O
,	O
they	O
settle	O
into	O
a	O
more	O
relaxed	O
level	O
flight	O
.	O

As	O
shown	O
in	O
Tables	O
1	O
and	O
2	O
,	O
although	O
the	O
mean	O
wingbeat	O
frequencies	O
of	O
the	O
Pileated	B-Species
Woodpeckers	E-Species
in	O
DN	O
'	O
s	O
video	O
are	O
slower	O
than	O
the	O
8	O
.	O
6	O
s	O
-	O
1	O
recorded	O
for	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
[	O
1	O
,	O
3	O
,	O
5	O
]	O
the	O
first	O
four	O
wingbeats	O
,	O
the	O
initial	O
escape	O
response	O
,	O
are	O
faster	O
than	O
those	O
claimed	O
for	O
Pileated	B-Species
Woodpeckers	E-Species
in	O
the	O
literature	O
[	O
1	O
,	O
3	O
,	O
5	O
]	O
.	O

For	O
the	O
four	O
escape	O
flights	O
,	O
the	O
mean	O
frequency	O
values	O
for	O
the	O
first	O
four	O
wingbeats	O
are	O
7	O
.	O
1	O
,	O
6	O
.	O
7	O
,	O
8	O
.	O
6	O
,	O
and	O
8	O
.	O
0	O
s	O
-	O
1	O
,	O
respectively	O
.	O

The	O
8	O
.	O
6	O
beats	O
s	O
-	O
1	O
of	O
the	O
bird	O
identified	O
in	O
the	O
Luneau	O
video	O
,	O
while	O
consistent	O
with	O
the	O
limited	O
data	O
(	O
n	O
=	O
1	O
;	O
see	O
Discussion	O
)	O
for	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
,	O
is	O
equally	O
consistent	O
with	O
Pileated	B-Species
Woodpecker	E-Species
in	O
its	O
initial	O
escape	O
flight	O
.	O

The	O
bird	O
in	O
the	O
Luneau	O
video	O
maintains	O
a	O
frequency	O
of	O
8	O
.	O
6	O
s	O
-	O
1	O
for	O
the	O
next	O
four	O
wingbeats	O
too	O
,	O
whereas	O
the	O
Pileated	B-Species
Woodpeckers	E-Species
recorded	O
here	O
all	O
slowed	O
their	O
flight	O
as	O
they	O
prepared	O
to	O
land	O
in	O
nearby	O
trees	O
.	O

There	O
are	O
no	O
data	O
to	O
suggest	O
whether	O
Pileated	B-Species
Woodpeckers	E-Species
can	O
maintain	O
a	O
wingbeat	O
frequency	O
approaching	O
8	O
.	O
6	O
s	O
-	O
1	O
for	O
eight	O
or	O
more	O
wingbeats	O
,	O
like	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
.	O

It	O
remains	O
possible	O
that	O
the	O
flight	O
pattern	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
unusual	O
for	O
Pileated	B-Species
Woodpecker	E-Species
,	O
but	O
a	O
frequency	O
of	O
8	O
.	O
6	O
s	O
-	O
1	O
is	O
consistent	O
with	O
a	O
Pileated	B-Species
Woodpecker	E-Species
gaining	O
initial	O
speed	O
and	O
height	O
in	O
escape	O
flight	O
,	O
and	O
by	O
itself	O
cannot	O
be	O
taken	O
as	O
strong	O
evidence	O
that	O
the	O
Luneau	O
video	O
bird	O
was	O
an	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
.	O

This	O
is	O
discussed	O
further	O
below	O
.	O

Plumage	O
pattern	O
of	O
Pileated	B-Species
Woodpeckers	E-Species
in	O
flight	O

The	O
video	O
of	O
Pileated	B-Species
Woodpeckers	E-Species
in	O
flight	O
was	O
obtained	O
in	O
avi	O
format	O
,	O
decompiled	O
and	O
examined	O
frame	O
by	O
frame	O
.	O

Comparisons	O
of	O
Pileated	B-Species
Woodpecker	E-Species
images	O
with	O
key	O
images	O
of	O
Luneau	O
video	O
are	O
shown	O
in	O
Figures	O
1	O
and	O
2	O
,	O
and	O
suggest	O
a	O
genuine	O
resemblance	O
between	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
and	O
a	O
Pileated	B-Species
Woodpecker	E-Species
.	O

Analysis	O
is	O
complicated	O
by	O
the	O
different	O
digital	O
processing	O
of	O
the	O
two	O
videos	O
,	O
and	O
in	O
the	O
case	O
of	O
the	O
Nolin	O
videos	O
it	O
is	O
important	O
to	O
concentrate	O
only	O
on	O
those	O
frames	O
or	O
part	O
-	O
frames	O
where	O
apparent	O
plumage	O
features	O
are	O
not	O
an	O
artifact	O
of	O
blurred	O
images	O
.	O

Thirty	O
-	O
six	O
frames	O
from	O
the	O
fourth	O
example	O
of	O
Pileated	O
escape	O
flight	O
,	O
which	O
most	O
resembled	O
the	O
flight	O
path	O
of	O
the	O
Luneau	O
video	O
bird	O
,	O
were	O
analysed	O
systematically	O
frame	O
by	O
frame	O
.	O

They	O
represent	O
seven	O
complete	O
wingbeats	O
(	O
1	O
.	O
20	O
s	O
from	O
the	O
middle	O
of	O
the	O
second	O
wingbeat	O
to	O
middle	O
of	O
wingbeat	O
9	O
)	O
and	O
were	O
directly	O
compared	O
frame	O
-	O
by	O
-	O
frame	O
with	O
the	O
equivalent	O
fields	O
(	O
middle	O
wingbeat	O
2	O
-	O
middle	O
wingbeat	O
9	O
)	O
of	O
the	O
Luneau	O
video	O
.	O

This	O
comparison	O
is	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
images	O
of	O
the	O
birds	O
are	O
not	O
identical	O
,	O
but	O
in	O
every	O
frame	O
of	O
the	O
36	O
frames	O
available	O
,	O
there	O
are	O
sufficient	O
similarities	O
to	O
suggest	O
that	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
consistent	O
with	O
the	O
known	O
Pileated	B-Species
Woodpecker	E-Species
.	O

Further	O
comparisons	O
of	O
the	O
Luneau	O
bird	O
with	O
the	O
other	O
three	O
Pileated	S-Species
escape	O
flights	O
recorded	O
are	O
presented	O
in	O
the	O
supplementary	O
material	O
(	O
see	O
Additional	O
file	O
1	O
)	O
.	O

Key	O
findings	O
of	O
the	O
video	O
analysis	O
are	O
:	O

1	O
.	O

Pileated	B-Species
Woodpeckers	E-Species
flying	O
near	O
-	O
horizontally	O
away	O
from	O
the	O
observer	O
show	O
much	O
more	O
white	O
in	O
poor	O
-	O
quality	O
video	O
than	O
would	O
be	O
expected	O
from	O
their	O
general	O
plumage	O
pattern	O
.	O

They	O
present	O
an	O
appearance	O
of	O
a	O
black	O
-	O
bodied	O
bird	O
with	O
largely	O
white	O
wings	O
and	O
black	O
wingtips	O
,	O
very	O
similar	O
to	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
;	O
compare	O
in	O
particular	O
Figure	O
1B	O
,	O
frame	O
758	O
,	O
with	O
Figure	O
1A	O
,	O
frame	O
283	O
.	O
3	O
.	O

The	O
expected	O
appearance	O
of	O
the	O
upperwing	O
of	O
Pileated	B-Species
Woodpecker	E-Species
-	O
mostly	O
black	O
with	O
a	O
small	O
white	O
patch	O
at	O
the	O
base	O
of	O
the	O
primaries	O
-	O
is	O
often	O
not	O
seen	O
,	O
and	O
is	O
only	O
clearly	O
resolvable	O
when	O
birds	O
are	O
flying	O
near	O
-	O
vertically	O
before	O
landing	O
on	O
a	O
tree	O
trunk	O
;	O
something	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
did	O
not	O
do	O
.	O

2	O
.	O

The	O
black	O
trailing	O
edge	O
to	O
the	O
underwing	O
of	O
Pileated	B-Species
Woodpecker	E-Species
is	O
often	O
very	O
inconspicuous	O
and	O
may	O
disappear	O
completely	O
.	O

Due	O
to	O
motion	O
and	O
flexion	O
of	O
the	O
wing	O
,	O
the	O
black	O
trailing	O
edge	O
is	O
much	O
more	O
obvious	O
towards	O
the	O
wingtips	O
.	O

This	O
produces	O
an	O
apparent	O
plumage	O
pattern	O
that	O
matches	O
the	O
patterns	O
shown	O
by	O
the	O
Luneau	O
video	O
bird	O
(	O
compare	O
Figure	O
1B	O
,	O
frames	O
175	O
and	O
457	O
with	O
Figure	O
1A	O
,	O
frames	O
300	O
and	O
416	O
.	O
7	O
)	O
.	O

In	O
many	O
frames	O
of	O
Pileated	B-Species
Woodpecker	E-Species
,	O
a	O
black	O
trailing	O
edge	O
to	O
the	O
wing	O
is	O
discernable	O
(	O
though	O
due	O
to	O
bleeding	O
of	O
white	O
as	O
a	O
video	O
artifact	O
,	O
it	O
appears	O
narrower	O
than	O
it	O
really	O
is	O
)	O
.	O

However	O
,	O
analysis	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
in	O
light	O
of	O
images	O
of	O
known	O
Pileated	B-Species
Woodpeckers	E-Species
confirms	O
that	O
a	O
similar	O
black	O
trailing	O
edge	O
to	O
the	O
wing	O
is	O
discernable	O
in	O
some	O
frames	O
of	O
the	O
Luneau	O
video	O
(	O
compare	O
Figure	O
1B	O
,	O
frame	O
775	O
with	O
Figure	O
1A	O
,	O
frame	O
366	O
.	O
7	O
:	O
the	O
apparent	O
plumage	O
patterns	O
are	O
similar	O
,	O
and	O
inconsistent	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
)	O
.	O

It	O
is	O
argued	O
here	O
that	O
the	O
hypothesis	O
put	O
forward	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
is	O
correct	O
,	O
and	O
that	O
the	O
black	O
trailing	O
edge	O
of	O
the	O
underwing	O
of	O
Pileated	B-Species
Woodpecker	E-Species
can	O
indeed	O
,	O
due	O
to	O
flexion	O
of	O
the	O
wings	O
during	O
the	O
downstroke	O
,	O
be	O
misinterpreted	O
as	O
the	O
black	O
leading	O
edge	O
and	O
wingtips	O
of	O
the	O
upperwing	O
of	O
an	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
.	O

3	O
.	O

Figure	O
3	O
shows	O
that	O
the	O
plumage	O
patterns	O
shown	O
by	O
the	O
Luneau	O
bird	O
,	O
throughout	O
several	O
wingbeat	O
cycles	O
,	O
are	O
compatible	O
with	O
Pileated	B-Species
Woodpecker	E-Species
.	O

The	O
three	O
plumage	O
features	O
described	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
that	O
are	O
incompatible	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
(	O
black	O
secondary	O
feathers	O
on	O
upper	O
surface	O
of	O
left	O
wing	O
,	O
brighter	O
white	O
primary	O
bases	O
,	O
and	O
a	O
black	O
band	O
curling	O
round	O
the	O
wing	O
tip	O
)	O
are	O
seen	O
consistently	O
in	O
the	O
Luneau	O
video	O
and	O
are	O
recapitulated	O
throughout	O
the	O
video	O
of	O
Pileated	B-Species
Woodpecker	E-Species
.	O

Discussion	O

Evidence	O
is	O
presented	O
here	O
to	O
show	O
that	O
the	O
distinctive	O
plumage	O
features	O
of	O
Pileated	B-Species
Woodpecker	E-Species
are	O
surprisingly	O
difficult	O
to	O
resolve	O
in	O
poor	O
-	O
quality	O
video	O
of	O
birds	O
in	O
escape	O
flight	O
away	O
from	O
the	O
camera	O
,	O
and	O
that	O
they	O
can	O
show	O
apparent	O
plumage	O
patterns	O
that	O
might	O
more	O
readily	O
be	O
associated	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
.	O

Irrespective	O
of	O
the	O
identity	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
,	O
this	O
knowledge	O
will	O
be	O
critical	O
to	O
assessment	O
of	O
further	O
claims	O
of	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpeckers	E-Species
during	O
the	O
current	O
intensive	O
search	O
effort	O
.	O

It	O
is	O
,	O
however	O
,	O
suggested	O
here	O
that	O
critical	O
frames	O
used	O
for	O
identification	O
of	O
the	O
Luneau	O
video	O
woodpecker	O
as	O
an	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
are	O
also	O
consistent	O
with	O
Pileated	B-Species
Woodpecker	E-Species
.	O

The	O
wingbeat	O
frequency	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
also	O
perhaps	O
consistent	O
with	O
Pileated	B-Species
Woodpecker	E-Species
,	O
at	O
least	O
for	O
short	O
periods	O
of	O
flight	O
.	O

Analysis	O
of	O
the	O
videos	O
of	O
Pileated	B-Species
Woodpecker	E-Species
has	O
supported	O
the	O
hypothesised	O
interpretations	O
of	O
key	O
frames	O
of	O
the	O
Luneau	O
video	O
by	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
.	O

Although	O
the	O
rebuttal	O
of	O
that	O
comment	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
asserted	O
that	O
flexion	O
and	O
motion	O
of	O
wings	O
of	O
Pileated	B-Species
Woodpeckers	E-Species
could	O
not	O
produce	O
the	O
images	O
seen	O
in	O
the	O
Luneau	O
video	O
,	O
it	O
has	O
been	O
shown	O
here	O
that	O
they	O
can	O
.	O

The	O
Luneau	O
video	O
as	O
presented	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
1	O
]	O
,	O
shows	O
features	O
that	O
are	O
consistent	O
with	O
Pileated	B-Species
Woodpecker	E-Species
,	O
and	O
inconsistent	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
.	O

It	O
is	O
argued	O
in	O
this	O
paper	O
that	O
,	O
in	O
fact	O
,	O
the	O
black	O
trailing	O
edge	O
of	O
the	O
wing	O
of	O
a	O
Pileated	B-Species
Woodpecker	E-Species
is	O
seen	O
clearly	O
in	O
the	O
Luneau	O
video	O
,	O
during	O
the	O
downstroke	O
of	O
the	O
wingbeat	O
cycle	O
,	O
but	O
that	O
it	O
has	O
been	O
misinterpreted	O
as	O
black	O
wingtips	O
(	O
Figure	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

A	O
fuller	O
analysis	O
of	O
the	O
Luneau	O
video	O
by	O
the	O
Cornell	O
University	O
team	O
is	O
presented	O
online	O
[	O
7	O
]	O
.	O

Although	O
it	O
is	O
not	O
peer	O
-	O
reviewed	O
,	O
the	O
points	O
this	O
article	O
makes	O
should	O
be	O
taken	O
into	O
account	O
.	O

The	O
authors	O
summarise	O
nine	O
diagnostic	O
traits	O
from	O
their	O
analysis	O
of	O
the	O
Luneau	O
video	O
that	O
identify	O
the	O
bird	O
as	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
.	O

These	O
are	O
listed	O
and	O
discussed	O
point	O
-	O
by	O
point	O
below	O
.	O

1	O
.	O

'	O
The	O
underwing	O
pattern	O
in	O
flight	O
consistently	O
appears	O
largely	O
white	O
,	O
giving	O
the	O
appearance	O
of	O
having	O
black	O
wingtips	O
but	O
lacking	O
any	O
black	O
along	O
the	O
rear	O
,	O
or	O
trailing	O
edge	O
.	O
'	O

Data	O
presented	O
in	O
this	O
paper	O
show	O
that	O
this	O
statement	O
is	O
not	O
wholly	O
supported	O
,	O
and	O
in	O
any	O
case	O
the	O
underwing	O
of	O
Pileated	B-Species
Woodpeckers	E-Species
can	O
present	O
the	O
same	O
appearance	O
.	O

2	O
.	O

'	O
The	O
upperwing	O
pattern	O
in	O
flight	O
consistently	O
shows	O
a	O
broad	O
,	O
white	O
trailing	O
edge	O
,	O
with	O
no	O
frames	O
demonstrating	O
the	O
conspicuous	O
dark	O
rear	O
border	O
to	O
be	O
expected	O
of	O
normal	O
Pileated	B-Species
Woodpeckers	E-Species
.	O
'	O

Notwithstanding	O
that	O
certain	O
frames	O
of	O
the	O
Luneau	O
video	O
(	O
e	O
.	O
g	O
.	O
frame	O
350	O
)	O
do	O
appear	O
to	O
show	O
a	O
black	O
trailing	O
edge	O
to	O
the	O
upperwing	O
,	O
data	O
presented	O
in	O
this	O
paper	O
shows	O
that	O
,	O
at	O
this	O
angle	O
of	O
view	O
and	O
resolution	O
of	O
video	O
,	O
Pileated	B-Species
Woodpeckers	E-Species
also	O
may	O
fail	O
to	O
show	O
this	O
feature	O
.	O

This	O
analysis	O
has	O
shown	O
that	O
the	O
hypothesis	O
presented	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
is	O
plausible	O
,	O
i	O
.	O
e	O
.	O
that	O
some	O
of	O
the	O
frames	O
interpreted	O
by	O
[	O
1	O
]	O
to	O
show	O
the	O
upperwing	O
of	O
an	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
may	O
in	O
fact	O
show	O
large	O
amounts	O
of	O
white	O
and	O
the	O
black	O
trailing	O
edge	O
from	O
the	O
underwing	O
of	O
a	O
Pileated	B-Species
Woodpecker	E-Species
.	O

3	O
.	O

'	O
The	O
wings	O
are	O
longer	O
relative	O
to	O
the	O
body	O
diameter	O
than	O
in	O
Pileated	B-Species
Woodpecker	E-Species
and	O
consistent	O
with	O
the	O
wing	O
shape	O
of	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
.	O
'	O

Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
agreed	O
that	O
accurate	O
measurements	O
were	O
not	O
possible	O
from	O
the	O
video	O
images	O
presented	O
in	O
their	O
original	O
paper	O
[	O
1	O
]	O
,	O
and	O
it	O
seems	O
unlikely	O
that	O
much	O
confidence	O
can	O
be	O
placed	O
in	O
the	O
wing	O
-	O
length	O
measurements	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
.	O

Comparison	O
of	O
,	O
for	O
example	O
,	O
Figure	O
1A	O
,	O
frame	O
283	O
.	O
3	O
with	O
Figure	O
1B	O
,	O
frame	O
578	O
suggests	O
that	O
any	O
differences	O
will	O
be	O
very	O
difficult	O
to	O
prove	O
.	O

4	O
.	O

'	O
Reenactment	O
of	O
the	O
scene	O
using	O
life	O
-	O
sized	O
,	O
realistically	O
painted	O
,	O
dynamically	O
flapping	O
models	O
produced	O
images	O
remarkably	O
similar	O
to	O
those	O
of	O
the	O
Luneau	O
video	O
using	O
the	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
model	O
,	O
and	O
images	O
clearly	O
identifiable	O
as	O
Pileated	B-Species
Woodpecker	E-Species
using	O
a	O
model	O
of	O
that	O
species	O
.	O
'	O

Interpretation	O
of	O
model	O
re	O
-	O
enactments	O
is	O
hampered	O
by	O
the	O
fact	O
that	O
the	O
stiff	O
,	O
flat	O
-	O
winged	O
models	O
cannot	O
reflect	O
the	O
wing	O
flexion	O
and	O
curvature	O
of	O
real	O
birds	O
.	O

Reenactment	O
of	O
the	O
scene	O
using	O
real	O
Pileated	B-Species
Woodpeckers	E-Species
has	O
produced	O
images	O
remarkably	O
similar	O
to	O
the	O
Luneau	O
video	O
.	O

5	O
.	O

'	O
The	O
wingbeat	O
frequency	O
is	O
8	O
.	O
6	O
beats	O
per	O
second	O
,	O
which	O
is	O
almost	O
identical	O
to	O
that	O
recorded	O
for	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
(	O
as	O
documented	O
by	O
one	O
acoustic	O
record	O
from	O
1935	O
)	O
.	O

The	O
wing	O
-	O
beat	O
frequencies	O
of	O
Pileated	B-Species
Woodpecker	E-Species
are	O
not	O
known	O
to	O
exceed	O
7	O
.	O
5	O
beats	O
per	O
second	O
,	O
and	O
more	O
typically	O
range	O
between	O
3	O
and	O
6	O
beats	O
per	O
second	O
.	O
'	O

The	O
fact	O
that	O
in	O
only	O
four	O
recorded	O
escape	O
flights	O
of	O
Pileated	B-Species
Woodpecker	E-Species
,	O
two	O
were	O
recorded	O
for	O
which	O
the	O
initial	O
escape	O
flight	O
wingbeat	O
frequency	O
(	O
8	O
.	O
0	O
s	O
-	O
1	O
and	O
8	O
.	O
6	O
s	O
-	O
1	O
)	O
exceeded	O
that	O
previously	O
recorded	O
for	O
this	O
species	O
shows	O
that	O
previous	O
datasets	O
were	O
too	O
limited	O
to	O
make	O
this	O
conclusion	O
.	O

Birds	O
flap	O
more	O
rapidly	O
at	O
take	O
off	O
to	O
gain	O
altitude	O
and	O
speed	O
than	O
they	O
do	O
in	O
sustained	O
level	O
flight	O
:	O
Pileated	B-Species
Woodpecker	E-Species
flight	O
data	O
in	O
the	O
literature	O
[	O
1	O
,	O
4	O
,	O
5	O
]	O
was	O
derived	O
from	O
the	O
work	O
of	O
Tobalske	O
[	O
8	O
]	O
,	O
which	O
explicitly	O
excluded	O
the	O
initial	O
take	O
-	O
off	O
period	O
,	O
and	O
therefore	O
cannot	O
be	O
used	O
to	O
support	O
the	O
elimination	O
of	O
Pileated	B-Species
Woodpecker	E-Species
in	O
the	O
Luneau	O
video	O
.	O

Furthermore	O
,	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
consistently	O
gaining	O
height	O
from	O
a	O
low	O
position	O
above	O
water	O
and	O
,	O
whatever	O
its	O
species	O
,	O
might	O
be	O
expected	O
to	O
flap	O
more	O
rapidly	O
than	O
if	O
it	O
were	O
in	O
level	O
flight	O
.	O

Tanner	O
[	O
9	O
]	O
noted	O
that	O
Pileated	B-Species
Woodpeckers	E-Species
can	O
maintain	O
extended	O
fast	O
direct	O
flight	O
.	O

He	O
was	O
of	O
the	O
opinion	O
that	O
flight	O
pattern	O
was	O
not	O
a	O
useful	O
character	O
for	O
separating	O
the	O
two	O
species	O
in	O
the	O
field	O
,	O
and	O
that	O
Pileated	B-Species
Woodpeckers	E-Species
frequently	O
fly	O
in	O
a	O
manner	O
that	O
was	O
in	O
no	O
way	O
different	O
to	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpeckers	E-Species
.	O

The	O
figure	O
of	O
8	O
.	O
6	O
wingbeats	O
per	O
second	O
for	O
the	O
Luneau	O
bird	O
(	O
data	O
reanalysed	O
here	O
)	O
is	O
taken	O
as	O
consistent	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
on	O
the	O
basis	O
of	O
analysis	O
of	O
a	O
single	O
archival	O
audio	O
recording	O
[	O
3	O
]	O
.	O

The	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
in	O
that	O
audio	O
tape	O
is	O
clearly	O
flapping	O
its	O
wings	O
,	O
but	O
without	O
accompanying	O
visual	O
confirmation	O
it	O
is	O
not	O
clear	O
that	O
it	O
is	O
in	O
flight	O
.	O

In	O
general	O
,	O
larger	O
birds	O
are	O
expected	O
to	O
flap	O
their	O
wings	O
more	O
slowly	O
than	O
smaller	O
birds	O
of	O
comparable	O
wing	O
morphology	O
.	O

Tobalske	O
[	O
8	O
]	O
showed	O
that	O
,	O
across	O
species	O
,	O
smaller	O
woodpeckers	O
tend	O
to	O
flap	O
more	O
quickly	O
than	O
larger	O
ones	O
,	O
and	O
that	O
there	O
was	O
considerable	O
intraspecific	O
variation	O
.	O

The	O
assertion	O
that	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpeckers	E-Species
flap	O
their	O
wings	O
more	O
quickly	O
than	O
Pileated	B-Species
Woodpeckers	E-Species
is	O
therefore	O
counterintuitive	O
.	O

Further	O
comment	O
is	O
conjecture	O
:	O
while	O
the	O
flight	O
pattern	O
and	O
wing	O
posture	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
may	O
be	O
unusual	O
,	O
it	O
has	O
not	O
been	O
shown	O
that	O
it	O
is	O
outside	O
the	O
range	O
of	O
variability	O
of	O
Pileated	B-Species
Woodpecker	E-Species
,	O
and	O
cannot	O
therefore	O
be	O
used	O
to	O
eliminate	O
the	O
possibility	O
that	O
it	O
was	O
the	O
commoner	O
species	O
.	O

6	O
.	O

'	O
White	O
plumage	O
on	O
the	O
back	O
is	O
visible	O
on	O
the	O
retreating	O
bird	O
as	O
it	O
begins	O
to	O
gain	O
altitude	O
.	O

Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
has	O
white	O
on	O
the	O
back	O
;	O
Pileated	B-Species
Woodpecker	E-Species
has	O
entirely	O
black	O
back	O
.	O
'	O

This	O
was	O
discussed	O
by	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
,	O
who	O
argued	O
that	O
the	O
images	O
thought	O
to	O
show	O
white	O
on	O
the	O
dorsum	O
were	O
too	O
small	O
to	O
be	O
accepted	O
uncritically	O
.	O

In	O
all	O
the	O
frames	O
of	O
the	O
Luneau	O
video	O
that	O
appear	O
to	O
show	O
white	O
on	O
the	O
dorsum	O
,	O
the	O
bird	O
is	O
distant	O
(	O
dorsal	O
white	O
is	O
not	O
visible	O
on	O
the	O
higher	O
resolution	O
images	O
earlier	O
in	O
the	O
video	O
)	O
and	O
partially	O
obscured	O
,	O
making	O
it	O
difficult	O
to	O
distinguish	O
dorsum	O
from	O
wing	O
.	O

Spurious	O
areas	O
of	O
white	O
pixels	O
appear	O
as	O
artifacts	O
in	O
both	O
videos	O
.	O

Nevertheless	O
,	O
this	O
remains	O
the	O
best	O
evidence	O
that	O
the	O
Luneau	O
bird	O
was	O
not	O
a	O
standard	O
Pileated	B-Species
Woodpecker	E-Species
.	O

7	O
.	O

'	O
The	O
dorsal	O
view	O
of	O
the	O
right	O
wing	O
as	O
it	O
begins	O
to	O
unfold	O
shows	O
a	O
triangle	O
of	O
white	O
that	O
matches	O
in	O
size	O
and	O
position	O
the	O
white	O
on	O
the	O
folded	O
wing	O
of	O
an	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
beginning	O
to	O
launch	O
into	O
flight	O
.	O
'	O

No	O
further	O
comment	O
is	O
provided	O
here	O
.	O

An	O
alternative	O
explanation	O
was	O
offered	O
by	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
and	O
rebutted	O
by	O
Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
.	O

The	O
statement	O
requires	O
a	O
degree	O
of	O
certainty	O
about	O
the	O
position	O
of	O
the	O
wing	O
.	O

(	O
8	O
)	O
'	O
The	O
distance	O
between	O
the	O
wrist	O
area	O
and	O
the	O
tip	O
of	O
the	O
tail	O
(	O
32	O
-	O
36	O
cm	O
,	O
as	O
measured	O
when	O
the	O
bird	O
begins	O
to	O
take	O
flight	O
)	O
is	O
comparable	O
to	O
known	O
measurements	O
of	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
and	O
considerably	O
larger	O
than	O
even	O
the	O
largest	O
Pileated	B-Species
Woodpecker	E-Species
we	O
measured	O
.	O
'	O

As	O
stated	O
under	O
(	O
3	O
)	O
,	O
above	O
,	O
there	O
is	O
general	O
agreement	O
that	O
accurate	O
measurements	O
are	O
not	O
possible	O
from	O
the	O
Luneau	O
video	O
because	O
too	O
many	O
uncontrolled	O
variables	O
are	O
involved	O
[	O
4	O
,	O
5	O
]	O
.	O

9	O
.	O

'	O
Only	O
20	O
seconds	O
before	O
the	O
woodpecker	O
flees	O
,	O
a	O
bird	O
with	O
the	O
size	O
and	O
color	O
pattern	O
of	O
an	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
was	O
perched	O
within	O
3	O
m	O
of	O
the	O
site	O
from	O
which	O
the	O
woodpecker	O
took	O
flight	O
.	O
'	O

This	O
would	O
be	O
a	O
strong	O
argument	O
if	O
it	O
could	O
be	O
shown	O
that	O
the	O
object	O
in	O
question	O
was	O
a	O
bird	O
and	O
not	O
,	O
as	O
is	O
now	O
apparently	O
thought	O
likely	O
,	O
a	O
section	O
of	O
branch	O
or	O
tree	O
stump	O
[	O
10	O
]	O
.	O

The	O
Luneau	O
video	O
reveals	O
several	O
white	O
triangular	O
patches	O
apparently	O
visible	O
on	O
or	O
around	O
tree	O
trunks	O
,	O
most	O
or	O
all	O
of	O
which	O
must	O
therefore	O
be	O
images	O
of	O
tree	O
topography	O
or	O
video	O
artifacts	O
.	O

This	O
was	O
discussed	O
in	O
the	O
literature	O
(	O
see	O
[	O
4	O
,	O
5	O
]	O
)	O
.	O

Central	O
to	O
the	O
identification	O
of	O
the	O
flying	O
bird	O
seen	O
in	O
the	O
Luneau	O
video	O
was	O
the	O
evidence	O
that	O
plumage	O
and	O
flight	O
patterns	O
were	O
inconsistent	O
with	O
Pileated	B-Species
Woodpecker	E-Species
.	O

A	O
very	O
basic	O
video	O
analysis	O
presented	O
here	O
has	O
suggested	O
that	O
this	O
may	O
not	O
be	O
the	O
case	O
,	O
and	O
that	O
further	O
research	O
is	O
needed	O
.	O

Any	O
identification	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
as	O
an	O
Ivory	B-Species
-	I-Species
bill	E-Species
must	O
take	O
into	O
account	O
the	O
data	O
presented	O
here	O
and	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
,	O
which	O
shows	O
it	O
is	O
largely	O
consistent	O
with	O
Pileated	B-Species
Woodpecker	E-Species
and	O
points	O
out	O
apparent	O
inconsistencies	O
with	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
.	O

This	O
does	O
not	O
of	O
course	O
necessarily	O
imply	O
that	O
the	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
is	O
extinct	O
,	O
nor	O
indeed	O
entirely	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
was	O
one	O
.	O

There	O
appears	O
to	O
be	O
no	O
reason	O
to	O
question	O
the	O
anecdotal	O
sight	O
records	O
of	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
presented	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
1	O
]	O
(	O
or	O
in	O
many	O
online	O
sources	O
)	O
,	O
because	O
some	O
of	O
them	O
appear	O
credible	O
,	O
albeit	O
brief	O
.	O

Audio	O
evidence	O
has	O
since	O
been	O
published	O
[	O
11	O
]	O
although	O
this	O
too	O
is	O
far	O
from	O
conclusive	O
.	O

However	O
,	O
to	O
regard	O
the	O
Luneau	O
video	O
by	O
itself	O
as	O
presenting	O
anything	O
other	O
than	O
an	O
unidentified	O
woodpecker	O
falls	O
below	O
the	O
standards	O
of	O
proof	O
normally	O
required	O
for	O
scientific	O
publication	O
:	O
the	O
images	O
are	O
not	O
good	O
enough	O
.	O

The	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
may	O
persist	O
in	O
continental	O
North	O
America	O
,	O
and	O
there	O
is	O
enough	O
anecdotal	O
evidence	O
to	O
make	O
this	O
a	O
possibility	O
,	O
but	O
the	O
Luneau	O
video	O
does	O
not	O
support	O
the	O
case	O
.	O

The	O
balance	O
of	O
evidence	O
would	O
suggest	O
that	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
more	O
likely	O
to	O
have	O
been	O
a	O
Pileated	B-Species
Woodpecker	E-Species
,	O
but	O
the	O
search	O
for	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
should	O
continue	O
.	O

While	O
this	O
paper	O
was	O
under	O
review	O
,	O
a	O
report	O
of	O
sight	O
records	O
and	O
sound	O
recordings	O
of	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpeckers	E-Species
was	O
published	O
from	O
a	O
location	O
in	O
Florida	O
[	O
12	O
]	O
.	O

This	O
very	O
exciting	O
claim	O
is	O
strengthened	O
by	O
reports	O
of	O
sighting	O
of	O
the	O
white	O
dorsal	O
stripes	O
on	O
one	O
bird	O
in	O
flight	O
.	O

Unfortunately	O
,	O
several	O
sightings	O
were	O
made	O
without	O
optical	O
aids	O
and	O
cannot	O
be	O
considered	O
proven	O
.	O

The	O
'	O
kent	O
'	O
calls	O
recorded	O
from	O
the	O
Florida	O
location	O
are	O
spectrographically	O
similar	O
to	O
the	O
'	O
bleat	O
'	O
calls	O
of	O
young	O
White	B-Species
-	I-Species
tailed	I-Species
Deer	E-Species
,	O
as	O
described	O
in	O
Richardson	O
et	O
al	O
[	O
13	O
]	O
.	O

A	O
clear	O
photograph	O
will	O
be	O
required	O
from	O
this	O
location	O
too	O
before	O
the	O
presence	O
of	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpeckers	E-Species
can	O
be	O
considered	O
confirmed	O
.	O

It	O
is	O
hoped	O
that	O
this	O
paper	O
will	O
help	O
with	O
assessment	O
of	O
any	O
further	O
low	O
quality	O
photographs	O
or	O
videos	O
.	O

Conclusion	O

Flight	O
and	O
plumage	O
patterns	O
of	O
the	O
putative	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
recorded	O
in	O
Arkansas	O
in	O
2005	O
are	O
recapitulated	O
by	O
confirmed	O
Pileated	B-Species
Woodpeckers	E-Species
.	O

The	O
bird	O
in	O
the	O
Arkansas	O
video	O
is	O
best	O
regarded	O
as	O
not	O
fully	O
identified	O
,	O
and	O
is	O
probably	O
a	O
Pileated	B-Species
Woodpecker	E-Species
.	O

Methods	O

Video	O
recording	O

Pileated	B-Species
Woodpeckers	E-Species
were	O
attracted	O
to	O
a	O
bird	O
feeder	O
containing	O
suet	O
at	O
Grants	O
Trail	O
,	O
Dayton	O
,	O
OH	O
45459	O
.	O

The	O
suet	O
feeder	O
was	O
placed	O
approximately	O
2	O
.	O
1	O
m	O
high	O
on	O
a	O
tree	O
trunk	O
,	O
and	O
the	O
distance	O
to	O
the	O
suet	O
feeder	O
from	O
the	O
observation	O
point	O
was	O
approximately	O
5	O
m	O
.	O

Birds	O
on	O
the	O
feeder	O
were	O
startled	O
by	O
movement	O
of	O
window	O
blinds	O
on	O
January	O
28	O
and	O
February	O
5	O
,	O
2006	O
,	O
and	O
their	O
escape	O
flights	O
were	O
filmed	O
using	O
a	O
Sony	O
Hi	O
-	O
8	O
SteadyShot	O
video	O
camera	O
at	O
29	O
.	O
97	O
frames	O
s	O
-	O
1	O
.	O

At	O
least	O
two	O
birds	O
feature	O
in	O
the	O
videos	O
,	O
male	O
and	O
female	O
.	O

Analogue	O
tape	O
was	O
converted	O
to	O
digital	O
by	O
connecting	O
the	O
Hi	O
-	O
8	O
camera	O
directly	O
to	O
a	O
Sony	O
DCR	O
-	O
HC30	O
digital	O
video	O
camera	O
and	O
recording	O
onto	O
that	O
camera	O
'	O
s	O
mini	O
dv	O
cassette	O
.	O

The	O
resulting	O
images	O
were	O
converted	O
to	O
an	O
avi	O
file	O
using	O
Windows	O
Movie	O
Maker	O
on	O
a	O
Windows	O
XP	O
PC	O
.	O

The	O
video	O
is	O
freely	O
available	O
in	O
wmv	O
format	O
[	O
14	O
]	O
and	O
in	O
avi	O
format	O
from	O
the	O
author	O
or	O
David	O
Nolin	O
(	O
via	O
the	O
author	O
)	O
.	O

The	O
video	O
was	O
decompiled	O
using	O
Blaze	O
Media	O
Pro	O
(	O
Mystik	O
Media	O
,	O
Hampstead	O
,	O
NC	O
,	O
USA	O
)	O
for	O
a	O
detailed	O
analysis	O
.	O

Import	O
into	O
Avid	O
(R)	O
Xpress	O
Pro	O
HD	O
for	O
deinterlacing	O
did	O
not	O
reduce	O
the	O
wing	O
flicker	O
seen	O
in	O
the	O
images	O
,	O
and	O
further	O
professional	O
processing	O
could	O
not	O
improve	O
the	O
resolution	O
,	O
so	O
the	O
original	O
decompiled	O
file	O
was	O
used	O
for	O
analysis	O
.	O

Hence	O
some	O
frames	O
contain	O
two	O
overlaid	O
images	O
,	O
which	O
may	O
lower	O
the	O
resolution	O
in	O
some	O
cases	O
.	O

The	O
decompiled	O
file	O
was	O
examined	O
frame	O
by	O
frame	O
and	O
compared	O
to	O
the	O
decompiled	O
images	O
of	O
the	O
putative	O
Ivory	B-Species
-	I-Species
billed	I-Species
Woodpecker	E-Species
presented	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
1	O
]	O
.	O

Wingbeat	O
frequencies	O
were	O
calculated	O
by	O
noting	O
the	O
frame	O
number	O
of	O
the	O
midpoint	O
of	O
the	O
downstroke	O
of	O
each	O
wingbeat	O
(	O
e	O
.	O
g	O
.	O
Figure	O
1B	O
,	O
frame	O
758	O
)	O
and	O
calculating	O
the	O
length	O
of	O
time	O
taken	O
per	O
wingbeat	O
as	O
(	O
number	O
of	O
frames	O
between	O
downstroke	O
midpoints	O
)	O
/	O
29	O
.	O
97	O
.	O

Authors	O
'	O
contributions	O

JMC	O
performed	O
the	O
data	O
analysis	O
and	O
drafted	O
the	O
manuscript	O
.	O

Supplementary	O
Material	O

A	O
global	O
gene	O
evolution	O
analysis	O
on	O
Vibrionaceae	O
family	O
using	O
phylogenetic	O
profile	O

Abstract	O

Background	O

Vibrionaceae	O
represent	O
a	O
significant	O
portion	O
of	O
the	O
cultivable	O
heterotrophic	O
sea	O
bacteria	O
;	O
they	O
strongly	O
affect	O
nutrient	O
cycling	O
and	O
some	O
species	O
are	O
devastating	O
pathogens	O
.	O

In	O
this	O
work	O
we	O
propose	O
an	O
improved	O
phylogenetic	O
profile	O
analysis	O
on	O
14	O
Vibrionaceae	O
genomes	O
,	O
to	O
study	O
the	O
evolution	O
of	O
this	O
family	O
on	O
the	O
basis	O
of	O
gene	O
content	O
.	O

The	O
phylogenetic	O
profile	O
is	O
based	O
on	O
the	O
observation	O
that	O
genes	O
involved	O
in	O
the	O
same	O
process	O
(	O
e	O
.	O
g	O
.	O
metabolic	O
pathway	O
or	O
structural	O
complex	O
)	O
tend	O
to	O
be	O
concurrently	O
present	O
or	O
absent	O
within	O
different	O
genomes	O
.	O

This	O
allows	O
the	O
prediction	O
of	O
hypothetical	O
functions	O
on	O
the	O
basis	O
of	O
a	O
shared	O
phylogenetic	O
profiles	O
.	O

Moreover	O
this	O
approach	O
is	O
useful	O
to	O
identify	O
putative	O
laterally	O
transferred	O
elements	O
on	O
the	O
basis	O
of	O
their	O
presence	O
on	O
distantly	O
phylogenetically	O
related	O
bacteria	O
.	O

Results	O

Vibrionaceae	O
ORFs	O
were	O
aligned	O
against	O
all	O
the	O
available	O
bacterial	O
proteomes	O
.	O

Phylogenetic	O
profile	O
is	O
defined	O
as	O
an	O
array	O
of	O
distances	O
,	O
based	O
on	O
aminoacid	O
substitution	O
matrixes	O
,	O
from	O
single	O
genes	O
to	O
all	O
their	O
orthologues	O
.	O

Final	O
phylogenetic	O
profiles	O
,	O
derived	O
from	O
non	O
-	O
redundant	O
list	O
of	O
all	O
ORFs	O
,	O
was	O
defined	O
as	O
the	O
median	O
of	O
all	O
the	O
profiles	O
belonging	O
to	O
the	O
cluster	O
.	O

The	O
resulting	O
phylogenetic	O
profiles	O
matrix	O
contains	O
gene	O
clusters	O
on	O
the	O
rows	O
and	O
organisms	O
on	O
the	O
columns	O
.	O

Cluster	O
analysis	O
identified	O
groups	O
of	O
"	O
core	O
genes	O
"	O
with	O
a	O
widespread	O
high	O
similarity	O
across	O
all	O
the	O
organisms	O
and	O
several	O
clusters	O
that	O
contain	O
genes	O
homologous	O
only	O
to	O
a	O
limited	O
set	O
of	O
organisms	O
.	O

On	O
each	O
of	O
these	O
clusters	O
,	O
COG	O
class	O
enrichment	O
has	O
been	O
calculated	O
.	O

The	O
analysis	O
reveals	O
that	O
clusters	O
of	O
core	O
genes	O
have	O
the	O
highest	O
number	O
of	O
enriched	O
classes	O
,	O
while	O
the	O
others	O
are	O
enriched	O
just	O
for	O
few	O
of	O
them	O
like	O
DNA	O
replication	O
,	O
recombination	O
and	O
repair	O
.	O

Conclusion	O

We	O
found	O
that	O
mobile	O
elements	O
have	O
heterogeneous	O
profiles	O
not	O
only	O
across	O
the	O
entire	O
set	O
of	O
organisms	O
,	O
but	O
also	O
within	O
Vibrionaceae	O
;	O
this	O
confirms	O
their	O
great	O
influence	O
on	O
bacteria	O
evolution	O
even	O
inside	O
the	O
same	O
family	O
.	O

Furthermore	O
,	O
several	O
hypothetical	O
proteins	O
highly	O
correlate	O
with	O
mobile	O
elements	O
profiles	O
suggesting	O
a	O
possible	O
horizontal	O
transfer	O
mechanism	O
for	O
the	O
evolution	O
of	O
these	O
genes	O
.	O

Finally	O
,	O
we	O
suggested	O
the	O
putative	O
role	O
of	O
some	O
ORFs	O
having	O
an	O
unknown	O
function	O
on	O
the	O
basis	O
of	O
their	O
phylogenetic	O
profile	O
similarity	O
to	O
well	O
characterized	O
genes	O
.	O

Background	O

Over	O
the	O
past	O
ten	O
years	O
,	O
a	O
great	O
number	O
of	O
microbial	O
genomes	O
have	O
been	O
sequenced	O
covering	O
a	O
wide	O
representation	O
of	O
prokaryots	O
as	O
well	O
as	O
multiple	O
strains	O
of	O
some	O
species	O
.	O

The	O
study	O
of	O
these	O
genomes	O
both	O
by	O
computational	O
and	O
experimental	O
approaches	O
has	O
highly	O
improved	O
our	O
understanding	O
on	O
physiology	O
,	O
phylogenetic	O
relationship	O
and	O
pathogenicity	O
of	O
many	O
organisms	O
.	O

Furthermore	O
,	O
it	O
has	O
provided	O
new	O
knowledge	O
on	O
microbial	O
genome	O
evolution	O
,	O
revealing	O
a	O
gene	O
core	O
shared	O
by	O
the	O
great	O
majority	O
of	O
bacteria	O
,	O
genes	O
characteristic	O
of	O
particular	O
groups	O
and	O
"	O
novel	O
"	O
genes	O
that	O
possibly	O
originated	O
by	O
lateral	O
gene	O
transfer	O
from	O
some	O
unknown	O
source	O
.	O

Analysis	O
performed	O
on	O
closely	O
related	O
genomes	O
revealed	O
that	O
a	O
substantial	O
fraction	O
of	O
genes	O
in	O
any	O
genome	O
seem	O
to	O
be	O
strain	O
specific	O
.	O

These	O
genes	O
might	O
sometime	O
arise	O
by	O
gene	O
duplication	O
followed	O
by	O
a	O
rapid	O
divergence	O
,	O
or	O
by	O
lineage	O
-	O
specific	O
loss	O
of	O
genes	O
in	O
one	O
strain	O
,	O
resulting	O
in	O
a	O
unique	O
gene	O
in	O
other	O
strains	O
.	O

However	O
,	O
there	O
are	O
several	O
lines	O
of	O
evidence	O
indicating	O
that	O
lateral	O
gene	O
transfer	O
may	O
be	O
the	O
main	O
mechanism	O
to	O
acquire	O
novel	O
genes	O
.	O

Indeed	O
,	O
this	O
could	O
be	O
one	O
of	O
the	O
main	O
forces	O
driving	O
bacterial	O
adaptation	O
and	O
evolution	O
.	O

Phage	O
DNA	O
is	O
thought	O
to	O
be	O
one	O
of	O
the	O
main	O
vectors	O
for	O
lateral	O
gene	O
transfer	O
among	O
bacteria	O
[	O
1	O
]	O
and	O
many	O
virulence	O
factors	O
from	O
bacterial	O
pathogen	O
are	O
phage	O
encoded	O
[	O
2	O
]	O
.	O

For	O
example	O
,	O
the	O
genes	O
for	O
CT	O
,	O
the	O
most	O
important	O
virulence	O
factor	O
of	O
V	B-Species
.	I-Species
cholerae	E-Species
,	O
are	O
encoded	O
in	O
the	O
genome	O
of	O
phage	O
CTX	O
phi	O
,	O
integrated	O
in	O
the	O
bacterial	O
chromosome	O
1	O
.	O

Since	O
lateral	O
gene	O
transfer	O
plays	O
a	O
relevant	O
role	O
in	O
bacterial	O
evolution	O
,	O
the	O
reconstruction	O
of	O
phylogeny	O
is	O
very	O
complex	O
and	O
phylogenetic	O
trees	O
built	O
by	O
standard	O
sequence	O
analysis	O
may	O
not	O
lead	O
to	O
a	O
reliable	O
picture	O
of	O
the	O
evolutionary	O
history	O
.	O

In	O
fact	O
,	O
alternative	O
trees	O
can	O
be	O
obtained	O
when	O
different	O
proteins	O
are	O
considered	O
.	O

For	O
many	O
aspects	O
the	O
classification	O
of	O
bacteria	O
on	O
the	O
basis	O
of	O
their	O
global	O
gene	O
content	O
may	O
give	O
a	O
better	O
description	O
of	O
their	O
evolutionary	O
history	O
.	O

This	O
may	O
be	O
particularly	O
important	O
when	O
bacteria	O
of	O
the	O
same	O
group	O
are	O
compared	O
,	O
since	O
newly	O
acquired	O
genes	O
could	O
be	O
relevant	O
to	O
confer	O
peculiar	O
features	O
that	O
allows	O
the	O
exploitation	O
of	O
different	O
ecological	O
niches	O
.	O

In	O
this	O
study	O
we	O
propose	O
a	O
bioinformatic	O
procedure	O
to	O
investigate	O
bacterial	O
genome	O
evolution	O
,	O
taking	O
into	O
account	O
the	O
global	O
gene	O
content	O
,	O
as	O
well	O
as	O
sequence	O
similarity	O
.	O

We	O
based	O
our	O
analysis	O
on	O
modified	O
phylogenetic	O
profiles	O
[	O
3	O
]	O
;	O
however	O
,	O
we	O
do	O
not	O
consider	O
only	O
the	O
presence	O
/	O
absence	O
of	O
orthologue	O
genes	O
,	O
but	O
also	O
their	O
distance	O
,	O
based	O
on	O
a	O
substitution	O
matrix	O
.	O

A	O
phylogenetic	O
profile	O
is	O
a	O
non	O
-	O
sequence	O
-	O
homology	O
-	O
based	O
method	O
developed	O
to	O
infer	O
a	O
possible	O
functional	O
relationship	O
between	O
genes	O
.	O

It	O
is	O
based	O
on	O
the	O
idea	O
that	O
proteins	O
that	O
are	O
involved	O
in	O
the	O
same	O
metabolic	O
pathway	O
or	O
structural	O
complex	O
are	O
likely	O
to	O
evolve	O
in	O
a	O
correlate	O
fashion	O
and	O
during	O
evolution	O
appear	O
phylogenetically	O
linked	O
,	O
showing	O
a	O
tendency	O
to	O
be	O
either	O
preserved	O
or	O
eliminated	O
as	O
a	O
whole	O
.	O

Therefore	O
,	O
genes	O
showing	O
similar	O
phylogenetic	O
profiles	O
are	O
likely	O
to	O
be	O
functionally	O
related	O
.	O

We	O
extended	O
the	O
use	O
of	O
phylogenetic	O
profiles	O
to	O
produce	O
an	O
evolutionary	O
tree	O
based	O
on	O
a	O
hierarchical	O
clusterization	O
of	O
organisms	O
with	O
similar	O
phylogenetic	O
profiles	O
.	O

For	O
this	O
study	O
we	O
took	O
the	O
whole	O
gene	O
dataset	O
of	O
320	O
prokaryotic	O
genomes	O
,	O
however	O
,	O
we	O
limited	O
the	O
analysis	O
to	O
the	O
orthologous	O
groups	O
that	O
are	O
present	O
in	O
at	O
least	O
one	O
of	O
the	O
14	O
considered	O
species	O
of	O
the	O
Vibrionaceae	O
family	O
.	O

These	O
bacteria	O
belong	O
to	O
the	O
Gammaproteobacteria	O
group	O
and	O
are	O
highly	O
abundant	O
in	O
aquatic	O
environment	O
,	O
they	O
strongly	O
influence	O
nutrient	O
cycling	O
and	O
various	O
species	O
are	O
also	O
devastating	O
pathogens	O
.	O

Since	O
we	O
focused	O
our	O
analysis	O
on	O
this	O
particular	O
group	O
,	O
the	O
aim	O
of	O
this	O
study	O
is	O
not	O
the	O
construction	O
of	O
a	O
global	O
evolutionary	O
tree	O
,	O
but	O
rather	O
a	O
Vibrionaceae	O
perspective	O
of	O
bacterial	O
diversity	O
,	O
based	O
on	O
phylogenetic	O
profiles	O
.	O

Results	O
and	O
discussion	O

Phylogenetic	O
matrix	O

The	O
analysis	O
was	O
performed	O
on	O
14	O
bacteria	O
belonging	O
to	O
the	O
Vibrionaceae	O
family	O
(	O
Table	O
1	O
)	O
.	O

The	O
redundant	O
list	O
of	O
Vibrionaceae	O
ORFs	O
was	O
clustered	O
to	O
reduce	O
the	O
number	O
of	O
proteins	O
to	O
analyze	O
and	O
the	O
phylogenetic	O
profile	O
for	O
each	O
cluster	O
was	O
calculated	O
as	O
described	O
in	O
the	O
Method	O
section	O
.	O

Many	O
authors	O
proposed	O
and	O
successfully	O
applied	O
different	O
measure	O
methods	O
to	O
calculate	O
the	O
phylogenetic	O
profile	O
values	O
.	O

Pellegrini	O
et	O
al	O
.	O

[	O
3	O
]	O
firstly	O
proposed	O
a	O
phylogenetic	O
profile	O
described	O
as	O
a	O
string	O
of	O
bits	O
,	O
each	O
bit	O
representing	O
the	O
absence	O
or	O
presence	O
of	O
an	O
homologous	O
gene	O
in	O
a	O
given	O
genome	O
.	O

This	O
method	O
lacks	O
a	O
weighting	O
procedure	O
,	O
giving	O
the	O
same	O
weight	O
(	O
value	O
1	O
)	O
to	O
all	O
the	O
sequences	O
that	O
are	O
considered	O
homologous	O
given	O
a	O
similarity	O
threshold	O
.	O

Enault	O
and	O
colleagues	O
proposed	O
an	O
improved	O
phylogenetic	O
profile	O
based	O
on	O
a	O
normalized	O
Blastp	O
bit	O
score	O
[	O
4	O
]	O
.	O

This	O
method	O
,	O
compared	O
to	O
the	O
approach	O
implemented	O
by	O
Pellegrini	O
,	O
allows	O
weighting	O
each	O
point	O
of	O
the	O
profile	O
proportionally	O
to	O
the	O
length	O
and	O
the	O
quality	O
of	O
the	O
alignment	O
.	O

Jingchun	O
and	O
colleagues	O
optimized	O
the	O
phylogenetic	O
profiles	O
method	O
by	O
integrating	O
phylogenetic	O
relationships	O
among	O
reference	O
organisms	O
and	O
sequence	O
homology	O
information	O
,	O
based	O
on	O
E	O
-	O
value	O
score	O
,	O
to	O
improve	O
prediction	O
accuracy	O
[	O
5	O
]	O
.	O

The	O
measure	O
index	O
I	O
proposed	O
in	O
this	O
work	O
is	O
similar	O
to	O
the	O
others	O
described	O
above	O
,	O
taking	O
into	O
account	O
both	O
the	O
quality	O
and	O
the	O
length	O
of	O
the	O
alignment	O
using	O
a	O
substitution	O
matrix	O
.	O

Moreover	O
our	O
approach	O
considers	O
also	O
the	O
total	O
length	O
of	O
the	O
sequences	O
,	O
penalizing	O
good	O
alignments	O
occurring	O
between	O
ORFs	O
having	O
different	O
lengths	O
and	O
taking	O
into	O
consideration	O
that	O
ORFs	O
could	O
differentiate	O
mainly	O
for	O
the	O
presence	O
of	O
functional	O
domains	O
.	O

The	O
final	O
phylogenetic	O
profile	O
for	O
each	O
cluster	O
was	O
defined	O
as	O
the	O
median	O
of	O
all	O
the	O
profiles	O
belonging	O
to	O
the	O
cluster	O
,	O
named	O
"	O
meta	O
-	O
profile	O
"	O
,	O
which	O
describes	O
the	O
profile	O
of	O
conserved	O
ORFs	O
belonging	O
to	O
an	O
entire	O
family	O
.	O

Hierarchical	O
cluster	O
analysis	O

A	O
hierarchical	O
cluster	O
analysis	O
was	O
performed	O
on	O
the	O
entire	O
phylogenetic	O
profile	O
matrix	O
and	O
it	O
was	O
calculated	O
a	O
statistical	O
support	O
based	O
on	O
bootstrap	O
method	O
for	O
the	O
nodes	O
of	O
the	O
columns	O
tree	O
(	O
Fig	O
1	O
)	O
.	O

The	O
branch	O
tree	O
colors	O
represent	O
the	O
bootstrap	O
percentage	O
support	O
.	O

This	O
constitutes	O
a	O
phylogenetic	O
tree	O
based	O
on	O
gene	O
content	O
using	O
Vibrionaceae	O
ORFs	O
as	O
a	O
reference	O
.	O

Genomes	O
belonging	O
to	O
the	O
same	O
taxonomic	O
group	O
tend	O
to	O
cluster	O
together	O
and	O
the	O
Vibrionaceae	O
species	O
are	O
closely	O
related	O
.	O

As	O
expected	O
,	O
according	O
to	O
the	O
Vibrionaceae	O
branch	O
lengths	O
it	O
is	O
evident	O
that	O
variability	O
within	O
this	O
group	O
is	O
higher	O
compared	O
to	O
the	O
other	O
groups	O
.	O

The	O
dataset	O
used	O
for	O
phylogenetic	O
matrix	O
calculation	O
is	O
indeed	O
composed	O
by	O
Vibrionaceae	O
ORFs	O
.	O

This	O
implies	O
that	O
the	O
similarity	O
measures	O
between	O
these	O
ORFs	O
and	O
the	O
corresponding	O
orthologues	O
will	O
be	O
nearly	O
zero	O
in	O
most	O
of	O
the	O
other	O
species	O
and	O
significantly	O
higher	O
in	O
the	O
Vibrionaceae	O
family	O
,	O
increasing	O
the	O
variability	O
into	O
this	O
group	O
.	O

Moreover	O
the	O
average	O
percentage	O
of	O
clusters	O
shared	O
by	O
the	O
Vibrionaceae	O
members	O
is	O
only	O
47	O
.	O
5	O
%	O
(	O
average	O
number	O
of	O
shared	O
clusters	O
divided	O
by	O
the	O
total	O
number	O
of	O
clusters	O
)	O
that	O
again	O
indicates	O
a	O
high	O
variability	O
inside	O
this	O
family	O
.	O

It	O
is	O
also	O
interesting	O
to	O
note	O
that	O
organisms	O
belonging	O
to	O
the	O
same	O
or	O
closely	O
related	O
taxa	O
split	O
into	O
different	O
subgroups	O
.	O

This	O
highlights	O
the	O
existence	O
of	O
a	O
high	O
variability	O
among	O
lineages	O
,	O
due	O
to	O
genetic	O
and	O
evolutionary	O
processes	O
such	O
as	O
lateral	O
gene	O
transfer	O
,	O
concerted	O
evolution	O
and	O
gene	O
duplication	O
[	O
6	O
]	O
.	O

In	O
terms	O
of	O
gene	O
content	O
,	O
the	O
organisms	O
more	O
related	O
to	O
the	O
Vibrionaceae	O
belong	O
to	O
the	O
gamma	O
and	O
beta	O
proteobacteria	O
.	O

In	O
particular	O
Altermonadales	O
,	O
Enterobacteriales	O
and	O
Burkholderiales	O
are	O
closely	O
related	O
to	O
Vibrionaceae	O
,	O
and	O
share	O
the	O
higher	O
number	O
of	O
cluster	O
of	O
genes	O
(	O
average	O
percentage	O
of	O
20	O
%	O
)	O
.	O

As	O
expected	O
,	O
Archea	O
are	O
the	O
most	O
distant	O
group	O
sharing	O
just	O
3	O
.	O
8	O
%	O
of	O
clusters	O
.	O

Clusters	O
and	O
genes	O
distribution	O
,	O
as	O
shown	O
in	O
Fig	O
2	O
,	O
reveals	O
that	O
the	O
number	O
of	O
clusters	O
and	O
genes	O
shared	O
by	O
the	O
organisms	O
decreases	O
as	O
the	O
number	O
of	O
organisms	O
considered	O
increases	O
.	O

The	O
analysis	O
was	O
performed	O
considering	O
for	O
each	O
cluster	O
profile	O
the	O
number	O
of	O
organisms	O
sharing	O
the	O
same	O
numbers	O
of	O
clusters	O
(	O
and	O
genes	O
)	O
.	O

The	O
majority	O
of	O
gene	O
cluster	O
groups	O
no	O
more	O
than	O
21	O
species	O
on	O
a	O
total	O
of	O
320	O
.	O

The	O
highest	O
blue	O
spike	O
corresponds	O
to	O
the	O
higher	O
number	O
of	O
genes	O
shared	O
by	O
105	O
groups	O
of	O
14	O
organisms	O
.	O

Among	O
these	O
groups	O
,	O
as	O
expected	O
,	O
Vibrionaceae	O
are	O
highly	O
represented	O
.	O

Other	O
species	O
represented	O
are	O
Colwellia	B-Species
psychrerythraea	I-Species
34H	E-Species
and	O
Shewanella	B-Species
oneidensis	E-Species
,	O
that	O
belong	O
to	O
the	O
Alteromonadales	O
family	O
.	O

The	O
cluster	O
analysis	O
performed	O
on	O
genes	O
is	O
shown	O
in	O
Fig	O
.	O

3	O
.	O

From	O
now	O
on	O
,	O
to	O
avoid	O
confusing	O
interpretation	O
between	O
clusters	O
derived	O
from	O
the	O
cluster	O
analysis	O
and	O
cluster	O
derived	O
from	O
the	O
ORFs	O
clustering	O
we	O
will	O
use	O
the	O
term	O
"	O
gene	O
"	O
in	O
place	O
of	O
cluster	O
of	O
ORFs	O
.	O

The	O
different	O
gradient	O
of	O
color	O
,	O
from	O
bright	O
to	O
dark	O
red	O
,	O
represents	O
decreasing	O
similarity	O
values	O
.	O

The	O
cluster	O
analysis	O
allows	O
the	O
detection	O
of	O
three	O
main	O
groups	O
of	O
genes	O
.	O

The	O
first	O
one	O
(	O
Fig	O
3	O
,	O
panel	O
B	O
)	O
contains	O
the	O
most	O
conserved	O
and	O
established	O
genes	O
shared	O
almost	O
by	O
all	O
the	O
organisms	O
.	O

These	O
core	O
genes	O
can	O
be	O
defined	O
as	O
the	O
set	O
of	O
all	O
genes	O
shared	O
as	O
orthologous	O
by	O
all	O
members	O
of	O
an	O
evolutionary	O
coherent	O
group	O
.	O

In	O
our	O
analysis	O
we	O
identify	O
four	O
clusters	O
,	O
for	O
a	O
total	O
of	O
145	O
genes	O
,	O
shared	O
by	O
all	O
the	O
320	O
organisms	O
.	O

The	O
ORFs	O
belonging	O
to	O
these	O
clusters	O
are	O
predicted	O
to	O
codify	O
for	O
the	O
ATP	O
binding	O
subunit	O
of	O
ABC	O
transporters	O
(	O
annotated	O
as	O
ABC	O
-	O
type	O
polar	O
amino	O
acid	O
transport	O
system	O
,	O
ABC	O
-	O
type	O
antimicrobial	O
peptide	O
transport	O
system	O
,	O
ABC	O
-	O
type	O
histidine	O
transport	O
system	O
and	O
ABC	O
-	O
type	O
transport	O
system	O
involved	O
in	O
lysophospholipase	O
L1	O
biosynthesis	O
)	O
.	O

This	O
finding	O
is	O
surprising	O
since	O
this	O
is	O
the	O
first	O
report	O
where	O
these	O
ORFs	O
are	O
assigned	O
to	O
the	O
core	O
genes	O
.	O

Anyway	O
two	O
different	O
explanations	O
can	O
be	O
traced	O
.	O

First	O
,	O
it	O
is	O
known	O
that	O
the	O
ABC	O
transporters	O
represent	O
an	O
essential	O
transport	O
system	O
in	O
the	O
prokaryotes	O
and	O
that	O
their	O
ATP	O
binding	O
subunits	O
are	O
apparently	O
overrepresented	O
compared	O
to	O
the	O
other	O
two	O
subunits	O
(	O
ligand	O
binding	O
and	O
permease	O
subunit	O
)	O
in	O
all	O
genomes	O
sequenced	O
thus	O
far	O
[	O
7	O
]	O
.	O

Second	O
,	O
one	O
organism	O
,	O
Buchnera	B-Species
aphidicola	E-Species
,	O
presents	O
these	O
genes	O
with	O
a	O
similarity	O
just	O
below	O
the	O
cut	O
-	O
off	O
used	O
for	O
the	O
analysis	O
,	O
but	O
they	O
have	O
been	O
considered	O
since	O
it	O
is	O
well	O
known	O
that	O
in	O
this	O
mutualistic	O
endosymbiont	O
the	O
accelerated	O
evolution	O
and	O
AT	O
bias	O
affect	O
all	O
its	O
genes	O
,	O
including	O
the	O
16S	O
rRNA	O
[	O
8	O
,	O
9	O
]	O
.	O

The	O
dataset	O
used	O
for	O
the	O
analysis	O
includes	O
genomes	O
in	O
draft	O
quality	O
(	O
Vibrio	B-Species
cholerae	I-Species
0395	E-Species
,	O
Vibrio	B-Species
cholerae	I-Species
MO10	E-Species
,	O
Vibrio	B-Species
cholerae	I-Species
RC385	E-Species
,	O
Vibrio	B-Species
cholerae	I-Species
V51	E-Species
,	O
Vibrio	B-Species
cholerae	I-Species
V52	E-Species
,	O
Photobacterium	B-Species
profundum	I-Species
3TCK	E-Species
,	O
Vibrio	B-Species
MED222	E-Species
,	O
Vibrio	B-Species
splendidus12B01	E-Species
)	O
.	O

Wrong	O
ORFs	O
prediction	O
or	O
missing	O
genes	O
due	O
to	O
incomplete	O
genome	O
sequences	O
can	O
explain	O
the	O
low	O
number	O
of	O
core	O
genes	O
identified	O
.	O

To	O
avoid	O
such	O
problems	O
we	O
repeated	O
the	O
analysis	O
excluding	O
the	O
draft	O
genomes	O
and	O
thus	O
considering	O
312	O
genomes	O
.	O

The	O
results	O
,	O
reported	O
in	O
Table	O
2	O
,	O
show	O
an	O
increased	O
number	O
of	O
the	O
core	O
genes	O
and	O
in	O
particular	O
ribosomal	O
proteins	O
and	O
tRNA	O
synthetase	O
,	O
as	O
reported	O
by	O
Charlesbois	O
and	O
Doolittle	O
[	O
10	O
]	O
.	O

This	O
could	O
be	O
considered	O
as	O
a	O
sort	O
of	O
"	O
minimal	O
genome	O
"	O
containing	O
the	O
group	O
of	O
genes	O
that	O
are	O
necessary	O
to	O
maintain	O
a	O
free	O
-	O
living	O
organism	O
.	O

The	O
low	O
number	O
of	O
genes	O
shared	O
by	O
all	O
the	O
organisms	O
can	O
be	O
due	O
to	O
many	O
factors	O
.	O

First	O
of	O
all	O
we	O
used	O
the	O
Vibrionaceae	O
ORFs	O
as	O
a	O
reference	O
,	O
limiting	O
the	O
number	O
of	O
genes	O
we	O
were	O
able	O
to	O
identify	O
.	O

It	O
was	O
further	O
demonstrated	O
that	O
the	O
core	O
gene	O
size	O
decreases	O
as	O
more	O
genome	O
sequences	O
are	O
analyzed	O
[	O
10	O
]	O
.	O

Genes	O
that	O
are	O
considered	O
to	O
belong	O
to	O
the	O
core	O
set	O
when	O
close	O
organisms	O
are	O
compared	O
,	O
are	O
classified	O
as	O
flexible	O
genes	O
when	O
distantly	O
related	O
genomes	O
are	O
analyzed	O
[	O
6	O
]	O
.	O

Finally	O
,	O
genes	O
within	O
core	O
genomes	O
might	O
be	O
transferred	O
or	O
replaced	O
,	O
introducing	O
new	O
versions	O
of	O
existing	O
genes	O
into	O
genomes	O
.	O

Such	O
transfers	O
can	O
replace	O
even	O
highly	O
conserved	O
genes	O
by	O
non	O
-	O
homologous	O
counterparts	O
but	O
the	O
advantages	O
provided	O
are	O
difficult	O
to	O
explain	O
.	O

It	O
is	O
also	O
to	O
take	O
into	O
consideration	O
that	O
many	O
symbiotic	O
and	O
parasitic	O
bacteria	O
undergo	O
a	O
reduction	O
of	O
their	O
genomes	O
,	O
loosing	O
many	O
genes	O
required	O
by	O
free	O
-	O
living	O
cell	O
.	O

The	O
second	O
group	O
(	O
Fig	O
3	O
,	O
panel	O
C	O
)	O
represents	O
genes	O
shared	O
mainly	O
among	O
Vibrionaceae	O
and	O
other	O
gamma	O
proteobacteria	O
(	O
as	O
Altermonadales	O
,	O
Burkholderiales	O
and	O
Enterobactidiales	O
)	O
.	O

Finally	O
,	O
the	O
third	O
group	O
(	O
Fig	O
.	O
3	O
,	O
panel	O
D	O
)	O
is	O
composed	O
by	O
genes	O
that	O
are	O
mainly	O
specific	O
to	O
the	O
Vibrionaceae	O
.	O

k	O
-	O
mean	O
cluster	O
analysis	O
and	O
cluster	O
enrichment	O

We	O
performed	O
a	O
k	O
-	O
means	O
cluster	O
analysis	O
,	O
setting	O
the	O
k	O
value	O
to	O
14	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

4	O
,	O
the	O
clusters	O
3	O
,	O
4	O
,	O
11	O
,	O
13	O
and	O
14	O
contain	O
the	O
higher	O
percentage	O
of	O
genes	O
,	O
accounting	O
for	O
more	O
that	O
50	O
%	O
of	O
the	O
total	O
genes	O
,	O
while	O
clusters	O
9	O
and	O
10	O
contain	O
the	O
lower	O
number	O
of	O
ORFs	O
(	O
3	O
%	O
of	O
genes	O
)	O
.	O

The	O
variance	O
in	O
each	O
k	O
-	O
means	O
cluster	O
is	O
very	O
low	O
(	O
Fig	O
.	O
4	O
)	O
,	O
meaning	O
that	O
the	O
clusters	O
contain	O
genes	O
with	O
compact	O
and	O
similar	O
profiles	O
.	O

As	O
described	O
in	O
Fig	O
.	O

4	O
,	O
the	O
majority	O
of	O
the	O
clusters	O
(	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
9	O
,	O
12	O
,	O
13	O
)	O
contains	O
genes	O
with	O
a	O
similar	O
profile	O
,	O
with	O
the	O
average	O
values	O
(	O
red	O
line	O
)	O
near	O
zero	O
,	O
except	O
for	O
the	O
presence	O
of	O
some	O
spikes	O
correspondent	O
to	O
an	O
increasing	O
similarity	O
with	O
some	O
isolated	O
organisms	O
.	O

As	O
shown	O
in	O
Table	O
3	O
,	O
clusters	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
9	O
contains	O
genes	O
that	O
have	O
a	O
high	O
similarity	O
in	O
a	O
small	O
subset	O
of	O
organisms	O
.	O

The	O
majority	O
of	O
these	O
ORFs	O
are	O
annotated	O
as	O
hypothetical	O
proteins	O
or	O
phage	O
related	O
proteins	O
.	O

Clusters	O
8	O
,	O
10	O
and	O
14	O
present	O
genes	O
shared	O
among	O
almost	O
all	O
the	O
organisms	O
.	O

In	O
particular	O
cluster	O
10	O
is	O
composed	O
by	O
the	O
core	O
genes	O
described	O
before	O
having	O
an	O
high	O
value	O
of	O
similarity	O
widespread	O
among	O
all	O
the	O
organisms	O
;	O
cluster	O
8	O
contains	O
genes	O
shared	O
mainly	O
by	O
gamma	O
proteobacteria	O
and	O
cluster	O
14	O
is	O
composed	O
of	O
genes	O
in	O
common	O
between	O
Vibrionaceae	O
and	O
Enterobacteriaceae	O
.	O

A	O
functional	O
annotation	O
has	O
been	O
performed	O
on	O
each	O
gene	O
cluster	O
using	O
COG	O
(	O
Cluster	O
of	O
Orthologous	O
Genes	O
)	O
,	O
KEGG	O
pathway	O
map	O
and	O
GO	O
databases	O
.	O

For	O
each	O
k	O
-	O
mean	O
cluster	O
the	O
enrichment	O
probability	O
with	O
respect	O
to	O
the	O
total	O
number	O
of	O
clusters	O
has	O
been	O
obtained	O
with	O
the	O
hypergeometric	O
distribution	O
.	O

Fig	O
.	O

5	O
shows	O
COG	O
enrichment	O
results	O
for	O
each	O
cluster	O
.	O

As	O
expected	O
clusters	O
represented	O
by	O
conserved	O
genes	O
(	O
cluster	O
8	O
,	O
10	O
and	O
14	O
)	O
have	O
the	O
higher	O
number	O
of	O
enriched	O
COG	O
codes	O
,	O
while	O
cluster	O
specific	O
of	O
few	O
organisms	O
are	O
characterized	O
by	O
a	O
small	O
number	O
of	O
enriched	O
COGs	O
.	O

The	O
majority	O
of	O
clusters	O
presents	O
COG	O
codes	O
enrichment	O
for	O
S	O
(	O
function	O
unknown	O
)	O
,	O
R	O
(	O
poorly	O
characterized	O
)	O
and	O
-	O
(	O
absence	O
of	O
COG	O
code	O
)	O
categories	O
.	O

This	O
is	O
due	O
to	O
the	O
large	O
abundance	O
of	O
unknown	O
and	O
hypothetical	O
proteins	O
presents	O
in	O
the	O
Vibrionaceae	O
proteomes	O
.	O

It	O
is	O
worth	O
noting	O
that	O
cluster	O
3	O
,	O
mainly	O
represented	O
by	O
Photobacterium	B-Species
profundum	I-Species
SS9	E-Species
ORFs	O
,	O
is	O
enriched	O
only	O
by	O
C	O
(	O
Energy	O
production	O
and	O
conversion	O
)	O
,	O
L	O
(	O
DNA	O
replication	O
,	O
recombination	O
and	O
repair	O
)	O
and	O
M	O
(	O
Cell	O
envelope	O
biogenesis	O
,	O
outer	O
membrane	O
)	O
.	O

Probably	O
the	O
L	O
class	O
overrepresentation	O
is	O
determined	O
by	O
the	O
high	O
number	O
of	O
transposons	O
that	O
are	O
present	O
in	O
the	O
SS9	O
genome	O
[	O
11	O
]	O
.	O

The	O
role	O
played	O
by	O
these	O
transposable	O
elements	O
in	O
the	O
survival	O
of	O
this	O
deep	O
-	O
sea	O
bacterium	O
it	O
is	O
still	O
a	O
matter	O
of	O
debate	O
[	O
12	O
]	O
.	O

In	O
addition	O
V	B-Species
.	I-Species
vulnificus	I-Species
YJ016	E-Species
and	O
V	B-Species
.	I-Species
vulnificus	I-Species
CMCP6	E-Species
(	O
cluster	O
13	O
)	O
seem	O
to	O
share	O
genes	O
belonging	O
to	O
the	O
enriched	O
COG	O
classes	O
K	O
(	O
Transcription	O
)	O
,	O
L	O
and	O
T	O
(	O
Signal	O
transduction	O
mechanisms	O
)	O
.	O

It	O
was	O
previously	O
reported	O
an	O
enrichment	O
in	O
genes	O
belonging	O
to	O
the	O
transcription	O
class	O
in	O
the	O
genome	O
of	O
V	B-Species
.	I-Species
vulnificus	E-Species
respect	O
to	O
the	O
V	B-Species
.	I-Species
cholerae	E-Species
genome	O
[	O
13	O
]	O
.	O

This	O
class	O
is	O
clearly	O
related	O
to	O
the	O
T	O
class	O
and	O
seems	O
to	O
indicate	O
that	O
this	O
organism	O
is	O
able	O
to	O
receive	O
and	O
translate	O
in	O
a	O
transcriptional	O
response	O
specific	O
environmental	O
signals	O
.	O

Despite	O
this	O
,	O
the	O
large	O
majority	O
of	O
the	O
genes	O
in	O
clusters	O
3	O
and	O
13	O
lacks	O
COG	O
annotation	O
.	O

Cluster	O
7	O
,	O
as	O
shown	O
in	O
Table	O
3	O
,	O
accounts	O
organisms	O
with	O
large	O
genome	O
size	O
(	O
see	O
Table	O
1	O
)	O
.	O

This	O
can	O
explain	O
the	O
fact	O
the	O
this	O
cluster	O
contains	O
almost	O
all	O
the	O
COG	O
class	O
enriched	O
and	O
suggests	O
a	O
more	O
complex	O
and	O
flexible	O
life	O
-	O
style	O
of	O
these	O
organisms	O
compared	O
to	O
the	O
other	O
Vibrionaceae	O
members	O
.	O

KEGG	O
annotation	O
is	O
limited	O
to	O
metabolic	O
or	O
structural	O
complex	O
network	O
and	O
so	O
a	O
reduced	O
number	O
of	O
genes	O
have	O
a	O
KEGG	O
entry	O
.	O

This	O
causes	O
the	O
presence	O
of	O
clusters	O
without	O
enriched	O
map	O
(	O
cluster	O
2	O
-	O
5	O
,	O
7	O
,	O
13	O
,	O
see	O
Fig	O
5	O
)	O
.	O

Also	O
in	O
this	O
case	O
,	O
the	O
clusters	O
presenting	O
the	O
higher	O
number	O
of	O
significant	O
KEGG	O
map	O
are	O
those	O
containing	O
the	O
conserved	O
genes	O
.	O

The	O
most	O
enriched	O
KEGG	O
clusters	O
are	O
cluster	O
14	O
,	O
10	O
and	O
8	O
accounting	O
for	O
the	O
majority	O
of	O
the	O
metabolic	O
pathways	O
.	O

Cluster	O
1	O
is	O
enriched	O
for	O
map3080	O
(	O
type	O
IV	O
secretion	O
system	O
)	O
.	O

In	O
fact	O
V	B-Species
.	I-Species
fischeri	E-Species
genome	O
contains	O
10	O
separate	O
pilus	O
gene	O
clusters	O
,	O
including	O
eight	O
type	O
-	O
IV	O
pilus	O
loci	O
.	O

The	O
presence	O
of	O
multiple	O
pilus	O
gene	O
clusters	O
suggests	O
that	O
different	O
pili	O
may	O
be	O
expressed	O
in	O
different	O
environments	O
or	O
during	O
multiple	O
stages	O
of	O
its	O
development	O
as	O
a	O
symbiont	O
[	O
14	O
]	O
.	O

Cluster	O
11	O
is	O
enriched	O
for	O
map3090	O
(	O
type	O
II	O
secretion	O
system	O
)	O
.	O

The	O
type	O
II	O
pathway	O
is	O
conserved	O
among	O
gram	O
-	O
negative	O
bacteria	O
,	O
including	O
many	O
pathogens	O
,	O
and	O
secretes	O
a	O
variety	O
of	O
virulence	O
factors	O
and	O
degradative	O
enzymes	O
[	O
15	O
]	O
.	O

Cluster	O
9	O
is	O
enriched	O
for	O
map	O
00860	O
(	O
Porphyrin	O
and	O
chlorophyll	O
metabolism	O
)	O
.	O

These	O
genes	O
are	O
involved	O
in	O
the	O
cobalamin	O
(	O
coenzyme	O
B12	O
)	O
biosynthetic	O
pathway	O
[	O
16	O
]	O
.	O

Some	O
organisms	O
,	O
such	O
as	O
Salmonella	B-Species
typhimurium	E-Species
and	O
Klebsiella	B-Species
pneumoniae	E-Species
,	O
can	O
synthesize	O
cobalamin	O
de	O
novo	O
[	O
17	O
]	O
,	O
while	O
E	B-Species
.	I-Species
coli	E-Species
and	O
large	O
part	O
of	O
the	O
Vibrionaceae	O
perform	O
cobalamin	O
biosynthesis	O
only	O
when	O
provided	O
with	O
cobinamide	O
.	O

It	O
is	O
interesting	O
to	O
observe	O
that	O
the	O
genes	O
belonging	O
to	O
the	O
de	O
novo	O
pathway	O
are	O
only	O
shared	O
by	O
Archea	O
,	O
some	O
other	O
organisms	O
like	O
Salmonella	O
,	O
Pseudomonas	O
and	O
Vibrio	B-Species
MED222	E-Species
.	O

Finally	O
cluster	O
6	O
is	O
enriched	O
by	O
map2010	O
(	O
ABC	O
transporter	O
)	O
,	O
map2020	O
(	O
two	O
-	O
component	O
system	O
)	O
,	O
map2030	O
and	O
map2031	O
(	O
bacterial	O
chemotaxis	O
)	O
,	O
map2040	O
(	O
Flagellar	O
assembly	O
)	O
and	O
map3090	O
(	O
type	O
II	O
secretion	O
system	O
)	O
.	O

This	O
cluster	O
contains	O
genes	O
shared	O
with	O
a	O
high	O
similarity	O
by	O
all	O
Vibrio	O
and	O
with	O
a	O
lower	O
similarity	O
with	O
Photobacterium	B-Species
profundum	E-Species
species	O
.	O

Among	O
the	O
Vibrio	O
species	O
the	O
organisms	O
showing	O
the	O
highest	O
similarity	O
(	O
Tab	O
.	O
3	O
)	O
are	O
V	B-Species
.	I-Species
cholerae	E-Species
strains	O
.	O

Vibrionaceae	O
specific	O
genes	O

We	O
identify	O
1940	O
clusters	O
specific	O
to	O
the	O
Vibrionaceae	O
.	O

All	O
the	O
Vibrionaceae	O
considered	O
in	O
the	O
analysis	O
share	O
108	O
clusters	O
.	O

Among	O
these	O
genes	O
we	O
identify	O
ToxR	O
and	O
ToxS	O
genes	O
.	O

ToxR	O
gene	O
encodes	O
a	O
transmembrane	O
regulatory	O
protein	O
firstly	O
identified	O
in	O
V	B-Species
.	I-Species
cholerae	E-Species
,	O
in	O
which	O
it	O
co	O
-	O
ordinates	O
many	O
virulence	O
factors	O
in	O
response	O
to	O
several	O
environmental	O
parameters	O
[	O
18	O
]	O
.	O

V	B-Species
.	I-Species
cholerae	E-Species
ToxR	O
activity	O
is	O
enhanced	O
by	O
a	O
second	O
transmembrane	O
protein	O
,	O
ToxS	O
,	O
encoded	O
downstream	O
toxR	O
[	O
19	O
]	O
.	O

This	O
family	O
of	O
proteins	O
is	O
involved	O
in	O
response	O
to	O
temperature	O
,	O
pH	O
,	O
osmolarity	O
and	O
in	O
Photobacterium	B-Species
profundum	I-Species
SS9	E-Species
,	O
a	O
piezophilic	O
bacterium	O
,	O
to	O
hydrostatic	O
pressure	O
[	O
20	O
]	O
.	O

The	O
widespread	O
presence	O
of	O
these	O
genes	O
among	O
the	O
Vibrionaceae	O
suggests	O
their	O
importance	O
in	O
regulatory	O
mechanisms	O
.	O

We	O
identify	O
two	O
other	O
noteworthy	O
groups	O
of	O
genes	O
composed	O
by	O
257	O
and	O
160	O
genes	O
respectively	O
shared	O
just	O
by	O
two	O
strains	O
,	O
mainly	O
annotated	O
as	O
"	O
hypothetical	O
protein	O
"	O
.	O

The	O
first	O
group	O
of	O
genes	O
is	O
shared	O
between	O
Photobacterium	B-Species
profundum	I-Species
SS9	E-Species
and	O
Photobacterium	B-Species
profundum	I-Species
3TCK	E-Species
,	O
while	O
the	O
second	O
is	O
shared	O
between	O
V	B-Species
.	I-Species
vulnificus	I-Species
CMCP6	E-Species
and	O
YJ016	S-Species
.	O

These	O
strains	O
are	O
closely	O
related	O
and	O
this	O
explains	O
the	O
high	O
number	O
of	O
shared	O
genes	O
;	O
while	O
,	O
inside	O
the	O
Vibrionaceae	O
family	O
,	O
the	O
number	O
of	O
specific	O
shared	O
genes	O
highly	O
decreases	O
,	O
showing	O
a	O
high	O
inter	O
-	O
species	O
variability	O
(	O
Fig	O
.	O
6	O
)	O

Prophages	O
and	O
transposases	O

Prophages	O
recover	O
different	O
biological	O
roles	O
both	O
as	O
quantitatively	O
important	O
genetic	O
elements	O
of	O
the	O
bacterial	O
chromosome	O
,	O
and	O
as	O
vectors	O
of	O
lateral	O
gene	O
transfer	O
among	O
bacteria	O
,	O
due	O
to	O
their	O
characters	O
of	O
mobile	O
DNA	O
elements	O
.	O

Indeed	O
,	O
numerous	O
virulence	O
factors	O
from	O
bacterial	O
pathogens	O
are	O
phage	O
encoded	O
.	O

It	O
was	O
postulated	O
that	O
this	O
role	O
of	O
prophages	O
is	O
not	O
limited	O
to	O
pathogenic	O
bacteria	O
but	O
some	O
adaptations	O
of	O
nonpathogenic	O
strains	O
to	O
their	O
ecological	O
niche	O
might	O
also	O
be	O
mediated	O
by	O
prophages	O
acquisition	O
[	O
21	O
]	O
.	O

To	O
better	O
understand	O
the	O
importance	O
of	O
mobile	O
elements	O
within	O
Vibrionaceae	O
family	O
,	O
we	O
performed	O
a	O
hierarchical	O
cluster	O
analysis	O
using	O
gene	O
profiles	O
annotated	O
as	O
"	O
phage	O
protein	O
"	O
and	O
"	O
transposase	O
"	O
,	O
for	O
a	O
total	O
of	O
172	O
clusters	O
of	O
genes	O
(	O
Fig	O
7	O
)	O
.	O

We	O
found	O
that	O
a	O
high	O
inter	O
-	O
strain	O
genetic	O
variability	O
exists	O
and	O
phages	O
and	O
transposases	O
are	O
both	O
shared	O
by	O
almost	O
all	O
Vibrionaceae	O
,	O
and	O
specific	O
to	O
just	O
some	O
organisms	O
.	O

We	O
identified	O
five	O
major	O
clusters	O
of	O
mobile	O
elements	O
that	O
are	O
specific	O
to	O
a	O
single	O
organism	O
.	O

A	O
group	O
composed	O
by	O
26	O
clusters	O
containing	O
both	O
transposase	O
and	O
phage	O
proteins	O
seem	O
to	O
be	O
unique	O
to	O
V	B-Species
.	I-Species
splendiduds	I-Species
12B01	E-Species
(	O
Fig	O
7	O
)	O
.	O

Another	O
one	O
composed	O
by	O
16	O
clusters	O
is	O
specific	O
of	O
V	B-Species
.	I-Species
vulnificus	I-Species
CMCP6	E-Species
(	O
Fig	O
7	O
)	O
while	O
V	B-Species
.	I-Species
parahaemoliticus	E-Species
has	O
a	O
cluster	O
of	O
11	O
genes	O
(	O
Fig	O
7	O
)	O
.	O

Moreover	O
there	O
is	O
another	O
group	O
of	O
transposases	O
and	O
phage	O
genes	O
shared	O
mainly	O
by	O
V	B-Species
.	I-Species
cholerae	E-Species
0395	O
,	O
Shewanella	B-Species
oneidensis	E-Species
and	O
V	B-Species
.	I-Species
cholerae	E-Species
V51	O
(	O
Fig	O
7	O
)	O
.	O

Finally	O
a	O
big	O
cluster	O
of	O
almost	O
30	O
genes	O
,	O
all	O
predicted	O
to	O
codify	O
for	O
transposases	O
,	O
was	O
found	O
in	O
P	B-Species
.	I-Species
profundum	I-Species
SS9	E-Species
genome	O
(	O
Fig	O
.	O
7	O
)	O
.	O

The	O
high	O
presence	O
of	O
transposases	O
in	O
this	O
bacterium	O
seems	O
to	O
correlate	O
with	O
its	O
deep	O
-	O
sea	O
habitat	O
,	O
a	O
feature	O
presumably	O
shared	O
with	O
other	O
deep	O
-	O
sea	O
microorganisms	O
[	O
12	O
]	O
.	O

As	O
shown	O
in	O
Fig	O
7	O
,	O
many	O
of	O
the	O
clusters	O
well	O
conserved	O
in	O
an	O
organism	O
,	O
are	O
partially	O
shared	O
with	O
a	O
low	O
similarity	O
by	O
other	O
organisms	O
.	O

This	O
agrees	O
with	O
the	O
idea	O
that	O
prophages	O
are	O
not	O
maintained	O
in	O
the	O
genome	O
over	O
a	O
long	O
period	O
of	O
time	O
and	O
part	O
of	O
their	O
genes	O
may	O
be	O
deleted	O
from	O
the	O
chromosome	O
.	O

Moreover	O
,	O
microarray	O
analysis	O
and	O
PCR	O
scanning	O
demonstrated	O
that	O
prophages	O
are	O
frequently	O
strain	O
specific	O
within	O
a	O
given	O
bacterial	O
species	O
[	O
22	O
-	O
24	O
]	O
.	O

According	O
to	O
the	O
modular	O
theory	O
of	O
phage	O
evolution	O
,	O
phage	O
genomes	O
are	O
mosaics	O
of	O
modules	O
,	O
groups	O
of	O
genes	O
functionally	O
related	O
,	O
that	O
are	O
free	O
to	O
recombine	O
in	O
genetic	O
exchanges	O
between	O
distinct	O
phages	O
infecting	O
the	O
same	O
cell	O
[	O
21	O
]	O
.	O

This	O
can	O
result	O
in	O
the	O
occurrences	O
of	O
different	O
part	O
of	O
phage	O
distributed	O
in	O
far	O
related	O
genomes	O
.	O

Phylogenetic	O
profile	O
of	O
some	O
transposases	O
is	O
similar	O
to	O
the	O
phage	O
ones	O
,	O
suggesting	O
a	O
possible	O
transfer	O
mechanism	O
phage	O
-	O
mediated	O
for	O
such	O
mobile	O
elements	O
.	O

Conclusion	O

In	O
this	O
work	O
we	O
propose	O
an	O
improved	O
phylogenetic	O
profile	O
analysis	O
on	O
14	O
Vibrionaceae	O
genomes	O
,	O
to	O
study	O
this	O
family	O
on	O
the	O
basis	O
of	O
gene	O
content	O
.	O

Using	O
a	O
phylogenetic	O
profile	O
for	O
each	O
cluster	O
of	O
genes	O
defined	O
as	O
the	O
median	O
of	O
all	O
the	O
profiles	O
belonging	O
to	O
the	O
cluster	O
(	O
meta	O
-	O
profile	O
)	O
we	O
investigate	O
the	O
evolution	O
of	O
groups	O
of	O
ORFs	O
belonging	O
to	O
the	O
entire	O
family	O
.	O

A	O
two	O
-	O
way	O
cluster	O
analysis	O
allows	O
us	O
to	O
identify	O
similarity	O
structures	O
on	O
the	O
entire	O
phylogenetic	O
matrix	O
composed	O
by	O
8	O
,	O
239	O
clusters	O
of	O
genes	O
and	O
320	O
organisms	O
.	O

The	O
phylogenetic	O
tree	O
obtained	O
with	O
the	O
cluster	O
analysis	O
does	O
not	O
reflect	O
the	O
global	O
evolutionary	O
tree	O
because	O
of	O
the	O
Vibrionaceae	O
ORFs	O
dataset	O
used	O
for	O
the	O
analysis	O
,	O
but	O
rather	O
can	O
be	O
considered	O
as	O
the	O
Vibrionaceae	O
perspective	O
of	O
bacterial	O
diversity	O
.	O

The	O
phylogenetic	O
tree	O
reflects	O
the	O
evolutionary	O
processes	O
that	O
shape	O
genomes	O
,	O
as	O
lateral	O
gene	O
transfer	O
,	O
genes	O
genesis	O
and	O
loss	O
.	O

In	O
this	O
context	O
,	O
the	O
tree	O
allows	O
to	O
group	O
together	O
genomes	O
on	O
the	O
base	O
of	O
their	O
global	O
gene	O
content	O
.	O

We	O
found	O
that	O
genomes	O
belonging	O
to	O
the	O
same	O
taxonomic	O
group	O
tend	O
to	O
cluster	O
together	O
and	O
that	O
Vibrionaceae	O
species	O
are	O
closely	O
related	O
.	O

Moreover	O
organisms	O
belonging	O
to	O
the	O
same	O
or	O
closely	O
related	O
taxa	O
split	O
into	O
different	O
subgroups	O
,	O
confirming	O
the	O
existence	O
of	O
a	O
high	O
variability	O
among	O
lineages	O
,	O
due	O
to	O
genetic	O
and	O
evolutionary	O
process	O
such	O
as	O
lateral	O
gene	O
transfer	O
,	O
concerted	O
evolution	O
and	O
genes	O
duplication	O
.	O

On	O
the	O
other	O
hand	O
several	O
groups	O
of	O
genes	O
characterised	O
by	O
different	O
homogeneous	O
profiles	O
have	O
been	O
identified	O
.	O

In	O
particular	O
we	O
found	O
,	O
1	O
)	O
a	O
set	O
of	O
conserved	O
genes	O
(	O
with	O
a	O
high	O
similarity	O
values	O
across	O
all	O
organisms	O
)	O
that	O
reflects	O
the	O
"	O
minimal	O
genome	O
"	O
composition	O
defined	O
in	O
other	O
previous	O
works	O
;	O
2	O
)	O
a	O
set	O
of	O
genes	O
mainly	O
shared	O
by	O
Vibrionaceae	O
and	O
other	O
Gamma	O
proteobacteria	O
and	O
3	O
)	O
genes	O
specific	O
to	O
different	O
sets	O
of	O
Vibrionaceae	O
.	O

Finally	O
a	O
further	O
analysis	O
on	O
prophage	O
and	O
transposase	O
has	O
confirmed	O
the	O
high	O
inter	O
-	O
strain	O
genetic	O
variability	O
even	O
among	O
closely	O
related	O
species	O
.	O

The	O
increasing	O
number	O
of	O
genomes	O
included	O
in	O
this	O
type	O
of	O
analysis	O
surely	O
add	O
new	O
sorces	O
of	O
variability	O
and	O
noise	O
,	O
anyway	O
we	O
think	O
that	O
the	O
use	O
of	O
meta	O
-	O
profiles	O
can	O
be	O
useful	O
for	O
complexity	O
reduction	O
and	O
data	O
analysis	O
to	O
study	O
global	O
gene	O
evolution	O
.	O

Methods	O

Datasets	O

The	O
Vibrionaceae	O
species	O
used	O
in	O
this	O
analysis	O
were	O
selected	O
among	O
the	O
freely	O
available	O
complete	O
and	O
draft	O
genome	O
sequences	O
.	O

The	O
proteomes	O
of	O
V	B-Species
.	I-Species
cholerae	I-Species
N16961	E-Species
,	O
V	B-Species
.	I-Species
parahaemolyticus	E-Species
,	O
V	B-Species
.	I-Species
vulnificus	I-Species
YJ016	E-Species
,	O
V	B-Species
.	I-Species
vulnificus	I-Species
CMCP6	E-Species
,	O
V	B-Species
.	I-Species
fischeri	I-Species
ES114	E-Species
,	O
Photobacterium	B-Species
profundum	I-Species
SS9	E-Species
were	O
downloaded	O
from	O
the	O
NCBI	O
ftp	O
site	O
[	O
25	O
]	O
.	O

Protein	O
sequences	O
of	O
Vibrio	B-Species
cholerae	I-Species
MO10	E-Species
,	O
Vibrio	B-Species
cholerae	I-Species
0395	E-Species
,	O
Vibrio	B-Species
cholerae	I-Species
RC385	E-Species
,	O
Vibrio	B-Species
cholerae	I-Species
V51	E-Species
,	O
Vibrio	B-Species
cholerae	I-Species
V52	E-Species
were	O
downloaded	O
from	O
the	O
NCBI	O
genome	O
database	O
,	O
while	O
sequences	O
of	O
Vibrio	B-Species
MED222	E-Species
,	O
Vibrio	B-Species
splendidus	I-Species
12B01	E-Species
,	O
Photobacterium	B-Species
profundum	I-Species
3TCK	E-Species
from	O
the	O
J	O
.	O

Craig	O
Venter	O
Institute	O
web	O
site	O
.	O

The	O
320	O
complete	O
genomes	O
update	O
at	O
03	O
/	O
06	O
were	O
downloaded	O
from	O
the	O
NCBI	O
ftp	O
site	O
.	O

Similarity	O
search	O
and	O
phylogenetic	O
profile	O
construction	O

All	O
the	O
Vibrionaceae	O
ORFs	O
were	O
merged	O
generating	O
a	O
redundant	O
list	O
of	O
59	O
,	O
669	O
proteins	O
and	O
were	O
compared	O
to	O
all	O
open	O
reading	O
frame	O
from	O
320	O
bacterial	O
and	O
archeal	O
genomes	O
using	O
Blastp	O
.	O

To	O
determine	O
the	O
presence	O
of	O
an	O
orthologous	O
we	O
used	O
a	O
combination	O
of	O
three	O
different	O
thresholds	O
;	O
a	O
similarity	O
value	O
equal	O
to	O
or	O
higher	O
than	O
30	O
%	O
,	O
an	O
alignment	O
length	O
equal	O
or	O
higher	O
than	O
70	O
%	O
and	O
an	O
Evalue	O
score	O
lower	O
than	O
or	O
equal	O
to	O
e	O
-	O
6	O
.	O

After	O
determining	O
the	O
presence	O
of	O
an	O
orthologous	O
gene	O
,	O
we	O
computed	O
a	O
similarity	O
index	O
I	O
for	O
each	O
pair	O
of	O
orthologous	O
(	O
a	O
point	O
of	O
the	O
phylogenetic	O
profile	O
)	O
as	O
follow	O
:	O

I	O
=	O
SqsSqq	O
.	O
min	O
(	O
lq	O
,	O
ls	O
)	O
max	O
(	O
lq	O
,	O
ls	O
)	O

MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGjbqscqGH9aqpdaWcaaqaaiabdofatnaaBaaaleaacqWGXbqCcqWGZbWCaeqaaaGcbaGaem4uam1aaSbaaSqaaiabdghaXjabdghaXbqabaaaaOGaeyyXIC9aaSaaaeaacyGGTbqBcqGGPbqAcqGGUbGBcqGGOaakcqWGSbaBdaWgaaWcbaGaemyCaehabeaakiabcYcaSiabdYgaSnaaBaaaleaacqWGZbWCaeqaaOGaeiykaKcabaGagiyBa0MaeiyyaeMaeiiEaGNaeiikaGIaemiBaW2aaSbaaSqaaiabdghaXbqabaGccqGGSaalcqWGSbaBdaWgaaWcbaGaem4CamhabeaakiabcMcaPaaaaaa	O
@	O
532D	O
@	O

where	O
lq	O
and	O
ls	O
are	O
the	O
query	O
and	O
subject	O
length	O
sequence	O
respectively	O
and	O
Sqs	O
is	O
the	O
similarity	O
score	O
between	O
the	O
query	O
and	O
the	O
subject	O
sequence	O
.	O

Sqs	O
is	O
defined	O
as	O
follow	O
:	O

Sqs	O
=	O
sum	O
i	O
=	O
1M	O
alpha	O
Aqi	O
,	O
Asi	O
+	O
GP	O

MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGtbWudaWgaaWcbaGaemyCaeNaem4Camhabeaakiabg2da9maaqahabaacciGae8xSde2aaSbaaSqaaiabdgeabjabdghaXjabdMgaPjabcYcaSiabdgeabjabdohaZjabdMgaPbqabaaabaGaemyAaKMaeyypa0JaeGymaedabaGaemyta0eaniabggHiLdGccqGHRaWkcqWGhbWrcqWGqbauaaa	O
@	O
4620	O
@	O

where	O
M	O
is	O
the	O
match	O
length	O
between	O
the	O
query	O
and	O
subject	O
sequence	O
;	O
Aqi	O
and	O
Asi	O
respectively	O
the	O
query	O
and	O
subject	O
amino	O
acid	O
in	O
position	O
i	O
;	O
alpha	O
the	O
BLOSUM	O
substitution	O
matrix	O
value	O
for	O
amino	O
acid	O
pair	O
Aqi	O
,	O
Asi	O
and	O
GP	O
the	O
gap	O
penalty	O
.	O

GP	O
is	O
defined	O
as	O
follow	O
:	O

GP	O
=	O
GOP	O
+	O
GEP	O
(	O
k	O
-	O
1	O
)	O

where	O
GOP	O
is	O
the	O
Gap	O
Open	O
Penalty	O
set	O
to	O
-	O
11	O
,	O
GEP	O
the	O
Gap	O
Extension	O
Penalty	O
set	O
to	O
-	O
1	O
and	O
k	O
the	O
gap	O
length	O
.	O

Sqq	O
represents	O
the	O
score	O
of	O
the	O
self	O
-	O
aligned	O
query	O
sequence	O
.	O

Sqs	O
is	O
always	O
smaller	O
than	O
Sqq	O
and	O
the	O
score	O
S	O
range	O
between	O
0	O
and	O
1	O
.	O

In	O
order	O
to	O
take	O
into	O
account	O
also	O
the	O
different	O
sequence	O
lengths	O
,	O
we	O
multiplied	O
the	O
score	O
S	O
by	O
the	O
ratio	O
between	O
the	O
minimum	O
length	O
between	O
query	O
and	O
subject	O
and	O
the	O
maximum	O
length	O
between	O
query	O
and	O
subjects	O
.	O

In	O
this	O
way	O
the	O
total	O
score	O
is	O
weighted	O
on	O
the	O
base	O
of	O
the	O
length	O
,	O
resulting	O
in	O
a	O
lower	O
similarity	O
value	O
if	O
the	O
lengths	O
of	O
the	O
sequences	O
are	O
different	O
.	O

The	O
phylogenetic	O
profile	O
for	O
each	O
ORF	O
is	O
an	O
array	O
of	O
index	O
I	O
with	O
length	O
equal	O
to	O
the	O
number	O
of	O
genomes	O
considered	O
(	O
320	O
)	O
.	O

ORFs	O
clustering	O

The	O
redundant	O
list	O
of	O
59	O
,	O
669	O
Vibrionaceae	O
ORFs	O
contained	O
multiple	O
copies	O
of	O
the	O
same	O
genes	O
due	O
to	O
the	O
presence	O
of	O
conserved	O
genes	O
in	O
the	O
considered	O
genomes	O
.	O

In	O
order	O
to	O
reduce	O
the	O
redundancy	O
,	O
we	O
clustered	O
proteins	O
using	O
a	O
two	O
-	O
step	O
approach	O
.	O

The	O
first	O
step	O
is	O
based	O
on	O
COG	O
(	O
Cluster	O
of	O
Othologous	O
Genes	O
)	O
annotation	O
.	O

COG	O
classifies	O
conserved	O
genes	O
according	O
to	O
their	O
homologous	O
relationships	O
.	O

All	O
the	O
Vibrionaceae	O
ORFs	O
were	O
annotated	O
using	O
COG	O
clusters	O
and	O
proteins	O
sharing	O
the	O
same	O
COG	O
code	O
were	O
considered	O
belonging	O
to	O
the	O
same	O
cluster	O
.	O

In	O
particular	O
,	O
the	O
annotation	O
process	O
consists	O
of	O
a	O
similarity	O
search	O
of	O
all	O
the	O
ORFs	O
against	O
the	O
COG	O
proteins	O
using	O
blast	O
and	O
considering	O
the	O
best	O
hit	O
for	O
each	O
protein	O
.	O

43	O
,	O
024	O
ORFs	O
presented	O
a	O
similarity	O
with	O
a	O
COG	O
entry	O
,	O
producing	O
2	O
,	O
463	O
different	O
clusters	O
.	O

In	O
the	O
second	O
step	O
,	O
the	O
remaining	O
16	O
,	O
645	O
ORFs	O
without	O
similarity	O
with	O
any	O
COG	O
entry	O
were	O
clustered	O
using	O
CD	O
-	O
HIT	O
software	O
[	O
26	O
]	O
.	O

CD	O
-	O
HIT	O
program	O
clusters	O
protein	O
sequence	O
database	O
at	O
high	O
sequence	O
identity	O
threshold	O
and	O
efficiently	O
removes	O
high	O
sequence	O
redundancy	O
.	O

This	O
last	O
clustering	O
process	O
produced	O
9	O
,	O
613	O
different	O
groups	O
of	O
similar	O
proteins	O
.	O

Finally	O
from	O
the	O
12	O
,	O
076	O
total	O
clusters	O
obtained	O
by	O
this	O
methodology	O
,	O
those	O
composed	O
by	O
ORFs	O
that	O
do	O
not	O
have	O
any	O
ortologous	O
genes	O
(	O
with	O
a	O
phylogenetic	O
profile	O
composed	O
by	O
an	O
array	O
with	O
all	O
zero	O
values	O
except	O
for	O
one	O
position	O
match	O
with	O
itself	O
)	O
were	O
eliminated	O
,	O
resulting	O
in	O
a	O
dataset	O
composed	O
by	O
8	O
,	O
239	O
distinct	O
clusters	O
.	O

The	O
final	O
phylogenetic	O
profile	O
for	O
each	O
cluster	O
(	O
meta	O
-	O
profile	O
)	O
was	O
defined	O
as	O
the	O
median	O
of	O
all	O
the	O
profiles	O
belonging	O
to	O
the	O
cluster	O
.	O

At	O
the	O
end	O
of	O
these	O
procedures	O
the	O
final	O
phylogenetic	O
matrix	O
was	O
composed	O
by	O
8	O
,	O
239	O
rows	O
(	O
cluster	O
of	O
genes	O
)	O
and	O
320	O
columns	O
(	O
organisms	O
)	O
.	O

In	O
each	O
cell	O
the	O
median	O
of	O
the	O
index	O
in	O
the	O
cluster	O
was	O
reported	O
.	O

Cluster	O
analysis	O

Several	O
clustering	O
techniques	O
have	O
been	O
used	O
to	O
identify	O
the	O
similarity	O
structure	O
underneath	O
our	O
data	O
.	O

A	O
k	O
-	O
means	O
and	O
a	O
two	O
-	O
way	O
hierarchical	O
cluster	O
analysis	O
with	O
Euclidean	O
distance	O
and	O
complete	O
linkage	O
were	O
performed	O
on	O
the	O
phylogenetic	O
matrix	O
.	O

The	O
goal	O
of	O
a	O
cluster	O
analysis	O
is	O
to	O
partition	O
the	O
elements	O
into	O
subsets	O
without	O
any	O
constrains	O
or	O
a	O
priori	O
information	O
,	O
so	O
that	O
two	O
criteria	O
are	O
satisfied	O
:	O
homogeneity	O
,	O
elements	O
inside	O
a	O
cluster	O
are	O
highly	O
similar	O
to	O
each	O
other	O
;	O
and	O
separation	O
,	O
elements	O
from	O
different	O
clusters	O
have	O
low	O
similarity	O
to	O
each	O
other	O
.	O

The	O
Figure	O
of	O
Merit	O
(	O
FOM	O
)	O
is	O
a	O
measure	O
of	O
fit	O
of	O
the	O
expression	O
patterns	O
for	O
the	O
clusters	O
produced	O
by	O
a	O
particular	O
algorithm	O
that	O
estimates	O
the	O
predictive	O
power	O
of	O
a	O
clustering	O
algorithm	O
.	O

It	O
is	O
computed	O
by	O
removing	O
each	O
sample	O
in	O
turn	O
from	O
the	O
data	O
set	O
,	O
clustering	O
genes	O
based	O
on	O
the	O
remaining	O
data	O
,	O
and	O
calculating	O
the	O
fit	O
of	O
the	O
withheld	O
sample	O
to	O
the	O
clustering	O
pattern	O
obtained	O
from	O
the	O
other	O
samples	O
.	O

On	O
our	O
data	O
FOM	O
analysis	O
identified	O
the	O
best	O
number	O
of	O
k	O
-	O
means	O
clusters	O
between	O
10	O
and	O
15	O
.	O

We	O
decided	O
to	O
set	O
k	O
(	O
in	O
the	O
k	O
-	O
means	O
analysis	O
)	O
equal	O
to	O
14	O
.	O

In	O
each	O
of	O
these	O
14	O
clusters	O
subsequent	O
hierarchical	O
cluster	O
analysis	O
was	O
performed	O
with	O
bootstrap	O
cluster	O
assessment	O
.	O

All	O
the	O
previous	O
analyses	O
were	O
performed	O
with	O
TMEV	O
software	O
[	O
27	O
]	O
,	O
freely	O
available	O
at	O
[	O
28	O
]	O
.	O

Enrichment	O
categories	O

Each	O
cluster	O
of	O
genes	O
has	O
been	O
annotated	O
according	O
to	O
COG	O
code	O
,	O
GO	O
terms	O
and	O
KEGG	O
pathway	O
maps	O
.	O

Class	O
enrichment	O
(	O
with	O
respect	O
to	O
the	O
entire	O
matrix	O
)	O
has	O
been	O
calculated	O
according	O
to	O
the	O
hypergeometric	O
distribution	O
that	O
was	O
used	O
to	O
obtain	O
the	O
chance	O
probability	O
of	O
observing	O
the	O
number	O
of	O
genes	O
annotated	O
with	O
a	O
particular	O
COG	O
,	O
GO	O
and	O
KEGG	O
category	O
among	O
the	O
selected	O
cluster	O
.	O

The	O
probability	O
P	O
of	O
observing	O
at	O
least	O
k	O
genes	O
of	O
a	O
functional	O
category	O
within	O
a	O
group	O
of	O
n	O
genes	O
is	O
given	O
by	O
:	O

P	O
=	O
sum	O
i	O
=	O
kn	O
(	O
fi	O
)	O
(	O
g	O
-	O
fn	O
-	O
i	O
)	O
(	O
gn	O
)	O

MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGqbaucqGH9aqpdaaeWbqaamaalaaabaWaaeWaaeaafaqabeGabaaabaGaemOzaygabaGaemyAaKgaaaGaayjkaiaawMcaamaabmaabaqbaeqabiqaaaqaaiabdEgaNjabgkHiTiabdAgaMbqaaiabd6gaUjabgkHiTiabdMgaPbaaaiaawIcacaGLPaaaaeaadaqadaqaauaabeqaceaaaeaacqWGNbWzaeaacqWGUbGBaaaacaGLOaGaayzkaaaaaaWcbaGaemyAaKMaeyypa0Jaem4AaSgabaGaemOBa4ganiabggHiLdaaaa	O
@	O
47C6	O
@	O

where	O
f	O
is	O
the	O
total	O
number	O
of	O
genes	O
with	O
the	O
same	O
category	O
(	O
in	O
the	O
matrix	O
)	O
and	O
g	O
is	O
the	O
total	O
number	O
of	O
genes	O
in	O
our	O
matrix	O
.	O

A	O
secondary	O
structural	O
common	O
core	O
in	O
the	O
ribosomal	O
ITS2	O
(	O
internal	O
transcribed	O
spacer	O
)	O
of	O

Culexspecies	O
from	O
diverse	O
geographical	O
locations	O

Abstract	O

In	O
the	O
present	O
study	O
,	O
sequence	O
and	O
structural	O
analysis	O
of	O
ITS2	O
region	O
(	O
the	O
spacer	O
segment	O
between	O
5	O
.	O
8S	O
and	O
28S	O
rRNA	O
of	O

mature	O
rRNA	O
sequences	O
)	O
of	O
7	O
Culex	O
species	O
belonging	O
to	O
5	O
different	O
geographical	O
locations	O
was	O
carried	O
out	O
.	O

Alignment	O
of	O
the	O

ITS2	O
sequence	O
from	O
the	O
7	O
species	O
revealed	O
8	O
homologous	O
domains	O
.	O

Four	O
species	O
namely	O
C	B-Species
.	I-Species
vishnui	E-Species
,	O
C	B-Species
.	I-Species
annulus	E-Species
,	O
C	B-Species
.	I-Species
pipiens	E-Species
,	O

C	B-Species
.	I-Species
quiquefasciatusshowed	E-Species
high	O
sequence	O
(	O
98	O
-	O
100	O
%	O
)	O
and	O
RNA	O
secondary	O
structure	O
similarity	O
.	O

The	O
ITS2	O
similarity	O
among	O
different	O

species	O
is	O
high	O
despite	O
their	O
varying	O
geographical	O
locations	O
.	O

Several	O
common	O
features	O
of	O
secondary	O
structure	O
are	O
shared	O
among	O

these	O
species	O
,	O
with	O
some	O
of	O
them	O
supported	O
by	O
compensatory	O
changes	O
,	O
suggesting	O
the	O
significant	O
role	O
by	O
ITS2	O
as	O
an	O
RNA	O
domain	O

during	O
ribosome	O
biogenesis	O
.	O

Background	O

Culex	O
mosquito	O
species	O
have	O
been	O
described	O
from	O
a	O
wide	O
range	O
of	O
environments	O
and	O
are	O
involved	O
in	O
pathogen	O
transmission	O
from	O

human	S-Species
to	O
reservoirs	O
and	O
vice	O
-	O
versa	O
.	O

[	O
1	O
]	O
Sequence	O
similarity	O
have	O
been	O

reported	O
for	O
ITS2	O
(	O
the	O
spacer	O
segments	O
between	O
5	O
.	O
8S	O
and	O
28S	O
rRNA	O
of	O
mature	O
rRNA	O
sequences	O
)	O
from	O
5	O
Culex	O
species	O
of	O
diverse	O

geographic	O
locations	O
.	O

[	O
3	O
-	O
4	O
-	O

5	O
-	O
9	O
-	O

20	O
]	O
The	O
ITS	O
spacers	O
are	O
versatile	O
as	O
genetic	O
markers	O
and	O
have	O
been	O
used	O
for	O
the	O
determination	O
of	O
taxonomic	O

classification	O
.	O

[	O
17	O
]	O
Recent	O
functional	O
analyses	O
performed	O
on	O
yeast	S-Species
ribosomal	O

RNA	O
genes	O
clearly	O
show	O
that	O
the	O
structural	O
integrity	O
of	O
the	O
transcribed	O
spacer	O
regions	O
is	O
an	O
essential	O
prerequisite	O
for	O
the	O
correct	O

processing	O
of	O
mature	O
rRNA	O
and	O
for	O
the	O
biogenesis	O
of	O
active	O
ribosomal	O
subunits	O
.	O

[	O
2	O
-	O

3	O
]	O
The	O
derivation	O
of	O
reliable	O
secondary	O
structure	O
models	O
for	O
each	O
transcribed	O
spacer	O

region	O
would	O
represent	O
a	O
major	O
step	O
towards	O
a	O
detailed	O
understanding	O
of	O
their	O
biological	O
roles	O
.	O

Comparative	O
sequence	O
analysis	O
provides	O
a	O
powerful	O
tool	O
for	O
identifying	O
biologically	O
relevant	O
folding	O
patterns	O
in	O
RNA	O
molecules	O
.	O

[	O
4	O
]	O
This	O
involves	O
collection	O
of	O
sequences	O
exhibiting	O
substantial	O
nucleotide	O

differences	O
while	O
retaining	O
unequivocal	O
sequence	O
similarity	O
.	O

However	O
,	O
a	O
high	O
degree	O
of	O
sequence	O
variation	O
in	O
the	O
transcribed	O

spacers	O
is	O
known	O
even	O
among	O
closely	O
related	O
species	O
.	O

[	O
5	O
-	O
6	O
-	O
7	O
]	O
Here	O
,	O
we	O
analyze	O
ITS2	O
from	O
7	O

Culex	O
species	O
characteristic	O
of	O
5	O
different	O
geographical	O
locations	O
to	O
assemble	O
common	O
RNA	O
structural	O
features	O
.	O

Methodology	O

Dataset	O

ITS2	O
nucleotide	O
sequences	O
from	O
7	O
Culex	O
mosquitoes	O
characteristic	O
of	O
5	O
geographical	O
locations	O
(	O
Italy	O
,	O
China	O
,	O
Africa	O
,	O

America	O
,	O
and	O
Japan	O
)	O
were	O
downloaded	O
from	O
GenBank	O
(	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
genbank	O

)	O
.	O
The	O
GenBank	O
accession	O
numbers	O
for	O
ITS2	O
sequences	O

from	O
C	B-Species
.	I-Species
pipens	E-Species
(	O
North	O
America	O
)	O
,	O
C	B-Species
.	I-Species
tritaeniorhynchus	E-Species
(	O
China	O
)	O
,	O
C	B-Species
.	I-Species
quinquefasciatus	E-Species

(	O
Africa	O
)	O
,	O
C	B-Species
.	I-Species
tarsalis	E-Species
(	O
Italy	O
)	O
,	O
C	B-Species
.	I-Species
annulus	E-Species
(	O
China	O
)	O
,	O
C	B-Species
.	I-Species
pseudovishnui	E-Species

(	O
China	O
)	O
,	O
and	O
C	B-Species
.	I-Species
vishnui	E-Species
(	O
Japan	O
)	O
were	O
X75817	O
,	O
AF305558	O
,	O
Z48468	O
,	O
U33031	O
,	O
AF453488	O
,	O
AF453498	O
and	O
AF165900	O
,	O

respectively	O
.	O

Sequence	O
alignments	O

Multiple	O
sequence	O
alignments	O
were	O
performed	O
using	O
CLUSTALW	O
with	O
a	O
gap	O
opening	O
penalty	O
of	O
15	O
and	O
gap	O
extension	O
penalty	O
of	O
6	O
.	O
66	O
.	O

[	O
8	O
]	O

Secondary	O
structure	O
prediction	O

The	O
RNA	O
secondary	O
structures	O
for	O
ITS2	O
were	O
predicted	O
using	O
RNADRAW	O
.	O

[	O
21	O
]	O

RNADRAW	O
predicts	O
RNA	O
structures	O
by	O
identifying	O
suboptimal	O
structures	O
using	O
the	O
free	O
energy	O
optimization	O
methodology	O
at	O
a	O
default	O

temperature	O
of	O
370	O
degrees	O
C	O
.	O

In	O
the	O
current	O
study	O
,	O
ITS2	O
and	O
5	O
.	O
8S	O
regions	O
(	O
the	O
first	O
170	O
nucleotides	O
)	O
were	O
used	O
for	O
RNA	O
structure	O

prediction	O
.	O

The	O
minimum	O
energy	O
structure	O
prediction	O
algorithm	O
in	O
RNADRAW	O
was	O
ported	O
from	O
the	O
RNAFOLD	O
program	O
included	O
in	O
the	O

Vienna	O
RNA	O
package	O
.	O

[	O
24	O
]	O
The	O
dynamic	O
programming	O
algorithm	O
employed	O
in	O

RNADRAW	O
was	O
based	O
on	O
the	O
work	O
of	O
Zuker	O
and	O
Stiegler	O
[	O
25	O
]	O
and	O
uses	O
energy	O

parameters	O
taken	O
from	O
Turner	O
[	O
26	O
]	O
,	O
Freier	O
[	O
27	O
]	O
and	O
Jaeger	O
.	O

[	O
28	O
]	O

Phylogenetic	O
analysis	O

The	O
phylogenetic	O
Genebee	O
service	O
was	O
used	O
for	O
phylogenetic	O
tree	O
construction	O
.	O

[	O
22	O

]	O

RNA	O
fold	O

The	O
Sribo	O
program	O
in	O
Sfold	O
(	O
Statistical	O
Folding	O
and	O
Rational	O
Design	O
of	O
Nucleic	O
Acids	O
)	O
was	O

used	O
to	O
predict	O
the	O
probable	O
target	O
accessibility	O
sites	O
(	O
loops	O
)	O
for	O
trans	O
-	O
cleaving	O
ribozymes	O
in	O
ITS2	O
.	O

[	O
24	O
]	O
The	O
prediction	O
of	O
accessibility	O
is	O
based	O
on	O
a	O
statistical	O
sample	O
of	O
the	O
Boltzmann	O

ensemble	O
for	O
secondary	O
structures	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
likelihood	O
of	O
unpaired	O
sites	O
for	O
potential	O
ribozyme	O
target	O
.	O

Each	O
mRNA	O

exists	O
as	O
a	O
population	O
of	O
different	O
structures	O
.	O

Hence	O
,	O
stochastic	O
approach	O
to	O
the	O
evaluation	O
of	O
accessible	O
sites	O
was	O
found	O

appropriate	O
.	O

[	O
29	O
]	O
The	O
probability	O
profiling	O
approach	O
by	O
Ding	O
and	O
Lawrence	O

[	O
30	O
]	O
reveals	O
target	O
sites	O
that	O
are	O
commonly	O
accessible	O
for	O

a	O
large	O
number	O
of	O
statistically	O
representative	O
structures	O
in	O
the	O
target	O
RNA	O
.	O

This	O
novel	O
approach	O
bypasses	O
the	O
long	O
-	O
standing	O

difficulty	O
in	O
accessibility	O
evaluation	O
due	O
to	O
limited	O
representation	O
of	O
probable	O
structures	O
due	O
to	O
high	O
statistical	O
confidence	O

in	O
predictions	O
.	O

The	O
probability	O
profile	O
for	O
individual	O
bases	O
(	O
W	O
=	O
1	O
)	O
is	O
produced	O
for	O
the	O
region	O
that	O

includes	O
a	O
triplet	O
and	O
two	O
flanking	O
sequences	O
of	O
15	O
bases	O
each	O
in	O
every	O
site	O
of	O
the	O
selected	O
cleavage	O
triplet	O
(	O
e	O
.	O
g	O
.	O
,	O
GUC	O
)	O
.	O

Results	O
and	O
Discussion	O

ITS2	O
sequences	O
showed	O
a	O
taxonomic	O
trend	O
similar	O
to	O
that	O
in	O
phylogeny	O
construction	O
(	O
Figure	O
1A	O

)	O
.	O

A	O
multiple	O
sequence	O
alignment	O

of	O
5	O
.	O
8S	O
rDNA	O
and	O
ITS2	O
showed	O
in	O
Figure	O
1B	O
indicated	O
that	O
more	O
distantly	O
related	O
species	O
have	O

lower	O
sequence	O
similarity	O
in	O
the	O

ITS2	O
region	O
.	O

The	O
predicted	O
features	O
of	O
ITS2	O
using	O
RNADRAW	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
stems	O

(	O
double	O
stranded	O
paired	O
regions	O
)	O

stabilize	O
RNA	O
secondary	O
structures	O
and	O
the	O
number	O
of	O
stems	O
present	O
in	O
each	O
ITS2	O
is	O
given	O
(	O
Table	O
1	O
)	O
.	O

ITS2	O
RNA	O
structures	O
from	O

C	B-Species
.	I-Species
pipiens	E-Species
and	O
C	B-Species
.	I-Species
quinquefasciatus	E-Species
have	O
the	O
highest	O
negative	O
free	O
energy	O
(	O
-	O
149	O
.	O
38	O
Kcal	O
and	O

-	O
148	O
.	O
23	O
Kcal	O
)	O
followed	O
by	O
C	B-Species
.	I-Species
tarsalis	E-Species
(	O
-	O
129	O
.	O
2	O
)	O
,	O
C	B-Species
.	I-Species
annulus	E-Species
and	O
then	O
by	O
C	B-Species
.	I-Species
vishnui	E-Species

(	O
-	O
115	O
.	O
3	O
)	O
,	O
C	B-Species
.	I-Species
pseudovishnui	E-Species
(	O
-	O
105	O
.	O
66	O
)	O
and	O
C	B-Species
.	I-Species
tritaeniorhyncus	E-Species
(	O
-	O
82	O
.	O
57	O
)	O
.	O

Visual	O
comparison	O
shows	O

that	O
this	O
is	O
related	O
to	O
the	O
trend	O
in	O
the	O
cladogram	O
given	O
in	O
Figure	O
1A	O
.	O

A	O
high	O
degree	O
of	O
sequence	O
similarity	O
is	O
observed	O
at	O
the	O

5	O
'	O
end	O
compared	O
to	O
the	O
3	O
'	O
end	O
(	O
Figure	O
1A	O
)	O
.	O

This	O
is	O
due	O
to	O
factors	O
such	O
as	O
genetic	O
drift	O
,	O
the	O
relative	O
number	O
and	O
size	O
of	O
repeats	O
,	O

rates	O
of	O
unequal	O
crossover	O
,	O
gene	O
conversion	O
,	O
immigration	O
and	O
the	O
number	O
of	O
the	O
loci	O
influencing	O
the	O
length	O
.	O

[	O
10	O
]	O
Furthermore	O
,	O
a	O
high	O
level	O
of	O
sequence	O
similarity	O
is	O
found	O
between	O
C	O
.	O

annulus	O
and	O
C	B-Species
.	I-Species
vishnui	E-Species
as	O
well	O
as	O
C	B-Species
.	I-Species
quinquefasciatus	E-Species
and	O
C	B-Species
.	E-Species

pipiens	S-Species
.	O

The	O
simple	O
tandem	O
repeats	O
shown	O
in	O
Figure	O
1B	O
as	O
bolded	O
regions	O
are	O
found	O
to	O
be	O
similar	O
.	O

This	O
similarity	O
is	O
seen	O
in	O
corresponding	O

RNA	O
structures	O
and	O
computed	O
energies	O
.	O

The	O
Culex	O
species	O
considered	O
in	O
this	O
study	O
were	O
then	O
grouped	O
into	O
three	O
classes	O
based	O
on	O
the	O
similarity	O
of	O

RNA	O
stems	O
and	O
loops	O
.	O

Despite	O
their	O
different	O
geographic	O
locations	O
with	O
varying	O
eco	O
-	O
climatic	O
conditions	O
,	O
class	O
I	O

(	O
C	B-Species
.	I-Species
annulus	E-Species
,	O
C	B-Species
.	I-Species
pseudovishnui	E-Species
and	O
C	B-Species
.	I-Species
vishnui	E-Species
)	O
isolates	O
(	O
China	O
and	O
Japan	O
)	O
showed	O
high	O
similarity	O

in	O
secondary	O
structural	O
features	O
.	O

Similar	O
observations	O
were	O
seen	O
in	O
class	O
II	O
(	O
C	B-Species
.	I-Species
pipiens	E-Species
,	O
C	B-Species
.	I-Species
quinquefasciatus	E-Species
and	O

C	B-Species
.	I-Species
tarsalis	E-Species
)	O
isolates	O
from	O
North	O
America	O
and	O
Africa	O
.	O

[	O
19	O
]	O

A	O
high	O
degree	O
of	O
similarity	O
in	O
the	O
5	O
.	O
8S	O
region	O
unlike	O
the	O
ITS2	O
is	O
shown	O
for	O
different	O
isolates	O
due	O
to	O
relative	O
evolutionary	O

selection	O
.	O

[	O
9	O
]	O
The	O
loops	O
11	O
and	O
12	O
having	O
sequences	O
UGUCG	O
and	O
CUUCGGUG	O
,	O

respectively	O
are	O
highly	O
conserved	O
in	O
all	O
classes	O
.	O

Figure	O
1C	O
shows	O
the	O
distribution	O
of	O
different	O
types	O
of	O
loops	O
(	O
hairpin	O
,	O
bulge	O
,	O
multi	O
branched	O
,	O
interior	O
and	O
exterior	O
)	O
among	O

different	O
isolates	O
.	O

The	O
segments	O
of	O
the	O
ITS2	O
having	O
score	O
>=	O
50	O
are	O
further	O
probed	O
carefully	O
for	O
target	O
site	O
to	O
assess	O
the	O

likelihood	O
of	O
unpaired	O
segments	O
.	O

Interestingly	O
,	O
the	O
observed	O
phylogenetic	O
trend	O
was	O
identified	O
with	O
respect	O
to	O
the	O
target	O

accessibility	O
sites	O
for	O
the	O
seven	O
Culex	O
isolates	O
.	O

The	O
order	O
of	O
preference	O
is	O
interior	O
loop	O
,	O
bulge	O
loop	O
,	O
multiple	O

branched	O
loop	O
,	O
hairpin	O
loop	O
and	O
exterior	O
loops	O
in	O
all	O
the	O
isolates	O
.	O

Several	O
homologous	O
domains	O
were	O
observed	O
in	O
the	O
ITS	O
regions	O
of	O
Aedes	O
mosquito	O
species	O
by	O
Wesson	O

et	O
al	O
[	O
11	O
]	O
and	O
was	O
shown	O
that	O
these	O
domains	O
base	O
pair	O
to	O

form	O
a	O
core	O
region	O
central	O
to	O

several	O
stem	O
features	O
.	O

This	O
suggested	O
that	O
conserved	O
core	O
region	O
of	O
rDNA	O
is	O
more	O
important	O
for	O
a	O
functional	O
rRNA	O
folding	O

pattern	O
.	O

Barker	O
found	O
that	O
ITS2	O
is	O
unique	O
in	O
the	O
16	O
populations	O
of	O
Boophilus	B-Species
microplus	E-Species
,	O
Boophilus	B-Species
decoloratus	E-Species
,	O

Rhipicephalus	B-Species
appendiculatus	E-Species
,	O
Rhipicephalus	B-Species
zambesiensis	E-Species
,	O
Rhipicephalus	B-Species
evertsi	E-Species
,	O
Rhipicephalus	B-Species
sanguineus	E-Species
,	O
Rhipicephalus	O

turanicus	O
,	O
Rhipicephalus	B-Species
pumilio	E-Species
and	O
Rhipicephalus	B-Species
camicasi	E-Species
from	O
different	O
geographical	O
locations	O
.	O

[	O
12	O
]	O
These	O
results	O
suggest	O
that	O
the	O
differences	O
and	O
similarity	O
observed	O

in	O
the	O
ITS2	O
of	O
different	O
species	O
are	O
not	O
simply	O
accumulated	O
due	O
to	O
random	O
mutation	O
and	O
have	O
evolved	O
for	O
functional	O
selection	O

in	O
ribosome	O
biogenesis	O
.	O

However	O
,	O
it	O
was	O
shown	O
in	O
three	O
related	O
mosquito	O
genera	O
(	O
Aedes	O
,	O
Psorophora	O
and	O
Haemogogus	S-Species
)	O

that	O
the	O
intra	O
-	O
spacer	O
variable	O
regions	O
appear	O
to	O
co	O
-	O
evolve	O
and	O
that	O
ITS2	O
variation	O
is	O
constrained	O
by	O
its	O
secondary	O
structure	O
.	O

[	O
11	O
]	O
Further	O
studies	O
have	O
demonstrated	O
that	O
the	O
ITS2	O
is	O
essential	O

for	O
the	O
correct	O
and	O
efficient	O
processing	O
and	O
maturation	O
of	O
26S	O
rRNA	O
ribosomal	O
units	O
.	O

[	O

13	O
]	O
Furthermore	O
,	O
the	O
information	O
required	O
for	O
the	O
efficient	O
removal	O
of	O
ITS2	O
from	O
its	O
RNA	O
precursor	O
is	O
not	O

localized	O
but	O
dispersed	O
throughout	O
the	O
ITS2	O
region	O
.	O

Thus	O
,	O
insertions	O
and	O
deletions	O
(	O
indels	O
)	O
that	O
affect	O
secondary	O
structures	O

alter	O
rRNA	O
processing	O
.	O

Critical	O
changes	O
in	O
the	O
rRNA	O
folding	O
pattern	O
due	O
to	O
evolutionary	O
sequence	O
variation	O
in	O
the	O
ITS	O
spacer	O

regions	O
may	O
thus	O
have	O
an	O
important	O
role	O
on	O
the	O
kinetics	O
of	O
precursor	O
rRNA	O
formation	O
for	O
the	O
efficient	O
functioning	O
of	O
rDNA	O
clusters	O
.	O

Conclusion	O

Comparison	O
of	O
ITS2	O
sequences	O
from	O
different	O
isolates	O
of	O
Culex	O
show	O
similarity	O
and	O
variations	O
.	O

Surprisingly	O
,	O
species	O
displaying	O

sequence	O
similarity	O
belong	O
to	O
different	O
geographical	O
locations	O
with	O
diverse	O
climatic	O
and	O
ecological	O
conditions	O
.	O

This	O
implies	O
that	O

the	O
ITS2	O
regions	O
have	O
less	O
selective	O
pressure	O
than	O
the	O
ribosomal	O
regions	O
.	O

Several	O
common	O
structural	O
folds	O
were	O
shared	O
among	O
the	O

selected	O
mosquitoes	O
for	O
maintaining	O
functional	O
equivalents	O
.	O

Construction	O
of	O
an	O
evolutionary	O
tree	O
using	O
more	O
isolates	O
of	O

Culex	O
will	O
provide	O
an	O
understanding	O
for	O
their	O
functional	O
selection	O
.	O

Integration	O
in	O
primary	O
community	O
care	O
networks	O
(	O
PCCNs	O
)	O
:	O
examination	O
of	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
in	O
a	O
national	O
demonstration	O
project	O
in	O
Taiwan	O

Abstract	O

Background	O

Taiwan	O
'	O
s	O
primary	O
community	O
care	O
network	O
(	O
PCCN	O
)	O
demonstration	O
project	O
,	O
funded	O
by	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
on	O
March	O
2003	O
,	O
was	O
established	O
to	O
discourage	O
hospital	O
shopping	O
behavior	O
of	O
people	S-Species
and	O
drive	O
the	O
traditional	O
fragmented	O
health	O
care	O
providers	O
into	O
cooperate	O
care	O
models	O
.	O

Between	O
2003	O
and	O
2005	O
,	O
268	O
PCCNs	O
were	O
established	O
.	O

This	O
study	O
profiled	O
the	O
individual	O
members	O
in	O
the	O
PCCNs	O
to	O
study	O
the	O
nature	O
and	O
extent	O
to	O
which	O
their	O
network	O
infrastructures	O
have	O
been	O
integrated	O
among	O
the	O
members	O
(	O
clinics	O
and	O
hospitals	O
)	O
within	O
individual	O
PCCNs	O
.	O

Methods	O

The	O
thorough	O
questionnaire	O
items	O
,	O
covering	O
the	O
network	O
working	O
infrastructures	O
-	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
integration	O
in	O
PCCNs	O
,	O
were	O
developed	O
with	O
validity	O
and	O
reliability	O
confirmed	O
.	O

One	O
thousand	O
five	O
hundred	O
and	O
fifty	O
-	O
seven	O
clinics	O
that	O
had	O
belonged	O
to	O
PCCNs	O
for	O
more	O
than	O
one	O
year	O
,	O
based	O
on	O
the	O
2003	O
-	O
2005	O
Taiwan	O
Primary	O
Community	O
Care	O
Network	O
List	O
,	O
were	O
surveyed	O
by	O
mail	O
.	O

Nine	O
hundred	O
and	O
twenty	O
-	O
eight	O
clinic	O
members	O
responded	O
to	O
the	O
surveys	O
giving	O
a	O
59	O
.	O
6	O
%	O
response	O
rate	O
.	O

Results	O

Overall	O
,	O
the	O
PCCNs	O
'	O
members	O
had	O
higher	O
involvement	O
in	O
the	O
governance	O
infrastructure	O
,	O
which	O
was	O
usually	O
viewed	O
as	O
the	O
most	O
important	O
for	O
establishment	O
of	O
core	O
values	O
in	O
PCCNs	O
'	O
organization	O
design	O
and	O
management	O
at	O
the	O
early	O
integration	O
stage	O
.	O

In	O
addition	O
,	O
it	O
found	O
that	O
there	O
existed	O
a	O
higher	O
extent	O
of	O
integration	O
of	O
clinical	O
,	O
marketing	O
,	O
and	O
information	O
infrastructures	O
among	O
the	O
hospital	O
-	O
clinic	O
member	O
relationship	O
than	O
those	O
among	O
clinic	O
members	O
within	O
individual	O
PCCNs	O
.	O

The	O
financial	O
infrastructure	O
was	O
shown	O
the	O
least	O
integrated	O
relative	O
to	O
other	O
functional	O
infrastructures	O
at	O
the	O
early	O
stage	O
of	O
PCCN	O
formation	O
.	O

Conclusion	O

There	O
was	O
still	O
room	O
for	O
better	O
integrated	O
partnerships	O
,	O
as	O
evidenced	O
by	O
the	O
great	O
variety	O
of	O
relationships	O
and	O
differences	O
in	O
extent	O
of	O
integration	O
in	O
this	O
study	O
.	O

In	O
addition	O
to	O
provide	O
how	O
the	O
network	O
members	O
have	O
done	O
for	O
their	O
initial	O
work	O
at	O
the	O
early	O
stage	O
of	O
network	O
forming	O
in	O
this	O
study	O
,	O
the	O
detailed	O
surveyed	O
items	O
,	O
the	O
concepts	O
proposed	O
by	O
the	O
managerial	O
and	O
theoretical	O
professionals	O
,	O
could	O
be	O
a	O
guide	O
for	O
those	O
health	O
care	O
providers	O
who	O
have	O
willingness	O
to	O
turn	O
their	O
business	O
into	O
multi	O
-	O
organizations	O
.	O

Background	O

Taiwan	O
'	O
s	O
National	O
Health	O
Insurance	O
(	O
NHI	O
)	O
under	O
the	O
control	O
of	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O
,	O
was	O
launched	O
in	O
March	O
1995	O
to	O
replace	O
its	O
social	O
insurance	O
system	O
that	O
was	O
covering	O
59	O
%	O
of	O
its	O
population	O
:	O
government	O
employees	O
,	O
labourers	O
,	O
farmers	O
and	O
servicemen	O
[	O
1	O
]	O
.	O

By	O
June	O
2003	O
the	O
number	O
of	O
people	S-Species
insured	O
had	O
reached	O
21	O
,	O
956	O
,	O
729	O
(	O
99	O
%	O
)	O
.	O

There	O
were	O
17	O
,	O
259	O
medical	O
providers	O
(	O
92	O
%	O
)	O
,	O
including	O
575	O
hospitals	O
and	O
16	O
,	O
684	O
clinics	O
contracted	O
with	O
the	O
BNHI	O
for	O
serving	O
the	O
enrolled	O
population	O
.	O

The	O
unique	O
phenomenon	O
characterized	O
in	O
Taiwan	O
health	O
care	O
industry	O
different	O
from	O
those	O
in	O
the	O
western	O
countries	O
is	O
the	O
freedom	O
of	O
patients	S-Species
to	O
choose	O
the	O
health	O
care	O
providers	O
they	O
want	O
,	O
no	O
matter	O
what	O
their	O
disease	O
severity	O
is	O
.	O

Furthermore	O
,	O
Taiwan	O
people	S-Species
favor	O
the	O
larger	O
scales	O
of	O
facilities	O
and	O
this	O
fallacy	O
leads	O
to	O
the	O
phenomenon	O
of	O
big	O
-	O
hospital	O
shopping	O
.	O

For	O
example	O
,	O
people	S-Species
choose	O
the	O
medical	O
centers	O
which	O
are	O
accredited	O
as	O
the	O
highest	O
level	O
of	O
medical	O
science	O
in	O
Taiwan	O
when	O
they	O
only	O
suffer	O
from	O
a	O
common	O
cold	O
.	O

In	O
the	O
spring	O
of	O
2003	O
,	O
the	O
SARS	O
epidemic	O
viciously	O
attacked	O
the	O
health	O
of	O
Taiwan	O
'	O
s	O
people	S-Species
.	O

The	O
people	S-Species
'	O
s	O
freedom	O
to	O
choose	O
medical	O
providers	O
caused	O
the	O
national	O
health	O
authority	O
to	O
barely	O
control	O
and	O
traced	O
the	O
flow	O
of	O
epidemic	O
.	O

This	O
event	O
made	O
Taiwan	O
national	O
health	O
authorities	O
rethink	O
what	O
happened	O
and	O
how	O
it	O
damaged	O
under	O
the	O
traditional	O
fragmented	O
health	O
care	O
providers	O
in	O
Taiwan	O
.	O

One	O
health	O
reform	O
launched	O
was	O
named	O
the	O
"	O
Primary	O
Community	O
Care	O
Network	O
(	O
PCCN	O
)	O
demonstration	O
project	O
"	O
,	O
a	O
nationwide	O
health	O
care	O
financing	O
program	O
funded	O
by	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O
in	O
March	O
2003	O
and	O
it	O
was	O
a	O
new	O
model	O
for	O
the	O
Taiwan	O
government	O
to	O
redefine	O
the	O
role	O
of	O
family	O
physicians	O
in	O
the	O
health	O
care	O
delivery	O
system	O
.	O

A	O
PCCN	O
in	O
Taiwan	O
consists	O
of	O
a	O
group	O
of	O
clinic	O
physicians	O
whose	O
medical	O
jobs	O
are	O
viewed	O
as	O
family	O
care	O
and	O
at	O
least	O
one	O
hospital	O
for	O
secondary	O
or	O
tertiary	O
care	O
.	O

The	O
idea	O
of	O
member	O
component	O
design	O
in	O
PCCNs	O
was	O
aimed	O
to	O
lead	O
the	O
Taiwan	O
citizens	O
to	O
choose	O
one	O
clinic	O
physician	O
as	O
their	O
personal	O
family	O
physician	O
for	O
health	O
maintenance	O
and	O
this	O
family	O
physician	O
also	O
would	O
have	O
the	O
responsibility	O
of	O
referring	O
the	O
patients	S-Species
to	O
specialty	O
care	O
if	O
necessary	O
.	O

From	O
a	O
national	O
health	O
authority	O
perspective	O
,	O
they	O
expected	O
the	O
Taiwan	O
people	S-Species
to	O
put	O
an	O
end	O
to	O
their	O
fallacy	O
that	O
"	O
bigger	O
is	O
better	O
"	O
for	O
health	O
care	O
organizations	O
and	O
establish	O
the	O
idea	O
of	O
"	O
human	S-Species
health	O
"	O
,	O
starting	O
with	O
prevention	O
and	O
primary	O
care	O
,	O
followed	O
by	O
secondary	O
or	O
tertiary	O
care	O
,	O
emphasizing	O
health	O
promotion	O
and	O
maintenance	O
instead	O
of	O
disease	O
curing	O
.	O

Furthermore	O
,	O
it	O
could	O
decrease	O
the	O
inappropriateness	O
of	O
medical	O
usage	O
,	O
i	O
.	O
e	O
.	O
,	O
over	O
-	O
uses	O
of	O
secondary	O
and	O
tertiary	O
medical	O
services	O
in	O
the	O
high	O
-	O
tech	O
hospitals	O
.	O

In	O
addition	O
,	O
the	O
national	O
health	O
authority	O
was	O
expected	O
to	O
drive	O
the	O
traditional	O
fragmented	O
heath	O
care	O
providers	O
into	O
coordinated	O
medical	O
multidisciplinary	O
teams	O
and	O
share	O
the	O
limited	O
medical	O
resources	O
through	O
the	O
PCCN	O
demonstration	O
project	O
.	O

In	O
summary	O
,	O
the	O
PCCN	O
demonstration	O
project	O
was	O
aimed	O
to	O
:	O
1	O
)	O
change	O
the	O
traditional	O
patients	S-Species
'	O
customs	O
of	O
freely	O
choosing	O
health	O
care	O
organizations	O
and	O
establish	O
referral	O
channels	O
along	O
the	O
continuum	O
of	O
care	O
,	O
and	O
2	O
)	O
establish	O
partnerships	O
among	O
the	O
primary	O
care	O
clinics	O
and	O
hospitals	O
to	O
provide	O
a	O
continuum	O
of	O
health	O
care	O
services	O
.	O

It	O
was	O
also	O
expected	O
to	O
establish	O
the	O
primary	O
care	O
system	O
of	O
family	O
physicians	O
to	O
provide	O
whole	O
-	O
people	S-Species
health	O
care	O
and	O
improve	O
care	O
quality	O
[	O
1	O
]	O
.	O

Partnership	O
structures	O
in	O
the	O
PCCNs	O
represent	O
the	O
virtual	O
vertical	O
(	O
i	O
.	O
e	O
.	O
,	O
between	O
the	O
member	O
clinics	O
and	O
hospitals	O
)	O
and	O
virtual	O
horizontal	O
(	O
i	O
.	O
e	O
.	O
,	O
among	O
the	O
member	O
clinics	O
)	O
aspects	O
of	O
organizing	O
,	O
which	O
designate	O
the	O
formal	O
relationships	O
between	O
individuals	O
and	O
the	O
total	O
network	O
and	O
include	O
organizational	O
design	O
to	O
ensure	O
effective	O
communication	O
,	O
coordination	O
,	O
and	O
integration	O
across	O
the	O
total	O
network	O
.	O

Each	O
PCCN	O
consists	O
of	O
five	O
to	O
ten	O
clinics	O
:	O
half	O
of	O
them	O
should	O
offer	O
the	O
services	O
of	O
general	O
medicine	O
,	O
internal	O
medicine	O
,	O
surgery	O
,	O
obstetrics	O
and	O
gynecology	O
,	O
pediatric	O
,	O
or	O
family	O
medicine	O
.	O

And	O
each	O
PCCN	O
has	O
a	O
central	O
headquarters	O
,	O
usually	O
in	O
one	O
of	O
the	O
clinic	O
facilities	O
,	O
to	O
coordinate	O
and	O
integrate	O
the	O
network	O
.	O

All	O
the	O
clinic	O
physicians	O
in	O
a	O
PCCN	O
are	O
assigned	O
the	O
roles	O
of	O
"	O
family	O
physicians	O
"	O
or	O
"	O
gatekeepers	O
"	O
who	O
recruit	O
people	S-Species
from	O
the	O
local	O
community	O
,	O
keep	O
background	O
and	O
medical	O
files	O
on	O
them	O
,	O
certify	O
family	O
physician	O
education	O
training	O
programs	O
,	O
and	O
hold	O
office	O
hours	O
in	O
the	O
member	O
hospital	O
,	O
where	O
they	O
serve	O
as	O
joint	O
faculty	O
members	O
for	O
further	O
medical	O
consultations	O
or	O
medical	O
utilizations	O
of	O
labs	O
and	O
tests	O
,	O
if	O
necessary	O
.	O

In	O
addition	O
,	O
the	O
hospital	O
member	O
is	O
asked	O
to	O
help	O
clinic	O
physicians	O
in	O
their	O
network	O
to	O
set	O
up	O
a	O
medical	O
information	O
system	O
,	O
share	O
hospital	O
resources	O
(	O
medical	O
equipment	O
and	O
library	O
literature	O
)	O
with	O
the	O
clinic	O
physicians	O
in	O
their	O
network	O
and	O
establish	O
referral	O
channels	O
among	O
the	O
network	O
members	O
.	O

Furthermore	O
,	O
this	O
new	O
demonstration	O
model	O
tries	O
to	O
minimize	O
the	O
barriers	O
to	O
patient	S-Species
access	O
by	O
setting	O
up	O
24	O
-	O
hour	O
a	O
day	O
,	O
7	O
-	O
day	O
a	O
week	O
medical	O
consultation	O
telephone	O
lines	O
for	O
providing	O
urgent	O
services	O
onsite	O
and	O
for	O
taking	O
care	O
of	O
the	O
patients	S-Species
whose	O
family	O
physicians	O
'	O
practices	O
are	O
closed	O
to	O
assure	O
seamless	O
care	O
channels	O
.	O

The	O
BNHI	O
funded	O
these	O
extra	O
demonstration	O
actions	O
,	O
at	O
around	O
one	O
hundred	O
thousand	O
US	O
dollars	O
(	O
i	O
.	O
e	O
.	O
,	O
NT	O
$	O
3	O
,	O
500	O
,	O
000	O
)	O
for	O
each	O
PCCN	O
under	O
the	O
current	O
fee	O
-	O
for	O
-	O
service	O
payment	O
system	O
[	O
1	O
]	O
.	O

Figure	O
1	O
describes	O
the	O
organizational	O
structure	O
of	O
individual	O
PCCNs	O
introduced	O
in	O
the	O
demonstration	O
project	O
in	O
Taiwan	O
.	O

To	O
date	O
,	O
the	O
PCCN	O
demonstration	O
project	O
has	O
been	O
in	O
operation	O
for	O
more	O
than	O
three	O
years	O
.	O

There	O
have	O
been	O
268	O
PCCNs	O
formed	O
in	O
the	O
period	O
of	O
2003	O
to	O
2005	O
around	O
Taiwan	O
.	O

The	O
geographical	O
distributions	O
of	O
PCCNs	O
and	O
their	O
members	O
were	O
described	O
in	O
Table	O
1	O
.	O

Analyzing	O
all	O
1	O
,	O
557	O
participating	O
clinic	O
members	O
in	O
the	O
demonstration	O
project	O
in	O
terms	O
of	O
medical	O
specialties	O
,	O
they	O
cover	O
general	O
medicine	O
,	O
internal	O
medicine	O
,	O
surgeries	O
,	O
obstetrics	O
and	O
gynecology	O
,	O
pediatrics	O
,	O
family	O
medicines	O
,	O
otolaryngology	O
,	O
ophthalmology	O
,	O
rehabilitation	O
medicine	O
,	O
dermatology	O
,	O
and	O
psychiatry	O
,	O
with	O
237	O
clinics	O
providing	O
more	O
than	O
two	O
specialties	O
.	O

On	O
the	O
other	O
hand	O
,	O
each	O
PCCN	O
recruits	O
at	O
least	O
one	O
district	O
or	O
regional	O
accredited	O
hospital	O
for	O
acute	O
care	O
demands	O
(	O
required	O
for	O
network	O
members	O
)	O
and	O
a	O
medical	O
center	O
for	O
tertiary	O
care	O
support	O
(	O
not	O
required	O
for	O
network	O
members	O
)	O
.	O

There	O
are	O
6	O
medical	O
centers	O
,	O
52	O
regional	O
hospitals	O
,	O
and	O
71	O
district	O
hospitals	O
joining	O
in	O
the	O
demonstration	O
project	O
.	O

See	O
Table	O
1	O
for	O
more	O
detailed	O
information	O
about	O
the	O
PCCN	O
members	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
few	O
empirical	O
studies	O
of	O
the	O
working	O
relationships	O
that	O
have	O
developed	O
between	O
members	O
of	O
the	O
PCCN	O
program	O
.	O

Partnership	O
needs	O
a	O
method	O
to	O
determine	O
at	O
an	O
early	O
stage	O
,	O
to	O
make	O
sure	O
whether	O
they	O
are	O
making	O
the	O
most	O
of	O
collaboration	O
[	O
2	O
]	O
and	O
the	O
acceptance	O
of	O
the	O
contracting	O
networks	O
in	O
Taiwan	O
as	O
an	O
organizational	O
innovation	O
worthy	O
of	O
greater	O
diffusion	O
deserves	O
to	O
be	O
explored	O
.	O

Therefore	O
,	O
this	O
study	O
used	O
a	O
structured	O
questionnaire	O
to	O
characterize	O
the	O
relationship	O
among	O
the	O
members	O
in	O
the	O
individual	O
PCCNs	O
,	O
with	O
regard	O
to	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financing	O
,	O
as	O
well	O
as	O
information	O
integration	O
infrastructures	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
descriptive	O
analyses	O
in	O
detail	O
to	O
map	O
the	O
partnership	O
developments	O
,	O
to	O
enrich	O
the	O
body	O
of	O
knowledge	O
of	O
the	O
partner	O
relationships	O
and	O
to	O
help	O
policy	O
makers	O
understand	O
the	O
coordinated	O
efforts	O
of	O
these	O
health	O
care	O
providers	O
which	O
have	O
developed	O
under	O
this	O
system	O
.	O

It	O
also	O
provides	O
the	O
recommendations	O
for	O
heath	O
policy	O
decision	O
-	O
making	O
and	O
management	O
of	O
networks	O
of	O
health	O
care	O
providers	O
for	O
the	O
future	O
involvement	O
.	O

Methods	O

This	O
study	O
was	O
aimed	O
at	O
providing	O
descriptive	O
analyses	O
to	O
map	O
the	O
partnership	O
development	O
.	O

To	O
understand	O
the	O
actual	O
integration	O
actions	O
done	O
by	O
network	O
members	O
,	O
the	O
theoretical	O
concept	O
employed	O
by	O
network	O
partnerships	O
were	O
described	O
and	O
then	O
the	O
derived	O
survey	O
instrument	O
was	O
developed	O
.	O

Theoretical	O
framework	O
for	O
organization	O
design	O
of	O
network	O
integration	O

The	O
rapid	O
organizational	O
changes	O
in	O
the	O
health	O
care	O
industry	O
have	O
driven	O
theorists	O
from	O
every	O
discipline	O
and	O
across	O
the	O
world	O
to	O
seek	O
an	O
approach	O
that	O
allows	O
organizations	O
to	O
flourish	O
.	O

Organization	O
theory	O
allows	O
investigators	O
to	O
profile	O
an	O
organization	O
from	O
the	O
aspect	O
of	O
patterns	O
and	O
regularities	O
in	O
organizational	O
design	O
and	O
behavior	O
.	O

In	O
the	O
early	O
20th	O
century	O
,	O
classical	O
management	O
theorists	O
claimed	O
that	O
an	O
organization	O
has	O
"	O
a	O
best	O
way	O
"	O
to	O
be	O
organized	O
and	O
managed	O
[	O
3	O
]	O
.	O

That	O
implied	O
that	O
all	O
organizations	O
would	O
own	O
the	O
"	O
same	O
"	O
organizational	O
styles	O
or	O
structures	O
.	O

In	O
the	O
1960s	O
,	O
several	O
theorists	O
[	O
4	O
-	O
8	O
]	O
challenged	O
this	O
assumption	O
by	O
applying	O
a	O
"	O
contingency	O
approach	O
"	O
to	O
propose	O
that	O
there	O
is	O
no	O
best	O
way	O
to	O
organize	O
an	O
organization	O
,	O
and	O
that	O
the	O
effectiveness	O
of	O
an	O
organizational	O
structure	O
varies	O
with	O
the	O
situation	O
of	O
an	O
organization	O
.	O

Furthermore	O
,	O
it	O
is	O
proposed	O
that	O
the	O
best	O
way	O
to	O
organize	O
an	O
organization	O
depends	O
on	O
the	O
nature	O
of	O
the	O
environment	O
to	O
which	O
the	O
organization	O
relates	O
.	O

Contingency	O
theory	O
delineates	O
the	O
concepts	O
"	O
organization	O
'	O
s	O
internal	O
features	O
,	O
"	O
"	O
the	O
demands	O
of	O
organizational	O
environments	O
,	O
"	O
"	O
best	O
adaptation	O
,	O
"	O
and	O
,	O
the	O
most	O
important	O
and	O
difficult	O
of	O
all	O
,	O
"	O
best	O
match	O
"	O
[	O
9	O
]	O
.	O

Lawrence	O
&	O
Lorsch	O
[	O
7	O
]	O
argued	O
that	O
environments	O
characterized	O
by	O
uncertainty	O
and	O
rapid	O
rates	O
of	O
change	O
in	O
market	O
conditions	O
or	O
technology	O
impose	O
different	O
demands	O
,	O
including	O
constraints	O
and	O
opportunities	O
,	O
on	O
organizations	O
than	O
do	O
placid	O
and	O
stable	O
environments	O
.	O

Similarly	O
to	O
Lawrence	O
and	O
Lorsch	O
'	O
s	O
views	O
mentioned	O
above	O
,	O
Galbraith	O
[	O
10	O
,	O
11	O
]	O
stressed	O
the	O
contingency	O
perspective	O
on	O
information	O
processing	O
.	O

The	O
information	O
-	O
processing	O
approach	O
emphasizes	O
that	O
environment	O
,	O
size	O
,	O
and	O
technology	O
impose	O
different	O
information	O
-	O
processing	O
requirements	O
on	O
organizations	O
,	O
and	O
thus	O
an	O
organization	O
must	O
be	O
designed	O
to	O
encourage	O
information	O
flow	O
in	O
both	O
vertical	O
and	O
horizontal	O
directions	O
to	O
achieve	O
the	O
overall	O
tasks	O
of	O
the	O
organization	O
and	O
,	O
finally	O
,	O
organizational	O
effectiveness	O
[	O
11	O
-	O
14	O
]	O
.	O

Some	O
theorists	O
have	O
criticized	O
conventional	O
contingency	O
theorists	O
who	O
presume	O
that	O
organizational	O
structure	O
is	O
driven	O
by	O
the	O
environment	O
.	O

Child	O
[	O
15	O
]	O
,	O
Miller	O
[	O
16	O
]	O
,	O
Van	O
de	O
Ven	O
and	O
Drazin	O
[	O
17	O
]	O
,	O
and	O
Tushman	O
and	O
Romanelli	O
[	O
18	O
]	O
raised	O
such	O
criticisms	O
;	O
they	O
argued	O
that	O
organizations	O
become	O
what	O
they	O
are	O
not	O
only	O
because	O
of	O
the	O
environment	O
,	O
but	O
also	O
because	O
of	O
choices	O
made	O
by	O
members	O
,	O
especially	O
choices	O
about	O
strategy	O
and	O
organizational	O
design	O
.	O

As	O
Thompson	O
'	O
s	O
words	O
in	O
the	O
book	O
Organizations	O
in	O
Action	O
[	O
8	O
]	O
put	O
it	O
,	O
"	O
organizations	O
are	O
not	O
determined	O
simply	O
by	O
their	O
environments	O
(	O
p	O
.	O
27	O
)	O
.	O
"	O
He	O
also	O
pointed	O
out	O
that	O
"	O
administration	O
may	O
innovate	O
on	O
any	O
or	O
all	O
of	O
the	O
necessary	O
dimensions	O
,	O
but	O
only	O
to	O
the	O
extent	O
that	O
innovations	O
are	O
acceptable	O
to	O
those	O
on	O
whom	O
the	O
organization	O
can	O
and	O
must	O
depend	O
.	O
"	O
Instead	O
of	O
assuming	O
that	O
administrators	O
are	O
highly	O
constrained	O
in	O
their	O
decisions	O
,	O
strategic	O
contingency	O
theorists	O
emphasized	O
"	O
the	O
importance	O
of	O
choice	O
,	O
"	O
that	O
is	O
,	O
"	O
the	O
freedom	O
of	O
agency	O
"	O
[	O
15	O
]	O
.	O

Furthermore	O
,	O
Pfeffer	O
[	O
19	O
]	O
explicitly	O
pointed	O
out	O
that	O
"	O
organizational	O
structures	O
are	O
the	O
outcomes	O
of	O
political	O
contests	O
within	O
organizations	O
(	O
p	O
.	O
38	O
)	O
.	O
"	O

Daft	O
[	O
14	O
]	O
proposed	O
a	O
top	O
management	O
model	O
to	O
delineate	O
how	O
"	O
a	O
strategy	O
is	O
a	O
plan	O
for	O
interacting	O
with	O
the	O
competitive	O
environment	O
to	O
achieve	O
organizational	O
goals	O
.	O
"	O
He	O
stated	O
that	O
the	O
major	O
responsibility	O
of	O
top	O
management	O
is	O
to	O
determine	O
the	O
goals	O
,	O
strategy	O
,	O
and	O
design	O
of	O
an	O
organization	O
to	O
adapt	O
to	O
a	O
changing	O
environment	O
.	O

To	O
assess	O
the	O
external	O
and	O
internal	O
environments	O
of	O
an	O
organization	O
seems	O
to	O
be	O
the	O
first	O
task	O
for	O
top	O
managers	O
in	O
defining	O
an	O
organization	O
'	O
s	O
goals	O
and	O
missions	O
.	O

Then	O
,	O
guided	O
by	O
the	O
goals	O
and	O
missions	O
of	O
the	O
organization	O
,	O
top	O
managers	O
shape	O
the	O
design	O
of	O
the	O
organization	O
,	O
including	O
structural	O
forms	O
,	O
information	O
system	O
,	O
technology	O
,	O
human	S-Species
resources	O
,	O
organizational	O
culture	O
,	O
and	O
inter	O
-	O
organizational	O
linkages	O
,	O
to	O
achieve	O
the	O
final	O
organizational	O
performance	O
.	O

Integration	O
refers	O
to	O
the	O
mechanisms	O
of	O
coordination	O
,	O
the	O
ways	O
guided	O
to	O
partnership	O
goals	O
to	O
fit	O
internal	O
and	O
external	O
conditions	O
[	O
7	O
,	O
20	O
,	O
21	O
]	O
.	O

In	O
the	O
early	O
1990s	O
,	O
proposals	O
for	O
US	O
national	O
health	O
care	O
reform	O
recognized	O
the	O
need	O
for	O
integrating	O
mechanisms	O
to	O
achieve	O
both	O
financial	O
success	O
and	O
quality	O
of	O
care	O
of	O
a	O
well	O
-	O
organized	O
system	O
of	O
care	O
[	O
22	O
,	O
23	O
]	O
.	O

Several	O
researchers	O
also	O
viewed	O
inter	O
-	O
organizational	O
cooperation	O
as	O
resource	O
exchanges	O
,	O
including	O
client	O
referrals	O
,	O
money	O
,	O
and	O
staff	O
[	O
24	O
-	O
27	O
]	O
.	O

From	O
practical	O
ways	O
of	O
viewing	O
integration	O
,	O
the	O
success	O
of	O
integration	O
lies	O
in	O
the	O
coordinative	O
mechanisms	O
and	O
partnership	O
working	O
that	O
support	O
it	O
[	O
28	O
]	O
,	O
including	O
an	O
administrative	O
organization	O
that	O
coordinates	O
the	O
operations	O
of	O
various	O
health	O
care	O
services	O
;	O
a	O
management	O
information	O
system	O
that	O
integrates	O
clinical	O
,	O
utilization	O
,	O
and	O
financial	O
data	O
and	O
follows	O
clients	O
across	O
different	O
settings	O
;	O
a	O
care	O
coordination	O
program	O
such	O
as	O
case	O
management	O
or	O
disease	O
management	O
that	O
works	O
with	O
clients	O
to	O
arrange	O
health	O
care	O
services	O
;	O
and	O
a	O
financial	O
mechanism	O
that	O
enables	O
pooling	O
of	O
funds	O
across	O
services	O
[	O
29	O
-	O
35	O
]	O
.	O

Fox	O
[	O
36	O
]	O
suggested	O
the	O
success	O
of	O
integrated	O
health	O
networks	O
should	O
ensure	O
that	O
the	O
new	O
business	O
link	O
such	O
aspects	O
as	O
technology	O
,	O
functional	O
skills	O
,	O
customer	O
access	O
,	O
management	O
,	O
or	O
products	O
that	O
can	O
be	O
shared	O
across	O
both	O
the	O
core	O
and	O
the	O
new	O
business	O
;	O
to	O
conduct	O
market	O
financial	O
evaluation	O
;	O
to	O
share	O
the	O
risk	O
of	O
vertical	O
integration	O
with	O
outside	O
entities	O
,	O
to	O
develop	O
the	O
management	O
structure	O
that	O
can	O
reflect	O
the	O
degree	O
of	O
coordination	O
necessary	O
to	O
support	O
the	O
core	O
business	O
activities	O
;	O
to	O
ensure	O
that	O
the	O
integration	O
strategy	O
meets	O
the	O
needs	O
of	O
customers	O
,	O
including	O
medical	O
treatment	O
,	O
the	O
use	O
of	O
medical	O
technology	O
,	O
and	O
the	O
preferred	O
methods	O
of	O
purchase	O
;	O
and	O
to	O
measure	O
the	O
new	O
business	O
by	O
its	O
value	O
to	O
the	O
enterprise	O
as	O
a	O
whole	O
,	O
rather	O
than	O
by	O
its	O
profitability	O
as	O
a	O
stand	O
-	O
alone	O
entity	O
.	O

In	O
summary	O
,	O
the	O
effects	O
that	O
integration	O
in	O
inter	O
-	O
organizational	O
designs	O
has	O
on	O
network	O
management	O
were	O
substantial	O
from	O
a	O
managerial	O
perspective	O
.	O

Borrowing	O
the	O
ideas	O
of	O
strategic	O
contingency	O
perspective	O
[	O
8	O
,	O
15	O
,	O
19	O
]	O
and	O
top	O
management	O
model	O
[	O
14	O
]	O
,	O
it	O
could	O
be	O
imply	O
that	O
success	O
(	O
organization	O
performance	O
)	O
in	O
reengineering	O
a	O
network	O
lies	O
in	O
the	O
integration	O
of	O
process	O
and	O
services	O
(	O
see	O
Figure	O
1	O
)	O
,	O
including	O
leadership	O
/	O
governing	O
structure	O
,	O
teamwork	O
between	O
disciplines	O
and	O
patient	S-Species
care	O
,	O
financial	O
planning	O
,	O
and	O
information	O
systems	O
,	O
characterized	O
as	O
the	O
constructs	O
of	O
governance	O
,	O
clinical	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
,	O
respectively	O
,	O
in	O
this	O
study	O
.	O

In	O
addition	O
,	O
another	O
construct	O
,	O
marketing	O
infrastructure	O
,	O
was	O
especially	O
important	O
and	O
designed	O
to	O
explore	O
for	O
PCCNs	O
in	O
this	O
study	O
because	O
of	O
patients	S-Species
'	O
freedom	O
of	O
making	O
healthcare	O
choice	O
and	O
the	O
traditional	O
fragmented	O
health	O
care	O
systems	O
by	O
individual	O
health	O
care	O
organizations	O
in	O
Taiwan	O
.	O

One	O
major	O
reason	O
for	O
Taiwan	O
people	S-Species
'	O
s	O
hospital	O
shopping	O
preferences	O
was	O
that	O
Taiwan	O
people	S-Species
usually	O
believe	O
the	O
bigger	O
the	O
facility	O
,	O
the	O
better	O
capacities	O
a	O
facility	O
has	O
no	O
matter	O
on	O
any	O
aspect	O
from	O
medical	O
professionals	O
to	O
tangible	O
medical	O
equipment	O
and	O
plants	O
.	O

And	O
this	O
fallacy	O
made	O
the	O
public	O
want	O
to	O
overuse	O
the	O
facility	O
with	O
high	O
-	O
tech	O
medical	O
services	O
no	O
matter	O
if	O
it	O
fits	O
their	O
needs	O
.	O

From	O
the	O
health	O
policy	O
and	O
management	O
perspectives	O
,	O
therefore	O
,	O
the	O
health	O
care	O
providers	O
were	O
encouraged	O
to	O
market	O
their	O
services	O
as	O
a	O
new	O
corporate	O
identity	O
and	O
brand	O
strategy	O
[	O
37	O
]	O
,	O
including	O
offering	O
tangible	O
resources	O
such	O
as	O
books	O
,	O
libraries	O
,	O
medical	O
equipment	O
,	O
and	O
intangible	O
resources	O
such	O
as	O
knowledge	O
and	O
information	O
exchanges	O
(	O
education	O
)	O
and	O
reputation	O
sharing	O
one	O
another	O
among	O
PCCN	O
members	O
.	O

Furthermore	O
,	O
through	O
the	O
process	O
of	O
marketing	O
resource	O
exchanges	O
,	O
therefore	O
,	O
each	O
PCCN	O
could	O
establish	O
the	O
images	O
of	O
"	O
one	O
system	O
,	O
one	O
brand	O
and	O
quality	O
"	O
for	O
the	O
public	O
and	O
for	O
the	O
health	O
care	O
providers	O
.	O

It	O
also	O
makes	O
it	O
be	O
more	O
visible	O
to	O
the	O
public	O
.	O

The	O
five	O
integration	O
infrastructures	O
of	O
network	O
management	O
were	O
constructed	O
as	O
a	O
conceptual	O
framework	O
in	O
this	O
study	O
to	O
help	O
to	O
portray	O
how	O
the	O
PCCN	O
members	O
have	O
done	O
.	O

The	O
survey	O
instrument	O
development	O
was	O
described	O
in	O
the	O
following	O
.	O

Survey	O
instrument	O
development	O
:	O
integration	O
infrastructures	O
and	O
measurements	O
of	O
partnerships	O

Based	O
on	O
the	O
five	O
integration	O
infrastructures	O
of	O
network	O
management	O
,	O
the	O
structured	O
questionnaire	O
were	O
derived	O
from	O
extensive	O
literature	O
reviews	O
.	O

Governance	O
infrastructure	O

Governance	O
assumes	O
the	O
broad	O
responsibility	O
for	O
organizational	O
goals	O
and	O
survival	O
and	O
involves	O
the	O
series	O
process	O
of	O
setting	O
and	O
monitoring	O
organizational	O
goals	O
and	O
strategy	O
development	O
through	O
a	O
board	O
of	O
representatives	O
[	O
38	O
]	O
.	O

Governance	O
or	O
administrative	O
integration	O
infrastructure	O
in	O
establishing	O
network	O
partnerships	O
refers	O
to	O
administrative	O
structures	O
(	O
or	O
responsibilities	O
)	O
created	O
to	O
facilitate	O
communication	O
,	O
clear	O
lines	O
of	O
authority	O
,	O
accountability	O
,	O
and	O
responsibility	O
for	O
patient	S-Species
care	O
services	O
;	O
to	O
negotiate	O
budgets	O
and	O
financial	O
trade	O
-	O
offs	O
;	O
and	O
to	O
present	O
a	O
cohesive	O
,	O
consistent	O
message	O
in	O
interactions	O
with	O
external	O
agencies	O
and	O
the	O
community	O
[	O
29	O
,	O
39	O
-	O
41	O
]	O
and	O
most	O
important	O
for	O
members	O
in	O
contract	O
agreements	O
,	O
to	O
manage	O
participation	O
[	O
33	O
]	O
.	O

From	O
a	O
multidisciplinary	O
perspective	O
,	O
Mitchell	O
and	O
Shortell	O
[	O
42	O
]	O
applied	O
the	O
concepts	O
of	O
governance	O
and	O
management	O
characteristics	O
in	O
effective	O
community	O
health	O
partnerships	O
.	O

The	O
construct	O
of	O
governance	O
involved	O
several	O
tasks	O
,	O
including	O
setting	O
priorities	O
for	O
strategic	O
goals	O
,	O
choosing	O
the	O
membership	O
composition	O
,	O
obtaining	O
the	O
necessary	O
financial	O
resources	O
,	O
and	O
setting	O
up	O
the	O
accountability	O
systems	O
,	O
and	O
so	O
on	O
.	O

The	O
construct	O
of	O
the	O
management	O
refers	O
to	O
the	O
tasks	O
of	O
engaging	O
and	O
maintaining	O
organizational	O
members	O
'	O
interest	O
in	O
a	O
shared	O
vision	O
and	O
mission	O
,	O
providing	O
appropriate	O
structures	O
and	O
coordination	O
mechanisms	O
for	O
the	O
specified	O
strategies	O
,	O
promoting	O
constructive	O
conflicts	O
and	O
managing	O
destructive	O
conflicts	O
,	O
implementing	O
information	O
systems	O
to	O
monitor	O
the	O
dynamics	O
,	O
adjusting	O
the	O
leadership	O
in	O
the	O
overall	O
membership	O
,	O
and	O
so	O
on	O
.	O

The	O
issues	O
of	O
governance	O
and	O
administrative	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
2	O
,	O
38	O
,	O
40	O
,	O
41	O
,	O
43	O
-	O
47	O
]	O
:	O

*	O
planning	O
the	O
shared	O
visions	O
and	O
missions	O

*	O
determining	O
the	O
shared	O
service	O
strategies	O
,	O
cooperation	O
priorities	O
,	O
policies	O
and	O
principles	O

*	O
identifying	O
the	O
information	O
needed	O
and	O
how	O
to	O
get	O
it	O

*	O
organizing	O
the	O
network	O
dynamics	O
and	O
member	O
roles	O

*	O
leading	O
and	O
managing	O
the	O
conflicts	O
and	O
communication	O

*	O
designing	O
and	O
controlling	O
the	O
shared	O
network	O
performance	O
systems	O
,	O
including	O
indicator	O
settings	O
,	O
feedbacks	O
,	O
and	O
accountability	O
.	O

Clinical	O
infrastructure	O

The	O
idea	O
of	O
care	O
integration	O
begins	O
through	O
such	O
public	O
programs	O
that	O
include	O
social	O
workers	O
in	O
public	O
welfare	O
departments	O
,	O
caseworkers	O
in	O
mental	O
health	O
,	O
or	O
nurses	O
in	O
public	O
health	O
departments	O
.	O

In	O
the	O
late	O
1980s	O
,	O
care	O
integration	O
was	O
deemed	O
necessary	O
for	O
the	O
streamlining	O
of	O
care	O
and	O
negotiating	O
the	O
maze	O
of	O
long	O
-	O
term	O
care	O
services	O
.	O

At	O
that	O
time	O
,	O
it	O
was	O
referred	O
to	O
as	O
service	O
coordination	O
or	O
case	O
management	O
,	O
or	O
in	O
other	O
related	O
terms	O
[	O
29	O
]	O
.	O

The	O
purpose	O
of	O
care	O
integration	O
is	O
to	O
work	O
directly	O
with	O
patients	S-Species
and	O
their	O
families	O
over	O
time	O
to	O
help	O
them	O
arrange	O
and	O
manage	O
the	O
complex	O
resources	O
that	O
patients	S-Species
may	O
need	O
to	O
maintain	O
health	O
and	O
independent	O
functioning	O
.	O

At	O
the	O
same	O
time	O
,	O
care	O
integration	O
is	O
used	O
to	O
achieve	O
the	O
most	O
cost	O
-	O
effective	O
use	O
possible	O
of	O
scarce	O
resources	O
,	O
by	O
steering	O
patients	S-Species
to	O
the	O
health	O
,	O
social	O
,	O
and	O
support	O
services	O
most	O
appropriate	O
for	O
them	O
at	O
a	O
given	O
time	O
[	O
29	O
]	O
.	O

Conrad	O
and	O
Dowling	O
[	O
33	O
]	O
pointed	O
out	O
that	O
to	O
coordinate	O
and	O
integrate	O
patient	S-Species
care	O
relies	O
on	O
connecting	O
patient	S-Species
services	O
at	O
the	O
different	O
stages	O
of	O
the	O
patient	S-Species
care	O
processes	O
.	O

Care	O
coordination	O
in	O
integrated	O
networks	O
can	O
be	O
achieved	O
through	O
integration	O
of	O
training	O
programs	O
and	O
some	O
clinical	O
services	O
,	O
provision	O
of	O
complementary	O
clinical	O
capabilities	O
,	O
clinical	O
geographic	O
proximity	O
design	O
,	O
clear	O
role	O
definition	O
of	O
each	O
institution	O
,	O
commitment	O
and	O
flexibility	O
of	O
leaderships	O
and	O
medical	O
staffs	O
,	O
and	O
the	O
support	O
of	O
a	O
large	O
referring	O
physician	O
groups	O
embracing	O
the	O
affiliation	O
concepts	O
[	O
48	O
]	O
.	O

The	O
issues	O
of	O
clinical	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
48	O
-	O
50	O
]	O
:	O

*	O
planning	O
and	O
differentiating	O
target	O
markets	O
based	O
on	O
the	O
clinical	O
services	O
of	O
the	O
network	O
members	O

*	O
uniting	O
individual	O
clinical	O
professionals	O
for	O
clinical	O
project	O
planning	O

*	O
designing	O
patient	S-Species
-	O
centered	O
care	O
or	O
case	O
management	O
teams	O

*	O
establishing	O
committees	O
responsible	O
for	O
patient	S-Species
-	O
centered	O
case	O
report	O
meetings	O
,	O
case	O
referral	O
,	O
transfer	O
,	O
and	O
tracing	O
,	O
file	O
management	O
(	O
record	O
and	O
information	O
exchanges	O
)	O
,	O
clinical	O
quality	O
management	O
(	O
quality	O
assurance	O
,	O
improvement	O
,	O
risk	O
and	O
malpractice	O
management	O
,	O
and	O
utilization	O
review	O
)	O
,	O
and	O
medical	O
continuing	O
education	O
and	O
on	O
-	O
job	O
education	O
.	O

Marketing	O
infrastructure	O

Marketing	O
integration	O
refers	O
to	O
how	O
to	O
work	O
together	O
as	O
a	O
whole	O
both	O
from	O
the	O
provider	O
and	O
patient	S-Species
perspectives	O
.	O

One	O
of	O
the	O
case	O
reports	O
interviewing	O
developing	O
integrated	O
delivery	O
system	O
or	O
networks	O
realized	O
that	O
the	O
most	O
important	O
thing	O
is	O
how	O
an	O
integrated	O
system	O
or	O
network	O
is	O
promoted	O
and	O
what	O
is	O
promoted	O
for	O
the	O
consumers	O
[	O
51	O
]	O
,	O
including	O
focusing	O
on	O
product	O
development	O
,	O
making	O
sure	O
the	O
branding	O
holds	O
together	O
,	O
marketing	O
directly	O
to	O
consumers	O
,	O
demonstrating	O
values	O
to	O
consumers	O
,	O
and	O
even	O
conducting	O
marketing	O
research	O
to	O
make	O
efforts	O
for	O
the	O
long	O
term	O
.	O

In	O
a	O
health	O
care	O
network	O
with	O
several	O
organizational	O
members	O
and	O
target	O
patients	S-Species
,	O
the	O
marketing	O
infrastructure	O
in	O
PCCNs	O
here	O
refers	O
to	O
provider	O
members	O
'	O
marketing	O
,	O
meaning	O
the	O
resource	O
sharing	O
and	O
market	O
development	O
in	O
a	O
PCCN	O
as	O
a	O
whole	O
.	O

The	O
issues	O
of	O
the	O
marketing	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
37	O
,	O
52	O
-	O
54	O
]	O
:	O

*	O
sharing	O
the	O
literature	O
and	O
facility	O
publications	O
among	O
the	O
network	O
members	O

*	O
uniting	O
public	O
promotions	O
such	O
as	O
united	O
activities	O
,	O
electronic	O
and	O
paper	O
media	O
for	O
enhancing	O
the	O
network	O
reputation	O
as	O
"	O
one	O
system	O
,	O
one	O
brand	O
and	O
quality	O
"	O

*	O
differentiating	O
target	O
markets	O
of	O
the	O
network	O
for	O
competing	O
in	O
the	O
medical	O
industry	O
.	O

Financial	O
infrastructure	O

Comprehensive	O
,	O
flexible	O
,	O
and	O
adequate	O
financing	O
is	O
a	O
goal	O
of	O
the	O
ideal	O
continuum	O
of	O
care	O
.	O

That	O
component	O
is	O
the	O
most	O
critical	O
and	O
challenging	O
to	O
manage	O
under	O
the	O
changes	O
in	O
the	O
health	O
care	O
delivery	O
environment	O
.	O

Gillies	O
et	O
al	O
.	O

[	O
30	O
]	O
suggested	O
that	O
integrating	O
financial	O
management	O
across	O
operating	O
units	O
adds	O
the	O
greatest	O
value	O
to	O
systems	O
or	O
organizations	O
.	O

In	O
one	O
case	O
study	O
,	O
Bramson	O
et	O
al	O
.	O

[	O
55	O
]	O
also	O
showed	O
that	O
reducing	O
costs	O
through	O
joint	O
purchasing	O
by	O
the	O
radiology	O
departments	O
of	O
a	O
vertically	O
integrated	O
health	O
system	O
could	O
yield	O
substantial	O
savings	O
.	O

The	O
issues	O
of	O
the	O
financial	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
:	O

*	O
budgeting	O

*	O
uniting	O
equipment	O
,	O
medical	O
materials	O
,	O
and	O
drug	O
purchasing	O
and	O
routine	O
administrative	O
stuff	O
management	O

*	O
pooling	O
recruitment	O
funds	O

*	O
designing	O
a	O
financial	O
risk	O
and	O
sharing	O
mechanism	O
.	O

Information	O
infrastructure	O

Information	O
is	O
an	O
essential	O
component	O
of	O
an	O
organization	O
.	O

A	O
complete	O
information	O
system	O
can	O
help	O
an	O
organization	O
to	O
integrate	O
its	O
individual	O
units	O
and	O
efficiently	O
manage	O
the	O
continuum	O
.	O

The	O
ideal	O
information	O
system	O
for	O
a	O
continuum	O
of	O
care	O
was	O
conceived	O
of	O
and	O
formed	O
in	O
the	O
mid	O
-	O
1980s	O
[	O
56	O
]	O
.	O

During	O
the	O
late	O
1980s	O
,	O
computer	O
technology	O
began	O
to	O
make	O
an	O
information	O
system	O
feasible	O
and	O
affordable	O
through	O
new	O
computer	O
chips	O
with	O
expanded	O
capability	O
and	O
networking	O
technology	O
.	O

In	O
the	O
1990s	O
,	O
the	O
individual	O
services	O
of	O
the	O
continuum	O
upgraded	O
their	O
information	O
systems	O
to	O
combine	O
clinical	O
,	O
financial	O
,	O
and	O
utilization	O
data	O
[	O
29	O
]	O
.	O

Some	O
studies	O
have	O
argued	O
that	O
the	O
quality	O
of	O
information	O
systems	O
can	O
drive	O
costs	O
down	O
,	O
because	O
a	O
good	O
information	O
system	O
can	O
give	O
physicians	O
easy	O
electronic	O
access	O
to	O
complete	O
the	O
documentation	O
of	O
the	O
patients	S-Species
'	O
clinical	O
records	O
,	O
better	O
inform	O
them	O
about	O
reimbursement	O
and	O
capitation	O
issues	O
,	O
help	O
them	O
easily	O
associate	O
and	O
manage	O
cases	O
together	O
,	O
and	O
achieve	O
a	O
higher	O
level	O
of	O
professional	O
satisfaction	O
[	O
57	O
,	O
58	O
]	O
.	O

Using	O
Inova	O
Health	O
System	O
,	O
an	O
integrated	O
delivery	O
system	O
in	O
northern	O
Virginia	O
,	O
as	O
an	O
example	O
,	O
Wager	O
,	O
Heda	O
,	O
and	O
Austin	O
[	O
59	O
]	O
showed	O
that	O
by	O
developing	O
a	O
health	O
information	O
network	O
within	O
an	O
integrated	O
delivery	O
system	O
,	O
Inova	O
can	O
have	O
a	O
clinical	O
transaction	O
system	O
for	O
hospitals	O
and	O
other	O
entities	O
,	O
a	O
data	O
repository	O
for	O
decision	O
support	O
and	O
outcome	O
management	O
,	O
a	O
managed	O
care	O
information	O
system	O
to	O
support	O
managed	O
care	O
and	O
capitation	O
contracts	O
,	O
and	O
greater	O
capability	O
to	O
acquire	O
physicians	O
.	O

The	O
issues	O
of	O
information	O
coordination	O
include	O
[	O
60	O
-	O
68	O
]	O
:	O

*	O
establishing	O
an	O
electronic	O
medical	O
record	O
system	O
,	O
regional	O
information	O
network	O
for	O
patient	S-Species
clinical	O
and	O
administrative	O
data	O
,	O
clinical	O
service	O
arrangements	O
and	O
administrative	O
work	O

*	O
uniting	O
the	O
system	O
information	O
management	O
and	O
web	O
pages	O
.	O

The	O
structured	O
questionnaire	O
was	O
developed	O
with	O
the	O
wording	O
of	O
practical	O
managerial	O
actions	O
based	O
on	O
the	O
five	O
concepts	O
just	O
mentioned	O
.	O

There	O
were	O
19	O
survey	O
items	O
on	O
governance	O
infrastructure	O
,	O
25	O
on	O
clinical	O
infrastructure	O
,	O
13	O
on	O
marketing	O
infrastructure	O
,	O
20	O
on	O
financial	O
infrastructure	O
,	O
and	O
7	O
on	O
information	O
infrastructure	O
.	O

All	O
84	O
items	O
were	O
,	O
simultaneously	O
,	O
applied	O
to	O
examine	O
the	O
relationships	O
of	O
the	O
clinic	O
'	O
s	O
peer	O
members	O
and	O
the	O
relationship	O
of	O
clinic	O
and	O
hospital	O
members	O
in	O
a	O
PCCN	O
,	O
and	O
it	O
resulted	O
in	O
a	O
total	O
of	O
168	O
survey	O
questions	O
.	O

The	O
detailed	O
information	O
of	O
the	O
item	O
questions	O
was	O
listed	O
in	O
Table	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
.	O

The	O
structured	O
questionnaires	O
were	O
drafted	O
from	O
previous	O
literatures	O
and	O
then	O
examined	O
by	O
two	O
academic	O
professors	O
for	O
theoretical	O
accuracy	O
.	O

Then	O
one	O
pilot	O
study	O
was	O
pre	O
-	O
tested	O
for	O
the	O
PCCN	O
pioneers	O
(	O
i	O
.	O
e	O
.	O
,	O
92	O
network	O
clinic	O
members	O
)	O
and	O
116	O
hospital	O
providers	O
which	O
have	O
partner	O
relationships	O
with	O
other	O
health	O
care	O
organizations	O
(	O
i	O
.	O
e	O
.	O
,	O
hospitals	O
,	O
clinics	O
,	O
long	O
-	O
term	O
care	O
facilities	O
)	O
.	O

The	O
wordings	O
and	O
meanings	O
of	O
each	O
question	O
item	O
were	O
revised	O
to	O
assure	O
content	O
validity	O
.	O

The	O
Cronbach	O
alpha	O
values	O
for	O
the	O
five	O
integration	O
constructs	O
-	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
finance	O
,	O
and	O
information	O
infrastructure	O
were	O
0	O
.	O
946	O
,	O
0	O
.	O
958	O
,	O
0	O
.	O
932	O
,	O
0	O
.	O
944	O
,	O
and	O
0	O
.	O
898	O
for	O
the	O
measures	O
of	O
clinic	O
-	O
clinic	O
member	O
relationships	O
;	O
and	O
0	O
.	O
945	O
,	O
0	O
.	O
949	O
,	O
0	O
.	O
916	O
,	O
0	O
.	O
948	O
,	O
and	O
0	O
.	O
896	O
for	O
the	O
measures	O
of	O
clinic	O
-	O
hospital	O
member	O
relationships	O
.	O

Study	O
subjects	O

To	O
find	O
the	O
member	O
partnership	O
,	O
we	O
sent	O
questionnaires	O
to	O
1	O
,	O
557	O
individual	O
clinics	O
which	O
had	O
belonged	O
to	O
PCCNs	O
for	O
at	O
least	O
one	O
year	O
,	O
based	O
on	O
information	O
contained	O
in	O
the	O
Taiwan	O
Primary	O
Community	O
Care	O
Network	O
List	O
(	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
2003	O
,	O
2004	O
and	O
2005	O
)	O
.	O

We	O
let	O
clinic	O
members	O
in	O
all	O
PCCNs	O
point	O
out	O
how	O
they	O
coordinate	O
with	O
their	O
peer	O
clinic	O
members	O
and	O
hospital	O
members	O
within	O
a	O
PCCN	O
because	O
individual	O
clinic	O
members	O
could	O
be	O
better	O
informants	O
than	O
hospital	O
members	O
,	O
which	O
need	O
to	O
deal	O
with	O
multiple	O
clinic	O
relationships	O
and	O
therefore	O
might	O
find	O
it	O
hard	O
to	O
describe	O
the	O
coordination	O
involvement	O
one	O
by	O
one	O
with	O
clinic	O
members	O
.	O

Moreover	O
,	O
networks	O
form	O
for	O
various	O
reasons	O
and	O
it	O
might	O
lead	O
to	O
the	O
various	O
involvements	O
by	O
individual	O
network	O
members	O
(	O
i	O
.	O
e	O
.	O
,	O
hospital	O
and	O
clinic	O
members	O
)	O
.	O

Therefore	O
,	O
using	O
the	O
participating	O
clinics	O
as	O
individual	O
survey	O
units	O
,	O
the	O
results	O
could	O
portray	O
the	O
overall	O
dynamics	O
and	O
processes	O
more	O
authentically	O
and	O
detailed	O
throughout	O
all	O
PCCNs	O
in	O
the	O
demonstration	O
project	O
.	O

Nine	O
hundred	O
and	O
twenty	O
-	O
eight	O
clinics	O
responded	O
(	O
59	O
.	O
6	O
%	O
)	O
,	O
with	O
239	O
clinics	O
in	O
the	O
Taipei	O
region	O
,	O
165	O
in	O
the	O
northern	O
region	O
,	O
241	O
in	O
the	O
central	O
region	O
,	O
108	O
in	O
the	O
southern	O
region	O
,	O
150	O
in	O
the	O
Kao	O
-	O
Ping	O
region	O
,	O
and	O
15	O
in	O
the	O
eastern	O
region	O
of	O
Taiwan	O
.	O

Ten	O
clinics	O
had	O
not	O
mentioned	O
their	O
practicing	O
locations	O
.	O

There	O
is	O
no	O
statistically	O
significant	O
difference	O
in	O
geographical	O
distribution	O
between	O
the	O
respondents	O
and	O
the	O
study	O
population	O
(	O
chi	O
2	O
=	O
4	O
.	O
208	O
,	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Analytical	O
techniques	O

The	O
data	O
was	O
first	O
analyzed	O
descriptively	O
with	O
frequency	O
counts	O
(	O
percentage	O
)	O
for	O
each	O
survey	O
item	O
,	O
instead	O
of	O
using	O
mean	O
as	O
a	O
statistical	O
method	O
,	O
because	O
the	O
variation	O
among	O
the	O
respondents	O
may	O
not	O
represent	O
the	O
normal	O
distribution	O
and	O
it	O
might	O
ignore	O
the	O
extreme	O
values	O
for	O
the	O
respondents	O
'	O
answers	O
.	O

To	O
compare	O
how	O
the	O
respondents	O
perceived	O
the	O
strength	O
of	O
integration	O
existing	O
in	O
clinic	O
-	O
clinic	O
and	O
clinic	O
-	O
hospital	O
relationships	O
,	O
paired	O
t	O
-	O
tests	O
were	O
performed	O
for	O
individual	O
survey	O
items	O
,	O
using	O
the	O
original	O
numerical	O
scores	O
.	O

Results	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
governance	O
infrastructure	O

With	O
regard	O
to	O
the	O
governance	O
infrastructures	O
,	O
the	O
frequency	O
was	O
counted	O
for	O
each	O
survey	O
item	O
with	O
recalculated	O
scales	O
:	O
disagree	O
(	O
Likert	O
scale	O
1	O
and	O
2	O
)	O
,	O
fair	O
(	O
Likert	O
scale	O
3	O
)	O
,	O
and	O
agree	O
(	O
Likert	O
scale	O
4	O
and	O
5	O
)	O
with	O
individual	O
items	O
.	O

In	O
clinic	O
-	O
clinic	O
relationship	O
(	O
Table	O
2	O
)	O
,	O
the	O
majority	O
of	O
clinic	O
members	O
agree	O
that	O
the	O
determined	O
deals	O
were	O
obeyed	O
(	O
Table	O
2	O
,	O
item	O
1	O
:	O
88	O
.	O
69	O
%	O
)	O
,	O
the	O
goals	O
and	O
strategies	O
of	O
members	O
were	O
well	O
-	O
understood	O
(	O
Table	O
2	O
,	O
item	O
16	O
:	O
79	O
.	O
74	O
%	O
)	O
,	O
and	O
the	O
united	O
principals	O
for	O
individual	O
members	O
were	O
developed	O
(	O
Table	O
2	O
,	O
item	O
15	O
:	O
79	O
.	O
42	O
%	O
)	O
.	O

The	O
higher	O
percentages	O
were	O
also	O
found	O
in	O
clinic	O
-	O
hospital	O
relationship	O
in	O
the	O
same	O
items	O
(	O
Table	O
2	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
establishing	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
,	O
item	O
11	O
:	O
27	O
.	O
91	O
%	O
)	O
,	O
designing	O
and	O
employing	O
the	O
network	O
performance	O
indicators	O
(	O
Table	O
2	O
,	O
item	O
3	O
:	O
21	O
.	O
23	O
%	O
)	O
,	O
and	O
establishing	O
communication	O
models	O
and	O
channels	O
(	O
Table	O
2	O
,	O
item	O
12	O
:	O
19	O
.	O
94	O
%	O
)	O
still	O
occupied	O
higher	O
percentages	O
not	O
developed	O
and	O
deserved	O
to	O
been	O
made	O
the	O
focus	O
of	O
more	O
efforts	O
in	O
the	O
future	O
.	O

Paired	O
t	O
-	O
test	O
analyses	O
for	O
all	O
individual	O
survey	O
items	O
of	O
governance	O
infrastructure	O
showed	O
that	O
the	O
deals	O
obeyed	O
(	O
Table	O
2	O
,	O
item1	O
)	O
and	O
plans	O
and	O
goals	O
controlled	O
(	O
Table	O
2	O
,	O
item	O
2	O
)	O
were	O
achieved	O
more	O
in	O
clinic	O
-	O
clinic	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
hospital	O
relationships	O
;	O
however	O
,	O
the	O
design	O
of	O
network	O
performance	O
indicators	O
(	O
Table	O
2	O
,	O
item	O
3	O
)	O
,	O
development	O
of	O
disintegration	O
policy	O
and	O
principals	O
(	O
Table	O
2	O
,	O
item	O
8	O
)	O
,	O
and	O
the	O
establishment	O
of	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
,	O
item	O
11	O
)	O
were	O
reached	O
more	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
clinic	O
relationships	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
clinical	O
infrastructure	O

Examining	O
the	O
extent	O
of	O
clinical	O
infrastructure	O
for	O
network	O
members	O
,	O
establishing	O
two	O
-	O
directed	O
patient	S-Species
referral	O
systems	O
and	O
patient	S-Species
referral	O
information	O
files	O
(	O
Table	O
3	O
,	O
items	O
35	O
&	O
37	O
)	O
and	O
uniting	O
medical	O
continuing	O
education	O
and	O
on	O
-	O
job	O
education	O
(	O
Table	O
3	O
,	O
item	O
34	O
)	O
were	O
shown	O
at	O
a	O
highly	O
implemented	O
rate	O
in	O
clinic	O
-	O
clinic	O
(	O
more	O
than	O
70	O
%	O
)	O
and	O
clinic	O
-	O
hospital	O
(	O
more	O
than	O
80	O
%	O
)	O
relationships	O
.	O

On	O
the	O
other	O
hand	O
,	O
network	O
members	O
had	O
higher	O
percentages	O
(	O
more	O
than	O
40	O
%	O
)	O
not	O
to	O
think	O
about	O
the	O
possible	O
integration	O
mechanisms	O
including	O
establishing	O
committees	O
to	O
deal	O
with	O
medical	O
malpractice	O
(	O
Table	O
3	O
,	O
item	O
44	O
)	O
,	O
planning	O
and	O
differentiating	O
clinical	O
market	O
areas	O
(	O
Table	O
3	O
,	O
item	O
20	O
)	O
,	O
and	O
designing	O
patient	S-Species
-	O
centered	O
case	O
management	O
teams	O
(	O
Table	O
3	O
,	O
item	O
22	O
)	O
.	O

Overall	O
,	O
there	O
was	O
better	O
clinical	O
integration	O
involvement	O
for	O
all	O
the	O
described	O
items	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
clinic	O
relationships	O
within	O
a	O
network	O
in	O
this	O
study	O
(	O
see	O
Table	O
3	O
,	O
paired	O
t	O
-	O
tests	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
marketing	O
infrastructure	O

For	O
marketing	O
planning	O
,	O
the	O
clinics	O
had	O
better	O
integrated	O
marketing	O
activities	O
with	O
their	O
respective	O
hospitals	O
than	O
with	O
peer	O
clinic	O
members	O
within	O
PCCNs	O
for	O
all	O
studied	O
items	O
(	O
Table	O
4	O
,	O
paired	O
t	O
-	O
test	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Examining	O
the	O
clinic	O
-	O
clinic	O
relationships	O
,	O
uniting	O
social	O
activities	O
(	O
Table	O
4	O
,	O
item	O
53	O
)	O
,	O
sharing	O
the	O
individual	O
facility	O
reports	O
for	O
updated	O
services	O
(	O
Table	O
4	O
,	O
item	O
46	O
)	O
,	O
public	O
promotion	O
(	O
Table	O
4	O
,	O
item	O
54	O
)	O
,	O
and	O
uniting	O
and	O
joining	O
the	O
facility	O
activities	O
(	O
Table	O
4	O
,	O
item	O
51	O
)	O
were	O
the	O
top	O
four	O
marketing	O
works	O
done	O
among	O
clinic	O
members	O
(	O
more	O
than	O
60	O
%	O
implemented	O
rate	O
)	O
;	O
and	O
those	O
items	O
also	O
showed	O
a	O
higher	O
implemented	O
rate	O
(	O
more	O
than	O
70	O
%	O
)	O
between	O
clinic	O
and	O
hospital	O
members	O
.	O

On	O
the	O
other	O
hand	O
,	O
facility	O
assets	O
such	O
as	O
reports	O
(	O
Table	O
4	O
,	O
item	O
49	O
)	O
,	O
and	O
professional	O
literatures	O
and	O
books	O
(	O
Table	O
4	O
,	O
item	O
45	O
)	O
were	O
not	O
well	O
-	O
shared	O
among	O
clinic	O
members	O
(	O
"	O
never	O
-	O
thinking	O
"	O
rate	O
:	O
42	O
.	O
13	O
%	O
)	O
.	O

In	O
addition	O
,	O
uniting	O
the	O
network	O
publication	O
could	O
make	O
more	O
efforts	O
in	O
the	O
future	O
(	O
"	O
never	O
-	O
thinking	O
"	O
rate	O
in	O
item	O
50	O
:	O
39	O
.	O
98	O
%	O
)	O
.	O

The	O
room	O
for	O
clinic	O
-	O
hospital	O
partnership	O
to	O
think	O
about	O
acting	O
was	O
kind	O
of	O
different	O
from	O
those	O
in	O
the	O
clinic	O
-	O
clinic	O
relationship	O
.	O

In	O
addition	O
to	O
the	O
uniting	O
publication	O
that	O
can	O
be	O
encouraged	O
to	O
improve	O
the	O
clinic	O
-	O
hospital	O
relationship	O
(	O
Table	O
4	O
,	O
item	O
50	O
:	O
27	O
.	O
48	O
%	O
)	O
,	O
cooperating	O
in	O
research	O
projects	O
(	O
Table	O
4	O
,	O
item	O
52	O
:	O
25	O
.	O
00	O
%	O
)	O
and	O
identifying	O
and	O
differentiating	O
target	O
markets	O
(	O
Table	O
4	O
,	O
item	O
57	O
:	O
24	O
.	O
57	O
%	O
)	O
had	O
still	O
more	O
opportunities	O
to	O
be	O
focused	O
on	O
in	O
the	O
future	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
financial	O
infrastructure	O

The	O
PCCN	O
members	O
were	O
found	O
to	O
have	O
a	O
lower	O
extent	O
of	O
financial	O
integration	O
as	O
evidenced	O
by	O
higher	O
percentage	O
of	O
'	O
'	O
never	O
thinking	O
'	O
'	O
scale	O
about	O
the	O
survey	O
items	O
on	O
almost	O
all	O
items	O
(	O
see	O
Table	O
5	O
)	O
.	O

Slightly	O
more	O
integration	O
(	O
that	O
is	O
,	O
'	O
'	O
acting	O
'	O
'	O
rate	O
)	O
was	O
found	O
in	O
only	O
four	O
items	O
both	O
in	O
clinic	O
-	O
clinic	O
relationships	O
and	O
in	O
clinic	O
-	O
hospital	O
relationships	O
,	O
including	O
uniting	O
budget	O
planning	O
(	O
Table	O
5	O
:	O
item	O
58	O
)	O
,	O
sharing	O
places	O
,	O
materials	O
,	O
and	O
equipment	O
(	O
Table	O
5	O
:	O
item	O
68	O
)	O
,	O
uniting	O
budgeting	O
for	O
certain	O
services	O
(	O
Table	O
5	O
:	O
items	O
72	O
)	O
,	O
and	O
designing	O
the	O
resource	O
distribution	O
principals	O
based	O
on	O
the	O
whole	O
network	O
goals	O
(	O
Table	O
5	O
:	O
item	O
77	O
)	O
.	O

Further	O
examining	O
the	O
financial	O
infrastructure	O
in	O
clinic	O
-	O
clinic	O
relationship	O
and	O
clinic	O
-	O
hospital	O
relationship	O
,	O
paired	O
-	O
t	O
tests	O
revealed	O
that	O
clinic	O
-	O
hospital	O
partnerships	O
were	O
involved	O
more	O
in	O
places	O
,	O
materials	O
,	O
and	O
equipment	O
sharing	O
and	O
maintenance	O
(	O
Table	O
5	O
,	O
items	O
62	O
and	O
68	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
higher	O
financial	O
infrastructure	O
coordination	O
exists	O
in	O
clinic	O
-	O
clinic	O
relationships	O
(	O
Table	O
5	O
,	O
items	O
58	O
,	O
59	O
,	O
63	O
-	O
65	O
,	O
72	O
,	O
74	O
,	O
75	O
,	O
and	O
77	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
information	O
infrastructure	O

There	O
was	O
significantly	O
greater	O
integration	O
of	O
information	O
in	O
clinic	O
-	O
hospital	O
than	O
clinic	O
-	O
clinic	O
relationships	O
in	O
all	O
items	O
in	O
this	O
category	O
(	O
Table	O
6	O
,	O
paired	O
t	O
-	O
tests	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
greatest	O
integration	O
was	O
found	O
in	O
electronic	O
patient	S-Species
records	O
(	O
Table	O
6	O
:	O
item	O
78	O
)	O
,	O
followed	O
by	O
information	O
integration	O
for	O
patient	S-Species
data	O
(	O
Table	O
6	O
:	O
item	O
79	O
)	O
and	O
clinical	O
service	O
arrangements	O
(	O
Table	O
6	O
:	O
item	O
81	O
)	O
.	O

The	O
lowest	O
level	O
of	O
integration	O
in	O
information	O
infrastructure	O
was	O
found	O
in	O
administrative	O
works	O
such	O
as	O
registration	O
,	O
billing	O
and	O
so	O
on	O
(	O
Table	O
6	O
:	O
item	O
82	O
,	O
'	O
'	O
never	O
-	O
thinking	O
'	O
'	O
rate	O
more	O
than	O
50	O
%	O
)	O
within	O
network	O
members	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
surveyed	O
943	O
clinics	O
that	O
had	O
belonged	O
to	O
Taiwan	O
PCCNs	O
for	O
more	O
than	O
a	O
year	O
to	O
understand	O
the	O
nature	O
and	O
extent	O
of	O
integration	O
to	O
which	O
they	O
and	O
their	O
associated	O
PCCN	O
members	O
(	O
clinics	O
and	O
hospitals	O
)	O
had	O
in	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
.	O

It	O
was	O
found	O
a	O
wide	O
variance	O
in	O
the	O
kind	O
and	O
degree	O
of	O
integration	O
among	O
them	O
and	O
a	O
lot	O
of	O
room	O
for	O
better	O
integration	O
(	O
Table	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
)	O
.	O

From	O
the	O
governance	O
perspective	O
,	O
we	O
found	O
lower	O
integration	O
was	O
found	O
in	O
the	O
establishment	O
of	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
:	O
item	O
11	O
)	O
among	O
member	O
clinics	O
and	O
member	O
hospitals	O
.	O

Coordination	O
could	O
be	O
viewed	O
from	O
different	O
perspectives	O
,	O
including	O
the	O
use	O
of	O
standardized	O
languages	O
and	O
forms	O
,	O
organizational	O
rules	O
and	O
procedures	O
,	O
the	O
establishment	O
of	O
common	O
rules	O
,	O
policies	O
,	O
and	O
procedures	O
,	O
and	O
the	O
monitoring	O
through	O
memos	O
,	O
reports	O
,	O
and	O
a	O
computerized	O
information	O
system	O
[	O
69	O
,	O
70	O
]	O
.	O

Facing	O
the	O
cumbersome	O
integration	O
processes	O
,	O
it	O
suggests	O
that	O
each	O
PCCN	O
'	O
s	O
headquarters	O
should	O
become	O
actively	O
involved	O
and	O
clarify	O
the	O
authority	O
,	O
responsibility	O
and	O
accountability	O
of	O
individual	O
members	O
,	O
identify	O
the	O
potential	O
conflict	O
sources	O
,	O
and	O
publicize	O
the	O
rules	O
and	O
regulation	O
of	O
network	O
integration	O
dynamics	O
covering	O
decision	O
making	O
processes	O
,	O
market	O
planning	O
,	O
clinical	O
teamwork	O
designs	O
,	O
and	O
financial	O
reports	O
of	O
individual	O
network	O
members	O
.	O

These	O
actions	O
could	O
enhance	O
the	O
trust	O
and	O
respect	O
of	O
network	O
members	O
one	O
another	O
and	O
could	O
improve	O
the	O
small	O
extent	O
of	O
integration	O
found	O
in	O
this	O
study	O
about	O
the	O
mechanisms	O
for	O
communication	O
models	O
and	O
channels	O
in	O
the	O
PCCNs	O
(	O
Table	O
2	O
:	O
item	O
12	O
)	O
.	O

From	O
the	O
network	O
management	O
perspective	O
,	O
communication	O
could	O
occur	O
between	O
the	O
various	O
entities	O
such	O
as	O
between	O
hospital	O
and	O
clinics	O
,	O
primary	O
care	O
physicians	O
and	O
specialists	O
,	O
managers	O
and	O
clinical	O
professionals	O
,	O
and	O
even	O
among	O
the	O
clinical	O
professionals	O
in	O
the	O
network	O
.	O

To	O
develop	O
effective	O
and	O
timely	O
communication	O
channels	O
was	O
the	O
key	O
for	O
the	O
management	O
of	O
integrated	O
organizations	O
[	O
30	O
-	O
32	O
]	O
and	O
could	O
alleviate	O
the	O
tensions	O
that	O
sometimes	O
occur	O
in	O
the	O
dynamics	O
of	O
the	O
multi	O
-	O
organizations	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
found	O
a	O
low	O
level	O
of	O
involvement	O
of	O
medical	O
teams	O
in	O
medical	O
projects	O
,	O
patient	S-Species
-	O
centered	O
case	O
management	O
,	O
and	O
case	O
report	O
meetings	O
among	O
the	O
network	O
members	O
(	O
Table	O
3	O
:	O
item	O
21	O
,	O
22	O
,	O
and	O
23	O
)	O
from	O
a	O
clinical	O
integration	O
perspective	O
.	O

Several	O
researchers	O
have	O
addressed	O
that	O
clinical	O
integration	O
providing	O
a	O
process	O
of	O
medical	O
management	O
,	O
care	O
management	O
,	O
case	O
management	O
,	O
and	O
patient	S-Species
management	O
designed	O
to	O
transform	O
the	O
traditionally	O
fragmented	O
delivery	O
system	O
into	O
a	O
more	O
cohesive	O
system	O
[	O
71	O
]	O
,	O
and	O
lead	O
to	O
higher	O
service	O
quality	O
and	O
assure	O
financial	O
objectives	O
[	O
72	O
,	O
73	O
]	O
.	O

More	O
attention	O
could	O
be	O
paid	O
to	O
these	O
activities	O
in	O
the	O
future	O
.	O

In	O
addition	O
,	O
it	O
was	O
also	O
found	O
less	O
integration	O
in	O
planning	O
and	O
differentiating	O
clinical	O
market	O
areas	O
(	O
Table	O
3	O
,	O
item	O
20	O
)	O
among	O
the	O
network	O
members	O
in	O
the	O
category	O
of	O
clinical	O
infrastructure	O
.	O

This	O
may	O
result	O
from	O
the	O
existing	O
specialty	O
diversities	O
in	O
individual	O
PCCNs	O
,	O
which	O
might	O
not	O
need	O
to	O
involve	O
planning	O
and	O
differentiating	O
market	O
area	O
based	O
on	O
the	O
members	O
'	O
clinical	O
services	O
at	O
the	O
early	O
stage	O
of	O
network	O
development	O
.	O

There	O
was	O
more	O
involvement	O
in	O
marketing	O
efforts	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
in	O
clinic	O
-	O
clinic	O
relationships	O
.	O

Generally	O
speaking	O
,	O
hospitals	O
have	O
more	O
resources	O
(	O
i	O
.	O
e	O
.	O
,	O
money	O
,	O
human	S-Species
resources	O
,	O
materials	O
,	O
and	O
physical	O
assets	O
)	O
than	O
clinics	O
,	O
which	O
might	O
explain	O
the	O
stronger	O
marketing	O
involvements	O
between	O
the	O
clinic	O
and	O
hospital	O
members	O
,	O
including	O
the	O
library	O
sharing	O
(	O
books	O
and	O
literatures	O
)	O
,	O
facility	O
brochure	O
dissemination	O
,	O
public	O
promoting	O
,	O
and	O
medical	O
research	O
cooperation	O
.	O

These	O
integration	O
efforts	O
also	O
meet	O
the	O
expectation	O
of	O
the	O
national	O
health	O
authority	O
for	O
resource	O
sharing	O
and	O
medical	O
quality	O
image	O
enhancement	O
among	O
the	O
health	O
care	O
providers	O
.	O

Financial	O
infrastructure	O
was	O
found	O
to	O
be	O
the	O
least	O
integrated	O
,	O
with	O
most	O
items	O
never	O
considered	O
.	O

Perhaps	O
the	O
only	O
reason	O
for	O
the	O
higher	O
score	O
of	O
budget	O
planning	O
activities	O
(	O
Table	O
5	O
:	O
items	O
58	O
and	O
77	O
)	O
was	O
that	O
BHNI	O
required	O
each	O
PCCN	O
to	O
design	O
and	O
determine	O
its	O
budgeting	O
arrangement	O
in	O
advance	O
before	O
joining	O
the	O
demonstration	O
project	O
.	O

While	O
slightly	O
more	O
financial	O
involvement	O
was	O
made	O
among	O
network	O
members	O
(	O
Table	O
5	O
:	O
items	O
68	O
,	O
72	O
&	O
73	O
)	O
,	O
possibly	O
due	O
to	O
similar	O
needs	O
,	O
there	O
remains	O
a	O
lot	O
of	O
room	O
for	O
financial	O
integration	O
in	O
the	O
future	O
.	O

There	O
was	O
a	O
need	O
for	O
networks	O
to	O
develop	O
electronic	O
information	O
systems	O
,	O
though	O
creating	O
and	O
managing	O
an	O
integrated	O
information	O
system	O
involves	O
very	O
detailed	O
work	O
.	O

Most	O
of	O
the	O
clinics	O
surveyed	O
have	O
focused	O
more	O
on	O
the	O
individual	O
public	O
members	O
'	O
administrative	O
works	O
such	O
as	O
filing	O
patient	S-Species
medical	O
records	O
,	O
collecting	O
and	O
managing	O
network	O
patient	S-Species
clinical	O
data	O
,	O
and	O
scheduling	O
clinical	O
services	O
,	O
which	O
were	O
required	O
by	O
the	O
BNHI	O
.	O

The	O
factors	O
for	O
the	O
health	O
care	O
managers	O
to	O
adopt	O
the	O
integrated	O
clinical	O
information	O
systems	O
include	O
the	O
decision	O
of	O
make	O
or	O
buy	O
,	O
adoption	O
leadership	O
,	O
adoption	O
objectives	O
,	O
implementation	O
leadership	O
,	O
phased	O
versus	O
simultaneous	O
implementation	O
,	O
parallel	O
systems	O
,	O
information	O
technology	O
implementation	O
policies	O
and	O
practices	O
,	O
use	O
levels	O
and	O
resistance	O
,	O
and	O
realized	O
benefits	O
and	O
return	O
on	O
investment	O
calculation	O
[	O
66	O
]	O
,	O
which	O
might	O
be	O
very	O
cumbersome	O
and	O
time	O
-	O
consuming	O
.	O

It	O
suggests	O
that	O
the	O
network	O
partners	O
might	O
be	O
engaged	O
,	O
firstly	O
,	O
more	O
in	O
simpler	O
network	O
cooperation	O
such	O
as	O
the	O
administrative	O
systems	O
for	O
patient	S-Species
admission	O
to	O
the	O
network	O
members	O
and	O
establishing	O
united	O
web	O
pages	O
for	O
patients	S-Species
to	O
access	O
their	O
family	O
physicians	O
and	O
network	O
members	O
for	O
medical	O
and	O
public	O
promotion	O
purposes	O
.	O

And	O
for	O
further	O
integrated	O
information	O
investments	O
,	O
efforts	O
must	O
be	O
redirected	O
for	O
network	O
members	O
to	O
work	O
together	O
to	O
define	O
the	O
approach	O
to	O
specific	O
classes	O
of	O
integration	O
for	O
the	O
long	O
term	O
[	O
74	O
]	O
.	O

Conclusion	O

This	O
study	O
tried	O
to	O
portray	O
and	O
trace	O
how	O
the	O
facility	O
participants	S-Species
were	O
involved	O
in	O
the	O
Taiwan	O
PCCNs	O
.	O

It	O
was	O
found	O
that	O
Taiwan	O
PCCNs	O
'	O
members	O
had	O
higher	O
involvement	O
in	O
the	O
governance	O
infrastructure	O
,	O
which	O
was	O
usually	O
viewed	O
as	O
the	O
most	O
important	O
for	O
establishment	O
of	O
core	O
values	O
in	O
PCCNs	O
'	O
organization	O
design	O
and	O
management	O
.	O

There	O
existed	O
a	O
higher	O
extent	O
of	O
integration	O
of	O
clinical	O
,	O
marketing	O
,	O
and	O
information	O
infrastructures	O
among	O
the	O
hospital	O
-	O
clinic	O
member	O
relationship	O
than	O
those	O
among	O
clinic	O
members	O
within	O
individual	O
PCCNs	O
.	O

The	O
financial	O
infrastructure	O
was	O
shown	O
the	O
least	O
integrated	O
relative	O
to	O
other	O
functional	O
infrastructures	O
at	O
the	O
early	O
stage	O
of	O
PCCN	O
formation	O
.	O

Page	O
[	O
43	O
]	O
argued	O
that	O
networks	O
form	O
and	O
grow	O
for	O
various	O
reasons	O
,	O
however	O
,	O
only	O
some	O
of	O
them	O
could	O
be	O
compatible	O
with	O
the	O
iterative	O
processes	O
of	O
collaboration	O
.	O

Some	O
participants	S-Species
in	O
the	O
PCCNs	O
may	O
simply	O
seek	O
short	O
-	O
term	O
economic	O
gains	O
and	O
have	O
little	O
interest	O
in	O
joint	O
learning	O
and	O
continuous	O
improvement	O
.	O

From	O
an	O
organizational	O
design	O
perspective	O
,	O
the	O
old	O
phrase	O
proposed	O
by	O
the	O
wisdom	O
of	O
the	O
saying	O
about	O
developing	O
the	O
integrated	O
organizations	O
(	O
networks	O
)	O
should	O
be	O
-	O
"	O
coming	O
together	O
is	O
the	O
beginning	O
,	O
and	O
working	O
together	O
is	O
the	O
success	O
.	O
"	O
Page	O
[	O
43	O
]	O
examined	O
the	O
virtual	O
provider	O
organizations	O
such	O
as	O
physician	O
-	O
hospital	O
organizations	O
and	O
pointed	O
out	O
the	O
issue	O
of	O
the	O
provider	O
attitudes	O
and	O
behaviors	O
as	O
the	O
critically	O
successful	O
continuous	O
improvements	O
in	O
the	O
health	O
care	O
environments	O
.	O

A	O
wide	O
variance	O
of	O
degree	O
of	O
network	O
integration	O
in	O
Taiwan	O
PCCNs	O
still	O
leaves	O
room	O
to	O
improve	O
.	O

In	O
this	O
study	O
,	O
the	O
thoroughly	O
surveyed	O
items	O
,	O
that	O
is	O
,	O
the	O
potential	O
network	O
design	O
content	O
,	O
were	O
employed	O
.	O

In	O
addition	O
to	O
provide	O
how	O
the	O
network	O
members	O
have	O
done	O
their	O
initial	O
work	O
at	O
the	O
early	O
stage	O
of	O
network	O
forming	O
in	O
this	O
study	O
,	O
the	O
detailed	O
surveyed	O
items	O
,	O
the	O
concepts	O
proposed	O
by	O
the	O
managerial	O
and	O
theoretical	O
professionals	O
,	O
could	O
be	O
also	O
a	O
guide	O
for	O
those	O
health	O
care	O
providers	O
who	O
have	O
a	O
willingness	O
to	O
join	O
multi	O
-	O
organizations	O
.	O

It	O
suggests	O
that	O
health	O
care	O
providers	O
could	O
take	O
more	O
detailed	O
looks	O
about	O
those	O
surveyed	O
items	O
and	O
give	O
some	O
possible	O
opportunities	O
to	O
create	O
the	O
potential	O
actions	O
.	O

Further	O
research	O
could	O
be	O
empirically	O
done	O
to	O
explore	O
the	O
relative	O
influence	O
of	O
these	O
integration	O
mechanisms	O
on	O
the	O
effectiveness	O
of	O
organizational	O
partnerships	O
.	O

The	O
partnerships	O
within	O
each	O
PCCN	O
represent	O
various	O
relationships	O
that	O
depend	O
on	O
how	O
much	O
the	O
members	O
are	O
engaged	O
in	O
the	O
projects	O
.	O

In	O
addition	O
to	O
the	O
macro	O
concepts	O
including	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
explored	O
in	O
this	O
study	O
,	O
other	O
managerial	O
issues	O
for	O
integrated	O
organizations	O
were	O
also	O
suggested	O
such	O
as	O
formation	O
of	O
an	O
integrated	O
cultural	O
atmosphere	O
,	O
human	S-Species
resources	O
management	O
,	O
physician	O
involvement	O
,	O
mission	O
and	O
commitment	O
establishment	O
,	O
from	O
micro	O
organizational	O
behavior	O
perspective	O
[	O
30	O
-	O
32	O
,	O
34	O
,	O
36	O
,	O
75	O
,	O
76	O
]	O
.	O

Micro	O
managerial	O
and	O
longitudinal	O
research	O
designs	O
could	O
be	O
employed	O
to	O
more	O
precisely	O
catch	O
the	O
never	O
completing	O
integration	O
efforts	O
in	O
the	O
future	O
.	O

Abbreviations	O

primary	O
community	O
care	O
network	O
(	O
PCCN	O
)	O
;	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

BYJL	O
independently	O
designed	O
and	O
conducted	O
this	O
study	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Recombinant	O
activated	O
protein	O
C	O
in	O
sepsis	O
:	O
endothelium	O
protection	O
or	O
endothelium	O
therapy	O
?	O

Abstract	O

Endothelium	O
dysfunction	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
sepsis	O
.	O

Looney	O
and	O
Mattay	O
,	O
in	O
the	O
previous	O
issue	O
of	O
Critical	O
Care	O
,	O
highlight	O
the	O
role	O
of	O
activated	O
protein	O
C	O
(	O
APC	O
)	O
as	O
a	O
protective	O
endothelial	O
drug	O
in	O
septic	O
situations	O
.	O

Nevertheless	O
,	O
the	O
results	O
of	O
in	O
vivo	O
studies	O
are	O
less	O
explicit	O
and	O
it	O
remains	O
uncertain	O
whether	O
these	O
properties	O
are	O
relevant	O
in	O
human	S-Species
septic	O
shock	O
.	O

Before	O
considering	O
recombinant	O
APC	O
(	O
rAPC	O
)	O
as	O
a	O
therapeutic	O
drug	O
for	O
the	O
endothelium	O
,	O
we	O
have	O
to	O
demonstrate	O
its	O
efficiency	O
to	O
protect	O
or	O
to	O
reduce	O
endothelium	O
injury	O
when	O
infused	O
a	O
long	O
time	O
after	O
the	O
septic	O
challenge	O
.	O

Nevertheless	O
,	O
if	O
rAPC	O
is	O
efficient	O
when	O
infused	O
in	O
the	O
early	O
phase	O
of	O
septic	O
challenge	O
,	O
we	O
thus	O
need	O
to	O
treat	O
our	O
patients	S-Species
earlier	O
.	O

At	O
the	O
least	O
,	O
genetically	O
engineered	O
variants	O
have	O
been	O
designed	O
with	O
greater	O
anti	O
-	O
apoptotic	O
activity	O
and	O
reduced	O
anticoagulant	O
activity	O
relative	O
to	O
wild	O
-	O
type	O
APC	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
demonstrate	O
the	O
usefulness	O
of	O
these	O
variants	O
in	O
septic	O
shock	O
therapy	O
.	O

The	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
(	O
rAPC	O
)	O
is	O
one	O
of	O
the	O
hottest	O
topics	O
in	O
septic	O
shock	O
therapy	O
.	O

The	O
pivotal	O
phase	O
3	O
placebo	O
-	O
controlled	O
Protein	O
C	O
Worldwide	O
Evaluation	O
in	O
Severe	O
Sepsis	O
(	O
PROWESS	O
)	O
clinical	O
trial	O
demonstrated	O
a	O
19	O
.	O
4	O
%	O
relative	O
risk	O
reduction	O
in	O
28	O
-	O
day	O
mortality	O
(	O
6	O
.	O
1	O
%	O
absolute	O
risk	O
reduction	O
)	O
with	O
an	O
increased	O
risk	O
(	O
3	O
.	O
5	O
%	O
versus	O
2	O
.	O
0	O
%	O
)	O
of	O
serious	O
bleeding	O
events	O
compared	O
with	O
placebo	O
.	O

Two	O
recent	O
and	O
important	O
articles	O
have	O
highlighted	O
the	O
role	O
of	O
APC	O
as	O
a	O
protective	O
endothelial	O
drug	O
[	O
1	O
]	O
and	O
as	O
a	O
cyto	O
-	O
protective	O
drug	O
[	O
2	O
]	O
.	O

Beneficial	O
effects	O
of	O
rAPC	O
in	O
the	O
PROWESS	O
study	O
were	O
thought	O
to	O
be	O
related	O
to	O
a	O
reduction	O
in	O
coagulation	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
a	O
reduction	O
in	O
inflammatory	O
response	O
to	O
sepsis	O
[	O
3	O
]	O
.	O

Post	O
-	O
PROWESS	O
investigations	O
have	O
been	O
associated	O
with	O
a	O
myriad	O
of	O
cellular	O
or	O
animal	O
studies	O
demonstrating	O
that	O
rAPC	O
,	O
through	O
reactions	O
mediated	O
by	O
endothelial	O
protein	O
C	O
receptor	O
and	O
the	O
effector	O
receptor	O
,	O
protease	O
activated	O
receptor	O
-	O
1	O
,	O
acts	O
directly	O
on	O
cells	O
to	O
exert	O
multiple	O
cytoprotective	O
effects	O
including	O
:	O
down	O
regulation	O
of	O
pro	O
-	O
inflammatory	O
gene	O
expression	O
[	O
4	O
]	O
;	O
anti	O
-	O
inflammatory	O
activities	O
[	O
5	O
]	O
;	O
anti	O
-	O
apoptotic	O
activity	O
[	O
6	O
]	O
;	O
and	O
protection	O
of	O
endothelial	O
barrier	O
function	O
[	O
1	O
,	O
2	O
]	O
.	O

Endothelium	O
dysfunction	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
sepsis	O
[	O
7	O
]	O
.	O

Sepsis	O
,	O
per	O
se	O
,	O
may	O
induce	O
phenotypic	O
modulations	O
of	O
the	O
endothelium	O
through	O
direct	O
or	O
indirect	O
interaction	O
of	O
the	O
endothelial	O
layer	O
with	O
components	O
of	O
the	O
bacterial	O
wall	O
,	O
inducing	O
a	O
myriad	O
of	O
host	O
-	O
derived	O
factors	O
from	O
endothelial	O
cells	O
.	O

Phenotypic	O
modifications	O
include	O
changes	O
in	O
pro	O
-	O
coagulant	O
and	O
proadhesive	O
properties	O
,	O
increased	O
endothelial	O
permeability	O
,	O
endothelial	O
cell	O
apoptosis	O
and	O
changes	O
in	O
vasomotor	O
properties	O
;	O
the	O
last	O
of	O
these	O
is	O
crucial	O
since	O
vasoplegia	O
is	O
directly	O
related	O
to	O
septic	O
shock	O
mortality	O
.	O

Recent	O
animal	O
and	O
human	S-Species
data	O
have	O
suggested	O
that	O
rAPC	O
may	O
improve	O
both	O
vascular	O
and	O
myocardial	O
dysfunction	O
and	O
vascular	O
reactivity	O
to	O
catecholamine	O
during	O
endotoxin	O
and	O
/	O
or	O
septic	O
challenge	O
[	O
8	O
,	O
9	O
]	O
.	O

From	O
bench	O
to	O
bedside	O

Experimental	O
evidence	O
supports	O
a	O
role	O
of	O
APC	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
endothelium	O
through	O
both	O
direct	O
and	O
indirect	O
mechanisms	O
.	O

Nevertheless	O
,	O
the	O
results	O
of	O
in	O
vivo	O
studies	O
are	O
less	O
explicit	O
.	O

In	O
a	O
retrospective	O
study	O
of	O
septic	O
shock	O
in	O
humans	S-Species
,	O
Monnet	O
and	O
colleagues	O
[	O
9	O
]	O
demonstrated	O
that	O
APC	O
infusion	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
delivered	O
norepinephrine	O
.	O

Wiel	O
and	O
colleagues	O
[	O
10	O
]	O
demonstrated	O
in	O
a	O
rabbit	S-Species
model	O
of	O
endotoxin	O
induced	O
shock	O
that	O
APC	O
decreased	O
aorta	O
endothelial	O
injury	O
.	O

By	O
contrast	O
,	O
in	O
a	O
lung	O
model	O
of	O
endotoxin	O
induced	O
inflammation	O
,	O
Robriquet	O
and	O
colleagues	O
[	O
11	O
]	O
demonstrated	O
a	O
trend	O
to	O
an	O
increased	O
vascular	O
permeability	O
using	O
high	O
doses	O
of	O
human	S-Species
APC	O
.	O

This	O
last	O
result	O
was	O
in	O
sharp	O
contrast	O
with	O
the	O
results	O
obtained	O
by	O
Nick	O
and	O
colleagues	O
[	O
12	O
]	O
in	O
a	O
human	S-Species
model	O
of	O
pulmonary	O
endotoxin	O
administration	O
.	O

APC	O
appears	O
to	O
improve	O
mortality	O
in	O
septic	O
shock	O
with	O
a	O
high	O
APACHE	O
2	O
score	O
and	O
is	O
potentially	O
detrimental	O
in	O
severe	O
sepsis	O
.	O

In	O
rats	O
,	O
APC	O
markedly	O
decreased	O
tumour	O
necrosis	O
factor	O
concentrations	O
whereas	O
they	O
remained	O
unchanged	O
in	O
either	O
human	S-Species
septic	O
shock	O
or	O
endotoxemia	O
.	O

The	O
question	O
arises	O
,	O
therefore	O
,	O
as	O
to	O
whether	O
it	O
is	O
truly	O
possible	O
to	O
reconcile	O
all	O
these	O
discrepancies	O
?	O

Moreover	O
,	O
can	O
these	O
stirring	O
laboratory	O
data	O
be	O
translated	O
into	O
clinical	O
practice	O
?	O

Limitations	O
of	O
experimental	O
studies	O
:	O
endothelium	O
protection	O
versus	O
endothelium	O
therapy	O

Clearly	O
,	O
in	O
cellular	O
and	O
animal	O
models	O
,	O
rAPC	O
has	O
been	O
given	O
either	O
as	O
a	O
pre	O
-	O
treatment	O
or	O
concurrent	O
with	O
septic	O
challenge	O
.	O

This	O
mode	O
of	O
administration	O
favours	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
rAPC	O
,	O
which	O
are	O
particularly	O
efficient	O
in	O
murine	S-Species
models	O
in	O
protecting	O
the	O
endothelium	O
from	O
cytokine	O
-	O
mediated	O
apoptosis	O
or	O
upregulation	O
of	O
endothelial	O
adhesion	O
molecules	O
.	O

Thus	O
,	O
studies	O
using	O
post	O
-	O
injury	O
treatment	O
are	O
needed	O
in	O
models	O
that	O
mimic	O
septic	O
shock	O
,	O
such	O
as	O
experimental	O
pneumonia	O
or	O
peritonitis	O
treated	O
by	O
antibiotics	O
and	O
volume	O
resuscitation	O
,	O
and	O
where	O
the	O
effects	O
of	O
rAPC	O
would	O
be	O
investigated	O
16	O
to	O
24	O
hours	O
after	O
septic	O
challenge	O
.	O

If	O
we	O
can	O
demonstrate	O
the	O
efficiency	O
of	O
rAPC	O
to	O
protect	O
or	O
to	O
reduce	O
endothelium	O
injury	O
in	O
these	O
conditions	O
,	O
we	O
can	O
ultimately	O
postulate	O
that	O
rAPC	O
is	O
also	O
a	O
therapeutic	O
drug	O
for	O
the	O
endothelium	O
.	O

The	O
earlier	O
the	O
better	O

If	O
rAPC	O
is	O
efficient	O
when	O
infused	O
in	O
the	O
early	O
phase	O
of	O
septic	O
challenge	O
,	O
we	O
thus	O
need	O
to	O
treat	O
our	O
patients	S-Species
earlier	O
.	O

At	O
least	O
two	O
studies	O
suggest	O
that	O
treatment	O
with	O
rAPC	O
within	O
24	O
hours	O
may	O
carry	O
a	O
larger	O
survival	O
advantage	O
for	O
patients	S-Species
with	O
severe	O
sepsis	O
,	O
compared	O
with	O
those	O
treated	O
more	O
than	O
24	O
hours	O
after	O
organ	O
dysfunction	O
[	O
13	O
]	O
.	O

Interventions	O
directed	O
at	O
specific	O
endpoints	O
,	O
when	O
initiated	O
early	O
in	O
the	O
'	O
golden	O
hours	O
'	O
of	O
a	O
patient	O
'	O
s	O
condition	O
,	O
seem	O
to	O
be	O
promising	O
[	O
14	O
]	O
.	O

The	O
beneficial	O
effects	O
of	O
earlier	O
administration	O
of	O
rAPC	O
to	O
appropriate	O
patients	S-Species
may	O
fit	O
into	O
this	O
paradigm	O
.	O

The	O
future	O

Extensive	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
focused	O
on	O
the	O
cytoprotective	O
effects	O
of	O
APC	O
and	O
most	O
authors	O
agree	O
that	O
its	O
anticoagulant	O
and	O
cytoprotective	O
effects	O
are	O
mediated	O
by	O
distinct	O
APC	O
structural	O
features	O
.	O

Positively	O
charged	O
residues	O
in	O
surface	O
loops	O
in	O
the	O
APC	O
protease	O
domain	O
have	O
been	O
identified	O
as	O
participating	O
in	O
the	O
anticoagulant	O
activity	O
but	O
not	O
in	O
cellular	O
effects	O
.	O

Hence	O
,	O
variants	O
have	O
been	O
designed	O
with	O
greater	O
anti	O
-	O
apoptotic	O
activity	O
and	O
reduced	O
anticoagulant	O
activity	O
relative	O
to	O
wild	O
-	O
type	O
APC	O
[	O
2	O
]	O
.	O

Whether	O
these	O
genetically	O
engineered	O
variants	O
actually	O
provide	O
superior	O
pharmacological	O
properties	O
remains	O
to	O
be	O
elucidated	O
in	O
vivo	O
.	O

Such	O
investigations	O
may	O
allow	O
the	O
design	O
of	O
therapeutic	O
APC	O
variants	O
with	O
decreased	O
anticoagulant	O
activity	O
to	O
reduce	O
the	O
risk	O
of	O
bleeding	O
on	O
the	O
one	O
hand	O
,	O
but	O
also	O
with	O
normal	O
cytoprotective	O
properties	O
in	O
order	O
to	O
retain	O
full	O
beneficial	O
effects	O
on	O
sepsis	O
outcome	O
.	O

Abbreviations	O

PROWESS	O
=	O
Protein	O
C	O
Worldwide	O
Evaluation	O
in	O
Severe	O
Sepsis	O
;	O
rAPC	O
=	O
recombinant	O
activated	O
protein	O
C	O
.	O

Competing	O
interests	O

BL	O
has	O
received	O
reimbursements	O
and	O
funding	O
from	O
Eli	O
Lilly	O
,	O
France	O
.	O

Carbonic	O
Anhydrase	O
Inhibitors	O
.	O

Part	O
541	O
:	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O
A	O
New	O
Class	O
of	O
Antiglaucoma	O
Agents	O

Abstract	O

Metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
inhibitory	O
properties	O
were	O
recently	O
shown	O
to	O
be	O
useful	O
as	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
lowering	O
agents	O
in	O
experimental	O
animals	O
,	O
and	O
might	O
be	O
developed	O
as	O
a	O
novel	O
class	O
of	O
antiglaucoma	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
CA	O
inhibitor	O
and	O
of	O
the	O
metal	O
complexes	O
containing	O
main	O
group	O
metal	O
ions	O
,	O
such	O
as	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
Al	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
and	O
the	O
new	O
sulfonamide	O
as	O
well	O
as	O
5	O
-	O
amino	O
-	O
1	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
as	O
ligands	O
.	O

The	O
new	O
complexes	O
were	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
CA	O
I	O
,	O
II	O
and	O
IV	O
.	O

Some	O
of	O
them	O
(	O
but	O
not	O
the	O
parent	O
sulfonamides	O
)	O
strongly	O
lowered	O
IOP	O
in	O
rabbits	S-Species
when	O
administered	O
as	O
a	O
2	O
%	O
solution	O
into	O
the	O
eye	O
.	O

CARBONIC	O
ANHYDRASE	O
INHIBITORS	O
.	O

Part	O
54	O
METAL	O
COMPLEXES	O
OF	O
HETEROCYCLIC	O
SULFONAMIDES	O
:	O
A	O
NEW	O
CLASS	O
OF	O
ANTIGLAUCOMA	O
AGENTS	O
Claudiu	O
T	O
.	O

Supuran	O
*	O
,	O
Andrea	O
Scozzafava	O

and	O
Andrei	O
Jitianu	O
2	O

Universit	O
&	O
degli	O
Studi	O
,	O
Dipartimento	O
di	O
Chimica	O
,	O
Laboratorio	O
di	O
Chimica	O
Inorganica	O
e	O
Bioinorganica	O
,	O
Via	O
Gino	O
Capponi	O
7	O
,	O
1	O
-	O
50121	O
,	O
Florence	O
,	O
Italy	O
2	O
"	O
I	O
.	O
G	O
.	O

Murgulescu	O
"	O
Institute	O
of	O
Physical	O
Chemistry	O
,	O
Academia	O
Romana	O
,	O
Spl	O
.	O

Independentei	O
202	O
,	O
R	O
-	O
77208	O
Bucharest	O
,	O
Roumania	O
Abstract	O
:	O
Metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
inhibitory	O
properties	O
were	O
recently	O
shown	O
to	O
be	O
useful	O
as	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
lowering	O
agents	O
in	O
experimental	O
animals	O
,	O
and	O
might	O
be	O
developed	O
as	O
a	O
novel	O
class	O
of	O
antiglaucoma	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
CA	O
inhibitor	O
and	O
of	O
the	O
metal	O
complexes	O
containing	O
main	O
group	O
metal	O
ions	O
,	O
such	O
as	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
AI	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
and	O
the	O
new	O
sulfonamide	O
as	O
well	O
as	O
5	O
-	O
amino	O
-	O
l	O
,	O
3	O
,	O
4thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
as	O
ligands	O
.	O

The	O
new	O
complexes	O
were	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
CA	O
I	O
,	O
II	O
and	O
IV	O
.	O

Some	O
of	O
them	O
(	O
but	O
not	O
the	O
parent	O
sulfonamides	O
)	O
strongly	O
lowered	O
IOP	O
in	O
rabbits	S-Species
when	O
administered	O
as	O
a	O
2	O
%	O
solution	O
into	O
the	O
eye	O
.	O

Introduction	O
Sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
,	O
EC	O
4	O
.	O
2	O
.	O
1	O
.	O
1	O
)	O
inhibitory	O
properties	O
[	O
2	O
]	O
such	O
as	O
acetazolamide	O
1	O
,	O
methazolamide	O
2	O
,	O
ethoxzolamide	O
3	O
and	O
dichlorophenamide	O
4	O
have	O
been	O
used	O
for	O
more	O
than	O
40	O
years	O
as	O
pressure	O
lowering	O
systemic	O
drugs	O
in	O
the	O
treatment	O
of	O
open	O
-	O
angle	O
glaucoma	O
[	O
3	O
,	O
4	O
]	O
.	O

Their	O
effect	O
is	O
due	O
to	O
inhibition	O
of	O
at	O
least	O
two	O
CA	O
isozymes	O
present	O
within	O
cilliary	O
processes	O
of	O
the	O
eye	O
,	O
ie	O
,	O
CA	O
II	O
and	O
CA	O
IV	O
,	O
which	O
is	O
followed	O
by	O
lowered	O
bicarbonate	O
formation	O
and	O
reduction	O
of	O
aqueous	O
humor	O
secretion	O
[	O
5	O
-	O
7	O
]	O
.	O

Their	O
main	O
drawback	O
is	O
constituted	O
by	O
side	O
effects	O
such	O
as	O
fatigue	O
,	O
augmented	O
diuresis	O
,	O
or	O
paresthesias	O
,	O
due	O
to	O
CA	O
inhibition	O
in	O
other	O
tissues	O
/	O
organs	O
than	O
the	O
target	O
one	O
,	O
ie	O
,	O
the	O
eye	O
[	O
8	O
]	O
.	O

N	O
-	O
-	O
N	O

XN	O
-	O
-	O
N	O
EtO	O
S	O

NH	O
2	O

O	O

NH	O
O	O
:	O
S	O
-	O
-	O
-	O
-	O
O	O

NHEt	O

The	O
above	O
-	O
mentioned	O
side	O
effects	O
are	O
absent	O
in	O
the	O
case	O
in	O
which	O
the	O
inhibitor	O
has	O
topical	O
activity	O
,	O
and	O
is	O
applied	O
directly	O
into	O
the	O
eye	O
.	O

This	O
route	O
has	O
been	O
demonstrated	O
only	O
in	O
1983	O
by	O
Maren	O
'	O
s	O
group	O
[	O
9	O
]	O
and	O
was	O
followed	O
by	O
the	O
development	O
of	O
the	O
first	O
clinical	O
agent	O
of	O
this	O
type	O
,	O
dorzolamide	O
5	O
[	O
10	O
,	O
11	O
]	O
.	O

Dorzolamide	O
(	O
Trusopt	O
)	O
has	O
been	O
introduced	O
in	O
clinical	O
use	O
in	O
1995	O
in	O
USA	O
and	O
Europe	O
and	O
it	O
constituted	O
the	O
beginning	O
of	O
a	O
radically	O
new	O
treatment	O
of	O
glaucoma	O
,	O
devoid	O
of	O
the	O
severe	O
side	O
effects	O
observed	O
with	O
the	O
systemic	O
inhibitors	O
[	O
4	O
-	O
6	O
]	O
.	O

The	O
success	O
of	O
topical	O
antiglaucoma	O
CA	O
inhibitors	O
fostered	O
much	O
research	O
in	O
the	O
synthesis	O
and	O
clinical	O
evaluation	O
of	O
other	O
types	O
of	O
such	O
compounds	O
[	O
12	O
-	O
15	O
]	O
.	O

307	O

Vol	O
.	O

4	O
,	O
No	O
.	O
6	O
,	O
1997	O

Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O
A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O

On	O
the	O
other	O
hand	O
,	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
of	O
type	O
1	O
-	O
5	O
have	O
been	O
recently	O
prepared	O
by	O
two	O
groups	O
16	O
-	O
20	O
]	O
,	O
and	O
it	O
was	O
proved	O
that	O
they	O
possess	O
much	O
stronger	O
CA	O
inhibitory	O
properties	O
than	O
the	O
sulfonamides	O
from	O
which	O
they	O
were	O
prepared	O
18	O
-	O
22	O
]	O
.	O

Although	O
the	O
mechanism	O
of	O
CA	O
inhibition	O
of	O
the	O
metal	O
complexes	O
is	O
presently	O
unknown	O
,	O
it	O
was	O
hypothesized	O
that	O
their	O
increased	O
inhibitory	O
power	O
might	O
be	O
due	O
to	O
two	O
processes	O
,	O
occurring	O
separately	O
or	O
in	O
concert	O
,	O
ie	O
,	O
(	O
i	O
)	O
dissociation	O
of	O
the	O
complex	O
inhibitor	O
in	O
sulfonamide	O
anions	O
and	O
metal	O
ions	O
(	O
in	O
diluted	O
solution	O
)	O
,	O
which	O
in	O
turn	O
both	O
interact	O
thereafter	O
with	O
the	O
enzyme	O
,	O
at	O
different	O
binding	O
sites	O
,	O
and	O
(	O
ii	O
)	O
direct	O
interaction	O
of	O
the	O
undissociated	O
complex	O
with	O
the	O
enzyme	O
,	O
and	O
more	O
specifically	O
with	O
the	O
hydrophilic	O
patch	O
at	O
the	O
entrance	O
of	O
CA	O
II	O
active	O
site	O
[	O
23	O
]	O
,	O
this	O
being	O
the	O
isozyme	O
most	O
susceptible	O
to	O
inhibition	O
with	O
this	O
class	O
of	O
compounds	O
[	O
2	O
,	O
22	O
]	O
.	O

Whether	O
initially	O
the	O
first	O
mechanism	O
of	O
action	O
mentioned	O
above	O
was	O
favored	O
by	O
us	O
[	O
22	O
]	O
,	O
recent	O
evidences	O
suggested	O
that	O
the	O
undissociated	O
complex	O
might	O
be	O
the	O
inhibitory	O
species	O
,	O
at	O
least	O
for	O
some	O
isozymes	O
[	O
24	O
]	O
.	O

Since	O
metal	O
complexes	O
are	O
much	O
more	O
inhibitory	O
than	O
the	O
parent	O
sulfonamide	O
from	O
which	O
they	O
were	O
prepared	O
,	O
it	O
appeared	O
of	O
interest	O
to	O
test	O
whether	O
this	O
property	O
might	O
be	O
useful	O
for	O
their	O
use	O
in	O
lowering	O
IOP	O
in	O
experimental	O
animals	O
and	O
whence	O
as	O
a	O
possible	O
glaucoma	O
therapy	O
.	O

Recently	O
we	O
proved	O
[	O
25	O
,	O
26	O
]	O
that	O
some	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
(	O
which	O
themselves	O
do	O
not	O
possess	O
IOP	O
lowering	O
properties	O
)	O
act	O
as	O
very	O
powerful	O
such	O
agents	O
when	O
administered	O
as	O
diluted	O
solutions	O
directly	O
into	O
the	O
eye	O
of	O
experimental	O
animals	O
,	O
and	O
would	O
thus	O
offer	O
the	O
possibility	O
of	O
developing	O
such	O
totally	O
novel	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
possessing	O
strong	O
CA	O
inhibitory	O
properties	O
,	O
ie	O
,	O
5	O
-	O
(	O
chloroacetamido	O
)	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
,	O
and	O
of	O
the	O
metal	O
complexes	O
of	O
this	O
sulfonamide	O
and	O
of	O
5	O
-	O
amino	O
-	O
1	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
,	O
containing	O
some	O
main	O
group	O
metal	O
ions	O
.	O

The	O
new	O
compounds	O
have	O
been	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
were	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
hCA	O
I	O
,	O
hCA	O
II	O
and	O
bCA	O
IV	O
(	O
h	O
human	S-Species
;	O
b	O
bovine	S-Species
;	O
these	O
are	O
the	O
isozymes	O
considered	O
to	O
play	O
a	O
critical	O
role	O
in	O
aqueous	O
humour	O
secretion	O
within	O
the	O
eye	O
of	O
higher	O
vertebrates	O
[	O
2	O
-	O
5	O
]	O
)	O
.	O

Materials	O
and	O
Methods	O

Melting	O
points	O
were	O
recorded	O
with	O
a	O
heating	O
plate	O
microscope	O
and	O
are	O
not	O
corrected	O
.	O

IR	O
spectra	O
were	O
recorded	O
in	O
KBr	O
pellets	O
with	O
a	O
Carl	O
Zeiss	O
IR	O
-	O
80	O
instrument	O
.	O

1H	O
-	O
NMR	O
spectra	O
were	O
recorded	O
in	O
DMSO	O
-	O
d6	O
as	O
solvent	O
,	O
with	O
a	O
Bruker	O
CPX200	O
instrument	O
.	O

Chemical	O
shifts	O
are	O
reported	O
as	O
values	O
,	O
relative	O
to	O
Me4Si	O
as	O
internal	O
standard	O
.	O

Conductimetric	O
measurements	O
were	O
done	O
at	O
room	O
temperature	O
(	O
1	O
mM	O
concentration	O
of	O
complex	O
)	O
in	O
DMSO	O
solution	O
with	O
a	O
Fisher	O
conductimeter	O
.	O

Elemental	O
analyses	O
were	O
done	O
by	O
combustion	O
for	O
C	O
,	O
H	O
,	O
N	O
with	O
an	O
automated	O
Carlo	O
Erba	O
analyzer	O
,	O
and	O
gravimetrically	O
for	O
the	O
metal	O
ions	O
,	O
and	O
were	O
0	O
.	O
4	O
%	O
of	O
the	O
theoretical	O
values	O
.	O

Thermogravimetric	O
measurements	O
were	O
done	O
in	O
air	O
,	O
at	O
a	O
heating	O
rate	O
of	O
10C	O
/	O
min	O
.	O
,	O
with	O
a	O
Perkin	O
Elmer	O
3600	O
thermobalance	O
.	O

Sulfonamides	O
used	O
as	O
standards	O
in	O
the	O
enzymatic	O
assay	O
(	O
except	O
for	O
5	O
)	O
,	O
acetazolamide	O
,	O
pyridine	O
,	O
and	O
chloroacetyl	O
chloride	O
used	O
for	O
the	O
preparation	O
of	O
compound	O
7	O
,	O
solvents	O
as	O
well	O
as	O
inorganic	O
reagents	O
were	O
from	O
Sigma	O
,	O
Merck	O
and	O
Carlo	O
Erba	O
.	O

5	O
-	O
Amino	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
6	O
was	O
prepared	O
from	O
acetazolamide	O
by	O
literature	O
procedures	O
[	O
27	O
]	O
,	O
by	O
desacetylation	O
with	O
concentrated	O
hydrochloric	O
acid	O
,	O
followed	O
by	O
neutralization	O
with	O
sodium	O
bicarbonate	O
of	O
the	O
corresponding	O
hydrochloride	O
(	O
Scheme	O
1	O
)	O
.	O

Dorzolamide	O
hydrochloride	O
5	O
was	O
from	O
Merck	O
,	O
Sharp	O
and	O
Dohme	O
or	O
was	O
prepared	O
as	O
described	O
by	O
Ponticello	O
et	O
al	O
10	O
,	O
11	O
]	O
.	O

Human	S-Species
CA	O
and	O
CA	O
II	O
cDNAs	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
strain	O
BL21	O
(	O
DE3	O
)	O
from	O
the	O
plasmids	O
pACA	O
/	O
hCA	O
I	O
and	O
pACAdaCA	O
II	O
described	O
by	O
Forsman	O
et	O
al	O
.	O

[	O
28	O
]	O
(	O
the	O
two	O
plasmids	O
were	O
a	O
gift	O
from	O
Prof	O
.	O
Sven	O
Lindskog	O
,	O
Umea	O
University	O
,	O
Sweden	O
)	O
.	O

Cell	O
growth	O
conditions	O
were	O
those	O
described	O
by	O
Lindskog	O
'	O
s	O
group	O
[	O
29	O
]	O
,	O
and	O
enzymes	O
were	O
purified	O
by	O
affinity	O
chromatography	O
according	O
to	O
the	O
method	O
of	O
Khalifah	O
et	O
al	O
[	O
30	O
]	O
.	O

Enzyme	O
concentrations	O
were	O
determined	O
spectrophotometrically	O
at	O
280	O
nm	O
,	O
utilizing	O
a	O
molar	O
absorptivity	O
of	O
49	O
mM	O
-	O
l	O
.	O
cm	O
-	O
1	O
for	O
hCA	O
and	O
54	O
mM	O
-	O
l	O
.	O
cm	O
-	O
1	O
for	O
hCA	O
II	O
,	O
respectively	O
,	O
based	O
on	O
M	O
28	O
.	O
85	O
kDa	O
for	O
hCA	O
I	O
,	O
and	O
29	O
.	O
3	O
kDa	O
for	O
hCA	O
II	O
,	O
respectively	O
[	O
31	O
,	O
32	O
]	O
.	O

bCA	O
IV	O
was	O
isolated	O
from	O
bovine	S-Species
lung	O
microsomes	O
as	O
described	O
by	O
Maren	O
et	O
al	O
,	O
and	O
its	O
concentration	O
has	O
been	O
determined	O
by	O
titration	O
with	O
ethoxzolamide	O
[	O
33	O
]	O
.	O

Synthesis	O
of	O
5	O
-	O
(	O
chloroacetamido	O
)	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
7	O
An	O
amount	O
of	O
1	O
.	O
80	O
g	O
(	O
10	O
mmol	O
)	O
of	O
5	O
-	O
amino	O
-	O
1	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
6	O
was	O
suspended	O
in	O
20	O
mL	O
of	O
anhydrous	O
acetonitrile	O
and	O
0	O
.	O
9	O
mL	O
(	O
0	O
.	O
87g	O
,	O
11	O
mmol	O
)	O
of	O
pyridine	O
added	O
.	O

The	O
mixture	O
was	O
magnetically	O
stirred	O
at	O
4	O
C	O
for	O
10	O
minutes	O
,	O
then	O
10	O
.	O
5	O
mmol	O
of	O
monochloroacetyl	O
chloride	O
,	O
dissolved	O
in	O
3	O
mL	O
acetonitrile	O
,	O
were	O
added	O
dropwise	O
for	O
5	O
min	O
,	O
and	O
stirring	O
was	O
continued	O
for	O
other	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

After	O
an	O
additional	O
30	O
min	O
of	O
refluxation	O
,	O
followed	O
by	O
cooling	O
,	O
the	O
precipitated	O
crystals	O
were	O
filtered	O
and	O
recrystallized	O
from	O
ethanol	O
.	O

Yield	O
of	O
62	O
%	O
white	O
crystals	O
,	O
mp	O
246	O
-	O
248	O
o	O
lit	O
[	O
34	O
]	O
mp	O
IR	O
(	O
KBr	O
)	O
,	O
cm	O
-	O
l	O
:	O
590	O
,	O
610	O
,	O
660	O
,	O
790	O
,	O
935	O
,	O
1090	O
,	O
1115	O
,	O
1170	O
,	O
1350	O
,	O
1400	O
,	O
1550	O
,	O
1650	O
,	O
1720	O
,	O
2870	O
,	O
3280	O
3370	O
(	O
broad	O
)	O
;	O
UV	O
spectrum	O
,	O
,	O
max	O
,	O
nm	O
(	O
lg	O
)	O
:	O
255	O
(	O
3	O
.	O
50	O
)	O
;	O
288	O
(	O
4	O
.	O
37	O
)	O
H	O
-	O
NMR	O
(	O
DMSO	O
-	O
d6	O
)	O
,	O
i	O
,	O
ppm	O
:	O
2	O
.	O
96	O
(	O
s	O
,	O
2H	O
,	O
CH2	O
)	O
;	O
8	O
.	O
20	O
(	O
s	O
,	O
2H	O
,	O
SOzNH2	O
)	O
;	O
12	O
.	O
22	O
(	O
s	O
,	O
1H	O
,	O
CONH	O
)	O
.	O

Analysis	O
,	O
found	O
:	O
C	O
,	O
18	O
.	O
56	O
;	O
H	O
,	O
1	O
.	O
88	O
;	O
N	O
,	O
21	O
.	O
76	O
;	O
S	O
,	O
24	O
.	O
62	O
%	O
;	O
C4HsC1N403S2	O
requires	O
"	O
C	O
,	O
18	O
.	O
72	O
;	O
H	O
,	O
1	O
.	O
96	O
;	O
N	O
,	O
21	O
.	O
83	O
;	O
S	O
,	O
24	O
.	O
98	O
%	O
.	O

General	O
procedure	O
for	O
the	O
preparation	O
of	O
compounds	O
8	O
-	O
20	O
An	O
amount	O
of	O
6	O
mmol	O
of	O
sodium	O
salt	O
of	O
sulfonamides	O
6	O
or	O
7	O
was	O
prepared	O
by	O
reacting	O
the	O
corresponding	O
sulfonamide	O
with	O
the	O
required	O
amount	O
of	O
an	O
alcoholic	O
1N	O
NaOH	O
solution	O
,	O
in	O
ethanol	O
as	O
solvent	O
.	O

To	O
this	O
308	O

Claudiu	O
T	O
.	O
Supuran	O
et	O
al	O
.	O

Metal	O
-	O
Based	O
Drugs	O

solution	O
was	O
added	O
the	O
aqueous	O
metal	O
salt	O
(	O
Zn	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
AI	O
(	O
III	O
)	O
,	O
Cd	O
(	O
II	O
)	O
chlorides	O
,	O
and	O
Be	O
(	O
II	O
)	O
,	O
Pb	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
nitrate	O
)	O
solution	O
,	O
working	O
in	O
molar	O
ratios	O
RSOzNH	O
-	O
Mn	O
+	O
of	O
2	O
:	O
1	O
for	O
the	O
divalent	O
cations	O
and	O
3	O
:	O
1	O
for	O
the	O
trivalent	O
cation	O
,	O
respectively	O
.	O

The	O
aqueous	O
-	O
alcoholic	O
reaction	O
mixture	O
was	O
heated	O
on	O
a	O
steam	O
bath	O
for	O
one	O
hour	O
,	O
adjusting	O
the	O
pH	O
at	O
7	O
if	O
necessary	O
,	O
and	O
after	O
being	O
cooled	O
at	O
0	O
C	O
the	O
precipitated	O
complexes	O
were	O
filtered	O
and	O
thoroughly	O
washed	O
with	O
alcohol	O
-	O
water	O
1	O
:	O
1	O
(	O
v	O
/	O
v	O
)	O
and	O
air	O
dried	O
.	O

Yields	O
were	O
in	O
the	O
range	O
of	O
85	O
-	O
90	O
%	O
.	O

The	O
obtained	O
white	O
powders	O
of	O
compounds	O
8	O
-	O
20	O
melted	O
with	O
decomposition	O
at	O
temperatures	O
higher	O
than	O
350	O
C	O
,	O
and	O
were	O
poorly	O
soluble	O
in	O
water	O
and	O
alcohol	O
,	O
but	O
had	O
good	O
solubilities	O
in	O
DMSO	O
,	O
DMF	O
as	O
well	O
as	O
mixtures	O
of	O
DMSO	O
-	O
water	O
,	O
DMF	O
-	O
water	O
.	O

Pharmacology	O
Carbonic	O
anhydrase	O
inhibition	O
Initial	O
rates	O
of	O
4	O
-	O
nitrophenyl	O
acetate	O
hydrolysis	O
catalysed	O
by	O
different	O
CA	O
isozymes	O
were	O
monitored	O
spectrophotometrically	O
,	O
at	O
400	O
rim	O
,	O
with	O
a	O
Cary	O
3	O
instrument	O
interfaced	O
with	O
an	O
IBM	O
compatible	O
PC	O
[	O
35	O
]	O
.	O

Solutions	O
of	O
substrate	O
were	O
prepared	O
in	O
anhydrous	O
acetonitrile	O
;	O
the	O
substrate	O
concentrations	O
varied	O
between	O
2	O
.	O
10	O
-	O
2	O
and	O
1	O
.	O
10	O
-	O
6	O
M	O
,	O
working	O
at	O
25C	O
.	O

A	O
molar	O
absorption	O
coefficient	O
of	O
18	O
,	O
400	O
M	O
-	O
l	O
.	O
cm	O
-	O
1	O
was	O
used	O
for	O
the	O
4	O
-	O
nitrophenolate	O
formed	O
by	O
hydrolysis	O
,	O
in	O
the	O
conditions	O
of	O
the	O
experiments	O
(	O
pH	O
7	O
.	O
40	O
)	O
,	O
as	O
reported	O
in	O
the	O
literature	O
[	O
35	O
]	O
.	O

Non	O
-	O
enzymatic	O
hydrolysis	O
rates	O
were	O
always	O
subtracted	O
from	O
the	O
observed	O
rates	O
.	O

Duplicate	O
experiments	O
were	O
done	O
for	O
each	O
inhibitor	O
concentration	O
,	O
and	O
the	O
values	O
reported	O
throughout	O
the	O
paper	O
are	O
the	O
mean	O
of	O
such	O
results	O
.	O

Stock	O
solutions	O
of	O
inhibitor	O
(	O
1	O
mM	O
)	O
were	O
prepared	O
in	O
distilled	O
-	O
deionized	O
water	O
with	O
1020	O
%	O
(	O
v	O
/	O
v	O
)	O
DMSO	O
(	O
which	O
is	O
not	O
inhibitory	O
at	O
these	O
concentrations	O
[	O
2	O
]	O
)	O
and	O
dilutions	O
up	O
to	O
0	O
.	O
01	O
nM	O
were	O
done	O
thereafter	O
with	O
distilled	O
-	O
deionized	O
water	O
.	O

Inhibitor	O
and	O
enzyme	O
solutions	O
were	O
preincubated	O
together	O
for	O
10	O
min	O
at	O
room	O
temperature	O
prior	O
to	O
assay	O
,	O
in	O
order	O
to	O
allow	O
for	O
the	O
formation	O
of	O
the	O
E	O
-	O
I	O
complex	O
.	O

The	O
inhibition	O
constant	O
KI	O
was	O
determined	O
as	O
described	O
by	O
Pocket	O
and	O
Stone	O
[	O
35	O
]	O
.	O

Enzyme	O
concentrations	O
were	O
3	O
.	O
3	O
nM	O
for	O
hCA	O
II	O
,	O
l0	O
nM	O
for	O
hCA	O
and	O
34	O
nM	O
for	O
bCA	O
IV	O
(	O
this	O
isozyme	O
has	O
a	O
decreased	O
esterase	O
activity	O
[	O
36	O
]	O
and	O
higher	O
concentrations	O
had	O
to	O
be	O
used	O
for	O
the	O
-	O
measurements	O
)	O
.	O

Measurement	O
of	O
tonometric	O
lOP	O
Adult	O
male	O
New	O
Zealand	O
albino	O
rabbits	S-Species
weighing	O
2	O
-	O
3	O
kg	O
were	O
used	O
in	O
the	O
experiments	O
(	O
three	O
animals	O
were	O
used	O
for	O
each	O
inhibitor	O
studied	O
)	O
.	O

The	O
experimental	O
procedures	O
conform	O
to	O
the	O
Association	O
for	O
Research	O
in	O
Vision	O
and	O
Ophthalmology	O
Resolution	O
on	O
the	O
use	O
of	O
animals	O
.	O

The	O
rabbits	S-Species
were	O
kept	O
in	O
individual	O
cages	O
with	O
food	O
and	O
water	O
provided	O
ad	O
libitum	O
.	O

The	O
animals	O
were	O
maintained	O
on	O
a	O
12	O
h	O
:	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
in	O
a	O
temperature	O
controlled	O
room	O
,	O
at	O
22	O
-	O
26	O
C	O
.	O

Solutions	O
of	O
inhibitors	O
(	O
2	O
%	O
,	O
by	O
weight	O
)	O
were	O
obtained	O
in	O
DMSOwater	O
(	O
2	O
:	O
3	O
,	O
v	O
/	O
v	O
)	O
due	O
to	O
the	O
low	O
water	O
solubility	O
of	O
some	O
of	O
these	O
derivatives	O
.	O

Control	O
experiments	O
with	O
DMSO	O
(	O
at	O
the	O
same	O
concentration	O
as	O
that	O
used	O
for	O
obtaining	O
the	O
inhibitors	O
solutions	O
showed	O
that	O
it	O
does	O
not	O
possess	O
IOP	O
lowering	O
or	O
increasing	O
effects	O
.	O

IOP	O
was	O
measured	O
using	O
a	O
Digilab	O
30R	O
pneumatonometer	O
(	O
BioRad	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
as	O
described	O
by	O
Maren	O
'	O
s	O
group	O
[	O
37	O
-	O
39	O
]	O
.	O

The	O
pressure	O
readings	O
were	O
matched	O
with	O
two	O
-	O
point	O
standard	O
pressure	O
measurements	O
at	O
least	O
twice	O
each	O
day	O
using	O
a	O
Digilab	O
Calibration	O
verifier	O
.	O

All	O
IOP	O
measurements	O
were	O
done	O
by	O
the	O
same	O
investigator	O
with	O
the	O
same	O
tonometer	O
.	O

One	O
drop	O
of	O
0	O
.	O
2	O
%	O
oxybuprocaine	O
hydrochloride	O
(	O
novesine	O
,	O
Sandoz	O
)	O
diluted	O
1	O
"	O
1	O
with	O
saline	O
was	O
instilled	O
in	O
each	O
eye	O
immediately	O
before	O
each	O
set	O
of	O
pressure	O
measurements	O
.	O

IOP	O
was	O
measured	O
three	O
times	O
at	O
each	O
time	O
interval	O
,	O
and	O
the	O
means	O
reported	O
.	O

IOP	O
was	O
measured	O
first	O
immediately	O
before	O
drug	O
administration	O
,	O
then	O
at	O
30	O
min	O
after	O
the	O
instillation	O
of	O
the	O
pharmacological	O
agent	O
,	O
and	O
then	O
each	O
30	O
minutes	O
for	O
a	O
period	O
of	O
several	O
hours	O
.	O

For	O
all	O
IOP	O
experiments	O
drug	O
was	O
administered	O
to	O
only	O
one	O
eye	O
,	O
leaving	O
the	O
contralateral	O
eye	O
as	O
an	O
untreated	O
control	O
.	O

The	O
ocular	O
hypotensive	O
activity	O
is	O
expressed	O
as	O
the	O
average	O
difference	O
in	O
IOP	O
between	O
the	O
treated	O
and	O
control	O
eye	O
,	O
in	O
this	O
way	O
minimizing	O
the	O
diurnal	O
,	O
seasonal	O
and	O
interindividual	O
variations	O
commonly	O
observed	O
in	O
the	O
rabbit	S-Species
[	O
37	O
-	O
39	O
]	O
.	O

All	O
data	O
are	O
expressed	O
as	O
mean	O
SE	O
,	O
using	O
a	O
one	O
-	O
tailed	O
test	O
.	O

Results	O
and	O
Discussion	O
Reaction	O
of	O
5	O
-	O
amino	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
6	O
[	O
19b	O
]	O
with	O
chloroacteyl	O
chloride	O
in	O
the	O
presence	O
of	O
pyridine	O
afforded	O
5	O
-	O
(	O
chloroacetamido	O
)	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
7	O
,	O
by	O
the	O
procedure	O
already	O
reported	O
by	O
Young	O
et	O
al	O
.	O

[	O
34	O
]	O
(	O
Scheme	O
1	O
)	O
.	O

The	O
sulfonamide	O
7	O
has	O
been	O
characterized	O
by	O
elemental	O
analysis	O
and	O
spectroscopic	O
methods	O
which	O
confirmed	O
its	O
structure	O
(	O
only	O
its	O
m	O
.	O
p	O
.	O
has	O
been	O
reported	O
in	O
ref	O
.	O
[	O
34	O
]	O
)	O
.	O

The	O
sodium	O
salt	O
of	O
sulfonamides	O
6	O
and	O
7	O
,	O
obtained	O
in	O
situ	O
from	O
the	O
corresponding	O
sulfonamide	O
and	O
sodium	O
hydroxide	O
,	O
were	O
then	O
used	O
for	O
the	O
preparation	O
of	O
coordination	O
compounds	O
,	O
containing	O
the	O
following	O
metal	O
ions	O
:	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
Al	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
.	O

Mention	O
should	O
be	O
made	O
that	O
although	O
5	O
-	O
amino	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
6	O
is	O
the	O
parent	O
compound	O
of	O
important	O
sulfonamide	O
CA	O
inhibitors	O
,	O
such	O
as	O
acetazolamide	O
,	O
benzolamide	O
,	O
methazolamide	O
,	O
etc	O
.	O
,	O
its	O
coordination	O
chemistry	O
has	O
been	O
scarcely	O
investigated	O
up	O
to	O
now	O
[	O
22	O
,	O
40	O
]	O
.	O

The	O
new	O
complexes	O
prepared	O
in	O
this	O
work	O
are	O
shown	O
in	O
Table	O
I	O
.	O
Both	O
compounds	O
containing	O
the	O
sulfonamide	O
-	O
deprotonated	O
species	O
of	O
sulfonamide	O
7	O
(	O
LH	O
)	O
,	O
as	O
well	O
as	O
complexes	O
in	O
which	O
the	O
anion	O
of	O
5amino	O
-	O
1	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
(	O
tda	O
)	O
act	O
as	O
ligands	O
,	O
have	O
been	O
prepared	O
.	O

In	O
fact	O
in	O
another	O
work	O
[	O
40	O
]	O
it	O
was	O
documented	O
that	O
in	O
some	O
cases	O
,	O
sulfonamides	O
derived	O
from	O
this	O
ring	O
system	O
may	O
undergo	O
hydrolysis	O
to	O

309	O

Vol	O
.	O

4	O
,	O
No	O
.	O
6	O
,	O
1997	O

Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
.	O
"	O
A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O

the	O
moiety	O
substituting	O
the	O
5	O
position	O
,	O
with	O
the	O
formation	O
of	O
5	O
-	O
amino	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
6	O
,	O
which	O
thereafter	O
coordinates	O
metal	O
ions	O
present	O
in	O
solution	O
.	O

N	O
CIH	O
N	O

I	O

N	O
+	O
NaHCO	O
2	O

N	O
2	O

S	O
'	O

-	O
NaCl	O

I	O
S	O

N	O

II	O

SO2NH	O

1	O
_	O
12	O
O	O
Py	O
/	O
MeCN	O

6Htda	O
+	O
CIOCCH2CI	O

0	O
Cl	O
CH	O
2	O
Scheme	O
1	O

HN	O

.	O
I	O

N	O

N	O

S	O
7	O
:	O
LH	O

II	O

SqNH	O

Thus	O
,	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
complex	O
[	O
Zn	O
(	O
tda	O
)	O
2	O
(	O
NH3	O
)	O
]	O
.	O
H20	O
prepared	O
in	O
this	O
way	O
has	O
recently	O
been	O
reported	O
by	O
this	O
group	O
[	O
40	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
the	O
ligand	O
7	O
has	O
not	O
been	O
hydrolyzed	O
(	O
during	O
the	O
preparation	O
of	O
the	O
coordination	O
compounds	O
)	O
in	O
the	O
presence	O
of	O
the	O
metal	O
ion	O
to	O
5	O
-	O
amino	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2sulfonamide	O
and	O
chloroacetate	O
,	O
the	O
metal	O
complexes	O
contining	O
6	O
as	O
ligand	O
have	O
been	O
prepared	O
from	O
the	O
last	O
(	O
pure	O
)	O
compound	O
(	O
as	O
sodium	O
salt	O
)	O
and	O
the	O
corresponding	O
metal	O
salt	O
,	O
by	O
the	O
general	O
procedure	O
described	O
in	O
the	O
Experimental	O
part	O
.	O

Table	O
I	O
:	O
Prepared	O
complexes	O
8	O
-	O
20	O
,	O
containing	O
the	O
conjugate	O
bases	O
of	O
sulfonamides	O
6	O
and	O
7	O
as	O
ligands	O
and	O
their	O
elemental	O
analysis	O
data	O
.	O

L	O
stands	O
for	O
the	O
sulfonamide	O
deprotonated	O
species	O
of	O
7	O
,	O
whereas	O
tda	O
for	O
the	O
sulfonamide	O
deprotonated	O
species	O
of	O
5	O
-	O
amino	O
-	O
1	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
6	O
.	O

No	O
.	O
8	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
19	O
20	O

Complex	O

Yield	O

(	O
%	O
)	O

%	O
Ma	O

Analysis	O
(	O
calculated	O
/	O
found	O
)	O
%	O
H	O
b	O
%	O
C	O
b	O
13	O
.	O
0	O
/	O
13	O
.	O
1	O
11	O
.	O
0	O
/	O
10	O
.	O
8	O
11	O
.	O
3	O
/	O
11	O
.	O
4	O
10	O
.	O
2	O
/	O
10	O
.	O
1	O
8	O
.	O
5	O
/	O
8	O
.	O
1	O
7	O
.	O
9	O
/	O
7	O
.	O
9	O
12	O
.	O
7	O
/	O
12	O
.	O
8	O
18	O
.	O
4	O
/	O
18	O
.	O
1	O
18	O
.	O
1	O
/	O
17	O
.	O
9	O
16	O
.	O
6	O
/	O
16	O
.	O
2	O
15	O
.	O
3	O
/	O
14	O
.	O
9	O
13	O
.	O
4	O
/	O
13	O
.	O
3	O
12	O
.	O
7	O
/	O
12	O
.	O
5	O
1	O
.	O
6	O
/	O
1	O
.	O
3	O
2	O
.	O
7	O
/	O
2	O
.	O
3	O
1	O
.	O
4	O
/	O
1	O
.	O
1	O
1	O
.	O
2	O
/	O
1	O
.	O
2	O
1	O
.	O
0	O
/	O
1	O
.	O
2	O
1	O
.	O
6	O
/	O
1	O
.	O
3	O
1	O
.	O
6	O
/	O
1	O
.	O
6	O
1	O
.	O
5	O
/	O
1	O
.	O
5	O
1	O
.	O
5	O
/	O
1	O
.	O
3	O
1	O
.	O
3	O
/	O
1	O
.	O
4	O
1	O
.	O
2	O
/	O
1	O
.	O
1	O
1	O
.	O
1	O
/	O
1	O
.	O
2	O
1	O
.	O
0	O
/	O
1	O
.	O
0	O

%	O
N	O
b	O
30	O
.	O
4	O
/	O
30	O
.	O
2	O
25	O
.	O
6	O
/	O
25	O
.	O
5	O
26	O
.	O
4	O
/	O
26	O
.	O
4	O
13	O
.	O
7	O
/	O
23	O
.	O
3	O
20	O
.	O
0	O
/	O
19	O
.	O
8	O
18	O
.	O
6	O
/	O
18	O
.	O
5	O
29	O
.	O
7	O
/	O
29	O
.	O
6	O
21	O
.	O
5	O
/	O
21	O
.	O
3	O
21	O
.	O
1	O
/	O
20	O
.	O
8	O
19	O
.	O
4	O
/	O
19	O
.	O
3	O
17	O
.	O
9	O
/	O
17	O
.	O
8	O
15	O
.	O
7	O
/	O
15	O
.	O
6	O
14	O
.	O
8	O
/	O
14	O
.	O
6	O

[	O
Be	O
(	O
tda	O
)	O
2	O
]	O
[	O
Mg	O
(	O
tda	O
)	O
2	O
]	O
.	O
3	O
H20	O
[	O
Zn	O
(	O
tda	O
)	O
2	O
]	O
[	O
Cd	O
(	O
tda	O
)	O
2	O
]	O
[	O
Hg	O
(	O
tda	O
)	O
2	O
]	O
[	O
Pb	O
(	O
tda	O
)	O
z	O
(	O
OH2	O
)	O
2	O
]	O
[	O
Al	O
(	O
tda	O
)	O
3	O
]	O
[	O
BeL2	O
]	O
[	O
ALL3	O
]	O
[	O
ZnL2	O
]	O
[	O
CdL2	O
]	O
[	O
HgL2	O
]	O
[	O
PbLz	O
(	O
OH2	O
)	O
2	O
]	O

78	O
76	O
83	O
90	O
95	O
84	O
72	O
75	O
59	O
87	O
88	O
92	O
95	O

2	O
.	O
4	O
/	O
2	O
.	O
5	O
5	O
.	O
5	O
/	O
5	O
.	O
1	O
15	O
.	O
4	O
/	O
15	O
.	O
0	O
23	O
.	O
8	O
/	O
24	O
.	O
1	O
35	O
.	O
8	O
/	O
35	O
.	O
7	O
34	O
.	O
4	O
/	O
34	O
.	O
7	O
4	O
.	O
7	O
/	O
4	O
.	O
4	O
1	O
.	O
7	O
/	O
1	O
.	O
6	O
3	O
.	O
4	O
/	O
3	O
.	O
5	O
11	O
.	O
3	O
/	O
11	O
.	O
5	O
18	O
.	O
0	O
/	O
18	O
.	O
1	O
28	O
.	O
1	O
/	O
28	O
.	O
3	O
27	O
.	O
4	O
/	O
27	O
.	O
2	O

aBy	O
gravimetry	O
;	O
bBy	O
combustion	O
.	O

The	O
new	O
complexes	O
have	O
also	O
been	O
characterized	O
by	O
spectroscopic	O
,	O
conductimetric	O
and	O
thermogravimetric	O
measurements	O
(	O
Table	O
II	O
)	O
.	O

By	O
comparing	O
the	O
IR	O
spectra	O
of	O
the	O
complexes	O
and	O
the	O
corresponding	O
ligands	O
,	O
the	O
following	O
observations	O
should	O
be	O
made	O
:	O
(	O
i	O
)	O
the	O
shift	O
of	O
the	O
two	O
sulfonamido	O
vibrations	O
(	O
both	O
the	O
symmetric	O
as	O
well	O
as	O
the	O
the	O
assymetric	O
one	O
)	O
,	O
towards	O
lower	O
wavenumbers	O
in	O
the	O
spectra	O
of	O
the	O
complexes	O
,	O
as	O
compared	O
to	O
the	O
spectra	O
of	O
the	O
corresponding	O
ligand	O
(	O
Table	O
II	O
)	O
,	O
as	O
already	O
documented	O
previously	O
for	O
similar	O
complexes	O
[	O
13	O
-	O
22	O
]	O
.	O

This	O
is	O
a	O
direct	O
indication	O
that	O
the	O
deprotonated	O
sulfonamido	O
310	O

Claudiu	O
T	O
.	O
Supuran	O
et	O
al	O
.	O

Metal	O
-	O
Based	O
Drugs	O

moieties	O
of	O
the	O
ligands	O
interacts	O
with	O
the	O
metal	O
ions	O
in	O
the	O
newly	O
prepared	O
coordination	O
compounds	O
;	O
(	O
ii	O
)	O
the	O
amide	O
vibrations	O
(	O
the	O
most	O
intense	O
such	O
bands	O
at	O
1670	O
-	O
1680	O
cm	O
-	O
1	O
)	O
of	O
ligand	O
7	O
appear	O
unchanged	O
in	O
the	O
IR	O
spectra	O
of	O
complexes	O
15	O
-	O
20	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
these	O
moieties	O
do	O
not	O
participate	O
in	O
coordination	O
of	O
the	O
metal	O
ions	O
;	O
(	O
iii	O
)	O
the	O
C	O
-	O
N	O
stretching	O
vibration	O
in	O
the	O
spectra	O
of	O
the	O
prepared	O
complexes	O
is	O
shifted	O
with	O
5	O
-	O
20	O
cm	O
-	O
1	O
towards	O
lower	O
wavenumbers	O
,	O
as	O
compared	O
to	O
the	O
same	O
vibration	O
in	O
the	O
spectra	O
of	O
sulfonamides	O
6	O
and	O
7	O
,	O
indicating	O
that	O
one	O
of	O
the	O
endocyclic	O
nitrogens	O
of	O
the	O
thiadiazolic	O
ring	O
(	O
presumably	O
N3	O
)	O
acts	O
as	O
donor	O
atom	O
,	O
as	O
already	O
documented	O
by	O
X	O
-	O
ray	O
crystallographic	O
and	O
spectroscopic	O
determinations	O
on	O
complexes	O
of	O
other	O
sulfonamides	O
(	O
such	O
as	O
1	O
-	O
3	O
)	O
with	O
divalent	O
metal	O
ions	O
[	O
13	O
-	O
22	O
]	O
(	O
Table	O
II	O
)	O
;	O
(	O
iv	O
)	O
changes	O
in	O
the	O
region	O
3100	O
-	O
3160	O
cm	O
-	O
,	O
as	O
the	O
bands	O
present	O
in	O
the	O
spectra	O
of	O
sulfonamides	O
6	O
,	O
7	O
are	O
present	O
in	O
the	O
spectra	O
of	O
complexes	O
8	O
-	O
20	O
too	O
,	O
but	O
they	O
are	O
not	O
well	O
resolved	O
,	O
and	O
have	O
a	O
smaller	O
intensity	O
.	O

This	O
is	O
probably	O
due	O
to	O
deprotonation	O
of	O
the	O
SO2NH2	O
moiety	O
and	O
participation	O
in	O
the	O
binding	O
of	O
cations	O
;	O
(	O
v	O
)	O
the	O
amino	O
vibrations	O
from	O
3320	O
cm	O
-	O
in	O
the	O
spectra	O
of	O
6	O
appear	O
unchanged	O
in	O
the	O
spectra	O
of	O
its	O
complexes	O
8	O
-	O
14	O
(	O
data	O
not	O
s	O
.	O
hown	O
)	O
.	O

In	O
the	O
1H	O
-	O
NMR	O
spectra	O
of	O
compound	O
6	O
and	O
its	O
metal	O
complexes	O
,	O
the	O
signal	O
of	O
the	O
amino	O
group	O
has	O
been	O
evidenced	O
as	O
a	O
broad	O
singlet	O
centered	O
at	O
4	O
.	O
54	O
ppm	O
(	O
Table	O
II	O
)	O
,	O
which	O
is	O
not	O
exchangeable	O
by	O
addition	O
of	O
D20	O
into	O
the	O
NMR	O
tube	O
,	O
in	O
contrast	O
to	O
the	O
sulfonamido	O
NH2	O
protons	O
(	O
which	O
readily	O
exchange	O
)	O
.	O

This	O
proves	O
that	O
the	O
5	O
-	O
amino	O
moiety	O
is	O
not	O
involved	O
in	O
binding	O
the	O
metal	O
ions	O
,	O
as	O
already	O
shown	O
in	O
the	O
X	O
-	O
ray	O
crystallographic	O
work	O
of	O
the	O
complex	O
[	O
Zn	O
(	O
tda	O
)	O
z	O
(	O
NH3	O
)	O
]	O
.	O
H20	O
previously	O
reported	O
[	O
40	O
]	O
.	O

For	O
sulfonamide	O
7	O
the	O
CONH	O
proton	O
resonates	O
as	O
a	O
singlet	O
at	O
12	O
.	O
22	O
ppm	O
.	O

In	O
complexes	O
15	O
-	O
20	O
only	O
very	O
minor	O
shifts	O
of	O
this	O
signal	O
were	O
evidenced	O
(	O
Table	O
II	O
)	O
,	O
proving	O
basically	O
that	O
the	O
CONH	O
moiety	O
does	O
not	O
interact	O
with	O
the	O
metal	O
ions	O
in	O
these	O
complexes	O
.	O

Table	O
II	O
:	O
Spectroscopic	O
,	O
thermogravimetric	O
and	O
conductimetric	O
data	O
for	O
compounds	O
6	O
-	O
20	O
.	O

1H	O
-	O
NMR	O
Spectrab	O
Comp	O
.	O

IR	O
Spectraa	O
,	O
cm	O
-	O
1	O
as	O
v	O
(	O
C	O
=	O
N	O
)	O
CONH	O
,	O
i	O
(	O
ppm	O
)	O
v	O
(	O
SO2	O
)	O
S	O
;	O
v	O
(	O
SO2	O
)	O
6	O
8	O
9	O
10	O
11	O

TG	O
analysisc	O
calc	O
.	O
/	O
found	O

Conductimetryd	O
AM	O
(	O
-	O
1	O
x	O
cm2x	O
mol	O
-	O
)	O
2	O
7	O
4	O
5	O
3	O
2	O
2	O
6	O
3	O
4	O
2	O
9	O
3	O
2	O
8	O

12	O
13	O
14	O
7	O
15	O
16	O
17	O
18	O
19	O
20	O

1170	O
;	O
1150	O
;	O
1150	O
;	O
1145	O
;	O
1145	O
;	O
1140	O
;	O
1145	O
;	O
1150	O
;	O
1170	O
;	O
1130	O
;	O
1140	O
;	O
1140	O
;	O
1150	O
;	O
1140	O
;	O
1145	O
;	O

1350	O
1300	O
1305	O
1300	O
1305	O
1300	O
1300	O
1300	O
1350	O
1335	O
1330	O
1330	O
1330	O
1335	O
1330	O

1610	O
1600	O
1600	O
1600	O
1600	O
1590	O
1605	O
1605	O
1610	O
1605	O
1610	O
1610	O
1605	O
1600	O
1600	O

A	O
A	O
A	O
A	O
A	O
A	O
A	O

e	O
e	O

12	O
.	O
3	O
/	O
12	O
.	O
1f	O
e	O
e	O
e	O
5	O
.	O
9	O
/	O
5	O
.	O
7g	O

A	O
12	O
.	O
22	O
(	O
1H	O
)	O
12	O
.	O
19	O
(	O
2H	O
)	O
12	O
.	O
18	O
(	O
3H	O
)	O
12	O
.	O
20	O
(	O
2H	O
)	O
12	O
.	O
18	O
(	O
2H	O
)	O
12	O
.	O
19	O
(	O
2H	O
)	O
12	O
.	O
21	O
(	O
2H	O
)	O

e	O
e	O
e	O
e	O
e	O
e	O
e	O
4	O
.	O
7	O
/	O
4	O
.	O
8g	O

a	O
In	O
KBr	O
;	O
bin	O
DMSO	O
-	O
d6	O
;	O
A	O
the	O
signal	O
of	O
the	O
5	O
-	O
amino	O
group	O
of	O
6	O
(	O
appearing	O
in	O
the	O
ligand	O
at	O
4	O
.	O
54	O
ppm	O
as	O
a	O
broad	O
singlet	O
)	O
appears	O
at	O
the	O
same	O
chemical	O
shift	O
(	O
4	O
.	O
50	O
4	O
.	O
55	O
ppm	O
)	O
in	O
complexes	O
8	O
-	O
14	O
;	O
cWeight	O
loss	O
between	O
70	O
-	O
250	O
C	O
;	O
d	O
mM	O
solution	O
,	O
in	O
DMF	O
,	O
at	O
25C	O
;	O
e	O
No	O
weight	O
loss	O
seen	O
under	O
250	O
C	O
;	O
fCorresponding	O
to	O
three	O
lattice	O
water	O
molecules	O
lost	O
at	O
70	O
-	O
110C	O
,	O
and	O
gCorresponding	O
to	O
two	O
coordinated	O
water	O
molecules	O
,	O
lost	O
at	O
160	O
-	O
180	O
C	O
.	O

Thermogravimetric	O
analysis	O
showed	O
the	O
presence	O
of	O
uncoordinated	O
water	O
molecules	O
in	O
the	O
molecule	O
of	O
complex	O
9	O
(	O
the	O
three	O
waters	O
were	O
lost	O
in	O
a	O
single	O
step	O
,	O
between	O
70	O
-	O
110	O
C	O
)	O
and	O
of	O
coordinated	O
water	O
in	O
the	O
molecules	O
of	O
the	O
lead	O
(	O
II	O
)	O
derivatives	O
13	O
and	O
20	O
.	O

All	O
these	O
compounds	O
behaved	O
as	O
non	O
-	O
electrolytes	O
in	O
DMF	O
as	O
solvent	O
(	O
Table	O
II	O
)	O
.	O

Mention	O
should	O
be	O
made	O
that	O
the	O
Mg	O
(	O
II	O
)	O
complex	O
of	O
sulfonamide	O
7	O
could	O
not	O
be	O
isolated	O
.	O

Instead	O
,	O
only	O
the	O
correponding	O
complex	O
of	O
5	O
-	O
amino	O
-	O
l	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
has	O
been	O
obtained	O
from	O
reaction	O
mixtures	O
containing	O
magnesium	O
salts	O
and	O
the	O
sodium	O
salt	O
of	O
7	O
,	O
probably	O
due	O
to	O
a	O
metal	O
ion	O
assisted	O
hydrolysis	O
of	O
7	O
to	O
6	O
and	O
chloroacetate	O
.	O

Generally	O
such	O
hydrolytic	O
processes	O
involve	O
highly	O
acidic	O
conditions	O
and	O
prolonged	O
heating	O
of	O
the	O
5	O
-	O
alkylamido	O
-	O
1	O
,	O
3	O
,	O
4	O
-	O
thiadiazole	O
-	O
2	O
-	O
sulfonamide	O
derivatives	O
[	O
41	O
]	O
,	O
but	O
they	O
might	O
become	O
milder	O
by	O
taking	O
into	O
account	O
the	O
putative	O
catalytic	O
effect	O
of	O
Mg2	O
+	O
ions	O
reported	O
here	O
.	O

The	O
data	O
shown	O
above	O
lead	O
to	O
the	O
conclusion	O
that	O
ligand	O
7	O
shares	O
a	O
common	O
coordination	O
chemistry	O
with	O
acetazolamide	O
1	O
with	O
which	O
it	O
is	O
structurally	O
related	O
,	O
whereas	O
6	O
probably	O
also	O
behaves	O
similarly	O
to	O
acetazolamide	O
in	O
the	O
sense	O
that	O
the	O
5	O
-	O
amino	O
group	O
seems	O
not	O
to	O
be	O
involved	O
in	O
coordinating	O
metal	O
ions	O
,	O
at	O
311	O

Vol	O
.	O

4	O
,	O
No	O
.	O
6	O
,	O
1997	O

Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O
A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O

least	O
in	O
the	O
complexes	O
reported	O
by	O
us	O
here	O
(	O
and	O
also	O
in	O
the	O
compound	O
characterized	O
by	O
X	O
-	O
ray	O
crystallography	O
mentioned	O
above	O
[	O
40	O
]	O
)	O
.	O

Thus	O
,	O
in	O
all	O
complexes	O
reported	O
here	O
these	O
sulfonamides	O
(	O
as	O
monodeprotonated	O
species	O
at	O
the	O
SO2NH	O
2	O
moieties	O
)	O
act	O
as	O
bidentate	O
ligands	O
,	O
through	O
the	O
endocyclic	O
N	O
-	O
3	O
and	O
the	O
NH	O
-	O
groups	O
.	O

The	O
proposed	O
formulae	O
of	O
the	O
new	O
complxes	O
are	O
shown	O
below	O
.	O

Except	O
for	O
the	O
two	O
Pb	O
(	O
II	O
)	O
complexes	O
13	O
and	O
20	O
,	O
as	O
well	O
as	O
the	O
AI	O
(	O
III	O
)	O
derivatives	O
14	O
and	O
16	O
,	O
which	O
presumably	O
are	O
pseudo	O
-	O
octahedral	O
,	O
the	O
other	O
derivatives	O
are	O
supposed	O
to	O
contain	O
tetrahedral	O
M	O
(	O
II	O
)	O
ions	O
.	O

R	O

R	O
13	O
"	O
R	O
=	O
20	O
"	O
R	O
=	O

H2N	O

CICH2CONH	O

14	O
:	O
R	O
=	O
16	O
:	O
R	O
=	O

H2N	O
CICH2CONH	O

The	O
compounds	O
6	O
-	O
20	O
together	O
with	O
the	O
standard	O
CA	O
inhibitors	O
1	O
-	O
5	O
were	O
assayed	O
for	O
inhibition	O
against	O
three	O
isozymes	O
,	O
hCA	O
I	O
,	O
hCA	O
II	O
and	O
bCA	O
IV	O
(	O
Table	O
III	O
)	O
.	O

As	O
seen	O
from	O
the	O
above	O
data	O
,	O
the	O
chloracetamido	O
derivative	O
is	O
more	O
inhibitory	O
than	O
acetazolamide	O
,	O
methazolamide	O
and	O
dichlorophenamide	O
,	O
whereas	O
the	O
unacylated	O
compound	O
6	O
is	O
less	O
inhibitory	O
than	O
the	O
above	O
sulfonamides	O
.	O

The	O
metal	O
complexes	O
820	O
are	O
much	O
more	O
inhibitory	O
than	O
the	O
sulfonamides	O
from	O
which	O
they	O
derive	O
6	O
,	O
7	O
and	O
than	O
all	O
other	O
simple	O
sulfonamides	O
assayed	O
.	O

They	O
behave	O
similarly	O
to	O
the	O
metal	O
complexes	O
of	O
acetazolamide	O
,	O
methazolamide	O
or	O
dorzolamide	O
previously	O
reported	O
by	O
this	O
group	O
,	O
which	O
were	O
all	O
more	O
inhibitory	O
than	O
the	O
parent	O
sulfonamide	O
from	O
which	O
were	O
prepared	O
[	O
16	O
-	O
22	O
,	O
40	O
]	O
.	O

Particularly	O
strong	O
inhibition	O
was	O
observed	O
for	O
the	O
Zn	O
(	O
II	O
)	O
,	O
Hg	O
(	O
II	O
)	O
,	O
Pb	O
(	O
II	O
)	O
and	O
Cd	O
(	O
II	O
)	O
complexes	O
,	O
especially	O
against	O
CA	O
II	O
and	O
CA	O
IV	O
,	O
the	O
isozymes	O
critical	O
for	O
aqueous	O
humor	O
formation	O
.	O

In	O
vivo	O
IOP	O
lowering	O
experiments	O
were	O
done	O
in	O
rabbits	S-Species
with	O
some	O
of	O
the	O
new	O
compounds	O
prepared	O
in	O
the	O
present	O
work	O
,	O
such	O
as	O
the	O
sulfonamides	O
6	O
and	O
7	O
,	O
and	O
their	O
Zn	O
(	O
II	O
)	O
complexes	O
,	O
which	O
were	O
among	O
the	O
strong	O
CA	O
II	O
and	O
CA	O
IV	O
inhibitors	O
in	O
the	O
obtained	O
series	O
.	O

Some	O
of	O
the	O
IOP	O
lowering	O
data	O
at	O
half	O
an	O
hour	O
and	O
one	O
hour	O
after	O
the	O
instillation	O
of	O
one	O
drop	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
within	O
the	O
rabbit	S-Species
eye	O
are	O
shown	O
in	O
312	O

Claudiu	O
T	O
.	O
Supuran	O
et	O
al	O
.	O

Metal	O
-	O
Based	O
Drugs	O

Table	O
IV	O
,	O
with	O
dorzolamide	O
(	O
at	O
the	O
same	O
concentration	O
)	O
as	O
standard	O
.	O

In	O
Fig	O
.	O
the	O
time	O
dependence	O
of	O
IOP	O
lowering	O
with	O
dorzolamide	O
5	O
and	O
the	O
two	O
Zn	O
(	O
II	O
)	O
complexes	O
10	O
and	O
17	O
is	O
presented	O
.	O

Table	O
III	O
.	O

CA	O
inhibition	O
data	O
with	O
the	O
standard	O
inhibitors	O
1	O
-	O
5	O
,	O
the	O
sulfonamides	O
6	O
and	O
7	O
,	O
and	O
their	O
metal	O
complexes	O
8	O
-	O
20	O
.	O

No	O
1	O
2	O
3	O
4	O
5	O
6	O
7	O
8	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
19	O
20	O
a	O

Inhibitor	O

KI	O
hCA	O
Ia	O
900	O
780	O
25	O
1200	O
>	O
50	O
,	O
000	O
1550	O
640	O
1050	O
350	O
50	O
40	O
12	O
80	O
240	O
120	O
80	O
40	O
40	O
9	O
15	O

(	O
nM	O
)	O
bCA	O
IVb	O
220	O
240	O
13	O
380	O
43	O
780	O
24	O
540	O
220	O
25	O
19	O
10	O
26	O
110	O
12	O
16	O
9	O
10	O
5	O
10	O

hCA	O
IIa	O
12	O
14	O
8	O
38	O
9	O
230	O
5	O
190	O
110	O
15	O
14	O
7	O
10	O
76	O
5	O
4	O
3	O
3	O
2	O
5	O

Acetazolamide	O
Methazolamide	O
Ethoxzolamide	O

Dichlorophenamide	O
Dorzolamide	O

Human	S-Species
(	O
cloned	O
)	O
isozymes	O
;	O
b	O
From	O
bovine	S-Species
lung	O
microsomes	O
.	O

Table	O
IV	O
:	O
IOP	O
lowering	O
following	O
topical	O
application	O
of	O
CA	O
inhibitors	O
,	O
half	O
an	O
hour	O
and	O
one	O
hour	O
after	O
instillation	O
into	O
the	O
eye	O
of	O
a	O
drop	O
(	O
50	O
L	O
)	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
.	O

Inhibitor	O

lOP	O
SE	O
1	O
/	O
2	O
h	O

a	O

(	O
mm	O
Hg	O
)	O
lh	O
4	O
.	O
1	O
0	O
.	O
15	O
0	O
0	O
.	O
09	O
0	O
0	O
.	O
09	O
5	O
.	O
0	O
0	O
.	O
12	O
8	O
.	O
1	O
0	O
.	O
21	O
Dorzolamide	O
5	O
6	O
7	O
10	O
17	O
a	O

2	O
.	O
2	O
0	O
.	O
10	O
0	O
0	O
.	O
10	O
0	O
0	O
.	O
10	O
2	O
.	O
00	O
.	O
09	O
8	O
.	O
0	O
0	O
.	O
14	O

IOP	O

IOP	O
control	O
eye	O
"	O
IOP	O
treated	O
eye	O
(	O
N	O
3	O
)	O
.	O

As	O
seen	O
from	O
the	O
above	O
data	O
,	O
the	O
sulfonamides	O
6	O
and	O
7	O
are	O
totally	O
ineffective	O
as	O
lOP	O
lowering	O
agents	O
,	O
similarly	O
to	O
the	O
classical	O
clinically	O
used	O
inhibitors	O
of	O
type	O
1	O
-	O
5	O
[	O
2	O
,	O
3	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
dorzolamide	O
,	O
the	O
first	O
topical	O
sulfonamide	O
used	O
clinically	O
in	O
the	O
treatment	O
of	O
glaucoma	O
is	O
an	O
effective	O
such	O
agent	O
,	O
with	O
a	O
decrease	O
of	O
lOP	O
of	O
around	O
4	O
mm	O
Hg	O
,	O
one	O
hour	O
after	O
administration	O
directly	O
into	O
the	O
eye	O
(	O
Table	O
IV	O
)	O
.	O

From	O
the	O
data	O
of	O
this	O
table	O
,	O
it	O
is	O
obvious	O
that	O
the	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
investigated	O
by	O
us	O
behave	O
as	O
much	O
more	O
effective	O
IOP	O
lowering	O
agents	O
than	O
dorzolamide	O
,	O
and	O
their	O
effect	O
is	O
generally	O
longerlasting	O
(	O
Fig	O
.	O
1	O
)	O
.	O

A	O
last	O
remark	O
should	O
be	O
made	O
about	O
the	O
possible	O
mechanism	O
of	O
action	O
of	O
the	O
new	O
class	O
of	O
IOP	O
lowering	O
agents	O
.	O

Obviously	O
,	O
their	O
activity	O
is	O
due	O
to	O
inhibition	O
of	O
CA	O
isozymes	O
present	O
in	O
the	O
cilliary	O
processes	O
within	O
the	O
eye	O
,	O
similarly	O
to	O
other	O
topically	O
active	O
sulfonamides	O
[	O
2	O
-	O
6	O
]	O
.	O

The	O
fact	O
that	O
the	O
sulfonamide	O
per	O
se	O
is	O
inactive	O
via	O
the	O
topical	O
route	O
,	O
whereas	O
the	O
metal	O
complexes	O
result	O
much	O
better	O
than	O
the	O
drug	O

313	O

Vol	O
.	O

4	O
,	O
No	O
.	O
6	O
,	O
1997	O

Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
.	O
"	O
A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O

dorzolamide	O
,	O
indicates	O
that	O
the	O
presence	O
of	O
metal	O
ions	O
in	O
the	O
molecules	O
of	O
these	O
CA	O
inhibitors	O
is	O
essential	O
and	O
confers	O
them	O
completely	O
new	O
properties	O
.	O

Lowering	O
of	O
IOP	O
(	O
ram	O
Hg	O
)	O

"	O
|	O
|	O
,	O

/	O

"	O
,	O
,	O

'	O
"	O
,	O
.	O
,	O

,	O
<	O

.	O
7	O
,	O
/	O

/	O

.	O
6	O

-	O
0	O

-	O
10	O
0	O

2	O

Time	O
(	O
hours	O
)	O

Fig	O
l	O
"	O
Time	O
dependence	O
of	O
IOP	O
lowering	O
with	O
dorzolamide	O
(	O
curve	O
1	O
)	O
;	O
the	O
zinc	O
complex	O
10	O
(	O
curve	O
3	O
)	O
and	O
the	O
zinc	O
complex	O
17	O
(	O
curve	O
3	O
)	O
,	O
after	O
topical	O
administration	O
of	O
one	O
drop	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
in	O
rabbit	S-Species
.	O

Preliminary	O
results	O
from	O
this	O
laboratory	O
indicate	O
that	O
the	O
metal	O
complexes	O
of	O
topically	O
active	O
sulfonamides	O
show	O
also	O
increased	O
lOP	O
lowering	O
effects	O
with	O
respect	O
to	O
the	O
complexes	O
prepared	O
in	O
the	O
present	O
study	O
[	O
42	O
]	O
.	O

Our	O
hypothesis	O
is	O
that	O
the	O
presence	O
of	O
the	O
metal	O
ion	O
in	O
the	O
molecules	O
of	O
these	O
complex	O
inhibitors	O
induces	O
a	O
dramatic	O
change	O
in	O
their	O
physico	O
-	O
chemical	O
properties	O
as	O
compared	O
to	O
those	O
of	O
the	O
parent	O
sulfonamide	O
.	O

This	O
phenomenon	O
is	O
certainly	O
governed	O
by	O
the	O
strong	O
polarization	O
induced	O
by	O
the	O
metal	O
ions	O
.	O

In	O
this	O
way	O
,	O
it	O
is	O
quite	O
probable	O
that	O
the	O
right	O
balance	O
between	O
the	O
lipo	O
-	O
and	O
hydrosolubility	O
of	O
these	O
compounds	O
is	O
achieved	O
,	O
which	O
has	O
been	O
considered	O
to	O
be	O
the	O
critical	O
factor	O
for	O
not	O
observing	O
topical	O
activity	O
in	O
the	O
classical	O
CA	O
inhibitors	O
,	O
such	O
as	O
acetazolamide	O
,	O
methazolamide	O
and	O
ethoxzolamide	O
,	O
which	O
were	O
either	O
too	O
lipophilic	O
or	O
too	O
hy	O
.	O
drosoluble	O
[	O
2	O
,	O
3	O
]	O
.	O

So	O
,	O
by	O
choosing	O
different	O
metal	O
ions	O
and	O
diverse	O
sulfonamides	O
,	O
much	O
larger	O
possibilities	O
arise	O
to	O
finely	O
tune	O
the	O
pharmacological	O
properties	O
which	O
strongly	O
influence	O
the	O
value	O
of	O
a	O
drug	O
.	O

In	O
conclusion	O
we	O
describe	O
here	O
a	O
novel	O
class	O
of	O
lOP	O
lowering	O
agents	O
,	O
ie	O
,	O
the	O
metal	O
complexes	O
of	O
sulfonamide	O
CA	O
inhibitors	O
.	O

These	O
derivatives	O
appear	O
to	O
be	O
very	O
active	O
and	O
longer	O
lasting	O
than	O
the	O
drug	O
dorzolamide	O
,	O
and	O
might	O
constitute	O
the	O
premises	O
for	O
a	O
new	O
generation	O
of	O
antiglaucoma	O
drugs	O
.	O

Acknowledgments	O
.	O

We	O
are	O
grateful	O
to	O
Prof	O
.	O

S	O
.	O

Lindskog	O
(	O
Umea	O
Univ	O
.	O
,	O
Sweden	O
)	O
for	O
the	O
gift	O
of	O
the	O
hCA	O
and	O
II	O
plasmids	O
.	O

References	O
Preceding	O
part	O
of	O
this	O
series	O
"	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Ilies	O
MA	O
,	O
Iorga	O
B	O
,	O
Cristea	O
T	O
,	O
Chiraleu	O
F	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O
Eur	O
J	O
Med	O
Chem	O
,	O
submitted	O
.	O

2	O
Supuran	O
CT	O
(	O
1994	O
)	O
"	O
Carbonic	O
anhydrase	O
inhibitors	O
"	O
In	O
Carbonic	O
Anhydrase	O
and	O
Modulation	O
of	O
Physiologic	O
and	O
Pathologic	O
Processes	O
in	O
the	O
Organism	O
,	O
(	O
Puscas	O
I	O
,	O
Ed	O
)	O
Helicon	O
,	O
Timisoara	O
,	O
pp	O
.	O

29	O
-	O
111	O
.	O

3	O
Maren	O
TH	O
(	O
1991	O
)	O
"	O
The	O
links	O
among	O
biochemistry	O
,	O
physiology	O
and	O
pharmacology	O
in	O
carbonic	O
anhydrase	O
mediated	O
systems	O
"	O
.	O

In	O
Carbonic	O
Anhydrase	O
From	O
Biochemistry	O
and	O
Genetics	O
to	O
Physiology	O
and	O
Clinical	O
Medicine	O
,	O
(	O
Botr6	O
F	O
,	O
Gros	O
G	O
,	O
Storey	O
BT	O
Eds	O
)	O
VCH	O
,	O
Weinheim	O
,	O
pp	O
.	O

186	O
-	O
207	O
.	O

4	O
Bayer	O
A	O
,	O
Ferrari	O
F	O
,	O
Maren	O
TH	O
,	O
Erb	O
C	O
(	O
1996	O
)	O
dFr	O
Ophtalrnol	O
19	O
,	O
3	O
:	O
57	O
-	O
362	O
.	O

:	O
5	O
Maren	O
TH	O
,	O
Conroy	O
CW	O
,	O
Wynns	O
GC	O
,	O
Levy	O
NS	O
(	O
1997	O
)	O
d	O
Ocul	O
Pharrnacol	O
Therapeut	O
13	O
,	O
23	O
-	O
30	O
.	O

6	O
Sugrue	O
MF	O
(	O
1996	O
)	O
d	O
Ocul	O
Pharmacol	O
Ther	O
12	O
,	O
363	O
-	O
376	O
.	O

7	O
Bartlett	O
JD	O
,	O
Jaanus	O
SD	O
(	O
1989	O
)	O
"	O
Carbonic	O
anhydrase	O
inhibitors	O
"	O
.	O

In	O
Clinical	O
Ocular	O
Pharmacology	O
,	O
Second	O
Edition	O
,	O
Butterworths	O
Publishers	O
,	O
Boston	O
,	O
pp	O
.	O

2	O
:	O
54	O
-	O
263	O
.	O

8	O
Alward	O
PD	O
,	O
Wilensky	O
JT	O
(	O
1981	O
)	O
Arch	O
Ophthalmo199	O
,	O
1973	O
-	O
1976	O
.	O

314	O

Claudiu	O
T	O
.	O
Supuran	O
et	O
al	O
.	O

Metal	O
-	O
Based	O
Drugs	O

9	O
Maren	O
TH	O
,	O
Jankowska	O
L	O
,	O
Sanyal	O
G	O
,	O
Edelhauser	O
HF	O
(	O
1983	O
)	O
Exp	O
Eye	O
Res	O
36	O
,	O
457	O
-	O
480	O
.	O

10	O
a	O
)	O
Ponticello	O
GS	O
,	O
Freedman	O
MB	O
,	O
Habecker	O
CN	O
,	O
Lyle	O
PA	O
,	O
Schwam	O
H	O
,	O
Varga	O
SL	O
,	O
Christy	O
ME	O
,	O
Randall	O
WC	O
,	O
Baldwin	O
JJ	O
(	O
1987	O
)	O
J	O
Med	O
Chem	O
30	O
,	O
591	O
-	O
597	O
;	O
b	O
)	O
Greer	O
J	O
,	O
Erickson	O
JW	O
,	O
Baldwin	O
JJ	O
,	O
Varney	O
MD	O
(	O
1994	O
)	O
J	O
Med	O
Chem	O
37	O
,	O
1035	O
-	O
1054	O
.	O

11	O
Baldwin	O
JJ	O
,	O
Ponticello	O
GS	O
,	O
Anderson	O
GS	O
,	O
Christy	O
ME	O
,	O
Murcko	O
MA	O
,	O
Randall	O
WC	O
,	O
Schwam	O
H	O
,	O
Sugrue	O
MF	O
,	O
Springer	O
JP	O
,	O
Gautheron	O
P	O
,	O
Grove	O
J	O
,	O
Mallorga	O
P	O
,	O
Viader	O
MP	O
,	O
McKeever	O
BM	O
,	O
Navia	O
MA	O
(	O
1989	O
)	O
J	O
Med	O
Chem	O
32	O
,	O
2510	O
-	O
2513	O
.	O

12	O
Chow	O
K	O
,	O
Lai	O
R	O
,	O
Holmes	O
JM	O
,	O
Wijono	O
M	O
,	O
Wheeler	O
LA	O
,	O
Garst	O
ME	O
(	O
1996	O
)	O
EurJMed	O
Chem	O
31	O
,	O
175	O
-	O
186	O
.	O

13	O
Supuran	O
CT	O
,	O
Nicolae	O
A	O
,	O
Popescu	O
A	O
(	O
1996	O
)	O
Eur	O
JMed	O
Chem	O
31	O
,	O
431	O
-	O
438	O
.	O

14	O
Supuran	O
CT	O
,	O
Popescu	O
A	O
,	O
Ilisiu	O
M	O
,	O
Costandache	O
A	O
,	O
Banciu	O
MD	O
(	O
1996	O
)	O
Eur	O
JMed	O
Chem	O
31	O
,	O
439	O
-	O
448	O
.	O

15	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Popescu	O
A	O
,	O
Bobes	O
-	O
Tureac	O
R	O
,	O
Banciu	O
A	O
,	O
Creanga	O
A	O
,	O
Bobes	O
-	O
Tureac	O
G	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O
Eur	O
JMed	O
Chem	O
32	O
,	O
445	O
-	O
452	O
.	O

16	O
Alzuet	O
G	O
,	O
Casanova	O
J	O
,	O
Ramirez	O
JA	O
,	O
Borras	O
J	O
,	O
Carugo	O
O	O
(	O
1995	O
)	O
J	O
Inorg	O
Bioehem	O
57	O
,	O
219	O
-	O
234	O
.	O

17	O
Sumalan	O
SL	O
,	O
Casanova	O
J	O
,	O
Alzuet	O
G	O
,	O
Borras	O
J	O
,	O
Castifieiras	O
A	O
,	O
Supuran	O
CT	O
(	O
1996	O
)	O
J	O
Inorg	O
Biochem	O
62	O
,	O
3139	O
.	O

18	O
a	O
)	O
Supuran	O
CT	O
(	O
1995	O
)	O
Metal	O
Based	O
Drugs	O
2	O
,	O
327	O
-	O
330	O
;	O
b	O
)	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
Metal	O
Based	O
Drugs	O
4	O
,	O
19	O
-	O
26	O
.	O

19	O
a	O
)	O
Borras	O
J	O
,	O
Cristea	O
T	O
,	O
Supuran	O
CT	O
(	O
1996	O
)	O
,	O
Main	O
Group	O
Met	O
Chem	O
19	O
,	O
339	O
-	O
346	O
;	O
b	O
)	O
Jitianu	O
A	O
,	O
Ilies	O
MA	O
,	O
Briganti	O
F	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
Metal	O
Based	O
Drugs	O
4	O
,	O
1	O
-	O
7	O
.	O

20	O
a	O
)	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
12	O
,	O
37	O
-	O
51	O
;	O
b	O
)	O
Supuran	O
CT	O
,	O
Briganti	O
F	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
12	O
,	O
175	O
-	O
190	O
.	O

21	O
Mincione	O
G	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
Metal	O
Based	O
Drugs	O
4	O
,	O
27	O
-	O
34	O
.	O

22	O
Alzuet	O
G	O
,	O
Ferrer	O
S	O
,	O
Borras	O
J	O
,	O
Supuran	O
CT	O
(	O
1994	O
)	O
Roum	O
Chem	O
Quart	O
Rev	O
2	O
,	O
283	O
-	O
300	O
.	O

23	O
Briganti	O
F	O
,	O
Mangani	O
S	O
,	O
Orioli	O
P	O
,	O
Scozzafava	O
A	O
,	O
Vernaglione	O
G	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
Biochemistry	O
36	O
,	O
10384	O
-	O
10392	O
.	O

24	O
Borras	O
J	O
,	O
Casanova	O
J	O
,	O
Cristea	O
T	O
,	O
Gheorghe	O
A	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
,	O
Tudor	O
V	O
(	O
1996	O
)	O
Metal	O
Based	O
Drugs	O
3	O
,	O
143	O
-	O
148	O
.	O

25	O
Supuran	O
CT	O
,	O
Mincione	O
F	O
,	O
Scozzafava	O
A	O
,	O
Briganti	O
F	O
,	O
Mincione	O
G	O
,	O
Ilies	O
MA	O
(	O
1997	O
)	O
Eur	O
J	O
Med	O
Chem	O
,	O
in	O

press	O
.	O

26	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Saramet	O
I	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
,	O
in	O
press	O
.	O

27	O
Jitianu	O
A	O
,	O
Ilies	O
MA	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
Main	O
Group	O
Met	O
Chem	O
20	O
,	O
151	O
-	O
156	O
.	O

28	O
Forsman	O
C	O
,	O
Behravan	O
G	O
,	O
Osterman	O
A	O
,	O
Jonsson	O
BH	O
(	O
1988	O
)	O
Acta	O
Chem	O
Scand	O
B42	O
,	O
314	O
-	O
318	O
.	O

29	O
Behravan	O
G	O
,	O
Jonasson	O
P	O
,	O
Jonsson	O
BH	O
,	O
Lindskog	O
S	O
(	O
1991	O
)	O
Eur	O
JBiochem	O
198	O
,	O
589	O
-	O
592	O
.	O

30	O
Khalifah	O
RG	O
,	O
Strader	O
DJ	O
,	O
Bryant	O
SH	O
,	O
Gibson	O
SM	O
(	O
1977	O
)	O
Biochemistry	O
16	O
,	O
2241	O
-	O
2247	O
.	O

31	O
Nyman	O
PO	O
,	O
Lindskog	O
S	O
(	O
1964	O
)	O
Biochim	O
Biophys	O
Acta	O
85	O
,	O
141	O
-	O
151	O
.	O

32	O
Henderson	O
LE	O
,	O
Henriksson	O
D	O
,	O
Nyman	O
PO	O
(	O
1976	O
)	O
JBiol	O
Chem	O
251	O
,	O
5457	O
-	O
5463	O
.	O

33	O
Maren	O
TH	O
,	O
Wynns	O
GC	O
,	O
Wistrand	O
PJ	O
(	O
1993	O
)	O
Mol	O
Pharmaco144	O
,	O
901	O
-	O
906	O
.	O

34	O
Young	O
RW	O
,	O
Wood	O
KH	O
,	O
Vaughan	O
JR	O
,	O
Anderson	O
GW	O
(	O
1956	O
)	O
J	O
Am	O
Chem	O
Soc	O
78	O
,	O
4649	O
-	O
4654	O
.	O

35	O
Pocker	O
Y	O
,	O
Stone	O
JT	O
(	O
1967	O
)	O
Biochemistry	O
6	O
,	O
668	O
-	O
678	O
.	O

36	O
Baird	O
TT	O
,	O
Waheed	O
A	O
,	O
Okuyama	O
T	O
,	O
Sly	O
WS	O
,	O
Fierke	O
CA	O
(	O
1997	O
)	O
Biochemistry	O
36	O
,	O
2669	O
-	O
2678	O
.	O

37	O
Maren	O
TH	O
,	O
Bar	O
-	O
Ilan	O
A	O
,	O
Conroy	O
CW	O
,	O
Brechue	O
WF	O
(	O
1990	O
)	O
Exp	O
Eye	O
Res	O
50	O
,	O
27	O
-	O
36	O
.	O

38	O
Maren	O
TH	O
,	O
Brechue	O
WF	O
,	O
Bar	O
-	O
Ilan	O
A	O
(	O
1992	O
)	O
Exp	O
Eye	O
Res	O
55	O
,	O
73	O
-	O
79	O
.	O

39	O
Brechue	O
WF	O
,	O
Maren	O
TH	O
(	O
1993	O
)	O
Invest	O
Ophthalmol	O
Vis	O
Sci	O
34	O
,	O
2581	O
-	O
2587	O
.	O

40	O
Borja	O
P	O
,	O
Alzuet	O
G	O
,	O
Server	O
-	O
Carri6	O
J	O
,	O
Borras	O
J	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
J	O
Biol	O
Inorg	O
Chem	O
(	O
JBIC	O
)	O
,	O
in	O
press	O
.	O

41	O
Supuran	O
CT	O
,	O
Balaban	O
AT	O
,	O
Gheorghiu	O
MD	O
,	O
Schiketanz	O
A	O
,	O
Dinculescu	O
A	O
,	O
Puscas	O
I	O
(	O
1990	O
)	O
Rev	O
Roum	O
Chim	O
35	O
,	O
399	O
-	O
405	O
.	O

42	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
unpublished	O
results	O
.	O

Received	O
:	O
September	O
24	O
,	O
1997	O
Accepted	O
:	O
October	O
17	O
,	O
1997	O
Received	O
in	O
revised	O
camera	O
-	O
ready	O
format	O
"	O
October	O
23	O
,	O
1997	O

315	O

Synthesis	O
,	O
Characterization	O
and	O
Antitumour	O
Activity	O
of	O
Some	O
Butyltin	O
(	O
IV	O
)	O
Cysteaminates	O
and	O
N	O
,	O
N	O
-	O
Dimethylcysteaminates	O

Abstract	O

The	O
synthesis	O
and	O
characterization	O
of	O
four	O
di	O
-	O
and	O
tri	O
-	O
n	O
-	O
butyltin	O
cysteaminates	O
and	O
N	O
,	O
N	O
-	O
dimethylcysteaminates	O
and	O
three	O
protonated	O
/	O
quaternized	O
derivatives	O
are	O
reported	O
.	O

They	O
all	O
exhibit	O
moderate	O
or	O
high	O
in	O
vitro	O
cytotoxic	O
activity	O
.	O

Six	O
of	O
seven	O
compounds	O
presented	O
in	O
this	O
work	O
are	O
more	O
active	O
than	O
cisplatin	O
,	O
etoposide	O
and	O
5	O
-	O
fluorouracil	O
,	O
but	O
less	O
active	O
than	O
methotrexate	O
and	O
doxorubicin	O
.	O

Metal	O
Based	O
Drugs	O

Vol	O
.	O

7	O
,	O
Nr	O
.	O

5	O
,	O
2000	O

SYNTHESIS	O
,	O
CHARACTERIZATION	O
AND	O
ANTITUMOUR	O
ACTITY	O
OF	O
SOME	O
BUTYLTIN	O
(	O
IV	O
)	O
CYSTEAMINATES	O
AND	O
N	O
,	O
N	O
-	O
DIMETHYLCYSTEAMINATES	O
Marcel	O
Gielen	O
Karel	O
Handlir	O
.	O
2	O
,	O
Martin	O
Hollein	O
and	O
Dick	O
de	O
Vos	O
2	O
3	O

Departement	O
of	O
General	O
and	O
Organic	O
Chemistry	O
AOSC	O
,	O
Faculty	O
of	O
Applied	O
Sciences	O
,	O
Free	O
University	O
of	O
Brussels	O
VUV	O
,	O
Pleinlaan	O
2	O
,	O
B	O
-	O
1050	O
Brussels	O
,	O
Belgium	O
Departement	O
of	O
General	O
and	O
Inorganic	O
Chemistry	O
,	O
Faculty	O
of	O
Chemical	O
Technology	O
,	O
University	O
of	O
Pafdubice	O
,	O
Nam	O
.	O

Cs	O
.	O
legii	O
565	O
,	O
53210	O
Pardubice	O
,	O
Czech	O
Republic	O
Pharmachemie	O
B	O
.	O

V	O
.	O
,	O
Haarlem	O
,	O
the	O
Netherlands	O
Abstract	O
.	O

The	O
synthesis	O
and	O
characterization	O
of	O
four	O
di	O
-	O
and	O
tri	O
-	O
n	O
-	O
butyltin	O
cysteaminates	O
and	O
_	O
N	O
,	O
N	O
-	O
dimethylcysteaminates	O
and	O
three	O
protonated	O
/	O
quaternized	O
derivatives	O
are	O
reported	O
.	O

They	O
all	O
exhibit	O
moderate	O
or	O
high	O
in	O
vitro	O
cytotoxic	O
activity	O
.	O

Six	O
of	O
seven	O
compounds	O
presented	O
in	O
this	O
work	O
are	O
more	O
active	O
than	O
cisplatin	O
,	O
etoposide	O
and	O
5	O
-	O
fluorouracil	O
,	O
but	O
less	O
active	O
than	O
methotrexate	O
and	O
doxorubiein	O
.	O

Introduction	O
.	O

Several	O
organotin	O
cysteaminates	O
(	O
aminoethylthiolates	O
)	O
have	O
been	O
studied	O
1	O
-	O
4	O
as	O
compounds	O
with	O
potentially	O
high	O
biological	O
activity	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
cytotoxic	O
effect	O
.	O

The	O
present	O
paper	O
reports	O
the	O
synthesis	O
and	O
characterization	O
of	O
di	O
-	O
and	O
tri	O
-	O
n	O
-	O
butyltin	O
cysteaminates	O
and	O
their	O
N	O
,	O
N	O
-	O
dimethyl	O
analogues	O
and	O
their	O
in	O
vitro	O
cytotoxicity	O
.	O

It	O
is	O
shown	O
that	O
a	O
correct	O
evaluation	O
of	O
the	O
biological	O
activity	O
of	O
organotin	O
compounds	O
remains	O
5	O
often	O
hampered	O
by	O
their	O
low	O
water	O
solubility	O
.	O

Therefore	O
,	O
we	O
focused	O
on	O
the	O
synthesis	O
of	O
derivatives	O
with	O
potentially	O
higher	O
water	O
solubility	O
by	O
introducing	O
ionic	O
groups	O
into	O
the	O
molecule	O
by	O
protonation	O
or	O
quatemization	O
of	O
a	O
nitrogen	O
atom	O
.	O

Results	O
and	O
discussion	O
.	O

3	O

2	O

4	O

(	O
n	O
-	O
Bu	O
)	O
n	O
Sn	O
[	O
SCH2	O
-	O
CH2	O
-	O
NHm	O
(	O
CH3	O
)	O
2	O
-	O
m	O
]	O
4	O
-	O
n	O

n	O
=	O
3	O
,	O
n	O
=	O
3	O
,	O
n	O
=	O
2	O
,	O
n	O
=	O
2	O
,	O

m	O
=	O
2	O
m	O
=	O
O	O
m	O
=	O
2	O
m	O
=	O
O	O

(	O
1	O
)	O
(	O
2	O
)	O
(	O
3	O
)	O
(	O
4	O
)	O

3	O

2	O

4	O

(	O
n	O
-	O
Bu	O
)	O
3	O
Sn	O
S	O
-	O
CH2	O
-	O
CH2	O
-	O
NHm	O
(	O
CH3	O
)	O
3	O
.	O
m	O
X	O

m	O
=	O
3	O
,	O
x	O
=	O
cn3so3	O
(	O
5	O
)	O
m	O
1	O
,	O
X	O
=	O
CH3SO3	O
(	O
6	O
)	O
m	O
0	O
,	O
X	O
I	O
(	O
7	O
)	O

n	O
-	O
Bu	O
CH3	O
-	O
CH2	O
-	O
CH2	O
-	O
CH2	O

(	O
2	O
)	O
,	O
di	O
-	O
nTri	O
-	O
n	O
-	O
butyltin	O
cysteaminate	O
(	O
1	O
)	O
,	O
tri	O
-	O
n	O
-	O
butyltin	O
N	O
,	O
N	O
-	O
dimethylcysteaminate	O
butyltin	O
bis	O
(	O
cysteaminate	O
)	O
(	O
3	O
)	O
and	O
di	O
-	O
n	O
-	O
butyltin	O
bis	O
(	O
N	O
,	O
N	O
-	O
dimethylcysteaminate	O
)	O
(	O
4	O
)	O
were	O
prepared	O
by	O
the	O
reaction	O
of	O
the	O
sodium	O
cysteaminate	O
(	O
prepared	O
in	O
situ	O
by	O
the	O
reaction	O
of	O
sodium	O
methylate	O
with	O
the	O
hydrochloride	O
of	O
eysteamine	O
)	O
with	O
the	O
suitable	O
di	O
-	O
or	O
tri	O
-	O
n	O
-	O
butyltin	O
chloride	O
in	O
chloroform	O
following	O
reference	O
by	O
the	O
reactions	O
of	O
the	O
The	O
methanesulphonates	O
5	O
and	O
6	O
were	O
respectively	O
synthesized	O
equimolar	O
amount	O
of	O
methane	O
sulphonic	O
acid	O
in	O
unprotonated	O
analogs	O
1	O
and	O
2	O
with	O
an	O
chloroform	O
.	O

After	O
purification	O
on	O
a	O
short	O
column	O
of	O
alumina	O
and	O
evaporation	O
of	O
the	O
solvent	O
,	O
colourless	O
viscous	O
oils	O
were	O
obtained	O
.	O

The	O
quaternized	O
methyl	O
derivative	O
of	O
2	O
,	O
the	O
methiodide	O
(	O
7	O
)	O
,	O
was	O
prepared	O
by	O
its	O
reaction	O
with	O
methyl	O
iodide	O
in	O
benzene	O
and	O
purified	O
by	O
recrystalization	O
from	O
chloroform	O
.	O

233	O

M	O
.	O

Gielen	O
,	O
K	O
.	O

Handlir	O
,	O
M	O
.	O

Hollein	O
and	O
D	O
.	O

de	O
Vos	O
Synthesis	O
,	O
Characterization	O
and	O
Antitumor	O
Activity	O
ofSome	O
Butyltin	O
(	O
IV	O
)	O
Cysteaminates	O
and	O
N	O
,	O
N	O
-	O
Dimethylcysteaminates	O

86	O
77	O
85	O
3	O
(	O
C4H9	O
)	O
2Sn	O
(	O
SCH2CH2NH2	O
)	O
2	O
90	O
4	O
(	O
C4Hg	O
)	O
zSn	O
(	O
SCH2CHzN	O
(	O
CH3	O
)	O
2	O
)	O
2	O
92	O
oil	O
5	O
(	O
C4H9	O
)	O
3	O
SnSCH2CH2NH3	O
CH3SO3	O
94	O
6	O
oil	O
(	O
C4H9	O
)	O
3	O
SnSCH2CH2NH	O
(	O
CH3	O
)	O
2	O
CH3SO3	O
118	O
-	O
120	O
74	O
7	O
(	O
C4H9	O
)	O
.	O
SnSCH	O
.	O
CH	O
.	O
N	O
(	O
CH3	O
)	O
31	O
The	O
elemental	O
analyses	O
(	O
C	O
,	O
H	O
,	O
N	O
,	O
Sn	O
)	O
agree	O
satisfactorily	O
with	O
the	O
proposed	O
formul	O

Table	O
1	O
.	O

Melting	O
points	O
and	O
yields	O
for	O
.	O
.	O
c0mP0unds	O
1	O
(	O
)	O
rmula	O
,	O
2	O
comp	O
.	O

1	O
(	O
C4H9	O
)	O
3SnSCHzCH2NH2	O
2	O
(	O
C4H9	O
)	O
3SnSCHzCH2N	O
(	O
CH3	O
)	O
2	O

7	O
.	O

m	O
.	O
p	O
.	O
,	O
.	O
.	O
b	O
.	O
p	O
.	O
.	O
,	O
.	O
C	O
120	O
-	O
123	O
/	O
40	O
Pa	O
129	O
-	O
131	O
/	O
35	O
Pa	O
167	O
-	O
169	O
/	O
35	O
Pa	O
172	O
-	O
174	O
/	O
40	O
Pa	O

'	O
o	O
'	O

yield	O
,	O
.	O
%	O

Compounds	O
1	O
-	O
4	O
,	O
and	O
7	O
,	O
are	O
poorly	O
soluble	O
in	O
aqueous	O
solutions	O
(	O
<	O
mg	O
/	O
mL	O
)	O
.	O

Compounds	O
5	O
and	O
6	O
exhibit	O
higher	O
water	O
solubilities	O
(	O
ca	O
.	O
2	O
mg	O
/	O
mL	O
)	O
.	O

Compounds	O
1	O
7	O
are	O
soluble	O
in	O
a	O
therapeutic	O
solution	O
(	O
0	O
,	O
103	O
M	O
solution	O
of	O
NaCl	O
in	O
water	O
/	O
DMSO	O
1	O
/	O
9	O
)	O
.	O

A	O
white	O
turbidity	O
appears	O
in	O
these	O
solutions	O
only	O
after	O
several	O
hours	O
due	O
to	O
slow	O
hydrolysis	O
.	O

Compounds	O
1	O
7	O
were	O
characterized	O
by	O
multinuclear	O
NMR	O
spectroscopy	O
.	O

The	O
NMR	O
parameters	O
are	O
given	O
in	O
Table	O
2	O
.	O

Table	O
2	O
.	O

Resonances	O
of	O
13C	O
,	O
(	O
ca	O
20	O
%	O
sol	O
.	O
v	O
/	O
v	O
)	O
1	O
'	O
compound	O

SN	O
and	O
ll9Sn	O
NMR	O
spectra	O
of	O
2	O

the	O
compounds	O
1	O
-	O
7	O
in	O
CDCI3	O
5	O
86	O
.	O
3	O
13	O
.	O
45	O

6	O
'	O
'	O
S	O
'	O
n	O
)	O
,	O
"	O
ppm	O
6	O
(	O
3c	O
)	O
a	O
,	O
ppm	O

x	O

77	O
.	O
6	O
12	O
.	O
3	O

77	O
.	O
5	O
12	O
.	O
75	O

3	O
-	O
28	O
.	O
9	O
22	O
.	O
38	O

38	O
.	O
'	O
18	O
.	O
78	O

4	O

6	O
'	O
'	O
89	O
.	O
5	O
13	O
.	O
45	O

7	O
93	O
.	O
2	O
13	O
.	O
60	O

(	O
332	O
)	O
27	O
.	O
93	O

(	O
331	O
)	O
27	O
.	O
97	O

(	O
495	O
)	O
28	O
.	O
27	O

(	O
438	O
)	O
27	O
.	O
51	O

(	O
322	O
)	O
28	O
.	O
30	O

(	O
350	O
)	O
28	O
.	O
34	O

(	O
339	O
)	O
28	O
.	O
47	O

(	O
21	O
.	O
3	O
)	O
26	O
.	O
32	O

(	O
21	O
.	O
1	O
)	O
26	O
.	O
38	O

(	O
28	O
.	O
4	O
)	O
26	O
.	O
42	O

(	O
26	O
.	O
4	O
)	O
25	O
.	O
90	O

(	O
21	O
.	O
4	O
)	O
26	O
.	O
85	O

(	O
21	O
.	O
3	O
)	O
26	O
.	O
81	O

(	O
22	O
.	O
0	O
)	O
26	O
.	O
91	O

(	O
59	O
.	O
6	O
)	O
12	O
.	O
89	O

(	O
59	O
.	O
8	O
)	O
12	O
.	O
95	O

(	O
87	O
.	O
1	O
)	O
13	O
.	O
35	O

(	O
83	O
.	O
8	O
)	O
12	O
.	O
82	O

(	O
62	O
.	O
7	O
)	O
13	O
.	O
45	O

(	O
61	O
.	O
4	O
)	O
13	O
.	O
58	O

62	O
.	O
2	O
)	O
14	O
.	O
00	O

(	O
-	O
)	O
30	O
.	O
31	O
45	O
.	O
02	O

(	O
-	O
)	O
23	O
.	O
59	O
63	O
.	O
12	O
44	O
.	O
71	O

(	O
-	O
)	O
30	O
.	O
04	O
44	O
.	O
44	O

(	O
-	O
)	O
23	O
.	O
84	O
61	O
.	O
84	O
44	O
.	O
46	O

(	O
-	O
)	O
23	O
.	O
92	O
43	O
.	O
08	O

(	O
-	O
;	O

(	O
-	O
)	O

20	O
.	O
94	O
19	O
.	O
70	O
60	O
.	O
94	O
69	O
.	O
49	O
43	O
.	O
42	O
54	O
.	O
18	O
39	O
.	O
15	O
39	O
.	O
16	O
-	O
360	O
.	O
4	O
-	O
354	O
.	O
0	O
-	O
355	O
.	O
3	O
-	O
354	O
.	O
4	O
-	O
349	O
.	O
4	O
-	O
344	O
.	O
2	O
-	O
325	O
.	O
8	O
1	O
.	O
1	O
6	O
.	O
2	O
1	O
.	O
5	O
1	O
.	O
5	O
12	O
.	O
7	O
11	O
.	O
7	O
30	O
.	O
1	O
13	O
a	O
'	O
values	O
of	O
nJ	O
(	O
n	O
J	O
9	O
Sn	O
,	O
,	O
C	O
)	O
c0uplihg	O
constants	O
in	O
Hz	O
'	O
for	O
Carbon	O
ato	O
]	O
ns	O
in	O
parentlee	O
'	O
s	O
difference	O
btween	O
(	O
N	O
)	O
for	O
the	O
organo	O
.	O
i	O
compound	O
and	O
free	O
cysteamine	O
,	O
6	O
(	O
N	O
)	O
361	O
.	O
5	O
ppm	O
;	O
N	O
,	O
N	O
-	O
dimethylcysteamine	O
,	O
5	O
(	O
N	O
)	O
-	O
355	O
.	O
9	O
ppm	O
)	O
not	O
observed	O

C	O
resonances	O
were	O
assigned	O
on	O
the	O
basis	O
of	O
the	O
values	O
of	O
n	O
J	O
(	O
119	O
Sn	O
,	O
13	O
C	O
)	O
coupling	O
constants	O
and	O
standard	O
13	O
C	O
-	O
APT	O
techniques	O
utilization	O
in	O
agreement	O
with	O
ref	O
.	O
.	O

The	O
values	O
of	O
119	O
Sn	O
chemical	O
shifts	O
are	O
found	O
in	O
the	O
interval	O
characteristic	O
for	O
fourcoordinated	O
tin	O
6	O
,	O
7	O
.	O

The	O
values	O
of	O
the	O
coupling	O
constants	O
j	O
(	O
1	O
lqSn	O
,	O
13C	O
)	O
agree	O
with	O
the	O
structure	O
proposed	O
.	O

Compound	O
3	O
is	O
characterized	O
by	O
a	O
somewhat	O
larger	O
upfield	O
shift	O
,	O
close	O
to	O
the	O
upper	O
limit	O
of	O
the	O
above	O
mentioned	O
interval	O
,	O
together	O
with	O
a	O
high	O
value	O
of	O
1j	O
(	O
l	O
lqSn	O
,	O
13C	O
)	O
(	O
495	O
Hz	O
)	O
.	O

67	O
The	O
C	O
-	O
Sn	O
-	O
C	O
angle	O
,	O
est	O
'	O
mated	O
,	O
from	O
this	O
value	O
of	O
coupling	O
constant	O
is	O
124	O
According	O
to	O
ref	O
.	O
this	O
behaviour	O
can	O
be	O
due	O
to	O
intermolecular	O
association	O
increasing	O
the	O
coordinatitn	O
number	O
of	O
tin	O
in	O
concentrated	O
solutions	O
,	O
as	O
suggested	O
by	O
the	O
concentration	O
dependence	O
of	O
tS	O
(	O
Sn	O
)	O
and	O
cryoscopic	O
measurements	O
in	O
benzene	O
.	O

The	O
values	O
of	O
the	O
6	O
(	O
SN	O
)	O
chemical	O
shifts	O
of	O
compounds	O
1	O
,	O
2	O
and	O
4	O
only	O
slightly	O
differ	O
from	O
the	O
(	O
15N	O
)	O
values	O
of	O
the	O
free	O
cysteamine	O
.	O

The	O
significantly	O
larger	O
i	O
(	O
15N	O
)	O
chemical	O
shift	O
of	O
compound	O
3	O
is	O
however	O
much	O
lower	O
than	O
those	O
of	O
compounds	O
5	O
,	O
6	O
and	O
7	O
containing	O
a	O
N	O
interaction	O
in	O
compounds	O
1	O
tetracoordinated	O
nitrogen	O
atom	O
.	O

It	O
can	O
be	O
stated	O
that	O
the	O
Sn	O
4	O
is	O
negligible	O
or	O
only	O
very	O
weak	O
in	O
chlorofom	O
solutions	O
.	O

This	O
conclusion	O
is	O
not	O
in	O
contradiction	O
with	O
the	O
proved	O
Sn	O
N	O
interaction	O
found	O
in	O
the	O
solid	O
state	O
8	O
.	O

13	O

.	O

,	O

234	O

Metal	O
Based	O
Drugs	O

Vol	O
.	O

7	O
,	O
Nr	O
.	O

5	O
,	O
2000	O

Antitumour	O
activity	O
.	O

The	O
results	O
of	O
the	O
in	O
vitro	O
antitumour	O
tests	O
of	O
compounds	O
1	O
7	O
are	O
given	O
in	O
Table	O
3	O
as	O
the	O
inhibition	O
doses	O
IDs0	O
observed	O
against	O
a	O
panel	O
of	O
seven	O
human	O
tumour	O
cell	O
lines	O
,	O
MCF	O
-	O
7	O
and	O
EVSA	O
-	O
T	O
,	O
two	O
breast	O
cancers	O
,	O
WiDr	O
,	O
a	O
colon	O
cancer	O
,	O
IGROV	O
,	O
an	O
ovarian	O
cancer	O
,	O
M19	O
MEL	O
,	O
a	O
melanoma	O
,	O
A248	O
,	O
a	O
renal	O
cancer	O
,	O
and	O
H226	O
,	O
a	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

The	O
antitumour	O
tests	O
results	O
are	O
compared	O
with	O
those	O
obtained	O
for	O
clinically	O
used	O
reference	O
compounds9	O
like	O
cisplatin	O
,	O
doxorubicin	O
,	O
etoposide	O
,	O
5	O
-	O
fluorouracil	O
and	O
methotrexate	O
.	O

Table	O
3	O
.	O

Inhibition	O
doses	O

comp	O
.	O

1	O
2	O
3	O
4	O
5	O
6	O
7	O

MF	O
-	O
7	O
41	O
41	O
51	O
78	O
30	O
90	O
385	O
699	O
10	O
2	O
594	O
750	O
18	O

EVSA	O
-	O
T	O
33	O
35	O
45	O
65	O
<	O
3	O
57	O
367	O

IDs0	O
of	O
compounds	O
WiDr	O
39	O
39	O
211	O
331	O
19	O
40	O
339	O

1	O
-	O
7	O
and	O
of	O
five	O
reference	O
compounds	O
.	O

IGROV	O
M19MEL	O
A498	O
H226	O
67	O
44	O
85	O
39	O
46	O
78	O
88	O
39	O
68	O
70	O
118	O
72	O
110	O
129	O
108	O
112	O
31	O
29	O
36	O
42	O
83	O
133	O
77	O
111	O
327	O
758	O
576	O
411	O
169	O
60	O
580	O
297	O
7	O
558	O
16	O
505	O
442	O
23	O

cisplatin	O
doxorubicin	O

etoposide	O
5	O
-	O
fluorouracil	O

422	O
8	O
317	O
475	O
5	O

methotrexate	O

967	O
11	O
150	O
225	O
<	O
3	O

2	O
253	O
90	O
314	O
143	O
37	O

3	O
369	O
199	O
3	O
934	O
340	O
2	O
287	O

It	O
is	O
evident	O
from	O
Table	O
3	O
that	O
all	O
studied	O
compounds	O
exhibit	O
excellent	O
cytostatic	O
activities	O
,	O
except	O
compound	O
7	O
showing	O
only	O
moderate	O
activity	O
.	O

Compounds	O
1	O
6	O
are	O
more	O
active	O
than	O
cisplatin	O
and	O
,	O
in	O
most	O
cases	O
,	O
than	O
etoposide	O
and	O
5	O
-	O
fluorouracil	O
.	O

Their	O
activity	O
is	O
lower	O
than	O
that	O
of	O
doxorubicin	O
and	O
methotrexate	O
in	O
most	O
cases	O
for	O
the	O
studied	O
cancer	O
cell	O
lines	O
.	O

The	O
very	O
limited	O
set	O
of	O
acquired	O
activity	O
values	O
show	O
that	O
the	O
activity	O
of	O
tri	O
-	O
n	O
-	O
butyltin	O
are	O
higher	O
than	O
those	O
of	O
di	O
-	O
n	O
-	O
butyl	O
analogues	O
(	O
1	O
>	O
3	O
,	O
2	O
>	O
4	O
)	O
for	O
all	O
cell	O
lines	O
,	O
especially	O
compounds	O
against	O
WiDr	O
.	O

The	O
N	O
,	O
N	O
-	O
dimethyl	O
derivatives	O
exhibit	O
an	O
activity	O
comparable	O
to	O
or	O
somewhat	O
higher	O
than	O
that	O
of	O
unmethylated	O
compounds	O
.	O

Compound	O
8	O
,	O
with	O
a	O
quaternized	O
nitrogen	O
,	O
exhibits	O
the	O
lowest	O
cytotoxic	O
activities	O
,	O
approximatively	O
9	O
times	O
lower	O
than	O
compound	O
2	O
.	O

It	O
might	O
be	O
underlined	O
that	O
the	O
ionic	O
more	O
water	O
-	O
soluble	O
compounds	O
5	O
and	O
6	O
are	O
not	O
more	O
active	O
than	O
the	O
uncharged	O
analogs	O
1	O
-	O
4	O
,	O
whereas	O
the	O
hydrophilic	O
organotin	O
polyoxacarboxylates	O
exhibit	O
much	O
higher	O
in	O
vitro	O
activities	O
than	O
other	O
organotin	O
carxylates	O
51	O
Compounds	O
5	O
and	O
6	O
(	O
with	O
a	O
protonated	O
nitrogen	O
)	O
exhibit	O
activities	O
comparable	O
or	O
even	O
considerably	O
higher	O
(	O
compound	O
5	O
)	O
against	O
EVSA	O
-	O
T	O
than	O
the	O
corresponding	O
unprotonated	O
compounds	O
.	O

Compound	O
7	O
(	O
with	O
a	O
quaternized	O
nitrogen	O
)	O
exhibits	O
the	O
lowest	O
cytostatic	O
activities	O
,	O
approximately	O
9	O
times	O
should	O
however	O
be	O
mentioned	O
that	O
another	O
ionic	O
organotin	O
lower	O
than	O
compound	O
2	O
.	O

It	O
compound	O
,	O
bis	O
(	O
dicyclohexyl	O
)	O
ammonium	O
bis	O
(	O
2	O
,	O
6	O
-	O
pyridinecarboxyla	O
,	O
to	O
)	O
di	O
-	O
n	O
-	O
butylstannate	O
,	O
where	O
the	O
organotin	O
moiety	O
is	O
this	O
time	O
anionic	O
,	O
is	O
also	O
as	O
active	O
as	O
the	O
uncharged	O
analog	O
l	O
.	O

All	O
NMR	O
spectra	O
were	O
recorded	O
on	O
a	O
Bruker	O
AMX	O
360	O
instrument	O
using	O
a	O
5	O
mm	O
multinuclear	O
tuneable	O
probe	O
.	O

The	O
residual	O
CHCI3	O
resonance	O
at	O
7	O
.	O
24	O
ppm	O
was	O
used	O
as	O
reference	O
for	O
the	O
H	O
soectra	O
and	O
the	O
central	O
13CDCI3	O
resonance	O
at	O
77	O
.	O
0	O
ppm	O
,	O
for	O
the	O
13C	O
spectra	O
.	O

The	O
119	O
Sn	O
chemical	O
shifts	O
were	O
refered	O
to	O
the	O
external	O
tetramethyltin	O
[	O
6	O
(	O
119	O
Sn	O
)	O
0	O
.	O
0	O
]	O
.	O

The	O
15N	O
NMR	O
spectra	O
were	O
measur	O
;	O
l	O
using	O
the	O
INEPT	O
technique	O
or	O
in	O
inverse	O
-	O
gated	O
mode	O
.	O

(	O
reference	O
:	O
Instrumentation	O
.	O

external	O
nitromethane	O
,	O
[	O
5	O
(	O
'	O
N	O
)	O
0	O
.	O
0	O
]	O
)	O
.	O

The	O
protocol	O
followed	O
for	O
the	O
in	O
vitro	O
antitumour	O
screenings	O
has	O
been	O
already	O
reported	O
10	O
.	O

Acknowledgements	O
.	O

K	O
.	O

H	O
.	O
and	O
M	O
H	O
.	O
thank	O
the	O
Grant	O
Agency	O
of	O
the	O
Czech	O
Republic	O
(	O
Grant	O
No	O
.	O
203	O
/	O
00	O
/	O
0920	O
)	O
and	O
the	O
Ministry	O
o	O
"	O
Education	O
,	O
Youth	O
and	O
Sport	O
of	O
the	O
Czech	O
republic	O
,	O
associated	O
with	O
EU	O
in	O
the	O
COST	O
8	O
.	O
20	O
program	O
for	O
financial	O
support	O
of	O
this	O
work	O
.	O

We	O
are	O
grateful	O
to	O
Mr	O
.	O
R	O
.	O

G	O
.	O

Experimental	O
Oostrum	O
,	O
Dr	O
.	O
J	O
.	O
verweij	O
,	O
Prof	O
.	O

Dr	O
.	O
G	O
.	O

Stoter	O
,	O
r	O
.	O
K	O
.	O

Nooter	O
,	O
Laboratory	O
of	O
Chemotherapy	O
and	O
Pharmacology	O
,	O
Department	O
of	O
Medical	O
Oncology	O
,	O
Rotterdam	O
Cancer	O
235	O

M	O
.	O

Gielen	O
,	O
K	O
.	O

Handlir	O
,	O
M	O
.	O

HoHein	O
and	O
D	O
.	O

de	O
Vos	O
Synthesis	O
,	O
Characterization	O
and	O
Antitumor	O
Activity	O
ofSome	O
Butyltin	O
(	O
IV	O
)	O
Cysteaminates	O
and	O
N	O
,	O
N	O
-	O
Dimethylcysteaminates	O

Institute	O
,	O
NL	O
3008	O
AE	O
,	O
Rotterdam	O
,	O
The	O
Netherlands	O
,	O
for	O
performing	O
the	O
in	O
vitro	O
tests	O
.	O

This	O
research	O
was	O
supported	O
by	O
the	O
Fund	O
for	O
Scientific	O
Research	O
Flanders	O
(	O
Belgium	O
)	O
,	O
grant	O
nr	O
G	O
.	O
0074	O
.	O
00	O
,	O
M	O
.	O

G	O
.	O
)	O
.	O

References	O
.	O

1	O
.	O

B	O
.	O
S	O
.	O

Saraswat	O
,	O
J	O
.	O

Mason	O
,	O
Polyhedron	O
(	O
9	O
)	O
,	O
5	O
(	O
1986	O
)	O
,	O
1449	O
.	O

2	O
.	O

G	O
.	O

Domazetis	O
,	O
R	O
.	O

J	O
.	O

Magee	O
,	O
B	O
.	O

D	O
.	O

James	O
,	O
J	O
.	O

Organomet	O
.	O

Chem	O
,	O
162	O
(	O
1978	O
)	O
,	O
239	O
.	O

3	O
.	O

J	O
.	O
D	O
.	O

Cashion	O
,	O
G	O
.	O

Domazetis	O
,	O
B	O
.	O

D	O
.	O

James	O
,	O
J	O
.	O

Organomet	O
.	O

Chem	O
,	O
185	O
(	O
1980	O
)	O
,	O
433	O
.	O

4	O
.	O

G	O
.	O

Domazetis	O
,	O
R	O
.	O

J	O
.	O

Magee	O
,	O
B	O
.	O

D	O
.	O

James	O
,	O
J	O
.	O

Organomet	O
.	O

Chem	O
,	O
148	O
(	O
1978	O
)	O
,	O
339	O
.	O

5	O
.	O

G	O
.	O

Atassi	O
,	O
Rev	O
.	O

Si	O
Ge	O
Sn	O
Pb	O
Cpds	O
,	O
8	O
(	O
1985	O
)	O
,	O
219	O
;	O
M	O
.	O

Kemmer	O
,	O
M	O
.	O

Gielen	O
,	O
M	O
.	O

Biesemans	O
,	O
D	O
.	O

de	O
Vos	O
,	O
R	O
.	O

Willem	O
,	O
Metal	O
-	O
Based	O
Drugs	O
5	O
(	O
1998	O
)	O
,	O
189	O
;	O
M	O
.	O

Gielen	O
,	O
M	O
.	O

Biesemans	O
,	O
D	O
.	O

de	O
Vos	O
,	O
R	O
.	O

Willem	O
,	O
J	O
.	O

Inorg	O
.	O

Biochem	O
.	O
,	O
79	O
(	O
2000	O
)	O
,	O
139	O
.	O

6	O
.	O

J	O
.	O

Holecek	O
,	O
A	O
.	O

Lycka	O
,	O
Inorg	O
.	O

Chim	O
.	O

Acta	O
,	O
118	O
(	O
1986	O
)	O
,	O
L	O
15	O
.	O

7	O
.	O

J	O
.	O

Holecek	O
,	O
M	O
.	O

Nadvomik	O
,	O
K	O
.	O

Handlir	O
,	O
A	O
.	O

Lycka	O
,	O
J	O
.	O

Organomet	O
.	O

Chem	O
.	O
,	O
315	O
(	O
1986	O
)	O
,	O
299	O
.	O

8	O
.	O

B	O
.	O
D	O
.	O

James	O
,	O
R	O
.	O

J	O
.	O

Magee	O
,	O
W	O
.	O

C	O
.	O

Patalinghug	O
,	O
B	O
.	O

W	O
.	O

Skelton	O
,	O
A	O
.	O

H	O
.	O

White	O
,	O
J	O
.	O

Organomet	O
.	O

Chem	O
,	O
467	O
(	O
1994	O
)	O
,	O
51	O
9	O
.	O

P	O
.	O

Skehan	O
,	O
R	O
.	O

Storeng	O
,	O
D	O
.	O

Scudiero	O
,	O
A	O
.	O

Monks	O
,	O
J	O
.	O

McMahon	O
,	O
D	O
.	O

Vistica	O
,	O
J	O
.	O

T	O
.	O

Warren	O
,	O
H	O
.	O

Bokesh	O
,	O
S	O
.	O

Kenney	O
,	O
M	O
.	O

R	O
.	O

Boyd	O
,	O
J	O
.	O
.	O

Natl	O
.	O

Cancer	O
lnst	O
.	O
,	O
82	O
(	O
1990	O
)	O
,	O
1107	O
.	O

10	O
.	O

Y	O
.	O

P	O
.	O

Kepers	O
,	O
G	O
.	O

J	O
.	O

Peters	O
,	O
J	O
.	O

Van	O
Ark	O
-	O
Otte	O
,	O
B	O
.	O

Winograd	O
,	O
H	O
.	O

M	O
.	O

Pinedo	O
,	O
Eur	O
.	O

J	O
.	O

Cancer	O
,	O
27	O
(	O
1991	O
)	O
,	O
897	O
.	O

11	O
.	O

M	O
.	O

Kemmer	O
,	O
L	O
.	O

Ghys	O
,	O
M	O
.	O

Gielen	O
,	O
M	O
.	O

Biesemans	O
,	O
E	O
.	O

R	O
.	O

T	O
.	O

Tiekink	O
,	O
R	O
.	O

Willem	O
,	O
J	O
.	O

Organomet	O
.	O

Chem	O
.	O

582	O
(	O
1999	O
)	O
,	O
195	O
.	O

12	O
.	O

S	O
.	O

W	O
.	O

Ng	O
,	O
V	O
.	O

G	O
.	O

Kumar	O
Das	O
,	O
J	O
.	O

Holecek	O
,	O
A	O
.	O

Lycka	O
,	O
M	O
.	O

Gielen	O
,	O
M	O
.	O

G	O
.	O

B	O
.	O

Drew	O
,	O
Appl	O
.	O

Organomet	O
.	O

Chem	O
.	O

11	O
(	O
1997	O
)	O
,	O
3	O
9	O
.	O

Received	O
"	O
September	O
22	O
,	O
2000	O
Accepted	O
-	O
October	O
19	O
,	O
2000	O
Received	O
in	O
revised	O
camera	O
-	O
ready	O
format	O
-	O
October	O
20	O
,	O
2000	O

236	O

Genomic	O
-	O
Bioinformatic	O
Analysis	O
of	O
Transcripts	O
Enriched	O
in	O
the	O
Third	O
-	O
Stage	O
Larva	O
of	O
the	O
Parasitic	O
Nematode	O
Ascaris	B-Species
suum	E-Species

Abstract	O

Differential	O
transcription	O
in	O
Ascaris	B-Species
suum	E-Species
was	O
investigated	O
using	O
a	O
genomic	O
-	O
bioinformatic	O
approach	O
.	O

A	O
cDNA	O
archive	O
enriched	O
for	O
molecules	O
in	O
the	O
infective	O
third	O
-	O
stage	O
larva	O
(	O
L3	O
)	O
of	O
A	B-Species
.	I-Species
suum	E-Species
was	O
constructed	O
by	O
suppressive	O
-	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
,	O
and	O
a	O
subset	O
of	O
cDNAs	O
from	O
3075	O
clones	O
subjected	O
to	O
microarray	O
analysis	O
using	O
cDNA	O
probes	O
derived	O
from	O
RNA	O
from	O
different	O
developmental	O
stages	O
of	O
A	B-Species
.	I-Species
suum	E-Species
.	O

The	O
cDNAs	O
(	O
n	O
=	O
498	O
)	O
shown	O
by	O
microarray	O
analysis	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
were	O
sequenced	O
and	O
subjected	O
to	O
bioinformatic	O
analyses	O
using	O
a	O
semi	O
-	O
automated	O
pipeline	O
(	O
ESTExplorer	O
)	O
.	O

Using	O
gene	O
ontology	O
(	O
GO	O
)	O
,	O
235	O
of	O
these	O
molecules	O
were	O
assigned	O
to	O
'	O
biological	O
process	O
'	O
(	O
n	O
=	O
68	O
)	O
,	O
'	O
cellular	O
component	O
'	O
(	O
n	O
=	O
50	O
)	O
,	O
or	O
'	O
molecular	O
function	O
'	O
(	O
n	O
=	O
117	O
)	O
.	O

Of	O
the	O
91	O
clusters	O
assembled	O
,	O
56	O
molecules	O
(	O
61	O
.	O
5	O
%	O
)	O
had	O
homologues	O
/	O
orthologues	O
in	O
the	O
free	O
-	O
living	O
nematodes	O
Caenorhabditis	B-Species
elegans	E-Species
and	O
C	B-Species
.	I-Species
briggsae	E-Species
and	O
/	O
or	O
other	O
organisms	O
,	O
whereas	O
35	O
(	O
38	O
.	O
5	O
%	O
)	O
had	O
no	O
significant	O
similarity	O
to	O
any	O
sequences	O
available	O
in	O
current	O
gene	O
databases	O
.	O

Transcripts	O
encoding	O
protein	O
kinases	O
,	O
protein	O
phosphatases	O
(	O
and	O
their	O
precursors	O
)	O
,	O
and	O
enolases	O
were	O
abundantly	O
represented	O
in	O
the	O
L3	O
of	O
A	B-Species
.	I-Species
suum	E-Species
,	O
as	O
were	O
molecules	O
involved	O
in	O
cellular	O
processes	O
,	O
such	O
as	O
ubiquitination	O
and	O
proteasome	O
function	O
,	O
gene	O
transcription	O
,	O
protein	O
-	O
protein	O
interactions	O
,	O
and	O
function	O
.	O

In	O
silico	O
analyses	O
inferred	O
the	O
C	B-Species
.	I-Species
elegans	E-Species
orthologues	O
/	O
homologues	O
(	O
n	O
=	O
50	O
)	O
to	O
be	O
involved	O
in	O
apoptosis	O
and	O
insulin	O
signaling	O
(	O
2	O
%	O
)	O
,	O
ATP	O
synthesis	O
(	O
2	O
%	O
)	O
,	O
carbon	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
fatty	O
acid	O
biosynthesis	O
(	O
2	O
%	O
)	O
,	O
gap	O
junction	O
(	O
2	O
%	O
)	O
,	O
glucose	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
or	O
porphyrin	O
metabolism	O
(	O
2	O
%	O
)	O
,	O
although	O
34	O
(	O
68	O
%	O
)	O
of	O
them	O
could	O
not	O
be	O
mapped	O
to	O
a	O
specific	O
metabolic	O
pathway	O
.	O

Small	O
numbers	O
of	O
these	O
50	O
molecules	O
were	O
predicted	O
to	O
be	O
secreted	O
(	O
10	O
%	O
)	O
,	O
anchored	O
(	O
2	O
%	O
)	O
,	O
and	O
/	O
or	O
transmembrane	O
(	O
12	O
%	O
)	O
proteins	O
.	O

Functionally	O
,	O
17	O
(	O
34	O
%	O
)	O
of	O
them	O
were	O
predicted	O
to	O
be	O
associated	O
with	O
(	O
non	O
-	O
wild	O
-	O
type	O
)	O
RNAi	O
phenotypes	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
the	O
majority	O
being	O
embryonic	O
lethality	O
(	O
Emb	O
)	O
(	O
13	O
types	O
;	O
58	O
.	O
8	O
%	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
(	O
23	O
.	O
5	O
%	O
)	O
and	O
larval	O
lethality	O
(	O
Lvl	O
)	O
(	O
47	O
%	O
)	O
.	O

A	O
genetic	O
interaction	O
network	O
was	O
predicted	O
for	O
these	O
17	O
C	B-Species
.	I-Species
elegans	E-Species
orthologues	O
,	O
revealing	O
highly	O
significant	O
interactions	O
for	O
nine	O
molecules	O
associated	O
with	O
embryonic	O
and	O
larval	O
development	O
(	O
66	O
.	O
9	O
%	O
)	O
,	O
information	O
storage	O
and	O
processing	O
(	O
5	O
.	O
1	O
%	O
)	O
,	O
cellular	O
processing	O
and	O
signaling	O
(	O
15	O
.	O
2	O
%	O
)	O
,	O
metabolism	O
(	O
6	O
.	O
1	O
%	O
)	O
,	O
and	O
unknown	O
function	O
(	O
6	O
.	O
7	O
%	O
)	O
.	O

The	O
potential	O
roles	O
of	O
these	O
molecules	O
in	O
development	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
known	O
roles	O
of	O
their	O
homologues	O
/	O
orthologues	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
and	O
some	O
other	O
nematodes	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
provide	O
a	O
basis	O
for	O
future	O
functional	O
genomic	O
studies	O
to	O
elucidate	O
molecular	O
aspects	O
governing	O
larval	O
developmental	O
processes	O
in	O
A	B-Species
.	I-Species
suum	E-Species
and	O
/	O
or	O
the	O
transition	O
to	O
parasitism	O
.	O

Introduction	O

Parasitic	O
nematodes	O
are	O
of	O
major	O
socio	O
-	O
economic	O
importance	O
in	O
animals	O
.	O

For	O
example	O
,	O
hundreds	O
of	O
millions	O
of	O
people	S-Species
are	O
infected	O
with	O
geohelminths	O
(	O
soil	O
-	O
transmitted	O
worms	O
)	O
,	O
such	O
as	O
blood	O
-	O
feeding	O
hookworms	O
Ancylostoma	B-Species
duodenale	E-Species
and	O
/	O
or	O
Necator	B-Species
americanus	E-Species
,	O
Trichuris	B-Species
trichiura	E-Species
and	O
Ascaris	O
spp	O
.	O

[	O
1	O
]	O
,	O
causing	O
serious	O
adverse	O
effects	O
on	O
human	S-Species
health	O
,	O
particularly	O
in	O
children	S-Species
.	O

Similarly	O
,	O
parasitic	O
nematodes	O
of	O
livestock	O
,	O
such	O
as	O
pigs	S-Species
,	O
also	O
cause	O
substantial	O
economic	O
losses	O
due	O
to	O
subclinical	O
and	O
clinical	O
diseases	O
,	O
with	O
billions	O
of	O
dollars	O
spent	O
annually	O
on	O
the	O
treatment	O
and	O
control	O
of	O
gastro	O
-	O
intestinal	O
nematodes	O
.	O

In	O
addition	O
to	O
the	O
socioeconomic	O
impact	O
that	O
these	O
parasites	O
have	O
,	O
there	O
is	O
potential	O
for	O
the	O
emergence	O
of	O
resistance	O
in	O
them	O
against	O
all	O
of	O
the	O
main	O
classes	O
of	O
(	O
nematocidal	O
)	O
compounds	O
used	O
to	O
treat	O
the	O
diseases	O
they	O
cause	O
[	O
2	O
]	O
-	O
[	O
5	O
]	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
significant	O
need	O
to	O
work	O
toward	O
discovering	O
new	O
compounds	O
to	O
control	O
these	O
parasites	O
.	O

Gaining	O
an	O
improved	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
parasite	O
development	O
provides	O
such	O
an	O
avenue	O
.	O

Compared	O
with	O
the	O
free	O
-	O
living	O
nematode	O
Caenorhabditis	B-Species
elegans	E-Species
,	O
there	O
is	O
very	O
little	O
information	O
on	O
fundamental	O
molecular	O
aspects	O
of	O
development	O
in	O
parasitic	O
nematodes	O
[	O
6	O
]	O
-	O
[	O
8	O
]	O
.	O

Since	O
the	O
genome	O
sequence	O
of	O
C	B-Species
.	I-Species
elegans	E-Species
was	O
published	O
in	O
1998	O
[	O
9	O
]	O
,	O
many	O
aspects	O
of	O
the	O
molecular	O
biology	O
of	O
this	O
nematode	O
have	O
been	O
elucidated	O
.	O

For	O
instance	O
,	O
microarray	O
analyses	O
have	O
been	O
used	O
to	O
examine	O
developmental	O
and	O
gender	O
-	O
enriched	O
gene	O
expression	O
[	O
10	O
]	O
,	O
[	O
11	O
]	O
,	O
and	O
the	O
functions	O
of	O
more	O
than	O
96	O
%	O
of	O
the	O
C	B-Species
.	I-Species
elegans	E-Species
genes	O
have	O
been	O
assessed	O
by	O
double	O
-	O
stranded	O
RNA	O
interference	O
(	O
RNAi	O
,	O
or	O
gene	O
silencing	O
;	O
[	O
12	O
]	O
)	O
[	O
13	O
]	O
-	O
[	O
18	O
]	O
.	O

Comparative	O
analyses	O
of	O
genetic	O
data	O
sets	O
have	O
shown	O
that	O
parasitic	O
nematodes	O
usually	O
share	O
~	O
50	O
-	O
70	O
%	O
of	O
genes	O
with	O
C	B-Species
.	I-Species
elegans	E-Species
(	O
e	O
.	O
g	O
.	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
)	O
.	O

There	O
is	O
similarity	O
in	O
other	O
features	O
(	O
such	O
as	O
basic	O
body	O
plan	O
and	O
moulting	O
)	O
between	O
C	B-Species
.	I-Species
elegans	E-Species
and	O
parasitic	O
nematodes	O
,	O
suggesting	O
that	O
some	O
molecular	O
pathways	O
are	O
relatively	O
conserved	O
[	O
8	O
]	O
,	O
[	O
21	O
]	O
.	O

Understanding	O
the	O
pathways	O
linked	O
to	O
basic	O
nematode	O
biology	O
and	O
development	O
could	O
have	O
important	O
implications	O
for	O
finding	O
new	O
ways	O
of	O
disrupting	O
these	O
pathways	O
and	O
thus	O
facilitate	O
the	O
identification	O
of	O
new	O
drug	O
targets	O
.	O

Despite	O
the	O
advances	O
in	O
genomic	O
technologies	O
[	O
7	O
]	O
,	O
[	O
22	O
]	O
-	O
[	O
29	O
]	O
and	O
the	O
study	O
of	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
there	O
is	O
a	O
paucity	O
of	O
information	O
on	O
the	O
genomics	O
of	O
parasitic	O
nematodes	O
of	O
animals	O
,	O
particularly	O
in	O
relation	O
to	O
development	O
.	O

Also	O
considering	O
the	O
major	O
socioeconomic	O
impact	O
of	O
Ascaris	O
and	O
ascariasis	O
in	O
humans	S-Species
and	O
pigs	S-Species
[	O
30	O
]	O
-	O
[	O
32	O
]	O
,	O
several	O
characteristics	O
,	O
including	O
the	O
large	O
size	O
of	O
the	O
adult	O
worm	O
(	O
providing	O
the	O
opportunity	O
of	O
investigating	O
individual	O
organ	O
systems	O
and	O
tissues	O
)	O
,	O
the	O
ability	O
to	O
maintain	O
Ascaris	O
in	O
the	O
pig	S-Species
,	O
store	O
eggs	O
and	O
culture	O
larvae	O
in	O
vitro	O
for	O
relatively	O
long	O
periods	O
of	O
time	O
(	O
months	O
to	O
years	O
)	O
[	O
32	O
]	O
as	O
well	O
as	O
the	O
discovery	O
that	O
RNAi	O
achieves	O
"	O
cross	O
-	O
species	O
"	O
gene	O
silencing	O
for	O
a	O
selected	O
number	O
of	O
genes	O
[	O
33	O
]	O
,	O
[	O
34	O
]	O
and	O
the	O
imminent	O
genome	O
sequence	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
sanger	O
.	O
ac	O
.	O
uk	O
/	O
Projects	O
/	O
Helminths	O
/	O
)	O
all	O
indicate	O
that	O
Ascaris	O
could	O
serve	O
as	O
a	O
powerful	O
model	O
system	O
for	O
investigating	O
reproductive	O
and	O
developmental	O
processes	O
in	O
nematodes	O
.	O

In	O
the	O
present	O
study	O
,	O
Ascaris	O
from	O
pigs	S-Species
was	O
used	O
to	O
study	O
molecules	O
abundantly	O
transcribed	O
in	O
the	O
infective	O
third	O
-	O
stage	O
larva	O
(	O
L3	O
)	O
.	O

Following	O
the	O
oral	O
ingestion	O
of	O
Ascaris	O
eggs	O
by	O
the	O
host	O
(	O
human	S-Species
or	O
pig	S-Species
)	O
,	O
L3s	O
are	O
released	O
and	O
then	O
invade	O
/	O
penetrate	O
predominantly	O
the	O
caecal	O
wall	O
[	O
35	O
]	O
to	O
then	O
undergo	O
hepato	O
-	O
pulmonary	O
migration	O
,	O
after	O
which	O
ultimately	O
the	O
adult	O
females	O
and	O
males	O
establish	O
and	O
develop	O
in	O
the	O
small	O
intestine	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

The	O
molecular	O
mechanisms	O
linked	O
to	O
host	O
invasion	O
and	O
parasite	O
development	O
are	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
constructed	O
an	O
L3	O
-	O
enriched	O
cDNA	O
library	O
using	O
the	O
method	O
of	O
suppressive	O
-	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
,	O
explored	O
transcription	O
of	O
a	O
representative	O
subset	O
of	O
molecules	O
by	O
microarray	O
analysis	O
and	O
conducted	O
bioinformatic	O
analyses	O
to	O
characterize	O
these	O
molecules	O
,	O
map	O
them	O
to	O
biochemical	O
pathways	O
and	O
predict	O
genetic	O
interactions	O
based	O
on	O
comparisons	O
with	O
C	B-Species
.	I-Species
elegans	E-Species
and	O
/	O
or	O
other	O
organisms	O
.	O

Materials	O
and	O
Methods	O

Production	O
of	O
Different	O
Developmental	O
Stages	O
of	O
Ascaris	O

Experimental	O
pigs	S-Species
(	O
8	O
-	O
12	O
weeks	O
of	O
age	O
)	O
were	O
purchased	O
from	O
and	O
maintained	O
in	O
the	O
Experimental	O
Animal	O
Center	O
of	O
South	O
China	O
Agricultural	O
University	O
.	O

These	O
pigs	S-Species
were	O
treated	O
humanely	O
,	O
according	O
to	O
the	O
Animal	O
Ethics	O
procedures	O
and	O
guidelines	O
of	O
the	O
People	O
'	O
s	O
Republic	O
of	O
China	O
.	O

Adult	O
worms	O
(	O
males	O
and	O
females	O
)	O
of	O
A	B-Species
.	I-Species
suum	E-Species
were	O
collected	O
from	O
the	O
small	O
intestines	O
of	O
pigs	S-Species
from	O
an	O
abattoir	O
in	O
Shenzhen	O
,	O
China	O
.	O

Infective	O
eggs	O
and	O
infective	O
L3s	O
of	O
A	B-Species
.	I-Species
suum	E-Species
were	O
produced	O
according	O
to	O
the	O
methods	O
described	O
previously	O
[	O
38	O
]	O
.	O

In	O
brief	O
,	O
eggs	O
from	O
the	O
uteri	O
of	O
adult	O
females	O
of	O
A	B-Species
.	I-Species
suum	E-Species
were	O
collected	O
and	O
incubated	O
at	O
28	O
degrees	O
C	O
for	O
28	O
days	O
to	O
allow	O
them	O
to	O
develop	O
to	O
infective	O
eggs	O
(	O
containing	O
infective	O
L3s	O
)	O
.	O

To	O
obtain	O
pure	O
infective	O
L3s	O
,	O
7	O
.	O
5	O
%	O
v	O
/	O
v	O
sodium	O
hypochlorite	O
was	O
used	O
to	O
treat	O
the	O
larvated	O
eggs	O
at	O
37	O
degrees	O
C	O
overnight	O
and	O
then	O
the	O
eggs	O
were	O
shaken	O
with	O
glass	O
-	O
beads	O
;	O
then	O
,	O
the	O
exsheathed	O
L3s	O
and	O
shells	O
were	O
separated	O
by	O
density	O
gradient	O
centrifugation	O
using	O
lymphocyte	O
separating	O
medium	O
(	O
LSM	O
)	O
[	O
38	O
]	O
.	O

Following	O
the	O
experimental	O
infection	O
of	O
helminth	O
-	O
free	O
pigs	S-Species
with	O
infective	O
Ascaris	O
eggs	O
as	O
described	O
previously	O
[	O
39	O
]	O
,	O
the	O
L3s	O
from	O
livers	O
and	O
in	O
lungs	O
as	O
well	O
as	O
L4s	O
in	O
intestines	O
were	O
isolated	O
according	O
to	O
an	O
established	O
method	O
[	O
40	O
]	O
.	O

All	O
parasite	O
materials	O
were	O
snap	O
-	O
frozen	O
in	O
liquid	O
nitrogen	O
prior	O
to	O
storage	O
at	O
-	O
70	O
degrees	O
C	O
.	O

Construction	O
of	O
the	O
cDNA	O
Library	O
by	O
Subtractive	O
-	O
Suppressive	O
Hybridization	O
(	O
SSH	O
)	O

Total	O
RNA	O
was	O
isolated	O
from	O
adult	O
females	O
and	O
males	O
,	O
different	O
larval	O
stages	O
or	O
eggs	O
of	O
A	B-Species
.	I-Species
suum	E-Species
using	O
TriPure	O
reagent	O
(	O
Roche	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

Equal	O
amounts	O
of	O
total	O
RNA	O
from	O
each	O
stage	O
or	O
sex	O
were	O
pooled	O
.	O

The	O
mRNA	O
was	O
isolated	O
using	O
the	O
Oligotex	O
mRNA	O
Kit	O
(	O
Qiagen	O
)	O
,	O
following	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

SSH	O
was	O
carried	O
out	O
using	O
the	O
PCR	O
-	O
Select	O
cDNA	O
Subtraction	O
kit	O
(	O
Clontech	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

In	O
brief	O
,	O
cDNA	O
synthesized	O
from	O
mRNAs	O
from	O
infective	O
L3s	O
was	O
subtracted	O
against	O
cDNA	O
synthesized	O
from	O
the	O
pooled	O
mRNA	O
from	O
all	O
other	O
stages	O
included	O
herein	O
.	O

The	O
SSH	O
library	O
was	O
constructed	O
using	O
infective	O
L3s	O
as	O
the	O
tester	O
and	O
pooled	O
cDNAs	O
from	O
all	O
other	O
stages	O
as	O
the	O
driver	O
.	O

The	O
effectiveness	O
of	O
this	O
subtraction	O
process	O
has	O
already	O
been	O
demonstrated	O
in	O
previous	O
studies	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O

The	O
cDNA	O
obtained	O
following	O
SSH	O
was	O
cloned	O
into	O
the	O
pGEM	O
-	O
T	O
Easy	O
plasmid	O
vector	O
(	O
Promega	O
)	O
and	O
competent	O
Escherichia	B-Species
coli	E-Species
(	O
JM109	O
)	O
transformed	O
.	O

Positive	O
clones	O
,	O
picked	O
randomly	O
(	O
based	O
on	O
blue	O
/	O
white	O
selection	O
)	O
,	O
were	O
grown	O
overnight	O
in	O
Luria	O
Bertani	O
(	O
LB	O
)	O
medium	O
(	O
shaking	O
,	O
37	O
degrees	O
C	O
)	O
.	O

Individual	O
inserts	O
were	O
PCR	O
-	O
amplified	O
using	O
"	O
nested	O
primers	O
"	O
1	O
and	O
2R	O
from	O
the	O
Subtraction	O
kit	O
(	O
Clontech	O
)	O
and	O
examined	O
by	O
agarose	O
electrophoresis	O
.	O

Preparation	O
of	O
Microarray	O
Slides	O

Clones	O
(	O
n	O
=	O
3075	O
)	O
from	O
the	O
subtracted	O
library	O
were	O
picked	O
and	O
cultured	O
overnight	O
in	O
LB	O
containing	O
ampicillin	O
(	O
1000	O
IU	O
/	O
ml	O
)	O
in	O
sealed	O
96	O
-	O
well	O
blocks	O
.	O

Five	O
micro	O
l	O
of	O
culture	O
suspension	O
from	O
each	O
well	O
were	O
transferred	O
into	O
individual	O
wells	O
thermocycling	O
(	O
96	O
-	O
well	O
)	O
plates	O
and	O
the	O
inserts	O
PCR	O
-	O
amplified	O
using	O
primers	O
1	O
and	O
2R	O
.	O

Following	O
a	O
10	O
min	O
denaturation	O
step	O
at	O
94	O
degrees	O
C	O
,	O
the	O
amplification	O
proceeded	O
for	O
25	O
cycles	O
of	O
10	O
s	O
at	O
94	O
degrees	O
C	O
,	O
30	O
s	O
at	O
68	O
degrees	O
C	O
and	O
1	O
.	O
5	O
min	O
at	O
72	O
degrees	O
C	O
,	O
with	O
a	O
final	O
extension	O
for	O
5	O
min	O
at	O
72	O
degrees	O
C	O
.	O

Products	O
were	O
resolved	O
in	O
agarose	O
gels	O
,	O
ethanol	O
precipitated	O
,	O
re	O
-	O
suspended	O
in	O
16	O
micro	O
l	O
of	O
"	O
spotting	O
solution	O
"	O
(	O
Shanghai	O
BioStar	O
Genechip	O
,	O
Inc	O
)	O
to	O
a	O
final	O
concentration	O
of	O
~	O
500	O
ng	O
per	O
micro	O
l	O
,	O
before	O
being	O
printed	O
on	O
to	O
glass	O
slides	O
(	O
in	O
duplicate	O
)	O
using	O
a	O
robotic	O
arrayer	O
.	O

Sixteen	O
blanks	O
(	O
using	O
spotting	O
solution	O
only	O
)	O
and	O
the	O
same	O
number	O
of	O
negative	O
(	O
irrelevant	O
cDNAs	O
with	O
no	O
relationship	O
to	O
Ascaris	O
)	O
were	O
also	O
printed	O
on	O
to	O
slides	O
and	O
served	O
as	O
negative	O
controls	O
;	O
beta	O
-	O
actin	O
of	O
A	B-Species
.	I-Species
suum	E-Species
served	O
as	O
a	O
positive	O
control	O
to	O
assess	O
the	O
efficiency	O
of	O
labeling	O
and	O
hybridization	O
.	O

The	O
slides	O
were	O
air	O
-	O
dried	O
for	O
2	O
h	O
,	O
and	O
cDNA	O
in	O
the	O
spots	O
were	O
cross	O
-	O
linked	O
at	O
254	O
mJ	O
.	O

The	O
printed	O
slides	O
were	O
stored	O
at	O
4	O
degrees	O
C	O
.	O

Labeling	O
of	O
cDNA	O
Probes	O
with	O
Fluorescent	O
Dyes	O
,	O
and	O
Microarray	O
Analysis	O

The	O
cDNAs	O
produced	O
from	O
total	O
RNA	O
from	O
A	B-Species
.	I-Species
suum	E-Species
eggs	O
,	O
infective	O
L3s	O
,	O
L3s	O
isolated	O
from	O
pig	S-Species
liver	O
or	O
lung	O
,	O
fourth	O
-	O
stage	O
larvae	O
(	O
L4s	O
)	O
,	O
adult	O
males	O
or	O
females	O
[	O
as	O
described	O
in	O
the	O
section	O
'	O
Construction	O
of	O
the	O
cDNA	O
Library	O
by	O
Subtractive	O
-	O
Suppressive	O
Hybridization	O
(	O
SSH	O
)	O
'	O
]	O
were	O
labeled	O
with	O
cyanine	O
dyes	O
.	O

Cy3	O
or	O
Cy5	O
-	O
dCTP	O
was	O
incorporated	O
into	O
cDNA	O
produced	O
from	O
30	O
micro	O
g	O
of	O
total	O
RNA	O
by	O
direct	O
labeling	O
in	O
a	O
reverse	O
transcription	O
reaction	O
using	O
an	O
oligo	O
(	O
dT	O
)	O
primer	O
.	O

Labeled	O
cDNA	O
was	O
purified	O
using	O
DyeEx	O
columns	O
(	O
Qiagen	O
)	O
.	O

Microarray	O
slides	O
were	O
incubated	O
with	O
a	O
pre	O
-	O
hybridization	O
solution	O
[	O
5	O
x	O
SSC	O
,	O
1	O
%	O
bovine	S-Species
serum	O
albumin	O
(	O
BSA	O
)	O
,	O
0	O
.	O
1	O
%	O
sodium	O
dodecyl	O
-	O
sulphate	O
(	O
SDS	O
)	O
]	O
for	O
6	O
h	O
at	O
42	O
degrees	O
C	O
.	O

After	O
pre	O
-	O
hybridization	O
,	O
the	O
microarray	O
slides	O
were	O
incubated	O
with	O
'	O
pooled	O
'	O
Cy3	O
and	O
Cy5	O
-	O
labeled	O
probes	O
in	O
hybridization	O
solution	O
(	O
5	O
x	O
SSC	O
,	O
1	O
%	O
BSA	O
,	O
0	O
.	O
1	O
%	O
SDS	O
)	O
,	O
in	O
the	O
dark	O
at	O
42	O
degrees	O
C	O
for	O
18	O
h	O
,	O
and	O
then	O
washed	O
in	O
solution	O
I	O
(	O
1	O
x	O
SSC	O
,	O
0	O
.	O
2	O
%	O
SDS	O
)	O
for	O
10	O
min	O
,	O
followed	O
by	O
solution	O
II	O
(	O
0	O
.	O
1	O
x	O
SSC	O
,	O
0	O
.	O
2	O
%	O
SDS	O
)	O
for	O
10	O
min	O
at	O
60	O
degrees	O
C	O
,	O
according	O
to	O
the	O
protocols	O
provided	O
by	O
Shanghai	O
BioStar	O
Genechip	O
,	O
Inc	O
.	O

A	O
"	O
dye	O
flip	O
"	O
was	O
carried	O
out	O
to	O
control	O
for	O
any	O
bias	O
in	O
hybridization	O
signal	O
between	O
the	O
Cy	O
-	O
labeled	O
cDNA	O
probes	O
(	O
produced	O
for	O
two	O
distinct	O
mRNA	O
populations	O
)	O
.	O

The	O
slides	O
were	O
dried	O
and	O
scanned	O
(	O
ScanArray	O
4000	O
scanner	O
)	O
using	O
image	O
acquisition	O
software	O
(	O
Shanghai	O
BioStar	O
Genechip	O
Inc	O
.	O
)	O
and	O
a	O
range	O
of	O
laser	O
power	O
and	O
photo	O
-	O
multiplier	O
tube	O
intensities	O
.	O

The	O
mean	O
hybridization	O
signal	O
(	O
derived	O
from	O
four	O
replicates	O
of	O
the	O
same	O
array	O
)	O
were	O
corrected	O
for	O
background	O
,	O
normalized	O
[	O
43	O
]	O
,	O
log2	O
-	O
transformed	O
and	O
then	O
subjected	O
to	O
statistical	O
analysis	O
employing	O
the	O
students	O
t	O
-	O
test	O
in	O
a	O
spreadsheet	O
(	O
Excel	O
,	O
Microsoft	O
,	O
USA	O
)	O
.	O

The	O
microarray	O
data	O
were	O
analysed	O
for	O
differential	O
cDNA	O
hybridization	O
(	O
>	O
2	O
.	O
0	O
-	O
fold	O
to	O
114	O
.	O
3	O
-	O
fold	O
)	O
between	O
L3	O
and	O
each	O
of	O
the	O
other	O
stages	O
(	O
eggs	O
,	O
lung	O
and	O
liver	O
L3s	O
,	O
L4	O
,	O
adult	O
female	O
and	O
adult	O
male	O
)	O
.	O

Verification	O
of	O
Differential	O
Hybridization	O
by	O
Reverse	O
Transcription	O
-	O
Coupled	O
Polymerase	O
Chain	O
Reaction	O
(	O
RT	O
-	O
PCR	O
)	O
Analysis	O

For	O
a	O
subset	O
(	O
n	O
=	O
17	O
)	O
of	O
representative	O
ESTs	O
(	O
rESTs	O
)	O
,	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
verify	O
the	O
differential	O
transcription	O
recorded	O
by	O
microarray	O
analysis	O
.	O

Double	O
-	O
stranded	O
cDNA	O
was	O
synthesized	O
from	O
total	O
RNA	O
(	O
separately	O
)	O
from	O
each	O
stage	O
or	O
sex	O
of	O
A	B-Species
.	I-Species
suum	E-Species
using	O
reverse	O
transcriptase	O
(	O
Superscript	O
III	O
,	O
Invitrogen	O
)	O
.	O

Briefly	O
,	O
5	O
micro	O
g	O
of	O
total	O
RNA	O
were	O
added	O
to	O
14	O
micro	O
l	O
of	O
H2O	O
and	O
1	O
micro	O
l	O
of	O
oligo	O
d	O
(	O
T	O
)	O
n	O
=	O
12	O
-	O
18	O
primer	O
(	O
0	O
.	O
5	O
micro	O
g	O
/	O
micro	O
l	O
)	O
,	O
heated	O
to	O
70	O
degrees	O
C	O
for	O
10	O
min	O
and	O
chilled	O
on	O
ice	O
.	O

First	O
-	O
and	O
second	O
-	O
strand	O
cDNAs	O
were	O
synthesized	O
via	O
the	O
addition	O
of	O
4	O
micro	O
l	O
of	O
first	O
-	O
strand	O
cDNA	O
buffer	O
(	O
250	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
8	O
.	O
3	O
,	O
375	O
mM	O
KCl	O
and	O
15	O
mM	O
MgCl2	O
)	O
,	O
2	O
micro	O
l	O
of	O
0	O
.	O
1	O
M	O
dithiothreitol	O
,	O
and	O
1	O
micro	O
l	O
of	O
10	O
mM	O
of	O
each	O
dNTP	O
,	O
followed	O
by	O
an	O
incubation	O
at	O
25	O
degrees	O
C	O
(	O
10	O
min	O
)	O
,	O
42	O
degrees	O
C	O
(	O
50	O
min	O
)	O
and	O
70	O
degrees	O
C	O
(	O
15	O
min	O
)	O
.	O

One	O
-	O
tenth	O
of	O
each	O
double	O
-	O
stranded	O
cDNA	O
produced	O
was	O
then	O
used	O
as	O
a	O
template	O
in	O
the	O
PCR	O
.	O

The	O
transcripts	O
were	O
amplified	O
from	O
individual	O
cDNAs	O
by	O
PCR	O
using	O
oligonucleotide	O
primers	O
(	O
sequences	O
available	O
upon	O
request	O
)	O
designed	O
to	O
each	O
EST	O
.	O

The	O
PCR	O
amplification	O
of	O
a	O
portion	O
(	O
209	O
bp	O
)	O
of	O
the	O
beta	O
-	O
actin	O
gene	O
(	O
accession	O
no	O
.	O
BI594141	O
)	O
using	O
forward	O
primer	O
(	O
5	O
'	O
-	O
CTCGAAACAAGAATACGATG	O
-	O
3	O
'	O
)	O
and	O
reverse	O
primer	O
(	O
5	O
'	O
-	O
ACATGTGCCGTTGTATGATG	O
-	O
3	O
'	O
)	O
,	O
previously	O
determined	O
to	O
be	O
present	O
in	O
all	O
developmental	O
stages	O
and	O
both	O
sexes	O
of	O
A	B-Species
.	I-Species
suum	E-Species
[	O
44	O
]	O
,	O
served	O
as	O
a	O
positive	O
control	O
.	O

Samples	O
without	O
template	O
(	O
no	O
-	O
DNA	O
controls	O
)	O
were	O
included	O
in	O
each	O
PCR	O
run	O
.	O

The	O
following	O
cycling	O
conditions	O
were	O
employed	O
:	O
one	O
cycle	O
at	O
94	O
degrees	O
C	O
(	O
5	O
min	O
)	O
,	O
94	O
degrees	O
C	O
(	O
30	O
s	O
)	O
,	O
60	O
degrees	O
C	O
(	O
30	O
s	O
)	O
and	O
72	O
degrees	O
C	O
(	O
30	O
s	O
)	O
for	O
30	O
cycles	O
,	O
followed	O
by	O
a	O
final	O
extension	O
of	O
70	O
degrees	O
C	O
(	O
7	O
min	O
)	O
.	O

Following	O
the	O
PCR	O
,	O
5	O
micro	O
l	O
of	O
individual	O
amplicons	O
were	O
resolved	O
in	O
ethidium	O
bromide	O
-	O
stained	O
agarose	O
gels	O
(	O
2	O
%	O
)	O
and	O
then	O
photographed	O
upon	O
transillumination	O
.	O

The	O
relative	O
band	O
intensities	O
were	O
analyzed	O
using	O
UVIsoft	O
Image	O
Acquisition	O
and	O
Analysis	O
software	O
(	O
UVITEC	O
)	O
.	O

The	O
specificity	O
and	O
identity	O
of	O
individual	O
amplicons	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
using	O
the	O
same	O
primers	O
(	O
separately	O
)	O
as	O
employed	O
for	O
their	O
amplification	O
.	O

Sequencing	O
and	O
Bioinformatics	O
Analyses	O

Clones	O
from	O
the	O
SSH	O
cDNA	O
library	O
with	O
increased	O
hybridization	O
in	O
microarray	O
analysis	O
to	O
the	O
infective	O
L3	O
compared	O
with	O
other	O
stages	O
were	O
sequenced	O
using	O
standard	O
technology	O
[	O
45	O
]	O
.	O

The	O
nucleotide	O
sequences	O
have	O
been	O
deposited	O
in	O
the	O
GenBank	O
database	O
under	O
accession	O
numbers	O
ES290984	O
-	O
ES291074	O
.	O

Following	O
the	O
processing	O
of	O
the	O
sequences	O
(	O
i	O
.	O
e	O
.	O
,	O
removal	O
of	O
vector	O
sequences	O
,	O
quality	O
assurance	O
and	O
clustering	O
)	O
,	O
contigs	O
or	O
singletons	O
from	O
individual	O
clusters	O
were	O
subjected	O
to	O
BLASTx	O
(	O
NCBI	O
:	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
)	O
and	O
BLASTn	O
(	O
EMBL	O
-	O
EBI	O
Parasite	O
Genome	O
Blast	O
Server	O
:	O
www	O
.	O
ebi	O
.	O
ac	O
.	O
uk	O
)	O
analysis	O
to	O
identify	O
putative	O
homologues	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
other	O
nematodes	O
and	O
other	O
organisms	O
(	O
e	O
-	O
value	O
of	O
<=	O
1e	O
-	O
05	O
)	O
.	O

Peptides	O
inferred	O
from	O
ESTs	O
were	O
classified	O
functionally	O
using	O
Interproscan	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
ebi	O
.	O
ac	O
.	O
uk	O
/	O
InterProScan	O
/	O
)	O
employing	O
the	O
default	O
search	O
parameters	O
.	O

WormBase	O
(	O
www	O
.	O
wormbase	O
.	O
org	O
)	O
was	O
interrogated	O
extensively	O
for	O
relevant	O
information	O
on	O
C	B-Species
.	I-Species
elegans	E-Species
homologues	O
/	O
orthologues	O
,	O
including	O
RNAi	O
phenotypic	O
,	O
transcriptomic	O
,	O
proteomic	O
and	O
interactomic	O
data	O
.	O

ESTs	O
with	O
homologues	O
/	O
orthologues	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
and	O
other	O
nematodes	O
were	O
also	O
subjected	O
to	O
analysis	O
employing	O
the	O
KEGG	O
Orthology	O
-	O
Based	O
Annotation	O
System	O
(	O
KOBAS	O
)	O
(	O
www	O
.	O
kobas	O
.	O
cbi	O
.	O
pku	O
.	O
edu	O
.	O
cn	O
)	O
,	O
which	O
predicts	O
the	O
biochemical	O
pathways	O
in	O
which	O
molecules	O
are	O
involved	O
.	O

The	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
inferred	O
from	O
selected	O
ESTs	O
with	O
orthologues	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
were	O
also	O
subjected	O
to	O
"	O
secretome	O
analysis	O
"	O
using	O
the	O
program	O
SignalP	O
v	O
.	O
2	O
.	O
0	O
www	O
.	O
cbs	O
.	O
dtu	O
.	O
dk	O
/	O
services	O
/	O
SignalP	O
/	O
)	O
,	O
employing	O
both	O
the	O
neural	O
network	O
and	O
hidden	O
Markov	O
models	O
to	O
predict	O
signal	O
peptides	O
and	O
/	O
or	O
anchors	O
[	O
46	O
]	O
-	O
[	O
48	O
]	O
.	O

Also	O
,	O
transmembrane	O
domains	O
were	O
predicted	O
using	O
the	O
program	O
TMHMM	O
(	O
www	O
.	O
cbs	O
.	O
dtu	O
.	O
dk	O
/	O
services	O
/	O
TMHMM	O
/	O
;	O
[	O
49	O
]	O
-	O
[	O
51	O
]	O
)	O
,	O
and	O
subcellular	O
localization	O
inferred	O
employing	O
the	O
program	O
WoLF	O
PSORT	O
(	O
http	O
:	O
/	O
/	O
wolfpsort	O
.	O
org	O
/	O
;	O
[	O
52	O
]	O
)	O
.	O

The	O
method	O
established	O
by	O
Zhong	O
and	O
Sternberg	O
[	O
53	O
]	O
was	O
used	O
to	O
predict	O
the	O
interactions	O
for	O
C	B-Species
.	I-Species
elegans	E-Species
orthologues	O
of	O
the	O
L3	O
-	O
enriched	O
molecules	O
from	O
Ascaris	O
.	O

In	O
brief	O
,	O
interaction	O
,	O
phenotypic	O
,	O
expression	O
and	O
gene	O
ontology	O
data	O
from	O
fruitfly	S-Species
,	O
yeast	S-Species
,	O
mouse	S-Species
and	O
human	S-Species
were	O
integrated	O
using	O
a	O
na	O
i	O
ve	O
Bayesian	O
model	O
to	O
predict	O
genetic	O
interactions	O
among	O
C	B-Species
.	I-Species
elegans	E-Species
genes	O
(	O
[	O
45	O
]	O
,	O
[	O
53	O
]	O
;	O
Zhong	O
and	O
Sternberg	O
,	O
unpublished	O
)	O
.	O

The	O
predicted	O
networks	O
resulting	O
from	O
the	O
analyses	O
were	O
saved	O
in	O
a	O
graphic	O
display	O
file	O
(	O
gdf	O
)	O
format	O
and	O
examined	O
using	O
the	O
graph	O
exploration	O
system	O
available	O
at	O
http	O
:	O
/	O
/	O
graphexploration	O
.	O
cond	O
.	O
org	O
/	O
.	O

Images	O
were	O
labeled	O
and	O
saved	O
in	O
the	O
joint	O
photographic	O
experts	O
group	O
(	O
jpeg	O
)	O
format	O
.	O

Results	O

To	O
identify	O
molecules	O
transcribed	O
abundantly	O
in	O
the	O
L3	O
of	O
A	B-Species
.	I-Species
suum	E-Species
,	O
an	O
enriched	O
cDNA	O
library	O
was	O
constructed	O
by	O
SSH	O
.	O

From	O
a	O
total	O
of	O
3075	O
clones	O
from	O
this	O
library	O
,	O
2921	O
(	O
95	O
%	O
)	O
were	O
shown	O
to	O
contain	O
an	O
insert	O
(	O
which	O
could	O
be	O
amplified	O
by	O
PCR	O
)	O
.	O

From	O
2671	O
(	O
92	O
%	O
)	O
of	O
these	O
clones	O
,	O
amplicons	O
representing	O
single	O
bands	O
of	O
~	O
400	O
to	O
600	O
bp	O
in	O
size	O
were	O
produced	O
.	O

These	O
latter	O
amplicons	O
were	O
arrayed	O
(	O
in	O
duplicate	O
)	O
on	O
to	O
slides	O
and	O
then	O
hybridized	O
with	O
Cy3	O
-	O
labeled	O
L3	O
-	O
cDNA	O
or	O
with	O
Cy5	O
-	O
labeled	O
cDNA	O
from	O
eggs	O
,	O
liver	O
/	O
lung	O
L3s	O
,	O
L4s	O
,	O
adult	O
female	O
or	O
adult	O
male	O
of	O
Ascaris	O
.	O

Dye	O
flip	O
was	O
conducted	O
to	O
verify	O
the	O
hybridization	O
data	O
.	O

Of	O
the	O
2671	O
(	O
duplicate	O
)	O
spots	O
,	O
1526	O
had	O
a	O
significant	O
difference	O
in	O
hybridization	O
between	O
infective	O
L3	O
cDNA	O
and	O
cDNAs	O
from	O
all	O
other	O
stages	O
or	O
sexes	O
of	O
A	B-Species
.	I-Species
suum	E-Species
,	O
of	O
which	O
515	O
had	O
a	O
>	O
2	O
.	O
0	O
-	O
fold	O
increased	O
hybridization	O
for	O
the	O
L3	O
.	O

In	O
order	O
to	O
independently	O
verify	O
the	O
hybridization	O
results	O
in	O
the	O
microarray	O
,	O
a	O
PCR	O
-	O
based	O
analysis	O
of	O
a	O
selected	O
subset	O
(	O
n	O
=	O
17	O
)	O
clones	O
was	O
conducted	O
using	O
specific	O
primer	O
pairs	O
.	O

Having	O
verified	O
the	O
specificity	O
and	O
identity	O
of	O
individual	O
amplicons	O
by	O
sequencing	O
,	O
PCR	O
results	O
were	O
reproducible	O
(	O
based	O
on	O
multiple	O
runs	O
on	O
different	O
days	O
)	O
and	O
~	O
94	O
%	O
(	O
16	O
of	O
17	O
)	O
concordant	O
with	O
those	O
of	O
the	O
microarray	O
analysis	O
(	O
not	O
shown	O
)	O
.	O

There	O
was	O
complete	O
concordance	O
for	O
representative	O
clones	O
associated	O
with	O
a	O
differential	O
signal	O
of	O
>=	O
3	O
.	O
0	O
-	O
fold	O
in	O
the	O
microarray	O
.	O

The	O
clones	O
linked	O
to	O
the	O
515	O
spots	O
representing	O
increased	O
transcription	O
(	O
>	O
2	O
.	O
0	O
-	O
fold	O
)	O
in	O
infective	O
L3	O
compared	O
with	O
the	O
other	O
developmental	O
stages	O
or	O
sexes	O
included	O
were	O
subjected	O
to	O
sequencing	O
.	O

The	O
498	O
sequences	O
(	O
length	O
:	O
550	O
+/-	O
115	O
bp	O
)	O
determined	O
were	O
then	O
subjected	O
to	O
detailed	O
bioinformatic	O
analyses	O
.	O

There	O
were	O
91	O
unique	O
clusters	O
(	O
accession	O
numbers	O
ES290984	O
-	O
ES291074	O
)	O
,	O
of	O
which	O
55	O
were	O
singletons	O
(	O
sequences	O
determined	O
once	O
)	O
.	O

Of	O
56	O
molecules	O
(	O
61	O
.	O
5	O
%	O
)	O
with	O
significant	O
similarity	O
to	O
sequences	O
other	O
than	O
A	B-Species
.	I-Species
suum	E-Species
in	O
the	O
databases	O
interrogated	O
,	O
50	O
(	O
54	O
.	O
9	O
%	O
)	O
had	O
C	B-Species
.	I-Species
elegans	E-Species
or	O
C	B-Species
.	I-Species
briggsae	E-Species
homologues	O
,	O
and	O
six	O
had	O
similarity	O
to	O
ESTs	O
already	O
sequenced	O
from	O
ascaridoid	O
and	O
/	O
or	O
other	O
parasitic	O
nematodes	O
,	O
and	O
/	O
or	O
other	O
organisms	O
(	O
Table	O
1	O
)	O
.	O

A	O
significant	O
proportion	O
(	O
38	O
.	O
4	O
%	O
)	O
did	O
not	O
have	O
any	O
similarity	O
in	O
sequence	O
to	O
any	O
organisms	O
for	O
which	O
data	O
are	O
presently	O
available	O
.	O

Comparative	O
analysis	O
specifically	O
against	O
A	B-Species
.	I-Species
suum	E-Species
EST	O
data	O
sets	O
(	O
n	O
~	O
42	O
,	O
000	O
)	O
available	O
in	O
public	O
databases	O
confirmed	O
independently	O
that	O
the	O
majority	O
of	O
molecules	O
(	O
>	O
60	O
%	O
)	O
were	O
present	O
exclusively	O
in	O
the	O
infective	O
L3	O
stage	O
or	O
were	O
orphans	O
.	O

As	O
gene	O
ontology	O
(	O
GO	O
)	O
provides	O
a	O
hierarchy	O
that	O
unifies	O
the	O
descriptions	O
of	O
biological	O
,	O
cellular	O
and	O
molecular	O
functions	O
[	O
54	O
]	O
,	O
this	O
approach	O
was	O
employed	O
to	O
predict	O
the	O
classification	O
and	O
gene	O
function	O
of	O
molecules	O
enriched	O
in	O
infective	O
L3	O
of	O
A	B-Species
.	I-Species
suum	E-Species
.	O

A	O
summary	O
of	O
the	O
GO	O
categories	O
of	O
these	O
molecules	O
is	O
displayed	O
in	O
Fig	O
.	O

1	O
.	O

Of	O
the	O
91	O
contigs	O
,	O
32	O
(	O
35	O
%	O
)	O
could	O
be	O
functionally	O
assigned	O
to	O
'	O
biological	O
process	O
'	O
(	O
n	O
=	O
38	O
)	O
,	O
'	O
cellular	O
component	O
'	O
(	O
n	O
=	O
17	O
)	O
and	O
'	O
molecular	O
function	O
'	O
(	O
n	O
=	O
64	O
)	O
.	O

The	O
most	O
common	O
subcategories	O
were	O
gluconeogenesis	O
(	O
13	O
%	O
)	O
and	O
metabolic	O
process	O
(	O
13	O
%	O
)	O
within	O
'	O
biological	O
process	O
'	O
,	O
extracellular	O
region	O
(	O
24	O
%	O
)	O
within	O
'	O
cellular	O
component	O
'	O
,	O
and	O
catalytic	O
activity	O
(	O
11	O
%	O
)	O
and	O
phosphoenolpyruvate	O
carboxykinase	O
activity	O
(	O
8	O
%	O
)	O
within	O
'	O
molecular	O
function	O
'	O
(	O
Table	O
S1	O
)	O
.	O

A	O
focused	O
KOBAS	O
analysis	O
inferred	O
the	O
50	O
C	B-Species
.	I-Species
elegans	E-Species
orthologues	O
/	O
homologues	O
to	O
be	O
involved	O
in	O
apoptosis	O
and	O
insulin	O
signaling	O
(	O
2	O
%	O
)	O
,	O
ATP	O
synthesis	O
(	O
2	O
%	O
)	O
,	O
carbon	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
fatty	O
acid	O
biosynthesis	O
(	O
2	O
%	O
)	O
,	O
gap	O
junction	O
(	O
2	O
%	O
)	O
,	O
glucose	O
metabolism	O
(	O
6	O
%	O
)	O
or	O
porphyrin	O
metabolism	O
(	O
2	O
%	O
)	O
,	O
although	O
34	O
(	O
68	O
%	O
)	O
of	O
them	O
could	O
not	O
be	O
mapped	O
to	O
a	O
specific	O
metabolic	O
pathway	O
(	O
Table	O
2	O
)	O
.	O

Of	O
these	O
50	O
molecules	O
,	O
small	O
numbers	O
were	O
predicted	O
to	O
be	O
secreted	O
(	O
10	O
%	O
)	O
,	O
anchored	O
(	O
2	O
%	O
)	O
and	O
/	O
or	O
transmembrane	O
(	O
12	O
%	O
)	O
proteins	O
(	O
Table	O
2	O
)	O
.	O

Functionally	O
,	O
17	O
(	O
34	O
%	O
)	O
of	O
the	O
50	O
molecules	O
were	O
associated	O
with	O
(	O
non	O
-	O
wild	O
-	O
type	O
)	O
RNAi	O
phenotypes	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
the	O
majority	O
displaying	O
embryonic	O
lethality	O
(	O
Emb	O
)	O
(	O
13	O
types	O
;	O
58	O
.	O
8	O
%	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
(	O
23	O
.	O
5	O
%	O
)	O
and	O
larval	O
lethality	O
(	O
Lvl	O
)	O
(	O
47	O
%	O
)	O
(	O
Table	O
2	O
)	O
.	O

Extending	O
this	O
analysis	O
,	O
a	O
relatively	O
complex	O
genetic	O
interaction	O
network	O
was	O
predicted	O
for	O
the	O
17	O
C	B-Species
.	I-Species
elegans	E-Species
orthologues	O
(	O
i	O
.	O
e	O
.	O
,	O
with	O
non	O
-	O
wild	O
-	O
type	O
RNAi	O
phenotypes	O
)	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Statistically	O
highly	O
significant	O
interactions	O
were	O
predicted	O
for	O
nine	O
of	O
the	O
C	B-Species
.	I-Species
elegans	E-Species
genes	O
;	O
the	O
top	O
five	O
interactors	O
are	O
displayed	O
in	O
Fig	O
.	O

2	O
.	O

The	O
gene	O
ontology	O
categories	O
for	O
eight	O
selected	O
C	B-Species
.	I-Species
elegans	E-Species
genes	O
(	O
F33D11	O
.	O
10	O
,	O
F55A12	O
.	O
8	O
,	O
kin	O
-	O
2	O
,	O
mec	O
-	O
12	O
,	O
mup	O
-	O
2	O
,	O
pab	O
-	O
1	O
,	O
rpl	O
-	O
22	O
and	O
T21B10	O
.	O
2	O
)	O
included	O
:	O
embryonic	O
development	O
,	O
egg	O
hatching	O
,	O
larval	O
development	O
and	O
/	O
or	O
growth	O
.	O

The	O
other	O
categories	O
included	O
:	O
positive	O
regulation	O
of	O
growth	O
rate	O
(	O
F55A12	O
.	O
8	O
,	O
kin	O
-	O
2	O
,	O
mup	O
-	O
2	O
,	O
pab	O
-	O
1	O
,	O
rpl	O
-	O
22	O
and	O
T21B10	O
.	O
2	O
)	O
and	O
gamete	O
generation	O
and	O
locomotory	O
behaviour	O
(	O
kin	O
-	O
2	O
,	O
mup	O
-	O
2	O
,	O
pab	O
-	O
1	O
and	O
F55A12	O
.	O
8	O
,	O
kin	O
-	O
2	O
,	O
mup	O
-	O
2	O
,	O
respectively	O
)	O
.	O

The	O
C	B-Species
.	I-Species
elegans	E-Species
homologue	O
egl	O
-	O
3	O
was	O
predicted	O
to	O
be	O
involved	O
in	O
proteolysis	O
(	O
see	O
www	O
.	O
wormbase	O
.	O
org	O
)	O
.	O

All	O
nine	O
C	B-Species
.	I-Species
elegans	E-Species
orthologues	O
were	O
predicted	O
to	O
interact	O
directly	O
with	O
a	O
total	O
of	O
296	O
(	O
range	O
:	O
5	O
-	O
75	O
)	O
other	O
genes	O
and	O
,	O
in	O
particular	O
,	O
a	O
direct	O
genetic	O
interaction	O
was	O
predicted	O
between	O
pab	O
-	O
1	O
and	O
T21B10	O
.	O
2	O
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
296	O
interactors	O
were	O
associated	O
with	O
embryonic	O
and	O
larval	O
development	O
(	O
n	O
=	O
198	O
;	O
66	O
.	O
9	O
%	O
)	O
,	O
information	O
storage	O
and	O
processing	O
(	O
n	O
=	O
15	O
;	O
5	O
.	O
1	O
%	O
)	O
,	O
cellular	O
processes	O
and	O
signalling	O
(	O
n	O
=	O
45	O
;	O
15	O
.	O
2	O
%	O
)	O
and	O
metabolism	O
(	O
n	O
=	O
18	O
;	O
6	O
.	O
1	O
%	O
)	O
;	O
the	O
precise	O
function	O
of	O
some	O
of	O
the	O
interactors	O
(	O
n	O
=	O
20	O
;	O
6	O
.	O
7	O
%	O
)	O
is	O
presently	O
unknown	O
(	O
Table	O
S2	O
)	O
.	O

Discussion	O

The	O
present	O
study	O
investigated	O
transcripts	O
in	O
infective	O
L3s	O
of	O
A	B-Species
.	I-Species
suum	E-Species
using	O
a	O
genomic	O
-	O
bioinformatic	O
platform	O
.	O

The	O
focus	O
was	O
on	O
comparisons	O
with	O
C	B-Species
.	I-Species
elegans	E-Species
homologues	O
/	O
orthologues	O
,	O
because	O
the	O
entire	O
genome	O
sequence	O
of	O
this	O
nematode	O
is	O
known	O
[	O
9	O
]	O
and	O
because	O
there	O
is	O
a	O
wealth	O
of	O
information	O
on	O
the	O
localization	O
and	O
functionality	O
of	O
its	O
molecules	O
(	O
www	O
.	O
wormbase	O
.	O
org	O
;	O
http	O
:	O
/	O
/	O
elegans	O
.	O
bcgsc	O
.	O
bc	O
.	O
ca	O
/	O
knockout	O
.	O
shtml	O
)	O
.	O

The	O
functions	O
of	O
most	O
genes	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
have	O
been	O
assessed	O
using	O
RNAi	O
(	O
e	O
.	O
g	O
.	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
17	O
]	O
,	O
[	O
55	O
]	O
,	O
[	O
56	O
]	O
)	O
in	O
the	O
hermaphroditic	O
stage	O
,	O
whereas	O
there	O
is	O
a	O
paucity	O
of	O
functional	O
information	O
available	O
for	O
Ascaris	O
and	O
other	O
parasitic	O
nematodes	O
of	O
animals	O
[	O
57	O
]	O
,	O
[	O
58	O
]	O
.	O

Following	O
the	O
microarray	O
analysis	O
of	O
>	O
2500	O
ESTs	O
from	O
the	O
SSH	O
library	O
,	O
498	O
cDNAs	O
inferred	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
,	O
based	O
on	O
hybridization	O
signal	O
,	O
were	O
sequenced	O
and	O
subjected	O
to	O
comprehensive	O
in	O
silico	O
analyses	O
.	O

Of	O
the	O
91	O
clusters	O
of	O
molecules	O
categorized	O
,	O
50	O
(	O
54	O
.	O
9	O
%	O
)	O
had	O
C	B-Species
.	I-Species
elegans	E-Species
homologues	O
/	O
orthologues	O
with	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
could	O
be	O
mapped	O
to	O
key	O
pathways	O
.	O

The	O
statistically	O
significant	O
genetic	O
interactions	O
predicted	O
for	O
9	O
of	O
the	O
50	O
C	B-Species
.	I-Species
elegans	E-Species
orthologues	O
[	O
namely	O
egl	O
-	O
3	O
,	O
F33D11	O
.	O
10	O
,	O
F55A12	O
.	O
8	O
,	O
kin	O
-	O
2	O
,	O
mec	O
-	O
12	O
,	O
mup	O
-	O
2	O
,	O
pab	O
-	O
1	O
,	O
rpl	O
-	O
22	O
and	O
T21B10	O
.	O
2	O
(	O
=	O
enol	O
-	O
1	O
)	O
]	O
and	O
the	O
interaction	O
network	O
included	O
genes	O
encoding	O
kinases	O
,	O
alpha	O
-	O
tubulins	O
,	O
enolases	O
,	O
troponin	O
and	O
other	O
named	O
and	O
unnamed	O
proteins	O
.	O

Eight	O
of	O
these	O
molecules	O
(	O
enol	O
-	O
1	O
,	O
pab	O
-	O
1	O
,	O
F33D11	O
.	O
10	O
,	O
rpl	O
-	O
22	O
,	O
F55A12	O
.	O
8	O
mec	O
-	O
12	O
,	O
mup	O
-	O
2	O
and	O
kin	O
-	O
2	O
)	O
have	O
known	O
or	O
predicted	O
roles	O
in	O
embryonic	O
and	O
larval	O
growth	O
and	O
development	O
,	O
gamete	O
generation	O
,	O
locomotory	O
behaviour	O
or	O
other	O
biological	O
processes	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
(	O
see	O
www	O
.	O
wormbase	O
.	O
org	O
)	O
.	O

The	O
enolase	O
encoded	O
by	O
enol	O
-	O
1	O
is	O
predicted	O
to	O
play	O
a	O
role	O
in	O
glycolysis	O
,	O
gluconeogenesis	O
,	O
phenylalanine	O
,	O
tyrosine	O
and	O
tryptophan	O
biosynthesis	O
(	O
cf	O
.	O
[	O
59	O
]	O
)	O
.	O

Since	O
glucose	O
is	O
the	O
main	O
source	O
for	O
ATP	O
production	O
,	O
the	O
alteration	O
in	O
these	O
key	O
glycolytic	O
enzymes	O
may	O
lead	O
to	O
cellular	O
dysfunction	O
,	O
such	O
as	O
impaired	O
ion	O
-	O
motive	O
ATPase	O
required	O
to	O
maintain	O
potential	O
gradients	O
,	O
operate	O
pumps	O
and	O
maintain	O
membrane	O
lipid	O
asymmetry	O
[	O
60	O
]	O
.	O

Bioinformatic	O
analysis	O
for	O
transmembrane	O
helices	O
(	O
TMHMM	O
)	O
and	O
peptide	O
signal	O
sequences	O
(	O
SignalP	O
)	O
predicted	O
ENOL	O
-	O
1	O
to	O
be	O
a	O
non	O
-	O
secreted	O
protein	O
localized	O
to	O
the	O
cytoplasm	O
(	O
cf	O
.	O
Table	O
2	O
)	O
.	O

Nonetheless	O
,	O
enolases	O
are	O
often	O
detected	O
in	O
the	O
excretory	O
/	O
secretory	O
(	O
ES	O
)	O
products	O
of	O
parasitic	O
helminths	O
,	O
including	O
adult	O
A	B-Species
.	I-Species
suum	E-Species
[	O
61	O
]	O
,	O
and	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
triggering	O
of	O
nitric	O
oxide	O
production	O
by	O
host	O
cells	O
.	O

The	O
enol	O
-	O
1	O
orthologue	O
of	O
C	B-Species
.	I-Species
elegans	E-Species
has	O
been	O
predicted	O
to	O
interact	O
specifically	O
with	O
the	O
polyadenylate	O
binding	O
protein	O
gene	O
,	O
pab	O
-	O
1	O
,	O
inferred	O
to	O
be	O
involved	O
in	O
coordinated	O
gene	O
transcription	O
and	O
expression	O
during	O
normal	O
larval	O
development	O
[	O
16	O
]	O
.	O

Poly	O
(	O
A	O
)	O
-	O
binding	O
proteins	O
(	O
PABPs	O
)	O
are	O
recognized	O
to	O
be	O
central	O
to	O
the	O
regulation	O
of	O
mRNA	O
translation	O
and	O
stability	O
[	O
62	O
]	O
.	O

Present	O
evidence	O
suggests	O
that	O
the	O
expression	O
of	O
PAB	O
-	O
1	O
is	O
regulated	O
by	O
an	O
oligo	O
-	O
pyrimidine	O
tract	O
in	O
response	O
to	O
cell	O
growth	O
and	O
relates	O
to	O
coordinated	O
growth	O
regulation	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
[	O
62	O
]	O
.	O

Furthermore	O
,	O
gene	O
silencing	O
of	O
pab	O
-	O
1	O
and	O
its	O
selected	O
interactors	O
(	O
see	O
Fig	O
.	O
2	O
)	O
leads	O
to	O
embryonic	O
lethal	O
(	O
Emb	O
)	O
,	O
slow	O
growth	O
(	O
Slo	O
)	O
and	O
sterile	O
progeny	O
(	O
Stp	O
)	O
phenotypes	O
(	O
see	O
www	O
.	O
wormbase	O
.	O
org	O
)	O
.	O

Another	O
gene	O
(	O
F33D11	O
.	O
10	O
;	O
EST	O
code	O
4F10	O
;	O
see	O
Table	O
2	O
)	O
which	O
encodes	O
an	O
ATP	O
-	O
dependent	O
RNA	O
helicase	O
and	O
is	O
associated	O
with	O
embryonic	O
lethal	O
(	O
Emb	O
)	O
and	O
larval	O
lethal	O
(	O
Lvl	O
)	O
RNAi	O
phenotypes	O
,	O
was	O
shown	O
to	O
be	O
highly	O
transcribed	O
in	O
infective	O
L3s	O
of	O
A	B-Species
.	I-Species
suum	E-Species
.	O

Helicases	O
are	O
involved	O
in	O
a	O
variety	O
of	O
RNA	O
metabolic	O
processes	O
,	O
including	O
translation	O
initiation	O
,	O
pre	O
-	O
mRNA	O
splicing	O
,	O
pre	O
-	O
rRNA	O
processing	O
,	O
rRNA	O
maturation	O
and	O
RNA	O
degradation	O
[	O
63	O
]	O
,	O
and	O
are	O
crucial	O
for	O
life	O
cycle	O
progression	O
,	O
sex	O
determination	O
and	O
early	O
embryogenesis	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
[	O
60	O
]	O
.	O

The	O
high	O
transcription	O
levels	O
of	O
a	O
homologue	O
/	O
orthologue	O
in	O
the	O
L3	O
of	O
A	B-Species
.	I-Species
suum	E-Species
might	O
suggest	O
a	O
similar	O
role	O
in	O
this	O
ascaridoid	O
.	O

Similarly	O
,	O
the	O
coordination	O
of	O
the	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
is	O
required	O
for	O
normal	O
growth	O
and	O
cell	O
proliferation	O
during	O
larval	O
development	O
.	O

The	O
high	O
transcription	O
level	O
for	O
the	O
ribosomal	O
protein	O
gene	O
homologue	O
rpl	O
-	O
22	O
(	O
large	O
subunit	O
family	O
member	O
;	O
EST	O
code	O
26G12	O
,	O
see	O
Table	O
2	O
)	O
in	O
the	O
infective	O
L3	O
of	O
A	B-Species
.	I-Species
suum	E-Species
compared	O
with	O
other	O
developmental	O
stages	O
is	O
likely	O
to	O
reflect	O
the	O
substantial	O
rate	O
of	O
cell	O
growth	O
in	O
this	O
stage	O
[	O
64	O
]	O
.	O

The	O
gene	O
(	O
F55A12	O
.	O
8	O
,	O
EST	O
code	O
4G11	O
;	O
see	O
Table	O
2	O
)	O
encoding	O
an	O
acetyl	O
-	O
transferase	O
with	O
a	O
putative	O
ATPase	O
domain	O
,	O
shown	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
of	O
A	B-Species
.	I-Species
suum	E-Species
,	O
was	O
predicted	O
to	O
interact	O
with	O
75	O
other	O
genes	O
all	O
involved	O
in	O
energy	O
production	O
and	O
/	O
or	O
RNA	O
processing	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Several	O
molecules	O
involved	O
in	O
ATP	O
synthesis	O
and	O
mitochondrial	O
pathways	O
(	O
e	O
.	O
g	O
.	O
,	O
cytochrome	O
oxidase	O
c	O
subunits	O
1	O
,	O
2	O
and	O
3	O
,	O
ADP	O
/	O
ATP	O
translocases	O
,	O
NADH	O
dehydrogenases	O
,	O
ATPases	O
and	O
ATP	O
synthetases	O
)	O
have	O
been	O
reported	O
previously	O
to	O
be	O
highly	O
represented	O
in	O
the	O
L3	O
stage	O
of	O
Anisakis	B-Species
simplex	E-Species
[	O
65	O
]	O
,	O
thus	O
supporting	O
the	O
proposal	O
that	O
substantial	O
energy	O
is	O
required	O
for	O
larval	O
development	O
as	O
well	O
as	O
the	O
transition	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
and	O
the	O
invasion	O
of	O
the	O
host	O
.	O

There	O
is	O
also	O
likely	O
to	O
be	O
a	O
substantial	O
energy	O
requirement	O
for	O
muscle	O
contraction	O
linked	O
to	O
larval	O
motility	O
in	O
A	B-Species
.	I-Species
suum	E-Species
,	O
as	O
the	O
L3s	O
penetrate	O
the	O
caecal	O
wall	O
in	O
the	O
porcine	O
host	O
,	O
before	O
undergoing	O
hepato	O
-	O
pulmonary	O
migration	O
[	O
35	O
]	O
.	O

Accordingly	O
,	O
genes	O
encoding	O
a	O
specialized	O
tubulin	O
expressed	O
in	O
mechanoreceptors	O
(	O
mec	O
-	O
12	O
,	O
EST	O
code	O
13E09	O
)	O
and	O
a	O
troponin	O
(	O
mup	O
-	O
2	O
,	O
EST	O
code	O
01G03	O
;	O
see	O
Table	O
2	O
)	O
,	O
both	O
predicted	O
to	O
interact	O
with	O
a	O
total	O
number	O
of	O
32	O
tubulin	O
-	O
and	O
myosin	O
-	O
encoding	O
genes	O
,	O
also	O
supported	O
a	O
link	O
to	O
extensive	O
muscle	O
contraction	O
and	O
motility	O
in	O
A	B-Species
.	I-Species
suum	E-Species
L3s	O
.	O

Also	O
,	O
neuroactive	O
peptides	O
are	O
required	O
to	O
regulate	O
the	O
responsiveness	O
of	O
nematode	O
larvae	O
to	O
mechanical	O
stimuli	O
[	O
66	O
]	O
.	O

A	O
homologue	O
encoded	O
by	O
egl	O
-	O
3	O
was	O
shown	O
to	O
be	O
highly	O
transcribed	O
in	O
the	O
L3	O
of	O
A	B-Species
.	I-Species
suum	E-Species
;	O
EGL	O
-	O
3	O
is	O
predicted	O
to	O
be	O
a	O
pro	O
-	O
hormone	O
convertase	O
involved	O
in	O
the	O
maturation	O
of	O
neuropeptides	O
and	O
could	O
be	O
associated	O
with	O
mechano	O
-	O
sensory	O
responses	O
and	O
touch	O
sensitivity	O
linked	O
to	O
the	O
host	O
invasion	O
.	O

A	O
regulatory	O
subunit	O
of	O
a	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
(	O
kin	O
-	O
2	O
,	O
EST	O
code	O
22H01	O
;	O
see	O
Table	O
2	O
)	O
was	O
predicted	O
to	O
interact	O
with	O
72	O
other	O
genes	O
all	O
involved	O
in	O
diverse	O
cellular	O
processes	O
,	O
such	O
as	O
nuclear	O
trafficking	O
,	O
and	O
DNA	O
replication	O
and	O
repair	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Based	O
on	O
gene	O
ontology	O
terms	O
,	O
kin	O
-	O
2	O
is	O
implicated	O
in	O
gamete	O
generation	O
,	O
growth	O
,	O
larval	O
development	O
,	O
post	O
-	O
embryonic	O
body	O
morphogenesis	O
,	O
signal	O
transduction	O
and	O
/	O
or	O
protein	O
amino	O
acid	O
phosphorylation	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Gene	O
silencing	O
of	O
kin	O
-	O
2	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
leads	O
to	O
phenotypes	O
,	O
such	O
as	O
larval	O
lethal	O
(	O
Lvl	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
,	O
body	O
morphology	O
defect	O
(	O
Bmd	O
)	O
,	O
dumpy	O
(	O
Dpy	O
)	O
,	O
uncoordinated	O
(	O
Unc	O
)	O
and	O
sterile	O
progeny	O
(	O
Stp	O
)	O
(	O
www	O
.	O
wormbase	O
.	O
org	O
)	O
,	O
suggesting	O
that	O
its	O
homologue	O
in	O
A	B-Species
.	I-Species
suum	E-Species
is	O
central	O
to	O
larval	O
maturation	O
.	O

The	O
KOBAS	O
analysis	O
predicted	O
the	O
protein	O
KIN	O
-	O
2	O
to	O
be	O
involved	O
in	O
the	O
insulin	O
-	O
signaling	O
pathway	O
,	O
previously	O
implicated	O
in	O
controlling	O
the	O
exit	O
from	O
dauer	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
and	O
the	O
activation	O
of	O
L3s	O
of	O
the	O
canine	B-Species
hookworm	E-Species
,	O
Ancylostoma	B-Species
caninum	E-Species
,	O
following	O
exsheathment	O
[	O
67	O
]	O
.	O

In	O
a	O
recent	O
study	O
,	O
Brand	O
and	O
Hawdon	O
[	O
68	O
]	O
were	O
able	O
to	O
inhibit	O
(	O
with	O
a	O
phosphoinositide	O
-	O
3	O
-	O
OH	O
-	O
kinase	O
inhibitor	O
)	O
the	O
activation	O
of	O
infective	O
L3s	O
of	O
both	O
of	O
the	O
hookworms	O
Ancylostoma	B-Species
caninum	E-Species
and	O
Ancylostoma	B-Species
ceylanicum	E-Species
via	O
the	O
insulin	O
signaling	O
pathway	O
,	O
thus	O
lending	O
some	O
credence	O
to	O
the	O
hypothesis	O
that	O
this	O
pathway	O
plays	O
an	O
critical	O
role	O
in	O
regulating	O
the	O
transition	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
[	O
68	O
]	O
.	O

Recently	O
,	O
it	O
has	O
been	O
proposed	O
that	O
transcriptional	O
and	O
feeding	O
responses	O
to	O
serum	O
-	O
stimulation	O
in	O
Ancylostoma	B-Species
caninum	E-Species
are	O
regulated	O
by	O
parallel	O
systems	O
,	O
with	O
the	O
insulin	O
signaling	O
pathway	O
playing	O
a	O
significant	O
role	O
in	O
the	O
'	O
resumption	O
of	O
feeding	O
'	O
in	O
activated	O
larvae	O
[	O
69	O
]	O
.	O

Protein	O
kinases	O
are	O
also	O
likely	O
to	O
be	O
involved	O
in	O
pathways	O
linked	O
to	O
sexual	O
maturation	O
in	O
developing	O
larvae	O
.	O

As	O
already	O
proposed	O
for	O
adult	O
stages	O
of	O
H	B-Species
.	I-Species
contortus	E-Species
[	O
45	O
]	O
,	O
the	O
protein	O
kinase	O
gene	O
cdk	O
-	O
1	O
is	O
predicted	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
germline	O
,	O
oogenesis	O
and	O
spermiogenesis	O
pathways	O
of	O
this	O
parasitic	O
nematode	O
.	O

Other	O
protein	O
kinases	O
,	O
such	O
as	O
PEPCK	O
,	O
and	O
phosphatases	O
,	O
were	O
shown	O
herein	O
to	O
be	O
transcribed	O
at	O
high	O
levels	O
in	O
the	O
L3	O
stage	O
compared	O
with	O
other	O
developmental	O
stages	O
of	O
A	B-Species
.	I-Species
suum	E-Species
(	O
see	O
Table	O
2	O
)	O
,	O
which	O
is	O
in	O
accordance	O
to	O
findings	O
reported	O
recently	O
for	O
Anisakis	B-Species
simplex	E-Species
[	O
65	O
]	O
.	O

Due	O
to	O
their	O
major	O
regulatory	O
effects	O
in	O
eukaryotic	O
signaling	O
events	O
and	O
regulatory	O
and	O
sensory	O
functions	O
,	O
protein	O
kinases	O
have	O
been	O
considered	O
interesting	O
targets	O
for	O
anti	O
-	O
parasitic	O
drugs	O
[	O
70	O
]	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
has	O
given	O
some	O
interesting	O
insights	O
into	O
early	O
molecular	O
processes	O
in	O
the	O
L3	O
of	O
A	B-Species
.	I-Species
suum	E-Species
.	O

Approximately	O
60	O
%	O
of	O
the	O
transcripts	O
enriched	O
in	O
the	O
L3	O
stage	O
of	O
A	B-Species
.	I-Species
suum	E-Species
have	O
homologues	O
/	O
orthologues	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
.	O

The	O
bioinformatic	O
analyses	O
of	O
selected	O
molecules	O
suggest	O
that	O
a	O
complex	O
genetic	O
network	O
regulates	O
or	O
controls	O
larval	O
growth	O
and	O
development	O
in	O
A	B-Species
.	I-Species
suum	E-Species
L3s	O
,	O
and	O
some	O
of	O
these	O
might	O
be	O
involved	O
in	O
or	O
regulate	O
the	O
switch	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
.	O

Some	O
caution	O
is	O
warranted	O
in	O
drawing	O
conclusions	O
regarding	O
molecular	O
mechanisms	O
regulating	O
the	O
transition	O
to	O
parasitism	O
in	O
parasitic	O
nematodes	O
from	O
information	O
on	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
as	O
latter	O
is	O
a	O
free	O
-	O
living	O
nematode	O
.	O

Also	O
,	O
while	O
the	O
method	O
of	O
data	O
integration	O
is	O
essential	O
for	O
the	O
reliable	O
prediction	O
of	O
genetic	O
interactions	O
,	O
it	O
might	O
limit	O
the	O
capacity	O
of	O
the	O
approach	O
somewhat	O
to	O
infer	O
nematode	O
-	O
specific	O
interactions	O
.	O

As	O
additional	O
datasets	O
of	O
genes	O
and	O
gene	O
functions	O
become	O
available	O
for	O
various	O
parasitic	O
nematodes	O
,	O
more	O
informed	O
inferences	O
can	O
be	O
made	O
regarding	O
the	O
functions	O
of	O
nematode	O
-	O
specific	O
genes	O
,	O
particularly	O
those	O
involved	O
in	O
the	O
transition	O
to	O
parasitism	O
.	O

The	O
imminent	O
genome	O
sequence	O
of	O
A	B-Species
.	I-Species
suum	E-Species
(	O
http	O
:	O
/	O
/	O
www	O
.	O
sanger	O
.	O
ac	O
.	O
uk	O
/	O
Projects	O
/	O
Helminths	O
/	O
)	O
should	O
all	O
assist	O
in	O
this	O
endeavour	O
.	O

Also	O
,	O
functional	O
analysis	O
of	O
selected	O
molecules	O
representing	O
selected	O
ESTs	O
identified	O
herein	O
,	O
utilizing	O
gene	O
silencing	O
approaches	O
established	O
recently	O
[	O
33	O
]	O
,	O
[	O
34	O
]	O
,	O
could	O
provide	O
some	O
insights	O
into	O
developmental	O
processes	O
in	O
Ascaris	O
and	O
related	O
ascaridoid	O
nematodes	O
and	O
provide	O
avenues	O
for	O
the	O
development	O
of	O
novel	O
approaches	O
for	O
their	O
control	O
.	O

Supporting	O
Information	O

Minocycline	O
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
neuroinflammation	O
,	O
sickness	O
behavior	O
,	O
and	O
anhedonia	O

Abstract	O

Background	O

Activation	O
of	O
the	O
peripheral	O
innate	O
immune	O
system	O
stimulates	O
the	O
secretion	O
of	O
CNS	O
cytokines	O
that	O
modulate	O
the	O
behavioral	O
symptoms	O
of	O
sickness	O
.	O

Excessive	O
production	O
of	O
cytokines	O
by	O
microglia	O
,	O
however	O
,	O
may	O
cause	O
long	O
-	O
lasting	O
behavioral	O
and	O
cognitive	O
complications	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
minocycline	O
,	O
an	O
anti	O
-	O
inflammatory	O
agent	O
and	O
purported	O
microglial	O
inhibitor	O
,	O
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
neuroinflammation	O
,	O
sickness	O
behavior	O
,	O
and	O
anhedonia	O
.	O

Methods	O

In	O
the	O
first	O
set	O
of	O
experiments	O
the	O
effect	O
of	O
minocycline	O
pretreatment	O
on	O
LPS	O
-	O
induced	O
microglia	O
activation	O
was	O
assessed	O
in	O
BV	O
-	O
2	O
microglia	O
cell	O
cultures	O
.	O

In	O
the	O
second	O
study	O
,	O
adult	O
(	O
3	O
-	O
6	O
m	O
)	O
BALB	O
/	O
c	O
mice	S-Species
received	O
an	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
injection	O
of	O
vehicle	O
or	O
minocycline	O
(	O
50	O
mg	O
/	O
kg	O
)	O
for	O
three	O
consecutive	O
days	O
.	O

On	O
the	O
third	O
day	O
,	O
mice	S-Species
were	O
also	O
injected	O
(	O
i	O
.	O
p	O
.	O
)	O
with	O
saline	O
or	O
Escherichia	B-Species
coli	E-Species
LPS	O
(	O
0	O
.	O
33	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
(	O
i	O
.	O
e	O
.	O
,	O
sickness	O
and	O
anhedonia	O
)	O
and	O
markers	O
of	O
neuroinflammation	O
(	O
i	O
.	O
e	O
.	O
,	O
microglia	O
activation	O
and	O
inflammatory	O
cytokines	O
)	O
were	O
determined	O
.	O

In	O
the	O
final	O
study	O
,	O
adult	O
and	O
aged	O
BALB	O
/	O
c	O
mice	S-Species
were	O
treated	O
with	O
the	O
same	O
minocycline	O
and	O
LPS	O
injection	O
regimen	O
and	O
markers	O
of	O
neuroinflammation	O
were	O
determined	O
.	O

All	O
data	O
were	O
analyzed	O
using	O
Statistical	O
Analysis	O
Systems	O
General	O
Linear	O
Model	O
procedures	O
and	O
were	O
subjected	O
to	O
one	O
-	O
,	O
two	O
-	O
,	O
or	O
three	O
-	O
way	O
ANOVA	O
to	O
determine	O
significant	O
main	O
effects	O
and	O
interactions	O
.	O

Results	O

Minocycline	O
blocked	O
LPS	O
-	O
stimulated	O
inflammatory	O
cytokine	O
secretion	O
in	O
the	O
BV	O
-	O
2	O
microglia	O
-	O
derived	O
cell	O
line	O
and	O
reduced	O
LPS	O
-	O
induced	O
Toll	O
-	O
like	O
-	O
receptor	O
-	O
2	O
(	O
TLR2	O
)	O
surface	O
expression	O
on	O
brain	O
microglia	O
.	O

Moreover	O
,	O
minocycline	O
facilitated	O
the	O
recovery	O
from	O
sickness	O
behavior	O
(	O
i	O
.	O
e	O
.	O
,	O
anorexia	O
,	O
weight	O
loss	O
,	O
and	O
social	O
withdrawal	O
)	O
and	O
prevented	O
anhedonia	O
in	O
adult	O
mice	S-Species
challenged	O
with	O
LPS	O
.	O

Furthermore	O
,	O
the	O
minocycline	O
associated	O
recovery	O
from	O
LPS	O
-	O
induced	O
sickness	O
behavior	O
was	O
paralleled	O
by	O
reduced	O
mRNA	O
levels	O
of	O
Interleukin	O
(	O
IL	O
)	O
-	O
1	O
beta	O
,	O
IL	O
-	O
6	O
,	O
and	O
indoleamine	O
2	O
,	O
3	O
dioxygenase	O
(	O
IDO	O
)	O
in	O
the	O
cortex	O
and	O
hippocampus	O
.	O

Finally	O
,	O
in	O
aged	O
mice	S-Species
,	O
where	O
exaggerated	O
neuroinflammation	O
was	O
elicited	O
by	O
LPS	O
,	O
minocycline	O
pretreatment	O
was	O
still	O
effective	O
in	O
markedly	O
reducing	O
mRNA	O
levels	O
of	O
IL	O
-	O
1	O
beta	O
,	O
TLR2	O
and	O
IDO	O
in	O
the	O
hippocampus	O
.	O

Conclusion	O

These	O
data	O
indicate	O
that	O
minocycline	O
mitigates	O
neuroinflammation	O
in	O
the	O
adult	O
and	O
aged	O
brain	O
and	O
modulates	O
the	O
cytokine	O
-	O
associated	O
changes	O
in	O
motivation	O
and	O
behavior	O
.	O

Background	O

The	O
bi	O
-	O
directional	O
communication	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
necessary	O
for	O
mounting	O
the	O
appropriate	O
immunological	O
,	O
physiological	O
,	O
and	O
behavioral	O
responses	O
to	O
immune	O
stimulation	O
[	O
1	O
]	O
.	O

CNS	O
innate	O
immune	O
cells	O
including	O
microglia	O
and	O
macrophages	O
play	O
integral	O
roles	O
in	O
receiving	O
and	O
propagating	O
inflammatory	O
signals	O
that	O
are	O
initiated	O
at	O
the	O
periphery	O
.	O

Activation	O
of	O
peripheral	O
innate	O
immune	O
cells	O
elicits	O
the	O
secretion	O
of	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
alpha	O
.	O
)	O
,	O
that	O
use	O
neural	O
[	O
2	O
,	O
3	O
]	O
,	O
humoral	O
[	O
4	O
]	O
and	O
blood	O
brain	O
barrier	O
pathways	O
[	O
5	O
]	O
to	O
relay	O
this	O
signal	O
to	O
the	O
CNS	O
.	O

This	O
inflammatory	O
signal	O
,	O
in	O
turn	O
,	O
induces	O
CNS	O
macrophages	O
and	O
microglia	O
to	O
produce	O
the	O
same	O
cytokines	O
[	O
6	O
]	O
,	O
which	O
target	O
neuronal	O
substrates	O
and	O
elicit	O
a	O
sickness	O
behavior	O
syndrome	O
that	O
is	O
normally	O
adaptive	O
and	O
beneficial	O
to	O
the	O
host	O
[	O
1	O
]	O
.	O

An	O
amplified	O
or	O
excessive	O
inflammatory	O
cytokine	O
response	O
in	O
the	O
brain	O
,	O
however	O
,	O
is	O
associated	O
with	O
a	O
myriad	O
of	O
complications	O
including	O
cognitive	O
dysfunction	O
[	O
7	O
-	O
10	O
]	O
,	O
prolonged	O
sickness	O
behavior	O
[	O
11	O
-	O
14	O
]	O
,	O
and	O
depressive	O
-	O
like	O
behavior	O
[	O
15	O
]	O
.	O

Microglia	O
are	O
primarily	O
involved	O
in	O
immune	O
surveillance	O
[	O
16	O
,	O
17	O
]	O
,	O
but	O
when	O
activated	O
have	O
macrophage	O
-	O
like	O
capabilities	O
including	O
phagocytosis	O
,	O
inflammatory	O
cytokine	O
production	O
,	O
and	O
antigen	O
presentation	O
[	O
18	O
]	O
.	O

Normally	O
these	O
neuroinflammatory	O
changes	O
are	O
transient	O
with	O
microglia	O
returning	O
to	O
a	O
resting	O
state	O
as	O
the	O
immune	O
stimulus	O
is	O
resolved	O
.	O

Aging	O
or	O
neurological	O
disease	O
,	O
however	O
,	O
may	O
provide	O
a	O
brain	O
environment	O
where	O
microglia	O
are	O
more	O
"	O
reactive	O
or	O
primed	O
"	O
to	O
a	O
peripheral	O
immune	O
challenge	O
[	O
19	O
]	O
.	O

Recent	O
findings	O
indicate	O
that	O
several	O
markers	O
of	O
glial	O
activation	O
such	O
as	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
,	O
complement	O
receptors	O
,	O
and	O
scavenger	O
receptors	O
are	O
increased	O
in	O
brain	O
during	O
normal	O
aging	O
[	O
13	O
,	O
20	O
-	O
26	O
]	O
.	O

Furthermore	O
,	O
we	O
and	O
others	O
have	O
reported	O
that	O
a	O
biological	O
consequence	O
of	O
this	O
reactive	O
glial	O
profile	O
is	O
an	O
exaggerated	O
neuroinflammatory	O
response	O
to	O
innate	O
immune	O
challenge	O
[	O
9	O
,	O
10	O
,	O
12	O
-	O
14	O
,	O
27	O
,	O
28	O
]	O
.	O

Active	O
microglia	O
and	O
CNS	O
macrophages	O
also	O
contribute	O
to	O
the	O
production	O
of	O
oxidative	O
and	O
neuroactive	O
mediators	O
that	O
may	O
influence	O
behavior	O
.	O

For	O
instance	O
,	O
inflammatory	O
cytokines	O
in	O
the	O
CNS	O
upregulate	O
the	O
enzyme	O
IDO	O
[	O
29	O
,	O
30	O
]	O
,	O
which	O
metabolizes	O
tryptophan	O
(	O
TRP	O
)	O
into	O
L	O
-	O
kynurenine	O
(	O
KYN	O
)	O
[	O
31	O
]	O
.	O

TRP	O
degradation	O
to	O
KYN	O
can	O
reduce	O
TRP	O
levels	O
that	O
are	O
required	O
for	O
serotonin	O
synthesis	O
[	O
32	O
]	O
and	O
can	O
lead	O
to	O
the	O
production	O
of	O
neuroactive	O
mediators	O
including	O
3	O
-	O
hydroxykynurenine	O
(	O
3HK	O
)	O
and	O
quinolinic	O
acid	O
(	O
QUIN	O
)	O
[	O
31	O
]	O
.	O

High	O
levels	O
of	O
3HK	O
and	O
QUIN	O
induce	O
neuronal	O
damage	O
through	O
oxidative	O
stress	O
[	O
33	O
]	O
and	O
over	O
stimulation	O
of	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptors	O
[	O
34	O
,	O
35	O
]	O
.	O

A	O
recent	O
study	O
indicates	O
that	O
while	O
several	O
cell	O
types	O
in	O
the	O
CNS	O
express	O
IDO	O
,	O
only	O
microglia	O
maintain	O
all	O
the	O
enzymes	O
required	O
to	O
produce	O
3HK	O
and	O
QUIN	O
[	O
36	O
]	O
.	O

Because	O
IDO	O
mediated	O
TRP	O
degradation	O
impacts	O
both	O
serotonergic	O
and	O
glutamatergic	O
pathways	O
,	O
this	O
may	O
be	O
an	O
important	O
mechanism	O
underlying	O
mood	O
and	O
behavior	O
complications	O
concomitant	O
with	O
inflammation	O
[	O
37	O
-	O
39	O
]	O
.	O

Because	O
activated	O
microglia	O
are	O
suspected	O
to	O
cause	O
or	O
exacerbate	O
several	O
neurodegenerative	O
diseases	O
,	O
pharmacological	O
strategies	O
to	O
suppress	O
microglial	O
activity	O
are	O
being	O
explored	O
as	O
therapies	O
.	O

Minocycline	O
is	O
a	O
tetracycline	O
derived	O
antibiotic	O
that	O
has	O
anti	O
-	O
inflammatory	O
properties	O
in	O
the	O
CNS	O
that	O
are	O
separate	O
from	O
its	O
antimicrobial	O
action	O
[	O
40	O
]	O
.	O

Minocycline	O
readily	O
crosses	O
the	O
blood	O
brain	O
barrier	O
and	O
attenuates	O
inflammation	O
associated	O
with	O
microglial	O
activation	O
.	O

For	O
example	O
,	O
minocycline	O
blocks	O
the	O
deleterious	O
effects	O
of	O
neuroinflammation	O
on	O
neurogenesis	O
,	O
long	O
-	O
term	O
potentiation	O
,	O
and	O
neuronal	O
survival	O
[	O
41	O
-	O
43	O
]	O
.	O

The	O
mechanism	O
of	O
action	O
is	O
unclear	O
,	O
but	O
recent	O
studies	O
indicate	O
that	O
minocycline	O
abrogates	O
MAPkinase	O
and	O
NF	O
kappa	O
B	O
dependent	O
signaling	O
pathways	O
in	O
primary	O
microglia	O
and	O
microglia	O
cell	O
cultures	O
[	O
44	O
]	O
.	O

Moreover	O
,	O
in	O
the	O
brain	O
of	O
rats	S-Species
,	O
minocycline	O
abrogates	O
microglial	O
expression	O
of	O
CD11b	O
and	O
MHC	O
II	O
through	O
a	O
protein	O
kinase	O
-	O
c	O
dependent	O
mechanism	O
[	O
45	O
]	O
.	O

This	O
is	O
relevant	O
because	O
minocycline	O
attenuates	O
neuroinflammation	O
in	O
several	O
rodent	O
models	O
of	O
disease	O
including	O
Amyotrophic	O
Lateral	O
Sclerosis	O
[	O
46	O
]	O
,	O
Experimental	O
Autoimmune	O
Encephalomyelitis	O
(	O
EAE	O
)	O
[	O
45	O
]	O
and	O
MPTP	O
-	O
induced	O
Parkinson	O
'	O
s	O
disease	O
[	O
47	O
]	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
minocycline	O
facilitates	O
the	O
recovery	O
from	O
cytokine	O
-	O
mediated	O
sickness	O
behavior	O
is	O
unknown	O
.	O

The	O
present	O
study	O
investigated	O
the	O
degree	O
to	O
which	O
minocycline	O
-	O
an	O
anti	O
-	O
inflammatory	O
agent	O
and	O
purported	O
microglial	O
inhibitor	O
-	O
reduced	O
LPS	O
-	O
induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
.	O

We	O
show	O
that	O
minocycline	O
blocked	O
LPS	O
-	O
stimulated	O
inflammatory	O
cytokine	O
secretion	O
in	O
the	O
BV	O
-	O
2	O
microglia	O
-	O
derived	O
cell	O
line	O
and	O
reduced	O
LPS	O
-	O
induced	O
Toll	O
-	O
like	O
-	O
receptor	O
-	O
2	O
(	O
TLR2	O
)	O
surface	O
expression	O
on	O
brain	O
microglia	O
.	O

Moreover	O
,	O
our	O
data	O
show	O
that	O
minocycline	O
pretreatment	O
attenuated	O
LPS	O
-	O
induced	O
weight	O
loss	O
,	O
social	O
withdrawal	O
,	O
and	O
anhedonia	O
in	O
adult	O
mice	S-Species
.	O

The	O
attenuation	O
of	O
sickness	O
behavior	O
was	O
paralleled	O
with	O
minocycline	O
dependent	O
decrease	O
in	O
markers	O
of	O
neuroinflammation	O
(	O
IL	O
-	O
1	O
beta	O
,	O
TLR2	O
,	O
and	O
IDO	O
)	O
in	O
adult	O
and	O
aged	O
mice	S-Species
.	O

These	O
findings	O
support	O
our	O
hypothesis	O
that	O
the	O
ability	O
to	O
mitigate	O
cytokine	O
expression	O
in	O
the	O
brain	O
during	O
systemic	O
inflammatory	O
events	O
may	O
be	O
useful	O
in	O
preventing	O
cognitive	O
and	O
behavioral	O
deficits	O
.	O

Methods	O

Animals	O

Male	O
BALB	O
/	O
c	O
mice	S-Species
,	O
adults	O
(	O
3	O
month	O
old	O
)	O
and	O
juvenile	O
(	O
3	O
-	O
4	O
week	O
old	O
)	O
were	O
purchased	O
from	O
Harlan	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

For	O
age	O
comparisons	O
,	O
male	O
BALB	O
/	O
c	O
mice	S-Species
(	O
3	O
-	O
4	O
and	O
20	O
-	O
22	O
month	O
old	O
)	O
were	O
purchased	O
from	O
the	O
National	O
Institute	O
on	O
Aging	O
specific	O
pathogen	O
free	O
colony	O
.	O

Upon	O
arrival	O
,	O
mice	S-Species
were	O
individually	O
housed	O
in	O
polypropylene	O
cages	O
and	O
maintained	O
at	O
21	O
degrees	O
C	O
under	O
a	O
12	O
h	O
light	O
:	O
12	O
h	O
dark	O
cycle	O
with	O
ad	O
libitum	O
access	O
to	O
water	O
and	O
rodent	O
chow	O
.	O

At	O
the	O
end	O
of	O
each	O
study	O
,	O
mice	S-Species
were	O
examined	O
postmortem	O
for	O
gross	O
signs	O
of	O
disease	O
(	O
e	O
.	O
g	O
.	O
,	O
splenomeglia	O
or	O
tumors	O
)	O
.	O

Data	O
from	O
mice	S-Species
determined	O
to	O
be	O
unhealthy	O
were	O
excluded	O
from	O
analysis	O
(	O
<	O
5	O
%	O
)	O
.	O

All	O
procedures	O
were	O
in	O
accordance	O
with	O
the	O
National	O
Institute	O
of	O
Health	O
Guidelines	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
and	O
were	O
approved	O
by	O
The	O
Ohio	O
State	O
University	O
Institutional	O
Laboratory	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O

Cell	O
culture	O

BV	O
-	O
2	O
microglia	O
cell	O
lines	O
were	O
cultured	O
in	O
growth	O
medium	O
(	O
DMEM	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
sodium	O
bicarbonate	O
3	O
.	O
7	O
g	O
/	O
l	O
,	O
200	O
mM	O
glutamine	O
,	O
100	O
U	O
/	O
ml	O
penicillin	O
G	O
,	O
100	O
mu	O
g	O
/	O
ml	O
streptomycin	O
,	O
0	O
.	O
25	O
mu	O
g	O
/	O
ml	O
fungizone	O
)	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

Cultures	O
were	O
maintained	O
at	O
37	O
degrees	O
C	O
with	O
95	O
%	O
humidity	O
and	O
5	O
%	O
CO2	O
and	O
growth	O
medium	O
was	O
replenished	O
every	O
third	O
day	O
until	O
confluence	O
.	O

Cultures	O
were	O
washed	O
twice	O
and	O
supplemented	O
with	O
warm	O
growth	O
medium	O
containing	O
experimental	O
treatments	O
.	O

Cell	O
viability	O
was	O
measured	O
by	O
the	O
MTS	O
cell	O
proliferation	O
assay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

CNS	O
macrophage	O
/	O
microglia	O
isolation	O

CNS	O
macrophages	O
and	O
microglia	O
were	O
collected	O
from	O
whole	O
brain	O
homogenates	O
as	O
described	O
previously	O
[	O
48	O
]	O
,	O
but	O
with	O
several	O
modifications	O
.	O

Mice	S-Species
were	O
euthanized	O
by	O
CO2	O
asphyxiation	O
and	O
whole	O
brains	O
were	O
collected	O
.	O

Brains	O
were	O
homogenized	O
in	O
Hank	O
'	O
s	O
balanced	O
salt	O
solution	O
(	O
HBSS	O
)	O
pH	O
7	O
.	O
4	O
.	O

Brain	O
homogenates	O
were	O
passed	O
through	O
a	O
70	O
mu	O
m	O
nylon	O
cell	O
strainer	O
and	O
centrifuged	O
at	O
400	O
x	O
g	O
for	O
10	O
min	O
.	O

Supernatants	O
were	O
removed	O
and	O
cell	O
pellets	O
were	O
re	O
-	O
suspended	O
in	O
70	O
%	O
isotonic	O
Percoll	O
(	O
GE	O
-	O
healthcare	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
at	O
room	O
temperature	O
.	O

A	O
discontinuous	O
Percoll	O
density	O
gradient	O
was	O
set	O
up	O
as	O
follows	O
:	O
70	O
%	O
,	O
35	O
%	O
,	O
and	O
0	O
%	O
isotonic	O
Percoll	O
.	O

This	O
suspension	O
was	O
centrifuged	O
for	O
30	O
minutes	O
at	O
400	O
x	O
g	O
.	O

A	O
mixed	O
population	O
of	O
CNS	O
macrophages	O
and	O
microglia	O
was	O
collected	O
from	O
the	O
interphase	O
between	O
the	O
70	O
%	O
and	O
35	O
%	O
Percoll	O
layers	O
.	O

Cells	O
were	O
washed	O
and	O
then	O
re	O
-	O
suspended	O
in	O
sterile	O
HBSS	O
.	O

The	O
number	O
of	O
viable	O
cells	O
was	O
determined	O
using	O
a	O
hemacytometer	O
and	O
0	O
.	O
2	O
%	O
trypan	O
blue	O
staining	O
.	O

Flow	O
cytometry	O

Flow	O
cytometric	O
analysis	O
of	O
microglial	O
cell	O
surface	O
markers	O
was	O
performed	O
as	O
described	O
previously	O
,	O
but	O
with	O
a	O
few	O
modifications	O
[	O
48	O
]	O
.	O

In	O
brief	O
,	O
Fc	O
receptors	O
on	O
macrophages	O
and	O
microglia	O
were	O
blocked	O
with	O
anti	O
-	O
CD16	O
/	O
CD32	O
antibody	O
(	O
eBiosciences	O
,	O
CA	O
)	O
.	O

Next	O
,	O
cells	O
were	O
incubated	O
with	O
either	O
Panel	O
-	O
1	O
(	O
anti	O
-	O
CD11b	O
APC	O
,	O
anti	O
-	O
CD45	O
FITC	O
,	O
and	O
anti	O
-	O
MHC	O
II	O
PE	O
from	O
eBiosciences	O
,	O
CA	O
)	O
or	O
Panel	O
-	O
2	O
antibodies	O
(	O
anti	O
-	O
CD11b	O
APC	O
,	O
anti	O
-	O
CD45	O
FITC	O
,	O
and	O
anti	O
-	O
TLR2	O
PE	O
from	O
eBiosciences	O
,	O
CA	O
)	O
.	O

Expression	O
of	O
these	O
surface	O
receptors	O
was	O
determined	O
by	O
flow	O
cytometry	O
using	O
a	O
Becton	O
-	O
Dickinson	O
FACSCaliber	O
four	O
color	O
Cytometer	O
.	O

Thirty	O
thousand	O
events	O
were	O
collected	O
and	O
microglia	O
were	O
differentiated	O
from	O
macrophages	O
based	O
on	O
the	O
levels	O
of	O
CD11b	O
and	O
CD45	O
surface	O
expression	O
.	O

Microglia	O
stain	O
CD11b	O
+	O
/	O
CD45low	O
and	O
macrophages	O
stain	O
CD11b	O
+	O
/	O
CD45high	O
[	O
48	O
,	O
49	O
]	O
.	O

Flow	O
data	O
were	O
analyzed	O
using	O
FlowJo	O
software	O
(	O
Tree	O
Star	O
,	O
San	O
Carlos	O
,	O
CA	O
)	O
.	O

Behavior	O
tests	O

Social	O
exploratory	O
behavior	O

To	O
assess	O
the	O
motivation	O
to	O
engage	O
in	O
social	O
exploratory	O
behavior	O
,	O
a	O
novel	O
juvenile	O
conspecific	O
was	O
introduced	O
into	O
the	O
test	O
subject	O
'	O
s	O
home	O
cage	O
for	O
a	O
10	O
-	O
min	O
period	O
.	O

Behavior	O
was	O
video	O
taped	O
and	O
the	O
cumulative	O
amount	O
of	O
time	O
the	O
subject	O
engaged	O
in	O
social	O
investigation	O
was	O
determined	O
from	O
the	O
video	O
records	O
by	O
a	O
trained	O
observer	O
who	O
was	O
blind	O
to	O
the	O
experimental	O
treatments	O
.	O

Baseline	O
social	O
behavior	O
was	O
measured	O
at	O
time	O
0	O
for	O
all	O
experimental	O
treatments	O
.	O

Social	O
behavior	O
was	O
determined	O
as	O
the	O
amount	O
of	O
time	O
that	O
the	O
experimental	O
subject	O
spent	O
investigating	O
(	O
e	O
.	O
g	O
.	O
,	O
anogenital	O
sniffing	O
,	O
trailing	O
)	O
the	O
juvenile	O
.	O

Results	O
are	O
expressed	O
as	O
percent	O
decrease	O
in	O
time	O
engaged	O
in	O
social	O
behavior	O
compared	O
to	O
respective	O
baseline	O
measures	O
.	O

Sucrose	O
preference	O

To	O
assess	O
sucrose	O
preference	O
,	O
mice	S-Species
were	O
provided	O
two	O
solutions	O
,	O
water	O
or	O
water	O
supplemented	O
with	O
2	O
%	O
sucrose	O
,	O
in	O
50	O
ml	O
conical	O
tubes	O
with	O
stoppers	O
fitted	O
with	O
ball	O
-	O
type	O
sipper	O
tubes	O
.	O

Prior	O
to	O
testing	O
conditions	O
,	O
all	O
mice	S-Species
were	O
acclimated	O
to	O
the	O
two	O
bottle	O
test	O
choice	O
.	O

All	O
mice	S-Species
drank	O
both	O
the	O
water	O
and	O
the	O
2	O
%	O
sucrose	O
solution	O
,	O
but	O
preferred	O
drinking	O
the	O
sucrose	O
over	O
the	O
water	O
(	O
data	O
not	O
shown	O
)	O
.	O

On	O
the	O
day	O
of	O
testing	O
,	O
mice	S-Species
were	O
fluid	O
and	O
food	O
deprived	O
for	O
2	O
h	O
prior	O
to	O
testing	O
[	O
50	O
]	O
.	O

At	O
the	O
start	O
of	O
the	O
dark	O
phase	O
of	O
the	O
photoperiod	O
,	O
drinking	O
water	O
and	O
the	O
2	O
%	O
sucrose	O
solution	O
were	O
placed	O
in	O
the	O
home	O
cage	O
overnight	O
(	O
15	O
h	O
)	O
.	O

At	O
the	O
end	O
of	O
each	O
testing	O
period	O
the	O
fluid	O
content	O
of	O
the	O
conical	O
tubes	O
was	O
measured	O
and	O
sucrose	O
preference	O
was	O
determined	O
using	O
the	O
equation	O
:	O
Sucrose	O
intake	O
/	O
Total	O
fluid	O
intake	O
(	O
water	O
+	O
sucrose	O
intake	O
)	O
x	O
100	O
[	O
51	O
]	O
.	O

Plasma	O
cytokine	O
measurement	O

IL	O
-	O
6	O
and	O
IL	O
-	O
1	O
beta	O
were	O
measured	O
in	O
the	O
plasma	O
as	O
previously	O
described	O
[	O
52	O
]	O
.	O

In	O
brief	O
,	O
mice	S-Species
were	O
euthanized	O
by	O
CO2	O
asphyxiation	O
and	O
blood	O
was	O
collected	O
by	O
cardiac	O
puncture	O
into	O
EDTA	O
coated	O
syringes	O
.	O

Samples	O
were	O
centrifuged	O
(	O
6000	O
x	O
g	O
for	O
15	O
min	O
at	O
4	O
degrees	O
C	O
)	O
and	O
plasma	O
was	O
collected	O
and	O
stored	O
frozen	O
(	O
-	O
80	O
degrees	O
C	O
)	O
until	O
assaying	O
.	O

Plasma	O
samples	O
were	O
assayed	O
for	O
IL	O
-	O
6	O
using	O
a	O
customized	O
ELISA	O
that	O
we	O
have	O
described	O
in	O
detail	O
[	O
52	O
]	O
and	O
for	O
IL	O
-	O
1	O
beta	O
using	O
a	O
commercial	O
ELISA	O
kit	O
(	O
R	O
&	O
D	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
.	O

Assays	O
were	O
sensitive	O
to	O
8	O
pg	O
/	O
ml	O
of	O
IL	O
-	O
6	O
and	O
1	O
.	O
5	O
pg	O
/	O
ml	O
of	O
IL	O
-	O
1	O
beta	O
,	O
and	O
inter	O
-	O
and	O
intra	O
-	O
assay	O
coefficients	O
of	O
variation	O
were	O
less	O
than	O
10	O
%	O
.	O

Real	O
time	O
PCR	O

Total	O
RNA	O
was	O
isolated	O
from	O
brain	O
using	O
the	O
Tri	O
Reagent	O
protocol	O
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

RNA	O
samples	O
were	O
subjected	O
to	O
a	O
DNase	O
I	O
digestion	O
procedure	O
and	O
then	O
reverse	O
transcribed	O
to	O
cDNA	O
using	O
a	O
RT	O
RETROscript	O
kit	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
.	O

Quantitative	O
real	O
time	O
PCR	O
was	O
performed	O
using	O
the	O
Applied	O
Biosystems	O
(	O
Foster	O
,	O
CA	O
)	O
Assay	O
-	O
on	O
Demand	O
Gene	O
Expression	O
protocol	O
as	O
previously	O
described	O
[	O
13	O
]	O
.	O

In	O
brief	O
,	O
cDNA	O
was	O
amplified	O
by	O
real	O
time	O
PCR	O
where	O
a	O
target	O
cDNA	O
(	O
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
6	O
,	O
MHC	O
II	O
,	O
TLR2	O
,	O
or	O
IDO	O
)	O
and	O
a	O
reference	O
cDNA	O
(	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
were	O
amplified	O
simultaneously	O
using	O
an	O
oligonucleotide	O
probe	O
with	O
a	O
5	O
'	O
fluorescent	O
reporter	O
dye	O
(	O
6	O
-	O
FAM	O
)	O
and	O
a	O
3	O
'	O
quencher	O
dye	O
(	O
NFQ	O
)	O
.	O

Fluorescence	O
was	O
determined	O
on	O
an	O
ABI	O
PRISM	O
7300	O
-	O
sequence	O
detection	O
system	O
(	O
Applied	O
Biosystems	O
,	O
CA	O
)	O
.	O

Data	O
were	O
analyzed	O
using	O
the	O
comparative	O
threshold	O
cycle	O
(	O
Ct	O
)	O
method	O
and	O
results	O
are	O
expressed	O
as	O
fold	O
difference	O
.	O

Experimental	O
protocols	O

For	O
the	O
cell	O
culture	O
studies	O
,	O
minocycline	O
was	O
prepared	O
in	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
and	O
BV	O
-	O
2	O
cells	O
were	O
washed	O
and	O
replenished	O
with	O
growth	O
mediumsupplemented	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
100	O
,	O
200	O
,	O
or	O
400	O
mu	O
g	O
/	O
ml	O
minocycline	O
.	O

After	O
30	O
min	O
,	O
LPS	O
at	O
10	O
ng	O
/	O
ml	O
was	O
added	O
to	O
the	O
culture	O
medium	O
.	O

Supernatants	O
were	O
collected	O
4	O
h	O
later	O
and	O
IL	O
-	O
6	O
and	O
IL	O
-	O
1	O
beta	O
concentrations	O
were	O
determined	O
by	O
ELISA	O
.	O

Total	O
proteins	O
were	O
determined	O
from	O
cell	O
culture	O
homogenates	O
by	O
the	O
Bio	O
-	O
Rad	O
Dc	O
protein	O
assay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Bio	O
-	O
Rad	O
Lboratories	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

Each	O
treatment	O
was	O
replicated	O
a	O
minimum	O
of	O
four	O
times	O
.	O

Cell	O
viability	O
was	O
confirmed	O
by	O
the	O
MTS	O
cell	O
proliferation	O
assay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

For	O
all	O
mouse	S-Species
studies	O
,	O
minocycline	O
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
was	O
dissolved	O
in	O
sterile	O
water	O
and	O
sonicated	O
to	O
ensure	O
complete	O
solubilization	O
.	O

In	O
the	O
first	O
mouse	S-Species
study	O
,	O
adult	O
male	O
BALB	O
/	O
c	O
mice	S-Species
received	O
an	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
injection	O
of	O
vehicle	O
or	O
minocycline	O
(	O
50	O
mg	O
/	O
kg	O
)	O
for	O
three	O
consecutive	O
days	O
.	O

On	O
the	O
3rd	O
day	O
,	O
mice	S-Species
were	O
also	O
injected	O
i	O
.	O
p	O
.	O
with	O
saline	O
or	O
Escherichia	B-Species
coli	E-Species
LPS	O
(	O
0	O
.	O
33	O
mg	O
/	O
kg	O
;	O
serotype	O
0127	O
:	O
B8	O
,	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
and	O
were	O
euthanized	O
by	O
CO2	O
asphyxiation	O
24	O
h	O
later	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
LPS	O
dosage	O
was	O
selected	O
because	O
it	O
elicits	O
a	O
proinflammatory	O
cytokine	O
response	O
in	O
the	O
brain	O
resulting	O
in	O
mild	O
transient	O
sickness	O
behavior	O
in	O
adult	O
mice	S-Species
[	O
13	O
,	O
53	O
]	O
.	O

Macrophage	O
/	O
microglial	O
cells	O
were	O
isolated	O
from	O
whole	O
brain	O
homogenates	O
and	O
TLR2	O
and	O
MHC	O
II	O
surface	O
expression	O
were	O
determined	O
by	O
flow	O
cytometry	O
.	O

The	O
minocycline	O
injection	O
regimen	O
and	O
dosage	O
was	O
selected	O
because	O
a	O
repeated	O
pretreatment	O
course	O
with	O
minocycline	O
is	O
necessary	O
to	O
attenuate	O
neuroinflammation	O
[	O
41	O
-	O
43	O
,	O
45	O
]	O
.	O

In	O
the	O
second	O
study	O
,	O
adult	O
male	O
BALB	O
/	O
c	O
mice	S-Species
received	O
an	O
i	O
.	O
p	O
.	O
injection	O
with	O
vehicle	O
or	O
minocycline	O
for	O
three	O
consecutive	O
days	O
.	O

On	O
the	O
third	O
day	O
,	O
motivation	O
to	O
engage	O
in	O
social	O
behavior	O
was	O
determined	O
immediately	O
before	O
i	O
.	O
p	O
.	O
injection	O
of	O
saline	O
or	O
LPS	O
(	O
0	O
.	O
33	O
mg	O
/	O
kg	O
)	O
and	O
again	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
24	O
h	O
later	O
(	O
n	O
=	O
8	O
)	O
.	O

Body	O
weight	O
and	O
food	O
intake	O
were	O
measured	O
at	O
each	O
time	O
point	O
over	O
the	O
24	O
h	O
period	O
.	O

In	O
a	O
related	O
,	O
but	O
separate	O
study	O
,	O
adult	O
mice	S-Species
were	O
treated	O
with	O
minocycline	O
and	O
LPS	O
as	O
described	O
and	O
anhedonia	O
was	O
assessed	O
24	O
-	O
39	O
h	O
following	O
i	O
.	O
p	O
.	O
injection	O
of	O
saline	O
or	O
LPS	O
(	O
0	O
.	O
33	O
mg	O
/	O
kg	O
)	O
(	O
n	O
=	O
15	O
)	O
.	O

Body	O
weight	O
,	O
food	O
intake	O
,	O
water	O
intake	O
,	O
and	O
sucrose	O
intake	O
were	O
determined	O
over	O
the	O
testing	O
period	O
.	O

In	O
the	O
third	O
study	O
,	O
adult	O
BALB	O
/	O
c	O
mice	S-Species
were	O
treated	O
with	O
minocycline	O
and	O
then	O
LPS	O
as	O
described	O
.	O

Mice	S-Species
were	O
euthanized	O
by	O
CO2	O
asphyxiation	O
4	O
later	O
.	O

Brains	O
were	O
removed	O
and	O
dissected	O
to	O
collect	O
different	O
brain	O
regions	O
.	O

Brain	O
regions	O
were	O
stored	O
at	O
-	O
20	O
degrees	O
C	O
in	O
RNAlater	O
(	O
Qiagen	O
,	O
CA	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
brain	O
samples	O
and	O
assayed	O
using	O
quantitative	O
PCR	O
(	O
n	O
=	O
8	O
)	O
.	O

Plasma	O
was	O
also	O
collected	O
and	O
stored	O
(	O
-	O
80	O
degrees	O
C	O
)	O
until	O
assaying	O
.	O

In	O
a	O
final	O
study	O
,	O
adult	O
(	O
3	O
-	O
4	O
month	O
old	O
)	O
or	O
aged	O
(	O
20	O
-	O
22	O
month	O
old	O
)	O
male	O
BALB	O
/	O
c	O
mice	S-Species
were	O
treated	O
with	O
minocycline	O
and	O
LPS	O
as	O
described	O
and	O
euthanized	O
4	O
h	O
later	O
.	O

Brains	O
were	O
dissected	O
to	O
collect	O
different	O
brain	O
regions	O
and	O
were	O
stored	O
at	O
-	O
20	O
degrees	O
C	O
in	O
RNAlater	O
(	O
Qiagen	O
,	O
CA	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
the	O
hippocampus	O
and	O
assayed	O
using	O
quantitative	O
PCR	O
(	O
n	O
=	O
8	O
)	O
.	O

Statistical	O
analysis	O

All	O
data	O
were	O
analyzed	O
using	O
Statistical	O
Analysis	O
Systems	O
(	O
SAS	O
)	O
General	O
Linear	O
Model	O
procedures	O
.	O

Data	O
were	O
subjected	O
to	O
one	O
,	O
two	O
-	O
(	O
Mino	O
x	O
LPS	O
,	O
Age	O
x	O
LPS	O
,	O
Mino	O
x	O
Age	O
)	O
or	O
three	O
-	O
way	O
(	O
Mino	O
x	O
LPS	O
x	O
Time	O
,	O
Mino	O
x	O
LPS	O
x	O
Age	O
)	O
ANOVA	O
to	O
determine	O
significant	O
main	O
effects	O
and	O
interactions	O
between	O
main	O
factors	O
.	O

When	O
appropriate	O
,	O
differences	O
between	O
treatment	O
means	O
were	O
evaluated	O
by	O
an	O
F	O
-	O
protected	O
t	O
-	O
test	O
using	O
the	O
Least	O
-	O
Significant	O
Difference	O
procedure	O
of	O
SAS	O
.	O

All	O
data	O
are	O
expressed	O
as	O
treatment	O
means	O
+/-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

Results	O

Minocycline	O
attenuates	O
LPS	O
-	O
induced	O
cytokine	O
production	O
in	O
BV	O
-	O
2	O
microglia	O

Minocycline	O
is	O
a	O
tetracycline	O
-	O
type	O
antibiotic	O
that	O
has	O
anti	O
-	O
inflammatory	O
properties	O
in	O
the	O
CNS	O
[	O
41	O
-	O
43	O
,	O
45	O
]	O
.	O

To	O
determine	O
the	O
degree	O
to	O
which	O
minocycline	O
suppresses	O
microglia	O
activation	O
,	O
BV	O
-	O
2	O
microglia	O
-	O
derived	O
cell	O
lines	O
were	O
used	O
.	O

In	O
the	O
first	O
experiment	O
,	O
BV	O
-	O
2	O
cells	O
were	O
treated	O
with	O
LPS	O
and	O
IL	O
-	O
6	O
production	O
was	O
determined	O
4	O
h	O
later	O
.	O

Fig	O
.	O

1A	O
shows	O
that	O
LPS	O
increased	O
IL	O
-	O
6	O
production	O
in	O
a	O
dose	O
dependent	O
manner	O
F	O
(	O
5	O
,	O
23	O
)	O
=	O
101	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
second	O
experiment	O
,	O
BV	O
-	O
2	O
cells	O
were	O
incubated	O
with	O
DMSO	O
or	O
minocycline	O
and	O
then	O
stimulated	O
with	O
LPS	O
.	O

Minocycline	O
reduced	O
LPS	O
-	O
induced	O
IL	O
-	O
6	O
secretion	O
in	O
a	O
dose	O
dependent	O
manner	O
(	O
Mino	O
x	O
LPS	O
interaction	O
,	O
F	O
(	O
4	O
,	O
23	O
)	O
=	O
16	O
.	O
87	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
Fig	O
.	O
1B	O
)	O
.	O

Minocycline	O
pretreatment	O
had	O
a	O
similar	O
anti	O
-	O
inflammatory	O
effect	O
on	O
LPS	O
-	O
stimulated	O
IL	O
-	O
1	O
beta	O
secretion	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

In	O
a	O
third	O
experiment	O
,	O
minocycline	O
suppressed	O
LPS	O
-	O
induced	O
MHC	O
II	O
,	O
TLR2	O
,	O
IL	O
-	O
1	O
beta	O
,	O
and	O
IL	O
-	O
6	O
mRNA	O
levels	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
for	O
each	O
,	O
Fig	O
.	O
1D	O
)	O
.	O

The	O
MTS	O
assay	O
verified	O
that	O
neither	O
cell	O
survival	O
nor	O
proliferation	O
was	O
affected	O
by	O
the	O
experimental	O
treatments	O
(	O
data	O
not	O
shown	O
)	O
.	O

LPS	O
-	O
induced	O
TLR2	O
surface	O
expression	O
on	O
microglia	O
is	O
reduced	O
by	O
minocycline	O

Because	O
minocycline	O
attenuated	O
LPS	O
-	O
induced	O
cytokine	O
secretion	O
and	O
TLR2	O
mRNA	O
expression	O
in	O
BV	O
-	O
2	O
cells	O
we	O
next	O
sought	O
to	O
determine	O
if	O
minocycline	O
suppresses	O
markers	O
of	O
microglial	O
activation	O
in	O
the	O
brain	O
of	O
mice	S-Species
.	O

Mice	S-Species
were	O
injected	O
i	O
.	O
p	O
.	O
with	O
vehicle	O
or	O
minocycline	O
for	O
3	O
consecutive	O
days	O
then	O
challenged	O
with	O
saline	O
or	O
LPS	O
i	O
.	O
p	O
.	O

Markers	O
of	O
activation	O
,	O
TLR2	O
and	O
MHC	O
II	O
,	O
were	O
determined	O
on	O
microglia	O
collected	O
24	O
h	O
later	O
.	O

The	O
representative	O
bivariate	O
density	O
plot	O
in	O
Fig	O
.	O

2A	O
shows	O
that	O
there	O
were	O
two	O
populations	O
of	O
CD11b	O
/	O
CD45	O
positive	O
cells	O
and	O
that	O
more	O
cells	O
stained	O
CD11b	O
+	O
/	O
CD45low	O
(	O
microglia	O
)	O
than	O
CD11b	O
+	O
/	O
CD45high	O
(	O
CNS	O
macrophages	O
)	O
.	O

ANOVA	O
revealed	O
that	O
LPS	O
injection	O
increased	O
TLR2	O
surface	O
expression	O
on	O
microglia	O
(	O
F	O
(	O
1	O
,	O
20	O
)	O
=	O
17	O
.	O
6	O
,	O
P	O
<	O
0	O
.	O
004	O
,	O
Fig	O
.	O
2B	O
&	O
D	O
)	O
,	O
but	O
this	O
induction	O
was	O
abrogated	O
by	O
minocycline	O
pretreatment	O
(	O
Tendency	O
for	O
Mino	O
x	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
20	O
)	O
=	O
2	O
.	O
66	O
,	O
P	O
=	O
0	O
.	O
10	O
,	O
Fig	O
.	O
2C	O
&	O
D	O
)	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
because	O
minocycline	O
and	O
saline	O
controls	O
did	O
not	O
differ	O
in	O
their	O
TLR2	O
expression	O
,	O
these	O
data	O
were	O
grouped	O
together	O
as	O
the	O
Control	O
group	O
(	O
Fig	O
.	O
2B	O
&	O
C	O
)	O
.	O

In	O
addition	O
,	O
neither	O
minocycline	O
nor	O
LPS	O
treatment	O
had	O
a	O
significant	O
main	O
effect	O
on	O
MHC	O
class	O
II	O
surface	O
expression	O
on	O
microglia	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
indicate	O
that	O
minocycline	O
attenuated	O
LPS	O
-	O
induced	O
TLR2	O
expression	O
on	O
microglia	O
.	O

Minocycline	O
facilitates	O
the	O
recovery	O
from	O
LPS	O
-	O
induced	O
sickness	O
behavior	O

CNS	O
macrophages	O
and	O
microglia	O
produce	O
inflammatory	O
cytokines	O
and	O
secondary	O
messengers	O
that	O
modulate	O
behavioral	O
responses	O
.	O

Therefore	O
,	O
we	O
next	O
investigated	O
if	O
minocycline	O
reduced	O
the	O
sickness	O
response	O
associated	O
with	O
peripheral	O
LPS	O
injection	O
.	O

In	O
this	O
experiment	O
,	O
adult	O
mice	S-Species
were	O
treated	O
with	O
minocycline	O
and	O
LPS	O
as	O
described	O
.	O

Social	O
exploratory	O
behavior	O
was	O
measured	O
before	O
i	O
.	O
p	O
.	O

LPS	O
injection	O
and	O
again	O
2	O
,	O
4	O
,	O
8	O
,	O
and	O
24	O
h	O
later	O
.	O

Fig	O
.	O

3A	O
shows	O
that	O
LPS	O
injection	O
caused	O
a	O
reduction	O
in	O
social	O
exploratory	O
behavior	O
(	O
F	O
(	O
1	O
,	O
57	O
)	O
=	O
218	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
that	O
was	O
time	O
dependent	O
(	O
F	O
(	O
4	O
,	O
57	O
)	O
=	O
66	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Moreover	O
,	O
the	O
LPS	O
-	O
associated	O
reduction	O
in	O
social	O
exploration	O
was	O
attenuated	O
by	O
minocycline	O
(	O
Mino	O
x	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
57	O
)	O
=	O
7	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
007	O
)	O
.	O

For	O
example	O
,	O
at	O
8	O
h	O
post	O
LPS	O
,	O
social	O
exploration	O
was	O
reduced	O
by	O
35	O
%	O
in	O
minocycline	O
pretreated	O
mice	S-Species
given	O
LPS	O
compared	O
to	O
a	O
67	O
%	O
reduction	O
in	O
vehicle	O
pretreated	O
mice	S-Species
given	O
LPS	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

While	O
minocycline	O
administration	O
alone	O
reduced	O
food	O
intake	O
and	O
body	O
weight	O
in	O
control	O
mice	S-Species
(	O
P	O
<	O
0	O
.	O
05	O
,	O
for	O
each	O
)	O
,	O
it	O
also	O
protected	O
against	O
LPS	O
-	O
associated	O
anorexia	O
(	O
Mino	O
x	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
60	O
)	O
=	O
70	O
.	O
0	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
Fig	O
.	O
3B	O
)	O
and	O
weight	O
loss	O
(	O
Mino	O
x	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
60	O
)	O
=	O
29	O
.	O
7	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
Fig	O
.	O
3C	O
)	O
.	O

Because	O
sickness	O
can	O
also	O
be	O
associated	O
with	O
longer	O
lasting	O
changes	O
in	O
motivation	O
[	O
38	O
]	O
,	O
we	O
next	O
sought	O
to	O
determine	O
if	O
minocycline	O
abrogated	O
LPS	O
-	O
induced	O
anhedonia	O
[	O
54	O
,	O
55	O
]	O
.	O

In	O
this	O
experiment	O
,	O
mice	S-Species
were	O
subjected	O
to	O
the	O
same	O
minocycline	O
injection	O
regimen	O
and	O
LPS	O
challenge	O
as	O
above	O
and	O
sucrose	O
preference	O
was	O
assessed	O
24	O
-	O
39	O
h	O
post	O
LPS	O
injection	O
.	O

By	O
24	O
h	O
post	O
LPS	O
injection	O
,	O
food	O
and	O
water	O
intake	O
returned	O
to	O
baseline	O
and	O
LPS	O
treated	O
mice	S-Species
still	O
exhibited	O
a	O
marked	O
reduction	O
in	O
sucrose	O
preference	O
from	O
24	O
-	O
39	O
h	O
(	O
F	O
(	O
1	O
,	O
59	O
)	O
=	O
14	O
.	O
3	O
,	O
P	O
<	O
0	O
.	O
003	O
)	O
.	O

Moreover	O
,	O
this	O
LPS	O
-	O
dependent	O
reduction	O
in	O
sucrose	O
preference	O
was	O
prevented	O
by	O
minocycline	O
pretreatment	O
(	O
Mino	O
x	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
59	O
)	O
=	O
9	O
.	O
9	O
,	O
P	O
<	O
0	O
.	O
004	O
,	O
Fig	O
.	O
4	O
)	O
.	O

For	O
example	O
,	O
minocycline	O
pretreated	O
mice	S-Species
injected	O
with	O
LPS	O
maintained	O
the	O
same	O
strong	O
preference	O
for	O
sucrose	O
as	O
saline	O
and	O
minocycline	O
controls	O
(	O
i	O
.	O
e	O
.	O
,	O
approximately	O
85	O
%	O
preference	O
)	O
.	O

These	O
data	O
can	O
be	O
interpreted	O
to	O
indicate	O
that	O
minocycline	O
blocks	O
anhedonia	O
associated	O
with	O
peripheral	O
LPS	O
challenge	O
.	O

Minocycline	O
reduces	O
LPS	O
-	O
induced	O
neuroinflammation	O

Pro	O
-	O
inflammatory	O
cytokines	O
in	O
the	O
CNS	O
are	O
partially	O
responsible	O
for	O
the	O
behavioral	O
symptoms	O
of	O
sickness	O
(	O
e	O
.	O
g	O
.	O
,	O
anorexia	O
,	O
social	O
withdrawal	O
,	O
and	O
anhedonia	O
)	O
[	O
1	O
]	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
degree	O
to	O
which	O
minocycline	O
reduces	O
neuroinflammation	O
(	O
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
6	O
,	O
and	O
IDO	O
)	O
after	O
peripheral	O
injection	O
of	O
LPS	O
.	O

In	O
this	O
experiment	O
,	O
mice	S-Species
were	O
subjected	O
to	O
the	O
minocycline	O
injection	O
regimen	O
and	O
LPS	O
challenge	O
as	O
above	O
and	O
cytokine	O
mRNA	O
levels	O
were	O
determined	O
in	O
the	O
cortex	O
and	O
hippocampus	O
4	O
h	O
after	O
LPS	O
injection	O
.	O

In	O
mice	S-Species
pretreated	O
with	O
vehicle	O
,	O
LPS	O
markedly	O
increased	O
IL	O
-	O
1	O
beta	O
mRNA	O
levels	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
62	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
cortex	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
17	O
.	O
25	O
,	O
P	O
<	O
0	O
.	O
0003	O
)	O
.	O

The	O
LPS	O
-	O
induced	O
IL	O
-	O
1	O
beta	O
mRNA	O
expression	O
was	O
reduced	O
in	O
both	O
brain	O
regions	O
in	O
mice	S-Species
receiving	O
minocycline	O
prior	O
to	O
LPS	O
injection	O
:	O
(	O
hippocampus	O
,	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
9	O
.	O
63	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
cortex	O
,	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
7	O
.	O
23	O
,	O
P	O
=	O
0	O
.	O
08	O
,	O
Fig	O
.	O

5A	O
)	O
.	O

LPS	O
caused	O
a	O
similar	O
induction	O
of	O
IL	O
-	O
6	O
mRNA	O
levels	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
37	O
.	O
2	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
cortex	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
22	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
minocycline	O
pretreatment	O
only	O
significantly	O
attenuated	O
LPS	O
-	O
induced	O
IL	O
-	O
6	O
mRNA	O
levels	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
10	O
.	O
27	O
,	O
P	O
<	O
0	O
.	O
004	O
,	O
Fig	O
.	O
5B	O
)	O
.	O

IDO	O
mRNA	O
levels	O
were	O
determined	O
from	O
the	O
same	O
RNA	O
pool	O
.	O

Fig	O
.	O

6D	O
shows	O
that	O
LPS	O
injection	O
increased	O
IDO	O
mRNA	O
expression	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
11	O
.	O
69	O
,	O
P	O
<	O
0	O
.	O
002	O
)	O
and	O
cortex	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
5	O
.	O
26	O
,	O
P	O
<	O
0	O
.	O
03	O
)	O
.	O

This	O
LPS	O
-	O
induced	O
IDO	O
mRNA	O
expression	O
was	O
attenuated	O
by	O
minocycline	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
11	O
.	O
69	O
,	O
P	O
<	O
0	O
.	O
002	O
)	O
and	O
cortex	O
(	O
F	O
(	O
1	O
,	O
31	O
)	O
=	O
5	O
.	O
26	O
,	O
P	O
<	O
0	O
.	O
03	O
)	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
IDO	O
mRNA	O
was	O
undetected	O
in	O
saline	O
treated	O
mice	S-Species
.	O

Therefore	O
,	O
the	O
fold	O
IDO	O
change	O
was	O
relative	O
to	O
the	O
IDO	O
mRNA	O
levels	O
in	O
mice	S-Species
receiving	O
minocycline	O
prior	O
to	O
LPS	O
.	O

Minocycline	O
reduces	O
LPS	O
-	O
induced	O
IL	O
-	O
6	O
,	O
but	O
not	O
IL	O
-	O
1	O
beta	O
,	O
in	O
the	O
plasma	O

Because	O
cytokine	O
signals	O
can	O
be	O
relayed	O
from	O
the	O
periphery	O
to	O
the	O
brain	O
by	O
humoral	O
pathways	O
[	O
56	O
]	O
,	O
plasma	O
cytokine	O
levels	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
1	O
beta	O
were	O
determined	O
4	O
h	O
post	O
LPS	O
injection	O
.	O

As	O
expected	O
,	O
LPS	O
injection	O
caused	O
a	O
marked	O
increase	O
in	O
plasma	O
IL	O
-	O
1	O
beta	O
(	O
F	O
(	O
1	O
,	O
36	O
)	O
=	O
52	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
IL	O
-	O
6	O
levels	O
(	O
F	O
(	O
1	O
,	O
36	O
)	O
34	O
.	O
01	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Minocycline	O
pretreatment	O
reduced	O
LPS	O
-	O
induced	O
IL	O
-	O
6	O
levels	O
in	O
the	O
plasma	O
(	O
F	O
(	O
1	O
,	O
36	O
)	O
6	O
.	O
68	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
but	O
had	O
no	O
significant	O
main	O
effect	O
on	O
LPS	O
-	O
induced	O
IL	O
-	O
1	O
beta	O
levels	O
(	O
Fig	O
.	O
6	O
)	O
.	O

Minocycline	O
attenuates	O
LPS	O
-	O
induced	O
exaggerated	O
neuroinflammation	O
in	O
aged	O
mice	S-Species

Aged	O
BALB	O
/	O
c	O
mice	S-Species
(	O
22	O
-	O
24	O
m	O
)	O
have	O
an	O
exaggerated	O
neuroinflammatory	O
response	O
to	O
LPS	O
injection	O
[	O
10	O
,	O
13	O
,	O
14	O
]	O
.	O

Therefore	O
,	O
we	O
next	O
sought	O
to	O
determine	O
if	O
the	O
heightened	O
inflammatory	O
response	O
in	O
the	O
brain	O
of	O
aged	O
mice	S-Species
was	O
reduced	O
by	O
minocycline	O
.	O

In	O
this	O
experiment	O
,	O
adult	O
and	O
aged	O
mice	S-Species
were	O
subjected	O
to	O
the	O
minocycline	O
injection	O
regimen	O
and	O
LPS	O
challenge	O
as	O
above	O
.	O

As	O
we	O
have	O
reported	O
previously	O
,	O
MHC	O
II	O
mRNA	O
expression	O
was	O
increased	O
by	O
age	O
(	O
P	O
<	O
0	O
.	O
03	O
,	O
Fig	O
.	O
7A	O
)	O
[	O
13	O
,	O
14	O
]	O
,	O
but	O
MHC	O
II	O
levels	O
were	O
unaffected	O
by	O
either	O
LPS	O
or	O
minocycline	O
treatment	O
(	O
not	O
shown	O
)	O
.	O

Consistent	O
with	O
the	O
data	O
presented	O
in	O
Fig	O
.	O

2	O
,	O
ANOVA	O
revealed	O
a	O
significant	O
main	O
effect	O
of	O
LPS	O
injection	O
on	O
TLR2	O
mRNA	O
expression	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1	O
,	O
63	O
)	O
=	O
85	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Moreover	O
,	O
LPS	O
caused	O
a	O
greater	O
increase	O
in	O
TLR2	O
mRNA	O
in	O
the	O
hippocampus	O
of	O
aged	O
mice	S-Species
compared	O
to	O
adults	O
(	O
LPS	O
x	O
Age	O
interaction	O
,	O
F	O
(	O
1	O
,	O
63	O
)	O
=	O
12	O
.	O
70	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Furthermore	O
,	O
minocycline	O
pretreatment	O
attenuated	O
LPS	O
-	O
induced	O
TLR2	O
mRNA	O
levels	O
in	O
both	O
adult	O
and	O
aged	O
mice	S-Species
(	O
Mino	O
x	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
63	O
)	O
=	O
9	O
.	O
02	O
,	O
P	O
<	O
0	O
.	O
004	O
)	O
.	O

Parallel	O
to	O
the	O
results	O
for	O
TLR2	O
,	O
LPS	O
caused	O
a	O
greater	O
increase	O
in	O
IL	O
-	O
1	O
beta	O
and	O
IDO	O
mRNA	O
levels	O
in	O
hippocampus	O
of	O
aged	O
mice	S-Species
compared	O
to	O
adults	O
(	O
Age	O
x	O
LPS	O
,	O
F	O
(	O
1	O
,	O
60	O
)	O
=	O
8	O
.	O
64	O
,	O
P	O
<	O
0	O
.	O
01	O
for	O
IL	O
-	O
1	O
beta	O
and	O
F	O
(	O
1	O
,	O
60	O
)	O
=	O
4	O
.	O
0	O
,	O
P	O
<	O
0	O
.	O
05	O
for	O
IDO	O
)	O
.	O

Minocycline	O
pretreatment	O
attenuated	O
LPS	O
-	O
induced	O
mRNA	O
levels	O
of	O
IL	O
-	O
1	O
beta	O
(	O
Mino	O
x	O
LPS	O
,	O
F	O
(	O
1	O
,	O
60	O
)	O
=	O
8	O
.	O
76	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
Fig	O
.	O
7C	O
)	O
and	O
IDO	O
(	O
Mino	O
x	O
LPS	O
,	O
F	O
(	O
1	O
,	O
60	O
)	O
=	O
9	O
.	O
7	O
,	O
P	O
<	O
0	O
.	O
003	O
,	O
Fig	O
.	O
7D	O
)	O
.	O

While	O
LPS	O
induced	O
higher	O
IL	O
-	O
6	O
mRNA	O
levels	O
in	O
the	O
hippocampus	O
of	O
both	O
adult	O
and	O
aged	O
mice	S-Species
(	O
F	O
(	O
1	O
,	O
59	O
)	O
=	O
44	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
there	O
was	O
not	O
an	O
Age	O
x	O
LPS	O
interaction	O
.	O

Minocycline	O
pretreatment	O
attenuated	O
the	O
LPS	O
-	O
induced	O
increase	O
in	O
hippocampal	O
IL	O
-	O
6	O
mRNA	O
(	O
Mino	O
x	O
LPS	O
,	O
F	O
(	O
1	O
,	O
59	O
)	O
=	O
5	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
02	O
,	O
Fig	O
.	O
7E	O
)	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
minocycline	O
pretreatment	O
was	O
effective	O
in	O
attenuating	O
the	O
exaggerated	O
neuroinflammation	O
in	O
aged	O
mice	S-Species
.	O

Discussion	O

In	O
the	O
elderly	O
,	O
systemic	O
infection	O
is	O
associated	O
with	O
an	O
increased	O
frequency	O
of	O
behavioral	O
and	O
cognitive	O
complications	O
[	O
57	O
,	O
58	O
]	O
.	O

We	O
have	O
reported	O
that	O
stimulation	O
of	O
the	O
peripheral	O
immune	O
system	O
in	O
older	O
(	O
20	O
-	O
24	O
m	O
)	O
BALB	O
/	O
c	O
mice	S-Species
causes	O
exaggerated	O
neuroinflammation	O
that	O
is	O
paralleled	O
by	O
prolonged	O
sickness	O
[	O
13	O
]	O
,	O
impaired	O
working	O
memory	O
[	O
10	O
]	O
,	O
and	O
depressive	O
-	O
like	O
behaviors	O
[	O
15	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
that	O
can	O
modulate	O
cytokine	O
-	O
mediated	O
pathways	O
in	O
the	O
brain	O
.	O

Here	O
we	O
show	O
that	O
minocycline	O
treatment	O
reduced	O
LPS	O
-	O
induced	O
TLR2	O
expression	O
in	O
BV	O
-	O
2	O
cells	O
and	O
on	O
microglia	O
isolated	O
from	O
adult	O
mice	S-Species
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
minocycline	O
was	O
effective	O
in	O
facilitating	O
the	O
recovery	O
from	O
LPS	O
-	O
induced	O
sickness	O
and	O
preventing	O
anhedonia	O
in	O
adult	O
mice	S-Species
.	O

Furthermore	O
,	O
we	O
show	O
that	O
minocycline	O
attenuated	O
LPS	O
-	O
induced	O
neuroinflammation	O
in	O
adults	O
and	O
normalized	O
the	O
exaggerated	O
neuroinflammation	O
in	O
aged	O
mice	S-Species
.	O

Our	O
findings	O
,	O
using	O
cell	O
culture	O
and	O
animal	O
experiments	O
,	O
support	O
the	O
notion	O
that	O
minocycline	O
attenuates	O
microglial	O
activation	O
and	O
limits	O
production	O
of	O
inflammatory	O
mediators	O
.	O

For	O
instance	O
,	O
minocycline	O
pretreatment	O
of	O
BV	O
-	O
2	O
cultures	O
decreased	O
LPS	O
-	O
stimulated	O
cytokine	O
production	O
in	O
a	O
dose	O
dependent	O
manner	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

In	O
BV	O
-	O
2	O
cells	O
,	O
minocycline	O
also	O
attenuated	O
mRNA	O
expression	O
of	O
inflammatory	O
genes	O
including	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1	O
beta	O
,	O
MHC	O
II	O
,	O
and	O
TLR2	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
other	O
studies	O
using	O
minocycline	O
and	O
LPS	O
in	O
BV	O
-	O
2	O
cells	O
[	O
44	O
,	O
59	O
]	O
.	O

Based	O
on	O
these	O
data	O
we	O
next	O
investigated	O
if	O
microglial	O
activation	O
could	O
be	O
attenuated	O
in	O
the	O
brain	O
.	O

Because	O
LPS	O
increases	O
brain	O
cytokine	O
production	O
we	O
expected	O
that	O
MHC	O
II	O
expression	O
would	O
also	O
be	O
increased	O
.	O

Contrary	O
to	O
our	O
predictions	O
,	O
neither	O
MHC	O
II	O
mRNA	O
levels	O
(	O
Fig	O
.	O
7	O
)	O
in	O
the	O
brain	O
nor	O
MHC	O
II	O
surface	O
expression	O
on	O
microglia	O
(	O
CD11b	O
+	O
/	O
CD45low	O
)	O
(	O
data	O
not	O
shown	O
)	O
were	O
increased	O
by	O
LPS	O
injection	O
.	O

In	O
an	O
EAE	O
model	O
,	O
minocycline	O
reduced	O
microglial	O
expression	O
of	O
MHC	O
II	O
[	O
45	O
]	O
,	O
but	O
one	O
key	O
difference	O
from	O
our	O
study	O
is	O
that	O
the	O
induction	O
of	O
EAE	O
pathology	O
requires	O
functional	O
antigen	O
presentation	O
on	O
MHC	O
II	O
[	O
60	O
]	O
.	O

It	O
is	O
postulated	O
that	O
microglia	O
have	O
several	O
activation	O
states	O
that	O
depend	O
on	O
the	O
specific	O
inflammatory	O
stimulus	O
[	O
61	O
]	O
.	O

Thus	O
,	O
in	O
situations	O
of	O
transient	O
peripheral	O
innate	O
immune	O
stimulation	O
,	O
markers	O
in	O
the	O
CNS	O
such	O
as	O
Toll	O
-	O
Like	O
receptors	O
[	O
6	O
]	O
may	O
be	O
indicative	O
of	O
microglia	O
activation	O
.	O

In	O
support	O
of	O
this	O
premise	O
,	O
our	O
data	O
show	O
that	O
LPS	O
injection	O
increases	O
TLR2	O
surface	O
expression	O
on	O
microglia	O
(	O
CD11b	O
+	O
/	O
CD45low	O
)	O
,	O
which	O
is	O
inhibited	O
by	O
minocycline	O
pretreatment	O
(	O
Fig	O
.	O
2	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
other	O
studies	O
showing	O
that	O
central	O
or	O
peripheral	O
LPS	O
challenge	O
increases	O
TLR2	O
mRNA	O
in	O
the	O
brain	O
[	O
6	O
,	O
14	O
]	O
.	O

Taken	O
together	O
our	O
findings	O
can	O
be	O
interpreted	O
to	O
suggest	O
that	O
minocycline	O
attenuates	O
pathways	O
associated	O
with	O
microglia	O
activation	O
following	O
peripheral	O
LPS	O
challenge	O
.	O

One	O
of	O
the	O
important	O
findings	O
of	O
this	O
study	O
was	O
that	O
reduction	O
of	O
neuroinflammation	O
by	O
minocycline	O
was	O
associated	O
with	O
facilitated	O
recovery	O
from	O
LPS	O
-	O
induced	O
sickness	O
behavior	O
.	O

These	O
results	O
are	O
akin	O
to	O
our	O
previous	O
work	O
with	O
the	O
anti	O
-	O
oxidant	O
,	O
alpha	O
-	O
tocopherol	O
[	O
52	O
]	O
,	O
and	O
an	O
NFKB	O
decoy	O
inhibitor	O
[	O
62	O
]	O
.	O

Consistent	O
with	O
our	O
previous	O
studies	O
[	O
52	O
,	O
53	O
,	O
62	O
,	O
63	O
]	O
,	O
reductions	O
in	O
neuroinflammatory	O
cytokines	O
(	O
Fig	O
.	O
5	O
)	O
did	O
not	O
prevent	O
the	O
induction	O
of	O
the	O
LPS	O
-	O
induced	O
sickness	O
response	O
(	O
2	O
-	O
4	O
h	O
)	O
,	O
but	O
rather	O
facilitated	O
the	O
recovery	O
from	O
sickness	O
(	O
8	O
-	O
24	O
h	O
)	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

Recovery	O
may	O
be	O
a	O
critical	O
issue	O
because	O
brain	O
cytokines	O
and	O
the	O
corresponding	O
physiological	O
and	O
behavioral	O
responses	O
are	O
beneficial	O
to	O
the	O
host	O
[	O
1	O
]	O
.	O

The	O
potential	O
risk	O
for	O
a	O
maladaptive	O
response	O
occurs	O
when	O
the	O
normally	O
transient	O
neuroinflammatory	O
response	O
is	O
amplified	O
or	O
protracted	O
[	O
64	O
]	O
.	O

Therefore	O
pharmacological	O
agents	O
,	O
similar	O
to	O
minocycline	O
,	O
that	O
attenuate	O
neuroinflammatory	O
responses	O
,	O
but	O
do	O
not	O
completely	O
inhibit	O
them	O
,	O
may	O
be	O
important	O
in	O
preventing	O
the	O
development	O
of	O
more	O
severe	O
and	O
long	O
-	O
lasting	O
cognitive	O
and	O
behavioral	O
complications	O
.	O

The	O
results	O
of	O
the	O
sucrose	O
preference	O
experiments	O
support	O
the	O
idea	O
that	O
limiting	O
exposure	O
to	O
neuroinflammation	O
decreases	O
the	O
duration	O
of	O
behavioral	O
responses	O
.	O

For	O
example	O
,	O
while	O
minocycline	O
did	O
not	O
inhibit	O
cytokine	O
expression	O
(	O
Fig	O
.	O
5	O
)	O
or	O
the	O
induction	O
of	O
sickness	O
(	O
Fig	O
.	O
3A	O
)	O
,	O
minocycline	O
pretreatment	O
completely	O
reversed	O
the	O
reduction	O
in	O
sucrose	O
preference	O
(	O
i	O
.	O
e	O
.	O
,	O
anhedonia	O
)	O
associated	O
with	O
LPS	O
injection	O
(	O
Fig	O
.	O
4	O
)	O
.	O

It	O
is	O
also	O
important	O
to	O
mention	O
that	O
while	O
LPS	O
-	O
associated	O
sickness	O
and	O
anhedonia	O
are	O
interrelated	O
,	O
these	O
behaviors	O
can	O
be	O
differentiated	O
from	O
one	O
another	O
.	O

For	O
instance	O
,	O
reduced	O
social	O
exploration	O
was	O
evident	O
2	O
-	O
24	O
h	O
post	O
injection	O
(	O
Fig	O
.	O
3A	O
)	O
,	O
but	O
only	O
decreased	O
sucrose	O
preference	O
was	O
exhibited	O
24	O
to	O
39	O
h	O
later	O
(	O
Fig	O
.	O
4	O
)	O
.	O

This	O
separation	O
between	O
behaviors	O
is	O
consistent	O
with	O
other	O
studies	O
investigating	O
sickness	O
and	O
longer	O
-	O
lasting	O
changes	O
in	O
motivation	O
[	O
15	O
,	O
65	O
,	O
66	O
]	O
.	O

IDO	O
mediated	O
TRP	O
metabolism	O
represents	O
a	O
potential	O
connection	O
between	O
activation	O
of	O
CNS	O
innate	O
immune	O
cells	O
and	O
longer	O
lasting	O
behavioral	O
responses	O
.	O

IDO	O
mediated	O
TRP	O
metabolism	O
in	O
the	O
brain	O
may	O
affect	O
behavior	O
by	O
impacting	O
both	O
serotonin	O
and	O
glutamate	O
pathways	O
[	O
39	O
]	O
.	O

We	O
have	O
reported	O
that	O
IDO	O
induction	O
and	O
activity	O
is	O
amplified	O
in	O
the	O
brain	O
of	O
aged	O
mice	S-Species
and	O
is	O
associated	O
with	O
prolonged	O
depressive	O
-	O
like	O
behavior	O
[	O
15	O
]	O
.	O

Here	O
we	O
show	O
that	O
IDO	O
mRNA	O
induction	O
is	O
blocked	O
by	O
minocycline	O
in	O
the	O
brain	O
of	O
both	O
adult	O
and	O
aged	O
mice	S-Species
(	O
Figs	O
.	O
5	O
&	O
7	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
recent	O
report	O
showing	O
a	O
causal	O
relationship	O
between	O
IDO	O
activity	O
and	O
acute	O
depressive	O
effects	O
in	O
adult	O
CD	O
-	O
1	O
mice	S-Species
.	O

In	O
this	O
study	O
,	O
O	O
'	O
Connor	O
et	O
al	O
.	O
report	O
that	O
both	O
1	O
-	O
methyl	O
tryptophan	O
(	O
a	O
competitive	O
inhibitor	O
of	O
IDO	O
)	O
and	O
minocycline	O
blocked	O
IDO	O
induction	O
and	O
prevented	O
depressive	O
-	O
like	O
immobility	O
in	O
the	O
tail	O
suspension	O
and	O
forced	O
swimming	O
tests	O
[	O
66	O
]	O
.	O

Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
minocycline	O
blockade	O
of	O
IDO	O
induction	O
may	O
explain	O
the	O
abrogation	O
of	O
LPS	O
-	O
induced	O
anhedonia	O
.	O

Another	O
interesting	O
finding	O
was	O
that	O
while	O
minocycline	O
pretreatment	O
in	O
adult	O
mice	S-Species
attenuated	O
LPS	O
-	O
induced	O
brain	O
IL	O
-	O
1	O
beta	O
at	O
4	O
h	O
(	O
Fig	O
.	O
5	O
)	O
,	O
it	O
had	O
no	O
effect	O
on	O
plasma	O
IL	O
-	O
1	O
beta	O
levels	O
(	O
Fig	O
.	O
6	O
)	O
.	O

Because	O
IL	O
-	O
1	O
beta	O
signals	O
can	O
be	O
relayed	O
from	O
the	O
periphery	O
to	O
the	O
brain	O
by	O
humoral	O
pathways	O
[	O
5	O
]	O
,	O
these	O
findings	O
suggest	O
that	O
minocycline	O
has	O
anti	O
-	O
inflammatory	O
properties	O
within	O
the	O
brain	O
.	O

These	O
data	O
are	O
consistent	O
with	O
related	O
findings	O
that	O
minocycline	O
readily	O
crosses	O
the	O
blood	O
brain	O
barrier	O
to	O
elicit	O
an	O
anti	O
-	O
inflammatory	O
effect	O
[	O
41	O
-	O
43	O
]	O
.	O

With	O
regard	O
to	O
IL	O
-	O
6	O
,	O
minocycline	O
pretreatment	O
attenuated	O
both	O
brain	O
and	O
plasma	O
levels	O
at	O
4	O
h	O
post	O
LPS	O
injection	O
.	O

Because	O
circulating	O
IL	O
-	O
6	O
levels	O
can	O
be	O
increased	O
by	O
CNS	O
mediated	O
pathways	O
including	O
activation	O
of	O
the	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
[	O
67	O
]	O
and	O
the	O
sympathetic	O
nervous	O
system	O
[	O
68	O
]	O
,	O
the	O
specific	O
reduction	O
in	O
plasma	O
IL	O
-	O
6	O
by	O
minocycline	O
may	O
reflect	O
the	O
reduction	O
in	O
brain	O
inflammation	O
at	O
4	O
h	O
(	O
Fig	O
.	O
5	O
)	O
.	O

In	O
support	O
of	O
this	O
notion	O
,	O
we	O
and	O
others	O
have	O
reported	O
that	O
i	O
.	O
c	O
.	O
v	O
.	O
injection	O
of	O
LPS	O
or	O
IL	O
-	O
1	O
beta	O
increase	O
plasma	O
IL	O
-	O
6	O
levels	O
,	O
but	O
not	O
IL	O
-	O
1	O
beta	O
levels	O
[	O
14	O
,	O
68	O
,	O
69	O
]	O
.	O

The	O
final	O
critical	O
finding	O
of	O
this	O
study	O
was	O
that	O
minocycline	O
was	O
effective	O
in	O
attenuating	O
neuroinflammation	O
independent	O
of	O
age	O
.	O

Consistent	O
with	O
other	O
aging	O
and	O
neuroinflammation	O
studies	O
,	O
our	O
data	O
show	O
that	O
LPS	O
caused	O
exaggerated	O
neuroinflammation	O
in	O
aged	O
mice	S-Species
compared	O
to	O
adults	O
[	O
10	O
,	O
13	O
-	O
15	O
]	O
.	O

It	O
is	O
important	O
to	O
mention	O
that	O
while	O
there	O
was	O
an	O
age	O
-	O
related	O
difference	O
in	O
MHC	O
II	O
expression	O
in	O
the	O
hippocampus	O
of	O
saline	O
treated	O
mice	S-Species
(	O
Fig	O
.	O
7A	O
)	O
there	O
was	O
not	O
an	O
age	O
-	O
related	O
difference	O
in	O
IL	O
-	O
1	O
beta	O
and	O
IL	O
-	O
6	O
mRNA	O
levels	O
.	O

These	O
data	O
differ	O
from	O
a	O
previous	O
report	O
using	O
BALB	O
/	O
c	O
mice	S-Species
showing	O
an	O
increase	O
in	O
IL	O
-	O
6	O
in	O
older	O
mice	S-Species
[	O
70	O
]	O
.	O

This	O
may	O
be	O
because	O
the	O
mice	S-Species
used	O
in	O
the	O
present	O
study	O
were	O
approximately	O
4	O
months	O
younger	O
than	O
the	O
mice	S-Species
used	O
previously	O
.	O

Nonetheless	O
,	O
microglia	O
can	O
be	O
primed	O
or	O
reactive	O
with	O
increased	O
MHC	O
II	O
expression	O
,	O
but	O
do	O
not	O
necessarily	O
produce	O
inflammatory	O
cytokines	O
in	O
this	O
state	O
[	O
19	O
]	O
.	O

The	O
key	O
results	O
are	O
that	O
peripheral	O
LPS	O
injection	O
causes	O
a	O
greater	O
induction	O
of	O
TLR2	O
,	O
IL	O
-	O
1	O
beta	O
,	O
and	O
IDO	O
mRNA	O
in	O
the	O
aged	O
brain	O
than	O
in	O
the	O
adult	O
brain	O
and	O
that	O
minocycline	O
pretreatment	O
normalizes	O
this	O
age	O
-	O
related	O
exaggerated	O
neuroinflammation	O
(	O
Fig	O
.	O
7	O
)	O
.	O

These	O
findings	O
are	O
also	O
important	O
because	O
an	O
amplified	O
neuroinflammatory	O
response	O
in	O
the	O
aged	O
brain	O
is	O
a	O
precursor	O
to	O
complications	O
including	O
deficits	O
in	O
working	O
memory	O
,	O
memory	O
consolidation	O
,	O
and	O
depressive	O
-	O
like	O
behavior	O
[	O
9	O
,	O
10	O
,	O
15	O
]	O
.	O

Based	O
on	O
the	O
biochemical	O
and	O
behavioral	O
data	O
obtained	O
from	O
this	O
study	O
,	O
we	O
predict	O
that	O
minocycline	O
will	O
abrogate	O
the	O
prolonged	O
LPS	O
-	O
induced	O
sickness	O
[	O
13	O
]	O
and	O
depressive	O
-	O
like	O
behavior	O
exhibited	O
by	O
aged	O
BALB	O
/	O
c	O
mice	S-Species
[	O
15	O
]	O
.	O

We	O
acknowledge	O
,	O
however	O
,	O
that	O
future	O
studies	O
are	O
necessary	O
to	O
test	O
these	O
predictions	O
.	O

Conclusion	O

The	O
present	O
study	O
demonstrates	O
that	O
minocycline	O
reduces	O
LPS	O
-	O
induced	O
microglial	O
activation	O
,	O
CNS	O
cytokine	O
production	O
,	O
and	O
behavioral	O
symptoms	O
of	O
sickness	O
(	O
e	O
.	O
g	O
.	O
,	O
social	O
withdrawal	O
and	O
anhedonia	O
)	O
.	O

These	O
findings	O
are	O
potentially	O
important	O
because	O
they	O
indicate	O
that	O
minocycline	O
can	O
be	O
used	O
to	O
mitigate	O
cytokine	O
expression	O
in	O
the	O
brain	O
and	O
have	O
a	O
beneficial	O
affect	O
on	O
behavioral	O
responses	O
.	O

Taken	O
together	O
,	O
these	O
data	O
support	O
the	O
idea	O
that	O
pharmacological	O
strategies	O
aimed	O
at	O
decreasing	O
neuroinflammation	O
associated	O
with	O
microglial	O
activation	O
are	O
important	O
for	O
improving	O
recovery	O
from	O
sickness	O
and	O
reducing	O
the	O
frequency	O
of	O
neurobehavioral	O
complications	O
.	O

List	O
of	O
abbreviations	O

3	O
-	O
Hydroxy	O
-	O
L	O
-	O
Kynuriene	O
(	O
3HK	O
)	O
,	O
Allophycocyanin	O
(	O
APC	O
)	O
,	O
Analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
Central	O
Nervous	O
System	O
(	O
CNS	O
)	O
,	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
Medium	O
(	O
DMEM	O
)	O
,	O
Dimethyl	O
Sulfoxide	O
(	O
DMSO	O
)	O
,	O
Experimental	O
Autoimmune	O
Encephalomyelitis	O
(	O
EAE	O
)	O
,	O
Enzyme	O
Linked	O
Immmunosorbent	O
Assay	O
(	O
ELISA	O
)	O
,	O
Fluorescein	O
Isothiocyanate	O
(	O
FITC	O
)	O
,	O
Fetal	O
Bovine	S-Species
Serum	O
(	O
FBS	O
)	O
,	O
Hank	O
'	O
s	O
Balanced	O
Salt	O
Solution	O
(	O
HBSS	O
)	O
,	O
Indoleamine	O
2	O
,	O
3	O
dioxygenase	O
(	O
IDO	O
)	O
,	O
Intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
,	O
Intracerebroventricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
,	O
Interleukin	O
(	O
IL	O
)	O
,	O
Kynurenine	O
(	O
KYN	O
)	O
,	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Major	O
Histocompatibility	O
Complex	O
class	O
II	O
(	O
MHC	O
II	O
)	O
,	O
Mitogen	O
Activated	O
Protein	O
Kinase	O
(	O
MAP	O
-	O
kinase	O
)	O
,	O
Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
,	O
R	O
-	O
Phycoerthrin	O
(	O
PE	O
)	O
,	O
Quinolinic	O
acid	O
(	O
QUIN	O
)	O
,	O
Statistical	O
Analysis	O
Systems	O
(	O
SAS	O
)	O
,	O
Standard	O
Error	O
of	O
the	O
Mean	O
(	O
SEM	O
)	O
,	O
Toll	O
-	O
like	O
Receptor	O
-	O
2	O
(	O
TLR2	O
)	O
,	O
and	O
Tryptophan	O
(	O
TRP	O
)	O
.	O

Competing	O
interests	O

The	O
authors	O
of	O
this	O
manuscript	O
declare	O
that	O
there	O
are	O
no	O
actual	O
or	O
potential	O
conflicts	O
of	O
interest	O
.	O

The	O
authors	O
affirm	O
that	O
there	O
are	O
no	O
financial	O
,	O
personal	O
or	O
other	O
relationships	O
with	O
other	O
people	S-Species
or	O
organizations	O
that	O
have	O
inappropriately	O
influenced	O
or	O
biased	O
their	O
research	O
.	O

Authors	O
'	O
contributions	O

CJH	O
was	O
involved	O
in	O
research	O
experimentation	O
,	O
completion	O
of	O
statistical	O
analysis	O
,	O
and	O
writing	O
of	O
the	O
manuscript	O
.	O

YH	O
,	O
AW	O
,	O
MH	O
and	O
JH	O
assisted	O
with	O
experimentation	O
and	O
data	O
analysis	O
.	O

MB	O
and	O
JFS	O
contributed	O
to	O
the	O
design	O
of	O
the	O
experiments	O
and	O
assisted	O
in	O
editing	O
the	O
manuscript	O
.	O

JPG	O
directed	O
all	O
aspects	O
of	O
this	O
research	O
project	O
including	O
the	O
experimental	O
design	O
,	O
research	O
experimentation	O
,	O
completion	O
of	O
statistical	O
analysis	O
,	O
and	O
writing	O
of	O
the	O
manuscript	O
.	O

A	O
case	O
of	O
demand	O
ischemia	O
from	O
phendimetrazine	O

Abstract	O

Introduction	O

Phendimetrazine	O
is	O
a	O
medication	O
currently	O
being	O
used	O
to	O
help	O
patients	S-Species
with	O
weight	O
loss	O
.	O

It	O
shares	O
a	O
chemical	O
structure	O
with	O
amphetamines	O
.	O

As	O
such	O
,	O
it	O
shares	O
some	O
of	O
the	O
same	O
toxicities	O
,	O
which	O
can	O
include	O
cardiac	O
toxicity	O
.	O

This	O
case	O
highlights	O
this	O
principle	O
.	O

Case	O
presentation	O

a	O
54	O
year	O
old	O
Caucasian	O
female	O
presented	O
to	O
our	O
urgent	O
care	O
facility	O
with	O
complaints	O
of	O
chest	O
pains	O
and	O
other	O
symptoms	O
suggestive	O
of	O
acute	O
coronary	O
syndrome	O
.	O

Ultimately	O
,	O
she	O
was	O
transferred	O
to	O
the	O
emergency	O
room	O
.	O

After	O
evaluation	O
there	O
,	O
it	O
appeared	O
she	O
was	O
having	O
demand	O
ischemia	O
from	O
prescription	O
diet	O
pills	O

Conclusion	O

This	O
case	O
report	O
demonstrates	O
the	O
potential	O
dangers	O
of	O
amphetamine	O
based	O
diet	O
pills	O
.	O

There	O
have	O
been	O
other	O
cases	O
of	O
cardiomyopathies	O
related	O
to	O
phendimetrazine	O
,	O
but	O
it	O
is	O
something	O
that	O
is	O
rarely	O
recognized	O
in	O
an	O
outpatient	O
setting	O
.	O

A	O
case	O
such	O
as	O
this	O
demonstrates	O
the	O
importance	O
of	O
obtaining	O
a	O
careful	O
medication	O
history	O
in	O
all	O
patients	S-Species
and	O
in	O
recognizing	O
diet	O
pills	O
with	O
an	O
amphetamine	O
base	O
can	O
cause	O
cardiac	O
toxicity	O
.	O

Case	O
presentation	O

A	O
54	O
year	O
-	O
old	O
Caucasian	O
female	O
presented	O
to	O
our	O
urgent	O
care	O
facility	O
complaining	O
of	O
nausea	O
and	O
vomiting	O
,	O
sense	O
of	O
impending	O
doom	O
and	O
vague	O
chest	O
pain	O
radiating	O
toward	O
her	O
left	O
side	O
for	O
about	O
five	O
hours	O
.	O

She	O
never	O
had	O
similar	O
symptoms	O
in	O
the	O
past	O
.	O

She	O
also	O
denied	O
anything	O
that	O
could	O
have	O
precipitated	O
these	O
symptoms	O
.	O

Her	O
only	O
past	O
medical	O
history	O
was	O
significant	O
for	O
spina	O
bifida	O
.	O

Her	O
medications	O
included	O
occasional	O
Fiorinal	O
(	O
unknown	O
dose	O
)	O
,	O
Xanax	O
0	O
.	O
5	O
mg	O
as	O
needed	O
,	O
and	O
Phendimetrazine	O
(	O
unclear	O
dose	O
)	O
.	O

Her	O
social	O
history	O
was	O
significant	O
for	O
smoking	O
1	O
/	O
2	O
pack	O
per	O
day	O
cigarette	O
use	O
.	O

She	O
denied	O
alcohol	O
use	O
.	O

Family	O
history	O
was	O
non	O
contributory	O
.	O

She	O
worked	O
from	O
home	O
.	O

Her	O
physical	O
exam	O
showed	O
a	O
tachycardia	O
of	O
around	O
100	O
beats	O
per	O
minute	O
,	O
respiratory	O
rate	O
of	O
16	O
,	O
temperature	O
of	O
98	O
.	O
1	O
,	O
and	O
O2	O
saturation	O
of	O
100	O
%	O
on	O
room	O
air	O
.	O

She	O
was	O
approximately	O
5	O
'	O
7	O
"	O
and	O
145	O
pounds	O
.	O

In	O
general	O
,	O
she	O
was	O
an	O
anxious	O
appearing	O
,	O
diaphoretic	O
woman	S-Species
in	O
moderate	O
distress	O
,	O
she	O
had	O
no	O
elevated	O
JVD	O
at	O
30	O
degrees	O
,	O
her	O
heart	O
was	O
tachycardic	O
,	O
but	O
otherwise	O
without	O
murmur	O
,	O
gallops	O
,	O
or	O
rubs	O
,	O
her	O
lungs	O
were	O
clear	O
,	O
abdomen	O
soft	O
,	O
and	O
she	O
had	O
no	O
peripheral	O
edema	O
.	O

An	O
EKG	O
was	O
checked	O
which	O
appears	O
below	O
(	O
figure	O
1	O
)	O
.	O

After	O
examination	O
,	O
there	O
was	O
concern	O
for	O
acute	O
coronary	O
syndrome	O
(	O
ACS	O
)	O
.	O

She	O
was	O
given	O
nitroglycerin	O
with	O
relief	O
of	O
her	O
chest	O
discomfort	O
.	O

She	O
was	O
also	O
given	O
aspirin	O
to	O
chew	O
.	O

EMS	O
was	O
called	O
and	O
she	O
was	O
transferred	O
to	O
a	O
local	O
emergency	O
room	O
.	O

She	O
was	O
hospitalized	O
there	O
for	O
three	O
days	O
and	O
after	O
her	O
discharge	O
,	O
we	O
got	O
permission	O
from	O
her	O
to	O
request	O
records	O
.	O

While	O
hospitalized	O
,	O
she	O
was	O
ruled	O
out	O
for	O
ACS	O
with	O
negative	O
troponins	O
.	O

She	O
was	O
also	O
given	O
beta	O
blockade	O
which	O
resolved	O
her	O
tachycardia	O
and	O
her	O
T	O
wave	O
changes	O
on	O
EKG	O
.	O

The	O
next	O
morning	O
,	O
she	O
had	O
an	O
adenosine	O
stress	O
test	O
which	O
revealed	O
normal	O
uptake	O
with	O
no	O
areas	O
of	O
ischemia	O
and	O
an	O
ejection	O
fraction	O
of	O
55	O
%	O
.	O

She	O
was	O
monitored	O
for	O
one	O
more	O
day	O
and	O
then	O
discharged	O
with	O
instructions	O
to	O
discontinue	O
her	O
diet	O
pills	O
.	O

Discussion	O

Phendimetrazine	O
is	O
a	O
medication	O
currently	O
being	O
used	O
for	O
weight	O
loss	O
,	O
with	O
potential	O
for	O
illicit	O
use	O
.	O

It	O
has	O
a	O
similar	O
chemical	O
composition	O
of	O
amphetamines	O
,	O
which	O
is	O
thought	O
to	O
account	O
for	O
its	O
clinical	O
actions	O
[	O
1	O
]	O
.	O

Amphetamines	O
are	O
well	O
recognized	O
as	O
an	O
etiology	O
of	O
cardiac	O
ischemia	O
,	O
however	O
phendimetrazine	O
is	O
more	O
rarely	O
described	O
in	O
the	O
literature	O
as	O
causing	O
cardiac	O
events	O
.	O

[	O
2	O
,	O
3	O
]	O
.	O

Acute	O
effects	O
include	O
hyperpyrexia	O
,	O
mydriasis	O
,	O
chest	O
pain	O
,	O
arrhytmias	O
,	O
delirium	O
,	O
and	O
,	O
rhabdomylosis	O
,	O
among	O
others	O
[	O
2	O
]	O
.	O

Long	O
term	O
use	O
has	O
been	O
associated	O
with	O
dilated	O
cardiomyopathies	O
,	O
some	O
of	O
which	O
have	O
resolved	O
with	O
discontinuation	O
of	O
the	O
medication	O
[	O
3	O
]	O
.	O

In	O
this	O
particular	O
case	O
,	O
it	O
appears	O
she	O
may	O
have	O
developed	O
a	O
demand	O
ischemia	O
from	O
the	O
medication	O
.	O

It	O
is	O
not	O
known	O
how	O
much	O
of	O
the	O
drug	O
she	O
was	O
taking	O
.	O

Initially	O
,	O
she	O
was	O
resistant	O
to	O
accepting	O
that	O
phendimetrazine	O
could	O
induce	O
side	O
effects	O
,	O
and	O
there	O
was	O
suspicion	O
that	O
she	O
could	O
have	O
been	O
taking	O
more	O
of	O
the	O
drug	O
that	O
recommended	O
.	O

In	O
addition	O
,	O
she	O
was	O
not	O
prescribed	O
the	O
medication	O
and	O
would	O
not	O
admit	O
to	O
where	O
she	O
obtained	O
it	O
.	O

As	O
the	O
public	O
seems	O
to	O
have	O
more	O
focus	O
on	O
using	O
medications	O
to	O
induce	O
weight	O
loss	O
,	O
this	O
may	O
be	O
a	O
more	O
recognized	O
complication	O
and	O
heart	O
conditions	O
should	O
likely	O
be	O
monitored	O
prior	O
to	O
starting	O
amphetamine	O
based	O
weight	O
loss	O
pills	O
.	O

Conclusion	O

Due	O
to	O
potentially	O
detrimental	O
effects	O
of	O
this	O
medication	O
,	O
phendimetrazine	O
should	O
be	O
used	O
cautiously	O
in	O
many	O
situations	O
.	O

As	O
it	O
shares	O
its	O
chemical	O
structure	O
with	O
amphetamines	O
,	O
it	O
also	O
shares	O
many	O
of	O
the	O
side	O
effects	O
and	O
the	O
potential	O
for	O
abuse	O
/	O
addiction	O
.	O

There	O
have	O
been	O
other	O
reports	O
in	O
literature	O
describing	O
adverse	O
outcomes	O
from	O
phendimetrazine	O
as	O
well	O
as	O
other	O
weight	O
loss	O
medications	O
.	O

Therefore	O
,	O
cautious	O
use	O
is	O
warranted	O
.	O

Abbreviations	O

ACS	O
:	O
Acute	O
Coronary	O
Syndrome	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

DL	O
,	O
JJ	O
,	O
GG	O
have	O
all	O
been	O
involved	O
in	O
and	O
approve	O
of	O
the	O
writing	O
of	O
this	O
case	O
presentation	O
.	O

Consent	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
for	O
publication	O
purposes	O
.	O

A	O
copy	O
can	O
be	O
obtained	O
if	O
requested	O
by	O
the	O
Editor	O
in	O
Chief	O
of	O
this	O
journal	O
.	O

Advanced	O
software	O
concepts	O
for	O
employing	O
microcomputers	O
in	O
the	O

laboratory	O

Abstract	O

IIII	O

II	O

,	O
Advanced	O
software	O
concepts	O
for	O

employing	O
microcomputers	O
in	O
the	O
laboratory	O
Scott	O
B	O
.	O
Tilden	O
and	O
M	O
.	O
Bonner	O
Denton	O
,	O
Department	O
of	O
Chemistry	O
,	O
University	O
of	O
Arizona	O
,	O
Tucson	O
,	O
Arizona	O
85721	O
,	O
USA	O
.	O

Introduction	O
While	O
a	O
proliferation	O
of	O
commercial	O
chemical	O
instrumentation	O
is	O
appearing	O
today	O
employing	O
microprocessors	O
for	O
a	O
variety	O
of	O
control	O
and	O
data	O
reduction	O
applications	O
,	O
the	O
great	O
potential	O
of	O
microprocessors	O
has	O
not	O
been	O
exploited	O
extensively	O
for	O
individual	O
custom	O
applications	O
.	O

The	O
primary	O
reason	O
for	O
this	O
phenomenon	O
is	O
altogether	O
too	O
clear	O
microprocessor	O
software	O
is	O
either	O
difficult	O
to	O
develop	O
or	O
inefficient	O
in	O
memory	O
requirements	O
and	O
speed	O
.	O

This	O
problem	O
is	O
even	O
more	O
important	O
in	O
situations	O
requiring	O
constant	O
software	O

modification	O
.	O

Initially	O
,	O
most	O
instrument	O
manufacturers	O
utilized	O
cross	O
assemblers	O
supported	O
on	O
large	O
"	O
number	O
cruncher	O
"	O
computers	O
to	O
generate	O
the	O
required	O
machine	O
code	O
binary	O
program	O
.	O

More	O
recently	O
,	O
the	O
trend	O
has	O
been	O
toward	O
the	O
use	O
of	O
a	O
"	O
developmental	O
system	O
"	O
(	O
at	O
a	O
cost	O
comparable	O
to	O
a	O
moderate	O
minicomputer	O
-	O
the	O
authors	O
use	O
the	O
term	O
"	O
mini	O
"	O
in	O
contrast	O
to	O
"	O
micro	O
"	O
reluctantly	O
because	O
of	O
the	O
ever	O
increasing	O
overlap	O
in	O
computing	O
capability	O
)	O
to	O
write	O
and	O
debug	O
assembly	O
level	O
porgrams	O
which	O
are	O
subsequently	O
converted	O
to	O
binary	O
and	O
incorporated	O
into	O
an	O
instrument	O
in	O
the	O
form	O
of	O
"	O
read	O
only	O
memory	O
"	O
(	O
ROM	O
)	O
.	O

While	O
this	O
approach	O

Interpretative	O
Machine	O
Code	O

Source	O
Code	O
File	O

to	O
Execute	O
Command	O
A	O
Hachine	O
Code	O
Various	O

to	O
Execute	O
Comma	O
nd	O
B	O
ne	O
Code	O

'	O
commands	O
making	O
up	O

,	O
lachi	O

to	O
Execute	O
Command	O
C	O

users	O
source	O
program	O

i	O

Machine	O
Code	O

to	O
Execute	O
Command	O
D	O

etc	O
.	O

Figure	O
1	O
.	O

The	O
interpretative	O
cycle	O
of	O
common	O
types	O
of	O
languages	O
such	O
as	O
BASIC	O
.	O

After	O
examining	O
each	O
command	O
in	O
the	O
source	O
file	O
,	O
the	O
interpreter	O
searches	O
for	O
and	O
branches	O
to	O
the	O
corresponding	O
block	O
of	O
machine	O
code	O
;	O
thus	O
,	O
program	O
execution	O
always	O
remains	O
within	O
the	O
interpreter	O
.	O

128	O

The	O
Journal	O
of	O
Automatic	O
Chemistry	O

Tilden	O
&	O
Denton	O
IIII	O

Advanced	O
software	O
concepts	O

III	O

Users	O
Source	O
File	O

The	O
Compiler	O

Command	O
A	O

Comma	O
nd	O
B	O
Command	O
C	O
Command	O
D	O
etc	O
.	O

/	O
z	O
/	O
li	O
i	O

II	O

.	O
Machine	O
Code	O

etc	O
.	O

.	O
lachi	O
ne	O
Code	O

to	O
Execute	O
Command	O
A	O

etc	O
.	O
to	O
Execute	O

Machine	O
Code	O

to	O
Execute	O
Command	O
C	O

Machine	O
Code	O

etc	O
.	O

Figure	O
2	O
.	O

Note	O
that	O
the	O
compiler	O
transforms	O
each	O
source	O
"	O
command	O
"	O
into	O
executable	O
machine	O
code	O
.	O

This	O
code	O
will	O
,	O
subsequently	O
,	O
be	O
loaded	O
and	O
executed	O
independently	O
of	O
the	O
compiler	O
.	O

has	O
proven	O
cost	O
effective	O
for	O
high	O
volume	O
mass	O
produced	O
applications	O
,	O
it	O
possesses	O
serious	O
limitations	O
for	O
system	O
updates	O
and	O
custom	O
applications	O
.	O

Additionally	O
,	O
the	O
ability	O
to	O
program	O
efficiently	O
at	O
the	O
assembly	O
level	O
is	O
a	O
talent	O
requiring	O
a	O
significant	O
expenditure	O
of	O
time	O
to	O
develop	O
.	O

During	O
the	O
past	O
several	O
years	O
,	O
a	O
virtual	O
deluge	O
of	O
sophisticated	O
,	O
flexible	O
,	O
high	O
performance	O
computer	O
hardware	O
has	O
been	O
introduced	O
primarily	O
aimed	O
at	O
a	O
rapidly	O
growing	O
"	O
hobbyist	O
"	O
market	O
.	O

Manufacturers	O
quickly	O
realilsed	O
that	O
to	O
sell	O
the	O
public	O
hardware	O
,	O
some	O
form	O
of	O
reasonably	O
high	O
level	O
software	O
must	O
be	O
made	O
available	O
.	O

A	O
variety	O
of	O
BASIC	O
interpreters	O
,	O
ranging	O
from	O
rather	O
"	O
dumb	O
"	O
to	O
"	O
quite	O
intelligent	O
"	O
have	O
since	O
evolved	O
.	O

The	O
more	O
intelligent	O
BASIC	O
interpreters	O
have	O
several	O
highly	O
attractive	O
attributes	O
for	O
"	O
hobbyist	O
"	O
applications	O
.	O

The	O
language	O
is	O
both	O
easy	O
to	O
master	O
and	O
conversational	O
.	O

Error	O
and	O
caution	O
messages	O
are	O
provided	O
as	O
aids	O
during	O
programming	O
.	O

Why	O
not	O
apply	O
the	O
"	O
hobbyist	O
"	O
technology	O
toward	O
the	O
implementation	O
of	O
custom	O
laboratory	O
systems	O
?	O

Many	O
investigators	O
have	O
and	O
,	O
no	O
doubt	O
,	O
many	O
more	O
will	O
take	O
this	O
approach	O
.	O

However	O
,	O
BASIC	O
interpreters	O
possess	O
serious	O
limitations	O
in	O
terms	O
of	O
system	O
speed	O
,	O
flexibility	O
and	O
input	O
/	O
output	O
(	O
I	O
/	O
O	O
)	O
capabilities	O
.	O

In	O
BASIC	O
,	O
each	O
command	O
must	O
first	O
be	O
interpreted	O
and	O
then	O
executed	O
(	O
see	O
Figure	O
1	O
)	O
.	O

In	O
many	O
cases	O
,	O
the	O
interpretation	O
process	O
takes	O
much	O
more	O
time	O
than	O
the	O
actual	O
execution	O
.	O

This	O
problem	O
is	O
compounded	O
by	O
the	O
fact	O
that	O
commands	O
interpreted	O
in	O
the	O
past	O
must	O
be	O
re	O
-	O
interpreted	O
each	O
time	O
they	O
are	O
used	O
causing	O
iterative	O
programs	O
to	O
be	O
very	O
slow	O
.	O

While	O
speed	O
is	O
often	O
not	O
a	O
serious	O
limitation	O
in	O
playing	O
computer	O
games	O
,	O
laboratory	O
application	O
requiring	O
high	O
speed	O
data	O
acquisition	O
and	O
/	O
or	O
data	O
manipulation	O
are	O
common	O
.	O

Additionally	O
,	O
the	O
more	O
intelligent	O
BASICs	O
make	O
very	O
inefficient	O
use	O
of	O
memory	O
often	O
requiring	O
minimum	O
of	O
12	O
or	O
16	O
K	O
bytes	O
(	O
twelve	O
or	O
sixteen	O
thousand	O
eight	O
bit	O
words	O
)	O
'	O
Volume	O

cS	O

H	O

A	O

D	O

H	O
Figure	O
3	O
.	O

The	O
'	O
threaded	O
'	O
code	O
approach	O
used	O
in	O
CONVERS	O
.	O

In	O
'	O
threaded	O
'	O
code	O
programming	O
modules	O
for	O
sub	O
-	O
routines	O
are	O
used	O
repetitively	O
in	O
a	O
variety	O
of	O
combinations	O
to	O
allow	O
implementation	O
of	O
an	O
infinite	O
number	O
of	O
functions	O
.	O

Note	O
that	O
the	O
flow	O
of	O
logic	O
threads	O
its	O
way	O
in	O
a	O
very	O
non	O
.	O
linear	O
fashion	O
through	O
these	O
modules	O
.	O

No	O
.	O
3	O
April	O
1979	O

129	O

Tilden	O

&	O
Denton	O

Advanced	O
software	O
concepts	O
|	O
I	O

Stack	O

Upper	O
Memory	O
Bound	O

User	O
'	O
s	O
Application	O
Dictionaries	O

4	O
.	O
5k	O
Octal	O
CONVERS	O
-	O
Di	O
sk	O
Operating	O
System	O

3	O
.	O
7k	O
Octal	O
Standard	O
High	O

Level	O
Dictionary	O
1	O
.	O
2k	O
Octal	O
Initial	O
Machine	O

Code	O
Dictionary	O

I	O
@	O
@	O
Octal	O

Figure	O
4	O
.	O

Memory	O
map	O
of	O
the	O
CON	O
VERS	O
dictionary	O
.	O

The	O
stack	O
which	O
is	O
composed	O
of	O
data	O
parameters	O
etc	O
.	O
acts	O
as	O
a	O
constantly	O
expanding	O
or	O
contracting	O
memory	O
buffer	O
which	O
allows	O
one	O
subroutine	O
to	O
communicate	O
with	O
another	O
without	O
either	O
needing	O
to	O
know	O
the	O
other	O
'	O
s	O
location	O
.	O

In	O
contrast	O
to	O
interpreters	O
,	O
high	O
level	O
compilers	O
,	O
such	O
as	O
FORTRAN	O
,	O
offer	O
a	O
much	O
faster	O
"	O
run	O
time	O
"	O
execution	O
speed	O
.	O

This	O
is	O
accomplished	O
through	O
generation	O
of	O
the	O
required	O
machine	O
code	O
during	O
a	O
series	O
of	O
programming	O
operations	O
.	O

Compilers	O
using	O
FORTRAN	O
,	O
which	O
are	O
designed	O
to	O
run	O
on	O
many	O
minicomputers	O
and	O
some	O
micros	O
,	O
often	O
first	O
transform	O
user	O
symbolic	O
source	O
code	O
into	O
assembly	O
code	O
.	O

An	O
assembler	O
program	O
,	O
subsequently	O
,	O
transforms	O
this	O
into	O
the	O
required	O
machine	O
code	O
.	O

This	O
ready	O
-	O
to	O
-	O
run	O
machine	O
code	O
is	O
often	O
loaded	O
along	O
with	O
a	O
run	O
time	O
package	O
which	O
executes	O
in	O
the	O
manner	O
shown	O
in	O
Figure	O
2	O
.	O

While	O
this	O
approach	O
greatly	O
improves	O
execution	O
speed	O
,	O
the	O
need	O
for	O
loading	O
several	O
different	O
soft	O
-	O
ware	O
routines	O
increases	O
the	O
"	O
hassle	O
"	O
associated	O
with	O
editing	O
and	O
debugging	O
.	O

Thus	O
,	O
this	O
makes	O
some	O
form	O
of	O
mass	O
memory	O
,	O
such	O
as	O
a	O
disk	O
or	O
magnetic	O
tape	O
,	O
almost	O
mandatory	O
.	O

Additionally	O
,	O
I	O
/	O
O	O
algorithms	O
generally	O
must	O
be	O
implemented	O
in	O
assembly	O
level	O
code	O
!	O

One	O
obvious	O
question	O
immediately	O
arises	O
-	O
why	O
not	O
incorporate	O
the	O
most	O
desirable	O
characteristics	O
of	O
both	O
interpreters	O
and	O
compilers	O
into	O
a	O
single	O
language	O
?	O

Additionally	O
,	O
due	O
to	O
the	O
unique	O
requirements	O
found	O
in	O
many	O
applications	O
,	O
why	O
not	O
allow	O
the	O
programmer	O
additional	O
flexibility	O
by	O
providing	O
him	O
with	O
the	O
ability	O
to	O
actually	O
develop	O
his	O
own	O
individual	O
modifications	O
and	O
additions	O
to	O
the	O
language	O
itself	O
?	O

Other	O
desirable	O
features	O
would	O
include	O
high	O
memory	O
efficiency	O
,	O
high	O
level	O
I	O
]	O
O	O
programming	O
,	O
ease	O
of	O
understanding	O
the	O
language	O
'	O
s	O
"	O
inter	O
-	O
working	O
"	O
and	O
the	O
ability	O
to	O
be	O
transferred	O
from	O
one	O
CPU	O
to	O
another	O
with	O
minimum	O
effort	O
.	O

Type	O
"	O
ACQUIRE	O
"	O

ACQUIRE	O

#	O
of	O
characters	O

A	O
G	O

FORMAT	O
T	O
PLOT	O

START	O
SCAN	O
GALC	O
%	O
T	O

DISPLAY	O
RETURN	O

EXECUTIVE	O

Figure	O
5	O
.	O

If	O
a	O
previously	O
defined	O
program	O
name	O
(	O
A	O
CO	O
U	O
R	O
tQ	O
is	O
entered	O
when	O
in	O
EXECUTE	O
mode	O
,	O
a	O
dictionary	O
search	O
takes	O
place	O
locating	O
the	O
ACQUIRE	O
entry	O
.	O

Once	O
found	O
,	O
this	O
entry	O
contains	O
all	O
the	O
required	O
machine	O
code	O
and	O
/	O
or	O
calls	O
to	O
addresses	O
of	O
other	O
previously	O
compiled	O
machine	O
code	O
modules	O
to	O
completely	O
execute	O
the	O
desired	O
function	O
.	O

130	O

The	O
Journal	O
of	O
Automatic	O
Chemistry	O

Tilden	O
&	O
Denton	O

Advanced	O
software	O
concepts	O

2000	O

VARIABLE	O
VARIABLE	O

START	O
STOP	O

5000	O
20	O

VARIABLE	O
VARIABLE	O
7	O

INCREMENT	O

0	O

LOCATION	O

A	O
/	O
D7	O

INDEVICE	O
START	O

INITIALIZE	O
STEP	O

@	O

LOCATION	O

LOCATION	O

@	O

INCREMENT	O
5	O
INDEVICE	O

@	O

+	O
10	O

LOCATION	O

DELAY	O
MOVE	O
SCAN	O

BEGIN	O
-	O
HERE	O
LOCATION	O

AND	O

IF	O
DELAY	O

A	O
/	O
D7	O

ELSE	O

BEGIN	O

THEN	O

@	O

5	O

OUTDEVICE	O

STEP	O

INITIALIZE	O

BEGIN	O
-	O
HERE	O

MOVE	O

LOCATION	O

@	O

STOP	O

@	O

>	O

IF	O

END	O

ELSE	O

BEGIN	O

THEN	O

3000	O
6500	O
10	O

START	O
START	O

INCREMENT	O

SCAN	O

Figure	O
6	O
.	O

Ten	O
lines	O
of	O
typical	O
CONVERS	O
code	O
to	O
scan	O
wavelengths	O
between	O
two	O
easily	O
changed	O
limits	O
and	O
acquire	O
data	O
.	O

By	O
reference	O
to	O
notes	O
in	O
the	O
text	O
it	O
can	O
be	O
easily	O
understood	O
.	O

NOTE	O
:	O
a	O
number	O
or	O
name	O
pushes	O
the	O
number	O
of	O
address	O
occupied	O
by	O
the	O
name	O
on	O
the	O
stack	O
.	O

The	O
symbol	O
@	O
,	O
pips	O
the	O
top	O
number	O
from	O
the	O
stack	O
uses	O
it	O
as	O
the	O
address	O
from	O
which	O
to	O
obtain	O
a	O
number	O
and	O
pushes	O
that	O
number	O
on	O
the	O
stack	O
.	O

Development	O
of	O
CONVERS	O
During	O
the	O
past	O
two	O
years	O
,	O
a	O
different	O
approach	O
to	O
software	O
has	O
been	O
taking	O
place	O
at	O
the	O
University	O
of	O
Arizona	O
referred	O
to	O
as	O
an	O
"	O
Interpretive	O
Compiler	O
"	O
called	O
CONVERS	O
.	O

This	O
package	O
,	O
which	O
is	O
conceptually	O
similar	O
to	O
the	O
FORTH	O
language	O
currently	O
being	O
used	O
in	O
several	O
minicomputerastronomical	O
applications	O
]	O
,	O
is	O
able	O
to	O
provide	O
many	O
of	O
the	O
desirable	O
features	O
found	O
in	O
both	O
interpreters	O
and	O
compilers	O
by	O
separating	O
the	O
compile	O
and	O
execute	O
states	O
(	O
as	O
a	O
compiler	O
does	O
)	O
while	O
maintaining	O
a	O
resident	O
user	O
interactive	O
and	O
conversational	O
executive	O
which	O
oversees	O
system	O
operation	O
.	O

The	O
ability	O
to	O
realise	O
such	O
advanced	O
software	O
capabilities	O
in	O
a	O
very	O
modest	O
amount	O
of	O
memory	O
(	O
less	O
than	O
4	O
K	O
bytes	O
on	O
an	O
8080	O
based	O
micro	O
)	O
is	O
the	O
direct	O
result	O
of	O
exploiting	O
threaded	O
code	O
programming	O
techniques	O
(	O
see	O
Figure	O
3	O
)	O
.	O

The	O
approach	O
involves	O
highly	O
efficient	O
use	O
of	O
simple	O
macroinstructions	O
to	O
build	O
more	O
complex	O
subroutines	O
which	O
are	O
recombined	O
with	O
additional	O
macroinstructions	O
to	O
form	O
super	O
subroutines	O
.	O

This	O
process	O
of	O
combining	O
previously	O
defined	O
modules	O
to	O
form	O
ever	O
increasingly	O
sophisticated	O
routines	O
for	O
performing	O
the	O
task	O
at	O
hand	O
is	O
the	O
essence	O
of	O
threaded	O
code	O
programming	O
.	O

When	O
initially	O
loaded	O
and	O
running	O
,	O
CONVERS	O
acts	O
much	O
like	O
an	O
interpreter	O
,	O
i	O
.	O
e	O
.	O
it	O
is	O
conversational	O
,	O
ready	O
to	O
either	O
execute	O
a	O
previously	O
programmed	O
algorithm	O
or	O
accept	O
a	O
new	O
one	O
.	O

However	O
,	O
in	O
contrast	O
to	O
BASIC	O
,	O
when	O
a	O
new	O
program	O
is	O
being	O
entered	O
under	O
CONVERS	O
,	O
it	O
is	O
immediately	O
transformed	O
into	O
binary	O
machine	O
code	O
or	O
to	O
the	O
binary	O
starting	O
addresses	O
of	O
other	O
previously	O
entered	O
and	O
compiled	O
machine	O
code	O
programs	O
.	O

During	O
this	O
process	O
,	O
the	O
operator	O
is	O
kept	O
informed	O
of	O
the	O
status	O
of	O
the	O
program	O
by	O
a	O
series	O
of	O
error	O
and	O
diagnostic	O
Volume	O

messages	O
.	O

When	O
the	O
new	O
program	O
has	O
been	O
completed	O
,	O
it	O
is	O
entered	O
in	O
a	O
program	O
library	O
or	O
dictionary	O
,	O
which	O
is	O
constantly	O
building	O
up	O
from	O
low	O
memory	O
(	O
see	O
Figure	O
4	O
)	O
.	O

If	O
the	O
operator	O
now	O
wants	O
to	O
execute	O
this	O
program	O
,	O
he	O
can	O
request	O
it	O
from	O
his	O
terminal	O
.	O

A	O
dictionary	O
search	O
will	O
begin	O
at	O
the	O
last	O
entry	O
and	O
progress	O
until	O
the	O
requested	O
program	O
is	O
located	O
.	O

Once	O
located	O
,	O
the	O
requested	O
program	O
will	O
run	O
in	O
its	O
entirety	O
without	O
need	O
for	O
any	O
additional	O
dictionary	O
searches	O
.	O

For	O
example	O
,	O
let	O
us	O
assume	O
an	O
algorithm	O
,	O
called	O
ACQUIRE	O
,	O
has	O
been	O
programmed	O
to	O
take	O
data	O
from	O
some	O
hypothetical	O
experimental	O
system	O
.	O

When	O
ACQUIRE	O
is	O
requested	O
from	O
the	O
terminal	O
,	O
a	O
dictionary	O
search	O
is	O
initiated	O
.	O

The	O
program	O
names	O
ACQUIRE	O
(	O
see	O
Figure	O
5	O
)	O
,	O
once	O
located	O
,	O
contains	O
the	O
starting	O
addresses	O
of	O
a	O
series	O
of	O
previously	O
defined	O
modules	O
which	O
implement	O
the	O
various	O
steps	O
necessary	O
to	O
perform	O
the	O
desired	O
experiment	O
.	O

For	O
example	O
,	O
the	O
module	O
SCAN	O
which	O
might	O
be	O
intended	O
to	O
scan	O
a	O
monochromator	O
'	O
s	O
wavelength	O
in	O
some	O
desired	O
manner	O
has	O
been	O
previously	O
defined	O
and	O
tested	O
.	O

This	O
ability	O
to	O
easily	O
test	O
each	O
module	O
separately	O
and	O
then	O
efficiently	O
combine	O
a	O
series	O
of	O
modules	O
to	O
perform	O
a	O
more	O
complex	O
function	O
,	O
test	O
this	O
function	O
,	O
and	O
then	O
employ	O
.	O
it	O
in	O
a	O
vastly	O
more	O
complex	O
function	O
,	O
etc	O
.	O
,	O
i	O
.	O
e	O
.	O
testing	O
each	O
step	O
as	O
the	O
threaded	O
code	O
is	O
made	O
increasingly	O
complex	O
,	O
is	O
a	O
major	O
factor	O
contributing	O
to	O
the	O
speed	O
with	O
which	O
software	O
can	O
be	O
developed	O
using	O
CONVERS	O
.	O

Use	O
of	O
a	O
software	O
stack	O
also	O
contributes	O
toward	O
improved	O
memory	O
efficiency	O
and	O
simplified	O
programming	O
.	O

The	O
stack	O
is	O
an	O
area	O
of	O
memory	O
set	O
aside	O
to	O
handle	O
parameters	O
,	O
data	O
numbers	O
,	O
etc	O
.	O

One	O
of	O
the	O
primary	O
advantages	O
of	O
the	O
stack	O
is	O
that	O
entries	O
can	O
leave	O
temporary	O
parameters	O
on	O
the	O
stack	O
without	O
having	O
to	O
assign	O
specific	O
131	O

No	O
.	O
3	O
April	O
1979	O

Tilden	O
&	O
Denton	O

Advanced	O
software	O
concepts	O

DUAL	O
REGULATED	O
POWER	O
SUPPLY	O
I0	O
KV	O
I00	O

GRATING	O

PIEZOELECTRIC	O
TRANSLATOR	O

OP	O
TOACOUS	O
TIC	O
CELL	O

,	O
.	O
.	O

C02He	O
,	O
N2	O

MIRROR	O
TRANSLATOR	O

CHOPPER	O

POWER	O
DE	O
TECTOR	O

STEPPER	O
MOTOR	O

DRIVER	O

ADC	O

LOCK	O
-	O
IN	O
AMP	O

CONTROLLER	O

LOCK	O
-	O
IN	O

AMP	O

MICROFLOPPY	O

DISK	O
24K	O
RAM	O

1	O

Figure	O
7	O
.	O

The	O
optoacoustic	O
experiment	O
in	O
which	O
a	O
microcomputer	O
is	O
used	O
to	O
control	O
laser	O
wavelength	O
and	O
to	O
monitor	O
laser	O
power	O
and	O
optoacoustic	O
signal	O
.	O

memory	O
locations	O
to	O
store	O
them	O
.	O

This	O
not	O
only	O
can	O
save	O
considerable	O
memory	O
,	O
but	O
also	O
allows	O
programs	O
to	O
be	O
easily	O
relocatable	O
since	O
one	O
algorithm	O
need	O
only	O
know	O
that	O
a	O
previous	O
routine	O
left	O
so	O
many	O
words	O
of	O
data	O
,	O
etc	O
.	O
on	O
the	O
stack	O
.	O

It	O
need	O
not	O
know	O
where	O
the	O
previous	O
routine	O
is	O
nor	O
even	O
where	O
the	O
stack	O
is	O
located	O
.	O

A	O
series	O
of	O
stack	O
handling	O
routines	O
,	O
which	O
should	O
appear	O
quite	O
familiar	O
to	O
many	O
small	O
calculator	O
users	O
,	O
provide	O
an	O
array	O
of	O
capabilities	O
,	O
including	O
the	O
ability	O
to	O
PUSH	O
a	O
number	O
on	O
the	O
stack	O
,	O
POP	O
,	O
it	O
off	O
,	O
duplicate	O
it	O
,	O
SWAP	O
the	O
top	O
two	O
numbers	O
,	O
locate	O
a	O
number	O
some	O
distance	O
into	O
the	O
stack	O
,	O
and	O
copy	O
it	O
on	O
top	O
of	O
the	O
stack	O
,	O
etc	O
.	O

Additionally	O
,	O
a	O
variety	O
of	O
logic	O
functions	O
familiar	O
to	O
the	O
minicomputer	O
user	O
are	O
provided	O
including	O
OR	O
,	O
AND	O
,	O
shift	O
left	O
,	O
shift	O
right	O
,	O
greater	O
than	O
,	O
less	O
than	O
,	O
etc	O
.	O

Input	O
/	O
output	O
(	O
I	O
/	O
O	O
)	O
is	O
normally	O
accomplished	O
using	O
the	O
stack	O
in	O
conjunction	O
with	O
the	O
INDEVICE	O
or	O
OUTDEVICE	O
commands	O
.	O

For	O
example	O
,	O
to	O
take	O
data	O
from	O
a	O
device	O
located	O
at	O
I	O
/	O
O	O
,	O
port	O
7	O
,	O
the	O
number	O
seven	O
is	O
"	O
pushed	O
"	O
onto	O
the	O
stack	O
(	O
7	O
)	O
,	O
goes	O
to	O
this	O
I	O
/	O
O	O
port	O
,	O
takes	O
in	O
a	O
number	O
and	O
"	O
pushes	O
"	O
the	O
number	O
on	O
the	O
stack	O
.	O

OUTDEVICE	O
functions	O
in	O
a	O
similar	O
manner	O
,	O
requiring	O
the	O
number	O
to	O
be	O
sent	O
to	O
the	O
desired	O
device	O
to	O
be	O
"	O
pushed	O
"	O
onto	O
the	O
stack	O
followed	O
by	O
the	O
device	O
'	O
s	O
I	O
/	O
O	O
port	O
address	O
.	O

Hence	O
,	O
to	O
send	O
the	O
number	O
131	O
to	O
device	O
11	O
,	O
the	O
number	O
131	O
is	O
pushed	O
on	O
the	O
stack	O
followed	O
by	O
11	O
and	O
then	O
OUTDEVICE	O
.	O

This	O
"	O
pops	O
"	O
the	O
top	O
number	O
(	O
11	O
)	O
from	O
the	O
stack	O
,	O
uses	O
it	O
as	O
the	O
output	O
port	O
and	O
then	O
sends	O
the	O
number	O
131	O
to	O
that	O
location	O
.	O

SOUND	O

BELL	O

BELL	O

BELL	O

The	O
colon	O
denotes	O
changing	O
from	O
EXECUTE	O
to	O
COMPILE	O
mode	O
.	O

After	O
typing	O
the	O
name	O
of	O
the	O
new	O
routine	O
,	O
in	O
this	O
case	O
to	O
be	O
called	O
SOUND	O
,	O
typing	O
the	O
name	O
of	O
the	O
earlier	O
defined	O
routine	O
(	O
BELL	O
a	O
previously	O
defined	O
simple	O
program	O
to	O
rng	O
the	O
terminal	O
bell	O
)	O
initiates	O
a	O
dictionary	O
search	O
to	O
locate	O
this	O
routine	O
'	O
s	O
starting	O
address	O
which	O
subsequentially	O
is	O
entered	O
three	O
times	O
.	O

The	O
resulting	O
SOUND	O
routine	O
contains	O
machine	O
code	O
calls	O
to	O
the	O
BE	O
LL	O
routine	O
which	O
,	O
itself	O
,	O
is	O
composed	O
of	O
machine	O
code	O
.	O

Of	O
course	O
,	O
SOUND	O
could	O
also	O
have	O
been	O
defined	O
using	O
a	O
DO	O
-	O
LOOP	O
,	O
i	O
.	O
e	O
.	O
SOUND	O
3	O

DO	O

BELL	O

LOOP	O

where	O
the	O
numbers	O
three	O
and	O
one	O
set	O
the	O
upper	O
and	O
lower	O
indices	O
.	O

If	O
it	O
were	O
desirable	O
to	O
change	O
the	O
actual	O
number	O
of	O
bell	O
rings	O
from	O
some	O
other	O
program	O
,	O
this	O
value	O
could	O
be	O
defined	O
as	O
a	O
VARIABLE	O
let	O
'	O
s	O
call	O
it	O
NOISE	O
.	O

3	O

VARIABLE	O
NOISE	O

In	O
this	O
case	O
,	O
the	O
number	O
three	O
is	O
first	O
pushed	O
on	O
the	O
stack	O
,	O
VARIABLE	O
transfers	O
the	O
top	O
number	O
on	O
the	O
stack	O
(	O
the	O
three	O
)	O
to	O
a	O
dictionary	O
location	O
named	O
NOISE	O
.	O

If	O
SOUND	O
were	O
now	O
defined	O
as	O
:	O
SOUND	O

NOISE	O

@	O

DO	O

BELL	O

LOOP	O

Applications	O
of	O
CONVERS	O
To	O
appreciate	O
the	O
ease	O
with	O
which	O
real	O
programs	O
can	O
be	O
written	O
,	O
a	O
few	O
examples	O
will	O
be	O
considered	O
.	O

A	O
trivial	O
program	O
,	O
called	O
SOUND	O
,	O
which	O
rings	O
the	O
terminal	O
bell	O
three	O
times	O
,	O
might	O
be	O
written	O
:	O
132	O

the	O
bell	O
would	O
again	O
ring	O
three	O
times	O
.	O

In	O
this	O
case	O
,	O
when	O
the	O
word	O
NOISE	O
iS	O
encountered	O
,	O
its	O
address	O
is	O
pushed	O
on	O
the	O
stack	O
,	O
the	O
@	O
is	O
a	O
simple	O
program	O
which	O
goes	O
to	O
the	O
address	O
indicated	O
on	O
the	O
top	O
of	O
the	O
stack	O
(	O
that	O
of	O
NOISE	O
)	O
and	O
replaces	O
it	O
with	O
the	O
actual	O
value	O
located	O
at	O
that	O
address	O
(	O
the	O
number	O
three	O
)	O
.	O

At	O
any	O
future	O
time	O
,	O
the	O
value	O
of	O
VARIABLE	O
can	O
be	O
changed	O
by	O
"	O
pushing	O
"	O
the	O
new	O
value	O
onto	O
the	O
stack	O
,	O
followed	O
by	O
the	O
address	O
of	O
the	O
variable	O
to	O
be	O
changed	O
,	O
generated	O
by	O
its	O
name	O
and	O
an	O
exclamation	O
mark	O
.	O

To	O
change	O
N	O
O	O
IS	O
E	O
to	O
5	O
,	O
The	O
Journal	O
of	O
Automatic	O
Chemistry	O

Tilden	O
&	O
Denton	O

Advanced	O
software	O
concepts	O

5	O
NOISE	O
a	O
number	O
five	O
is	O
pushed	O
onto	O
the	O
stack	O
,	O
NOISE	O
pushes	O
its	O
address	O
on	O
the	O
stack	O
,	O
and	O
goes	O
to	O
the	O
address	O
indicated	O
by	O
the	O
"	O
top	O
"	O
number	O
on	O
the	O
stack	O
and	O
deposits	O
the	O
next	O
number	O
.	O

Now	O
sound	O
would	O
ring	O
the	O
terminal	O
bell	O
five	O
times	O
.	O

A	O
much	O
less	O
trivial	O
program	O
which	O
could	O
be	O
written	O
to	O
scan	O
and	O
take	O
data	O
from	O
a	O
monochromator	O
equipped	O
with	O
a	O

DENCO	O
SM2A	O
stepper	O
motor	O
controller	O
[	O
2	O
]	O
(	O
the	O
SM2A	O
takes	O
a	O
parallel	O
number	O
as	O
an	O
address	O
,	O
sends	O
one	O
of	O
two	O
stepper	O
motors	O
to	O
this	O
location	O
and	O
outputs	O
an	O
arrival	O
flag	O
when	O
the	O
address	O
is	O
reached	O
)	O
is	O
given	O
in	O
Figure	O
6	O
.	O

Assume	O
that	O
the	O
experimental	O
system	O
is	O
configured	O
so	O
the	O
SM2A	O
is	O
at	O
I	O
/	O
O	O
,	O
port	O
5	O
and	O
an	O
analog	O
to	O
digital	O
converter	O
to	O
acquire	O
data	O
is	O
at	O
I	O
/	O
O	O
,	O
port	O
7	O
.	O

Let	O
us	O
assume	O
that	O
,	O
initially	O
,	O
a	O
scan	O
is	O
designed	O
from	O
a	O
starting	O
stepper	O
motor	O
location	O
of	O
2000	O
to	O
a	O
final	O
location	O
of	O
5000	O
,	O
taking	O
data	O
every	O
20	O
steps	O
.	O

The	O
program	O
illustrated	O
in	O
figure	O
6	O
acts	O
in	O
the	O
following	O
manner	O
.	O

Line	O
defines	O
a	O
variable	O
called	O
START	O
to	O
be	O
2000	O
,	O
which	O
is	O
the	O
starting	O
location	O
of	O
fhe	O
scan	O
.	O

The	O
end	O
of	O
the	O
scan	O
is	O
defined	O
as	O
5000	O
in	O
the	O
next	O
line	O
.	O

Line	O
3	O
defines	O
the	O
increment	O
between	O
data	O
points	O
.	O

A	O
variable	O
called	O
LOCATION	O
where	O
the	O
.	O
next	O
address	O
is	O
stored	O
is	O
defined	O
in	O
line	O
4	O
.	O
.	O

Colon	O
,	O
in	O
line	O
5	O
,	O
puts	O
the	O
system	O
in	O
the	O
compile	O
mode	O
,	O
A	O
/	O
D7	O
will	O
be	O
the	O
name	O
of	O
the	O
module	O
which	O
when	O
called	O
will	O
cause	O
a	O
7	O
to	O
be	O
pushed	O
onto	O
the	O
stack	O
.	O

INDEVICE	O
will	O
'	O
pop	O
'	O
it	O
back	O
off	O
and	O
use	O
it	O
as	O
a	O
device	O
address	O
to	O
go	O
and	O
take	O
a	O
data	O
point	O
and	O
push	O
the	O
data	O
onto	O
the	O
stack	O
.	O

Line	O
6	O
defines	O
a	O
module	O
INITIALIZE	O
,	O
START	O
puts	O
its	O
address	O
on	O
the	O
stack	O
,	O
@	O
replaces	O
the	O
address	O
with	O
the	O
value	O
at	O
that	O
address	O
,	O
LOCATION	O
puts	O
its	O
address	O
on	O
the	O
stack	O
,	O
'	O
!	O
'	O
goes	O
to	O
the	O
address	O
specified	O
by	O
the	O
number	O
on	O
the	O
stack	O
and	O
deposits	O
the	O
second	O
number	O
and	O
the	O
net	O
result	O
value	O
at	O
START	O
is	O
put	O
into	O
LOCATION	O
.	O

Line	O
7	O
defines	O
STEP	O
to	O
take	O
values	O
from	O

LOCATION	O
and	O
INCREMENT	O
adds	O
them	O
together	O
and	O
puts	O
the	O
result	O
into	O
LOCATION	O
,	O
i	O
.	O
e	O
.	O
LOCATION	O
puts	O
its	O
address	O
on	O
the	O
stack	O
,	O
@	O
replaces	O
the	O
top	O
value	O
on	O
the	O
stack	O
with	O
the	O
number	O
stored	O
at	O
the	O
address	O
,	O
INCREMENT	O
@	O
gets	O
the	O
value	O
at	O
INCREMENT	O
and	O
puts	O
it	O
in	O
to	O
the	O
stack	O
,	O
and	O
adds	O
the	O
top	O
two	O
stack	O
numbers	O
and	O
pushes	O
the	O
result	O
on	O
the	O
stack	O
.	O

LOCATION	O
puts	O
its	O
address	O
on	O
the	O
stack	O
and	O
goes	O
to	O
the	O
address	O
specified	O
by	O
the	O
top	O
number	O
on	O
the	O
stack	O
and	O
deposits	O
the	O
second	O
number	O
.	O

Themodule	O
defined	O
in	O
line	O
8	O
takes	O
a	O
number	O
from	O
the	O
stepper	O
motor	O
controller	O
(	O
assume	O
device	O
numbered	O
5	O
)	O
pushes	O
on	O
the	O
stack	O
,	O
and	O
pushes	O
the	O
value	O
10	O
on	O
the	O
stack	O
and	O
does	O
a	O
logical	O
AND	O
to	O
see	O
if	O
the	O
controllers	O
flag	O
is	O
set	O
,	O
if	O
this	O
is	O
true	O
the	O
A	O
/	O
D7	O
module	O
will	O
be	O
called	O
to	O
input	O
data	O
,	O
if	O
the	O
flag	O
is	O
not	O
set	O
,	O
the	O
program	O
is	O
returned	O
to	O
BEGIN	O
-	O
HERE	O
.	O

Therefore	O
the	O
DELAY	O
module	O
is	O
a	O
loop	O
waiting	O
for	O
the	O
stepper	O
motor	O
to	O
arrive	O
at	O
its	O
new	O
location	O
followed	O
by	O
a	O
call	O
to	O
A	O
/	O
D7	O
data	O
acquisition	O
module	O
.	O

MOVE	O
defined	O
in	O
line	O
9	O
gets	O
the	O
value	O
stored	O
at	O
LOCATION	O
pushes	O
the	O
device	O
code	O
onto	O
the	O
stack	O
performs	O
an	O
outdevice	O
(	O
which	O
uses	O
the	O
top	O
stack	O
number	O
as	O
a	O
1	O
/	O
0	O
port	O
address	O
to	O
send	O
the	O
next	O
value	O
to	O
call	O
the	O
STEP	O
module	O
(	O
ie	O
the	O
value	O
at	O
LOCATION	O
)	O
,	O
this	O
increments	O
LOCATION	O
by	O
the	O
INCREM	O
E	O
N	O
T	O
value	O
and	O
finally	O
calls	O
D	O
E	O
L	O
A	O
Y	O
and	O
waits	O
for	O
a	O
flag	O
from	O
the	O
stepper	O
motor	O
controller	O
to	O
signal	O
its	O
arrival	O
at	O
the	O
desired	O
address	O
and	O
then	O
takes	O
a	O
data	O
point	O
.	O

The	O
final	O
line	O
shown	O
in	O
the	O
example	O
Called	O
SCAN	O
itself	O
calls	O
the	O
INITIALIZE	O
module	O
(	O
which	O
sets	O
LOCATION	O
to	O
the	O
START	O
location	O
for	O
the	O
Scan	O
)	O
it	O
also	O
calls	O
MOVE	O
(	O
which	O
sends	O
this	O
value	O
to	O
the	O
motor	O
LOCATION	O
controller	O
,	O
increments	O
the	O
value	O
stored	O
in	O
LOCATION	O
by	O
INCREMENT	O
and	O
calls	O
DELAY	O
which	O
waits	O
for	O
the	O
motor	O
to	O
arrive	O
and	O
then	O
takes	O
a	O
data	O
point	O
)	O
.	O

Next	O
the	O
incremented	O
value	O
from	O
LOCATION	O
is	O
placed	O
on	O
the	O
stack	O
(	O
LOCATION	O
)	O
followed	O
by	O
the	O
STOP	O

I0	O
KW	O
AMPLIFIER	O
MATCHING	O

,	O
NETWORKIS	O
PREAMP	O

MOTOR	O
CON	O
TROL	O
ER	O

MICRODISK	O
90K	O
byte	O

INTEL	O
8080	O
based	O
MICROCOMPUTER	O
16K	O

RAM	O

Figure	O
8	O
.	O

A	O
schematic	O
of	O
the	O
inductively	O
coupled	O
plasma	O
emission	O
spectrometer	O
in	O
which	O
the	O
microcomputer	O
is	O
used	O
to	O
control	O
radio	O
frequency	O
power	O
and	O
'	O
flame	O
'	O
positioning	O
as	O
well	O
as	O
to	O
monitor	O
light	O
intensity	O
.	O

Volume	O

No	O
.	O
3	O
April	O
1979	O

133	O

Tilden	O
&	O
Denton	O

Advanced	O
software	O
concepts	O

value	O
(	O
STOP	O
@	O
)	O
,	O
the	O
two	O
are	O
compared	O
to	O
to	O
see	O
if	O
the	O
incremented	O
value	O
at	O
LOCATION	O
is	O
larger	O
then	O
the	O
STOP	O
value	O
,	O
if	O
it	O
is	O
the	O
program	O
ends	O
,	O
if	O
not	O
,	O
it	O
repeats	O
the	O
process	O
starting	O
at	O
BEGIN	O
-	O
-	O
HERE	O
.	O

It	O
should	O
be	O
noted	O
that	O
whilst	O
many	O
variables	O
have	O
been	O
pushed	O
on	O
the	O
stack	O
,	O
only	O
the	O
data	O
will	O
remain	O
,	O
since	O
each	O
time	O
a	O
value	O
is	O
used	O
it	O
is	O
'	O
popped	O
'	O
(	O
removed	O
)	O
from	O
the	O
stack	O
.	O

If	O
a	O
different	O
spectra	O
region	O
is	O
to	O
be	O
scanned	O
i	O
.	O
e	O
.	O
from	O
3000	O
to	O
6500	O
with	O
10	O
increments	O
the	O
variables	O
need	O
only	O
be	O

>	O

data	O
acquisition	O
programs	O
have	O
been	O
easily	O
implemented	O
.	O

Memory	O
requirements	O
and	O
operating	O
speed	O
have	O
been	O
found	O
to	O
be	O
far	O
superior	O
to	O
conventional	O
approaches	O
.	O

Additionally	O
,	O
new	O
system	O
users	O
have	O
encountered	O
a	O
difficulty	O
in	O
utilising	O
previously	O
developed	O
custom	O
software	O
for	O
a	O
particular	O
experiment	O
even	O
when	O
documentation	O
was	O
vague	O
.	O

Discussion	O
The	O
authors	O
hope	O
that	O
this	O
short	O
introduction	O
to	O
only	O
a	O
few	O
of	O
the	O
concepts	O
employed	O
in	O
CONVERS	O
will	O
generate	O
interest	O
in	O
its	O
capabilities	O
.	O

A	O
much	O
more	O
complete	O
discussion	O
is	O
available	O
in	O
the	O
form	O
of	O
a	O
user	O
'	O
s	O
manual	O
[	O
3	O
]	O
available	O
from	O
the	O
authors	O
.	O

changed	O
thus	O
3000	O
START	O
!	O

6500	O
STOP	O
10	O
INCREMENT	O
and	O
type	O
SCAN	O
,	O
system	O
will	O
now	O
scan	O
from	O
3000	O
to	O
6500	O
taking	O
data	O
every	O
10	O
steps	O
.	O

While	O
the	O
code	O
might	O
look	O
a	O
little	O
strange	O
at	O
first	O
,	O
it	O
quickly	O
becomes	O
very	O
easy	O
to	O
work	O
with	O
.	O

The	O
SCAN	O
program	O
of	O
Figure	O
6	O
could	O
be	O
combined	O
with	O
other	O
modules	O
as	O
shown	O
in	O
Figure	O
5	O
to	O
perform	O
some	O
more	O
complex	O
experimental	O
function	O
.	O

Each	O
module	O
of	O
the	O
program	O
can	O
be	O
easily	O
tried	O
out	O
to	O
ensure	O
that	O
it	O
is	O
operational	O
before	O
proceeding	O
with	O
the	O
next	O
.	O

Presently	O
,	O
CONVERS	O
is	O
being	O
used	O
in	O
the	O
authors	O
'	O
laboratories	O
for	O
a	O
variety	O
of	O
spectrochemical	O
investigations	O
,	O
including	O
laser	O
excited	O
optoacoustic	O
spectroscopy	O
(	O
Figure	O
7	O
)	O
and	O
inductively	O
coupled	O
plasma	O
optical	O
emission	O
spectroscopy	O
(	O
Figure	O
8	O
)	O
.	O

Rather	O
complex	O
interactive	O
control	O
and	O

ACKNOWLEDGEMENTS	O
The	O
development	O
of	O
the	O
CONVERS	O
system	O
was	O
partially	O
supported	O
by	O
the	O
Office	O
of	O
Naval	O
Research	O
and	O
a	O
Alfred	O
P	O
.	O
Cloan	O
Foundation	O
Research	O
Fellowship	O
to	O
M	O
.	O

Bonnet	O
Denton	O
.	O

REFERENCES	O
C	O
.	O

Moore	O
,	O
Astronomical	O
Astrophysics	O
Supplemental	O
,	O
15	O
,	O
(	O
1974	O
)	O
497	O
.	O

[	O
2	O
]	O
M	O
.	O
B	O
.	O

Denton	O
,	O
J	O
.	O
D	O
.	O

Mack	O
,	O
M	O
.	O
W	O
.	O

Routh	O
and	O
D	O
.	O
B	O
.	O

SwartzClmerican	O

[	O
3	O
]	O

Laboratory	O
,	O
8	O
,	O
69	O
(	O
1976	O
)	O
.	O

CONVERS	O
An	O
Interpretive	O
Compiler	O
,	O
developed	O
by	O
Scott	O
B	O
.	O
Tilden	O
and	O
M	O
.	O

Bonner	O
Denton	O
,	O
Department	O
of	O
Chemistry	O
,	O
University	O
of	O
Arizona	O
,	O
Tucson	O
,	O
Arizona	O
85721	O
,	O
USA	O
.	O

The	O
use	O
of	O
a	O
microcomputer	O
for	O
flexible	O
automation	O
of	O
a	O
liquid	O

chromatograph	O
A	O
.	O
D	O
.	O

Mills	O
,	O
i	O
.	O

Mackenzie	O
and	O
R	O
.	O
J	O
.	O

Dolphin	O
*	O
Philips	O
Research	O
Laboratories	O
,	O
Redhill	O
,	O
Surrey	O
,	O
RH1	O
5HA	O
,	O
U	O
.	O
K	O
.	O

Introduction	O
Microprocessors	O
are	O
being	O
used	O
to	O
add	O
inexpensive	O
automatic	O
control	O
and	O
data	O
handling	O
facilities	O
to	O
a	O
variety	O
of	O
chemical	O
instruments	O
.	O

With	O
a	O
microcomputer	O
it	O
is	O
now	O
possible	O
to	O
realise	O
the	O
flexibility	O
formerly	O
available	O
only	O
with	O
a	O
relatively	O
large	O
and	O
expensive	O
minicomputer	O
in	O
an	O
instrument	O
little	O
different	O
in	O
size	O
and	O
cost	O
from	O
one	O
controlled	O
by	O
inflexible	O
hardware	O
.	O

In	O
many	O
ways	O
chromatography	O
is	O
an	O
ideal	O
process	O
for	O
such	O
automation	O
.	O

Most	O
instruments	O
are	O
given	O
a	O
high	O
workload	O
and	O
,	O
although	O
many	O
applications	O
may	O
be	O
routine	O
and	O
repetitive	O
,	O
the	O
versatility	O
of	O
the	O
technique	O
requires	O
an	O
instrument	O
which	O
can	O
easily	O
be	O
used	O
in	O
a	O
variety	O
of	O
modes	O
.	O

In	O
addition	O
to	O
improving	O
the	O
convenience	O
to	O
the	O
user	O
,	O
automation	O
of	O
a	O
liquid	O
chromatrograph	O
should	O
enhance	O
the	O
performance	O
of	O
the	O
instrument	O
.	O

Some	O
aspects	O
of	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
which	O
can	O
benefit	O
in	O
this	O
way	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
Accurate	O
control	O
of	O
solvent	O
flow	O
rate	O
will	O
compensate	O
for	O
changes	O
in	O
pressure	O
drop	O
and	O
lead	O
to	O
more	O
reliable	O
retention	O
times	O
.	O

(	O
2	O
)	O
The	O
composition	O
of	O
the	O
mobile	O
phase	O
can	O
be	O
accurately	O
controlled	O
in	O
either	O
isocratic	O
or	O
gradient	O
elution	O
chromatography	O
using	O
,	O
for	O
example	O
,	O
a	O
proportioning	O
valve	O
on	O
the	O
low	O
pressure	O
side	O
of	O
the	O
pump	O
.	O

(	O
3	O
)	O
Automatic	O
sampling	O
can	O
be	O
operated	O
in	O
a	O
variety	O
of	O
modes	O
to	O
process	O
a	O
number	O
of	O
samples	O
without	O
supervision	O
.	O

It	O
is	O
also	O
more	O
precise	O
than	O
manual	O
injection	O
.	O

(	O
4	O
)	O
A	O
built	O
-	O
in	O
data	O
handling	O
facility	O
can	O
present	O
the	O
analyst	O
with	O
an	O
easily	O
read	O
post	O
-	O
run	O
report	O
of	O
the	O
analytical	O
results	O
with	O
accurate	O
peak	O
area	O
measurements	O
even	O
for	O
peaks	O
which	O
are	O
poorly	O
resolved	O
.	O

Although	O
liquid	O
chromatographs	O
incorporating	O
microprocessors	O
for	O
control	O
and	O
data	O
handling	O
purposes	O
are	O
commercially	O
available	O
,	O
these	O
instruments	O
are	O
,	O
so	O
far	O
,	O
This	O
paper	O
describes	O
,	O
in	O
detail	O
,	O
the	O
relatively	O
inflexible	O
.	O
automation	O
of	O
a	O
liquid	O
chromatograph	O
using	O
an	O
inexpensive	O
general	O
purpose	O
microcomputer	O
,	O
which	O
has	O
previously	O
been	O
applied	O
in	O
atomic	O
absorption	O
spectrophotometry	O
[	O
1	O
]	O
and	O
for	O
column	O
switching	O
in	O
HPLC	O
2	O
]	O
.	O

Figure	O
illustrates	O
the	O
interconnection	O
of	O
the	O
chromatograph	O
and	O
the	O
microcomputer	O
which	O
controls	O
the	O
mobile	O
phase	O
flow	O
rate	O
,	O
operates	O
an	O
automatic	O
sampler	O
and	O
analyses	O
data	O
from	O
the	O
detector	O
.	O

The	O
control	O
and	O
data	O
handling	O
functions	O
are	O
integrated	O
in	O
a	O
program	O
which	O
enables	O
the	O
user	O
to	O
communicate	O
with	O
the	O
instrument	O
,	O
in	O
plain	O
English	O
,	O
via	O
a	O
visual	O
display	O
unit	O
(	O
VDU	O
)	O
or	O
teletypewriter	O
keyboard	O
.	O

A	O
variety	O
of	O
operational	O
modes	O
is	O
offered	O
,	O
giving	O
the	O
analyst	O
an	O
opportunity	O
to	O
establish	O
the	O
best	O
conditions	O
for	O
a	O
particular	O
separation	O
before	O
leaving	O
the	O
instrument	O
to	O
perform	O
its	O
given	O
tasks	O
without	O
further	O
interaction	O
.	O

The	O
microcomputer	O
Hardware	O
The	O
computer	O
is	O
a	O
general	O
purpose	O
instrument	O
constructed	O
using	O
a	O
set	O
of	O
ready	O
made	O
circuit	O
cards	O
(	O
Philips	O
,	O
Science	O
and	O
The	O
Journal	O
of	O
Automatic	O
Chemistry	O

*	O
Present	O
address	O
:	O
lye	O
Unicam	O
Ltd	O
.	O
,	O
York	O
Street	O
,	O
Cambridge	O
,	O
CB1	O
2PX	O
,	O
U	O
.	O
K	O
.	O

134	O

TOPS	O
+	O
+	O
FATCAT	O
:	O
Fast	O
flexible	O
structural	O
alignment	O
using	O
constraints	O
derived	O
from	O
TOPS	O
+	O
Strings	O
Model	O

Abstract	O

Background	O

Protein	O
structure	O
analysis	O
and	O
comparison	O
are	O
major	O
challenges	O
in	O
structural	O
bioinformatics	O
.	O

Despite	O
the	O
existence	O
of	O
many	O
tools	O
and	O
algorithms	O
,	O
very	O
few	O
of	O
them	O
have	O
managed	O
to	O
capture	O
the	O
intuitive	O
understanding	O
of	O
protein	O
structures	O
developed	O
in	O
structural	O
biology	O
,	O
especially	O
in	O
the	O
context	O
of	O
rapid	O
database	O
searches	O
.	O

Such	O
intuitions	O
could	O
help	O
speed	O
up	O
similarity	O
searches	O
and	O
make	O
it	O
easier	O
to	O
understand	O
the	O
results	O
of	O
such	O
analyses	O
.	O

Results	O

We	O
developed	O
a	O
TOPS	O
+	O
+	O
FATCAT	O
algorithm	O
that	O
uses	O
an	O
intuitive	O
description	O
of	O
the	O
proteins	O
'	O
structures	O
as	O
captured	O
in	O
the	O
popular	O
TOPS	O
diagrams	O
to	O
limit	O
the	O
search	O
space	O
of	O
the	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
in	O
the	O
flexible	O
alignment	O
of	O
protein	O
structures	O
performed	O
by	O
the	O
FATCAT	O
algorithm	O
.	O

The	O
TOPS	O
+	O
+	O
FATCAT	O
algorithm	O
is	O
faster	O
than	O
FATCAT	O
by	O
more	O
than	O
an	O
order	O
of	O
magnitude	O
with	O
a	O
minimal	O
cost	O
in	O
classification	O
and	O
alignment	O
accuracy	O
.	O

For	O
beta	O
-	O
rich	O
proteins	O
its	O
accuracy	O
is	O
better	O
than	O
FATCAT	O
,	O
because	O
the	O
TOPS	O
+	O
strings	O
models	O
contains	O
important	O
information	O
of	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
-	O
bond	O
patterns	O
between	O
the	O
beta	O
-	O
strand	O
SSEs	O
(	O
Secondary	O
Structural	O
Elements	O
)	O
.	O

We	O
show	O
that	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
errors	O
,	O
rare	O
as	O
they	O
are	O
,	O
can	O
be	O
clearly	O
linked	O
to	O
oversimplifications	O
of	O
the	O
TOPS	O
diagrams	O
and	O
can	O
be	O
corrected	O
by	O
the	O
development	O
of	O
more	O
precise	O
secondary	O
structure	O
element	O
definitions	O
.	O

Software	O
Availability	O

The	O
benchmark	O
analysis	O
results	O
and	O
the	O
compressed	O
archive	O
of	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
program	O
for	O
Linux	O
platform	O
can	O
be	O
downloaded	O
from	O
the	O
following	O
web	O
site	O
:	O

Conclusion	O

TOPS	O
+	O
+	O
FATCAT	O
provides	O
FATCAT	O
accuracy	O
and	O
insights	O
into	O
protein	O
structural	O
changes	O
at	O
a	O
speed	O
comparable	O
to	O
sequence	O
alignments	O
,	O
opening	O
up	O
a	O
possibility	O
of	O
interactive	O
protein	O
structure	O
similarity	O
searches	O
.	O

Background	O

Structural	O
biology	O
is	O
one	O
of	O
the	O
most	O
successful	O
fields	O
of	O
modern	O
biology	O
.	O

Over	O
50	O
,	O
000	O
solved	O
protein	O
structures	O
illustrate	O
details	O
of	O
many	O
specific	O
biological	O
processes	O
.	O

The	O
same	O
data	O
also	O
provide	O
us	O
with	O
information	O
about	O
the	O
global	O
features	O
of	O
protein	O
structure	O
space	O
and	O
can	O
be	O
studied	O
to	O
discover	O
the	O
evolutionary	O
,	O
physical	O
,	O
and	O
mathematical	O
rules	O
governing	O
them	O
.	O

How	O
many	O
fundamentally	O
different	O
protein	O
shapes	O
(	O
folds	O
)	O
are	O
there	O
?	O

How	O
do	O
protein	O
structures	O
evolve	O
?	O

How	O
do	O
new	O
structural	O
features	O
appear	O
,	O
and	O
if	O
they	O
are	O
coupled	O
with	O
changes	O
in	O
function	O
,	O
how	O
does	O
this	O
process	O
occur	O
?	O

Such	O
questions	O
can	O
be	O
studied	O
by	O
classifying	O
,	O
comparing	O
and	O
analyzing	O
known	O
protein	O
structures	O
.	O

Two	O
different	O
,	O
but	O
synergistic	O
strategies	O
are	O
typically	O
used	O
for	O
this	O
purpose	O
.	O

In	O
classification	O
systems	O
such	O
as	O
SCOP	O
[	O
1	O
]	O
or	O
CATH	O
[	O
2	O
]	O
,	O
human	S-Species
intuition	O
is	O
used	O
to	O
simplify	O
the	O
description	O
of	O
protein	O
structures	O
to	O
a	O
manageable	O
size	O
,	O
and	O
a	O
human	S-Species
eye	O
,	O
sometimes	O
supported	O
by	O
automated	O
analysis	O
,	O
can	O
recognize	O
patterns	O
and	O
types	O
of	O
structures	O
.	O

In	O
the	O
second	O
approach	O
,	O
specialized	O
comparison	O
algorithms	O
,	O
such	O
as	O
DALI	O
[	O
3	O
]	O
,	O
CE	O
[	O
4	O
]	O
,	O
or	O
FATCAT	O
[	O
5	O
]	O
can	O
be	O
used	O
to	O
calculate	O
a	O
distance	O
-	O
like	O
metric	O
in	O
the	O
protein	O
structure	O
space	O
.	O

This	O
in	O
turn	O
can	O
be	O
used	O
to	O
cluster	O
proteins	O
into	O
groups	O
.	O

Many	O
such	O
algorithms	O
have	O
been	O
developed	O
over	O
the	O
past	O
few	O
decades	O
and	O
have	O
been	O
mostly	O
used	O
for	O
the	O
classification	O
of	O
protein	O
structures	O
into	O
families	O
.	O

An	O
exact	O
solution	O
of	O
an	O
alignment	O
between	O
two	O
structures	O
is	O
formally	O
equivalent	O
to	O
a	O
threading	O
problem	O
and	O
is	O
therefore	O
NP	O
-	O
complete	O
[	O
6	O
]	O
.	O

However	O
,	O
a	O
practical	O
solution	O
can	O
be	O
obtained	O
by	O
heuristics	O
reducing	O
the	O
problem	O
to	O
a	O
manageable	O
size	O
[	O
7	O
]	O
.	O

In	O
human	S-Species
classification	O
systems	O
,	O
the	O
protein	O
is	O
usually	O
reduced	O
to	O
a	O
set	O
of	O
several	O
structural	O
elements	O
,	O
which	O
obviously	O
involve	O
many	O
arbitrary	O
thresholds	O
.	O

Automated	O
algorithms	O
have	O
the	O
same	O
problem	O
and	O
also	O
suffer	O
from	O
inconsistencies	O
between	O
different	O
numerical	O
measures	O
of	O
protein	O
structure	O
similarity	O
[	O
8	O
]	O
.	O

Interestingly	O
,	O
despite	O
these	O
problems	O
,	O
results	O
of	O
different	O
approaches	O
are	O
broadly	O
similar	O
.	O

They	O
all	O
identify	O
approximately	O
a	O
few	O
hundred	O
general	O
classes	O
of	O
protein	O
structures	O
,	O
usually	O
called	O
folds	O
[	O
1	O
]	O
or	O
topologies	O
[	O
2	O
]	O
,	O
distinguished	O
by	O
how	O
the	O
main	O
chain	O
of	O
the	O
protein	O
folds	O
around	O
itself	O
in	O
the	O
three	O
-	O
dimensional	O
space	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
comparison	O
of	O
different	O
approaches	O
,	O
both	O
between	O
and	O
within	O
the	O
two	O
classes	O
,	O
shows	O
that	O
fold	O
/	O
topologies	O
(	O
or	O
cluster	O
)	O
definitions	O
are	O
somewhat	O
fuzzy	O
,	O
with	O
some	O
proteins	O
being	O
occasionally	O
difficult	O
to	O
classify	O
and	O
joining	O
different	O
groups	O
depending	O
on	O
various	O
assumptions	O
.	O

This	O
lead	O
some	O
to	O
question	O
the	O
concept	O
of	O
the	O
fold	O
[	O
9	O
]	O
,	O
but	O
practical	O
application	O
of	O
protein	O
structure	O
comparison	O
leaves	O
little	O
doubt	O
that	O
protein	O
structure	O
space	O
has	O
some	O
natural	O
granularity	O
that	O
overlaps	O
well	O
with	O
the	O
traditional	O
fold	O
classification	O
.	O

Comparison	O
and	O
classification	O
of	O
protein	O
structures	O
is	O
significantly	O
simplified	O
by	O
the	O
fact	O
that	O
proteins	O
have	O
naturally	O
modular	O
structures	O
,	O
being	O
mostly	O
composed	O
of	O
locally	O
regular	O
structures	O
:	O
alpha	O
helices	O
and	O
beta	O
strands	O
.	O

These	O
two	O
types	O
of	O
secondary	O
structures	O
constitute	O
a	O
little	O
over	O
50	O
%	O
of	O
an	O
average	O
protein	O
'	O
s	O
length	O
.	O

With	O
the	O
average	O
length	O
of	O
a	O
secondary	O
structure	O
being	O
around	O
10	O
amino	O
acids	O
,	O
this	O
makes	O
it	O
possible	O
to	O
describe	O
protein	O
structure	O
as	O
an	O
arrangement	O
of	O
a	O
much	O
smaller	O
number	O
of	O
elements	O
.	O

Protein	O
structures	O
are	O
often	O
visualized	O
in	O
a	O
simplified	O
form	O
,	O
with	O
the	O
so	O
-	O
called	O
ribbon	O
diagram	O
with	O
secondary	O
structures	O
shown	O
as	O
helices	O
and	O
arrows	O
being	O
the	O
most	O
popular	O
(	O
see	O
Figure	O
1	O
)	O
.	O

This	O
picture	O
can	O
be	O
simplified	O
further	O
by	O
showing	O
individual	O
secondary	O
structure	O
elements	O
as	O
simple	O
symbols	O
(	O
circles	O
or	O
boxes	O
/	O
triangles	O
)	O
.	O

These	O
depictions	O
,	O
called	O
fold	O
diagrams	O
,	O
originally	O
proposed	O
in	O
the	O
70s	O
[	O
10	O
-	O
12	O
]	O
are	O
best	O
captured	O
by	O
a	O
TOPS	O
(	O
Topology	O
of	O
Protein	O
Structures	O
)	O
algorithm	O
,	O
which	O
attempts	O
to	O
automate	O
the	O
process	O
of	O
creation	O
of	O
the	O
topology	O
cartoon	O
[	O
13	O
]	O
.	O

While	O
useful	O
in	O
protein	O
classification	O
,	O
such	O
simplified	O
descriptions	O
are	O
not	O
used	O
in	O
the	O
most	O
popular	O
automated	O
protein	O
structure	O
comparison	O
algorithms	O
such	O
as	O
DALI	O
[	O
3	O
]	O
or	O
CE	O
[	O
4	O
]	O
.	O

Kleywegt	O
and	O
Jones	O
developed	O
a	O
method	O
for	O
finding	O
similar	O
motifs	O
based	O
on	O
comparing	O
distance	O
matrices	O
that	O
are	O
constructed	O
by	O
representing	O
protein	O
as	O
a	O
set	O
of	O
SSEs	O
with	O
their	O
directional	O
vectors	O
and	O
angle	O
between	O
those	O
vectors	O
[	O
14	O
]	O
.	O

Programs	O
that	O
used	O
SSEs	O
either	O
for	O
structure	O
comparison	O
based	O
on	O
hierarchical	O
superposition	O
of	O
both	O
SSEs	O
and	O
atomic	O
representation	O
[	O
15	O
]	O
or	O
for	O
finding	O
common	O
substructures	O
in	O
the	O
comparison	O
process	O
based	O
on	O
subgraph	O
isomorphism	O
,	O
such	O
as	O
[	O
16	O
,	O
17	O
]	O
and	O
recent	O
applications	O
of	O
the	O
TOPS	O
diagram	O
[	O
18	O
,	O
19	O
]	O
,	O
usually	O
struggle	O
with	O
translating	O
the	O
comparison	O
results	O
from	O
the	O
secondary	O
structure	O
to	O
the	O
individual	O
residue	O
level	O
.	O

Although	O
the	O
SSM	O
method	O
uses	O
graph	O
-	O
matching	O
procedures	O
at	O
the	O
SSE	O
level	O
followed	O
by	O
an	O
interactive	O
3D	O
alignment	O
of	O
the	O
protein	O
C	O
-	O
alpha	O
atom	O
[	O
20	O
]	O
,	O
it	O
lacks	O
the	O
topological	O
relationships	O
between	O
the	O
SSEs	O
,	O
which	O
are	O
essential	O
features	O
in	O
identifying	O
common	O
scaffolds	O
in	O
distantly	O
related	O
proteins	O
.	O

A	O
TOPS	O
pattern	O
was	O
used	O
to	O
guide	O
the	O
sequence	O
alignment	O
,	O
for	O
instance	O
,	O
to	O
build	O
multiple	O
structural	O
alignments	O
of	O
the	O
distantly	O
related	O
family	O
of	O
beta	O
-	O
rich	O
protein	O
domains	O
[	O
21	O
]	O
.	O

The	O
Multiple	O
Sequence	O
Alignment	O
Tool	O
(	O
MSAT	O
)	O
automates	O
this	O
approach	O
,	O
merging	O
it	O
with	O
a	O
popular	O
ClustalW	O
program	O
[	O
22	O
]	O
.	O

DALI	O
[	O
3	O
]	O
,	O
CE	O
[	O
4	O
]	O
or	O
FATCAT	O
[	O
5	O
]	O
introduce	O
their	O
own	O
methods	O
of	O
decomposing	O
the	O
protein	O
structure	O
into	O
smaller	O
units	O
,	O
such	O
as	O
7	O
x	O
7	O
dense	O
distance	O
map	O
fragments	O
(	O
DALIs	O
)	O
or	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
(	O
CE	O
and	O
FATCAT	O
)	O
.	O

The	O
large	O
number	O
of	O
such	O
fragments	O
and	O
the	O
combinations	O
of	O
the	O
fragments	O
that	O
need	O
to	O
be	O
evaluated	O
by	O
structure	O
comparison	O
programs	O
is	O
the	O
main	O
reason	O
for	O
the	O
significant	O
computational	O
requirements	O
of	O
such	O
algorithms	O
.	O

However	O
,	O
more	O
importantly	O
,	O
TOPS	O
+	O
method	O
is	O
used	O
here	O
to	O
enable	O
a	O
structural	O
comparison	O
that	O
takes	O
into	O
account	O
flexibility	O
in	O
protein	O
structures	O
and	O
not	O
only	O
classifies	O
the	O
differences	O
,	O
but	O
also	O
can	O
recognize	O
such	O
rearrangements	O
-	O
which	O
is	O
a	O
first	O
such	O
application	O
using	O
the	O
SSEs	O
language	O
.	O

In	O
this	O
contribution	O
,	O
we	O
explore	O
the	O
question	O
of	O
whether	O
it	O
would	O
be	O
possible	O
to	O
combine	O
insights	O
provided	O
by	O
topology	O
diagrams	O
into	O
automated	O
protein	O
structure	O
alignment	O
algorithms	O
,	O
focusing	O
on	O
the	O
FATCAT	O
program	O
developed	O
previously	O
in	O
our	O
group	O
.	O

Methods	O

Flexible	O
structure	O
alignment	O
method	O
FATCAT	O

FATCAT	O
[	O
5	O
]	O
is	O
a	O
unique	O
structure	O
alignment	O
method	O
that	O
allows	O
for	O
flexibility	O
in	O
the	O
structures	O
being	O
compared	O
.	O

It	O
builds	O
the	O
alignment	O
by	O
chaining	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
[	O
23	O
]	O
together	O
using	O
a	O
unified	O
scoring	O
function	O
where	O
AFP	O
extensions	O
,	O
gaps	O
,	O
and	O
twists	O
each	O
have	O
their	O
specific	O
scores	O
(	O
Figure	O
2	O
)	O
.	O

Introducing	O
a	O
twist	O
into	O
the	O
alignment	O
is	O
penalized	O
,	O
but	O
this	O
penalty	O
may	O
be	O
compensated	O
for	O
by	O
the	O
gain	O
in	O
the	O
score	O
of	O
the	O
resulting	O
alignment	O
(	O
i	O
.	O
e	O
.	O
,	O
longer	O
alignment	O
and	O
/	O
or	O
better	O
RMSD	O
)	O
.	O

Rigid	O
alignment	O
can	O
be	O
treated	O
as	O
a	O
special	O
case	O
,	O
in	O
which	O
no	O
twist	O
is	O
allowed	O
in	O
chaining	O
AFPs	O
.	O

FATCAT	O
program	O
provides	O
alignment	O
in	O
both	O
,	O
"	O
rigid	O
"	O
mode	O
and	O
"	O
flexible	O
"	O
(	O
default	O
)	O
mode	O
.	O

FATCAT	O
,	O
as	O
well	O
as	O
most	O
other	O
protein	O
structure	O
comparison	O
programs	O
,	O
is	O
very	O
slow	O
when	O
compared	O
to	O
sequence	O
alignments	O
.	O

The	O
computing	O
time	O
of	O
FATCAT	O
is	O
determined	O
by	O
the	O
size	O
of	O
the	O
collection	O
of	O
AFPs	O
detected	O
between	O
the	O
two	O
structures	O
being	O
compared	O
.	O

FATCAT	O
is	O
available	O
from	O
a	O
server	O
with	O
an	O
option	O
to	O
search	O
in	O
SCOP	O
or	O
PDB	O
databases	O
for	O
similar	O
structures	O
.	O

This	O
search	O
typically	O
takes	O
between	O
8	O
to	O
16	O
hours	O
of	O
CPU	O
time	O
,	O
and	O
this	O
is	O
the	O
main	O
obstacle	O
to	O
broader	O
use	O
of	O
this	O
option	O
.	O

FATCAT	O
has	O
been	O
used	O
to	O
construct	O
a	O
Flexible	O
Structure	O
Neighborhood	O
(	O
FSN	O
)	O
database	O
that	O
contains	O
pre	O
-	O
computed	O
results	O
of	O
structure	O
similarity	O
searches	O
and	O
it	O
takes	O
several	O
weeks	O
of	O
CPU	O
time	O
to	O
update	O
the	O
FSN	O
database	O
.	O

Other	O
protein	O
structure	O
comparison	O
resources	O
,	O
such	O
as	O
DALI	O
or	O
CE	O
have	O
very	O
similar	O
problems	O
.	O

TOPS	O
cartoons	O
and	O
TOPS	O
graph	O
models	O

As	O
discussed	O
in	O
the	O
Background	O
,	O
TOPS	O
cartoons	O
capture	O
the	O
simplified	O
,	O
fold	O
-	O
level	O
description	O
of	O
protein	O
structure	O
and	O
at	O
the	O
same	O
time	O
can	O
be	O
automated	O
[	O
24	O
]	O
.	O

The	O
TOPS	O
algorithm	O
uses	O
structural	O
features	O
such	O
as	O
hydrogen	O
bonds	O
and	O
chirality	O
of	O
the	O
beta	O
strands	O
to	O
provide	O
a	O
scoring	O
function	O
to	O
optimize	O
the	O
cartoon	O
(	O
see	O
Figure	O
1	O
(	O
b	O
)	O
)	O
.	O

In	O
TOPS	O
,	O
the	O
secondary	O
structural	O
elements	O
(	O
SSEs	O
)	O
are	O
derived	O
from	O
the	O
DSSP	O
program	O
[	O
25	O
]	O
.	O

Based	O
on	O
TOPS	O
cartoons	O
,	O
a	O
formal	O
graph	O
model	O
and	O
graph	O
-	O
based	O
definitions	O
of	O
protein	O
topology	O
and	O
pattern	O
discovery	O
and	O
comparison	O
methods	O
were	O
developed	O
[	O
26	O
,	O
27	O
]	O
.	O

The	O
TOPS	O
database	O
and	O
comparison	O
,	O
pattern	O
discovery	O
and	O
matching	O
programs	O
are	O
accessible	O
from	O
.	O

Novel	O
TOPS	O
+	O
and	O
TOPS	O
+	O
strings	O
models	O

The	O
TOPS	O
model	O
was	O
further	O
enhanced	O
to	O
incorporate	O
features	O
such	O
as	O
protein	O
-	O
ligand	O
interaction	O
information	O
and	O
more	O
detailed	O
secondary	O
structural	O
segment	O
information	O
.	O

This	O
enhanced	O
model	O
is	O
called	O
TOPS	O
+	O
model	O
(	O
see	O
Figure	O
3a	O
)	O
.	O

This	O
TOPS	O
+	O
model	O
can	O
be	O
described	O
formally	O
in	O
a	O
TOPS	O
+	O
strings	O
language	O
(	O
Figure	O
3b	O
)	O
at	O
a	O
reduced	O
linear	O
level	O
.	O

The	O
enhanced	O
TOPS	O
+	O
strings	O
models	O
can	O
be	O
used	O
in	O
fast	O
string	O
-	O
based	O
structure	O
matching	O
and	O
comparison	O
,	O
at	O
the	O
same	O
time	O
avoiding	O
issues	O
of	O
NP	O
-	O
completeness	O
associated	O
with	O
graph	O
alignments	O
.	O

In	O
detail	O
,	O
each	O
node	O
(	O
SSE	O
segment	O
)	O
of	O
the	O
TOPS	O
+	O
strings	O
is	O
described	O
by	O
its	O
type	O
,	O
orientation	O
,	O
PDB	O
start	O
number	O
,	O
segment	O
length	O
,	O
total	O
number	O
of	O
incoming	O
(	O
InArc	O
)	O
and	O
outgoing	O
(	O
OutArc	O
)	O
arcs	O
(	O
edges	O
)	O
,	O
total	O
number	O
of	O
ArcTypes	O
,	O
and	O
total	O
number	O
of	O
ligand	O
arcs	O
(	O
LigArc	O
)	O
.	O

The	O
type	O
of	O
the	O
segment	O
(	O
SSEType	O
)	O
could	O
be	O
one	O
of	O
[	O
E	O
,	O
e	O
,	O
H	O
,	O
h	O
,	O
U	O
,	O
u	O
]	O
,	O
where	O
,	O
"	O
E	O
"	O
and	O
"	O
e	O
"	O
represent	O
the	O
"	O
up	O
"	O
-	O
and	O
"	O
down	O
"	O
-	O
oriented	O
beta	O
strands	O
;	O
"	O
H	O
"	O
and	O
"	O
h	O
"	O
indicate	O
the	O
"	O
up	O
"	O
-	O
and	O
"	O
down	O
"	O
-	O
oriented	O
alpha	O
helices	O
;	O
and	O
"	O
U	O
"	O
and	O
"	O
u	O
"	O
represent	O
ligand	O
-	O
bound	O
and	O
ligand	O
-	O
free	O
loops	O
.	O

The	O
InArcType	O
can	O
be	O
classified	O
as	O
an	O
/	O
a	O
[	O
R	O
,	O
L	O
,	O
P	O
,	O
A	O
]	O
,	O
where	O
"	O
R	O
"	O
and	O
"	O
L	O
"	O
represent	O
right	O
and	O
left	O
chiralities	O
;	O
and	O
"	O
P	O
"	O
and	O
"	O
A	O
"	O
represent	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
bonds	O
,	O
respectively	O
.	O

The	O
OutArcType	O
is	O
represented	O
in	O
a	O
similar	O
manner	O
by	O
[	O
R	O
'	O
,	O
L	O
'	O
,	O
P	O
'	O
,	O
A	O
'	O
]	O
.	O

Ligand	O
arcs	O
are	O
indicated	O
by	O
LT	O
=	O
AA	O
,	O
where	O
LT	O
is	O
the	O
ligand	O
type	O
and	O
AA	O
is	O
the	O
PDB	O
number	O
.	O

For	O
example	O
,	O
Figure	O
3	O
(	O
a	O
)	O
and	O
3	O
(	O
b	O
)	O
contain	O
visual	O
representations	O
of	O
TOPS	O
+	O
and	O
TOPS	O
+	O
strings	O
models	O
,	O
respectively	O
,	O
for	O
the	O
protein	O
domain	O
d1fnb	O
_	O
1	O
.	O

Here	O
the	O
triangles	O
represent	O
the	O
beta	O
strands	O
;	O
the	O
red	O
curve	O
represents	O
the	O
alpha	O
helix	O
;	O
gray	O
ellipsoids	O
indicate	O
loops	O
;	O
and	O
green	O
arcs	O
indicate	O
hydrogen	O
bonds	O
between	O
two	O
beta	O
strands	O
,	O
called	O
anti	O
-	O
parallel	O
beta	O
sheets	O
.	O

The	O
length	O
of	O
a	O
TOPS	O
+	O
strings	O
model	O
is	O
defined	O
by	O
number	O
of	O
SSEs	O
;	O
thus	O
,	O
the	O
length	O
of	O
d1fnb	O
_	O
1	O
is	O
19	O
.	O

For	O
further	O
details	O
,	O
see	O
[	O
28	O
]	O
.	O

TOPS	O
+	O
strings	O
comparison	O
method	O

TOPS	O
+	O
is	O
a	O
comparison	O
method	O
that	O
computes	O
a	O
distance	O
between	O
TOPS	O
+	O
strings	O
models	O
of	O
two	O
proteins	O
based	O
on	O
a	O
dynamic	O
programming	O
approach	O
and	O
identifies	O
the	O
longest	O
common	O
subsequence	O
(	O
LCS	O
)	O
,	O
consisting	O
of	O
the	O
list	O
of	O
the	O
topologically	O
equivalent	O
SSEs	O
between	O
two	O
proteins	O
.	O

For	O
example	O
,	O
Figure	O
3	O
(	O
c	O
)	O
shows	O
the	O
TOPS	O
+	O
strings	O
alignment	O
between	O
Dihydropteridine	O
reductase	O
proteins	O
from	O
rat	O
(	O
1dhr	O
)	O
and	O
human	S-Species
(	O
1hdr	O
)	O
.	O

The	O
TOPS	O
+	O
strings	O
models	O
for	O
1dhr	O
and	O
1hdr	O
are	O
represented	O
by	O
a	O
linear	O
string	O
-	O
model	O
,	O
where	O
a	O
yellow	O
triangle	O
and	O
red	O
curves	O
indicate	O
the	O
beta	O
strands	O
and	O
alpha	O
helices	O
in	O
their	O
"	O
up	O
"	O
or	O
"	O
down	O
"	O
orientations	O
,	O
respectively	O
.	O

The	O
grey	O
line	O
and	O
purple	O
stubs	O
represent	O
the	O
loop	O
regions	O
and	O
the	O
NAD	O
ligand	O
interactions	O
,	O
respectively	O
.	O

Note	O
that	O
the	O
ligand	O
-	O
interaction	O
information	O
is	O
optional	O
and	O
in	O
this	O
work	O
we	O
have	O
not	O
used	O
it	O
.	O

The	O
incoming	O
and	O
outgoing	O
arcs	O
are	O
depicted	O
in	O
the	O
SSEs	O
(	O
top	O
and	O
bottom	O
of	O
the	O
beta	O
strands	O
)	O
,	O
where	O
red	O
and	O
green	O
arcs	O
represent	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
-	O
bond	O
interactions	O
that	O
show	O
beta	O
-	O
sheet	O
information	O
,	O
while	O
yellow	O
and	O
blue	O
arcs	O
indicate	O
the	O
right	O
and	O
left	O
chirality	O
relationships	O
between	O
the	O
SSEs	O
.	O

A	O
pink	O
arrow	O
between	O
the	O
TOPS	O
+	O
strings	O
elements	O
indicates	O
the	O
conserved	O
SSE	O
.	O

The	O
dotted	O
arrows	O
indicate	O
the	O
conserved	O
alpha	O
helices	O
and	O
beta	O
strands	O
,	O
while	O
the	O
plain	O
arrows	O
indicate	O
the	O
conserved	O
loop	O
regions	O
.	O

TOPS	O
+	O
+	O
FATCAT	O
method	O

In	O
this	O
work	O
,	O
we	O
want	O
to	O
test	O
the	O
general	O
idea	O
of	O
pruning	O
the	O
search	O
space	O
of	O
the	O
FATCAT	O
comparison	O
process	O
using	O
topological	O
constraints	O
derived	O
from	O
the	O
TOPS	O
+	O
strings	O
alignment	O
.	O

Many	O
of	O
the	O
AFPs	O
considered	O
in	O
the	O
FATCAT	O
alignment	O
could	O
be	O
easily	O
eliminated	O
from	O
the	O
comparison	O
by	O
constraining	O
the	O
alignment	O
region	O
.	O

Here	O
we	O
explore	O
constraints	O
obtained	O
from	O
the	O
TOPS	O
+	O
strings	O
alignment	O
,	O
which	O
identifies	O
topologically	O
equivalent	O
secondary	O
structure	O
elements	O
(	O
alpha	O
helices	O
,	O
beta	O
strands	O
,	O
and	O
loops	O
)	O
for	O
this	O
purpose	O
.	O

Such	O
equivalences	O
define	O
blocks	O
that	O
restrict	O
the	O
alignment	O
region	O
;	O
AFPs	O
that	O
fall	O
outside	O
these	O
regions	O
are	O
simply	O
not	O
considered	O
(	O
see	O
Figure	O
4	O
(	O
b	O
)	O
)	O
.	O

We	O
introduce	O
a	O
parameter	O
r	O
to	O
control	O
the	O
strictness	O
of	O
constraints	O
by	O
TOPS	O
+	O
strings	O
alignments	O
;	O
r	O
equals	O
0	O
if	O
the	O
alignment	O
region	O
is	O
strictly	O
restrained	O
by	O
TOPS	O
+	O
strings	O
alignment	O
,	O
and	O
r	O
is	O
set	O
to	O
1	O
by	O
default	O
in	O
our	O
program	O
to	O
allow	O
certain	O
flexibility	O
to	O
the	O
constrained	O
alignment	O
region	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

We	O
then	O
can	O
speed	O
up	O
the	O
FATCAT	O
alignment	O
by	O
considering	O
only	O
the	O
AFPs	O
within	O
the	O
constrained	O
alignment	O
area	O
(	O
Figure	O
4	O
(	O
d	O
)	O
)	O
.	O

The	O
rigid	O
structural	O
alignment	O
can	O
be	O
treated	O
as	O
a	O
special	O
case	O
of	O
TOPS	O
+	O
+	O
FATCAT	O
,	O
in	O
which	O
no	O
twist	O
is	O
allowed	O
in	O
chaining	O
AFPs	O
.	O

However	O
,	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
program	O
provides	O
alignment	O
in	O
both	O
,	O
"	O
rigid	O
"	O
mode	O
and	O
"	O
flexible	O
"	O
mode	O
(	O
default	O
)	O
.	O

Benchmarking	O

For	O
benchmarking	O
and	O
comparison	O
,	O
we	O
have	O
used	O
the	O
PDB40	O
dataset	O
of	O
1	O
,	O
901	O
protein	O
domain	O
pairs	O
(	O
DP	O
)	O
corresponding	O
to	O
SCOP	O
version	O
1	O
.	O
61	O
from	O
the	O
ASTRAL	O
database	O
[	O
29	O
]	O
.	O

Table	O
1	O
provides	O
the	O
SCOP	O
superfamily	O
level	O
homolog	O
versus	O
non	O
-	O
homolog	O
statistics	O
for	O
the	O
four	O
main	O
SCOP	O
classes	O
i	O
.	O
e	O
.	O
,	O
all	O
-	O
alpha	O
,	O
all	O
-	O
beta	O
,	O
alpha	O
/	O
beta	O
,	O
alpha	O
+	O
beta	O
,	O
and	O
all	O
proteins	O
regardless	O
of	O
their	O
structural	O
classes	O
.	O

Evaluation	O
Analyses	O

We	O
performed	O
the	O
Receiver	O
Operating	O
Characteristics	O
(	O
ROC	O
)	O
curve	O
and	O
the	O
AUC	O
(	O
Area	O
Under	O
the	O
ROC	O
Curve	O
)	O
analyses	O
to	O
compare	O
the	O
performance	O
of	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
with	O
the	O
original	O
FATCAT	O
method	O
,	O
using	O
SCOP	O
classification	O
at	O
the	O
superfamily	O
level	O
as	O
a	O
standard	O
of	O
comparison	O
[	O
30	O
]	O
.	O

Results	O

ROC	O
and	O
AUC	O
Analyses	O

We	O
have	O
compared	O
the	O
performance	O
of	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
against	O
the	O
original	O
FATCAT	O
method	O
using	O
the	O
SCOP	O
classification	O
information	O
at	O
the	O
superfamily	O
level	O
.	O

We	O
have	O
plotted	O
the	O
ROC	O
curves	O
based	O
on	O
P	O
-	O
values	O
obtained	O
from	O
the	O
FATCAT	O
and	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
.	O

We	O
have	O
plotted	O
the	O
ROC	O
curves	O
separately	O
for	O
the	O
main	O
SCOP	O
classes	O
,	O
i	O
.	O
e	O
.	O
,	O
all	O
-	O
alpha	O
,	O
all	O
-	O
beta	O
,	O
alpha	O
/	O
beta	O
,	O
alpha	O
+	O
beta	O
,	O
and	O
all	O
proteins	O
regardless	O
of	O
the	O
class	O
they	O
belong	O
to	O
(	O
see	O
Figure	O
5	O
(	O
a	O
)	O
to	O
5	O
(	O
e	O
)	O
)	O
.	O

In	O
the	O
graph	O
,	O
the	O
x	O
-	O
and	O
y	O
-	O
axes	O
represent	O
the	O
false	O
positive	O
and	O
true	O
positive	O
rates	O
of	O
the	O
performance	O
of	O
the	O
comparison	O
methods	O
respectively	O
.	O

In	O
the	O
legend	O
,	O
rF	O
-	O
pvalue	O
and	O
fF	O
-	O
pvalue	O
indicate	O
results	O
from	O
the	O
rigid	O
and	O
flexible	O
FATCAT	O
methods	O
,	O
respectively	O
;	O
similarly	O
,	O
rT2F	O
-	O
pvalue	O
and	O
fT2F	O
-	O
pvalue	O
represent	O
the	O
rigid	O
and	O
flexible	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
,	O
respectively	O
.	O

We	O
have	O
calculated	O
the	O
AUC	O
values	O
for	O
all	O
the	O
SCOP	O
classes	O
based	O
on	O
ROC	O
curves	O
obtained	O
from	O
the	O
FATCAT	O
and	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
with	O
the	O
flexible	O
/	O
rigid	O
options	O
(	O
see	O
Table	O
2	O
)	O
.	O

For	O
all	O
protein	O
classes	O
,	O
the	O
rigid	O
FATCAT	O
performs	O
best	O
,	O
usually	O
followed	O
by	O
the	O
flexible	O
FATCAT	O
,	O
the	O
rigid	O
TOPS	O
+	O
+	O
FATCAT	O
,	O
and	O
the	O
flexible	O
TOPS	O
+	O
+	O
FATCAT	O
.	O

The	O
performance	O
of	O
all	O
four	O
methods	O
is	O
best	O
for	O
all	O
alpha	O
and	O
all	O
beta	O
proteins	O
,	O
and	O
all	O
four	O
perform	O
markedly	O
worse	O
(	O
but	O
similar	O
to	O
each	O
other	O
)	O
for	O
alpha	O
/	O
beta	O
proteins	O
.	O

Only	O
alpha	O
+	O
beta	O
proteins	O
show	O
a	O
clear	O
difference	O
between	O
the	O
FATCAT	O
and	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
TOPS	O
+	O
strings	O
models	O
consider	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
properties	O
of	O
the	O
beta	O
-	O
sheet	O
information	O
in	O
the	O
form	O
of	O
total	O
number	O
of	O
incoming	O
and	O
outgoing	O
arcs	O
with	O
their	O
ArcTypes	O
.	O

Thus	O
,	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
discriminates	O
the	O
protein	O
domain	O
pairs	O
more	O
efficiently	O
compared	O
to	O
the	O
original	O
FATCAT	O
method	O
.	O

For	O
example	O
,	O
in	O
the	O
all	O
-	O
beta	O
protein	O
domain	O
pairs	O
,	O
both	O
the	O
flexible	O
and	O
the	O
rigid	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
perform	O
well	O
.	O

The	O
flexible	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
covers	O
nearly	O
84	O
%	O
of	O
protein	O
domains	O
with	O
0	O
%	O
false	O
positives	O
,	O
but	O
the	O
flexible	O
and	O
rigid	O
FATCAT	O
methods	O
cover	O
only	O
76	O
%	O
and	O
49	O
%	O
of	O
the	O
true	O
positives	O
,	O
respectively	O
,	O
with	O
0	O
%	O
false	O
positives	O
.	O

The	O
zoomed	O
-	O
in	O
version	O
of	O
the	O
ROC	O
curves	O
with	O
up	O
to	O
10	O
%	O
false	O
positives	O
for	O
all	O
-	O
beta	O
rich	O
protein	O
families	O
is	O
shown	O
in	O
Figure	O
5	O
(	O
f	O
)	O
;	O
where	O
both	O
the	O
rigid	O
TOPS	O
+	O
+	O
FATCAT	O
(	O
green	O
)	O
and	O
flexible	O
(	O
red	O
)	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
have	O
coverage	O
rates	O
of	O
82	O
%	O
and	O
84	O
%	O
true	O
positives	O
respectively	O
with	O
0	O
%	O
false	O
positives	O
.	O

The	O
overall	O
results	O
for	O
all	O
protein	O
classes	O
show	O
that	O
TOPS	O
+	O
+	O
FATCAT	O
performance	O
is	O
only	O
slightly	O
lower	O
(	O
3	O
%	O
-	O
7	O
%	O
AUC	O
value	O
difference	O
(	O
see	O
Table	O
2	O
)	O
)	O
as	O
compared	O
to	O
FATCAT	O
while	O
providing	O
a	O
significant	O
,	O
more	O
than	O
10	O
-	O
fold	O
speedup	O
(	O
see	O
next	O
section	O
)	O
.	O

AFP	O
and	O
Runtime	O
Analyses	O

We	O
tested	O
both	O
the	O
FATCAT	O
and	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
using	O
the	O
Mac	O
OS	O
X	O
version	O
10	O
.	O
4	O
.	O
10	O
computer	O
system	O
with	O
a	O
2	O
x	O
2	O
.	O
66	O
-	O
GHz	O
Dual	O
-	O
Core	O
Intel	O
Xeon	O
processor	O
and	O
1	O
-	O
GB	O
667	O
MHz	O
memory	O
.	O

We	O
have	O
performed	O
runtime	O
analysis	O
on	O
1	O
,	O
901	O
protein	O
domain	O
pairs	O
and	O
counted	O
the	O
total	O
number	O
of	O
AFPs	O
and	O
the	O
corresponding	O
runtime	O
from	O
both	O
the	O
FATCAT	O
and	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
.	O

The	O
results	O
show	O
an	O
exponential	O
increase	O
in	O
AFPs	O
(	O
Figure	O
6	O
(	O
b	O
)	O
)	O
and	O
corresponding	O
runtime	O
(	O
Figure	O
6	O
(	O
a	O
)	O
)	O
for	O
the	O
FATCAT	O
method	O
as	O
compared	O
to	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
(	O
see	O
Table	O
3	O
)	O
For	O
example	O
,	O
the	O
average	O
number	O
of	O
AFPs	O
for	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
is	O
530	O
,	O
but	O
the	O
average	O
number	O
of	O
AFPs	O
for	O
the	O
FATCAT	O
method	O
is	O
15	O
,	O
019	O
.	O

This	O
represents	O
the	O
number	O
of	O
average	O
AFPs	O
used	O
by	O
the	O
FATCAT	O
method	O
is	O
increased	O
by	O
a	O
factor	O
of	O
28	O
(	O
see	O
Table	O
3	O
)	O
.	O

This	O
result	O
leads	O
to	O
the	O
conclusion	O
that	O
TOPS	O
+	O
+	O
FATCAT	O
is	O
22	O
times	O
faster	O
compared	O
to	O
the	O
FATCAT	O
because	O
this	O
method	O
must	O
take	O
into	O
account	O
more	O
number	O
of	O
AFPs	O
in	O
the	O
comparison	O
process	O
(	O
see	O
Table	O
3	O
)	O
.	O

Case	O
Studies	O

While	O
the	O
overall	O
accuracy	O
of	O
both	O
rigid	O
and	O
flexible	O
FATCAT	O
methods	O
is	O
better	O
than	O
their	O
TOPS	O
+	O
+	O
FATCAT	O
equivalents	O
,	O
an	O
interesting	O
example	O
where	O
the	O
opposite	O
is	O
true	O
lies	O
in	O
the	O
comparison	O
of	O
two	O
proteins	O
,	O
d2trxa	O
_	O
(	O
108	O
aa	O
)	O
from	O
Escherichia	B-Species
coli	E-Species
and	O
d1kte	O
_	O
_	O
(	O
105	O
aa	O
)	O
from	O
Sus	B-Species
scrofa	E-Species
(	O
pig	S-Species
)	O
from	O
the	O
thioredoxin	O
-	O
like	O
superfamily	O
.	O

For	O
this	O
pair	O
,	O
the	O
flexible	O
_	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
provides	O
an	O
alignment	O
with	O
88	O
equivalent	O
positions	O
with	O
1	O
.	O
67	O
A	O
chain	O
RMSD	O
and	O
3	O
.	O
06	O
A	O
of	O
optimal	O
RMSD	O
without	O
any	O
twist	O
,	O
giving	O
the	O
alignment	O
with	O
10	O
%	O
sequence	O
identity	O
(	O
see	O
Table	O
4	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
flexible	O
_	O
FATCAT	O
method	O
provides	O
an	O
alignment	O
with	O
86	O
aligned	O
positions	O
using	O
a	O
twist	O
in	O
the	O
C	O
-	O
terminal	O
region	O
;	O
it	O
has	O
a	O
higher	O
chain	O
RMSD	O
of	O
5	O
.	O
14	O
A	O
,	O
and	O
its	O
optimal	O
RMSD	O
is	O
3	O
.	O
48	O
A	O
.	O

For	O
more	O
information	O
regarding	O
the	O
chain	O
and	O
optimal	O
RMSDs	O
refer	O
[	O
5	O
]	O
.	O

The	O
flexible	O
_	O
FATCAT	O
method	O
uses	O
the	O
twist	O
to	O
align	O
a	O
helix	O
in	O
the	O
C	O
-	O
terminal	O
region	O
,	O
which	O
is	O
positioned	O
incorrectly	O
with	O
a	O
beta	O
-	O
sheet	O
core	O
(	O
see	O
Table	O
4	O
)	O
.	O

Figure	O
7	O
(	O
a	O
)	O
shows	O
the	O
superposition	O
of	O
d2trxa	O
_	O
(	O
gray	O
)	O
and	O
d1kte	O
_	O
_	O
(	O
orange	O
)	O
domains	O
from	O
the	O
flexible	O
_	O
FATCAT	O
method	O
,	O
where	O
the	O
blue	O
color	O
indicates	O
the	O
d1kte	O
_	O
_	O
protein	O
domain	O
from	O
the	O
flexible	O
_	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
.	O

The	O
incorrect	O
alignment	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
alpha	O
helix	O
of	O
the	O
d1kte	O
_	O
_	O
domain	O
(	O
orange	O
)	O
is	O
visible	O
in	O
the	O
core	O
of	O
the	O
beta	O
-	O
sheet	O
region	O
.	O

Figure	O
7	O
(	O
b	O
)	O
and	O
7	O
(	O
c	O
)	O
shows	O
the	O
AFPs	O
from	O
the	O
flexible	O
_	O
FATCAT	O
and	O
flexible	O
_	O
TOPS	O
+	O
+	O
FATCAT	O
methods	O
,	O
respectively	O
.	O

The	O
hinge	O
region	O
provides	O
a	O
twist	O
in	O
the	O
flexible	O
_	O
FATCAT	O
method	O
indicated	O
by	O
an	O
arrow	O
and	O
the	O
AFPs	O
represented	O
by	O
a	O
different	O
color	O
(	O
see	O
Figure	O
7	O
(	O
b	O
)	O
)	O
.	O

In	O
this	O
case	O
,	O
the	O
alignment	O
constraints	O
from	O
the	O
TOPS	O
+	O
strings	O
alignment	O
allow	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
to	O
avoid	O
a	O
spurious	O
alignment	O
.	O

The	O
Erythrocruorin	O
protein	O
domain	O
d1eca	O
_	O
_	O
(	O
136	O
aa	O
)	O
from	O
Chironomus	B-Species
thummi	E-Species
and	O
the	O
Phycocyanin	O
alpha	O
subunit	O
protein	O
domain	O
d1cpca	O
_	O
(	O
162	O
aa	O
)	O
from	O
Fremyella	B-Species
diplosiphon	E-Species
(	O
Cyanobacterium	O
)	O
belong	O
to	O
the	O
Globin	O
-	O
like	O
superfamily	O
.	O

For	O
these	O
protein	O
domain	O
pairs	O
,	O
the	O
FATCAT	O
method	O
provides	O
a	O
better	O
alignment	O
with	O
120	O
and	O
118	O
aligned	O
positions	O
with	O
the	O
chain	O
RMSD	O
of	O
4	O
.	O
02	O
A	O
based	O
on	O
the	O
flexible	O
and	O
rigid	O
options	O
,	O
respectively	O
.	O

The	O
flexible	O
_	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
gives	O
an	O
alignment	O
of	O
63	O
aligned	O
positions	O
with	O
the	O
3	O
.	O
23	O
A	O
optimal	O
RMSD	O
and	O
the	O
6	O
.	O
28	O
A	O
chain	O
RMSD	O
.	O

In	O
this	O
case	O
,	O
the	O
flexible	O
_	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
misses	O
the	O
N	O
-	O
terminal	O
region	O
helix	O
and	O
misaligns	O
some	O
helices	O
.	O

For	O
example	O
,	O
Figure	O
8	O
(	O
a	O
)	O
shows	O
the	O
superposition	O
of	O
d1eca	O
_	O
_	O
(	O
gray	O
)	O
and	O
d1cpca	O
_	O
(	O
orange	O
)	O
domains	O
from	O
the	O
flexible	O
_	O
FATCAT	O
method	O
,	O
while	O
d1cpca	O
_	O
(	O
blue	O
)	O
domain	O
is	O
from	O
the	O
flexible	O
_	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
.	O

The	O
AFP	O
chaining	O
alignment	O
and	O
the	O
actual	O
alignment	O
from	O
FATCAT	O
are	O
shown	O
in	O
Figure	O
8	O
(	O
b	O
)	O
and	O
8	O
(	O
e	O
)	O
,	O
respectively	O
.	O

Figure	O
8	O
(	O
c	O
)	O
shows	O
the	O
AFP	O
alignment	O
from	O
TOPS	O
+	O
+	O
FATCAT	O
,	O
in	O
which	O
this	O
method	O
misses	O
the	O
N	O
-	O
terminal	O
region	O
and	O
incorrectly	O
aligns	O
some	O
of	O
the	O
C	O
-	O
terminal	O
regions	O
(	O
see	O
Figure	O
8	O
(	O
d	O
)	O
)	O
.	O

However	O
,	O
the	O
rigid	O
_	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
produces	O
an	O
alignment	O
of	O
108	O
aligned	O
positions	O
with	O
optimal	O
and	O
chain	O
RMSDs	O
of	O
3	O
.	O
22	O
A	O
and	O
6	O
.	O
28	O
A	O
respectively	O
.	O

In	O
general	O
,	O
TOPS	O
comparison	O
does	O
not	O
work	O
well	O
for	O
alpha	O
-	O
rich	O
proteins	O
due	O
to	O
the	O
lack	O
of	O
hydrogen	O
bonds	O
between	O
SSEs	O
[	O
26	O
]	O
.	O

The	O
same	O
is	O
true	O
for	O
TOPS	O
+	O
strings	O
comparison	O
to	O
some	O
extent	O
;	O
however	O
,	O
this	O
method	O
takes	O
advantage	O
of	O
ligand	O
-	O
interaction	O
information	O
to	O
compare	O
protein	O
domains	O
more	O
efficiently	O
;	O
for	O
example	O
the	O
DNA	O
binding	O
motifs	O
such	O
as	O
helix	O
-	O
turn	O
-	O
helix	O
and	O
helix	O
-	O
loop	O
-	O
helix	O
can	O
be	O
easily	O
recognized	O
[	O
28	O
]	O
.	O

However	O
,	O
we	O
have	O
not	O
explored	O
that	O
ligand	O
pattern	O
discovery	O
option	O
within	O
the	O
TOPS	O
+	O
strings	O
comparison	O
in	O
this	O
paper	O
.	O

In	O
addition	O
,	O
the	O
TOPS	O
+	O
strings	O
alignment	O
provides	O
only	O
a	O
basic	O
alignment	O
;	O
the	O
scoring	O
function	O
to	O
find	O
the	O
best	O
alignment	O
has	O
not	O
been	O
optimized	O
.	O

These	O
problems	O
can	O
be	O
addressed	O
in	O
future	O
development	O
by	O
considering	O
the	O
advanced	O
TOPS	O
+	O
and	O
TOPS	O
+	O
strings	O
models	O
based	O
on	O
helix	O
-	O
helix	O
packing	O
relationships	O
and	O
SSE	O
-	O
ligand	O
interaction	O
properties	O
together	O
with	O
the	O
right	O
and	O
left	O
chiralities	O
.	O

Furthermore	O
,	O
the	O
TOPS	O
+	O
strings	O
comparison	O
can	O
be	O
optimized	O
in	O
both	O
the	O
comparison	O
process	O
as	O
well	O
as	O
in	O
the	O
alignment	O
process	O
in	O
order	O
to	O
take	O
into	O
account	O
indels	O
(	O
insertion	O
/	O
deletion	O
)	O
of	O
SSEs	O
which	O
exist	O
in	O
nature	O
across	O
the	O
different	O
members	O
of	O
the	O
protein	O
superfamilies	O
[	O
31	O
]	O
.	O

Discussion	O
and	O
conclusion	O

The	O
overall	O
results	O
for	O
all	O
protein	O
classes	O
show	O
that	O
TOPS	O
+	O
+	O
FATCAT	O
performance	O
is	O
only	O
slightly	O
lower	O
(	O
3	O
%	O
-	O
7	O
%	O
AUC	O
value	O
difference	O
)	O
as	O
compared	O
to	O
FATCAT	O
while	O
providing	O
a	O
significant	O
,	O
more	O
than	O
10	O
-	O
fold	O
speedup	O
.	O

The	O
main	O
reason	O
for	O
the	O
discrepancies	O
is	O
that	O
TOPS	O
+	O
strings	O
alignments	O
occasionally	O
misalign	O
the	O
secondary	O
structure	O
elements	O
and	O
subsequent	O
FATCAT	O
alignment	O
,	O
constrained	O
by	O
the	O
TOPS	O
+	O
strings	O
alignment	O
,	O
cannot	O
overcome	O
the	O
earlier	O
errors	O
.	O

There	O
is	O
a	O
clear	O
trade	O
-	O
off	O
between	O
the	O
runtime	O
and	O
the	O
accuracy	O
;	O
limiting	O
the	O
pool	O
of	O
fragments	O
being	O
compared	O
speeds	O
up	O
the	O
algorithm	O
but	O
results	O
in	O
(	O
slightly	O
)	O
lower	O
accuracy	O
.	O

At	O
the	O
same	O
time	O
,	O
these	O
results	O
offer	O
clear	O
suggestions	O
for	O
future	O
development	O
.	O

Using	O
a	O
more	O
advanced	O
version	O
of	O
the	O
TOPS	O
+	O
strings	O
comparison	O
method	O
would	O
remove	O
some	O
of	O
the	O
false	O
positives	O
might	O
be	O
at	O
a	O
cost	O
of	O
significantly	O
slowing	O
the	O
total	O
performance	O
of	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
method	O
.	O

Authors	O
'	O
contributions	O

MV	O
developed	O
the	O
TOPS	O
+	O
+	O
FATCAT	O
algorithm	O
,	O
performed	O
the	O
calculations	O
and	O
prepared	O
the	O
figures	O
,	O
YY	O
provided	O
advice	O
and	O
oversight	O
in	O
the	O
project	O
,	O
verified	O
the	O
code	O
and	O
provided	O
FATCAT	O
results	O
for	O
comparison	O
,	O
AG	O
contributed	O
to	O
the	O
original	O
idea	O
and	O
to	O
writing	O
of	O
the	O
manuscript	O
.	O

Are	O
there	O
sensitive	O
subgroups	O
for	O
the	O
effects	O
of	O
airborne	O
particles	O
?	O

Abstract	O

Recent	O
studies	O
have	O
shown	O
that	O
particulate	O
air	O
pollution	O
is	O
a	O
risk	O
factor	O
for	O
hospitalization	O
for	O
heart	O
and	O
lung	O
disease	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
what	O
subpopulations	O
are	O
most	O
sensitive	O
to	O
this	O
pollutant	O
.	O

We	O
analyzed	O
Medicare	O
hospital	O
admissions	O
for	O
heart	O
disease	O
,	O
chronic	O
obstructive	O
pulmonary	O
disorders	O
(	O
COPD	O
)	O
and	O
pneumonia	O
in	O
Chicago	O
,	O
Cook	O
County	O
,	O
Illinois	O
,	O
between	O
1985	O
and	O
1994	O
.	O

We	O
examined	O
whether	O
previous	O
admissions	O
or	O
secondary	O
diagnoses	O
for	O
selected	O
conditions	O
predisposed	O
persons	S-Species
to	O
having	O
a	O
greater	O
risk	O
from	O
air	O
pollution	O
.	O

We	O
also	O
considered	O
effect	O
modification	O
by	O
age	O
,	O
sex	O
,	O
and	O
race	O
.	O

We	O
found	O
that	O
the	O
air	O
-	O
pollution	O
-	O
associated	O
increase	O
in	O
hospital	O
admissions	O
for	O
cardiovascular	O
diseases	O
was	O
almost	O
doubled	O
in	O
subjects	O
with	O
concurrent	O
respiratory	O
infections	O
.	O

The	O
risk	O
was	O
also	O
increased	O
by	O
a	O
previous	O
admission	O
for	O
conduction	O
disorders	O
.	O

For	O
COPD	O
and	O
pneumonia	O
admissions	O
,	O
diagnosis	O
of	O
conduction	O
disorders	O
or	O
dysrhythmias	O
increased	O
the	O
risk	O
of	O
particulate	O
matter	O
<	O
10	O
microm	O
in	O
aerodynamic	O
diameter	O
(	O
PM	O
(	O
10	O
)	O
)	O
-	O
associated	O
admissions	O
.	O

Persons	S-Species
with	O
asthma	O
had	O
twice	O
the	O
risk	O
of	O
a	O
PM	O
(	O
10	O
)	O
-	O
associated	O
pneumonia	O
admission	O
and	O
persons	S-Species
with	O
heart	O
failure	O
had	O
twice	O
the	O
risk	O
of	O
PM	O
(	O
10	O
)	O
-	O
induced	O
COPD	O
admissions	O
.	O

The	O
PM	O
(	O
10	O
)	O
effect	O
did	O
not	O
vary	O
by	O
sex	O
,	O
age	O
,	O
and	O
race	O
.	O

These	O
results	O
suggest	O
that	O
patients	S-Species
with	O
acute	O
respiratory	O
infections	O
or	O
defects	O
in	O
the	O
electrical	O
control	O
of	O
the	O
heart	O
are	O
a	O
risk	O
group	O
for	O
particulate	O
matter	O
effects	O
.	O

Articles	O

Are	O
There	O
Sensitive	O
Subgroups	O
for	O
the	O
Effects	O
of	O
Airborne	O
Particles	O
?	O

Antonella	O
Zanobetti	O
,	O
1	O
Joel	O
Schwartz	O
,	O
1	O
,	O
2	O
and	O
Diane	O
Gold1	O
,	O
2	O
1Environmental	O

Epidemiology	O
Program	O
,	O
Department	O
of	O
Environmental	O
Health	O
,	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
Boston	O
,	O
Massachusetts	O
,	O
USA	O
;	O
2Channing	O
Laboratory	O
,	O
Department	O
of	O
Medicine	O
,	O
Harvard	O
Medical	O
School	O
and	O
Brigham	O
and	O
Women	S-Species
'	O
s	O
Hospital	O
,	O
Boston	O
,	O
Massachusetts	O
,	O
USA	O

Recent	O
studies	O
have	O
shown	O
that	O
particulate	O
air	O
pollution	O
is	O
a	O
risk	O
factor	O
for	O
hospitalization	O
for	O
heart	O
and	O
lung	O
disease	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
what	O
subpopulations	O
are	O
most	O
sensitive	O
to	O
this	O
pollutant	O
.	O

We	O
analyzed	O
Medicare	O
hospital	O
admissions	O
for	O
heart	O
disease	O
,	O
chronic	O
obstructive	O
pulmonary	O
disorders	O
(	O
COPD	O
)	O
and	O
pneumonia	O
in	O
Chicago	O
,	O
Cook	O
County	O
,	O
Illinois	O
,	O
between	O
1985	O
and	O
1994	O
.	O

We	O
examined	O
whether	O
previous	O
admissions	O
or	O
secondary	O
diagnoses	O
for	O
selected	O
conditions	O
predisposed	O
persons	S-Species
to	O
having	O
a	O
greater	O
risk	O
from	O
air	O
pollution	O
.	O

We	O
also	O
considered	O
effect	O
modification	O
by	O
age	O
,	O
sex	O
,	O
and	O
race	O
.	O

We	O
found	O
that	O
the	O
air	O
-	O
pollution	O
-	O
associated	O
increase	O
in	O
hospital	O
admissions	O
for	O
cardiovascular	O
diseases	O
was	O
almost	O
doubled	O
in	O
subjects	O
with	O
concurrent	O
respiratory	O
infections	O
.	O

The	O
risk	O
was	O
also	O
increased	O
by	O
a	O
previous	O
admission	O
for	O
conduction	O
disorders	O
.	O

For	O
COPD	O
and	O
pneumonia	O
admissions	O
,	O
diagnosis	O
of	O
conduction	O
disorders	O
or	O
dysrhythmias	O
increased	O
the	O
risk	O
of	O
particulate	O
matter	O
<	O
10	O
<FFFD>	O
m	O
in	O
aerodynamic	O
diameter	O
(	O
PM10	O
)	O
-	O
associated	O
admissions	O
.	O

Persons	S-Species
with	O
asthma	O
had	O
twice	O
the	O
risk	O
of	O
a	O
PM10	O
-	O
associated	O
pneumonia	O
admission	O
and	O
persons	S-Species
with	O
heart	O
failure	O
had	O
twice	O
the	O
risk	O
of	O
PM10	O
-	O
induced	O
COPD	O
admissions	O
.	O

The	O
PM10	O
effect	O
did	O
not	O
vary	O
by	O
sex	O
,	O
age	O
,	O
and	O
race	O
.	O

These	O
results	O
suggest	O
that	O
patients	S-Species
with	O
acute	O
respiratory	O
infections	O
or	O
defects	O
in	O
the	O
electrical	O
control	O
of	O
the	O
heart	O
are	O
a	O
risk	O
group	O
for	O
particulate	O
matter	O
effects	O
.	O

Key	O
words	O
:	O
effect	O
modification	O
,	O
hospital	O
admissions	O
,	O
particulate	O
air	O
pollution	O
.	O

Environ	O
Health	O
Perspect	O
108	O
:	O
841	O
<FFFD>	O
845	O
(	O
2000	O
)	O
.	O

[	O
Online	O
28	O
July	O
2000	O
]	O
http	O
:	O
/	O
/	O
ehpnet1	O
.	O
niehs	O
.	O
nih	O
.	O
gov	O
/	O
docs	O
/	O
2000	O
/	O
108p841	O
-	O
845zanobetti	O
/	O
abstract	O
.	O
html	O

Particulate	O
air	O
pollution	O
has	O
been	O
associated	O
with	O
increases	O
in	O
daily	O
deaths	O
and	O
hospital	O
admissions	O
in	O
studies	O
all	O
over	O
the	O
world	O
(	O
1	O
<FFFD>	O
15	O
)	O
.	O

These	O
associations	O
are	O
now	O
well	O
documented	O
but	O
little	O
is	O
known	O
,	O
as	O
yet	O
,	O
of	O
the	O
characteristics	O
of	O
persons	S-Species
that	O
put	O
them	O
at	O
increased	O
risk	O
of	O
adverse	O
events	O
related	O
to	O
particulate	O
air	O
pollution	O
.	O

This	O
has	O
been	O
identified	O
as	O
a	O
key	O
data	O
gap	O
(	O
16	O
)	O
.	O

Schwartz	O
and	O
Dockery	O
(	O
17	O
)	O
reported	O
that	O
persons	S-Species
older	O
than	O
65	O
years	O
of	O
age	O
had	O
a	O
somewhat	O
increased	O
risk	O
of	O
death	O
,	O
and	O
this	O
has	O
been	O
confirmed	O
in	O
other	O
studies	O
(	O
18	O
)	O
.	O

A	O
more	O
detailed	O
examination	O
of	O
particulate	O
matter	O
-	O
related	O
risk	O
by	O
deciles	O
of	O
age	O
(	O
19	O
)	O
showed	O
the	O
risk	O
beginning	O
to	O
increase	O
at	O
approximately	O
40	O
years	O
of	O
age	O
and	O
reaching	O
its	O
maximum	O
for	O
those	O
75	O
years	O
of	O
age	O
and	O
older	O
.	O

In	O
addition	O
to	O
age	O
,	O
several	O
studies	O
suggest	O
that	O
persons	S-Species
with	O
respiratory	O
illness	O
are	O
at	O
increased	O
risk	O
for	O
cardiovascular	O
effects	O
associated	O
with	O
air	O
pollution	O
.	O

An	O
examination	O
of	O
death	O
certificates	O
on	O
high	O
-	O
and	O
low	O
-	O
air	O
pollution	O
days	O
reported	O
a	O
substantial	O
difference	O
in	O
the	O
proportion	O
of	O
deaths	O
from	O
cardiovascular	O
causes	O
that	O
had	O
respiratory	O
disease	O
as	O
a	O
contributing	O
cause	O
of	O
death	O
(	O
19	O
)	O
.	O

A	O
recent	O
follow	O
-	O
up	O
study	O
of	O
a	O
cohort	O
of	O
persons	S-Species
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
in	O
Barcelona	O
,	O
Spain	O
,	O
found	O
an	O
association	O
between	O
particulate	O
air	O
pollution	O
and	O
all	O
-	O
cause	O
mortality	O
in	O
the	O
cohort	O
(	O
20	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
risk	O
per	O
microgram	O
per	O
cubic	O
meter	O
of	O
exposure	O
was	O
substantially	O
greater	O
than	O
that	O
for	O
the	O
general	O
population	O
.	O

Environmental	O
Health	O
Perspectives	O

Controlled	O
exposure	O
of	O
animals	O
with	O
chronic	O
bronchitis	O
and	O
control	O
animals	O
to	O
concentrated	O
air	O
particles	O
also	O
demonstrated	O
a	O
potentiating	O
effect	O
of	O
chronic	O
lung	O
disease	O
in	O
the	O
response	O
to	O
airborne	O
particles	O
(	O
21	O
)	O
.	O

This	O
has	O
led	O
to	O
the	O
hypothesis	O
that	O
the	O
cardiovascular	O
effects	O
of	O
air	O
pollution	O
are	O
predominantly	O
in	O
persons	S-Species
with	O
chronic	O
lung	O
disease	O
.	O

There	O
has	O
been	O
even	O
less	O
done	O
to	O
examine	O
potential	O
modifiers	O
of	O
the	O
effects	O
of	O
airborne	O
particles	O
on	O
hospital	O
admissions	O
.	O

The	O
existing	O
literature	O
on	O
comorbidity	O
shows	O
that	O
comorbidity	O
per	O
se	O
seems	O
to	O
increase	O
the	O
risk	O
of	O
adverse	O
outcomes	O
(	O
22	O
<FFFD>	O
30	O
)	O
.	O

Little	O
is	O
known	O
about	O
the	O
role	O
of	O
these	O
comorbidities	O
as	O
effect	O
modifiers	O
for	O
the	O
effects	O
of	O
air	O
pollution	O
.	O

This	O
study	O
uses	O
data	O
from	O
the	O
Medicare	O
system	O
to	O
examine	O
potential	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
medical	O
conditions	O
that	O
may	O
increase	O
a	O
person	S-Species
'	O
s	O
risk	O
of	O
hospital	O
admissions	O
associated	O
with	O
particulate	O
air	O
pollution	O
.	O

In	O
addition	O
,	O
we	O
examine	O
potential	O
effect	O
modification	O
by	O
age	O
,	O
race	O
,	O
and	O
sex	O
.	O

Materials	O
and	O
Methods	O
Health	O
data	O
.	O

The	O
Health	O
Care	O
Financing	O
Administration	O
(	O
Baltimore	O
,	O
MD	O
)	O
maintains	O
records	O
of	O
every	O
hospital	O
admission	O
for	O
Medicare	O
participants	S-Species
in	O
the	O
United	O
States	O
.	O

Persons	S-Species
in	O
this	O
database	O
have	O
a	O
unique	O
identifier	O
.	O

Using	O
this	O
identifier	O
,	O
we	O
traced	O
every	O
hospital	O
admission	O
for	O
heart	O
and	O
lung	O
disease	O
for	O
each	O
person	S-Species
in	O
Cook	O
County	O
,	O
Illinois	O
,	O
between	O
1985	O
and	O
1994	O
.	O

We	O
chose	O
Cook	O
County	O
because	O
it	O
is	O
the	O
most	O
populous	O

county	O
in	O
the	O
United	O
States	O
with	O
daily	O
monitoring	O
for	O
particulate	O
matter	O
with	O
aerodynamic	O
diameter	O
<	O
10	O
<FFFD>	O
m	O
(	O
PM10	O
)	O
.	O

The	O
data	O
were	O
then	O
analyzed	O
to	O
look	O
at	O
effect	O
modification	O
by	O
concurrent	O
and	O
preexisting	O
conditions	O
as	O
well	O
as	O
by	O
age	O
,	O
race	O
,	O
and	O
sex	O
.	O

To	O
establish	O
a	O
baseline	O
risk	O
,	O
we	O
computed	O
daily	O
counts	O
of	O
hospital	O
admissions	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
[	O
International	O
Classification	O
of	O
Disease	O
,	O
9th	O
edition	O
,	O
World	O
Health	O
Organization	O
,	O
Geneva	O
(	O
ICD	O
-	O
9	O
)	O
code	O
390	O
<FFFD>	O
429	O
]	O
,	O
pneumonia	O
(	O
ICD	O
-	O
9	O
code	O
480	O
<FFFD>	O
487	O
)	O
,	O
and	O
COPD	O
(	O
ICD	O
-	O
9	O
code	O
490	O
<FFFD>	O
496	O
,	O
excluding	O
493	O
)	O
.	O

The	O
association	O
between	O
these	O
daily	O
counts	O
and	O
PM10	O
was	O
examined	O
for	O
the	O
years	O
1988	O
<FFFD>	O
1994	O
,	O
when	O
daily	O
PM10	O
monitoring	O
data	O
were	O
available	O
in	O
Chicago	O
.	O

Once	O
our	O
baseline	O
risks	O
were	O
established	O
,	O
we	O
examined	O
three	O
classes	O
of	O
potential	O
effect	O
modifiers	O
.	O

First	O
,	O
we	O
looked	O
at	O
whether	O
previous	O
admissions	O
for	O
selected	O
conditions	O
predisposed	O
persons	S-Species
to	O
having	O
a	O
greater	O
risk	O
from	O
air	O
pollution	O
.	O

For	O
each	O
of	O
the	O
three	O
admission	O
categories	O
(	O
CVD	O
,	O
pneumonia	O
,	O
and	O
COPD	O
)	O
,	O
we	O
considered	O
10	O
causes	O
(	O
defined	O
by	O
a	O
previous	O
admission	O
)	O
as	O
effect	O
modifiers	O
:	O
COPD	O
(	O
ICD	O
-	O
9	O
code	O
490	O
<FFFD>	O
496	O
except	O
493	O
)	O
,	O
asthma	O
(	O
ICD	O
-	O
9	O
code	O
493	O
)	O
,	O
acute	O
bronchitis	O
(	O
ICD	O
-	O
9	O
code	O
466	O
)	O
,	O
acute	O
respiratory	O
illness	O
(	O
ICD	O
-	O
9	O
code	O
460	O
<FFFD>	O
466	O
)	O
,	O
pneumonia	O
(	O
ICD	O
-	O
9	O
code	O
480	O
<FFFD>	O
487	O
)	O
,	O
CVD	O
(	O
ICD	O
-	O
9	O
code	O
390	O
<FFFD>	O
429	O
)	O
,	O
myocardial	O
infarction	O
(	O
ICD	O
-	O
9	O
code	O
410	O
)	O
,	O
congestive	O
heart	O
failure	O
(	O
ICD	O
-	O
9	O
code	O
428	O
)	O
,	O
conduction	O
disorders	O
(	O
ICD	O
-	O
9	O
code	O
426	O
)	O
,	O
and	O
dysrhythmias	O
(	O
ICD9	O
code	O
427	O
)	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
persons	S-Species
with	O
these	O
conditions	O
had	O
higher	O
risks	O
of	O
subsequent	O
PM10	O
-	O
related	O
admissions	O
,	O
we	O
computed	O
separate	O
daily	O
counts	O
of	O
admissions	O
for	O
our	O
three	O
target	O
causes	O
,	O
stratified	O
by	O
whether	O
or	O
not	O
the	O
person	S-Species
admitted	O
had	O
been	O
previously	O
admitted	O
for	O
the	O
hypothesized	O
predisposing	O
condition	O
.	O

Separate	O
analyses	O
were	O
then	O
performed	O
within	O
each	O
strata	O
to	O
see	O
if	O
the	O
effects	O
of	O
PM10	O
differed	O
by	O
strata	O
.	O

Address	O
correspondence	O
to	O
A	O
.	O

Zanobetti	O
,	O
Department	O
of	O
Environmental	O
Health	O
,	O
Environmental	O
Epidemiology	O
Program	O
,	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
665	O
Huntington	O
Avenue	O
,	O
Boston	O
,	O
MA	O
02115	O
USA	O
.	O

Telephone	O
:	O
(	O
617	O
)	O
4324642	O
.	O

Fax	O
:	O
(	O
617	O
)	O
277	O
-	O
2382	O
.	O

E	O
-	O
mail	O
:	O
azanob	O
@	O
sparc6a	O
.	O
harvard	O
.	O
edu	O
Supported	O
by	O
NIEHS	O
grant	O
ES07937	O
.	O

Received	O
18	O
January	O
2000	O
;	O
accepted	O
18	O
April	O
2000	O
.	O

<FFFD>	O
VOLUME	O
108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O

841	O

Articles	O

<FFFD>	O

Zanobetti	O
et	O
al	O
.	O

The	O
second	O
set	O
of	O
potential	O
predisposing	O
conditions	O
included	O
secondary	O
diagnoses	O
associated	O
with	O
the	O
index	O
admission	O
.	O

These	O
could	O
represent	O
the	O
presence	O
of	O
a	O
chronic	O
condition	O
(	O
e	O
.	O
g	O
.	O
,	O
COPD	O
)	O
that	O
has	O
not	O
resulted	O
in	O
a	O
previous	O
hospital	O
admission	O
.	O

They	O
could	O
also	O
represent	O
acute	O
conditions	O
that	O
may	O
have	O
increased	O
the	O
subjects	O
'	O
sensitivity	O
to	O
air	O
pollution	O
.	O

For	O
example	O
,	O
if	O
respiratory	O
infections	O
modified	O
the	O
effect	O
of	O
particulate	O
matter	O
on	O
the	O
cardiovascular	O
health	O
of	O
persons	S-Species
with	O
underlying	O
heart	O
disease	O
,	O
then	O
the	O
risk	O
of	O
a	O
hospital	O
admission	O
for	O
heart	O
disease	O
might	O
be	O
different	O
in	O
persons	S-Species
with	O
infections	O
.	O

If	O
this	O
were	O
true	O
,	O
then	O
the	O
risk	O
ratio	O
of	O
a	O
10	O
-	O
<FFFD>	O
g	O
/	O
m3	O
increase	O
of	O
PM10	O
on	O
cardiovascular	O
admissions	O
of	O
persons	S-Species
with	O
a	O
concurrent	O
respiratory	O
infection	O
would	O
be	O
different	O
from	O
the	O
ratio	O
in	O
persons	S-Species
without	O
respiratory	O
infection	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
computed	O
separate	O
daily	O
counts	O
of	O
admissions	O
for	O
events	O
with	O
and	O
without	O
the	O
concurrent	O
conditions	O
hypothesized	O
to	O
increase	O
sensitivity	O
to	O
air	O
pollution	O
.	O

These	O
were	O
taken	O
as	O
the	O
same	O
10	O
conditions	O
in	O
the	O
first	O
analysis	O
with	O
certain	O
exclusions	O
for	O
pairing	O
that	O
would	O
be	O
illogical	O
.	O

That	O
is	O
,	O
the	O
concurrent	O
diagnosis	O
of	O
a	O
specific	O
cardiac	O
condition	O
was	O
not	O
treated	O
as	O
an	O
effect	O
modifier	O
for	O
admissions	O
for	O
any	O
cardiovascular	O
condition	O
.	O

Likewise	O
,	O
pneumonia	O
and	O
COPD	O
were	O
not	O
possible	O
concurrent	O
conditions	O
for	O
each	O
other	O
.	O

The	O
third	O
set	O
of	O
predisposing	O
conditions	O
considered	O
was	O
being	O
older	O
than	O
75	O
years	O
of	O
age	O
,	O
nonwhite	O
,	O
and	O
female	O
.	O

These	O
were	O
examined	O
for	O
all	O
three	O
outcomes	O
.	O

We	O
obtained	O
weather	O
data	O
for	O
O	O
'	O
Hare	O
Airport	O
from	O
the	O
EarthInfo	O
CD	O
-	O
ROM	O
(	O
EarthInfo	O
CD	O
NCDC	O
Surface	O
Airways	O
,	O
EarthInfo	O
Inc	O
.	O
,	O
Boulder	O
,	O
CO	O
)	O
,	O
and	O
we	O
obtained	O
air	O
pollution	O
data	O
from	O
the	O
U	O
.	O
S	O
.	O

Environmental	O
Protection	O
Agency	O
Aerometric	O
Information	O
Retrieval	O
System	O
network	O
(	O
31	O
)	O
.	O

running	O
-	O
line	O
smoother	O
,	O
loess	O
(	O
35	O
)	O
,	O
was	O
chosen	O
to	O
estimate	O
the	O
smooth	O
function	O
.	O

To	O
control	O
for	O
weather	O
variables	O
and	O
day	O
of	O
the	O
week	O
,	O
we	O
chose	O
the	O
smoothing	O
parameter	O
that	O
minimized	O
the	O
Akaike	O
'	O
s	O
information	O
criterion	O
(	O
36	O
)	O
.	O

To	O
model	O
seasonality	O
we	O
chose	O
the	O
smoothing	O
parameter	O
that	O
minimized	O
the	O
sum	O
of	O
the	O
autocorrelation	O
of	O
the	O
residuals	O
while	O
removing	O
seasonal	O
patterns	O
.	O

Two	O
autoregressive	O
terms	O
(	O
37	O
)	O
were	O
added	O
in	O
the	O
model	O
to	O
eliminate	O
the	O
remaining	O
serial	O
correlation	O
from	O
the	O
residuals	O
.	O

We	O
used	O
the	O
mean	O
of	O
PM10	O
on	O
the	O
day	O
of	O
the	O
admission	O
and	O
the	O
day	O
before	O
the	O
admission	O
as	O
our	O
exposure	O
variable	O
.	O

This	O
gives	O
results	O
that	O
are	O
similar	O
to	O
those	O
obtained	O
fitting	O
a	O
full	O
distributed	O
lag	O
model	O
(	O
38	O
)	O
.	O

PM10	O
was	O
treated	O
linearly	O
.	O

Our	O
baseline	O
models	O
used	O
the	O
daily	O
counts	O
of	O
CVD	O
,	O
pneumonia	O
,	O
and	O
COPD	O
admissions	O
as	O
outcomes	O
.	O

We	O
then	O
subdivided	O
those	O
counts	O
by	O
the	O
presence	O
or	O
absence	O
of	O
the	O
potential	O
effect	O
modifier	O
and	O
reestimated	O
our	O
regressions	O
on	O
those	O
subgroups	O
.	O

We	O
considered	O
effect	O
modification	O
to	O
be	O
indicated	O
when	O
the	O
estimates	O
of	O
PM10	O
in	O
the	O
group	O
with	O
the	O
condition	O
was	O
outside	O
of	O
the	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
the	O
effect	O
estimate	O
in	O
persons	S-Species
without	O
the	O
condition	O
.	O

Results	O
Table	O
1	O
shows	O
the	O
mean	O
daily	O
admissions	O
for	O
COPD	O
,	O
cardiovascular	O
,	O
and	O
pneumonia	O
both	O
overall	O
and	O
in	O
the	O
presence	O
of	O
the	O
potential	O
effect	O
modifiers	O
.	O

For	O
some	O
effect	O
modifiers	O
such	O
as	O
conduction	O
disorders	O
or	O
myocardial	O
infarctions	O
,	O
the	O
counts	O
in	O
conjunction	O
with	O
our	O
respiratory	O
outcomes	O
are	O

low	O
,	O
which	O
limits	O
power	O
.	O

In	O
general	O
,	O
the	O
numbers	O
are	O
lower	O
for	O
examining	O
effect	O
modification	O
by	O
previous	O
admissions	O
than	O
for	O
effect	O
modification	O
by	O
concurrent	O
diagnosis	O
.	O

This	O
is	O
as	O
expected	O
because	O
many	O
clinically	O
relevant	O
comorbidities	O
may	O
never	O
have	O
resulted	O
in	O
a	O
hospital	O
admission	O
.	O

Table	O
2	O
shows	O
the	O
25th	O
,	O
50th	O
,	O
and	O
75th	O
percentile	O
values	O
for	O
the	O
environmental	O
variables	O
.	O

The	O
mean	O
value	O
for	O
PM10	O
is	O
33	O
<FFFD>	O
g	O
/	O
m3	O
.	O

The	O
daily	O
values	O
for	O
PM10	O
were	O
computed	O
as	O
the	O
average	O
of	O
10	O
monitors	O
,	O
two	O
of	O
which	O
measured	O
PM10	O
almost	O
every	O
day	O
and	O
the	O
others	O
less	O
frequently	O
(	O
38	O
)	O
.	O

Table	O
3	O
shows	O
the	O
mean	O
daily	O
counts	O
of	O
CVD	O
,	O
COPD	O
,	O
and	O
pneumonia	O
by	O
sex	O
,	O
age	O
groups	O
,	O
and	O
race	O
.	O

The	O
distribution	O
by	O
sex	O
is	O
almost	O
even	O
,	O
although	O
the	O
counts	O
of	O
admissions	O
for	O
males	O
are	O
generally	O
lower	O
(	O
approximately	O
10	O
%	O
)	O
than	O
for	O
females	O
,	O
particularly	O
for	O
cardiovascular	O
diseases	O
.	O

The	O
counts	O
of	O
CVD	O
,	O
COPD	O
,	O
and	O
pneumonia	O
admissions	O
were	O
similar	O
for	O
people	S-Species
65	O
<FFFD>	O
75	O
or	O
75	O
years	O
of	O
age	O
and	O
older	O
.	O

Tables	O
4	O
<FFFD>	O
6	O
show	O
the	O
results	O
for	O
the	O
effect	O
PM10	O
overall	O
and	O
stratifying	O
by	O
concurrent	O
diagnosis	O
and	O
previous	O
admissions	O
.	O

These	O
are	O
expressed	O
as	O
the	O
percentage	O
increase	O
for	O
10	O
<FFFD>	O
g	O
/	O
m3	O
PM10	O
.	O

Table	O
4	O
shows	O
the	O
results	O
for	O
CVD	O
.	O

A	O
10	O
-	O
<FFFD>	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
was	O
associated	O
with	O
a	O
1	O
.	O
31	O
%	O
(	O
5	O
%	O
CI	O
,	O
0	O
.	O
97	O
%	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
66	O
%	O
)	O
increase	O
in	O
hospital	O
admissions	O
for	O
heart	O
disease	O
in	O
all	O
elderly	O
persons	S-Species
.	O

A	O
concurrent	O
(	O
not	O
previous	O
)	O
diagnosis	O
of	O
COPD	O
modified	O
the	O
risk	O
of	O
PM10	O
-	O
associated	O
admissions	O
for	O
heart	O
disease	O
.	O

However	O
,	O
significant	O
associations	O
were	O
still	O
seen	O
between	O
PM10	O

Table	O
1	O
.	O

Mean	O
daily	O
counts	O
of	O
admissions	O
,	O
Chicago	O
1986	O
<FFFD>	O
1994	O
,	O
for	O
COPD	O
,	O
CVD	O
,	O
and	O
pneumonia	O
overall	O
and	O
by	O
concurrent	O
diagnosis	O
and	O
by	O
previous	O
admissions	O
.	O

By	O
concurrent	O
diagnosis	O
COPD	O
CVD	O
Pneumonia	O
Overall	O
Respiratory	O
disease	O
Acute	O
bronchitis	O
Acute	O
respiratory	O
infections	O
Pneumonia	O
Asthma	O
COPD	O
Cardiovascular	O
disease	O
CVD	O
Conduction	O
disorders	O
Cardiac	O
dysrhythmias	O
Congestive	O
heart	O
failure	O
Myocardial	O
infarction	O
NA	O
,	O
not	O
applicable	O
.	O

By	O
previous	O
admissions	O
COPD	O
CVD	O
Pneumonia	O
7	O
.	O
8	O
0	O
.	O
8	O
0	O
.	O
9	O
1	O
.	O
6	O
0	O
.	O
9	O
2	O
.	O
7	O
2	O
.	O
1	O
0	O
.	O
0	O
0	O
.	O
4	O
0	O
.	O
9	O
0	O
.	O
3	O
102	O
.	O
1	O
1	O
.	O
6	O
1	O
.	O
8	O
7	O
.	O
3	O
1	O
.	O
5	O
2	O
.	O
0	O
54	O
.	O
7	O
1	O
.	O
0	O
9	O
.	O
9	O
24	O
.	O
2	O
11	O
.	O
4	O
26	O
.	O
5	O
0	O
.	O
9	O
1	O
.	O
0	O
6	O
.	O
4	O
0	O
.	O
7	O
1	O
.	O
4	O
7	O
.	O
2	O
0	O
.	O
2	O
1	O
.	O
5	O
3	O
.	O
1	O
1	O
.	O
0	O

Methods	O
We	O
analyzed	O
the	O
data	O
with	O
a	O
generalized	O
additive	O
robust	O
Poisson	O
regression	O
model	O
(	O
32	O
)	O
.	O

This	O
approach	O
has	O
become	O
the	O
norm	O
in	O
such	O
studies	O
(	O
14	O
,	O
33	O
,	O
34	O
)	O
.	O

In	O
the	O
generalized	O
additive	O
model	O
the	O
outcome	O
is	O
assumed	O
to	O
depend	O
on	O
a	O
sum	O
of	O
nonparametric	O
smooth	O
functions	O
for	O
each	O
variable	O
that	O
models	O
the	O
potential	O
nonlinear	O
dependence	O
of	O
daily	O
admission	O
on	O
weather	O
and	O
season	O
.	O

The	O
model	O
is	O
of	O
the	O
form	O
:	O
log	O
[	O
E	O
(	O
Yt	O
)	O
]	O
=	O
0	O
+	O
S1	O
(	O
X1	O
)	O
+	O
.	O
.	O
.	O

+	O
Sp	O
(	O
Xp	O
)	O
where	O
E	O
(	O
Yt	O
)	O
is	O
the	O
expected	O
value	O
of	O
the	O
daily	O
count	O
of	O
admissions	O
Yt	O
and	O
Si	O
are	O
the	O
smooth	O
functions	O
of	O
the	O
covariates	O
Xi	O
.	O

We	O
examined	O
temperature	O
,	O
previous	O
day	O
'	O
s	O
temperature	O
,	O
relative	O
humidity	O
,	O
barometric	O
pressure	O
,	O
and	O
day	O
of	O
week	O
covariates	O
.	O

The	O
locally	O
weighted	O

7	O
.	O
8	O
0	O
.	O
1	O
0	O
.	O
3	O
0	O
.	O
4	O
0	O
.	O
1	O
NA	O
4	O
.	O
7	O
0	O
.	O
2	O
1	O
.	O
4	O
1	O
.	O
8	O
0	O
.	O
1	O

102	O
.	O
1	O
0	O
.	O
9	O
1	O
.	O
3	O
4	O
.	O
0	O
1	O
.	O
8	O
13	O
.	O
4	O
NA	O
NA	O
NA	O
NA	O
NA	O

26	O
.	O
5	O
0	O
.	O
3	O
0	O
.	O
3	O
NA	O
0	O
.	O
9	O
6	O
.	O
9	O
14	O
.	O
7	O
0	O
.	O
6	O
4	O
.	O
6	O
7	O
.	O
3	O
0	O
.	O
4	O

Table	O
2	O
.	O

25th	O
,	O
50th	O
,	O
and	O
75th	O
percentile	O
values	O
for	O
the	O
environmental	O
variables	O
in	O
Chicago	O
,	O
1988	O
<FFFD>	O
1994	O
.	O

Temperature	O
(	O
<FFFD>	O
F	O
)	O
35	O
51	O
67	O
Relative	O
humidity	O
62	O
70	O
79	O
Barometric	O
pressure	O
29	O
.	O
2	O
29	O
.	O
3	O
29	O
.	O
4	O
PM10	O
(	O
<FFFD>	O
g	O
/	O
m3	O
)	O
23	O
33	O
46	O

Table	O
3	O
.	O

Mean	O
daily	O
counts	O
of	O
admissions	O
by	O
sex	O
,	O
race	O
,	O
and	O
age	O
groups	O
,	O
Chicago	O
,	O
1986	O
<FFFD>	O
1994	O
.	O

Group	O
Overall	O
Female	O
Nonwhite	O
Age	O
>	O
75	O
years	O
COPD	O
7	O
.	O
8	O
4	O
.	O
2	O
1	O
.	O
6	O
3	O
.	O
7	O
CVD	O
102	O
.	O
1	O
59	O
.	O
4	O
21	O
.	O
0	O
55	O
.	O
1	O
Pneumonia	O
26	O
.	O
5	O
14	O
.	O
7	O
5	O
.	O
2	O
17	O
.	O
4	O

842	O

VOLUME	O

108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O
<FFFD>	O
Environmental	O
Health	O
Perspectives	O

Articles	O

<FFFD>	O

Effects	O
of	O
particles	O
on	O
sensitive	O
subgroups	O

and	O
heart	O
disease	O
admissions	O
in	O
persons	S-Species
without	O
COPD	O
listed	O
as	O
either	O
a	O
comorbidity	O
or	O
a	O
cause	O
of	O
previous	O
admission	O
(	O
Table	O
4	O
)	O
.	O

A	O
significant	O
association	O
was	O
also	O
seen	O
in	O
persons	S-Species
without	O
any	O
respiratory	O
disease	O
as	O
a	O
concurrent	O
diagnosis	O
,	O
although	O
the	O
risk	O
is	O
much	O
lower	O
than	O
in	O
persons	S-Species
with	O
respiratory	O
disease	O
.	O

However	O
,	O
the	O
risk	O
associated	O
with	O
PM10	O
was	O
roughly	O
doubled	O
in	O
subjects	O
with	O
concurrent	O
respiratory	O
infections	O
and	O
the	O
risk	O
estimates	O
in	O
those	O
subjects	O
were	O
outside	O
the	O
95	O
%	O
CI	O
of	O
the	O
risk	O
in	O
patients	S-Species
without	O
concurrent	O
respiratory	O
infections	O
.	O

A	O
previous	O
admission	O
for	O
conduction	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
heart	O
block	O
)	O
increased	O
the	O
risk	O
of	O
a	O
PM10	O
-	O
related	O
subsequent	O
admission	O
for	O
any	O
heart	O
condition	O
,	O
and	O
a	O
weaker	O
indication	O
of	O
effect	O
modification	O
was	O
seen	O
for	O
persons	S-Species
with	O
previous	O
admission	O
for	O
dysrhythmias	O
.	O

In	O
contrast	O
heart	O
failure	O
and	O
previous	O
myocardial	O
infarctions	O
were	O
highly	O
insignificant	O
as	O
effect	O
modifiers	O
.	O

Table	O
5	O
shows	O
the	O
results	O
for	O
COPD	O
.	O

Overall	O
,	O
there	O
is	O
a	O
1	O
.	O
89	O
%	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
8	O
<FFFD>	O
3	O
.	O
0	O
)	O
increase	O
in	O
COPD	O
admissions	O
for	O
a	O
10	O
<FFFD>	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
.	O

The	O
results	O
of	O
the	O
stratified	O
analysis	O
suggest	O
that	O
preexisting	O
heart	O
disease	O
modifies	O
Table	O
4	O
.	O

Percentage	O
increase	O
in	O
hospital	O
admissions	O
for	O
CVD	O
in	O
all	O
persons	S-Species
and	O
by	O
concurrent	O
diagnosis	O
and	O
previous	O
admissions	O
.	O

PM10	O
2	O
.	O
5	O
%	O
CI	O
97	O
.	O
5	O
%	O
CI	O
All	O
persons	S-Species
1	O
.	O
31	O
By	O
concurrent	O
diagnosis	O
Respiratory	O
disease	O
All	O
respiratory	O
disease	O
With	O
1	O
.	O
65	O
Without	O
0	O
.	O
98	O
Acute	O
bronchitis	O
With	O
2	O
.	O
50	O
Without	O
1	O
.	O
07	O
Acute	O
respiratory	O
infections	O
With	O
2	O
.	O
71	O
Without	O
1	O
.	O
06	O
Pneumonia	O
With	O
1	O
.	O
95	O
Without	O
1	O
.	O
03	O
COPD	O
With	O
1	O
.	O
59	O
Without	O
1	O
.	O
08	O
By	O
previous	O
admissions	O
Respiratory	O
disease	O
All	O
respiratory	O
disease	O
With	O
1	O
.	O
18	O
Without	O
1	O
.	O
08	O
COPD	O
With	O
1	O
.	O
48	O
Without	O
1	O
.	O
09	O
Asthma	O
With	O
1	O
.	O
71	O
Without	O
1	O
.	O
08	O
Cardiovascular	O
disease	O
Conduction	O
disorders	O
With	O
2	O
.	O
89	O
Without	O
1	O
.	O
07	O
Cardiac	O
dyshrethmias	O
With	O
1	O
.	O
61	O
Without	O
1	O
.	O
04	O
0	O
.	O
97	O
1	O
.	O
66	O

the	O
risk	O
of	O
COPD	O
admissions	O
on	O
high	O
particle	O
days	O
.	O

Previous	O
admissions	O
for	O
any	O
cardiovascular	O
disease	O
increased	O
the	O
risk	O
of	O
a	O
PM10associated	O
COPD	O
admission	O
approximately	O
2	O
.	O
5	O
-	O
fold	O
.	O

A	O
previous	O
heart	O
failure	O
admission	O
caused	O
an	O
even	O
more	O
striking	O
increase	O
in	O
the	O
PM10	O
effect	O
.	O

Previous	O
admissions	O
for	O
dysrhythmias	O
and	O
conduction	O
defects	O
were	O
rare	O
(	O
Table	O
1	O
)	O
with	O
no	O
power	O
to	O
examine	O
effect	O
modifications	O
.	O

Listings	O
as	O
concurrent	O
diagnoses	O
were	O
more	O
common	O
and	O
here	O
they	O
joined	O
heart	O
failure	O
in	O
increasing	O
the	O
risk	O
of	O
PM	O
10	O
-	O
associated	O
COPD	O
admissions	O
.	O

For	O
COPD	O
there	O
was	O
also	O
some	O
indication	O
that	O
concurrent	O
pneumonia	O
or	O
an	O
acute	O
respiratory	O
infection	O
admission	O
in	O
the	O
last	O
year	O
increased	O
risk	O
.	O

The	O
low	O
numbers	O
made	O
these	O
estimates	O
less	O
precise	O
,	O
however	O
.	O

The	O
percentage	O
increase	O
in	O
pneumonia	O
admission	O
(	O
Table	O
6	O
)	O
for	O
10	O
<FFFD>	O
g	O
/	O
m3	O
PM10	O
is	O
higher	O
than	O
for	O
COPD	O
or	O
CVD	O
with	O
an	O
increase	O
of	O
2	O
.	O
34	O
%	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
66	O
<FFFD>	O
3	O
.	O
0	O
)	O
.	O

As	O
with	O
COPD	O
,	O
persons	S-Species
with	O
heart	O
disease	O
appeared	O
at	O
higher	O
risk	O
of	O
pneumonia	O
hospital	O
admissions	O
associated	O
with	O
particulate	O
air	O
pollution	O
.	O

Here	O
diagnoses	O
suggestive	O
of	O
impaired	O
autonomic	O
control	O
of	O
the	O
heart	O
,	O
such	O
as	O
conduction	O
disorders	O
or	O
dysrhythmias	O
,	O
were	O
associated	O
with	O
increased	O
risk	O
for	O
PM	O
10	O
effects	O
on	O
pneumonia	O
admissions	O
.	O

Unlike	O
COPD	O
,	O
no	O
difference	O
was	O
seen	O
for	O
congestive	O
heart	O
failure	O
.	O

Persons	S-Species
with	O
asthma	O
Table	O
5	O
.	O

Percentage	O
increase	O
in	O
hospital	O
admissions	O
for	O
COPD	O
in	O
all	O
persons	S-Species
and	O
by	O
concurrent	O
diagnosis	O
and	O
previous	O
admissions	O
.	O

PM10	O
2	O
.	O
5	O
%	O
CI	O
97	O
.	O
5	O
%	O
CI	O
All	O
persons	S-Species
1	O
.	O
89	O
By	O
concurrent	O
diagnosis	O
Respiratory	O
disease	O
Pneumonia	O
With	O
4	O
.	O
00	O
Without	O
1	O
.	O
51	O
Cardiovascular	O
disease	O
Conduction	O
disorders	O
With	O
2	O
.	O
34	O
Without	O
1	O
.	O
60	O
Cardiac	O
dysrhythmias	O
With	O
3	O
.	O
09	O
Without	O
1	O
.	O
43	O
Congestive	O
heart	O
failure	O
With	O
2	O
.	O
90	O
Without	O
1	O
.	O
39	O
By	O
previous	O
admissions	O
Respiratory	O
disease	O
Acute	O
respiratory	O
infections	O
With	O
3	O
.	O
20	O
Without	O
1	O
.	O
70	O
Cardiovascular	O
disease	O
CVD	O
With	O
2	O
.	O
90	O
Without	O
1	O
.	O
18	O
Congestive	O
heart	O
failure	O
With	O
4	O
.	O
37	O
Without	O
1	O
.	O
14	O
Within	O
1	O
year	O
6	O
.	O
04	O
0	O
.	O
80	O
2	O
.	O
99	O

had	O
twice	O
the	O
risk	O
of	O
a	O
PM10	O
-	O
induced	O
pneumonia	O
admission	O
as	O
persons	S-Species
without	O
asthma	O
.	O

Table	O
7	O
shows	O
the	O
results	O
by	O
sex	O
,	O
age	O
,	O
and	O
race	O
.	O

None	O
of	O
the	O
effect	O
size	O
estimates	O
for	O
any	O
of	O
the	O
stratification	O
variables	O
were	O
outside	O
of	O
the	O
95	O
%	O
CI	O
for	O
the	O
opposite	O
strata	O
.	O

There	O
was	O
a	O
tendency	O
for	O
the	O
effect	O
of	O
PM10	O
on	O
CVD	O
admissions	O
to	O
be	O
higher	O
for	O
females	O
,	O
whereas	O
the	O
effect	O
on	O
pneumonia	O
admissions	O
was	O
higher	O
for	O
males	O
.	O

In	O
general	O
,	O
we	O
found	O
somewhat	O
larger	O
effects	O
on	O
whites	O
compared	O
to	O
nonwhites	O
,	O
and	O
for	O
persons	S-Species
older	O
than	O
75	O
years	O
of	O
age	O
compared	O
to	O
younger	O
persons	S-Species
.	O

Discussion	O
In	O
this	O
analysis	O
we	O
examined	O
whether	O
the	O
effect	O
of	O
PM10	O
on	O
the	O
risk	O
of	O
hospital	O
admission	O
for	O
heart	O
and	O
lung	O
disease	O
was	O
different	O
depending	O
on	O
the	O
presence	O
of	O
comorbidities	O
.	O

We	O
found	O
that	O
PM10	O
was	O
associated	O
with	O
hospital	O
admissions	O
for	O
all	O
three	O
causes	O
(	O
CVD	O
,	O
COPD	O
,	O
and	O
pneumonia	O
)	O
and	O
we	O
found	O
not	O
a	O
general	O
increase	O
in	O
PM10	O
related	O
risk	O
with	O
comorbidities	O
,	O
but	O
a	O
specific	O
pattern	O
that	O
is	O
suggestive	O
of	O
potential	O
mechanisms	O
and	O
consistent	O
with	O
other	O
recent	O
epidemiologic	O
and	O
toxicologic	O
findings	O
.	O

One	O
major	O
finding	O
of	O
this	O
study	O
is	O
that	O
preexisting	O
cardiovascular	O
disease	O
,	O
particularly	O
impaired	O
autonomic	O
control	O
(	O
conduction	O
defects	O
and	O
dysrhythmias	O
)	O
and	O
heart	O
failure	O
,	O
substantially	O
increased	O
the	O
risk	O
of	O
respiratory	O
admissions	O
associated	O
with	O
airborne	O
particles	O
.	O

In	O
fact	O
,	O
recent	O
human	S-Species
studies	O
have	O
shown	O
that	O
exposure	O
to	O
particulate	O
air	O
pollution	O
is	O
a	O
risk	O
factor	O
for	O
reduced	O
heart	O
rate	O
variability	O
(	O
39	O
<FFFD>	O
41	O
)	O
.	O

Reduced	O
heart	O
rate	O
variability	O
is	O
an	O
adverse	O
response	O
and	O
a	O
risk	O
factor	O
for	O
arrhythmia	O
.	O

A	O
new	O
study	O
of	O
defibrillator	O
discharges	O
in	O
patients	S-Species
with	O
implanted	O
cardioverter	O
defibrillators	O
found	O
that	O
discharges	O
were	O
associated	O
with	O
air	O
pollution	O
(	O
42	O
)	O
.	O

Exposure	O
to	O
combustion	O
Table	O
6	O
.	O

Percentage	O
increase	O
in	O
hospital	O
admissions	O
for	O
pneumonia	O
in	O
all	O
persons	S-Species
and	O
by	O
concurrent	O
diagnosis	O
and	O
previous	O
admissions	O
.	O

PM10	O
All	O
persons	S-Species
By	O
concurrent	O
diagnosis	O
Respiratory	O
disease	O
Asthma	O
With	O
Without	O
Cardiovascular	O
disease	O
Conduction	O
disorders	O
With	O
Without	O
Cardiac	O
dysrhythmias	O
With	O
Without	O
By	O
previous	O
admissions	O
Cardiovascular	O
disease	O
Cardiac	O
dysrhythmias	O
With	O
Without	O
2	O
.	O
34	O
2	O
.	O
5	O
%	O
CI	O
97	O
.	O
5	O
%	O
CI	O
1	O
.	O
66	O
3	O
.	O
02	O

1	O
.	O
10	O
0	O
.	O
64	O
<FFFD>	O
0	O
.	O
47	O
0	O
.	O
76	O
0	O
.	O
18	O
0	O
.	O
76	O
0	O
.	O
55	O
0	O
.	O
72	O
0	O
.	O
85	O
0	O
.	O
75	O

2	O
.	O
20	O
1	O
.	O
33	O
5	O
.	O
55	O
1	O
.	O
37	O
5	O
.	O
30	O
1	O
.	O
37	O
3	O
.	O
36	O
1	O
.	O
35	O
2	O
.	O
34	O
1	O
.	O
41	O

<FFFD>	O
0	O
.	O
45	O
0	O
.	O
47	O
<FFFD>	O
4	O
.	O
42	O
0	O
.	O
58	O
0	O
.	O
64	O
0	O
.	O
33	O
0	O
.	O
77	O
0	O
.	O
24	O

8	O
.	O
65	O
2	O
.	O
57	O
9	O
.	O
59	O
2	O
.	O
64	O
5	O
.	O
60	O
2	O
.	O
55	O
5	O
.	O
08	O
2	O
.	O
55	O

0	O
.	O
45	O
0	O
.	O
76	O
<FFFD>	O
0	O
.	O
40	O
0	O
.	O
78	O
<FFFD>	O
0	O
.	O
43	O
0	O
.	O
77	O
0	O
.	O
22	O
0	O
.	O
76	O
0	O
.	O
75	O
0	O
.	O
72	O

1	O
.	O
91	O
1	O
.	O
41	O
3	O
.	O
40	O
1	O
.	O
40	O
3	O
.	O
89	O
1	O
.	O
39	O
5	O
.	O
63	O
1	O
.	O
38	O
2	O
.	O
48	O
1	O
.	O
36	O

4	O
.	O
18	O
2	O
.	O
07	O
7	O
.	O
92	O
1	O
.	O
99	O
<FFFD>	O
<FFFD>	O

1	O
.	O
01	O
1	O
.	O
46	O
4	O
.	O
28	O
1	O
.	O
37	O
<FFFD>	O
<FFFD>	O

7	O
.	O
46	O
2	O
.	O
69	O
11	O
.	O
69	O
2	O
.	O
61	O
<FFFD>	O
<FFFD>	O

<FFFD>	O
1	O
.	O
38	O
0	O
.	O
66	O
0	O
.	O
99	O
<FFFD>	O
0	O
.	O
01	O
1	O
.	O
43	O
0	O
.	O
05	O
2	O
.	O
10	O

8	O
.	O
01	O
2	O
.	O
76	O
4	O
.	O
85	O
2	O
.	O
39	O
7	O
.	O
40	O
2	O
.	O
24	O
10	O
.	O
14	O

3	O
.	O
47	O
2	O
.	O
08	O

1	O
.	O
21	O
1	O
.	O
45	O

5	O
.	O
79	O
2	O
.	O
71	O

Increases	O
are	O
for	O
a	O
10	O
-	O
<FFFD>	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
.	O

Increases	O
are	O
for	O
a	O
10	O
-	O
<FFFD>	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
.	O

Increases	O
are	O
for	O
a	O
10	O
-	O
<FFFD>	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
.	O

Environmental	O
Health	O
Perspectives	O

<FFFD>	O
VOLUME	O
108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O

843	O

Articles	O

<FFFD>	O

Zanobetti	O
et	O
al	O
.	O

Table	O
7	O
.	O

Effect	O
modification	O
by	O
sex	O
,	O
race	O
,	O
and	O
age	O
groups	O
for	O
10	O
<FFFD>	O
g	O
/	O
m3	O
PM10	O
.	O

%	O
All	O
persons	S-Species
Male	O
Female	O
White	O
Non	O
-	O
white	O
Age	O
>	O
75	O
Age	O
75	O
1	O
.	O
89	O
1	O
.	O
34	O
2	O
.	O
19	O
1	O
.	O
65	O
1	O
.	O
07	O
2	O
.	O
20	O
1	O
.	O
33	O
COPD	O
(	O
95	O
%	O
CI	O
)	O
(	O
0	O
.	O
80	O
,	O
2	O
.	O
99	O
)	O
(	O
<FFFD>	O
0	O
.	O
14	O
,	O
2	O
.	O
84	O
)	O
(	O
0	O
.	O
81	O
,	O
3	O
.	O
59	O
)	O
(	O
0	O
.	O
51	O
,	O
2	O
.	O
81	O
)	O
(	O
<FFFD>	O
1	O
.	O
11	O
,	O
3	O
.	O
3	O
)	O
(	O
0	O
.	O
72	O
,	O
3	O
.	O
69	O
)	O
(	O
0	O
.	O
03	O
,	O
2	O
.	O
65	O
)	O
%	O
1	O
.	O
31	O
1	O
.	O
07	O
1	O
.	O
21	O
1	O
.	O
20	O
0	O
.	O
70	O
1	O
.	O
28	O
0	O
.	O
93	O
CVD	O
(	O
95	O
%	O
CI	O
)	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
66	O
)	O
(	O
0	O
.	O
62	O
,	O
1	O
.	O
51	O
)	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
6	O
)	O
(	O
0	O
.	O
86	O
,	O
1	O
.	O
55	O
)	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
3	O
)	O
(	O
0	O
.	O
88	O
,	O
1	O
.	O
69	O
)	O
(	O
0	O
.	O
51	O
,	O
1	O
.	O
35	O
)	O
%	O
2	O
.	O
34	O
2	O
.	O
65	O
1	O
.	O
91	O
2	O
.	O
45	O
1	O
.	O
91	O
2	O
.	O
12	O
2	O
.	O
52	O
Pneumonia	O
(	O
95	O
%	O
CI	O
)	O
(	O
1	O
.	O
66	O
,	O
3	O
.	O
02	O
)	O
(	O
1	O
.	O
81	O
,	O
3	O
.	O
5	O
)	O
(	O
1	O
.	O
11	O
,	O
2	O
.	O
72	O
)	O
(	O
1	O
.	O
77	O
,	O
3	O
.	O
14	O
)	O
(	O
0	O
.	O
69	O
,	O
3	O
.	O
14	O
)	O
(	O
1	O
.	O
38	O
,	O
2	O
.	O
86	O
)	O
(	O
1	O
.	O
57	O
,	O
3	O
.	O
48	O
)	O

Figures	O
shown	O
are	O
the	O
percentage	O
increase	O
in	O
admissions	O
(	O
95	O
%	O
CI	O
)	O
.	O

particles	O
has	O
also	O
been	O
associated	O
with	O
arrhythmia	O
in	O
an	O
animal	O
model	O
(	O
43	O
)	O
and	O
changes	O
in	O
ST	O
segments	O
have	O
been	O
noted	O
as	O
well	O
(	O
44	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
suggest	O
persons	S-Species
with	O
defects	O
in	O
the	O
electrical	O
control	O
of	O
the	O
heart	O
are	O
also	O
at	O
higher	O
risk	O
of	O
respiratory	O
illness	O
after	O
exposure	O
to	O
airborne	O
particles	O
.	O

These	O
data	O
also	O
suggest	O
that	O
persons	S-Species
admitted	O
to	O
hospitals	O
for	O
pneumonia	O
during	O
an	O
air	O
pollution	O
episode	O
may	O
be	O
at	O
high	O
risk	O
for	O
clinically	O
significant	O
conduction	O
disorders	O
during	O
that	O
hospital	O
admission	O
.	O

Patients	S-Species
with	O
congestive	O
heart	O
failure	O
were	O
at	O
greater	O
risk	O
of	O
hospital	O
admissions	O
for	O
COPD	O
in	O
association	O
with	O
airborne	O
particles	O
.	O

Heart	O
failure	O
and	O
COPD	O
is	O
not	O
an	O
uncommon	O
combination	O
.	O

The	O
finding	O
that	O
these	O
patients	S-Species
are	O
at	O
higher	O
risk	O
for	O
admissions	O
associated	O
with	O
particulate	O
air	O
pollution	O
is	O
new	O
but	O
is	O
also	O
consistent	O
with	O
several	O
other	O
recent	O
reports	O
.	O

The	O
spontaneous	O
hypertensive	O
rat	S-Species
develops	O
a	O
model	O
of	O
heart	O
failure	O
,	O
and	O
recent	O
studies	O
have	O
reported	O
greater	O
sensitivity	O
to	O
particulate	O
air	O
pollution	O
in	O
these	O
rats	S-Species
.	O

These	O
include	O
both	O
electrocardiogram	O
abnormalities	O
(	O
44	O
)	O
and	O
pulmonary	O
toxicity	O
(	O
45	O
,	O
46	O
)	O
.	O

Similarly	O
,	O
in	O
an	O
epidemiologic	O
study	O
,	O
Hoek	O
et	O
al	O
.	O

(	O
47	O
)	O
,	O
found	O
a	O
higher	O
relative	O
risk	O
of	O
death	O
with	O
an	O
increase	O
in	O
PM10	O
for	O
congestive	O
heart	O
failure	O
deaths	O
than	O
other	O
deaths	O
.	O

The	O
potential	O
role	O
of	O
COPD	O
in	O
those	O
heart	O
failure	O
deaths	O
was	O
not	O
examined	O
.	O

Another	O
consistent	O
pattern	O
in	O
our	O
data	O
is	O
of	O
acute	O
respiratory	O
infections	O
increasing	O
susceptibility	O
to	O
airborne	O
particles	O
.	O

Acute	O
bronchitis	O
,	O
or	O
more	O
generally	O
acute	O
upper	O
respiratory	O
illnesses	O
,	O
as	O
well	O
as	O
pneumonia	O
,	O
increased	O
susceptibility	O
to	O
particle	O
-	O
associated	O
admissions	O
for	O
CVD	O
and	O
COPD	O
.	O

The	O
notion	O
that	O
air	O
pollution	O
exacerbates	O
acute	O
respiratory	O
infections	O
is	O
well	O
supported	O
by	O
studies	O
which	O
report	O
associations	O
between	O
airborne	O
particles	O
and	O
hospital	O
admissions	O
for	O
respiratory	O
infections	O
(	O
48	O
,	O
49	O
)	O
.	O

Zelikoff	O
et	O
al	O
.	O

(	O
50	O
)	O
exposed	O
rats	S-Species
infected	O
with	O
streptococcus	O
to	O
concentrated	O
air	O
particles	O
and	O
reported	O
a	O
significant	O
increase	O
in	O
bacterial	O
burdens	O
and	O
in	O
the	O
extent	O
of	O
pneumonia	O
compared	O
to	O
animals	O
exposed	O
to	O
filtrated	O
air	O
.	O

This	O
suggests	O
an	O
impaired	O
immune	O
response	O
.	O

Similarly	O
,	O
exposure	O
to	O
combustion	O

particles	O
enhances	O
influenza	O
infections	O
in	O
mice	S-Species
(	O
51	O
)	O
.	O

An	O
impaired	O
defense	O
to	O
respiratory	O
infection	O
is	O
a	O
major	O
reason	O
that	O
persons	S-Species
with	O
COPD	O
require	O
hospital	O
admission	O
.	O

If	O
airborne	O
particles	O
result	O
in	O
further	O
impairment	O
the	O
effect	O
modification	O
we	O
observe	O
makes	O
good	O
sense	O
.	O

The	O
effect	O
modification	O
for	O
heart	O
disease	O
admissions	O
is	O
more	O
relevant	O
.	O

This	O
modification	O
is	O
consistent	O
with	O
the	O
earlier	O
report	O
of	O
Schwartz	O
(	O
19	O
)	O
,	O
who	O
found	O
greater	O
reports	O
of	O
respiratory	O
complications	O
on	O
death	O
certificates	O
with	O
an	O
underlying	O
cause	O
of	O
heart	O
disease	O
if	O
the	O
death	O
occurred	O
on	O
a	O
day	O
with	O
high	O
levels	O
of	O
airborne	O
particles	O
.	O

Although	O
airborne	O
particle	O
exposure	O
has	O
been	O
associated	O
with	O
increased	O
exacerbation	O
of	O
asthma	O
(	O
2	O
,	O
12	O
,	O
48	O
,	O
52	O
<FFFD>	O
59	O
)	O
,	O
this	O
paper	O
is	O
the	O
first	O
to	O
suggest	O
that	O
asthmatics	O
are	O
more	O
susceptible	O
to	O
PM10	O
-	O
induced	O
pneumonia	O
exacerbation	O
or	O
to	O
cardiovascular	O
effects	O
.	O

The	O
effects	O
on	O
pneumonia	O
admissions	O
are	O
plausible	O
,	O
given	O
the	O
impaired	O
ability	O
to	O
fight	O
off	O
infections	O
in	O
asthmatics	O
with	O
mucus	O
plugs	O
and	O
the	O
evidence	O
the	O
airborne	O
particles	O
impair	O
the	O
lungs	O
'	O
ability	O
to	O
fight	O
off	O
bacterial	O
and	O
viral	O
infections	O
,	O
as	O
noted	O
earlier	O
.	O

The	O
increased	O
cardiovascular	O
sensitivity	O
,	O
albeit	O
weaker	O
,	O
is	O
interesting	O
.	O

If	O
airborne	O
particles	O
affect	O
the	O
cardiovascular	O
system	O
via	O
the	O
role	O
of	O
the	O
lung	O
in	O
autonomic	O
control	O
,	O
it	O
is	O
possible	O
that	O
asthmatics	O
would	O
be	O
more	O
sensitive	O
to	O
those	O
effects	O
.	O

Animal	O
models	O
of	O
asthma	O
showed	O
that	O
combustion	O
particles	O
enhance	O
the	O
asthmatic	O
response	O
to	O
aeroallergen	O
challenges	O
(	O
59	O
)	O
.	O

This	O
suggests	O
an	O
enhancement	O
of	O
pulmonary	O
response	O
in	O
asthmatics	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
diagnosis	O
of	O
asthma	O
is	O
problematic	O
in	O
the	O
elderly	O
,	O
and	O
crossover	O
with	O
COPD	O
is	O
possible	O
.	O

The	O
possibility	O
that	O
this	O
explains	O
our	O
results	O
is	O
reduced	O
by	O
our	O
failure	O
to	O
find	O
previous	O
hospital	O
admission	O
for	O
COPD	O
was	O
an	O
effect	O
modifier	O
for	O
the	O
effect	O
of	O
particles	O
on	O
cardiovascular	O
admissions	O
.	O

We	O
must	O
acknowledge	O
several	O
potential	O
limitations	O
of	O
this	O
study	O
.	O

First	O
,	O
we	O
considered	O
only	O
previous	O
admissions	O
that	O
occurred	O
within	O
Cook	O
County	O
.	O

Hence	O
persons	S-Species
with	O
previous	O
admissions	O
elsewhere	O
would	O
be	O
misclassified	O
to	O
our	O
reference	O
group	O
.	O

The	O
effect	O
of	O
this	O
would	O
be	O
to	O
reduce	O
the	O
difference	O
in	O
PM	O
10	O
effect	O
between	O
the	O
two	O
groups	O
.	O

VOLUME	O

Nevertheless	O
,	O
we	O
identified	O
some	O
interesting	O
interactions	O
.	O

We	O
cannot	O
exclude	O
the	O
possibility	O
that	O
there	O
are	O
areas	O
we	O
missed	O
for	O
this	O
reason	O
.	O

We	O
also	O
examined	O
interactions	O
in	O
a	O
log	O
relative	O
risk	O
model	O
,	O
which	O
is	O
inherently	O
multiplicative	O
.	O

Although	O
we	O
believe	O
this	O
is	O
justified	O
because	O
doubling	O
the	O
population	O
exposed	O
would	O
be	O
expected	O
to	O
double	O
the	O
pollution	O
associated	O
admissions	O
,	O
it	O
results	O
in	O
a	O
more	O
conservative	O
definition	O
of	O
interaction	O
than	O
would	O
an	O
additive	O
risk	O
model	O
.	O

Finally	O
,	O
our	O
exposure	O
is	O
clearly	O
measured	O
with	O
error	O
.	O

Most	O
of	O
this	O
error	O
is	O
Berkson	O
error	O
(	O
60	O
)	O
and	O
hence	O
will	O
introduce	O
no	O
bias	O
,	O
and	O
Zeger	O
et	O
al	O
.	O

(	O
60	O
)	O
showed	O
that	O
the	O
remaining	O
error	O
would	O
have	O
to	O
have	O
pathologic	O
correlations	O
with	O
other	O
variables	O
to	O
result	O
in	O
an	O
upward	O
bias	O
.	O

Another	O
important	O
result	O
from	O
this	O
study	O
,	O
of	O
course	O
,	O
is	O
an	O
estimate	O
of	O
the	O
magnitude	O
of	O
the	O
effect	O
of	O
airborne	O
particles	O
on	O
public	O
health	O
.	O

The	O
PM10	O
concentrations	O
in	O
Chicago	O
during	O
this	O
period	O
were	O
associated	O
with	O
approximately	O
1	O
,	O
600	O
additional	O
admissions	O
per	O
year	O
for	O
heart	O
disease	O
,	O
740	O
additional	O
admissions	O
per	O
year	O
for	O
pneumonia	O
,	O
and	O
170	O
additional	O
admissions	O
per	O
year	O
for	O
COPD	O
.	O

These	O
are	O
not	O
trivial	O
increases	O
in	O
serious	O
morbidity	O
.	O

The	O
results	O
of	O
our	O
study	O
should	O
be	O
replicated	O
in	O
additional	O
cities	O
,	O
although	O
they	O
do	O
begin	O
to	O
fill	O
in	O
some	O
missing	O
information	O
about	O
the	O
effects	O
of	O
airborne	O
particles	O
on	O
health	O
.	O

More	O
generally	O
airborne	O
particles	O
have	O
been	O
associated	O
with	O
a	O
broad	O
range	O
of	O
systemic	O
changes	O
including	O
heart	O
rate	O
variability	O
(	O
39	O
<FFFD>	O
41	O
)	O
,	O
increased	O
peripheral	O
neutrophils	O
(	O
61	O
<FFFD>	O
63	O
)	O
,	O
increased	O
plasma	O
viscosity	O
(	O
64	O
)	O
,	O
an	O
increase	O
in	O
blood	O
pressure	O
(	O
65	O
)	O
,	O
and	O
the	O
outcomes	O
mentioned	O
previously	O
.	O

The	O
role	O
of	O
these	O
systemic	O
changes	O
as	O
potential	O
sources	O
of	O
the	O
specific	O
effect	O
modifications	O
we	O
have	O
seen	O
should	O
be	O
an	O
area	O
of	O
fruitful	O
research	O
in	O
the	O
future	O
.	O

REFERENCES	O
AND	O
NOTES	O
1	O
.	O

Katsouyanni	O
K	O
,	O
Touloumi	O
G	O
,	O
Spix	O
C	O
,	O
Schwartz	O
J	O
,	O
Balducci	O
F	O
,	O
Medina	O
S	O
,	O
Rossi	O
G	O
,	O
Wojtyniak	O
D	O
,	O
Sunyer	O
J	O
,	O
Bacharova	O
L	O
,	O
et	O
al	O
.	O

Short	O
term	O
effects	O
of	O
ambient	O
sulphur	O
dioxide	O
and	O
particulate	O
matter	O
on	O
mortality	O
in	O
12	O
European	O
cities	O
:	O
results	O
from	O
time	O
series	O
data	O
from	O
the	O
APHEA	O
project	O
.	O

Br	O
Med	O
J	O
314	O
:	O
1658	O
<FFFD>	O
1663	O
(	O
1997	O
)	O
.	O

Pope	O
CA	O
,	O
Dockery	O
DW	O
,	O
Schwartz	O
J	O
.	O
Review	O
of	O
epidemiologic	O
evidence	O
of	O
health	O
effects	O
of	O
particulate	O
air	O
pollution	O
.	O

Inhal	O
Toxicol	O
7	O
:	O
1	O
<FFFD>	O
18	O
(	O
1995	O
)	O
.	O

Schwartz	O
J	O
.	O

Air	O
pollution	O
and	O
daily	O
mortality	O
:	O
a	O
review	O
and	O
meta	O
analysis	O
.	O

Environ	O
Res	O
64	O
:	O
36	O
<FFFD>	O
52	O
(	O
1994	O
)	O
.	O

Dominici	O
F	O
,	O
Samet	O
J	O
,	O
Zeger	O
SL	O
.	O

Combining	O
evidence	O
on	O
air	O
pollution	O
and	O
daily	O
mortality	O
from	O
the	O
largest	O
20	O
US	O
cities	O
:	O
a	O
hierarchical	O
modeling	O
strategy	O
.	O

R	O
Stat	O
Soc	O
Ser	O
A	O
,	O
in	O
press	O
.	O

Burnett	O
RT	O
,	O
Dales	O
RE	O
,	O
Raizenne	O
ME	O
,	O
Krewski	O
D	O
,	O
Summers	O
PW	O
,	O
Roberts	O
GR	O
,	O
Raad	O
-	O
Young	O
M	O
,	O
Dann	O
T	O
,	O
Brooke	O
T	O
.	O
Effects	O
of	O
low	O
ambient	O
levels	O
of	O
ozone	O
and	O
sulfates	O
on	O
the	O
frequency	O
of	O
respiratory	O
admissions	O
to	O
Ontario	O
hospitals	O
.	O

Environ	O
Res	O
65	O
:	O
172	O
<FFFD>	O
194	O
(	O
1994	O
)	O
.	O

Anderson	O
HR	O
,	O
Spix	O
C	O
,	O
Medina	O
S	O
,	O
Schouten	O
JP	O
,	O
Castellsague	O
J	O
,	O
Rossi	O
G	O
,	O
Zmirou	O
D	O
,	O
Touloumi	O
G	O
,	O
Wojtyniak	O
B	O
,	O
Ponka	O
A	O
,	O
et	O
al	O
.	O

Air	O
pollution	O
and	O
daily	O
admissions	O
for	O

2	O
.	O

3	O
.	O

4	O
.	O

5	O
.	O

6	O
.	O

844	O

108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O
<FFFD>	O
Environmental	O
Health	O
Perspectives	O

Articles	O

<FFFD>	O

Effects	O
of	O
particles	O
on	O
sensitive	O
subgroups	O

7	O
.	O

8	O
.	O

9	O
.	O

10	O
.	O

11	O
.	O

12	O
.	O

13	O
.	O

14	O
.	O

15	O
.	O

16	O
.	O

17	O
.	O

18	O
.	O

19	O
.	O

20	O
.	O

21	O
.	O

22	O
.	O

23	O
.	O

24	O
.	O

25	O
.	O

26	O
.	O

27	O
.	O

28	O
.	O

29	O
.	O

30	O
.	O

chronic	O
obstructive	O
pulmonary	O
disease	O
in	O
6	O
European	O
cities	O
:	O
results	O
from	O
the	O
APHEA	O
project	O
.	O

Eur	O
Respir	O
J	O
10	O
:	O
1064	O
<FFFD>	O
1071	O
(	O
1997	O
)	O
.	O

Schwartz	O
J	O
.	O
Short	O
term	O
fluctuations	O
in	O
air	O
pollution	O
and	O
hospital	O
admissions	O
of	O
the	O
elderly	O
for	O
respiratory	O
disease	O
.	O

Thorax	O
50	O
:	O
531	O
<FFFD>	O
538	O
(	O
1995	O
)	O
.	O

Schwartz	O
J	O
.	O

Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
heart	O
disease	O
in	O
eight	O
U	O
.	O
S	O
.	O
counties	O
.	O

Epidemiology	O
10	O
:	O
17	O
<FFFD>	O
22	O
(	O
1999	O
)	O
.	O

Schwartz	O
J	O
.	O

Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
the	O
elderly	O
in	O
Minneapolis	O
.	O

Arch	O
Environ	O
Health	O
49	O
:	O
366	O
<FFFD>	O
374	O
(	O
1994	O
)	O
.	O

Schwartz	O
J	O
.	O

Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
the	O
elderly	O
in	O
Birmingham	O
,	O
Alabama	O
.	O

Am	O
J	O
Epidemiol	O
139	O
:	O
589	O
<FFFD>	O
598	O
(	O
1994	O
)	O
.	O

Schwartz	O
J	O
.	O

Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
the	O
elderly	O
in	O
Detroit	O
,	O
MI	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
150	O
:	O
648	O
<FFFD>	O
655	O
(	O
1994	O
)	O
.	O

Pope	O
CA	O
III	O
.	O

Respiratory	O
disease	O
associated	O
with	O
community	O
air	O
pollution	O
and	O
a	O
steel	O
mill	O
,	O
Utah	O
valley	O
.	O

Am	O
J	O
Public	O
Health	O
79	O
:	O
623	O
<FFFD>	O
628	O
(	O
1989	O
)	O
.	O

Saldiva	O
PH	O
,	O
Pope	O
CA	O
,	O
Schwartz	O
J	O
,	O
Dockery	O
DW	O
,	O
Lichtenfels	O
AJ	O
,	O
Salge	O
JM	O
,	O
Barone	O
I	O
,	O
Bohm	O
GM	O
.	O

Air	O
pollution	O
and	O
mortality	O
in	O
elderly	O
people	S-Species
:	O
a	O
time	O
series	O
study	O
in	O
Sao	O
Paulo	O
,	O
Brazil	O
.	O

Arch	O
Environ	O
Health	O
50	O
:	O
159	O
<FFFD>	O
163	O
(	O
1995	O
)	O
.	O

Schwartz	O
,	O
J	O
.	O

Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
cardiovascular	O
disease	O
in	O
Tucson	O
.	O

Epidemiology	O
8	O
:	O
371	O
<FFFD>	O
177	O
(	O
1997	O
)	O
.	O

Delfino	O
RJ	O
,	O
Murphy	O
Moulton	O
AM	O
,	O
Becklake	O
MR	O
.	O

Emergency	O
room	O
visits	O
for	O
respiratory	O
illnesses	O
among	O
the	O
elderly	O
in	O
Montreal	O
:	O
association	O
with	O
low	O
level	O
ozone	O
exposure	O
.	O

Environ	O
Res	O
76	O
:	O
67	O
<FFFD>	O
77	O
(	O
1998	O
)	O
.	O

National	O
Research	O
Council	O
.	O

Research	O
Priorities	O
for	O
Airborne	O
Particulate	O
Matter	O
.	O

Washington	O
,	O
DC	O
:	O
National	O
Academy	O
Press	O
,	O
1998	O
.	O

Schwartz	O
J	O
,	O
Dockery	O
DW	O
.	O

Increased	O
mortality	O
in	O
Philadelphia	O
associated	O
with	O
daily	O
air	O
pollution	O
concentrations	O
.	O

Am	O
Rev	O
Respir	O
Dis	O
145	O
:	O
600	O
<FFFD>	O
604	O
(	O
1992	O
)	O
.	O

Samet	O
JM	O
,	O
Zeger	O
SL	O
,	O
Berhane	O
K	O
.	O

The	O
association	O
of	O
mortality	O
and	O
particulate	O
air	O
pollution	O
.	O

In	O
:	O
Particulate	O
Air	O
Pollution	O
and	O
Daily	O
Mortality	O
.	O

The	O
Phase	O
I	O
Report	O
of	O
the	O
Particle	O
Epidemiology	O
Evaluation	O
Project	O
.	O

Boston	O
,	O
MA	O
:	O
Health	O
Effects	O
Institute	O
,	O
1995	O
.	O

Schwartz	O
J	O
.	O
What	O
are	O
people	S-Species
dying	O
of	O
on	O
high	O
air	O
pollution	O
days	O
?	O

Environ	O
Res	O
64	O
:	O
26	O
<FFFD>	O
35	O
(	O
1994	O
)	O
.	O

Sunyer	O
J	O
,	O
Schwartz	O
J	O
,	O
Tobias	O
A	O
,	O
MacFarlane	O
D	O
,	O
Garcia	O
J	O
,	O
Anto	O
JM	O
.	O

Patients	S-Species
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
are	O
a	O
susceptible	O
population	O
of	O
dying	O
due	O
to	O
urban	O
particles	O
.	O

Am	O
J	O
Epidemiol	O
151	O
(	O
1	O
)	O
:	O
50	O
<FFFD>	O
56	O
(	O
2000	O
)	O
.	O

Godleski	O
JJ	O
,	O
Sioutas	O
C	O
,	O
Katler	O
M	O
,	O
Koutrakis	O
P	O
.	O
Death	O
from	O
inhalation	O
of	O
concentrated	O
air	O
particles	O
in	O
animal	O
models	O
of	O
pulmonary	O
disease	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
153	O
:	O
A15	O
(	O
1996	O
)	O
.	O

Matsui	O
K	O
,	O
Goldman	O
L	O
.	O
Comorbidity	O
as	O
a	O
correlate	O
of	O
length	O
of	O
stay	O
for	O
hospitalized	O
patients	S-Species
with	O
acute	O
chest	O
pain	O
.	O

J	O
Gen	O
Intern	O
Med	O
11	O
:	O
262	O
<FFFD>	O
268	O
(	O
1996	O
)	O
.	O

Charlson	O
M	O
,	O
Szatrowshi	O
TP	O
,	O
Peterson	O
J	O
,	O
Gold	O
J	O
.	O
Validation	O
of	O
a	O
combined	O
comorbidity	O
index	O
.	O

J	O
Clin	O
Epidemiol	O
47	O
:	O
1245	O
<FFFD>	O
1251	O
(	O
1994	O
)	O
.	O

Monane	O
M	O
,	O
Kanter	O
DS	O
,	O
Glynn	O
RJ	O
,	O
Avorn	O
J	O
.	O
Variability	O
in	O
length	O
of	O
hospitalization	O
for	O
stroke	O
.	O

The	O
role	O
of	O
managed	O
care	O
in	O
an	O
elderly	O
population	O
.	O

Arch	O
Neurol	O
53	O
:	O
848	O
(	O
1996	O
)	O
.	O

Hallstrom	O
AP	O
,	O
Cobb	O
LA	O
,	O
Yu	O
BH	O
.	O

Influence	O
of	O
comorbidity	O
on	O
the	O
outcome	O
of	O
patients	S-Species
treated	O
for	O
out	O
-	O
of	O
-	O
hospital	O
ventricular	O
fibrillation	O
.	O

Circulation	O
93	O
:	O
2019	O
<FFFD>	O
2022	O
(	O
1996	O
)	O
.	O

Malenka	O
DJ	O
,	O
Mclerran	O
D	O
,	O
Roos	O
N	O
,	O
Fisher	O
ES	O
,	O
Wennberg	O
JE	O
.	O

Using	O
administrative	O
data	O
to	O
describe	O
case	O
-	O
mix	O
:	O
a	O
comparison	O
with	O
the	O
medical	O
record	O
.	O

J	O
Clin	O
Epidemiol	O
47	O
:	O
1027	O
<FFFD>	O
1032	O
(	O
1994	O
)	O
.	O

Romano	O
PS	O
,	O
Roos	O
LL	O
,	O
Jollis	O
JG	O
.	O

Adapting	O
a	O
clinical	O
comorbidity	O
index	O
for	O
use	O
with	O
ICD	O
-	O
9	O
-	O
CM	O
administrative	O
data	O
:	O
differing	O
perspectives	O
.	O

J	O
Clin	O
Epidemiol	O
46	O
:	O
1075	O
<FFFD>	O
1079	O
(	O
1993	O
)	O
.	O

Deyo	O
RA	O
,	O
Cherkin	O
DC	O
,	O
Ciol	O
MA	O
.	O

Adapting	O
a	O
clinical	O
comorbidity	O
index	O
for	O
use	O
with	O
ICD	O
-	O
9CM	O
administrative	O
databases	O
.	O

J	O
Clin	O
Epidemiol	O
45	O
:	O
613	O
<FFFD>	O
619	O
(	O
1992	O
)	O
.	O

Charlson	O
ME	O
,	O
Pompei	O
P	O
,	O
Ales	O
KL	O
,	O
MacKenzie	O
CR	O
.	O

A	O
new	O
method	O
of	O
classifying	O
prognostic	O
comorbidity	O
in	O
longitudinal	O
studies	O
:	O
development	O
and	O
validation	O
.	O

J	O
Chronic	O
Dis	O
40	O
:	O
373	O
<FFFD>	O
383	O
(	O
1987	O
)	O
.	O

Librero	O
J	O
,	O
Peir	O
<FFFD>	O
S	O
,	O
Ordi	O
<FFFD>	O
ana	O
R	O
.	O

Chronic	O
comorbidity	O
and	O
outcomes	O
of	O
hospital	O
care	O
:	O
length	O
of	O
stay	O
,	O
mortality	O
,	O
and	O
readmission	O
at	O
30	O
and	O
365	O
days	O
.	O

J	O
Clin	O
Epidemiol	O
52	O
:	O
171	O
<FFFD>	O
179	O
(	O
1999	O
)	O
.	O

31	O
.	O

Nehls	O
GJ	O
,	O
Akland	O
GG	O
.	O

Procedures	O
for	O
handling	O
aerometric	O
data	O
.	O

J	O
Air	O
Pollut	O
Control	O
Assoc	O
23	O
:	O
180	O
<FFFD>	O
184	O
(	O
1973	O
)	O
.	O

32	O
.	O

Hastie	O
T	O
,	O
Tibshirani	O
R	O
.	O
Generalized	O
Additive	O
Models	O
.	O

London	O
:	O
Chapman	O
and	O
Hall	O
,	O
1990	O
.	O

33	O
.	O

Schwartz	O
J	O
.	O
Generalized	O
additive	O
models	O
in	O
epidemiology	O
.	O

In	O
:	O
International	O
Biometric	O
Society	O
,	O
Invited	O
Papers	O
.	O

17th	O
International	O
Biometric	O
Conference	O
,	O
8	O
<FFFD>	O
12	O
August	O
1994	O
,	O
Hamilton	O
,	O
Ontario	O
,	O
Canada	O
.	O

Washington	O
,	O
DC	O
:	O
International	O
Biometric	O
Society	O
,	O
1994	O
;	O
55	O
<FFFD>	O
80	O
.	O

34	O
.	O

Rossi	O
G	O
,	O
Vigotti	O
MA	O
,	O
Zanobetti	O
A	O
,	O
Repetto	O
F	O
,	O
Giannelle	O
V	O
,	O
Schwartz	O
J	O
.	O

Air	O
pollution	O
and	O
cause	O
specific	O
mortality	O
in	O
Milan	O
,	O
Italy	O
,	O
1980	O
<FFFD>	O
1989	O
.	O

Arch	O
Environ	O
Health	O
54	O
:	O
158	O
<FFFD>	O
164	O
(	O
1999	O
)	O
.	O

35	O
.	O

Cleveland	O
WS	O
,	O
Devlin	O
SJ	O
.	O

Robust	O
locally	O
-	O
weighted	O
regression	O
and	O
smoothing	O
scatterplots	O
.	O

J	O
Am	O
Stat	O
Assoc	O
74	O
:	O
829	O
<FFFD>	O
836	O
(	O
1988	O
)	O
.	O

36	O
.	O

Akaike	O
H	O
.	O
Information	O
theory	O
and	O
an	O
extension	O
of	O
the	O
maximum	O
likelihood	O
principal	O
.	O

In	O
:	O
2nd	O
International	O
Symposium	O
on	O
Information	O
Theory	O
(	O
Petrov	O
BN	O
,	O
Csaki	O
F	O
,	O
eds	O
)	O
.	O

Budapest	O
:	O
Akademiai	O
Kaiado	O
,	O
1973	O
;	O
267	O
<FFFD>	O
281	O
.	O

37	O
.	O

Brumback	O
BA	O
,	O
Ryan	O
LM	O
,	O
Schwartz	O
J	O
,	O
Neas	O
LM	O
,	O
Stark	O
PC	O
,	O
Burge	O
HA	O
.	O

Transitional	O
regression	O
models	O
with	O
application	O
to	O
environmental	O
time	O
series	O
.	O

J	O
Acoust	O
Soc	O
Am	O
95	O
(	O
449	O
)	O
:	O
16	O
<FFFD>	O
28	O
(	O
2000	O
)	O
.	O

38	O
.	O

Schwartz	O
J	O
.	O

The	O
distributed	O
lag	O
between	O
air	O
pollution	O
and	O
daily	O
deaths	O
.	O

Epidemiology	O
11	O
:	O
320	O
<FFFD>	O
326	O
(	O
2000	O
)	O
.	O

39	O
.	O

Pope	O
CA	O
III	O
,	O
Verrier	O
RL	O
,	O
Lovett	O
EG	O
,	O
Larson	O
AC	O
,	O
Raizenne	O
ME	O
,	O
Kanner	O
RE	O
,	O
Schwartz	O
J	O
,	O
Villegas	O
GM	O
,	O
Dockery	O
DW	O
.	O

Heart	O
rate	O
variability	O
associated	O
with	O
particulate	O
air	O
pollution	O
.	O

Am	O
Heart	O
J	O
138	O
:	O
890	O
<FFFD>	O
899	O
(	O
1999	O
)	O
.	O

40	O
.	O

Gold	O
DR	O
,	O
Litonjua	O
A	O
,	O
Schwartz	O
J	O
,	O
Lovett	O
E	O
,	O
Larson	O
A	O
,	O
Nearing	O
B	O
,	O
Allen	O
G	O
,	O
Verrier	O
M	O
,	O
Cherry	O
R	O
,	O
Verrier	O
R	O
.	O
Ambient	O
pollution	O
and	O
heart	O
rate	O
variability	O
.	O

Circulation	O
101	O
(	O
11	O
)	O
:	O
1267	O
<FFFD>	O
1273	O
(	O
2000	O
)	O
.	O

41	O
.	O

Liao	O
D	O
,	O
Creason	O
J	O
,	O
Shy	O
C	O
,	O
Williams	O
R	O
,	O
Watts	O
R	O
,	O
Zweidinger	O
R	O
.	O
Daily	O
variation	O
of	O
particulate	O
air	O
pollution	O
and	O
poor	O
cardiac	O
autonomic	O
control	O
in	O
the	O
elderly	O
.	O

Environ	O
Health	O
Perspect	O
107	O
:	O
521	O
<FFFD>	O
525	O
(	O
1999	O
)	O
.	O

42	O
.	O

Peters	O
A	O
,	O
Liu	O
E	O
,	O
Verrier	O
RL	O
,	O
Schwartz	O
J	O
,	O
Gold	O
DR	O
,	O
Mittelman	O
M	O
,	O
Baliff	O
J	O
,	O
Allen	O
G	O
,	O
Monahan	O
K	O
,	O
Dockery	O
DW	O
.	O

Air	O
pollution	O
and	O
incidences	O
of	O
cardiac	O
arrhythmia	O
.	O

Epidemiology	O
11	O
(	O
1	O
)	O
:	O
11	O
<FFFD>	O
17	O
(	O
2000	O
)	O
.	O

43	O
.	O

Godleski	O
JJ	O
,	O
Verrier	O
RL	O
,	O
Koutrakis	O
P	O
,	O
Catalano	O
P	O
.	O
Mechanisms	O
of	O
Morbidity	O
and	O
Mortality	O
from	O
Exposure	O
to	O
Ambient	O
Air	O
Particles	O
.	O

Health	O
Effects	O
Institute	O
Research	O
Report	O
91	O
.	O

Cambridge	O
,	O
MA	O
:	O
Health	O
Effects	O
Institute	O
,	O
2000	O
.	O

44	O
.	O

Watkinson	O
WP	O
,	O
Campen	O
MJ	O
,	O
Kodavanti	O
UP	O
,	O
Ledbetter	O
AD	O
,	O
Costa	O
DL	O
.	O

Effects	O
of	O
inhaled	O
residual	O
oil	O
fly	O
ash	O
particles	O
on	O
electrocardiographic	O
and	O
thermoregulatory	O
parameters	O
in	O
normal	O
and	O
compromised	O
rats	S-Species
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
157	O
:	O
A150	O
(	O
1998	O
)	O
.	O

45	O
.	O

Watkinson	O
WP	O
,	O
Campen	O
MJ	O
,	O
Costa	O
DL	O
.	O

Cardiac	O
arrhythmia	O
induction	O
after	O
exposure	O
to	O
residual	O
oil	O
fly	O
ash	O
particles	O
in	O
a	O
rodent	O
model	O
of	O
pulmonary	O
hypertension	O
.	O

Toxicol	O
Sci	O
41	O
:	O
209	O
<FFFD>	O
216	O
(	O
1998	O
)	O
.	O

46	O
.	O

Kodavanti	O
UP	O
,	O
Jackson	O
MC	O
,	O
Richards	O
J	O
,	O
Ledbetter	O
A	O
,	O
Costa	O
DL	O
.	O

Differential	O
pulmonary	O
responses	O
to	O
inhaled	O
emission	O
particulate	O
matter	O
(	O
PM	O
)	O
in	O
systemically	O
hypertensive	O
vs	O
.	O
normotensive	O
rats	S-Species
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
157	O
:	O
A260	O
(	O
1998	O
)	O
.	O

47	O
.	O

Hoek	O
G	O
,	O
Brunekreef	O
B	O
,	O
van	O
Wijnen	O
JH	O
.	O

Cardiovascular	O
mortality	O
response	O
to	O
air	O
pollution	O
is	O
strongest	O
for	O
heart	O
failure	O
and	O
thrombotic	O
causes	O
of	O
death	O
[	O
Abstract	O
]	O
.	O

Epidemiology	O
10	O
:	O
S177	O
(	O
1999	O
)	O
.	O

48	O
.	O

Bates	O
DV	O
,	O
Szito	O
R	O
.	O
Hospital	O
admissions	O
and	O
air	O
pollutants	O
in	O
southern	O
Ontario	O
:	O
the	O
acid	O
summer	O
haze	O
effect	O
.	O

Environ	O
Res	O
43	O
:	O
317	O
<FFFD>	O
331	O
(	O
1987	O
)	O
.	O

49	O
.	O

Pope	O
CA	O
III	O
.	O

Respiratory	O
disease	O
associated	O
with	O
community	O
air	O
pollution	O
and	O
a	O
steel	O
mill	O
,	O
Utah	O
valley	O
.	O

Am	O
J	O
Public	O
Health	O
79	O
:	O
623	O
<FFFD>	O
628	O
(	O
1989	O
)	O
.	O

50	O
.	O

Zelikoff	O
JT	O
,	O
Nadziejko	O
C	O
,	O
Fang	O
T	O
,	O
Gordon	O
C	O
,	O
Premdass	O
C	O
,	O
Cohen	O
MD	O
.	O

Short	O
term	O
,	O
low	O
-	O
dose	O
inhalation	O
of	O
ambient	O
particulate	O
matter	O
exacerbates	O
ongoing	O
pneumococcal	O
infections	O
in	O
Streptococcus	O
Pneumoniae	O
-	O
infected	O
rates	O
.	O

In	O
:	O
Proceedings	O
of	O
the	O
Third	O
Colloquium	O
on	O
Particulate	O
Air	O
Pollution	O
and	O
Human	S-Species
Health	O
(	O
Phalen	O
RF	O
,	O
Bell	O
YM	O
,	O
eds	O
)	O
.	O

Irvine	O
,	O
CA	O
:	O
Air	O
Pollution	O
Health	O
Effects	O
Laboratory	O
,	O
University	O
of	O
California	O
,	O
1999	O
;	O
8	O
-	O
94	O
<FFFD>	O
8	O
-	O
101	O
.	O

51	O
.	O

Clarke	O
RW	O
,	O
Hemenway	O
DR	O
,	O
Frank	O
R	O
,	O
Kleeberger	O
SR	O
,	O
Longphre	O
MV	O
,	O
Jakab	O
GJ	O
.	O

Particle	O
associated	O
sulfate	O
exposure	O
enhances	O
murine	O
influenza	O
mortality	O
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
155	O
:	O
A245	O
(	O
1997	O
)	O
.	O

52	O
.	O

Pope	O
CA	O
,	O
Dockery	O
DW	O
,	O
Spengler	O
JD	O
,	O
Raizenne	O
ME	O
.	O

Respiratory	O
health	O
and	O
PM10	O
pollution	O
:	O
a	O
daily	O
time	O
series	O
analysis	O
.	O

Am	O
Rev	O
Respir	O
Dis	O
144	O
:	O
668	O
<FFFD>	O
674	O
(	O
1991	O
)	O
.	O

53	O
.	O

Schwartz	O
J	O
,	O
Koenig	O
J	O
,	O
Slater	O
D	O
,	O
Larson	O
T	O
.	O
Particulate	O
air	O
pollution	O
and	O
hospital	O
emergency	O
visits	O
for	O
asthma	O
in	O
Seattle	O
.	O

Am	O
Rev	O
Respir	O
Dis	O
147	O
:	O
826	O
<FFFD>	O
831	O
(	O
1993	O
)	O
.	O

54	O
.	O

Thurston	O
GD	O
,	O
Ito	O
K	O
,	O
Lippman	O
M	O
,	O
Hayes	O
CG	O
,	O
Bates	O
DV	O
.	O

Respiratory	O
hospital	O
admissions	O
and	O
summertime	O
haze	O
air	O
pollution	O
in	O
Toronto	O
,	O
Ontario	O
:	O
consideration	O
of	O
the	O
role	O
of	O
acid	O
aerosols	O
.	O

Environ	O
Res	O
65	O
:	O
271	O
<FFFD>	O
290	O
(	O
1994	O
)	O
.	O

55	O
.	O

Norris	O
G	O
,	O
YoungPong	O
SN	O
,	O
Koenig	O
JQ	O
,	O
Larson	O
TV	O
,	O
Sheppard	O
L	O
,	O
Stout	O
JW	O
.	O

An	O
association	O
between	O
fine	O
particles	O
and	O
asthma	O
emergency	O
department	O
visits	O
for	O
children	S-Species
in	O
Seattle	O
.	O

Environ	O
Health	O
Perspect	O
107	O
:	O
489	O
<FFFD>	O
493	O
(	O
1999	O
)	O
.	O

56	O
.	O

Hamada	O
K	O
,	O
Goldsmith	O
CW	O
,	O
Kobzik	O
L	O
.	O

Air	O
pollutant	O
aerosols	O
allow	O
airway	O
sensitization	O
to	O
allergen	O
in	O
juvenile	O
mice	S-Species
.	O

Am	O
J	O
Resp	O
Crit	O
Care	O
Med	O
A28	O
(	O
1999	O
)	O
.	O

57	O
.	O

Lambert	O
AL	O
,	O
Selgrade	O
M	O
,	O
Dong	O
W	O
,	O
Winsett	O
D	O
,	O
Gilmour	O
M	O
.	O
Enhanced	O
allergic	O
sensitization	O
by	O
residual	O
oil	O
fly	O
ash	O
particles	O
is	O
mediated	O
by	O
soluble	O
metal	O
constituents	O
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
159	O
:	O
A26	O
(	O
1999	O
)	O
.	O

58	O
.	O

Dailey	O
LA	O
,	O
Madden	O
MC	O
,	O
Devlin	O
RB	O
.	O

Do	O
airway	O
epithelial	O
cells	O
from	O
normal	O
and	O
asthmatic	O
donors	O
respond	O
differently	O
to	O
an	O
in	O
vitro	O
challenge	O
with	O
a	O
particulate	O
pollutant	O
?	O

[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
157	O
:	O
A598	O
(	O
1998	O
)	O
.	O

59	O
.	O

Gilmour	O
MI	O
,	O
Winsett	O
D	O
,	O
Selgrade	O
MJ	O
,	O
Costa	O
DL	O
.	O

Residual	O
oil	O
fly	O
ash	O
exposure	O
enhances	O
allergic	O
sensitization	O
to	O
house	O
dust	O
mite	O
in	O
rats	S-Species
and	O
augments	O
immune	O
-	O
mediated	O
inflammation	O
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
155	O
:	O
A244	O
(	O
1997	O
)	O
.	O

60	O
.	O

Zeger	O
SL	O
,	O
Thomas	O
D	O
,	O
Dominici	O
F	O
,	O
Samet	O
JM	O
,	O
Schwartz	O
JM	O
,	O
Dockery	O
D	O
,	O
Cohen	O
A	O
.	O
Exposure	O
measurement	O
error	O
in	O
time	O
<FFFD>	O
series	O
studies	O
of	O
air	O
pollution	O
:	O
concepts	O
and	O
consequences	O
.	O

Environ	O
Health	O
Perspect	O
108	O
:	O
419	O
<FFFD>	O
426	O
(	O
2000	O
)	O
.	O

61	O
.	O

Salvi	O
S	O
,	O
Blomberg	O
A	O
,	O
Rudell	O
B	O
,	O
Kelly	O
F	O
,	O
Sandstrom	O
T	O
,	O
Holgate	O
ST	O
,	O
Frew	O
A	O
.	O
Acute	O
inflammatory	O
responses	O
in	O
the	O
airways	O
and	O
peripheral	O
blood	O
after	O
short	O
-	O
term	O
exposure	O
to	O
diesel	O
exhaust	O
in	O
healthy	O
human	S-Species
volunteers	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
159	O
:	O
702	O
<FFFD>	O
709	O
(	O
1999	O
)	O
.	O

62	O
.	O

Tan	O
WC	O
,	O
van	O
Eeden	O
S	O
,	O
Qiu	O
DW	O
,	O
Liam	O
BL	O
,	O
Dyachokova	O
Y	O
,	O
Hogg	O
JL	O
.	O

Particulate	O
air	O
pollution	O
,	O
bone	O
marrow	O
stimulation	O
and	O
the	O
pathogenesis	O
of	O
excess	O
cardiovascular	O
and	O
pulmonary	O
deaths	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
155	O
:	O
1441	O
<FFFD>	O
1447	O
(	O
1997	O
)	O
.	O

63	O
.	O

Gordon	O
T	O
,	O
Nadziejko	O
C	O
,	O
Schlesinger	O
R	O
,	O
Chen	O
LC	O
.	O

Pulmonary	O
and	O
cardiovascular	O
effects	O
of	O
acute	O
exposure	O
to	O
concentrated	O
ambient	O
particulate	O
matter	O
in	O
rats	S-Species
.	O

Toxicol	O
Lett	O
96	O
<FFFD>	O
97	O
:	O
285	O
<FFFD>	O
288	O
(	O
1998	O
)	O
.	O

64	O
.	O

Peters	O
A	O
,	O
Doering	O
A	O
,	O
Wichmann	O
HE	O
,	O
Koenig	O
W	O
.	O
Increased	O
plasma	O
viscosity	O
during	O
an	O
air	O
pollution	O
episode	O
:	O
a	O
link	O
to	O
mortality	O
?	O

Lancet	O
349	O
(	O
9065	O
)	O
:	O
1582	O
<FFFD>	O
1587	O
(	O
1997	O
)	O
.	O

65	O
.	O

Peters	O
A	O
,	O
Stieberv	O
J	O
,	O
Doering	O
A	O
,	O
Wichmann	O
HE	O
.	O

Is	O
systolic	O
blood	O
pressure	O
associated	O
with	O
air	O
pollution	O
?	O

[	O
Abstract	O
]	O
.	O

Epidemiology	O
10	O
(	O
4	O
)	O
:	O
S177	O
(	O
1999	O
)	O
.	O

Environmental	O
Health	O
Perspectives	O

<FFFD>	O
VOLUME	O
108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O

845	O

Syndrome	O
of	O
arachnomelia	O
in	O
Simmental	O
cattle	S-Species

Abstract	O

Background	O

The	O
syndrome	O
of	O
arachnomelia	O
is	O
an	O
inherited	O
malformation	O
mainly	O
of	O
limbs	O
,	O
back	O
and	O
head	O
in	O
cattle	S-Species
.	O

At	O
present	O
the	O
arachnomelia	O
syndrome	O
has	O
been	O
well	O
known	O
mainly	O
in	O
Brown	O
Swiss	O
cattle	S-Species
.	O

Nevertheless	O
,	O
the	O
arachnomelia	O
syndrome	O
had	O
been	O
observed	O
in	O
the	O
Hessian	O
Simmental	O
population	O
during	O
the	O
decade	O
1964	O
-	O
1974	O
.	O

Recently	O
,	O
stillborn	O
Simmental	O
calves	S-Species
were	O
observed	O
having	O
a	O
morphology	O
similar	O
to	O
the	O
arachnomelia	O
syndrome	O
.	O

The	O
goal	O
of	O
this	O
work	O
was	O
the	O
characterization	O
of	O
the	O
morphology	O
and	O
genealogy	O
of	O
the	O
syndrome	O
in	O
Simmental	O
to	O
establish	O
the	O
basis	O
for	O
an	O
effective	O
management	O
of	O
the	O
disease	O
.	O

Results	O

The	O
first	O
pathologically	O
confirmed	O
arachnomelia	O
syndrome	O
-	O
cases	O
in	O
the	O
current	O
Simmental	O
population	O
appeared	O
in	O
the	O
year	O
2005	O
.	O

By	O
2007	O
,	O
an	O
additional	O
140	O
calves	S-Species
with	O
the	O
arachnomelia	O
syndrome	O
were	O
identified	O
.	O

The	O
major	O
pathological	O
findings	O
were	O
malformed	O
bones	O
affecting	O
the	O
head	O
,	O
long	O
bones	O
of	O
the	O
legs	O
and	O
the	O
vertebral	O
column	O
.	O

It	O
could	O
be	O
shown	O
that	O
,	O
with	O
the	O
exception	O
of	O
two	O
cases	O
that	O
were	O
considered	O
as	O
phenocopies	O
,	O
all	O
of	O
the	O
paternal	O
and	O
about	O
two	O
-	O
third	O
of	O
the	O
maternal	O
pedigrees	O
of	O
the	O
affected	O
calves	S-Species
could	O
be	O
traced	O
back	O
to	O
one	O
common	O
founder	O
.	O

Together	O
with	O
the	O
data	O
from	O
experimental	O
matings	O
,	O
the	O
pedigree	O
data	O
support	O
an	O
autosomal	O
recessive	O
mutation	O
being	O
the	O
etiology	O
of	O
the	O
arachnomelia	O
syndrome	O
.	O

The	O
frequency	O
of	O
the	O
mutation	O
in	O
the	O
current	O
population	O
was	O
estimated	O
to	O
be	O
3	O
.	O
32	O
%	O
.	O

Conclusion	O

We	O
describe	O
the	O
repeated	O
occurrence	O
of	O
the	O
arachnomelia	O
syndrome	O
in	O
Simmental	O
calves	S-Species
.	O

It	O
resembles	O
completely	O
the	O
same	O
defect	O
occurring	O
in	O
the	O
Brown	O
Swiss	O
breed	O
.	O

The	O
mutation	O
became	O
relatively	O
widespread	O
amongst	O
the	O
current	O
population	O
.	O

Therefore	O
,	O
a	O
control	O
system	O
has	O
to	O
be	O
established	O
and	O
it	O
is	O
highly	O
desirable	O
to	O
map	O
the	O
disease	O
and	O
develop	O
a	O
genetic	O
test	O
system	O
.	O

Background	O

In	O
the	O
year	O
2006	O
a	O
syndrome	O
was	O
described	O
in	O
the	O
German	O
and	O
Austrian	O
Simmental	O
(	O
Fleckvieh	O
,	O
as	O
it	O
is	O
locally	O
called	O
,	O
is	O
the	O
main	O
dual	O
-	O
purpose	O
breed	O
in	O
Germany	O
,	O
in	O
short	O
called	O
Simmental	O
in	O
the	O
further	O
text	O
)	O
population	O
,	O
that	O
was	O
pathologically	O
similar	O
to	O
the	O
arachnomelia	O
syndrome	O
in	O
Brown	O
Swiss	O
cattle	S-Species
[	O
1	O
]	O
.	O

The	O
congenital	O
arachnomelia	O
syndrome	O
(	O
AS	O
,	O
OMIA	O
Phene	O
ID	O
139	O
,	O
Group	O
000059	O
)	O
is	O
mainly	O
a	O
malformation	O
of	O
the	O
skeletal	O
system	O
in	O
cattle	S-Species
that	O
was	O
initially	O
described	O
by	O
Rieck	O
and	O
Schade	O
[	O
2	O
]	O
in	O
Holstein	O
Friesian	O
,	O
Red	O
Holstein	O
and	O
Simmental	O
.	O

The	O
main	O
pathological	O
changes	O
are	O
skeletal	O
malformations	O
of	O
the	O
legs	O
,	O
the	O
spinal	O
column	O
and	O
the	O
skull	O
.	O

The	O
legs	O
are	O
thinner	O
and	O
appear	O
longer	O
than	O
normal	O
(	O
dolichostenomelia	O
,	O
arachnomelia	O
)	O
since	O
the	O
diameter	O
of	O
the	O
diaphyses	O
is	O
reduced	O
.	O

These	O
long	O
bones	O
are	O
more	O
fragile	O
and	O
,	O
in	O
combination	O
with	O
stiffened	O
joints	O
,	O
they	O
tend	O
to	O
fracture	O
during	O
calving	O
.	O

The	O
fetlock	O
joints	O
are	O
deformed	O
,	O
often	O
stiffened	O
and	O
show	O
hyperextension	O
.	O

The	O
malformation	O
of	O
the	O
spinal	O
column	O
leads	O
to	O
kyphosis	O
and	O
scoliosis	O
.	O

The	O
skull	O
malformations	O
are	O
characterized	O
by	O
a	O
shortened	O
lower	O
jaw	O
(	O
brachygnathia	O
inferior	O
)	O
,	O
convex	O
rounding	O
of	O
the	O
frontal	O
bone	O
leading	O
to	O
a	O
marked	O
stop	O
(	O
"	O
pointer	O
head	O
"	O
)	O
and	O
rotation	O
of	O
the	O
anterior	O
cranium	O
.	O

In	O
some	O
cases	O
,	O
additional	O
malformations	O
like	O
hydrocephalus	O
externus	O
develop	O
[	O
2	O
-	O
5	O
]	O
.	O

Since	O
the	O
report	O
of	O
Rieck	O
and	O
Schade	O
[	O
2	O
]	O
no	O
further	O
cases	O
were	O
reported	O
in	O
Simmental	O
cattle	S-Species
,	O
but	O
in	O
the	O
1980s	O
the	O
syndrome	O
was	O
dispersed	O
in	O
another	O
breed	O
,	O
the	O
European	O
Brown	O
Swiss	O
cattle	S-Species
,	O
by	O
the	O
use	O
of	O
American	O
Brown	O
Swiss	O
sires	O
[	O
4	O
,	O
6	O
]	O
.	O

In	O
Brown	O
Swiss	O
an	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
was	O
supposed	O
and	O
a	O
control	O
program	O
based	O
on	O
the	O
identification	O
of	O
carriers	O
by	O
pedigree	O
analyses	O
was	O
established	O
[	O
5	O
]	O
.	O

Recently	O
,	O
four	O
cases	O
of	O
arachnomelia	O
syndrome	O
were	O
reported	O
in	O
Italy	O
[	O
3	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
data	O
of	O
152	O
pathologically	O
confirmed	O
cases	O
of	O
arachnomelia	O
syndrome	O
in	O
Simmental	O
that	O
were	O
collected	O
from	O
October	O
2005	O
to	O
March	O
2007	O
.	O

We	O
describe	O
the	O
pathological	O
findings	O
,	O
the	O
familial	O
occurrence	O
and	O
an	O
estimate	O
of	O
the	O
frequency	O
of	O
the	O
diseases	O
allele	O
in	O
Simmental	O
cattle	S-Species
.	O

Additional	O
support	O
for	O
the	O
mode	O
of	O
inheritance	O
and	O
the	O
genetic	O
basis	O
of	O
the	O
arachnomelia	O
syndrome	O
is	O
given	O
by	O
the	O
result	O
of	O
experimental	O
matings	O
of	O
obligate	O
carriers	O
.	O

Results	O
and	O
discussion	O

AS	O
has	O
not	O
been	O
reported	O
again	O
in	O
Simmental	O
since	O
its	O
first	O
description	O
in	O
the	O
1970s	O
,	O
more	O
than	O
thirteen	O
years	O
ago	O
.	O

In	O
autumn	O
2004	O
a	O
number	O
of	O
stillborn	O
calves	S-Species
with	O
similar	O
malformations	O
of	O
the	O
legs	O
and	O
head	O
were	O
recorded	O
within	O
the	O
monitoring	O
system	O
of	O
anomalies	O
in	O
Simmental	O
.	O

Some	O
of	O
these	O
calves	S-Species
were	O
sent	O
to	O
the	O
veterinary	O
service	O
laboratory	O
for	O
examination	O
,	O
and	O
in	O
December	O
2005	O
the	O
first	O
15	O
cases	O
of	O
AS	O
were	O
pathologically	O
confirmed	O
.	O

Subsequently	O
,	O
farmers	O
and	O
veterinarians	O
had	O
been	O
encouraged	O
to	O
report	O
cases	O
by	O
an	O
information	O
leaflet	O
and	O
various	O
articles	O
in	O
local	O
trade	O
journals	O
.	O

An	O
increasing	O
number	O
of	O
suspected	O
cases	O
was	O
reported	O
and	O
an	O
additional	O
136	O
affected	O
calves	S-Species
were	O
identified	O
by	O
pathological	O
examination	O
by	O
June	O
2007	O
.	O

Familial	O
occurrence	O
and	O
case	O
presentation	O
of	O
the	O
syndrome	O
of	O
arachnomelia	O

The	O
geographical	O
origins	O
of	O
the	O
cases	O
were	O
the	O
southern	O
part	O
of	O
Germany	O
and	O
Austria	O
,	O
reflecting	O
the	O
regional	O
distribution	O
of	O
the	O
Simmental	O
breed	O
.	O

Both	O
sexes	O
were	O
equally	O
represented	O
in	O
the	O
152	O
(	O
80	O
male	O
,	O
72	O
female	O
,	O
chi	O
2	O
=	O
0	O
.	O
21	O
,	O
p	O
=	O
0	O
.	O
64	O
)	O
affected	O
calves	S-Species
.	O

The	O
largest	O
number	O
of	O
cases	O
was	O
registered	O
in	O
2006	O
(	O
Figure	O
1	O
)	O
.	O

In	O
retrospect	O
,	O
it	O
could	O
be	O
shown	O
that	O
the	O
main	O
reason	O
for	O
the	O
rapid	O
increase	O
of	O
cases	O
in	O
the	O
years	O
2005	O
and	O
2006	O
was	O
the	O
high	O
popularity	O
of	O
certain	O
sires	O
carrying	O
the	O
AS	O
mutation	O
(	O
ROMEL	O
,	O
ISO	O
-	O
Nr	O
.	O
276000911043667	O
,	O
born	O
in	O
1995	O
;	O
EGEL	O
,	O
276000915512806	O
,	O
1985	O
;	O
REXON	O
,	O
276000913008210	O
,	O
1989	O
)	O
.	O

The	O
latter	O
two	O
sires	O
represent	O
the	O
key	O
-	O
nodes	O
of	O
the	O
pedigree	O
pathways	O
of	O
the	O
mutation	O
from	O
the	O
founder	O
into	O
the	O
current	O
population	O
(	O
Figure	O
2	O
)	O
.	O

ROMEL	O
,	O
for	O
example	O
,	O
sired	O
more	O
than	O
40	O
,	O
000	O
cows	S-Species
4	O
to	O
6	O
years	O
ago	O
.	O

Furthermore	O
,	O
115	O
sons	O
of	O
ROMEL	O
born	O
from	O
2001	O
to	O
2005	O
are	O
registered	O
and	O
listed	O
in	O
the	O
breeding	O
database	O
[	O
7	O
]	O
.	O

These	O
progeny	O
were	O
now	O
mated	O
to	O
ROMEL	O
and	O
sons	O
or	O
grandsons	O
of	O
EGEL	O
and	O
REXON	O
resulting	O
in	O
a	O
high	O
probability	O
for	O
the	O
occurrence	O
of	O
affected	O
calves	S-Species
.	O

Increasing	O
awareness	O
of	O
the	O
disease	O
and	O
abandoning	O
of	O
selling	O
the	O
semen	O
from	O
carriers	O
led	O
to	O
a	O
sharp	O
drop	O
of	O
cases	O
in	O
2007	O
.	O

The	O
disease	O
was	O
successfully	O
managed	O
by	O
efficient	O
collaboration	O
of	O
the	O
Institute	O
for	O
Animal	O
Breeding	O
of	O
the	O
Bavarian	O
State	O
Research	O
Centre	O
for	O
Agriculture	O
(	O
LfL	O
)	O
,	O
the	O
Landeskuratorium	O
der	O
Erzeugerringe	O
f	O
u	O
r	O
tierische	O
Veredelung	O
in	O
Bayern	O
e	O
.	O
V	O
(	O
LKV	O
)	O
,	O
the	O
Bavarian	O
Animal	O
Health	O
Service	O
(	O
TGD	O
)	O
and	O
breeding	O
organizations	O
.	O

Pathological	O
findings	O

Calves	S-Species
under	O
suspicion	O
of	O
the	O
arachnomelia	O
syndrome	O
were	O
sent	O
to	O
the	O
pathology	O
department	O
of	O
the	O
TGD	O
for	O
macroscopic	O
examination	O
.	O

The	O
observed	O
major	O
pathological	O
findings	O
were	O
(	O
1	O
)	O
facial	O
deformation	O
,	O
including	O
brachygnathia	O
inferior	O
and	O
concave	O
rounding	O
of	O
the	O
maxilla	O
forming	O
a	O
dent	O
(	O
'	O
pointer	O
-	O
head	O
'	O
)	O
;	O
(	O
2	O
)	O
abnormally	O
thin	O
diaphyses	O
of	O
the	O
long	O
bones	O
(	O
the	O
outer	O
diameter	O
of	O
the	O
diaphyses	O
is	O
diminished	O
,	O
whereas	O
the	O
width	O
of	O
the	O
substantia	O
compacta	O
is	O
normal	O
)	O
leading	O
to	O
frequent	O
fractures	O
of	O
the	O
metacarpus	O
and	O
metatarsus	O
in	O
the	O
course	O
of	O
forced	O
birth	O
assistance	O
(	O
'	O
spider	O
-	O
legs	O
'	O
,	O
dolichostenomelia	O
)	O
.	O

The	O
deformations	O
of	O
other	O
bones	O
of	O
the	O
legs	O
were	O
less	O
apparent	O
and	O
the	O
scapula	O
was	O
usually	O
unaffected	O
;	O
(	O
3	O
)	O
angular	O
deformations	O
of	O
the	O
distal	O
parts	O
of	O
the	O
legs	O
characterized	O
by	O
bilateral	O
stiff	O
and	O
hyperextended	O
fetlocks	O
with	O
the	O
extremity	O
of	O
the	O
toe	O
forward	O
and	O
parallel	O
to	O
the	O
trunk	O
of	O
the	O
body	O
;	O
and	O
(	O
4	O
)	O
defects	O
of	O
the	O
vertebral	O
column	O
(	O
kyphosis	O
and	O
scoliosis	O
)	O
,	O
but	O
not	O
of	O
the	O
ribs	O
(	O
Figure	O
3A	O
-	O
C	O
)	O
.	O

Additionally	O
,	O
inconsistent	O
pathological	O
findings	O
included	O
cerebral	O
herniation	O
combined	O
with	O
a	O
malformed	O
foramen	O
magnum	O
,	O
microphthalmia	O
,	O
and	O
external	O
and	O
internal	O
hydrocephalus	O
.	O

The	O
latter	O
seem	O
to	O
develop	O
secondarily	O
,	O
due	O
to	O
the	O
enlarged	O
foramen	O
magnum	O
.	O

Histological	O
examination	O
of	O
selected	O
cases	O
revealed	O
the	O
presence	O
of	O
hemorrhages	O
at	O
the	O
osteochondral	O
junction	O
of	O
the	O
epiphysis	O
and	O
an	O
abrupt	O
transmission	O
from	O
chondral	O
to	O
osteogenic	O
tissue	O
.	O

Cases	O
never	O
showed	O
isolated	O
malformations	O
,	O
e	O
.	O
g	O
.	O
of	O
the	O
head	O
or	O
legs	O
,	O
but	O
usually	O
a	O
combination	O
of	O
all	O
pathological	O
findings	O
that	O
are	O
characteristic	O
for	O
the	O
syndrome	O
.	O

Nevertheless	O
,	O
the	O
degree	O
of	O
the	O
lesions	O
ranged	O
from	O
obvious	O
spider	O
-	O
leg	O
cases	O
to	O
moderate	O
or	O
mild	O
changes	O
,	O
making	O
a	O
definite	O
diagnosis	O
difficult	O
.	O

The	O
latter	O
cases	O
(	O
3	O
)	O
were	O
excluded	O
from	O
the	O
initial	O
pedigree	O
analyses	O
.	O

Meanwhile	O
,	O
an	O
indirect	O
gene	O
test	O
is	O
available	O
that	O
has	O
been	O
developed	O
at	O
the	O
Institute	O
for	O
Animal	O
Breeding	O
of	O
the	O
Bavarian	O
State	O
Research	O
Centre	O
for	O
Agriculture	O
(	O
ITZ	O
)	O
and	O
it	O
could	O
be	O
shown	O
that	O
these	O
cases	O
are	O
most	O
probably	O
not	O
genetically	O
affected	O
(	O
Buitkamp	O
et	O
al	O
.	O
,	O
in	O
preparation	O
)	O
.	O

Carrier	O
identification	O

Two	O
criteria	O
were	O
used	O
for	O
carrier	O
identification	O
.	O

The	O
first	O
was	O
the	O
presence	O
of	O
a	O
calf	S-Species
that	O
was	O
diagnosed	O
by	O
pathological	O
investigation	O
.	O

In	O
many	O
cases	O
more	O
than	O
one	O
affected	O
calf	S-Species
per	O
sire	O
was	O
identified	O
[	O
8	O
]	O
.	O

Some	O
sires	O
had	O
only	O
one	O
affected	O
calf	S-Species
,	O
but	O
a	O
large	O
number	O
of	O
risk	O
-	O
matings	O
.	O

In	O
these	O
cases	O
a	O
second	O
criterion	O
,	O
the	O
statistical	O
evaluation	O
of	O
risk	O
-	O
matings	O
,	O
was	O
used	O
to	O
identify	O
potential	O
phenocopies	O
.	O

For	O
this	O
purpose	O
,	O
the	O
probability	O
of	O
observing	O
only	O
a	O
single	O
affected	O
calf	S-Species
among	O
a	O
certain	O
number	O
of	O
risk	O
-	O
matings	O
of	O
the	O
sire	O
in	O
question	O
was	O
calculated	O
.	O

Risk	O
-	O
matings	O
were	O
defined	O
as	O
matings	O
with	O
direct	O
progenies	O
of	O
identified	O
AS	O
carriers	O
.	O

The	O
probability	O
of	O
observing	O
an	O
affected	O
calf	S-Species
depends	O
also	O
on	O
the	O
probability	O
that	O
such	O
a	O
calf	S-Species
is	O
reported	O
to	O
the	O
LKV	O
.	O

We	O
assumed	O
this	O
probability	O
to	O
be	O
50	O
%	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
probability	O
of	O
observing	O
only	O
one	O
affected	O
calf	S-Species
is	O
lower	O
than	O
1	O
.	O
0	O
percent	O
,	O
if	O
at	O
least	O
104	O
risk	O
-	O
matings	O
are	O
given	O
for	O
a	O
single	O
sire	O
.	O

In	O
this	O
case	O
it	O
is	O
very	O
likely	O
that	O
the	O
single	O
affected	O
calf	S-Species
is	O
a	O
phenocopy	O
.	O

In	O
2006	O
and	O
2007	O
this	O
was	O
the	O
case	O
for	O
two	O
sires	O
used	O
for	O
artificial	O
insemination	O
that	O
had	O
no	O
pedigree	O
connection	O
to	O
SEMPER	O
(	O
see	O
below	O
)	O
.	O

Experimental	O
matings	O
of	O
obligate	O
carriers	O

Four	O
out	O
of	O
seven	O
cows	S-Species
that	O
were	O
known	O
AS	O
carriers	O
brought	O
to	O
the	O
facilities	O
of	O
the	O
ITZ	O
were	O
used	O
for	O
embryo	O
transfer	O
(	O
Table	O
1	O
)	O
.	O

33	O
of	O
the	O
60	O
recipients	O
(	O
55	O
%	O
)	O
were	O
confirmed	O
pregnant	O
on	O
day	O
35	O
.	O

Four	O
of	O
the	O
33	O
pregnant	O
heifers	O
(	O
12	O
%	O
)	O
aborted	O
between	O
days	O
36	O
and	O
49	O
of	O
pregnancy	O
.	O

Of	O
the	O
remaining	O
29	O
recipients	O
,	O
6	O
were	O
slaughtered	O
on	O
day	O
150	O
,	O
6	O
on	O
day	O
200	O
,	O
and	O
17	O
animals	O
on	O
day	O
225	O
of	O
pregnancy	O
(	O
Table	O
1	O
)	O
.	O

Four	O
fetuses	O
(	O
three	O
male	O
and	O
one	O
female	O
)	O
out	O
of	O
29	O
(	O
14	O
%	O
)	O
showed	O
the	O
typical	O
pathological	O
changes	O
of	O
the	O
arachnomelia	O
syndrome	O
as	O
described	O
above	O
(	O
Figure	O
4C	O
,	O
D	O
)	O
.	O

All	O
other	O
fetuses	O
showed	O
no	O
signs	O
of	O
AS	O
(	O
Figure	O
4A	O
,	O
B	O
)	O
.	O

Male	O
fetuses	O
represented	O
76	O
%	O
(	O
22	O
of	O
29	O
)	O
of	O
pregnancies	O
(	O
chi	O
2	O
=	O
3	O
.	O
123	O
,	O
p	O
=	O
0	O
.	O
077	O
,	O
Yates	O
corrected	O
for	O
sample	O
size	O
<	O
30	O
)	O
.	O

Female	O
weight	O
(	O
Table	O
2	O
)	O
,	O
crown	O
-	O
rump	O
length	O
at	O
day	O
225	O
and	O
chest	O
circumference	O
at	O
day	O
225	O
of	O
normal	O
fetuses	O
were	O
lower	O
than	O
that	O
of	O
male	O
fetuses	O
.	O

Fetuses	O
that	O
were	O
affected	O
by	O
the	O
arachnomelia	O
syndrome	O
showed	O
lower	O
weight	O
than	O
normal	O
fetuses	O
.	O

The	O
affected	O
and	O
the	O
normal	O
fetuses	O
had	O
similar	O
crown	O
-	O
rump	O
length	O
,	O
but	O
the	O
chest	O
circumference	O
of	O
affected	O
fetuses	O
was	O
higher	O
than	O
that	O
of	O
normal	O
fetuses	O
(	O
Table	O
2	O
)	O
.	O

Due	O
to	O
the	O
small	O
number	O
of	O
affected	O
female	O
fetuses	O
,	O
a	O
comparison	O
with	O
unaffected	O
animals	O
for	O
sex	O
was	O
not	O
possible	O
.	O

To	O
compare	O
unaffected	O
and	O
affected	O
animals	O
in	O
total	O
,	O
the	O
data	O
were	O
analyzed	O
for	O
statistical	O
differences	O
by	O
the	O
non	O
parametric	O
Mann	O
-	O
Whitney	O
-	O
Test	O
.	O

The	O
only	O
trait	O
that	O
was	O
significantly	O
different	O
between	O
unaffected	O
and	O
affected	O
fetuses	O
was	O
the	O
chest	O
circumference	O
(	O
p	O
=	O
0	O
.	O
004	O
,	O
Table	O
2	O
)	O
.	O

The	O
body	O
weight	O
of	O
AS	O
affected	O
calves	S-Species
was	O
tendentially	O
lower	O
than	O
that	O
of	O
normal	O
calves	S-Species
.	O

Since	O
affected	O
calves	S-Species
did	O
not	O
have	O
different	O
crown	O
-	O
rump	O
-	O
length	O
and	O
their	O
chest	O
circumference	O
was	O
even	O
higher	O
,	O
this	O
can	O
best	O
be	O
explained	O
by	O
a	O
reduced	O
bone	O
mass	O
.	O

Pedigree	O
Analysis	O
and	O
mode	O
of	O
inheritance	O

Eight	O
-	O
generation	O
pedigrees	O
of	O
all	O
cases	O
were	O
extracted	O
from	O
the	O
joint	O
German	O
and	O
Austria	O
pedigree	O
data	O
and	O
screened	O
for	O
common	O
ancestors	O
.	O

The	O
pedigree	O
of	O
the	O
majority	O
of	O
affected	O
calves	S-Species
(	O
paternal	O
line	O
150	O
,	O
maternal	O
line	O
106	O
out	O
of	O
152	O
,	O
Table	O
3	O
)	O
could	O
be	O
traced	O
back	O
to	O
one	O
founder	O
,	O
SEMPER	O
(	O
ISO	O
-	O
Nr	O
.	O
27000979299305	O
)	O
,	O
a	O
sire	O
born	O
in	O
1964	O
,	O
6	O
-	O
9	O
generations	O
before	O
the	O
affected	O
calves	S-Species
were	O
born	O
(	O
Figure	O
2	O
)	O
.	O

Most	O
of	O
the	O
affected	O
calves	S-Species
inherited	O
the	O
AS	O
mutation	O
via	O
REXON	O
or	O
EGEL	O
(	O
Table	O
3	O
,	O
Figure	O
2	O
)	O
.	O

In	O
44	O
cases	O
the	O
maternal	O
paths	O
were	O
not	O
linked	O
to	O
the	O
common	O
pedigree	O
(	O
Table	O
3	O
)	O
.	O

One	O
explanation	O
would	O
be	O
the	O
existence	O
of	O
additional	O
,	O
hereto	O
unknown	O
origins	O
of	O
the	O
mutation	O
.	O

This	O
could	O
happen	O
if	O
the	O
AS	O
mutation	O
is	O
much	O
more	O
ancient	O
and	O
additional	O
pedigree	O
paths	O
exist	O
or	O
if	O
an	O
independent	O
mutation	O
event	O
happened	O
leading	O
to	O
the	O
same	O
phenotype	O
.	O

An	O
alternative	O
,	O
more	O
plausible	O
explanation	O
could	O
be	O
the	O
occurrence	O
of	O
misparentages	O
.	O

It	O
is	O
well	O
known	O
that	O
in	O
the	O
pre	O
parentage	O
-	O
test	O
era	O
,	O
the	O
frequency	O
of	O
false	O
paternity	O
,	O
especially	O
of	O
the	O
cows	S-Species
,	O
was	O
reasonable	O
high	O
(	O
up	O
to	O
23	O
%	O
[	O
9	O
]	O
)	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
good	O
chance	O
of	O
a	O
false	O
registry	O
within	O
6	O
-	O
9	O
generations	O
.	O

There	O
is	O
strong	O
support	O
for	O
the	O
assumption	O
that	O
the	O
AS	O
is	O
regulated	O
by	O
a	O
single	O
autosomal	O
locus	O
acting	O
in	O
a	O
recessive	O
manner	O
.	O

First	O
of	O
all	O
,	O
the	O
pedigree	O
structure	O
of	O
the	O
affected	O
calves	S-Species
in	O
Simmental	O
can	O
best	O
be	O
explained	O
by	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O

The	O
paternal	O
branch	O
of	O
the	O
pedigree	O
could	O
be	O
traced	O
back	O
to	O
one	O
sire	O
,	O
SEMPER	O
,	O
for	O
all	O
affected	O
calves	S-Species
,	O
the	O
maternal	O
branch	O
in	O
the	O
majority	O
of	O
the	O
cases	O
.	O

Inbreeding	O
loops	O
over	O
a	O
few	O
generations	O
are	O
present	O
in	O
several	O
pedigrees	O
of	O
affected	O
calves	S-Species
,	O
e	O
.	O
g	O
.	O
cases	O
P3364	O
and	O
P1787	O
(	O
Figure	O
2	O
)	O
.	O

Sex	O
-	O
dependent	O
inheritance	O
can	O
obviously	O
be	O
excluded	O
and	O
a	O
dominant	O
mode	O
with	O
reduced	O
penetrance	O
seems	O
to	O
be	O
unlikely	O
.	O

Secondly	O
,	O
the	O
experimental	O
matings	O
resulted	O
in	O
4	O
affected	O
and	O
25	O
unaffected	O
fetuses	O
,	O
a	O
result	O
that	O
most	O
closely	O
resembles	O
the	O
expectation	O
of	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O

Thirdly	O
,	O
the	O
occurrence	O
of	O
cases	O
corresponded	O
well	O
with	O
the	O
numbers	O
expected	O
under	O
the	O
assumption	O
of	O
a	O
recessively	O
acting	O
mutation	O
.	O

We	O
tested	O
this	O
on	O
the	O
progeny	O
of	O
ROMEL	O
,	O
the	O
largest	O
dataset	O
available	O
from	O
one	O
carrier	O
.	O

We	O
analyzed	O
the	O
period	O
from	O
the	O
beginning	O
of	O
the	O
recording	O
system	O
for	O
malformations	O
to	O
May	O
2007	O
.	O

In	O
that	O
period	O
44	O
,	O
170	O
calves	S-Species
were	O
born	O
that	O
were	O
sired	O
by	O
ROMEL	O
.	O

From	O
these	O
,	O
662	O
were	O
considered	O
as	O
risk	O
pairings	O
,	O
i	O
.	O
e	O
.	O
the	O
mother	O
had	O
a	O
risk	O
of	O
0	O
.	O
5	O
to	O
be	O
a	O
carrier	O
(	O
i	O
.	O
e	O
.	O
one	O
of	O
the	O
grandparents	O
was	O
an	O
obligate	O
carrier	O
)	O
and	O
35	O
calves	S-Species
out	O
of	O
these	O
were	O
diagnosed	O
as	O
affected	O
.	O

Since	O
it	O
is	O
expected	O
that	O
about	O
1	O
/	O
2	O
to	O
1	O
/	O
3	O
of	O
the	O
affected	O
calves	S-Species
were	O
recorded	O
,	O
this	O
result	O
is	O
very	O
close	O
to	O
the	O
expected	O
1	O
:	O
7	O
ratio	O
of	O
affected	O
to	O
unaffected	O
calves	S-Species
.	O

Moreover	O
,	O
these	O
findings	O
are	O
concordant	O
with	O
the	O
historical	O
description	O
of	O
the	O
arachnomelia	O
syndrome	O
in	O
Simmental	O
[	O
2	O
]	O
and	O
the	O
analyses	O
of	O
cases	O
in	O
Brown	O
Swiss	O
[	O
5	O
]	O
.	O

Finally	O
,	O
when	O
applying	O
linkage	O
analyses	O
using	O
microsatellite	O
markers	O
,	O
evaluations	O
with	O
a	O
model	O
assuming	O
recessive	O
autosomal	O
inheritance	O
gave	O
the	O
highest	O
lod	O
scores	O
(	O
Buitkamp	O
et	O
al	O
.	O
,	O
in	O
preparation	O
)	O
.	O

Allelic	O
frequency	O
of	O
carriers	O
in	O
the	O
present	O
Simmental	O
cow	S-Species
population	O

Since	O
the	O
arachnomelia	O
syndrome	O
-	O
allele	O
was	O
passed	O
to	O
the	O
current	O
population	O
through	O
two	O
parental	O
lines	O
(	O
REXON	O
and	O
EGEL	O
)	O
and	O
the	O
main	O
carriers	O
are	O
known	O
,	O
it	O
is	O
possible	O
to	O
estimate	O
the	O
frequency	O
of	O
the	O
disease	O
allele	O
by	O
an	O
allele	O
-	O
counting	O
method	O
[	O
10	O
]	O
.	O

The	O
allelic	O
frequency	O
was	O
calculated	O
for	O
all	O
cows	S-Species
from	O
the	O
breeding	O
population	O
who	O
were	O
alive	O
in	O
June	O
2007	O
.	O

In	O
10	O
.	O
4	O
percent	O
of	O
the	O
pedigrees	O
of	O
540	O
,	O
725	O
cows	S-Species
an	O
identified	O
carrier	O
was	O
found	O
and	O
the	O
probability	O
that	O
individual	O
cows	S-Species
were	O
carrier	O
of	O
the	O
arachnomelia	O
syndrome	O
-	O
allele	O
was	O
calculated	O
.	O

E	O
.	O
g	O
.	O
in	O
14	O
,	O
740	O
and	O
41	O
,	O
032	O
cases	O
a	O
known	O
carrier	O
appeared	O
as	O
sire	O
and	O
grandsire	O
,	O
respectively	O
.	O

In	O
these	O
cases	O
the	O
probability	O
of	O
transmitting	O
the	O
allele	O
is	O
50	O
and	O
25	O
percent	O
,	O
respectively	O
,	O
if	O
no	O
further	O
carrier	O
is	O
present	O
in	O
the	O
two	O
generation	O
pedigree	O
.	O

The	O
averaged	O
rate	O
of	O
the	O
arachnomelia	O
syndrome	O
carriers	O
based	O
on	O
known	O
carriers	O
over	O
all	O
cows	S-Species
alive	O
in	O
Bavarian	O
Simmental	O
was	O
3	O
.	O
32	O
percent	O
.	O

Using	O
this	O
approach	O
,	O
the	O
frequency	O
of	O
carriers	O
was	O
calculated	O
for	O
each	O
year	O
(	O
always	O
based	O
on	O
the	O
actual	O
datasets	O
from	O
August	O
2008	O
)	O
from	O
2003	O
to	O
2008	O
(	O
Figure	O
1	O
)	O
.	O

The	O
calculations	O
were	O
done	O
twice	O
,	O
considering	O
all	O
known	O
carriers	O
together	O
,	O
and	O
also	O
by	O
using	O
only	O
ROMEL	O
as	O
a	O
carrier	O
to	O
show	O
the	O
numeric	O
contribution	O
of	O
his	O
progeny	O
(	O
Figure	O
1	O
)	O
.	O

For	O
these	O
analyses	O
,	O
the	O
sires	O
that	O
are	O
designated	O
to	O
be	O
non	O
-	O
carriers	O
by	O
the	O
number	O
of	O
risk	O
pairings	O
without	O
having	O
a	O
case	O
or	O
the	O
indirect	O
gene	O
test	O
are	O
set	O
as	O
non	O
-	O
carrier	O
.	O

Therefore	O
,	O
these	O
frequencies	O
are	O
slightly	O
lower	O
than	O
the	O
initial	O
frequency	O
estimate	O
of	O
3	O
.	O
32	O
percent	O
.	O

Conclusion	O

The	O
cases	O
of	O
malformed	O
Simmental	O
calves	S-Species
presented	O
here	O
showed	O
the	O
same	O
morphology	O
described	O
in	O
the	O
arachnomelia	O
syndrome	O
in	O
Brown	O
Swiss	O
[	O
e	O
.	O
g	O
.	O
[	O
3	O
]	O
]	O
,	O
even	O
though	O
there	O
is	O
a	O
certain	O
morphological	O
variation	O
from	O
mild	O
to	O
severe	O
malformations	O
.	O

The	O
main	O
findings	O
,	O
brachygnathia	O
inferior	O
and	O
convex	O
frontal	O
bone	O
of	O
the	O
face	O
,	O
deformation	O
of	O
vertebrae	O
,	O
and	O
dysplasia	O
of	O
the	O
limbs	O
,	O
namely	O
the	O
diaphyses	O
of	O
metatarsus	O
and	O
-	O
carpus	O
and	O
the	O
fetlocks	O
,	O
can	O
best	O
be	O
explained	O
by	O
irregularly	O
developed	O
bone	O
structure	O
at	O
the	O
corresponding	O
locations	O
.	O

Without	O
pathological	O
examination	O
it	O
is	O
difficult	O
to	O
distinguish	O
the	O
arachnomelia	O
syndrome	O
from	O
other	O
malformations	O
of	O
the	O
limbs	O
.	O

Therefore	O
,	O
low	O
numbers	O
of	O
cases	O
in	O
Simmental	O
probably	O
passed	O
unrecognized	O
before	O
2005	O
.	O

In	O
that	O
year	O
the	O
allelic	O
frequency	O
of	O
the	O
disease	O
in	O
the	O
cow	S-Species
population	O
increased	O
sharply	O
because	O
some	O
sires	O
that	O
had	O
been	O
carriers	O
of	O
the	O
mutation	O
had	O
become	O
very	O
popular	O
2	O
-	O
4	O
years	O
before	O
.	O

The	O
identification	O
of	O
a	O
common	O
ancestor	O
,	O
the	O
results	O
from	O
the	O
experimental	O
matings	O
and	O
the	O
analyses	O
of	O
numbers	O
of	O
cases	O
from	O
risk	O
matings	O
strongly	O
support	O
the	O
hypothesis	O
of	O
an	O
autosomal	O
recessively	O
inherited	O
disease	O
.	O

Furthermore	O
,	O
this	O
assumption	O
is	O
concordant	O
with	O
the	O
historical	O
description	O
of	O
the	O
syndrome	O
in	O
Simmental	O
and	O
Brown	O
Swiss	O
.	O

The	O
allelic	O
frequency	O
of	O
the	O
arachnomelia	O
syndrome	O
in	O
the	O
current	O
population	O
is	O
well	O
above	O
3	O
percent	O
and	O
a	O
substantial	O
number	O
of	O
progeny	O
from	O
known	O
carriers	O
with	O
superior	O
genetic	O
merit	O
shall	O
be	O
used	O
as	O
sires	O
during	O
the	O
next	O
years	O
.	O

Therefore	O
,	O
a	O
control	O
system	O
has	O
to	O
be	O
established	O
and	O
the	O
arachnomelia	O
syndrome	O
-	O
gene	O
should	O
be	O
mapped	O
as	O
a	O
prerequisite	O
for	O
the	O
development	O
of	O
an	O
indirect	O
gene	O
test	O
for	O
carrier	O
identification	O
.	O

The	O
availability	O
of	O
pathologically	O
well	O
characterized	O
cases	O
from	O
the	O
field	O
and	O
from	O
the	O
ET	O
-	O
generated	O
full	O
-	O
sib	O
families	O
will	O
be	O
an	O
excellent	O
material	O
for	O
a	O
genetic	O
mapping	O
procedure	O
.	O

Methods	O

Recording	O
system	O
for	O
congenital	O
malformations	O

A	O
system	O
for	O
monitoring	O
inherited	O
congenital	O
malformations	O
in	O
Bavarian	O
cattle	S-Species
populations	O
was	O
established	O
by	O
the	O
Institute	O
for	O
Animal	O
Breeding	O
of	O
the	O
Bavarian	O
State	O
Research	O
Centre	O
for	O
Agriculture	O
(	O
ITZ	O
)	O
in	O
cooperation	O
with	O
the	O
Bavarian	O
milk	O
recording	O
organization	O
(	O
LKV	O
)	O
[	O
11	O
]	O
.	O

In	O
short	O
,	O
a	O
questionnaire	O
was	O
developed	O
for	O
detailed	O
recording	O
of	O
malformed	O
calves	S-Species
.	O

The	O
malformation	O
was	O
described	O
according	O
to	O
its	O
location	O
(	O
e	O
.	O
g	O
.	O
head	O
,	O
legs	O
)	O
and	O
its	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
hernia	O
)	O
.	O

The	O
standardized	O
data	O
were	O
stored	O
in	O
a	O
database	O
at	O
the	O
LKV	O
,	O
that	O
is	O
evaluated	O
monthly	O
for	O
a	O
potential	O
genetic	O
background	O
of	O
malformations	O
.	O

Sires	O
that	O
fit	O
into	O
the	O
pedigree	O
(	O
progeny	O
of	O
REXON	O
or	O
EGEL	O
)	O
with	O
at	O
least	O
one	O
affected	O
calf	S-Species
with	O
confirmed	O
paternity	O
were	O
defined	O
as	O
obligate	O
carriers	O
and	O
marked	O
in	O
the	O
breeding	O
information	O
system	O
[	O
7	O
]	O
.	O

In	O
cases	O
without	O
connection	O
to	O
the	O
pedigree	O
and	O
only	O
one	O
recorded	O
calf	S-Species
the	O
number	O
of	O
"	O
risk	O
pairings	O
"	O
(	O
matings	O
to	O
cows	S-Species
where	O
at	O
least	O
one	O
parent	O
is	O
a	O
known	O
carrier	O
,	O
enabling	O
the	O
calculation	O
of	O
the	O
probability	O
for	O
the	O
occurrence	O
of	O
cases	O
)	O
was	O
calculated	O
.	O

When	O
the	O
probability	O
that	O
a	O
case	O
occurs	O
was	O
above	O
99	O
%	O
for	O
the	O
sire	O
in	O
question	O
the	O
case	O
was	O
considered	O
to	O
be	O
a	O
phenocopy	O
.	O

The	O
number	O
of	O
calves	S-Species
affected	O
by	O
the	O
arachnomelia	O
syndrome	O
and	O
their	O
parentage	O
is	O
routinely	O
published	O
[	O
8	O
]	O
.	O

Pathological	O
examinations	O

Pathological	O
examinations	O
followed	O
standard	O
procedures	O
.	O

Calves	S-Species
were	O
photographed	O
and	O
size	O
and	O
weight	O
measurements	O
were	O
recorded	O
.	O

Tissue	O
specimens	O
from	O
the	O
condyle	O
(	O
epiphysis	O
)	O
and	O
from	O
the	O
diaphysis	O
of	O
the	O
femur	O
were	O
collected	O
for	O
histological	O
examination	O
.	O

Specimens	O
were	O
fixed	O
in	O
10	O
%	O
formalin	O
and	O
kept	O
in	O
a	O
decalcifying	O
solution	O
(	O
Ossafixonafor	O
)	O
for	O
24	O
hours	O
.	O

Thereafter	O
,	O
specimens	O
were	O
processed	O
in	O
an	O
automated	O
embedding	O
system	O
,	O
sectioned	O
at	O
4	O
-	O
6	O
microns	O
and	O
finally	O
stained	O
with	O
haematoxyline	O
and	O
eosin	O
.	O

Experimental	O
matings	O
and	O
embryo	O
transfer	O

Known	O
carriers	O
of	O
the	O
arachnomelia	O
syndrome	O
(	O
seven	O
cows	S-Species
that	O
had	O
produced	O
at	O
least	O
one	O
affected	O
calf	S-Species
)	O
were	O
brought	O
to	O
the	O
facilities	O
of	O
the	O
ITZ	O
for	O
embryo	O
transfer	O
(	O
Table	O
1	O
)	O
.	O

Late	O
morulae	O
and	O
blastocysts	O
collected	O
on	O
day	O
7	O
(	O
day	O
0	O
=	O
estrus	O
)	O
from	O
superovulated	O
donor	O
cows	S-Species
were	O
nonsurgically	O
transferred	O
to	O
heifers	O
[	O
12	O
]	O
.	O

Mode	O
of	O
inheritance	O
and	O
allele	O
frequency	O

The	O
pedigree	O
of	O
all	O
cases	O
was	O
constructed	O
from	O
the	O
pedigree	O
that	O
is	O
used	O
for	O
the	O
joint	O
breeding	O
evaluation	O
of	O
Germany	O
and	O
Austria	O
.	O

The	O
graphical	O
presentation	O
of	O
the	O
pedigree	O
was	O
performed	O
with	O
the	O
Pedigraph	O
TM	O
software	O
[	O
13	O
]	O
.	O

The	O
allelic	O
frequency	O
of	O
the	O
AS	O
mutation	O
in	O
the	O
current	O
cow	S-Species
population	O
was	O
estimated	O
from	O
ancestors	O
with	O
known	O
genotypes	O
following	O
the	O
allele	O
-	O
counting	O
method	O
[	O
10	O
]	O
.	O

For	O
this	O
reason	O
two	O
generation	O
pedigrees	O
of	O
herd	O
book	O
cows	S-Species
in	O
Bavarian	O
Simmental	O
were	O
analyzed	O
for	O
obligate	O
carriers	O
.	O

We	O
considered	O
all	O
cows	S-Species
that	O
were	O
alive	O
in	O
June	O
2007	O
and	O
included	O
in	O
the	O
herd	O
book	O
.	O

All	O
animals	O
were	O
bred	O
by	O
the	O
use	O
of	O
artificial	O
insemination	O
.	O

Statistical	O
analyses	O

The	O
non	O
parametric	O
Mann	O
-	O
Whitney	O
-	O
Test	O
was	O
performed	O
using	O
SPSS	O
Version	O
14	O
.	O
0	O
,	O
the	O
Chi	O
-	O
square	O
test	O
was	O
performed	O
using	O
R	O
2	O
.	O
4	O
.	O
0	O
[	O
14	O
]	O
.	O

Authors	O
'	O
contributions	O

JB	O
drafted	O
the	O
manuscript	O
and	O
analyzed	O
the	O
pedigrees	O
.	O

BL	O
conceived	O
the	O
monitoring	O
system	O
for	O
inherited	O
diseases	O
.	O

RE	O
extracted	O
the	O
data	O
from	O
the	O
database	O
and	O
estimated	O
the	O
allelic	O
frequencies	O
of	O
the	O
arachnomelia	O
syndrome	O
.	O

HR	O
and	O
MW	O
performed	O
the	O
embryo	O
collection	O
,	O
transfer	O
and	O
recorded	O
the	O
morpho	O
-	O
metrical	O
data	O
of	O
the	O
experimental	O
matings	O
.	O

BS	O
examined	O
the	O
calves	S-Species
pathologically	O
.	O

NM	O
and	O
KG	O
participated	O
in	O
study	O
design	O
and	O
coordination	O
and	O
critically	O
revised	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Suggestions	O
Concerning	O
the	O
Use	O
of	O
the	O
Subclavian	O
which	O
Arises	O
from	O
the	O
Aorta	O
in	O
the	O
Treatment	O
of	O
the	O
Tetralogy	O
of	O
Fallot	O
*	O

Abstract	O

Images	O

SUGGESTIONS	O
CONCERNING	O
THE	O
USE	O
OF	O
THE	O
SUBCLAVIAN	O

WHICH	O
ARISES	O
FROM	O
THE	O
AORTA	O
IN	O
THE	O
TREATMENT	O

OF	O
THE	O
TETRALOGY	O
OF	O
FALLOT	O
*	O

HARRIS	O
B	O
.	O

SHUMACKER	O
,	O
JR	O
.	O
*	O
*	O

In	O
Blalock	O
'	O
s	O
early	O
experience	O
with	O
the	O
operative	O
treatment	O
of	O
the	O
tetralogy	O
of	O
Fallot	O
,	O
the	O
two	O
subclavian	O
,	O
the	O
innominate	O
,	O
and	O
carotid	O
arteries	O
were	O
all	O
used	O
for	O
anastomosis	O
to	O
the	O
pulmonary	O
artery	O
.	O

Soon	O
,	O
however	O
,	O
it	O
became	O
evident	O
that	O
use	O
of	O
the	O
innominate	O
or	O
carotid	O
was	O
followed	O
by	O
a	O
relatively	O
high	O
incidence	O
of	O
complications	O
resulting	O
from	O
cerebral	O
ischemia	O
.	O

Blalock	O
suggested	O
,	O
therefore	O
,	O
that	O
the	O
subclavian	O
be	O
used	O
by	O
preference	O
.	O

The	O
subclavian	O
branch	O
of	O
the	O
innominate	O
does	O
not	O
become	O
kinked	O
or	O
badly	O
angulated	O
when	O
it	O
is	O
turned	O
down	O
for	O
the	O
anastomosis	O
,	O
and	O
a	O
good	O
functional	O
result	O
almost	O
invariably	O
follows	O
the	O
completion	O
of	O
a	O
satisfactory	O
anastomosis	O
.	O

The	O
subclavian	O
which	O
arises	O
directly	O
from	O
the	O
aorta	O
,	O
on	O
the	O
other	O
hand	O
,	O
tends	O
to	O
form	O
a	O
bad	O
angle	O
when	O
it	O
is	O
brought	O
down	O
for	O
the	O
anastomosis	O
,	O
and	O
,	O
indeed	O
,	O
near	O
its	O
point	O
of	O
origin	O
it	O
may	O
be	O
so	O
flattened	O
out	O
against	O
the	O
relatively	O
rigid	O
aortic	O
wall	O
as	O
to	O
obstruct	O
all	O
blood	O
flow	O
through	O
it	O
.	O

These	O
considerations	O
led	O
Blalock	O
to	O
recommend	O
the	O
use	O
of	O
the	O
former	O
except	O
in	O
infants	S-Species
under	O
two	O
years	O
of	O
age	O
in	O
whom	O
this	O
artery	O
may	O
be	O
too	O
small	O
and	O
in	O
adults	O
or	O
children	S-Species
over	O
twelve	O
years	O
old	O
or	O
five	O
feet	O
tall	O
with	O
a	O
left	O
aortic	O
arch	O
in	O
whom	O
it	O
is	O
often	O
too	O
short	O
to	O
permit	O
a	O
satisfactory	O
anastomosis	O
.	O
7	O
'	O

In	O
contrast	O
,	O
Paine	O
and	O
Varco	O
,	O
'	O
Lam	O
,	O
6	O
Holman	O
,	O
'	O
Olim	O
,	O
7	O
and	O
others	O
have	O
preferred	O
to	O
use	O
the	O
subclavian	O
which	O
arises	O
from	O
the	O
aorta	O
and	O
have	O
obtained	O
generally	O
excellent	O
results	O
.	O

They	O
point	O
out	O
that	O
the	O
tendency	O
to	O
kinking	O
of	O
the	O
artery	O
is	O
more	O
a	O
theoretical	O
than	O
a	O
practical	O
disadvantage	O
,	O
that	O
the	O
exposure	O
and	O
dissection	O
of	O
both	O
the	O
pulmonary	O
artery	O
and	O
the	O
subclavian	O
are	O
easier	O
on	O
the	O
side	O
of	O
the	O
aortic	O
arch	O
,	O
that	O
both	O
vessels	O
are	O
generally	O
longer	O
than	O
on	O
the	O
opposite	O
side	O
and	O
that	O
,	O
as	O
a	O
general	O
rule	O
,	O
the	O
anastomosis	O
can	O
be	O
accomplished	O
more	O
readily	O
.	O

The	O
practical	O
usefulness	O
of	O
a	O
third	O
systemic	O
vessel	O
,	O
namely	O
the	O
aorta	O
,	O
was	O
demonstrated	O
by	O
the	O
development	O
of	O
a	O
technique	O
for	O
side	O
-	O
to	O
-	O
side	O
aortic	O
pulmonary	O
anastomosis	O
by	O
Potts	O
and	O
his	O
associates	O
.	O
"	O
0	O
In	O
spite	O
of	O
the	O
preferences	O
held	O
by	O
individual	O
operators	O
for	O
use	O
of	O
one	O
vessel	O
or	O
another	O
,	O
the	O
fact	O
remains	O
,	O
as	O
Blalock	O
has	O
emphasized	O
,	O
that	O
there	O
is	O
always	O
present	O
a	O
usable	O
systemic	O
vessel	O
provided	O
a	O
suitable	O
pulmonary	O
artery	O
is	O
available	O
.	O

Nevertheless	O
,	O
the	O
choice	O
of	O
the	O
systemic	O
artery	O
in	O
each	O
individual	O
patient	S-Species
is	O
important	O
since	O
in	O
certain	O
cases	O
one	O
or	O
another	O
is	O
unsuitable	O
.	O

*	O
From	O
the	O
Department	O
of	O
Surgery	O
,	O
the	O
Indiana	O
University	O
Medical	O
Center	O
,	O
Indianapolis	O
,	O
Indiana	O
.	O

Aided	O
by	O
a	O
contract	O
between	O
the	O
Office	O
of	O
Naval	O
Research	O
,	O
Department	O
of	O
the	O
Navy	O
,	O
and	O
Indiana	O
University	O
.	O

*	O
*	O
Resident	O
Surgeon	O
,	O
New	O
Haven	O
Hospital	O
,	O
1937	O
-	O
1938	O
.	O

Received	O
for	O
publication	O
April	O
26	O
,	O
1951	O
.	O

TREATMENT	O
OF	O
TETRALOGY	O
OF	O
FALLOT	O

It	O
has	O
been	O
my	O
custom	O
to	O
follow	O
a	O
policy	O
rather	O
similar	O
to	O
that	O
outlined	O
by	O
Blalock	O
.	O

The	O
subclavian	O
branch	O
of	O
the	O
innominate	O
has	O
generally	O
been	O
preferred	O
in	O
patients	S-Species
ranging	O
between	O
two	O
and	O
twelve	O
years	O
of	O
age	O
and	O
in	O
older	O
individuals	O
in	O
whom	O
there	O
is	O
a	O
right	O
aortic	O
arch	O
.	O

In	O
others	O
the	O
thoracotomy	O
is	O
usually	O
made	O
on	O
the	O
side	O
of	O
the	O
aortic	O
arch	O
,	O
and	O
either	O
the	O
aorta	O
itself	O
or	O
the	O
subclavian	O
arising	O
from	O
the	O
aorta	O
is	O
used	O
for	O
the	O
anastomosis	O
.	O

My	O
experience	O
with	O
the	O
use	O
of	O
the	O
subclavian	O
originating	O
from	O
the	O
aorta	O
is	O
small	O
and	O
the	O
results	O
have	O
not	O
been	O
as	O
good	O
as	O
those	O
which	O
others	O
have	O
reported	O
.	O

One	O
eighteen	O
-	O
month	O
-	O
old	O
child	S-Species
died	O
the	O
day	O
after	O
operation	O
and	O
was	O
found	O
at	O
post	O
-	O
mortem	O
examination	O
to	O
have	O
an	O
occluded	O
anastomosis	O
.	O

In	O
one	O
three	O
-	O
year	O
-	O
old	O
child	S-Species
and	O
one	O
twenty	O
-	O
year	O
-	O
old	O
woman	S-Species
a	O
poor	O
result	O
was	O
obtained	O
and	O
a	O
second	O
operation	O
upon	O
the	O
other	O
side	O
was	O
necessary	O
.	O

In	O
two	O
additional	O
cases	O
the	O
result	O
was	O
only	O
fair	O
.	O

Excluding	O
the	O
patients	S-Species
mentioned	O
in	O
the	O
present	O
report	O
,	O
only	O
in	O
two	O
was	O
an	O
unquestionably	O
good	O
result	O
obtained	O
.	O

Recently	O
,	O
in	O
several	O
cases	O
in	O
which	O
failure	O
seemed	O
evident	O
a	O
modification	O
has	O
been	O
required	O
in	O
order	O
to	O
obtain	O
a	O
functioning	O
shunt	O
.	O

Since	O
these	O
modifications	O
proved	O
successful	O
and	O
since	O
these	O
threats	O
of	O
failure	O
tax	O
one	O
'	O
s	O
ingenuiity	O
at	O
the	O
time	O
of	O
operation	O
,	O
I	O
have	O
thought	O
it	O
might	O
be	O
helpful	O
to	O
describe	O
the	O
procedures	O
employed	O
and	O
to	O
illustrate	O
them	O
with	O
case	O
reports	O
.	O

One	O
is	O
a	O
method	O
which	O
obviously	O
has	O
very	O
limited	O
applicability	O
,	O
while	O
the	O
otlher	O
would	O
seem	O
to	O
be	O
rather	O
generally	O
applicable	O
.	O

The	O
first	O
consists	O
of	O
the	O
transplantation	O
of	O
the	O
origin	O
of	O
the	O
subclavian	O
to	O
a	O
more	O
suitable	O
portion	O
of	O
the	O
aorta	O
.	O

Case	O
report	O

The	O
patient	S-Species
was	O
a	O
19	O
-	O
year	O
-	O
old	O
girl	S-Species
who	O
had	O
been	O
cyanotic	O
since	O
the	O
age	O
of	O
six	O
months	O
.	O

She	O
had	O
developed	O
normally	O
but	O
was	O
always	O
limited	O
in	O
exercise	O
capacity	O
.	O

In	O
her	O
early	O
years	O
of	O
school	O
she	O
was	O
taken	O
to	O
school	O
by	O
her	O
parents	O
and	O
carried	O
to	O
and	O
from	O
her	O
seat	O
in	O
the	O
classroom	O
.	O

She	O
did	O
reasonably	O
well	O
in	O
high	O
school	O
,	O
being	O
driven	O
to	O
and	O
from	O
the	O
school	O
,	O
but	O
she	O
got	O
into	O
severe	O
difficulty	O
when	O
she	O
attempted	O
to	O
attend	O
college	O
.	O

The	O
longer	O
distances	O
between	O
classes	O
and	O
the	O
necessity	O
for	O
climbing	O
stairs	O
precipitated	O
a	O
downhill	O
course	O
,	O
with	O
increasing	O
dyspnea	O
,	O
more	O
marked	O
cyanosis	O
and	O
fatigue	O
,	O
and	O
the	O
onset	O
of	O
bouts	O
of	O
loss	O
of	O
consciousness	O
.	O

The	O
latter	O
occurred	O
several	O
times	O
daily	O
.	O

One	O
which	O
was	O
witnessed	O
by	O
her	O
physician	O
lasted	O
45	O
minutes	O
;	O
he	O
feared	O
it	O
would	O
prove	O
fatal	O
.	O

Ordinarily	O
,	O
she	O
could	O
not	O
walk	O
more	O
than	O
half	O
a	O
block	O
.	O

There	O
was	O
marked	O
cyanosis	O
of	O
the	O
nails	O
and	O
mucous	O
membranes	O
and	O
to	O
a	O
lesser	O
extent	O
of	O
the	O
skin	O
.	O

Clubbing	O
was	O
very	O
prominent	O
.	O

All	O
the	O
results	O
of	O
physical	O
and	O
laboratory	O
examination	O
fitted	O
in	O
with	O
a	O
diagnosis	O
of	O
tetralogy	O
of	O
Fallot	O
.	O

The	O
hematocrit	O
ranged	O
between	O
83	O
and	O
90	O
.	O

Oxygen	O
saturation	O
of	O
arterial	O
blood	O
was	O
65	O
per	O
cent	O
at	O
complete	O
rest	O
.	O

The	O
aortic	O
arch	O
was	O
on	O
the	O
left	O
side	O
.	O

On	O
October	O
26	O
,	O
1949	O
a	O
left	O
lateral	O
thoracotomy	O
was	O
performed	O
,	O
the	O
pleural	O
cavity	O
being	O
entered	O
through	O
the	O
bed	O
of	O
the	O
fifth	O
rib	O
.	O

There	O
was	O
evident	O
greatly	O
increased	O
collateral	O
circulation	O
in	O
the	O
mediastinum	O
and	O
hilum	O
.	O

The	O
pulmonary	O
artery	O
appeared	O
to	O
have	O
markedly	O
reduced	O
blood	O
flow	O
,	O
was	O
very	O
short	O
,	O
small	O
,	O
and	O
thin	O
-	O
walled	O
.	O

Its	O
diameter	O
was	O
less	O
than	O
5	O
mm	O
.	O

The	O
aorta	O
seemed	O
to	O
be	O
bowed	O
out	O
laterally	O
in	O
an	O
unusual	O
fashion	O
and	O
the	O
short	O
pulmonary	O
artery	O
could	O
not	O
possibly	O
be	O
brought	O
out	O
over	O
it	O
.	O

The	O
subclavian	O
artery	O
was	O
relatively	O
small	O
,	O
having	O

487	O

YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O

a	O
diameter	O
of	O
only	O
about	O
4	O
mm	O
.	O
but	O
it	O
seemed	O
rather	O
long	O
.	O

It	O
was	O
apparent	O
that	O
a	O
Pott	O
'	O
s	O
procedure	O
was	O
impossible	O
and	O
that	O
an	O
end	O
-	O
to	O
-	O
side	O
subclavian	O
pulmonary	O
artery	O
anastomosis	O
would	O
be	O
doomed	O
to	O
failure	O
.	O

Hence	O
,	O
the	O
subclavian	O
artery	O
was	O
divided	O
at	O
the	O
level	O
of	O
its	O
first	O
branch	O
,	O
the	O
pulmonary	O
artery	O
was	O
divided	O
proximally	O
,	O
and	O
an	O
end	O
-	O
to	O
-	O
end	O
subclavian	O
-	O
pulmonary	O
anastomosis	O
was	O
carried	O
out	O
.	O

This	O
was	O
done	O
with	O
ease	O
.	O

When	O
the	O
clamps	O
were	O
removed	O
,	O
however	O
,	O
no	O
blood	O
flowed	O
through	O
it	O
.	O

The	O
softwalled	O
subclavian	O
was	O
completely	O
flattened	O
out	O
against	O
the	O
relatively	O
rigid	O
aorta	O
(	O
Fig	O
.	O
1	O
)	O
.	O

When	O
the	O
hilar	O
structures	O
were	O
forcibly	O
elevated	O
in	O
a	O
cephalad	O
direction	O
the	O
subclavian	O
immediately	O
filled	O
and	O
pulsated	O
normally	O
and	O
a	O
thrill	O
could	O
be	O
felt	O
.	O

Simple	O
expansion	O
of	O
the	O
lungs	O
,	O
however	O
,	O
failed	O
to	O
achieve	O
this	O
result	O
and	O
I	O
could	O
conceive	O
of	O
no	O
way	O
in	O
which	O
the	O
hilar	O
region	O
could	O
be	O
held	O
in	O
a	O
more	O
cephalad	O
direction	O
.	O

The	O
subclavian	O
was	O
then	O
ligated	O
at	O
the	O
point	O
where	O
it	O
came	O
off	O
the	O
aorta	O
and	O
its	O
proximal	O
end	O
was	O
anastomosed	O
end	O
-	O
to	O
-	O
side	O
to	O
the	O
descending	O
aorta	O
.	O

It	O
now	O
pulsated	O
vigorously	O
as	O
did	O
the	O
pulmonary	O
artery	O
.	O

In	O
spite	O
of	O
the	O
good	O
pulsation	O
no	O
thrill	O
was	O
palpable	O
.	O

The	O
patient	S-Species
had	O
an	O
uneventful	O
but	O
disappointing	O
convalescence	O
.	O

She	O
remained	O
markedly	O
cyanotic	O
and	O
no	O
continuous	O
bruit	O
was	O
audible	O
.	O

When	O
she	O
left	O
the	O
hospital	O
14	O
days	O
after	O
operation	O
there	O
was	O
no	O
improvement	O
in	O
her	O
appearance	O
,	O
hematocrit	O
,	O
or	O
arterial	O
oxygen	O
saturation	O
.	O

Surprisingly	O
enough	O
she	O
reported	O
progress	O
on	O
each	O
follow	O
-	O
up	O
examination	O
.	O

By	O
the	O
end	O
of	O
seven	O
weeks	O
she	O
was	O
obviously	O
less	O
cyanotic	O
,	O
her	O
hematocrit	O
was	O
77	O
,	O
and	O
she	O
was	O
able	O
to	O
walk	O
a	O
number	O
of	O
blocks	O
and	O
to	O
climb	O
a	O
flight	O
of	O
stairs	O
without	O
difficulty	O
.	O

She	O
reported	O
that	O
she	O
had	O
danced	O
and	O
roller	O
-	O
skated	O
without	O
much	O
trouble	O
.	O

Shortly	O
thereafter	O
a	O
continuous	O
murmur	O
was	O
audible	O
in	O
the	O
left	O
chest	O
.	O

She	O
continued	O
to	O
improve	O
and	O
in	O
January	O
entered	O
a	O
southern	O
college	O
.	O

She	O
did	O
well	O
.	O

At	O
least	O
once	O
a	O
day	O
,	O
often	O
twice	O
,	O
she	O
walked	O
without	O
difficulty	O
from	O
the	O
campus	O
into	O
town	O
and	O
back	O
,	O
a	O
distance	O
of	O
ten	O
blocks	O
each	O
way	O
.	O

She	O
played	O
a	O
little	O
tennis	O
,	O
learned	O
to	O
swim	O
,	O
and	O
began	O
to	O
dance	O
,	O
including	O
jitterbugging	O
.	O

When	O
she	O
xvas	O
seen	O
in	O
June	O
,	O
her	O
color	O
was	O
good	O
,	O
although	O
there	O
was	O
still	O
slight	O
cyanosis	O
of	O
lips	O
and	O
nail	O
beds	O
.	O

There	O
was	O
a	O
very	O
loud	O
,	O
continuous	O
murmur	O
in	O
the	O
left	O
chest	O
.	O

The	O
following	O
fall	O
she	O
transferred	O
to	O
a	O
midwestern	O
university	O
.	O

She	O
got	O
along	O
reasonably	O
well	O
but	O
not	O
as	O
well	O
as	O
she	O
had	O
in	O
a	O
warmer	O
climate	O
and	O
on	O
more	O
level	O
terrain	O
.	O

She	O
walked	O
four	O
or	O
five	O
blocks	O
up	O
and	O
down	O
hills	O
between	O
classes	O
without	O
difficulty	O
in	O
good	O
weather	O
but	O
complained	O
of	O
some	O
dyspnea	O
and	O
fatigue	O
on	O
cold	O
,	O
windy	O
days	O
.	O

She	O
attended	O
dances	O
and	O
often	O
danced	O
each	O
number	O
throughout	O
the	O
evening	O
without	O
trouble	O
.	O

When	O
seen	O
in	O
December	O
she	O
looked	O
well	O
.	O

Her	O
color	O
was	O
good	O
and	O
clubbing	O
was	O
definitely	O
less	O
marked	O
than	O
it	O
had	O
been	O
previously	O
.	O

She	O
had	O
a	O
severe	O
cold	O
at	O
the	O
time	O
.	O

Her	O
oxygen	O
saturation	O
of	O
arterial	O
blood	O
was	O
75	O
per	O
cent	O
at	O
rest	O
and	O
it	O
did	O
not	O
fall	O
when	O
she	O
stood	O
or	O
still	O
-	O
walked	O
.	O

The	O
hematocrit	O
was	O
69	O
.	O

There	O
was	O
audible	O
the	O
same	O
loud	O
continuous	O
murmur	O
in	O
the	O
left	O
chest	O
.	O

Though	O
the	O
patient	S-Species
has	O
been	O
markedly	O
improved	O
,	O
it	O
is	O
recognized	O
that	O
the	O
result	O
is	O
not	O
as	O
good	O
as	O
is	O
commonly	O
obtained	O
when	O
patients	S-Species
with	O
more	O
adequate	O
pulmonary	O
arteries	O
are	O
treated	O
by	O
the	O
conventional	O
anastomosis	O
of	O
a	O
systemic	O
artery	O
to	O
the	O
side	O
of	O
the	O
pulmonary	O
artery	O
.	O

Nevertheless	O
,	O
the	O
patient	S-Species
has	O
thus	O
far	O
been	O
given	O
such	O
good	O
health	O
and	O
relatively	O
normal	O
capacity	O
for	O
ordinary	O
activity	O
that	O
further	O
operation	O
has	O
seemed	O
unwarranted	O
,	O
though	O
the	O
possibility	O
of	O
some	O
future	O
attempt	O
at	O
creation	O
of	O
an	O
additional	O
shunt	O
is	O
being	O
kept	O
in	O
mind	O
.	O

The	O
second	O
procedure	O
embodies	O
the	O
cephalad	O
transplantation	O
of	O
the	O
pulmonary	O
artery	O
by	O
a	O
plastic	O
repair	O
of	O
the	O
incision	O
in	O
the	O
hilar	O
and	O
mediastinal	O
pleural	O
structures	O
.	O

488	O

FIG	O
.	O

1	O
.	O

Drawing	O
illustrating	O
the	O
condition	O
which	O
existed	O
in	O
the	O
first	O
case	O
after	O
completion	O
of	O
the	O
anastomosis	O
(	O
A	O
)	O
and	O
its	O
correction	O
by	O
transplantation	O
of	O
the	O
origin	O
of	O
the	O
subclavian	O
(	O
B	O
)	O
.	O

FIG	O
.	O

2	O
.	O

Drawing	O
illustrating	O
correction	O
of	O
obstruction	O
to	O
blood	O
flow	O
through	O
the	O
subclavian	O
artery	O
by	O
inverted	O
T	O
or	O
L	O
plastic	O
closure	O
of	O
the	O
defect	O
in	O
the	O
hilar	O
and	O
mediastinal	O
structures	O
.	O

TREATMENT	O
OF	O
TETRALOGY	O
OF	O
FALLOT	O

Case	O
reports	O

The	O
first	O
patient	S-Species
was	O
a	O
fully	O
grown	O
young	O
man	S-Species
of	O
17	O
with	O
tetralogy	O
of	O
Fallot	O
which	O
caused	O
considerable	O
incapacity	O
.	O

He	O
was	O
admitted	O
to	O
the	O
hospital	O
on	O
July	O
18	O
,	O
1950	O
and	O
was	O
operated	O
upon	O
two	O
days	O
later	O
.	O

He	O
was	O
known	O
to	O
have	O
a	O
left	O
aortic	O
arch	O
,	O
and	O
a	O
left	O
lateral	O
thoracotomy	O
was	O
performed	O
.	O

The	O
aorta	O
was	O
freed	O
for	O
a	O
side	O
-	O
to	O
-	O
side	O
anastomosis	O
with	O
the	O
pulmonary	O
artery	O
.	O

So	O
much	O
difficulty	O
was	O
encountered	O
,	O
however	O
,	O
in	O
placing	O
the	O
aortic	O
clamp	O
in	O
proper	O
position	O
for	O
making	O
a	O
satisfactory	O
incision	O
in	O
the	O
aorta	O
that	O
the	O
procedure	O
was	O
abandoned	O
and	O
an	O
end	O
-	O
to	O
-	O
side	O
subclavian	O
-	O
pulmonary	O
artery	O
anastomosis	O
accomplished	O
instead	O
.	O

The	O
pulmonary	O
artery	O
was	O
of	O
fair	O
size	O
,	O
having	O
an	O
estimated	O
diameter	O
of	O
1	O
cm	O
.	O

The	O
subclavian	O
artery	O
appeared	O
to	O
be	O
quite	O
long	O
and	O
it	O
was	O
of	O
very	O
satisfactory	O
size	O
,	O
having	O
a	O
diameter	O
of	O
about	O
6	O
mm	O
.	O

To	O
my	O
dismay	O
,	O
the	O
first	O
portion	O
of	O
the	O
soft	O
-	O
walled	O
subclavian	O
artery	O
was	O
completely	O
flattened	O
out	O
against	O
the	O
rather	O
rigid	O
wall	O
of	O
the	O
aorta	O
and	O
no	O
blood	O
flow	O
through	O
it	O
could	O
be	O
demonstrated	O
,	O
there	O
being	O
no	O
subclavian	O
pulsation	O
nor	O
thrill	O
in	O
the	O
pulmonary	O
artery	O
.	O

If	O
one	O
forcefully	O
elevated	O
the	O
hilum	O
of	O
the	O
lung	O
in	O
a	O
cephalad	O
direction	O
,	O
the	O
obstruction	O
disappeared	O
,	O
the	O
subclavian	O
artery	O
began	O
to	O
pulsate	O
,	O
and	O
a	O
thrill	O
could	O
be	O
palpated	O
.	O

When	O
the	O
lung	O
was	O
allowed	O
to	O
assume	O
its	O
usual	O
position	O
,	O
the	O
subclavian	O
obstruction	O
was	O
again	O
evident	O
and	O
could	O
not	O
be	O
prevented	O
by	O
full	O
expansion	O
of	O
the	O
lung	O
.	O

It	O
was	O
found	O
that	O
the	O
hilar	O
region	O
and	O
the	O
pulmonary	O
artery	O
could	O
be	O
maintained	O
in	O
a	O
satisfactory	O
cephalad	O
position	O
by	O
traction	O
upward	O
upon	O
the	O
cuff	O
of	O
hilar	O
pleura	O
and	O
the	O
adjacent	O
vascular	O
sheath	O
and	O
that	O
these	O
structures	O
were	O
sufficiently	O
strong	O
so	O
that	O
traction	O
could	O
be	O
maintained	O
upon	O
them	O
with	O
a	O
small	O
hemostat	O
.	O

The	O
defect	O
in	O
the	O
mediastinal	O
and	O
hilar	O
tissues	O
was	O
then	O
repaired	O
using	O
a	O
sort	O
of	O
inverted	O
T	O
-	O
plastic	O
closure	O
.	O

By	O
this	O
maneuver	O
success	O
was	O
achieved	O
in	O
elevating	O
the	O
pulmonary	O
artery	O
in	O
a	O
cephalad	O
direction	O
so	O
that	O
the	O
subclavian	O
obstruction	O
was	O
relieved	O
and	O
excellent	O
pulsation	O
was	O
evident	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

A	O
fairly	O
good	O
continuous	O
thrill	O
was	O
palpable	O
.	O

The	O
patient	S-Species
had	O
an	O
uneventful	O
convalescence	O
.	O

When	O
last	O
seen	O
on	O
January	O
16	O
,	O
1951	O
he	O
had	O
excellent	O
color	O
without	O
any	O
visible	O
cyanosis	O
.	O

The	O
clubbing	O
seemed	O
to	O
have	O
decreased	O
somewhat	O
.	O

A	O
continuous	O
murmur	O
was	O
audible	O
.	O

He	O
stated	O
that	O
he	O
noted	O
no	O
limitation	O
of	O
exercise	O
capacity	O
.	O

In	O
outlining	O
his	O
activities	O
he	O
said	O
that	O
,	O
among	O
other	O
things	O
,	O
he	O
was	O
doing	O
a	O
great	O
deal	O
of	O
ice	O
-	O
skating	O
and	O
was	O
playing	O
ice	O
hockey	O
regularly	O
.	O

He	O
was	O
planning	O
to	O
start	O
college	O
work	O
the	O
following	O
month	O
.	O

The	O
second	O
patient	S-Species
was	O
a	O
16	O
-	O
year	O
-	O
old	O
boy	S-Species
who	O
had	O
been	O
cyanotic	O
since	O
birth	O
.	O

His	O
physical	O
development	O
was	O
somewhat	O
retarded	O
and	O
he	O
was	O
slow	O
in	O
learning	O
to	O
sit	O
and	O
walk	O
.	O

Until	O
he	O
had	O
grown	O
old	O
enough	O
to	O
be	O
self	O
-	O
conscious	O
about	O
it	O
he	O
had	O
always	O
squatted	O
when	O
he	O
was	O
tired	O
.	O

By	O
perseverance	O
he	O
had	O
managed	O
to	O
do	O
more	O
than	O
one	O
would	O
have	O
suspected	O
he	O
could	O
from	O
the	O
degree	O
of	O
his	O
cyanosis	O
.	O

He	O
could	O
walk	O
as	O
much	O
as	O
five	O
or	O
six	O
blocks	O
at	O
a	O
slow	O
pace	O
.	O

He	O
was	O
fond	O
of	O
drums	O
and	O
managed	O
to	O
play	O
occasionally	O
with	O
an	O
orchestra	O
in	O
a	O
somewhat	O
restricted	O
fashion	O
.	O

For	O
the	O
past	O
few	O
months	O
he	O
had	O
had	O
more	O
dyspnea	O
,	O
fatigability	O
,	O
and	O
seemed	O
to	O
be	O
going	O
downhill	O
generally	O
.	O

The	O
results	O
of	O
physical	O
and	O
laboratory	O
studies	O
were	O
rather	O
typical	O
of	O
the	O
tetralogy	O
of	O
Fallot	O
.	O

Clubbing	O
was	O
marked	O
,	O
the	O
nailbeds	O
and	O
mucous	O
membranes	O
were	O
a	O
rather	O
deep	O
purplish	O
-	O
blue	O
color	O
,	O
and	O
the	O
skin	O
had	O
a	O
dusky	O
cyanotic	O
tint	O
.	O

The	O
aortic	O
arch	O
was	O
determined	O
to	O
be	O
on	O
the	O
left	O
.	O

On	O
July	O
21	O
,	O
1950	O
a	O
left	O
lateral	O
thoracotomy	O
was	O
performed	O
,	O
the	O
pleural	O
cavity	O
being	O
entered	O
through	O
the	O
bed	O
of	O
the	O
fourth	O
rib	O
.	O

There	O
was	O
a	O
rather	O
marked	O
increase	O
in	O
the	O
collateral	O
circulation	O
in	O
the	O
mediastinum	O
and	O
the	O
hilar	O
region	O
.	O

The	O
pulmonary	O
artery	O
was	O
easily	O
dissected	O
free	O
.	O

It	O
was	O
fairly	O
long	O
and	O
was	O
about	O
1	O
cm	O
.	O
in	O
diameter	O
.	O

The	O
subclavian	O
artery	O
seemed	O
quite	O
long	O
and	O
was	O
of	O
adequate	O
size	O
,	O
having	O
a	O
diameter	O
of	O
about	O
5	O
mm	O
.	O

An	O
end	O
-	O
to	O
-	O
side	O
sub9lavian	O
pulmonary	O
anastomosis	O
was	O
performed	O
.	O

Again	O
in	O
this	O
case	O
,	O
however	O
,	O
the	O
first	O
part	O
of	O
the	O
subclavian	O
was	O
acutely	O
angulated	O
and	O
completely	O
flattened	O
out	O
against	O
the	O
aortic	O
wall	O
.	O

There	O
was	O
no	O

489	O

YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O

pulsation	O
in	O
the	O
subclavian	O
and	O
no	O
thrill	O
in	O
the	O
pulmonary	O
.	O

In	O
this	O
instance	O
also	O
,	O
good	O
blood	O
flow	O
through	O
the	O
subclavian	O
artery	O
was	O
evident	O
whenever	O
the	O
hilar	O
structures	O
were	O
elevated	O
in	O
a	O
cephalad	O
direction	O
but	O
no	O
pulsation	O
was	O
demonstrable	O
simply	O
by	O
expanding	O
fully	O
the	O
lung	O
.	O

Again	O
,	O
a	O
sort	O
of	O
inverted	O
T	O
-	O
plastic	O
closure	O
of	O
the	O
defect	O
in	O
the	O
hilum	O
and	O
mediastinum	O
brought	O
about	O
a	O
cephalad	O
elevation	O
of	O
the	O
pulmonary	O
artery	O
so	O
that	O
tension	O
was	O
released	O
and	O
there	O
was	O
excellent	O
pulsation	O
in	O
the	O
subclavian	O
artery	O
.	O

A	O
thrill	O
was	O
now	O
palpable	O
.	O

Convalescence	O
was	O
uneventful	O
.	O

Improvement	O
in	O
color	O
was	O
evident	O
within	O
a	O
few	O
days	O
and	O
his	O
color	O
was	O
excellent	O
by	O
the	O
time	O
he	O
was	O
discharged	O
from	O
the	O
hospital	O
on	O
the	O
thirteenth	O
postoperative	O
day	O
.	O

He	O
rapidly	O
found	O
that	O
he	O
was	O
now	O
able	O
to	O
lead	O
a	O
quite	O
normal	O
sort	O
of	O
life	O
.	O

When	O
he	O
was	O
seen	O
on	O
December	O
9	O
he	O
stated	O
that	O
he	O
had	O
no	O
limitation	O
in	O
exercise	O
capacity	O
.	O

He	O
could	O
walk	O
rapidly	O
without	O
fatigue	O
.	O

He	O
was	O
going	O
to	O
school	O
and	O
was	O
playing	O
the	O
drums	O
in	O
a	O
professional	O
orchestra	O
three	O
or	O
four	O
nights	O
each	O
week	O
.	O

There	O
was	O
some	O
diminution	O
in	O
the	O
clubbing	O
and	O
his	O
color	O
was	O
excellent	O
.	O

There	O
was	O
a	O
loud	O
continuous	O
bruit	O
audible	O
in	O
the	O
chest	O
.	O

On	O
March	O
27	O
the	O
arterial	O
oxygen	O
saturation	O
was	O
88	O
.	O
2	O
per	O
cent	O
.	O

When	O
I	O
first	O
used	O
this	O
procedure	O
I	O
was	O
rather	O
surprised	O
that	O
such	O
tissues	O
would	O
hold	O
sutures	O
and	O
serve	O
satisfactorily	O
to	O
elevate	O
the	O
hilum	O
.	O

On	O
occasions	O
I	O
had	O
previously	O
toyed	O
with	O
the	O
idea	O
of	O
suturing	O
hilar	O
pleura	O
to	O
the	O
mediastinal	O
pleura	O
but	O
had	O
abandoned	O
it	O
as	O
impractical	O
because	O
the	O
sutures	O
seemed	O
to	O
pull	O
out	O
whenever	O
there	O
was	O
any	O
tension	O
whatsoever	O
.	O

If	O
the	O
procedure	O
is	O
to	O
be	O
successful	O
,	O
it	O
is	O
essential	O
that	O
the	O
sutures	O
encompass	O
any	O
adjacent	O
areolar	O
and	O
fibrous	O
tissue	O
and	O
especially	O
the	O
so	O
-	O
called	O
vascular	O
sheath	O
which	O
surrounds	O
both	O
pulmonary	O
artery	O
and	O
aorta	O
and	O
is	O
dissected	O
free	O
during	O
the	O
course	O
of	O
the	O
operation	O
.	O

Fortunately	O
,	O
in	O
its	O
proximal	O
portion	O
the	O
sheath	O
about	O
the	O
pulmonary	O
artery	O
gains	O
added	O
strength	O
from	O
the	O
extension	O
into	O
it	O
of	O
a	O
reflection	O
of	O
the	O
fibrous	O
pericardium	O
.	O

Sutures	O
through	O
the	O
mediastinal	O
pleura	O
in	O
the	O
region	O
of	O
the	O
aortic	O
arch	O
purposely	O
include	O
the	O
perivascular	O
tissues	O
which	O
have	O
been	O
stripped	O
off	O
the	O
aorta	O
and	O
subclavian	O
artery	O
and	O
also	O
any	O
other	O
available	O
tissue	O
which	O
may	O
lend	O
strength	O
,	O
such	O
as	O
the	O
divided	O
ends	O
of	O
the	O
supreme	O
intercostal	O
vein	O
or	O
other	O
vessels	O
which	O
lhave	O
been	O
transected	O
and	O
ligated	O
.	O

The	O
exact	O
method	O
of	O
repair	O
will	O
vary	O
from	O
case	O
to	O
case	O
.	O

By	O
placing	O
the	O
sutures	O
properly	O
it	O
would	O
seem	O
possible	O
sometimes	O
to	O
displace	O
the	O
pulmonary	O
artery	O
laterally	O
as	O
well	O
as	O
in	O
a	O
cephalad	O
direction	O
if	O
such	O
a	O
maneuver	O
was	O
thought	O
to	O
be	O
desirable	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

On	O
occasions	O
one	O
would	O
close	O
the	O
pleural	O
defect	O
fairly	O
snugly	O
,	O
on	O
others	O
leave	O
it	O
wide	O
open	O
in	O
places	O
.	O

Discussion	O

Though	O
there	O
is	O
always	O
available	O
some	O
suitable	O
systemic	O
vessel	O
and	O
though	O
the	O
major	O
concern	O
in	O
the	O
operative	O
treatment	O
of	O
the	O
tetralogy	O
of	O
Fallot	O
is	O
the	O
adequacy	O
of	O
the	O
pulmonary	O
artery	O
,	O
from	O
time	O
to	O
time	O
one	O
may	O
find	O
the	O
achievement	O
of	O
a	O
satisfactory	O
result	O
thwarted	O
by	O
the	O
local	O
anatomical	O
characteristics	O
regardless	O
of	O
one	O
'	O
s	O
choice	O
of	O
procedure	O
.	O

Consequently	O
,	O
those	O
modifications	O
which	O
may	O
add	O
to	O
the	O
likelihood	O
of	O
a	O
successful	O
outcome	O
are	O
important	O
.	O

Blalock	O
"	O
'	O
pointed	O
out	O
the	O
practicability	O
of	O
performing	O
an	O
end	O
-	O
toend	O
subclavian	O
-	O
pulmonary	O
artery	O
anastomosis	O
whenever	O
the	O
pulmonary	O
artery	O
is	O
judged	O
too	O
small	O
or	O
the	O
subclavian	O
too	O
short	O
for	O
a	O
satisfactory	O
end	O

490	O

TREATMENT	O
OF	O
TETRALOGY	O
OF	O
FALLOT	O
491	O

to	O
-	O
side	O
anastomosis	O
.	O

Holman	O
'	O
feels	O
that	O
a	O
poorly	O
functioning	O
shunt	O
after	O
end	O
-	O
to	O
-	O
side	O
anastomosis	O
can	O
usually	O
be	O
corrected	O
by	O
proximal	O
division	O
of	O
the	O
subclavian	O
artery	O
,	O
thus	O
in	O
effect	O
converting	O
the	O
procedure	O
into	O
an	O
end	O
-	O
to	O
-	O
end	O
anastomosis	O
.	O

If	O
a	O
satisfactory	O
end	O
-	O
to	O
-	O
side	O
suture	O
of	O
subclavian	O
and	O
pulmonary	O
arteries	O
or	O
side	O
-	O
to	O
-	O
side	O
aortic	O
pulmonary	O
anastomosis	O
seems	O
difficult	O
to	O
achieve	O
,	O
one	O
may	O
occasionally	O
find	O
it	O
useful	O
to	O
divide	O
the	O
upper	O
lobe	O
branch	O
of	O
the	O
pulmonary	O
artery	O
and	O
carry	O
out	O
an	O
end	O
-	O
to	O
-	O
end	O
suture	O
of	O
the	O
subclavian	O
and	O
the	O
proximal	O
end	O
of	O
the	O
upper	O
lobe	O
branch	O
.	O

Potts	O
and	O
Smith	O
'	O
performed	O
an	O
anastomosis	O
between	O
the	O
proximal	O
end	O
of	O
the	O
upper	O
lobe	O
branch	O
and	O
the	O
side	O
of	O
the	O
aorta	O
in	O
a	O
case	O
in	O
which	O
complete	O
temporary	O
occlusion	O
of	O
the	O
main	O
pulmonary	O
artery	O
was	O
withstood	O
poorly	O
.	O

I	O
have	O
found	O
this	O
principle	O
of	O
division	O
of	O
the	O
upper	O
lobe	O
branch	O
and	O
use	O
of	O
its	O
proximal	O
end	O
of	O
value	O
in	O
obtaining	O
a	O
suitable	O
subclavian	O
pulmonary	O
anastomosis	O
when	O
the	O
subclavian	O
seemed	O
to	O
have	O
inadequate	O
length	O
.	O

On	O
occasions	O
when	O
the	O
systemic	O
vessel	O
seems	O
too	O
short	O
,	O
one	O
may	O
elect	O
to	O
interpose	O
a	O
free	O
vascular	O
transplant	O
,	O
3	O
"	O
'	O
a	O
modification	O
I	O
first	O
employed	O
in	O
1946	O
though	O
unfortunately	O
not	O
with	O
success	O
in	O
this	O
instance	O
.	O

The	O
operation	O
performed	O
in	O
my	O
first	O
patient	S-Species
constitutes	O
in	O
reality	O
the	O
use	O
of	O
the	O
subclavian	O
artery	O
as	O
an	O
autogenous	O
graft	O
between	O
the	O
aorta	O
and	O
pulmonary	O
artery	O
.	O

It	O
will	O
obviously	O
not	O
often	O
be	O
the	O
procedure	O
of	O
choice	O
but	O
sometimes	O
may	O
be	O
found	O
a	O
useful	O
measure	O
in	O
converting	O
an	O
apparently	O
inadequate	O
functional	O
shunt	O
into	O
a	O
good	O
one	O
.	O

If	O
my	O
initial	O
experiences	O
with	O
the	O
plastic	O
repair	O
of	O
the	O
defect	O
in	O
the	O
mediastinal	O
and	O
hilar	O
structures	O
are	O
characteristic	O
of	O
what	O
may	O
be	O
expected	O
of	O
this	O
procedure	O
,	O
it	O
would	O
seem	O
to	O
have	O
wide	O
applicability	O
whenever	O
a	O
poorly	O
functioning	O
subclavian	O
-	O
pulmonary	O
shunt	O
seems	O
correctable	O
by	O
cephalad	O
transplantation	O
of	O
the	O
hilar	O
structures	O
and	O
the	O
consequent	O
release	O
of	O
tension	O
.	O

I	O
was	O
unaware	O
of	O
any	O
reference	O
in	O
the	O
literature	O
to	O
its	O
use	O
until	O
belatedly	O
I	O
discovered	O
that	O
I	O
had	O
overlooked	O
a	O
statement	O
in	O
the	O
legend	O
of	O
one	O
of	O
the	O
excellent	O
drawings	O
in	O
Blalock	O
'	O
s	O
paper	O
on	O
surgical	O
procedures	O
in	O
pulmonic	O
stenosis	O
.	O
'	O
Here	O
he	O
states	O
that	O
suture	O
of	O
the	O
pleura	O
of	O
the	O
superior	O
aspect	O
of	O
the	O
hilum	O
to	O
the	O
mediastinal	O
pleura	O
may	O
effectively	O
elevate	O
a	O
little	O
the	O
pulmonary	O
artery	O
.	O

Perhaps	O
our	O
more	O
detailed	O
consideration	O
of	O
this	O
maneuver	O
may	O
add	O
to	O
its	O
general	O
usefulness	O
.	O

REFERENCES	O

1	O
Blalock	O
,	O
A	O
.	O
:	O
The	O
technique	O
of	O
creation	O
of	O
an	O
artificial	O
ductus	O
arteriosus	O
in	O
the	O

treatment	O
of	O
pulmonic	O
stenosis	O
.	O

J	O
.	O

Thorac	O
.	O

Surg	O
.	O
,	O
1947	O
,	O
16	O
,	O
244	O
.	O

2	O
Blalock	O
,	O
A	O
.	O
:	O
Surgical	O
procedures	O
employed	O
and	O
anatomical	O
variations	O
encountered	O

in	O
the	O
treatment	O
of	O
congenital	O
pulmonic	O
stenosis	O
.	O

Surg	O
.	O
,	O
Gyn	O
.	O

Obst	O
.	O
,	O
1948	O
,	O
87	O
,	O
385	O
.	O

3	O
Gross	O
,	O
R	O
.	O

E	O
.	O
,	O
Bill	O
,	O
A	O
.	O

H	O
.	O
,	O
Jr	O
.	O
,	O
and	O
Pierce	O
,	O
E	O
.	O

C	O
.	O
:	O
Methods	O
for	O
preservation	O
and	O

transplantation	O
of	O
aortic	O
grafts	O
.	O

Observation	O
on	O
arterial	O
grafts	O
in	O
dogs	S-Species
.	O

Report	O
of	O
transplantation	O
of	O
preserved	O
arterial	O
grafts	O
in	O
nine	O
human	S-Species
cases	O
.	O

Surg	O
.	O
,	O
Gyn	O
.	O

Obst	O
.	O
,	O
1949	O
,	O
88	O
,	O
689	O
.	O

4	O
Holman	O
,	O
E	O
.	O
:	O
The	O
surgery	O
of	O
pulmonary	O
stenosis	O
.	O

Experiences	O
with	O
left	O
subclavian	O

to	O
left	O
pulmonary	O
artery	O
anastomosis	O
.	O

J	O
.	O

Thorac	O
.	O

Surg	O
.	O
,	O
1949	O
,	O
18	O
,	O
827	O
.	O

5	O
Johnson	O
,	O
J	O
.	O
,	O
Kirby	O
,	O
C	O
.	O

K	O
.	O
,	O
Greifenstein	O
,	O
F	O
.	O

E	O
.	O
,	O
and	O
Costillo	O
,	O
A	O
.	O
:	O
The	O
experimental	O

and	O
clinical	O
use	O
of	O
vein	O
grafts	O
to	O
replace	O
defects	O
of	O
large	O
arteries	O
.	O

Surgery	O
,	O
1949	O
,	O
26	O
,	O
945	O
.	O

492	O
YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O

6	O
Lam	O
,	O
C	O
.	O

R	O
.	O
:	O
The	O
choice	O
of	O
the	O
side	O
for	O
approach	O
in	O
operations	O
for	O
pulmonary	O

stenosis	O
.	O

J	O
.	O

Thorac	O
.	O

Surg	O
.	O
,	O
1949	O
,	O
18	O
,	O
661	O
.	O

7	O
Olim	O
,	O
C	O
.	O

B	O
.	O
:	O
Experiences	O
in	O
the	O
surgical	O
treatment	O
of	O
congenital	O
pulmonary	O

stenosis	O
.	O

American	O
Surgeon	O
,	O
1951	O
,	O
17	O
,	O
245	O
.	O

8	O
Paine	O
,	O
J	O
.	O

R	O
.	O
and	O
Varco	O
,	O
R	O
.	O

C	O
.	O
:	O
Experiences	O
with	O
the	O
surgical	O
treatment	O
of	O
pul	O

monic	O
stenosis	O
.	O

Surgery	O
,	O
1948	O
,	O
24	O
,	O
355	O
.	O

9	O
Potts	O
,	O
W	O
.	O

J	O
.	O
and	O
Smith	O
,	O
S	O
.	O
:	O
New	O
surgical	O
procedures	O
in	O
certain	O
cases	O
of	O
congenital	O

pulmonary	O
stenosis	O
.	O

Arch	O
.	O

Surg	O
.	O
,	O
1949	O
,	O
59	O
,	O
491	O
.	O

10	O
Potts	O
,	O
W	O
.	O

J	O
.	O
,	O
Smith	O
S	O
.	O
,	O
and	O
Gibson	O
,	O
S	O
.	O
:	O
Anastomosis	O
of	O
the	O
aorta	O
to	O
a	O
pulmonary	O

artery	O
;	O
certain	O
types	O
in	O
congenital	O
heart	O
disease	O
.	O

J	O
.	O

Am	O
.	O

M	O
.	O

Ass	O
.	O
,	O
1946	O
,	O
132	O
,	O
627	O
.	O

Tissue	O
remodeling	O
:	O
a	O
mating	O
-	O
induced	O
differentiation	O
program	O
for	O
the	O
Drosophila	S-Species
oviduct	O

Abstract	O

Background	O

In	O
both	O
vertebrates	O
and	O
invertebrates	O
,	O
the	O
oviduct	O
is	O
an	O
epithelial	O
tube	O
surrounded	O
by	O
visceral	O
muscles	O
that	O
serves	O
as	O
a	O
conduit	O
for	O
gamete	O
transport	O
between	O
the	O
ovary	O
and	O
uterus	O
.	O

While	O
Drosophila	O
is	O
a	O
model	O
system	O
for	O
tubular	O
organ	O
development	O
,	O
few	O
studies	O
have	O
addressed	O
the	O
development	O
of	O
the	O
fly	S-Species
'	O
s	O
oviduct	O
.	O

Recent	O
studies	O
in	O
Drosophila	O
have	O
identified	O
mating	O
-	O
responsive	O
genes	O
and	O
proteins	O
whose	O
levels	O
in	O
the	O
oviduct	O
are	O
altered	O
by	O
mating	O
.	O

Since	O
many	O
of	O
these	O
molecules	O
(	O
e	O
.	O
g	O
.	O
Muscle	O
LIM	O
protein	O
84B	O
,	O
Coracle	O
,	O
Neuroglian	O
)	O
have	O
known	O
roles	O
in	O
the	O
differentiation	O
of	O
muscle	O
and	O
epithelia	O
of	O
other	O
organs	O
,	O
mating	O
may	O
trigger	O
similar	O
differentiation	O
events	O
in	O
the	O
oviduct	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
mating	O
mediates	O
the	O
last	O
stages	O
of	O
oviduct	O
differentiation	O
in	O
which	O
organ	O
-	O
specific	O
specializations	O
arise	O
.	O

Results	O

Using	O
electron	O
-	O
and	O
confocal	O
-	O
microscopy	O
we	O
identified	O
tissue	O
-	O
wide	O
post	O
-	O
mating	O
changes	O
in	O
the	O
oviduct	O
including	O
differentiation	O
of	O
cellular	O
junctions	O
,	O
remodeling	O
of	O
extracellular	O
matrix	O
,	O
increased	O
myofibril	O
formation	O
,	O
and	O
increased	O
innervation	O
.	O

Analysis	O
of	O
once	O
-	O
and	O
twice	O
-	O
mated	O
females	O
reveals	O
that	O
some	O
mating	O
-	O
responsive	O
proteins	O
respond	O
only	O
to	O
the	O
first	O
mating	O
,	O
while	O
others	O
respond	O
to	O
both	O
matings	O
.	O

Conclusion	O

We	O
uncovered	O
ultrastructural	O
changes	O
in	O
the	O
mated	O
oviduct	O
that	O
are	O
consistent	O
with	O
the	O
roles	O
that	O
mating	O
-	O
responsive	O
proteins	O
play	O
in	O
muscle	O
and	O
epithelial	O
differentiation	O
elsewhere	O
.	O

This	O
suggests	O
that	O
mating	O
triggers	O
the	O
late	O
differentiation	O
of	O
the	O
oviduct	O
.	O

Furthermore	O
,	O
we	O
suggest	O
that	O
mating	O
-	O
responsive	O
proteins	O
that	O
respond	O
only	O
to	O
the	O
first	O
mating	O
are	O
involved	O
in	O
the	O
final	O
maturation	O
of	O
the	O
oviduct	O
while	O
proteins	O
that	O
remain	O
responsive	O
to	O
later	O
matings	O
are	O
also	O
involved	O
in	O
maintenance	O
and	O
ongoing	O
function	O
of	O
the	O
oviduct	O
.	O

Taken	O
together	O
,	O
our	O
results	O
establish	O
the	O
oviduct	O
as	O
an	O
attractive	O
system	O
to	O
address	O
mechanisms	O
that	O
regulate	O
the	O
late	O
stages	O
of	O
differentiation	O
and	O
maintenance	O
of	O
a	O
tubular	O
organ	O
.	O

Background	O

Most	O
internal	O
organs	O
,	O
including	O
the	O
vascular	O
and	O
respiratory	O
systems	O
and	O
the	O
gastro	O
-	O
intestinal	O
and	O
urinary	O
-	O
genital	O
tracts	O
are	O
comprised	O
of	O
a	O
single	O
epithelial	O
tube	O
or	O
a	O
network	O
of	O
tubes	O
.	O

Tubular	O
organs	O
serve	O
as	O
conduits	O
for	O
the	O
transport	O
of	O
gases	O
,	O
liquids	O
,	O
or	O
solutes	O
,	O
and	O
serve	O
as	O
barriers	O
between	O
biological	O
compartments	O
.	O

To	O
create	O
tubes	O
with	O
specific	O
flow	O
and	O
barrier	O
properties	O
,	O
the	O
morphology	O
of	O
the	O
tube	O
must	O
be	O
precisely	O
specified	O
during	O
development	O
and	O
modulated	O
by	O
physiology	O
.	O

To	O
accommodate	O
specific	O
physiological	O
roles	O
,	O
tissue	O
-	O
specific	O
programs	O
for	O
differentiation	O
are	O
employed	O
at	O
the	O
last	O
stages	O
of	O
development	O
.	O

While	O
much	O
is	O
known	O
about	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
tube	O
formation	O
[	O
1	O
-	O
6	O
]	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
that	O
regulate	O
the	O
late	O
stages	O
of	O
differentiation	O
in	O
which	O
organ	O
-	O
specific	O
specializations	O
arise	O
.	O

The	O
conservation	O
of	O
genes	O
and	O
similarity	O
in	O
tubular	O
organ	O
design	O
across	O
taxa	O
make	O
Drosophila	O
an	O
excellent	O
model	O
for	O
understanding	O
organogenesis	O
in	O
higher	O
animals	O
.	O

In	O
Drosophila	O
,	O
the	O
best	O
understood	O
tubular	O
organs	O
from	O
a	O
developmental	O
point	O
of	O
view	O
are	O
the	O
trachea	O
and	O
salivary	O
gland	O
.	O

Studies	O
of	O
these	O
organs	O
reveal	O
a	O
general	O
program	O
for	O
tubular	O
organ	O
development	O
,	O
in	O
which	O
combinatorial	O
expression	O
of	O
global	O
patterning	O
genes	O
specifies	O
positions	O
within	O
the	O
embryo	O
for	O
the	O
subsequent	O
activation	O
of	O
tissue	O
-	O
specific	O
early	O
genes	O
and	O
transcription	O
factors	O
.	O

This	O
program	O
results	O
in	O
the	O
activation	O
of	O
downstream	O
genes	O
involved	O
in	O
terminal	O
differentiation	O
of	O
organ	O
-	O
specific	O
specializations	O
such	O
as	O
the	O
cuticle	O
that	O
lines	O
the	O
tracheal	O
lumen	O
[	O
1	O
,	O
2	O
,	O
4	O
,	O
7	O
-	O
9	O
]	O
.	O

The	O
Drosophila	S-Species
female	O
reproductive	O
tract	O
is	O
another	O
tubular	O
system	O
,	O
consisting	O
of	O
the	O
uterus	O
and	O
a	O
common	O
oviduct	O
(	O
the	O
main	O
tube	O
)	O
that	O
branches	O
into	O
two	O
lateral	O
oviducts	O
.	O

Regional	O
differences	O
in	O
function	O
are	O
observed	O
along	O
the	O
length	O
of	O
the	O
tract	O
,	O
with	O
egg	O
activation	O
occurring	O
largely	O
at	O
the	O
proximal	O
end	O
,	O
in	O
the	O
lateral	O
oviducts	O
,	O
and	O
fertilization	O
occurring	O
at	O
the	O
distal	O
end	O
,	O
in	O
the	O
uterus	O
[	O
10	O
,	O
11	O
]	O
.	O

Unlike	O
other	O
tubular	O
organs	O
,	O
little	O
is	O
known	O
about	O
the	O
development	O
of	O
the	O
female	O
reproductive	O
tract	O
.	O

However	O
,	O
regional	O
differences	O
in	O
function	O
suggest	O
the	O
presence	O
of	O
region	O
-	O
specific	O
differentiation	O
programs	O
within	O
the	O
female	O
reproductive	O
tract	O
.	O

In	O
Drosophila	O
,	O
mating	O
induces	O
changes	O
in	O
female	O
behavior	O
and	O
physiology	O
via	O
molecules	O
transmitted	O
in	O
the	O
seminal	O
fluid	O
.	O

These	O
changes	O
are	O
rapid	O
and	O
lead	O
to	O
a	O
mated	O
female	O
state	O
which	O
is	O
profoundly	O
different	O
from	O
the	O
unmated	O
female	O
state	O
.	O

While	O
an	O
unmated	O
female	O
lays	O
few	O
eggs	O
and	O
readily	O
accepts	O
the	O
courtship	O
efforts	O
of	O
a	O
male	O
,	O
a	O
mated	O
female	O
exhibits	O
increased	O
egg	O
-	O
laying	O
and	O
actively	O
rejects	O
males	O
[	O
12	O
-	O
19	O
]	O
.	O

Microarray	O
studies	O
of	O
whole	O
flies	S-Species
reveal	O
that	O
the	O
changes	O
in	O
egg	O
-	O
laying	O
rate	O
are	O
accompanied	O
by	O
a	O
change	O
in	O
gene	O
expression	O
.	O

Within	O
three	O
hours	O
of	O
mating	O
there	O
is	O
an	O
increase	O
in	O
expression	O
of	O
a	O
small	O
number	O
of	O
genes	O
[	O
20	O
,	O
21	O
]	O
.	O

Rapid	O
changes	O
in	O
gene	O
expression	O
,	O
as	O
well	O
as	O
protein	O
abundance	O
,	O
have	O
also	O
been	O
observed	O
in	O
the	O
female	O
reproductive	O
tract	O
[	O
22	O
,	O
23	O
]	O
.	O

In	O
the	O
upper	O
reproductive	O
tract	O
(	O
lateral	O
and	O
common	O
oviducts	O
,	O
hereafter	O
,	O
oviduct	O
)	O
,	O
mating	O
induces	O
an	O
increase	O
in	O
immune	O
related	O
transcripts	O
and	O
down	O
regulates	O
transcription	O
factors	O
involved	O
in	O
cell	O
growth	O
and	O
differentiation	O
.	O

At	O
the	O
protein	O
level	O
mating	O
induces	O
increased	O
abundance	O
of	O
proteins	O
associated	O
with	O
muscle	O
assembly	O
and	O
function	O
and	O
cytoskeletal	O
proteins	O
associated	O
with	O
epithelial	O
morphogenesis	O
[	O
23	O
]	O
.	O

Since	O
many	O
of	O
these	O
mating	O
-	O
responsive	O
proteins	O
act	O
in	O
late	O
differentiation	O
pathways	O
of	O
muscle	O
and	O
epithelia	O
elsewhere	O
(	O
e	O
.	O
g	O
.	O
Bent	O
,	O
Muscle	O
LIM	O
protein	O
84B	O
(	O
Mlp84B	O
)	O
,	O
Neuroglian	O
(	O
Nrg	O
)	O
,	O
Coracle	O
(	O
Cora	O
)	O
)	O
,	O
we	O
hypothesize	O
that	O
mating	O
triggers	O
similar	O
differentiation	O
in	O
the	O
oviduct	O
.	O

To	O
test	O
our	O
hypothesis	O
we	O
characterized	O
the	O
ultrastructure	O
of	O
oviduct	O
epithelia	O
and	O
muscle	O
,	O
as	O
well	O
as	O
the	O
pattern	O
of	O
innervation	O
before	O
and	O
after	O
mating	O
.	O

We	O
then	O
examined	O
the	O
effect	O
of	O
different	O
mating	O
regimes	O
on	O
oviduct	O
mating	O
-	O
responsive	O
cytoskeletal	O
proteins	O
and	O
on	O
female	O
reproductive	O
output	O
.	O

Our	O
results	O
suggest	O
that	O
active	O
tissue	O
remodeling	O
takes	O
place	O
in	O
the	O
oviduct	O
epithelia	O
and	O
musculature	O
in	O
response	O
to	O
mating	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
innervation	O
of	O
the	O
oviduct	O
after	O
mating	O
.	O

Our	O
results	O
show	O
that	O
the	O
reproductive	O
tract	O
is	O
an	O
attractive	O
system	O
to	O
address	O
mechanisms	O
that	O
regulate	O
the	O
late	O
stages	O
of	O
tissue	O
differentiation	O
in	O
a	O
tubular	O
organ	O
.	O

Unlike	O
other	O
tubular	O
organs	O
,	O
the	O
last	O
differentiation	O
stage	O
of	O
the	O
oviduct	O
is	O
triggered	O
by	O
an	O
extrinsic	O
cue	O
(	O
mating	O
)	O
.	O

This	O
makes	O
it	O
possible	O
to	O
experimentally	O
control	O
the	O
onset	O
of	O
differentiation	O
,	O
with	O
an	O
opportunity	O
to	O
independently	O
examine	O
the	O
effects	O
of	O
mating	O
and	O
age	O
.	O

In	O
addition	O
,	O
it	O
allows	O
us	O
to	O
examine	O
processes	O
essential	O
for	O
reproduction	O
.	O

Results	O

Mating	O
induces	O
changes	O
in	O
oviduct	O
lumen	O

Our	O
previous	O
molecular	O
profiling	O
showed	O
that	O
mating	O
promotes	O
changes	O
in	O
actin	O
-	O
based	O
cytoskeletal	O
molecules	O
and	O
suggests	O
that	O
mating	O
triggers	O
molecular	O
changes	O
and	O
tissue	O
remodeling	O
in	O
the	O
female	O
reproductive	O
tract	O
that	O
mediate	O
its	O
progression	O
to	O
a	O
mature	O
functional	O
stage	O
[	O
23	O
]	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechanisms	O
that	O
underlie	O
this	O
progression	O
,	O
we	O
used	O
light	O
and	O
electron	O
microscopy	O
to	O
determine	O
the	O
morphological	O
status	O
of	O
the	O
oviduct	O
in	O
unmated	O
and	O
mated	O
3	O
-	O
day	O
old	O
females	O
.	O

In	O
nearly	O
all	O
mated	O
reproductive	O
tracts	O
processed	O
for	O
microscopy	O
(	O
8	O
/	O
9	O
)	O
,	O
an	O
egg	O
was	O
located	O
in	O
one	O
of	O
the	O
lateral	O
oviducts	O
,	O
whereas	O
an	O
egg	O
was	O
never	O
observed	O
in	O
the	O
oviduct	O
of	O
unmated	O
reproductive	O
tracts	O
(	O
5	O
/	O
5	O
)	O
(	O
Figure	O
1	O
)	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
previous	O
studies	O
that	O
report	O
increased	O
ovulation	O
and	O
egg	O
-	O
laying	O
at	O
6	O
h	O
post	O
-	O
mating	O
[	O
24	O
]	O
.	O

In	O
all	O
unmated	O
reproductive	O
tracts	O
examined	O
,	O
the	O
region	O
between	O
the	O
lateral	O
oviducts	O
and	O
the	O
middle	O
of	O
the	O
common	O
oviduct	O
was	O
either	O
tapered	O
or	O
constricted	O
,	O
whereas	O
this	O
region	O
appeared	O
relaxed	O
in	O
the	O
mated	O
reproductive	O
tract	O
(	O
Figure	O
1A	O
and	O
1D	O
)	O
.	O

These	O
observations	O
raise	O
the	O
possibility	O
that	O
the	O
lumen	O
is	O
narrow	O
in	O
the	O
unmated	O
oviduct	O
and	O
larger	O
in	O
the	O
mated	O
oviduct	O
.	O

To	O
address	O
this	O
possibility	O
,	O
we	O
collected	O
serial	O
1	O
mu	O
m	O
longitudinal	O
sections	O
through	O
the	O
reproductive	O
tracts	O
of	O
unmated	O
and	O
mated	O
females	O
and	O
stained	O
these	O
sections	O
with	O
toluidine	O
blue	O
to	O
survey	O
the	O
appearance	O
of	O
the	O
lumen	O
along	O
the	O
entire	O
length	O
of	O
the	O
oviduct	O
(	O
Figure	O
1B	O
and	O
1E	O
)	O
.	O

Our	O
examination	O
reveals	O
that	O
,	O
in	O
unmated	O
reproductive	O
tracts	O
,	O
the	O
lateral	O
oviduct	O
lumen	O
has	O
an	O
irregular	O
shape	O
,	O
while	O
the	O
common	O
oviduct	O
lumen	O
appears	O
straight	O
.	O

Moreover	O
,	O
in	O
all	O
the	O
unmated	O
reproductive	O
tracts	O
sectioned	O
,	O
we	O
detected	O
patches	O
of	O
darkly	O
stained	O
material	O
in	O
the	O
lumen	O
of	O
the	O
lower	O
common	O
oviduct	O
.	O

In	O
the	O
mated	O
reproductive	O
tract	O
,	O
the	O
lumen	O
of	O
the	O
upper	O
oviduct	O
(	O
defined	O
as	O
the	O
lateral	O
oviduct	O
and	O
upper	O
part	O
of	O
the	O
common	O
oviduct	O
)	O
has	O
an	O
irregular	O
shape	O
,	O
and	O
the	O
lumen	O
of	O
the	O
lower	O
oviduct	O
(	O
defined	O
as	O
the	O
lower	O
part	O
of	O
common	O
oviduct	O
)	O
appears	O
straight	O
.	O

In	O
addition	O
,	O
the	O
lumen	O
of	O
the	O
lower	O
oviduct	O
appears	O
wider	O
in	O
mated	O
than	O
unmated	O
reproductive	O
tracts	O
(	O
Figure	O
1C	O
and	O
1F	O
)	O
.	O

Interestingly	O
,	O
darkly	O
stained	O
material	O
was	O
not	O
detected	O
in	O
the	O
oviduct	O
lumen	O
of	O
mated	O
females	O
.	O

This	O
observation	O
appears	O
to	O
be	O
consistent	O
with	O
the	O
description	O
made	O
by	O
Mahowald	O
et	O
al	O
.	O

[	O
25	O
]	O
,	O
who	O
reported	O
that	O
the	O
oviduct	O
lumen	O
of	O
unmated	O
females	O
is	O
nearly	O
filled	O
with	O
an	O
intima	O
-	O
like	O
matrix	O
and	O
that	O
this	O
matrix	O
is	O
reduced	O
after	O
mating	O
.	O

Because	O
3	O
-	O
day	O
-	O
old	O
mated	O
females	O
lay	O
eggs	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
lumenal	O
material	O
and	O
increase	O
in	O
lumen	O
size	O
in	O
mated	O
females	O
occurred	O
before	O
or	O
after	O
the	O
passage	O
of	O
eggs	O
.	O

We	O
suggest	O
that	O
mating	O
directly	O
or	O
indirectly	O
induces	O
morphological	O
changes	O
in	O
the	O
oviduct	O
that	O
facilitate	O
egg	O
passage	O
through	O
the	O
duct	O
.	O

Taken	O
together	O
,	O
our	O
observations	O
lead	O
us	O
to	O
propose	O
that	O
the	O
oviduct	O
lumen	O
is	O
closed	O
and	O
/	O
or	O
obstructed	O
in	O
the	O
unmated	O
reproductive	O
tract	O
,	O
and	O
that	O
mating	O
induces	O
changes	O
in	O
the	O
epithelia	O
and	O
/	O
or	O
muscle	O
that	O
"	O
open	O
"	O
the	O
oviduct	O
lumen	O
.	O

Initial	O
formation	O
of	O
cell	O
-	O
cell	O
junctions	O
in	O
oviduct	O
epithelia	O
is	O
mating	O
-	O
independent	O

To	O
determine	O
whether	O
mating	O
induces	O
specific	O
morphological	O
changes	O
in	O
the	O
oviduct	O
epithelia	O
post	O
-	O
mating	O
,	O
we	O
next	O
examined	O
the	O
ultrastructure	O
of	O
the	O
oviduct	O
epithelia	O
in	O
unmated	O
and	O
mated	O
reproductive	O
tracts	O
.	O

Since	O
molecular	O
profiling	O
demonstrates	O
that	O
proteins	O
associated	O
with	O
cellular	O
junctions	O
such	O
as	O
alpha	O
-	O
and	O
beta	O
-	O
Spectrin	O
(	O
Spec	O
)	O
,	O
Cora	O
,	O
and	O
Nrg	O
[	O
23	O
]	O
increase	O
post	O
-	O
mating	O
,	O
we	O
first	O
determined	O
the	O
status	O
of	O
the	O
cellular	O
junctions	O
in	O
the	O
oviduct	O
epithelia	O
of	O
unmated	O
females	O
,	O
and	O
whether	O
these	O
junctions	O
change	O
post	O
-	O
mating	O
.	O

In	O
Drosophila	O
,	O
most	O
ectodermally	O
derived	O
epithelia	O
(	O
such	O
as	O
the	O
epidermis	O
and	O
trachea	O
)	O
,	O
with	O
a	O
few	O
exceptions	O
,	O
are	O
joined	O
apically	O
by	O
a	O
belt	O
-	O
like	O
adherens	O
junction	O
called	O
the	O
zonal	O
adherens	O
junction	O
(	O
ZA	O
)	O
followed	O
basally	O
by	O
a	O
septate	O
junction	O
(	O
SJ	O
)	O
[	O
26	O
]	O
.	O

Our	O
analysis	O
reveals	O
that	O
the	O
oviduct	O
is	O
lined	O
,	O
along	O
its	O
entire	O
length	O
,	O
by	O
a	O
monolayered	O
epithelium	O
comprised	O
of	O
squamous	O
-	O
type	O
cells	O
.	O

Although	O
region	O
-	O
specific	O
differences	O
in	O
morphology	O
were	O
observed	O
,	O
all	O
oviduct	O
epithelia	O
examined	O
,	O
in	O
both	O
unmated	O
and	O
mated	O
females	O
,	O
are	O
joined	O
along	O
their	O
lateral	O
membranes	O
by	O
an	O
extensive	O
SJ	O
and	O
lack	O
an	O
apical	O
ZA	O
(	O
Figure	O
2	O
)	O
.	O

SJs	O
and	O
ZAs	O
form	O
complete	O
belts	O
that	O
surround	O
the	O
epithelial	O
cell	O
,	O
thus	O
making	O
these	O
junctions	O
easily	O
visible	O
in	O
transverse	O
sections	O
through	O
the	O
epithelium	O
.	O

Because	O
ZAs	O
were	O
not	O
detected	O
in	O
our	O
transverse	O
sections	O
through	O
the	O
oviduct	O
,	O
this	O
implies	O
that	O
ZAs	O
never	O
formed	O
,	O
or	O
developed	O
earlier	O
and	O
were	O
lost	O
(	O
Figure	O
2D	O
)	O
.	O

Interestingly	O
,	O
we	O
did	O
not	O
detect	O
any	O
ultrastructural	O
differences	O
in	O
the	O
SJs	O
at	O
6	O
h	O
post	O
-	O
mating	O
,	O
but	O
we	O
did	O
uncover	O
differences	O
in	O
SJ	O
ultrastructure	O
in	O
different	O
regions	O
of	O
the	O
oviduct	O
.	O

Based	O
on	O
their	O
ultrastructure	O
,	O
two	O
types	O
of	O
SJs	O
,	O
smooth	O
and	O
pleated	O
,	O
can	O
be	O
distinguished	O
in	O
Drosophila	O
[	O
26	O
]	O
.	O

Smooth	O
SJs	O
are	O
distinguished	O
by	O
the	O
lack	O
of	O
visible	O
septae	O
and	O
the	O
appearance	O
of	O
electron	O
dense	O
material	O
in	O
the	O
intercellular	O
space	O
,	O
while	O
pleated	O
SJs	O
are	O
distinguished	O
by	O
the	O
ladder	O
-	O
like	O
appearance	O
of	O
septae	O
.	O

In	O
the	O
lateral	O
oviducts	O
and	O
upper	O
common	O
oviduct	O
,	O
septa	O
were	O
not	O
detected	O
in	O
the	O
SJ	O
,	O
thus	O
these	O
SJs	O
represent	O
smooth	O
SJs	O
or	O
an	O
immature	O
stage	O
of	O
pleated	O
SJ	O
(	O
Figure	O
2A	O
,	O
2A	O
'	O
,	O
2A	O
"	O
)	O
.	O

In	O
contrast	O
,	O
a	O
ladder	O
-	O
like	O
arrangement	O
of	O
septae	O
was	O
often	O
visible	O
in	O
the	O
SJs	O
of	O
the	O
lower	O
common	O
oviduct	O
(	O
Figure	O
2C	O
'	O
)	O
,	O
thus	O
these	O
SJs	O
can	O
be	O
classified	O
as	O
pleated	O
.	O

Unlike	O
the	O
smooth	O
-	O
like	O
SJs	O
of	O
the	O
upper	O
oviduct	O
,	O
the	O
pleated	O
SJs	O
of	O
the	O
lower	O
oviduct	O
are	O
followed	O
basally	O
by	O
spot	O
type	O
adherens	O
junction	O
(	O
spot	O
AJs	O
)	O
(	O
Figure	O
2B	O
,	O
2B	O
'	O
;	O
additional	O
file	O
1	O
)	O
.	O

Further	O
analysis	O
is	O
necessary	O
to	O
determine	O
if	O
the	O
SJs	O
of	O
the	O
upper	O
and	O
lower	O
oviduct	O
represent	O
different	O
types	O
or	O
different	O
developmental	O
stages	O
.	O

Our	O
findings	O
demonstrate	O
that	O
the	O
initial	O
formation	O
of	O
SJs	O
,	O
as	O
well	O
as	O
spot	O
AJs	O
in	O
the	O
lower	O
oviduct	O
,	O
are	O
mating	O
-	O
independent	O
.	O

This	O
raises	O
an	O
interesting	O
question	O
.	O

Why	O
are	O
SJ	O
proteins	O
such	O
as	O
Cora	O
and	O
Nrg	O
up	O
-	O
regulated	O
post	O
-	O
mating	O
if	O
SJs	O
are	O
formed	O
prior	O
to	O
mating	O
?	O

It	O
is	O
possible	O
that	O
the	O
increased	O
expression	O
of	O
SJ	O
proteins	O
is	O
associated	O
with	O
functional	O
changes	O
in	O
polarized	O
secretion	O
post	O
-	O
mating	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
SJs	O
play	O
an	O
unexpected	O
role	O
in	O
regulating	O
the	O
apical	O
secretion	O
of	O
specialized	O
extracellular	O
matrix	O
molecules	O
in	O
the	O
trachea	O
[	O
27	O
,	O
28	O
]	O
,	O
and	O
that	O
these	O
molecules	O
are	O
important	O
regulators	O
of	O
lumen	O
size	O
.	O

Mating	O
modulates	O
apical	O
secretory	O
activity	O
in	O
the	O
oviduct	O

Given	O
the	O
presence	O
of	O
extensive	O
SJs	O
in	O
the	O
oviduct	O
and	O
the	O
role	O
of	O
SJs	O
in	O
regulating	O
apical	O
secretion	O
of	O
extracellular	O
matrix	O
molecules	O
in	O
other	O
epithelia	O
(	O
e	O
.	O
g	O
.	O
trachea	O
)	O
,	O
we	O
asked	O
if	O
mating	O
modulates	O
apical	O
secretion	O
in	O
the	O
oviduct	O
epithelia	O
.	O

Our	O
ultrastructural	O
analysis	O
reveals	O
that	O
different	O
regions	O
of	O
the	O
oviduct	O
display	O
different	O
apical	O
membrane	O
morphology	O
(	O
i	O
.	O
e	O
microvilli	O
or	O
pleats	O
)	O
(	O
see	O
Figures	O
2	O
and	O
additional	O
file	O
2A	O
and	O
2A	O
)	O
,	O
but	O
all	O
epithelia	O
are	O
covered	O
by	O
an	O
electron	O
dense	O
apical	O
extracellular	O
matrix	O
(	O
AECM	O
)	O
and	O
a	O
thin	O
layer	O
of	O
cuticle	O
.	O

We	O
found	O
that	O
mating	O
induces	O
ultrastructural	O
changes	O
in	O
the	O
AECM	O
and	O
cuticle	O
in	O
both	O
the	O
upper	O
and	O
lower	O
oviduct	O
.	O

In	O
the	O
upper	O
oviduct	O
of	O
the	O
unmated	O
female	O
,	O
the	O
AECM	O
varies	O
in	O
thickness	O
along	O
the	O
apical	O
surface	O
(	O
Figure	O
3A	O
)	O
.	O

Some	O
areas	O
have	O
little	O
AECM	O
,	O
while	O
other	O
areas	O
are	O
covered	O
by	O
a	O
distinct	O
layer	O
of	O
AECM	O
(	O
~	O
1	O
-	O
2	O
mu	O
m	O
in	O
thickness	O
;	O
Figure	O
3B	O
)	O
.	O

However	O
,	O
the	O
AECM	O
of	O
mated	O
females	O
is	O
more	O
evenly	O
distributed	O
along	O
the	O
apical	O
surface	O
,	O
(	O
~	O
2	O
mu	O
m	O
in	O
thickness	O
;	O
Figure	O
3E	O
)	O
.	O

Strikingly	O
,	O
the	O
AECM	O
and	O
cuticle	O
of	O
mated	O
females	O
have	O
a	O
ruffled	O
appearance	O
,	O
suggesting	O
that	O
the	O
AECM	O
and	O
cuticle	O
have	O
increased	O
in	O
surface	O
area	O
(	O
Figure	O
3F	O
)	O
.	O

Electron	O
dense	O
granules	O
up	O
to	O
~	O
1	O
.	O
5	O
mu	O
m	O
in	O
diameter	O
were	O
occasionally	O
observed	O
in	O
both	O
the	O
AECM	O
and	O
cell	O
cytoplasm	O
(	O
Figure	O
3F	O
)	O
.	O

Although	O
further	O
analysis	O
is	O
needed	O
to	O
determine	O
the	O
role	O
of	O
these	O
granules	O
in	O
the	O
oviduct	O
epithelia	O
,	O
it	O
is	O
possible	O
that	O
these	O
granules	O
participate	O
in	O
the	O
secretion	O
and	O
deposition	O
of	O
the	O
AECM	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
polarized	O
secretion	O
via	O
the	O
AECM	O
,	O
while	O
ongoing	O
in	O
the	O
upper	O
oviduct	O
of	O
the	O
unmated	O
female	O
is	O
enhanced	O
and	O
/	O
or	O
modulated	O
post	O
-	O
mating	O
.	O

Post	O
-	O
mating	O
changes	O
in	O
AECM	O
ultrastructure	O
are	O
also	O
observed	O
in	O
the	O
lower	O
common	O
oviduct	O
.	O

However	O
,	O
unlike	O
the	O
AECM	O
of	O
the	O
upper	O
oviduct	O
,	O
the	O
AECM	O
of	O
the	O
lower	O
oviduct	O
is	O
well	O
developed	O
prior	O
to	O
mating	O
.	O

In	O
the	O
lower	O
oviduct	O
of	O
the	O
unmated	O
female	O
,	O
the	O
AECM	O
consists	O
of	O
an	O
amorphous	O
electron	O
dense	O
material	O
and	O
is	O
unevenly	O
distributed	O
,	O
forming	O
a	O
thick	O
,	O
bulbous	O
layer	O
above	O
the	O
plasma	O
membrane	O
in	O
some	O
regions	O
(	O
additional	O
file	O
2	O
)	O
.	O

Matrix	O
-	O
like	O
material	O
is	O
also	O
observed	O
in	O
the	O
lumen	O
,	O
but	O
this	O
material	O
is	O
more	O
electron	O
dense	O
than	O
the	O
AECM	O
(	O
additional	O
file	O
2A	O
and	O
2A	O
)	O
.	O

In	O
the	O
mated	O
female	O
,	O
the	O
AECM	O
is	O
flattened	O
against	O
the	O
plasma	O
membrane	O
and	O
is	O
uniformly	O
distributed	O
along	O
the	O
apical	O
surface	O
(	O
additional	O
file	O
2B	O
and	O
2B	O
)	O
.	O

Matrix	O
-	O
like	O
material	O
was	O
not	O
observed	O
in	O
the	O
center	O
of	O
the	O
lumen	O
,	O
but	O
small	O
pools	O
of	O
very	O
electron	O
dense	O
material	O
were	O
detected	O
in	O
the	O
spaces	O
between	O
the	O
epithelial	O
folds	O
(	O
additional	O
file	O
2C	O
and	O
2C	O
)	O
.	O

This	O
may	O
explain	O
why	O
lumenal	O
matrix	O
was	O
not	O
detected	O
at	O
the	O
light	O
microscopic	O
level	O
in	O
the	O
mated	O
female	O
oviduct	O
(	O
see	O
Figure	O
1E	O
and	O
1F	O
)	O
.	O

Taken	O
together	O
,	O
our	O
observations	O
suggest	O
that	O
the	O
lower	O
common	O
oviduct	O
is	O
a	O
site	O
of	O
active	O
apical	O
secretion	O
in	O
both	O
mated	O
and	O
unmated	O
females	O
,	O
and	O
that	O
matrix	O
secretion	O
,	O
particularly	O
in	O
the	O
lumen	O
,	O
is	O
reduced	O
post	O
-	O
mating	O
.	O

These	O
findings	O
raise	O
the	O
intriguing	O
possibility	O
that	O
the	O
AECM	O
and	O
lumenal	O
matrix	O
function	O
as	O
a	O
plug	O
in	O
the	O
lower	O
oviduct	O
,	O
and	O
that	O
mating	O
induces	O
the	O
breakdown	O
of	O
this	O
plug	O
.	O

Mating	O
induces	O
changes	O
in	O
hemi	O
-	O
adherens	O
junctions	O
in	O
upper	O
oviduct	O

In	O
addition	O
to	O
modulating	O
secretion	O
at	O
the	O
apical	O
membrane	O
,	O
mating	O
induces	O
changes	O
at	O
the	O
basolateral	O
membrane	O
.	O

In	O
many	O
epithelia	O
,	O
one	O
of	O
the	O
last	O
steps	O
of	O
differentiation	O
is	O
the	O
development	O
of	O
a	O
layer	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
called	O
the	O
basal	O
lamina	O
that	O
covers	O
the	O
apical	O
and	O
/	O
or	O
basal	O
membranes	O
and	O
the	O
concomitant	O
development	O
of	O
hemi	O
-	O
adherens	O
junctions	O
(	O
HAJs	O
)	O
.	O

HAJs	O
connect	O
the	O
cell	O
cytoskeleton	O
with	O
the	O
ECM	O
and	O
are	O
formed	O
at	O
virtually	O
all	O
cell	O
surfaces	O
that	O
contact	O
an	O
ECM	O
.	O

HAJs	O
can	O
be	O
distinguished	O
at	O
the	O
ultrastructural	O
level	O
as	O
a	O
patch	O
-	O
like	O
,	O
electron	O
dense	O
undercoat	O
of	O
the	O
plasma	O
membrane	O
that	O
opposes	O
the	O
basal	O
lamina	O
(	O
[	O
26	O
]	O
;	O
Figure	O
3G	O
,	O
3H	O
)	O
.	O

In	O
the	O
Drosophila	S-Species
embryo	O
,	O
the	O
HAJs	O
and	O
basal	O
lamina	O
are	O
formed	O
at	O
the	O
same	O
time	O
[	O
26	O
]	O
.	O

Because	O
the	O
basal	O
lamina	O
is	O
established	O
at	O
a	O
time	O
when	O
the	O
majority	O
of	O
extracellular	O
matrix	O
molecules	O
are	O
actively	O
secreted	O
[	O
26	O
,	O
29	O
]	O
,	O
this	O
suggests	O
that	O
the	O
formation	O
of	O
HAJs	O
is	O
tightly	O
coordinated	O
with	O
the	O
secretion	O
of	O
the	O
ECM	O
.	O

One	O
of	O
the	O
most	O
striking	O
post	O
-	O
mating	O
changes	O
observed	O
in	O
the	O
oviduct	O
epithelia	O
was	O
the	O
appearance	O
of	O
numerous	O
HAJs	O
along	O
the	O
basolateral	O
membrane	O
in	O
the	O
upper	O
oviduct	O
(	O
Figure	O
3	O
)	O
.	O

The	O
importance	O
of	O
HAJs	O
,	O
particularly	O
in	O
the	O
upper	O
oviduct	O
,	O
is	O
underscored	O
by	O
the	O
extensive	O
infolding	O
of	O
the	O
basolateral	O
membrane	O
that	O
is	O
observed	O
in	O
both	O
unmated	O
and	O
mated	O
females	O
(	O
Figure	O
3A	O
and	O
3E	O
)	O
.	O

The	O
infolded	O
membrane	O
gives	O
rise	O
to	O
a	O
highly	O
branched	O
intercellular	O
space	O
that	O
is	O
filled	O
with	O
an	O
ECM	O
(	O
Figure	O
3C	O
and	O
3G	O
)	O
.	O

This	O
ECM	O
is	O
contiguous	O
with	O
the	O
basal	O
lamina	O
that	O
surrounds	O
the	O
epithelia	O
.	O

Few	O
HAJs	O
were	O
observed	O
in	O
the	O
upper	O
oviduct	O
of	O
the	O
unmated	O
female	O
,	O
and	O
these	O
were	O
largely	O
restricted	O
to	O
the	O
basal	O
membrane	O
,	O
and	O
not	O
observed	O
along	O
the	O
basolateral	O
infolding	O
(	O
Figure	O
3C	O
)	O
.	O

In	O
contrast	O
,	O
numerous	O
HAJs	O
appear	O
along	O
the	O
basolateral	O
infolding	O
post	O
-	O
mating	O
in	O
this	O
region	O
of	O
the	O
oviduct	O
(	O
Figure	O
3F	O
-	O
3H	O
)	O
.	O

In	O
addition	O
,	O
the	O
intercellular	O
space	O
appears	O
wider	O
post	O
-	O
mating	O
(	O
Figure	O
3C	O
-	O
3D	O
and	O
3G	O
-	O
3H	O
)	O
,	O
suggesting	O
that	O
mating	O
induces	O
increased	O
secretion	O
and	O
/	O
or	O
deposition	O
of	O
the	O
ECM	O
in	O
this	O
cellular	O
compartment	O
and	O
brings	O
the	O
ECM	O
to	O
a	O
threshold	O
concentration	O
that	O
can	O
support	O
the	O
development	O
of	O
HAJs	O
.	O

HAJs	O
were	O
also	O
detected	O
along	O
the	O
basal	O
membrane	O
,	O
but	O
they	O
were	O
not	O
detected	O
along	O
the	O
apical	O
membrane	O
even	O
though	O
this	O
membrane	O
was	O
covered	O
by	O
an	O
ECM	O
.	O

Interestingly	O
,	O
while	O
the	O
basolateral	O
membrane	O
forms	O
very	O
shallow	O
folds	O
in	O
the	O
lower	O
oviduct	O
(	O
see	O
additional	O
file	O
2	O
)	O
,	O
HAJs	O
were	O
observed	O
along	O
this	O
membrane	O
in	O
unmated	O
reproductive	O
tracts	O
(	O
data	O
not	O
shown	O
)	O
,	O
thus	O
suggesting	O
that	O
the	O
epithelia	O
is	O
more	O
differentiated	O
in	O
this	O
region	O
of	O
the	O
oviduct	O
,	O
and	O
that	O
the	O
differentiation	O
of	O
the	O
upper	O
and	O
lower	O
oviduct	O
may	O
be	O
under	O
different	O
control	O
.	O

Muscle	O
differentiation	O
is	O
enhanced	O
post	O
-	O
mating	O

While	O
we	O
uncovered	O
post	O
-	O
mating	O
changes	O
in	O
the	O
oviduct	O
epithelia	O
that	O
might	O
facilitate	O
its	O
transition	O
to	O
a	O
high	O
egg	O
-	O
laying	O
state	O
,	O
this	O
transition	O
may	O
also	O
be	O
mediated	O
by	O
changes	O
in	O
oviduct	O
muscle	O
properties	O
and	O
/	O
or	O
activity	O
.	O

The	O
oviduct	O
is	O
lined	O
by	O
circular	O
muscle	O
fibers	O
with	O
supercontractile	O
characteristics	O
[	O
30	O
]	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
mef2	O
and	O
mlp84B	O
genes	O
that	O
regulate	O
muscle	O
differentiation	O
,	O
are	O
expressed	O
and	O
increased	O
post	O
-	O
mating	O
in	O
the	O
oviduct	O
,	O
as	O
well	O
as	O
in	O
the	O
sperm	O
storage	O
regions	O
of	O
the	O
reproductive	O
tract	O
[	O
22	O
,	O
23	O
]	O
.	O

This	O
suggests	O
that	O
mating	O
induces	O
muscle	O
differentiation	O
in	O
the	O
reproductive	O
tract	O
.	O

Muscle	O
differentiation	O
is	O
characterized	O
by	O
the	O
assembly	O
of	O
myofilaments	O
into	O
bundles	O
called	O
myofibrils	O
.	O

As	O
muscles	O
differentiate	O
,	O
myofibrils	O
and	O
z	O
-	O
bodies	O
appear	O
simultaneously	O
,	O
and	O
increase	O
in	O
number	O
until	O
the	O
cytoplasm	O
is	O
filled	O
with	O
myofibrils	O
[	O
31	O
]	O
.	O

Like	O
epithelia	O
,	O
one	O
of	O
the	O
last	O
steps	O
of	O
muscle	O
differentiation	O
is	O
the	O
secretion	O
of	O
a	O
basal	O
lamina	O
that	O
surrounds	O
the	O
muscle	O
fiber	O
.	O

To	O
determine	O
if	O
mating	O
induces	O
structural	O
changes	O
in	O
muscles	O
(	O
such	O
as	O
increased	O
myofibrils	O
)	O
we	O
examined	O
the	O
ultrastructure	O
of	O
muscle	O
fibers	O
in	O
the	O
upper	O
and	O
lower	O
parts	O
of	O
the	O
oviduct	O
.	O

Our	O
analysis	O
revealed	O
that	O
,	O
in	O
both	O
unmated	O
and	O
mated	O
reproductive	O
tracts	O
,	O
the	O
muscles	O
of	O
the	O
lower	O
oviduct	O
are	O
highly	O
differentiated	O
as	O
evidenced	O
by	O
the	O
high	O
density	O
of	O
myofibrils	O
,	O
well	O
developed	O
and	O
aligned	O
z	O
-	O
bodies	O
,	O
and	O
secretion	O
of	O
a	O
thick	O
,	O
electron	O
dense	O
basal	O
lamina	O
(	O
Figure	O
4E	O
and	O
4F	O
)	O
.	O

In	O
contrast	O
,	O
muscle	O
fibers	O
in	O
the	O
lateral	O
oviducts	O
and	O
upper	O
common	O
oviduct	O
appear	O
less	O
differentiated	O
than	O
muscles	O
in	O
the	O
lower	O
common	O
oviduct	O
,	O
as	O
evidenced	O
by	O
the	O
lesser	O
density	O
of	O
myofibrils	O
and	O
z	O
-	O
bodies	O
,	O
and	O
little	O
or	O
no	O
basal	O
lamina	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

Moreover	O
,	O
the	O
muscles	O
of	O
the	O
upper	O
oviduct	O
appear	O
more	O
differentiated	O
in	O
the	O
mated	O
than	O
in	O
unmated	O
reproductive	O
tracts	O
(	O
Figure	O
4A	O
-	O
4D	O
)	O
.	O

Interestingly	O
,	O
we	O
observed	O
neighboring	O
muscle	O
fibers	O
in	O
different	O
states	O
of	O
differentiation	O
in	O
the	O
lateral	O
oviducts	O
in	O
both	O
unmated	O
and	O
mated	O
reproductive	O
tracts	O
,	O
but	O
not	O
elsewhere	O
in	O
the	O
oviduct	O
(	O
Figure	O
4B	O
)	O
.	O

These	O
results	O
suggest	O
that	O
mating	O
enhances	O
the	O
rate	O
of	O
muscle	O
differentiation	O
in	O
the	O
upper	O
oviduct	O
,	O
and	O
that	O
muscle	O
differentiation	O
is	O
delayed	O
in	O
the	O
upper	O
as	O
compared	O
to	O
the	O
lower	O
oviduct	O
.	O

The	O
increased	O
muscle	O
differentiation	O
in	O
the	O
upper	O
oviduct	O
is	O
not	O
dramatic	O
and	O
likely	O
reflects	O
the	O
short	O
post	O
-	O
mating	O
period	O
examined	O
in	O
this	O
study	O
.	O

The	O
delayed	O
differentiation	O
of	O
the	O
upper	O
oviduct	O
muscles	O
resembles	O
the	O
delay	O
in	O
the	O
onset	O
of	O
development	O
between	O
the	O
adult	O
thoracic	O
muscles	O
and	O
abdominal	O
muscles	O
during	O
metamorphosis	O
[	O
32	O
]	O
.	O

Since	O
the	O
ovaries	O
and	O
the	O
other	O
parts	O
of	O
the	O
reproductive	O
tract	O
are	O
known	O
to	O
have	O
different	O
segmental	O
origins	O
[	O
33	O
]	O
,	O
we	O
hypothesize	O
that	O
different	O
parts	O
of	O
the	O
oviduct	O
develop	O
at	O
different	O
rates	O
or	O
begin	O
development	O
at	O
different	O
times	O
.	O

Increased	O
innervation	O
in	O
the	O
oviduct	O
post	O
-	O
mating	O

Nerve	O
-	O
muscle	O
interactions	O
play	O
an	O
important	O
role	O
in	O
regulating	O
adult	O
muscle	O
development	O
and	O
refining	O
the	O
final	O
pattern	O
of	O
innervation	O
[	O
34	O
,	O
35	O
]	O
.	O

Given	O
that	O
oviduct	O
muscle	O
differentiation	O
is	O
enhanced	O
post	O
-	O
mating	O
,	O
we	O
predicted	O
that	O
mating	O
either	O
directly	O
or	O
indirectly	O
induces	O
changes	O
in	O
innervation	O
.	O

To	O
address	O
this	O
prediction	O
,	O
we	O
quantified	O
the	O
number	O
of	O
nerve	O
terminals	O
or	O
boutons	O
innervating	O
the	O
lateral	O
oviducts	O
and	O
common	O
oviduct	O
in	O
unmated	O
and	O
mated	O
reproductive	O
tracts	O
.	O

Studies	O
of	O
oviduct	O
innervation	O
in	O
Drosophila	O
reveal	O
that	O
the	O
fly	S-Species
'	O
s	O
oviduct	O
receives	O
aminergic	O
,	O
peptidergic	O
and	O
glutamatergic	O
input	O
[	O
30	O
,	O
36	O
-	O
39	O
]	O
.	O

In	O
both	O
larval	O
and	O
adult	O
Drosophila	O
,	O
different	O
types	O
of	O
boutons	O
are	O
formed	O
by	O
neurons	O
that	O
express	O
different	O
neurotransmitters	O
and	O
modulators	O
[	O
40	O
-	O
42	O
]	O
.	O

By	O
similarity	O
to	O
the	O
boutons	O
described	O
at	O
the	O
larval	O
and	O
adult	O
neuromuscular	O
junction	O
,	O
Middleton	O
et	O
al	O
.	O

[	O
30	O
]	O
report	O
that	O
the	O
fly	S-Species
'	O
s	O
oviduct	O
is	O
innervated	O
by	O
glutamatergic	O
type	O
I	O
boutons	O
and	O
tyraminergic	O
/	O
octopaminergic	O
type	O
II	O
boutons	O
.	O

Rodgriguez	O
-	O
Valentin	O
et	O
al	O
.	O

[	O
43	O
]	O
further	O
report	O
that	O
the	O
oviduct	O
type	O
II	O
boutons	O
co	O
-	O
express	O
octopamine	O
and	O
glutamate	O
.	O

The	O
neurons	O
that	O
give	O
rise	O
to	O
the	O
type	O
I	O
innervation	O
have	O
not	O
been	O
identified	O
.	O

However	O
,	O
it	O
is	O
well	O
established	O
that	O
type	O
II	O
innervation	O
arises	O
from	O
octopaminergic	O
neurons	O
located	O
in	O
the	O
abdominal	O
ganglion	O
[	O
30	O
,	O
43	O
]	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
shown	O
that	O
some	O
or	O
all	O
of	O
these	O
neurons	O
express	O
a	O
GAL4	O
insertion	O
line	O
for	O
the	O
bullwinkle	O
(	O
bwk	O
)	O
gene	O
[	O
43	O
]	O
.	O

Bwk	O
encodes	O
a	O
HMG	O
-	O
box	O
containing	O
putative	O
transcription	O
factor	O
[	O
44	O
]	O
.	O

To	O
determine	O
if	O
mating	O
induces	O
any	O
changes	O
in	O
the	O
number	O
of	O
type	O
I	O
and	O
II	O
boutons	O
innervating	O
the	O
oviduct	O
muscles	O
,	O
we	O
used	O
the	O
pan	O
-	O
neural	O
marker	O
,	O
anti	O
-	O
HRP	O
to	O
label	O
all	O
oviduct	O
boutons	O
in	O
unmated	O
and	O
mated	O
females	O
.	O

To	O
distinguish	O
between	O
type	O
I	O
and	O
II	O
boutons	O
we	O
used	O
an	O
antibody	O
against	O
the	O
Disc	O
Large	O
(	O
DLG	O
)	O
protein	O
[	O
45	O
]	O
.	O

Type	O
I	O
boutons	O
were	O
identified	O
by	O
their	O
DLG	O
postsynaptic	O
staining	O
and	O
large	O
size	O
(	O
>	O
8	O
mu	O
m	O
in	O
diameter	O
)	O
(	O
Figure	O
4G	O
)	O
,	O
while	O
type	O
II	O
boutons	O
were	O
distinguished	O
by	O
their	O
absence	O
of	O
DLG	O
staining	O
and	O
smaller	O
size	O
(	O
<	O
2	O
mu	O
m	O
)	O
(	O
Figure	O
4H	O
)	O
.	O

We	O
find	O
that	O
type	O
I	O
and	O
II	O
boutons	O
innervate	O
the	O
lateral	O
oviducts	O
and	O
common	O
oviduct	O
,	O
and	O
that	O
the	O
type	O
I	O
innervation	O
is	O
restricted	O
to	O
a	O
few	O
axons	O
that	O
run	O
parallel	O
to	O
the	O
length	O
of	O
the	O
oviduct	O
,	O
while	O
the	O
type	O
II	O
innervation	O
is	O
more	O
widespread	O
.	O

We	O
quantified	O
the	O
number	O
of	O
boutons	O
in	O
the	O
lateral	O
oviducts	O
and	O
common	O
oviduct	O
and	O
observed	O
a	O
74	O
%	O
increase	O
in	O
bouton	O
number	O
in	O
the	O
lateral	O
oviduct	O
and	O
a	O
66	O
%	O
increase	O
in	O
the	O
common	O
oviduct	O
post	O
-	O
mating	O
(	O
Figure	O
4I	O
)	O
.	O

More	O
over	O
,	O
we	O
observed	O
no	O
significant	O
change	O
in	O
the	O
number	O
of	O
type	O
I	O
boutons	O
in	O
the	O
lateral	O
oviduct	O
and	O
common	O
oviduct	O
.	O

However	O
,	O
we	O
detected	O
a	O
1	O
.	O
5	O
-	O
fold	O
increase	O
in	O
the	O
number	O
of	O
type	O
II	O
boutons	O
in	O
the	O
lateral	O
oviduct	O
and	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
in	O
type	O
II	O
innervation	O
in	O
the	O
common	O
oviduct	O
.	O

Dramatic	O
increases	O
in	O
bouton	O
growth	O
are	O
also	O
observed	O
during	O
development	O
.	O

For	O
example	O
,	O
a	O
ten	O
-	O
fold	O
increase	O
in	O
bouton	O
number	O
is	O
observed	O
at	O
the	O
neuromuscular	O
junction	O
during	O
the	O
larval	O
period	O
[	O
46	O
]	O
.	O

To	O
determine	O
if	O
the	O
increase	O
in	O
type	O
II	O
innervation	O
was	O
specific	O
to	O
mating	O
or	O
reflected	O
normal	O
growth	O
in	O
3	O
day	O
-	O
old	O
females	O
,	O
we	O
quantified	O
type	O
I	O
and	O
II	O
innervation	O
in	O
the	O
oviducts	O
of	O
5	O
day	O
-	O
old	O
unmated	O
females	O
.	O

We	O
found	O
no	O
significant	O
difference	O
in	O
type	O
I	O
and	O
II	O
innervation	O
in	O
unmated	O
3	O
day	O
-	O
old	O
and	O
5	O
-	O
day	O
-	O
old	O
females	O
,	O
indicating	O
that	O
mating	O
,	O
either	O
directly	O
or	O
indirectly	O
,	O
induces	O
a	O
dramatic	O
increase	O
in	O
type	O
II	O
innervation	O
(	O
Figure	O
4I	O
)	O
.	O

To	O
determine	O
if	O
the	O
post	O
-	O
mating	O
increase	O
in	O
innervation	O
is	O
unique	O
to	O
the	O
oviduct	O
,	O
we	O
asked	O
if	O
mating	O
induces	O
a	O
global	O
change	O
in	O
innervation	O
.	O

We	O
quantified	O
bouton	O
number	O
in	O
the	O
adult	O
ventral	O
midline	O
muscles	O
of	O
the	O
5th	O
abdominal	O
segment	O
.	O

These	O
muscles	O
are	O
innervated	O
by	O
boutons	O
that	O
increase	O
in	O
number	O
during	O
metamorphosis	O
[	O
47	O
]	O
.	O

No	O
significant	O
difference	O
in	O
bouton	O
number	O
was	O
detected	O
at	O
these	O
muscles	O
in	O
unmated	O
and	O
mated	O
females	O
(	O
additional	O
file	O
3	O
)	O
.	O

Though	O
further	O
analysis	O
is	O
needed	O
,	O
this	O
suggests	O
that	O
the	O
post	O
-	O
mating	O
increase	O
in	O
innervation	O
is	O
oviduct	O
-	O
specific	O
.	O

Because	O
the	O
type	O
II	O
boutons	O
are	O
octopaminergic	O
,	O
the	O
increased	O
type	O
II	O
innervation	O
may	O
result	O
in	O
increased	O
octopamine	O
(	O
OA	O
)	O
release	O
in	O
the	O
oviduct	O
.	O

In	O
support	O
of	O
this	O
possibility	O
,	O
we	O
have	O
preliminary	O
evidence	O
that	O
OA	O
is	O
released	O
in	O
the	O
oviduct	O
post	O
-	O
mating	O
(	O
Heifetz	O
and	O
Wolfner	O
,	O
in	O
preparation	O
)	O
.	O

Studies	O
in	O
locust	O
and	O
Drosophila	O
demonstrate	O
that	O
OA	O
inhibits	O
oviduct	O
contraction	O
,	O
while	O
glutamate	O
activates	O
oviduct	O
contraction	O
[	O
30	O
,	O
43	O
,	O
48	O
]	O
.	O

In	O
Drosophila	O
,	O
electrical	O
stimulation	O
of	O
the	O
posterior	O
abdominal	O
nerve	O
gives	O
rise	O
to	O
a	O
series	O
of	O
muscle	O
contractions	O
in	O
the	O
oviduct	O
followed	O
by	O
a	O
period	O
of	O
muscle	O
fatigue	O
or	O
relaxation	O
[	O
43	O
]	O
.	O

This	O
pattern	O
of	O
muscle	O
contraction	O
and	O
relaxation	O
may	O
facilitate	O
the	O
proper	O
movement	O
of	O
the	O
egg	O
through	O
the	O
oviduct	O
.	O

In	O
their	O
study	O
of	O
bwk	O
expressing	O
neurons	O
that	O
innervate	O
the	O
oviduct	O
,	O
Rodriguez	O
-	O
Valentin	O
et	O
al	O
.	O

[	O
43	O
]	O
show	O
that	O
OA	O
and	O
glutamate	O
interact	O
to	O
produce	O
the	O
pattern	O
of	O
oviduct	O
contraction	O
and	O
relaxation	O
described	O
above	O
.	O

It	O
is	O
therefore	O
possible	O
that	O
the	O
post	O
-	O
mating	O
increase	O
in	O
type	O
II	O
innervation	O
in	O
the	O
oviduct	O
plays	O
an	O
important	O
role	O
in	O
the	O
increased	O
rate	O
of	O
ovulation	O
and	O
egg	O
-	O
laying	O
observed	O
post	O
-	O
mating	O
.	O

Female	O
mating	O
history	O
affects	O
the	O
enrichment	O
of	O
cytosekeletal	O
proteins	O
in	O
the	O
oviduct	O

To	O
gain	O
insights	O
into	O
the	O
role	O
of	O
cytoskeletal	O
protein	O
enrichment	O
(	O
[	O
23	O
]	O
;	O
additional	O
file	O
4	O
)	O
in	O
mediating	O
the	O
morphological	O
changes	O
detected	O
in	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
different	O
mating	O
regimes	O
on	O
cytoskeletal	O
protein	O
abundance	O
.	O

We	O
focused	O
on	O
a	O
subset	O
of	O
mating	O
-	O
responsive	O
cytoskeletal	O
proteins	O
with	O
well	O
established	O
roles	O
in	O
the	O
differentiation	O
of	O
muscle	O
and	O
epithelia	O
.	O

These	O
include	O
:	O
(	O
i	O
)	O
Mlp84B	O
which	O
regulates	O
the	O
late	O
differentiation	O
pathway	O
of	O
muscle	O
[	O
49	O
]	O
;	O
(	O
ii	O
)	O
Cora	O
and	O
Nrg	O
which	O
are	O
required	O
for	O
the	O
formation	O
of	O
septate	O
junctions	O
in	O
epithelia	O
[	O
50	O
]	O
,	O
and	O
(	O
iii	O
)	O
Hu	O
-	O
li	O
tai	O
shao	O
(	O
Hts	O
)	O
,	O
also	O
known	O
as	O
adducin	O
-	O
like	O
protein	O
,	O
which	O
functions	O
in	O
assembly	O
of	O
the	O
cytoskeletal	O
network	O
.	O

Na	O
+	O
pump	O
alpha	O
subunit	O
(	O
ATP	O
alpha	O
)	O
,	O
another	O
protein	O
associated	O
with	O
septate	O
junctions	O
in	O
epithelia	O
,	O
is	O
not	O
a	O
mating	O
-	O
responsive	O
protein	O
and	O
was	O
used	O
as	O
a	O
control	O
.	O

Using	O
western	O
blots	O
,	O
we	O
first	O
determined	O
the	O
abundance	O
of	O
the	O
cytoskeletal	O
proteins	O
in	O
oviducts	O
of	O
3	O
-	O
day	O
-	O
old	O
unmated	O
and	O
mated	O
females	O
at	O
6	O
hrs	O
post	O
-	O
mating	O
.	O

We	O
confirmed	O
the	O
proteomic	O
results	O
of	O
Kalpenikov	O
et	O
al	O
.	O

[	O
23	O
]	O
and	O
found	O
that	O
mating	O
increases	O
the	O
abundance	O
of	O
all	O
proteins	O
,	O
except	O
ATP	O
alpha	O
in	O
mated	O
oviducts	O
relative	O
to	O
their	O
abundance	O
in	O
unmated	O
oviducts	O
(	O
Figure	O
5A	O
)	O
.	O

To	O
determine	O
whether	O
the	O
increased	O
abundance	O
of	O
mating	O
-	O
responsive	O
proteins	O
persists	O
for	O
longer	O
times	O
post	O
-	O
mating	O
,	O
we	O
examined	O
oviducts	O
of	O
10	O
-	O
day	O
-	O
old	O
females	O
that	O
mated	O
once	O
at	O
3	O
days	O
of	O
age	O
,	O
and	O
calculated	O
the	O
abundance	O
of	O
the	O
mating	O
-	O
responsive	O
proteins	O
relative	O
to	O
their	O
level	O
in	O
oviducts	O
of	O
3	O
-	O
day	O
-	O
old	O
unmated	O
females	O
.	O

We	O
found	O
no	O
change	O
or	O
a	O
slight	O
increase	O
in	O
the	O
relative	O
abundance	O
of	O
all	O
cytoskeletal	O
proteins	O
except	O
Mlp84B	O
at	O
7	O
days	O
post	O
-	O
mating	O
(	O
Figure	O
5A	O
)	O
.	O

Strikingly	O
,	O
the	O
level	O
of	O
Mlp84B	O
declines	O
by	O
7	O
days	O
post	O
-	O
mating	O
to	O
the	O
level	O
observed	O
prior	O
to	O
mating	O
.	O

Thus	O
Mlp84B	O
levels	O
rise	O
and	O
fall	O
after	O
mating	O
,	O
while	O
the	O
epithelial	O
-	O
related	O
proteins	O
rapidly	O
rise	O
and	O
are	O
maintained	O
at	O
a	O
high	O
level	O
after	O
mating	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
a	O
second	O
mating	O
might	O
trigger	O
an	O
increase	O
in	O
Mlp84B	O
protein	O
expression	O
as	O
observed	O
in	O
3	O
-	O
day	O
-	O
old	O
females	O
at	O
6	O
h	O
post	O
-	O
mating	O
.	O

To	O
test	O
this	O
possibility	O
,	O
females	O
were	O
mated	O
twice	O
(	O
once	O
at	O
day	O
3	O
,	O
and	O
once	O
on	O
day	O
10	O
of	O
age	O
)	O
,	O
and	O
their	O
oviducts	O
were	O
examined	O
at	O
6	O
hrs	O
after	O
the	O
second	O
mating	O
.	O

We	O
calculated	O
the	O
abundance	O
of	O
the	O
cytoskeletal	O
proteins	O
in	O
the	O
twice	O
mated	O
oviducts	O
relative	O
to	O
their	O
abundance	O
in	O
oviducts	O
of	O
3	O
-	O
day	O
-	O
old	O
unmated	O
females	O
.	O

Our	O
results	O
show	O
that	O
a	O
second	O
mating	O
has	O
little	O
or	O
no	O
effect	O
on	O
Mlp84B	O
abundance	O
.	O

Thus	O
,	O
Mlp84B	O
may	O
represent	O
a	O
class	O
of	O
mating	O
-	O
responsive	O
proteins	O
that	O
is	O
only	O
needed	O
after	O
the	O
first	O
mating	O
.	O

Interestingly	O
,	O
the	O
effect	O
of	O
the	O
second	O
mating	O
on	O
the	O
epithelial	O
-	O
related	O
mating	O
-	O
responsive	O
proteins	O
appears	O
to	O
be	O
different	O
for	O
each	O
protein	O
.	O

While	O
Cora	O
levels	O
drop	O
to	O
the	O
level	O
observed	O
in	O
3	O
-	O
day	O
-	O
old	O
unmated	O
females	O
,	O
Nrg	O
and	O
Hts	O
are	O
maintained	O
at	O
a	O
high	O
level	O
.	O

To	O
determine	O
if	O
the	O
changes	O
in	O
cytoskeletal	O
protein	O
abundance	O
are	O
mating	O
-	O
dependent	O
we	O
measured	O
their	O
abundance	O
in	O
the	O
oviducts	O
of	O
unmated	O
5	O
-	O
and	O
10	O
-	O
day	O
-	O
old	O
females	O
.	O

We	O
calculated	O
their	O
abundance	O
relative	O
to	O
their	O
level	O
in	O
oviducts	O
of	O
unmated	O
3	O
-	O
day	O
-	O
old	O
females	O
(	O
Figure	O
5B	O
)	O
.	O

We	O
rationalized	O
that	O
if	O
the	O
change	O
in	O
cytoskeletal	O
protein	O
abundance	O
is	O
mating	O
-	O
dependent	O
we	O
will	O
not	O
see	O
similar	O
changes	O
in	O
unmated	O
females	O
.	O

We	O
observed	O
a	O
slow	O
increase	O
in	O
the	O
relative	O
abundance	O
of	O
all	O
mating	O
-	O
responsive	O
proteins	O
with	O
time	O
post	O
-	O
eclosion	O
(	O
Figure	O
5B	O
)	O
.	O

Because	O
unmated	O
females	O
lay	O
more	O
eggs	O
as	O
they	O
age	O
(	O
see	O
additional	O
file	O
5C	O
)	O
one	O
possible	O
interpretation	O
of	O
the	O
increased	O
level	O
of	O
cytoskeletal	O
proteins	O
in	O
unmated	O
females	O
is	O
that	O
these	O
proteins	O
are	O
associated	O
with	O
an	O
intrinsic	O
program	O
for	O
oviduct	O
maturation	O
and	O
that	O
mating	O
accelerates	O
this	O
process	O
to	O
maximize	O
egg	O
-	O
laying	O
efficacy	O
.	O

Alternatively	O
,	O
it	O
is	O
possible	O
that	O
the	O
slow	O
increase	O
in	O
protein	O
abundance	O
observed	O
in	O
unmated	O
females	O
is	O
due	O
to	O
the	O
passage	O
of	O
eggs	O
through	O
the	O
oviduct	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
mating	O
is	O
essential	O
to	O
fine	O
-	O
tune	O
the	O
levels	O
of	O
the	O
mating	O
-	O
responsive	O
proteins	O
examined	O
in	O
this	O
study	O
.	O

Because	O
the	O
changes	O
in	O
cytoskeletal	O
protein	O
abundance	O
are	O
different	O
in	O
unmated	O
and	O
mated	O
females	O
,	O
this	O
suggests	O
that	O
the	O
post	O
-	O
mating	O
changes	O
are	O
mating	O
-	O
dependent	O
.	O

Furthermore	O
,	O
we	O
suggest	O
that	O
these	O
post	O
-	O
mating	O
changes	O
are	O
linked	O
to	O
changes	O
in	O
oviduct	O
function	O
.	O

Early	O
or	O
prior	O
mating	O
increases	O
fecundity	O

In	O
Drosophila	O
,	O
female	O
fecundity	O
decreases	O
with	O
age	O
[	O
51	O
-	O
54	O
]	O
.	O

It	O
has	O
been	O
proposed	O
that	O
this	O
decrease	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
the	O
loss	O
of	O
germline	O
and	O
somatic	O
stem	O
cells	O
[	O
55	O
]	O
.	O

Since	O
the	O
expression	O
of	O
the	O
oviduct	O
cytoskeletal	O
proteins	O
examined	O
in	O
this	O
study	O
change	O
with	O
age	O
and	O
mating	O
experience	O
,	O
the	O
state	O
of	O
the	O
oviduct	O
may	O
also	O
play	O
a	O
role	O
in	O
fecundity	O
.	O

To	O
separate	O
the	O
effects	O
of	O
age	O
and	O
mating	O
,	O
we	O
measured	O
the	O
fecundity	O
of	O
females	O
that	O
mated	O
twice	O
,	O
first	O
at	O
3	O
days	O
post	O
-	O
eclosion	O
and	O
again	O
at	O
10	O
days	O
,	O
and	O
compared	O
that	O
to	O
the	O
fecundity	O
of	O
females	O
that	O
mated	O
once	O
at	O
3	O
days	O
and	O
females	O
that	O
mated	O
once	O
at	O
10	O
days	O
.	O

Fecundity	O
was	O
measured	O
as	O
the	O
number	O
of	O
eggs	O
laid	O
per	O
day	O
per	O
female	O
during	O
the	O
first	O
three	O
days	O
after	O
mating	O
.	O

Once	O
-	O
mated	O
3	O
-	O
day	O
-	O
old	O
females	O
laid	O
nearly	O
twice	O
as	O
many	O
eggs	O
as	O
once	O
-	O
mated	O
10	O
-	O
day	O
-	O
old	O
females	O
during	O
the	O
three	O
days	O
examined	O
(	O
24	O
.	O
5	O
+/-	O
0	O
.	O
7	O
versus	O
13	O
.	O
3	O
+/-	O
0	O
.	O
9	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Twice	O
-	O
mated	O
10	O
-	O
day	O
-	O
old	O
females	O
also	O
laid	O
about	O
50	O
%	O
more	O
eggs	O
than	O
once	O
-	O
mated	O
females	O
of	O
the	O
same	O
age	O
(	O
19	O
.	O
3	O
+/-	O
0	O
.	O
9	O
versus	O
13	O
.	O
3	O
+/-	O
0	O
.	O
9	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
but	O
about	O
20	O
%	O
fewer	O
than	O
laid	O
by	O
once	O
-	O
mated	O
3	O
-	O
day	O
-	O
old	O
females	O
during	O
the	O
three	O
days	O
examined	O
(	O
19	O
.	O
3	O
+/-	O
0	O
.	O
9	O
versus	O
24	O
.	O
5	O
+/-	O
0	O
.	O
7	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
(	O
Figure	O
6A	O
,	O
see	O
also	O
additional	O
file	O
5A	O
and	O
5B	O
)	O
.	O

Thus	O
,	O
the	O
difference	O
in	O
fecundity	O
between	O
once	O
-	O
mated	O
10	O
-	O
day	O
-	O
old	O
and	O
once	O
-	O
mated	O
3	O
-	O
day	O
-	O
old	O
females	O
is	O
not	O
a	O
result	O
of	O
age	O
alone	O
.	O

Rather	O
the	O
main	O
determinant	O
of	O
fecundity	O
at	O
10	O
days	O
is	O
whether	O
there	O
had	O
been	O
a	O
prior	O
mating	O
at	O
3	O
days	O
.	O

We	O
also	O
calculated	O
the	O
fertility	O
(	O
number	O
of	O
adults	O
eclosed	O
)	O
of	O
once	O
-	O
and	O
twice	O
-	O
mated	O
females	O
.	O

Once	O
-	O
mated	O
3	O
-	O
day	O
-	O
old	O
females	O
are	O
more	O
fertile	O
than	O
once	O
-	O
mated	O
10	O
-	O
day	O
-	O
old	O
females	O
(	O
69	O
.	O
5	O
+/-	O
1	O
.	O
6	O
%	O
versus	O
56	O
.	O
1	O
+/-	O
3	O
.	O
0	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
slightly	O
more	O
fertile	O
than	O
twice	O
-	O
mated	O
10	O
-	O
day	O
-	O
old	O
females	O
(	O
69	O
.	O
5	O
+/-	O
1	O
.	O
6	O
%	O
versus	O
62	O
.	O
7	O
+/-	O
2	O
.	O
4	O
%	O
,	O
p	O
<	O
0	O
.	O
015	O
)	O
(	O
Figure	O
6B	O
,	O
see	O
also	O
additional	O
file	O
5D	O
)	O
.	O

Because	O
there	O
is	O
no	O
significant	O
difference	O
in	O
fertility	O
between	O
once	O
-	O
mated	O
and	O
twice	O
-	O
mated	O
10	O
-	O
day	O
-	O
old	O
females	O
,	O
this	O
suggests	O
that	O
(	O
1	O
)	O
a	O
prior	O
mating	O
has	O
no	O
significant	O
effect	O
on	O
the	O
fertility	O
of	O
10	O
-	O
day	O
-	O
old	O
mated	O
females	O
and	O
(	O
2	O
)	O
fertility	O
decreases	O
with	O
age	O
.	O

One	O
intriguing	O
interpretation	O
of	O
these	O
results	O
is	O
that	O
an	O
early	O
mating	O
increases	O
fecundity	O
which	O
partially	O
compensates	O
for	O
the	O
age	O
-	O
related	O
decrease	O
in	O
fertility	O
.	O

Thus	O
,	O
cytoskeletal	O
mating	O
-	O
responsive	O
protein	O
changes	O
may	O
be	O
associated	O
with	O
structural	O
changes	O
in	O
the	O
oviduct	O
that	O
result	O
in	O
increased	O
fecundity	O
.	O

This	O
may	O
counteract	O
the	O
effects	O
of	O
decreased	O
fertility	O
on	O
the	O
reproductive	O
output	O
.	O

Discussion	O

Despite	O
the	O
use	O
of	O
Drosophila	O
as	O
a	O
model	O
system	O
for	O
organ	O
-	O
level	O
biology	O
and	O
the	O
emerging	O
parallels	O
between	O
mammalian	O
and	O
Drosophila	S-Species
reproductive	O
biology	O
[	O
56	O
]	O
,	O
this	O
is	O
the	O
first	O
integrative	O
tissue	O
-	O
wide	O
study	O
of	O
post	O
-	O
mating	O
changes	O
in	O
the	O
Drosophila	S-Species
oviduct	O
.	O

Our	O
results	O
provide	O
several	O
lines	O
of	O
evidence	O
at	O
the	O
molecular	O
,	O
morphological	O
and	O
physiological	O
levels	O
suggesting	O
that	O
mating	O
induces	O
tissue	O
-	O
wide	O
differentiation	O
in	O
the	O
oviduct	O
.	O

Moreover	O
,	O
we	O
identify	O
ultrastructural	O
changes	O
in	O
the	O
mated	O
oviduct	O
that	O
are	O
consistent	O
with	O
the	O
roles	O
that	O
some	O
of	O
the	O
mating	O
-	O
responsive	O
proteins	O
examined	O
in	O
this	O
study	O
(	O
e	O
.	O
g	O
.	O
Mlp84B	O
,	O
Cora	O
,	O
Nrg	O
)	O
are	O
reported	O
to	O
play	O
in	O
muscle	O
and	O
epithelial	O
differentiation	O
elsewhere	O
.	O

For	O
example	O
,	O
the	O
increased	O
abundance	O
of	O
Mlp84B	O
,	O
a	O
major	O
regulator	O
of	O
the	O
late	O
differentiation	O
pathway	O
of	O
muscle	O
[	O
49	O
]	O
is	O
consistent	O
with	O
the	O
increased	O
muscle	O
differentiation	O
in	O
the	O
upper	O
oviduct	O
post	O
-	O
mating	O
(	O
Figure	O
4A	O
-	O
4F	O
)	O
.	O

Similarly	O
,	O
the	O
increased	O
abundance	O
of	O
Cora	O
and	O
Nrg	O
,	O
molecules	O
that	O
are	O
essential	O
for	O
SJ	O
development	O
and	O
function	O
[	O
50	O
]	O
is	O
consistent	O
with	O
the	O
observation	O
that	O
SJs	O
in	O
the	O
upper	O
oviduct	O
are	O
immature	O
and	O
/	O
or	O
that	O
mating	O
induces	O
changes	O
in	O
the	O
apical	O
extracellular	O
matrix	O
whose	O
secretion	O
may	O
be	O
regulated	O
,	O
in	O
part	O
,	O
by	O
SJs	O
as	O
occurs	O
in	O
the	O
trachea	O
[	O
27	O
,	O
28	O
]	O
.	O

Other	O
post	O
-	O
mating	O
changes	O
that	O
indicate	O
that	O
mating	O
induces	O
tissue	O
-	O
wide	O
differentiation	O
include	O
increased	O
HAJs	O
along	O
the	O
basolateral	O
membrane	O
and	O
increased	O
innervation	O
.	O

Analysis	O
of	O
protein	O
abundance	O
following	O
different	O
mating	O
regimes	O
(	O
unmated	O
,	O
once	O
-	O
mated	O
,	O
twice	O
-	O
mated	O
)	O
gave	O
us	O
further	O
insights	O
into	O
the	O
possible	O
roles	O
that	O
mating	O
-	O
responsive	O
proteins	O
play	O
in	O
the	O
oviduct	O
.	O

For	O
example	O
,	O
Mlp84B	O
is	O
only	O
responsive	O
to	O
the	O
first	O
mating	O
,	O
while	O
the	O
epithelial	O
proteins	O
examined	O
(	O
Cora	O
,	O
Nrg	O
and	O
Hts	O
)	O
are	O
responsive	O
to	O
the	O
first	O
and	O
second	O
mating	O
.	O

Furthermore	O
,	O
the	O
response	O
to	O
the	O
second	O
mating	O
is	O
different	O
from	O
the	O
response	O
to	O
the	O
first	O
mating	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
Mlp84B	O
is	O
required	O
for	O
the	O
final	O
maturation	O
of	O
the	O
oviduct	O
,	O
while	O
the	O
epithelial	O
proteins	O
examined	O
are	O
required	O
for	O
both	O
the	O
maturation	O
and	O
maintenance	O
of	O
the	O
oviduct	O
at	O
a	O
high	O
functional	O
state	O
.	O

Moreover	O
,	O
the	O
post	O
-	O
mating	O
pattern	O
of	O
Mlp84B	O
supports	O
the	O
idea	O
that	O
the	O
first	O
mating	O
induces	O
the	O
final	O
maturation	O
of	O
the	O
oviduct	O
.	O

The	O
rise	O
and	O
fall	O
of	O
Mlp84B	O
abundance	O
after	O
the	O
first	O
mating	O
(	O
Figure	O
5	O
)	O
parallels	O
the	O
expression	O
pattern	O
of	O
Mlp84B	O
during	O
development	O
where	O
peaks	O
in	O
Mlp84B	O
transcription	O
occur	O
during	O
periods	O
of	O
embryogenesis	O
and	O
metamorphosis	O
when	O
muscle	O
is	O
differentiating	O
[	O
49	O
]	O
.	O

Using	O
different	O
mating	O
regimes	O
we	O
tested	O
whether	O
the	O
first	O
/	O
early	O
mating	O
is	O
essential	O
for	O
maintenance	O
of	O
high	O
reproductive	O
output	O
in	O
the	O
second	O
mating	O
.	O

Our	O
results	O
suggest	O
that	O
mating	O
at	O
an	O
early	O
age	O
is	O
essential	O
to	O
achieve	O
maximum	O
reproductive	O
output	O
(	O
i	O
.	O
e	O
.	O
high	O
fecundity	O
and	O
fertility	O
)	O
.	O

Since	O
the	O
first	O
mating	O
increases	O
reproductive	O
output	O
(	O
evidence	O
from	O
our	O
mating	O
regime	O
experiments	O
)	O
,	O
it	O
is	O
likely	O
that	O
the	O
ultrastructural	O
changes	O
detected	O
in	O
mated	O
3	O
-	O
day	O
-	O
old	O
females	O
lead	O
to	O
a	O
highly	O
functional	O
oviduct	O
.	O

We	O
suggest	O
that	O
the	O
final	O
maturation	O
of	O
the	O
oviduct	O
includes	O
a	O
mating	O
-	O
dependent	O
stage	O
.	O

We	O
propose	O
that	O
during	O
the	O
first	O
few	O
days	O
post	O
-	O
eclosion	O
,	O
the	O
oviduct	O
undergoes	O
the	O
first	O
phase	O
of	O
differentiation	O
,	O
after	O
which	O
the	O
oviduct	O
is	O
developmentally	O
poised	O
for	O
a	O
rapid	O
response	O
to	O
an	O
extrinsic	O
cue	O
(	O
mating	O
)	O
.	O

Mating	O
then	O
triggers	O
the	O
second	O
phase	O
of	O
maturation	O
(	O
tissue	O
remodeling	O
and	O
modulation	O
)	O
which	O
is	O
essential	O
for	O
proper	O
oviduct	O
function	O
(	O
Figure	O
7	O
)	O
.	O

We	O
further	O
propose	O
that	O
the	O
second	O
phase	O
of	O
maturation	O
consists	O
of	O
processes	O
that	O
are	O
mating	O
-	O
independent	O
and	O
-	O
dependent	O
,	O
and	O
that	O
both	O
of	O
these	O
pathways	O
are	O
essential	O
to	O
produce	O
a	O
functional	O
oviduct	O
.	O

For	O
example	O
,	O
initial	O
formation	O
of	O
SJs	O
occurs	O
prior	O
to	O
mating	O
(	O
mating	O
-	O
independent	O
)	O
while	O
the	O
increased	O
apical	O
secretion	O
and	O
development	O
of	O
HAJs	O
are	O
mating	O
-	O
dependent	O
.	O

The	O
oviduct	O
musculature	O
is	O
an	O
example	O
where	O
both	O
mating	O
-	O
independent	O
and	O
-	O
dependent	O
processes	O
play	O
a	O
role	O
.	O

Muscles	O
are	O
highly	O
differentiated	O
in	O
the	O
lower	O
oviduct	O
prior	O
to	O
mating	O
,	O
while	O
muscle	O
differentiation	O
is	O
ongoing	O
in	O
the	O
upper	O
oviduct	O
and	O
increases	O
after	O
mating	O
.	O

Although	O
the	O
onset	O
of	O
muscle	O
differentiation	O
in	O
both	O
regions	O
is	O
mating	O
-	O
independent	O
,	O
the	O
further	O
differentiation	O
of	O
muscle	O
in	O
the	O
upper	O
oviduct	O
is	O
mating	O
-	O
dependent	O
.	O

Another	O
possible	O
interpretation	O
of	O
the	O
role	O
of	O
mating	O
on	O
oviduct	O
maturation	O
is	O
that	O
mating	O
accelerates	O
and	O
synchronizes	O
processes	O
that	O
are	O
essential	O
for	O
the	O
functional	O
maturation	O
of	O
the	O
oviduct	O
.	O

It	O
will	O
therefore	O
be	O
interesting	O
to	O
examine	O
the	O
oviducts	O
of	O
older	O
females	O
to	O
determine	O
the	O
status	O
of	O
oviduct	O
maturation	O
.	O

What	O
is	O
the	O
benefit	O
of	O
mating	O
-	O
induced	O
differentiation	O
of	O
the	O
oviduct	O
tissues	O
?	O

Unmated	O
females	O
are	O
capable	O
of	O
laying	O
eggs	O
,	O
albeit	O
at	O
a	O
reduced	O
rate	O
as	O
compared	O
to	O
mated	O
females	O
of	O
the	O
same	O
age	O
.	O

One	O
possible	O
interpretation	O
is	O
that	O
reproduction	O
is	O
energetically	O
costly	O
,	O
thus	O
delaying	O
oviduct	O
maturation	O
until	O
sperm	O
is	O
available	O
is	O
advantageous	O
to	O
the	O
female	O
.	O

This	O
may	O
reflect	O
the	O
evolution	O
of	O
a	O
mechanism	O
to	O
optimize	O
reproductive	O
capacity	O
in	O
early	O
adulthood	O
in	O
short	O
-	O
lived	O
animals	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
events	O
at	O
the	O
cellular	O
,	O
molecular	O
and	O
physiological	O
levels	O
that	O
are	O
part	O
of	O
an	O
efficient	O
and	O
specific	O
program	O
for	O
reproduction	O
.	O

Drosophila	O
affords	O
us	O
the	O
opportunity	O
to	O
uncover	O
the	O
signaling	O
pathways	O
that	O
coordinate	O
these	O
events	O
to	O
produce	O
a	O
physiologically	O
functional	O
organ	O
.	O

Methods	O

Flies	O

Wild	O
-	O
type	O
Canton	O
-	O
S	O
flies	S-Species
were	O
used	O
for	O
the	O
fecundity	O
/	O
fertility	O
experiments	O
and	O
confocal	O
analysis	O
.	O

Wild	O
-	O
type	O
Canton	O
-	O
S5	O
[	O
57	O
]	O
flies	S-Species
were	O
used	O
for	O
electron	O
microscopy	O
.	O

All	O
flies	S-Species
were	O
kept	O
in	O
a	O
12	O
hrs	O
light	O
/	O
dark	O
cycle	O
at	O
23	O
+/-	O
2	O
degrees	O
C	O
.	O

Upon	O
eclosion	O
,	O
females	O
and	O
males	O
were	O
collected	O
on	O
ice	O
and	O
held	O
separately	O
until	O
3	O
(	O
females	O
and	O
males	O
)	O
or	O
10	O
(	O
females	O
)	O
days	O
of	O
age	O
.	O

Sample	O
preparation	O

For	O
all	O
assays	O
(	O
unless	O
described	O
differently	O
)	O
unmated	O
females	O
were	O
placed	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
and	O
observed	O
until	O
mating	O
initiated	O
.	O

At	O
the	O
end	O
of	O
mating	O
,	O
females	O
were	O
aspirated	O
into	O
fresh	O
vials	O
and	O
held	O
for	O
6	O
hrs	O
.	O

At	O
6	O
hrs	O
after	O
the	O
start	O
of	O
mating	O
,	O
females	O
were	O
placed	O
on	O
ice	O
for	O
dissection	O
.	O

Previous	O
molecular	O
studies	O
indicate	O
changes	O
in	O
protein	O
abundance	O
at	O
3	O
hrs	O
post	O
-	O
mating	O
.	O

We	O
hypothesize	O
that	O
these	O
molecular	O
changes	O
will	O
translate	O
into	O
morphological	O
changes	O
in	O
the	O
next	O
few	O
hours	O
.	O

We	O
chose	O
to	O
analyze	O
the	O
morphology	O
of	O
mated	O
females	O
at	O
6	O
h	O
post	O
-	O
mating	O
as	O
opposed	O
to	O
later	O
times	O
post	O
-	O
mating	O
because	O
the	O
changes	O
observed	O
at	O
later	O
times	O
may	O
be	O
due	O
,	O
in	O
part	O
,	O
to	O
the	O
high	O
rate	O
of	O
eggs	O
passing	O
through	O
the	O
oviduct	O
.	O

Electron	O
microscopy	O

Reproductive	O
tracts	O
were	O
dissected	O
in	O
Schneider	O
'	O
s	O
Drosophila	S-Species
medium	O
(	O
Sigma	O
)	O
on	O
ice	O
and	O
processed	O
for	O
electron	O
microscopy	O
as	O
described	O
in	O
[	O
42	O
]	O
.	O

Tracts	O
were	O
flat	O
-	O
embedded	O
between	O
two	O
sheets	O
of	O
Aclar	O
(	O
Electron	O
Microscopy	O
Sciences	O
)	O
,	O
which	O
allowed	O
us	O
to	O
image	O
the	O
entire	O
tract	O
at	O
the	O
light	O
microscopic	O
level	O
prior	O
to	O
sectioning	O
.	O

Sections	O
were	O
cut	O
on	O
a	O
Reichart	O
Ultracut	O
microtome	O
.	O

One	O
-	O
mu	O
m	O
thick	O
sections	O
were	O
stained	O
with	O
1	O
%	O
toluidine	O
blue	O
,	O
and	O
viewed	O
with	O
a	O
Zeiss	O
Axoplan	O
microscope	O
.	O

Ultrathin	O
sections	O
(	O
~	O
100	O
nm	O
)	O
were	O
mounted	O
on	O
formvar	O
grids	O
,	O
stained	O
with	O
lead	O
citrate	O
,	O
and	O
viewed	O
with	O
a	O
Philips	O
/	O
FEI	O
Morgagni	O
268	O
TEM	O
at	O
80	O
kV	O
.	O

Our	O
analysis	O
is	O
based	O
on	O
4	O
unmated	O
samples	O
and	O
3	O
mated	O
samples	O
.	O

Two	O
unmated	O
samples	O
were	O
cut	O
in	O
the	O
longitudinal	O
plane	O
and	O
two	O
additional	O
unmated	O
samples	O
were	O
cut	O
in	O
the	O
transverse	O
plane	O
,	O
while	O
one	O
mated	O
sample	O
was	O
cut	O
in	O
the	O
longitudinal	O
plane	O
and	O
two	O
additional	O
mated	O
samples	O
were	O
cut	O
in	O
the	O
transverse	O
plane	O
.	O

For	O
longitudinal	O
sections	O
,	O
the	O
entire	O
tract	O
was	O
re	O
-	O
embedded	O
and	O
cut	O
.	O

For	O
samples	O
cut	O
in	O
the	O
transverse	O
plane	O
,	O
the	O
flat	O
-	O
embedded	O
reproductive	O
tract	O
was	O
divided	O
into	O
three	O
regions	O
:	O
(	O
1	O
)	O
lateral	O
oviducts	O
and	O
upper	O
common	O
oviducts	O
,	O
(	O
2	O
)	O
middle	O
common	O
oviduct	O
,	O
and	O
(	O
3	O
)	O
lower	O
common	O
oviduct	O
.	O

Each	O
region	O
was	O
re	O
-	O
embedded	O
and	O
sectioned	O
.	O

It	O
is	O
beyond	O
the	O
scope	O
of	O
this	O
paper	O
to	O
describe	O
all	O
three	O
regions	O
,	O
and	O
our	O
analysis	O
focuses	O
on	O
the	O
uppermost	O
and	O
lowermost	O
regions	O
.	O

Immunocytochemistry	O

Reproductive	O
tracts	O
were	O
dissected	O
in	O
Yamamoto	O
'	O
s	O
Ringer	O
(	O
10	O
mM	O
MOPS	O
;	O
80	O
mM	O
NaCl	O
;	O
10	O
mM	O
KCL	O
;	O
0	O
.	O
2	O
mM	O
MgCl2	O
;	O
0	O
.	O
1	O
mM	O
CaCl2	O
)	O
with	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
sucrose	O
on	O
ice	O
,	O
fixed	O
in	O
4	O
%	O
paraphormaldehyde	O
in	O
PBS	O
(	O
phosphate	O
-	O
buffered	O
saline	O
;	O
0	O
.	O
85	O
%	O
NaCl	O
,	O
1	O
.	O
4	O
mM	O
KH2	O
PO4	O
,	O
8	O
mM	O
Na2	O
HPO4	O
,	O
pH	O
7	O
.	O
4	O
)	O
for	O
45	O
min	O
and	O
then	O
washed	O
in	O
PBS	O
.	O

The	O
reproductive	O
tracts	O
were	O
then	O
incubated	O
in	O
blocking	O
solution	O
(	O
0	O
.	O
5	O
%	O
Triton	O
x	O
-	O
100	O
,	O
3	O
%	O
NGS	O
,	O
0	O
.	O
1	O
%	O
BSA	O
)	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
.	O

The	O
following	O
primary	O
antibodies	O
,	O
reagents	O
,	O
and	O
dilutions	O
were	O
used	O
:	O
Cy3	O
-	O
conjugated	O
goat	S-Species
anti	O
-	O
HRP	O
,	O
1	O
:	O
200	O
(	O
Jackson	O
Immunochemicals	O
,	O
West	O
Grove	O
,	O
PA	O
)	O
;	O
mouse	S-Species
anti	O
-	O
Disc	O
Large	O
(	O
DLG	O
)	O
,	O
1	O
:	O
1000	O
(	O
Developmental	O
Hybridoma	O
Bank	O
)	O
,	O
Alexa	O
Fluor	O
488	O
-	O
phalloidin	O
,	O
1	O
:	O
200	O
(	O
Invitrogen	O
,	O
Molecular	O
Probes	O
,	O
Scotland	O
)	O
.	O

Secondary	O
antibodies	O
were	O
Alexa	O
Flour	O
488	O
-	O
conjugated	O
Goat	S-Species
anti	O
-	O
mouse	S-Species
,	O
1	O
:	O
200	O
and	O
Alexa	O
Flour	O
546	O
-	O
conjugated	O
Goat	S-Species
anti	O
-	O
rabbit	S-Species
,	O
1	O
:	O
200	O
(	O
Invitrogen	O
,	O
Molecular	O
Probes	O
,	O
Scotland	O
)	O
.	O

Reproductive	O
tracts	O
were	O
incubated	O
with	O
the	O
different	O
primary	O
antibodies	O
(	O
diluted	O
in	O
PBS	O
+	O
0	O
.	O
2	O
%	O
Triton	O
x	O
-	O
100	O
)	O
for	O
2	O
hr	O
at	O
room	O
temperature	O
,	O
washed	O
with	O
PBST	O
,	O
incubated	O
with	O
secondary	O
antibodies	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
and	O
washed	O
with	O
PBS	O
.	O

Reproductive	O
tracts	O
of	O
the	O
different	O
treatments	O
were	O
mounted	O
with	O
Antifade	O
media	O
[	O
58	O
]	O
on	O
a	O
multi	O
-	O
well	O
glass	O
slide	O
(	O
Hendley	O
-	O
Essex	O
,	O
UK	O
)	O
.	O

For	O
each	O
treatment	O
(	O
unmated	O
,	O
mated	O
)	O
and	O
antibody	O
/	O
reagent	O
(	O
HRP	O
,	O
DLG	O
,	O
phalloidin	O
)	O
a	O
minimum	O
of	O
ten	O
reproductive	O
tracts	O
from	O
at	O
least	O
two	O
independent	O
biological	O
replicates	O
were	O
prepared	O
.	O

Confocal	O
microscopy	O

Reproductive	O
tracts	O
were	O
viewed	O
with	O
a	O
Zeiss	O
510	O
laser	O
scanning	O
confocal	O
microscope	O
using	O
20	O
x	O
and	O
60	O
x	O
objective	O
with	O
additional	O
zooming	O
.	O

Optical	O
sections	O
from	O
different	O
focal	O
plans	O
of	O
each	O
reproductive	O
tract	O
region	O
(	O
lateral	O
oviducts	O
,	O
common	O
oviduct	O
,	O
uterus	O
)	O
were	O
collected	O
and	O
projected	O
as	O
a	O
reconstructed	O
three	O
-	O
dimensional	O
image	O
using	O
LSM	O
image	O
browser	O
(	O
version	O
3	O
,	O
5	O
,	O
0	O
,	O
376	O
)	O
software	O
.	O

Image	O
collections	O
were	O
identical	O
for	O
each	O
of	O
the	O
different	O
reproductive	O
tract	O
regions	O
analyzed	O
.	O

Quantitation	O
of	O
bouton	O
number	O

To	O
quantify	O
the	O
number	O
of	O
boutons	O
in	O
the	O
lateral	O
and	O
common	O
oviducts	O
we	O
used	O
ImageJ	O
software	O
(	O
1	O
.	O
37b	O
,	O
National	O
Institutes	O
of	O
Health	O
)	O
to	O
analyze	O
confocal	O
images	O
of	O
anti	O
-	O
HRP	O
and	O
anti	O
-	O
DLG	O
labeled	O
boutons	O
in	O
the	O
oviduct	O
.	O

The	O
number	O
of	O
boutons	O
per	O
unit	O
area	O
was	O
quantified	O
with	O
the	O
Particle	O
Analysis	O
Tool	O
.	O

Briefly	O
,	O
to	O
differentiate	O
between	O
the	O
boutons	O
,	O
the	O
particle	O
analysis	O
tool	O
requires	O
the	O
image	O
to	O
be	O
a	O
"	O
binary	O
"	O
image	O
(	O
i	O
.	O
e	O
.	O
,	O
black	O
or	O
white	O
)	O
,	O
thus	O
we	O
first	O
converted	O
the	O
images	O
to	O
gray	O
scale	O
.	O

We	O
then	O
set	O
a	O
"	O
threshold	O
"	O
range	O
so	O
that	O
pixels	O
in	O
the	O
image	O
whose	O
value	O
lies	O
in	O
this	O
range	O
are	O
converted	O
to	O
black	O
;	O
pixels	O
with	O
values	O
outside	O
this	O
range	O
are	O
converted	O
to	O
white	O
.	O

We	O
next	O
defined	O
a	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
within	O
the	O
oviduct	O
to	O
count	O
particles	O
(	O
i	O
.	O
e	O
.	O
count	O
boutons	O
)	O
.	O

This	O
ROI	O
was	O
saved	O
and	O
served	O
to	O
measure	O
the	O
number	O
of	O
boutons	O
per	O
unit	O
area	O
in	O
each	O
treatment	O
.	O

For	O
each	O
oviduct	O
we	O
counted	O
the	O
number	O
of	O
anti	O
-	O
HRP	O
and	O
anti	O
-	O
DLG	O
labeled	O
boutons	O
in	O
two	O
ROIs	O
within	O
the	O
lateral	O
oviducts	O
and	O
two	O
ROIs	O
in	O
the	O
common	O
oviduct	O
.	O

One	O
-	O
way	O
ANOVA	O
(	O
SPSS	O
15	O
.	O
0	O
)	O
was	O
used	O
to	O
measure	O
the	O
difference	O
in	O
bouton	O
number	O
per	O
unit	O
area	O
in	O
different	O
regions	O
of	O
the	O
oviducts	O
,	O
in	O
both	O
unmated	O
and	O
mated	O
females	O
.	O

Quantitation	O
of	O
cytoskeleton	O
proteins	O

Sample	O
preparation	O

To	O
evaluate	O
the	O
effect	O
of	O
mating	O
on	O
the	O
abundance	O
of	O
the	O
cytoskeleton	O
proteins	O
tested	O
,	O
females	O
were	O
:	O
(	O
i	O
)	O
aged	O
for	O
3	O
days	O
,	O
mated	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
and	O
their	O
oviducts	O
were	O
dissected	O
after	O
6	O
hrs	O
post	O
-	O
mating	O
(	O
Once3	O
)	O
;	O
(	O
ii	O
)	O
aged	O
for	O
3	O
days	O
,	O
mated	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
and	O
their	O
oviducts	O
were	O
dissected	O
after	O
7	O
days	O
(	O
Once3	O
day10	O
)	O
;	O
(	O
iii	O
)	O
aged	O
for	O
3	O
days	O
,	O
mated	O
first	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
and	O
held	O
singly	O
for	O
7	O
days	O
.	O

At	O
10	O
days	O
of	O
age	O
,	O
female	O
were	O
mated	O
again	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
.	O

Oviducts	O
were	O
dissected	O
at	O
6	O
hrs	O
post	O
-	O
second	O
mating	O
(	O
Twice3	O
&	O
10	O
)	O
.	O

We	O
also	O
examined	O
5	O
-	O
day	O
-	O
old	O
and	O
10	O
-	O
day	O
-	O
old	O
unmated	O
females	O
(	O
UM5	O
,	O
UM10	O
respectively	O
)	O
.	O

SDS	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
Western	O
blotting	O

For	O
each	O
mating	O
regime	O
,	O
sixty	O
oviducts	O
were	O
pooled	O
and	O
30	O
mu	O
l	O
of	O
SDS	O
-	O
PAGE	O
sample	O
buffer	O
was	O
added	O
as	O
described	O
in	O
[	O
59	O
]	O
.	O

Samples	O
were	O
boiled	O
,	O
and	O
then	O
frozen	O
at	O
-	O
20	O
degrees	O
C	O
until	O
loading	O
.	O

SDS	O
-	O
PAGE	O
was	O
performed	O
on	O
12	O
%	O
polyacrylamide	O
gels	O
and	O
western	O
blotted	O
as	O
in	O
[	O
60	O
]	O
.	O

Proteins	O
were	O
cross	O
-	O
linked	O
to	O
the	O
filter	O
.	O

The	O
following	O
primary	O
antibodies	O
and	O
dilutions	O
were	O
used	O
:	O
mouse	S-Species
anti	O
-	O
Neuroglian	O
(	O
kindly	O
provided	O
by	O
M	O
.	O
Hortsch	O
)	O
1	O
:	O
250	O
;	O
Guinea	B-Species
pig	E-Species
anti	O
-	O
Coracle	O
(	O
kindly	O
provided	O
by	O
R	O
.	O
G	O
.	O
Fehon	O
)	O
1	O
:	O
2500	O
;	O
rabbit	S-Species
anti	O
-	O
Mlp84B	O
(	O
kindly	O
provided	O
by	O
M	O
.	O
Beckerle	O
)	O
1	O
:	O
1000	O
;	O
mouse	S-Species
anti	O
-	O
hts	O
(	O
1B1	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
,	O
DSHB	O
)	O
1	O
:	O
75	O
;	O
mouse	S-Species
anti	O
-	O
Na	O
,	O
K	O
-	O
ATPase	O
(	O
alpha	O
5	O
,	O
DSHB	O
)	O
1	O
:	O
100	O
.	O

Secondary	O
antibodies	O
included	O
:	O
anti	O
-	O
Guinea	B-Species
pig	E-Species
IgG	O
(	O
peroxidase	O
conjugated	O
)	O
,	O
anti	O
-	O
Rabbit	S-Species
IgG	O
and	O
anti	O
-	O
Mouse	S-Species
IgG	O
(	O
developed	O
in	O
goat	S-Species
,	O
Sigma	O
,	O
Israel	O
)	O
1	O
:	O
10	O
,	O
000	O
.	O

Proteins	O
were	O
visualized	O
using	O
an	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
)	O
detection	O
system	O
(	O
Amersham	O
Piscataway	O
,	O
NJ	O
)	O
.	O

Analysis	O

The	O
developed	O
film	O
was	O
scanned	O
and	O
the	O
signal	O
intensity	O
(	O
protein	O
abundance	O
)	O
of	O
each	O
band	O
was	O
determined	O
using	O
ImageJ	O
software	O
(	O
1	O
.	O
37d	O
,	O
National	O
Institutes	O
of	O
Health	O
)	O
.	O

We	O
evaluated	O
protein	O
abundance	O
by	O
measuring	O
the	O
mean	O
gray	O
value	O
of	O
a	O
specific	O
band	O
and	O
the	O
background	O
.	O

The	O
mean	O
gray	O
value	O
of	O
the	O
background	O
was	O
then	O
subtracted	O
from	O
that	O
of	O
the	O
measured	O
band	O
.	O

Relative	O
protein	O
abundance	O
in	O
mated	O
oviduct	O
vs	O
.	O
3	O
-	O
day	O
-	O
old	O
unmated	O
oviduct	O
was	O
then	O
calculated	O
.	O

Four	O
independent	O
biological	O
replicates	O
were	O
prepared	O
for	O
each	O
mating	O
status	O
.	O

The	O
reported	O
abundance	O
(	O
see	O
Figure	O
5	O
)	O
is	O
the	O
relative	O
ratio	O
(	O
mated	O
/	O
unmated	O
or	O
unmated	O
/	O
unmated	O
)	O
of	O
at	O
least	O
three	O
replicates	O
that	O
showed	O
the	O
same	O
trend	O
.	O

Examination	O
of	O
female	O
reproductive	O
output	O

Mating	O
regimes	O

To	O
evaluate	O
the	O
effect	O
of	O
mating	O
on	O
reproductive	O
output	O
females	O
were	O
treated	O
as	O
follows	O
:	O
(	O
i	O
)	O
aged	O
for	O
3	O
days	O
and	O
mated	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
(	O
Once3	O
)	O
;	O
(	O
ii	O
)	O
aged	O
for	O
10	O
days	O
and	O
mated	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
(	O
Once10	O
)	O
;	O
(	O
iii	O
)	O
aged	O
for	O
3	O
days	O
,	O
mated	O
first	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
,	O
held	O
for	O
7	O
days	O
and	O
mated	O
again	O
with	O
3	O
-	O
day	O
-	O
old	O
unmated	O
males	O
(	O
Twice3	O
&	O
10	O
)	O
.	O

In	O
all	O
cases	O
male	O
and	O
female	O
pairs	O
were	O
observed	O
to	O
record	O
mating	O
initiation	O
and	O
termination	O
.	O

Analysis	O

Following	O
mating	O
,	O
females	O
were	O
aspirated	O
into	O
fresh	O
vials	O
,	O
held	O
singly	O
and	O
allowed	O
to	O
lay	O
eggs	O
for	O
6	O
hrs	O
,	O
then	O
transferred	O
daily	O
(	O
each	O
24	O
hrs	O
)	O
to	O
fresh	O
vials	O
.	O

The	O
number	O
of	O
eggs	O
laid	O
and	O
the	O
number	O
of	O
eclosed	O
adults	O
were	O
counted	O
from	O
vials	O
created	O
at	O
6	O
hrs	O
,	O
1	O
,	O
2	O
and	O
3	O
days	O
post	O
-	O
mating	O
.	O

To	O
ascertain	O
the	O
baseline	O
of	O
female	O
egg	O
-	O
laying	O
,	O
we	O
also	O
included	O
in	O
our	O
experiment	O
unmated	O
females	O
that	O
were	O
kept	O
in	O
the	O
same	O
conditions	O
as	O
mated	O
females	O
.	O

The	O
number	O
of	O
eggs	O
laid	O
by	O
unmated	O
females	O
was	O
counted	O
from	O
vials	O
created	O
at	O
6	O
hrs	O
,	O
1	O
,	O
2	O
and	O
3	O
days	O
after	O
placing	O
the	O
females	O
in	O
the	O
holding	O
vials	O
.	O

In	O
addition	O
,	O
we	O
also	O
recorded	O
the	O
pattern	O
of	O
unmated	O
female	O
egg	O
-	O
laying	O
for	O
10	O
days	O
.	O

To	O
determine	O
the	O
effect	O
of	O
different	O
mating	O
regimes	O
on	O
female	O
reproductive	O
output	O
(	O
i	O
.	O
e	O
.	O
fecundity	O
and	O
fertility	O
)	O
,	O
we	O
used	O
One	O
-	O
way	O
ANOVA	O
(	O
SPSS	O
15	O
.	O
0	O
)	O
.	O

Abbreviations	O

Nrg	O
:	O
Neuroglian	O
;	O
Cora	O
:	O
Coracle	O
;	O
Spec	O
:	O
alpha	O
-	O
and	O
beta	O
-	O
Spectrin	O
;	O
SJ	O
:	O
septate	O
junction	O
;	O
SSJ	O
:	O
smooth	O
septate	O
junction	O
;	O
PSJ	O
:	O
pleated	O
septate	O
junction	O
;	O
ZA	O
:	O
zonal	O
adherens	O
junction	O
;	O
AJ	O
:	O
adherens	O
junction	O
;	O
AECM	O
:	O
apical	O
extracellular	O
matrix	O
;	O
ECM	O
:	O
extracellular	O
matrix	O
;	O
HAJ	O
:	O
hemi	O
-	O
adherens	O
junction	O
;	O
SAJ	O
:	O
spot	O
adherens	O
junction	O
;	O
OA	O
:	O
Octopamine	O
;	O
Hts	O
:	O
Hu	O
-	O
li	O
tai	O
shao	O
;	O
ATP	O
alpha	O
:	O
Na	O
+	O
pump	O
alpha	O
subunit	O
;	O
Mlp84B	O
:	O
Muscle	O
LIM	O
protein	O
at	O
84B	O
;	O
DLG	O
:	O
Disc	O
Large	O
;	O
HRP	O
:	O
horseradish	S-Species
peroxidas	O
;	O
UM	O
:	O
unmated	O
;	O
M	O
:	O
mated	O
.	O

Authors	O
'	O
contributions	O

AK	O
and	O
PKR	O
contributed	O
equally	O
to	O
this	O
manuscript	O
.	O

AK	O
,	O
PKR	O
and	O
YH	O
conceived	O
and	O
designed	O
the	O
project	O
and	O
analyzed	O
the	O
data	O
.	O

AK	O
performed	O
the	O
confocal	O
,	O
Western	O
blots	O
and	O
fertility	O
assays	O
.	O

PKR	O
and	O
AK	O
performed	O
the	O
light	O
microscopy	O
.	O

PKR	O
conducted	O
the	O
electron	O
microscopy	O
.	O

AK	O
,	O
PKR	O
and	O
YH	O
wrote	O
the	O
manuscript	O
.	O

RRH	O
contributed	O
to	O
design	O
of	O
the	O
study	O
and	O
revision	O
of	O
the	O
manuscript	O
.	O

All	O
authors	O
participated	O
in	O
the	O
discussion	O
and	O
approval	O
of	O
the	O
final	O
manuscript	O
.	O

Supplementary	O
Material	O

Efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
(R)	O
)	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
affecting	O
the	O
first	O
metatarsophalangeal	O
joint	O
of	O
the	O
foot	O
(	O
hallux	O
limitus	O
)	O
:	O
study	O
protocol	O
for	O
a	O
randomised	O
placebo	O
controlled	O
trial	O

Abstract	O

Background	O

Osteoarthritis	O
of	O
the	O
first	O
metatarsophalangeal	O
joint	O
(	O
MPJ	O
)	O
of	O
the	O
foot	O
,	O
termed	O
hallux	O
limitus	O
,	O
is	O
common	O
and	O
painful	O
.	O

Numerous	O
non	O
-	O
surgical	O
interventions	O
have	O
been	O
proposed	O
for	O
this	O
disorder	O
,	O
however	O
there	O
is	O
limited	O
evidence	O
for	O
their	O
efficacy	O
.	O

Intra	O
-	O
articular	O
injections	O
of	O
hyaluronan	O
have	O
shown	O
beneficial	O
effects	O
in	O
case	O
-	O
series	O
and	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
of	O
the	O
first	O
metatarsophalangeal	O
joint	O
.	O

However	O
,	O
no	O
study	O
has	O
evaluated	O
the	O
efficacy	O
of	O
this	O
form	O
of	O
treatment	O
using	O
a	O
randomised	O
placebo	O
controlled	O
trial	O
.	O

This	O
article	O
describes	O
the	O
design	O
of	O
a	O
randomised	O
placebo	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
(R)	O
)	O
to	O
reduce	O
pain	O
and	O
improve	O
function	O
in	O
people	S-Species
with	O
hallux	O
limitus	O
.	O

Methods	O

One	O
hundred	O
and	O
fifty	O
community	O
-	O
dwelling	O
men	S-Species
and	O
women	S-Species
aged	O
18	O
years	O
and	O
over	O
with	O
hallux	O
limitus	O
(	O
who	O
satisfy	O
inclusion	O
and	O
exclusion	O
criteria	O
)	O
will	O
be	O
recruited	O
.	O

Participants	S-Species
will	O
be	O
randomised	O
,	O
using	O
a	O
computer	O
-	O
generated	O
random	O
number	O
sequence	O
,	O
to	O
receive	O
a	O
single	O
intra	O
-	O
articular	O
injection	O
of	O
up	O
to	O
1	O
ml	O
hyaluronan	O
(	O
Synvisc	O
(R)	O
)	O
or	O
sterile	O
saline	O
(	O
placebo	O
)	O
into	O
the	O
first	O
MPJ	O
.	O

The	O
injections	O
will	O
be	O
performed	O
by	O
an	O
interventional	O
radiologist	O
using	O
fluoroscopy	O
to	O
ensure	O
accurate	O
deposition	O
of	O
the	O
hyaluronan	O
in	O
the	O
joint	O
.	O

Participants	S-Species
will	O
be	O
given	O
the	O
option	O
of	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
(R)	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
either	O
1	O
or	O
3	O
months	O
post	O
-	O
treatment	O
if	O
there	O
is	O
no	O
improvement	O
in	O
pain	O
and	O
the	O
participant	S-Species
has	O
not	O
experienced	O
severe	O
adverse	O
effects	O
after	O
the	O
first	O
injection	O
.	O

The	O
primary	O
outcome	O
measures	O
will	O
be	O
the	O
pain	O
and	O
function	O
subscales	O
of	O
the	O
Foot	O
Health	O
Status	O
Questionnaire	O
.	O

The	O
secondary	O
outcome	O
measures	O
will	O
be	O
pain	O
at	O
the	O
first	O
MPJ	O
(	O
during	O
walking	O
and	O
at	O
rest	O
)	O
,	O
stiffness	O
at	O
the	O
first	O
MPJ	O
,	O
passive	O
non	O
-	O
weightbearing	O
dorsiflexion	O
of	O
the	O
first	O
MPJ	O
,	O
plantar	O
flexion	O
strength	O
of	O
the	O
toe	O
-	O
flexors	O
of	O
the	O
hallux	O
,	O
global	O
satisfaction	O
with	O
the	O
treatment	O
,	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
assessed	O
using	O
the	O
Short	O
-	O
Form	O
-	O
36	O
version	O
two	O
questionnaire	O
)	O
,	O
magnitude	O
of	O
symptom	O
change	O
,	O
use	O
of	O
pain	O
-	O
relieving	O
medication	O
and	O
changes	O
in	O
dynamic	O
plantar	O
pressure	O
distribution	O
(	O
maximum	O
force	O
and	O
peak	O
pressure	O
)	O
during	O
walking	O
.	O

Data	O
will	O
be	O
collected	O
at	O
baseline	O
,	O
then	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
treatment	O
.	O

Data	O
will	O
be	O
analysed	O
using	O
the	O
intention	O
to	O
treat	O
principle	O
.	O

Discussion	O

This	O
study	O
is	O
the	O
first	O
randomised	O
placebo	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
(R)	O
)	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
of	O
the	O
first	O
MPJ	O
(	O
hallux	O
limitus	O
)	O
.	O

The	O
study	O
has	O
been	O
pragmatically	O
designed	O
to	O
ensure	O
that	O
the	O
study	O
findings	O
can	O
be	O
implemented	O
into	O
clinical	O
practice	O
if	O
this	O
form	O
of	O
treatment	O
is	O
found	O
to	O
be	O
an	O
effective	O
treatment	O
strategy	O
.	O

Trial	O
registration	O

Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
:	O
ACTRN12607000654459	O

Background	O

Osteoarthritis	O
(	O
OA	O
)	O
is	O
a	O
degenerative	O
joint	O
disease	O
that	O
commonly	O
presents	O
within	O
the	O
first	O
metatarsophalangeal	O
joint	O
(	O
MPJ	O
)	O
of	O
the	O
foot	O
.	O

The	O
terms	O
hallux	O
limitus	O
and	O
hallux	O
rigidus	O
have	O
frequently	O
been	O
used	O
interchangeably	O
to	O
describe	O
differing	O
severities	O
of	O
pain	O
and	O
limitation	O
of	O
motion	O
associated	O
with	O
OA	O
at	O
the	O
first	O
MPJ	O
[	O
1	O
]	O
.	O

Hallux	O
limitus	O
is	O
a	O
progressive	O
osteoarthritic	O
condition	O
of	O
the	O
first	O
MPJ	O
that	O
may	O
advance	O
to	O
an	O
end	O
-	O
stage	O
presentation	O
of	O
hallux	O
rigidus	O
where	O
the	O
joint	O
fuses	O
and	O
there	O
is	O
a	O
complete	O
restriction	O
of	O
motion	O
[	O
1	O
]	O
.	O

First	O
MPJ	O
OA	O
is	O
the	O
second	O
most	O
common	O
disorder	O
affecting	O
the	O
foot	O
after	O
hallux	O
valgus	O
[	O
2	O
]	O
.	O

The	O
prevalence	O
of	O
the	O
condition	O
increases	O
with	O
age	O
,	O
and	O
it	O
has	O
been	O
reported	O
that	O
radiographic	O
changes	O
in	O
the	O
first	O
MPJ	O
affect	O
are	O
evident	O
in	O
approximately	O
46	O
%	O
of	O
women	S-Species
and	O
32	O
%	O
of	O
men	S-Species
at	O
60	O
years	O
of	O
age	O
[	O
3	O
]	O
.	O

Osteoarthritis	O
at	O
the	O
first	O
MPJ	O
is	O
characterised	O
by	O
the	O
symptoms	O
of	O
pain	O
and	O
stiffness	O
at	O
the	O
joint	O
[	O
1	O
]	O
.	O

Secondary	O
painful	O
symptoms	O
relate	O
to	O
compensations	O
during	O
gait	O
that	O
may	O
occur	O
due	O
to	O
the	O
reduced	O
motion	O
of	O
the	O
first	O
MPJ	O
[	O
1	O
]	O
.	O

The	O
presence	O
of	O
pain	O
associated	O
with	O
first	O
MPJ	O
OA	O
impacts	O
on	O
normal	O
walking	O
and	O
quality	O
of	O
life	O
[	O
4	O
]	O
.	O

Treatment	O
of	O
hallux	O
limitus	O
involves	O
conservative	O
measures	O
(	O
such	O
as	O
physical	O
therapy	O
,	O
foot	O
orthoses	O
,	O
footwear	O
modification	O
,	O
joint	O
manipulation	O
and	O
injection	O
with	O
corticosteroid	O
)	O
[	O
5	O
]	O
,	O
or	O
surgical	O
intervention	O
(	O
either	O
joint	O
-	O
salvage	O
or	O
joint	O
-	O
destructive	O
procedures	O
)	O
[	O
6	O
]	O
.	O

Pharmacological	O
treatment	O
is	O
also	O
often	O
undertaken	O
as	O
an	O
adjunct	O
for	O
pain	O
relief	O
in	O
the	O
management	O
of	O
hallux	O
limitus	O
[	O
6	O
]	O
.	O

However	O
,	O
although	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
cyclooxygenase	O
-	O
2	O
inhibitors	O
have	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
management	O
of	O
various	O
forms	O
of	O
OA	O
,	O
gastrointestinal	O
complications	O
remain	O
a	O
concern	O
[	O
7	O
]	O
.	O

In	O
light	O
of	O
these	O
limitations	O
with	O
existing	O
treatments	O
,	O
an	O
alternative	O
treatment	O
termed	O
'	O
viscosupplementation	O
'	O
-	O
the	O
intra	O
-	O
articular	O
injection	O
of	O
hyaluronan	O
into	O
arthritic	O
joints	O
with	O
the	O
aim	O
of	O
restoring	O
the	O
viscoelasticity	O
of	O
the	O
synovial	O
fluid	O
[	O
8	O
]	O
-	O
has	O
been	O
proposed	O
and	O
has	O
attracted	O
considerable	O
attention	O
in	O
the	O
medical	O
literature	O
as	O
a	O
treatment	O
for	O
OA	O
[	O
9	O
]	O
.	O

In	O
particular	O
,	O
both	O
the	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
and	O
European	O
League	O
Against	O
Rheumatism	O
(	O
EULAR	O
)	O
recommend	O
hyaluronan	O
in	O
the	O
management	O
of	O
OA	O
of	O
the	O
knee	O
[	O
10	O
,	O
11	O
]	O
.	O

Although	O
the	O
results	O
of	O
systematic	O
reviews	O
investigating	O
the	O
effectiveness	O
of	O
this	O
type	O
of	O
treatment	O
for	O
knee	O
OA	O
are	O
controversial	O
,	O
the	O
most	O
recent	O
update	O
of	O
the	O
Cochrane	O
systematic	O
review	O
evaluating	O
viscosupplementation	O
for	O
the	O
treatment	O
of	O
knee	O
OA	O
concluded	O
that	O
viscosupplementation	O
was	O
both	O
safe	O
and	O
effective	O
for	O
the	O
treatment	O
of	O
OA	O
and	O
was	O
superior	O
or	O
equivalent	O
to	O
any	O
form	O
of	O
systemic	O
intervention	O
or	O
intra	O
-	O
articular	O
corticosteroids	O
[	O
9	O
,	O
12	O
]	O
.	O

Despite	O
there	O
being	O
a	O
large	O
number	O
of	O
studies	O
investigating	O
the	O
effectiveness	O
of	O
hyaluronan	O
for	O
knee	O
OA	O
,	O
few	O
studies	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
form	O
of	O
treatment	O
for	O
OA	O
at	O
the	O
first	O
MPJ	O
[	O
13	O
]	O
.	O

In	O
a	O
case	O
-	O
series	O
retrospective	O
study	O
,	O
14	O
patients	S-Species
with	O
radiographically	O
confirmed	O
OA	O
at	O
the	O
first	O
MPJ	O
that	O
received	O
up	O
to	O
3	O
intra	O
-	O
articular	O
injections	O
of	O
1	O
ml	O
hyaluronan	O
(	O
Ostenil	O
(R)	O
Mini	O
)	O
(	O
sodium	O
hyaluronate	O
)	O
reported	O
a	O
statistically	O
significant	O
reduction	O
in	O
pain	O
(	O
reported	O
using	O
a	O
visual	O
analogue	O
scale	O
)	O
after	O
6	O
months	O
[	O
14	O
]	O
.	O

The	O
treatment	O
was	O
well	O
tolerated	O
,	O
with	O
3	O
/	O
14	O
(	O
21	O
%	O
)	O
participants	S-Species
reporting	O
mild	O
adverse	O
reactions	O
at	O
the	O
injection	O
site	O
.	O

In	O
another	O
study	O
,	O
Pons	O
et	O
al	O
[	O
13	O
]	O
compared	O
a	O
single	O
intra	O
-	O
articular	O
injection	O
of	O
1	O
ml	O
Ostenil	O
(R)	O
Mini	O
(	O
sodium	O
hyaluronate	O
)	O
with	O
1	O
ml	O
Trigon	O
depot	O
(R)	O
(	O
triamcinolone	O
acetonide	O
,	O
a	O
corticosteroid	O
)	O
for	O
the	O
treatment	O
of	O
painful	O
,	O
grade	O
1	O
hallux	O
limitus	O
(	O
Karasick	O
and	O
Wapner	O
[	O
15	O
]	O
scale	O
)	O
in	O
37	O
participants	S-Species
(	O
40	O
feet	O
)	O
[	O
13	O
]	O
.	O

Both	O
treatment	O
groups	O
showed	O
statistically	O
significant	O
reductions	O
in	O
pain	O
at	O
rest	O
or	O
on	O
palpation	O
for	O
up	O
to	O
12	O
weeks	O
post	O
-	O
injection	O
.	O

However	O
,	O
hyaluronan	O
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
greater	O
reduction	O
in	O
pain	O
during	O
walking	O
and	O
greater	O
improvement	O
in	O
the	O
American	O
Orthopaedic	O
Foot	O
and	O
Ankle	O
Society	O
(	O
AOFAS	O
)	O
hallux	O
MPJ	O
score	O
compared	O
to	O
treatment	O
with	O
triamcinolone	O
acetonide	O
.	O

The	O
treatment	O
with	O
hyaluronan	O
was	O
well	O
tolerated	O
,	O
with	O
2	O
/	O
20	O
(	O
10	O
%	O
)	O
participants	S-Species
reporting	O
mild	O
adverse	O
reactions	O
at	O
the	O
injection	O
site	O
.	O

Although	O
both	O
of	O
these	O
studies	O
suggest	O
that	O
intra	O
-	O
articular	O
hyaluronan	O
is	O
safe	O
and	O
effective	O
for	O
the	O
treatment	O
of	O
hallux	O
limitus	O
,	O
neither	O
used	O
a	O
placebo	O
control	O
group	O
[	O
13	O
,	O
14	O
]	O
.	O

This	O
limitation	O
is	O
significant	O
as	O
a	O
placebo	O
effect	O
can	O
account	O
for	O
79	O
%	O
of	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
treatment	O
[	O
16	O
]	O
.	O

Further	O
,	O
both	O
studies	O
are	O
limited	O
in	O
that	O
neither	O
of	O
the	O
studies	O
used	O
blinding	O
of	O
both	O
the	O
participants	S-Species
and	O
assessors	O
in	O
their	O
protocols	O
.	O

It	O
is	O
therefore	O
possible	O
that	O
the	O
positive	O
effects	O
of	O
hyaluronan	O
may	O
have	O
been	O
overestimated	O
.	O

Accordingly	O
,	O
the	O
aims	O
of	O
this	O
project	O
are	O
to	O
conduct	O
a	O
double	O
blind	O
randomised	O
controlled	O
trial	O
to	O
determine	O
the	O
effectiveness	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
(R)	O
)	O
on	O
(	O
i	O
)	O
foot	O
pain	O
and	O
function	O
;	O
(	O
ii	O
)	O
the	O
range	O
of	O
motion	O
of	O
the	O
first	O
MPJ	O
;	O
(	O
iii	O
)	O
the	O
strength	O
of	O
the	O
plantarflexor	O
muscles	O
of	O
the	O
first	O
MPJ	O
;	O
(	O
iv	O
)	O
the	O
health	O
related	O
quality	O
of	O
life	O
;	O
and	O
(	O
v	O
)	O
the	O
use	O
of	O
pain	O
-	O
relieving	O
medications	O
in	O
people	S-Species
with	O
hallux	O
limitus	O
.	O

The	O
study	O
protocol	O
is	O
presented	O
in	O
this	O
paper	O
,	O
consistent	O
with	O
the	O
recommendations	O
of	O
Editorial	O
Board	O
of	O
BioMed	O
Central	O
[	O
17	O
]	O
.	O

Methods	O

Design	O

This	O
study	O
is	O
a	O
parallel	O
group	O
,	O
participant	S-Species
and	O
assessor	O
blinded	O
,	O
randomised	O
controlled	O
trial	O
with	O
a	O
6	O
month	O
follow	O
-	O
up	O
(	O
Figure	O
1	O
)	O
.	O

It	O
has	O
been	O
developed	O
using	O
the	O
principles	O
described	O
by	O
Osteoarthritis	O
Research	O
Society	O
International	O
(	O
OARSI	O
)	O
Clinical	O
Trials	O
Task	O
Force	O
guidelines	O
[	O
18	O
]	O
.	O

Participants	S-Species
will	O
be	O
randomised	O
to	O
receive	O
a	O
single	O
intra	O
-	O
articular	O
injection	O
of	O
up	O
to	O
1	O
ml	O
hyaluronan	O
(	O
Synvisc	O
(R)	O
)	O
or	O
sterile	O
saline	O
(	O
placebo	O
)	O
into	O
the	O
first	O
MPJ	O
.	O

Allocation	O
to	O
either	O
the	O
Synvisc	O
(R)	O
or	O
placebo	O
groups	O
will	O
be	O
achieved	O
using	O
a	O
computer	O
-	O
generated	O
random	O
number	O
sequence	O
.	O

The	O
allocation	O
sequence	O
will	O
be	O
generated	O
and	O
held	O
by	O
an	O
external	O
person	S-Species
not	O
directly	O
involved	O
in	O
the	O
trial	O
.	O

Concealment	O
of	O
the	O
allocation	O
sequence	O
will	O
be	O
ensured	O
as	O
each	O
participant	S-Species
'	O
s	O
allocation	O
will	O
be	O
contained	O
in	O
a	O
sealed	O
opaque	O
envelope	O
.	O

Envelopes	O
will	O
be	O
made	O
opaque	O
by	O
using	O
a	O
sheet	O
of	O
aluminium	O
foil	O
inside	O
the	O
envelope	O
.	O

In	O
addition	O
,	O
a	O
system	O
using	O
carbon	O
paper	O
will	O
be	O
employed	O
so	O
the	O
details	O
(	O
name	O
and	O
date	O
of	O
recruitment	O
)	O
are	O
transferred	O
from	O
the	O
outside	O
of	O
the	O
envelope	O
to	O
the	O
paper	O
inside	O
the	O
envelope	O
containing	O
the	O
allocation	O
prior	O
to	O
opening	O
the	O
seal	O
.	O

Assessors	O
and	O
participants	S-Species
will	O
be	O
blinded	O
to	O
group	O
allocation	O
.	O

Participants	S-Species
will	O
be	O
given	O
the	O
option	O
of	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
(R)	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
on	O
days	O
30	O
or	O
90	O
if	O
there	O
is	O
no	O
improvement	O
in	O
pain	O
and	O
the	O
participant	S-Species
has	O
not	O
experienced	O
severe	O
adverse	O
effects	O
after	O
the	O
first	O
injection	O
)	O
.	O

Participants	S-Species

The	O
Human	O
Studies	O
Ethics	O
Committee	O
at	O
La	O
Trobe	O
University	O
(	O
Human	O
Ethics	O
Committee	O
Application	O
No	O
.	O
07	O
-	O
45	O
)	O
and	O
the	O
Radiation	O
Advisory	O
Committee	O
of	O
the	O
Victorian	O
Department	O
of	O
Human	O
Services	O
have	O
given	O
approval	O
for	O
the	O
study	O
.	O

Written	O
informed	O
consent	O
will	O
be	O
obtained	O
from	O
all	O
participants	S-Species
prior	O
to	O
their	O
participation	O
.	O

People	S-Species
with	O
hallux	O
limitus	O
will	O
be	O
recruited	O
from	O
a	O
number	O
of	O
sources	O
:	O

(	O
i	O
)	O
advertisements	O
in	O
relevant	O
Melbourne	O
(	O
Australia	O
)	O
newspapers	O
;	O

(	O
ii	O
)	O
mail	O
-	O
out	O
advertisements	O
to	O
health	O
-	O
care	O
practitioners	O
in	O
Melbourne	O
;	O

(	O
iii	O
)	O
advertisements	O
using	O
relevant	O
internet	O
web	O
-	O
sites	O
(	O
including	O
)	O
;	O

(	O
iv	O
)	O
posters	O
displayed	O
in	O
local	O
retirement	O
villages	O
,	O
community	O
centres	O
and	O
universities	O
located	O
in	O
Melbourne	O
.	O

Respondents	O
will	O
initially	O
be	O
screened	O
by	O
telephone	O
interview	O
to	O
ensure	O
they	O
are	O
suitable	O
for	O
the	O
study	O
.	O

Suitable	O
individuals	O
will	O
then	O
be	O
invited	O
to	O
participate	O
in	O
the	O
study	O
and	O
attend	O
an	O
initial	O
assessment	O
.	O

To	O
be	O
included	O
in	O
the	O
study	O
,	O
participants	S-Species
must	O
meet	O
the	O
following	O
inclusion	O
criteria	O
:	O

(	O
i	O
)	O
be	O
aged	O
at	O
least	O
18	O
years	O
;	O

(	O
ii	O
)	O
report	O
having	O
symptoms	O
of	O
pain	O
,	O
during	O
walking	O
or	O
rest	O
,	O
in	O
the	O
first	O
MPJ	O
for	O
at	O
least	O
3	O
months	O
;	O

(	O
iii	O
)	O
report	O
having	O
pain	O
rated	O
at	O
least	O
20	O
mm	O
on	O
a	O
100	O
mm	O
visual	O
analogue	O
pain	O
scale	O
(	O
VAPS	O
)	O
;	O

(	O
iv	O
)	O
have	O
pain	O
upon	O
palpation	O
of	O
the	O
dorsal	O
aspect	O
of	O
the	O
first	O
MPJ	O
;	O

(	O
v	O
)	O
radiographic	O
evidence	O
of	O
OA	O
(	O
score	O
1	O
or	O
2	O
for	O
either	O
osteophytes	O
or	O
joint	O
space	O
narrowing	O
using	O
a	O
previously	O
published	O
radiographic	O
classification	O
)	O
[	O
19	O
]	O
at	O
the	O
first	O
MPJ	O
.	O

(	O
vi	O
)	O
able	O
to	O
walk	O
household	O
distances	O
(	O
>	O
50	O
meters	O
)	O
without	O
the	O
aid	O
of	O
a	O
walker	O
,	O
crutches	O
or	O
cane	O
;	O

(	O
vii	O
)	O
be	O
willing	O
to	O
attend	O
the	O
La	O
Trobe	O
University	O
Medical	O
Centre	O
(	O
Melbourne	O
,	O
Australia	O
)	O
for	O
treatment	O
with	O
either	O
Synvisc	O
(R)	O
or	O
placebo	O
(	O
single	O
intra	O
-	O
articular	O
injection	O
)	O
and	O
attend	O
the	O
Health	O
Sciences	O
Clinic	O
at	O
La	O
Trobe	O
University	O
(	O
Melbourne	O
,	O
Australia	O
)	O
for	O
the	O
initial	O
assessment	O
and	O
the	O
outcome	O
measurements	O
(	O
at	O
baseline	O
and	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
treatment	O
)	O
;	O

(	O
viii	O
)	O
not	O
receive	O
other	O
intra	O
-	O
articular	O
injections	O
into	O
the	O
first	O
MPJ	O
during	O
the	O
course	O
of	O
the	O
study	O
,	O
apart	O
from	O
those	O
dictated	O
by	O
the	O
study	O
;	O

(	O
ix	O
)	O
be	O
willing	O
to	O
discontinue	O
taking	O
all	O
pain	O
-	O
relieving	O
medications	O
(	O
analgesics	O
and	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
medications	O
(	O
NSAIDs	O
)	O
,	O
except	O
paracetamol	O
up	O
to	O
4	O
g	O
/	O
day	O
,	O
taken	O
by	O
mouth	O
or	O
applied	O
topically	O
)	O
:	O

-	O
for	O
at	O
least	O
14	O
days	O
prior	O
to	O
the	O
baseline	O
assessment	O
;	O

-	O
during	O
the	O
study	O
period	O
(	O
6	O
months	O
after	O
the	O
final	O
treatment	O
with	O
Synvisc	O
(R)	O
)	O
.	O

Participants	S-Species
who	O
do	O
take	O
paracetamol	O
need	O
to	O
discontinue	O
its	O
use	O
at	O
least	O
24	O
hours	O
prior	O
to	O
the	O
baseline	O
assessment	O
and	O
follow	O
-	O
up	O
assessments	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
after	O
the	O
treatment	O
;	O

(	O
x	O
)	O
be	O
willing	O
to	O
not	O
receive	O
any	O
physical	O
therapy	O
on	O
the	O
involved	O
MPJ	O
or	O
trial	O
of	O
shoe	O
modifications	O
or	O
foot	O
orthoses	O
during	O
the	O
study	O
period	O
.	O

Exclusion	O
criteria	O
for	O
participants	S-Species
in	O
this	O
study	O
will	O
be	O
:	O

(	O
i	O
)	O
Severe	O
radiographic	O
evidence	O
of	O
OA	O
(	O
score	O
3	O
for	O
either	O
osteophytes	O
or	O
joint	O
space	O
narrowing	O
)	O
at	O
the	O
first	O
MPJ	O
using	O
a	O
previously	O
published	O
radiographic	O
classification	O
[	O
19	O
]	O
;	O

(	O
ii	O
)	O
previous	O
surgery	O
on	O
the	O
first	O
MPJ	O
;	O

(	O
iii	O
)	O
intra	O
-	O
articular	O
steroid	O
,	O
or	O
any	O
other	O
intra	O
-	O
articular	O
injection	O
at	O
the	O
first	O
MPJ	O
in	O
the	O
previous	O
6	O
months	O
;	O

(	O
iv	O
)	O
treatment	O
with	O
systemic	O
steroid	O
(	O
excluding	O
inhalation	O
or	O
topical	O
steroids	O
)	O
,	O
immunosuppressives	O
or	O
anticoagulants	O
(	O
except	O
for	O
acetylsalicylic	O
acid	O
at	O
dosages	O
of	O
up	O
to	O
325	O
mg	O
/	O
day	O
)	O
;	O

(	O
v	O
)	O
presence	O
of	O
joint	O
infection	O
(	O
s	O
)	O
of	O
the	O
foot	O
;	O

(	O
vi	O
)	O
significant	O
deformity	O
of	O
the	O
first	O
MPJ	O
including	O
hallux	O
abducto	O
valgus	O
(	O
grade	O
of	O
3	O
or	O
4	O
scored	O
using	O
the	O
Manchester	O
Scale	O
[	O
20	O
]	O
;	O

(	O
vii	O
)	O
presence	O
of	O
peripheral	O
vascular	O
disease	O
.	O

Peripheral	O
vascular	O
disease	O
will	O
be	O
considered	O
to	O
be	O
present	O
if	O
any	O
of	O
the	O
following	O
are	O
present	O
[	O
21	O
]	O
;	O

*	O
past	O
history	O
of	O
,	O
vascular	O
surgery	O
,	O
Raynaud	O
'	O
s	O
phenomenon	O
,	O
vasculitis	O
associated	O
with	O
connective	O
tissue	O
diseases	O
,	O
Buerger	O
'	O
s	O
disease	O
,	O
arterial	O
emboli	O
,	O
deep	O
vein	O
thrombosis	O
or	O
lower	O
limb	O
ulcers	O
;	O

*	O
history	O
of	O
intermittent	O
claudication	O
or	O
rest	O
pain	O
;	O

*	O
presence	O
of	O
atrophy	O
,	O
ulcers	O
or	O
significant	O
oedema	O
;	O

*	O
inability	O
to	O
palpate	O
at	O
least	O
one	O
pedal	O
pulse	O
;	O

*	O
Ankle	O
Brachial	O
Pressure	O
Index	O
<	O
0	O
.	O
9	O
;	O

(	O
viii	O
)	O
presence	O
of	O
one	O
or	O
more	O
conditions	O
that	O
can	O
confound	O
pain	O
and	O
functional	O
assessments	O
of	O
the	O
first	O
MPJ	O
,	O
such	O
as	O
metatarsalgia	O
,	O
plantar	O
fasciitis	O
,	O
pre	O
-	O
dislocation	O
syndrome	O
,	O
sprains	O
of	O
the	O
foot	O
,	O
Achilles	O
tendinopathy	O
,	O
degenerative	O
joint	O
disease	O
of	O
the	O
foot	O
(	O
other	O
than	O
the	O
first	O
MPJ	O
)	O
or	O
painful	O
corns	O
and	O
callus	O
;	O

(	O
ix	O
)	O
planning	O
to	O
undergo	O
any	O
surgical	O
procedure	O
or	O
receive	O
any	O
injections	O
,	O
apart	O
from	O
those	O
dictated	O
by	O
the	O
study	O
,	O
at	O
the	O
involved	O
first	O
MPJ	O
during	O
the	O
study	O
period	O
;	O

(	O
x	O
)	O
presence	O
of	O
systemic	O
inflammatory	O
condition	O
or	O
infection	O
,	O
such	O
as	O
inflammatory	O
arthritis	O
,	O
diagnosed	O
with	O
rheumatoid	O
arthritis	O
,	O
ankylosing	O
spondylitis	O
,	O
psoriatic	O
arthritis	O
,	O
reactive	O
arthritis	O
,	O
septic	O
arthritis	O
,	O
acute	O
pseudogout	O
,	O
or	O
any	O
other	O
connective	O
tissue	O
disease	O
;	O

(	O
xi	O
)	O
evidence	O
of	O
gout	O
or	O
other	O
musculoskeletal	O
disease	O
other	O
than	O
OA	O
within	O
the	O
feet	O
.	O

Gout	O
will	O
be	O
screened	O
for	O
using	O
clinical	O
history	O
and	O
physical	O
assessment	O
(	O
painful	O
joint	O
,	O
abrupt	O
onset	O
,	O
swelling	O
)	O
,	O
radiographic	O
assessment	O
(	O
asymmetrical	O
joint	O
swelling	O
,	O
subcortical	O
cysts	O
without	O
erosion	O
and	O
tophi	O
)	O
as	O
well	O
as	O
serum	O
uric	O
acid	O
levels	O
(	O
hyperuricaemia	O
=	O
serum	O
uric	O
acid	O
>	O
mean	O
+	O
2	O
SD	O
from	O
normal	O
population	O
)	O
[	O
22	O
]	O
;	O

(	O
xii	O
)	O
active	O
skin	O
disease	O
or	O
infection	O
in	O
the	O
area	O
of	O
the	O
injection	O
site	O
;	O

(	O
xiii	O
)	O
any	O
medical	O
condition	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigators	O
,	O
makes	O
the	O
participant	S-Species
unsuitable	O
for	O
inclusion	O
(	O
e	O
.	O
g	O
.	O
,	O
severe	O
progressive	O
chronic	O
disease	O
,	O
malignancy	O
,	O
bleeding	O
disorder	O
,	O
clinically	O
important	O
pain	O
in	O
a	O
part	O
of	O
the	O
musculoskeletal	O
system	O
other	O
than	O
the	O
first	O
MPJ	O
,	O
or	O
fibromyalgia	O
)	O
;	O

(	O
xiv	O
)	O
pregnant	O
or	O
lactating	O
women	S-Species
,	O
or	O
women	S-Species
who	O
are	O
of	O
child	S-Species
bearing	O
age	O
or	O
have	O
not	O
undergone	O
menopause	O
(	O
Synvisc	O
(R)	O
has	O
not	O
been	O
tested	O
in	O
pregnant	O
women	S-Species
or	O
women	S-Species
who	O
are	O
nursing	O
)	O
;	O

(	O
xv	O
)	O
cognitive	O
impairment	O
(	O
defined	O
as	O
a	O
score	O
of	O
<	O
7	O
on	O
the	O
Short	O
Portable	O
Mental	O
Status	O
Questionnaire	O
)	O
[	O
23	O
]	O
;	O

(	O
xvi	O
)	O
known	O
hypersensitivity	O
(	O
allergy	O
)	O
to	O
hyaluronan	O
preparations	O
,	O
or	O
to	O
avian	O
proteins	O
,	O
feathers	O
or	O
egg	O
products	O
;	O

(	O
xvii	O
)	O
involvement	O
in	O
any	O
clinical	O
research	O
study	O
in	O
the	O
previous	O
3	O
months	O
that	O
could	O
be	O
considered	O
to	O
affect	O
the	O
results	O
of	O
this	O
study	O
.	O

Intra	O
-	O
articular	O
injections	O
for	O
the	O
treatment	O
groups	O

Participants	S-Species
will	O
be	O
randomised	O
to	O
receive	O
a	O
single	O
intra	O
-	O
articular	O
injection	O
of	O
up	O
to	O
1	O
ml	O
of	O
hyaluronan	O
(	O
Synvisc	O
(R)	O
;	O
Genzyme	O
Biosurgery	O
,	O
Genzyme	O
Corporation	O
,	O
NJ	O
,	O
USA	O
)	O
or	O
sterile	O
saline	O
(	O
placebo	O
)	O
into	O
the	O
first	O
MPJ	O
.	O

Each	O
2	O
ml	O
ampoule	O
of	O
Synvisc	O
(R)	O
contains	O
16	O
mg	O
of	O
hylan	O
G	O
-	O
F	O
20	O
(	O
cross	O
-	O
linked	O
hylan	O
polymers	O
;	O
hylan	O
A	O
and	O
B	O
)	O
,	O
17	O
mg	O
sodium	O
chloride	O
,	O
0	O
.	O
32	O
mg	O
disodium	O
hydrogen	O
phosphate	O
,	O
0	O
.	O
08	O
mg	O
sodium	O
dihydrogen	O
phosphate	O
monohydrate	O
.	O

The	O
hyaluronan	O
is	O
extracted	O
from	O
chicken	S-Species
combs	O
and	O
the	O
purified	O
material	O
has	O
an	O
average	O
molecular	O
weight	O
of	O
6	O
,	O
000	O
kDa	O
.	O

The	O
injections	O
will	O
be	O
performed	O
by	O
the	O
same	O
experienced	O
interventional	O
radiologist	O
(	O
AEZ	O
)	O
using	O
fluoroscopic	O
imaging	O
to	O
ensure	O
accurate	O
deposition	O
of	O
the	O
hyaluronan	O
within	O
the	O
joint	O
.	O

As	O
the	O
Synvisc	O
(R)	O
is	O
provided	O
in	O
ampoules	O
that	O
are	O
labelled	O
with	O
the	O
product	O
name	O
,	O
it	O
will	O
not	O
be	O
possible	O
to	O
blind	O
the	O
injector	O
,	O
however	O
this	O
person	S-Species
is	O
not	O
involved	O
in	O
generation	O
of	O
the	O
allocation	O
order	O
,	O
recruitment	O
,	O
assessment	O
or	O
data	O
analysis	O
.	O

The	O
intra	O
-	O
articular	O
injection	O
will	O
be	O
performed	O
using	O
a	O
21	O
gauge	O
(	O
0	O
.	O
80	O
x	O
19	O
mm	O
)	O
Surflo	O
(R)	O
(	O
Terumo	O
(R)	O
Corp	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
winged	O
infusion	O
set	O
under	O
aseptic	O
procedures	O
.	O

Either	O
a	O
dorso	O
-	O
lateral	O
or	O
dorso	O
-	O
medial	O
approach	O
for	O
injection	O
will	O
be	O
used	O
at	O
the	O
discretion	O
of	O
the	O
injector	O
(	O
depending	O
on	O
which	O
approach	O
provides	O
minimum	O
interference	O
from	O
the	O
osteophytes	O
at	O
the	O
first	O
MPJ	O
joint	O
margins	O
)	O
.	O

No	O
anaesthetic	O
will	O
be	O
used	O
.	O

If	O
the	O
participant	S-Species
has	O
bilateral	O
painful	O
first	O
MPJs	O
,	O
only	O
one	O
side	O
(	O
the	O
most	O
painful	O
side	O
)	O
will	O
be	O
treated	O
and	O
used	O
for	O
data	O
collection	O
.	O

The	O
injector	O
will	O
record	O
the	O
volume	O
of	O
the	O
agent	O
that	O
is	O
injected	O
.	O

Participants	S-Species
will	O
be	O
given	O
the	O
option	O
of	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
(R)	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
on	O
days	O
30	O
or	O
90	O
if	O
there	O
is	O
no	O
improvement	O
in	O
pain	O
(	O
assessed	O
using	O
the	O
VAPS	O
for	O
pain	O
during	O
walking	O
or	O
at	O
rest	O
)	O
and	O
the	O
participant	S-Species
has	O
not	O
experienced	O
severe	O
adverse	O
effects	O
after	O
the	O
first	O
injection	O
)	O
.	O

Assessments	O

Initial	O
assessments	O

An	O
initial	O
assessment	O
will	O
be	O
performed	O
to	O
determine	O
the	O
eligibility	O
of	O
participants	S-Species
for	O
this	O
study	O
.	O

Demographic	O
data	O
will	O
be	O
collected	O
including	O
the	O
age	O
,	O
gender	O
,	O
height	O
and	O
weight	O
of	O
participants	S-Species
.	O

Data	O
will	O
also	O
be	O
obtained	O
concerning	O
the	O
presentation	O
of	O
symptoms	O
(	O
foot	O
affected	O
,	O
duration	O
of	O
symptoms	O
)	O
.	O

If	O
the	O
participant	S-Species
has	O
bilateral	O
painful	O
first	O
MPJs	O
,	O
the	O
most	O
painful	O
side	O
will	O
be	O
used	O
for	O
data	O
collection	O
and	O
subsequent	O
treatment	O
.	O

To	O
establish	O
eligibility	O
for	O
the	O
study	O
,	O
participants	S-Species
will	O
undergo	O
a	O
clinical	O
assessment	O
,	O
have	O
one	O
set	O
of	O
dorso	O
-	O
plantar	O
and	O
lateral	O
weight	O
-	O
bearing	O
x	O
-	O
rays	O
taken	O
of	O
their	O
feet	O
to	O
grade	O
the	O
severity	O
of	O
first	O
MPJ	O
OA	O
as	O
well	O
as	O
undergo	O
a	O
blood	O
test	O
to	O
assess	O
serum	O
uric	O
acid	O
levels	O
(	O
to	O
exclude	O
gout	O
)	O
.	O

Weightbearing	O
dorso	O
-	O
plantar	O
and	O
lateral	O
radiographic	O
views	O
will	O
be	O
obtained	O
from	O
both	O
feet	O
with	O
the	O
participant	S-Species
standing	O
in	O
a	O
relaxed	O
bipedal	O
stance	O
position	O
.	O

All	O
x	O
-	O
rays	O
will	O
be	O
taken	O
by	O
the	O
same	O
medical	O
imaging	O
department	O
using	O
a	O
Shimadzu	O
UD150LRII	O
50	O
kw	O
/	O
30	O
kHz	O
Generator	O
and	O
0	O
.	O
6	O
/	O
1	O
.	O
2	O
P18DE	O
-	O
80S	O
high	O
speed	O
x	O
-	O
ray	O
tube	O
from	O
a	O
ceiling	O
suspended	O
tube	O
mount	O
.	O

AGFA	O
MD40	O
CR	O
digital	O
phosphor	O
plates	O
in	O
a	O
24	O
cm	O
x	O
30	O
cm	O
cassette	O
will	O
be	O
used	O
.	O

For	O
dorso	O
-	O
plantar	O
projections	O
,	O
the	O
x	O
-	O
ray	O
tube	O
will	O
be	O
angled	O
15	O
degrees	O
cephalad	O
and	O
centered	O
at	O
the	O
base	O
of	O
the	O
third	O
metatarsal	O
.	O

For	O
lateral	O
projections	O
,	O
the	O
tube	O
will	O
be	O
angled	O
90	O
degrees	O
and	O
centered	O
at	O
the	O
base	O
of	O
the	O
third	O
metatarsal	O
.	O

The	O
film	O
focus	O
distance	O
will	O
be	O
set	O
at	O
100	O
cm	O
[	O
19	O
]	O
.	O

Baseline	O
assessments	O
and	O
outcome	O
measures	O

Participants	S-Species
who	O
are	O
eligible	O
for	O
the	O
study	O
will	O
be	O
invited	O
to	O
attend	O
a	O
baseline	O
assessment	O
.	O

During	O
the	O
baseline	O
assessment	O
,	O
participants	S-Species
will	O
undergo	O
primary	O
and	O
secondary	O
outcome	O
measurements	O
prior	O
to	O
receiving	O
their	O
injection	O
.	O

The	O
outcome	O
measurements	O
have	O
been	O
developed	O
in	O
accordance	O
of	O
the	O
recommendations	O
of	O
the	O
OARSI	O
Clinical	O
Trials	O
Task	O
Force	O
guidelines	O
[	O
18	O
]	O
.	O

Primary	O
outcome	O
measures	O

Outcome	O
measurements	O
(	O
primary	O
and	O
secondary	O
)	O
will	O
occur	O
at	O
four	O
time	O
-	O
points	O
at	O
baseline	O
,	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
treatment	O
(	O
after	O
the	O
intra	O
-	O
articular	O
injection	O
of	O
Synvisc	O
(R)	O
or	O
placebo	O
)	O
.	O

The	O
assessor	O
performing	O
the	O
measurements	O
will	O
be	O
blinded	O
as	O
to	O
which	O
treatment	O
group	O
participants	S-Species
have	O
been	O
allocated	O
to	O
.	O

Participants	S-Species
who	O
receive	O
a	O
second	O
treatment	O
at	O
day	O
30	O
or	O
90	O
will	O
be	O
followed	O
for	O
a	O
further	O
30	O
days	O
or	O
90	O
days	O
respectively	O
and	O
undergo	O
outcome	O
measurements	O
at	O
7	O
or	O
9	O
months	O
respectively	O
.	O

The	O
primary	O
outcome	O
measures	O
will	O
be	O
the	O
Pain	O
and	O
Function	O
subscales	O
of	O
the	O
Foot	O
Health	O
Status	O
Questionnaire	O
(	O
FHSQ	O
)	O
[	O
24	O
]	O
.	O

The	O
FHSQ	O
includes	O
13	O
questions	O
that	O
assess	O
four	O
domains	O
of	O
foot	O
health	O
,	O
Foot	O
pain	O
,	O
Foot	O
function	O
,	O
Footwear	O
and	O
General	O
foot	O
health	O
.	O

The	O
FHSQ	O
has	O
been	O
subjected	O
to	O
an	O
extensive	O
validation	O
(	O
content	O
,	O
criterion	O
and	O
construct	O
validity	O
)	O
process	O
.	O

It	O
has	O
a	O
high	O
test	O
-	O
retest	O
reliability	O
(	O
intraclass	O
correlation	O
coefficients	O
ranging	O
from	O
0	O
.	O
74	O
to	O
0	O
.	O
92	O
)	O
and	O
a	O
high	O
degree	O
of	O
internal	O
consistency	O
(	O
Cronbach	O
'	O
s	O
alpha	O
ranging	O
from	O
0	O
.	O
85	O
to	O
0	O
.	O
88	O
)	O
[	O
24	O
]	O
.	O

Rigorous	O
reviews	O
have	O
rated	O
it	O
as	O
one	O
of	O
the	O
highest	O
quality	O
foot	O
health	O
status	O
measures	O
currently	O
available	O
[	O
25	O
-	O
27	O
]	O
.	O

Secondary	O
outcome	O
measures	O

The	O
secondary	O
outcome	O
measures	O
will	O
be	O
:	O

(	O
i	O
)	O
Severity	O
of	O
pain	O

Severity	O
of	O
pain	O
at	O
the	O
first	O
MPJ	O
during	O
walking	O
,	O
and	O
during	O
rest	O
,	O
over	O
the	O
past	O
week	O
will	O
be	O
assessed	O
using	O
a	O
100	O
mm	O
visual	O
analogue	O
pain	O
scale	O
.	O

The	O
left	O
side	O
of	O
the	O
scale	O
(	O
0	O
mm	O
)	O
will	O
be	O
labelled	O
"	O
no	O
pain	O
"	O
and	O
the	O
right	O
side	O
of	O
the	O
scale	O
(	O
100	O
mm	O
)	O
will	O
be	O
labelled	O
"	O
worst	O
pain	O
possible	O
"	O
for	O
each	O
question	O
[	O
25	O
,	O
28	O
]	O
.	O

(	O
ii	O
)	O
Severity	O
and	O
duration	O
of	O
stiffness	O
at	O
the	O
first	O
metatarsophalangeal	O
joint	O

The	O
severity	O
of	O
stiffness	O
at	O
the	O
first	O
MPJ	O
during	O
walking	O
over	O
the	O
past	O
week	O
will	O
be	O
assessed	O
using	O
a	O
100	O
mm	O
visual	O
analogue	O
scale	O
.	O

The	O
left	O
side	O
of	O
the	O
scale	O
(	O
0	O
mm	O
)	O
will	O
be	O
labelled	O
"	O
not	O
stiff	O
at	O
all	O
"	O
and	O
the	O
right	O
side	O
of	O
the	O
scale	O
(	O
100	O
mm	O
)	O
will	O
be	O
labelled	O
"	O
most	O
stiff	O
possible	O
"	O
.	O

The	O
average	O
duration	O
of	O
stiffness	O
at	O
the	O
first	O
MPJ	O
over	O
the	O
past	O
week	O
will	O
be	O
assessed	O
using	O
a	O
four	O
category	O
scale	O
response	O
.	O

The	O
responses	O
are	O
:	O
"	O
none	O
"	O
,	O
"	O
1	O
-	O
15	O
minutes	O
"	O
,	O
"	O
16	O
-	O
30	O
minutes	O
"	O
and	O
"	O
greater	O
than	O
30	O
minutes	O
"	O
[	O
29	O
]	O
.	O

(	O
iii	O
)	O
Passive	O
,	O
non	O
-	O
weightbearing	O
dorsiflexion	O
range	O
of	O
motion	O
of	O
the	O
first	O
metatarsophalangeal	O
joint	O

First	O
MPJ	O
dorsiflexion	O
range	O
of	O
motion	O
will	O
be	O
measured	O
using	O
a	O
goniometer	O
as	O
the	O
maximum	O
angle	O
at	O
which	O
the	O
hallux	O
cannot	O
be	O
passively	O
moved	O
into	O
further	O
extension	O
in	O
a	O
non	O
-	O
weightbearing	O
position	O
(	O
Figure	O
2	O
)	O
[	O
30	O
]	O
.	O

The	O
test	O
will	O
be	O
performed	O
two	O
times	O
and	O
the	O
average	O
will	O
be	O
used	O
for	O
analysis	O
.	O

This	O
measurement	O
technique	O
shows	O
high	O
intra	O
-	O
reliability	O
(	O
ICC	O
=	O
0	O
.	O
95	O
,	O
standard	O
error	O
of	O
mean	O
=	O
1	O
.	O
3	O
degrees	O
)	O
[	O
30	O
]	O
.	O

(	O
iv	O
)	O
Plantar	O
flexion	O
strength	O
of	O
the	O
toe	O
-	O
flexors	O
of	O
the	O
hallux	O

Plantar	O
flexion	O
strength	O
of	O
the	O
toe	O
-	O
flexors	O
of	O
the	O
hallux	O
will	O
be	O
measured	O
using	O
the	O
Mat	O
Scan	O
(R)	O
plantar	O
pressure	O
measurement	O
device	O
[	O
31	O
]	O
.	O

Participants	S-Species
will	O
be	O
seated	O
with	O
the	O
hip	O
,	O
knee	O
,	O
and	O
ankle	O
at	O
90	O
degrees	O
and	O
their	O
foot	O
placed	O
over	O
the	O
Mat	O
Scan	O
(R)	O
plantar	O
pressure	O
measurement	O
device	O
(	O
Tekscan	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
(	O
Figure	O
3a	O
)	O
.	O

This	O
system	O
consists	O
of	O
a	O
5	O
-	O
mm	O
thick	O
floor	O
mat	O
(	O
432	O
x	O
368	O
mm	O
)	O
incorporating	O
2288	O
resistive	O
sensors	O
(	O
1	O
.	O
4	O
sensors	O
/	O
cm2	O
)	O
sampling	O
at	O
a	O
rate	O
of	O
40	O
Hz	O
.	O

The	O
mat	O
will	O
be	O
calibrated	O
for	O
each	O
participant	S-Species
using	O
his	O
or	O
her	O
own	O
bodyweight	O
before	O
each	O
testing	O
session	O
.	O

Participants	S-Species
will	O
be	O
instructed	O
to	O
use	O
their	O
toe	O
-	O
flexor	O
muscles	O
to	O
maximally	O
push	O
their	O
hallux	O
down	O
on	O
the	O
MatScan	O
(R)	O
device	O
and	O
forces	O
under	O
the	O
hallux	O
will	O
be	O
recorded	O
(	O
Figure	O
3b	O
)	O
.	O

The	O
test	O
will	O
be	O
performed	O
three	O
times	O
for	O
the	O
hallux	O
and	O
the	O
maximal	O
force	O
will	O
be	O
used	O
for	O
analysis	O
.	O

The	O
test	O
-	O
retest	O
reliability	O
of	O
this	O
measurement	O
technique	O
has	O
previously	O
been	O
shown	O
to	O
be	O
high	O
,	O
with	O
intraclass	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
=	O
0	O
.	O
88	O
(	O
95	O
%	O
CI	O
0	O
.	O
81	O
-	O
0	O
.	O
93	O
)	O
[	O
31	O
]	O
.	O

(	O
vi	O
)	O
Plantar	O
pressure	O
measurement	O

Plantar	O
pressures	O
will	O
be	O
recorded	O
during	O
level	O
barefoot	O
walking	O
using	O
the	O
MatScan	O
(R)	O
system	O
(	O
Tekscan	O
(R)	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
.	O

The	O
two	O
-	O
step	O
gait	O
initiation	O
protocol	O
will	O
be	O
used	O
to	O
obtain	O
foot	O
pressure	O
data	O
,	O
as	O
it	O
requires	O
fewer	O
trials	O
than	O
the	O
mid	O
-	O
gait	O
protocol	O
and	O
has	O
similar	O
re	O
-	O
test	O
reliability	O
[	O
32	O
]	O
.	O

Three	O
trials	O
will	O
be	O
recorded	O
,	O
which	O
has	O
been	O
found	O
to	O
be	O
sufficient	O
to	O
ensure	O
adequate	O
reliability	O
of	O
pressure	O
data	O
[	O
32	O
,	O
33	O
]	O
.	O

Following	O
data	O
collection	O
,	O
the	O
Research	O
Foot	O
(R)	O
software	O
(	O
version	O
5	O
.	O
24	O
)	O
will	O
be	O
used	O
to	O
construct	O
individual	O
"	O
masks	O
"	O
to	O
determine	O
maximum	O
force	O
(	O
kg	O
)	O
and	O
peak	O
pressure	O
(	O
kg	O
/	O
cm2	O
)	O
under	O
seven	O
regions	O
of	O
the	O
foot	O
:	O
hallux	O
,	O
lesser	O
toes	O
,	O
1st	O
MPJ	O
,	O
2nd	O
MPJ	O
,	O
3rd	O
to	O
5th	O
MPJs	O
,	O
midfoot	O
and	O
heel	O
(	O
Figure	O
4a	O
)	O
.	O

For	O
each	O
region	O
,	O
the	O
median	O
of	O
the	O
three	O
trials	O
will	O
be	O
used	O
for	O
analysis	O
.	O

Typical	O
plantar	O
pressure	O
recordings	O
from	O
a	O
participant	S-Species
are	O
shown	O
in	O
Figure	O
4b	O
.	O

(	O
vi	O
)	O
Global	O
satisfaction	O
with	O
the	O
treatment	O

Global	O
satisfaction	O
with	O
the	O
treatment	O
will	O
be	O
assessed	O
using	O
a	O
5	O
-	O
point	O
Likert	O
scale	O
,	O
as	O
well	O
as	O
a	O
dichotomous	O
(	O
yes	O
/	O
no	O
)	O
scale	O
.	O

The	O
five	O
point	O
-	O
Likert	O
scale	O
will	O
ask	O
"	O
How	O
satisfied	O
are	O
you	O
with	O
the	O
treatment	O
you	O
received	O
for	O
your	O
big	O
-	O
toe	O
joint	O
pain	O
?	O
"	O
,	O
and	O
will	O
have	O
the	O
following	O
five	O
responses	O
:	O
"	O
Dissatisfied	O
"	O
,	O
"	O
Only	O
moderately	O
satisfied	O
"	O
,	O
"	O
Fairly	O
satisfied	O
"	O
,	O
"	O
Clearly	O
satisfied	O
"	O
and	O
"	O
Very	O
satisfied	O
"	O
.	O

The	O
dichotomous	O
scale	O
of	O
satisfaction	O
will	O
be	O
answered	O
as	O
"	O
Yes	O
"	O
'	O
or	O
"	O
No	O
"	O
in	O
response	O
to	O
the	O
question	O
:	O
"	O
Would	O
you	O
recommend	O
the	O
treatment	O
that	O
you	O
received	O
to	O
someone	O
else	O
with	O
big	O
-	O
toe	O
joint	O
pain	O
"	O
.	O

(	O
vii	O
)	O
Health	O
related	O
quality	O
of	O
life	O

The	O
Short	O
-	O
Form	O
-	O
36	O
(	O
version	O
two	O
)	O
(	O
SF	O
-	O
36	O
)	O
questionnaire	O
will	O
be	O
used	O
to	O
assess	O
health	O
related	O
quality	O
of	O
life	O
.	O

The	O
SF	O
-	O
36	O
is	O
a	O
36	O
question	O
survey	O
that	O
measures	O
eight	O
health	O
concepts	O
most	O
affected	O
by	O
disease	O
and	O
treatment	O
.	O

The	O
eight	O
health	O
concepts	O
can	O
then	O
be	O
used	O
to	O
form	O
two	O
summary	O
measures	O
:	O
Physical	O
health	O
and	O
Mental	O
health	O
.	O

The	O
Short	O
Form	O
-	O
36	O
(	O
SF	O
-	O
36	O
)	O
has	O
been	O
extensively	O
validated	O
and	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
instruments	O
to	O
measure	O
health	O
status	O
.	O

The	O
SF	O
-	O
36	O
shows	O
content	O
,	O
concurrent	O
,	O
criterion	O
,	O
construct	O
,	O
and	O
predictive	O
evidence	O
of	O
validity	O
.	O

The	O
reliability	O
of	O
the	O
eight	O
concepts	O
and	O
two	O
summary	O
measures	O
has	O
been	O
assessed	O
using	O
both	O
internal	O
consistency	O
and	O
test	O
-	O
retest	O
methods	O
.	O

Reliability	O
statistics	O
have	O
exceeded	O
0	O
.	O
80	O
[	O
34	O
-	O
37	O
]	O
.	O

(	O
viii	O
)	O
Self	O
-	O
reported	O
magnitude	O
of	O
symptom	O
change	O

Self	O
-	O
reported	O
magnitude	O
of	O
symptom	O
change	O
will	O
be	O
measured	O
using	O
a	O
15	O
-	O
point	O
Likert	O
scale	O
.	O

The	O
scale	O
will	O
ask	O
participants	S-Species
"	O
how	O
much	O
have	O
your	O
symptoms	O
in	O
your	O
big	O
-	O
toe	O
joint	O
have	O
changed	O
from	O
the	O
beginning	O
of	O
the	O
study	O
to	O
now	O
?	O
"	O
.	O

The	O
fifteen	O
responses	O
will	O
range	O
from	O
"	O
A	O
very	O
great	O
deal	O
better	O
"	O
to	O
"	O
A	O
very	O
great	O
deal	O
worse	O
"	O
.	O

(	O
ix	O
)	O
Use	O
of	O
rescue	O
medications	O
to	O
relieve	O
pain	O
at	O
the	O
first	O
metatarsophalangeal	O
joint	O

The	O
number	O
of	O
participants	S-Species
who	O
consumed	O
rescue	O
medication	O
(	O
e	O
.	O
g	O
.	O
,	O
paracetamol	O
)	O
and	O
mean	O
consumption	O
of	O
rescue	O
medication	O
to	O
relieve	O
pain	O
at	O
the	O
first	O
MPJ	O
(	O
mean	O
grams	O
of	O
paracetamol	O
/	O
participant	S-Species
/	O
month	O
]	O
will	O
be	O
assessed	O
using	O
a	O
medications	O
diary	O
that	O
participants	S-Species
will	O
self	O
-	O
complete	O
[	O
38	O
,	O
39	O
]	O
.	O

The	O
diary	O
will	O
be	O
returned	O
to	O
the	O
assessor	O
at	O
monthly	O
intervals	O
for	O
analysis	O
.	O

(	O
x	O
)	O
Frequency	O
and	O
severity	O
of	O
adverse	O
events	O
as	O
safety	O
variables	O

The	O
frequency	O
(	O
number	O
of	O
participants	S-Species
affected	O
and	O
number	O
of	O
cases	O
)	O
and	O
types	O
of	O
adverse	O
events	O
(	O
including	O
adverse	O
drug	O
reactions	O
)	O
in	O
each	O
treatment	O
group	O
during	O
the	O
trial	O
will	O
be	O
recorded	O
using	O
a	O
questionnaire	O
that	O
participants	S-Species
will	O
complete	O
during	O
the	O
follow	O
-	O
up	O
appointments	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
treatment	O
[	O
40	O
]	O
.	O

To	O
classify	O
the	O
'	O
type	O
'	O
of	O
adverse	O
event	O
,	O
a	O
blinded	O
assessor	O
will	O
classify	O
the	O
adverse	O
event	O
as	O
being	O
serious	O
or	O
non	O
-	O
serious	O
[	O
40	O
]	O
.	O

Any	O
serious	O
adverse	O
events	O
,	O
defined	O
as	O
adverse	O
events	O
leading	O
to	O
serious	O
disability	O
,	O
hospital	O
admission	O
,	O
or	O
prolongation	O
of	O
hospitalisation	O
,	O
life	O
-	O
threatening	O
events	O
;	O
or	O
death	O
)	O
will	O
be	O
further	O
classified	O
using	O
the	O
International	O
Classification	O
of	O
Diseases	O
(	O
ICD	O
)	O
codes	O
[	O
41	O
]	O
.	O

Non	O
-	O
serious	O
adverse	O
events	O
will	O
include	O
both	O
local	O
(	O
pain	O
,	O
effusion	O
and	O
heat	O
,	O
with	O
each	O
classified	O
as	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
and	O
systemic	O
adverse	O
events	O
.	O

An	O
open	O
-	O
response	O
type	O
format	O
will	O
also	O
be	O
available	O
for	O
participant	S-Species
responses	O
.	O

Sample	O
size	O

The	O
sample	O
size	O
for	O
the	O
study	O
has	O
been	O
pre	O
-	O
specified	O
using	O
an	O
a	O
priori	O
power	O
analysis	O
using	O
the	O
primary	O
outcome	O
measure	O
of	O
the	O
pain	O
domain	O
of	O
the	O
FHSQ	O
[	O
42	O
]	O
.	O

One	O
hundred	O
and	O
forty	O
two	O
participants	S-Species
(	O
i	O
.	O
e	O
.	O
71	O
per	O
group	O
)	O
will	O
provide	O
power	O
of	O
90	O
%	O
to	O
detect	O
a	O
minimally	O
important	O
difference	O
in	O
the	O
pain	O
domain	O
of	O
the	O
FHSQ	O
(	O
i	O
.	O
e	O
.	O
14	O
points	O
on	O
the	O
FHSQ	O
questionnaire	O
)	O
with	O
the	O
significance	O
level	O
set	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

A	O
difference	O
of	O
14	O
points	O
was	O
determined	O
to	O
be	O
a	O
clinically	O
significant	O
difference	O
worth	O
detecting	O
[	O
43	O
]	O
and	O
a	O
standard	O
deviation	O
of	O
25	O
was	O
derived	O
from	O
a	O
previous	O
report	O
[	O
44	O
]	O
.	O

This	O
calculation	O
included	O
a	O
5	O
%	O
drop	O
-	O
out	O
rate	O
[	O
13	O
]	O
.	O

However	O
,	O
we	O
will	O
aim	O
to	O
recruit	O
150	O
participants	S-Species
(	O
~	O
75	O
participants	S-Species
per	O
intervention	O
group	O
)	O
.	O

Further	O
,	O
we	O
have	O
conservatively	O
ignored	O
the	O
extra	O
precision	O
provided	O
by	O
covariate	O
analysis	O
when	O
estimating	O
the	O
sample	O
size	O
.	O

Statistical	O
analysis	O

Statistical	O
analysis	O
will	O
be	O
undertaken	O
using	O
SPSS	O
version	O
14	O
.	O
0	O
(	O
SPSS	O
Corp	O
,	O
Chicago	O
,	O
Ill	O
,	O
USA	O
)	O
and	O
STATA	O
8	O
(	O
Stata	O
Corp	O
,	O
College	O
Station	O
,	O
Tex	O
.	O
,	O
USA	O
)	O
statistical	O
software	O
.	O

All	O
analyses	O
will	O
be	O
conducted	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
principle	O
using	O
all	O
randomised	O
participants	S-Species
[	O
45	O
-	O
47	O
]	O
.	O

Missing	O
data	O
will	O
be	O
replaced	O
with	O
the	O
last	O
score	O
carried	O
forward	O
[	O
48	O
]	O
.	O

Standard	O
tests	O
for	O
normal	O
distribution	O
will	O
be	O
used	O
and	O
transformation	O
carried	O
out	O
if	O
required	O
.	O

Demographic	O
characteristics	O
(	O
gender	O
,	O
age	O
,	O
weight	O
,	O
height	O
,	O
body	O
mass	O
index	O
)	O
will	O
be	O
determined	O
for	O
the	O
baseline	O
visit	O
for	O
each	O
treatment	O
group	O
.	O

Summary	O
statistics	O
will	O
be	O
calculated	O
for	O
duration	O
of	O
symptoms	O
,	O
side	O
affected	O
(	O
left	O
,	O
right	O
,	O
bilateral	O
)	O
,	O
grade	O
of	O
OA	O
at	O
the	O
first	O
MPJ	O
[	O
19	O
]	O
as	O
well	O
as	O
all	O
primary	O
and	O
secondary	O
outcome	O
measurements	O
for	O
each	O
treatment	O
group	O
.	O

Analyses	O
will	O
be	O
conducted	O
on	O
1	O
,	O
3	O
and	O
6	O
month	O
outcome	O
measures	O
.	O

The	O
continuously	O
-	O
scored	O
outcome	O
measures	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
will	O
be	O
compared	O
using	O
analysis	O
of	O
covariance	O
with	O
baseline	O
scores	O
and	O
intervention	O
group	O
entered	O
as	O
independent	O
variables	O
[	O
49	O
,	O
50	O
]	O
.	O

The	O
exception	O
to	O
this	O
will	O
be	O
the	O
plantar	O
pressure	O
measurements	O
which	O
will	O
be	O
analysed	O
at	O
baseline	O
,	O
1	O
,	O
3	O
and	O
6	O
months	O
using	O
two	O
-	O
way	O
repeated	O
measures	O
analysis	O
of	O
variance	O
statistics	O
.	O

Post	O
-	O
hoc	O
comparisons	O
will	O
be	O
performed	O
using	O
Bonferroni	O
-	O
adjusted	O
t	O
-	O
tests	O
.	O

Nominal	O
and	O
ordinal	O
scaled	O
data	O
will	O
be	O
compared	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
using	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
and	O
chi	O
-	O
square	O
analyses	O
(	O
or	O
Fisher	O
'	O
s	O
exact	O
test	O
where	O
appropriate	O
)	O
respectively	O
.	O

Effect	O
sizes	O
will	O
be	O
determined	O
using	O
Cohen	O
'	O
s	O
d	O
(	O
continuous	O
scaled	O
data	O
)	O
or	O
odds	O
ratios	O
(	O
nominal	O
scaled	O
data	O
and	O
ordinal	O
scaled	O
data	O
)	O
as	O
appropriate	O
.	O

The	O
outcome	O
measurements	O
obtained	O
at	O
7	O
or	O
9	O
months	O
for	O
participants	S-Species
that	O
receive	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
(R)	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
on	O
days	O
30	O
or	O
90	O
respectively	O
,	O
will	O
also	O
be	O
analysed	O
as	O
described	O
above	O
.	O

These	O
analyses	O
will	O
be	O
classified	O
as	O
secondary	O
outcomes	O
.	O

Discussion	O

This	O
study	O
is	O
a	O
randomised	O
placebo	O
controlled	O
trial	O
designed	O
to	O
investigate	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
(R)	O
)	O
to	O
reduce	O
pain	O
and	O
improve	O
function	O
in	O
people	S-Species
with	O
OA	O
of	O
the	O
first	O
MPJ	O
(	O
hallux	O
limitus	O
)	O
.	O

Two	O
studies	O
have	O
previously	O
investigated	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
for	O
the	O
treatment	O
of	O
first	O
MPJ	O
OA	O
[	O
13	O
,	O
14	O
]	O
.	O

However	O
,	O
neither	O
of	O
these	O
studies	O
used	O
a	O
placebo	O
control	O
group	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
randomised	O
controlled	O
trial	O
using	O
intra	O
-	O
articular	O
hyaluronan	O
for	O
OA	O
of	O
the	O
first	O
MPJ	O
.	O

The	O
use	O
of	O
a	O
placebo	O
control	O
group	O
is	O
essential	O
for	O
studies	O
evaluating	O
the	O
effects	O
of	O
intra	O
-	O
articular	O
therapies	O
as	O
there	O
is	O
likely	O
to	O
be	O
a	O
large	O
placebo	O
response	O
related	O
to	O
the	O
injection	O
procedure	O
and	O
this	O
may	O
inflate	O
the	O
results	O
in	O
uncontrolled	O
evaluations	O
[	O
51	O
]	O
.	O

Indeed	O
,	O
a	O
recent	O
meta	O
-	O
analysis	O
of	O
hyaluronan	O
for	O
knee	O
OA	O
concluded	O
that	O
a	O
placebo	O
effect	O
accounted	O
for	O
79	O
%	O
of	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
[	O
16	O
]	O
.	O

The	O
study	O
protocol	O
and	O
outcome	O
measures	O
have	O
been	O
developed	O
in	O
accordance	O
of	O
the	O
recommendations	O
of	O
the	O
OARSI	O
Clinical	O
Trials	O
Task	O
Force	O
guidelines	O
[	O
18	O
]	O
.	O

The	O
outcome	O
measures	O
are	O
pain	O
and	O
function	O
subscales	O
of	O
the	O
FHSQ	O
,	O
pain	O
and	O
stiffness	O
at	O
the	O
first	O
MPJ	O
,	O
range	O
of	O
motion	O
(	O
dorsiflexion	O
)	O
of	O
the	O
first	O
MPJ	O
,	O
plantar	O
flexion	O
strength	O
of	O
muscles	O
of	O
the	O
first	O
MPJ	O
,	O
generic	O
health	O
related	O
quality	O
of	O
life	O
(	O
SF	O
-	O
36	O
)	O
,	O
patient	S-Species
satisfaction	O
with	O
treatment	O
,	O
consumption	O
of	O
rescue	O
medication	O
as	O
well	O
as	O
frequency	O
and	O
nature	O
of	O
adverse	O
effects	O
.	O

These	O
outcomes	O
will	O
be	O
measured	O
at	O
baseline	O
then	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
after	O
treatment	O
.	O

Previous	O
research	O
suggests	O
that	O
the	O
effects	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
persist	O
for	O
up	O
to	O
12	O
months	O
following	O
treatment	O
[	O
9	O
,	O
38	O
]	O
.	O

Thus	O
,	O
the	O
use	O
of	O
follow	O
-	O
up	O
assessments	O
at	O
6	O
month	O
post	O
-	O
treatment	O
will	O
allow	O
us	O
to	O
determine	O
if	O
the	O
effects	O
,	O
if	O
any	O
,	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
persist	O
in	O
the	O
longer	O
term	O
.	O

Participants	S-Species
will	O
be	O
given	O
the	O
option	O
of	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
(R)	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
on	O
days	O
30	O
or	O
90	O
if	O
there	O
is	O
no	O
improvement	O
in	O
their	O
symptoms	O
.	O

Although	O
this	O
has	O
the	O
potential	O
to	O
complicate	O
the	O
interpretation	O
of	O
the	O
results	O
of	O
the	O
study	O
,	O
this	O
protocol	O
was	O
included	O
as	O
it	O
is	O
likely	O
to	O
be	O
more	O
reflective	O
of	O
clinical	O
practice	O
[	O
14	O
]	O
,	O
and	O
this	O
is	O
in	O
keeping	O
with	O
the	O
pragmatic	O
nature	O
of	O
this	O
trial	O
.	O

In	O
summary	O
,	O
this	O
project	O
is	O
the	O
first	O
randomised	O
controlled	O
trial	O
to	O
be	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
for	O
reducing	O
pain	O
and	O
improving	O
function	O
in	O
people	S-Species
with	O
hallux	O
limitus	O
.	O

The	O
study	O
protocol	O
,	O
including	O
interventions	O
,	O
have	O
been	O
pragmatically	O
designed	O
to	O
ensure	O
that	O
the	O
study	O
findings	O
are	O
generaliseable	O
to	O
clinical	O
practice	O
.	O

Recruitment	O
for	O
the	O
study	O
will	O
commence	O
in	O
June	O
2008	O
,	O
and	O
we	O
expect	O
final	O
results	O
to	O
be	O
available	O
in	O
mid	O
-	O
2010	O
.	O

Competing	O
interests	O

HBM	O
and	O
KBL	O
are	O
Editor	O
-	O
in	O
-	O
Chief	O
and	O
Deputy	O
Editor	O
-	O
in	O
-	O
Chief	O
,	O
respectively	O
,	O
of	O
Journal	O
of	O
Foot	O
and	O
Ankle	O
Research	O
.	O

It	O
is	O
journal	O
policy	O
that	O
editors	O
are	O
removed	O
from	O
the	O
peer	O
review	O
and	O
editorial	O
decision	O
making	O
processes	O
for	O
papers	O
they	O
have	O
co	O
-	O
authored	O
.	O

Authors	O
'	O
contributions	O

SEM	O
,	O
HBM	O
,	O
KBL	O
and	O
CJH	O
conceived	O
the	O
idea	O
and	O
obtained	O
funding	O
for	O
the	O
study	O
.	O

SEM	O
,	O
HBM	O
,	O
KBL	O
,	O
AEZ	O
and	O
JDL	O
designed	O
the	O
trial	O
protocol	O
.	O

SEM	O
,	O
HBM	O
,	O
KBL	O
and	O
GVZ	O
drafted	O
the	O
manuscript	O
.	O

All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

p8	O
inhibits	O
the	O
growth	O
of	O
human	S-Species
pancreatic	O
cancer	O
cells	O
and	O
its	O
expression	O
is	O
induced	O
through	O
pathways	O
involved	O
in	O
growth	O
inhibition	O
and	O
repressed	O
by	O
factors	O
promoting	O
cell	O
growth	O

Abstract	O

Background	O

p8	O
is	O
a	O
stress	O
-	O
induced	O
protein	O
with	O
multiple	O
functions	O
and	O
biochemically	O
related	O
to	O
the	O
architectural	O
factor	O
HMG	O
-	O
I	O
/	O
Y	O
.	O

We	O
analyzed	O
the	O
expression	O
and	O
function	O
of	O
p8	O
in	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
.	O

Methods	O

Expression	O
of	O
p8	O
was	O
silenced	O
in	O
the	O
human	S-Species
pancreatic	O
cancer	O
cell	O
lines	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
by	O
infection	O
with	O
a	O
retrovirus	O
expressing	O
p8	O
RNA	O
in	O
the	O
antisense	O
orientation	O
.	O

Cell	O
growth	O
was	O
measured	O
in	O
control	O
and	O
p8	O
-	O
silenced	O
cells	O
.	O

Influence	O
on	O
p8	O
expression	O
of	O
the	O
induction	O
of	O
intracellular	O
pathways	O
promoting	O
cellular	O
growth	O
or	O
growth	O
arrest	O
was	O
monitored	O
.	O

Results	O

p8	O
-	O
silenced	O
cells	O
grew	O
more	O
rapidly	O
than	O
control	O
cells	O
transfected	O
with	O
the	O
empty	O
retrovirus	O
.	O

Activation	O
of	O
the	O
Ras	O
-->	O
Raf	O
-->	O
MEK	O
-->	O
ERK	O
and	O
JNK	O
intracellular	O
pathways	O
down	O
-	O
regulated	O
p8	O
expression	O
.	O

In	O
addition	O
,	O
the	O
MEK1	O
/	O
2	O
inhibitor	O
U0126	O
and	O
the	O
JNK	O
inhibitor	O
SP600125	O
up	O
-	O
regulates	O
expression	O
of	O
p8	O
.	O

Conversely	O
,	O
p38	O
or	O
TGF	O
beta	O
-	O
1	O
induced	O
p8	O
expression	O
whereas	O
the	O
specific	O
p38	O
inhibitor	O
SB203580	O
down	O
-	O
regulated	O
p8	O
expression	O
.	O

Finally	O
,	O
TGF	O
beta	O
-	O
1	O
induction	O
was	O
in	O
part	O
mediated	O
through	O
p38	O
.	O

Conclusions	O

p8	O
inhibits	O
the	O
growth	O
of	O
human	S-Species
pancreatic	O
cancer	O
cells	O
.	O

p8	O
expression	O
is	O
induced	O
through	O
pathways	O
involved	O
in	O
growth	O
inhibition	O
and	O
repressed	O
by	O
factors	O
that	O
promote	O
cell	O
growth	O
.	O

These	O
results	O
suggest	O
that	O
p8	O
belongs	O
to	O
a	O
pathway	O
regulating	O
the	O
growth	O
of	O
pancreatic	O
cancer	O
cells	O
.	O

Background	O

While	O
studying	O
the	O
molecular	O
response	O
of	O
the	O
injured	O
pancreas	O
,	O
we	O
identified	O
a	O
new	O
gene	O
,	O
called	O
p8	O
,	O
whose	O
expression	O
is	O
strongly	O
induced	O
during	O
the	O
acute	O
phase	O
of	O
pancreatitis	O
[	O
1	O
]	O
.	O

Further	O
experiments	O
have	O
shown	O
that	O
p8	O
mRNA	O
is	O
activated	O
in	O
almost	O
all	O
cells	O
in	O
response	O
to	O
several	O
stresses	O
[	O
2	O
]	O
,	O
including	O
minimal	O
stresses	O
such	O
as	O
after	O
routine	O
change	O
of	O
the	O
culture	O
medium	O
in	O
the	O
absence	O
of	O
any	O
added	O
substance	O
[	O
3	O
]	O
,	O
indicating	O
that	O
p8	O
is	O
a	O
ubiquitous	O
protein	O
induced	O
by	O
cellular	O
stress	O
.	O

The	O
p8	O
gene	O
was	O
cloned	O
in	O
human	S-Species
,	O
rat	S-Species
,	O
mouse	S-Species
,	O
and	O
Xenopus	B-Species
laevis	E-Species
[	O
1	O
,	O
4	O
-	O
6	O
]	O
,	O
conceptually	O
translated	O
from	O
the	O
Drosophila	B-Species
melanogaster	E-Species
genome	O
or	O
deduced	O
from	O
EST	O
libraries	O
(	O
Bos	B-Species
taurus	E-Species
,	O
Xenopus	B-Species
tropicalis	E-Species
,	O
Zebrafish	S-Species
,	O
Orzzias	B-Species
latipes	E-Species
,	O
Bombyx	B-Species
mori	E-Species
and	O
Paralichthys	B-Species
olivaceous	E-Species
)	O
.	O

The	O
overall	O
degree	O
of	O
homology	O
with	O
human	S-Species
p8	O
ranged	O
from	O
81	O
to	O
40	O
%	O
.	O

Secondary	O
structure	O
prediction	O
methods	O
indicated	O
that	O
within	O
the	O
homologous	O
region	O
of	O
the	O
eleven	O
proteins	O
,	O
there	O
is	O
a	O
basic	O
Helix	O
-	O
Loop	O
-	O
Helix	O
secondary	O
structure	O
motif	O
,	O
characteristic	O
of	O
some	O
classes	O
of	O
transcription	O
factors	O
[	O
1	O
]	O
.	O

Even	O
though	O
a	O
small	O
protein	O
such	O
as	O
p8	O
would	O
not	O
need	O
a	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
to	O
be	O
transported	O
to	O
the	O
nucleus	O
,	O
a	O
clear	O
NLS	O
can	O
be	O
predicted	O
for	O
the	O
eleven	O
proteins	O
comprising	O
a	O
bipartite	O
domain	O
of	O
positively	O
charged	O
aminoacids	O
.	O

In	O
addition	O
,	O
a	O
nuclear	O
/	O
cytoplasmic	O
location	O
has	O
been	O
demonstrated	O
for	O
human	S-Species
p8	O
upon	O
overexpression	O
of	O
the	O
recombinant	O
protein	O
and	O
immunohistochemistry	O
[	O
4	O
]	O
,	O
and	O
for	O
recombinant	O
Xenopus	B-Species
laevis	E-Species
p8	O
fused	O
to	O
green	O
fluorescent	O
protein	O
[	O
6	O
]	O
.	O

Homology	O
searching	O
in	O
databases	O
did	O
not	O
reveal	O
significant	O
similarity	O
of	O
p8	O
with	O
other	O
proteins	O
of	O
known	O
function	O
.	O

However	O
,	O
biochemical	O
properties	O
of	O
the	O
mammalian	O
p8	O
proteins	O
are	O
shared	O
by	O
some	O
high	O
mobility	O
group	O
proteins	O
(	O
HMG	O
)	O
[	O
7	O
]	O
,	O
particularly	O
by	O
the	O
HMG	O
-	O
I	O
/	O
Y	O
family	O
.	O

The	O
overall	O
identity	O
of	O
human	S-Species
p8	O
with	O
human	S-Species
HMG	O
-	O
I	O
/	O
Y	O
is	O
only	O
about	O
35	O
%	O
,	O
but	O
the	O
molecular	O
mass	O
,	O
isoelectric	O
point	O
,	O
hydrophilicity	O
plot	O
,	O
the	O
resistance	O
to	O
denaturation	O
after	O
heating	O
at	O
100	O
degrees	O
C	O
and	O
the	O
charge	O
separation	O
are	O
very	O
similar	O
[	O
8	O
]	O
.	O

The	O
p8	O
protein	O
seems	O
to	O
bind	O
DNA	O
weakly	O
,	O
as	O
shown	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
without	O
preference	O
for	O
DNA	O
sequences	O
.	O

Finally	O
,	O
human	S-Species
p8	O
has	O
also	O
been	O
shown	O
to	O
be	O
a	O
substrate	O
for	O
protein	O
kinase	O
A	O
in	O
vitro	O
and	O
phosphorylated	O
p8	O
has	O
a	O
higher	O
content	O
of	O
secondary	O
structure	O
and	O
binding	O
to	O
DNA	O
is	O
highly	O
increased	O
[	O
8	O
]	O
.	O

An	O
architectural	O
role	O
in	O
transcription	O
has	O
been	O
proposed	O
for	O
this	O
protein	O
,	O
in	O
analogy	O
with	O
the	O
HMG	O
-	O
I	O
/	O
Y	O
proteins	O
,	O
and	O
a	O
recent	O
work	O
seems	O
to	O
confirm	O
this	O
hypothesis	O
[	O
9	O
]	O
.	O

Functions	O
of	O
p8	O
appear	O
to	O
be	O
multiple	O
and	O
complex	O
.	O

For	O
example	O
,	O
p8	O
mRNA	O
expression	O
was	O
strongly	O
induced	O
in	O
3T3	O
cells	O
upon	O
TGF	O
beta	O
-	O
1	O
treatment	O
which	O
in	O
turn	O
enhances	O
the	O
Smad	O
-	O
transactivating	O
function	O
responsible	O
for	O
TGF	O
beta	O
-	O
1	O
activity	O
[	O
10	O
]	O
.	O

We	O
also	O
found	O
that	O
p8	O
is	O
involved	O
in	O
cell	O
cycle	O
regulation	O
since	O
p8	O
-	O
deficient	O
embryonic	O
fibroblasts	O
grew	O
more	O
rapidly	O
and	O
incorporated	O
more	O
[	O
3H	O
]	O
thymidine	O
and	O
BrdU	O
than	O
p8	O
-	O
expressing	O
cells	O
[	O
11	O
]	O
.	O

Moreover	O
,	O
expression	O
of	O
p8	O
in	O
breast	O
cancer	O
-	O
derived	O
cells	O
seems	O
to	O
mediate	O
the	O
inhibition	O
of	O
cell	O
growth	O
induced	O
by	O
1	O
,	O
25	O
-	O
Dihydroxyvitamin	O
D3	O
[	O
12	O
]	O
.	O

On	O
the	O
contrary	O
,	O
we	O
also	O
reported	O
that	O
p8	O
may	O
promote	O
cell	O
growth	O
when	O
overexpressed	O
in	O
Cos	O
-	O
7	O
,	O
AR42J	O
and	O
HeLa	O
cells	O
[	O
1	O
,	O
4	O
]	O
.	O

In	O
addition	O
,	O
p8	O
seems	O
to	O
be	O
involved	O
in	O
other	O
intracellular	O
functions	O
such	O
as	O
apoptosis	O
since	O
p8	O
-	O
expressing	O
fibroblasts	O
are	O
more	O
sensitive	O
than	O
p8	O
-	O
deficient	O
fibroblasts	O
to	O
the	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
.	O

Also	O
,	O
p8	O
is	O
required	O
for	O
endothelin	O
-	O
induced	O
mesangial	O
cell	O
hypertrophy	O
in	O
diabetic	O
kidney	O
,	O
in	O
a	O
mechanism	O
involving	O
ERK	O
,	O
JNK	O
and	O
PI3	O
kinase	O
[	O
13	O
]	O
.	O

p8	O
seems	O
to	O
play	O
a	O
functional	O
role	O
in	O
the	O
initiation	O
of	O
LH	O
beta	O
gene	O
expression	O
during	O
embryonic	O
cell	O
differentiation	O
[	O
14	O
]	O
.	O

Moreover	O
,	O
the	O
Drosophila	B-Species
melanogaster	E-Species
p8	O
homologue	O
is	O
involved	O
in	O
response	O
to	O
starvation	O
and	O
might	O
be	O
activated	O
to	O
stop	O
cell	O
growth	O
in	O
case	O
of	O
nutrient	O
deprivation	O
[	O
15	O
]	O
.	O

Finally	O
,	O
a	O
particularly	O
attractive	O
role	O
in	O
tumour	O
progression	O
was	O
recently	O
proposed	O
for	O
p8	O
[	O
16	O
]	O
.	O

Fibroblasts	O
obtained	O
from	O
p8	O
-	O
expressing	O
or	O
p8	O
-	O
deficient	O
animals	O
were	O
transformed	O
with	O
a	O
retroviral	O
vector	O
expressing	O
both	O
the	O
rasV12	O
mutated	O
protein	O
and	O
the	O
E1A	O
adenoviral	O
oncogene	O
.	O

In	O
soft	O
-	O
agar	O
assays	O
,	O
transformed	O
p8	O
-	O
expressing	O
cells	O
formed	O
colonies	O
at	O
high	O
frequency	O
,	O
as	O
expected	O
,	O
but	O
p8	O
-	O
deficient	O
transformed	O
fibroblasts	O
were	O
unable	O
to	O
form	O
colonies	O
.	O

Similarly	O
,	O
transformed	O
p8	O
-	O
expressing	O
cells	O
produced	O
tumours	O
in	O
all	O
athymic	O
nude	B-Species
mice	E-Species
when	O
injected	O
subcutaneously	O
or	O
intraperitoneally	O
,	O
whereas	O
transformed	O
p8	O
-	O
deficient	O
fibroblasts	O
did	O
not	O
.	O

On	O
the	O
other	O
hand	O
,	O
studies	O
by	O
another	O
laboratory	O
revealed	O
that	O
expression	O
of	O
the	O
Com1	O
protein	O
[	O
17	O
]	O
,	O
which	O
is	O
identical	O
to	O
human	S-Species
p8	O
,	O
mediates	O
the	O
growth	O
of	O
tumour	O
cells	O
after	O
metastatic	O
establishment	O
in	O
a	O
secondary	O
organ	O
,	O
indicating	O
that	O
activated	O
expression	O
of	O
Com1	O
/	O
p8	O
in	O
metastatic	O
cells	O
is	O
required	O
for	O
tumour	O
progression	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
p8	O
is	O
involved	O
in	O
the	O
cellular	O
pathway	O
(	O
s	O
)	O
required	O
for	O
tumour	O
progression	O
and	O
metastasis	O
.	O

Our	O
aim	O
is	O
to	O
check	O
the	O
relevance	O
of	O
p8	O
to	O
cancer	O
progression	O
in	O
human	S-Species
.	O

As	O
a	O
first	O
step	O
,	O
we	O
investigated	O
in	O
the	O
present	O
study	O
the	O
function	O
of	O
p8	O
in	O
two	O
cell	O
lines	O
derived	O
from	O
human	S-Species
pancreatic	O
cancer	O
.	O

We	O
observed	O
that	O
inhibition	O
of	O
p8	O
expression	O
increased	O
the	O
cells	O
growth	O
rate	O
.	O

In	O
addition	O
,	O
activations	O
of	O
the	O
Ras	O
-->	O
Raf	O
-->	O
MEK	O
-->	O
ERK	O
and	O
JNK	O
intracellular	O
pathways	O
,	O
which	O
promote	O
the	O
growth	O
of	O
pancreatic	O
cells	O
,	O
down	O
-	O
regulated	O
p8	O
expression	O
,	O
whereas	O
activation	O
of	O
p38	O
or	O
TGF	O
beta	O
-	O
1	O
,	O
which	O
inhibit	O
cell	O
growth	O
,	O
induced	O
its	O
expression	O
.	O

It	O
was	O
concluded	O
that	O
i	O
/	O
p8	O
inhibits	O
the	O
growth	O
of	O
human	S-Species
pancreatic	O
cancer	O
cell	O
lines	O
,	O
ii	O
/	O
p8	O
expression	O
is	O
induced	O
through	O
pathways	O
involved	O
in	O
growth	O
inhibition	O
and	O
,	O
conversely	O
,	O
repressed	O
by	O
factors	O
that	O
promote	O
cell	O
growth	O
.	O

Results	O

p8	O
is	O
silenced	O
in	O
pancreatic	O
cancer	O
cells	O
by	O
infection	O
with	O
a	O
retrovirus	O
expressing	O
p8	O
RNA	O
in	O
the	O
antisense	O
orientation	O

Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
pancreatic	O
cells	O
were	O
chosen	O
for	O
this	O
study	O
because	O
,	O
on	O
the	O
one	O
hand	O
,	O
both	O
cells	O
express	O
higher	O
level	O
of	O
p8	O
(	O
Figure	O
1	O
)	O
and	O
,	O
on	O
the	O
other	O
hand	O
,	O
because	O
Panc	O
-	O
1	O
is	O
wild	O
-	O
type	O
for	O
Smad4	O
/	O
DPC4	O
and	O
mutated	O
for	O
K	O
-	O
ras	O
,	O
while	O
BxPc	O
-	O
3	O
is	O
Smad4	O
/	O
DPC4	O
mutated	O
and	O
K	O
-	O
ras	O
wild	O
-	O
type	O
[	O
18	O
,	O
19	O
]	O
,	O
therefore	O
representing	O
different	O
mechanisms	O
of	O
transformation	O
and	O
different	O
genetic	O
backgrounds	O
.	O

K	O
-	O
ras	O
and	O
Smad4	O
/	O
DPC4	O
mutations	O
are	O
the	O
major	O
mechanisms	O
involved	O
in	O
pancreatic	O
cancer	O
development	O
.	O

We	O
inhibited	O
p8	O
expression	O
in	O
both	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
pancreatic	O
cells	O
by	O
infecting	O
cells	O
with	O
a	O
retrovirus	O
expressing	O
the	O
p8	O
asRNA	O
(	O
antisense	O
RNA	O
)	O
and	O
carrying	O
the	O
puromycin	O
resistance	O
.	O

The	O
antibiotic	O
-	O
selected	O
cells	O
were	O
analyzed	O
by	O
Western	O
blotting	O
to	O
evaluate	O
the	O
intracellular	O
amounts	O
of	O
p8	O
protein	O
.	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
the	O
p8	O
protein	O
was	O
clearly	O
visible	O
in	O
both	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
pancreatic	O
cells	O
infected	O
with	O
the	O
empty	O
retrovirus	O
but	O
almost	O
undetectable	O
in	O
cells	O
infected	O
with	O
the	O
retrovirus	O
encoding	O
the	O
p8	O
asRNA	O
showed	O
,	O
indicating	O
that	O
our	O
anti	O
-	O
sense	O
strategy	O
is	O
efficient	O
to	O
silence	O
p8	O
gene	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
.	O

Preliminary	O
studies	O
had	O
been	O
conducted	O
to	O
select	O
the	O
best	O
strategy	O
to	O
inhibit	O
p8	O
expression	O
.	O

We	O
compared	O
the	O
efficacy	O
of	O
the	O
stable	O
transfection	O
of	O
a	O
siRNA	O
,	O
using	O
a	O
retroviral	O
expression	O
vector	O
to	O
the	O
asRNA	O
strategy	O
described	O
above	O
.	O

In	O
our	O
hands	O
,	O
the	O
antisense	O
strategy	O
worked	O
best	O
,	O
as	O
judged	O
from	O
Western	O
blot	O
assessment	O
of	O
p8	O
protein	O
expression	O
(	O
data	O
not	O
shown	O
)	O
.	O

p8	O
-	O
silenced	O
pancreatic	O
cells	O
grow	O
more	O
rapidly	O

We	O
compared	O
in	O
the	O
two	O
cell	O
lines	O
the	O
influence	O
on	O
growth	O
parameters	O
of	O
blocking	O
p8	O
expression	O
with	O
the	O
p8	O
asRNA	O
.	O

Figure	O
3	O
shows	O
that	O
both	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
cells	O
in	O
which	O
p8	O
has	O
been	O
silenced	O
grew	O
more	O
rapidly	O
than	O
cells	O
infected	O
with	O
the	O
empty	O
vector	O
suggesting	O
that	O
inhibition	O
by	O
p8	O
of	O
pancreatic	O
cancer	O
cell	O
growth	O
is	O
independent	O
from	O
the	O
mechanism	O
of	O
transformation	O
and	O
genetic	O
background	O
.	O

Serum	O
-	O
stimulated	O
cellular	O
growth	O
down	O
-	O
regulates	O
p8	O
expression	O

Fetal	O
calf	S-Species
serum	O
,	O
which	O
contains	O
a	O
complex	O
mix	O
of	O
growth	O
factors	O
,	O
can	O
be	O
used	O
as	O
inductor	O
of	O
cell	O
growth	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
expression	O
of	O
p8	O
mRNA	O
was	O
down	O
-	O
regulated	O
in	O
both	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
when	O
the	O
cells	O
were	O
shifted	O
from	O
culture	O
media	O
containing	O
0	O
.	O
1	O
%	O
fetal	O
calf	S-Species
serum	O
to	O
media	O
containing	O
10	O
%	O
FCS	O
.	O

p8	O
protein	O
showed	O
a	O
similar	O
behavior	O
.	O

These	O
results	O
show	O
that	O
p8	O
expression	O
is	O
down	O
-	O
regulated	O
in	O
growing	O
pancreatic	O
cells	O
.	O

The	O
Ras	O
-->	O
Raf	O
-->	O
MEK	O
-->	O
ERK	O
pathway	O
down	O
-	O
regulates	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O

Most	O
human	S-Species
pancreatic	O
cancers	O
harbor	O
mutations	O
in	O
the	O
K	O
-	O
ras	O
oncogene	O
,	O
which	O
happens	O
relatively	O
early	O
in	O
pancreatic	O
tumorigenesis	O
[	O
20	O
]	O
.	O

The	O
oncogenic	O
mutation	O
of	O
the	O
K	O
-	O
ras	O
gene	O
stabilizes	O
the	O
Ras	O
protein	O
in	O
a	O
GTP	O
-	O
bound	O
form	O
,	O
which	O
is	O
constitutively	O
active	O
and	O
make	O
the	O
cells	O
grow	O
more	O
rapidly	O
.	O

Contrary	O
to	O
the	O
activated	O
Ras	O
protein	O
,	O
p8	O
inhibits	O
cell	O
growth	O
(	O
Figure	O
3	O
)	O
.	O

We	O
looked	O
whether	O
the	O
Ras	O
-->	O
Raf	O
-->	O
MEK	O
-->	O
ERK	O
pathway	O
was	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
p8	O
expression	O
,	O
and	O
which	O
step	O
(	O
s	O
)	O
were	O
critical	O
.	O

Figure	O
5	O
shown	O
that	O
expression	O
of	O
a	O
mutated	O
form	O
of	O
the	O
Ras	O
protein	O
(	O
rasV12	O
)	O
in	O
BxPc	O
-	O
3	O
cells	O
,	O
which	O
are	O
wild	O
-	O
type	O
for	O
ras	O
,	O
resulted	O
in	O
decreased	O
p8	O
mRNA	O
concentration	O
and	O
protein	O
level	O
suggesting	O
that	O
the	O
activated	O
ras	O
inhibits	O
p8	O
expression	O
.	O

Figure	O
6	O
shows	O
that	O
overexpression	O
of	O
Raf	O
,	O
but	O
not	O
of	O
Raf301	O
(	O
a	O
negative	O
mutant	O
of	O
Raf	O
)	O
,	O
and	O
of	O
ERK	O
also	O
inhibited	O
the	O
expression	O
of	O
the	O
p8	O
-	O
CAT	O
construct	O
in	O
Panc	O
-	O
1	O
as	O
well	O
as	O
in	O
BxPc	O
-	O
3	O
.	O

Finally	O
,	O
the	O
MEK1	O
/	O
2	O
specific	O
inhibitor	O
U0126	O
[	O
21	O
]	O
activated	O
p8	O
mRNA	O
expression	O
in	O
pancreatic	O
cells	O
whether	O
they	O
carry	O
mutated	O
ras	O
(	O
Panc	O
-	O
1	O
)	O
or	O
wild	O
-	O
type	O
(	O
BxPc	O
-	O
3	O
)	O
.	O

Similar	O
results	O
were	O
observed	O
when	O
expression	O
of	O
the	O
p8	O
protein	O
was	O
monitored	O
by	O
Western	O
blotting	O
(	O
Figure	O
7	O
)	O
.	O

Activation	O
of	O
the	O
JNK	O
pathway	O
down	O
-	O
regulates	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O

c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
is	O
another	O
major	O
MAPK	O
pathway	O
which	O
converts	O
extracellular	O
signals	O
into	O
expression	O
of	O
specific	O
target	O
genes	O
through	O
phosphorylation	O
and	O
activation	O
of	O
transcription	O
factors	O
.	O

JNK	O
activation	O
has	O
been	O
implicated	O
in	O
various	O
,	O
often	O
opposite	O
cellular	O
responses	O
,	O
such	O
as	O
cell	O
proliferation	O
,	O
transformation	O
and	O
apoptosis	O
.	O

As	O
shown	O
in	O
Figure	O
8	O
,	O
overexpression	O
of	O
JNK	O
down	O
-	O
regulates	O
the	O
gene	O
reporter	O
activity	O
of	O
the	O
p8	O
-	O
CAT	O
construct	O
in	O
Panc	O
-	O
1	O
cells	O
.	O

Similar	O
results	O
were	O
found	O
in	O
BxPc	O
-	O
3	O
cells	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
the	O
JNK	O
specific	O
inhibitor	O
SP600125	O
[	O
22	O
]	O
up	O
-	O
regulates	O
expression	O
of	O
the	O
p8	O
mRNA	O
and	O
p8	O
protein	O
(	O
Figure	O
9	O
)	O
.	O

These	O
results	O
show	O
that	O
the	O
JNK	O
pathway	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
p8	O
expression	O
.	O

The	O
p38	O
pathway	O
up	O
-	O
regulates	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O

The	O
p38	O
signal	O
transduction	O
pathway	O
also	O
plays	O
an	O
essential	O
role	O
in	O
regulating	O
several	O
cell	O
functions	O
including	O
growth	O
,	O
response	O
to	O
inflammation	O
,	O
differentiation	O
and	O
apoptosis	O
.	O

In	O
fact	O
,	O
in	O
pancreatic	O
cancer	O
cells	O
,	O
p38	O
is	O
a	O
strong	O
inhibitor	O
of	O
proliferation	O
[	O
23	O
]	O
contrary	O
to	O
the	O
Ras	O
-->	O
Raf	O
-->	O
MEK	O
-->	O
ERK	O
and	O
JNK	O
pathways	O
.	O

We	O
therefore	O
analyzed	O
the	O
putative	O
role	O
of	O
the	O
p38	O
pathway	O
in	O
regulating	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
.	O

Figure	O
10	O
shows	O
that	O
over	O
-	O
expression	O
of	O
the	O
plasmid	O
encoding	O
p38	O
significantly	O
increases	O
p8	O
-	O
CAT	O
activity	O
in	O
Panc	O
-	O
1	O
as	O
well	O
as	O
in	O
BxPc	O
-	O
3	O
cells	O
.	O

Then	O
,	O
cells	O
were	O
treated	O
with	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
p38	O
[	O
24	O
]	O
,	O
and	O
p8	O
expression	O
was	O
measured	O
.	O

p8	O
mRNA	O
as	O
well	O
as	O
the	O
encoded	O
protein	O
were	O
down	O
-	O
regulated	O
after	O
inhibition	O
of	O
the	O
p38	O
activity	O
(	O
Figure	O
11	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
p38	O
pathway	O
is	O
a	O
positive	O
regulator	O
of	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
.	O

TGF	O
beta	O
-	O
1	O
up	O
-	O
regulates	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O

The	O
most	O
prominent	O
biological	O
activity	O
of	O
TGF	O
beta	O
-	O
1	O
is	O
its	O
potent	O
inhibition	O
of	O
cell	O
growth	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
including	O
pancreatic	O
cells	O
.	O

TGF	O
beta	O
-	O
1	O
signals	O
are	O
sent	O
through	O
two	O
types	O
of	O
transmembrane	O
serine	O
/	O
threonine	O
kinase	O
receptors	O
.	O

In	O
fact	O
,	O
TGF	O
beta	O
-	O
1	O
binds	O
and	O
brings	O
together	O
the	O
type	O
I	O
and	O
type	O
II	O
receptors	O
.	O

In	O
the	O
resulting	O
complex	O
,	O
the	O
constitutively	O
active	O
TGF	O
beta	O
-	O
1	O
type	O
II	O
receptor	O
phosphorylates	O
the	O
type	O
I	O
receptor	O
,	O
which	O
then	O
plays	O
a	O
major	O
role	O
in	O
transducing	O
the	O
signal	O
to	O
downstream	O
components	O
to	O
affect	O
gene	O
expression	O
through	O
phosphorylation	O
of	O
SMAD	O
proteins	O
.	O

Phosphorylated	O
receptor	O
-	O
regulated	O
SMADs	O
then	O
form	O
heteromeric	O
complexes	O
with	O
the	O
common	O
partner	O
SMAD4	O
.	O

These	O
heteromeric	O
complexes	O
then	O
move	O
to	O
the	O
nucleus	O
,	O
where	O
SMAD4	O
will	O
bind	O
DNA	O
and	O
contribute	O
to	O
transcriptional	O
activation	O
.	O

In	O
general	O
,	O
pancreatic	O
cancer	O
cells	O
present	O
with	O
defects	O
in	O
TGF	O
beta	O
-	O
1	O
signaling	O
and	O
are	O
resistant	O
to	O
TGF	O
beta	O
-	O
1	O
-	O
mediated	O
growth	O
suppression	O
.	O

Since	O
TGF	O
beta	O
-	O
1	O
and	O
p8	O
are	O
inhibitors	O
of	O
pancreatic	O
cell	O
growth	O
we	O
analyzed	O
whether	O
p8	O
could	O
mediate	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
effect	O
of	O
TGF	O
beta	O
-	O
1	O
.	O

First	O
,	O
we	O
found	O
that	O
treatment	O
of	O
Panc	O
-	O
1	O
cells	O
with	O
TGF	O
beta	O
-	O
1	O
increased	O
p8	O
mRNA	O
levels	O
and	O
p8	O
protein	O
as	O
judged	O
by	O
Western	O
blot	O
(	O
Figure	O
12	O
)	O
.	O

Then	O
,	O
to	O
confirm	O
that	O
overexpression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
,	O
we	O
analyzed	O
the	O
effect	O
of	O
some	O
constructs	O
expressing	O
constitutively	O
activated	O
type	O
I	O
TGF	O
beta	O
receptor	O
,	O
dominant	O
negative	O
type	O
II	O
TGF	O
beta	O
receptor	O
,	O
a	O
dominant	O
negative	O
of	O
Smad4	O
and	O
the	O
wild	O
-	O
type	O
Smad4	O
on	O
the	O
p8	O
-	O
CAT	O
activity	O
.	O

As	O
expected	O
,	O
the	O
constitutively	O
activated	O
type	O
I	O
TGF	O
beta	O
receptor	O
but	O
not	O
the	O
dominant	O
negative	O
type	O
II	O
TGF	O
beta	O
receptor	O
increased	O
CAT	O
activity	O
.	O

Also	O
,	O
expression	O
of	O
the	O
Smad4	O
,	O
contrary	O
to	O
that	O
of	O
the	O
negative	O
mutant	O
,	O
induced	O
p8	O
transcription	O
(	O
Figure	O
13	O
)	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
p8	O
is	O
positively	O
regulated	O
by	O
TGF	O
beta	O
-	O
1	O
.	O

Beside	O
the	O
Smad	O
proteins	O
,	O
TGF	O
beta	O
-	O
1	O
also	O
activates	O
the	O
p38	O
MAPK	O
pathway	O
in	O
pancreas	O
-	O
derived	O
cells	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
TGF	O
beta	O
-	O
1	O
induced	O
genes	O
[	O
25	O
]	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
p38	O
-	O
dependent	O
effect	O
of	O
TGF	O
beta	O
-	O
1	O
on	O
p8	O
transcription	O
.	O

As	O
shown	O
in	O
Figure	O
13	O
,	O
inhibition	O
of	O
p38	O
activity	O
with	O
the	O
SB203580	O
specific	O
inhibitor	O
decreased	O
about	O
40	O
%	O
the	O
activity	O
of	O
TGF	O
beta	O
-	O
1	O
on	O
the	O
p8	O
promoter	O
indicating	O
that	O
the	O
effect	O
of	O
TGF	O
beta	O
-	O
1	O
on	O
p8	O
promoter	O
is	O
mediated	O
by	O
both	O
p38	O
-	O
dependent	O
and	O
p38	O
-	O
independent	O
pathways	O
.	O

Discussion	O

Pancreatic	O
adenocarcinoma	O
is	O
the	O
fourth	O
leading	O
cause	O
of	O
death	O
from	O
malignant	O
diseases	O
[	O
26	O
]	O
.	O

The	O
aggressive	O
nature	O
of	O
the	O
neoplasia	O
,	O
the	O
lack	O
of	O
early	O
detection	O
,	O
and	O
the	O
limited	O
response	O
to	O
treatments	O
such	O
as	O
chemotherapy	O
and	O
radiotherapy	O
contribute	O
to	O
the	O
high	O
mortality	O
rate	O
of	O
the	O
disease	O
.	O

Therefore	O
,	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
leading	O
to	O
pancreatic	O
cancer	O
remains	O
a	O
major	O
goal	O
because	O
it	O
may	O
help	O
proposing	O
strategies	O
for	O
earlier	O
diagnosis	O
and	O
better	O
treatment	O
.	O

The	O
most	O
commonly	O
altered	O
genes	O
in	O
pancreatic	O
adenocarcinoma	O
are	O
K	O
-	O
ras	O
(	O
75	O
to	O
100	O
%	O
)	O
,	O
p16INK4a	O
(	O
95	O
%	O
)	O
,	O
p53	O
(	O
50	O
to	O
75	O
%	O
)	O
and	O
DPC4	O
(	O
50	O
%	O
)	O
[	O
27	O
-	O
31	O
]	O
.	O

Whereas	O
K	O
-	O
ras	O
is	O
a	O
proto	O
-	O
oncogene	O
all	O
the	O
others	O
are	O
tumour	O
suppressor	O
genes	O
.	O

Additional	O
genes	O
have	O
been	O
found	O
altered	O
at	O
lower	O
frequency	O
.	O

Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
pancreatic	O
cells	O
were	O
chosen	O
for	O
this	O
study	O
because	O
they	O
both	O
express	O
high	O
levels	O
of	O
p8	O
(	O
Figure	O
1	O
)	O
and	O
because	O
they	O
present	O
with	O
different	O
mechanisms	O
of	O
transformation	O
and	O
genetic	O
backgrounds	O
,	O
Panc	O
-	O
1	O
being	O
wild	O
-	O
type	O
for	O
Smad4	O
/	O
DPC4	O
but	O
mutated	O
for	O
K	O
-	O
ras	O
and	O
BxPc	O
-	O
3	O
mutated	O
for	O
Smad4	O
/	O
DPC4	O
and	O
wild	O
-	O
type	O
for	O
K	O
-	O
ras	O
[	O
18	O
,	O
19	O
]	O
.	O

This	O
work	O
presents	O
evidences	O
that	O
p8	O
inhibits	O
the	O
growth	O
rate	O
of	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
and	O
that	O
the	O
intracellular	O
pathways	O
promoting	O
cell	O
growth	O
down	O
-	O
regulate	O
p8	O
expression	O
whereas	O
those	O
promoting	O
growth	O
arrest	O
up	O
-	O
regulate	O
its	O
expression	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
p8	O
is	O
downstream	O
of	O
some	O
cell	O
growth	O
regulators	O
and	O
therefore	O
regulation	O
of	O
p8	O
expression	O
or	O
its	O
activity	O
could	O
be	O
used	O
as	O
a	O
target	O
for	O
treating	O
pancreatic	O
cancer	O
.	O

Silencing	O
p8	O
expression	O
was	O
able	O
to	O
strongly	O
promote	O
cell	O
growth	O
in	O
both	O
cell	O
types	O
,	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
,	O
suggesting	O
that	O
p8	O
may	O
act	O
downstream	O
of	O
the	O
ras	O
-	O
or	O
Smad4	O
/	O
DPC4	O
-	O
dependent	O
ways	O
.	O

Also	O
,	O
we	O
found	O
that	O
stimulating	O
cell	O
growth	O
by	O
the	O
complex	O
combination	O
of	O
growth	O
factors	O
contained	O
in	O
fetal	O
calf	S-Species
serum	O
down	O
-	O
regulated	O
expression	O
of	O
p8	O
whereas	O
,	O
on	O
the	O
contrary	O
,	O
treating	O
the	O
cells	O
with	O
TGF	O
beta	O
-	O
1	O
,	O
which	O
promotes	O
cell	O
cycle	O
arrest	O
,	O
stimulates	O
p8	O
expression	O
.	O

Therefore	O
,	O
p8	O
gene	O
expression	O
seems	O
to	O
be	O
regulated	O
in	O
opposite	O
directions	O
by	O
mechanisms	O
promoting	O
cell	O
growth	O
or	O
cell	O
cycle	O
arrest	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
while	O
p8	O
expression	O
is	O
under	O
the	O
control	O
of	O
cell	O
growth	O
regulatory	O
pathways	O
such	O
as	O
Ras	O
-->	O
Raf	O
-->	O
MEK	O
-->	O
ERK	O
,	O
JNK	O
,	O
p38	O
and	O
TGF	O
beta	O
-	O
1	O
,	O
p8	O
can	O
affect	O
cell	O
cycle	O
progression	O
,	O
suggesting	O
that	O
p8	O
is	O
a	O
target	O
for	O
factors	O
regulating	O
pancreatic	O
cell	O
growth	O
.	O

A	O
mechanism	O
by	O
which	O
p8	O
could	O
regulate	O
cell	O
cycle	O
progression	O
in	O
embryonic	O
fibroblasts	O
was	O
previously	O
proposed	O
[	O
11	O
]	O
.	O

In	O
fact	O
,	O
p8	O
seems	O
to	O
take	O
action	O
upstream	O
from	O
cyclin	O
-	O
dependent	O
kinases	O
because	O
the	O
intracellular	O
levels	O
and	O
activities	O
of	O
Cdk2	O
and	O
Cdk4	O
are	O
decreased	O
when	O
p8	O
is	O
expressed	O
.	O

Concomitantly	O
,	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p27	O
is	O
expressed	O
at	O
a	O
low	O
level	O
in	O
p8	O
-	O
deficient	O
cells	O
which	O
may	O
explain	O
the	O
increased	O
activity	O
of	O
Cdk2	O
and	O
Cdk4	O
.	O

The	O
mechanism	O
by	O
which	O
p8	O
regulates	O
the	O
intracellular	O
level	O
of	O
those	O
proteins	O
remains	O
to	O
be	O
determined	O
.	O

However	O
,	O
because	O
p8	O
is	O
a	O
transcriptional	O
cofactor	O
,	O
it	O
is	O
possible	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
molecules	O
takes	O
place	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
the	O
transcription	O
level	O
.	O

Interestingly	O
,	O
expression	O
of	O
p8	O
mRNA	O
seems	O
to	O
be	O
regulated	O
in	O
a	O
cell	O
type	O
-	O
and	O
stimulus	O
-	O
specific	O
manner	O
since	O
,	O
for	O
example	O
,	O
p38	O
can	O
induce	O
p8	O
expression	O
in	O
response	O
to	O
stress	O
in	O
fibroblasts	O
[	O
3	O
]	O
but	O
not	O
in	O
renal	O
mesangial	O
cells	O
treated	O
with	O
endothelin	O
[	O
13	O
]	O
.	O

In	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
p38	O
seems	O
to	O
play	O
a	O
major	O
role	O
since	O
it	O
is	O
involved	O
in	O
p8	O
activation	O
as	O
judged	O
by	O
transient	O
transfection	O
assays	O
and	O
using	O
a	O
specific	O
p38	O
inhibitor	O
(	O
Figures	O
10	O
and	O
11	O
)	O
.	O

In	O
addition	O
,	O
p38	O
is	O
also	O
involved	O
in	O
TGF	O
beta	O
-	O
1	O
-	O
induced	O
p8	O
expression	O
because	O
about	O
40	O
%	O
of	O
the	O
TGF	O
beta	O
-	O
1	O
effect	O
was	O
abolished	O
when	O
p38	O
activity	O
was	O
specifically	O
blocked	O
(	O
Figure	O
13	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
ERK	O
and	O
JNK	O
are	O
inducers	O
of	O
p8	O
expression	O
in	O
mesangial	O
cells	O
treated	O
with	O
endothelin	O
,	O
but	O
not	O
involved	O
in	O
the	O
activation	O
of	O
p8	O
in	O
response	O
to	O
stress	O
in	O
fibroblasts	O
[	O
3	O
]	O
,	O
and	O
even	O
repressors	O
in	O
pancreatic	O
cells	O
(	O
Figures	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
and	O
9	O
)	O
.	O

Finally	O
,	O
PI3	O
kinase	O
is	O
an	O
inducer	O
of	O
p8	O
expression	O
in	O
both	O
endothelin	O
-	O
mediated	O
p8	O
activation	O
in	O
mesangial	O
cells	O
[	O
13	O
]	O
and	O
pancreatic	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

Based	O
on	O
these	O
observations	O
,	O
overexpression	O
of	O
p8	O
could	O
be	O
considered	O
a	O
possible	O
goal	O
for	O
treating	O
pancreatic	O
tumours	O
,	O
in	O
order	O
to	O
limit	O
their	O
growth	O
.	O

However	O
,	O
we	O
previously	O
reported	O
that	O
p8	O
repression	O
would	O
prevent	O
rasV12	O
/	O
E1A	O
transformed	O
fibroblasts	O
from	O
evolving	O
as	O
tumours	O
in	O
nude	B-Species
mice	E-Species
[	O
16	O
]	O
.	O

This	O
apparent	O
contradiction	O
needs	O
to	O
be	O
resolved	O
before	O
considering	O
p8	O
as	O
a	O
target	O
for	O
treating	O
cancer	O
progression	O
.	O

Conclusions	O

In	O
conclusion	O
(	O
see	O
Figure	O
14	O
)	O
,	O
we	O
report	O
in	O
this	O
paper	O
that	O
inhibition	O
of	O
p8	O
expression	O
by	O
an	O
anti	O
-	O
sense	O
strategy	O
increases	O
the	O
growth	O
rate	O
of	O
both	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
.	O

Moreover	O
,	O
ERK	O
-	O
and	O
JNK	O
-	O
mediated	O
pathways	O
down	O
-	O
regulate	O
p8	O
expression	O
,	O
whereas	O
p38	O
and	O
TGF	O
beta	O
-	O
1	O
pathways	O
induce	O
p8	O
expression	O
.	O

Also	O
,	O
cell	O
growth	O
triggered	O
by	O
expression	O
of	O
a	O
RAS	O
mutated	O
protein	O
or	O
by	O
10	O
%	O
fetal	O
calf	S-Species
serum	O
induces	O
down	O
-	O
regulation	O
of	O
p8	O
expression	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
p8	O
is	O
an	O
intracellular	O
cell	O
growth	O
inhibitor	O
and	O
that	O
it	O
is	O
oppositely	O
regulated	O
by	O
growth	O
-	O
promoting	O
or	O
growth	O
-	O
inhibiting	O
factors	O
in	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
.	O

Material	O
and	O
Methods	O

Cell	O
lines	O
and	O
cell	O
culture	O
conditions	O

The	O
human	S-Species
pancreatic	O
cancer	O
cell	O
lines	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
were	O
a	O
kind	O
gift	O
of	O
Dr	O
C	O
.	O

Susini	O
(	O
INSERM	O
U	O
.	O
531	O
,	O
Toulouse	O
)	O
and	O
A	O
.	O

Hajri	O
(	O
IRCAD	O
,	O
Strasbourg	O
)	O
respectively	O
.	O

Panc	O
-	O
1	O
cells	O
were	O
grown	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	S-Species
serum	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
100	O
IU	O
/	O
ml	O
penicilin	O
G	O
and	O
100	O
mu	O
g	O
/	O
ml	O
streptomycin	O
.	O

BxPc	O
-	O
3	O
were	O
cultivated	O
in	O
RPMI	O
1640	O
medium	O
in	O
the	O
presence	O
of	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
4	O
.	O
5	O
g	O
/	O
L	O
glucose	O
,	O
10	O
mM	O
Hepes	O
,	O
1	O
.	O
0	O
mM	O
sodium	O
pyruvate	O
,	O
10	O
%	O
fetal	O
calf	S-Species
serum	O
and	O
100	O
IU	O
/	O
ml	O
penicilin	O
G	O
and	O
100	O
mu	O
g	O
/	O
ml	O
streptomycin	O
.	O

Human	S-Species
recombinant	O
TGF	O
beta	O
-	O
1	O
was	O
obtained	O
from	O
Sigma	O
,	O
and	O
specific	O
SB203580	O
,	O
U0126	O
and	O
SP600125	O
inhibitors	O
were	O
from	O
Calbiochem	O
and	O
utilized	O
at	O
10	O
mu	O
M	O
.	O

Expression	O
plasmids	O

Expression	O
plamids	O
encoding	O
p38	O
(	O
pCEFL	O
HA	O
p38	O
)	O
,	O
Erk2	O
(	O
pcDNAIII	O
HA	O
ERK2	O
)	O
,	O
JNK	O
(	O
pcDNAIIIB	O
HA	O
JNK	O
)	O
,	O
the	O
wild	O
-	O
type	O
Raf	O
(	O
pcDNA	O
RAF	O
BXB	O
)	O
and	O
the	O
Raf	O
dominant	O
negative	O
(	O
pcDNA	O
RAF	O
301	O
K375W	O
)	O
were	O
obtained	O
from	O
O	O
Coso	O
(	O
University	O
of	O
Buenos	O
Aires	O
)	O
.	O

Plamids	O
encoding	O
the	O
constitutively	O
activated	O
type	O
I	O
TGF	O
beta	O
receptor	O
(	O
RI	O
ACT	O
)	O
,	O
the	O
dominant	O
negative	O
type	O
II	O
TGF	O
beta	O
receptor	O
(	O
RII	O
DN	O
)	O
and	O
the	O
Smad4	O
dominant	O
negative	O
(	O
DPC4	O
1	O
-	O
514	O
a	O
.	O
a	O
.	O
)	O
were	O
obtained	O
from	O
R	O
Urrutia	O
(	O
Mayo	O
Clinic	O
,	O
Rochester	O
)	O
and	O
the	O
wild	O
type	O
Smad4	O
was	O
from	O
C	O
Heldin	O
(	O
Ludwig	O
Institute	O
,	O
Uppsala	O
)	O
.	O

Pancreatic	O
p8	O
-	O
deficient	O
cells	O

To	O
silence	O
p8	O
expression	O
in	O
pancreatic	O
cells	O
,	O
we	O
infected	O
these	O
cells	O
with	O
a	O
retrovirus	O
expressing	O
human	S-Species
p8	O
in	O
the	O
antisense	O
orientation	O
.	O

The	O
retroviral	O
vector	O
was	O
constructed	O
as	O
follows	O
:	O
human	S-Species
p8	O
cDNA	O
was	O
subcloned	O
in	O
HindIII	O
and	O
XhoI	O
restriction	O
sites	O
of	O
the	O
pLPC	O
plasmid	O
(	O
obtained	O
from	O
S	O
.	O
Lowe	O
)	O
in	O
the	O
antisense	O
orientation	O
.	O

Amphotrope	O
human	S-Species
p8	O
expressing	O
retrovirus	O
was	O
then	O
generated	O
by	O
transient	O
transfection	O
using	O
Phoenix	O
amphotrope	O
packaging	O
cells	O
.	O

Viral	O
supernatant	O
was	O
used	O
to	O
infect	O
Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
pancreatic	O
cells	O
and	O
the	O
population	O
of	O
p8	O
-	O
silenced	O
cells	O
was	O
isolated	O
by	O
selection	O
in	O
presence	O
of	O
puromycin	O
(	O
1	O
mu	O
g	O
/	O
ml	O
)	O
.	O

As	O
control	O
,	O
cells	O
were	O
infected	O
with	O
the	O
pLPC	O
empty	O
vector	O
.	O

p8	O
expression	O
in	O
arrested	O
and	O
growing	O
cells	O

One	O
million	O
of	O
Panc	O
-	O
1	O
or	O
BxPc	O
-	O
3	O
cells	O
were	O
cultivated	O
on	O
10	O
-	O
cm	O
Petri	O
plates	O
in	O
standard	O
conditions	O
(	O
with	O
10	O
%	O
FCS	O
)	O
.	O

After	O
48	O
h	O
,	O
culture	O
media	O
were	O
changed	O
for	O
fresh	O
media	O
with	O
FCS	O
restricted	O
to	O
0	O
.	O
1	O
%	O
,	O
in	O
order	O
to	O
stop	O
growth	O
.	O

After	O
24	O
hours	O
of	O
growth	O
arrest	O
,	O
culture	O
medium	O
was	O
replaced	O
either	O
by	O
medium	O
with	O
10	O
%	O
fetal	O
calf	S-Species
serum	O
to	O
resume	O
cell	O
growth	O
or	O
,	O
as	O
control	O
,	O
by	O
medium	O
with	O
0	O
.	O
1	O
%	O
fetal	O
calf	S-Species
serum	O
.	O

Twenty	O
four	O
hours	O
later	O
cells	O
were	O
recovered	O
and	O
RNA	O
and	O
protein	O
extracted	O
.	O

p8	O
expression	O
in	O
TGF	O
beta	O
-	O
1	O
-	O
treated	O
Panc	O
-	O
1	O
cells	O

One	O
million	O
of	O
Panc	O
-	O
1	O
cells	O
were	O
cultivated	O
in	O
10	O
-	O
cm	O
culture	O
dishes	O
for	O
48	O
hours	O
under	O
standard	O
conditions	O
before	O
TGF	O
beta	O
-	O
1	O
treatment	O
.	O

Human	S-Species
recombinant	O
TGF	O
beta	O
-	O
1	O
(	O
5	O
ng	O
/	O
ml	O
)	O
was	O
added	O
to	O
cells	O
,	O
without	O
changing	O
the	O
culture	O
medium	O
,	O
and	O
cells	O
were	O
collected	O
12	O
hours	O
later	O
for	O
RNA	O
and	O
protein	O
preparation	O
.	O

BxPc	O
-	O
3	O
rasV12	O
-	O
expressing	O
cells	O

pLPC	O
-	O
rasV12	O
and	O
pLPC	O
plasmids	O
were	O
obtained	O
from	O
S	O
.	O

Lowe	O
.	O

Phoenix	O
amphotrope	O
packaging	O
cells	O
(	O
106	O
)	O
were	O
plated	O
in	O
a	O
6	O
-	O
well	O
plate	O
,	O
incubated	O
for	O
24	O
hours	O
,	O
then	O
transfected	O
with	O
PEI	O
with	O
5	O
mu	O
g	O
of	O
retroviral	O
plasmid	O
.	O

After	O
48	O
hours	O
,	O
the	O
medium	O
containing	O
virus	O
was	O
filtered	O
(	O
0	O
.	O
45	O
mu	O
m	O
filter	O
,	O
Millipore	O
)	O
to	O
obtain	O
the	O
viral	O
supernatant	O
.	O

Target	O
BxPc	O
-	O
3	O
were	O
plated	O
at	O
2	O
x	O
105	O
cells	O
per	O
35	O
-	O
mm	O
dish	O
and	O
incubated	O
overnight	O
.	O

For	O
infections	O
,	O
the	O
culture	O
medium	O
was	O
replaced	O
by	O
an	O
appropriate	O
mix	O
of	O
the	O
viral	O
supernatant	O
and	O
culture	O
medium	O
(	O
V	O
/	O
V	O
)	O
,	O
supplemented	O
with	O
4	O
mu	O
g	O
/	O
ml	O
polybrene	O
(	O
Sigma	O
)	O
,	O
and	O
cells	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
.	O

BxPc	O
-	O
3	O
rasV12	O
-	O
expressing	O
cells	O
were	O
selected	O
with	O
puromycin	O
(	O
1	O
mu	O
g	O
/	O
ml	O
)	O
.	O

Cells	O
infected	O
with	O
the	O
pLPC	O
empty	O
vector	O
were	O
used	O
as	O
control	O
.	O

Western	O
-	O
blot	O
analyses	O

One	O
hundred	O
mu	O
g	O
of	O
total	O
protein	O
extracted	O
from	O
cells	O
was	O
separated	O
with	O
standard	O
procedures	O
on	O
15	O
.	O
0	O
%	O
SDS	O
-	O
PAGE	O
using	O
the	O
Mini	O
Protean	O
System	O
(	O
Bio	O
-	O
Rad	O
)	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
(	O
Sigma	O
)	O
.	O

The	O
intracellular	O
level	O
of	O
p8	O
was	O
estimated	O
by	O
Western	O
blot	O
using	O
a	O
polyclonal	O
antibody	O
(	O
1	O
:	O
1000	O
)	O
raised	O
against	O
human	S-Species
p8	O
[	O
4	O
]	O
.	O

Growth	O
curves	O

One	O
hundred	O
thousand	O
cells	O
per	O
well	O
were	O
plated	O
in	O
a	O
series	O
of	O
35	O
-	O
mm	O
culture	O
dishes	O
.	O

The	O
cell	O
number	O
was	O
estimated	O
daily	O
in	O
triplicate	O
,	O
during	O
1	O
to	O
5	O
days	O
,	O
in	O
a	O
haemocytometer	O
.	O

Within	O
experiments	O
,	O
each	O
point	O
was	O
determined	O
at	O
least	O
two	O
times	O
.	O

Cell	O
transfection	O
and	O
gene	O
reporter	O
assays	O

Panc	O
-	O
1	O
and	O
BxPc	O
-	O
3	O
(	O
105	O
)	O
were	O
cultivated	O
in	O
30	O
mm	O
diameter	O
culture	O
dishes	O
for	O
24	O
hours	O
then	O
transiently	O
transfected	O
with	O
0	O
.	O
5	O
mu	O
g	O
of	O
p8	O
-	O
CAT	O
reporter	O
plasmid	O
and	O
0	O
.	O
5	O
mu	O
g	O
of	O
pCMV	O
/	O
beta	O
gal	O
plasmid	O
(	O
to	O
control	O
transfection	O
efficiency	O
)	O
using	O
the	O
Fugene	O
reagent	O
in	O
accordance	O
with	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Roche	O
Molecular	O
Biochemicals	O
)	O
.	O

The	O
p8	O
-	O
CAT	O
plasmid	O
is	O
the	O
previously	O
reported	O
p	O
-	O
1471	O
/	O
+	O
37p8	O
-	O
CAT	O
promoter	O
construct	O
[	O
5	O
]	O
.	O

Reporter	O
activities	O
were	O
measured	O
as	O
previously	O
described	O
[	O
5	O
]	O
.	O

Briefly	O
,	O
cell	O
extracts	O
were	O
prepared	O
with	O
the	O
reporter	O
lysis	O
buffer	O
(	O
Promega	O
)	O
24	O
hours	O
after	O
transfection	O
and	O
CAT	O
activity	O
was	O
determined	O
by	O
the	O
phase	O
extraction	O
procedure	O
[	O
32	O
]	O
and	O
beta	O
-	O
galactosidase	O
assay	O
was	O
performed	O
essentially	O
as	O
described	O
in	O
Sambrook	O
et	O
al	O
.	O

[	O
33	O
]	O
.	O

CAT	O
activity	O
was	O
normalized	O
to	O
beta	O
-	O
galactosidase	O
activity	O
.	O

Experiments	O
were	O
carried	O
out	O
in	O
triplicate	O
and	O
repeated	O
at	O
least	O
two	O
times	O
.	O

Expression	O
plasmids	O
(	O
0	O
.	O
5	O
mu	O
g	O
)	O
were	O
co	O
-	O
transfected	O
with	O
p8	O
-	O
CAT	O
and	O
pCMV	O
/	O
beta	O
gal	O
plasmids	O
as	O
indicated	O
.	O

RT	O
-	O
PCR	O
analysis	O

RNA	O
was	O
extracted	O
using	O
the	O
Trizol	O
(	O
Life	O
Technologies	O
)	O
procedure	O
.	O

Total	O
RNA	O
(	O
1	O
mu	O
g	O
)	O
was	O
analyzed	O
by	O
RT	O
-	O
PCR	O
with	O
the	O
SuperScript	O
(TM)	O
One	O
-	O
step	O
RT	O
-	O
PCR	O
System	O
and	O
the	O
Platinum	O
Taq	O
kit	O
(	O
Life	O
Technologies	O
)	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
using	O
different	O
numbers	O
of	O
cycles	O
to	O
verify	O
that	O
the	O
conditions	O
chosen	O
were	O
within	O
the	O
linear	O
range	O
.	O

The	O
mRNA	O
coding	O
for	O
p8	O
was	O
specifically	O
amplified	O
with	O
sense	O
(	O
5	O
'	O
GAAGAGAGGCAGGGAAGACA	O
3	O
'	O
)	O
and	O
antisense	O
(	O
5	O
'	O
CTGCCGTGCGTGTCTATTTA	O
3	O
'	O
)	O
primers	O
,	O
in	O
positions	O
72	O
and	O
643	O
of	O
the	O
cDNA	O
(	O
accession	O
#	O
NM	O
_	O
012385	O
)	O
,	O
respectively	O
.	O

As	O
control	O
,	O
the	O
transcript	O
coding	O
for	O
the	O
ribosomal	O
protein	O
RL3	O
was	O
specifically	O
amplified	O
for	O
22	O
cycles	O
with	O
sense	O
(	O
5	O
'	O
GAAAGAAGTCGTGGAGGCTG3	O
'	O
)	O
and	O
antisense	O
(	O
5	O
'	O
ATCTCATCCTGCCCAAACAC3	O
'	O
)	O
primers	O
,	O
in	O
positions	O
216	O
and	O
637	O
of	O
the	O
cDNA	O
,	O
respectively	O
.	O

Author	O
'	O
s	O
contributions	O

CM	O
prepared	O
cells	O
and	O
retrovirus	O
,	O
carried	O
out	O
RNA	O
purification	O
,	O
RT	O
-	O
PCR	O
,	O
Western	O
blots	O
,	O
and	O
cell	O
growth	O
experiments	O
,	O
NL	O
carried	O
out	O
CAT	O
assays	O
,	O
SV	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
analysis	O
of	O
data	O
,	O
JLI	O
participated	O
in	O
the	O
analysis	O
of	O
data	O
and	O
wrote	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Enzymatic	O
multiplex	O
DNA	O
sequencing	O
.	O

Abstract	O

The	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
has	O
been	O
reformulated	O
using	O
an	O
easily	O
implemented	O
,	O
multiplex	O
version	O
of	O
enzymatic	O
DNA	O
sequencing	O
.	O

By	O
utilizing	O
a	O
uniquely	O
tagged	O
primer	O
for	O
each	O
base	O
-	O
specific	O
sequencing	O
reaction	O
,	O
the	O
four	O
reactions	O
can	O
be	O
pooled	O
and	O
electrophoresed	O
in	O
a	O
single	O
lane	O
.	O

This	O
approach	O
has	O
been	O
previously	O
proposed	O
for	O
use	O
with	O
fluorescently	O
labelled	O
probes	O
(	O
1	O
)	O
,	O
and	O
is	O
analogous	O
to	O
the	O
principle	O
used	O
in	O
four	O
-	O
dye	O
fluorescence	O
sequencing	O
except	O
that	O
the	O
signals	O
are	O
resolved	O
following	O
electrophoresis	O
(	O
2	O
)	O
.	O

After	O
transfer	O
to	O
a	O
nylon	O
membrane	O
,	O
images	O
are	O
obtained	O
separately	O
for	O
each	O
of	O
the	O
four	O
reactions	O
by	O
hybridization	O
using	O
oligonucleotide	O
probes	O
.	O

The	O
images	O
can	O
then	O
be	O
superimposed	O
to	O
reconstitute	O
a	O
complete	O
sequence	O
pattern	O
.	O

In	O
this	O
way	O
the	O
correction	O
of	O
gel	O
distortion	O
effects	O
and	O
accurate	O
band	O
registration	O
are	O
considerably	O
simplified	O
,	O
as	O
each	O
of	O
the	O
four	O
base	O
-	O
specific	O
ladders	O
require	O
very	O
similar	O
corrections	O
.	O

The	O
methods	O
therefore	O
provide	O
the	O
basis	O
for	O
a	O
second	O
generation	O
of	O
more	O
accurate	O
and	O
reliable	O
film	O
reading	O
programs	O
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
conventional	O
multiplex	O
sequencing	O
.	O

Unlike	O
the	O
original	O
multiplex	O
protocol	O
(	O
3	O
)	O
,	O
the	O
approach	O
described	O
is	O
suitable	O
for	O
small	O
projects	O
,	O
as	O
multiple	O
cloning	O
vectors	O
are	O
not	O
used	O
.	O

Although	O
more	O
than	O
one	O
vector	O
can	O
be	O
utilized	O
,	O
only	O
a	O
library	O
of	O
fragments	O
cloned	O
into	O
any	O
single	O
phage	O
,	O
phagemid	O
or	O
plasmid	O
vector	O
is	O
actually	O
required	O
,	O
together	O
with	O
a	O
set	O
of	O
tagged	O
oligonucleotide	O
primers	O
.	O
Images	O

Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O
3301	O

Enzymatic	O
multiplex	O
DNA	O
sequencing	O

Mark	O
Chee	O

Medical	O
Research	O
Council	O
Laboratory	O
of	O
Molecular	O
Biology	O
,	O
Hills	O
Road	O
,	O
Cambridge	O
CB2	O
20H	O
,	O
UK	O

Received	O
March	O
15	O
,	O
1991	O
;	O
Revised	O
and	O
Accepted	O
May	O
2	O
,	O
1991	O

ABSTRACT	O

The	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
has	O
been	O
reformulated	O
using	O
an	O
easily	O
implemented	O
,	O
multiplex	O
version	O
of	O
enzymatic	O
DNA	O
sequencing	O
.	O

By	O
utilizing	O
a	O
uniquely	O
tagged	O
primer	O
for	O
each	O
base	O
-	O
specific	O
sequencing	O
reaction	O
,	O
the	O
four	O
reactions	O
can	O
be	O
pooled	O
and	O
electrophoresed	O
in	O
a	O
single	O
lane	O
.	O

This	O
approach	O
has	O
been	O
previously	O
proposed	O
for	O
use	O
with	O
fluorescently	O
labelled	O
probes	O
(	O
1	O
)	O
,	O
and	O
is	O
analogous	O
to	O
the	O
principle	O
used	O
in	O
four	O
-	O
dye	O
fluorescence	O
sequencing	O
except	O
that	O
the	O
signals	O
are	O
resolved	O
following	O
electrophoresis	O
(	O
2	O
)	O
.	O

After	O
transfer	O
to	O
a	O
nylon	O
membrane	O
,	O
images	O
are	O
obtained	O
separately	O
for	O
each	O
of	O
the	O
four	O
reactions	O
by	O
hybridization	O
using	O
oligonucleotide	O
probes	O
.	O

The	O
images	O
can	O
then	O
be	O
superimposed	O
to	O
reconstitute	O
a	O
complete	O
sequence	O
pattern	O
.	O

In	O
this	O
way	O
the	O
correction	O
of	O
gel	O
distortion	O
effects	O
and	O
accurate	O
band	O
registration	O
are	O
considerably	O
simplified	O
,	O
as	O
each	O
of	O
the	O
four	O
basespecific	O
ladders	O
require	O
very	O
similar	O
corrections	O
.	O

The	O
methods	O
therefore	O
provide	O
the	O
basis	O
for	O
a	O
second	O
generation	O
of	O
more	O
accurate	O
and	O
reliable	O
film	O
reading	O
programs	O
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
conventional	O
multiplex	O
sequencing	O
.	O

Unlike	O
the	O
original	O
multiplex	O
protocol	O
(	O
3	O
)	O
,	O
the	O
approach	O
described	O
is	O
suitable	O
for	O
small	O
projects	O
,	O
as	O
multiple	O
cloning	O
vectors	O
are	O
not	O
used	O
.	O

Although	O
more	O
than	O
one	O
vector	O
can	O
be	O
utilized	O
,	O
only	O
a	O
library	O
of	O
fragments	O
cloned	O
into	O
any	O
single	O
phage	O
.	O
phagemid	O
or	O
plasmid	O
vector	O
is	O
actually	O
required	O
,	O
together	O
with	O
a	O
set	O
of	O
tagged	O
oligonucleotide	O
primers	O
.	O

INTRODUCTION	O

The	O
community	O
of	O
biologists	O
is	O
undertaking	O
the	O
sequencing	O
of	O
representative	O
genomes	O
of	O
various	O
free	O
-	O
living	O
organisms	O
,	O
ranging	O
in	O
size	O
from	O
Mycoplasma	O
(	O
800kb	O
)	O
to	O
mammals	O
(	O
3	O
Gb	O
)	O
(	O
4	O
)	O
.	O

However	O
,	O
the	O
largest	O
contiguous	O
DNA	O
sequences	O
which	O
have	O
been	O
determined	O
so	O
far	O
are	O
the	O
genomes	O
of	O
several	O
dsDNA	O
eukaryotic	O
viruses	O
(	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
)	O
and	O
plant	O
chloroplasts	O
(	O
10	O
,	O
11	O
,	O
12	O
)	O
.	O

The	O
largest	O
of	O
these	O
is	O
the	O
229kb	O
genome	O
of	O
human	B-Species
cytomegalovirus	E-Species
(	O
8	O
)	O
.	O

The	O
difficulty	O
in	O
sequencing	O
millions	O
of	O
base	O
pairs	O
of	O
DNA	O
is	O
that	O
several	O
steps	O
in	O
the	O
methods	O
are	O
relatively	O
labour	O
intensive	O
,	O
although	O
the	O
sequencing	O
reactions	O
themselves	O
are	O
rapid	O
and	O
easily	O
performed	O
.	O

Two	O
limiting	O
steps	O
in	O
conventional	O
procedures	O
are	O
the	O
size	O
fractionation	O
of	O
sequencing	O
reaction	O
products	O
by	O
gel	O
electrophoresis	O
and	O
the	O
subsequent	O
reading	O
of	O
sequence	O
ladders	O
.	O

The	O
former	O
problem	O
can	O
be	O
overcome	O
by	O
multiplexing	O
,	O
which	O
theoretically	O
allows	O
an	O
enormous	O
amount	O
of	O

data	O
to	O
be	O
obtained	O
from	O
a	O
single	O
gel	O
by	O
processing	O
clones	O
as	O
mixtures	O
rather	O
than	O
individually	O
(	O
3	O
)	O
.	O

Each	O
sequence	O
in	O
the	O
mixture	O
is	O
labelled	O
by	O
a	O
unique	O
short	O
oligonucleotide	O
'	O
tag	O
'	O
sequence	O
.	O

This	O
allows	O
the	O
mixture	O
to	O
be	O
resolved	O
following	O
electrophoresis	O
:	O
the	O
superimposed	O
sequence	O
ladders	O
are	O
blotted	O
from	O
the	O
gel	O
to	O
a	O
nylon	O
membrane	O
,	O
and	O
detected	O
one	O
at	O
a	O
time	O
by	O
hybridization	O
using	O
tag	O
-	O
specific	O
oligonucleotide	O
probes	O
.	O

In	O
practice	O
,	O
at	O
least	O
50	O
sets	O
of	O
sequences	O
can	O
be	O
obtained	O
from	O
a	O
single	O
gel	O
(	O
3	O
)	O
.	O

Unfortunately	O
,	O
a	O
bottleneck	O
in	O
the	O
multiplex	O
procedure	O
is	O
the	O
reading	O
of	O
sequence	O
films	O
.	O

In	O
previous	O
large	O
-	O
scale	O
sequencing	O
projects	O
this	O
task	O
has	O
been	O
performed	O
with	O
the	O
aid	O
of	O
a	O
sonic	O
digitizer	O
(	O
13	O
,	O
14	O
)	O
.	O

Although	O
film	O
reading	O
programs	O
have	O
been	O
under	O
development	O
for	O
some	O
time	O
(	O
15	O
)	O
,	O
and	O
some	O
programs	O
are	O
commercially	O
available	O
,	O
their	O
error	O
rates	O
are	O
presently	O
more	O
variable	O
and	O
unpredictable	O
than	O
that	O
of	O
a	O
skilled	O
person	O
and	O
the	O
accurate	O
interpretation	O
of	O
film	O
-	O
imaged	O
sequence	O
ladders	O
by	O
computer	O
programs	O
is	O
difficult	O
to	O
achieve	O
in	O
routine	O
practice	O
.	O

Programs	O
specifically	O
designed	O
to	O
read	O
multiplex	O
films	O
have	O
an	O
advantage	O
.	O

This	O
is	O
because	O
a	O
sequence	O
image	O
can	O
be	O
used	O
as	O
an	O
'	O
internal	O
standard	O
'	O
to	O
help	O
interpret	O
other	O
images	O
derived	O
from	O
the	O
same	O
membrane	O
(	O
3	O
)	O
.	O

However	O
,	O
the	O
original	O
implementation	O
of	O
the	O
multiplex	O
strategy	O
used	O
chemical	O
sequencing	O
(	O
16	O
)	O
,	O
which	O
yields	O
a	O
more	O
complex	O
sequence	O
ladder	O
than	O
the	O
enzymatic	O
dideoxynucleotide	O
chain	O
-	O
termination	O
method	O
(	O
17	O
)	O
.	O

Most	O
successful	O
large	O
scale	O
sequencing	O
projects	O
have	O
used	O
the	O
chaintermination	O
method	O
and	O
bacteriophage	B-Species
M13	E-Species
vectors	O
,	O
which	O
allows	O
the	O
routine	O
production	O
of	O
clean	O
and	O
easily	O
interpretable	O
sequences	O
(	O
18	O
)	O
.	O

It	O
was	O
therefore	O
decided	O
to	O
adapt	O
the	O
original	O
multiplex	O
protocol	O
for	O
use	O
with	O
enzymatic	O
sequencing	O
,	O
using	O
tagged	O
primers	O
.	O

MATERIALS	O
AND	O
METHODS	O

Eight	O
oligonucleotide	O
sequencing	O
primers	O
were	O
synthesized	O
,	O
each	O
37	O
nucleotides	O
in	O
length	O
.	O

The	O
3	O
'	O
end	O
of	O
each	O
primer	O
consists	O
of	O
the	O
17	O
nucleotide	O
M13	O
universal	O
priming	O
sequence	O
[	O
GTAAAACGACGGCCAGT3	O
'	O
]	O
.	O

The	O
5	O
'	O
ends	O
of	O
the	O
primers	O
bear	O
different	O
20mer	O
tag	O
sequences	O
(	O
Figure	O
1	O
)	O
.	O

In	O
four	O
of	O
the	O
primers	O
,	O
UEO1C	O
,	O
UPOIC	O
,	O
UE02C	O
and	O
UP02C	O
,	O
these	O
tags	O
are	O
complementary	O
to	O
the	O
EO1	O
,	O
PO1	O
,	O
E02	O
and	O
P02	O
probe	O
sequences	O
respectively	O
(	O
copied	O
from	O
the	O
original	O
'	O
plex	O
'	O
vectors	O
(	O
3	O
)	O
)	O
.	O

A	O
second	O
set	O
of	O
four	O
primers	O
,	O
UJOL14C	O
,	O
UJOL15C	O
,	O
UJOL16C	O
and	O
UJOL17C	O
,	O
have	O
the	O
following	O
tag	O
sequences	O
:	O
5	O
'	O
CAAGTTTGAAGGTACTCATT	O
,	O
TATCAATTAAATTGTllTGAC	O
,	O
GTGTTGCTACCCAAGAAGCA	O
,	O
and	O
TGTCACTAGAGCTGTCACTT	O
,	O
respectively	O
.	O

The	O

?	O
=	O
)	O
1991	O
Oxford	O
University	O
Press	O

3302	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O

oligonucleotides	O
were	O
gel	O
-	O
purified	O
(	O
19	O
)	O
and	O
used	O
to	O
sequence	O
ssDNA	O
templates	O
prepared	O
by	O
phenol	O
extraction	O
(	O
20	O
)	O
or	O
SDS	O
denaturation	O
(	O
21	O
)	O
.	O

Conventional	O
sequencing	O
reactions	O
were	O
performed	O
as	O
previously	O
described	O
(	O
20	O
)	O
.	O

For	O
hybridization	O
experiments	O
,	O
radioactively	O
labelled	O
nucleotides	O
were	O
omitted	O
from	O
the	O
sequencing	O
reactions	O
.	O

Instead	O
,	O
the	O
21d	O
of	O
each	O
nucleotide	O
mix	O
added	O
to	O
the	O
reaction	O
mixture	O
consisted	O
of	O
the	O
following	O
:	O
'	O
A	O
'	O
mix	O
:	O
6	O
.	O
25MtM	O
dATP	O
,	O
62	O
.	O
5lM	O
ddATP	O
;	O
'	O
C	O
'	O
mix	O
:	O
6	O
.	O
25MM	O
dCTP	O
,	O
40MtM	O
ddCTP	O
;	O
'	O
G	O
'	O
mix	O
:	O
6	O
.	O
25MtM	O
dGTP	O
,	O
80MtM	O
ddGTP	O
;	O
'	O
T	O
'	O
mix	O
:	O
6	O
.	O
25MM	O
dTTP	O
,	O
250yM	O
ddTTP	O
;	O
as	O
well	O
as	O
125MM	O
of	O
each	O
of	O
the	O
three	O
other	O
dNTPs	O
in	O
each	O
mix	O
.	O

Apart	O
from	O
the	O
use	O
of	O
these	O
modified	O
mixes	O
,	O
no	O
changes	O
were	O
made	O
to	O
the	O
conventional	O
sequencing	O
procedure	O
(	O
20	O
)	O
.	O

Sequencing	O
reactions	O
were	O
pooled	O
and	O
ethanol	O
precipitated	O
as	O
appropriate	O
.	O

Precipitation	O
in	O
microtitre	O
trays	O
was	O
carried	O
out	O
as	O
follows	O
:	O
a	O
mixture	O
of	O
3	O
.	O
2M1	O
3M	O
NaAc	O
pH	O
5	O
.	O
0	O
and	O
112Mi1	O
EtOH	O
was	O
dispensed	O
to	O
individual	O
wells	O
of	O
a	O
microtitre	O
plate	O
(	O
Falcon	O
3911	O
or	O
Corning	O
25855	O
)	O
using	O
an	O
8	O
-	O
channel	O
pipettor	O
.	O

Each	O
set	O
of	O
four	O
reactions	O
was	O
added	O
to	O
the	O
EtOH	O
/	O
NaAc	O
mixture	O
,	O
and	O
the	O
tray	O
sealed	O
using	O
a	O
Falcon	O
3073	O
plate	O
sealer	O
.	O

The	O
samples	O
were	O
mixed	O
by	O
inversion	O
and	O
stored	O
at	O
-	O
20	O
?	O
C	O
for	O
30	O
minutes	O
.	O

The	O
DNA	O
was	O
collected	O
by	O
a	O
20	O
minute	O
centrifugation	O
at	O
4	O
000	O
rpm	O
in	O
an	O
IEC	O
Centra	O
3C	O
centrifuge	O
.	O

The	O
sealer	O
was	O
removed	O
,	O
and	O
the	O
plate	O
inverted	O
to	O
discard	O
the	O
supernatant	O
.	O

After	O
blotting	O
the	O
tray	O
on	O
tissue	O
paper	O
,	O
200MI	O
of	O
95	O
%	O
EtOH	O
was	O
added	O
to	O
each	O
well	O
.	O

The	O
plate	O
was	O
covered	O
with	O
a	O
plastic	O
lid	O
and	O
recentrifuged	O
for	O
2	O
minutes	O
.	O

The	O
EtOH	O
was	O
discarded	O
and	O
the	O
plate	O
inverted	O
for	O
several	O
minutes	O
on	O
tissue	O
paper	O
,	O
then	O
left	O
for	O
20	O
minutes	O
to	O
air	O
dry	O
.	O

Precipitated	O
samples	O
were	O
resuspended	O
in	O
6M1	O
deionized	O
water	O
by	O
vortexing	O
on	O
an	O
SMI	O
multi	O
-	O
tube	O
vortexer	O
for	O
1	O
minute	O
.	O

Samples	O
were	O
denatured	O
and	O
electrophoresed	O
on	O
6	O
%	O
polyacrylamide	O
buffer	O
gradient	O
gels	O
as	O
previously	O
described	O
(	O
20	O
)	O
.	O

Following	O
electrophoresis	O
,	O
the	O
gel	O
was	O
transferred	O
to	O
a	O
dry	O
piece	O
of	O
Whatman	O
3MM	O
blotting	O
paper	O
,	O
and	O
placed	O
on	O
a	O
second	O
sheet	O
of	O
blotting	O
paper	O
supported	O
on	O
a	O
glass	O
plate	O
and	O
saturated	O
in	O
4	O
x	O
SSC	O
(	O
SSC	O
:	O
150mM	O
NaCl	O
,	O
l5mM	O
trisodium	O
citrate	O
)	O
.	O

This	O
sheet	O
was	O
wicked	O
in	O
a	O
tray	O
containing	O
1	O
litre	O
of	O
4	O
x	O
SSC	O
.	O

The	O
DNA	O
was	O
transferred	O
to	O
a	O
nylon	O
membrane	O
(	O
Amersham	O
Hybond	O
N	O
)	O
by	O
capillary	O
blotting	O
overnight	O
(	O
22	O
)	O
.	O

DNA	O
was	O
fixed	O
to	O
the	O
membranes	O
by	O
U	O
.	O
V	O
.	O
crosslinking	O
(	O
23	O
)	O
.	O

Plex	O
oligonucleotide	O
probes	O
were	O
a	O
kind	O
gift	O
of	O
Dr	O
.	O
George	O
Church	O
.	O

Probes	O
were	O
tailed	O
at	O
their	O
3	O
'	O
ends	O
using	O
[	O
a	O
-	O
32p	O
]	O
dCTP	O
as	O
previously	O
described	O
(	O
3	O
)	O
.	O

For	O
the	O
preparation	O
of	O
digoxigenin	O
(	O
DIG	O
)	O
labelled	O
probes	O
,	O
identical	O
tailing	O
reactions	O
were	O
carried	O
out	O
substituting	O
I0pmols	O
of	O
DIG	O
-	O
II	O
dUTP	O
(	O
Boehringer	O
Mannheim	O
)	O
for	O
[	O
a	O
-	O
32P	O
]	O
dCTP	O
.	O

Membranes	O
were	O
prehybridized	O
for	O
at	O
least	O
10	O
minutes	O
in	O
4	O
x	O
SSC	O
,	O
5	O
x	O
Denhardts	O
'	O
(	O
0	O
.	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
each	O
of	O
BSA	O
(	O
heated	O
at	O
80	O
?	O
C	O
for	O
30	O
minutes	O
to	O
inactivate	O
any	O
alkaline	O
phosphatase	O
activity	O
)	O
,	O
Ficoll	O
(	O
Pharmacia	O
)	O
and	O
polyvinylpyrrolidone	O
)	O
,	O
0	O
.	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
SDS	O
,	O
5mM	O
NaHPO4	O
(	O
23	O
)	O
.	O

Hybridization	O
was	O
carried	O
out	O
in	O
25	O
-	O
50M1	O
of	O
prehybridization	O
buffer	O
per	O
cm2	O
of	O
membrane	O
.	O

The	O
probe	O
concentration	O
was	O
approximately	O
lnM	O
.	O

After	O
lh	O
at	O
42	O
?	O
C	O
,	O
unbound	O
probe	O
was	O
removed	O
by	O
five	O
1	O
minute	O
washes	O
at	O
room	O
temperature	O
in	O
1	O
x	O
SSC	O
,	O
0	O
.	O
5	O
%	O
SDS	O
(	O
200MI	O
/	O
cm2	O
membrane	O
)	O
.	O

Radioactive	O
blots	O
were	O
covered	O
in	O
Saran	O
wrap	O
and	O
exposed	O
to	O
film	O
immediately	O
.	O

Detection	O
of	O
DIG	O
labelled	O
probes	O
used	O
an	O
anti	O
-	O
DIG	O
antibodyalkaline	O
phosphatase	O
conjugate	O
(	O
Boehringer	O
Mannheim	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
,	O
except	O
that	O
all	O
volumes	O
were	O
reduced	O
by	O
70	O
%	O
and	O
the	O
conjugate	O
was	O
used	O
at	O
a	O
1	O
:	O
10	O
000	O
dilution	O
.	O

Blots	O
were	O
developed	O
in	O
25M1	O
of	O
100mM	O
Tris	O
.	O
Cl	O
pH9	O
.	O
5	O
,	O

mantane4	O
-	O
methoxy4	O
(	O
3	O
"	O
-	O
phosphoryloxy	O
)	O
phenyl	O
-	O
1	O
,	O
2	O
-	O
dioxetane	O
)	O
;	O
Tropix	O
)	O
/	O
cm2	O
for	O
30	O
minutes	O
at	O
37	O
?	O
C	O
,	O
prior	O
to	O
exposure	O
to	O
film	O
.	O

Probes	O
and	O
dioxetane	O
were	O
stripped	O
from	O
the	O
membranes	O
by	O
two	O
10	O
minute	O
washes	O
at	O
700C	O
with	O
0	O
.	O
2	O
%	O
SDS	O
,	O
2mM	O
EDTA	O
(	O
200	O
,	O
ul	O
/	O
cm2	O
membrane	O
)	O
.	O

The	O
hybridization	O
and	O
washing	O
procedures	O
were	O
carried	O
out	O
in	O
plastic	O
bags	O
.	O

However	O
,	O
washing	O
steps	O
have	O
also	O
been	O
performed	O
with	O
gentle	O
agitation	O
in	O
a	O
perspex	O
tub	O
(	O
43	O
x	O
27	O
x	O
15cm	O
)	O
mounted	O
on	O
a	O
reciprocal	O
shaker	O
,	O
with	O
equivalent	O
results	O
.	O

In	O
the	O
latter	O
case	O
a	O
minimum	O
wash	O
volume	O
of	O
500mls	O
was	O
used	O
.	O

The	O
use	O
of	O
a	O
tub	O
is	O
more	O
convenient	O
for	O
batch	O
processing	O
and	O
should	O
be	O
straightforward	O
to	O
automate	O
.	O

RESULTS	O

Autoradiograms	O
revealed	O
no	O
difference	O
in	O
sequence	O
quality	O
when	O
tagged	O
primers	O
were	O
used	O
instead	O
of	O
the	O
17mer	O
universal	O
primer	O
in	O
conventional	O
[	O
a	O
-	O
35S	O
]	O
dATP	O
labelled	O
sequencing	O
reactions	O
and	O
in	O
multiplex	O
hybridization	O
experiments	O
using	O
[	O
a	O
-	O
32P	O
]	O
dCTP	O
-	O
tailed	O
probes	O
(	O
results	O
not	O
shown	O
)	O
.	O

Experiments	O
were	O
then	O
conducted	O
to	O
determine	O
the	O
feasibility	O
of	O
pooling	O
the	O
four	O
base	O
reactions	O
for	O
each	O
clone	O
and	O
fractionating	O
them	O
in	O
a	O
single	O
lane	O
to	O
obtain	O
a	O
superimposed	O
but	O
interpretable	O
set	O
of	O
sequence	O
ladders	O
.	O

The	O
question	O
addressed	O
was	O
whether	O
or	O
not	O
difficulties	O
in	O
band	O
registration	O
might	O
arise	O
as	O
a	O
result	O
of	O
mobility	O
differences	O
between	O
the	O
different	O
primer	O
sequences	O
and	O
/	O
or	O
distortion	O
of	O
the	O
membrane	O
between	O
probings	O
.	O

It	O
is	O
relevant	O
that	O
an	O
automated	O
film	O
reader	O
employing	O
an	O
internal	O
standard	O
requires	O
that	O
the	O
nylon	O
membrane	O
does	O
not	O
undergo	O
significant	O
distortions	O
between	O
probings	O
(	O
George	O
Church	O
,	O
personal	O
communication	O
)	O
.	O

Clones	O
were	O
sequenced	O
using	O
the	O
four	O
tagged	O
primers	O
UEOlC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
,	O
one	O
for	O
each	O
base	O
reaction	O
(	O
Figure	O
1	O
)	O
.	O

The	O
A	O
,	O
C	O
,	O
G	O
and	O
T	O
reactions	O
for	O
each	O
clone	O
were	O
pooled	O
,	O
and	O
processed	O
as	O
described	O
above	O
.	O

A	O
complete	O
set	O
of	O
sequence	O
autoradiograms	O
was	O
obtained	O
from	O
four	O
consecutive	O
rounds	O
of	O
probing	O
with	O
[	O
a	O
-	O
32P	O
]	O
dCTP	O
-	O
labelled	O
oligonucleotides	O
.	O

Alignment	O
of	O
the	O
films	O
showed	O
that	O
sequence	O
-	O
specific	O
mobility	O
effects	O
and	O
distortion	O
of	O
the	O
membrane	O
between	O
probings	O
were	O
sufficiently	O
minor	O
to	O
allow	O
accurate	O
registration	O
of	O
the	O
bands	O
,	O
and	O
hence	O
accurate	O
reading	O
of	O
the	O
sequence	O
.	O

At	O
least	O
200	O
nucleotides	O
of	O
sequence	O
could	O
be	O
read	O
accurately	O
from	O
a	O
single	O
clone	O
by	O
simply	O
tracing	O
the	O
four	O
sets	O
of	O
bands	O
using	O
different	O
colours	O
,	O
overlaying	O
the	O
tracings	O
,	O
and	O
reading	O
the	O
bands	O
sequentially	O
.	O

In	O
order	O
to	O
assess	O
the	O
practicality	O
of	O
reading	O
the	O
sequences	O
by	O
machine	O
,	O
the	O
images	O
were	O
scanned	O
to	O
provide	O
optical	O
density	O
profiles	O
(	O
Figure	O
2	O
)	O
.	O

These	O
profiles	O
were	O
overlaid	O
,	O
and	O
were	O
found	O
to	O
be	O
sufficiently	O
in	O
register	O
to	O
allow	O
accurate	O
interpretation	O
of	O
the	O
sequence	O
for	O
at	O
least	O
300	O
nucleotides	O
.	O

This	O
was	O
essentially	O
the	O
limit	O
of	O
resolution	O
of	O
the	O
gel	O
for	O
accurate	O
manual	O
reading	O
.	O

In	O
order	O
to	O
ensure	O
that	O
the	O
relatively	O
minor	O
mobility	O
differences	O
observed	O
between	O
the	O
four	O
primers	O
were	O
not	O
coincidental	O
to	O
the	O
oligonucleotides	O
used	O
,	O
a	O
second	O
set	O
of	O
four	O
tagged	O
M13	O
universal	O
primers	O
was	O
synthesised	O
,	O
this	O
time	O
incorporating	O
20mer	O
sequences	O
derived	O
from	O
the	O
genome	O
of	O
murine	O
herpesvirus	O
-	O
68	O
(	O
UJOL14C	O
,	O
15C	O
,	O
16C	O
,	O
17C	O
)	O
.	O

Sequencing	O
reactions	O
were	O
performed	O
using	O
[	O
cx	O
-	O
35S	O
]	O
dATP	O
to	O
label	O
the	O
DNA	O
directly	O
.	O

Various	O
templates	O
were	O
sequenced	O
,	O
and	O
in	O
all	O
cases	O
correctly	O
ordered	O
sequence	O
ladders	O
were	O
obtained	O
following	O
conventional	O
electrophoresis	O
in	O
which	O
the	O
four	O
reactions	O
were	O
run	O
side	O
-	O
by	O
-	O
side	O
(	O
results	O
not	O
shown	O
)	O
.	O

Initial	O
hybridization	O
experiments	O
were	O
conducted	O
using	O
[	O
f	O
-	O
32p	O
]	O

dCTP	O
tailed	O
oligonucleotide	O
probes	O
.	O

However	O
,	O
the	O
use	O
of	O

lOOmM	O
NaCl	O
,	O
5OmM	O
MgC12	O
,	O
0	O
.	O
15mM	O
AMPPD	O
(	O
[	O
3	O
-	O
(	O
2	O
'	O
-	O
ada	O

B	O

C	O

'	O
Ordinary	O
'	O
Plex	O
'	O
4	O
-	O
CJ3	O
4	O
-	O
rn	O
+	O

Primeir	O
Primer	O

"	O
All	O
"	O
C	O
"	O
"	O
G	O
"	O
"	O
T	O
"	O

'	O
Plex	O
'	O
'	O
Ordinary	O
'	O
Pool	O
and	O

Vector	O
Vector	O
fractionate	O

Resolve	O
by	O
sequential	O

hybridizations	O

Sequencing	O
reactions	O

SequencingreactIo	O
product	O

Sequencing	O
reaction	O
product	O

-	O
n	O
;	O

=	O
=	O

-	O
=	O

-	O
n	O
:	O
=	O

Figure	O
1	O
.	O
Approaches	O
to	O
enzymatic	O
multiplex	O
DNA	O
sequencing	O
.	O
a	O
)	O
A	O
set	O
of	O
sequence	O
-	O
tagged	O
vectors	O
can	O
be	O
used	O
.	O

The	O
tag	O
site	O
is	O
shown	O
in	O
red	O
,	O
and	O
the	O
insert	O
to	O
be	O
sequenced	O
in	O
blue	O
.	O

However	O
,	O
the	O
original	O
plex	O
vectors	O
(	O
3	O
)	O
are	O
plasmids	O
,	O
and	O
therefore	O
amenable	O
only	O
to	O
dsDNA	O
sequencing	O
.	O
Sets	O
of	O
bacteriophage	B-Species
M13	E-Species
vectors	O
have	O
been	O
constructed	O
bearing	O
either	O
one	O
(	O
32	O
)	O
or	O
two	O
[	O
Chee	O
,	O
unpublished	O
]	O
of	O
the	O
plex	O
tag	O
sites	O
flanking	O
the	O
polylinker	O
,	O
which	O
can	O
be	O
used	O
for	O
this	O
approach	O
.	O

b	O
)	O
The	O
strategy	O
used	O
in	O
this	O
paper	O
.	O

In	O
this	O
case	O
the	O
tag	O
site	O
is	O
carried	O
on	O
the	O
primer	O
.	O

c	O
)	O
If	O
tagged	O
primers	O
are	O
used	O
,	O
there	O
is	O
no	O
practical	O
impediment	O
to	O
performing	O
each	O
base	O
reaction	O
using	O
a	O
different	O
primer	O
,	O
as	O
depicted	O
.	O

The	O
reactions	O
can	O
then	O
be	O
pooled	O
in	O
any	O
combination	O
desired	O
.	O

The	O
configuration	O
shown	O
,	O
in	O
which	O
the	O
four	O
reactions	O
are	O
electrophoresed	O
in	O
a	O
single	O
lane	O
,	O
is	O
designed	O
to	O
facilitate	O
accurate	O
band	O
registration	O
and	O
reading	O
by	O
an	O
automatic	O
film	O
reader	O
.	O

In	O
order	O
to	O
read	O
the	O
sequence	O
manually	O
,	O
base	O
reactions	O
would	O
be	O
run	O
side	O
-	O
by	O
-	O
side	O
.	O

The	O
logistics	O
of	O
processing	O
the	O
reactions	O
are	O
essentially	O
the	O
same	O
with	O
either	O
configuration	O
;	O
the	O
same	O
number	O
of	O
probings	O
are	O
required	O
.	O

Figure	O
2	O
.	O

Four	O
overlaid	O
one	O
-	O
dimensional	O
optical	O
density	O
profiles	O
for	O
a	O
single	O
clone	O
shown	O
in	O
two	O
overlapping	O
sections	O
.	O

The	O
optical	O
density	O
profiles	O
are	O
unprocessed	O
,	O
except	O
for	O
a	O
simple	O
transform	O
to	O
correct	O
for	O
the	O
relative	O
displacement	O
(	O
translation	O
and	O
rotation	O
)	O
of	O
the	O
four	O
images	O
from	O
which	O
they	O
are	O
extracted	O
.	O

The	O
profiles	O
read	O
5	O
'	O
to	O
3	O
'	O
from	O
right	O
to	O
left	O
.	O

Nucleotides	O
positions	O
66	O
to	O
214	O
from	O
the	O
start	O
of	O
the	O
universal	O
priming	O
site	O
are	O
shown	O
.	O

The	O
sequence	O
is	O
that	O
of	O
Bluescribe	O
M13	O
+	O
(	O
template	O
DNA	O
obtained	O
by	O
rescue	O
with	O
M13K07	O
helper	O
phage	O
(	O
30	O
)	O
)	O
,	O
and	O
was	O
determined	O
using	O
the	O
primers	O
UEOIC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
for	O
the	O
T	O
,	O
C	O
,	O
G	O
and	O
A	O

specific	O
reactions	O
respectively	O
.	O

Detection	O
was	O
by	O
autoradiography	O
following	O
hybridization	O
with	O
[	O
a	O
-	O
32p	O
]	O
dCTP	O
tailed	O
plex	O
probes	O
.	O

A	O

Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O
3303	O

I	O

3304	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O

a	O
)	O

175	O
-	O
.	O
.	O
.	O

-	O
w	O

.	O
m	O
;	O

b	O
)	O

182	O

a	O
:	O
.	O
.	O
.	O
.	O
.	O
.	O

F	O
.	O
VW	O

an	O

-	O
w	O

-	O
1	O

S	O
-	O
K	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
i	O

'	O
F	O
C	O
C	O
;	O
A	O
I1	O
'	O
CG	O
A	O

Figure	O
3	O
.	O

Four	O
separate	O
base	O
-	O
specific	O
reactions	O
imaged	O
from	O
a	O
single	O
lane	O
using	O
chemiluminescent	O
detection	O
.	O

The	O
clones	O
sequenced	O
are	O
:	O
a	O
)	O
Bluescribe	O
M13	O
+	O
(	O
obtained	O
by	O
rescue	O
with	O
M13K07	O
helper	O
phage	O
(	O
30	O
)	O
)	O
and	O
b	O
)	O
an	O
M13	O
recombinant	O
clone	O
prepared	O
in	O
a	O
microtitre	O
tray	O
(	O
21	O
)	O
(	O
a	O
kind	O
gift	O
of	O
Victoria	O
Smith	O
)	O
.	O

Nucleotide	O
positions	O
shown	O
on	O
the	O
figure	O
are	O
numbered	O
from	O
the	O
start	O
of	O
the	O
universal	O
priming	O
site	O
.	O

The	O
clones	O
were	O
sequenced	O
using	O
UEOlC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
for	O
the	O
T	O
,	O
C	O
,	O
G	O
and	O
A	O
specific	O
reactions	O
respectively	O
.	O

The	O
blot	O
was	O
probed	O
with	O
corresponding	O
DIG	O
-	O
11	O
-	O
dUTP	O
labelled	O
oligonucleotides	O
.	O

radioactivity	O
on	O
the	O
scale	O
envisioned	O
for	O
a	O
large	O
sequencing	O
project	O
is	O
undesirable	O
for	O
reasons	O
of	O
safety	O
.	O

The	O
relatively	O
long	O
exposure	O
times	O
required	O
(	O
6	O
to	O
24	O
hours	O
)	O
and	O
the	O
short	O
half	O
lives	O
of	O
the	O
probes	O
might	O
also	O
be	O
inconvenient	O
.	O

It	O
has	O
been	O
shown	O
that	O
a	O
biotin	O
/	O
streptavidin	O
/	O
alkaline	O
phosphatase	O
based	O
detection	O
system	O
used	O
in	O
conjunction	O
with	O
a	O
chemiluminescent	O
dioxetane	O
substrate	O
overcomes	O
these	O
disadvantages	O
(	O
24	O
,	O
25	O
,	O
26	O
)	O
.	O

We	O
utilized	O
a	O
different	O
bridging	O
system	O
with	O
similar	O
results	O
.	O

Digoxigenin	O
(	O
DIG	O
)	O
labelled	O
oligonucleotide	O
probes	O
were	O
detected	O
using	O
anti	O
-	O
DIG	O
antibody	O
-	O
alkaline	O
phosphatase	O
conjugates	O
and	O
a	O
chemiluminescent	O
dioxetane	O
substrate	O
.	O

Exposure	O
times	O
of	O
10	O
to	O
15	O
minutes	O
were	O
typically	O
required	O
,	O
following	O
a	O
one	O
hour	O
preincubation	O
period	O
(	O
Figure	O
3	O
)	O
.	O

In	O
our	O
hands	O
the	O
DIG	O
bridging	O
system	O
was	O
similar	O
in	O
sensitivity	O
to	O
the	O
streptavidin	O
based	O
system	O
(	O
24	O
)	O
,	O
and	O
the	O
practical	O
lower	O
limit	O
of	O
template	O
ssDNA	O
required	O
in	O
order	O
to	O
obtain	O
an	O
easily	O
interpretable	O
sequencing	O
ladder	O
was	O
estimated	O
to	O
be	O
in	O
the	O
range	O
of	O
20	O
to	O
50fmols	O
per	O
reaction	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
detection	O
was	O
limited	O
only	O
by	O
enzymaticallytriggered	O
background	O
luminescence	O
,	O
and	O
not	O
by	O
the	O
level	O
of	O
signal	O
obtained	O
.	O

The	O
nonradioactive	O
methods	O
described	O
have	O
been	O
used	O
successfully	O
in	O
an	O
8	O
-	O
plex	O
system	O
.	O

DISCUSSION	O

Although	O
the	O
original	O
multiplex	O
protocol	O
was	O
based	O
on	O
a	O
set	O
of	O
tagged	O
vectors	O
(	O
3	O
)	O
,	O
tagged	O
primers	O
have	O
also	O
been	O
used	O
or	O
proposed	O
for	O
various	O
forms	O
of	O
multiplex	O
DNA	O
sequencing	O
(	O
George	O
Church	O
,	O
personal	O
communication	O
;	O
2	O
,	O
27	O
)	O
.	O

For	O
example	O
,	O
a	O
proposal	O
was	O
recently	O
put	O
forward	O
for	O
multiplex	O
sequencing	O
using	O
sequence	O
-	O
labelled	O
primers	O
and	O
fluorophor	O
-	O
labelled	O
probes	O

(	O
1	O
)	O
,	O
similar	O
in	O
principle	O
to	O
the	O
methods	O
used	O
here	O
.	O

However	O
,	O
we	O
use	O
tagged	O
primers	O
and	O
the	O
superposition	O
of	O
the	O
four	O
sequencing	O
reactions	O
to	O
address	O
the	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
;	O
a	O
part	O
of	O
this	O
solution	O
is	O
to	O
utilize	O
M13	O
dideoxynucleotide	O
sequencing	O
,	O
thereby	O
improving	O
the	O
quality	O
of	O
the	O
data	O
to	O
be	O
analyzed	O
.	O

In	O
addition	O
,	O
the	O
proposal	O
for	O
fluorophor	O
-	O
labelled	O
probes	O
does	O
not	O
take	O
into	O
consideration	O
any	O
of	O
the	O
practical	O
sequencing	O
problems	O
addressed	O
here	O
,	O
and	O
,	O
in	O
the	O
version	O
described	O
,	O
remains	O
a	O
promising	O
but	O
unproven	O
scheme	O
for	O
large	O
scale	O
DNA	O
sequencing	O
.	O

There	O
are	O
several	O
advantages	O
to	O
tagging	O
primers	O
instead	O
of	O
vectors	O
.	O

Firstly	O
,	O
there	O
is	O
no	O
need	O
to	O
prepare	O
multiple	O
libraries	O
of	O
clones	O
in	O
special	O
vectors	O
.	O

This	O
means	O
that	O
workers	O
can	O
use	O
vector	O
/	O
host	O
combinations	O
that	O
yield	O
good	O
results	O
in	O
their	O
hands	O
,	O
and	O
an	O
increased	O
depth	O
of	O
multiplexing	O
can	O
easily	O
be	O
accomodated	O
by	O
synthesizing	O
more	O
primers	O
.	O

This	O
should	O
make	O
multiplexing	O
more	O
accessible	O
to	O
workers	O
undertaking	O
smaller	O
projects	O
.	O

A	O
theoretical	O
disadvantage	O
of	O
tagged	O
primers	O
is	O
that	O
the	O
procedure	O
can	O
only	O
be	O
multiplexed	O
following	O
primer	O
annealing	O
(	O
1	O
)	O
,	O
or	O
following	O
the	O
sequencing	O
reactions	O
(	O
this	O
paper	O
;	O
in	O
practice	O
,	O
pooling	O
immediately	O
after	O
the	O
annealing	O
step	O
might	O
lead	O
to	O
increased	O
backgrounds	O
if	O
one	O
or	O
more	O
primers	O
were	O
present	O
in	O
excess	O
over	O
their	O
template	O
DNAs	O
)	O
.	O

This	O
is	O
a	O
relatively	O
late	O
stage	O
.	O

In	O
the	O
original	O
procedure	O
(	O
3	O
)	O
,	O
clones	O
were	O
pooled	O
prior	O
to	O
amplification	O
by	O
growth	O
,	O
an	O
early	O
step	O
.	O

However	O
,	O
we	O
do	O
not	O
believe	O
the	O
sacrifice	O
to	O
be	O
of	O
practical	O
importance	O
when	O
using	O
phage	O
vectors	O
.	O

In	O
our	O
experience	O
,	O
recombinant	O
M13	O
phage	O
have	O
variable	O
growth	O
rates	O
and	O
the	O
effects	O
of	O
competition	O
are	O
likely	O
to	O
severely	O
limit	O
the	O
number	O
of	O
clones	O
that	O
can	O
usefully	O
be	O
pooled	O
for	O
growth	O
.	O

In	O
contrast	O
,	O
by	O
growing	O
clones	O
individually	O
,	O
the	O
depth	O
of	O
multiplexing	O
is	O
only	O
really	O
limited	O
by	O
probe	O
sensitivity	O
.	O

We	O
have	O
not	O
investigated	O
the	O
factors	O
influencing	O
variability	O
in	O
phage	O
growth	O
rates	O
.	O

It	O
is	O
worth	O
noting	O
that	O
reliable	O
protocols	O
have	O
been	O
developed	O
for	O
growing	O
large	O
numbers	O
of	O
individual	O
M13	O
clones	O
and	O
preparing	O
high	O
quality	O
ssDNA	O
templates	O
in	O
microtitre	O
trays	O
(	O
28	O
,	O
21	O
)	O
.	O

It	O
is	O
relatively	O
simple	O
to	O
prepare	O
manually	O
two	O
microtitre	O
trays	O
of	O
ssDNA	O
templates	O
(	O
192	O
clones	O
)	O
in	O
a	O
day	O
.	O

Sufficient	O
clones	O
can	O
be	O
prepared	O
in	O
a	O
week	O
to	O
sequence	O
a	O
20kb	O
fragment	O
to	O
a	O
redundancy	O
of	O
10	O
(	O
Victoria	O
Smith	O
,	O
personal	O
communication	O
)	O
.	O

In	O
this	O
laboratory	O
,	O
ssDNA	O
is	O
now	O
prepared	O
with	O
the	O
aid	O
of	O
a	O
commercially	O
available	O
robotic	O
workstation	O
(	O
21	O
)	O
.	O

As	O
sequencing	O
reactions	O
are	O
also	O
carried	O
out	O
in	O
microtitre	O
trays	O
,	O
manually	O
or	O
robotically	O
(	O
20	O
,	O
29	O
)	O
,	O
the	O
entire	O
M13	O
-	O
based	O
dideoxynucleotide	O
sequencing	O
procedure	O
is	O
amenable	O
to	O
automation	O
(	O
29	O
)	O
.	O

For	O
these	O
reasons	O
we	O
see	O
little	O
practical	O
advantage	O
in	O
pooling	O
clones	O
early	O
.	O

Finally	O
,	O
by	O
not	O
pooling	O
clones	O
early	O
,	O
the	O
ability	O
to	O
easily	O
retrieve	O
individual	O
clones	O
is	O
retained	O
,	O
which	O
may	O
facilitate	O
directed	O
sequencing	O
later	O
in	O
a	O
project	O
should	O
this	O
become	O
necessary	O
.	O

Multiplex	O
DNA	O
sequencing	O
is	O
currently	O
limited	O
by	O
the	O
lack	O
of	O
a	O
robust	O
computer	O
program	O
which	O
can	O
correct	O
for	O
the	O
large	O
variety	O
of	O
gel	O
and	O
sequencing	O
artefacts	O
that	O
are	O
normally	O
encountered	O
.	O

The	O
foundation	O
of	O
a	O
film	O
reading	O
program	O
is	O
the	O
ability	O
to	O
bring	O
into	O
register	O
precisely	O
vertical	O
arrays	O
of	O
base	O
-	O
specific	O
bands	O
.	O

This	O
requires	O
the	O
ability	O
to	O
track	O
lanes	O
,	O
correct	O
for	O
distortions	O
,	O
and	O
order	O
bands	O
based	O
on	O
their	O
relative	O
spacing	O
.	O

A	O
method	O
of	O
sequencing	O
which	O
has	O
successfully	O
overcome	O
the	O
problem	O
of	O
sequence	O
reading	O
uses	O
real	O
-	O
time	O
detection	O
of	O
fluorescently	O
labelled	O
DNA	O
samples	O
migrating	O
through	O
the	O
gel	O
(	O
2	O
)	O
.	O

This	O
system	O
also	O
utilizes	O
the	O
principle	O
of	O
running	O
the	O
four	O
base	O
reactions	O
down	O
the	O
same	O
lane	O
(	O
2	O
)	O
.	O

However	O
,	O
bands	O
are	O
detected	O
at	O
a	O
fixed	O
location	O

in	O
space	O
,	O
and	O
their	O
detection	O
is	O
separated	O
in	O
time	O
.	O

Hence	O
the	O

Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O
3305	O

problem	O
of	O
gel	O
distortion	O
is	O
essentially	O
avoided	O
,	O
although	O
corrections	O
for	O
the	O
different	O
mobilities	O
of	O
the	O
four	O
dyes	O
must	O
be	O
carried	O
out	O
.	O

In	O
contrast	O
,	O
we	O
utilize	O
the	O
advantages	O
of	O
single	O
lane	O
electrophoresis	O
to	O
address	O
the	O
problem	O
of	O
superimposing	O
four	O
relatively	O
large	O
and	O
complex	O
two	O
-	O
dimensional	O
images	O
.	O

Furthermore	O
,	O
by	O
using	O
sequence	O
-	O
tagged	O
oligonucleotides	O
which	O
are	O
detected	O
by	O
hybridization	O
,	O
a	O
much	O
greater	O
depth	O
of	O
multiplexing	O
can	O
realistically	O
be	O
achieved	O
than	O
by	O
real	O
-	O
time	O
detection	O
.	O

The	O
use	O
of	O
two	O
-	O
dimensional	O
colour	O
traces	O
to	O
depict	O
the	O
processed	O
output	O
of	O
a	O
film	O
reader	O
is	O
consistent	O
with	O
the	O
method	O
of	O
displaying	O
fluorescence	O
traces	O
,	O
and	O
should	O
facilitate	O
the	O
checking	O
and	O
editing	O
of	O
sequence	O
databases	O
in	O
which	O
both	O
kinds	O
of	O
data	O
have	O
been	O
entered	O
.	O

The	O
sequence	O
compilation	O
programs	O
used	O
in	O
this	O
laboratory	O
,	O
which	O
are	O
already	O
capable	O
of	O
handling	O
large	O
shotgun	O
databases	O
(	O
8	O
,	O
31	O
)	O
,	O
have	O
recently	O
undergone	O
extensive	O
improvements	O
(	O
Rodger	O
Staden	O
,	O
personal	O
communication	O
)	O
.	O

There	O
is	O
now	O
an	O
interactive	O
database	O
editor	O
which	O
allows	O
the	O
graphical	O
display	O
of	O
fluorescence	O
traces	O
,	O
and	O
it	O
is	O
envisaged	O
that	O
this	O
feature	O
could	O
be	O
extended	O
to	O
allow	O
the	O
handling	O
of	O
data	O
from	O
a	O
film	O
reader	O
when	O
a	O
suitable	O
machine	O
is	O
developed	O
.	O

ACKNOWLEDGEMENTS	O

I	O
am	O
particularly	O
grateful	O
to	O
George	O
Church	O
for	O
thought	O
-	O
provoking	O
discussions	O
and	O
gifts	O
of	O
vectors	O
and	O
oligonucleotide	O
probes	O
and	O
to	O
John	O
Sulston	O
for	O
advice	O
.	O

I	O
also	O
thank	O
Victoria	O
Smith	O
for	O
the	O
gift	O
of	O
DNA	O
samples	O
,	O
Bart	O
Barrell	O
for	O
long	O
-	O
term	O
support	O
,	O
Tom	O
O	O
'	O
Keefe	O
of	O
Milligen	O
/	O
Biosearch	O
for	O
lessons	O
in	O
multiplexing	O
and	O
Amersham	O
International	O
for	O
the	O
optical	O
density	O
overlays	O
shown	O
in	O
Figure	O
2	O
.	O

M	O
.	O
C	O
.	O

is	O
supported	O
by	O
a	O
fellowship	O
from	O
Applied	O
Biosystems	O
.	O

12	O
.	O

Hiratsuka	O
,	O
J	O
.	O
,	O
Shimada	O
,	O
H	O
.	O
,	O
Whittier	O
,	O
R	O
.	O
,	O
Ishibashi	O
,	O
T	O
.	O
,	O
Sakamoto	O
,	O
M	O
.	O
,	O
Mori	O
,	O

M	O
.	O
,	O
Kondo	O
,	O
C	O
.	O
,	O
Honju	O
,	O
Y	O
.	O
,	O
Sun	O
,	O
C	O
.	O

-	O
R	O
,	O
Meng	O
,	O
B	O
.	O

-	O
Y	O
,	O
Li	O
,	O
Y	O
.	O

-	O
Q	O
,	O
Kanno	O
,	O
A	O
.	O
,	O
Nisizawa	O
,	O
Y	O
.	O
,	O
Hirai	O
,	O
A	O
.	O
,	O
Shinozaki	O
,	O
K	O
.	O
and	O
Sugiura	O
,	O
M	O
.	O

(	O
1989	O
)	O
Molecular	O
and	O
General	O
Genetics	O
,	O
217	O
,	O
185	O
-	O
194	O
.	O

13	O
.	O

Komaromy	O
,	O
M	O
.	O
and	O
Govan	O
,	O
H	O
.	O

(	O
1984	O
)	O
Nucleic	O
Acids	O
Research	O
,	O
12	O
,	O
675	O
-	O
678	O
.	O

14	O
.	O

Staden	O
,	O
R	O
.	O

(	O
1984	O
)	O
Nucleic	O
Acids	O
Research	O
,	O
12	O
,	O
499	O
-	O
503	O
.	O

15	O
.	O

Elder	O
,	O
J	O
.	O

K	O
.	O
,	O
Green	O
,	O
D	O
.	O

K	O
.	O
and	O
Southern	O
,	O
E	O
.	O

M	O
.	O

(	O
1986	O
)	O
Nucleic	O
Acids	O

Research	O
,	O
14	O
,	O
417	O
-	O
424	O
.	O

16	O
.	O

Maxam	O
,	O
A	O
.	O

M	O
.	O
and	O
Gilbert	O
,	O
W	O
.	O

(	O
1977	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O

of	O
Sciences	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
,	O
74	O
,	O
560	O
-	O
564	O
.	O

17	O
.	O

Sanger	O
,	O
F	O
.	O
,	O
Nicklen	O
,	O
S	O
.	O
and	O
Coulson	O
,	O
A	O
.	O

R	O
.	O

(	O
1977	O
)	O
Proceedings	O
of	O
the	O
National	O

Academy	O
of	O
Sciences	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
,	O
74	O
,	O
5463	O
-	O
5467	O
.	O

18	O
.	O

Sanger	O
,	O
F	O
.	O
,	O
Coulson	O
,	O
A	O
.	O

R	O
.	O
,	O
Barrell	O
,	O
B	O
.	O

G	O
.	O
,	O
Smith	O
,	O
A	O
.	O

J	O
.	O

H	O
.	O
and	O
Roe	O
,	O
B	O
.	O

A	O
.	O

(	O
1980	O
)	O
Journal	O
of	O
Molecular	O
Biology	O
,	O
143	O
,	O
161	O
-	O
178	O
.	O

19	O
.	O

Applied	O
Biosystems	O
User	O
Bulletin	O
(	O
1987	O
)	O
13	O
,	O
11	O
-	O
16	O
.	O

20	O
.	O

Bankier	O
,	O
A	O
.	O

T	O
.	O
,	O
Weston	O
,	O
K	O
.	O

M	O
.	O
and	O
Barrell	O
,	O
B	O
.	O

G	O
.	O

(	O
1987	O
)	O
Methods	O
in	O

Enzymology	O
,	O
155	O
,	O
51	O
-	O
93	O
.	O

21	O
.	O

Smith	O
,	O
V	O
.	O
,	O
Brown	O
,	O
C	O
.	O

M	O
.	O
,	O
Bankier	O
,	O
A	O
.	O

T	O
.	O
and	O
Barrell	O
,	O
B	O
.	O

G	O
.	O

(	O
1990	O
)	O
DNA	O

Sequence	O
,	O
1	O
,	O
73	O
-	O
78	O
.	O

22	O
.	O

Southern	O
,	O
E	O
.	O

M	O
.	O

(	O
1975	O
)	O
Journal	O
of	O
Molecular	O
Biology	O
,	O
98	O
,	O
503	O
-	O
517	O
.	O

23	O
.	O

Church	O
,	O
G	O
.	O

M	O
.	O
and	O
Gilbert	O
,	O
W	O
.	O

(	O
1984	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O

of	O
Sciences	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
,	O
81	O
,	O
1991	O
-	O
1995	O
.	O

24	O
.	O

Beck	O
,	O
S	O
.	O
,	O
O	O
'	O
Keefe	O
,	O
T	O
.	O
,	O
Coull	O
,	O
J	O
.	O

M	O
.	O
and	O
Koster	O
,	O
H	O
.	O

(	O
1989	O
)	O
Nucleic	O
Acids	O

Research	O
,	O
17	O
,	O
5115	O
-	O
5123	O
.	O

25	O
.	O

Tizard	O
,	O
R	O
.	O
,	O
Cate	O
,	O
R	O
.	O

L	O
.	O
,	O
Ramachandran	O
,	O
K	O
.	O

L	O
.	O
,	O
Wysk	O
,	O
M	O
.	O
,	O
Voyta	O
,	O
J	O
.	O

C	O
.	O
,	O

Murphy	O
,	O
0	O
.	O

J	O
.	O
and	O
Bronstein	O
,	O
I	O
.	O

(	O
1990	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
,	O
87	O
,	O
4514	O
-	O
4518	O
.	O

26	O
.	O

Beck	O
,	O
S	O
.	O
and	O
Koster	O
,	O
H	O
.	O

(	O
1990	O
)	O
Analytical	O
Chemistry	O
,	O
62	O
,	O
2558	O
-	O
2570	O
.	O

27	O
.	O

Jacobson	O
,	O
K	O
.	O

B	O
.	O
,	O
Arlinghaus	O
,	O
H	O
.	O

F	O
.	O
,	O
Schmitt	O
,	O
H	O
.	O

W	O
.	O
,	O
Sachleben	O
,	O
R	O
.	O

A	O
.	O
,	O

Brown	O
,	O
G	O
.	O

M	O
.	O
,	O
Thonnard	O
,	O
N	O
.	O
,	O
Sloop	O
,	O
F	O
.	O

V	O
.	O
,	O
Foote	O
,	O
R	O
.	O

S	O
.	O
,	O
Larimer	O
,	O
F	O
.	O

W	O
.	O
,	O
Woychik	O
,	O
R	O
.	O

P	O
.	O
,	O
England	O
,	O
M	O
.	O

W	O
.	O
,	O
Burchett	O
,	O
K	O
.	O

L	O
.	O
and	O
Jacobson	O
,	O
D	O
.	O

A	O
.	O

(	O
1991	O
)	O
Genomics	O
,	O
9	O
,	O
51	O
-	O
59	O
.	O

28	O
.	O

Eperon	O
,	O
I	O
.	O

C	O
.	O

(	O
1986	O
)	O
Analytical	O
Biochemistry	O
,	O
56	O
,	O
406	O
-	O
412	O
.	O

29	O
.	O

Bankier	O
,	O
A	O
.	O

T	O
.	O
and	O
Barrell	O
,	O
B	O
.	O

G	O
.	O

(	O
1989	O
)	O
In	O
Howe	O
,	O
C	O
.	O

J	O
.	O
and	O
Ward	O
,	O
E	O
.	O

S	O
.	O

(	O
ed	O
)	O
,	O
Nucleic	O
acids	O
sequencing	O
:	O
a	O
practical	O
approach	O
.	O

IRL	O
Press	O
,	O
Oxford	O
,	O
Vol	O
.	O

1	O
,	O
pp	O
.	O

37	O
-	O
78	O
.	O

30	O
.	O

Vieira	O
,	O
J	O
.	O
and	O
Messing	O
,	O
J	O
.	O

(	O
1987	O
)	O
Methods	O
in	O
Enzymology	O
,	O
153	O
,	O
3	O
-	O
11	O
.	O

31	O
.	O

Davison	O
,	O
A	O
.	O

DNA	O
Sequence	O
,	O
in	O
press	O
.	O

32	O
.	O

Heller	O
,	O
C	O
.	O
,	O
Radley	O
,	O
E	O
.	O
,	O
Khurshid	O
,	O
F	O
.	O

A	O
.	O
and	O
Beck	O
,	O
S	O
.	O

Gene	O
,	O
in	O
press	O
.	O

REFERENCES	O

1	O
.	O

Yang	O
,	O
M	O
.	O

M	O
.	O
and	O
Youvan	O
,	O
D	O
.	O

C	O
.	O

(	O
1989	O
)	O
Biotechnology	O
,	O
7	O
,	O
576	O
-	O
580	O
.	O

2	O
.	O

Smith	O
,	O
L	O
.	O

M	O
.	O
,	O
Sanders	O
,	O
J	O
.	O

Z	O
.	O
,	O
Kaiser	O
,	O
R	O
.	O

J	O
.	O
,	O
Hughes	O
,	O
P	O
.	O
,	O
Dodd	O
,	O
C	O
.	O
,	O
Connell	O
,	O

C	O
.	O

R	O
.	O
,	O
Heiner	O
,	O
C	O
.	O
,	O
Kent	O
,	O
S	O
.	O

B	O
.	O

H	O
.	O
and	O
Hood	O
,	O
L	O
.	O

E	O
.	O

(	O
1986	O
)	O
Nature	O
,	O
321	O
,	O
674	O
-	O
679	O
.	O

3	O
.	O

Church	O
,	O
G	O
.	O

M	O
.	O
and	O
Kieffer	O
-	O
Higgins	O
,	O
S	O
.	O

(	O
1988	O
)	O
Science	O
,	O
240	O
,	O
185	O
-	O
188	O
.	O

4	O
.	O

Watson	O
,	O
J	O
.	O

D	O
.	O

(	O
1990	O
)	O
Science	O
,	O
248	O
,	O
44	O
-	O
49	O
.	O

5	O
.	O

Baer	O
,	O
R	O
.	O
,	O
Bankier	O
,	O
A	O
.	O

T	O
.	O
,	O
Biggin	O
,	O
M	O
.	O

D	O
.	O
,	O
Deininger	O
,	O
P	O
.	O

L	O
.	O
,	O
Farrell	O
,	O
P	O
.	O

J	O
.	O
,	O

Gibson	O
,	O
T	O
.	O

J	O
.	O
,	O
Hatfull	O
,	O
G	O
.	O
,	O
Hudson	O
,	O
G	O
.	O

S	O
.	O
,	O
Satchwell	O
,	O
S	O
.	O

C	O
.	O
,	O
Seguin	O
,	O
C	O
.	O
,	O
Tuffnell	O
,	O
P	O
.	O

S	O
.	O
and	O
Barrell	O
,	O
B	O
.	O

G	O
.	O

(	O
1984	O
)	O
Nature	O
,	O
310	O
,	O
207	O
-	O
211	O
.	O

6	O
.	O

Davison	O
,	O
A	O
.	O

J	O
.	O
and	O
Scott	O
,	O
J	O
.	O

E	O
.	O

(	O
1986	O
)	O
Journal	O
of	O
General	O
Virology	O
,	O
67	O
,	O

1759	O
-	O
1816	O
.	O

7	O
.	O

McGeoch	O
,	O
D	O
.	O

J	O
.	O
,	O
Dalrymple	O
,	O
M	O
.	O

A	O
.	O
,	O
Davison	O
,	O
A	O
.	O

J	O
.	O
,	O
Dolan	O
,	O
A	O
.	O
,	O
Frame	O
,	O

M	O
.	O

C	O
.	O
,	O
McNab	O
,	O
D	O
.	O
,	O
Perry	O
,	O
L	O
.	O

J	O
.	O
,	O
Scott	O
,	O
J	O
.	O

E	O
.	O
and	O
Taylor	O
,	O
P	O
.	O

(	O
1988	O
)	O
Journal	O
of	O
General	O
Virology	O
,	O
69	O
,	O
1531	O
-	O
1574	O
.	O

8	O
.	O

Chee	O
,	O
M	O
.	O

S	O
.	O
,	O
Bankier	O
,	O
A	O
.	O

T	O
.	O
,	O
Beck	O
,	O
S	O
.	O
,	O
Bohni	O
,	O
R	O
.	O
,	O
Brown	O
,	O
C	O
.	O

M	O
.	O
,	O
Cerny	O
,	O

R	O
.	O
,	O
Horsnell	O
,	O
T	O
.	O
,	O
Hutchison	O
III	O
,	O
C	O
.	O

A	O
.	O
,	O
Kouzarides	O
,	O
T	O
.	O
,	O
Martignetti	O
,	O
J	O
.	O

A	O
.	O
,	O
Satchwell	O
,	O
S	O
.	O

C	O
.	O
,	O
Tomlinson	O
,	O
P	O
.	O
,	O
Weston	O
,	O
K	O
.	O

M	O
.	O
and	O
Barrell	O
,	O
B	O
.	O

G	O
.	O

(	O
1990	O
)	O
Current	O
Topics	O
in	O
Microbiology	O
and	O
Immunology	O
,	O
154	O
,	O
125	O
-	O
169	O
.	O

9	O
.	O

Goebel	O
,	O
S	O
.	O

J	O
.	O
,	O
Johnson	O
,	O
G	O
.	O

P	O
.	O
,	O
Perkus	O
,	O
M	O
.	O

E	O
.	O
,	O
Davis	O
,	O
S	O
.	O

W	O
.	O
,	O
Winslow	O
,	O
J	O
.	O

P	O
.	O
and	O
Paoletti	O
,	O
E	O
.	O

(	O
1990	O
)	O
Virology	O
,	O
179	O
,	O
247	O
-	O
266	O
.	O

10	O
.	O

Ohyama	O
,	O
K	O
.	O
,	O
Fukuzawa	O
,	O
H	O
.	O
,	O
Kohchi	O
,	O
T	O
.	O
,	O
Shirai	O
,	O
H	O
.	O
,	O
Sano	O
,	O
T	O
.	O
,	O
Sano	O
,	O
S	O
.	O
,	O

Umesono	O
,	O
K	O
.	O
,	O
Shiki	O
,	O
Y	O
.	O
,	O
Takeuchi	O
,	O
M	O
.	O
,	O
Chang	O
,	O
Z	O
.	O
,	O
Aota	O
,	O
S	O
.	O

-	O
I	O
,	O
Inokuchi	O
,	O
H	O
.	O
and	O
Ozeki	O
,	O
H	O
.	O

(	O
1986	O
)	O
Nature	O
,	O
322	O
,	O
572	O
-	O
574	O
.	O

11	O
.	O

Shinozaki	O
,	O
K	O
.	O
,	O
Ohme	O
,	O
M	O
.	O
,	O
Tanaka	O
,	O
M	O
.	O
,	O
Wakasugi	O
,	O
T	O
.	O
,	O
Hayashida	O
,	O
N	O
.	O
,	O

Matsubayashi	O
,	O
T	O
.	O
,	O
Zaita	O
,	O
N	O
.	O
,	O
Chunwongse	O
,	O
J	O
.	O
,	O
Obokata	O
,	O
J	O
.	O
,	O
YamaguchiShinozaki	O
,	O
K	O
.	O
,	O
Ohto	O
,	O
C	O
.	O
,	O
Torazawa	O
,	O
K	O
.	O
,	O
Meng	O
,	O
B	O
.	O

Y	O
.	O
,	O
Sugita	O
,	O
M	O
.	O
,	O
Deno	O
,	O
H	O
.	O
,	O
Kamogashira	O
,	O
T	O
.	O
,	O
Yamada	O
,	O
K	O
.	O
,	O
Kusuda	O
,	O
J	O
.	O
,	O
Takaiwa	O
,	O
F	O
.	O
,	O
Kato	O
,	O
A	O
.	O
,	O
Tohdoh	O
,	O
N	O
.	O
,	O
Shimada	O
,	O
H	O
.	O
and	O
Sugiura	O
,	O
M	O
.	O

(	O
1986	O
)	O
EMBO	O
Journal	O
,	O
5	O
,	O
2043	O
-	O
2049	O
.	O

Mapping	O
irradiation	O
hybrids	O
to	O
cosmid	O
and	O
yeast	S-Species
artificial	O
chromosome	O
libraries	O
by	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
.	O

Abstract	O

A	O
direct	O
hybridization	O
protocol	O
is	O
described	O
for	O
screening	O
cosmid	O
and	O
yeast	S-Species
artificial	O
chromosome	O
libraries	O
with	O
pools	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
somatic	O
cell	O
or	O
irradiation	O
hybrids	O
.	O

This	O
method	O
eliminates	O
purification	O
,	O
cloning	O
and	O
analysis	O
of	O
each	O
individual	O
Alu	O
-	O
PCR	O
product	O
before	O
library	O
screening	O
.	O

A	O
series	O
of	O
human	S-Species
X	O
chromosome	O
irradiation	O
hybrids	O
were	O
mapped	O
by	O
this	O
method	O
,	O
using	O
a	O
cosmid	O
reference	O
library	O
for	O
comparisons	O
between	O
overlapping	O
hybrids	O
to	O
identify	O
interesting	O
clones	O
for	O
further	O
analysis	O
.	O
Images	O

Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O
3315	O

Mapping	O
irradiation	O
hybrids	O
to	O
cosmid	O
and	O
yeast	S-Species
artificial	O
chromosome	O
libraries	O
by	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O

Anthony	O
P	O
.	O
Monaco	O
*	O
,	O
Veronica	O
M	O
.	O
S	O
.	O
Lam2	O
,	O
Gunther	O
Zehetner	O
,	O
Gregory	O
G	O
.	O
Lennon	O
,	O
Christal	O
Douglas	O
,	O
Dean	O
Nizetic	O
,	O
Peter	O
N	O
.	O
Goodfellow1	O
and	O
Hans	O
Lehrach	O

Genome	O
Analysis	O
Laboratory	O
and	O
'	O
Molecular	O
Human	O
Genetics	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
44	O
Lincoln	O
'	O
s	O
Inn	O
Fields	O
,	O
London	O
WC2A	O
3PX	O
,	O
UK	O
and	O
2Department	O
of	O
Biochemistry	O
,	O
Li	O
Shu	O
Fan	O
Building	O
,	O
Sassoon	O
Road	O
,	O
University	O
of	O
Hong	O
Kong	O
,	O
Hong	O
Kong	O

Received	O
March	O
12	O
,	O
1991	O
;	O
Revised	O
and	O
Accepted	O
May	O
16	O
,	O
1991	O

ABSTRACT	O

A	O
direct	O
hybridization	O
protocol	O
is	O
described	O
for	O
screening	O
cosmid	O
and	O
yeast	S-Species
artificial	O
chromosome	O
libraries	O
with	O
pools	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
somatic	O
cell	O
or	O
irradiation	O
hybrids	O
.	O

This	O
method	O
eliminates	O
purification	O
,	O
cloning	O
and	O
analysis	O
of	O
each	O
individual	O
AluPCR	O
product	O
before	O
library	O
screening	O
.	O

A	O
series	O
of	O
human	S-Species
X	O
chromosome	O
irradiation	O
hybrids	O
were	O
mapped	O
by	O
this	O
method	O
,	O
using	O
a	O
cosmid	O
reference	O
library	O
for	O
comparisons	O
between	O
overlapping	O
hybrids	O
to	O
identify	O
interesting	O
clones	O
for	O
further	O
analysis	O
.	O

INTRODUCTION	O

The	O
generation	O
of	O
human	S-Species
DNA	O
probes	O
specific	O
for	O
individual	O
chromosomes	O
and	O
subregions	O
of	O
chromosomes	O
has	O
been	O
advanced	O
with	O
Alu	O
-	O
sequence	O
primed	O
polymerase	O
chain	O
reaction	O
amplification	O
(	O
Alu	O
-	O
PCR	O
,	O
1	O
-	O
3	O
)	O
.	O

This	O
method	O
specifically	O
amplifies	O
sequences	O
between	O
Alu	O
repeats	O
from	O
human	S-Species
DNA	O
in	O
somatic	O
cell	O
hybrids	O
and	O
yeast	S-Species
artificial	O
chromosomes	O
(	O
YACs	O
,	O
4	O
)	O
.	O

Individual	O
Alu	O
-	O
PCR	O
products	O
can	O
be	O
purified	O
from	O
agarose	O
gels	O
or	O
ligated	O
into	O
plasmid	O
vectors	O
to	O
screen	O
for	O
single	O
copy	O
sequences	O
.	O

Unique	O
Alu	O
-	O
PCR	O
products	O
are	O
then	O
localized	O
to	O
certain	O
chromosome	O
regions	O
using	O
DNA	O
blots	O
of	O
somatic	O
cell	O
hybrid	O
panels	O
.	O

Once	O
localized	O
,	O
Alu	O
-	O
PCR	O
fragments	O
can	O
be	O
screened	O
against	O
genomic	O
libraries	O
to	O
isolate	O
longer	O
DNA	O
fragments	O
from	O
the	O
region	O
of	O
interest	O
.	O

As	O
an	O
alternative	O
to	O
this	O
multistep	O
process	O
we	O
have	O
developed	O
a	O
hybridization	O
protocol	O
for	O
screening	O
of	O
cosmid	O
and	O
YAC	O
libraries	O
directly	O
with	O
pools	O
of	O
Alu	O
-	O
PCR	O
products	O
.	O

Two	O
new	O
human	S-Species
specific	O
Alu	O
primers	O
were	O
used	O
to	O
generate	O
DNA	O
probes	O
from	O
a	O
series	O
of	O
irradiation	O
-	O
reduced	O
hybrids	O
containing	O
multiple	O
human	S-Species
X	O
chromosome	O
fragments	O
of	O
1	O
-	O
2000	O
kb	O
on	O
a	O
hamster	O
chromosome	O
background	O
(	O
5	O
;	O
P	O
.	O
N	O
.	O
G	O
.	O
,	O
unpublished	O
)	O
.	O

The	O
Alu	O
-	O
PCR	O
products	O
were	O
hybridized	O
as	O
a	O
pool	O
of	O
probes	O
to	O
X	O
-	O
specific	O
cosmid	O
and	O
YAC	O
libraries	O
,	O
after	O

competitive	O
reassociation	O
with	O
an	O
excess	O
of	O
human	S-Species
DNA	O
to	O
both	O
the	O
library	O
filters	O
and	O
radioactively	O
labelled	O
Alu	O
-	O
PCR	O
products	O
.	O

Comparisons	O
were	O
made	O
between	O
clones	O
identified	O
by	O
overlapping	O
irradiation	O
hybrids	O
and	O
single	O
copy	O
DNA	O
probes	O
hybridized	O
to	O
the	O
cosmid	O
and	O
YAC	O
libraries	O
.	O

METHODS	O

Two	O
human	S-Species
Alu	O
sequence	O
primers	O
were	O
generated	O
which	O
were	O
shown	O
to	O
be	O
human	S-Species
specific	O
;	O
3144	O
from	O
the	O
3	O
'	O
end	O
of	O
Alu	O
:	O
5	O
'	O
-	O
GAGCGAGACTCCGTCTCAAA	O
-	O
3	O
'	O
and	O
2729	O
from	O
the	O
5	O
'	O
end	O
of	O
Alu	O
:	O
5	O
'	O
-	O
GTGGATCACCTGAGGTCAGGAGTTC	O
-	O
3	O
'	O
.	O

All	O
PCR	O
reactions	O
were	O
carried	O
out	O
with	O
100	O
ng	O
of	O
hybrid	O
DNA	O
and	O
0	O
.	O
7	O
,	O
^	O
g	O
of	O
a	O
single	O
Alu	O
primer	O
in	O
100	O
d41	O
of	O
0	O
.	O
01	O
M	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
3	O
,	O
0	O
.	O
0015	O
M	O
MgCl2	O
,	O
0	O
.	O
05	O
M	O
KCI	O
,	O
200	O
AtM	O
each	O
of	O
dNTPs	O
,	O
10	O
%	O
dimethlysulfoxide	O
,	O
and	O
2	O
.	O
5	O
units	O
of	O
Cetus	O
Taq	O
polymerase	O
.	O

Reactions	O
were	O
30	O
cycles	O
of	O
94	O
?	O
C	O
for	O
2	O
min	O
,	O
57	O
?	O
C	O
for	O
2	O
min	O
,	O
and	O
74	O
?	O
C	O
for	O
4	O
min	O
followed	O
by	O
a	O
final	O
extension	O
time	O
at	O
74	O
?	O
C	O
for	O
9	O
min	O
.	O

Reactions	O
products	O
were	O
analyzed	O
on	O
1	O
%	O
agarose	O
gels	O
and	O
shown	O
to	O
contain	O
between	O
five	O
and	O
twenty	O
fragments	O
,	O
with	O
sizes	O
ranging	O
from	O
0	O
.	O
1	O
to	O
2	O
.	O
0	O
kb	O
.	O

Chinese	B-Species
hamster	E-Species
DNA	O
and	O
no	O
DNA	O
PCR	O
reactions	O
were	O
done	O
to	O
control	O
for	O
non	O
-	O
human	S-Species
products	O
(	O
data	O
not	O
shown	O
)	O
.	O

Alu	O
-	O
PCR	O
products	O
were	O
separated	O
from	O
Alu	O
oligomers	O
over	O
Qiagen	O
columns	O
,	O
and	O
approximately	O
50	O
-	O
100	O
ng	O
were	O
labelled	O
by	O
random	O
hexamer	O
priming	O
(	O
6	O
)	O
.	O

The	O
radioactively	O
labelled	O
pool	O
of	O
fragments	O
was	O
prehybridized	O
with	O
37	O
.	O
5	O
,	O
^	O
g	O
of	O
total	O
human	S-Species
DNA	O
and	O
12	O
.	O
5	O
tsg	O
of	O
hamster	O
DNA	O
immobilized	O
on	O
a	O
cellulose	O
support	O
matrix	O
,	O
prepared	O
as	O
previously	O
described	O
(	O
7	O
)	O
.	O

Reactions	O
were	O
at	O
65	O
?	O
C	O
in	O
1	O
ml	O
of	O
0	O
.	O
75M	O
NaCl	O
,	O
0	O
.	O
05M	O
sodium	O
phosphate	O
pH	O
7	O
.	O
2	O
,	O
0	O
.	O
005M	O
EDTA	O
,	O
0	O
.	O
1	O
%	O
sodium	O
dodecyl	O
sulphate	O
(	O
SDS	O
)	O
,	O
0	O
.	O
5	O
mg	O
/	O
ml	O
heparin	O
,	O
and	O
100	O
jig	O
/	O
ml	O
denatured	O
salmon	O
sperm	O
DNA	O
.	O

The	O
cellulose	O
was	O
pelleted	O
and	O
the	O
supernatant	O
boiled	O
for	O
2	O
min	O
every	O
12	O
-	O
16	O
hours	O
(	O
three	O
times	O
in	O
two	O
days	O
)	O
.	O

Cosmid	O
and	O
YAC	O
library	O
filters	O
(	O
Hybond	O
N	O
+	O
,	O
Amersham	O
)	O
were	O
prehybridized	O
at	O
42	O
?	O
C	O
for	O
16	O
hours	O
with	O
100	O
jig	O
/	O
ml	O

*	O
To	O
whom	O
correspondence	O
should	O
be	O
addressed	O
at	O
Human	O
Genetics	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
Institute	O
of	O
Molecular	O
Medicine	O
,	O
John	O
Radcliffe	O
Hospital	O
,	O
Headington	O
,	O
Oxford	O
OX3	O
9DU	O
,	O
UK	O

1991	O
Oxford	O
University	O
Press	O

3316	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O

Chromosome	O
X	O

.	O
,	O
.	O
.	O
,	O
.	O
,	O
<	O

_	O
.	O
,	O
.	O

<	O
.	O
,	O

*	O
2	O
.	O
'	O
1	O
-	O
7	O
-	O
_	O

_	O
-	O
_	O
1	O
.	O

J	O

,	O
.	O
1	O
.	O
.	O

-	O
1	O
,	O
_	O
i	O
-	O
_	O
1	O
.	O

1	O

1	O
'	O
4	O
-	O
-	O
1	O
+	O

1	O
1	O
L	O
L	O
.	O

i	O

.	O
1	O
.	O

_	O
1	O

1	O
1	O
s	O
.	O

1	O
i	O

1	O
i	O
;	O
.	O

-	O
-	O
r	O
'	O
F	O
1	O
-	O

1	O
-	O
1	O
-	O
l	O

j	O
i	O
-	O
_	O
1	O
.	O

1	O

-	O
_	O
1	O
.	O
.	O

s	O
-	O
S	O
.	O

i	O
n	O
-	O
.	O

.	O
.	O

:	O
,	O
1	O
'	O
,	O
.	O

-	O
1	O
_	O
E	O
I	O
i	O
?	O

,	O
.	O

.	O
_	O
_	O
_	O

G	O
-	O

.	O

*	O
.	O
-	O
.	O
,	O
.	O
,	O
z	O

_	O

_	O
,	O

z	O
;	O
-	O
[	O
X1	O

21	O
,	O
In	O

27	O
38	O
45	O
48	O
54	O
74	O
86	O

I	O
1	O
I	O

I	O

I	O

107	O

MD	O

I	O

:	O
I	O
I	O

I	O
I	O

I	O
I	O

Figur	O
2a	O
and	O
2b	O
:	O
Hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
generated	O
with	O
Alu	O
primer	O
3144	O
from	O
irradiation	O
hybrid	O
48	O
to	O
duplicate	O
copies	O
of	O
22	O
x22cm	O
filters	O
containing	O
9216	O
human	S-Species
X	O
chromosome	O
cosmids	O
(	O
8	O
)	O
.	O

2c	O
:	O
Hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
generated	O
with	O
Alu	O
primer	O
3144	O
from	O
an	O
independent	O
hybrid	O
(	O
54	O
)	O
to	O
a	O
third	O
identical	O
cosmid	O
filter	O
.	O

Figure	O
1	O
:	O
A	O
schematic	O
diagram	O
of	O
the	O
human	S-Species
X	O
chromosome	O
alongside	O
the	O
approximate	O
cytogenetic	O
location	O
of	O
fragments	O
identified	O
in	O
nine	O
irradiation	O
hybrids	O
(	O
numbers	O
across	O
the	O
top	O
)	O
.	O

The	O
human	S-Species
X	O
fragments	O
were	O
identified	O
by	O
hybridization	O
of	O
27	O
known	O
DNA	O
markers	O
(	O
indicated	O
by	O
a	O
black	O
line	O
;	O
P	O
.	O
N	O
.	O
G	O
,	O
unpublished	O
)	O
or	O
by	O
cosmids	O
in	O
common	O
with	O
unique	O
X	O
chromosome	O
probes	O
in	O
the	O
reference	O
library	O
database	O
(	O
open	O
boxes	O
and	O
Table	O
1	O
)	O
.	O

The	O
size	O
of	O
the	O
lines	O
and	O
boxes	O
relate	O
to	O
the	O
best	O
cytogenetic	O
location	O
of	O
the	O
probes	O
used	O
according	O
to	O
Human	O
Gene	O
Mapping	O
10	O
.	O
5	O
(	O
14	O
)	O
and	O
does	O
not	O
indicate	O
the	O
physical	O
extent	O
of	O
the	O
irradiation	O
hybrid	O
fragments	O
.	O

denatured	O
and	O
sheared	O
total	O
human	S-Species
DNA	O
in	O
50	O
%	O
formamide	O
,	O
4XSSC	O
,	O
0	O
.	O
05	O
M	O
sodium	O
phosphate	O
pH	O
7	O
.	O
2	O
,	O
0	O
.	O
001	O
M	O
EDTA	O
,	O
10	O
%	O
dextran	O
sulphate	O
,	O
1	O
.	O
0	O
%	O
SDS	O
,	O
50	O
isg	O
/	O
ml	O
denatured	O
salmon	O
sperm	O
DNA	O
and	O
OxDenhardt	O
'	O
s	O
solution	O
.	O

The	O
radioactively	O
labelled	O
Alu	O
-	O
PCR	O
products	O
were	O
denatured	O
and	O
added	O
to	O
fresh	O

hybridization	O
solution	O
without	O
human	S-Species
DNA	O
competitor	O
at	O
1	O
x	O
106	O

cpm	O
/	O
ml	O
and	O
hybridized	O
at	O
42	O
?	O
C	O
for	O
16	O
hours	O
.	O

Filters	O
were	O
washed	O
in	O
0	O
.	O
1	O
xSSC	O
and	O
1	O
.	O
0	O
%	O
SDS	O
,	O
twice	O
at	O
room	O
temperature	O
and	O
twice	O
at	O
65	O
?	O
C	O
for	O
30	O
min	O
each	O
and	O
exposed	O
to	O
Kodak	O
X	O
-	O
OMAT	O
film	O
for	O
2	O
-	O
3	O
days	O
at	O
-	O
70	O
?	O
C	O
with	O
an	O
intensifying	O
screen	O
.	O

For	O
each	O
hybridization	O
,	O
two	O
sets	O
of	O
duplicate	O
cosmid	O
filters	O
were	O
used	O
from	O
the	O
ICRF	O
reference	O
library	O
system	O
(	O
8	O
)	O
,	O
each	O
containing	O
9216	O
flow	O
-	O
sorted	O
human	S-Species
X	O
chromosome	O
cosmid	O
clones	O
or	O
approximately	O
2	O
chromosome	O
equivalents	O
on	O
a	O
22	O
x	O
22	O
cm	O
filter	O
(	O
9	O
)	O
.	O

The	O
coordinates	O
of	O
signals	O
positive	O
on	O
duplicate	O
cosmid	O
filters	O
were	O
entered	O
into	O
the	O
reference	O
library	O
database	O
(	O
G	O
.	O
Z	O
,	O
unpublished	O
)	O
using	O
a	O
digitizing	O
tablet	O
.	O

For	O
the	O
X	O
chromosome	O
specific	O
YAC	O
library	O
(	O
A	O
.	O
P	O
.	O
M	O
.	O
and	O
H	O
.	O
L	O
.	O
,	O
unpublished	O
)	O
,	O
about	O
420	O
YAC	O
colonies	O
were	O
spotted	O
manually	O
onto	O
filters	O
from	O
96	O
well	O
microtiter	O
dishes	O
using	O
a	O
96	O
prong	O
device	O
.	O

After	O
growth	O
on	O
selective	O
media	O
for	O
3	O
days	O
,	O
YAC	O
filters	O
were	O
processed	O
for	O
hybridization	O
as	O
previously	O
described	O
(	O
10	O
)	O
.	O

RESULTS	O

A	O
panel	O
of	O
195	O
X	O
chromosome	O
irradiation	O
hybrids	O
was	O
constructed	O
(	O
50	O
,	O
000	O
rads	O
)	O
and	O
characterized	O
by	O
DNA	O
hybridization	O
using	O
27	O
X	O
chromosome	O
markers	O
and	O
flourescence	O
in	O
situ	O
hybridization	O
using	O
total	O
human	S-Species
DNA	O
as	O
probe	O
(	O
Benham	O
et	O
al	O
.	O
,	O
1989	O
;	O
P	O
.	O
N	O
.	O
G	O
.	O
,	O
unpublished	O
)	O
.	O

This	O
analysis	O
indicated	O
that	O
the	O
hybrids	O
contained	O
multiple	O
small	O
fragments	O
(	O
4	O
-	O
10	O
fragments	O
of	O
1000	O
-	O
5000	O
kb	O
each	O
)	O
with	O
a	O
preferential	O
retaining	O
of	O
centromere	O
sequences	O
(	O
90	O
%	O
)	O
.	O

From	O
this	O
panel	O
,	O
nine	O
irradiation	O
hybrids	O
were	O
chosen	O
that	O
contained	O
less	O
than	O
five	O
different	O
regions	O
by	O
DNA	O
probe	O
hybridizations	O
,	O
mostly	O
from	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
(	O
Fig	O
1	O
)	O
.	O

All	O
nine	O
hybrids	O
were	O
used	O
in	O
PCR	O
reactions	O
with	O
3	O
'	O
-	O
Alu	O
primer	O
3144	O
and	O
two	O
were	O
used	O
with	O
5	O
'	O
-	O
Alu	O

Figure	O
3	O
:	O
Hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
generated	O
with	O
Alu	O
primer	O
3144	O
from	O
irradiation	O
hybrid	O
54	O
to	O
a	O
filter	O
containing	O
420	O
YAC	O
clones	O
from	O
the	O
human	S-Species
X	O
chromosome	O
.	O

The	O
positive	O
YAC	O
was	O
also	O
identified	O
in	O
a	O
separate	O
hybridization	O
with	O
the	O
DMD	O
probe	O
P20	O
(	O
12	O
)	O
.	O

primer	O
2729	O
.	O

Example	O
hybridizations	O
to	O
a	O
human	S-Species
X	O
chromosome	O
cosmid	O
filter	O
in	O
Fig	O
2	O
shows	O
the	O
intensity	O
and	O
reliability	O
of	O
positive	O
clones	O
identified	O
on	O
duplicate	O
filters	O
with	O
Alu	O
-	O
PCR	O
products	O
from	O
the	O
same	O
irradiation	O
hybrid	O
(	O
48	O
)	O
and	O
the	O
independence	O
of	O
clones	O
identified	O
with	O
Alu	O
-	O
PCR	O
products	O
from	O
a	O
different	O
hybrid	O
(	O
54	O
)	O
.	O

Fig	O
3	O
shows	O
a	O
single	O
positive	O
YAC	O
clone	O
after	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
irradiation	O
hybrid	O
54	O
to	O
a	O
filter	O
containing	O
about	O
420	O
YAC	O
clones	O
specific	O
for	O
the	O
human	S-Species
X	O
chromosome	O
.	O

The	O
total	O
number	O
of	O
cosmids	O
identified	O
with	O
each	O
pool	O
of	O
AluPCR	O
products	O
for	O
each	O
hybrid	O
is	O
shown	O
in	O
Table	O
1	O
.	O

From	O
the	O
average	O
number	O
of	O
cosmids	O
identified	O
(	O
24	O
)	O
in	O
four	O
chromosome	O
equivalents	O
screened	O
and	O
the	O
estimated	O
average	O
DNA	O
content	O
in	O
each	O
hybrid	O
(	O
3000	O
-	O
15000	O
kb	O
)	O
,	O
the	O
Alu	O
-	O
PCR	O
products	O
generated	O
by	O
a	O
single	O
primer	O
were	O
calculated	O
on	O
average	O
to	O
be	O
300	O
-	O
1500	O
kb	O
apart	O
,	O
similar	O
to	O
published	O
estimates	O
for	O
this	O
method	O
(	O
1	O
,	O
2	O
)	O
.	O

Only	O
3	O
-	O
4	O
cosmids	O
were	O
identified	O
in	O
common	O
using	O
Alu	O
-	O
PCR	O
products	O
generated	O
with	O
either	O
3	O
'	O
or	O
5	O
'	O
Alu	O
primers	O
(	O
3144	O
or	O
2729	O
)	O
from	O
two	O
hybrids	O
(	O
38	O
and	O
45	O
)	O
.	O

This	O
shows	O
that	O
separate	O
products	O
were	O
amplified	O
with	O
the	O
two	O
Alu	O
primers	O
since	O
they	O
prime	O
synthesis	O
from	O
opposite	O
ends	O
of	O
the	O
Alu	O
consensus	O
sequence	O
and	O
Alu	O
sequences	O
are	O
oriented	O
in	O
the	O
genome	O
either	O
head	O
to	O
head	O
,	O

A	O

B	O

C	O

El	O

I0	O

Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O
3317	O

Table	O
1	O
.	O

Cosmids	O
identified	O
by	O
hybrids	O
and	O
unique	O
probes	O

hybrids	O
21	O
27	O
38	O
38	O
45	O
45	O
48	O
54	O
74	O
86	O
107	O
unique	O

primer	O
3144	O
3144	O
3144	O
2729	O
3144	O
2729	O
3144	O
3144	O
3144	O
33144	O
3144	O
probes	O

21	O
3144	O
59	O
1	O
27	O
3144	O
7	O
14	O
2	O
38	O
3144	O
3	O
1	O
28	O
2	O
38	O
2729	O
0	O
0	O
4	O
25	O
0	O
45	O
3144	O
13	O
2	O
2	O
0	O
32	O
3	O
45	O
2729	O
1	O
0	O
0	O
0	O
3	O
31	O
0	O
48	O
3144	O
10	O
2	O
4	O
0	O
2	O
0	O
28	O
3	O
54	O
3144	O
11	O
3	O
0	O
0	O
5	O
0	O
5	O
30	O
2	O
74	O
3144	O
5	O
0	O
0	O
0	O
4	O
0	O
5	O
12	O
20	O
3	O
86	O
3144	O
3	O
1	O
0	O
0	O
4	O
1	O
3	O
4	O
3	O
17	O
0	O
107	O
3144	O
1	O
0	O
1	O
1	O
0	O
0	O
3	O
0	O
0	O
0	O
13	O
0	O

tail	O
to	O
tail	O
or	O
head	O
to	O
tail	O
relative	O
to	O
each	O
other	O
.	O

Therefore	O
,	O
by	O
using	O
the	O
3	O
'	O
-	O
and	O
5	O
'	O
-	O
Alu	O
primers	O
in	O
separate	O
PCR	O
reactions	O
with	O
the	O
same	O
hybrid	O
DNA	O
,	O
the	O
total	O
number	O
of	O
products	O
and	O
cosmid	O
clones	O
identified	O
was	O
almost	O
doubled	O
.	O

Table	O
1	O
also	O
indicates	O
how	O
many	O
cosmids	O
were	O
identified	O
by	O
Alu	O
-	O
PCR	O
products	O
from	O
other	O
hybrids	O
,	O
and	O
16	O
cosmids	O
previously	O
identified	O
with	O
unique	O
DNA	O
probes	O
in	O
the	O
reference	O
library	O
database	O
.	O

As	O
can	O
be	O
seen	O
in	O
Fig	O
1	O
and	O
previous	O
irradiation	O
hybrid	O
analysis	O
,	O
there	O
is	O
a	O
preferential	O
retention	O
of	O
centromere	O
sequences	O
(	O
2	O
,	O
11	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
cosmids	O
identified	O
in	O
common	O
from	O
all	O
the	O
hybrids	O
positive	O
with	O
centromere	O
sequences	O
.	O

This	O
is	O
probably	O
due	O
to	O
a	O
paucity	O
of	O
Alu	O
repeats	O
in	O
the	O
correct	O
orientation	O
in	O
alphoid	O
centromere	O
sequences	O
and	O
thus	O
few	O
or	O
no	O
Alu	O
-	O
PCR	O
products	O
would	O
be	O
amplified	O
from	O
the	O
centromere	O
.	O

Cosmids	O
identified	O
in	O
common	O
by	O
several	O
irradiation	O
hybrids	O
(	O
Table	O
1	O
)	O
were	O
most	O
likely	O
from	O
regions	O
of	O
overlap	O
outside	O
the	O
centromere	O
area	O
as	O
shown	O
by	O
the	O
previous	O
DNA	O
probe	O
characterization	O
(	O
Fig	O
1	O
)	O
.	O

The	O
overlap	O
regions	O
between	O
hybrids	O
were	O
also	O
seen	O
by	O
16	O
cosmids	O
(	O
Table	O
1	O
,	O
Fig	O
1	O
)	O
that	O
were	O
hybridization	O
targets	O
of	O
unique	O
DNA	O
markers	O
in	O
the	O
reference	O
library	O
database	O
that	O
mapped	O
in	O
independent	O
experiments	O
to	O
the	O
overlap	O
region	O
.	O

At	O
least	O
for	O
several	O
cosmids	O
this	O
showed	O
that	O
the	O
Alu	O
-	O
PCR	O
products	O
identified	O
target	O
cosmids	O
that	O
were	O
definitely	O
from	O
the	O
expected	O
region	O
contained	O
in	O
the	O
hybrids	O
.	O

For	O
example	O
,	O
hybrids	O
21	O
and	O
54	O
were	O
both	O
shown	O
to	O
contain	O
part	O
of	O
the	O
Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
locus	O
(	O
Fig	O
1	O
;	O
P	O
.	O
N	O
.	O
G	O
.	O
,	O
unpublished	O
)	O
and	O
had	O
11	O
cosmids	O
in	O
common	O
,	O
including	O
one	O
identified	O
by	O
the	O
probe	O
P20	O
from	O
the	O
deletion	O
hotspot	O
region	O
of	O
the	O
DMD	O
gene	O
(	O
12	O
)	O
.	O

In	O
Fig	O
3	O
the	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
hybrid	O
54	O
identified	O
a	O
YAC	O
clone	O
which	O
was	O
also	O
positive	O
for	O
the	O
DMD	O
probe	O
P20	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
method	O
also	O
identified	O
fragments	O
in	O
the	O
hybrids	O
that	O
were	O
not	O
seen	O
in	O
the	O
initial	O
DNA	O
characterization	O
(	O
Fig	O
1	O
and	O
Table	O
1	O
)	O
.	O

Since	O
the	O
27	O
DNA	O
probes	O
were	O
not	O
close	O
enough	O
to	O
each	O
other	O
along	O
the	O
chromosome	O
to	O
detect	O
all	O
possible	O
hybrid	O
fragments	O
(	O
1000	O
-	O
5000	O
kb	O
)	O
,	O
many	O
regions	O
would	O
have	O
been	O
untested	O
.	O

For	O
example	O
,	O
AluPCR	O
products	O
from	O
hybrids	O
45	O
and	O
48	O
identified	O
several	O
cosmids	O
,	O
also	O
seen	O
by	O
the	O
cDNA	O
for	O
chronic	O
granulomatous	O
disease	O
gene	O
(	O
CYBB	O
,	O
13	O
)	O
in	O
Xp2	O
1	O
.	O
1	O
,	O
although	O
this	O
region	O
was	O
not	O
tested	O
in	O
the	O
original	O
hybrid	O
characterization	O
.	O

DISCUSSION	O

The	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
somatic	O
cell	O
hybrids	O
to	O
genomic	O
libraries	O
can	O
bypass	O
gel	O
purification	O
or	O
ligation	O
of	O
fragments	O
into	O
plasmid	O
vectors	O
and	O
individual	O
analysis	O
for	O
single	O
copy	O
sequences	O
.	O

Hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
as	O

a	O
pool	O
to	O
ordered	O
array	O
libraries	O
such	O
as	O
the	O
flow	O
-	O
sorted	O
X	O
chromosome	O
cosmid	O
library	O
(	O
9	O
)	O
,	O
allows	O
the	O
direct	O
comparison	O
of	O
overlapping	O
hybrids	O
to	O
pinpoint	O
cosmids	O
most	O
likely	O
to	O
be	O
from	O
the	O
region	O
of	O
interest	O
.	O

In	O
conjunction	O
with	O
the	O
reference	O
library	O
database	O
(	O
G	O
.	O
Z	O
,	O
unpublished	O
)	O
with	O
183	O
X	O
chromosome	O
probe	O
hybridization	O
entries	O
,	O
cosmids	O
identified	O
with	O
both	O
Alu	O
-	O
PCR	O
products	O
and	O
uniquely	O
mapped	O
X	O
probes	O
immediately	O
map	O
them	O
to	O
the	O
region	O
of	O
interest	O
and	O
proove	O
that	O
the	O
method	O
has	O
worked	O
.	O

Similar	O
hybridization	O
experiments	O
using	O
Alu	O
-	O
PCR	O
products	O
from	O
four	O
overlapping	O
irradiation	O
hybrids	O
identified	O
four	O
cosmids	O
in	O
common	O
that	O
mapped	O
to	O
the	O
region	O
of	O
overlap	O
by	O
independent	O
experiments	O
(	O
F	O
.	O
Muscatelli	O
,	O
A	O
.	O
P	O
.	O
M	O
.	O
,	O
P	O
.	O
N	O
.	O
G	O
.	O
,	O
H	O
.	O
L	O
.	O
and	O
M	O
.	O
Fontes	O
,	O
in	O
preparation	O
)	O
.	O

Since	O
only	O
27	O
probes	O
from	O
the	O
X	O
chromosome	O
were	O
used	O
to	O
initially	O
characterize	O
the	O
hybrids	O
and	O
the	O
length	O
of	O
individual	O
human	S-Species
fragments	O
in	O
the	O
irradiation	O
hybrids	O
is	O
about	O
1000	O
-	O
5000	O
kb	O
,	O
many	O
regions	O
could	O
have	O
been	O
undetected	O
in	O
the	O
original	O
analysis	O
.	O

The	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
to	O
the	O
cosmid	O
reference	O
library	O
detected	O
such	O
fragments	O
since	O
they	O
identified	O
cosmids	O
in	O
common	O
with	O
uniquely	O
mapped	O
probes	O
in	O
regions	O
not	O
tested	O
originally	O
(	O
Table	O
1	O
and	O
Fig	O
1	O
)	O
.	O

This	O
should	O
prove	O
to	O
be	O
a	O
sensitive	O
and	O
efficient	O
method	O
to	O
determine	O
content	O
and	O
overlap	O
of	O
irradiation	O
hybrids	O
in	O
conjunction	O
with	O
DNA	O
blot	O
hybridization	O
.	O

However	O
,	O
since	O
the	O
exact	O
length	O
of	O
the	O
human	S-Species
DNA	O
fragments	O
for	O
each	O
hybrid	O
and	O
the	O
spacing	O
of	O
Alu	O
-	O
PCR	O
products	O
along	O
the	O
chromosome	O
is	O
not	O
known	O
,	O
it	O
is	O
difficult	O
to	O
directly	O
correlate	O
the	O
number	O
of	O
target	O
cosmids	O
to	O
the	O
DNA	O
content	O
of	O
the	O
hybrids	O
.	O

The	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
irradiation	O
or	O
somatic	O
cell	O
hybrids	O
to	O
total	O
genomic	O
YAC	O
libraries	O
will	O
be	O
especially	O
useful	O
to	O
construct	O
long	O
range	O
YAC	O
contigs	O
from	O
specific	O
subregions	O
of	O
chromosomes	O
.	O

The	O
dissection	O
of	O
a	O
total	O
genomic	O
YAC	O
library	O
by	O
this	O
method	O
may	O
be	O
more	O
efficient	O
than	O
generating	O
chromosome	O
specific	O
YAC	O
libraries	O
from	O
somatic	O
cell	O
hybrids	O
(	O
usually	O
a	O
haploid	O
human	S-Species
chromosome	O
on	O
a	O
diploid	O
or	O
greater	O
rodent	O
background	O
)	O
or	O
flow	O
-	O
sorted	O
chromosomes	O
,	O
because	O
of	O
the	O
low	O
transformation	O
efficiency	O
of	O
yeast	S-Species
.	O

ACKNOWLEDGEMENTS	O

We	O
would	O
like	O
to	O
thank	O
Gert	O
-	O
Jan	O
Van	O
Ommen	O
for	O
the	O
probe	O
P20	O
and	O
Stuart	O
Orkin	O
for	O
the	O
CYBB	O
cDNA	O
probe	O
.	O

A	O
.	O
P	O
.	O
M	O
is	O
supported	O
in	O
part	O
by	O
a	O
research	O
fellowship	O
from	O
the	O
Muscular	O
Dystrophy	O
Association	O
of	O
America	O
.	O

V	O
.	O
M	O
.	O
S	O
.	O
L	O
.	O

is	O
supported	O
in	O
part	O
by	O
the	O
Medical	O
Research	O
Grant	O
of	O
the	O
University	O
of	O
Hong	O
Kong	O
.	O

Reference	O
library	O
filters	O
and	O
cosmids	O
identified	O
by	O
Alu	O
-	O
PCR	O
products	O
can	O
be	O
requested	O
from	O
the	O
Reference	O
Library	O
Database	O
,	O
ICRF	O
,	O
44	O
Lincoln	O
'	O
s	O
Inn	O
Fields	O
,	O
London	O
WC2A	O
3PX	O
,	O
U	O
.	O
K	O
.	O

3318	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No	O
.	O
12	O

REFERENCES	O

1	O
.	O

Nelson	O
,	O
D	O
.	O
L	O
.	O
,	O
Ledbetter	O
,	O
S	O
.	O
A	O
.	O
,	O
Corbo	O
,	O
L	O
.	O
,	O
Victoria	O
,	O
M	O
.	O
F	O
.	O
,	O
Ramirez	O
-	O
Solis	O
,	O

R	O
.	O
,	O
Webster	O
,	O
T	O
.	O
D	O
.	O
,	O
Ledbetter	O
,	O
D	O
.	O
H	O
.	O
,	O
and	O
Caskey	O
,	O
C	O
.	O
T	O
.	O

(	O
1989	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
86	O
:	O
6686	O
-	O
6690	O
.	O

2	O
.	O

Ledbetter	O
,	O
S	O
.	O
A	O
.	O
,	O
Nelson	O
,	O
D	O
.	O
L	O
.	O
,	O
Warren	O
,	O
S	O
.	O
T	O
.	O
,	O
and	O
Ledbetter	O
,	O
D	O
.	O
H	O
.	O

(	O
1990	O
)	O

Genomics	O
,	O
6	O
:	O
475	O
-	O
481	O
.	O

3	O
.	O

Cotter	O
,	O
F	O
.	O
E	O
.	O
,	O
Hampton	O
,	O
G	O
.	O
M	O
.	O
,	O
Nasipuri	O
,	O
S	O
.	O
,	O
Bodmer	O
,	O
W	O
.	O
F	O
.	O
,	O
and	O
Young	O

B	O
.	O
D	O
.	O

(	O
1990	O
)	O
Genomics	O
,	O
7	O
:	O
257	O
-	O
263	O
.	O

4	O
.	O

Burke	O
,	O
D	O
.	O
T	O
.	O
,	O
Carle	O
,	O
G	O
.	O
F	O
.	O
,	O
and	O
Olson	O
,	O
M	O
.	O
V	O
.	O

(	O
1987	O
)	O
Science	O
,	O
236	O
:	O
806	O
-	O
812	O
.	O

5	O
.	O

Benham	O
,	O
F	O
.	O
,	O
Hart	O
,	O
K	O
.	O
,	O
Crolla	O
,	O
J	O
.	O
,	O
Bobrow	O
,	O
M	O
.	O
,	O
Francavilla	O
,	O
M	O
.	O
,	O
and	O

Goodfellow	O
,	O
P	O
.	O
N	O
.	O

(	O
1989	O
)	O
Genomics	O
,	O
4	O
:	O
509	O
-	O
517	O
.	O

6	O
.	O

Feinberg	O
,	O
A	O
.	O
P	O
.	O
,	O
and	O
Vogelstein	O
,	O
B	O
.	O

(	O
1984	O
)	O
Anal	O
.	O

Biochem	O
.	O
,	O
137	O
:	O
266	O
-	O
267	O
.	O

7	O
.	O

Hochgeschwender	O
,	O
U	O
.	O
,	O
Sutciffe	O
,	O
J	O
.	O
G	O
.	O
,	O
and	O
Brennan	O
,	O
M	O
.	O
B	O
.	O

(	O
1989	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
86	O
:	O
8482	O
-	O
8486	O
.	O

8	O
.	O

Lehrach	O
,	O
H	O
.	O
,	O
Drmanac	O
,	O
R	O
.	O
,	O
Hoheisel	O
,	O
J	O
.	O
,	O
Larin	O
,	O
Z	O
.	O
,	O
Lennon	O
,	O
G	O
.	O
,	O
Monaco	O
,	O

A	O
.	O
P	O
.	O
,	O
Nizetic	O
,	O
D	O
.	O
,	O
Zehetner	O
,	O
G	O
.	O
,	O
and	O
Poustka	O
,	O
A	O
.	O

(	O
1990	O
)	O
In	O
Davies	O
,	O
K	O
.	O
E	O
.	O

&	O
Tilghman	O
,	O
S	O
.	O
M	O
.	O

(	O
eds	O
.	O
)	O
,	O
Genome	O
Analysis	O
Volume	O
1	O
:	O
Genetic	O
and	O
Physical	O
Mapping	O
.	O

Cold	O
Spring	O
Harbor	O
Laboratory	O
Press	O
,	O
Cold	O
Spring	O
Harbor	O
,	O
pp	O
.	O

39	O
-	O
81	O
.	O

9	O
.	O

Nizetic	O
,	O
D	O
.	O
,	O
Zehetner	O
,	O
G	O
.	O
,	O
Monaco	O
,	O
A	O
.	O
P	O
.	O
,	O
Gellen	O
,	O
L	O
.	O
,	O
Young	O
,	O
B	O
.	O
D	O
.	O
,	O
and	O

Lehrach	O
,	O
H	O
.	O

(	O
1991	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
88	O
:	O
3233	O
-	O
3237	O
.	O

10	O
.	O

Larin	O
,	O
Z	O
.	O
and	O
Lehrach	O
,	O
H	O
.	O

(	O
1990	O
)	O
Genet	O
.	O

Res	O
.	O

Camb	O
.	O
,	O
56	O
:	O
203	O
-	O
208	O
.	O

11	O
.	O

Cox	O
,	O
D	O
,	O
R	O
.	O
,	O
Pritchard	O
,	O
C	O
.	O
A	O
.	O
,	O
Uglum	O
,	O
E	O
.	O
,	O
Casher	O
,	O
D	O
.	O
,	O
Koborl	O
.	O

J	O
.	O
and	O
Myers	O
,	O

R	O
.	O
M	O
.	O

(	O
1989	O
)	O
Genomics	O
,	O
4	O
:	O
397	O
-	O
407	O
.	O

12	O
.	O

Wapenaar	O
,	O
M	O
.	O
C	O
.	O
,	O
Kievits	O
,	O
T	O
.	O
,	O
Hart	O
,	O
K	O
.	O
A	O
.	O
,	O
Abbs	O
S	O
.	O
,	O
Blonden	O
,	O
L	O
.	O
A	O
.	O
J	O
.	O
,	O

denDunnen	O
,	O
J	O
.	O
T	O
.	O
,	O
Grootscholten	O
,	O
P	O
.	O
M	O
.	O
,	O
Bakker	O
,	O
E	O
.	O
,	O
Verellen	O
-	O
Dumoulin	O
,	O
C	O
.	O
,	O
Bobrow	O
,	O
M	O
.	O
,	O
vanOmmen	O
,	O
G	O
.	O
J	O
.	O
B	O
.	O
,	O
and	O
Pearson	O
,	O
P	O
.	O
L	O
.	O

(	O
1988	O
)	O
Genomics	O
,	O
2	O
:	O
101	O
-	O
108	O
.	O

13	O
.	O

Royer	O
-	O
Pokora	O
,	O
B	O
.	O
,	O
Kunkel	O
,	O
L	O
.	O
M	O
.	O
,	O
Monaco	O
,	O
A	O
.	O
P	O
.	O
,	O
Goff	O
,	O
S	O
.	O
C	O
.	O
,	O
Newburger	O
,	O

P	O
.	O
E	O
.	O
,	O
Baehner	O
,	O
R	O
.	O
L	O
.	O
,	O
Cole	O
F	O
.	O
S	O
.	O
,	O
Curnette	O
J	O
.	O
T	O
.	O
,	O
and	O
Orkin	O
,	O
S	O
.	O
A	O
.	O

(	O
1986	O
)	O
Nature	O
,	O
322	O
:	O
32	O
-	O
38	O
.	O

14	O
.	O

Davies	O
,	O
K	O
.	O
E	O
.	O
,	O
Mandel	O
,	O
J	O
.	O
L	O
.	O
,	O
Monaco	O
,	O
A	O
.	O
P	O
.	O
,	O
Nussbaum	O
,	O
R	O
.	O
L	O
.	O
and	O
Willard	O
,	O

H	O
.	O
F	O
.	O

(	O
1990	O
)	O
Cytogenet	O
.	O

Cell	O
Genet	O
.	O

55	O
:	O
254	O
-	O
313	O
.	O

The	O
Caenorhabditis	B-Species
elegans	E-Species
genome	O
contains	O
monomorphic	O
minisatellites	O
and	O
simple	O
sequences	O
.	O

Abstract	O

Many	O
species	O
have	O
been	O
shown	O
to	O
contain	O
tandemly	O
repeated	O
short	O
sequence	O
DNA	O
known	O
as	O
minisatellites	O
and	O
simple	O
sequence	O
motifs	O
.	O

Due	O
to	O
allelic	O
variation	O
in	O
the	O
copy	O
number	O
of	O
the	O
repeat	O
unit	O
these	O
loci	O
are	O
usually	O
highly	O
polymorphic	O
.	O

Here	O
we	O
demonstrate	O
the	O
presence	O
of	O
sequences	O
in	O
the	O
genome	O
of	O
the	O
nematode	O
Caenorhabditis	B-Species
elegans	E-Species
which	O
are	O
homologous	O
to	O
two	O
sets	O
of	O
short	O
sequence	O
DNA	O
.	O

However	O
,	O
when	O
two	O
independent	O
strains	O
were	O
compared	O
no	O
polymorphism	O
for	O
these	O
sequences	O
could	O
be	O
detected	O
.	O
Images	O

Volume	O
17	O
Number	O
23	O
1989	O
Nucleic	O
Acids	O
Research	O

The	O
Caenorhabds	B-Species
elegans	E-Species
genome	O
contains	O
monomorphic	O
minisatellites	O
and	O
simple	O
sequences	O
Andrd	O
G	O
.	O
Uitterlinden	O
,	O
P	O
.	O
Eline	O
Slagboom	O
,	O
Thomas	O
E	O
.	O
Johnsonl	O
and	O
Jan	O
Vijg	O

Department	O
of	O
Molecular	O
Biology	O
,	O
TNO	O
Institute	O
for	O
Experimental	O
Gerontology	O
,	O
PO	O
Box	O
5815	O
,	O
2280	O
HV	O
Rijswijk	O
,	O
The	O
Netherlands	O
and	O
lInstitute	O
for	O
Behavioral	O
Genetics	O
,	O
University	O
of	O
Colorado	O
,	O
Boulder	O
,	O
CO	O
80309	O
,	O
USA	O

Received	O
October	O
27	O
,	O
1989	O
;	O
Accepted	O
November	O
3	O
,	O
1989	O

ABSTRACT	O

Many	O
species	O
have	O
been	O
shown	O
to	O
contain	O
tandemly	O
repeated	O
short	O
sequence	O
DNA	O
kinown	O
as	O
minisatellites	O
and	O
simple	O
sequence	O
motifs	O
.	O

Due	O
to	O
allelic	O
variation	O
in	O
the	O
copy	O
number	O
of	O
the	O
repeat	O
unit	O
these	O
loci	O
are	O
usually	O
highly	O
polymorphic	O
.	O

Here	O
we	O
demonstrate	O
the	O
presence	O
of	O
sequences	O
in	O
the	O
genome	O
of	O
the	O
nematode	O
Caenorhabditis	B-Species
elegans	E-Species
which	O
are	O
homologous	O
to	O
two	O
sets	O
of	O
short	O
sequence	O
DNA	O
.	O

However	O
,	O
when	O
two	O
independent	O
strains	O
were	O
compared	O
no	O
polymorphism	O
for	O
these	O
sequences	O
could	O
be	O
detected	O
.	O

INTRODUCTION	O

The	O
genome	O
of	O
many	O
species	O
,	O
including	O
lower	O
organisms	O
,	O
contain	O
minisatellite	O
sequences	O
and	O
so	O
-	O
called	O
simple	O
sequence	O
motifs	O
(	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

Due	O
to	O
extensive	O
variation	O
in	O
the	O
number	O
of	O
repeat	O
units	O
,	O
many	O
of	O
these	O
loci	O
have	O
been	O
shown	O
useful	O
as	O
polymorphic	O
markers	O
,	O
e	O
.	O
g	O
.	O
for	O
genetic	O
linkage	O
studies	O
and	O
identification	O
purposes	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
genome	O
of	O
the	O
nematode	O
Caenorhabditis	B-Species
elegans	E-Species
contains	O
sequences	O
that	O
are	O
homologous	O
to	O
the	O
minisatellite	O
core	O
sequence	O
33	O
.	O
6	O
(	O
1	O
)	O
and	O
to	O
the	O
simple	O
sequence	O
motif	O
(	O
AGC	O
)	O
n	O
.	O

Surprisingly	O
,	O
these	O
sequences	O
did	O
not	O
display	O
polymorphism	O
when	O
two	O
independent	O
C	B-Species
.	I-Species
elegans	E-Species
strains	O
,	O
Bristol	O
and	O
Bergerac	O
,	O
were	O
compared	O
.	O

MATERIALS	O
AND	O
METHODS	O
Genomic	O
DNA	O
from	O
nematodes	O

Genomic	O
DNA	O
was	O
isolated	O
according	O
to	O
standard	O
procedures	O
from	O
the	O
two	O
strains	O
Bergerac	O
(	O
BO	O
)	O
and	O
Bristol	O
(	O
strain	O
N2	O
)	O
.	O

These	O
strains	O
are	O
derived	O
from	O
two	O
different	O
individual	O
worms	O
isolated	O
in	O
France	O
and	O
England	O
,	O
respectively	O
.	O

Southern	O
blotting	O

Genomic	O
DNA	O
digests	O
(	O
5	O
Ag	O
)	O
were	O
separated	O
in	O
a	O
1	O
%	O
agarose	O
gel	O
in	O
1	O
x	O
TAE	O
(	O
40	O
mM	O
Tris	O
.	O
HCl	O
,	O
pH	O
7	O
.	O
4	O
/	O
20	O
mM	O
sodium	O
acetate	O
/	O
I	O
mM	O
NaEDTA	O
)	O
by	O
electrophoresis	O
at	O
75	O
V	O
for	O
16	O
h	O
.	O

Separation	O
patterns	O
were	O
transferred	O
to	O
Zetaprobe	O
membrane	O
(	O
BIORAD	O
)	O
in	O
0	O
.	O
4	O
N	O
NaOH	O
,	O
0	O
.	O
6	O
M	O
NaCl	O
in	O
a	O
vacu	O
-	O
blot	O
apparatus	O
(	O
LKB	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
minisatellite	O
and	O
simple	O
sequence	O
probes	O
used	O
were	O
prepared	O
essentially	O
as	O
described	O
(	O
5	O
)	O
.	O

The	O
Tcl	O
probe	O
is	O
a	O
plasmid	O
containing	O
an	O
insert	O
of	O
the	O
transposable	O
element	O
Tcl	O
(	O
4	O
)	O
.	O

All	O
probes	O
were	O
labelled	O
by	O
random	O
-	O
priming	O
.	O

Hybridization	O
was	O
performed	O
for	O
12	O
h	O
in	O
7	O
%	O
SDS	O
,	O
0	O
.	O
5	O
M	O
phosphate	O
buffer	O
,	O
1	O
mM	O
Na2EDTA	O
at	O
650C	O
.	O

Blots	O
were	O
washed	O
twice	O
in	O
2	O
.	O
5	O
x	O
SSC	O
at	O
650C	O
and	O
exposed	O
to	O
Kodak	O
XAR	O
-	O
5	O
film	O
with	O
intensifying	O
screens	O
.	O

Exposure	O
times	O
are	O
indicated	O
in	O
Fig	O
.	O

1	O
.	O

(	O
IRL	O
Press	O

Nucleic	O
Acids	O
Research	O

Volume	O
17	O
Number	O
23	O
1989	O

9527	O

Nucleic	O
Acids	O
Research	O

C	B-Species
.	I-Species
elegans	E-Species

N	O
0	O
$	O
8	O

_	O
_	O

:	O
,	O
s	O
,	O
.	O
.	O
e	O
:	O
*	O
.	O

,	O
~	O
:	O
:	O
:	O
:	O
:	O

.	O
4i	O

.	O
t	O
_	O
:	O
-	O
:	O
:	O
?	O
J	O
?	O
.	O
:	O

i	O
-	O

.	O
a	O

E	O
?	O
:	O
<	O
.	O

:	O
:	O
y	O
:	O

*	O
01	O

4	O
?	O
j	O
*	O

.	O
-	O
I	O

kb	O
-	O
27	O

-	O
9A	O
-	O

:	O
.	O
:	O
:	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O

Mi	O
.	O
.	O
.	O
.	O

-	O
4v3	O

IC	O
.	O
3	O

If	O
.	O
0r	O

MW	O

!	O
5	O
c6	O

I	O

"	O
R	O
1d	O
~	O
!	O

;	O
,	O

Figure	O
1	O
.	O

Southern	O
hybridization	O
analysis	O
of	O
Hae	O
III	O
,	O
Rsa	O
I	O
and	O
Eco	O
RI	O
digested	O
genomic	O
DNA	O
isolated	O
from	O
the	O
two	O
C	B-Species
.	I-Species
elegans	E-Species
strains	O
Bristol	O
(	O
N	O
)	O
and	O
Bergerac	O
(	O
B	O
)	O
.	O

The	O
probes	O
used	O
and	O
the	O
exposure	O
times	O
of	O
the	O
autoradiograph	O
are	O
indicated	O
below	O
the	O
figure	O
.	O

kb	O
=	O
kilo	O
basepairs	O
.	O

9528	O

*	O
:	O
.	O
.	O
?	O
.	O
;	O
.	O

.	O
*	O
.	O

i	O
.	O
.	O
.	O

:	O
"	O
.	O

ANN	O
&	O

'	O
ROW	O
:	O
.	O
lwmwww	O
.	O

.	O
Ammkw	O
.	O
l	O

4w	O
,	O

9	O

_	O
i	O
ob	O

Ill	O
a	O

Nucleic	O
Acids	O
Research	O

RESULTS	O

In	O
Figure	O
1	O
the	O
hybridization	O
patterns	O
are	O
shown	O
of	O
C	B-Species
.	I-Species
elegans	E-Species
genomic	O
DNA	O
digested	O
with	O
Hae	O
II	O
,	O
Rsa	O
I	O
and	O
Eco	O
RI	O
,	O
and	O
subsequently	O
hybridized	O
to	O
minisatellite	O
core	O
probe	O
33	O
.	O
6	O
,	O
the	O
simple	O
sequence	O
probe	O
(	O
AGC	O
)	O
n	O
and	O
Tcl	O
.	O

The	O
latter	O
probe	O
contains	O
a	O
member	O
of	O
the	O
Tcl	O
family	O
of	O
transposable	O
elements	O
which	O
is	O
present	O
in	O
different	O
copy	O
numbers	O
in	O
the	O
two	O
different	O
strains	O
(	O
4	O
)	O
.	O

The	O
hybridization	O
patterns	O
of	O
probes	O
33	O
.	O
6	O
and	O
(	O
AGC	O
)	O
n	O
obtained	O
after	O
Hae	O
Im	O
and	O
Rsa	O
I	O
digestion	O
and	O
the	O
differences	O
in	O
intensities	O
of	O
the	O
hybridizing	O
bands	O
is	O
reminiscent	O
of	O
DNA	O
-	O
fingerprint	O
patterns	O
obtained	O
with	O
these	O
probes	O
in	O
other	O
species	O
(	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

However	O
,	O
identical	O
hybridization	O
patterns	O
for	O
the	O
two	O
strains	O
with	O
the	O
three	O
enzymes	O
tested	O
indicated	O
that	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
these	O
sequences	O
are	O
monomorphic	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Based	O
on	O
the	O
number	O
of	O
hybridizing	O
bands	O
we	O
estimate	O
the	O
C	B-Species
.	I-Species
elegans	E-Species
genome	O
to	O
contain	O
about	O
30	O
33	O
.	O
6	O
homologous	O
loci	O
and	O
about	O
20	O
(	O
AGC	O
)	O
n	O
homologous	O
loci	O
.	O

Rehybridization	O
of	O
the	O
same	O
blot	O
with	O
a	O
Tcl	O
probe	O
revealed	O
extensive	O
RFLPs	O
due	O
to	O
the	O
different	O
copy	O
number	O
of	O
the	O
transposon	O
in	O
the	O
two	O
strains	O
,	O
a	O
phenomenon	O
which	O
has	O
been	O
described	O
previously	O
by	O
others	O
(	O
4	O
)	O
.	O

DISCUSSION	O

The	O
findings	O
presented	O
in	O
this	O
paper	O
indicate	O
that	O
polymorphism	O
of	O
minisatellite	O
sequences	O
and	O
simple	O
sequence	O
motifs	O
,	O
is	O
not	O
a	O
general	O
phenomenon	O
in	O
animal	O
species	O
.	O

So	O
far	O
,	O
only	O
some	O
species	O
of	O
whales	O
have	O
displayed	O
similar	O
high	O
levels	O
of	O
monomorphism	O
(	O
6	O
)	O
.	O

In	O
other	O
species	O
thus	O
far	O
tested	O
both	O
minisatellites	O
and	O
simple	O
sequences	O
display	O
high	O
to	O
very	O
high	O
levels	O
of	O
polymorphism	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
at	O
least	O
in	O
humans	S-Species
,	O
a	O
substantial	O
part	O
of	O
the	O
minisatellites	O
detected	O
by	O
core	O
probes	O
also	O
displays	O
high	O
levels	O
of	O
monomorphism	O
as	O
analysed	O
by	O
cloning	O
(	O
1	O
)	O
or	O
by	O
two	O
-	O
dimensional	O
DNA	O
fingerprinting	O
(	O
5	O
)	O
.	O

The	O
fact	O
that	O
nematodes	O
are	O
hermaphrodites	O
,	O
and	O
thus	O
inbred	O
,	O
might	O
be	O
a	O
contributing	O
factor	O
to	O
the	O
observed	O
lack	O
of	O
polymorphism	O
.	O

However	O
,	O
the	O
high	O
levels	O
of	O
polymorphism	O
detected	O
by	O
the	O
Tcl	O
probe	O
do	O
not	O
indicate	O
a	O
general	O
absence	O
of	O
events	O
causing	O
genetic	O
variation	O
.	O

Indeed	O
,	O
Eide	O
and	O
Anderson	O
(	O
7	O
)	O
showed	O
that	O
tandemly	O
repeated	O
duplications	O
in	O
the	O
unc	O
-	O
54	O
gene	O
of	O
C	B-Species
.	I-Species
elegans	E-Species
revert	O
at	O
high	O
frequencies	O
.	O

Since	O
in	O
all	O
cases	O
the	O
revertants	O
had	O
the	O
normal	O
genomic	O
configuration	O
this	O
suggests	O
that	O
unequal	O
crossing	O
-	O
over	O
does	O
occur	O
in	O
the	O
nematode	O
.	O

A	O
more	O
likely	O
explanation	O
for	O
the	O
monomorphic	O
nature	O
of	O
the	O
sequences	O
detected	O
with	O
33	O
.	O
6	O
and	O
(	O
AGC	O
)	O
n	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
is	O
selection	O
against	O
sequence	O
variants	O
at	O
these	O
loci	O
.	O

This	O
might	O
be	O
the	O
result	O
of	O
the	O
presence	O
of	O
a	O
particular	O
subset	O
of	O
minisatellites	O
and	O
/	O
or	O
simple	O
sequences	O
at	O
sites	O
in	O
the	O
genome	O
of	O
this	O
organism	O
,	O
e	O
.	O
g	O
.	O
in	O
coding	O
sequences	O
,	O
in	O
which	O
variation	O
in	O
copy	O
number	O
of	O
repeat	O
units	O
cannot	O
be	O
tolerated	O
.	O

An	O
example	O
of	O
such	O
a	O
coding	O
sequence	O
could	O
be	O
the	O
High	O
Mobility	O
Group	O
proteins	O
which	O
usually	O
have	O
stretches	O
of	O
identical	O
(	O
acidic	O
)	O
amino	O
acids	O
(	O
2	O
,	O
8	O
)	O
.	O

An	O
interesting	O
observation	O
in	O
this	O
respect	O
is	O
the	O
demonstration	O
of	O
the	O
absence	O
of	O
any	O
protein	O
polymorphisms	O
in	O
electrophoretic	O
comparisons	O
for	O
24	O
different	O
enzymes	O
between	O
the	O
Bristol	O
and	O
Bergerac	O
strains	O
(	O
9	O
)	O
.	O

An	O
important	O
step	O
in	O
understanding	O
this	O
phenomenon	O
will	O
therefore	O
be	O
the	O
isolation	O
and	O
analysis	O
of	O
individual	O
homologous	O
minisatellite	O
and	O
simple	O
sequence	O
loci	O
from	O
a	O
genomic	O
library	O
of	O
C	B-Species
.	I-Species
elegans	E-Species
.	O

REFERENCES	O

1	O
.	O

Jeffreys	O
,	O
A	O
.	O
J	O
.	O
,	O
Wilson	O
,	O
V	O
.	O
,	O
and	O
Thein	O
,	O
S	O
.	O
L	O
.	O

(	O
1985	O
)	O
Nature	O
314	O
,	O
67	O
-	O
73	O
.	O

2	O
.	O

Tautz	O
,	O
D	O
.	O
,	O
Trick	O
M	O
.	O
,	O
and	O
Dover	O
,	O
G	O
.	O
A	O
.	O

(	O
1986	O
)	O
Nature	O
322	O
,	O
652	O
-	O
656	O
.	O

3	O
.	O

Rogstad	O
,	O
S	O
.	O
H	O
.	O
,	O
Herwaldt	O
,	O
B	O
.	O
L	O
.	O
,	O
Schlesinger	O
,	O
P	O
.	O
H	O
.	O
,	O
and	O
Krogstad	O
,	O
D	O
.	O
J	O
.	O

(	O
1989	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

17	O
,	O
9	O
,	O
3610	O
.	O

4	O
.	O

Emmons	O
,	O
S	O
.	O
W	O
.	O
,	O
Yesner	O
,	O
L	O
.	O
,	O
Ruan	O
,	O
K	O
.	O
and	O
Katzenberg	O
,	O
D	O
.	O

(	O
1983	O
)	O
Cell	O
32	O
,	O
55	O
-	O
65	O
.	O

9529	O

Nucleic	O
Acids	O
Research	O

5	O
.	O

Uitterlinden	O
,	O
A	O
.	O
G	O
.	O
,	O
Slagboom	O
,	O
P	O
.	O
E	O
.	O
,	O
Knook	O
,	O
D	O
.	O
L	O
.	O
,	O
and	O
Vijg	O
,	O
J	O
.	O

(	O
1989	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

USA	O
86	O
,	O
2742	O
-	O
2746	O
.	O

6	O
.	O

Rus	O
Hoelzel	O
,	O
A	O
.	O
,	O
and	O
Amos	O
,	O
W	O
.	O

(	O
1988	O
)	O
Nature	O
333	O
,	O
305	O
.	O

7	O
.	O

Eide	O
,	O
D	O
.	O
,	O
and	O
Anderson	O
,	O
P	O
.	O

(	O
1985	O
)	O
Genetics	O
109	O
,	O
67	O
-	O
79	O
.	O

8	O
.	O

Pentecost	O
,	O
B	O
.	O
T	O
.	O
,	O
Wright	O
,	O
J	O
.	O
M	O
.	O
,	O
and	O
Dixon	O
,	O
G	O
.	O
H	O
.	O

(	O
1985	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

13	O
,	O
4871	O
-	O
4888	O
.	O

9	O
.	O

Butler	O
et	O
al	O
.	O

(	O
1981	O
)	O
J	O
.	O

Molec	O
.	O

Evolution	O
18	O
,	O
18	O
-	O
23	O
.	O

9530	O

This	O
article	O
,	O
submitted	O
on	O
disc	O
,	O
has	O
been	O
automatically	O

converted	O
into	O
this	O
typeset	O
format	O
by	O
the	O
publisher	O
.	O

How	O
can	O
Health	O
Behavior	O
Theory	O
be	O
made	O
more	O
useful	O
for	O
intervention	O
research	O
?	O

Abstract	O

Background	O

The	O
present	O
paper	O
expresses	O
the	O
author	O
'	O
s	O
views	O
about	O
the	O
practical	O
utility	O
of	O
Health	O
Behavior	O
Theory	O
for	O
health	O
behavior	O
intervention	O
research	O
.	O

The	O
views	O
are	O
skeptical	O
and	O
perhaps	O
even	O
a	O
bit	O
exaggerated	O
.	O

They	O
are	O
,	O
however	O
,	O
also	O
based	O
on	O
20	O
-	O
plus	O
years	O
of	O
in	O
-	O
the	O
-	O
trenches	O
research	O
focused	O
on	O
improving	O
health	O
behavior	O
practice	O
through	O
research	O
.	O

Discussion	O

The	O
author	O
'	O
s	O
research	O
has	O
been	O
theoretically	O
driven	O
and	O
has	O
involved	O
measurement	O
of	O
varying	O
variables	O
considered	O
to	O
be	O
important	O
theoretical	O
mediators	O
and	O
moderators	O
of	O
health	O
behavior	O
.	O

Regretfully	O
,	O
much	O
of	O
this	O
work	O
has	O
found	O
these	O
variables	O
wanting	O
in	O
basic	O
scientific	O
merit	O
.	O

Health	O
Behavior	O
Theory	O
as	O
we	O
have	O
known	O
it	O
over	O
the	O
last	O
25	O
years	O
or	O
so	O
has	O
been	O
dominated	O
by	O
conceptualizations	O
of	O
behavior	O
change	O
processes	O
that	O
highlight	O
cognitive	O
decision	O
-	O
making	O
.	O

Although	O
much	O
of	O
health	O
behavior	O
practice	O
targets	O
what	O
people	S-Species
do	O
rather	O
than	O
what	O
they	O
think	O
,	O
the	O
logic	O
of	O
focusing	O
on	O
thoughts	O
is	O
that	O
what	O
people	S-Species
think	O
about	O
is	O
the	O
key	O
to	O
what	O
they	O
will	O
do	O
in	O
the	O
future	O
,	O
and	O
that	O
interventions	O
that	O
can	O
measure	O
and	O
harness	O
those	O
processes	O
will	O
succeed	O
to	O
a	O
greater	O
extent	O
than	O
those	O
that	O
do	O
not	O
.	O

Unfortunately	O
,	O
in	O
the	O
author	O
'	O
s	O
experience	O
,	O
the	O
premise	O
of	O
cognitive	O
theories	O
has	O
fallen	O
short	O
empirically	O
in	O
a	O
number	O
of	O
ways	O
.	O

The	O
cognitive	O
schemata	O
favored	O
by	O
most	O
health	O
behavior	O
theories	O
are	O
difficult	O
to	O
measure	O
,	O
they	O
do	O
not	O
predict	O
behavioral	O
outcomes	O
very	O
well	O
,	O
there	O
is	O
little	O
evidence	O
that	O
they	O
cause	O
behavior	O
,	O
and	O
they	O
are	O
hard	O
to	O
change	O
directly	O
.	O

Summary	O

It	O
is	O
suggested	O
that	O
health	O
behavior	O
researchers	O
reconsider	O
their	O
use	O
of	O
these	O
theories	O
in	O
favor	O
of	O
models	O
whose	O
variables	O
are	O
more	O
accessible	O
to	O
observation	O
and	O
experimental	O
manipulation	O
and	O
that	O
most	O
importantly	O
have	O
strong	O
empirical	O
support	O
.	O

Background	O

The	O
author	O
has	O
been	O
conducting	O
research	O
on	O
behavioral	O
treatment	O
of	O
obesity	O
for	O
about	O
25	O
years	O
.	O

During	O
that	O
time	O
,	O
the	O
dominant	O
conceptual	O
models	O
guiding	O
intervention	O
development	O
have	O
been	O
cognitive	O
behavior	O
models	O
that	O
have	O
their	O
origin	O
in	O
psychological	O
theory	O
.	O

Those	O
most	O
often	O
cited	O
include	O
the	O
Health	O
Belief	O
Model	O
[	O
1	O
]	O
,	O
Protection	O
Motivation	O
Theory	O
[	O
2	O
]	O
,	O
Subjective	O
Expected	O
Utility	O
Theory	O
[	O
3	O
]	O
,	O
the	O
Theory	O
of	O
Reasoned	O
Action	O
[	O
4	O
]	O
,	O
Social	O
Cognitive	O
Theory	O
[	O
5	O
]	O
,	O
and	O
the	O
Transtheoretical	O
Model	O
[	O
6	O
]	O
.	O

All	O
of	O
these	O
theories	O
are	O
concerned	O
with	O
how	O
people	S-Species
make	O
behavioral	O
choices	O
and	O
the	O
general	O
idea	O
is	O
that	O
people	S-Species
decide	O
what	O
to	O
do	O
based	O
on	O
the	O
extent	O
to	O
which	O
they	O
expect	O
that	O
their	O
choices	O
will	O
produce	O
results	O
that	O
they	O
value	O
.	O

Much	O
of	O
the	O
content	O
of	O
the	O
theories	O
is	O
concerned	O
with	O
factors	O
that	O
may	O
affect	O
value	O
/	O
expectancy	O
calculations	O
.	O

As	O
summarized	O
by	O
Weinstein	O
in	O
a	O
comparative	O
review	O
of	O
four	O
social	O
psychological	O
theories	O
[	O
7	O
]	O
,	O
variables	O
thought	O
to	O
influence	O
value	O
/	O
expectancy	O
judgments	O
include	O
such	O
factors	O
as	O
perceived	O
rewards	O
of	O
current	O
behavior	O
,	O
self	O
-	O
efficacy	O
,	O
normative	O
beliefs	O
,	O
motivation	O
,	O
and	O
the	O
perceived	O
consequences	O
of	O
not	O
changing	O
behavior	O
.	O

Weinstein	O
'	O
s	O
summary	O
is	O
illustrative	O
of	O
the	O
fact	O
that	O
Health	O
Behavior	O
Theory	O
has	O
tended	O
to	O
be	O
particularly	O
interested	O
in	O
understanding	O
people	S-Species
'	O
s	O
motivation	O
to	O
change	O
behavior	O
rather	O
than	O
ability	O
to	O
change	O
.	O

Moreover	O
,	O
motivation	O
is	O
thought	O
to	O
be	O
the	O
result	O
of	O
a	O
relatively	O
complex	O
,	O
but	O
logical	O
,	O
interpretation	O
of	O
large	O
quantities	O
of	O
information	O
about	O
self	O
and	O
environment	O
.	O

The	O
theories	O
that	O
Weinstein	O
reviewed	O
deal	O
almost	O
exclusively	O
with	O
behavioral	O
decision	O
processes	O
in	O
people	S-Species
'	O
s	O
minds	O
.	O

They	O
have	O
few	O
if	O
any	O
terms	O
relating	O
to	O
how	O
information	O
gets	O
into	O
peoples	O
minds	O
or	O
how	O
subsets	O
of	O
it	O
receive	O
more	O
or	O
less	O
attention	O
.	O

Broader	O
health	O
behavior	O
theories	O
such	O
as	O
Social	O
Cognitive	O
Theory	O
or	O
the	O
Transtheoretical	O
model	O
have	O
addressed	O
issues	O
and	O
variables	O
outside	O
the	O
person	S-Species
to	O
a	O
greater	O
extent	O
,	O
but	O
the	O
fundamental	O
interest	O
in	O
and	O
belief	O
in	O
psychological	O
variables	O
as	O
the	O
key	O
force	O
in	O
determining	O
health	O
behavior	O
remains	O
.	O

The	O
implications	O
of	O
the	O
focus	O
of	O
health	O
behavior	O
theory	O
on	O
psychological	O
determinants	O
of	O
behavioral	O
decision	O
-	O
making	O
for	O
my	O
own	O
research	O
area	O
of	O
interest	O
,	O
obesity	O
treatment	O
,	O
are	O
several	O
.	O

One	O
is	O
the	O
inclusion	O
of	O
measures	O
of	O
psychological	O
characteristics	O
in	O
most	O
research	O
protocols	O
(	O
e	O
.	O
g	O
.	O
,	O
assessment	O
of	O
behavioral	O
intentions	O
,	O
self	O
-	O
efficacy	O
,	O
perception	O
of	O
barriers	O
to	O
change	O
,	O
perception	O
of	O
social	O
support	O
,	O
and	O
outcome	O
expectations	O
)	O
.	O

A	O
second	O
is	O
the	O
inclusion	O
of	O
treatment	O
elements	O
that	O
specifically	O
target	O
psychological	O
perceptions	O
and	O
processes	O
independent	O
of	O
the	O
diet	O
and	O
physical	O
activity	O
behaviors	O
that	O
actually	O
produce	O
weight	O
change	O
(	O
e	O
.	O
g	O
.	O
,	O
how	O
to	O
deal	O
with	O
emotional	O
eating	O
,	O
how	O
to	O
deal	O
with	O
the	O
frustration	O
of	O
lapses	O
and	O
relapses	O
,	O
and	O
how	O
to	O
talk	O
to	O
yourself	O
to	O
increase	O
self	O
-	O
motivation	O
)	O
.	O

A	O
third	O
is	O
the	O
belief	O
that	O
psychological	O
reactions	O
to	O
treatment	O
experiences	O
themselves	O
are	O
very	O
important	O
and	O
deserve	O
independent	O
attention	O
.	O

Common	O
behavioral	O
prescriptions	O
for	O
weight	O
-	O
loss	O
goals	O
and	O
frequency	O
of	O
self	O
-	O
weighing	O
are	O
exemplary	O
(	O
i	O
.	O
e	O
.	O
,	O
recommending	O
infrequent	O
weighing	O
to	O
prevent	O
discouraging	O
feedback	O
about	O
progress	O
and	O
encouraging	O
smaller	O
and	O
thus	O
"	O
more	O
attainable	O
"	O
behavior	O
and	O
weight	O
-	O
loss	O
goals	O
in	O
the	O
belief	O
that	O
they	O
will	O
be	O
more	O
motivating	O
)	O
.	O

The	O
problem	O
with	O
the	O
emphasis	O
on	O
cognitive	O
variables	O
in	O
weight	O
-	O
control	O
research	O
is	O
that	O
they	O
have	O
so	O
far	O
failed	O
to	O
meet	O
fundamental	O
scientific	O
criteria	O
for	O
empirical	O
verification	O
.	O

Thus	O
,	O
they	O
also	O
have	O
not	O
led	O
to	O
a	O
better	O
understanding	O
of	O
the	O
weight	O
-	O
loss	O
process	O
,	O
have	O
not	O
improved	O
our	O
ability	O
to	O
predict	O
weight	O
-	O
loss	O
outcomes	O
,	O
and	O
have	O
not	O
led	O
to	O
improvement	O
in	O
treatment	O
methods	O
.	O

In	O
some	O
cases	O
it	O
is	O
even	O
arguable	O
that	O
they	O
have	O
made	O
treatment	O
worse	O
.	O

I	O
will	O
illustrate	O
these	O
problems	O
with	O
results	O
from	O
my	O
own	O
research	O
.	O

Discussion	O

Like	O
most	O
behavioral	O
researchers	O
in	O
the	O
obesity	O
area	O
,	O
I	O
have	O
attempted	O
to	O
measure	O
elements	O
of	O
health	O
behavior	O
theory	O
in	O
every	O
obesity	O
intervention	O
project	O
I	O
have	O
ever	O
conducted	O
.	O

I	O
have	O
assessed	O
weight	O
-	O
loss	O
goals	O
,	O
behavioral	O
and	O
weight	O
-	O
loss	O
self	O
-	O
efficacy	O
,	O
psychological	O
well	O
-	O
being	O
,	O
perceived	O
barriers	O
to	O
diet	O
and	O
physical	O
activity	O
change	O
,	O
stages	O
-	O
of	O
-	O
change	O
,	O
and	O
perceived	O
social	O
support	O
.	O

How	O
well	O
have	O
empirical	O
examinations	O
of	O
these	O
factors	O
fared	O
as	O
predictors	O
of	O
success	O
in	O
weight	O
control	O
?	O

Self	O
-	O
efficacy	O

We	O
have	O
examined	O
the	O
predictive	O
value	O
of	O
self	O
-	O
efficacy	O
assessments	O
in	O
several	O
of	O
our	O
studies	O
and	O
describe	O
the	O
results	O
from	O
three	O
of	O
these	O
here	O
in	O
more	O
detail	O
[	O
8	O
-	O
10	O
]	O
.	O

In	O
the	O
first	O
study	O
,	O
self	O
-	O
efficacy	O
was	O
assessed	O
at	O
baseline	O
,	O
posttreatment	O
,	O
and	O
one	O
year	O
later	O
in	O
85	O
men	S-Species
participating	O
in	O
a	O
15	O
-	O
week	O
weight	O
-	O
loss	O
program	O
[	O
8	O
]	O
.	O

The	O
self	O
-	O
efficacy	O
instrument	O
had	O
subscales	O
for	O
emotional	O
states	O
(	O
e	O
.	O
g	O
.	O
,	O
anxiety	O
)	O
and	O
situations	O
(	O
e	O
.	O
g	O
.	O
,	O
eating	O
away	O
from	O
home	O
)	O
.	O

Higher	O
baseline	O
self	O
-	O
efficacy	O
on	O
both	O
subscales	O
was	O
associated	O
with	O
greater	O
weight	O
loss	O
in	O
treatment	O
and	O
at	O
1	O
-	O
and	O
2	O
-	O
year	O
follow	O
-	O
up	O
.	O

Emotional	O
self	O
-	O
efficacy	O
at	O
posttreatment	O
did	O
not	O
predict	O
weight	O
loss	O
at	O
1	O
-	O
or	O
2	O
-	O
year	O
follow	O
-	O
up	O
.	O

Situational	O
self	O
-	O
efficacy	O
at	O
posttreatment	O
predicted	O
weight	O
loss	O
at	O
1	O
-	O
year	O
but	O
not	O
2	O
-	O
year	O
follow	O
-	O
up	O
.	O

The	O
second	O
study	O
examined	O
mood	O
and	O
situational	O
self	O
-	O
efficacy	O
in	O
55	O
men	S-Species
and	O
58	O
women	S-Species
before	O
and	O
after	O
a	O
16	O
-	O
week	O
weight	O
-	O
loss	O
treatment	O
with	O
a	O
1	O
-	O
year	O
follow	O
-	O
up	O
[	O
9	O
]	O
.	O

Women	S-Species
had	O
lower	O
pretreatment	O
self	O
-	O
efficacy	O
than	O
men	S-Species
.	O

Self	O
-	O
efficacy	O
was	O
predictive	O
of	O
weight	O
loss	O
and	O
maintenance	O
in	O
men	S-Species
but	O
not	O
in	O
women	S-Species
.	O

Change	O
in	O
self	O
-	O
efficacy	O
over	O
time	O
was	O
positively	O
related	O
to	O
weight	O
change	O
in	O
women	S-Species
but	O
not	O
in	O
men	S-Species
.	O

The	O
third	O
study	O
examined	O
predictors	O
of	O
weight	O
change	O
over	O
a	O
2	O
-	O
year	O
period	O
in	O
460	O
men	S-Species
and	O
1172	O
women	S-Species
who	O
received	O
a	O
low	O
-	O
intensity	O
weight	O
-	O
loss	O
intervention	O
delivered	O
through	O
their	O
HMO	O
[	O
10	O
]	O
.	O

The	O
self	O
-	O
efficacy	O
measure	O
was	O
the	O
WEL	O
questionnaire	O
.	O

Men	S-Species
again	O
were	O
found	O
to	O
have	O
higher	O
baseline	O
self	O
-	O
efficacy	O
than	O
women	S-Species
.	O

Self	O
-	O
efficacy	O
did	O
not	O
predict	O
weight	O
change	O
in	O
men	S-Species
but	O
was	O
positively	O
,	O
though	O
weakly	O
,	O
related	O
to	O
weight	O
change	O
at	O
6	O
months	O
only	O
in	O
women	S-Species
.	O

Our	O
overall	O
conclusion	O
from	O
the	O
analyses	O
described	O
above	O
,	O
as	O
well	O
as	O
others	O
not	O
pursued	O
in	O
as	O
great	O
detail	O
,	O
is	O
that	O
self	O
-	O
efficacy	O
is	O
a	O
weak	O
predictor	O
of	O
weight	O
loss	O
and	O
is	O
inconsistent	O
across	O
study	O
populations	O
and	O
gender	O
.	O

It	O
tends	O
to	O
increase	O
with	O
weight	O
loss	O
.	O

However	O
,	O
treatment	O
-	O
induced	O
increases	O
in	O
efficacy	O
are	O
not	O
predictive	O
of	O
longer	O
-	O
term	O
weight	O
-	O
loss	O
success	O
.	O

Barriers	O
to	O
Adherence	O

We	O
have	O
also	O
attempted	O
to	O
measure	O
barriers	O
to	O
adherence	O
to	O
weight	O
-	O
control	O
behaviors	O
in	O
many	O
of	O
our	O
studies	O
[	O
11	O
-	O
14	O
]	O
.	O

The	O
instruments	O
used	O
for	O
this	O
have	O
typically	O
been	O
formatted	O
similarly	O
to	O
efficacy	O
questionnaires	O
in	O
that	O
people	S-Species
are	O
asked	O
to	O
indicate	O
how	O
difficult	O
they	O
find	O
situational	O
,	O
knowledge	O
,	O
and	O
motivational	O
challenges	O
to	O
achieving	O
diet	O
and	O
exercise	O
changes	O
.	O

The	O
findings	O
in	O
these	O
studies	O
have	O
been	O
quite	O
consistent	O
.	O

Baseline	O
assessments	O
of	O
perceived	O
barriers	O
to	O
behavior	O
change	O
are	O
not	O
predictive	O
of	O
weight	O
change	O
.	O

Weight	O
loss	O
is	O
associated	O
with	O
reported	O
decreases	O
in	O
perceived	O
barriers	O
.	O

Treatment	O
-	O
induced	O
change	O
in	O
perceived	O
barriers	O
are	O
not	O
predictive	O
of	O
future	O
weight	O
change	O
.	O

In	O
other	O
words	O
,	O
barrier	O
perceptions	O
as	O
we	O
have	O
measured	O
them	O
do	O
not	O
appear	O
to	O
have	O
pragmatic	O
significance	O
.	O

Weight	O
Goals	O

Goal	O
-	O
setting	O
has	O
long	O
been	O
of	O
interest	O
to	O
health	O
behavior	O
theory	O
and	O
in	O
recent	O
years	O
has	O
attracted	O
attention	O
in	O
weight	O
-	O
loss	O
research	O
when	O
it	O
was	O
realized	O
that	O
most	O
people	S-Species
who	O
enter	O
weight	O
-	O
loss	O
treatments	O
want	O
to	O
lose	O
a	O
lot	O
more	O
weight	O
than	O
is	O
realistic	O
given	O
the	O
potency	O
of	O
current	O
weight	O
-	O
loss	O
methodologies	O
[	O
15	O
]	O
.	O

When	O
asked	O
to	O
describe	O
weight	O
losses	O
they	O
deem	O
to	O
represent	O
"	O
dream	O
,	O
happy	O
,	O
acceptable	O
,	O
and	O
disappointing	O
,	O
"	O
many	O
individuals	O
in	O
treatment	O
fail	O
to	O
reach	O
even	O
"	O
disappointing	O
"	O
weight	O
losses	O
even	O
though	O
in	O
objective	O
medical	O
terms	O
the	O
results	O
are	O
positive	O
.	O

Based	O
on	O
the	O
argument	O
that	O
failure	O
to	O
reach	O
gratifying	O
weight	O
-	O
loss	O
goals	O
leads	O
to	O
psychological	O
distress	O
that	O
lowers	O
weight	O
self	O
-	O
efficacy	O
and	O
undermines	O
weight	O
-	O
loss	O
efforts	O
,	O
it	O
has	O
become	O
popular	O
to	O
recommend	O
counseling	O
in	O
weight	O
-	O
loss	O
treatments	O
specifically	O
targeting	O
the	O
lowering	O
of	O
weight	O
-	O
loss	O
goals	O
.	O

The	O
theoretical	O
argument	O
is	O
that	O
excessive	O
outcome	O
expectations	O
undermine	O
behavioral	O
efforts	O
.	O

We	O
have	O
now	O
completed	O
three	O
sets	O
of	O
formal	O
analyses	O
examining	O
whether	O
weight	O
goals	O
are	O
predictive	O
of	O
weight	O
-	O
loss	O
success	O
.	O

In	O
one	O
of	O
these	O
analyses	O
the	O
relationship	O
between	O
weight	O
-	O
loss	O
goals	O
,	O
weight	O
-	O
loss	O
goal	O
attainment	O
,	O
and	O
long	O
-	O
term	O
(	O
30	O
months	O
)	O
weight	O
-	O
loss	O
attainment	O
and	O
psychological	O
well	O
-	O
being	O
were	O
assessed	O
in	O
69	O
men	S-Species
and	O
61	O
women	S-Species
participating	O
in	O
an	O
intensive	O
behavioral	O
treatment	O
program	O
[	O
16	O
]	O
.	O

Results	O
indicated	O
that	O
weight	O
-	O
loss	O
goals	O
were	O
unrealistically	O
high	O
on	O
average	O
and	O
that	O
lower	O
goals	O
were	O
more	O
likely	O
to	O
be	O
reached	O
.	O

Nevertheless	O
,	O
weight	O
-	O
loss	O
goals	O
did	O
not	O
predict	O
either	O
short	O
-	O
or	O
long	O
-	O
term	O
weight	O
losses	O
and	O
were	O
not	O
associated	O
with	O
elevated	O
psychological	O
distress	O
.	O

Two	O
more	O
recent	O
analyses	O
we	O
have	O
conducted	O
looking	O
at	O
weight	O
-	O
loss	O
goals	O
as	O
predictors	O
of	O
success	O
have	O
produced	O
similar	O
results	O
[	O
Linde	O
JA	O
,	O
Jeffery	O
RW	O
,	O
Levy	O
RL	O
,	O
Pronk	O
NP	O
and	O
Boyle	O
RG	O
,	O
unpublished	O
data	O
[	O
17	O
]	O
]	O
.	O

Weight	O
-	O
loss	O
goals	O
either	O
did	O
not	O
predict	O
weight	O
loss	O
at	O
all	O
or	O
were	O
slightly	O
positively	O
related	O
to	O
weight	O
-	O
loss	O
success	O
.	O

Perceived	O
Social	O
Support	O

Perceived	O
social	O
support	O
is	O
another	O
psychological	O
factor	O
thought	O
to	O
influence	O
health	O
behavior	O
decision	O
-	O
making	O
.	O

We	O
have	O
measured	O
social	O
support	O
in	O
a	O
variety	O
of	O
ways	O
in	O
our	O
studies	O
,	O
ranging	O
from	O
single	O
-	O
item	O
questions	O
to	O
multipaged	O
assessments	O
attempting	O
to	O
differentiate	O
among	O
informational	O
,	O
instrumental	O
,	O
and	O
emotional	O
support	O
.	O

The	O
results	O
,	O
unfortunately	O
,	O
have	O
closely	O
paralleled	O
those	O
we	O
have	O
seen	O
with	O
other	O
assessments	O
of	O
barriers	O
to	O
adherence	O
.	O

Assessments	O
of	O
social	O
support	O
prior	O
to	O
treatment	O
do	O
not	O
predict	O
weight	O
loss	O
.	O

Average	O
reports	O
of	O
social	O
support	O
tend	O
to	O
parallel	O
weight	O
loss	O
itself	O
.	O

When	O
people	S-Species
lose	O
weight	O
they	O
report	O
more	O
social	O
support	O
.	O

When	O
they	O
regain	O
,	O
they	O
report	O
less	O
.	O

In	O
other	O
words	O
,	O
perceptions	O
of	O
social	O
support	O
are	O
not	O
predictive	O
of	O
success	O
in	O
weight	O
-	O
loss	O
treatments	O
.	O

Frequency	O
Weight	O
Self	O
-	O
monitoring	O

Self	O
-	O
monitoring	O
of	O
health	O
behavior	O
is	O
incorporated	O
into	O
many	O
health	O
behavior	O
theories	O
,	O
usually	O
as	O
part	O
of	O
a	O
person	S-Species
'	O
s	O
assessment	O
of	O
achieved	O
outcomes	O
.	O

Although	O
self	O
-	O
monitoring	O
is	O
usually	O
considered	O
a	O
positive	O
element	O
in	O
the	O
adoption	O
of	O
health	O
behavior	O
,	O
in	O
obesity	O
treatment	O
frequent	O
self	O
-	O
monitoring	O
of	O
weight	O
has	O
tended	O
to	O
be	O
down	O
-	O
played	O
or	O
even	O
discouraged	O
on	O
the	O
grounds	O
that	O
disappointing	O
results	O
(	O
i	O
.	O
e	O
.	O
,	O
less	O
than	O
desired	O
weight	O
change	O
)	O
may	O
undermine	O
motivation	O
.	O

This	O
is	O
another	O
example	O
in	O
which	O
health	O
behavior	O
theory	O
may	O
have	O
indirectly	O
led	O
to	O
incorrect	O
treatment	O
recommendations	O
.	O

In	O
weight	O
-	O
loss	O
treatments	O
,	O
active	O
discouragement	O
of	O
frequent	O
self	O
-	O
observation	O
of	O
weight	O
has	O
become	O
popular	O
based	O
on	O
the	O
premise	O
that	O
more	O
frequent	O
weighting	O
will	O
cause	O
psychological	O
stress	O
and	O
lower	O
self	O
-	O
efficacy	O
.	O

Recently	O
,	O
we	O
have	O
examined	O
the	O
relationship	O
between	O
frequency	O
of	O
self	O
-	O
weighing	O
and	O
body	O
weight	O
in	O
both	O
clinical	O
and	O
population	O
samples	O
and	O
have	O
found	O
,	O
somewhat	O
to	O
our	O
surprise	O
,	O
that	O
frequency	O
of	O
self	O
-	O
weighing	O
is	O
one	O
of	O
the	O
strongest	O
single	O
predictors	O
of	O
body	O
weight	O
cross	O
-	O
sectionally	O
,	O
and	O
change	O
in	O
the	O
frequency	O
of	O
self	O
-	O
weighing	O
is	O
one	O
of	O
the	O
strongest	O
predictors	O
of	O
weight	O
change	O
[	O
Linde	O
JA	O
,	O
Jeffery	O
RW	O
and	O
French	O
SA	O
,	O
unpublished	O
data	O
]	O
.	O

The	O
direction	O
of	O
predictions	O
,	O
however	O
,	O
is	O
opposite	O
that	O
derived	O
from	O
theory	O
.	O

People	S-Species
who	O
weigh	O
themselves	O
more	O
weigh	O
less	O
and	O
are	O
more	O
successful	O
in	O
losing	O
weight	O
.	O

Stage	O
-	O
of	O
-	O
Change	O

A	O
final	O
failure	O
of	O
current	O
health	O
behavior	O
theory	O
to	O
prove	O
useful	O
in	O
weight	O
-	O
control	O
research	O
is	O
a	O
recent	O
examination	O
of	O
the	O
relationship	O
between	O
a	O
stage	O
-	O
of	O
-	O
change	O
measure	O
adopted	O
from	O
Prochaska	O
and	O
short	O
-	O
and	O
long	O
-	O
term	O
weight	O
loss	O
[	O
18	O
]	O
.	O

Categories	O
of	O
precontemplation	O
,	O
contemplation	O
,	O
preparation	O
,	O
and	O
action	O
were	O
defined	O
based	O
on	O
questions	O
about	O
weight	O
-	O
loss	O
intentions	O
and	O
recent	O
weight	O
-	O
loss	O
attempts	O
.	O

Despite	O
a	O
large	O
sample	O
size	O
,	O
excellent	O
follow	O
-	O
up	O
rates	O
,	O
and	O
well	O
-	O
measured	O
objective	O
outcomes	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
that	O
staging	O
algorithms	O
recommended	O
by	O
proponents	O
of	O
the	O
Transtheoretical	O
Model	O
could	O
predict	O
weight	O
-	O
loss	O
outcomes	O
.	O

Experimental	O
Modification	O
of	O
Expectations	O

Our	O
most	O
recent	O
effort	O
to	O
utilize	O
health	O
behavior	O
theory	O
in	O
obesity	O
intervention	O
research	O
is	O
a	O
study	O
that	O
attempted	O
to	O
examine	O
the	O
effectiveness	O
of	O
experimentally	O
-	O
induced	O
outcome	O
expectancies	O
on	O
weight	O
loss	O
[	O
Finch	O
EA	O
,	O
Linde	O
JA	O
,	O
Jeffery	O
RW	O
,	O
Rothman	O
AJ	O
and	O
King	O
CM	O
,	O
unpublished	O
data	O
]	O
.	O

Obese	O
men	S-Species
and	O
women	S-Species
participated	O
in	O
an	O
8	O
-	O
week	O
weight	O
-	O
loss	O
program	O
with	O
18	O
-	O
month	O
follow	O
-	O
up	O
in	O
which	O
they	O
were	O
assigned	O
to	O
one	O
of	O
two	O
expectancy	O
groups	O
.	O

The	O
optimistic	O
group	O
was	O
told	O
that	O
focusing	O
exclusively	O
on	O
the	O
positive	O
benefits	O
of	O
weight	O
loss	O
would	O
be	O
valuable	O
in	O
ensuring	O
that	O
they	O
remained	O
motivated	O
in	O
their	O
weight	O
-	O
loss	O
efforts	O
and	O
was	O
given	O
assignments	O
during	O
weekly	O
group	O
sessions	O
and	O
homework	O
between	O
sessions	O
to	O
reinforce	O
this	O
optimistic	O
mindset	O
.	O

A	O
"	O
balanced	O
"	O
expectancy	O
group	O
received	O
the	O
instructions	O
that	O
focusing	O
on	O
both	O
the	O
positive	O
and	O
negative	O
aspects	O
of	O
weight	O
loss	O
,	O
a	O
balanced	O
approach	O
,	O
would	O
be	O
most	O
conducive	O
to	O
maintaining	O
weight	O
-	O
loss	O
motivation	O
.	O

This	O
group	O
also	O
received	O
assignments	O
to	O
reinforce	O
their	O
message	O
.	O

Results	O
of	O
this	O
study	O
indicated	O
that	O
the	O
expectation	O
induction	O
was	O
successful	O
initially	O
but	O
difficult	O
to	O
maintain	O
in	O
the	O
face	O
of	O
real	O
weight	O
-	O
loss	O
experience	O
.	O

We	O
were	O
also	O
unable	O
to	O
show	O
that	O
experimentally	O
-	O
induced	O
expectations	O
influenced	O
weight	O
-	O
loss	O
success	O
.	O

Summary	O
and	O
Conclusion	O

To	O
summarize	O
the	O
findings	O
described	O
above	O
,	O
I	O
have	O
had	O
considerable	O
difficulty	O
over	O
the	O
last	O
25	O
years	O
in	O
confirming	O
that	O
the	O
psychosocial	O
variables	O
favored	O
by	O
health	O
behavior	O
theory	O
are	O
of	O
much	O
value	O
for	O
obesity	O
intervention	O
research	O
.	O

They	O
do	O
not	O
predict	O
weight	O
loss	O
well	O
,	O
either	O
as	O
mediators	O
or	O
moderators	O
.	O

There	O
is	O
little	O
evidence	O
to	O
support	O
the	O
idea	O
that	O
targeting	O
them	O
for	O
intervention	O
improves	O
weight	O
-	O
loss	O
outcomes	O
.	O

It	O
is	O
,	O
of	O
course	O
,	O
arguable	O
that	O
the	O
weak	O
findings	O
relating	O
to	O
health	O
behavior	O
theory	O
variables	O
are	O
due	O
in	O
large	O
part	O
to	O
methodological	O
weaknesses	O
,	O
either	O
in	O
measurement	O
tools	O
and	O
/	O
or	O
their	O
frequency	O
of	O
measurement	O
.	O

I	O
would	O
argue	O
,	O
however	O
,	O
that	O
25	O
years	O
is	O
long	O
enough	O
to	O
wait	O
for	O
improved	O
methods	O
and	O
that	O
it	O
is	O
time	O
to	O
look	O
elsewhere	O
for	O
variables	O
that	O
better	O
predict	O
weight	O
-	O
change	O
outcomes	O
and	O
that	O
,	O
therefore	O
,	O
may	O
form	O
a	O
better	O
basis	O
for	O
improving	O
future	O
treatments	O
.	O

Implication	O
for	O
Weight	O
-	O
Loss	O
Treatment	O

Given	O
the	O
lack	O
of	O
success	O
finding	O
support	O
for	O
cognitive	O
mediators	O
of	O
behavior	O
change	O
in	O
weight	O
loss	O
,	O
one	O
might	O
surmise	O
that	O
progress	O
in	O
improving	O
weight	O
-	O
loss	O
interventions	O
over	O
the	O
last	O
20	O
years	O
must	O
have	O
been	O
dreary	O
indeed	O
.	O

Somewhat	O
surprisingly	O
,	O
however	O
,	O
that	O
is	O
not	O
the	O
case	O
.	O

In	O
fact	O
,	O
the	O
short	O
-	O
term	O
(	O
6	O
to	O
12	O
months	O
)	O
success	O
of	O
weight	O
-	O
loss	O
treatments	O
has	O
approximately	O
doubled	O
over	O
that	O
time	O
and	O
several	O
variables	O
have	O
been	O
identified	O
that	O
reliably	O
enhance	O
treatment	O
outcomes	O
.	O

It	O
has	O
been	O
clearly	O
shown	O
experimentally	O
that	O
increasing	O
treatment	O
length	O
[	O
19	O
]	O
,	O
prescribing	O
low	O
-	O
energy	O
intakes	O
[	O
20	O
]	O
,	O
prescribing	O
high	O
-	O
energy	O
expenditure	O
[	O
21	O
]	O
,	O
using	O
a	O
deposit	O
contract	O
and	O
group	O
-	O
based	O
reward	O
systems	O
[	O
22	O
]	O
,	O
and	O
simplifying	O
adherence	O
to	O
diet	O
through	O
meal	O
substitutes	O
[	O
23	O
]	O
and	O
exercise	O
by	O
providing	O
exercise	O
equipment	O
[	O
24	O
]	O
all	O
improve	O
initial	O
weight	O
loss	O
.	O

From	O
a	O
theoretical	O
perspective	O
,	O
however	O
,	O
one	O
thing	O
is	O
noteworthy	O
about	O
these	O
successful	O
innovations	O
.	O

Although	O
not	O
incompatible	O
with	O
health	O
behavior	O
theory	O
,	O
none	O
of	O
them	O
are	O
specifically	O
derived	O
from	O
cognitive	O
decision	O
-	O
making	O
models	O
.	O

Indeed	O
,	O
health	O
behavior	O
theory	O
does	O
not	O
include	O
variables	O
like	O
these	O
in	O
its	O
models	O
.	O

Where	O
Do	O
We	O
Go	O
From	O
Here	O
?	O

The	O
argument	O
above	O
about	O
the	O
practical	O
limitations	O
of	O
many	O
popular	O
theories	O
of	O
health	O
behavior	O
is	O
not	O
meant	O
to	O
be	O
a	O
call	O
to	O
abandon	O
theory	O
.	O

Behavior	O
scientists	O
have	O
amassed	O
much	O
useful	O
information	O
about	O
the	O
principles	O
underlying	O
human	S-Species
behavior	O
that	O
should	O
be	O
valuable	O
for	O
health	O
behavior	O
interventions	O
.	O

Much	O
is	O
known	O
about	O
human	S-Species
perception	O
,	O
learning	O
,	O
motivation	O
,	O
and	O
responsiveness	O
to	O
environmental	O
opportunities	O
and	O
contingencies	O
.	O

Health	O
behavior	O
intervention	O
lies	O
at	O
the	O
interface	O
between	O
people	S-Species
and	O
their	O
environment	O
.	O

Interventionists	O
change	O
aspects	O
of	O
the	O
environment	O
(	O
cues	O
,	O
information	O
,	O
behavioral	O
contingencies	O
)	O
with	O
the	O
intention	O
of	O
producing	O
changes	O
in	O
how	O
people	S-Species
behave	O
.	O

What	O
is	O
needed	O
to	O
advance	O
health	O
behavior	O
intervention	O
is	O
theory	O
that	O
addresses	O
relationships	O
between	O
modifiable	O
aspects	O
of	O
the	O
environment	O
and	O
behavior	O
.	O

There	O
is	O
no	O
doubt	O
that	O
cognitive	O
processes	O
are	O
involved	O
in	O
these	O
relationships	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
current	O
theories	O
capture	O
this	O
is	O
questionable	O
.	O

Data	O
now	O
available	O
suggest	O
that	O
easily	O
obtainable	O
information	O
about	O
people	S-Species
'	O
s	O
cognitive	O
processes	O
adds	O
little	O
to	O
our	O
ability	O
to	O
predict	O
the	O
results	O
of	O
interventions	O
.	O

Thus	O
,	O
it	O
may	O
be	O
wise	O
to	O
pay	O
more	O
attention	O
to	O
applied	O
theories	O
like	O
classical	O
behavior	O
theory	O
[	O
25	O
]	O
,	O
communications	O
theory	O
[	O
26	O
]	O
,	O
and	O
learning	O
theory	O
[	O
27	O
]	O
than	O
to	O
those	O
coming	O
out	O
of	O
the	O
social	O
cognitive	O
traditions	O
.	O

Competing	O
interests	O

None	O
declared	O
.	O
